<SEC-DOCUMENT>0001193125-26-055010.txt : 20260217
<SEC-HEADER>0001193125-26-055010.hdr.sgml : 20260217
<ACCEPTANCE-DATETIME>20260217170053
ACCESSION NUMBER:		0001193125-26-055010
CONFORMED SUBMISSION TYPE:	10-12B/A
PUBLIC DOCUMENT COUNT:		41
FILED AS OF DATE:		20260217
DATE AS OF CHANGE:		20260217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Atrium Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002093101
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-12B/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-43008
		FILM NUMBER:		26643241

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-401-7900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bryce Therapeutics, Inc.
		DATE OF NAME CHANGE:	20251022
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-12B/A
<SEQUENCE>1
<FILENAME>d42675d1012ba.htm
<DESCRIPTION>10-12B/A
<TEXT>
<HTML><HEAD>
<TITLE>10-12B/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on February 17, 2026 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>File No.</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;001-43008</FONT></B> </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No.&nbsp;2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>to
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL FORM FOR REGISTRATION OF SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;12(b) or (g)&nbsp;of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>The Securities Exchange Act of 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Atrium Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">39-4639499</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10578 Science Center Drive, Suite 125</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>92121</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(619) <FONT STYLE="white-space:nowrap">876-0700</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#8217;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be so Registered</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on Which Each Class&nbsp;is to be Registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Common Stock, $0.001 par value</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Stock Market LLC</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12(b)-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&#8194;&#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS REFERENCE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHEET BETWEEN ITEMS OF FORM 10 AND THE ATTACHED INFORMATION STATEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information required to be included herein is incorporated by reference to specifically identified portions of the body of the
information statement filed herewith as Exhibit 99.1 (the &#8220;Information Statement&#8221;). None of the information contained in the Information Statement shall be incorporated by reference herein or deemed to be a part hereof unless such
information is specifically incorporated by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Questions and Answers about the Separation and
Distribution,&#8221; &#8220;Information Statement Summary,&#8221; &#8220;Cautionary Statement Regarding Forward- Looking Statements,&#8221; &#8220;Business,&#8221; and &#8220;Where You Can Find More Information&#8221; of the Information Statement.
Those sections are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;1a.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Risk Factors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Information Statement Summary&#8221; and &#8220;Risk
Factors&#8221; in the Information Statement. Those sections are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Capitalization,&#8221; &#8220;Unaudited Pro Forma Combined
Financial Information,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Combined Financial Statements&#8221; of the Information Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Those sections are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Properties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the section &#8220;Business&#8212;Properties&#8221; of the Information Statement. That
section is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Security Ownership of Certain Beneficial Owners and Management </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the section &#8220;Security Ownership of Certain Beneficial Owners and
Management&#8221; of the Information Statement. That section is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Directors and Executive Officers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the section &#8220;Corporate Governance and Management&#8221; of the Information
Statement. That section is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Executive Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Corporate Governance and
<FONT STYLE="white-space:nowrap">Management&#8212;Non-Employee</FONT> Director Compensation,&#8221; &#8220;Corporate Governance and Management&#8212;Human Capital Management Committee Interlocks and Insider Participation&#8221; and &#8220;Executive
Compensation&#8221; of the Information Statement. Those sections are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Certain Relationships and Related Transactions, and Director Independence </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Certain Relationships and Related Party Transactions,&#8221;
&#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Corporate </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governance and Management&#8212;Director Independence&#8221; of the Information Statement. Those sections are incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legal Proceedings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the section &#8220;Business&#8212;Legal Proceedings&#8221; of the Information
Statement. That section is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Market Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Information Statement Summary,&#8221;
&#8220;Risk Factors,&#8221; &#8220;The Separation and Distribution,&#8221; &#8220;Dividend Policy,&#8221; &#8220;Corporate Governance and Management,&#8221; &#8220;Shares Eligible for Future Sale&#8221; and &#8220;Description of Securities&#8221; of
the Information Statement. Those sections are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description of Registrant&#8217;s Securities to be Registered </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Questions and Answers about the Separation and
Distribution,&#8221; &#8220;Information Statement Summary,&#8221; &#8220;The Separation and Distribution&#8221; and &#8220;Description of Securities&#8221; of the Information Statement. Those sections are incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;The Separation and Distribution&#8212;The Separation
Agreement&#8212;Indemnification,&#8221; &#8220;Executive Compensation&#8212;Limitation of Liability and Indemnification of Officers and Directors,&#8221; &#8220;Certain Relationships and Related Party Transactions&#8212;Indemnification
Agreements&#8221; and &#8220;Indemnification of Directors and Officers&#8221; of the Information Statement. Those sections are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Supplementary Data </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained under the sections &#8220;Unaudited Pro Forma Combined Financial Information,&#8221;
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Index to Combined Financial Statements&#8221; of the Information Statement. Those sections are incorporated herein by reference.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is contained in the section &#8220;Change in Independent Registered Public
Accounting Firm&#8221; of the Information Statement. That section is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Financial Statements </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information required by this item is contained under the section &#8220;Index to Combined Financial Statements&#8221; beginning on page <FONT STYLE="white-space:nowrap">F-1</FONT> of the Information Statement. That section is incorporated herein by
reference. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Exhibits </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are filed as exhibits hereto: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex21.htm">Separation and Distribution Agreement, dated as of October&nbsp;
25, 2025, among Avidity Biosciences, Inc., Atrium Therapeutics, Inc. and Novartis AG**&#094;</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex22.htm">Agreement and Plan of Merger, dated October&nbsp;
25, 2025, among Avidity Biosciences, Inc., Novartis AG and Ajax Acquisition Sub, Inc.**&#094;</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex31.htm">Amended and Restated Certificate of Incorporation, adopted as of February 12, 2026</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex32.htm">Amended and Restated Bylaws, adopted as of February 12, 2026</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex41.htm">Form of Common Stock Certificate of Atrium Therapeutics, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex101.htm">License Agreement, dated as of October&nbsp;25, 2025, by and between Avidity Biosciences, Inc. and Atrium Therapeutics,
Inc.**&#134;</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex102.htm">Form of Transition Services Agreement, by and between Avidity Biosciences, Inc. and Atrium Therapeutics, Inc.**&#134;</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex103.htm">Research Collaboration and License Agreement, dated as of April&nbsp;
17, 2019, by and between Eli Lilly and Company and Avidity Biosciences, Inc.**&#134;</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex104.htm">Research Collaboration and License Agreement, dated as of November&nbsp;
27, 2023, by and between Bristol-Myers Squibb Company and Avidity Biosciences, Inc.**&#134;</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex105.htm">Atrium Therapeutics, Inc. 2026 Incentive Award Plan, including forms of grant notices and agreements thereunder**#</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex106.htm">Form of Make Whole Restricted Stock Unit Grant Notice and Make Whole Restricted Stock Unit Agreement under the Atrium Therapeutics, Inc. 2026 Incentive Award Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312526029976/d42675dex107.htm">Atrium Therapeutics, Inc. 2026 Employee Stock Purchase Plan**#</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex108.htm">Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Kathleen Gallagher# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex109.htm">Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Husam Younis# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1010.htm">Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Steven Hughes# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1011.htm">Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Brendan Winslow# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1012.htm">Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Stephanie Kenney# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1013.htm">Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Rocio Martin Hoyos# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1014.htm">Atrium Therapeutics, Inc. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program# </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1015.htm">Form of Indemnification Agreement to be in effect following the Distribution </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex1016.htm">Amended and Restated Lease Agreement, dated December&nbsp;18, 2020, by and between <FONT STYLE="white-space:nowrap">ARE-SD</FONT> Region No.&nbsp;44, LLC and Avidity Biosciences, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2093101/000119312525314415/d42675dex161.htm">Letter re Change in Independent Registered Public Accounting Firm**</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of Subsidiaries &#8212; (None)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d42675dex991.htm">Preliminary Information Statement dated February 17, 2026 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> The omitted information is not material and is the type of information the Company customarily and actually treats as private or confidential. The Company has determined that the information is both
(i)&nbsp;not material and (ii)&nbsp;of the type that the Company treats as private and confidential. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Atrium Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February 17, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d42675dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ATRIUM THERAPEUTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Atrium Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware (the
&#8220;<U>Corporation</U>&#8221;), DOES HEREBY CERTIFY AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. That the name of this Corporation is Atrium Therapeutics, Inc. The
Corporation was originally incorporated under the name &#8220;Bryce Therapeutics, Inc.&#8221; by filing of its Certificate of Incorporation with the office of the Secretary of State of the State of Delaware (the &#8220;<U>Delaware
Secretary</U>&#8221;) on September&nbsp;30, 2025 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the &#8220;<U>Previous Certificate</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Amended and Restated Certificate of Incorporation (the &#8220;<U>Certificate of Incorporation</U>&#8221;), which both restates and
amends the provisions of the Previous Certificate, was duly adopted in accordance with Sections 228, 242 and 245 of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This Certificate of Incorporation shall become effective on the date of filing with the Delaware Secretary (the &#8220;<U>Effective
Date</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The text of the Previous Certificate is hereby restated and amended in its entirety to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST: The name of the Corporation is Atrium Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND: The address of the Corporation&#8217;s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls
Drive, Wilmington, New Castle County, Delaware 19808. The name of its registered agent at that address is Corporation Service Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD: The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for
which corporations may be organized under the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOURTH: The total number of shares of all
classes of stock which the Corporation shall have authority to issue is 440,000,000 shares, consisting of (a) 400,000,000 shares of Common Stock, $0.001 par value per share (&#8220;Common Stock&#8221;), and (b) 40,000,000 shares of Preferred Stock,
$0.001 par value per share (&#8220;Preferred Stock&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <U>COMMON STOCK.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights
of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock shall be entitled to one vote for each
share held by such holder; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as used herein, shall mean the
certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred
Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation or the General Corporation Law of
the State of Delaware. There shall be no cumulative voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Common Stock may be increased or decreased
(but not below the number of shares thereof then outstanding) irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of the State of Delaware. For the avoidance of doubt, and notwithstanding&nbsp;anything herein to
the contrary, subject to the rights of the holders of any Preferred Stock, Section&nbsp;242(d) of the General Corporation Law of the State of Delaware shall apply to amendments to this Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Dividends</U>. Dividends may be declared and paid on the Common Stock if, as and when determined by the Board of Directors subject to
any preferential dividend or other rights of any then outstanding Preferred Stock and to the requirements of applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<U>Liquidation</U>. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject
to any preferential or other rights of any then outstanding Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <U>PREFERRED STOCK.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein
and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors of the Corporation as hereinafter provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in
connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the General Corporation Law of
the State of Delaware, to determine and fix the number of shares of such series and to determine for each such series, such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional
or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such
resolutions, all to the fullest extent now or hereafter permitted by the General Corporation Law of the State of Delaware. The powers, preferences and relative, participating, optional and other special rights of each such series of Preferred Stock,
and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Without limiting the generality of the foregoing, the resolution or resolutions providing for the
issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any series of Preferred Stock pursuant to the terms
of this Certificate of Incorporation or any resolution or resolutions providing for the issuance of such series of stock adopted by the Board of Directors, the number of authorized shares of Preferred Stock may be increased or decreased (but not
below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of
the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIFTH: Except as otherwise provided herein, the Corporation reserves the right to amend, alter, change or repeal
any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders, directors or any other persons herein are granted
subject to this reservation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SIXTH: Upon this Certificate of Incorporation becoming effective pursuant to the General Corporation Law of
the State of Delaware, (the &#8220;Effective Time&#8221;), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">15,514.966-for-1</FONT></FONT> forward stock split (the &#8220;Stock Split&#8221;) of the Common Stock shall be effected
by which each share of Common Stock issued and outstanding or held in treasury immediately prior to the Effective Time shall automatically and without any further action by the holder thereof or the Corporation, be subdivided into 15,514.966 shares
of Common Stock. The reclassification of the shares of Common Stock shall be deemed to occur at the Effective Time. From and after the Stock Split, certificates that represented shares of Common Stock immediately prior to the Effective Time shall
represent the number of whole shares of Common Stock into which the shares of Common Stock represented by such certificate have been subdivided pursuant to the Stock Split; provided, however, that the Corporation shall not be obligated to issue
certificates evidencing the shares resulting from the Stock Split unless either the certificates evidencing such shares of Common Stock are delivered to the Corporation or its transfer agent, or the holder notifies the Corporation or its transfer
agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEVENTH: In furtherance and not in limitation of the powers conferred upon it by the General Corporation Law of the State of Delaware, and
subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the Bylaws of the Corporation. The stockholders may not adopt, amend, alter or repeal the Bylaws of the Corporation,
or adopt any provision inconsistent therewith, unless such action is approved, in addition to any other vote required by this Certificate of Incorporation, by the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class. Notwithstanding any other provisions of law, this
Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in
voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article SEVENTH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EIGHTH: To the fullest extent permitted by the General Corporation Law of the State of
Delaware as the same exists or may hereafter be amended, a director or officer of the Corporation shall not be liable to the Corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, as applicable.
No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director or officer of the Corporation for or with respect to any acts or omissions of such director or officer occurring
prior to such amendment or repeal. If the General Corporation Law of the State of Delaware is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of a director or officer of the
Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware as so amended. Solely for purposes of this Article EIGHTH, &#8220;officer&#8221; shall have the meaning provided in
Section&nbsp;102(b)(7) of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NINTH: This Article NINTH is inserted for the management
of the business and for the conduct of the affairs of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General Powers</U>. The business and affairs of the
Corporation shall be managed by or under the direction of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Number of Directors; Election of Directors</U>.
Subject to the rights of holders of any series of Preferred Stock to elect directors, the number of directors of the Corporation shall be fixed from time to time exclusively by a resolution adopted by the Board of Directors. Election of directors
need not be by written ballot, except as and to the extent provided in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Classes of Directors</U>.
Subject to the rights of holders of any series of Preferred Stock to elect directors, the Board of Directors shall be and is divided into three classes, designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class shall consist, as
nearly as may be possible, of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting the entire Board of Directors. The Board of Directors is authorized to assign members of the Board of Directors to
Class&nbsp;I, Class&nbsp;II or Class&nbsp;III. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Terms of Office</U>. Subject to the rights of holders of any series of Preferred
Stock to elect directors, each director shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected; <U>provided</U> that each director
initially assigned to Class&nbsp;I shall serve for a term expiring at the Corporation&#8217;s first annual meeting of stockholders held after the effectiveness of such classification; each director initially assigned to Class&nbsp;II shall serve for
a term expiring at the Corporation&#8217;s second annual meeting of stockholders held after the effectiveness of such classification; and each director initially assigned to Class&nbsp;III shall serve for a term expiring at the Corporation&#8217;s
third annual meeting of stockholders held after the effectiveness of such classification; provided further, that the term of each director shall continue until the election and qualification of his or her successor and be subject to his or her
earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Quorum</U>. The greater of (a)&nbsp;a majority of the directors then in office and <FONT
STYLE="white-space:nowrap">(b)&nbsp;one-third</FONT> of the number of directors fixed pursuant to Section&nbsp;2 of this Article NINTH shall constitute a quorum of the Board of Directors. If at any meeting of the Board of Directors there shall be
less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without notice other than announcement at the meeting, until a quorum is present. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Action at Meeting</U>. Every act or decision done or made by a majority of the
directors present at a meeting duly held at which a quorum is present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Removal</U>. Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed only for
cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock of the Corporation entitled to vote at an election of directors, voting
together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Vacancies</U>. Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly
created directorship in the Board of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders,
unless the Board of Directors determines by resolution that any such vacancy or newly created directorship shall be filled by the stockholders. A director elected to fill a vacancy or newly created directorship shall hold office until the next
election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to such director&#8217;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Stockholder Nominations and Introduction of Business, Etc.</U> Advance notice of stockholder nominations for election of directors and
other business to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Amendments to Article</U>. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the
Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock
of the Corporation entitled to vote thereon, voting together as a single class, shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article NINTH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TENTH: No action that is required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of
stockholders may be effected by written consent of stockholders in lieu of a meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser
percentage may be specified by law, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting
together as a single class, shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article TENTH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ELEVENTH: Special meetings of stockholders for any purpose or purposes may be called at any time only by the Board of Directors, the
chairperson of the Board of Directors, the chief executive officer or the president (in the absence of a chief executive officer), and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall
be limited to the purpose or purposes stated in the notice of meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be
specified by law, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single
class, shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article ELEVENTH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TWELFTH: Unless the Corporation consents in writing to the selection of an alternative
forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum
for (a)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (b)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee, agent or stockholder of the Corporation to the
Corporation or the Corporation&#8217;s stockholders, creditors or other constituents, (c)&nbsp;any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or this Certificate of
Incorporation or the Bylaws of the Corporation, or (d)&nbsp;any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as
defendants therein; <U>provided</U> that, the foregoing provisions of this Article TWELFTH will not apply to suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended, the Securities and Exchange Act of 1934,
as amended, or any other claim for which the federal courts have exclusive jurisdiction; and <U>provided further</U> that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter
jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of
America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. To the fullest extent permitted by applicable law, any person or entity purchasing or
otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article TWELFTH. Notwithstanding any other provisions of law, this Certificate of
Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the
outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article TWELFTH. If any provision or
provisions of this Article TWELFTH shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and
enforceability of such provisions in any other circumstance and of the remaining provisions of this Article TWELFTH (including, without limitation, each portion of any sentence of this Article TWELFTH containing any such provision held to be
invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed
by its duly authorized officer this 12th day of February 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATRIUM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d42675dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATRIUM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Delaware corporation) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS AMENDED AND RESTATED ON FEBRUARY 12, 2026 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE I - CORPORATE OFFICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGISTERED OFFICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OTHER OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE II - MEETINGS OF STOCKHOLDERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PLACE OF MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ANNUAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SPECIAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADVANCE NOTICE PROCEDURES FOR NOMINATIONS FOR ELECTION TO THE BOARD OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTICE OF STOCKHOLDERS&#8217; MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>QUORUM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADJOURNED MEETING; NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONDUCT OF BUSINESS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VOTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RECORD DATE FOR STOCKHOLDER NOTICE; VOTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PROXIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LIST OF STOCKHOLDERS ENTITLED TO VOTE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>POSTPONEMENT, ADJOURNMENT AND CANCELLATION OF MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INSPECTORS OF ELECTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III - DIRECTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>POWERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NUMBER OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RESIGNATION AND VACANCIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PLACE OF MEETINGS; MEETINGS BY TELEPHONE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGULAR MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SPECIAL MEETINGS; NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>QUORUM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>BOARD ACTION BY CONSENT WITHOUT A MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEES AND COMPENSATION OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REMOVAL OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV - COMMITTEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMMITTEES OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMMITTEE MINUTES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MEETINGS AND ACTION OF COMMITTEES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- i - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE V - OFFICERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>APPOINTMENT OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SUBORDINATE OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REMOVAL AND RESIGNATION OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VACANCIES IN OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REPRESENTATION OF SHARES OF OTHER ENTITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>AUTHORITY AND DUTIES OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI - RECORDS AND REPORTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAINTENANCE OF RECORDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VII - GENERAL MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>STOCK CERTIFICATES; PARTLY PAID SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MULTIPLES CLASSES OR SERIES OF STOCK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LOST CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONSTRUCTION; DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DIVIDENDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FISCAL YEAR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TRANSFER OF STOCK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>STOCK TRANSFER AGREEMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGISTERED STOCKHOLDERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WAIVER OF NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTICE BY ELECTRONIC TRANSMISSION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFINITION OF ELECTRONIC TRANSMISSION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX - INDEMNIFICATION AND ADVANCEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ACTIONS, SUITS AND PROCEEDINGS OTHER THAN BY OR IN THE RIGHT OF THE CORPORATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ACTIONS OR SUITS BY OR IN THE RIGHT OF THE CORPORATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INDEMNIFICATION FOR EXPENSES OF SUCCESSFUL PARTY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTIFICATION AND DEFENSE OF CLAIM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADVANCE OF EXPENSES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PROCEDURE FOR INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REMEDIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LIMITATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SUBSEQUENT AMENDMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OTHER RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PARTIAL INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INSURANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SAVINGS CLAUSE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE X - AMENDMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED BYLAWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATRIUM THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I - CORPORATE OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 REGISTERED OFFICE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registered office of Atrium Therapeutics, Inc. (the &#8220;<U>Corporation</U>&#8221;) shall be fixed in the Corporation&#8217;s certificate of incorporation, as the same may be amended and/or restated from time to time (the &#8220;<U>certificate of
incorporation</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 OTHER OFFICES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may have other offices at any place or places, either within or outside the State of Delaware, as the Corporation&#8217;s board
of directors (the &#8220;<U>Board</U>&#8221;) shall from time to time determine or the business of the Corporation may from time to time require. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II - MEETINGS OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 PLACE OF MEETINGS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings
of stockholders may be held at such place, if any, within or outside the State of Delaware, and at such time and date as designated by the Board (or its designee). The Board may, in its sole discretion, determine that a meeting of stockholders shall
not be held at any place, but may instead be held solely or in part by means of remote communication as authorized by Section&nbsp;211(a) of the General Corporation Law of the State of Delaware (the &#8220;<U>DGCL</U>&#8221;). In the absence of any
such designation or determination, stockholders&#8217; meetings shall be held at the Corporation&#8217;s principal executive office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2
ANNUAL MEETING. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall designate the place, if any, time and date of the annual meeting. At the annual meeting, directors shall
be elected and other proper business properly brought before the meeting in accordance with Section&nbsp;2.4 of these bylaws may be transacted. The Board may postpone, reschedule or cancel any previously scheduled annual meeting of stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 SPECIAL MEETING. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
special meeting of the stockholders may be called at any time only by the Board, chairperson of the Board, chief executive officer or president (in the absence of a chief executive officer) of the Corporation, and may not be called by any other
person or persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No business may be transacted at such special meeting other than the business specified in such notice to
stockholders. Nothing contained in this paragraph of this Section&nbsp;2.3 shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board may be held. The Board may postpone, reschedule or
cancel any previously scheduled special meeting of stockholders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To
be properly brought before an annual meeting, business must be (i)&nbsp;brought before the meeting by the Corporation and specified in a notice of meeting given by or at the direction of the Board, (ii)&nbsp;if not specified in a notice of meeting,
otherwise brought before the meeting by or at the direction of the Board (or a committee thereof) or the chairperson of the Board or (iii)&nbsp;otherwise properly brought before the meeting by a stockholder present in person who (A)&nbsp;(1) was a
stockholder of record of the Corporation both at the time of giving the notice provided for in this Section&nbsp;2.4 and at the time of the meeting, (2)&nbsp;is entitled to vote at the meeting and (3)&nbsp;has complied with this Section&nbsp;2.4 in
all applicable respects or (B)&nbsp;properly made such proposal in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (as so
amended and inclusive of such rules and regulations, the &#8220;<U>Exchange Act</U>&#8221;). The foregoing clause (iii)&nbsp;shall be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the
stockholders. Stockholders shall not be permitted to propose business to be brought before a special meeting of the stockholders, and the only matters that may be brought before a special meeting are the matters specified in the notice of meeting
given by or at the direction of the person calling the meeting pursuant to Section&nbsp;2.3 of these bylaws. For purposes of this Section&nbsp;2.4, &#8220;present in person&#8221; shall mean that the stockholder proposing that the business be
brought before the annual meeting of the Corporation, or a qualified representative of such proposing stockholder, appear at such annual meeting. A &#8220;qualified representative&#8221; of such proposing stockholder shall be a duly authorized
officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders
and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Stockholders seeking to nominate persons for election to the Board must
comply with Section&nbsp;2.5 of these bylaws, and this Section&nbsp;2.4 shall not be applicable to nominations except as expressly provided in Section&nbsp;2.5 of these bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without qualification, for business to be properly brought before an annual meeting by a stockholder, the stockholder of record must
(i)&nbsp;deliver Timely Notice (as defined below) thereof in writing and in proper form to the secretary of the Corporation and (ii)&nbsp;deliver any updates or supplements to such notice at the times and in the forms required by this
Section&nbsp;2.4. To be timely, a stockholder of record&#8217;s notice must be delivered to the principal executive offices of the Corporation not earlier than the one hundred twentieth (120th) day and not later than the close of business on the
ninetieth (90th) day prior to the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the preceding year&#8217;s annual meeting; <I>provided</I>, <I>however</I>, that if the date of the annual meeting is more than thirty (30)&nbsp;days
before or more than seventy (70)&nbsp;days after such anniversary date, notice by the stockholder of record to be timely must be so delivered, or mailed and received, not more than the one hundred twentieth (120th) day prior to such annual meeting
and not later than the close of business on (i)&nbsp;the ninetieth (90th) day prior to such annual meeting or, (ii)&nbsp;if later, the tenth (10th) day following the day on which public disclosure of the date of such annual meeting was first made by
the Corporation (such notice within such time periods, &#8220;<U>Timely Notice</U>&#8221;). In no event shall any adjournment, recess, rescheduling or postponement of an annual meeting or the announcement thereof commence a new time period (or
extend any time period) for the giving of Timely Notice as described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To be in proper form for purposes of this Section&nbsp;2.4, a stockholder of
record&#8217;s notice to the secretary of the Corporation shall set forth: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) As to each Proposing Person (as defined
below), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the name and address of such Proposing Person (including, without limitation, if applicable, the name and
address that appear on the Corporation&#8217;s books and records), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the class or series and number of shares of the
Corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by such Proposing Person, except that such Proposing Person shall
in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the date or dates such shares were acquired, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) the investment intent of such acquisition and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) any pledge by such Proposing Person with respect to any such shares (the disclosures to be made pursuant to the foregoing
clauses (A)&nbsp;through (E) are referred to as &#8220;<U>Stockholder Information</U>&#8221;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) As to each Proposing
Person, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the material terms and conditions of any &#8220;derivative security&#8221; (as such term is defined in Rule <FONT
STYLE="white-space:nowrap">16a-1(c)</FONT> under the Exchange Act) that constitutes a &#8220;call equivalent position&#8221; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act) or a &#8220;put
equivalent position&#8221; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or other derivative or synthetic arrangement in respect of any class or series of shares of the Corporation
(&#8220;<U>Synthetic Equity Position</U>&#8221;) that is, directly or indirectly, held or maintained by, held for the benefit of, or involving such Proposing Person, including, without limitation, (1)&nbsp;any option, warrant, convertible security,
stock appreciation right, future or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from
the value of any class or series of shares of the Corporation, (2)&nbsp;any derivative or synthetic arrangement having the characteristics of a long position or a short position in any class or series of shares of the Corporation, including, without
limitation, a stock loan transaction, a stock borrow transaction, or a share repurchase transaction or (3)&nbsp;any contract, derivative, swap or other transaction or series of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
transactions designed to (x)&nbsp;produce economic benefits and risks that correspond substantially to the ownership of any class or series of shares of the Corporation, (y)&nbsp;mitigate any
loss relating to, reduce the economic risk (of ownership or otherwise) of, or manage the risk of share price decrease in, any class or series of shares of the Corporation, or (z)&nbsp;increase or decrease the voting power in respect of any class or
series of shares of the Corporation of such Proposing Person, including, without limitation, due to the fact that the value of such contract, derivative, swap or other transaction or series of transactions is determined by reference to the price,
value or volatility of any class or series of shares of the Corporation, whether or not such instrument, contract or right shall be subject to settlement in the underlying class or series of shares of the Corporation, through the delivery of cash or
other property, or otherwise, and without regard to whether the holder thereof may have entered into transactions that hedge or mitigate the economic effect of such instrument, contract or right, or any other direct or indirect opportunity to profit
or share in any profit derived from any increase or decrease in the price or value of any class or series of shares of the Corporation; <I>provided</I> that, for the purposes of the definition of &#8220;Synthetic Equity Position,&#8221; the term
&#8220;derivative security&#8221; shall also include any security or instrument that would not otherwise constitute a &#8220;derivative security&#8221; as a result of any feature that would make any conversion, exercise or similar right or privilege
of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or
exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination; and, <I>provided</I>, <I>further</I>, that any Proposing Person satisfying the requirements of Rule <FONT
STYLE="white-space:nowrap">13d-1(b)(1)</FONT> under the Exchange Act (other than a Proposing Person that so satisfies Rule <FONT STYLE="white-space:nowrap">13d-1(b)(1)</FONT> under the Exchange Act solely by reason of Rule <FONT
STYLE="white-space:nowrap">13d-1(b)(1)(ii)(E))</FONT> shall not be required to disclose any Synthetic Equity Position that is, directly or indirectly, held or maintained by, held for the benefit of, or involving such Proposing Person as a hedge with
respect to a bona fide derivatives trade or position of such Proposing Person arising in the ordinary course of such Proposing Person&#8217;s business as a derivatives dealer, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) any rights to dividends on the shares of any class or series of shares of the Corporation owned beneficially by such
Proposing Person that are separated or separable from the underlying shares of the Corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) any material pending
or threatened legal proceeding in which such Proposing Person is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) any other material relationship between such Proposing Person, on the
one hand, and the Corporation, or any affiliate of the Corporation, on the other hand, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) any direct or indirect
material interest in any material contract or agreement of such Proposing Person with the Corporation or any affiliate of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting
agreement), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) the names and addresses of other stockholders (including beneficial owners) known by such Proposing
Person to financially or otherwise materially support the stockholder&#8217;s proposals or nominations, and to the extent known the class or series and number of all shares of the Corporation&#8217;s capital stock owned beneficially or of record by
each such other stockholder or other beneficial owner, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G) any proportionate interest in shares of the Corporation or a
Synthetic Equity Position held, directly or indirectly, by a general or limited partnership, limited liability company or similar entity in which any such Proposing Person (1)&nbsp;is a general partner or, directly or indirectly, beneficially owns
an interest in a general partner of such general or limited partnership or (2)&nbsp;is the manager, managing member or, directly or indirectly, beneficially owns an interest in the manager or managing member of such limited liability company or
similar entity, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(H) a representation that such Proposing Person intends or is part of a group which intends to deliver a
proxy statement or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding capital stock required to approve or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal;
<I>provided</I>, that the stockholder shall include a representation that it is a holder of record of stock of the Corporation at the time of providing the notice of the business, will be entitled to vote at the meeting and will be present in person
at the meeting to propose such business, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(I) any other information relating to such Proposing Person that would be
required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to
Section&nbsp;14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A)&nbsp;through (I) are referred to as &#8220;<U>Disclosable Interests</U>&#8221;); <I>provided</I>, <I>however</I>, that Disclosable Interests
shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to
prepare and submit the notice required by these bylaws on behalf of a beneficial owner; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) As to each item of business that the stockholder of record proposes to
bring before the annual meeting, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) a brief description of the business desired to be brought before the annual meeting,
the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the text of the proposal or business (including, without limitation, the text of any resolutions proposed for
consideration and in the event that such business includes a proposal to amend the bylaws of the Corporation, the language of the proposed amendment), </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) a reasonably detailed description of all agreements, arrangements and understandings (1)&nbsp;between or among any of the
Proposing Persons or (2)&nbsp;between or among any Proposing Person and any other person or entity (including, without limitation, their names) in connection with the proposal of such business by such stockholder, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) any other information relating to such item of business that would be required to be disclosed in a proxy statement or
other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act; <I>provided</I>, <I>however</I>, that the
disclosures required by this paragraph (iii)&nbsp;shall not include any disclosures with respect to any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to
prepare and submit the notice required by these bylaws on behalf of a beneficial owner; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) As to the stockholder of
record providing the notice of business proposed to be brought before an annual meeting, (A)&nbsp;a representation by the stockholder that it is a holder of record of the stock of the Corporation at the time of giving the notice, will be entitled to
vote at such meeting and will appear in person or by proxy at the meeting to propose such business or nomination and (B)&nbsp;a representation by the stockholder of record as to the completeness and accuracy of the information (including all
statements, descriptions, representations and certifications) set forth in the stockholder&#8217;s notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this
Section&nbsp;2.4, the term &#8220;<U>Proposing Person</U>&#8221; shall mean (i)&nbsp;the stockholder of record providing the notice of business proposed to be brought before an annual meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if
different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made, (iii)&nbsp;any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder or
beneficial owners in such solicitation and (iv)&nbsp;any person who is a member of a &#8220;group&#8221; (as such term is used in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-5</FONT> under the Exchange Act (or any successor provision)) with such
stockholder or beneficial owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Board may request that any Proposing Person furnish such additional information as
may be reasonably required by the Board. As a condition to any such business being deemed properly brought before a meeting of stockholders, such Proposing Person shall deliver such additional information within five (5)&nbsp;business days after it
has been requested by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) A Proposing Person shall further update and supplement its notice to the Corporation of its intent to
propose business at an annual meeting, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section&nbsp;2.4 shall be true and correct as of the record date for determining stockholders entitled
to vote at the annual meeting and as of the date that is ten (10)&nbsp;business days prior to the meeting or any adjournment, recess, rescheduling or postponement thereof, and such update and supplement shall be delivered to the secretary of the
Corporation at the principal executive offices of the Corporation not later than five (5)&nbsp;business days after the record date for determining stockholders entitled to vote at the annual meeting (in the case of the update and supplement required
to be made as of such record date), and not later than eight (8)&nbsp;business days prior to the date for the meeting or, if practicable, any adjournment, recess, rescheduling or postponement thereof (and, if not practicable, on the first
practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting or any adjournment, recess, rescheduling or
postponement thereof). For avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation&#8217;s rights with respect to any deficiencies in any notice
provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or
adding matters, business or resolutions proposed to be brought before a meeting of the stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Notwithstanding anything in these
bylaws to the contrary, no business shall be conducted at an annual meeting that is not properly brought before the meeting in accordance with this Section&nbsp;2.4. If the Board determines that any proposed business was not proposed in accordance
with this Section&nbsp;2.4, then except as otherwise required by law, at the meeting of stockholders, the presiding officer shall have the power and duty to declare such business was not properly brought before the meeting and in accordance with the
provisions of these bylaws, and such business shall be invalid and disregarded notwithstanding that proxies in respect of such vote may have been received by the Corporation. If at any meeting of stockholders, any business is proposed to be brought
before the meeting from the floor of the meeting, the presiding officer shall have the power and duty to determine whether the business was properly brought before the meeting in accordance with this Section&nbsp;2.4 and if he or she determines that
any proposed business was not proposed in accordance with this Section&nbsp;2.4, then except as otherwise required by law, he or she shall so declare to the meeting, and such business shall be invalid and disregarded notwithstanding that proxies in
respect of such vote may have been received by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) This Section&nbsp;2.4 is expressly intended to apply to any business
proposed to be brought before an annual meeting of stockholders other than any proposal made in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act and included in the Corporation&#8217;s proxy statement. In
addition to the requirements of this Section&nbsp;2.4 with respect to any business proposed to be brought before an annual meeting, each Proposing Person shall comply with all applicable requirements of the Exchange Act with respect to any such
business. Nothing in this Section&nbsp;2.4 shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the
Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) For purposes of these bylaws, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) &#8220;business day&#8221; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which
banking institutions in New York, New York are authorized or obligated by law or executive order to close, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)
&#8220;close of business&#8221; shall mean 5:00 p.m. local time at the principal executive offices of the Corporation, and if an applicable deadline falls on the close of business on a day that is not a business day, then the applicable deadline
shall be deemed to be the close of business on the immediately preceding business day; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) delivery of any notice or
materials by a stockholder as required under this Section&nbsp;2.4 and Section&nbsp;2.5 shall require both delivery by (x)&nbsp;hand, overnight courier service, or certified or registered mail, return receipt requested, in each case to the secretary
of the Corporation at the principal executive offices of the Corporation and (y)&nbsp;electronic mail to the secretary; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) &#8220;public disclosure&#8221; shall mean disclosure in a press release reported by a national news service or in a
document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 ADVANCE NOTICE PROCEDURES FOR NOMINATIONS FOR ELECTION TO THE BOARD OF DIRECTORS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Nominations of any person for election to the Board at an annual meeting or at a special meeting (but, in the case of a special meeting,
only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i)&nbsp;by or at the direction of the Board or any committee
or persons authorized to do so by the Board or these bylaws, or (ii)&nbsp;by a stockholder present in person who (A)&nbsp;was a stockholder of record of the Corporation both at the time of giving the notice provided for in this Section&nbsp;2.5 and
at the time of the meeting, (B)&nbsp;is entitled to vote at the meeting and (C)&nbsp;has complied with this Section&nbsp;2.5 as to such notice and nomination. For purposes of this Section&nbsp;2.5, &#8220;present in person&#8221; shall mean that the
stockholder of record nominating any person for election to the Board at the meeting of the Corporation, or a qualified representative of such stockholder, appear at such meeting. A &#8220;qualified representative&#8221; of such proposing
stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder
as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. The foregoing clause (ii)&nbsp;shall
be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting or special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) Without qualification, for a stockholder to make any nomination of a person or
persons for election to the Board at an annual meeting, the stockholder of record must (A)&nbsp;deliver Timely Notice (as defined in Section&nbsp;2.4(b) of these bylaws) thereof in writing and in proper form to the secretary of the Corporation,
(B)&nbsp;deliver the information, agreements and questionnaires with respect to such stockholder and its candidate for nomination as required to be set forth by this Section&nbsp;2.5, and (C)&nbsp;deliver any updates or supplements to such notice at
the times and in the forms required by this Section&nbsp;2.5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Without qualification, if the election of directors is
a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting, then for a stockholder to make any nomination of a person or persons for election to the Board at a special meeting, the stockholder of
record must (A)&nbsp;deliver timely notice thereof in writing and in proper form to the secretary of the Corporation at the principal executive offices of the Corporation, (B)&nbsp;deliver the information, agreements and questionnaires with respect
to such stockholder and its candidate for nomination as required by this Section&nbsp;2.5, and (C)&nbsp;deliver any updates or supplements to such notice at the times and in the forms required by this Section&nbsp;2.5. To be timely, a stockholder of
record&#8217;s notice for nominations to be made at a special meeting must be delivered to the principal executive offices of the Corporation not earlier than the one hundred twentieth (120th) day prior to such special meeting and not later than the
close of business on (1)&nbsp;the ninetieth (90th) day prior to such special meeting or, (2)&nbsp;if later, the tenth (10th) day following the day on which public disclosure (as defined in Section&nbsp;2.4 of these bylaws) of the date of such
special meeting was first made by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) In no event shall any adjournment, recess, rescheduling or
postponement of an annual meeting or special meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder of record&#8217;s notice as described above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) In no event may a Nominating Person (as defined below) provide Timely Notice with respect to a greater number of director
candidates than are subject to election by stockholders at the applicable meeting. If the Corporation shall, subsequent to such notice, increase the number of directors subject to election at the meeting, such notice as to any additional nominees
shall be due on the later of (i)&nbsp;the conclusion of the time period for Timely Notice, (ii)&nbsp;the date set forth in Section&nbsp;2.5(b)(ii) or (iii)&nbsp;the close of business on the tenth (10th) day following the date of public disclosure
(as defined in Section&nbsp;2.4) of such increase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To be in proper form for purposes of this Section&nbsp;2.5, a stockholder of
record&#8217;s notice to the secretary of the Corporation shall set forth: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) As to each Nominating Person, the
Stockholder Information (as defined in Section&nbsp;2.4(c)(i) of these bylaws, except that for purposes of this Section 2.5, the term &#8220;<U>Nominating Person</U>&#8221; shall be substituted for the term &#8220;<U>Proposing Person</U>&#8221; in
all places it appears in Section&nbsp;2.4(c)(i)); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) As to each Nominating Person, any Disclosable Interests (as defined in
Section&nbsp;2.4(c)(ii), except that for purposes of this Section&nbsp;2.5 the term &#8220;<U>Nominating Person</U>&#8221; shall be substituted for the term &#8220;<U>Proposing Person</U>&#8221; in all places it appears in Section&nbsp;2.4(c)(ii)
and the disclosure with respect to the business to be brought before the meeting in Section&nbsp;2.4(c)(ii) shall be made with respect to the election of directors at the meeting); and <I>provided</I> that, in lieu of including the information set
forth in Section&nbsp;2.4(c)(ii)(H), the Nominating Person&#8217;s notice for purposes of this Section&nbsp;2.5 shall include a representation as to whether the Nominating Person intends or is part of a group which intends to deliver a proxy
statement and solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of directors in support of director nominees other than the Corporation&#8217;s nominees in accordance with Rule <FONT
STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) As to each candidate whom a Nominating
Person proposes to nominate for election as a director, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) all information relating to such candidate for nomination
that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section&nbsp;14(a) under the Exchange Act (including
such candidate&#8217;s written consent to being named in a proxy statement and accompanying proxy card relating to the Corporation&#8217;s next meeting of stockholders at which directors are to be elected and to serving as a director for a full term
if elected), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) a description of any direct or indirect material interest in any material contract or agreement, between
or among any Nominating Person, on the one hand, and each candidate for nomination or his or her respective associates or any other participants in such solicitation, on the other hand, including, without limitation, all information that would be
required to be disclosed pursuant to Item 404 under Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> if such Nominating Person were the &#8220;registrant&#8221; for purposes of such rule and the candidate for nomination were a director or
executive officer of such registrant, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) a completed and signed written questionnaire (which questionnaire shall be
provided by the secretary of the Corporation upon written request of any stockholder of record identified by name within five (5)&nbsp;business days of such written request) with respect to the background, qualifications, stock ownership and
independence of such proposed nominee and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) a written representation and agreement (in the form provided by the
secretary of the Corporation upon written request of any stockholder of record identified by name within five (5)&nbsp;business days of such written request) that such candidate for nomination (I)&nbsp;is not and, if elected as a director during his
or her term of office, will not become a party to (x)&nbsp;any agreement, arrangement or understanding (whether oral or in writing) with, and has not given and will not give any commitment or assurance to, any person or entity as to how such
proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a &#8220;<U>Voting Commitment</U>&#8221;) or (y)&nbsp;any Voting Commitment that could limit or interfere with such proposed nominee&#8217;s
ability to comply, if elected as a director of the Corporation, with such proposed nominee&#8217;s fiduciary duties under applicable law, (2)&nbsp;is not, and will not become a party to, any agreement, arrangement or understanding (whether oral or
in writing) with any person or entity other than the Corporation with respect to any direct or indirect compensation or reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein or to the
Corporation, (3)&nbsp;if elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality, stock ownership and trading and other policies and guidelines of the Corporation
applicable to directors and in effect during such person&#8217;s term in office as a director (and, if requested by any candidate for nomination, the secretary of the Corporation shall provide to such candidate for nomination all such policies and
guidelines then in effect), and (4)&nbsp;if elected as a director of the Corporation, intends to serve the entire term until the next meeting at which such candidate would face <FONT STYLE="white-space:nowrap">re-election;</FONT> and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) As to the stockholder of record providing the notice of the nomination proposed to be made at the meeting, (A)&nbsp;a
representation by the stockholder that it is a holder of record of the stock of the Corporation at the time of giving the notice, will be entitled to vote at such meeting and will appear in person or by proxy at the meeting to propose such business
or nomination and (B)&nbsp;a representation by the stockholder of record as to the completeness and accuracy of the information (including all statements, descriptions, representations and certifications) set forth in the stockholder&#8217;s notice.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Section&nbsp;2.5, the term &#8220;<U>Nominating Person</U>&#8221; shall mean (i)&nbsp;the stockholder of record
providing the notice of the nomination proposed to be made at the meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made, (iii)&nbsp;any
participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder of beneficial owners in such solicitation and (iv)&nbsp;any person who is a member of a &#8220;group&#8221; (as such term is used in
<FONT STYLE="white-space:nowrap">Rule&nbsp;13d-5&nbsp;under</FONT> the Exchange Act (or any successor provision)) with such stockholder or beneficial owners. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Board may request that any Nominating Person furnish such additional information as may be reasonably required by the Board. As a
condition to any such nominations being deemed properly brought before a meeting of stockholders, such Nominating Person shall deliver such additional information within five (5)&nbsp;business days after it has been requested by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Board may also require any proposed candidate for nomination as a director to
furnish such other information as may reasonably be requested by the Board in writing prior to the meeting of stockholders at which such candidate&#8217;s nomination is to be acted upon. Without limiting the generality of the foregoing, the Board
may request such other information in order for the Board to determine the eligibility of such candidate for nomination to be an independent director of the Corporation or to comply with the director qualification standards and additional selection
criteria in accordance with the Corporation&#8217;s Corporate Governance Guidelines. As a condition to any such nominations being deemed properly brought before a meeting of stockholders, such other information shall be delivered to the secretary at
the principal executive offices of the Corporation (or any other office specified by the Corporation in any public announcement) not later than five (5)&nbsp;business days after the request by the Board has been delivered to, or mailed and received
by, the Nominating Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) A stockholder of record providing notice of any nomination proposed to be made at a meeting and any
candidate for nomination as a director shall further update and supplement such notice or the materials delivered pursuant to this Section&nbsp;2.5, as applicable, if necessary, so that the information provided or required to be provided in such
notice or by such candidate, as applicable, pursuant to this Section&nbsp;2.5 shall be true and correct as of the record date for determining stockholders entitled to vote at the meeting and as of the date that is ten (10)&nbsp;business days prior
to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to the secretary of the Corporation at the principal executive offices of the Corporation not later than five (5)&nbsp;business days after
the record date for determining stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8)&nbsp;business days prior to the date for the meeting or,
if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as
of ten (10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit
the Corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend
or update any nomination, including by changing or adding nominees, or to submit any new nomination or submit any new proposal, matters, business or resolutions proposed to be brought before a meeting of the stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) No candidate shall be eligible for nomination as a director of the Corporation unless such candidate for nomination and the Nominating
Person seeking to place such candidate&#8217;s name in nomination has complied with this Section&nbsp;2.5, as applicable. If the Board determines that any proposed nomination was not proposed in accordance with this Section&nbsp;2.5, then except as
otherwise required by law, at the meeting of stockholders, the presiding officer shall have the power and duty to declare such nomination was not properly brought before the meeting and in accordance with the provisions of these bylaws, and such
nomination shall be invalid and disregarded notwithstanding that proxies in respect of such vote may have been received by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation. If at any meeting of stockholders, any nomination is proposed to be brought before the meeting from the floor of the meeting, the presiding officer shall have the power and duty to
determine whether the nomination was properly brought before the meeting in accordance with this Section&nbsp;2.4, and if he or she determines that any proposed nomination was not proposed in accordance with this Section&nbsp;2.4, then except as
otherwise required by law, he or she shall so declare to the meeting, and such nomination shall be invalid and disregarded notwithstanding that proxies in respect of such vote may have been received by the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In addition to the requirements of this Section&nbsp;2.5 with respect to any nomination proposed to be made at a meeting, each Nominating
Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations. Notwithstanding the foregoing provisions of this Section&nbsp;2.5, unless otherwise required by law, (i)&nbsp;no Nominating Person shall
solicit proxies in support of director nominees other than the Corporation&#8217;s nominees unless such Nominating Person has complied with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act in connection with the
solicitation of such proxies, including the provision to the Corporation of notices required thereunder in a timely manner and (ii)&nbsp;if any Nominating Person (1)&nbsp;provides notice pursuant to Rule
<FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the Exchange Act and (2)&nbsp;subsequently fails to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(2)</FONT> and Rule
<FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder in a timely manner, or fails to timely provide reasonable evidence sufficient to
satisfy the Corporation that such Nominating Person has met the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act in accordance with the following sentence, then the nomination of each such
proposed nominee shall be disregarded (and such nominee disqualified from standing for election or <FONT STYLE="white-space:nowrap">re-election),</FONT> notwithstanding that the nominee is included as a nominee (as applicable) in the
Corporation&#8217;s proxy statement, notice of meeting or other proxy materials for any annual meeting (or any supplement thereto) and notwithstanding that proxies or votes in respect of the election of such proposed nominees may have been received
by the Corporation (which proxies and votes shall be disregarded). If any Nominating Person provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the Exchange Act, such Nominating Person shall deliver
to the Corporation, no later than seven (7)&nbsp;business days prior to the applicable meeting, reasonable evidence that it has met the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Notwithstanding anything in these bylaws to the contrary, no candidate for nomination shall be eligible to be seated as a director of
the Corporation unless nominated and elected in accordance with this Section&nbsp;2.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 NOTICE OF STOCKHOLDERS&#8217; MEETINGS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by law, the certificate of incorporation or these bylaws, the notice of any meeting of stockholders shall be given in
accordance with either Section&nbsp;2.7 or Section&nbsp;8.1 of these bylaws not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for
determining the stockholders entitled to notice of the meeting. The notice shall specify the place, if any, date and hour of the meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different
from the record date for determining stockholders entitled to notice of the meeting), the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case
of a special meeting, the purpose or purposes for which the meeting is called. Notice shall be deemed given as provided in Section&nbsp;232 of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any meeting of stockholders shall be deemed given: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it
appears on the Corporation&#8217;s records; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if electronically transmitted, as provided in Section&nbsp;8.1 of these bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or any other agent of the Corporation that
the notice has been given by mail or by a form of electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 QUORUM. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
provided by law, the certificate of incorporation or these bylaws, the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or
represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If,
however, a quorum is not present or represented at any meeting of the stockholders, then either (a)&nbsp;the chairperson of the meeting or (b)&nbsp;a majority in voting power of the stockholders entitled to vote thereon, present in person, or by
remote communication, if applicable, or represented by proxy, shall have power to adjourn the meeting from time to time in the manner provided in Section&nbsp;2.9 of these bylaws until a quorum is present or represented. At such adjourned meeting at
which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed. Where a separate vote by a class or classes or series is required, except as required by law or by the
certificate of incorporation or these bylaws, the holders of a majority of the voting power of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy, shall
constitute a quorum entitled to take action with respect to that vote on that matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 ADJOURNED MEETING; NOTICE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any meeting of stockholders may be adjourned from time to time, by the presiding person of the meeting, whether or not a quorum is present or
represented by proxy. When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any,
by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken or are provided in any other manner permitted by the DGCL. At the
adjourned meeting, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days, or if after the adjournment a new
record date for determining the stockholders entitled to vote is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the adjourned meeting as of the record date for
determining the stockholders entitled to notice of the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 CONDUCT OF BUSINESS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be
announced at the meeting by the person presiding over the meeting. After the polls close, no ballots, proxies or votes or any revocations or changes thereto shall be accepted. The Board may adopt by resolution such rules, regulations and procedures
for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and
authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing) and to do all such acts as, in the judgment of such presiding person, are
appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the presiding person of the meeting, may include, without limitation, the following: (a)&nbsp;the establishment
of an agenda or order of business for the meeting; (b)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules and procedures for removal of disruptive persons from the
meeting); (c) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as the presiding person of the meeting shall determine;
(d)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; (e)&nbsp;limitations on the time allotted to questions or comments by participants; and (f)&nbsp;restrictions on the use of cell phones, audio or video
recording devices and other devices at the meeting. The presiding person at any meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including, without limitation,
determinations with respect to the administration and/or interpretation of any of the rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person presiding over the meeting), shall, if the facts warrant,
determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not
properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the
rules of parliamentary procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 VOTING. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section&nbsp;2.13 of
these bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be otherwise provided in the certificate of incorporation, these bylaws or in
a preferred stock designation, each stockholder shall be entitled to one (1)&nbsp;vote for each share of capital stock held by such stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights, if any, of any series of preferred stock to elect additional directors under circumstances specified in a preferred
stock designation, at all duly called or convened meetings of stockholders, at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. All other elections and questions
presented to the stockholders at a duly called or convened meeting, at which a quorum is present, shall, unless a different or minimum vote is required by the certificate of incorporation, these bylaws, the rules or regulations of any stock exchange
applicable to the Corporation, or any law or regulation applicable to the Corporation or its securities, in which case such different or minimum vote shall be the applicable vote on the matter, be decided by the affirmative vote of the holders of a
majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting
of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 RECORD DATE FOR
STOCKHOLDER NOTICE; VOTING. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders
or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall, unless otherwise required by law, not be
more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board
determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled
to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the
meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided</I>, <I>however</I>, that the Board may fix a new record date for
determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of
stockholders entitled to vote in accordance herewith at the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Corporation may determine the
stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action,
the Board may fix a record date, which shall not be more than sixty (60)&nbsp;days prior to such action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day
on which the Board adopts the resolution relating thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14 PROXIES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy
authorized by an instrument in writing or by a transmission permitted by law, including Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Securities Exchange Act of 1934, as amended, filed in accordance with the procedure
established for the meeting, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be
governed by the provisions of Section&nbsp;212 of the DGCL. A proxy may be in the form of an electronic transmission which sets forth or is submitted with information from which it can be determined that the electronic transmission was authorized by
the stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than
white, which shall be reserved for the exclusive use by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15 LIST OF STOCKHOLDERS ENTITLED TO VOTE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the record date for the meeting of stockholders has been fixed, the Corporation shall prepare, no later than the tenth (10th) day before
such meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting (<I>provided</I>, <I>however</I>, if the record date for determining the stockholders entitled to vote is less than ten (10)&nbsp;days before the date
of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the date of the meeting), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in
the name of each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to
the meeting for a period of ten (10)&nbsp;days ending on the day before the meeting date: (a)&nbsp;on a reasonably accessible electronic network, <I>provided</I> that the information required to gain access to such list is provided with the notice
of the meeting, or (b)&nbsp;during ordinary business hours, at the Corporation&#8217;s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable
steps to ensure that such information is available only to stockholders of the Corporation. Except as otherwise provided by law, the stock ledger shall be the only evidence as to the identity of the stockholders entitled to vote in person or by
proxy and the number of shares held by each of them, and as to the stockholders entitled to examine the list of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.16
POSTPONEMENT, ADJOURNMENT AND CANCELLATION OF MEETING. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any previously scheduled annual or special meeting of the stockholders may be
postponed or adjourned, and any previously scheduled annual or special meeting of the stockholders may be canceled, by resolution of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.17 INSPECTORS OF ELECTION. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before any meeting of stockholders, the Board shall appoint an inspector or inspectors of election, who may be employees of the Corporation, to
act at the meeting or its adjournment or postponement and make a written report thereof. The number of inspectors shall be either one (1)&nbsp;or three (3). If any person appointed as inspector fails to appear or fails or refuses to act, then the
chairperson of the meeting may, and upon the request of any stockholder or a stockholder&#8217;s proxy shall, appoint a person to fill that vacancy. Unless otherwise required by law, inspectors may be officers, employees or agents of the
Corporation. Such inspectors shall have the duties prescribed by law. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath to execute faithfully the duties of inspector with strict impartiality and
according to the best of his or her ability. If there are three (3)&nbsp;inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all. Any report or certificate made
by the inspectors of election is prima facie evidence of the facts stated therein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III - DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 POWERS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
provisions of the DGCL and any limitations in the certificate of incorporation, the business and affairs of the Corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 NUMBER OF DIRECTORS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
authorized number of directors shall be determined from time to time exclusively by resolution of the Board, provided the Board shall consist of at least one (1)&nbsp;member. No reduction of the authorized number of directors shall have the effect
of removing any director before that director&#8217;s term of office expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 ELECTION, QUALIFICATION AND TERM OF OFFICE OF
DIRECTORS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;3.4 of these bylaws, each director, including, without limitation, a director elected to
fill a vacancy, shall hold office until the expiration of the term for which elected and until such director&#8217;s successor is elected and qualified or until such director&#8217;s earlier death, resignation or removal. Directors need not be
stockholders unless so required by the certificate of incorporation or these bylaws. The Corporation may also have, at the discretion of the Board, a chairperson of the Board and a vice chairperson of the Board. The certificate of incorporation or
these bylaws may prescribe other qualifications for directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 RESIGNATION AND VACANCIES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice given in writing or by electronic transmission to the chairperson of the Board or the
Corporation&#8217;s chief executive officer, president or secretary. When one or more directors so resigns and the resignation is effective at a future date, a majority of the directors then in office, including those who have so resigned, shall
have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this section in the filling of other vacancies.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation or these bylaws, vacancies and
newly created directorships resulting from any increase in the authorized number of directors shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by
a majority of the directors then in office, although less than a quorum, or by a sole remaining director. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which
the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified. A vacancy in the Board shall be deemed to exist under these bylaws in the case of the death, removal or resignation of any director.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 PLACE OF MEETINGS; MEETINGS BY TELEPHONE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may hold meetings, both regular and special, either within or outside the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board, or any committee designated by the
Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a
meeting pursuant to this bylaw shall constitute presence in person at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 REGULAR MEETINGS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board;
<I>provided</I> that any director who is absent when such determination is made shall be given notice of the determination. A regular meeting of the Board may be held without notice immediately after and at the same place as the annual meeting of
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 SPECIAL MEETINGS; NOTICE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board for any purpose or purposes may be called at any time by the chairperson of the Board, the chief executive
officer, the president, the secretary or a majority of the authorized number of directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of the time and place of special
meetings shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) delivered personally by hand, by courier or by telephone; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) sent by United States first-class mail, postage prepaid; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) sent by facsimile; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
sent by electronic mail, electronic transmission or other similar means, directed to each director at that director&#8217;s address, telephone number, facsimile number or electronic mail or other electronic address, as the case may be, as shown on
the Corporation&#8217;s records. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the notice is (a)&nbsp;delivered personally by hand, by courier or by telephone,
(b)&nbsp;sent by facsimile or (c)&nbsp;sent by electronic mail or electronic transmission, it shall be delivered or sent at least twenty-four (24)&nbsp;hours before the time of the holding of the meeting. If the notice is sent by United States mail,
it shall be deposited in the United States mail at least four (4)&nbsp;days before the time of the holding of the meeting. Any oral notice may be communicated to the director. The notice need not specify the place of the meeting (if the meeting is
to be held at the Corporation&#8217;s principal executive office) nor the purpose of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8 QUORUM. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by the DGCL, the certificate of incorporation or these bylaws, a quorum of the Board for the transaction of
business shall consist of a majority of the authorized numbers of directors fixed from time to time by the Board in accordance with the certificate of incorporation. The vote of a majority of the directors present at any meeting at which a quorum is
present shall be the act of the Board, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws. If a quorum is not present at any meeting of the Board, then the directors present thereat may
adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9 BOARD ACTION
BY CONSENT WITHOUT A MEETING. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or
permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or
writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form or shall be in electronic form if the minutes
are maintained in electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10 FEES AND COMPENSATION OF DIRECTORS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board, or any duly authorized committee thereof, shall
have the authority to fix the compensation, including fees and reimbursement of expenses, of directors for services to the Corporation in any capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11 REMOVAL OF DIRECTORS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of the shares of any series of preferred stock of the Corporation, the Board or any individual director
may be removed from office only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock of the Corporation entitled to vote
thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV - COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 COMMITTEES OF DIRECTORS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, from time to time, appoint such committees as may be permitted by applicable law. Such committees appointed by the Board shall
consist of one (1)&nbsp;or more of the directors of the Corporation. The Board may designate one (1)&nbsp;or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In
the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of
the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the
Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to (a)&nbsp;approve or
adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (b)&nbsp;adopt, amend or repeal any bylaw of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 COMMITTEE MINUTES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each committee shall keep regular minutes of its meetings and report the same to the Board when required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 MEETINGS AND ACTION OF COMMITTEES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.5 of these bylaws (place of meetings and meetings by telephone); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Section 3.6 of these bylaws (regular meetings); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Section 3.7 of these bylaws (special meetings and notice); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Section 3.8 of these bylaws (quorum); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Section 7.12 of these bylaws (waiver of notice); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Section 3.9 of these bylaws (action without a meeting), with such changes in the context of those bylaws as are necessary to substitute the
committee and its members for the Board and its members. However: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the time of regular meetings of committees may be
determined either by resolution of the Board or by resolution of the committee; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) special meetings of committees may
also be called by resolution of the Board; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) notice of special meetings of committees shall also be given to all
alternate members, who shall have the right to attend all meetings of the committee. The Board may adopt rules for the governance of any committee not inconsistent with the provisions (or any part thereof) of these bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V - OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 OFFICERS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of
the Corporation shall be a president and a secretary. The Corporation may also have, at the discretion of the Board, a chief executive officer, a chief financial officer or treasurer, one (1)&nbsp;or more vice presidents, one (1)&nbsp;or more
assistant vice presidents, one (1)&nbsp;or more assistant treasurers, one (1)&nbsp;or more assistant secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. The Board may assign such additional
titles to one or more of the officers as it shall deem appropriate. Any number of offices may be held by the same person unless specifically prohibited by applicable law, the certificate of incorporation or these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 APPOINTMENT OF OFFICERS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall appoint the officers of the Corporation, except such officers as may be appointed in accordance with the provisions of
Section&nbsp;5.3 of these bylaws, subject to the rights, if any, of an officer under any contract of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 SUBORDINATE
OFFICERS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may appoint, or empower the chief executive officer or, in the absence of a chief executive officer, the president, to
appoint, such other officers and agents as the business of the Corporation may require. Each of such officers shall hold office for such period, as is provided in these bylaws or as the Board may from time to time determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 REMOVAL AND RESIGNATION OF OFFICERS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may be removed, either with or without cause, by the Board at any regular or special meeting of the Board or, except in the case of
an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may resign at
any time by giving notice in writing or by electronic transmission to the Board, the chairperson of the Board, the chief executive officer, the president or the secretary. Any such resignation shall be effective when received by the person or
persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be
necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the Corporation under any contract with the resigning officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 VACANCIES IN OFFICES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
vacancy occurring in any office of the Corporation shall be filled by the Board or as provided in Section&nbsp;5.3 of these bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 REPRESENTATION OF SHARES OF OTHER ENTITIES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board, the president, any vice president, the treasurer, the secretary or assistant secretary of this Corporation, or
any other person authorized by the Board or the president or a vice president, is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all securities of any other entity or entities standing in the
name of this Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 AUTHORITY AND DUTIES OF OFFICERS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All officers of the Corporation shall respectively have such authority and perform such duties in the management of the business of the
Corporation as may be designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI - RECORDS AND REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 MAINTENANCE OF RECORDS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law, the Corporation shall, either at its principal executive office or at such place or places as designated by the
Board, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder, a copy of these bylaws as amended to date, accounting books and other records. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII - GENERAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract
or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board or within the agency power of an officer, no officer, agent or
employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 STOCK CERTIFICATES; PARTLY PAID SHARES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of the Corporation shall be represented by certificates <I>provided</I> that the Board may determine that some or all of any or all
classes or series of stock shall be uncertificated shares. Certificates for the shares of stock, if any, shall be in such form as is consistent with the certificate of incorporation and applicable law. Every holder of stock represented by a
certificate shall be entitled to have a certificate signed by, or in the name of the Corporation by any two authorized officers of the Corporation representing the number of shares registered in certificate form. Any or all of the signatures on the
certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is
issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may issue the whole or any part of its shares as partly paid and subject to
call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Corporation in the case of uncertificated partly
paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid shares of the
same class, but only upon the basis of the percentage of the consideration actually paid thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 MULTIPLES CLASSES OR SERIES OF
STOCK. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the
designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full
or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; <I>provided</I>, <I>however</I>, that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the
foregoing requirements, there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock a statement that the Corporation will furnish without charge to each stockholder who so
requests the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
Within a reasonable time after the issuance or transfer of uncertificated stock, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to
the DGCL or a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof
and the qualifications, limitations or restrictions of such preferences and/or rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 LOST CERTIFICATES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in this Section&nbsp;7.4, no new certificates for shares shall be issued to replace a previously issued certificate unless
the latter is surrendered to the Corporation in accordance with applicable law. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen
or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The Corporation may require, as a condition precedent to the issuance of a new certificate or certificates,
the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#8217;s legal representative, to give the Corporation a bond (or other adequate security) sufficient to indemnify the Corporation against any claim that may be
made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed or the issuance of such new certificate(s) or uncertificated shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 CONSTRUCTION; DEFINITIONS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction
of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term &#8220;person&#8221; includes both a corporation and a natural person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 DIVIDENDS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board,
subject to any restrictions contained in either (a)&nbsp;the DGCL or (b)&nbsp;the certificate of incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of the
Corporation&#8217;s capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may set apart out of any of the funds of the Corporation available for dividends a reserve or
reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 FISCAL YEAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal
year of the Corporation shall be fixed by resolution of the Board and may be changed by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 SEAL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the corporate
seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9 TRANSFER OF STOCK. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of the Corporation shall be transferable in the manner prescribed by law and in these bylaws. Shares of stock of the Corporation shall
be transferred on the books of the Corporation only by the holder of record thereof or by such holder&#8217;s attorney duly authorized in writing, upon surrender to the Corporation of the certificate or certificates representing such shares endorsed
by the appropriate person or persons (or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement or execution, transfer, authorization and other matters as the
Corporation may reasonably require, and accompanied by all necessary stock transfer stamps. To the fullest extent permitted by law, no transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in
the stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10 STOCK
TRANSFER AGREEMENTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one
or more classes or series of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes or series owned by such stockholders in any manner not prohibited by the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 REGISTERED STOCKHOLDERS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation, to the fullest extent permitted by law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to
vote as such owner; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of
shares; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another
person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12 WAIVER
OF NOTICE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a
written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice.
Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the
meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission
unless so required by the certificate of incorporation or these bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 NOTICE BY ELECTRONIC TRANSMISSION. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the certificate of
incorporation or these bylaws, any notice to stockholders given by the Corporation under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the
stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Corporation is unable to deliver by electronic transmission two (2)&nbsp;consecutive notices given by the Corporation in accordance
with such consent; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) such inability becomes known to the secretary or an assistant secretary of the Corporation or to the transfer
agent, or other person responsible for the giving of notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the inadvertent failure to treat such inability as a revocation shall not
invalidate any meeting or other action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice given pursuant to the preceding paragraph shall be deemed given: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of
(i)&nbsp;such posting and (ii)&nbsp;the giving of such separate notice; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) if by any other form of electronic transmission, when
directed to the stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or other
agent of the Corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 DEFINITION OF ELECTRONIC TRANSMISSION. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of these bylaws, an &#8220;electronic transmission&#8221; means any form of communication, not directly involving the physical
transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX - INDEMNIFICATION AND ADVANCEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 ACTIONS, SUITS AND PROCEEDINGS OTHER THAN BY OR IN THE RIGHT OF THE CORPORATION. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the
Corporation, or, while a director or officer of the Corporation, is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) (all such persons being referred to hereafter as an &#8220;<U>Indemnitee</U>&#8221;), or by reason of any action alleged to
have been taken or omitted in such capacity, against all expenses (including, without limitation, attorneys&#8217; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee
Retirement Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and
in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The
termination of any action, suit or proceeding by judgment, order, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 ACTIONS OR SUITS BY OR IN THE RIGHT OF THE CORPORATION. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of the Corporation, or, while a director or officer of
the Corporation, is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other
enterprise (including, without limitation, any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including, without limitation, attorneys&#8217; fees) actually and
reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the
best interests of the Corporation, except that no indemnification shall be made under this Section&nbsp;9.2 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to
the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of such liability but in view of all the circumstances of the case, Indemnitee
is fairly and reasonably entitled to indemnity for such expenses (including, without limitation, attorneys&#8217; fees) which the Court of Chancery of Delaware or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 INDEMNIFICATION FOR EXPENSES OF SUCCESSFUL PARTY. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of this Article IX, to the extent that an Indemnitee has been successful, on the merits or otherwise, in
defense of any action, suit or proceeding referred to in Sections 9.1 and 9.2 of these bylaws, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding, Indemnitee shall be indemnified to the fullest
extent permitted by law against all expenses (including, without limitation, attorneys&#8217; fees) actually and reasonably incurred by or on behalf of Indemnitee in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 NOTIFICATION AND DEFENSE OF CLAIM. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition precedent to an Indemnitee&#8217;s right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as
practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the
Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election
so to assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with such action, suit, proceeding or investigation, other than as provided below in this Section&nbsp;9.4. Indemnitee shall have the right to employ his or her own counsel in
connection with such action, suit, proceeding or investigation, but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless (a)&nbsp;the
employment of counsel by Indemnitee has been authorized by the Corporation, (b)&nbsp;counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant issue between the Corporation and
Indemnitee in the conduct of the defense of such action, suit, proceeding or investigation or (c)&nbsp;the Corporation shall not in fact have employed counsel to assume the defense of such action, suit, proceeding or investigation, in each of which
cases the fees and expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Article IX. The Corporation shall not be entitled, without the consent of Indemnitee, to assume the
defense of any claim brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (b)&nbsp;above. The Corporation shall not be required to indemnify Indemnitee
under this Article IX for any amounts paid in settlement of any action, suit, proceeding or investigation effected without its written consent. The Corporation shall not settle any action, suit, proceeding or investigation in any manner which would
impose any penalty or limitation on Indemnitee without Indemnitee&#8217;s written consent. Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 ADVANCE OF EXPENSES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Sections 9.4 and 9.6 of these bylaws, in the event of any threatened or pending action, suit, proceeding or
investigation of which the Corporation receives notice under this Article IX, any expenses (including, without limitation, attorneys&#8217; fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any
appeal therefrom shall be paid by the Corporation in advance of the final disposition of such matter to the fullest extent permitted by law; <I>provided</I>, <I>however</I>, that, to the extent required by law, the payment of such expenses incurred
by or on behalf of Indemnitee in advance of the final disposition of such matter shall be made only upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by
final judicial decision from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article IX or otherwise; and provided further that no such advancement of expenses
shall be made under this Article IX if it is determined (in the manner described in Section&nbsp;9.6 of these bylaws) that (a)&nbsp;Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the
best interests of the Corporation, or (b)&nbsp;with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking shall be accepted without reference to the financial
ability of Indemnitee to make such repayment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 PROCEDURE FOR INDEMNIFICATION AND ADVANCEMENT OF EXPENSES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain indemnification or advancement of expenses pursuant to Section&nbsp;9.1, 9.2, 9.3 or 9.5 of these bylaws, an Indemnitee
shall submit to the Corporation a written request. Any such advancement of expenses shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless (a)&nbsp;the Corporation has
assumed the defense pursuant to Section&nbsp;9.4 of these bylaws (and none of the circumstances described in Section&nbsp;9.4 of these bylaws that would nonetheless entitle the Indemnitee to indemnification for the fees and expenses of separate
counsel have occurred) or (b)&nbsp;the Corporation determines within such <FONT STYLE="white-space:nowrap">60-day</FONT> period that Indemnitee did not meet the applicable standard of conduct set forth in Section&nbsp;9.1, 9.2 or 9.5 of these
bylaws, as the case may be. Any such indemnification, unless ordered by a court, shall be made with respect to requests under Section&nbsp;9.1 or 9.2 of these bylaws only as authorized in the specific case upon a determination by the Corporation
that the indemnification of Indemnitee is proper because Indemnitee has met the applicable standard of conduct set forth in Section&nbsp;9.1 or 9.2 of these bylaws, as the case may be. Such determination shall be made in each instance (a)&nbsp;by a
majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the action, suit or proceeding in question (&#8220;disinterested directors&#8221;), whether or not a quorum, (b)&nbsp;by a committee of
disinterested directors designated by majority vote of disinterested directors, whether or not a quorum, (c)&nbsp;if there are no disinterested directors, or if the disinterested directors so direct, by independent legal counsel (who may, to the
extent permitted by law, be regular legal counsel to the Corporation) in a written opinion or (d)&nbsp;by the stockholders of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 REMEDIES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest
extent permitted by law, the right to indemnification or advancement of expenses as granted by this Article IX shall be enforceable by Indemnitee in any court of competent jurisdiction. Neither the failure of the Corporation to have made a
determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Corporation pursuant to Section&nbsp;9.6 of
these bylaws that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. In any suit brought by Indemnitee to enforce a
right to indemnification or advancement, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified,
or to such advancement of expenses, under this Article IX. Indemnitee&#8217;s expenses (including, without limitation, attorneys&#8217; fees) reasonably incurred in connection with successfully establishing Indemnitee&#8217;s right to
indemnification or advancement, in whole or in part, in any such proceeding shall also be indemnified by the Corporation to the fullest extent permitted by law. Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to
indemnification hereunder it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 LIMITATIONS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Article IX, except as set forth in Section&nbsp;9.7 of these bylaws, the Corporation shall not
indemnify an Indemnitee pursuant to this Article IX in connection with a proceeding (or part thereof) initiated by such Indemnitee unless the initiation thereof was approved by the Board. Notwithstanding anything to the contrary in this Article IX,
the Corporation shall not indemnify (or advance expenses to) an Indemnitee to the extent such Indemnitee is reimbursed (or advanced expenses) from the proceeds of insurance, and in the event the Corporation makes any indemnification (or advancement)
payments to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification (or advancement) payments to the Corporation to the extent of such insurance
reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9 SUBSEQUENT AMENDMENT. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amendment, termination or repeal of this Article IX or of the relevant provisions of the DGCL or any other applicable laws shall adversely
affect or diminish in any way the rights of any Indemnitee to indemnification or advancement of expenses under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to any actions,
transactions or facts occurring prior to the final adoption of such amendment, termination or repeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.10 OTHER RIGHTS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by this Article IX shall not be deemed exclusive of any other rights to which an
Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee&#8217;s official capacity
and as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of
Indemnitee. Nothing contained in this Article IX shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with officers and directors providing indemnification and advancement rights and procedures
different from those set forth in this Article IX. In addition, the Corporation may, to the extent authorized from time to time by the Board, grant indemnification and advancement rights to other employees or agents of the Corporation or other
persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article IX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.11
PARTIAL INDEMNIFICATION. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Indemnitee is entitled under any provision of this Article IX to indemnification by the Corporation for some or a portion
of the expenses (including, without limitation, attorneys&#8217; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended)
or amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation
shall nevertheless indemnify Indemnitee for the portion of such expenses (including, without limitation, attorneys&#8217; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the
Employee Retirement Income Security Act of 1974, as amended) or amounts paid in settlement to which Indemnitee is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.12
INSURANCE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or
agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) against any expense, liability or loss incurred by him or her in any such capacity, or
arising out of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.13 SAVINGS CLAUSE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Article IX or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall
nevertheless indemnify each Indemnitee as to any expenses (including, without limitation, attorneys&#8217; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement
Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the
Corporation, to the fullest extent permitted by any applicable portion of this Article IX that shall not have been invalidated and to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.14 DEFINITIONS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terms used in
this Article IX and defined in Section&nbsp;145(h) and Section&nbsp;145(i) of the DGCL shall have the respective meanings assigned to such terms in such Section&nbsp;145(h) and Section&nbsp;145(i). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X - AMENDMENTS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations set forth in Section&nbsp;9.9 of these bylaws or the provisions of the certificate of incorporation, the Board is
expressly empowered to adopt, amend or repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of the Corporation; <I>provided</I>, <I>however</I>, that, in addition to any vote of the
holders of any class or series of stock of the Corporation required by applicable law or by the certificate of incorporation, such action by stockholders shall require the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote thereon, voting together as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>d42675dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g42675dsp008.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp002.jpg" ALT="LOGO">
 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>5
<FILENAME>d42675dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATRIUM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 INCENTIVE AWARD PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAKE WHOLE RESTRICTED STOCK UNIT GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Make Whole Restricted Stock Unit Grant Notice (the &#8220;<B><I>Grant
Notice</I></B>&#8221;) have the meanings given to them in the 2026 Incentive Award Plan (as amended from time to time, the &#8220;<B><I>Plan</I></B>&#8221;) of Atrium Therapeutics, Inc. (the &#8220;<B><I>Company</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the participant listed below (&#8220;<B><I>Participant</I></B>&#8221;) the Make Whole Restricted Stock Units
described in this Grant Notice (the &#8220;<B><I>Make Whole RSUs</I></B>&#8221;), subject to the terms and conditions of the Plan and the Make Whole Restricted Stock Unit Agreement attached hereto as Exhibit A (the
&#8220;<B><I>Agreement</I></B>&#8221;), both of which are incorporated into this Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Make Whole RSUs:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">All Make Whole RSUs are fully vested as of the Grant Date.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company uses an electronic capitalization table system (such as E*Trade, Shareworks or Carta) and
the fields in this Grant Notice are blank or the information is otherwise provided in a different format electronically, the blank fields and other information will be deemed to come from the electronic capitalization system and is considered part
of this Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By electronically accepting this document, Participant agrees to be bound by the terms and conditions of the Plan,
the Agreement and this Grant Notice. Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all
provisions of this Grant Notice, the Agreement and the Plan. Participant has been provided with a copy or electronic access to a copy of the prospectus for the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions
or interpretations of the Administrator upon any questions arising under the Plan or relating to the Make Whole RSUs. Furthermore, by approving the Agreement and this Grant Notice, the Board hereby approves that this Award is approved under the
Company&#8217;s insider trading policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mandatory
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Sell-to-Cover</FONT></FONT></B>: By accepting this Award, Participant understands and agrees that as a condition of the grant of the Make Whole RSUs, Participant is required to
(1)&nbsp;sell that number of Shares determined in accordance with Section&nbsp;3.1 of the Agreement as may be necessary to satisfy all applicable Tax Withholding Obligations (as defined in the Agreement), and (2)&nbsp;to allow the brokerage firm
determined acceptable to the Company to pay the cash proceeds of such sale(s) to the Company to satisfy such Tax Withholding Obligations. Furthermore, Participant acknowledges that the Company will make a cash payment equal to the Tax Withholding
Obligations from the cash proceeds of such sale(s) directly to the appropriate taxing authorities. Participant agrees that he or she has carefully reviewed Section&nbsp;3.1 of the Agreement and that the representations and warranties set forth
therein are accurate and true as of the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Internet Availability of Plan Materials</B>: The Company will furnish Plan materials
(including the Plan, prospectus, annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and proxy statement and other information provided to the Company&#8217;s stockholders) relating to the Plan to Participant electronically, instead
of mailing printed copies of these materials to each person eligible to participate in the plans. This process is designed to expedite Participant&#8217;s receipt of the plan materials, reduce the costs of printing and distributing these materials,
and help conserve natural resources. These materials are available through the Company&#8217;s electronic capitalization table system (such as E*Trade, Shareworks or Carta) and the annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
and proxy statement and other information provided to our stockholders is also available on the Company&#8217;s website at www.atriumtherapeutics.com. The Plan is available through the Company&#8217;s electronic capitalization table system (such as
E*Trade, Shareworks or Carta). However, if Participant would prefer to receive printed copies of the Plan materials or information provided to the Company&#8217;s stockholders without charge, please contact: Atrium Therapeutics, Inc., Attn: Stock
Administration, 10578 Science Center Drive, Suite 125, San Diego, CA 92121, Telephone: (619) <FONT STYLE="white-space:nowrap">876-0700.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAKE WHOLE RESTRICTED STOCK UNIT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&#8195;Award
of Make Whole RSUs. The Company has granted the Make Whole RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<B><I>Grant Date</I></B>&#8221;). Each Make Whole RSU represents the right to receive one Share,
as set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&#8195;Incorporation of Terms of Plan. The Make Whole RSUs are subject to the terms and conditions set
forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3&#8195;Unsecured Promise. The Make Whole RSUs will at all times prior to settlement represent an unsecured Company obligation payable only
from the Company&#8217;s general assets. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VESTING; FORFEITURE AND SETTLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&#8195;Vesting. The Make Whole RSUs will vest according to the vesting schedule in the Grant Notice (the &#8220;<B><I>Vesting
Schedule</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&#8195;Settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Make Whole RSUs will be paid in Shares as soon as administratively practicable after the Distribution Effective
Time, but in no event after March&nbsp;15, 2027. For purposes of this Agreement, &#8220;<B><I>Distribution Effective Time</I></B>&#8221; means the effective time of the Distribution. In the event that the Distribution does not occur by
December&nbsp;31, 2026 or is abandoned or cancelled, the Make Whole RSUs will immediately and automatically be cancelled and forfeited upon the earlier of: (i)&nbsp;December&nbsp;31, 2026 and (ii)&nbsp;the date of such abandonment or cancellation.
Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not
cause such a violation (in accordance with Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(7)(ii)),</FONT> provided the Company reasonably believes the delay will not result in the imposition of excise taxes under
Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;All distributions shall be made by the Company in the form of whole shares of Common Stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAXATION AND TAX WITHHOLDING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&#8195;Tax Withholding; Mandatory <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Sell-to-Cover.</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the Make
Whole RSUs to Participant or his or her legal representative unless and until Participant or his or her legal representative will have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes required by
Applicable Law to be withheld in connection with the vesting or settlement of the Make Whole RSUs, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the Make Whole RSUs (the &#8220;<B><I>Tax
Withholding Obligation</I></B>&#8221;). Subject to Section&nbsp;9.5 of the Plan, the Company will have the authority and the right to deduct or withhold, or require Participant to remit to the Company, an amount sufficient to satisfy any Tax
Withholding Obligation, including, without limitation, the authority to deduct such amounts from other compensation payable to Participant by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195; (b)&nbsp;(i) Notwithstanding anything to the contrary contained in the Plan or this Section&nbsp;3.1, the Tax
Withholding Obligation shall automatically, and without further action by Participant, be satisfied by having the Company withhold taxes from the proceeds of the sale of the Shares through a mandatory sale arranged by the Company on
Participant&#8217;s behalf. In the event Participant&#8217;s Tax Withholding Obligation will be satisfied under this Section&nbsp;3.1(b), then the Company shall instruct any brokerage firm determined acceptable to the Company for such purpose to
sell on Participant&#8217;s behalf a whole number of Shares, at the then-prevailing market price, from those Shares issuable to Participant upon settlement of the Make Whole RSUs as is required to generate cash proceeds sufficient to satisfy
Participant&#8217;s Tax Withholding Obligation (with such Tax Withholding Obligation to be calculated based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes as of the date of
delivery). Such sale shall occur on the date on which Participant first becomes subject to the Tax Withholding Obligation (or as soon as practicable thereafter) and proceeds from each such sale will be made to the Company as soon as reasonably
practicable upon settlement thereof. Participant hereby acknowledges that the broker is under no obligation to arrange for such sale at any particular price, and the proceeds of any such sale pursuant to this provision may not be sufficient to
satisfy the Tax Withholding Obligation. Participant hereby appoints the Company as Participant&#8217;s agent and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to cooperate and communicate with the
broker and to instruct the broker with respect to the number of Shares to be sold under this provision. Participant acknowledges that it may not be possible to sell Shares pursuant to this provision due to (A)&nbsp;a legal or contractual restriction
applicable to Participant or to the broker, (B)&nbsp;a market disruption, (C)&nbsp;rules governing order execution priority on the stock exchange on which the Shares are traded, (D)&nbsp;a sale effected pursuant to this provision that fails to
comply (or in the reasonable opinion of the broker&#8217;s counsel is likely not to comply) with Rule 144 under the Securities Act or would result in a short-swing profit under Section&nbsp;16 of the Exchange Act, or (E)&nbsp;the Company&#8217;s
determination that sales may not be effected under this provision. In the event of the broker&#8217;s inability to sell Shares, Participant will continue to be responsible for the timely payment to the Company and/or its affiliates of the Tax
Withholding Obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Participant represents that (A)&nbsp;Participant shall have full
responsibility for compliance with (1)&nbsp;any reporting requirements under Rule 144 of the Securities Act and Section&nbsp;13 or 16 of the Exchange Act, (2)&nbsp;the short-swing profit recovery provisions under Section&nbsp;16 of the Exchange Act,
and (3)&nbsp;any federal, state or foreign securities laws or regulations concerning trading while aware of material nonpublic information; and (B)&nbsp;Participant is not subject to any legal, regulatory or contractual restriction or undertaking
that would prevent the broker from conducting the sales pursuant to this provision and shall immediately notify the Company if he or she becomes subject to a legal, regulatory or contractual restriction or undertaking that would prevent the broker
from making such sales pursuant to this provision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Participant acknowledges that: (A)&nbsp;Participant will be
responsible for all broker&#8217;s fees and other costs of sales pursuant to this Section&nbsp;3.1(b), and Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sales or for
any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond the broker&#8217;s or the Company&#8217;s reasonable control; (B)&nbsp;sales pursuant to this Section&nbsp;3.1(b) will be made as part of
a block trade with other participants of the Plan in which all participants receive an average price; and (C)&nbsp;if the proceeds of a sale pursuant to this Section&nbsp;3.1(b) exceed the amount owed, the Company will pay such excess in cash to
Participant as soon as reasonably practicable. Participant hereby agrees to execute and deliver to the broker any other agreements or documents as the broker reasonably deems necessary or appropriate to carry out the purposes and intent of this
Section&nbsp;3.1(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;To the extent that the Tax Withholding Obligation is not fully satisfied pursuant to
Section&nbsp;3.1(b) or Section&nbsp;3.1(b) does not apply, as set forth in Section&nbsp;9.5 of the Plan, the Company will have the right, but not the obligation, with respect to the Tax Withholding Obligation arising as a result of the vesting,
exercise or settlement of the Make Whole RSUs, to treat Participant&#8217;s failure to provide timely payment in accordance with Section&nbsp;9.5 of the Plan as Participant&#8217;s election to satisfy the Tax Withholding Obligation by requesting the
Company to withhold a net number of vested Shares otherwise issuable pursuant to the Make Whole RSUs having a then-current fair market value not exceeding the amount necessary to satisfy the Tax Withholding Obligation (with such Tax Withholding
Obligation to be calculated based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes as of the date of delivery) (provided, however, that if Participant is subject to Section&nbsp;16
of the Exchange Act at the time the Tax Withholding Obligation arises, any such action by the Company will require the prior approval of the Administrator) in accordance with Section&nbsp;9.5 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&#8195;Participant Responsibility; No Company Liability. Participant acknowledges that Participant is ultimately liable and responsible for
all taxes owed in connection with the Make Whole RSUs, regardless of any action the Company or any Subsidiary takes with respect to any Tax Withholding Obligations that arise in connection with the Make Whole RSUs. Neither the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company nor any Subsidiary makes any representation or undertaking regarding the tax treatment to Participant in connection with the awarding, vesting or settlement of the Make Whole RSUs or the
subsequent sale of Shares. The Company and its Subsidiaries do not commit and are under no obligation to structure the Make Whole RSUs to reduce or eliminate Participant&#8217;s tax liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&#8195;Representation. Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the
tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&#8195;Award Not Transferable; Other Restrictions. Without limiting the generality of any other provision hereof, the
Award will be subject to the restrictions on transferability set forth in Section&nbsp;9.1 of the Plan. Without limiting the generality of any other provision hereof, Participant hereby expressly acknowledges that Section&nbsp;10.8 (&#8220;<B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#8221;) and Section&nbsp;10.13 (&#8220;<B><I>Claw-back Provisions</I></B>&#8221;) of the Plan are expressly incorporated into this Agreement and are applicable to the Shares issued pursuant to
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&#8195;Adjustments. Participant acknowledges that the Make Whole RSUs and the Shares subject to the Make Whole RSUs
are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&#8195;Notices.
Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email
address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the
Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when
sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company
or upon receipt of a facsimile transmission confirmation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&#8195;Titles. Titles are provided herein for convenience only and are not
to serve as a basis for interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5&#8195;Conformity to Securities Laws. Participant
acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such
Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6&#8195;Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple
assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs,
legatees, legal representatives, successors and assigns of the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7&#8195;Limitations Applicable to Section&nbsp;16 Persons. Notwithstanding any other
provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Make Whole RSUs will be subject to any additional limitations set forth in any applicable
exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to Rule <FONT STYLE="white-space:nowrap">16b-3)</FONT> that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this
Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8&#8195;Entire Agreement. The Plan, the
Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. This Agreement may be
amended by the Company in accordance with Section&nbsp;9.6 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9&#8195;Agreement Severable. In the event that any provision of
the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10&#8195;Limitation on Participant&#8217;s Rights. Participation in the Plan confers no rights or interests other than as
herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets.
Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Make Whole RSUs, and rights no greater than the right to receive the Shares as a
general unsecured creditor with respect to the Make Whole RSUs, as and when settled pursuant to the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11&#8195;Rights as a Stockholder. Neither Participant nor any person claiming under or through Participant will have any of the rights or
privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or
its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein, after such issuance, recordation and delivery, Participant will have all the rights
of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12&#8195;Not a Contract of Employment. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to
continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of
Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13&#8195;Counterparts. The Grant Notice may be executed in one or more counterparts,
including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14&#8195;Governing Law. The provisions of the Plan and all Awards made thereunder, including the Make Whole RSUs, shall be governed by and
interpreted in accordance with the laws of the State of Delaware, disregarding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of any state that would require the application of the
laws of a jurisdiction other than such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15&#8195;Section 409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this Agreement and the
Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section&nbsp;409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder,
including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#8221;). The Administrator may, in its discretion, adopt such amendments
to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate
to comply with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;This Agreement is not intended to provide for any deferral
of compensation subject to Section&nbsp;409A of the Code, and, accordingly, the Shares issuable pursuant to the Make Whole RSUs hereunder shall be distributed to Participant no later than the later of: (A)&nbsp;the fifteenth (15th) day of the third
month following Participant&#8217;s first taxable year in which such Make Whole RSUs are no longer subject to a substantial risk of forfeiture, and (B)&nbsp;the fifteenth (15th) day of the third month following first taxable year of the Company in
which such Make Whole RSUs are no longer subject to substantial risk of forfeiture, as determined in accordance with Section&nbsp;409A and any Treasury Regulations and other guidance issued thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>6
<FILENAME>d42675dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2026 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathleen Gallagher </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Kathleen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
distribution (the &#8220;<B>Distribution</B>&#8221;) by Avidity Biosciences, Inc. (&#8220;<B>Avidity</B>&#8221;) of all the issued and outstanding shares of common stock, par value $0.001 per share of Atrium Therapeutics, Inc. (the
&#8220;<B>Company</B>&#8221;), you and the Company desire to enter into this Employment Agreement (this &#8220;<B>Agreement</B>&#8221;), which shall be effective from and after (and subject to the occurrence of) the date of the Distribution and
which shall supersede and replace your existing employment agreement with Avidity dated August&nbsp;29, 2024 (the &#8220;<B>Prior Agreement</B>&#8221;), which Prior Agreement is being transferred to the Company in connection with the Distribution,
upon such effectiveness. In the event that the Distribution does not occur, this Agreement shall be null and void, <I>ab initio</I>.<B> </B>The provisions set forth herein shall be in effect from and after the Distribution, and by entering into this
Agreement, you understand and agree that you shall have no further rights or claims under the Prior Agreement as of the date of the Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>Title. </B>You will serve as the Company&#8217;s Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>Duties. </B>In this position, you will be designated as an executive officer of the Company for purposes of Section&nbsp;16 of the
Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). You will be responsible for performing such duties as are customary for your position and any other duties or areas of responsibility that may be reasonably
requested from time to time by the Company&#8217;s Board of Directors (the &#8220;<B>Board</B>&#8221;), to whom you will report. You shall devote your best efforts and full business time, skill and attention to the performance of your duties. You
will also be expected to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the Company&#8217;s general employment policies or
practices, this Agreement will control. Your primary work location shall be [&#8195;&#8195;&#8195;&#8195;]. The Company reserves the right to reasonably require you to perform your duties at places other than your primary office location from time
to time, and to require reasonable business travel with reimbursement in a manner consistent with the Company&#8217;s travel reimbursement policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>Salary. </B>You will be paid an annual base salary of $625,000, less applicable deductions and withholdings, to be paid each month
in accordance with the Company&#8217;s payroll practices, as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>Benefits. </B>You will be
eligible to participate in the Company&#8217;s standard benefit programs, subject to the terms and conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information regarding these benefits
is available for your review upon request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>Equity Awards. </B>You will be eligible to receive Stock Awards (as defined
below) covering the Company&#8217;s common stock under the equity plans maintained by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>Performance Bonuses.</B>
Commencing in 2026,<B> </B>you will be eligible to earn an annual incentive bonus equal to fifty-five percent (55%) of your annual base salary (your &#8220;<B>Target Bonus</B>&#8221;) Whether you receive such a bonus, and the amount of any such
bonus, shall be determined by the Board<B> </B>(or duly authorized committee thereof) in its sole discretion, and shall be based upon achievement of performance objectives established by the Board (or duly authorized committee thereof) and other
criteria to be determined by the Board (or duly authorized committee thereof). Any bonus shall be paid within thirty (30)&nbsp;days after the Board&#8217;s (or such committee&#8217;s) determination that a bonus shall be awarded. Except as described
in Section&nbsp;7 below, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus. Therefore, if your employment is terminated either by you or the Company for any reason prior to the bonus being paid, you will not
have earned the bonus and no partial or prorated bonus will be paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT>
</B><B>Employment; </B><B>Termination.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment
with the Company will be <FONT STYLE="white-space:nowrap">&#8220;at-will.&#8221;</FONT> This means that either you or the Company may terminate your employment at any time, with or without Cause or Good Reason (each as defined below), and with or
without advance notice. In the event of your termination of employment for any reason, the Company shall pay to you (i)&nbsp;your fully earned but unpaid base salary, when due, through the date of your termination of employment at the rate then in
effect, (ii)&nbsp;accrued and unused vacation and/or paid time off, (iii)&nbsp;if your termination occurs after the occurrence of a Change of Control and after the conclusion of a calendar year in respect of which no annual bonus has yet been paid
(i.e., such termination occurs on or after January&nbsp;1, but before the designated payment date for the annual bonus in respect of such completed calendar year), your annual bonus for such completed calendar year based on actual performance as
determined by the Board (or duly authorized committee thereof), paid when annual bonuses are paid to the Company&#8217;s employees generally for such completed calendar year, but in all events prior to March&nbsp;15 of the calendar year in which
your termination occurs, plus (iv)&nbsp;all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which
you may be entitled pursuant to the terms of such plans or agreements at the time of your termination of employment (the &#8220;<B>Accrued Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Termination For </B><B>Cause; </B><B>Resignation Without Good Reason. </B>If, at any time, the Company terminates your employment
for Cause, you resign without Good Reason, or if either party terminates your employment as a result of your death or disability, you will receive the Accrued Obligations. Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<B>Termination Without Cause; Resignation With Good Reason Not
in Connection With a Change of Control. </B>If at any time other than during the Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your
employment as a result of your death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; (as defined under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h),</FONT> without
regard to any alternative definition thereunder, a &#8220;<B>Separation from Service</B>&#8221;), then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Severance
Benefits</B>&#8221;): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to twelve (12)&nbsp;months of your then current base salary (at
the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such
material diminution), to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Salary Severance</B>&#8221;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;if you timely elect continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(&#8220;<B>COBRA</B>&#8221;) for yourself and your covered dependents under the Company&#8217;s group health plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your
health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A)&nbsp;the close of the twelve (12)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration
of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the
termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>COBRA Payment </B><B>Period</B>&#8221;).<B> </B>Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums
could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Internal Revenue Code of 1986, as amended (the &#8220;<B>Code</B>&#8221;), or any statute or regulation of similar effect (including but not limited to the
2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day
of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings (such amount, the &#8220;<B>Special </B><B>Severance </B><B>Payment</B>&#8221;), for the
remainder of the COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first
payment under this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on
the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease
to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause shall cease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<B>Termination Without Cause; Resignation With Good Reason During the Change </B><B>of </B><B>Control Period. </B>If the Company
terminates your employment without Cause or you resign for Good Reason, and other than any termination of your employment as a result of your death or disability, in each case within fifty-nine (59)&nbsp;days prior to or twenty-four (24)&nbsp;months
following the effective date of a Change of Control (as defined herein) (the &#8220;<B>Change </B><B>of Control </B><B>Period</B>&#8221;), and provided such termination constitutes a Separation from Service, then subject to your obligations below,
you shall be entitled to receive the following severance benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#8220;<B>Change of Control Severance Benefits</B>&#8221;)<B> </B>in lieu of the Severance Benefits (and for the avoidance of doubt, in no event will you be entitled to both
the Severance Benefits and the Change of Control Severance Benefits): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to eighteen (18)&nbsp;months of your then
current base salary (at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in
effect prior to such material diminution), less all applicable withholdings and deductions, to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Change of Control </B><B>Salary
Severance</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;an amount equal to 150% of your Target Bonus for the calendar year in which your termination occurs
(at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such
material diminution), less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;an amount equal to your Target Bonus for the calendar year in which your termination occurs (at the rate in effect immediately
prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution), prorated for
the portion of the year that has elapsed through your date of termination of employment with the Company, less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#8217;s group health
plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the
earliest of (A)&nbsp;the close of the eighteen (18)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>Change </B><B>of Control COBRA Payment
</B><B>Period</B>&#8221;). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Code or
any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the
Company, in its sole discretion, may elect to instead pay you on the first day of each month of the Change of Control COBRA Payment Period, the Special Severance Payment, for the remainder of the Change of Control COBRA Payment Period. You may, but
are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special
Severance Payment, such payment will be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described
above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all
payments and obligations under this clause shall cease; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;acceleration of 100% of any unvested time-based Stock Awards. Such
acceleration shall be effective as of the later of (A)&nbsp;the effective date of your Separation from Service, or (B)&nbsp;the date of such Change of Control (for the avoidance of doubt, the accelerated vesting of any Stock Awards that are
performance-based shall be governed by the applicable equity plan and agreement or plan regarding such Stock Award pursuant to which they were granted). The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any
less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable
provisions shall continue to apply and shall not be limited by this clause (v)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<B>Conditions For Receipt of </B><B>Severance
</B><B>Benefits or Change of Control </B><B>Severance </B><B>Benefits. </B>The Severance Benefits or Change of Control Severance Benefits are conditional upon (x)&nbsp;your continuing to comply with your obligations under your Employee Invention
Assignment and Confidentiality Agreement; (y)&nbsp;your delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached hereto as <B>Exhibit </B><B>A </B>(the
&#8220;<B>Release</B>&#8221;), and any revocation period thereunder having expired, within sixty (60)&nbsp;days following your termination date; and (z)&nbsp;if you are a member of the Board, your resignation from the Board, to be effective no later
than the date of your termination date (or such other date as requested by the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<B>No Mitigation. </B>You shall not be
required in any way to mitigate the amount of any payment provided for in this Section&nbsp;7, including, without limitation, by seeking other employment, nor shall the amount of any payment provided for in this Section&nbsp;7 be reduced by any
compensation earned by you as the result of employment with another employer after the termination date of employment, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Definition of Cause. </B>For purposes of this Agreement, &#8220;<B>Cause</B>&#8221; shall mean one or more of the following:
(A)&nbsp;your willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy (B)&nbsp;your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct
that has caused or is reasonably expected to result in material injury to the Company; (C)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or (D)&nbsp;your willful breach of any of your obligations under any written agreement or covenant with the Company. The determination as to whether you are being terminated for Cause
shall be made in good faith by the Board. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate your employment at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Definition of Good Reason. </B>For purposes of this Agreement, &#8220;<B>Good
Reason</B>&#8221;<B> </B>shall mean your resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&#8195;a material reduction in your base salary or Target Bonus if such a reduction is not made in proportion to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reduction for all senior executives of the Company (and for the avoidance of doubt, following a Change of Control, the reference to senior executives of the
Company shall include, without limitation, the senior executives of the ultimate parent entity of the Company (or its successor)); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&#8195;a material reduction or material adverse change in your duties, responsibilities and/or authorities including, without limitation,
following a Change of Control, your ceasing to report to the Board of the ultimate parent entity of the Company (or its successor), and/or your ceasing to serve as the Chief Executive Officer of such ultimate parent entity; <I>provided that,</I>
prior to a Change of Control, it shall not constitute Good Reason if such reduction is a mere change of title alone or change in reporting relationship and <I>provided further that,</I> changes in your position, title and/or duties as a result of
the Distribution shall not constitute Good Reason; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&#8195;relocation of your principal place of employment to a place that increases
your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then- current principal place of employment immediately prior to such relocation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)&#8195;any other action or inaction that constitutes a material breach by the Company of this Agreement or any agreement under which you
provide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided, however that, such termination by you shall only be deemed for Good Reason pursuant to the foregoing definition if
(i)&nbsp;the Company is given written notice from you within ninety (90)&nbsp;days following the first occurrence of the condition that you consider to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy
such condition within thirty (30)&nbsp;days following such written notice, and (ii)&nbsp;you terminate employment within ninety (90)&nbsp;days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Definition of Change of Control. </B>For purposes of this Agreement, &#8220;<B>Change
</B><B>of </B><B>Control</B>&#8221; shall have the meaning given to such term in the Company&#8217;s 2026 Incentive Award Plan as in effect on the date hereof, it being understood that the Distribution will not constitute a Change of Control.
Notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes &#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting
the Change of Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1,409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for
such payment or benefit, to the extent required by Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;<B>Definition of Stock Awards. </B>For purposes of this
Agreement, &#8220;Stock Awards&#8221; shall mean all stock options, restricted stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award plans or agreements and any shares of stock issued upon
exercise thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>Section 409A. </B>It is intended that all of the severance benefits and other
payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Code Section&nbsp;409A. For purposes of Code Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of
separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of
your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are
deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to you prior to the earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of your Separation from Service with
the Company, (ii)&nbsp;the date of your death or (iii)&nbsp;such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code
Section&nbsp;409A(a)(2)( B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred. All reimbursements and <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that
such reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (A)&nbsp;any reimbursement is for expenses incurred during your lifetime (or during
a shorter period of time specified in this Agreement), (B) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (C)&nbsp;the reimbursement of any
eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (D)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.
Notwithstanding any provision to the contrary in this Agreement, to the extent any payments to you pursuant to this Agreement constitute &#8220;nonqualified deferred compensation&#8221; subject to Section&nbsp;409A of the Code or are intended to be
exempt from Section&nbsp;409A of the Code pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1</FONT> (b)(9)(iii), then, to the extent required by Section&nbsp;409A of the Code or to satisfy such exception, no
amount shall be payable pursuant to such sections unless your termination of employment constitutes a Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>Parachute Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Best </B><B>Pay </B><B>Provision. </B>In the event that any payment or benefit received or to be received by you pursuant to the
terms of any plan, arrangement or agreement (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment or benefit received in connection with a change in ownership or control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the
&#8220;<B>Total Payments</B>&#8221;) would be subject (in whole or part) to the excise tax (the &#8220;<B>Excise Tax</B>&#8221;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and
personal exemptions attributable to such unreduced Total Payments). Except to the extent that an alternative reduction order would result in a greater economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties
intend that the Total Payments shall be reduced in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to you that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or
benefits otherwise payable to you that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the
Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to you on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment
attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to
any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first
applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes
on you under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically
equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Determinations. </B>All determinations
regarding the application of this Section&nbsp;9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability
of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#8220;<B>280G </B><B>Firm</B>&#8221;).<B> </B>For purposes of determining whether and the extent to
which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G(b)(2) of
the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the
Code, in excess of the &#8220;base amount&#8221; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which you shall have waived at
such time and in such manner as not to constitute a &#8220;payment&#8221; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or
any deferred payment or benefit included in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be
performed pursuant to this Section&nbsp;9 shall be done by the 280G Firm in consultation with the Company. The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and the Company within fifteen
(15)&nbsp;days after notification from either the Company or you that you may receive payments which may be &#8220;parachute payments.&#8221; You and the Company will each provide the 280G Firm access to and copies of any books, records, and
documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the
280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>Confidentiality Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Confidentiality Obligations. </B>In connection with your employment, you have signed and agreed to abide by the Company&#8217;s
standard form of Employee Invention Assignment and Confidentiality Agreement, a copy of which is attached hereto as <B>Exhibit B </B>(the &#8220;<B>Confidentiality Agreement</B>&#8221;). In your work for the Company, you are expected not to use or
disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you are expected to use only that information which is generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto
Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that your employment does not create a conflict with any agreement
between you and a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Other </B><B>Protections. </B>You acknowledge that the Company has provided you with the
following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i)&nbsp;you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of confidential
information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii)&nbsp;you shall not be held criminally or civilly
liable under any Federal or State trade secret law for the disclosure of confidential information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii)&nbsp;if you file a
lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the confidential information to your attorney and use the confidential information in the court proceeding, if you file any document containing the
confidential information under seal, and do not disclose the confidential information, except pursuant to court order. In addition, nothing in this Agreement or the Confidentiality Agreement shall prevent you from (x)&nbsp;communicating directly
with, cooperating with, or providing information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading
Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeking permission from the Company, (y)&nbsp;exercising any rights you may have under Section&nbsp;7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity,
including collective action or discussion concerning wages or working conditions, or (z)&nbsp;discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any
other conduct that you have reason to believe is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>Arbitration. </B>To ensure the timely and economical resolution
of disputes that may arise in connection with your employment with the Company, to the extent permitted by applicable law, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement,
breach, performance, negotiation, execution, or interpretation of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> or if inapplicable, the California Arbitration Act, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single neutral arbitrator in Marin County,
California, chosen jointly by the parties, and will be conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/
or will be provided to you upon request without charge). If the parties cannot agree on an arbitrator, then JAMS shall appoint an arbitrator in accordance with JAMS rules. <B>By </B><B>agreeing </B><B>to this arbitration procedure, both you and the
Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </B>The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding. In
addition, all claims, disputes, or causes of action under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or
representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of
law rather than by arbitration. This paragraph shall not apply to an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a)&nbsp;have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of
the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would
be required of you if the dispute were filed in Superior Court. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>Successors. </B>This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our
respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Any successor to the Company (whether direct or indirect
and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially all of the Company&#8217;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform any of the Company&#8217;s obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>Miscellaneous. </B>This Agreement, including the exhibits hereto, is the complete and exclusive statement of all
of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral, including, without limitation, the Prior
Agreement. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the
Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid,
illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>Indemnification. </B>You will receive defense and be indemnified by the Company to the full extent of the provisions of the
Company&#8217;s charter and bylaws and applicable Delaware law and the Indemnification Agreement between you and the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>Withholding and </B><B>other </B><B>Deductions. </B>All compensation payable to you hereunder shall be subject to such deductions
as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<B>Notices. </B>All
notices or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one (1)&nbsp;business day after being sent by a nationally recognized
overnight delivery service, charges prepaid. Notices also may be given electronically via PDF and shall be effective on the date transmitted if confirmed within forty-eight (48)&nbsp;hours thereafter by a signed original sent in the manner provided
in the preceding sentence. Notice to you shall be sent to your most recent residence and personal email address on file with the Company. Notice to the Company shall be sent to its physical address set forth on the first page hereto and addressed to
the Chair of the Board at the email address provided by the Company for such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Best regards,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ATRIUM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Sarah Boyce</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chair of the Board</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>Accepted and agreed:&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;<U></U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:<U></U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Employment Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#8220;<U>Release</U>&#8221;) is made by and between Kathleen Gallagher
(&#8220;<U>Executive</U>&#8221;) and Atrium Therapeutics. (the &#8220;<U>Company</U>&#8221;) (collectively referred to as the &#8220;<U>Parties</U>&#8221; or individually referred to as a &#8220;<U>Party</U>&#8221;). Capitalized terms used but not
defined in this Release shall have the meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have
previously entered into that certain Employment Agreement, effective as of Month [&#8195;], 202[X] (the &#8220;<U>Employment Agreement</U>&#8221;) and that certain Confidentiality Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[&#8195;&#8195;&#8195;&#8195;], 20[&#8195;], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees (as defined
below).&#8195; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section&nbsp;7 of the Employment
Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#8217;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company
and Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Severance Payments and Benefits; Salary and Benefits</U>. Provided that the Effective
Date occurs and Executive continues to comply with this Release and the Continuing Obligations, the Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, payable at the
times set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive
the Accrued Obligations described in Section&nbsp;7(a) of the Employment Agreement, subject to and in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims (as defined below), the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries or affiliates, and any of their current, former and future officers, directors, equity holders,
managers, employees, agents, investors, lenders, creditors, attorneys, shareholders, members, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations
and assigns (collectively, the &#8220;<U>Releasees</U>&#8221;) related to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#8217;s own behalf and on behalf of any of
Executive&#8217;s affiliated companies or entities and any of their respective heirs, spouses, family members, executors, beneficiaries, trustees, administrators, legal representatives, agents, successors and assigns (collectively, the
&#8220;<U>Releasing Parties</U>&#8221;), other than with respect to the Retained Claims, knowingly and voluntarily, irrevocably and unconditionally, hereby and forever releases and discharges the Releasees from, and agrees not to sue concerning, or
in any manner to institute, prosecute, or pursue, any claim, complaint, charge, commitment, suit, controversy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, duty, obligation, or cause of action, cross-claim, counter claim, demand, debt, right, promise, contract, grievance, compensatory damages, liquidated damages, punitive or exemplary
damages, other damages, claims for costs and attorneys&#8217; fees, expenses, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this Release becomes effective and enforceable), relating to any
matters of any kind, and whether presently known or unknown, suspected or unsuspected, pending or not pending, that Executive or the Releasing Parties may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the date Executive signs this Release relating to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#8217;s employment or service relationship with the Company or any of its direct
or indirect subsidiaries and affiliates and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all claims relating to, or arising from,
Executive&#8217;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty,
breach of duty under applicable state law, and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful
discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory
estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation;
libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights
Act of 1964; the Civil Rights Act of 1991; the Civil Rights Act of 1866 and 1871; the National Labor Relation Act of 1935; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act of 1963; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act of
1988; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Immigration Reform and Control Act of 1986; the Pregnancy Discrimination Act; the Consolidated Omnibus Budget Reconciliation Act; the Sarbanes-Oxley Act of
2002; the Internal Revenue Code of 1986; any applicable Executive Order Programs; and their state and local counterparts, including the California Fair Employment and Housing Act, and the California Government Code Section&nbsp;12940, et. seq., each
as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the <FONT
STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#8217; fees and costs (all of the
foregoing, collectively referred to herein as the &#8220;<U>Claims</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL
AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;A GENERAL RELEASE DOES NOT
EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR
OR RELEASED PARTY.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER,
AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release does not release Claims that cannot be
released as a matter of law, including, but not limited to, (i)&nbsp;Claims that arise solely and completely after Executive executed this Release, (ii)&nbsp;Claims for breach or enforcement of this Release, (iii)&nbsp;Executive&#8217;s right to
report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the
Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, (iv)&nbsp;Executive&#8217;s right to file a charge with or
participate in a charge or investigation by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against
the Company for discrimination (with the understanding that Executive&#8217;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment other than as
otherwise noted above), (v) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#8217;s group benefit plans
pursuant to the terms and conditions of COBRA, (vi)&nbsp;Claims for indemnity under the bylaws of the Company, as provided for by California or Delaware law or under any applicable indemnification agreement or insurance policy with respect to
Executive&#8217;s liability as an employee, director or officer of the Company, (vii)&nbsp;Claims to any benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitlements vested as the date of separation of Executive&#8217;s employment pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#8217;s right
under applicable law and any Retained Claims. This Release further does not release Claims for the Company&#8217;s breach of its executory obligations under Section&nbsp;7 of the Employment Agreement. This Release does not prevent Executive from
cooperating with an investigation conducted by any governmental agencies, including without limitation the National Labor Relations Board (the &#8220;<U>NLRB</U>&#8221;). Nothing herein will prevent Executive from participating in an activity
permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a
trade secret that (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of
law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is sought to be made under seal. The claims described in this paragraph are referred to as the &#8220;<U>Retained Claims</U>.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;<U>ADEA</U>&#8221;), and that this Release is knowing and voluntary. Executive understands and agrees that this Release does not apply to any
rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this Release is in addition to anything of value to which Executive was already
entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive has the right to and is hereby advised to consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> calendar days from the date of initial receipt within which to consider this Release, although Executive may sign it at any time sooner, and
the Parties agree that such time period to review this Release shall not be extended upon any changes to this Release and any such changes are not material or were made at Executive&#8217;s request; (c)&nbsp;Executive has seven (7)&nbsp;calendar
days following Executive&#8217;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Release shall not be effective until the day immediately following this seven
(7)&nbsp;day revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)]
calendar day period identified above, Executive hereby acknowledges that Executive was afforded the opportunity to have a period of at least <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] calendar days to consider it and Executive has
freely and voluntarily chosen to waive the time period allotted for considering this Release. This Release will become effective on the day immediately following the seventh (7th) calendar day after Executive signed this Release (the
&#8220;<U>Effective Date</U>&#8221;). Executive further understands that Executive will not be given any severance benefits under Section&nbsp;7 of the Employment Agreement unless this Release is effective on or before the date that is fifty-five
(55)&nbsp;days following the date of Executive&#8217;s termination of employment. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For individuals age 40 or over, in the event of a group termination, to be 45 days with an OWBPA disclosure
added. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Terminations; Resignations</U>. Executive hereby confirms Executive&#8217;s
termination from all offices, directorships and other positions, if any, then held with the Company, effective as of the date of Executive&#8217;s termination of employment, and shall take all actions reasonably requested by the Company to
effectuate the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Executive Representations</U>. Executive represents and warrants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Executive has surrendered to the Company all lists, books and records of, or in connection with, the Company business, and all other
property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Executive is not owed wages, commissions, bonuses or other compensation, other than the Accrued Obligations and as set forth in
Section&nbsp;7(a) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the course of Executive&#8217;s employment, Executive did not sustain any
injuries for which Executive might be entitled to compensation pursuant to worker&#8217;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to
compensation pursuant to worker&#8217;s compensation law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Confirmation of Continuing Obligations</U>. Executive hereby
expressly reaffirms Executive&#8217;s continuing obligations under any agreements or other documents with the Company or any of the other Releasees, including, without limitation, Section&nbsp;10 of the Employment Agreement and the Confidentiality
Agreement, and Executive acknowledges that such obligations shall survive Executive&#8217;s termination of employment (collectively, the &#8220;<B>Continuing Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Assignment</U>. Executive represents and warrants to the Releasees that there has been no assignment or other transfer of any
interest in any claim that Executive may have against the Releasees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Severability</U>. In the event that any provision or any
portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Release shall continue in full force and effect
without said provision or portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><U>Governing Law;
Venue</U>. This Release shall be governed by and construed in accordance with the laws of the [State of California], without regard to the conflicts of laws principles thereof. Any action brought hereon shall be brought in the state or federal
courts sitting in [San Diego County, California], the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over such party
and consents to service of process in any manner authorized by [California] law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Dispute Resolution</U>. All disputes under
this Release shall be governed by Section 11 of the Employment Agreement. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be updated for employee location. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Entire Agreement; Modification</U>. This Release and the Confidentiality
Agreement (and the other documents referenced herein and therein, including the Continuing Obligations) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them
concerning such subject matter. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Counterparts; .pdf Signatures</U>. This Release may be executed in any number of counterparts, each of which
when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by .pdf file and upon such delivery the.pdf signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Voluntary Execution of Agreement</U>.
Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#8217;s claims
against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set
forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation, and execution of this Release by legal counsel of Executive&#8217;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands
the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive is fully aware of the legal and binding effect of this Release. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name: Kathleen Gallagher</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ATRIUM THERAPEUTICS.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:<U></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>7
<FILENAME>d42675dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2026 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Husam Younis </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Husam: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the distribution
(the &#8220;<B>Distribution</B>&#8221;) by Avidity Biosciences, Inc. (&#8220;<B>Avidity</B>&#8221;) of all the issued and outstanding shares of common stock, par value $0.001 per share of Atrium Therapeutics, Inc. (the &#8220;<B>Company</B>&#8221;),
you and the Company desire to enter into this Employment Agreement (this &#8220;<B>Agreement</B>&#8221;), which shall be effective from and after (and subject to the occurrence of) the date of the Distribution and which shall supersede and replace
your existing employment agreement with Avidity dated September&nbsp;4, 2024 (the &#8220;<B>Prior Agreement</B>&#8221;), which Prior Agreement is being transferred to the Company in connection with the Distribution, upon such effectiveness. In the
event that the Distribution does not occur, this Agreement shall be null and void, <I>ab initio</I>.<B> </B>The provisions set forth herein shall be in effect from and after the Distribution, and by entering into this Agreement, you understand and
agree that you shall have no further rights or claims under the Prior Agreement as of the date of the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>Title.
</B>You will serve as the Company&#8217;s Chief Scientific Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>Duties. </B>In this position, you will be designated as
an executive officer of the Company for purposes of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). You will be responsible for performing such duties as are customary for your position and
any other duties or areas of responsibility that may be reasonably requested from time to time by the Company&#8217;s Chief Executive Officer, to whom you will report. You shall devote your best efforts and full business time, skill and attention to
the performance of your duties. You will also be expected to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the
Company&#8217;s general employment policies or practices, this Agreement will control. Your primary work location shall be La Jolla, California. The Company reserves the right to reasonably require you to perform your duties at places other than
your primary office location from time to time, and to require reasonable business travel with reimbursement in a manner consistent with the Company&#8217;s travel reimbursement policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>Salary. </B>You will be paid an annual base salary of $490,000, less applicable deductions and withholdings, to be paid each month
in accordance with the Company&#8217;s payroll practices, as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>Benefits. </B>You will be
eligible to participate in the Company&#8217;s standard benefit programs, subject to the terms and conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information regarding these benefits
is available for your review upon request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>Equity Awards. </B>You will be eligible to receive Stock Awards (as defined
below) covering the Company&#8217;s common stock under the equity plans maintained by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>Performance Bonuses.</B>
Commencing in 2026,<B> </B>you will be eligible to earn an annual incentive bonus equal to forty percent (40%) of your annual base salary (your &#8220;<B>Target Bonus</B>&#8221;) Whether you receive such a bonus, and the amount of any such bonus,
shall be determined by the Company&#8217;s Board of Directors (the &#8220;<B>Board</B>&#8221;)<B> </B>(or duly authorized committee thereof) in its sole discretion, and shall be based upon achievement of performance objectives established by the
Board (or duly authorized committee thereof) and other criteria to be determined by the Board (or duly authorized committee thereof). Any bonus shall be paid within thirty (30)&nbsp;days after the Board&#8217;s (or such committee&#8217;s)
determination that a bonus shall be awarded. Except as described in Section&nbsp;7 below, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus. Therefore, if your employment is terminated either by you or the
Company for any reason prior to the bonus being paid, you will not have earned the bonus and no partial or prorated bonus will be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> </B><B>Employment; </B><B>Termination.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment with the Company will be <FONT
STYLE="white-space:nowrap">&#8220;at-will.&#8221;</FONT> This means that either you or the Company may terminate your employment at any time, with or without Cause or Good Reason (each as defined below), and with or without advance notice. In the
event of your termination of employment for any reason, the Company shall pay to you (i)&nbsp;your fully earned but unpaid base salary, when due, through the date of your termination of employment at the rate then in effect, (ii)&nbsp;accrued and
unused vacation and/or paid time off, (iii)&nbsp;if your termination occurs after the occurrence of a Change of Control and after the conclusion of a calendar year in respect of which no annual bonus has yet been paid (i.e., such termination occurs
on or after January&nbsp;1, but before the designated payment date for the annual bonus in respect of such completed calendar year), your annual bonus for such completed calendar year based on actual performance as determined by the Board (or duly
authorized committee thereof), paid when annual bonuses are paid to the Company&#8217;s employees generally for such completed calendar year, but in all events prior to March&nbsp;15 of the calendar year in which your termination occurs, plus
(iv)&nbsp;all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which you may be entitled pursuant to
the terms of such plans or agreements at the time of your termination of employment (the &#8220;<B>Accrued Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Termination For </B><B>Cause; </B><B>Resignation Without Good Reason. </B>If, at any time, the Company terminates your employment
for Cause, you resign without Good Reason, or if either party terminates your employment as a result of your death or disability, you will receive the Accrued Obligations. Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<B>Termination Without Cause; Resignation With Good Reason Not
in Connection With a Change of Control. </B>If at any time other than during the Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your
employment as a result of your death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; (as defined under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h),</FONT> without regard to any alternative definition thereunder, a &#8220;<B>Separation from Service</B>&#8221;),
then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Severance Benefits</B>&#8221;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to nine (9)&nbsp;months of your then current base salary (at the rate in effect immediately prior to the date of
your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such material diminution), to be paid in a lump sum on the
sixtieth (60th) day following your Separation from Service (the &#8220;<B>Salary Severance</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;if you timely
elect continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<B>COBRA</B>&#8221;) for yourself and your covered dependents under the Company&#8217;s group health plans following such termination or
resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A)&nbsp;the close of the
nine (9)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible for substantially equivalent health
insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>COBRA Payment </B><B>Period</B>&#8221;).<B> </B>Notwithstanding the foregoing,
if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Internal Revenue Code of 1986, as amended (the
&#8220;<B>Code</B>&#8221;), or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of
providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to
applicable tax withholdings (such amount, the &#8220;<B>Special </B><B>Severance </B><B>Payment</B>&#8221;), for the remainder of the COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of
COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to
the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule
described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and
all payments and obligations under this clause shall cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<B>Termination Without Cause; Resignation With Good Reason During
the Change </B><B>of </B><B>Control Period. </B>If the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your employment as a result of your death or disability, in each case within
fifty-nine (59)&nbsp;days prior to or twenty-four (24)&nbsp;months following the effective date of a Change of Control (as defined herein) (the &#8220;<B>Change </B><B>of Control </B><B>Period</B>&#8221;), and provided such termination constitutes a
Separation from Service, then subject to your obligations below, you shall be entitled to receive the following severance benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#8220;<B>Change of Control Severance Benefits</B>&#8221;)<B> </B>in lieu of the Severance Benefits (and for the avoidance of doubt, in no event will you be entitled to both
the Severance Benefits and the Change of Control Severance Benefits): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to twelve (12)&nbsp;months of your then
current base salary (at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in
effect prior to such material diminution), less all applicable withholdings and deductions, to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Change of Control </B><B>Salary
Severance</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;an amount equal to 100% of your Target Bonus for the calendar year in which your termination occurs
(at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such
material diminution), less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;an amount equal to your Target Bonus for the calendar year in which your termination occurs (at the rate in effect immediately
prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution), prorated for
the portion of the year that has elapsed through your date of termination of employment with the Company, less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#8217;s group health
plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the
earliest of (A)&nbsp;the close of the twelve (12)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>Change </B><B>of Control </B><B>COBRA
Payment </B><B>Period</B>&#8221;). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the
Code or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA
premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the Change of Control COBRA Payment Period, the Special Severance Payment, for the remainder of the Change of Control COBRA Payment Period.
You may, but are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case
of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described
above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all
payments and obligations under this clause shall cease; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;acceleration of 100% of any unvested time-based Stock Awards. Such
acceleration shall be effective as of the later of (A)&nbsp;the effective date of your Separation from Service, or (B)&nbsp;the date of such Change of Control (for the avoidance of doubt, the accelerated vesting of any Stock Awards that are
performance-based shall be governed by the applicable equity plan and agreement or plan regarding such Stock Award pursuant to which they were granted). The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any
less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable
provisions shall continue to apply and shall not be limited by this clause (v)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<B>Conditions For Receipt of </B><B>Severance
</B><B>Benefits or Change of Control </B><B>Severance </B><B>Benefits. </B>The Severance Benefits or Change of Control Severance Benefits are conditional upon (x)&nbsp;your continuing to comply with your obligations under your Employee Invention
Assignment and Confidentiality Agreement; (y)&nbsp;your delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached hereto as <B>Exhibit </B><B>A </B>(the
&#8220;<B>Release</B>&#8221;), and any revocation period thereunder having expired, within sixty (60)&nbsp;days following your termination date; and (z)&nbsp;if you are a member of the Board, your resignation from the Board, to be effective no later
than the date of your termination date (or such other date as requested by the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<B>No Mitigation. </B>You shall not be
required in any way to mitigate the amount of any payment provided for in this Section&nbsp;7, including, without limitation, by seeking other employment, nor shall the amount of any payment provided for in this Section&nbsp;7 be reduced by any
compensation earned by you as the result of employment with another employer after the termination date of employment, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Definition of Cause. </B>For purposes of this Agreement, &#8220;<B>Cause</B>&#8221; shall mean one or more of the following:
(A)&nbsp;your willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy (B)&nbsp;your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct
that has caused or is reasonably expected to result in material injury to the Company; (C)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or (D)&nbsp;your willful breach of any of your obligations under any written agreement or covenant with the Company. The determination as to whether you are being terminated for Cause
shall be made in good faith by the Board. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate your employment at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Definition of Good Reason. </B>For purposes of this Agreement, &#8220;<B>Good
Reason</B>&#8221;<B> </B>shall mean your resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&#8195;a material reduction in your base salary or Target Bonus if such a reduction is not made in proportion to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reduction for all senior executives of the Company (and for the avoidance of doubt, following a Change of Control, the reference to senior executives of the
Company shall include, without limitation, the senior executives of the ultimate parent entity of the Company (or its successor)); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&#8195;a material reduction or material adverse change in your duties, responsibilities and/or authorities including, without limitation,
following a Change of Control, your ceasing to report to the Chief Executive Officer of the ultimate parent entity of the Company (or its successor), and/or your ceasing to serve as the Chief Scientific Officer of such ultimate parent entity;
<I>provided that,</I> prior to a Change of Control, it shall not constitute Good Reason if such reduction is a mere change of title alone or change in reporting relationship and <I>provided further that,</I> changes in your position, title and/or
duties as a result of the Distribution shall not constitute Good Reason; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&#8195;relocation of your principal place of employment to a
place that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then- current principal place of employment immediately prior to such relocation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)&#8195;any other action or inaction that constitutes a material breach by the Company of this Agreement or any agreement under which you
provide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided, however that, such termination by you shall only be deemed for Good Reason pursuant to the foregoing definition if
(i)&nbsp;the Company is given written notice from you within ninety (90)&nbsp;days following the first occurrence of the condition that you consider to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy
such condition within thirty (30)&nbsp;days following such written notice, and (ii)&nbsp;you terminate employment within ninety (90)&nbsp;days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Definition of Change of Control. </B>For purposes of this Agreement, &#8220;<B>Change
</B><B>of </B><B>Control</B>&#8221; shall have the meaning given to such term in the Company&#8217;s 2026 Incentive Award Plan as in effect on the date hereof, it being understood that the Distribution will not constitute a Change of Control.
Notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes &#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting
the Change of Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1,409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for
such payment or benefit, to the extent required by Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;<B>Definition of Stock Awards. </B>For purposes of this
Agreement, &#8220;Stock Awards&#8221; shall mean all stock options, restricted stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award plans or agreements and any shares of stock issued upon
exercise thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>Section 409A. </B>It is intended that all of the severance benefits and other
payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Code Section&nbsp;409A. For purposes of Code Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of
separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of
your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are
deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to you prior to the earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of your Separation from Service with
the Company, (ii)&nbsp;the date of your death or (iii)&nbsp;such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code
Section&nbsp;409A(a)(2)( B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred. All reimbursements and <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that
such reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (A)&nbsp;any reimbursement is for expenses incurred during your lifetime (or during
a shorter period of time specified in this Agreement), (B) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (C)&nbsp;the reimbursement of any
eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (D)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.
Notwithstanding any provision to the contrary in this Agreement, to the extent any payments to you pursuant to this Agreement constitute &#8220;nonqualified deferred compensation&#8221; subject to Section&nbsp;409A of the Code or are intended to be
exempt from Section&nbsp;409A of the Code pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1</FONT> (b)(9)(iii), then, to the extent required by Section&nbsp;409A of the Code or to satisfy such exception, no
amount shall be payable pursuant to such sections unless your termination of employment constitutes a Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>Parachute Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Best </B><B>Pay </B><B>Provision. </B>In the event that any payment or benefit received or to be received by you pursuant to the
terms of any plan, arrangement or agreement (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment or benefit received in connection with a change in ownership or control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the
&#8220;<B>Total Payments</B>&#8221;) would be subject (in whole or part) to the excise tax (the &#8220;<B>Excise Tax</B>&#8221;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and
personal exemptions attributable to such unreduced Total Payments). Except to the extent that an alternative reduction order would result in a greater economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties
intend that the Total Payments shall be reduced in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to you that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or
benefits otherwise payable to you that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the
Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to you on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment
attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to
any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first
applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes
on you under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically
equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Determinations. </B>All determinations
regarding the application of this Section&nbsp;9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability
of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#8220;<B>280G </B><B>Firm</B>&#8221;).<B> </B>For purposes of determining whether and the extent to
which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G(b)(2) of
the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the
Code, in excess of the &#8220;base amount&#8221; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which you shall have waived at
such time and in such manner as not to constitute a &#8220;payment&#8221; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or
any deferred payment or benefit included in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be
performed pursuant to this Section&nbsp;9 shall be done by the 280G Firm in consultation with the Company. The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and the Company within fifteen
(15)&nbsp;days after notification from either the Company or you that you may receive payments which may be &#8220;parachute payments.&#8221; You and the Company will each provide the 280G Firm access to and copies of any books, records, and
documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the
280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>Confidentiality Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Confidentiality Obligations. </B>In connection with your employment, you have signed and agreed to abide by the Company&#8217;s
standard form of Employee Invention Assignment and Confidentiality Agreement, a copy of which is attached hereto as <B>Exhibit B </B>(the &#8220;<B>Confidentiality Agreement</B>&#8221;). In your work for the Company, you are expected not to use or
disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you are expected to use only that information which is generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto
Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that your employment does not create a conflict with any agreement
between you and a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Other </B><B>Protections. </B>You acknowledge that the Company has provided you with the
following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i)&nbsp;you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of confidential
information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii)&nbsp;you shall not be held criminally or civilly
liable under any Federal or State trade secret law for the disclosure of confidential information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii)&nbsp;if you file a
lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the confidential information to your attorney and use the confidential information in the court proceeding, if you file any document containing the
confidential information under seal, and do not disclose the confidential information, except pursuant to court order. In addition, nothing in this Agreement or the Confidentiality Agreement shall prevent you from (x)&nbsp;communicating directly
with, cooperating with, or providing information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading
Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeking permission from the Company, (y)&nbsp;exercising any rights you may have under Section&nbsp;7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity,
including collective action or discussion concerning wages or working conditions, or (z)&nbsp;discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any
other conduct that you have reason to believe is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>Arbitration. </B>To ensure the timely and economical resolution
of disputes that may arise in connection with your employment with the Company, to the extent permitted by applicable law, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement,
breach, performance, negotiation, execution, or interpretation of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> or if inapplicable, the California Arbitration Act, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single neutral arbitrator in Marin County,
California, chosen jointly by the parties, and will be conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/
or will be provided to you upon request without charge). If the parties cannot agree on an arbitrator, then JAMS shall appoint an arbitrator in accordance with JAMS rules. <B>By </B><B>agreeing </B><B>to this arbitration procedure, both you and the
Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </B>The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding. In
addition, all claims, disputes, or causes of action under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or
representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of
law rather than by arbitration. This paragraph shall not apply to an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a)&nbsp;have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of
the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would
be required of you if the dispute were filed in Superior Court. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>Successors. </B>This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our
respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Any successor to the Company (whether direct or indirect
and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially all of the Company&#8217;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform any of the Company&#8217;s obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>Miscellaneous. </B>This Agreement, including the exhibits hereto, is the complete and exclusive statement of all
of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral, including, without limitation, the Prior
Agreement. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the
Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid,
illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>Indemnification. </B>You will receive defense and be indemnified by the Company to the full extent of the provisions of the
Company&#8217;s charter and bylaws and applicable Delaware law and the Indemnification Agreement between you and the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>Withholding and </B><B>other </B><B>Deductions. </B>All compensation payable to you hereunder shall be subject to such deductions
as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<B>Notices. </B>All
notices or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one (1)&nbsp;business day after being sent by a nationally recognized
overnight delivery service, charges prepaid. Notices also may be given electronically via PDF and shall be effective on the date transmitted if confirmed within forty-eight (48)&nbsp;hours thereafter by a signed original sent in the manner provided
in the preceding sentence. Notice to you shall be sent to your most recent residence and personal email address on file with the Company. Notice to the Company shall be sent to its physical address set forth on the first page hereto and addressed to
the Company&#8217;s Chief Executive Officer at the email address provided by the Company for such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best regards, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>ATRIUM THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000;">Accepted and agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Husam Younis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Employment Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#8220;<U>Release</U>&#8221;) is made by and between Husam Younis (&#8220;<U>Executive</U>&#8221;) and
Atrium Therapeutics. (the &#8220;<U>Company</U>&#8221;) (collectively referred to as the &#8220;<U>Parties</U>&#8221; or individually referred to as a &#8220;<U>Party</U>&#8221;). Capitalized terms used but not defined in this Release shall have the
meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain
Employment Agreement, effective as of Month [&#8195;], 202[X] (the &#8220;<U>Employment Agreement</U>&#8221;) and that certain Confidentiality Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[&#8195;&#8195;&#8195;&#8195;], 20[&#8195;], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees (as defined
below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement,
which, pursuant to the Employment Agreement, are conditioned on Executive&#8217;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company and
Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Severance Payments and Benefits; Salary and Benefits</U>. Provided that the Effective Date
occurs and Executive continues to comply with this Release and the Continuing Obligations, the Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, payable at the times
set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive the
Accrued Obligations described in Section&nbsp;7(a) of the Employment Agreement, subject to and in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims (as defined below), the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries or affiliates, and any of their current, former and future officers, directors, equity holders,
managers, employees, agents, investors, lenders, creditors, attorneys, shareholders, members, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations
and assigns (collectively, the &#8220;<U>Releasees</U>&#8221;) related to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#8217;s own behalf and on behalf of any of
Executive&#8217;s affiliated companies or entities and any of their respective heirs, spouses, family members, executors, beneficiaries, trustees, administrators, legal representatives, agents, successors and assigns (collectively, the
&#8220;<U>Releasing Parties</U>&#8221;), other than with respect to the Retained Claims, knowingly and voluntarily, irrevocably and unconditionally, hereby and forever releases and discharges the Releasees from, and agrees not to sue concerning, or
in any manner to institute, prosecute, or pursue, any claim, complaint, charge, commitment, suit, controversy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, duty, obligation, or cause of action, cross-claim, counter claim, demand, debt, right, promise, contract, grievance, compensatory damages, liquidated damages, punitive or exemplary
damages, other damages, claims for costs and attorneys&#8217; fees, expenses, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this Release becomes effective and enforceable), relating to any
matters of any kind, and whether presently known or unknown, suspected or unsuspected, pending or not pending, that Executive or the Releasing Parties may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the date Executive signs this Release relating to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;any and all claims relating to or arising from Executive&#8217;s employment or service relationship with the Company or any of its
direct or indirect subsidiaries and affiliates and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;any and all claims relating to, or
arising from, Executive&#8217;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of
fiduciary duty, breach of duty under applicable state law, and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;any and all
claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and
implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business
practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil
Rights Act of 1964; the Civil Rights Act of 1991; the Civil Rights Act of 1866 and 1871; the National Labor Relation Act of 1935; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act of 1963; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act of
1988; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Immigration Reform and Control Act of 1986; the Pregnancy Discrimination Act; the Consolidated Omnibus Budget Reconciliation Act; the Sarbanes-Oxley Act of
2002; the Internal Revenue Code of 1986; any applicable Executive Order Programs; and their state and local counterparts, including the California Fair Employment and Housing Act, and the California Government Code Section&nbsp;12940, et. seq., each
as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the <FONT
STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#8217; fees and costs (all of the
foregoing, collectively referred to herein as the &#8220;<U>Claims</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL
AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;A GENERAL RELEASE DOES NOT
EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR
OR RELEASED PARTY.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER,
AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release does not release Claims that cannot be
released as a matter of law, including, but not limited to, (i)&nbsp;Claims that arise solely and completely after Executive executed this Release, (ii)&nbsp;Claims for breach or enforcement of this Release, (iii)&nbsp;Executive&#8217;s right to
report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the
Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, (iv)&nbsp;Executive&#8217;s right to file a charge with or
participate in a charge or investigation by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against
the Company for discrimination (with the understanding that Executive&#8217;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment other than as
otherwise noted above), (v) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#8217;s group benefit plans
pursuant to the terms and conditions of COBRA, (vi)&nbsp;Claims for indemnity under the bylaws of the Company, as provided for by California or Delaware law or under any applicable indemnification agreement or insurance policy with respect to
Executive&#8217;s liability as an employee, director or officer of the Company, (vii)&nbsp;Claims to any benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitlements vested as the date of separation of Executive&#8217;s employment pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#8217;s right
under applicable law and any Retained Claims. This Release further does not release Claims for the Company&#8217;s breach of its executory obligations under Section&nbsp;7 of the Employment Agreement. This Release does not prevent Executive from
cooperating with an investigation conducted by any governmental agencies, including without limitation the National Labor Relations Board (the &#8220;<U>NLRB</U>&#8221;). Nothing herein will prevent Executive from participating in an activity
permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a
trade secret that (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of
law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is sought to be made under seal. The claims described in this paragraph are referred to as the &#8220;<U>Retained Claims</U>.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;<U>ADEA</U>&#8221;), and that this Release is knowing and voluntary. Executive understands and agrees that this Release does not apply to any
rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this Release is in addition to anything of value to which Executive was already
entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive has the right to and is hereby advised to consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> calendar days from the date of initial receipt within which to consider this Release, although Executive may sign it at any time sooner, and
the Parties agree that such time period to review this Release shall not be extended upon any changes to this Release and any such changes are not material or were made at Executive&#8217;s request; (c)&nbsp;Executive has seven (7)&nbsp;calendar
days following Executive&#8217;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Release shall not be effective until the day immediately following this seven
(7)&nbsp;day revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)]
calendar day period identified above, Executive hereby acknowledges that Executive was afforded the opportunity to have a period of at least <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] calendar days to consider it and Executive has
freely and voluntarily chosen to waive the time period allotted for considering this Release. This Release will become effective on the day immediately following the seventh (7th) calendar day after Executive signed this Release (the
&#8220;<U>Effective Date</U>&#8221;). Executive further understands that Executive will not be given any severance benefits under Section&nbsp;7 of the Employment Agreement unless this Release is effective on or before the date that is fifty-five
(55)&nbsp;days following the date of Executive&#8217;s termination of employment. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For individuals age 40 or over, in the event of a group termination, to be 45 days with an OWBPA disclosure
added. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Terminations; Resignations</U>. Executive hereby confirms Executive&#8217;s
termination from all offices, directorships and other positions, if any, then held with the Company, effective as of the date of Executive&#8217;s termination of employment, and shall take all actions reasonably requested by the Company to
effectuate the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Executive Representations</U>. Executive represents and warrants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Executive has surrendered to the Company all lists, books and records of, or in connection with, the Company business, and all other
property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Executive is not owed wages, commissions, bonuses or other compensation, other than the Accrued Obligations and as set forth in
Section&nbsp;7(a) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the course of Executive&#8217;s employment, Executive did not sustain any
injuries for which Executive might be entitled to compensation pursuant to worker&#8217;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to
compensation pursuant to worker&#8217;s compensation law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Confirmation of Continuing Obligations</U>. Executive hereby
expressly reaffirms Executive&#8217;s continuing obligations under any agreements or other documents with the Company or any of the other Releasees, including, without limitation, Section&nbsp;10 of the Employment Agreement and the Confidentiality
Agreement, and Executive acknowledges that such obligations shall survive Executive&#8217;s termination of employment (collectively, the &#8220;<B>Continuing Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Assignment</U>. Executive represents and warrants to the Releasees that there has been no assignment or other transfer of any
interest in any claim that Executive may have against the Releasees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Severability</U>. In the event that any provision or any
portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Release shall continue in full force and effect
without said provision or portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><U>Governing Law;
Venue</U>. This Release shall be governed by and construed in accordance with the laws of the [State of California], without regard to the conflicts of laws principles thereof. Any action brought hereon shall be brought in the state or federal
courts sitting in [San Diego County, California], the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over such party
and consents to service of process in any manner authorized by [California] law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Dispute Resolution</U>. All disputes under
this Release shall be governed by Section 11 of the Employment Agreement. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be updated for employee location. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Entire Agreement; Modification</U>. This Release and the Confidentiality
Agreement (and the other documents referenced herein and therein, including the Continuing Obligations) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them
concerning such subject matter. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Counterparts; .pdf Signatures</U>. This Release may be executed in any number of counterparts, each of which
when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by .pdf file and upon such delivery the.pdf signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Voluntary Execution of Agreement</U>.
Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#8217;s claims
against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set
forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation, and execution of this Release by legal counsel of Executive&#8217;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands
the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive is fully aware of the legal and binding effect of this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EXECUTIVE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print&nbsp;Name:&nbsp;Husam&nbsp;Younis</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ATRIUM THERAPEUTICS.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>8
<FILENAME>d42675dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2026 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Hughes </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Steve: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the distribution
(the &#8220;<B>Distribution</B>&#8221;) by Avidity Biosciences, Inc. (&#8220;<B>Avidity</B>&#8221;) of all the issued and outstanding shares of common stock, par value $0.001 per share of Atrium Therapeutics, Inc. (the &#8220;<B>Company</B>&#8221;),
you and the Company desire to enter into this Employment Agreement (this &#8220;<B>Agreement</B>&#8221;), which shall be effective from and after (and subject to the occurrence of) the date of the Distribution and which shall supersede and replace
your existing employment agreement with Avidity dated August&nbsp;26, 2024 (the &#8220;<B>Prior Agreement</B>&#8221;), which Prior Agreement is being transferred to the Company in connection with the Distribution, upon such effectiveness. In the
event that the Distribution does not occur, this Agreement shall be null and void, <I>ab initio</I>.<B> </B>The provisions set forth herein shall be in effect from and after the Distribution, and by entering into this Agreement, you understand and
agree that you shall have no further rights or claims under the Prior Agreement as of the date of the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>Title.
</B>You will serve as the Company&#8217;s Chief Medical Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>Duties. </B>In this position, you will be designated as an
executive officer of the Company for purposes of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). You will be responsible for performing such duties as are customary for your position and
any other duties or areas of responsibility that may be reasonably requested from time to time by the Company&#8217;s Chief Executive Officer, to whom you will report. You shall devote your best efforts and full business time, skill and attention to
the performance of your duties. You will also be expected to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the
Company&#8217;s general employment policies or practices, this Agreement will control. Your primary work location shall be La Jolla, California. The Company reserves the right to reasonably require you to perform your duties at places other than
your primary office location from time to time, and to require reasonable business travel with reimbursement in a manner consistent with the Company&#8217;s travel reimbursement policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>Salary. </B>You will be paid an annual base salary of $593,424, less applicable deductions and withholdings, to be paid each month
in accordance with the Company&#8217;s payroll practices, as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>Benefits. </B>You will be
eligible to participate in the Company&#8217;s standard benefit programs, subject to the terms and conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information regarding these benefits
is available for your review upon request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>Equity Awards. </B>You will be eligible to receive Stock Awards (as defined
below) covering the Company&#8217;s common stock under the equity plans maintained by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>Performance Bonuses.</B>
Commencing in 2026,<B> </B>you will be eligible to earn an annual incentive bonus equal to forty-five percent (45%) of your annual base salary (your &#8220;<B>Target Bonus</B>&#8221;) Whether you receive such a bonus, and the amount of any such
bonus, shall be determined by the Company&#8217;s Board of Directors (the &#8220;<B>Board</B>&#8221;)<B> </B>(or duly authorized committee thereof) in its sole discretion, and shall be based upon achievement of performance objectives established by
the Board (or duly authorized committee thereof) and other criteria to be determined by the Board (or duly authorized committee thereof). Any bonus shall be paid within thirty (30)&nbsp;days after the Board&#8217;s (or such committee&#8217;s)
determination that a bonus shall be awarded. Except as described in Section&nbsp;7 below, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus. Therefore, if your employment is terminated either by you or the
Company for any reason prior to the bonus being paid, you will not have earned the bonus and no partial or prorated bonus will be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> </B><B>Employment; </B><B>Termination.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment with the Company will be <FONT
STYLE="white-space:nowrap">&#8220;at-will.&#8221;</FONT> This means that either you or the Company may terminate your employment at any time, with or without Cause or Good Reason (each as defined below), and with or without advance notice. In the
event of your termination of employment for any reason, the Company shall pay to you (i)&nbsp;your fully earned but unpaid base salary, when due, through the date of your termination of employment at the rate then in effect, (ii)&nbsp;accrued and
unused vacation and/or paid time off, (iii)&nbsp;if your termination occurs after the occurrence of a Change of Control and after the conclusion of a calendar year in respect of which no annual bonus has yet been paid (i.e., such termination occurs
on or after January&nbsp;1, but before the designated payment date for the annual bonus in respect of such completed calendar year), your annual bonus for such completed calendar year based on actual performance as determined by the Board (or duly
authorized committee thereof), paid when annual bonuses are paid to the Company&#8217;s employees generally for such completed calendar year, but in all events prior to March&nbsp;15 of the calendar year in which your termination occurs, plus
(iv)&nbsp;all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which you may be entitled pursuant to
the terms of such plans or agreements at the time of your termination of employment (the &#8220;<B>Accrued Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Termination For </B><B>Cause; </B><B>Resignation Without Good Reason. </B>If, at any time, the Company terminates your employment
for Cause, you resign without Good Reason, or if either party terminates your employment as a result of your death or disability, you will receive the Accrued Obligations. Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<B>Termination Without Cause; Resignation With Good Reason Not
in Connection With a Change of Control. </B>If at any time other than during the Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your
employment as a result of your death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; (as defined under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h),</FONT> without regard to any alternative definition thereunder, a &#8220;<B>Separation from Service</B>&#8221;),
then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Severance Benefits</B>&#8221;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to twelve (12)&nbsp;months of your then current base salary (at the rate in effect immediately prior to the date of
your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such material diminution), to be paid in a lump sum on the
sixtieth (60th) day following your Separation from Service (the &#8220;<B>Salary Severance</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;if you timely
elect continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<B>COBRA</B>&#8221;) for yourself and your covered dependents under the Company&#8217;s group health plans following such termination or
resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A)&nbsp;the close of the
twelve (12)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible for substantially equivalent health
insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>COBRA Payment </B><B>Period</B>&#8221;).<B> </B>Notwithstanding the foregoing,
if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Internal Revenue Code of 1986, as amended (the
&#8220;<B>Code</B>&#8221;), or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of
providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to
applicable tax withholdings (such amount, the &#8220;<B>Special </B><B>Severance </B><B>Payment</B>&#8221;), for the remainder of the COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of
COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to
the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule
described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and
all payments and obligations under this clause shall cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<B>Termination Without Cause; Resignation With Good Reason During
the Change </B><B>of </B><B>Control Period. </B>If the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your employment as a result of your death or disability, in each case within
fifty-nine (59)&nbsp;days prior to or twenty-four (24)&nbsp;months following the effective date of a Change of Control (as defined herein) (the &#8220;<B>Change </B><B>of Control </B><B>Period</B>&#8221;), and provided such termination constitutes a
Separation from Service, then subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Change of Control Severance Benefits</B>&#8221;)<B> </B>in lieu of the
Severance Benefits (and for the avoidance of doubt, in no event will you be entitled to both the Severance Benefits and the Change of Control Severance Benefits): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to eighteen (18)&nbsp;months of your then current base salary (at the rate in effect immediately prior to the date
of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such material diminution), less all applicable withholdings
and deductions, to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Change of Control </B><B>Salary Severance</B>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;an amount equal to 150% of your Target Bonus for the calendar year in which your termination occurs (at the rate in effect
immediately prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution),
less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;an amount equal to your Target Bonus for the calendar year in which your termination occurs (at the rate in effect immediately
prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution), prorated for
the portion of the year that has elapsed through your date of termination of employment with the Company, less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#8217;s group health
plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the
earliest of (A)&nbsp;the close of the eighteen (18)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>Change </B><B>of Control COBRA Payment
</B><B>Period</B>&#8221;). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Code or
any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the
Company, in its sole discretion, may elect to instead pay you on the first day of each month of the Change of Control COBRA Payment Period, the Special Severance Payment, for the remainder of the Change of Control COBRA Payment Period. You may, but
are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special
Severance Payment, such payment will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such
sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period
provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause shall cease; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;acceleration of 100% of any unvested time-based Stock Awards. Such acceleration shall be effective as of the later of (A)&nbsp;the
effective date of your Separation from Service, or (B)&nbsp;the date of such Change of Control (for the avoidance of doubt, the accelerated vesting of any Stock Awards that are performance-based shall be governed by the applicable equity plan and
agreement or plan regarding such Stock Award pursuant to which they were granted). The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such
Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable provisions shall continue to apply and shall not be limited by
this clause (v)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<B>Conditions For Receipt of </B><B>Severance </B><B>Benefits or Change of Control </B><B>Severance
</B><B>Benefits. </B>The Severance Benefits or Change of Control Severance Benefits are conditional upon (x)&nbsp;your continuing to comply with your obligations under your Employee Invention Assignment and Confidentiality Agreement; (y)&nbsp;your
delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached hereto as <B>Exhibit </B><B>A </B>(the &#8220;<B>Release</B>&#8221;), and any revocation period thereunder having expired,
within sixty (60)&nbsp;days following your termination date; and (z)&nbsp;if you are a member of the Board, your resignation from the Board, to be effective no later than the date of your termination date (or such other date as requested by the
Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<B>No Mitigation. </B>You shall not be required in any way to mitigate the amount of any payment provided for in this
Section&nbsp;7, including, without limitation, by seeking other employment, nor shall the amount of any payment provided for in this Section&nbsp;7 be reduced by any compensation earned by you as the result of employment with another employer after
the termination date of employment, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Definition of Cause. </B>For purposes of this Agreement, &#8220;<B>Cause</B>&#8221; shall mean one or more of the following:
(A)&nbsp;your willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy (B)&nbsp;your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct
that has caused or is reasonably expected to result in material injury to the Company; (C)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or (D)&nbsp;your willful breach of any of your obligations under any written agreement or covenant with the Company. The determination as to whether you are being terminated for Cause
shall be made in good faith by the Board. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate your employment at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Definition of Good Reason. </B>For purposes of this Agreement, &#8220;<B>Good
</B><B>Reason</B>&#8221;<B> </B>shall mean your resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&#8195;a material reduction in your base salary or Target Bonus if such a reduction is not made in proportion to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reduction for all senior executives of the Company (and for the avoidance of doubt, following a Change of Control, the reference to senior executives of the
Company shall include, without limitation, the senior executives of the ultimate parent entity of the Company (or its successor)); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&#8195;a material reduction or material adverse change in your duties, responsibilities and/or authorities including, without limitation,
following a Change of Control, your ceasing to report to the Chief Executive Officer of the ultimate parent entity of the Company (or its successor), and/or your ceasing to serve as the Chief Medical Officer of such ultimate parent entity;
<I>provided that,</I> prior to a Change of Control, it shall not constitute Good Reason if such reduction is a mere change of title alone or change in reporting relationship and <I>provided further that,</I> changes in your position, title and/or
duties as a result of the Distribution shall not constitute Good Reason; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&#8195;relocation of your principal place of employment to a
place that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then- current principal place of employment immediately prior to such relocation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)&#8195;any other action or inaction that constitutes a material breach by the Company of this Agreement or any agreement under which you
provide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided, however that, such termination by you shall only be deemed for Good Reason pursuant to the foregoing definition if
(i)&nbsp;the Company is given written notice from you within ninety (90)&nbsp;days following the first occurrence of the condition that you consider to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy
such condition within thirty (30)&nbsp;days following such written notice, and (ii)&nbsp;you terminate employment within ninety (90)&nbsp;days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Definition of Change of Control. </B>For purposes of this Agreement, &#8220;<B>Change
</B><B>of </B><B>Control</B>&#8221; shall have the meaning given to such term in the Company&#8217;s 2026 Incentive Award Plan as in effect on the date hereof, it being understood that the Distribution will not constitute a Change of Control.
Notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes &#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting
the Change of Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1,409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for
such payment or benefit, to the extent required by Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;<B>Definition of Stock Awards. </B>For purposes of this Agreement, &#8220;Stock
Awards&#8221; shall mean all stock options, restricted stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>Section 409A. </B>It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to
the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT
STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be
construed in a manner that complies with Code Section&nbsp;409A. For purposes of Code Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT>
your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder
shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be a &#8220;specified employee&#8221;
for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#8220;deferred compensation&#8221;, then to the extent
delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse taxation under Section&nbsp;409A, such payments shall not be provided to
you prior to the earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of your Separation from Service with the Company, (ii)&nbsp;the date of your death or (iii)&nbsp;such earlier
date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section&nbsp;409A(a)(2)( B)(i) period, all payments deferred pursuant to this
paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. All reimbursements and <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that such reimbursements or
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (A)&nbsp;any reimbursement is for expenses incurred during your lifetime (or during a shorter period of
time specified in this Agreement), (B) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (C)&nbsp;the reimbursement of any eligible expense
will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (D)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit. Notwithstanding any
provision to the contrary in this Agreement, to the extent any payments to you pursuant to this Agreement constitute &#8220;nonqualified deferred compensation&#8221; subject to Section&nbsp;409A of the Code or are intended to be exempt from
Section&nbsp;409A of the Code pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1</FONT> (b)(9)(iii), then, to the extent required by Section&nbsp;409A of the Code or to satisfy such exception, no amount shall be
payable pursuant to such sections unless your termination of employment constitutes a Separation from Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>Parachute Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Best </B><B>Pay </B><B>Provision. </B>In the event that any payment or benefit received or to be received by you pursuant to the
terms of any plan, arrangement or agreement (including any payment or benefit received in connection with a change in ownership or control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the
&#8220;<B>Total Payments</B>&#8221;) would be subject (in whole or part) to the excise tax (the &#8220;<B>Excise Tax</B>&#8221;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and
personal exemptions attributable to such unreduced Total Payments). Except to the extent that an alternative reduction order would result in a greater economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties
intend that the Total Payments shall be reduced in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to you that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or
benefits otherwise payable to you that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the
Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to you on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment
attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to
any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first
applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes
on you under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically
equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Determinations. </B>All determinations
regarding the application of this Section&nbsp;9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability
of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#8220;<B>280G </B><B>Firm</B>&#8221;).<B> </B>For purposes of determining whether and the extent to
which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G(b)(2) of
the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the
Code, in excess of the &#8220;base amount&#8221; (as defined in Section&nbsp;280G(b)(3) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which you shall have waived at such time and in such manner as not to
constitute a &#8220;payment&#8221; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or any deferred payment or benefit
included in the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be performed pursuant to this Section&nbsp;9
shall be done by the 280G Firm in consultation with the Company. The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and the Company within fifteen (15)&nbsp;days after notification from either
the Company or you that you may receive payments which may be &#8220;parachute payments.&#8221; You and the Company will each provide the 280G Firm access to and copies of any books, records, and documents as may be reasonably requested by the 280G
Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the 280G Firm for its services in connection with the
determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>Confidentiality
Obligations</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Confidentiality Obligations. </B>In connection with your employment, you have signed and agreed to abide by
the Company&#8217;s standard form of Employee Invention Assignment and Confidentiality Agreement, a copy of which is attached hereto as <B>Exhibit B </B>(the &#8220;<B>Confidentiality Agreement</B>&#8221;). In your work for the Company, you are
expected not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you are expected to use only that information which is generally
known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will
not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that your employment does not create a conflict with any
agreement between you and a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Other </B><B>Protections. </B>You acknowledge that the Company has provided you
with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i)&nbsp;you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of
confidential information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii)&nbsp;you shall not be held criminally or
civilly liable under any Federal or State trade secret law for the disclosure of confidential information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii)&nbsp;if you
file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the confidential information to your attorney and use the confidential information in the court proceeding, if you file any document
containing the confidential information under seal, and do not disclose the confidential information, except pursuant to court order. In addition, nothing in this Agreement or the Confidentiality Agreement shall prevent you from
(x)&nbsp;communicating directly with, cooperating with, or providing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange Commission, the U.S. Commodity
Futures Trading Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or seeking permission from the Company, (y)&nbsp;exercising any rights you
may have under Section&nbsp;7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity, including collective action or discussion concerning wages or working conditions, or (z)&nbsp;discussing or disclosing
information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any other conduct that you have reason to believe is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>Arbitration. </B>To ensure the timely and economical resolution of disputes that may arise in connection with your employment
with the Company, to the extent permitted by applicable law, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation
of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> or if
inapplicable, the California Arbitration Act, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single neutral arbitrator in Marin County, California, chosen jointly by the parties, and will be conducted
by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/ or will be provided to you upon request without charge). If the
parties cannot agree on an arbitrator, then JAMS shall appoint an arbitrator in accordance with JAMS rules. <B>By </B><B>agreeing </B><B>to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a
trial by jury or judge or </B><B>administrative proceeding. </B>The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding. In addition, all claims, disputes, or causes of action under this
paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the
claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding
class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to
an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such
relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or
all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would be required of you if the dispute were filed in Superior Court.
Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered
and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>Successors. </B>This Agreement is intended to bind and inure to the benefit of
and be enforceable by you and the Company, and our respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Any
successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and/or assets shall assume the obligations under this
Agreement and agree expressly to perform any of the Company&#8217;s obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>Miscellaneous.
</B>This Agreement, including the exhibits hereto, is the complete and exclusive statement of all of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with
regard to the subject matter hereof, whether written or oral, including, without limitation, the Prior Agreement. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be
modified, amended or extended except in a writing signed by you and a duly authorized officer of the Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any
other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid, illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be
governed in all aspects by the laws of the State of California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>Indemnification. </B>You will receive defense and be
indemnified by the Company to the full extent of the provisions of the Company&#8217;s charter and bylaws and applicable Delaware law and the Indemnification Agreement between you and the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>Withholding and </B><B>other </B><B>Deductions. </B>All compensation payable to you hereunder shall be subject to such deductions
as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<B>Notices. </B>All
notices or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one (1)&nbsp;business day after being sent by a nationally recognized
overnight delivery service, charges prepaid. Notices also may be given electronically via PDF and shall be effective on the date transmitted if confirmed within forty-eight (48)&nbsp;hours thereafter by a signed original sent in the manner provided
in the preceding sentence. Notice to you shall be sent to your most recent residence and personal email address on file with the Company. Notice to the Company shall be sent to its physical address set forth on the first page hereto and addressed to
the Company&#8217;s Chief Executive Officer at the email address provided by the Company for such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best regards, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATRIUM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000;">Accepted and agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Steven Hughes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Employment Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#8220;<U>Release</U>&#8221;) is made by and between Steven Hughes (&#8220;<U>Executive</U>&#8221;) and
Atrium Therapeutics. (the &#8220;<U>Company</U>&#8221;) (collectively referred to as the &#8220;<U>Parties</U>&#8221; or individually referred to as a &#8220;<U>Party</U>&#8221;). Capitalized terms used but not defined in this Release shall have the
meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain
Employment Agreement, effective as of Month [&#8195;], 202[X] (the &#8220;<U>Employment Agreement</U>&#8221;) and that certain Confidentiality Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[&#8195;&#8195;&#8195;&#8195;], 20[&#8195;], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees (as defined
below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement,
which, pursuant to the Employment Agreement, are conditioned on Executive&#8217;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company and
Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Severance Payments and Benefits; Salary and Benefits</U>. Provided that the Effective Date
occurs and Executive continues to comply with this Release and the Continuing Obligations, the Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, payable at the times
set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive the
Accrued Obligations described in Section&nbsp;7(a) of the Employment Agreement, subject to and in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims (as defined below), the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries or affiliates, and any of their current, former and future officers, directors, equity holders,
managers, employees, agents, investors, lenders, creditors, attorneys, shareholders, members, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations
and assigns (collectively, the &#8220;<U>Releasees</U>&#8221;) related to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#8217;s own behalf and on behalf of any of
Executive&#8217;s affiliated companies or entities and any of their respective heirs, spouses, family members, executors, beneficiaries, trustees, administrators, legal representatives, agents, successors and assigns (collectively, the
&#8220;<U>Releasing Parties</U>&#8221;), other than with respect to the Retained Claims, knowingly and voluntarily, irrevocably and unconditionally, hereby and forever releases and discharges the Releasees from, and agrees not to sue concerning, or
in any manner to institute, prosecute, or pursue, any claim, complaint, charge, commitment, suit, controversy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, duty, obligation, or cause of action, cross-claim, counter claim, demand, debt, right, promise, contract, grievance, compensatory damages, liquidated damages, punitive or exemplary
damages, other damages, claims for costs and attorneys&#8217; fees, expenses, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this Release becomes effective and enforceable), relating to any
matters of any kind, and whether presently known or unknown, suspected or unsuspected, pending or not pending, that Executive or the Releasing Parties may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the date Executive signs this Release relating to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#8217;s employment or service relationship with the Company or any of its direct
or indirect subsidiaries and affiliates and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all claims relating to, or arising from,
Executive&#8217;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty,
breach of duty under applicable state law, and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful
discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory
estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation;
libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights
Act of 1964; the Civil Rights Act of 1991; the Civil Rights Act of 1866 and 1871; the National Labor Relation Act of 1935; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act of 1963; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act of
1988; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Immigration Reform and Control Act of 1986; the Pregnancy Discrimination Act; the Consolidated Omnibus Budget Reconciliation Act; the Sarbanes-Oxley Act of
2002; the Internal Revenue Code of 1986; any applicable Executive Order Programs; and their state and local counterparts, including the California Fair Employment and Housing Act, and the California Government Code Section&nbsp;12940, et. seq., each
as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the <FONT
STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#8217; fees and costs (all of the
foregoing, collectively referred to herein as the &#8220;<U>Claims</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL
AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;A GENERAL RELEASE DOES NOT
EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR
OR RELEASED PARTY.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER,
AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release does not release Claims that cannot be
released as a matter of law, including, but not limited to, (i)&nbsp;Claims that arise solely and completely after Executive executed this Release, (ii)&nbsp;Claims for breach or enforcement of this Release, (iii)&nbsp;Executive&#8217;s right to
report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the
Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, (iv)&nbsp;Executive&#8217;s right to file a charge with or
participate in a charge or investigation by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against
the Company for discrimination (with the understanding that Executive&#8217;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment other than as
otherwise noted above), (v) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#8217;s group benefit plans
pursuant to the terms and conditions of COBRA, (vi)&nbsp;Claims for indemnity under the bylaws of the Company, as provided for by California or Delaware law or under any applicable indemnification agreement or insurance policy with respect to
Executive&#8217;s liability as an employee, director or officer of the Company, (vii)&nbsp;Claims to any benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitlements vested as the date of separation of Executive&#8217;s employment pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#8217;s right
under applicable law and any Retained Claims. This Release further does not release Claims for the Company&#8217;s breach of its executory obligations under Section&nbsp;7 of the Employment Agreement. This Release does not prevent Executive from
cooperating with an investigation conducted by any governmental agencies, including without limitation the National Labor Relations Board (the &#8220;<U>NLRB</U>&#8221;). Nothing herein will prevent Executive from participating in an activity
permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a
trade secret that (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of
law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is sought to be made under seal. The claims described in this paragraph are referred to as the &#8220;<U>Retained Claims</U>.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;<U>ADEA</U>&#8221;), and that this Release is knowing and voluntary. Executive understands and agrees that this Release does not apply to any
rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this Release is in addition to anything of value to which Executive was already
entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive has the right to and is hereby advised to consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> calendar days from the date of initial receipt within which to consider this Release, although Executive may sign it at any time sooner, and
the Parties agree that such time period to review this Release shall not be extended upon any changes to this Release and any such changes are not material or were made at Executive&#8217;s request; (c)&nbsp;Executive has seven (7)&nbsp;calendar
days following Executive&#8217;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Release shall not be effective until the day immediately following this seven
(7)&nbsp;day revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)]
calendar day period identified above, Executive hereby acknowledges that Executive was afforded the opportunity to have a period of at least <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] calendar days to consider it and Executive has
freely and voluntarily chosen to waive the time period allotted for considering this Release. This Release will become effective on the day immediately following the seventh (7th) calendar day after Executive signed this Release (the
&#8220;<U>Effective Date</U>&#8221;). Executive further understands that Executive will not be given any severance benefits under Section&nbsp;7 of the Employment Agreement unless this Release is effective on or before the date that is fifty-five
(55)&nbsp;days following the date of Executive&#8217;s termination of employment. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For individuals age 40 or over, in the event of a group termination, to be 45 days with an OWBPA disclosure
added. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Terminations; Resignations</U>. Executive hereby confirms Executive&#8217;s
termination from all offices, directorships and other positions, if any, then held with the Company, effective as of the date of Executive&#8217;s termination of employment, and shall take all actions reasonably requested by the Company to
effectuate the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Executive Representations</U>. Executive represents and warrants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Executive has surrendered to the Company all lists, books and records of, or in connection with, the Company business, and all other
property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Executive is not owed wages, commissions, bonuses or other compensation, other than the Accrued Obligations and as set forth in
Section&nbsp;7(a) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the course of Executive&#8217;s employment, Executive did not sustain any
injuries for which Executive might be entitled to compensation pursuant to worker&#8217;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to
compensation pursuant to worker&#8217;s compensation law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Confirmation of Continuing Obligations</U>. Executive hereby
expressly reaffirms Executive&#8217;s continuing obligations under any agreements or other documents with the Company or any of the other Releasees, including, without limitation, Section&nbsp;10 of the Employment Agreement and the Confidentiality
Agreement, and Executive acknowledges that such obligations shall survive Executive&#8217;s termination of employment (collectively, the &#8220;<B>Continuing Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Assignment</U>. Executive represents and warrants to the Releasees that there has been no assignment or other transfer of any
interest in any claim that Executive may have against the Releasees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Severability</U>. In the event that any provision or any
portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Release shall continue in full force and effect
without said provision or portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><U>Governing Law;
Venue</U>. This Release shall be governed by and construed in accordance with the laws of the [State of California], without regard to the conflicts of laws principles thereof. Any action brought hereon shall be brought in the state or federal
courts sitting in [San Diego County, California], the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over such party
and consents to service of process in any manner authorized by [California] law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Dispute Resolution</U>. All disputes under
this Release shall be governed by Section 11 of the Employment Agreement. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be updated for employee location. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Entire Agreement; Modification</U>. This Release and the Confidentiality
Agreement (and the other documents referenced herein and therein, including the Continuing Obligations) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them
concerning such subject matter. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Counterparts; .pdf Signatures</U>. This Release may be executed in any number of counterparts, each of which
when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by .pdf file and upon such delivery the.pdf signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Voluntary Execution of Agreement</U>.
Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#8217;s claims
against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set
forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation, and execution of this Release by legal counsel of Executive&#8217;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands
the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive is fully aware of the legal and binding effect of this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EXECUTIVE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print&nbsp;Name:&nbsp;Steven Hughes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ATRIUM THERAPEUTICS.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U><U>&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>9
<FILENAME>d42675dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2026 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brendan
Winslow </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Brendan: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the distribution (the &#8220;<B>Distribution</B>&#8221;) by Avidity Biosciences, Inc. (&#8220;<B>Avidity</B>&#8221;) of all
the issued and outstanding shares of common stock, par value $0.001 per share of Atrium Therapeutics, Inc. (the &#8220;<B>Company</B>&#8221;), you and the Company desire to enter into this Employment Agreement (this &#8220;<B>Agreement</B>&#8221;),
which shall be effective from and after (and subject to the occurrence of) the date of the Distribution and which shall supersede and replace your existing employment agreement with Avidity dated October&nbsp;25, 2024 (the &#8220;<B>Prior
Agreement</B>&#8221;), which Prior Agreement is being transferred to the Company in connection with the Distribution, upon such effectiveness. In the event that the Distribution does not occur, this Agreement shall be null and void, <I>ab
initio</I>.<B> </B>The provisions set forth herein shall be in effect from and after the Distribution, and by entering into this Agreement, you understand and agree that you shall have no further rights or claims under the Prior Agreement as of the
date of the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>Title. </B>You will serve as the Company&#8217;s Chief Financial Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>Duties. </B>In this position, you will be designated as an executive officer of the Company for purposes of Section&nbsp;16 of the
Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). You will be responsible for performing such duties as are customary for your position and any other duties or areas of responsibility that may be reasonably
requested from time to time by the Company&#8217;s Chief Executive Officer, to whom you will report. You shall devote your best efforts and full business time, skill and attention to the performance of your duties. You will also be expected to
adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the Company&#8217;s general employment policies or practices, this Agreement
will control. Your primary work location shall be La Jolla, California. The Company reserves the right to reasonably require you to perform your duties at places other than your primary office location from time to time, and to require reasonable
business travel with reimbursement in a manner consistent with the Company&#8217;s travel reimbursement policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>Salary.
</B>You will be paid an annual base salary of $490,000, less applicable deductions and withholdings, to be paid each month in accordance with the Company&#8217;s payroll practices, as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>Benefits. </B>You will be eligible to participate in the Company&#8217;s standard benefit programs, subject to the terms and
conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information regarding these benefits is available for your review upon request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>Equity Awards. </B>You will be eligible to receive Stock Awards (as defined
below) covering the Company&#8217;s common stock under the equity plans maintained by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>Performance Bonuses.</B>
Commencing in 2026,<B> </B>you will be eligible to earn an annual incentive bonus equal to forty percent (40%) of your annual base salary (your &#8220;<B>Target Bonus</B>&#8221;) Whether you receive such a bonus, and the amount of any such bonus,
shall be determined by the Company&#8217;s Board of Directors (the &#8220;<B>Board</B>&#8221;)<B> </B>(or duly authorized committee thereof) in its sole discretion, and shall be based upon achievement of performance objectives established by the
Board (or duly authorized committee thereof) and other criteria to be determined by the Board (or duly authorized committee thereof). Any bonus shall be paid within thirty (30)&nbsp;days after the Board&#8217;s (or such committee&#8217;s)
determination that a bonus shall be awarded. Except as described in Section&nbsp;7 below, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus. Therefore, if your employment is terminated either by you or the
Company for any reason prior to the bonus being paid, you will not have earned the bonus and no partial or prorated bonus will be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> </B><B>Employment; </B><B>Termination.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment with the Company will be <FONT
STYLE="white-space:nowrap">&#8220;at-will.&#8221;</FONT> This means that either you or the Company may terminate your employment at any time, with or without Cause or Good Reason (each as defined below), and with or without advance notice. In the
event of your termination of employment for any reason, the Company shall pay to you (i)&nbsp;your fully earned but unpaid base salary, when due, through the date of your termination of employment at the rate then in effect, (ii)&nbsp;accrued and
unused vacation and/or paid time off, (iii)&nbsp;if your termination occurs after the occurrence of a Change of Control and after the conclusion of a calendar year in respect of which no annual bonus has yet been paid (i.e., such termination occurs
on or after January&nbsp;1, but before the designated payment date for the annual bonus in respect of such completed calendar year), your annual bonus for such completed calendar year based on actual performance as determined by the Board (or duly
authorized committee thereof), paid when annual bonuses are paid to the Company&#8217;s employees generally for such completed calendar year, but in all events prior to March&nbsp;15 of the calendar year in which your termination occurs, plus
(iv)&nbsp;all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which you may be entitled pursuant to
the terms of such plans or agreements at the time of your termination of employment (the &#8220;<B>Accrued Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Termination For </B><B>Cause; </B><B>Resignation Without Good Reason. </B>If, at any time, the Company terminates your employment
for Cause, you resign without Good Reason, or if either party terminates your employment as a result of your death or disability, you will receive the Accrued Obligations. Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<B>Termination Without Cause; Resignation With Good Reason Not
in Connection With a Change of Control. </B>If at any time other than during the Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your
employment as a result of your death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; (as defined under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h),</FONT> without regard to any alternative definition thereunder, a &#8220;<B>Separation from Service</B>&#8221;),
then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Severance Benefits</B>&#8221;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to nine (9)&nbsp;months of your then current base salary (at the rate in effect immediately prior to the date of
your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such material diminution), to be paid in a lump sum on the
sixtieth (60th) day following your Separation from Service (the &#8220;<B>Salary Severance</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;if you timely
elect continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<B>COBRA</B>&#8221;) for yourself and your covered dependents under the Company&#8217;s group health plans following such termination or
resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A)&nbsp;the close of the
nine (9)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible for substantially equivalent health
insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>COBRA Payment </B><B>Period</B>&#8221;).<B> </B>Notwithstanding the foregoing,
if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Internal Revenue Code of 1986, as amended (the
&#8220;<B>Code</B>&#8221;), or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of
providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to
applicable tax withholdings (such amount, the &#8220;<B>Special </B><B>Severance </B><B>Payment</B>&#8221;), for the remainder of the COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of
COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to
the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule
described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and
all payments and obligations under this clause shall cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<B>Termination Without Cause; Resignation With Good Reason During
the Change </B><B>of </B><B>Control Period. </B>If the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your employment as a result of your death or disability, in each case within
fifty-nine (59)&nbsp;days prior to or twenty-four (24)&nbsp;months following the effective date of a Change of Control (as defined herein) (the &#8220;<B>Change </B><B>of Control </B><B>Period</B>&#8221;), and provided such termination constitutes a
Separation from Service, then subject to your obligations below, you shall be entitled to receive the following severance benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#8220;<B>Change of Control Severance Benefits</B>&#8221;)<B> </B>in lieu of the Severance Benefits (and for the avoidance of doubt, in no event will you be entitled to both
the Severance Benefits and the Change of Control Severance Benefits): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to twelve (12)&nbsp;months of your then
current base salary (at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in
effect prior to such material diminution), less all applicable withholdings and deductions, to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Change of Control </B><B>Salary
Severance</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;an amount equal to 100% of your Target Bonus for the calendar year in which your termination occurs
(at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such
material diminution), less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;an amount equal to your Target Bonus for the calendar year in which your termination occurs (at the rate in effect immediately
prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution), prorated for
the portion of the year that has elapsed through your date of termination of employment with the Company, less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#8217;s group health
plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the
earliest of (A)&nbsp;the close of the twelve (12)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>Change </B><B>of Control </B><B>COBRA
Payment </B><B>Period</B>&#8221;). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the
Code or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA
premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the Change of Control COBRA Payment Period, the Special Severance Payment, for the remainder of the Change of Control COBRA Payment Period.
You may, but are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case
of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described
above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all
payments and obligations under this clause shall cease; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;acceleration of 100% of any unvested time-based Stock Awards. Such
acceleration shall be effective as of the later of (A)&nbsp;the effective date of your Separation from Service, or (B)&nbsp;the date of such Change of Control (for the avoidance of doubt, the accelerated vesting of any Stock Awards that are
performance-based shall be governed by the applicable equity plan and agreement or plan regarding such Stock Award pursuant to which they were granted). The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any
less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable
provisions shall continue to apply and shall not be limited by this clause (v)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<B>Conditions For Receipt of </B><B>Severance
</B><B>Benefits or Change of Control </B><B>Severance </B><B>Benefits. </B>The Severance Benefits or Change of Control Severance Benefits are conditional upon (x)&nbsp;your continuing to comply with your obligations under your Employee Invention
Assignment and Confidentiality Agreement; (y)&nbsp;your delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached hereto as <B>Exhibit </B><B>A </B>(the
&#8220;<B>Release</B>&#8221;), and any revocation period thereunder having expired, within sixty (60)&nbsp;days following your termination date; and (z)&nbsp;if you are a member of the Board, your resignation from the Board, to be effective no later
than the date of your termination date (or such other date as requested by the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<B>No Mitigation. </B>You shall not be
required in any way to mitigate the amount of any payment provided for in this Section&nbsp;7, including, without limitation, by seeking other employment, nor shall the amount of any payment provided for in this Section&nbsp;7 be reduced by any
compensation earned by you as the result of employment with another employer after the termination date of employment, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Definition of Cause. </B>For purposes of this Agreement, &#8220;<B>Cause</B>&#8221; shall mean one or more of the following:
(A)&nbsp;your willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy (B)&nbsp;your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct
that has caused or is reasonably expected to result in material injury to the Company; (C)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or (D)&nbsp;your willful breach of any of your obligations under any written agreement or covenant with the Company. The determination as to whether you are being terminated for Cause
shall be made in good faith by the Board. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate your employment at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Definition of Good Reason. </B>For purposes of this Agreement, &#8220;<B>Good
Reason</B>&#8221;<B> </B>shall mean your resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&#8195;a material reduction in your base salary or Target Bonus if such a reduction is not made in proportion to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reduction for all senior executives of the Company (and for the avoidance of doubt, following a Change of Control, the reference to senior executives of the
Company shall include, without limitation, the senior executives of the ultimate parent entity of the Company (or its successor)); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&#8195;a material reduction or material adverse change in your duties, responsibilities and/or authorities including, without limitation,
following a Change of Control, your ceasing to report to the Chief Executive Officer of the ultimate parent entity of the Company (or its successor), and/or your ceasing to serve as the Chief Financial Officer of such ultimate parent entity;
<I>provided that,</I> prior to a Change of Control, it shall not constitute Good Reason if such reduction is a mere change of title alone or change in reporting relationship and <I>provided further that,</I> changes in your position, title and/or
duties as a result of the Distribution shall not constitute Good Reason; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&#8195;relocation of your principal place of employment to a
place that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then- current principal place of employment immediately prior to such relocation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)&#8195;any other action or inaction that constitutes a material breach by the Company of this Agreement or any agreement under which you
provide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided, however that, such termination by you shall only be deemed for Good Reason pursuant to the foregoing definition if
(i)&nbsp;the Company is given written notice from you within ninety (90)&nbsp;days following the first occurrence of the condition that you consider to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy
such condition within thirty (30)&nbsp;days following such written notice, and (ii)&nbsp;you terminate employment within ninety (90)&nbsp;days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Definition of Change of Control. </B>For purposes of this Agreement, &#8220;<B>Change
</B><B>of </B><B>Control</B>&#8221; shall have the meaning given to such term in the Company&#8217;s 2026 Incentive Award Plan as in effect on the date hereof, it being understood that the Distribution will not constitute a Change of Control.
Notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes &#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting
the Change of Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1,409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for
such payment or benefit, to the extent required by Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;<B>Definition of Stock Awards. </B>For purposes of this
Agreement, &#8220;Stock Awards&#8221; shall mean all stock options, restricted stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award plans or agreements and any shares of stock issued upon
exercise thereof. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>Section 409A. </B>It is intended that all of the severance benefits and other
payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Code Section&nbsp;409A. For purposes of Code Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of
separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of
your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are
deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to you prior to the earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of your Separation from Service with
the Company, (ii)&nbsp;the date of your death or (iii)&nbsp;such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code
Section&nbsp;409A(a)(2)( B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred. All reimbursements and <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that
such reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (A)&nbsp;any reimbursement is for expenses incurred during your lifetime (or during
a shorter period of time specified in this Agreement), (B) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (C)&nbsp;the reimbursement of any
eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (D)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.
Notwithstanding any provision to the contrary in this Agreement, to the extent any payments to you pursuant to this Agreement constitute &#8220;nonqualified deferred compensation&#8221; subject to Section&nbsp;409A of the Code or are intended to be
exempt from Section&nbsp;409A of the Code pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1</FONT> (b)(9)(iii), then, to the extent required by Section&nbsp;409A of the Code or to satisfy such exception, no
amount shall be payable pursuant to such sections unless your termination of employment constitutes a Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>Parachute Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Best </B><B>Pay </B><B>Provision. </B>In the event that any payment or benefit received or to be received by you pursuant to the
terms of any plan, arrangement or agreement (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment or benefit received in connection with a change in ownership or control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the
&#8220;<B>Total Payments</B>&#8221;) would be subject (in whole or part) to the excise tax (the &#8220;<B>Excise Tax</B>&#8221;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and
personal exemptions attributable to such unreduced Total Payments). Except to the extent that an alternative reduction order would result in a greater economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties
intend that the Total Payments shall be reduced in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to you that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or
benefits otherwise payable to you that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the
Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to you on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment
attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to
any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first
applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes
on you under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically
equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Determinations. </B>All determinations
regarding the application of this Section&nbsp;9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability
of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#8220;<B>280G </B><B>Firm</B>&#8221;).<B> </B>For purposes of determining whether and the extent to
which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G(b)(2) of
the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the
Code, in excess of the &#8220;base amount&#8221; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which you shall have waived at
such time and in such manner as not to constitute a &#8220;payment&#8221; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or
any deferred payment or benefit included in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be
performed pursuant to this Section&nbsp;9 shall be done by the 280G Firm in consultation with the Company. The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and the Company within fifteen
(15)&nbsp;days after notification from either the Company or you that you may receive payments which may be &#8220;parachute payments.&#8221; You and the Company will each provide the 280G Firm access to and copies of any books, records, and
documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the
280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>Confidentiality Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Confidentiality Obligations. </B>In connection with your employment, you have signed and agreed to abide by the Company&#8217;s
standard form of Employee Invention Assignment and Confidentiality Agreement, a copy of which is attached hereto as <B>Exhibit B </B>(the &#8220;<B>Confidentiality Agreement</B>&#8221;). In your work for the Company, you are expected not to use or
disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you are expected to use only that information which is generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto
Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that your employment does not create a conflict with any agreement
between you and a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Other </B><B>Protections. </B>You acknowledge that the Company has provided you with the
following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i)&nbsp;you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of confidential
information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii)&nbsp;you shall not be held criminally or civilly
liable under any Federal or State trade secret law for the disclosure of confidential information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii)&nbsp;if you file a
lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the confidential information to your attorney and use the confidential information in the court proceeding, if you file any document containing the
confidential information under seal, and do not disclose the confidential information, except pursuant to court order. In addition, nothing in this Agreement or the Confidentiality Agreement shall prevent you from (x)&nbsp;communicating directly
with, cooperating with, or providing information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading
Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeking permission from the Company, (y)&nbsp;exercising any rights you may have under Section&nbsp;7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity,
including collective action or discussion concerning wages or working conditions, or (z)&nbsp;discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any
other conduct that you have reason to believe is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>Arbitration. </B>To ensure the timely and economical resolution
of disputes that may arise in connection with your employment with the Company, to the extent permitted by applicable law, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement,
breach, performance, negotiation, execution, or interpretation of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> or if inapplicable, the California Arbitration Act, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single neutral arbitrator in Marin County,
California, chosen jointly by the parties, and will be conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/
or will be provided to you upon request without charge). If the parties cannot agree on an arbitrator, then JAMS shall appoint an arbitrator in accordance with JAMS rules. <B>By </B><B>agreeing </B><B>to this arbitration procedure, both you and the
Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </B>The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding. In
addition, all claims, disputes, or causes of action under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or
representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of
law rather than by arbitration. This paragraph shall not apply to an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a)&nbsp;have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of
the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would
be required of you if the dispute were filed in Superior Court. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>Successors. </B>This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our
respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Any successor to the Company (whether direct or indirect
and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially all of the Company&#8217;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform any of the Company&#8217;s obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>Miscellaneous. </B>This Agreement, including the exhibits hereto, is the complete and exclusive statement of all
of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral, including, without limitation, the Prior
Agreement. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the
Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid,
illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>Indemnification. </B>You will receive defense and be indemnified by the Company to the full extent of the provisions of the
Company&#8217;s charter and bylaws and applicable Delaware law and the Indemnification Agreement between you and the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>Withholding and </B><B>other </B><B>Deductions. </B>All compensation payable to you hereunder shall be subject to such deductions
as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<B>Notices. </B>All
notices or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one (1)&nbsp;business day after being sent by a nationally recognized
overnight delivery service, charges prepaid. Notices also may be given electronically via PDF and shall be effective on the date transmitted if confirmed within forty-eight (48)&nbsp;hours thereafter by a signed original sent in the manner provided
in the preceding sentence. Notice to you shall be sent to your most recent residence and personal email address on file with the Company. Notice to the Company shall be sent to its physical address set forth on the first page hereto and addressed to
the Company&#8217;s Chief Executive Officer at the email address provided by the Company for such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Best regards,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ATRIUM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; ">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>Accepted and agreed:&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;<U></U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Brendan Winslow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:<U></U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Employment Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#8220;<U>Release</U>&#8221;) is made by and between Brendan Winslow (&#8220;<U>Executive</U>&#8221;)
and Atrium Therapeutics. (the &#8220;<U>Company</U>&#8221;) (collectively referred to as the &#8220;<U>Parties&#8221;</U> or individually referred to as a &#8220;<U>Party</U>&#8221;). Capitalized terms used but not defined in this Release shall have
the meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain
Employment Agreement, effective as of Month [&#8195;], 202[X] (the &#8220;<U>Employment Agreement</U>&#8221;) and that certain Confidentiality Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[&#8195;&#8195;&#8195;&#8195;], 20[&#8195;], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees (as defined
below).&#8195; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section&nbsp;7 of the Employment
Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#8217;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company
and Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Severance Payments and Benefits; Salary and Benefits</U>. Provided that the Effective
Date occurs and Executive continues to comply with this Release and the Continuing Obligations, the Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, payable at the
times set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive
the Accrued Obligations described in Section&nbsp;7(a) of the Employment Agreement, subject to and in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims (as defined below), the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries or affiliates, and any of their current, former and future officers, directors, equity holders,
managers, employees, agents, investors, lenders, creditors, attorneys, shareholders, members, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations
and assigns (collectively, the &#8220;<U>Releasees</U>&#8221;) related to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#8217;s own behalf and on behalf of any of
Executive&#8217;s affiliated companies or entities and any of their respective heirs, spouses, family members, executors, beneficiaries, trustees, administrators, legal representatives, agents, successors and assigns (collectively, the
&#8220;<U>Releasing Parties</U>&#8221;), other than with respect to the Retained Claims, knowingly and voluntarily, irrevocably and unconditionally, hereby and forever releases and discharges the Releasees from, and agrees not to sue concerning, or
in any manner to institute, prosecute, or pursue, any claim, complaint, charge, commitment, suit, controversy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, duty, obligation, or cause of action, cross-claim, counter claim, demand, debt, right, promise, contract, grievance, compensatory damages, liquidated damages, punitive or exemplary
damages, other damages, claims for costs and attorneys&#8217; fees, expenses, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this Release becomes effective and enforceable), relating to any
matters of any kind, and whether presently known or unknown, suspected or unsuspected, pending or not pending, that Executive or the Releasing Parties may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the date Executive signs this Release relating to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#8217;s employment or service relationship with the Company or any of its direct
or indirect subsidiaries and affiliates and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all claims relating to, or arising from,
Executive&#8217;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty,
breach of duty under applicable state law, and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful
discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory
estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation;
libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights
Act of 1964; the Civil Rights Act of 1991; the Civil Rights Act of 1866 and 1871; the National Labor Relation Act of 1935; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act of 1963; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act of
1988; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Immigration Reform and Control Act of 1986; the Pregnancy Discrimination Act; the Consolidated Omnibus Budget Reconciliation Act; the Sarbanes-Oxley Act of
2002; the Internal Revenue Code of 1986; any applicable Executive Order Programs; and their state and local counterparts, including the California Fair Employment and Housing Act, and the California Government Code Section&nbsp;12940, et. seq., each
as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the <FONT
STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#8217; fees and costs (all of the
foregoing, collectively referred to herein as the &#8220;<U>Claims</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL
AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;A GENERAL RELEASE DOES NOT
EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR
OR RELEASED PARTY.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER,
AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release does not release Claims that cannot be
released as a matter of law, including, but not limited to, (i)&nbsp;Claims that arise solely and completely after Executive executed this Release, (ii)&nbsp;Claims for breach or enforcement of this Release, (iii)&nbsp;Executive&#8217;s right to
report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the
Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, (iv)&nbsp;Executive&#8217;s right to file a charge with or
participate in a charge or investigation by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against
the Company for discrimination (with the understanding that Executive&#8217;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment other than as
otherwise noted above), (v) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#8217;s group benefit plans
pursuant to the terms and conditions of COBRA, (vi)&nbsp;Claims for indemnity under the bylaws of the Company, as provided for by California or Delaware law or under any applicable indemnification agreement or insurance policy with respect to
Executive&#8217;s liability as an employee, director or officer of the Company, (vii)&nbsp;Claims to any benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitlements vested as the date of separation of Executive&#8217;s employment pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#8217;s right
under applicable law and any Retained Claims. This Release further does not release Claims for the Company&#8217;s breach of its executory obligations under Section&nbsp;7 of the Employment Agreement. This Release does not prevent Executive from
cooperating with an investigation conducted by any governmental agencies, including without limitation the National Labor Relations Board (the &#8220;<U>NLRB</U>&#8221;). Nothing herein will prevent Executive from participating in an activity
permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a
trade secret that (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of
law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is sought to be made under seal. The claims described in this paragraph are referred to as the &#8220;<U>Retained Claims</U>.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;<U>ADEA</U>&#8221;), and that this Release is knowing and voluntary. Executive understands and agrees that this Release does not apply to any
rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this Release is in addition to anything of value to which Executive was already
entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive has the right to and is hereby advised to consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> calendar days from the date of initial receipt within which to consider this Release, although Executive may sign it at any time sooner, and
the Parties agree that such time period to review this Release shall not be extended upon any changes to this Release and any such changes are not material or were made at Executive&#8217;s request; (c)&nbsp;Executive has seven (7)&nbsp;calendar
days following Executive&#8217;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Release shall not be effective until the day immediately following this seven
(7)&nbsp;day revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)]
calendar day period identified above, Executive hereby acknowledges that Executive was afforded the opportunity to have a period of at least <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] calendar days to consider it and Executive has
freely and voluntarily chosen to waive the time period allotted for considering this Release. This Release will become effective on the day immediately following the seventh (7th) calendar day after Executive signed this Release (the
&#8220;<U>Effective Date</U>&#8221;). Executive further understands that Executive will not be given any severance benefits under Section&nbsp;7 of the Employment Agreement unless this Release is effective on or before the date that is fifty-five
(55)&nbsp;days following the date of Executive&#8217;s termination of employment. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For individuals age 40 or over, in the event of a group termination, to be 45 days with an OWBPA disclosure
added. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Terminations; Resignations</U>. Executive hereby confirms Executive&#8217;s
termination from all offices, directorships and other positions, if any, then held with the Company, effective as of the date of Executive&#8217;s termination of employment, and shall take all actions reasonably requested by the Company to
effectuate the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Executive Representations</U>. Executive represents and warrants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Executive has surrendered to the Company all lists, books and records of, or in connection with, the Company business, and all other
property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Executive is not owed wages, commissions, bonuses or other compensation, other than the Accrued Obligations and as set forth in
Section&nbsp;7(a) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the course of Executive&#8217;s employment, Executive did not sustain any
injuries for which Executive might be entitled to compensation pursuant to worker&#8217;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to
compensation pursuant to worker&#8217;s compensation law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Confirmation of Continuing Obligations</U>. Executive hereby
expressly reaffirms Executive&#8217;s continuing obligations under any agreements or other documents with the Company or any of the other Releasees, including, without limitation, Section&nbsp;10 of the Employment Agreement and the Confidentiality
Agreement, and Executive acknowledges that such obligations shall survive Executive&#8217;s termination of employment (collectively, the &#8220;<B>Continuing Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Assignment</U>. Executive represents and warrants to the Releasees that there has been no assignment or other transfer of any
interest in any claim that Executive may have against the Releasees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Severability</U>. In the event that any provision or any
portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Release shall continue in full force and effect
without said provision or portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><U>Governing Law;
Venue</U>. This Release shall be governed by and construed in accordance with the laws of the [State of California], without regard to the conflicts of laws principles thereof. Any action brought hereon shall be brought in the state or federal
courts sitting in [San Diego County, California], the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over such party
and consents to service of process in any manner authorized by [California] law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Dispute Resolution</U>. All disputes under
this Release shall be governed by Section 11 of the Employment Agreement. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be updated for employee location. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Entire Agreement; Modification</U>. This Release and the Confidentiality
Agreement (and the other documents referenced herein and therein, including the Continuing Obligations) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them
concerning such subject matter. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Counterparts; .pdf Signatures</U>. This Release may be executed in any number of counterparts, each of which
when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by .pdf file and upon such delivery the.pdf signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Voluntary Execution of Agreement</U>.
Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#8217;s claims
against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set
forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation, and execution of this Release by legal counsel of Executive&#8217;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands
the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive is fully aware of the legal and binding effect of this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Print Name: Brendan Winslow</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ATRIUM THERAPEUTICS.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:<U></U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By:<U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;&#8194;&#8194;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>10
<FILENAME>d42675dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;,
2026 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephanie Kenney </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stephanie: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
distribution (the &#8220;<B>Distribution</B>&#8221;) by Avidity Biosciences, Inc. (&#8220;<B>Avidity</B>&#8221;) of all the issued and outstanding shares of common stock, par value $0.001 per share of Atrium Therapeutics, Inc. (the
&#8220;<B>Company</B>&#8221;), you and the Company desire to enter into this Employment Agreement (this &#8220;<B>Agreement</B>&#8221;), which shall be effective from and after (and subject to the occurrence of) the date of the Distribution and
which shall supersede and replace your existing employment agreement with Avidity dated June&nbsp;25, 2025 (the &#8220;<B>Prior Agreement</B>&#8221;), which Prior Agreement is being transferred to the Company in connection with the Distribution,
upon such effectiveness. In the event that the Distribution does not occur, this Agreement shall be null and void, <I>ab initio</I>.<B> </B>The provisions set forth herein shall be in effect from and after the Distribution, and by entering into this
Agreement, you understand and agree that you shall have no further rights or claims under the Prior Agreement as of the date of the Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>Title. </B>You will serve as the Company&#8217;s Chief Corporate Affairs Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>Duties. </B>In this position, you will be designated as an executive officer of the Company for purposes of Section&nbsp;16 of the
Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). You will be responsible for performing such duties as are customary for your position and any other duties or areas of responsibility that may be reasonably
requested from time to time by the Company&#8217;s Chief Executive Officer, to whom you will report. You shall devote your best efforts and full business time, skill and attention to the performance of your duties. You will also be expected to
adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the Company&#8217;s general employment policies or practices, this Agreement
will control. Your primary work location shall be [&#8195;&#8195;&#8195;&#8195;&#8195;]. The Company reserves the right to reasonably require you to perform your duties at places other than your primary office location from time to time, and to
require reasonable business travel with reimbursement in a manner consistent with the Company&#8217;s travel reimbursement policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>Salary. </B>You will be paid an annual base salary of $440,000, less applicable deductions and withholdings, to be paid each month
in accordance with the Company&#8217;s payroll practices, as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>Benefits. </B>You will be
eligible to participate in the Company&#8217;s standard benefit programs, subject to the terms and conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information regarding these benefits
is available for your review upon request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>Equity Awards. </B>You will be eligible to receive Stock Awards (as defined
below) covering the Company&#8217;s common stock under the equity plans maintained by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>Performance Bonuses.</B>
Commencing in 2026,<B> </B>you will be eligible to earn an annual incentive bonus equal to forty percent (40%) of your annual base salary (your &#8220;<B>Target Bonus</B>&#8221;) Whether you receive such a bonus, and the amount of any such bonus,
shall be determined by the Company&#8217;s Board of Directors (the &#8220;<B>Board</B>&#8221;)<B> </B>(or duly authorized committee thereof) in its sole discretion, and shall be based upon achievement of performance objectives established by the
Board (or duly authorized committee thereof) and other criteria to be determined by the Board (or duly authorized committee thereof). Any bonus shall be paid within thirty (30)&nbsp;days after the Board&#8217;s (or such committee&#8217;s)
determination that a bonus shall be awarded. Except as described in Section&nbsp;7 below, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus. Therefore, if your employment is terminated either by you or the
Company for any reason prior to the bonus being paid, you will not have earned the bonus and no partial or prorated bonus will be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> </B><B>Employment; </B><B>Termination.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment with the Company will be <FONT
STYLE="white-space:nowrap">&#8220;at-will.&#8221;</FONT> This means that either you or the Company may terminate your employment at any time, with or without Cause or Good Reason (each as defined below), and with or without advance notice. In the
event of your termination of employment for any reason, the Company shall pay to you (i)&nbsp;your fully earned but unpaid base salary, when due, through the date of your termination of employment at the rate then in effect, (ii)&nbsp;accrued and
unused vacation and/or paid time off, (iii)&nbsp;if your termination occurs after the occurrence of a Change of Control and after the conclusion of a calendar year in respect of which no annual bonus has yet been paid (i.e., such termination occurs
on or after January&nbsp;1, but before the designated payment date for the annual bonus in respect of such completed calendar year), your annual bonus for such completed calendar year based on actual performance as determined by the Board (or duly
authorized committee thereof), paid when annual bonuses are paid to the Company&#8217;s employees generally for such completed calendar year, but in all events prior to March&nbsp;15 of the calendar year in which your termination occurs, plus
(iv)&nbsp;all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which you may be entitled pursuant to
the terms of such plans or agreements at the time of your termination of employment (the &#8220;<B>Accrued Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Termination For </B><B>Cause; </B><B>Resignation Without Good Reason. </B>If, at any time, the Company terminates your employment
for Cause, you resign without Good Reason, or if either party terminates your employment as a result of your death or disability, you will receive the Accrued Obligations. Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<B>Termination Without Cause; Resignation With Good Reason Not
in Connection With a Change of Control. </B>If at any time other than during the Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your
employment as a result of your death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; (as defined under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h),</FONT> without regard to any alternative definition thereunder, a &#8220;<B>Separation from Service</B>&#8221;),
then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Severance Benefits</B>&#8221;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to nine (9)&nbsp;months of your then current base salary (at the rate in effect immediately prior to the date of
your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such material diminution), to be paid in a lump sum on the
sixtieth (60th) day following your Separation from Service (the &#8220;<B>Salary Severance</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;if you timely
elect continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<B>COBRA</B>&#8221;) for yourself and your covered dependents under the Company&#8217;s group health plans following such termination or
resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A)&nbsp;the close of the
nine (9)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible for substantially equivalent health
insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>COBRA Payment </B><B>Period</B>&#8221;).<B> </B>Notwithstanding the foregoing,
if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Internal Revenue Code of 1986, as amended (the
&#8220;<B>Code</B>&#8221;), or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of
providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to
applicable tax withholdings (such amount, the &#8220;<B>Special </B><B>Severance </B><B>Payment</B>&#8221;), for the remainder of the COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of
COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to
the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule
described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and
all payments and obligations under this clause shall cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<B>Termination Without Cause; Resignation With Good Reason During
the Change </B><B>of </B><B>Control Period. </B>If the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your employment as a result of your death or disability, in each case within
fifty-nine (59)&nbsp;days prior to or twenty-four (24)&nbsp;months following the effective date of a Change of Control (as defined herein) (the &#8220;<B>Change </B><B>of Control </B><B>Period</B>&#8221;), and provided such termination constitutes a
Separation from Service, then subject to your obligations below, you shall be entitled to receive the following severance benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#8220;<B>Change of Control Severance Benefits</B>&#8221;)<B> </B>in lieu of the Severance Benefits (and for the avoidance of doubt, in no event will you be entitled to both
the Severance Benefits and the Change of Control Severance Benefits): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to twelve (12)&nbsp;months of your then
current base salary (at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in
effect prior to such material diminution), less all applicable withholdings and deductions, to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Change of Control </B><B>Salary
Severance</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;an amount equal to 100% of your Target Bonus for the calendar year in which your termination occurs
(at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such
material diminution), less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;an amount equal to your Target Bonus for the calendar year in which your termination occurs (at the rate in effect immediately
prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution), prorated for
the portion of the year that has elapsed through your date of termination of employment with the Company, less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#8217;s group health
plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the
earliest of (A)&nbsp;the close of the twelve (12)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>Change </B><B>of Control </B><B>COBRA
Payment </B><B>Period</B>&#8221;). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the
Code or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA
premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the Change of Control COBRA Payment Period, the Special Severance Payment, for the remainder of the Change of Control COBRA Payment Period.
You may, but are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case
of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described
above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all
payments and obligations under this clause shall cease; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;acceleration of 100% of any unvested time-based Stock Awards. Such
acceleration shall be effective as of the later of (A)&nbsp;the effective date of your Separation from Service, or (B)&nbsp;the date of such Change of Control (for the avoidance of doubt, the accelerated vesting of any Stock Awards that are
performance-based shall be governed by the applicable equity plan and agreement or plan regarding such Stock Award pursuant to which they were granted). The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any
less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable
provisions shall continue to apply and shall not be limited by this clause (v)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<B>Conditions For Receipt of </B><B>Severance
</B><B>Benefits or Change of Control </B><B>Severance </B><B>Benefits. </B>The Severance Benefits or Change of Control Severance Benefits are conditional upon (x)&nbsp;your continuing to comply with your obligations under your Employee Invention
Assignment and Confidentiality Agreement; (y)&nbsp;your delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached hereto as <B>Exhibit </B><B>A </B>(the
&#8220;<B>Release</B>&#8221;), and any revocation period thereunder having expired, within sixty (60)&nbsp;days following your termination date; and (z)&nbsp;if you are a member of the Board, your resignation from the Board, to be effective no later
than the date of your termination date (or such other date as requested by the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<B>No Mitigation. </B>You shall not be
required in any way to mitigate the amount of any payment provided for in this Section&nbsp;7, including, without limitation, by seeking other employment, nor shall the amount of any payment provided for in this Section&nbsp;7 be reduced by any
compensation earned by you as the result of employment with another employer after the termination date of employment, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Definition of Cause. </B>For purposes of this Agreement, &#8220;<B>Cause</B>&#8221; shall mean one or more of the following:
(A)&nbsp;your willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy (B)&nbsp;your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct
that has caused or is reasonably expected to result in material injury to the Company; (C)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or (D)&nbsp;your willful breach of any of your obligations under any written agreement or covenant with the Company. The determination as to whether you are being terminated for Cause
shall be made in good faith by the Board. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate your employment at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Definition of Good Reason. </B>For purposes of this Agreement, &#8220;<B>Good
Reason</B>&#8221;<B> </B>shall mean your resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&#8195;a material reduction in your base salary or Target Bonus if such a reduction is not made in proportion to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reduction for all senior executives of the Company (and for the avoidance of doubt, following a Change of Control, the reference to senior executives of the
Company shall include, without limitation, the senior executives of the ultimate parent entity of the Company (or its successor)); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&#8195;a material reduction or material adverse change in your duties, responsibilities and/or authorities including, without limitation,
following a Change of Control, your ceasing to report to the Chief Executive Officer of the ultimate parent entity of the Company (or its successor), and/or your ceasing to serve as the Chief Corporate Affairs Officer of such ultimate parent entity;
<I>provided that,</I> prior to a Change of Control, it shall not constitute Good Reason if such reduction is a mere change of title alone or change in reporting relationship and <I>provided further that,</I> changes in your position, title and/or
duties as a result of the Distribution shall not constitute Good Reason; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&#8195;relocation of your principal place of employment to a
place that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then- current principal place of employment immediately prior to such relocation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&#8195;any other action or inaction that constitutes a material breach by the Company of this Agreement or any agreement under which you
provide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided, however that, such termination by you shall only be deemed for Good Reason pursuant to the foregoing definition if
(i)&nbsp;the Company is given written notice from you within ninety (90)&nbsp;days following the first occurrence of the condition that you consider to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy
such condition within thirty (30)&nbsp;days following such written notice, and (ii)&nbsp;you terminate employment within ninety (90)&nbsp;days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Definition of Change of Control. </B>For purposes of this Agreement, &#8220;<B>Change
</B><B>of </B><B>Control</B>&#8221; shall have the meaning given to such term in the Company&#8217;s 2026 Incentive Award Plan as in effect on the date hereof, it being understood that the Distribution will not constitute a Change of Control.
Notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes &#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting
the Change of Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1,409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for
such payment or benefit, to the extent required by Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;<B>Definition of Stock Awards. </B>For purposes of this
Agreement, &#8220;Stock Awards&#8221; shall mean all stock options, restricted stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award plans or agreements and any shares of stock issued upon
exercise thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>Section 409A. </B>It is intended that all of the severance benefits and other
payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Code Section&nbsp;409A. For purposes of Code Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of
separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of
your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are
deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to you prior to the earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of your Separation from Service with
the Company, (ii)&nbsp;the date of your death or (iii)&nbsp;such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code
Section&nbsp;409A(a)(2)( B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred. All reimbursements and <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that
such reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (A)&nbsp;any reimbursement is for expenses incurred during your lifetime (or during
a shorter period of time specified in this Agreement), (B) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (C)&nbsp;the reimbursement of any
eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (D)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.
Notwithstanding any provision to the contrary in this Agreement, to the extent any payments to you pursuant to this Agreement constitute &#8220;nonqualified deferred compensation&#8221; subject to Section&nbsp;409A of the Code or are intended to be
exempt from Section&nbsp;409A of the Code pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1</FONT> (b)(9)(iii), then, to the extent required by Section&nbsp;409A of the Code or to satisfy such exception, no
amount shall be payable pursuant to such sections unless your termination of employment constitutes a Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>Parachute Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Best </B><B>Pay </B><B>Provision. </B>In the event that any payment or benefit received or to be received by you pursuant to the
terms of any plan, arrangement or agreement (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment or benefit received in connection with a change in ownership or control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the
&#8220;<B>Total Payments</B>&#8221;) would be subject (in whole or part) to the excise tax (the &#8220;<B>Excise Tax</B>&#8221;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and
personal exemptions attributable to such unreduced Total Payments). Except to the extent that an alternative reduction order would result in a greater economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties
intend that the Total Payments shall be reduced in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to you that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or
benefits otherwise payable to you that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the
Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to you on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment
attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to
any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first
applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes
on you under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically
equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Determinations. </B>All determinations
regarding the application of this Section&nbsp;9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability
of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#8220;<B>280G </B><B>Firm</B>&#8221;).<B> </B>For purposes of determining whether and the extent to
which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G(b)(2) of
the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the
Code, in excess of the &#8220;base amount&#8221; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which you shall have waived at
such time and in such manner as not to constitute a &#8220;payment&#8221; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or
any deferred payment or benefit included in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be
performed pursuant to this Section&nbsp;9 shall be done by the 280G Firm in consultation with the Company. The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and the Company within fifteen
(15)&nbsp;days after notification from either the Company or you that you may receive payments which may be &#8220;parachute payments.&#8221; You and the Company will each provide the 280G Firm access to and copies of any books, records, and
documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the
280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>Confidentiality Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Confidentiality Obligations. </B>In connection with your employment, you have signed and agreed to abide by the Company&#8217;s
standard form of Employee Invention Assignment and Confidentiality Agreement, a copy of which is attached hereto as <B>Exhibit B </B>(the &#8220;<B>Confidentiality Agreement</B>&#8221;). In your work for the Company, you are expected not to use or
disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you are expected to use only that information which is generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto
Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that your employment does not create a conflict with any agreement
between you and a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Other </B><B>Protections. </B>You acknowledge that the Company has provided you with the
following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i)&nbsp;you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of confidential
information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii)&nbsp;you shall not be held criminally or civilly
liable under any Federal or State trade secret law for the disclosure of confidential information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii)&nbsp;if you file a
lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the confidential information to your attorney and use the confidential information in the court proceeding, if you file any document containing the
confidential information under seal, and do not disclose the confidential information, except pursuant to court order. In addition, nothing in this Agreement or the Confidentiality Agreement shall prevent you from (x)&nbsp;communicating directly
with, cooperating with, or providing information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading
Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeking permission from the Company, (y)&nbsp;exercising any rights you may have under Section&nbsp;7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity,
including collective action or discussion concerning wages or working conditions, or (z)&nbsp;discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any
other conduct that you have reason to believe is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>Arbitration. </B>To ensure the timely and economical resolution
of disputes that may arise in connection with your employment with the Company, to the extent permitted by applicable law, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement,
breach, performance, negotiation, execution, or interpretation of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> or if inapplicable, the California Arbitration Act, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single neutral arbitrator in Marin County,
California, chosen jointly by the parties, and will be conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/
or will be provided to you upon request without charge). If the parties cannot agree on an arbitrator, then JAMS shall appoint an arbitrator in accordance with JAMS rules. <B>By </B><B>agreeing </B><B>to this arbitration procedure, both you and the
Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </B>The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding. In
addition, all claims, disputes, or causes of action under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or
representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of
law rather than by arbitration. This paragraph shall not apply to an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a)&nbsp;have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of
the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would
be required of you if the dispute were filed in Superior Court. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>Successors. </B>This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our
respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Any successor to the Company (whether direct or indirect
and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially all of the Company&#8217;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform any of the Company&#8217;s obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>Miscellaneous. </B>This Agreement, including the exhibits hereto, is the complete and exclusive statement of all
of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral, including, without limitation, the Prior
Agreement. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the
Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid,
illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>Indemnification. </B>You will receive defense and be indemnified by the Company to the full extent of the provisions of the
Company&#8217;s charter and bylaws and applicable Delaware law and the Indemnification Agreement between you and the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>Withholding and </B><B>other </B><B>Deductions. </B>All compensation payable to you hereunder shall be subject to such deductions
as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<B>Notices. </B>All
notices or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one (1)&nbsp;business day after being sent by a nationally recognized
overnight delivery service, charges prepaid. Notices also may be given electronically via PDF and shall be effective on the date transmitted if confirmed within forty-eight (48)&nbsp;hours thereafter by a signed original sent in the manner provided
in the preceding sentence. Notice to you shall be sent to your most recent residence and personal email address on file with the Company. Notice to the Company shall be sent to its physical address set forth on the first page hereto and addressed to
the Company&#8217;s Chief Executive Officer at the email address provided by the Company for such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best regards, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATRIUM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Accepted and agreed:&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U><U>&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Stephanie Kenney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Employment Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#8220;Release&#8221;) is made by and between Stephanie Kenney (&#8220;Executive&#8221;) and Atrium
Therapeutics. (the &#8220;Company&#8221;) (collectively referred to as the &#8220;Parties&#8221; or individually referred to as a &#8220;Party&#8221;). Capitalized terms used but not defined in this Release shall have the meanings set forth in the
Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain Employment Agreement, effective
as of Month [&#8195;&#8195;&#8195;], 202[X] (the &#8220;Employment Agreement&#8221;) and that certain Confidentiality Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[&#8195;&#8195;&#8195;], 20[&#8195;], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees (as defined below).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, which,
pursuant to the Employment Agreement, are conditioned on Executive&#8217;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company and Executive
hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Severance Payments and Benefits; Salary and Benefits</U>. Provided that the Effective Date occurs and
Executive continues to comply with this Release and the Continuing Obligations, the Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, payable at the times set forth
in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive the Accrued
Obligations described in Section&nbsp;7(a) of the Employment Agreement, subject to and in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims (as defined below), the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries or affiliates, and any of their current, former and future officers, directors, equity holders,
managers, employees, agents, investors, lenders, creditors, attorneys, shareholders, members, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations
and assigns (collectively, the &#8220;<U>Releasees</U>&#8221;) related to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#8217;s own behalf and on behalf of any of
Executive&#8217;s affiliated companies or entities and any of their respective heirs, spouses, family members, executors, beneficiaries, trustees, administrators, legal representatives, agents, successors and assigns (collectively, the
&#8220;<U>Releasing Parties</U>&#8221;), other than with respect to the Retained Claims, knowingly and voluntarily, irrevocably and unconditionally, hereby and forever releases and discharges the Releasees from, and agrees not to sue concerning, or
in any manner to institute, prosecute, or pursue, any claim, complaint, charge, commitment, suit, controversy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, duty, obligation, or cause of action, cross-claim, counter claim, demand, debt, right, promise, contract, grievance, compensatory damages, liquidated damages, punitive or exemplary
damages, other damages, claims for costs and attorneys&#8217; fees, expenses, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this Release becomes effective and enforceable), relating to any
matters of any kind, and whether presently known or unknown, suspected or unsuspected, pending or not pending, that Executive or the Releasing Parties may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the date Executive signs this Release relating to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;any and all claims relating to or arising from Executive&#8217;s employment or service relationship with the Company or any of its
direct or indirect subsidiaries and affiliates and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;any and all claims relating to, or
arising from, Executive&#8217;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of
fiduciary duty, breach of duty under applicable state law, and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;any and all
claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and
implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business
practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil
Rights Act of 1964; the Civil Rights Act of 1991; the Civil Rights Act of 1866 and 1871; the National Labor Relation Act of 1935; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act of 1963; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act of
1988; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Immigration Reform and Control Act of 1986; the Pregnancy Discrimination Act; the Consolidated Omnibus Budget Reconciliation Act; the Sarbanes-Oxley Act of
2002; the Internal Revenue Code of 1986; any applicable Executive Order Programs; and their state and local counterparts, including the California Fair Employment and Housing Act, and the California Government Code Section&nbsp;12940, et. seq., each
as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;any claim for any loss, cost, damage, or expense arising out of any dispute over
the <FONT STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&#8195;any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive
has provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;any and all claims for attorneys&#8217; fees and costs (all
of the foregoing, collectively referred to herein as the &#8220;<U>Claims</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL
COUNSEL AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;A GENERAL RELEASE
DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE
THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release does not release Claims that
cannot be released as a matter of law, including, but not limited to, (i)&nbsp;Claims that arise solely and completely after Executive executed this Release, (ii)&nbsp;Claims for breach or enforcement of this Release, (iii)&nbsp;Executive&#8217;s
right to report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the
Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, (iv)&nbsp;Executive&#8217;s right to file a charge with or
participate in a charge or investigation by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against
the Company for discrimination (with the understanding that Executive&#8217;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment other than as
otherwise noted above), (v) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#8217;s group benefit plans
pursuant to the terms and conditions of COBRA, (vi)&nbsp;Claims for indemnity under the bylaws of the Company, as provided for by California or Delaware law or under any applicable indemnification agreement or insurance policy with respect to
Executive&#8217;s liability as an employee, director or officer of the Company, (vii)&nbsp;Claims to any benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitlements vested as the date of separation of Executive&#8217;s employment pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#8217;s right
under applicable law and any Retained Claims. This Release further does not release Claims for the Company&#8217;s breach of its executory obligations under Section&nbsp;7 of the Employment Agreement. This Release does not prevent Executive from
cooperating with an investigation conducted by any governmental agencies, including without limitation the National Labor Relations Board (the &#8220;<U>NLRB</U>&#8221;). Nothing herein will prevent Executive from participating in an activity
permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a
trade secret that (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of
law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is sought to be made under seal. The claims described in this paragraph are referred to as the &#8220;<U>Retained Claims</U>.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;<U>ADEA</U>&#8221;), and that this Release is knowing and voluntary. Executive understands and agrees that this Release does not apply to any
rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this Release is in addition to anything of value to which Executive was already
entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive has the right to and is hereby advised to consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> calendar days from the date of initial receipt within which to consider this Release, although Executive may sign it at any time sooner, and
the Parties agree that such time period to review this Release shall not be extended upon any changes to this Release and any such changes are not material or were made at Executive&#8217;s request; (c)&nbsp;Executive has seven (7)&nbsp;calendar
days following Executive&#8217;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Release shall not be effective until the day immediately following this seven
(7)&nbsp;day revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)]
calendar day period identified above, Executive hereby acknowledges that Executive was afforded the opportunity to have a period of at least <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] calendar days to consider it and Executive has
freely and voluntarily chosen to waive the time period allotted for considering this Release. This Release will become effective on the day immediately following the seventh (7th) calendar day after Executive signed this Release (the
&#8220;<U>Effective Date</U>&#8221;). Executive further understands that Executive will not be given any severance benefits under Section&nbsp;7 of the Employment Agreement unless this Release is effective on or before the date that is fifty-five
(55)&nbsp;days following the date of Executive&#8217;s termination of employment. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For individuals age 40 or over, in the event of a group termination, to be 45 days with an OWBPA disclosure
added. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Terminations; Resignations</U>. Executive hereby confirms Executive&#8217;s
termination from all offices, directorships and other positions, if any, then held with the Company, effective as of the date of Executive&#8217;s termination of employment, and shall take all actions reasonably requested by the Company to
effectuate the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Executive Representations</U>. Executive represents and warrants that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Executive has surrendered to the Company all lists, books and records of, or in connection with, the Company business, and all other
property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Executive is not owed wages, commissions, bonuses or other compensation, other than the Accrued Obligations and as set forth in
Section&nbsp;7(a) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the course of Executive&#8217;s employment, Executive did not sustain any
injuries for which Executive might be entitled to compensation pursuant to worker&#8217;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to
compensation pursuant to worker&#8217;s compensation law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Confirmation of Continuing Obligations</U>. Executive hereby
expressly reaffirms Executive&#8217;s continuing obligations under any agreements or other documents with the Company or any of the other Releasees, including, without limitation, Section&nbsp;10 of the Employment Agreement and the Confidentiality
Agreement, and Executive acknowledges that such obligations shall survive Executive&#8217;s termination of employment (collectively, the &#8220;<B>Continuing Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Assignment</U>. Executive represents and warrants to the Releasees that there has been no assignment or other transfer of any
interest in any claim that Executive may have against the Releasees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Severability</U>. In the event that any provision or any
portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Release shall continue in full force and effect
without said provision or portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><U>Governing Law;
Venue</U>. This Release shall be governed by and construed in accordance with the laws of the [State of California], without regard to the conflicts of laws principles thereof. Any action brought hereon shall be brought in the state or federal
courts sitting in [San Diego County, California], the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over such party
and consents to service of process in any manner authorized by [California] law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Dispute Resolution</U>. All disputes under
this Release shall be governed by Section&nbsp;11 of the Employment Agreement. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be updated for employee location. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Entire Agreement; Modification</U>. This Release and the Confidentiality
Agreement (and the other documents referenced herein and therein, including the Continuing Obligations) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them
concerning such subject matter. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Counterparts; .pdf Signatures</U>. This Release may be executed in any number of counterparts, each of which
when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by .pdf file and upon such delivery the.pdf signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Voluntary Execution of Agreement</U>.
Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#8217;s claims
against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set
forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation, and execution of this Release by legal counsel of Executive&#8217;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands
the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive is fully aware of the legal and binding effect of this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Print Name: Stephanie Kenney</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>ATRIUM THERAPEUTICS.</B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>11
<FILENAME>d42675dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rocio Martin Hoyos </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Rocio: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the distribution
(the &#8220;<B>Distribution</B>&#8221;) by Avidity Biosciences, Inc. (&#8220;<B>Avidity</B>&#8221;) of all the issued and outstanding shares of common stock, par value $0.001 per share of Atrium Therapeutics, Inc. (the &#8220;<B>Company</B>&#8221;),
you and the Company desire to enter into this Employment Agreement (this &#8220;<B>Agreement</B>&#8221;), which shall be effective from and after (and subject to the occurrence of) the date of the Distribution and which shall supersede and replace
your existing employment agreement with Avidity dated April&nbsp;11, 2024 (the &#8220;<B>Prior Agreement</B>&#8221;), which Prior Agreement is being transferred to the Company in connection with the Distribution, upon such effectiveness. In the
event that the Distribution does not occur, this Agreement shall be null and void, <I>ab initio</I>.<B> </B>The provisions set forth herein shall be in effect from and after the Distribution, and by entering into this Agreement, you understand and
agree that you shall have no further rights or claims under the Prior Agreement as of the date of the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>Title.
</B>You will serve as the Company&#8217;s Chief Strategy Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>Duties. </B>In this position, you will be designated as an
executive officer of the Company for purposes of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). You will be responsible for performing such duties as are customary for your position and
any other duties or areas of responsibility that may be reasonably requested from time to time by the Company&#8217;s Chief Executive Officer, to whom you will report. You shall devote your best efforts and full business time, skill and attention to
the performance of your duties. You will also be expected to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the
Company&#8217;s general employment policies or practices, this Agreement will control. Your primary work location shall be [&#8195;&#8195;&#8195;&#8195;]. The Company reserves the right to reasonably require you to perform your duties at places
other than your primary office location from time to time, and to require reasonable business travel with reimbursement in a manner consistent with the Company&#8217;s travel reimbursement policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>Salary. </B>You will be paid an annual base salary of $465,000, less applicable deductions and withholdings, to be paid each month
in accordance with the Company&#8217;s payroll practices, as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>Benefits. </B>You will be
eligible to participate in the Company&#8217;s standard benefit programs, subject to the terms and conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information regarding these benefits
is available for your review upon request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>Equity Awards. </B>You will be eligible to receive Stock Awards (as defined
below) covering the Company&#8217;s common stock under the equity plans maintained by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>Performance Bonuses.</B>
Commencing in 2026,<B> </B>you will be eligible to earn an annual incentive bonus equal to forty percent (40%) of your annual base salary (your &#8220;<B>Target Bonus</B>&#8221;) Whether you receive such a bonus, and the amount of any such bonus,
shall be determined by the Company&#8217;s Board of Directors (the &#8220;<B>Board</B>&#8221;)<B> </B>(or duly authorized committee thereof) in its sole discretion, and shall be based upon achievement of performance objectives established by the
Board (or duly authorized committee thereof) and other criteria to be determined by the Board (or duly authorized committee thereof). Any bonus shall be paid within thirty (30)&nbsp;days after the Board&#8217;s (or such committee&#8217;s)
determination that a bonus shall be awarded. Except as described in Section&nbsp;7 below, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus. Therefore, if your employment is terminated either by you or the
Company for any reason prior to the bonus being paid, you will not have earned the bonus and no partial or prorated bonus will be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> </B><B>Employment; </B><B>Termination.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment. </B>Your employment with the Company will be <FONT
STYLE="white-space:nowrap">&#8220;at-will.&#8221;</FONT> This means that either you or the Company may terminate your employment at any time, with or without Cause or Good Reason (each as defined below), and with or without advance notice. In the
event of your termination of employment for any reason, the Company shall pay to you (i)&nbsp;your fully earned but unpaid base salary, when due, through the date of your termination of employment at the rate then in effect, (ii)&nbsp;accrued and
unused vacation and/or paid time off, (iii)&nbsp;if your termination occurs after the occurrence of a Change of Control and after the conclusion of a calendar year in respect of which no annual bonus has yet been paid (i.e., such termination occurs
on or after January&nbsp;1, but before the designated payment date for the annual bonus in respect of such completed calendar year), your annual bonus for such completed calendar year based on actual performance as determined by the Board (or duly
authorized committee thereof), paid when annual bonuses are paid to the Company&#8217;s employees generally for such completed calendar year, but in all events prior to March&nbsp;15 of the calendar year in which your termination occurs, plus
(iv)&nbsp;all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which you may be entitled pursuant to
the terms of such plans or agreements at the time of your termination of employment (the &#8220;<B>Accrued Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Termination For </B><B>Cause; </B><B>Resignation Without Good Reason. </B>If, at any time, the Company terminates your employment
for Cause, you resign without Good Reason, or if either party terminates your employment as a result of your death or disability, you will receive the Accrued Obligations. Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<B>Termination Without Cause; Resignation With Good Reason Not
in Connection With a Change of Control. </B>If at any time other than during the Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your
employment as a result of your death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; (as defined under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h),</FONT> without regard to any alternative definition thereunder, a &#8220;<B>Separation from Service</B>&#8221;),
then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the &#8220;<B>Severance Benefits</B>&#8221;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to nine (9)&nbsp;months of your then current base salary (at the rate in effect immediately prior to the date of
your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in effect prior to such material diminution), to be paid in a lump sum on the
sixtieth (60th) day following your Separation from Service (the &#8220;<B>Salary Severance</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;if you timely
elect continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<B>COBRA</B>&#8221;) for yourself and your covered dependents under the Company&#8217;s group health plans following such termination or
resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A)&nbsp;the close of the
nine (9)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become eligible for substantially equivalent health
insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>COBRA Payment </B><B>Period</B>&#8221;).<B> </B>Notwithstanding the foregoing,
if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of Section&nbsp;105(h)(2) of the Internal Revenue Code of 1986, as amended (the
&#8220;<B>Code</B>&#8221;), or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of
providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to
applicable tax withholdings (such amount, the &#8220;<B>Special </B><B>Severance </B><B>Payment</B>&#8221;), for the remainder of the COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of
COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to
the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule
described above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and
all payments and obligations under this clause shall cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<B>Termination Without Cause; Resignation With Good Reason During
the Change </B><B>of </B><B>Control Period. </B>If the Company terminates your employment without Cause or you resign for Good Reason, and other than any termination of your employment as a result of your death or disability, in each case within
fifty-nine (59)&nbsp;days prior to or twenty-four (24)&nbsp;months following the effective date of a Change of Control (as defined herein) (the &#8220;<B>Change </B><B>of Control </B><B>Period</B>&#8221;), and provided such termination constitutes a
Separation from Service, then subject to your obligations below, you shall be entitled to receive the following severance benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#8220;<B>Change of Control Severance Benefits</B>&#8221;)<B> </B>in lieu of the Severance Benefits (and for the avoidance of doubt, in no event will you be entitled to both
the Severance Benefits and the Change of Control Severance Benefits): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;an amount equal to twelve (12)&nbsp;months of your then
current base salary (at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your base salary which would give rise to Good Reason for your resignation, the base salary in
effect prior to such material diminution), less all applicable withholdings and deductions, to be paid in a lump sum on the sixtieth (60th) day following your Separation from Service (the &#8220;<B>Change of Control </B><B>Salary
Severance</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;an amount equal to 100% of your Target Bonus for the calendar year in which your termination occurs
(at the rate in effect immediately prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such
material diminution), less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;an amount equal to your Target Bonus for the calendar year in which your termination occurs (at the rate in effect immediately
prior to the date of your termination of employment, or in the case of a material diminution in your Target Bonus which would give rise to Good Reason for your resignation, the Target Bonus in effect prior to such material diminution), prorated for
the portion of the year that has elapsed through your date of termination of employment with the Company, less all applicable withholdings and deductions, paid in a lump sum on the sixtieth (60th) day following your Separation from Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#8217;s group health
plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the
earliest of (A)&nbsp;the close of the twelve&nbsp;(12)&nbsp;month period following the termination of your employment, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;the date when you become
eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A)&nbsp;through (C), the &#8220;<B>Change </B><B>of Control
</B><B>COBRA Payment </B><B>Period</B>&#8221;). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of the nondiscrimination rules of
Section&nbsp;105(h)(2) of the Code or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu
of providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the Change of Control COBRA Payment Period, the Special Severance Payment, for the remainder of the Change of
Control COBRA Payment Period. You may, but are not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. On the sixtieth (60th) day following your Separation from Service, the Company will make the first payment under
this clause (and, in the case of the Special Severance Payment, such payment will be paid to you in a lump sum) equal to the aggregate amount of payments that the Company would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60th) day, with the balance of the payments paid thereafter on the schedule described
above. If you become eligible for coverage under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all
payments and obligations under this clause shall cease; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;acceleration of 100% of any unvested time-based Stock Awards. Such
acceleration shall be effective as of the later of (A)&nbsp;the effective date of your Separation from Service, or (B)&nbsp;the date of such Change of Control (for the avoidance of doubt, the accelerated vesting of any Stock Awards that are
performance-based shall be governed by the applicable equity plan and agreement or plan regarding such Stock Award pursuant to which they were granted). The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any
less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable
provisions shall continue to apply and shall not be limited by this clause (v)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<B>Conditions For Receipt of </B><B>Severance
</B><B>Benefits or Change of Control </B><B>Severance </B><B>Benefits. </B>The Severance Benefits or Change of Control Severance Benefits are conditional upon (x)&nbsp;your continuing to comply with your obligations under your Employee Invention
Assignment and Confidentiality Agreement; (y)&nbsp;your delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached hereto as <B>Exhibit </B><B>A </B>(the
&#8220;<B>Release</B>&#8221;), and any revocation period thereunder having expired, within sixty (60)&nbsp;days following your termination date; and (z)&nbsp;if you are a member of the Board, your resignation from the Board, to be effective no later
than the date of your termination date (or such other date as requested by the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<B>No Mitigation. </B>You shall not be
required in any way to mitigate the amount of any payment provided for in this Section&nbsp;7, including, without limitation, by seeking other employment, nor shall the amount of any payment provided for in this Section&nbsp;7 be reduced by any
compensation earned by you as the result of employment with another employer after the termination date of employment, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Definition of Cause. </B>For purposes of this Agreement, &#8220;<B>Cause</B>&#8221; shall mean one or more of the following:
(A)&nbsp;your willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy (B)&nbsp;your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct
that has caused or is reasonably expected to result in material injury to the Company; (C)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or (D)&nbsp;your willful breach of any of your obligations under any written agreement or covenant with the Company. The determination as to whether you are being terminated for Cause
shall be made in good faith by the Board. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate your employment at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Definition of Good Reason. </B>For purposes of this Agreement, &#8220;<B>Good
Reason</B>&#8221;<B> </B>shall mean your resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&#8195;a material reduction in your base salary or Target Bonus if such a reduction is not made in proportion to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reduction for all senior executives of the Company (and for the avoidance of doubt, following a Change of Control, the reference to senior executives of the
Company shall include, without limitation, the senior executives of the ultimate parent entity of the Company (or its successor)); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&#8195;a material reduction or material adverse change in your duties, responsibilities and/or authorities including, without limitation,
following a Change of Control, your ceasing to report to the Chief Executive Officer of the ultimate parent entity of the Company (or its successor), and/or your ceasing to serve as the Chief Strategy Officer of such ultimate parent entity;
<I>provided that,</I> prior to a Change of Control, it shall not constitute Good Reason if such reduction is a mere change of title alone or change in reporting relationship and <I>provided further that,</I> changes in your position, title and/or
duties as a result of the Distribution shall not constitute Good Reason; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&#8195;relocation of your principal place of employment to a
place that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then-current principal place of employment immediately prior to such relocation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)&#8195;any other action or inaction that constitutes a material breach by the Company of this Agreement or any agreement under which you
provide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided, however that, such termination by you shall only be deemed for Good Reason pursuant to the foregoing definition if
(i)&nbsp;the Company is given written notice from you within ninety (90)&nbsp;days following the first occurrence of the condition that you consider to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy
such condition within thirty (30)&nbsp;days following such written notice, and (ii)&nbsp;you terminate employment within ninety (90)&nbsp;days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Definition of Change of Control. </B>For purposes of this Agreement, &#8220;<B>Change
</B><B>of </B><B>Control</B>&#8221; shall have the meaning given to such term in the Company&#8217;s 2026 Incentive Award Plan as in effect on the date hereof, it being understood that the Distribution will not constitute a Change of Control.
Notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes &#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting
the Change of Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1,409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for
such payment or benefit, to the extent required by Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;<B>Definition of Stock Awards. </B>For purposes of this
Agreement, &#8220;Stock Awards&#8221; shall mean all stock options, restricted stock and such other awards granted pursuant to the Company&#8217;s stock option and equity incentive award plans or agreements and any shares of stock issued upon
exercise thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>Section 409A. </B>It is intended that all of the severance benefits and other
payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Code Section&nbsp;409A. For purposes of Code Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of
separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of
your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are
deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to you prior to the earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of your Separation from Service with
the Company, (ii)&nbsp;the date of your death or (iii)&nbsp;such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code
Section&nbsp;409A(a)(2)( B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred. All reimbursements and <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that
such reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (A)&nbsp;any reimbursement is for expenses incurred during your lifetime (or during
a shorter period of time specified in this Agreement), (B) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (C)&nbsp;the reimbursement of any
eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (D)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.
Notwithstanding any provision to the contrary in this Agreement, to the extent any payments to you pursuant to this Agreement constitute &#8220;nonqualified deferred compensation&#8221; subject to Section&nbsp;409A of the Code or are intended to be
exempt from Section&nbsp;409A of the Code pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1</FONT> (b)(9)(iii), then, to the extent required by Section&nbsp;409A of the Code or to satisfy such exception, no
amount shall be payable pursuant to such sections unless your termination of employment constitutes a Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>Parachute Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Best </B><B>Pay </B><B>Provision. </B>In the event that any payment or benefit received or to be received by you pursuant to the
terms of any plan, arrangement or agreement (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment or benefit received in connection with a change in ownership or control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the
&#8220;<B>Total Payments</B>&#8221;) would be subject (in whole or part) to the excise tax (the &#8220;<B>Excise Tax</B>&#8221;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and
personal exemptions attributable to such unreduced Total Payments). Except to the extent that an alternative reduction order would result in a greater economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties
intend that the Total Payments shall be reduced in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to you that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or
benefits otherwise payable to you that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the
Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to you on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment
attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to
any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first
applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes
on you under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically
equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Determinations. </B>All determinations
regarding the application of this Section&nbsp;9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability
of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#8220;<B>280G </B><B>Firm</B>&#8221;).<B> </B>For purposes of determining whether and the extent to
which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G(b)(2) of
the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the
Code, in excess of the &#8220;base amount&#8221; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which you shall have waived at
such time and in such manner as not to constitute a &#8220;payment&#8221; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or
any deferred payment or benefit included in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be
performed pursuant to this Section&nbsp;9 shall be done by the 280G Firm in consultation with the Company. The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and the Company within fifteen
(15)&nbsp;days after notification from either the Company or you that you may receive payments which may be &#8220;parachute payments.&#8221; You and the Company will each provide the 280G Firm access to and copies of any books, records, and
documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the
280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>Confidentiality Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<B>Confidentiality Obligations. </B>In connection with your employment, you have signed and agreed to abide by the Company&#8217;s
standard form of Employee Invention Assignment and Confidentiality Agreement, a copy of which is attached hereto as <B>Exhibit B </B>(the &#8220;<B>Confidentiality Agreement</B>&#8221;). In your work for the Company, you are expected not to use or
disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you are expected to use only that information which is generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto
Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that your employment does not create a conflict with any agreement
between you and a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<B>Other </B><B>Protections. </B>You acknowledge that the Company has provided you with the
following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i)&nbsp;you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of confidential
information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii)&nbsp;you shall not be held criminally or civilly
liable under any Federal or State trade secret law for the disclosure of confidential information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii)&nbsp;if you file a
lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the confidential information to your attorney and use the confidential information in the court proceeding, if you file any document containing the
confidential information under seal, and do not disclose the confidential information, except pursuant to court order. In addition, nothing in this Agreement or the Confidentiality Agreement shall prevent you from (x)&nbsp;communicating directly
with, cooperating with, or providing information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading
Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeking permission from the Company, (y)&nbsp;exercising any rights you may have under Section&nbsp;7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity,
including collective action or discussion concerning wages or working conditions, or (z)&nbsp;discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any
other conduct that you have reason to believe is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>Arbitration. </B>To ensure the timely and economical resolution
of disputes that may arise in connection with your employment with the Company, to the extent permitted by applicable law, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement,
breach, performance, negotiation, execution, or interpretation of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> or if inapplicable, the California Arbitration Act, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single neutral arbitrator in Marin County,
California, chosen jointly by the parties, and will be conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/
or will be provided to you upon request without charge). If the parties cannot agree on an arbitrator, then JAMS shall appoint an arbitrator in accordance with JAMS rules. <B>By </B><B>agreeing </B><B>to this arbitration procedure, both you and the
Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </B>The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding. In
addition, all claims, disputes, or causes of action under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or
representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of
law rather than by arbitration. This paragraph shall not apply to an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a)&nbsp;have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of
the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would
be required of you if the dispute were filed in Superior Court. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>Successors. </B>This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our
respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Any successor to the Company (whether direct or indirect
and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially all of the Company&#8217;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform any of the Company&#8217;s obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>Miscellaneous. </B>This Agreement, including the exhibits hereto, is the complete and exclusive statement of all
of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral, including, without limitation, the Prior
Agreement. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the
Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid,
illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>Indemnification. </B>You will receive defense and be indemnified by the Company to the full extent of the provisions of the
Company&#8217;s charter and bylaws and applicable Delaware law and the Indemnification Agreement between you and the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>Withholding and </B><B>other </B><B>Deductions. </B>All compensation payable to you hereunder shall be subject to such deductions
as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<B>Notices. </B>All
notices or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one (1)&nbsp;business day after being sent by a nationally recognized
overnight delivery service, charges prepaid. Notices also may be given electronically via PDF and shall be effective on the date transmitted if confirmed within forty-eight (48)&nbsp;hours thereafter by a signed original sent in the manner provided
in the preceding sentence. Notice to you shall be sent to your most recent residence and personal email address on file with the Company. Notice to the Company shall be sent to its physical address set forth on the first page hereto and addressed to
the Company&#8217;s Chief Executive Officer at the email address provided by the Company for such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best regards, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ATRIUM THERAPEUTICS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Kathleen Gallagher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Accepted and agreed:&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Rocio Martin Hoyos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Employment Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#8220;<U>Release</U>&#8221;) is made by and between Rocio Martin Hoyos
(&#8220;<U>Executive</U>&#8221;) and Atrium Therapeutics. (the &#8220;<U>Company</U>&#8221;) (collectively referred to as the &#8220;<U>Parties</U>&#8221; or individually referred to as a &#8220;<U>Party</U>&#8221;). Capitalized terms used but not
defined in this Release shall have the meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have
previously entered into that certain Employment Agreement, effective as of Month [&#8195;], 202[X] (the &#8220;<U>Employment Agreement</U>&#8221;) and that certain Confidentiality Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[&#8195;&#8195;&#8195;&#8195;&#8195;], 20[&#8195;], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees (as
defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section&nbsp;7 of the Employment
Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#8217;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company
and Executive hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Severance Payments and Benefits; Salary and Benefits</U>. Provided that the Effective
Date occurs and Executive continues to comply with this Release and the Continuing Obligations, the Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;7 of the Employment Agreement, payable at the
times set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive
the Accrued Obligations described in Section&nbsp;7(a) of the Employment Agreement, subject to and in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims (as defined below), the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries or affiliates, and any of their current, former and future officers, directors, equity holders,
managers, employees, agents, investors, lenders, creditors, attorneys, shareholders, members, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations
and assigns (collectively, the &#8220;<U>Releasees</U>&#8221;) related to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#8217;s own behalf and on behalf of any of
Executive&#8217;s affiliated companies or entities and any of their respective heirs, spouses, family members, executors, beneficiaries, trustees, administrators, legal representatives, agents, successors and assigns (collectively, the
&#8220;<U>Releasing Parties</U>&#8221;), other than with respect to the Retained Claims, knowingly and voluntarily, irrevocably and unconditionally, hereby and forever releases and discharges the Releasees from, and agrees not to sue concerning, or
in any manner to institute, prosecute, or pursue, any claim, complaint, charge, commitment, suit, controversy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, duty, obligation, or cause of action, cross-claim, counter claim, demand, debt, right, promise, contract, grievance, compensatory damages, liquidated damages, punitive or exemplary
damages, other damages, claims for costs and attorneys&#8217; fees, expenses, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this Release becomes effective and enforceable), relating to any
matters of any kind, and whether presently known or unknown, suspected or unsuspected, pending or not pending, that Executive or the Releasing Parties may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the date Executive signs this Release relating to Executive&#8217;s employment or service with the Company or its subsidiaries or termination therefrom, including, without limitation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#8217;s employment or service relationship with the Company or any of its direct
or indirect subsidiaries and affiliates and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all claims relating to, or arising from,
Executive&#8217;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty,
breach of duty under applicable state law, and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful
discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory
estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation;
libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights
Act of 1964; the Civil Rights Act of 1991; the Civil Rights Act of 1866 and 1871; the National Labor Relation Act of 1935; the Rehabilitation&nbsp;Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act of 1963; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act of
1988; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Immigration Reform and Control Act of 1986; the Pregnancy Discrimination Act; the Consolidated Omnibus Budget Reconciliation Act; the Sarbanes-Oxley Act of
2002; the Internal Revenue Code of 1986; any applicable Executive Order Programs; and their state and local counterparts, including the California Fair Employment and Housing Act, and the California Government Code Section&nbsp;12940, et. seq., each
as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the <FONT
STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#8217; fees and costs (all of the
foregoing, collectively referred to herein as the &#8220;<U>Claims</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL
AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;A GENERAL RELEASE DOES NOT
EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR
OR RELEASED PARTY.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER,
AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release does not release Claims that cannot be
released as a matter of law, including, but not limited to, (i)&nbsp;Claims that arise solely and completely after Executive executed this Release, (ii)&nbsp;Claims for breach or enforcement of this Release, (iii)&nbsp;Executive&#8217;s right to
report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the
Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, (iv)&nbsp;Executive&#8217;s right to file a charge with or
participate in a charge or investigation by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against
the Company for discrimination (with the understanding that Executive&#8217;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment other than as
otherwise noted above), (v) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#8217;s group benefit plans
pursuant to the terms and conditions of COBRA, (vi)&nbsp;Claims for indemnity under the bylaws of the Company, as provided for by California or Delaware law or under any applicable indemnification agreement or insurance policy with respect to
Executive&#8217;s liability as an employee, director or officer of the Company, (vii)&nbsp;Claims to any benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitlements vested as the date of separation of Executive&#8217;s employment pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#8217;s right
under applicable law and any Retained Claims. This Release further does not release Claims for the Company&#8217;s breach of its executory obligations under Section&nbsp;7 of the Employment Agreement. This Release does not prevent Executive from
cooperating with an investigation conducted by any governmental agencies, including without limitation the National Labor Relations Board (the &#8220;<U>NLRB</U>&#8221;). Nothing herein will prevent Executive from participating in an activity
permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a
trade secret that (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of
law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is sought to be made under seal. The claims described in this paragraph are referred to as the &#8220;<U>Retained Claims</U>.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;<U>ADEA</U>&#8221;), and that this Release is knowing and voluntary. Executive understands and agrees that this Release does not apply to any
rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this Release is in addition to anything of value to which Executive was already
entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive has the right to and is hereby advised to consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> calendar days from the date of initial receipt within which to consider this Release, although Executive may sign it at any time sooner, and
the Parties agree that such time period to review this Release shall not be extended upon any changes to this Release and any such changes are not material or were made at Executive&#8217;s request; (c)&nbsp;Executive has seven (7)&nbsp;calendar
days following Executive&#8217;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Release shall not be effective until the day immediately following this seven
(7)&nbsp;day revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)]
calendar day period identified above, Executive hereby acknowledges that Executive was afforded the opportunity to have a period of at least <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] calendar days to consider it and Executive has
freely and voluntarily chosen to waive the time period allotted for considering this Release. This Release will become effective on the day immediately following the seventh (7th) calendar day after Executive signed this Release (the
&#8220;<U>Effective Date</U>&#8221;). Executive further understands that Executive will not be given any severance benefits under Section&nbsp;7 of the Employment Agreement unless this Release is effective on or before the date that is fifty-five
(55)&nbsp;days following the date of Executive&#8217;s termination of employment. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For individuals age 40 or over, in the event of a group termination, to be 45 days with an OWBPA disclosure
added. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Terminations; Resignations</U>. Executive hereby confirms Executive&#8217;s
termination from all offices, directorships and other positions, if any, then held with the Company, effective as of the date of Executive&#8217;s termination of employment, and shall take all actions reasonably requested by the Company to
effectuate the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Executive Representations</U>. Executive represents and warrants that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Executive has surrendered to the Company all lists, books and records of, or in connection with, the Company business, and all other
property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Executive is not owed wages, commissions, bonuses or other compensation, other than the Accrued Obligations and as set forth in
Section&nbsp;7(a) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the course of Executive&#8217;s employment, Executive did not sustain any
injuries for which Executive might be entitled to compensation pursuant to worker&#8217;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to
compensation pursuant to worker&#8217;s compensation law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Confirmation of Continuing Obligations</U>. Executive hereby
expressly reaffirms Executive&#8217;s continuing obligations under any agreements or other documents with the Company or any of the other Releasees, including, without limitation, Section&nbsp;10 of the Employment Agreement and the Confidentiality
Agreement, and Executive acknowledges that such obligations shall survive Executive&#8217;s termination of employment (collectively, the &#8220;<B>Continuing Obligations</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Assignment</U>. Executive represents and warrants to the Releasees that there has been no assignment or other transfer of any
interest in any claim that Executive may have against the Releasees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Severability</U>. In the event that any provision or any
portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Release shall continue in full force and effect
without said provision or portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><U>Governing Law;
Venue</U>. This Release shall be governed by and construed in accordance with the laws of the [State of California], without regard to the conflicts of laws principles thereof. Any action brought hereon shall be brought in the state or federal
courts sitting in [San Diego County, California], the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over such party
and consents to service of process in any manner authorized by [California] law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Dispute Resolution</U>. All disputes under
this Release shall be governed by Section 11 of the Employment Agreement. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be updated for employee location. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Entire Agreement; Modification</U>. This Release and the Confidentiality
Agreement (and the other documents referenced herein and therein, including the Continuing Obligations) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them
concerning such subject matter. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Counterparts; .pdf Signatures</U>. This Release may be executed in any number of counterparts, each of which
when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by .pdf file and upon such delivery the.pdf signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Voluntary Execution of Agreement</U>.
Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#8217;s claims
against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set
forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation, and execution of this Release by legal counsel of Executive&#8217;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands
the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive is fully aware of the legal and binding effect of this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Print Name: Rocio Martin Hoyos</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>ATRIUM THERAPEUTICS.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>12
<FILENAME>d42675dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATRIUM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR COMPENSATION PROGRAM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[&#149;], 2026 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-employee</FONT> members of the board of directors (the &#8220;<B><I>Board</I></B>&#8221;) of Atrium Therapeutics, Inc. (the &#8220;<B><I>Company</I></B>&#8221;) shall receive cash and equity compensation as set forth
in this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program (as amended to date, this &#8220;<B><I>Program</I></B>&#8221;). This Program has been adopted under the Company&#8217;s 2026 Incentive Award Plan (such plan,
and any successor thereto, the &#8220;<B><I>Equity Plan</I></B>&#8221;). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the
Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#8221;) who is entitled to receive such cash or equity compensation,
unless such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director declines the receipt of such cash or equity compensation by written notice to the Company. This Program shall remain in effect until it is revised or rescinded by further
action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements for service as
a member of the Board between the Company and any of its <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. Capitalized terms not otherwise defined herein shall have the meanings ascribed in the Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Cash Compensation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Annual Retainers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director</U>. Each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director (other than the Chair of the Board) shall receive an annual retainer of $40,000 for service on the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Chair of the Board</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as Chair of the Board shall receive,
in lieu of the annual retainer in clause (i)&nbsp;above, an annual retainer of $70,000 for such service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional Annual
Retainers</U>. In addition, each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall receive the following additional annual retainers, as applicable: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Audit Committee</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as Chair of the Audit Committee shall
receive an additional annual retainer of $15,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as a member of the Audit Committee (other than the Chair) shall receive an additional annual retainer of
$7,500 for such service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Human Capital Management Committee</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
serving as Chair of the Human Capital Management Committee shall receive an additional annual retainer of $12,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as a member of the Human Capital Management
Committee (other than the Chair) shall receive an additional annual retainer of $6,000 for such service. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment of Retainers</U>. The annual retainers described in Sections 1(a) and 1(b)
shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director does not serve as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, or in the applicable positions described in Sections 1(a) or 1(b), for an entire calendar quarter, the
retainer paid to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall be prorated for the portion of such calendar quarter actually served as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, or in such position,
as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Equity Compensation</U>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall be granted the equity
awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Equity Plan, or any other applicable Company equity incentive plan then-maintained by the Company, and shall be granted
subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms previously approved from time to time by the Board. All applicable terms of the Equity Plan apply to this Program as if fully set
forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement. For the avoidance of doubt, the share numbers in this Section&nbsp;2 shall be subject to adjustment
as provided in the Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Initial Awards</U>. Each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is
initially elected or appointed to the Board shall receive the following award under the Equity Plan, or any other applicable Company equity incentive plan then-maintained by the Company, on the date of such initial election or appointment: an option
to purchase such number of shares of the Company&#8217;s common stock having a value of $235,000 on the grant date, calculated on the grant date in accordance with the Black-Scholes option pricing model (utilizing the same assumptions that the
Company utilizes in preparation of its financial statements) (the &#8220;<B><I>Initial Award</I></B>&#8221;). No <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall be granted Initial Awards more than once. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Subsequent Awards</U>. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who (i)&nbsp;is serving on the Board as of the
date of any annual meeting of the Company&#8217;s stockholders and has been serving as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for at least six months as of the date of such meeting, and (ii)&nbsp;will continue to serve as a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director immediately following such meeting, shall be automatically granted the following award under the Equity Plan, or any other applicable Company equity incentive plan then-maintained by the
Company, on the date of such annual meeting: an option to purchase such number of shares of the Company&#8217;s common stock having a value of $117,000 on the grant date, calculated on the grant date in accordance with the Black-Scholes option
pricing model (utilizing the same assumptions that the Company utilizes in preparation of its financial statements) (the &#8220;<B><I>Subsequent Award</I></B>&#8221;). For the avoidance of doubt, a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director elected for the first time to the Board at an annual meeting of the Company&#8217;s stockholders shall only receive the Initial Awards in connection with such election, and shall not
receive any Subsequent Awards on the date of such meeting as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination of Employment of Employee Directors</U>. Members of
the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive any Initial
Awards pursuant to Section&nbsp;2(a) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in
Section&nbsp;2(b) above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Terms of Awards Granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Purchase Price</U>. The per share exercise price of each option granted to a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall equal the Fair Market Value of a share of common stock on the date the option is granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Vesting</U>. Each Initial Award shall vest and become exercisable in substantially equal monthly installments over the three years
following the date of the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#8217;s election or appointment to the Board, subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director continuing in service on the Board
through each such vesting date. Each Subsequent Award shall vest and become exercisable on the first to occur of (A)&nbsp;the first anniversary of the date of grant or (B)&nbsp;the next occurring annual meeting of the Company&#8217;s stockholders,
subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director continuing in service on the Board through such vesting date. Unless the Board otherwise determines, no portion of an Initial Award or Subsequent Award which is unvested
and unexercisable at the time of a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#8217;s termination of service on the Board shall become vested and exercisable thereafter. Upon a Change of Control, all outstanding equity awards
granted under the Equity Plan, and any other equity incentive plan maintained by the Company, that are held by a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall become fully vested and exercisable, irrespective of any other
provisions of the Equity Plan or any award agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Term</U>. The term of each stock option granted to a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director shall be the earlier of (A)&nbsp;ten years from the date the option is granted or (B)&nbsp;ninety days following the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#8217;s
termination of service on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation Limits</U>. Notwithstanding anything to the contrary in this Program, all
compensation payable under this Program will be subject to any limits on the maximum amount of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director compensation set forth in the Equity Plan, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Reimbursements</U>. The Company shall reimburse each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for all reasonable,
documented, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel and other business expenses incurred by such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director in the performance of his or
her duties to the Company in accordance with the Company&#8217;s applicable expense reimbursement policies and procedures as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* &#8194;* &#8194;* &#8194;* &#8194;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>13
<FILENAME>d42675dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEMNIFICATION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (&#8220;<U>Agreement</U>&#8221;) is made as of _____________, 20__ by and between Atrium Therapeutics, Inc., a
Delaware corporation (the &#8220;<U>Company</U>&#8221;), and ______________, [a member of the Board of Directors / an officer] of the Company (&#8220;<U>Indemnitee</U>&#8221;). This Agreement supersedes and replaces any and all previous Agreements
between the Company and Indemnitee covering indemnification and advancement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company (the &#8220;<U>Board</U>&#8221;) believes that highly competent persons have become more
reluctant to serve publicly-held corporations as directors, officers, or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification and advancement of expenses against inordinate risks of
claims and actions against them arising out of their service to and activities on behalf of the corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board has
determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain
liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such
insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to
expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Bylaws and Certificate of Incorporation of the Company require
indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#8220;<U>DGCL</U>&#8221;). The Bylaws, Certificate of
Incorporation, and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and
other persons with respect to indemnification and advancement of expenses; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the uncertainties relating to such insurance, to
indemnification, and to advancement of expenses may increase the difficulty of attracting and retaining such persons; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board
has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased
certainty of such protection in the future; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate
itself to indemnify, and to advance expenses on behalf of, such persons to the Fullest Extent Permitted By Applicable Law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Indemnitee does not regard the protection available under the Bylaws, Certificate of Incorporation, DGCL and insurance as adequate in
the present circumstances, and may not be willing to serve or continue to serve as an officer or director without adequate additional protection, and the Company desires Indemnitee to serve or continue to serve in such capacity. Indemnitee is
willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified and be advanced expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Services to the Company</U>. Indemnitee has agreed to serve as a [director/officer] of the Company.
Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law). This Agreement does not create any obligation on the Company to continue Indemnitee
in such position and is not an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U>. As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<U>Agent</U>&#8221; means any person who is authorized by the Company or an Enterprise to act for or represent the interests of the
Company or an Enterprise, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) A &#8220;<U>Change in Control</U>&#8221; occurs upon the earliest to occur after the date of
this Agreement of any of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the
Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding securities effected through a transaction or
series of transactions (other than an offering of shares to the general public through a registration statement filed with the U.S. Securities and Exchange Commission or similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agency)
unless the change in relative beneficial ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Change in Board of Directors. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution
of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in
Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in
office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Corporate Transactions. The effective date of a merger, reorganization or consolidation of the Company with any other entity, other
than a merger, reorganization or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger, reorganization or consolidation continuing to represent (either by remaining outstanding or by
being converted into voting securities of the surviving entity or its direct or indirect parent) more than 50% of the combined voting power of the voting securities of the Company or such surviving entity (or, as applicable, a direct or indirect
parent of the Company or such surviving entity) outstanding immediately after such merger, reorganization or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;
<U>provided</U>, <U>however</U>, that a merger, reorganization or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person (other than those covered by the exceptions in
Section&nbsp;2(b)(vi)(2)) acquires more than 50% of the combined voting power of the Company&#8217;s then-outstanding securities shall not constitute a Change in Control; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or
disposition by the Company of all or substantially all of the Company&#8217;s assets; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Other Events. There occurs any other event
of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not
the Company is then subject to such reporting requirement, except the completion of the pro rata distribution shall not be considered a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained herein, a transaction shall not constitute a &#8220;Change in Control&#8221; for the purposes of this
definition if (1)&nbsp;the Company becomes a direct or indirect wholly owned subsidiary of a holding company and (2)&nbsp;the direct or indirect holders of the voting stock of such holding company immediately following that transaction are
substantially the same as the holders of the Company&#8217;s voting stock immediately prior to that transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) For purposes of this Section&nbsp;2(b), the following terms have the following
meanings: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<U>Exchange Act</U>&#8221; means the Securities Exchange Act of 1934, as amended from time to time.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<U>Person</U>&#8221; has the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act;
<U>provided</U>, <U>however</U>, that Person excludes (i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii)&nbsp;any corporation owned, directly or indirectly, by
the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<U>Beneficial Owner</U>&#8221; has the meaning given to such term in Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act; <U>provided</U>, <U>however</U>, that Beneficial Owner excludes any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of
the Company with another entity. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#8220;<U>Corporate Status</U>&#8221; describes the status of a person who is or
was acting as a director, officer, employee, fiduciary, or Agent of the Company or an Enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#8220;<U>Disinterested
Director</U>&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#8220;<U>Enterprise</U>&#8221; means any other corporation, limited liability company, partnership, joint venture, trust, employee
benefit plan or other entity for which Indemnitee is or was serving at the request of the Company as a director, officer, employee, or Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#8220;<U>Expenses</U>&#8221; means all reasonable direct and indirect costs, fees and expenses of any type or nature whatsoever and
specifically includes, without limitation, all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs,
telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other
disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also
include (i)&nbsp;Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its
equivalent, and (ii)&nbsp;for purposes of Section&nbsp;14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise. The
parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of
Indemnitee&#8217;s counsel as being reasonable in the good faith judgment of such counsel will be presumed conclusively to be reasonable. Expenses, however, do not include amounts paid in settlement by Indemnitee or the amount of judgments or fines
against Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#8220;<U>Fullest Extent Permitted By Applicable Law</U>&#8221; includes, but is not limited to: (a)&nbsp;to the
fullest extent permitted by the applicable provision of the DGCL, or the corresponding provision of any amendment to or replacement of the DGCL, and (b)&nbsp;to the fullest extent authorized or permitted by any amendments to or replacements of the
DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its directors and officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#8220;<U>Independent Counsel</U>&#8221; means a law firm, or a member of a law firm,
that is experienced in matters of corporation law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company or Indemnitee in any matter material to either such party (other than with respect
to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term &#8220;Independent Counsel&#8221; does not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an
action to determine Indemnitee&#8217;s rights under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#8220;<U>Potential Change in Control</U>&#8221; means the
occurrence of any of the following events: (i)&nbsp;the Company enters into any written or oral agreement, undertaking or arrangement, the consummation of which would result in the occurrence of a Change in Control; (ii)&nbsp;any Person or the
Company publicly announces an intention to take or consider taking actions which if consummated would constitute a Change in Control; (iii)&nbsp;the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in
Control has occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The term &#8220;<U>Proceeding</U>&#8221; includes any threatened, pending or completed action, suit, claim,
counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or
otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, <FONT
STYLE="white-space:nowrap">non-party</FONT> witness or otherwise by reason of Indemnitee&#8217;s Corporate Status or by reason of any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on
Indemnitee&#8217;s part while acting pursuant to Indemnitee&#8217;s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of
Expenses can be provided under this Agreement, and including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to Section&nbsp;14 of this Agreement to enforce the Indemnitee&#8217;s rights
under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Indemnity in Third-Party Proceedings</U>. The Company will indemnify Indemnitee in accordance
with the provisions of this Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this
Section&nbsp;3, the Company will indemnify Indemnitee to the Fullest Extent Permitted By Applicable Law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in
connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein,
if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that Indemnitee&#8217;s
conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Indemnity in Proceedings by or in the Right of the Company</U>. The Company will indemnify
Indemnitee in accordance with the provisions of this Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding brought by or in the right of the Company to procure a judgment in its favor. Pursuant
to this Section&nbsp;4, the Company will indemnify Indemnitee to the Fullest Extent Permitted By Applicable Law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or
any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. The Company will not indemnify Indemnitee for Expenses under this
Section&nbsp;4 related to any claim, issue or matter in a Proceeding for which Indemnitee has been finally adjudged by a court to be liable to the Company, unless, and only to the extent that, the Delaware Court of Chancery or any court in which the
Proceeding was brought determines upon application by Indemnitee that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</U>. Notwithstanding any other provisions of
this Agreement, to the Fullest Extent Permitted By Applicable Law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee in connection with any Proceeding the extent that Indemnitee is successful,
on the merits or otherwise. If Indemnitee is not wholly successful in such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company will indemnify Indemnitee against all
Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or related to each successfully resolved claim, issue or matter to the Fullest Extent Permitted By Applicable Law. For purposes of this
Section&nbsp;5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue or matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Indemnification For Expenses of a Witness</U>. Notwithstanding any other provision of this Agreement (other than
Section&nbsp;9) and to the Fullest Extent Permitted By Applicable Law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with any Proceeding to
which Indemnitee is not a party but to which Indemnitee is a witness, or is made (or asked) to respond to discovery requests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Partial Indemnification</U>. If Indemnitee is entitled under any provision of this Agreement to indemnification by the
Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Additional Indemnification</U>. Notwithstanding any limitation in Sections 3, 4, or 5, the Company will indemnify
Indemnitee to the Fullest Extent Permitted By Applicable Law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) for all
Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Exclusions</U>.
Notwithstanding any provision in this Agreement, the Company is not obligated under this Agreement to make any indemnification payment to Indemnitee in connection with any Proceeding: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except to
the extent provided in Section&nbsp;15(b) and except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) for (i)&nbsp;an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company
within the meaning of Section&nbsp;16(b) of the Exchange Act (as defined in Section&nbsp;2(b) hereof) or similar provisions of state statutory law or common law, (ii)&nbsp;any reimbursement of the Company by the Indemnitee of any bonus or other
incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting
restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &#8220;<U>Sarbanes-Oxley Act</U>&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in
violation of Section&nbsp;306 of the Sarbanes-Oxley Act) or (iii)&nbsp;any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee
of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section&nbsp;10D of the Exchange Act; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its
directors, officers, employees or other indemnitees, unless (i)&nbsp;the Proceeding or part of any Proceeding is to enforce Indemnitee&#8217;s rights to indemnification or advancement, of Expenses, including a Proceeding (or any part of any
Proceeding) initiated pursuant to Section&nbsp;14 of this Agreement, (ii)&nbsp;the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (iii)&nbsp;the Company provides the indemnification, in its sole
discretion, pursuant to the powers vested in the Company under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Advances of Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company will advance, to the extent not prohibited by law, the Expenses actually and reasonably incurred by Indemnitee in connection
with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee or any Proceeding (or any part of any Proceeding) initiated by Indemnitee if (i)&nbsp;the Proceeding or part of any Proceeding is to enforce Indemnitee&#8217;s rights to
obtain indemnification or advancement of Expenses from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company or Enterprise, including a proceeding initiated pursuant to Section&nbsp;14 or (ii)&nbsp;the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation,. The
Company will advance the Expenses within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Such statement or
statements shall reasonably evidence the Expenses incurred by the Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Advances will be unsecured and interest free.
Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company, thus Indemnitee qualifies for advances upon the execution of this
Agreement and delivery to the Company. No other form of undertaking is required other than the execution of this Agreement. The Company will make advances without regard to Indemnitee&#8217;s ability to repay the Expenses and without regard to
Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Procedure
for Notification of Claim for Indemnification or Advancement</U>.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Indemnitee will notify the Company in writing of any Proceeding with
respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. Indemnitee will include in the written notification to
the Company a description of the nature of the Proceeding and the facts underlying the Proceeding and provide such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what
extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. Indemnitee&#8217;s failure to notify the Company will not relieve the Company from any obligation it may have to Indemnitee under this Agreement,
and any delay in so notifying the Company will not constitute a waiver by Indemnitee of any rights under this Agreement unless, and to the extent that, such failure actually and materially prejudices the interests of the Company. The Secretary of
the Company will, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification or advancement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company will be entitled to participate in the Proceeding at its own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Procedure Upon Application for Indemnification</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless a Change in Control has occurred, the determination of Indemnitee&#8217;s entitlement to indemnification will be made: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum
of the Board; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by written opinion
provided by Independent Counsel selected by the Board; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) if so directed by the Board, by the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If a Change in Control has occurred, the determination of Indemnitee&#8217;s entitlement to indemnification will be made by written
opinion provided by Independent Counsel selected by Indemnitee (unless Indemnitee requests such selection be made by the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The
party selecting Independent Counsel pursuant to subsection (a)(iii) or (b)&nbsp;of this Section&nbsp;12 will provide written notice of the selection to the other party. The notified party may, within ten (10)&nbsp;days after receiving written notice
of the selection of Independent Counsel, deliver to the selecting party a written objection to such selection; <U>provided</U>, <U>however</U>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not
meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section&nbsp;2 of this Agreement, and the objection will set forth with particularity the factual basis of such assertion. Absent a proper and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timely objection, the person so selected will act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent
Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within thirty (30)&nbsp;days after the later of submission by Indemnitee of a written request for indemnification pursuant to
Section&nbsp;11(a) hereof and the final disposition of the Proceeding, Independent Counsel has not been selected or, if selected, any objection to has not been resolved, either the Company or Indemnitee may petition the Delaware Court or other court
of competent jurisdiction for resolution of any objection and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court designates. Upon the due commencement of any judicial proceeding or
arbitration pursuant to Section&nbsp;14(a) of this Agreement, Independent Counsel will be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Indemnitee will cooperate with the person, persons or entity making the determination with respect to Indemnitee&#8217;s entitlement to
indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee
and reasonably necessary to such determination. The Company will advance and pay any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making the indemnification determination irrespective of the determination as
to Indemnitee&#8217;s entitlement to indemnification and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing of the determination that Indemnitee is or is not
entitled to indemnification, including a description of any reason or basis for which indemnification has been denied and providing a copy of any written opinion provided to the Board by Independent Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within ten (10)&nbsp;days
after such determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U>Presumptions and Effect of Certain Proceedings</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;11(a) of this
Agreement, and the Company will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination
prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its
directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the determination of the Indemnitee&#8217;s entitlement to indemnification has not been made pursuant to Section&nbsp;12 within sixty
(60)&nbsp;days after the latter of (i)&nbsp;receipt by the Company of Indemnitee&#8217;s request for indemnification pursuant to Section&nbsp;11(a) and (ii)&nbsp;the final disposition of the Proceeding for which Indemnitee requested Indemnification
(the &#8220;<U>Determination Period</U>&#8221;), the requisite determination of entitlement to indemnification will, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee will be entitled to such indemnification,
absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a
prohibition of such indemnification under applicable law. The Determination Period may be extended for a reasonable time, not to exceed an additional thirty (30)&nbsp;days, if the person, persons or entity making the determination with respect to
entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, the Determination Period may be extended an additional fifteen
(15)&nbsp;days if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section&nbsp;12(a)(iv) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea
of <U>nolo</U> <U>contendere</U> or its equivalent, will not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good
faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#8217;s conduct was
unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges that a settlement or other disposition of any action, claim or
proceeding to which the Indemnitee is a party or potential party short of final judgment may be successful on the merits or otherwise if it permits the Indemnitee to avoid the expense, delay, distraction, disruption and uncertainty of litigation. In
the event that any action, claim or proceeding to which the Indemnitee is a party is resolved in any manner other than by adverse judgment against the Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or
without payment of money or other consideration), it shall to the Fullest Extent Permitted By Applicable Law be presumed that the Indemnitee has been successful on the merits or otherwise in such Proceeding, and the burden of proof and the burden of
persuasion by clear and convincing evidence to overcome this presumption shall be on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For purposes of any determination
of good faith, Indemnitee will be deemed to have acted in good faith if Indemnitee acted based on the records or books of account of the Company, its subsidiaries, or an Enterprise, including financial statements, or on information supplied to
Indemnitee by the directors or officers of the Company, its subsidiaries, or an Enterprise in the course of their duties, or on the advice of legal counsel for the Company, its subsidiaries, or an Enterprise or on information or records given or
reports made to the Company or an Enterprise by an independent certified public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Company, its subsidiaries, or an Enterprise.
Further, Indemnitee will be deemed to have acted in a manner &#8220;not opposed to the best interests of the Company,&#8221; as referred to in this Agreement if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in
the best interests of the participants and beneficiaries of an employee benefit plan. The provisions of this Section&nbsp;13(e) is not exclusive and does not limit in any way the other circumstances in which the Indemnitee may be deemed to have met
the applicable standard of conduct set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The knowledge and/or actions, or failure to act, of any director,
officer, trustee, partner, managing member, fiduciary, Agent or employee of the Company, its subsidiaries, or an Enterprise may not be imputed to Indemnitee for purposes of determining Indemnitee&#8217;s right to indemnification under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Remedies of Indemnitee</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Indemnitee may commence litigation against the Company in the Delaware Court of Chancery to obtain indemnification or advancement of
Expenses provided by this Agreement in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;the Company does not advance
Expenses pursuant to Section&nbsp;10 of this Agreement, (iii)&nbsp;the determination of entitlement to indemnification is not made pursuant to Section&nbsp;12 of this Agreement within the Determination Period, (iv)&nbsp;the Company does not
indemnify Indemnitee pursuant to Section&nbsp;5 or 6 or the second to last sentence of Section&nbsp;12(d) of this Agreement within ten (10)&nbsp;days after receipt by the Company of a written request therefor, (v)&nbsp;the Company does not indemnify
Indemnitee pursuant to Section&nbsp;3, 4, 7, or 8 of this Agreement within ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, or (vi)&nbsp;in the event that the Company or any other person takes or
threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the
Indemnitee hereunder. Alternatively, Indemnitee, at Indemnitee&#8217;s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee
must commence such Proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such Proceeding pursuant to this Section&nbsp;14(a); <U>provided</U>,
<U>however</U>, that the foregoing clause does not apply in respect of a Proceeding brought by Indemnitee to enforce Indemnitee&#8217;s rights under Section&nbsp;5 of this Agreement. The Company will not oppose Indemnitee&#8217;s right to seek any
such adjudication or award in arbitration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee
is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14 will be conducted in all respects as a <I>de novo</I> trial, or arbitration, on the merits and Indemnitee may not be prejudiced by
reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14 the Company will have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the
case may be and will not introduce evidence of the determination made pursuant to Section&nbsp;12 of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee
is entitled to indemnification, the Company will be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of
a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company is, to the fullest extent not prohibited by law, precluded from asserting in any judicial proceeding or arbitration commenced
pursuant to this Section&nbsp;14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and will stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) It is the intent of the Company that, to the Fullest Extent Permitted By Applicable Law, the Indemnitee not be required to
incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the
benefits intended to be extended to the Indemnitee hereunder. The Company, to the Fullest Extent Permitted By Applicable Law, will (within ten (10)&nbsp;days after receipt by the Company of a written request therefor) advance to Indemnitee such
Expenses which are incurred by Indemnitee in connection with any action concerning this Agreement, Indemnitee&#8217;s right to indemnification or advancement of Expenses from the Company, or concerning any directors&#8217; and officers&#8217;
liability insurance policies maintained by the Company and will indemnify Indemnitee against any and all such Expenses unless the court determines that each of the Indemnitee&#8217;s claims in such Proceeding were made in bad faith or were frivolous
or are prohibited by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U><FONT STYLE="white-space:nowrap">Non-exclusivity;</FONT> Survival of Rights; Insurance;
Subrogation</U>.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The indemnification and advancement of Expenses provided by this Agreement are not exclusive of any other rights to
which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. The indemnification and advancement of Expenses
provided by this Agreement may not be limited or restricted by any amendment, alteration or repeal of this Agreement in any way with respect to any action taken or omitted by Indemnitee in Indemnitee&#8217;s Corporate Status occurring prior to any
amendment, alteration or repeal of this Agreement. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Bylaws,
Certificate of Incorporation, or this Agreement, it is the intent of the parties hereto that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any
other right or remedy, and every other right and remedy is cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy
hereunder, or otherwise, will not prevent the concurrent assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company hereby
acknowledges that Indemnitee may have certain rights to indemnification, advancement of Expenses and/or insurance provided by one or more Persons with whom or which Indemnitee may be associated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company hereby acknowledges and agrees: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is the indemnitor of first resort with respect to any request for indemnification or advancement of
Expenses made pursuant to this Agreement concerning any Proceeding arising from or related to Indemnitee&#8217;s Corporate Status with the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is primarily liable for all indemnification and indemnification or advancement of Expenses
obligations for any Proceeding arising from or related to Indemnitee&#8217;s Corporate Status, whether created by law, organizational or constituent documents, contract (including this Agreement) or otherwise; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any obligation of any other Persons with whom or which Indemnitee may be associated to indemnify Indemnitee
and/or advance Expenses to Indemnitee in respect of any proceeding are secondary to the obligations of the Company&#8217;s obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company will indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent
provided herein without regard to any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated or insurer of any such Person; and </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Company irrevocably waives, relinquishes and releases any other Person with whom or which Indemnitee may be associated from any
claim of contribution, subrogation, reimbursement, exoneration or indemnification, or any other recovery of any kind in respect of amounts paid by the Company to Indemnitee pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the event any other Person with whom or which Indemnitee may be associated or their insurers advances or extinguishes any liability
or loss for Indemnitee, the payor has a right of subrogation against the Company or its insurers for all amounts so paid which would otherwise be payable by the Company or its insurers under this Agreement. In no event will payment by any other
Person with whom or which Indemnitee may be associated or their insurers affect the obligations of the Company hereunder or shift primary liability for the Company&#8217;s obligation to indemnify or advance of Expenses to any other Person with whom
or which Indemnitee may be associated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Any indemnification or advancement of Expenses provided by any other Person with whom or
which Indemnitee may be associated is specifically in excess over the Company&#8217;s obligation to indemnify and advance Expenses or any valid and collectible insurance (including but not limited to any malpractice insurance or professional errors
and omissions insurance) provided by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that the Company maintains an insurance policy or policies providing
liability insurance for directors, officers, employees, or Agents of the Enterprise, the Company will obtain a policy or policies covering Indemnitee to the maximum extent of the coverage available for any such director, officer, employee or Agent
under such policy or policies, including coverage in the event the Company does not or cannot, for any reason, indemnify or advance Expenses to Indemnitee as required by this Agreement. In all such insurance policies, the Indemnitee shall be named
as an insured in such a manner as to provide the Indemnitee with the same rights and benefits as are accorded to the most favorably insured of the Company&#8217;s directors and officers. If, at the time of the receipt of a notice of a claim pursuant
to this Agreement, the Company has director and officer liability insurance in effect, the Company will give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures
set forth in the respective policies. The Company will thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of
such policies. Indemnitee agrees to assist the Company efforts to cause the insurers to pay such amounts and will comply with the terms of such policies, including selection of approved panel counsel, if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee for any Proceeding concerning Indemnitee&#8217;s
Corporate Status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such Enterprise. The Company and Indemnitee intend that any such Enterprise (and its insurers) be
the indemnitor of first resort with respect to indemnification and advancement of Expenses for any Proceeding related to or arising from Indemnitee&#8217;s Corporate Status with such Enterprise. The Company&#8217;s obligation to indemnify and
advance Expenses to Indemnitee is secondary to the obligations the Enterprise or its insurers owe to Indemnitee. Indemnitee agrees to take all reasonably necessary and desirable action to obtain from an Enterprise indemnification and advancement of
Expenses for any Proceeding related to or arising from Indemnitee&#8217;s Corporate Status with such Enterprise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In the event of any payment made by the Company under this Agreement, the Company will
be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee from any Enterprise or insurance carrier. Indemnitee will execute all papers required and take all action necessary to secure such rights, including execution
of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>Duration of
Agreement</U>. This Agreement continues until and terminates upon the later of: (a)&nbsp;ten (10) years after the date that Indemnitee ceases to serve as a [director/officer] of the Company or (b)&nbsp;one (1) year after the final termination of any
Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any Proceeding commenced by Indemnitee pursuant to Section&nbsp;14 of this Agreement relating thereto. The
indemnification and advancement of Expenses rights provided by or granted pursuant to this Agreement are binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by
purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), continue as to an Indemnitee who has ceased to be a director, officer, employee or Agent of the Company or of any other Enterprise,
and inure to the benefit of Indemnitee and Indemnitee&#8217;s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Security</U>. To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time
to time provide security to Indemnitee for the Company&#8217;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to the Indemnitee, may not be revoked or released
without the prior written consent of Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. <U>Severability</U>. If any provision or provisions of this Agreement
is held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will not in any way be affected or impaired thereby and remain enforceable to the Fullest Extent Permitted By
Applicable Law; (b)&nbsp;such provision or provisions will be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the
provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will be
construed so as to give effect to the intent manifested thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Interpretation</U>. Any ambiguity in the terms of
this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification and advancement of Expenses permitted by law. The Company and Indemnitee intend that this Agreement provide to the Fullest Extent Permitted
By Applicable Law for indemnification in excess of that expressly provided, without limitation, by the Certificate of Incorporation, the Bylaws, vote of the Company stockholders or disinterested directors, or applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Enforcement</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a director or officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; <U>provided</U>, <U>however</U>, that this Agreement is a supplement to and in furtherance of the Certificate of
Incorporation, the Bylaws and applicable law, and is not a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall not seek from a court, or agree to, a &#8220;bar order&#8221; that would have the effect of prohibiting or limiting
Indemnitee&#8217;s rights to receive advancement of Expenses under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall require and cause any successor (including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all, substantially all or a substantial part of the business and/or assets of the Company) to expressly assume and agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform if no such succession had taken place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company and Indemnitee agree herein that a
monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that
Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee
shall not be precluded from seeking or obtaining any other relief to which Indemnitee may be entitled. The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary
restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be
required of Indemnitee by the court, and the Company hereby waives any such requirement of such a bond or undertaking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21.
<U>Modification and Waiver</U>. No supplement, modification, termination or amendment of this Agreement is binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement will be deemed or constitutes a
waiver of any other provisions of this Agreement nor will any waiver constitute a continuing waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Notice by
Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter
which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company does not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or
otherwise unless and only to the extent that such failure or delay materially prejudices the interests of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23.
<U>Notices</U>. All notices, requests, demands and other communications under this Agreement will be in writing and will be deemed to have been duly given if (a)&nbsp;delivered by hand to the other party, (b)&nbsp;one (1) day after deposit with
reputable overnight courier to the other party, specifying next day delivery, with written verification of receipt, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid or
(d)&nbsp;sent by facsimile transmission or electronic mail, with receipt of oral confirmation that such communication has been received if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to Indemnitee, at the address indicated on the signature page of this Agreement . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Name: &#8195;&#8199;&#8199;Atrium Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Address: &#8199;&#8199;10578 Science Center Drive, Suite 125 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8199;&#8199;San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: &#8199;General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to any
other address as may have been furnished to Indemnitee by the Company or to the Company by the Indemnitee, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Contribution</U>. To the Fullest Extent Permitted By Applicable Law, if the indemnification provided for in this Agreement
is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in
settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect
(i)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and
Agents) and Indemnitee in connection with such event(s) and/or transaction(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;25. <U>Applicable Law and Consent to Jurisdiction</U>. This Agreement and the
legal relations among the parties are governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee
pursuant to Section&nbsp;14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or Proceeding arising out of or in connection with this Agreement may, unless the Company consents in
writing to the selection of an alternate forum, be brought only in the Delaware Court of Chancery (or, if and only if the Delaware Court of Chancery lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and
only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent
to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or Proceeding arising out of or in connection with this Agreement, (iii)&nbsp;appoint, to the extent such party is not otherwise subject to service of process
in the State of Delaware, Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, as its agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process in connection with any
such action or proceeding against such party with the same legal force and validity as if such party had been personally served within the State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such action or Proceeding in
the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or Proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;26. <U>Identical Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which will for all
purposes be deemed to be an original but all of which together constitutes one and the same Agreement. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act
of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Only one such counterpart signed by the party against
whom enforceability is sought needs to be produced to evidence the existence of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;27. <U>Headings</U>. The
headings of this Agreement are inserted for convenience only and do not constitute part of this Agreement or affect the construction thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ATRIUM THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INDEMNITEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>14
<FILENAME>d42675dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED LEASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDED AND RESTATED LEASE AGREEMENT AMENDS, RESTATES AND SUPERSEDES IN ITS ENTIRETY THAT CERTAIN LEASE AGREEMENT DATED AS OF June&nbsp;1, 2020 (THE
&#8220;ORIGINAL LEASE&#8221;), BY AND BETWEEN TENANT (AS DEFINED BELOW) AND LANDLORD (AS DEFINED BELOW). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED
LEASE AGREEMENT (this &#8220;<B>Lease</B>&#8221;) is made this <U>18</U> day of December, 2020, between <B><FONT STYLE="white-space:nowrap">ARE-SD</FONT> REGION NO. 44, LLC</B>, a Delaware limited liability company (&#8220;<B>Landlord</B>&#8221;),
and <B>AVIDITY BIOSCIENCES, INC.</B>, a Delaware corporation (&#8220;<B>Tenant</B>&#8221;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Building:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10578 Science Center Drive, San Diego, California</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Premises:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">That certain portion of the Building (i)&nbsp;known as Suite 225, containing approximately 25,514 rentable square feet, and (ii)&nbsp;known as Suite 125, containing approximately 22,223 rentable square feet, as determined by
Landlord, all as shown on <B>Exhibit A</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Project:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The real property on which the Building in which the Premises are located, together with all improvements thereon and appurtenances thereto as described on <B>Exhibit B</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Base Rent:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$63.00 per rentable square foot of the Premises per year, subject to adjustment pursuant to <U>Section&nbsp;4</U> hereof.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rentable Area of Premises: </B>47,737 sq. ft. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rentable Area of Building: </B>148,167 sq. ft. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rentable
Area of Project: </B>298,589 sq. ft. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#8217;s Share of Operating Expenses of Building: </B>32.22% </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Building&#8217;s Share of Project: </B>49.62% </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Security
Deposit: </B>$250,619.25 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Target Commencement Date: </B>November 1, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rent Adjustment Percentage: </B>3% </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Base Term:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beginning on the Commencement Date and ending 60 months from the first day of the first full month following the Commencement Date<B>. </B>For clarity, if the Commencement Date occurs on the first day of a month, the expiration of
the Base Term shall be measured from that date. If the Commencement Date occurs on a day other than the first day of a month, the expiration of the Base Term shall be measured from the first day of the following month.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Permitted Use:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research and development laboratory, related office and other related uses consistent with the character of the Project and otherwise in compliance with the provisions of <U>Section&nbsp;7</U> hereof.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:55%; text-indent:-2%">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 2
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Address for Rent Payment:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Landlord&#8217;s Notice Address:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alexandria Real Estate Equities, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">26 North Euclid Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dept LA 23447</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pasadena, CA 91101</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pasadena, CA 91185-3447</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Corporate Secretary</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#8217;s Notice Address: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10578 Science Center Drive, Suite 225 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California
92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Lease Administrator </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
Exhibits and Addenda are attached hereto and incorporated herein by this reference: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[X] <B>EXHIBIT A </B>- PREMISES DESCRIPTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[X] <B>EXHIBIT B </B>&#8212; DESCRIPTION OF PROJECT</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[X] <B>EXHIBIT C </B>- WORK LETTER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[X] <B>EXHIBIT D </B>&#8212; COMMENCEMENT DATE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[X] <B>EXHIBIT E </B>&#8212; RULES AND REGULATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[X] <B>EXHIBIT F </B>&#8212; TENANT&#8217;S PERSONAL PROPERTY</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[X] <B>EXHIBIT G </B>&#8212; MAINTENANCE OBLIGATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[X] <B>EXHIBIT H </B>&#8212; CONTROL ZONES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[X] <B>EXHIBIT I </B>&#8212; RESERVED PARKING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[X] <B>EXHIBIT J </B>&#8212; SIGNAGE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[X] <B>EXHIBIT K </B>&#8212; EXPANSION SPACE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Lease of Premises</B>. Upon and subject to all of the terms and conditions hereof, Landlord hereby leases
the Premises to Tenant and Tenant hereby leases the Premises from Landlord. The portions of the Project which are for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> use of tenants of the Project are collectively referred to herein as the
&#8220;<B>Common Areas</B>.&#8221; Tenant shall have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right during the Term to use the Common Areas along with others having the right to use the Common Areas. Landlord reserves the right to
modify Common Areas, provided that such modifications do not materially adversely affect Tenant&#8217;s access to or use of the Premises for the Permitted Use. From and after the Commencement Date through the expiration of the Term, Tenant shall
have access to the Building and the Premises 24 hours a day, 7 days a week, 365 days a year, except in the case of emergencies, as the result of Legal Requirements, the performance by Landlord of any installation, maintenance or repairs, or any
other temporary interruptions, and otherwise subject to the terms of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Project Amenities (as defined in
<U>Section</U><U></U><U>&nbsp;5</U>) currently include, among other things, conferencing facilities located on the ground floor of the Building (the &#8220;<B>Ground Floor Conference Facilities</B>&#8221;). Use by Tenant of the Ground Floor
Conference Facilities shall be in common with other users with scheduling procedures reasonably determined by Landlord or Landlord&#8217;s then designated event operator (&#8220;<B>Project Event Operator</B>&#8221;). Tenant&#8217;s use of the Ground
Floor Conference Facilities shall be subject to the payment by Tenant of a fee equal to the quoted rates for the usage of the Ground Floor Conference Facilities in effect at the time of Tenant&#8217;s scheduling. Landlord and/or Project Event
Operator, shall have the right to institute, subject to the terms of <U>Section</U><U></U><U>&nbsp;26</U>, rules and regulations with respect to the Ground Floor Conference Facilities from time to time including, without limitation, (a)&nbsp;the
required use by tenants of the Project Event Operator for the catering of meetings and other events held at the Ground Floor Conference Facilities, (b)&nbsp;usage of and compliance with reservations systems governing the use of Ground Floor
Conference Facilities, and (c)&nbsp;the payment of additional costs in connection with the after-hours usage of the Ground Floor Conference Facilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Delivery; Acceptance of Premises; Commencement Date</B>. Landlord shall use reasonable efforts to deliver the Premises to Tenant on or
before the Target Commencement Date with Landlord&#8217;s Work Substantially Completed (&#8220;<B>Delivery</B>&#8221; or &#8220;<B>Deliver</B>&#8221;). If Landlord fails to timely Deliver the Premises, Landlord shall not be liable to Tenant for any
loss or damage resulting therefrom, and this Lease shall not be void or voidable except as provided herein. If Landlord does not Deliver the Premises within 90 days of the Target Commencement Date for any reason other than Force Majeure (as defined
in <U>Section</U><U></U><U>&nbsp;34</U>) delays and Tenant Delays, this Lease may be terminated by Landlord or Tenant by written notice to the other, and if so terminated by either: (a)&nbsp;the Security Deposit, or any balance thereof (i.e., after
deducting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 3
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therefrom all amounts to which Landlord is entitled under the provisions of this Lease), and any prepaid Base Rent, shall be promptly returned to Tenant, and (b)&nbsp;neither Landlord nor Tenant
shall have any further rights, duties or obligations under this Lease, except with respect to provisions which expressly survive termination of this Lease. As used herein, the terms &#8220;<B>Landlord&#8217;s Work</B>,&#8221; &#8220;<B>Tenant
Delays</B>&#8221; and &#8220;<B>Substantially Completed</B>&#8221; shall have the meanings set forth for such terms in the Work Letter. If neither Landlord nor Tenant elects to void this Lease within 5 business days of the lapse of such 90 day
period, such right to void this Lease shall be waived and this Lease shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant
acknowledge and agree that, as of the date of this Lease, a global pandemic has been declared with respect to <FONT STYLE="white-space:nowrap">COVID-19</FONT> (which is a Force Majeure event) which may delay Landlord&#8217;s Delivery of the
Premises. Notwithstanding anything to the contrary contained herein, the Target Commencement Date shall be extended 1 day for each day the Landlord&#8217;s design and/or construction of Landlord&#8217;s Work is delayed due to <FONT
STYLE="white-space:nowrap">COVID-19</FONT> related delays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant further acknowledge and agree that (i)&nbsp;as of the date
of this Lease, the City of San Diego (the &#8220;<B>City</B>&#8221;) is routinely taking longer to issue the permits and approvals (collectively, &#8220;<B>Permits</B>&#8221;) required for the design and construction of Landlord&#8217;s Work than
the timeframes contemplated by Landlord in the development of the schedule for the completion of Landlord&#8217;s Work (the &#8220;<B>Standard Issuance Period</B>&#8221;), and (ii)&nbsp;to the extent the issuance of any Permits required for the
design and/or construction of Landlord&#8217;s Work is delayed beyond the Standard Issuance Period (except for delays due to Landlord&#8217;s failure to timely provide the City with information requested from Landlord by the City (except to the
extent that such delays arise due to Tenant&#8217;s failure to provide Landlord information requested from Tenant by Landlord)), then the Target Commencement Date shall be delayed 1 day for each day following the expiration of the Standard Issuance
Period that the City fails to issue any such Permits (through and including the date that such Permits are issued by the City). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
&#8220;<B>Commencement Date</B>&#8221; shall be the earlier of: (i)&nbsp;the date Landlord Delivers the Premises to Tenant with Landlord&#8217;s Work Substantially Completed; and (ii)&nbsp;the date Landlord could have Delivered the Premises but for
Tenant Delays. Upon request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Commencement Date and the expiration date of the Term when such are established in the form of the &#8220;Acknowledgement of Commencement
Date&#8221; attached to this Lease as <B>Exhibit D</B>; <U>provided</U>, <U>however</U>, Tenant&#8217;s failure to execute and deliver such acknowledgment shall not affect Landlord&#8217;s rights hereunder. The &#8220;<B>Term</B>&#8221; of this
Lease shall be the Base Term, as defined above on the first page of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of
<U>Section</U><U></U><U>&nbsp;6</U> of the Work Letter, Landlord shall permit Tenant access to the Premises for a period of up to 45 days prior to the Commencement Date for Tenant&#8217;s installation and setup of furniture, fixtures and equipment
and Tenant&#8217;s installation of cabling (collectively, &#8220;<B>FF&amp;E Installation</B>&#8221;), provided that such FF&amp;E Installation is coordinated with Landlord, and Tenant complies with this Lease and all other reasonable restrictions
and conditions Landlord may impose. All such access shall be during normal business hours. Any access to the Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, excluding the obligation
to pay Base Rent or Operating Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the Work Letter or as otherwise expressly set forth in this Lease:
(x)&nbsp;Tenant shall accept the Premises in their condition as of the Commencement Date; (y)&nbsp;Landlord shall have no obligation for any defects in the Premises; and (z)&nbsp;Tenant&#8217;s taking possession of the Premises shall be conclusive
evidence that Tenant accepts the Premises and that the Premises were in good condition at the time possession was taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period
of 30 consecutive days after the Commencement Date, Landlord shall, at its sole cost and expense (which shall not constitute an Operating Expense), be responsible for any repairs that are required to be made to the Building Systems serving the
Premises, unless Tenant or any Tenant Party was responsible for the cause of such repair, in which case Tenant shall pay the cost. Tenant shall also be entitled to the benefit of any warranties issued to Landlord in connection with Landlord&#8217;s
Work. Nothing in this paragraph shall limit Landlord&#8217;s maintenance and repair obligations under <U>Section</U><U></U><U>&nbsp;13</U> of this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 4
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any
representation or warranty with respect to the condition of all or any portion of the Premises or the Project, and/or the suitability of the Premises or the Project for the conduct of Tenant&#8217;s business, and Tenant waives any implied warranty
that the Premises or the Project are suitable for the Permitted Use. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes any and all prior representations, inducements,
promises, agreements, understandings and negotiations which are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant&#8217;s representations, warranties, acknowledgments and agreements contained herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>3. Rent. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Base
Rent</B>. Pursuant to the terms of the Original Lease, Tenant delivered to Landlord the Security Deposit required under the Original Lease in the form of a Letter of Credit in the amount of $123,879.00 (the &#8220;<B>Original Letter of
Credit</B>&#8221;), and delivered the first month&#8217;s Base Rent due under the Original Lease in the amount of $123,879.00. The balance of Base Rent due and payable under this Lease for the first full calendar month, in the amount of $126,740.25
shall be due and payable concurrent with Tenant&#8217;s delivery of an executed copy of this Lease to Landlord. Landlord acknowledges and agrees that an amendment to the Original Letter of Credit to increase the Original Letter of Credit by the
balance of the Security Deposit due hereunder in the amount of $126,740.25 has been delivered to Landlord by Tenant prior to the date of this Lease. Tenant shall pay to Landlord in advance, without demand, abatement, deduction or <FONT
STYLE="white-space:nowrap">set-off,</FONT> monthly installments of Base Rent on or before the first day of each calendar month during the Term hereof, in lawful money of the United States of America, at the office of Landlord for payment of Rent set
forth above, or to such other person or at such other place as Landlord may from time to time designate in writing, or via federally insured wire transfer (including ACH) pursuant to the wire instructions provided by Landlord. Payments of Base Rent
for any fractional calendar month shall be prorated. The obligation of Tenant to pay Base Rent and other sums to Landlord and the obligations of Landlord under this Lease are independent obligations. Tenant shall have no right at any time to abate,
reduce, or <FONT STYLE="white-space:nowrap">set-off</FONT> any Rent (as defined in <U>Section</U><U></U><U>&nbsp;5</U>) due hereunder except for any abatement as may be expressly provided in this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Lease, so long as Tenant is not then in Default (as defined in Section&nbsp;20)
under this Lease, Tenant shall not be required to pay Base Rent with respect to the Premises for the period commencing on the first day of the 2nd full calendar month after the Commencement Date through the last day of the 6th full calendar month
after the Commencement Date (the &#8220;<B>Abatement Period</B>&#8221;). Tenant shall resume paying full Base Rent on the first day of the seventh full calendar month after the Commencement Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Additional Rent</B>. In addition to Base Rent, Tenant agrees to pay to Landlord as additional rent (&#8220;<B>Additional
Rent</B>&#8221;): (i) commencing on the Commencement Date, Tenant&#8217;s Share of &#8220;Operating Expenses&#8221; (as defined in <U>Section</U><U></U><U>&nbsp;5</U>), and (ii)&nbsp;any and all other amounts Tenant assumes or agrees to pay under
the provisions of this Lease, including, without limitation, any and all other sums that may become due by reason of any default of Tenant or failure to comply with the agreements, terms, covenants and conditions of this Lease to be performed by
Tenant, after any applicable notice and cure period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Base Rent Adjustments</B>. Base Rent shall be increased on each annual
anniversary of the Commencement Date (provided, however, that if the Commencement Date occurs on a day other than the first day of a calendar month, then Base Rent shall be increased on each annual anniversary of the first day of the first full
calendar month immediately following the Commencement Date) (each an &#8220;<B>Adjustment Date</B>&#8221;) by multiplying the Base Rent payable immediately before such Adjustment Date by the Rent Adjustment Percentage and adding the resulting amount
to the Base Rent payable immediately before such Adjustment Date. Base Rent, as so adjusted, shall thereafter be due as provided herein. Base Rent adjustments for any fractional calendar month shall be prorated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 5
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Operating Expense Payments</B>. Landlord shall deliver to Tenant a written estimate of
Operating Expenses for each calendar year during the Term (the &#8220;<B>Annual Estimate</B>&#8221;), which may be revised by Landlord from time to time during such calendar year. Commencing on the Commencement Date, and continuing thereafter on the
first day of each month during the Term, Tenant shall pay Landlord an amount equal to 1/12th of Tenant&#8217;s Share of the Annual Estimate. Payments for any fractional calendar month shall be prorated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<B>Operating Expenses</B>&#8221; means all costs and expenses of any kind or description whatsoever incurred or accrued each
calendar year by Landlord with respect to the Building (including the Building&#8217;s Share of all costs and expenses of any kind or description incurred or accrued by Landlord with respect to the Project which are not specific to the Building or
any other building located in the Project) (including, without duplication, Taxes (as defined in <U>Section</U><U></U><U>&nbsp;9</U>),capital repairs, improvements and replacements amortized over the lesser of 10 years and the useful life of such
capital repairs, improvements and replacements, the cost (including, without limitation, any subsidies which Landlord may provide in connection with the Project Amenities) of the common area amenities (the &#8220;<B>Project Amenities</B>&#8221;) now
or hereafter located at the Project which Project Amenities may include, without limitation, the Common Area fitness center, caf&eacute;, conference center, bocce ball court, barbeque pits and ping pong, and the costs of Landlord&#8217;s third party
property manager or, if there is no third party property manager, administration rent in the amount of 3% of Base Rent (provided that during the Abatement Period, Tenant shall nonetheless be required to pay administration rent each month equal to
the amount of the administration rent that Tenant would have been required to pay in the absence of there being an Abatement Period)), excluding only: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the original construction costs of the Project and renovation prior to the Commencement Date and costs of correcting defects in such
original construction or renovation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) capital expenditures for expansion of the Project; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) interest, principal payments of Mortgage (as defined in <U>Section</U><U></U><U>&nbsp;27</U>) debts of Landlord, financing costs and
amortization of funds borrowed by Landlord, whether secured or unsecured; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) depreciation of the Project (except for capital
improvements, the cost of which are permitted pursuant to this <U>Section</U><U></U><U>&nbsp;5</U> to be included in Operating Expenses); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) advertising, legal and space planning expenses and leasing commissions and other costs and expenses incurred in procuring and leasing space
to tenants for the Project, including any leasing office maintained in the Project, free rent and construction allowances for tenants; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
legal and other expenses incurred in the negotiation or enforcement of leases; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) completing, fixturing, improving, renovating, painting,
redecorating or other work, which Landlord pays for or performs for other tenants within their premises, and costs of correcting defects in such work; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) costs to be reimbursed by other tenants of the Project or third parties, or Taxes to be paid directly by Tenant or other tenants of the
Project, whether or not actually paid; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) salaries, wages, benefits and other compensation paid to officers and employees of Landlord who
are not assigned in whole or in part to the operation, management, maintenance or repair of the Project (which costs shall be prorated if such officers and employees are assigned to the Project only in part in proportion to the amount of time spent
by such employee on the Project); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 6
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) general organizational, administrative and overhead costs relating to maintaining
Landlord&#8217;s existence, either as a corporation, partnership, or other entity, including general corporate, legal and accounting expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) costs (including attorneys&#8217; fees and costs of settlement, judgments and payments in lieu thereof) incurred in connection with
disputes with tenants, other occupants, or prospective tenants, and costs and expenses, including legal fees, incurred in connection with negotiations or disputes with employees, consultants, management agents, leasing agents, purchasers or
mortgagees of the Building; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) costs incurred by Landlord due to the violation by Landlord, its employees, agents or contractors or any
tenant of the terms and conditions of any lease of space in the Project or any Legal Requirement (as defined in <U>Section</U><U></U><U>&nbsp;7</U>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) penalties, fines or interest incurred as a result of Landlord&#8217;s inability or failure to make payment of Taxes and/or to file any tax
or informational returns when due, or from Landlord&#8217;s failure to make any payment of Taxes required to be made by Landlord hereunder before delinquency; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services in or to the Project
to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third parties on a competitive basis; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)
costs of Landlord&#8217;s charitable or political contributions, or of fine art maintained at the Project; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) costs in connection with
services (including electricity), items or other benefits of a type which are not standard for the Project and which are not available to Tenant without specific charges therefor, but which are provided to another tenant or occupant of the Project,
whether or not such other tenant or occupant is specifically charged therefor by Landlord; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) costs incurred in the sale or refinancing
of the Project; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) net income taxes of Landlord or the owner of any interest in the Project, franchise, capital stock, gift, estate or
inheritance taxes or any federal, state or local documentary taxes imposed against the Project or any portion thereof or interest therein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) any costs incurred to remove, study, test or remediate Hazardous Materials in or about the Building or the Project (provided, however, that
the foregoing is in no event intended to limit Tenant&#8217;s obligations under <U>Section</U><U></U><U>&nbsp;28</U> or <U>Section</U><U></U><U>&nbsp;30</U> of this Lease); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) costs of removing abandoned HVAC and other equipment and related pipes, conduit and fixtures from the roof, or relocating antenna equipment
of third parties unrelated to Tenant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) reserves; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any expenses otherwise includable within Operating Expenses to the extent actually reimbursed by insurance (or would have been reimbursed
by insurance required to be carried by Landlord pursuant to <U>Section</U><U></U><U>&nbsp;17</U>); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) costs in connection with the
Amenities (as defined in <U>Section</U><U></U><U>&nbsp;41</U>) other than the Amenities Fee (as defined in <U>Section</U><U></U><U>&nbsp;41</U>) payable by Tenant pursuant to <U>Section</U><U></U><U>&nbsp;41</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) costs occasioned by condemnation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 7
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) any item that, if included in Operating Expenses, would involve a double collection for
such items by Landlord, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) any expenses otherwise includable within Operating Expenses to the extent actually reimbursed by persons
other than tenants of the Project under leases for space in the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding anything to the contrary contained
in this Lease, Operating Expenses incurred or accrued by Landlord with respect to any capital improvements which are reasonably expected by Landlord to reduce overall Operating Expenses (for example, without limitation, by reducing energy usage at
the Project) (the &#8220;<B>Energy Savings Costs</B>&#8221;) shall be amortized over a period of years equal to the least of (A) 10 years, (B)&nbsp;the useful life of such capital items, or (C)&nbsp;the quotient of (i)&nbsp;the Energy Savings Costs,
divided by (ii)&nbsp;the annual amount of Operating Expenses reasonably expected by Landlord to be saved as a result of such capital improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 90 days after the end of each calendar year (or such longer period as may be reasonably required), Landlord shall furnish to Tenant a
statement (an &#8220;<B>Annual Statement</B>&#8221;) showing in reasonable detail: (a)&nbsp;the total and Tenant&#8217;s Share of actual Operating Expenses for the previous calendar year, and (b)&nbsp;the total of Tenant&#8217;s payments in respect
of Operating Expenses for such year. If Tenant&#8217;s Share of actual Operating Expenses for such year exceeds Tenant&#8217;s payments of Operating Expenses for such year, the excess shall be due and payable by Tenant as Rent within 30 days after
delivery of such Annual Statement to Tenant. If Tenant&#8217;s payments of Operating Expenses for such year exceed Tenant&#8217;s Share of actual Operating Expenses for such year Landlord shall pay the excess to Tenant within 30 days after delivery
of such Annual Statement, except that after the expiration, or earlier termination of the Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord.
Landlord&#8217;s and Tenant&#8217;s obligations to pay any overpayments or deficiencies due pursuant to this paragraph shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Annual Statement shall be final and binding upon Tenant unless Tenant, within 90 days after Tenant&#8217;s receipt thereof, shall contest
any item therein by giving written notice to Landlord, specifying each item contested and the reason therefor. If, during such 90 day period, Tenant reasonably and in good faith questions or contests the accuracy of Landlord&#8217;s statement of
Tenant&#8217;s Share of Operating Expenses, Landlord will provide Tenant with access to Landlord&#8217;s books and records relating to the operation of the Project and such information as Landlord reasonably and in good faith determines to be
responsive to Tenant&#8217;s questions (the &#8220;<B>Expense Information</B>&#8221;). If after Tenant&#8217;s review of such Expense Information, Landlord and Tenant cannot agree upon the amount of Tenant&#8217;s Share of Operating Expenses, then
Tenant shall have the right to have an independent regionally recognized public accounting firm selected by Tenant, working pursuant to a fee arrangement other than a contingent fee (at Tenant&#8217;s sole cost and expense) and approved by Landlord
(which approval shall not be unreasonably withheld or delayed), audit and/or review the Expense Information for the year in question (the &#8220;<B>Independent Review</B>&#8221;). The results of any such Independent Review shall be binding on
Landlord and Tenant. If the Independent Review shows that the payments actually made by Tenant with respect to Operating Expenses for the calendar year in question exceeded Tenant&#8217;s Share of Operating Expenses for such calendar year, Landlord
shall at Landlord&#8217;s option either (i)&nbsp;credit the excess amount to the next succeeding installments of estimated Operating Expenses or (ii)&nbsp;pay the excess to Tenant within 30 days after delivery of such statement, except that after
the expiration or earlier termination of this Lease or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord. If the Independent Review shows that Tenant&#8217;s
payments with respect to Operating Expenses for such calendar year were less than Tenant&#8217;s Share of Operating Expenses for the calendar year, Tenant shall pay the deficiency to Landlord within 30 days after delivery of such statement. If the
Independent Review shows that Tenant has overpaid with respect to Operating Expenses by more than 5%, then Landlord shall reimburse Tenant for all costs incurred by Tenant for the Independent Review. Operating Expenses for the calendar years in
which Tenant&#8217;s obligation to share therein begins and ends shall be prorated. Notwithstanding anything set forth herein to the contrary, if the Building is not at least 95% occupied on average during any year of the Term, Tenant&#8217;s Share
of Operating Expenses for such year with respect to Variable Operating Expenses shall be computed as though the Building had been 95% occupied on average during such year. &#8220;Variable Operating Expenses&#8221; shall mean those Operating Expenses
which vary by occupancy including, without limitation, electricity, trash removal and other Utilities (as defined in <U>Section</U><U></U><U>&nbsp;11</U>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 8
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Tenant&#8217;s Share</B>&#8221; shall be the percentage set forth on the first page
of this Lease as Tenant&#8217;s Share as reasonably adjusted by Landlord for changes in the physical size of the Premises or the Project occurring thereafter. Landlord may equitably increase Tenant&#8217;s Share for any item of expense or cost
reimbursable by Tenant that relates to a repair, replacement, or service that benefits only the Premises or only a portion of the Project that includes the Premises or that varies with occupancy or use. Base Rent, Tenant&#8217;s Share of Operating
Expenses and all other amounts payable by Tenant to Landlord hereunder are collectively referred to herein as &#8220;<B>Rent</B>.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Security Deposit</B>. Tenant shall deposit with Landlord (the &#8220;<B>Security Deposit</B>&#8221;) for the performance of all of
Tenant&#8217;s obligations hereunder in the amount set forth on page 1 of this Lease, which Security Deposit shall be in the form of an unconditional and irrevocable letter of credit (the &#8220;<B>Letter of Credit</B>&#8221;): (i) in form and
substance reasonably satisfactory to Landlord, (ii)&nbsp;naming Landlord as beneficiary, (iii)&nbsp;expressly allowing Landlord to draw upon it at any time from time to time by delivering to the issuer notice that Landlord is entitled to draw
thereunder, (iv)&nbsp;issued by an FDIC-insured financial institution reasonably satisfactory to Landlord, and (v)&nbsp;redeemable by presentation of a sight draft in the State of California. If Tenant does not provide Landlord with a substitute
Letter of Credit complying with all of the requirements hereof at least 10 days before the stated expiration date of any then current Letter of Credit, Landlord shall have the right to draw the full amount of the current Letter of Credit and hold
the funds drawn in cash without obligation for interest thereon as the Security Deposit. The Security Deposit shall be held by Landlord as security for the performance of Tenant&#8217;s obligations under this Lease. The Security Deposit is not an
advance rental deposit or a measure of Landlord&#8217;s damages in case of Tenant&#8217;s default. Upon each occurrence of a Default (as defined in <U>Section</U><U></U><U>&nbsp;20</U>), Landlord may use all or any part of the Security Deposit to
pay delinquent payments due under this Lease, future rent damages under California Civil Code Section&nbsp;1951.2, and the cost of any damage, injury, expense or liability caused by such Default, without prejudice to any other remedy provided herein
or provided by law. Landlord&#8217;s right to use the Security Deposit under this <U>Section</U><U></U><U>&nbsp;6</U> includes the right to use the Security Deposit to pay future rent damages following the termination of this Lease pursuant to
<U>Section</U><U></U><U>&nbsp;21(c)</U> below. Tenant hereby waives the provisions of any law, now or hereafter in force, including, without limitation, California Civil Code Section&nbsp;1950.7, which provide that Landlord may claim from a security
deposit only those sums reasonably necessary to remedy defaults in the payment of Rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that Landlord may, in addition, claim those sums reasonably necessary to compensate
Landlord for any other loss or damage, foreseeable or unforeseeable, caused by the act or omission of Tenant or any officer, employee, agent or invitee of Tenant. Upon bankruptcy or other debtor-creditor proceedings against Tenant, the Security
Deposit shall be deemed to be applied first to the payment of Rent and other charges due Landlord for periods prior to the filing of such proceedings. Upon any such use of all or any portion of the Security Deposit, Tenant shall, within 5 business
days after demand from Landlord, restore the Security Deposit to its original amount set forth on page 1 of this Lease. If Tenant shall fully perform every provision of this Lease to be performed by Tenant, the Security Deposit, or any balance
thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant (or, at Landlord&#8217;s option, to the last assignee of Tenant&#8217;s interest hereunder) within 60
days after the expiration or earlier termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Landlord transfers its interest in the Project or this Lease, Landlord
shall either (a)&nbsp;transfer, at Landlord&#8217;s expense, any Security Deposit then held by Landlord to a person or entity assuming Landlord&#8217;s obligations under this <U>Section</U><U></U><U>&nbsp;6</U>, or (b)&nbsp;return to Tenant any
Security Deposit then held by Landlord and remaining after the deductions permitted herein. Upon such transfer to such transferee or the return of the Security Deposit to Tenant, Landlord shall have no further obligation with respect to the Security
Deposit, and Tenant&#8217;s right to the return of the Security Deposit shall apply solely against Landlord&#8217;s transferee. The Security Deposit is not an advance rental deposit or a measure of Landlord&#8217;s damages in case of Tenant&#8217;s
default. Landlord&#8217;s obligation respecting the Security Deposit is that of a debtor, not a trustee, and no interest shall accrue thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 9
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Use</B>. The Premises shall be used solely for the Permitted Use set forth in the basic
lease provisions on page 1 of this Lease, and in compliance with all laws, orders, judgments, ordinances, regulations, codes, directives, permits, licenses, covenants and restrictions now or hereafter applicable to the Premises, and to the use and
occupancy thereof, including, without limitation, the Americans With Disabilities Act, 42 U.S.C. &#167; 12101, et seq. (together with the regulations promulgated pursuant thereto, &#8220;<B>ADA</B>&#8221;) (collectively, &#8220;<B>Legal
Requirements</B>&#8221; and each, a &#8220;<B>Legal Requirement</B>&#8221;). Tenant shall, upon 5 business days&#8217; written notice from Landlord, discontinue any use of the Premises which is declared, in writing, by any Governmental Authority (as
defined in <U>Section</U><U></U><U>&nbsp;9</U>) having jurisdiction to be a violation of a Legal Requirement. Tenant will not use or permit the Premises to be used for any purpose or in any manner that would void Tenant&#8217;s or Landlord&#8217;s
insurance, increase the insurance risk, or cause the disallowance of any sprinkler or other credits. Tenant shall not permit any part of the Premises to be used as a &#8220;place of public accommodation&#8221;, as defined in the ADA or any similar
legal requirement. Tenant shall reimburse Landlord promptly upon demand for any additional premium charged for any such insurance policy by reason of Tenant&#8217;s failure to comply with the provisions of this Section or otherwise caused by
Tenant&#8217;s use and/or occupancy of the Premises. Tenant will use the Premises in a careful, safe and proper manner and will not commit or permit waste, overload the floor or structure of the Premises, subject the Premises to use that would
damage the Premises or obstruct or interfere with the rights of Landlord or other tenants or occupants of the Project, including conducting or giving notice of any auction, liquidation, or going out of business sale on the Premises, or using or
allowing the Premises to be used for any unlawful purpose. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations from the Premises from extending into Common Areas, or other
space in the Project. Tenant shall not place any machinery or equipment which will overload the floor in or upon the Premises or transport or move such items through the Common Areas of the Project or in the Project elevators without the prior
written consent of Landlord, which consent shall not be unreasonably withheld. Except as may be provided under the Work Letter, Tenant shall not, without the prior written consent of Landlord, use the Premises in any manner which will require
ventilation, air exchange, heating, gas, steam, electricity or water beyond the existing capacity of the Project as proportionately allocated to the Premises based upon Tenant&#8217;s Share as usually furnished for the Permitted Use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord shall be responsible, at Landlord&#8217;s cost and not as part of Operating Expenses, for the compliance of the Premises and the
Common Areas of the Project with Legal Requirements (including the ADA) as of the Commencement Date. Following the Commencement Date, Landlord shall, as an Operating Expense (to the extent such Legal Requirement is generally applicable to similar
buildings in the area in which the Project is located) and at Tenant&#8217;s expense (to the extent such Legal Requirement is triggered by reason of Tenant&#8217;s, as compared to other tenants of the Project, particular use of the Premises or
Tenant&#8217;s Alterations) make any alterations or modifications to the Common Areas or the exterior of the Building that are required by Legal Requirements. Except as provided in the 2 immediately preceding sentences, Tenant, at its sole expense,
shall make any alterations or modifications to the interior or the exterior of the Premises or the Project that are required by Legal Requirements (including, without limitation, compliance of the Premises with the ADA) related to Tenant&#8217;s
particular use or occupancy of the Premises or any Tenant Alterations. Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for any and all demands, claims, liabilities, losses, costs, expenses, actions, causes of
action, damages or judgments, and all reasonable expenses incurred in investigating or resisting the same (including, without limitation, reasonable attorneys&#8217; fees, charges and disbursements and costs of suit) (collectively,
&#8220;<B>Claims</B>&#8221;) arising out of or in connection with Legal Requirements related to Tenant&#8217;s particular use or occupancy of the Premises or any Tenant Alterations, and Tenant shall indemnify, defend, hold and save Landlord harmless
from and against any and all Claims arising out of or in connection with any failure of the Premises to comply with any Legal Requirement related to Tenant&#8217;s particular use or occupancy of the Premises or any Tenant Alterations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 10
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant acknowledges that Landlord may, but shall not be obligated to, seek to obtain
Leadership in Energy and Environmental Design (LEED), WELL Building Standard, or other similar &#8220;green&#8221; certification with respect to the Project and/or the Premises, and Tenant agrees to reasonably cooperate with Landlord, and to provide
such information and/or documentation as Landlord may reasonably request, in connection therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B>Holding Over</B>. If, with
Landlord&#8217;s express written consent, Tenant retains possession of the Premises after the termination of the Term, (i)&nbsp;unless otherwise agreed in such written consent, such possession shall be subject to immediate termination by Landlord at
any time, (ii) all of the other terms and provisions of this Lease (including, without limitation, the adjustment of Base Rent pursuant to <U>Section</U><U></U><U>&nbsp;4</U> hereof) shall remain in full force and effect (excluding any expansion or
renewal option or other similar right or option) during such holdover period, (iii)&nbsp;Tenant shall continue to pay Base Rent in the amount payable upon the date of the expiration or earlier termination of this Lease or such other amount as may be
agreed upon by Landlord and Tenant in such written consent, and (iv)&nbsp;all other payments shall continue under the terms of this Lease. If Tenant remains in possession of the Premises after the expiration or earlier termination of the Term
without the express written consent of Landlord, (A)&nbsp;Tenant shall become a tenant at sufferance upon the terms of this Lease except that the monthly rental shall be equal to 150% of Rent in effect during the last 30 days of the Term, and
(B)&nbsp;Tenant shall be responsible for all damages suffered by Landlord resulting from or occasioned by Tenant&#8217;s holding over, including consequential damages; provided, however, that Tenant shall not be liable for consequential damages in
connection with a holdover of 30 days or less. No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except as otherwise expressly provided, and this <U>Section</U><U></U><U>&nbsp;8</U> shall not
be construed as consent for Tenant to retain possession of the Premises. Acceptance by Landlord of Rent after the expiration of the Term or earlier termination of this Lease shall not result in a renewal or reinstatement of this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B>Taxes</B>. Landlord shall pay, as part of Operating Expenses, all taxes, levies, fees, assessments and governmental charges of any kind,
existing as of the Commencement Date or thereafter enacted (collectively referred to as &#8220;<B>Taxes</B>&#8221;), imposed by any federal, state, regional, municipal, local or other governmental authority or agency, including, without limitation,
quasi-public agencies (collectively, &#8220;<B>Governmental Authority</B>&#8221;) during the Term, including, without limitation, all Taxes: (i)&nbsp;imposed on or measured by or based, in whole or in part, on rent payable to (or gross receipts
received by) Landlord under this Lease and/or from the rental by Landlord of the Project or any portion thereof, or (ii)&nbsp;based on the square footage, assessed value or other measure or evaluation of any kind of the Premises or the Project, or
(iii)&nbsp;assessed or imposed by or on the operation or maintenance of any portion of the Premises or the Project, including parking, or (iv)&nbsp;assessed or imposed by, or at the direction of, or resulting from Legal Requirements, or
interpretations thereof, promulgated by any Governmental Authority, or (v)&nbsp;imposed as a license or other fee, charge, tax, or assessment on Landlord&#8217;s business or occupation of leasing space in the Project. Landlord may contest by
appropriate legal proceedings the amount, validity, or application of any Taxes or liens securing Taxes. Notwithstanding anything to the contrary contained herein, Landlord shall only charge Tenant for assessments as if those assessments were paid
by Landlord over the longest possible term which Landlord is permitted to pay for the applicable assessments without additional charge other than interest, if any, provided under the terms of the underlying assessments. Taxes shall not include
(a)&nbsp;any net income taxes, franchise taxes, capital levy taxes, transfer taxes, excess profits taxes, estate taxes, succession taxes or inheritance taxes imposed on Landlord except to the extent such net income taxes are in substitution for any
Taxes payable hereunder, or (b)&nbsp;any fines, penalties or interest incurred as a result of Landlord&#8217;s failure to pay any Tax when due. If any such Tax is levied or assessed directly against Tenant, then Tenant shall be responsible for and
shall pay the same at such times and in such manner as the taxing authority shall require. Tenant shall pay, prior to delinquency, any and all Taxes levied or assessed against any personal property or trade fixtures placed by Tenant in the Premises,
whether levied or assessed against Landlord or Tenant. If any Taxes on Tenant&#8217;s personal property or trade fixtures are levied against Landlord or Landlord&#8217;s property, or if the assessed valuation of the Project is increased by a value
attributable to improvements in or alterations to the Premises, whether owned by Landlord or Tenant and whether or not affixed to the real property so as to become a part thereof, higher than the base valuation on which Landlord from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> allocates Taxes to all tenants in the Project, Landlord shall have the right, but not the obligation, to pay such Taxes. Landlord&#8217;s determination of any
excess assessed valuation shall be binding and conclusive, absent manifest error. The amount of any such payment by Landlord shall constitute Additional Rent due from Tenant to Landlord immediately upon demand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 11
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B>Parking</B>. Subject to all applicable Legal Requirements, Force Majeure, a Taking (as
defined in <U>Section</U><U></U><U>&nbsp;19</U> below) and the exercise by Landlord of its rights hereunder, Tenant shall have the right, at no charge during the Base Term, to use 119 parking spaces, in common with other tenants of the Project,
which parking spaces shall be located in those areas of the Project designated for <FONT STYLE="white-space:nowrap">non-reserved</FONT> parking, subject in each case to Landlord&#8217;s rules and regulations. Landlord may allocate parking spaces
among Tenant and other tenants in the Project pro rata as described above if Landlord determines that such parking facilities are becoming crowded. As part of the Tenant Improvements, Landlord shall mark 4 of the 119 parking spaces available for use
by Tenant pursuant to the first sentence of this <U>Section</U><U></U><U>&nbsp;10</U> as reserved for use by Tenant and/or Tenant&#8217;s visitors. The cost of the marking of such spaces shall be paid for by Landlord. Such reserved spaces shall be
located in the areas of the second level of the Building&#8217;s subterranean parking facility designated on <B>Exhibit I </B>attached hereto; provided, however, that Landlord shall have the right to relocate any or all of such reserved spaces upon
30 days&#8217; written notice to Tenant. Landlord shall not be responsible for enforcing Tenant&#8217;s parking rights against any third parties, including other tenants of the Project or for enforcing any such reservation of parking spaces. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B>Utilities, Services</B>. Landlord shall provide, subject to the terms of this <U>Section</U><U></U><U>&nbsp;11</U>, water, electricity,
heat, light, power, sewer, and other utilities (including gas and fire sprinklers to the extent the Project is plumbed for such services), and, with respect to the Common Areas only, refuse and trash collection and janitorial services (collectively,
&#8220;<B>Utilities</B>&#8221;). Landlord shall pay, as Operating Expenses or subject to Tenant&#8217;s reimbursement obligation, for all Utilities used on the Premises, all maintenance charges for Utilities, and any storm sewer charges or other
similar charges for Utilities imposed by any Governmental Authority or Utility provider, and any taxes, penalties, surcharges or similar charges thereon. Landlord may cause, at Landlord&#8217;s expense (unless such separate metering is reasonably
determined by Landlord to be needed as a result of Tenant&#8217;s use of more than its pro rata share of Utilities), any Utilities to be separately metered or charged directly to Tenant by the provider. Tenant shall pay directly to the Utility
provider, prior to delinquency, any separately metered Utilities and services which may be furnished to Tenant or the Premises during the Term. Tenant shall pay, as part of Operating Expenses, its share of all charges for jointly metered Utilities
based upon consumption, as reasonably determined by Landlord. No interruption or failure of Utilities, from any cause whatsoever other than Landlord&#8217;s willful misconduct, shall result in eviction or constructive eviction of Tenant, termination
of this Lease or the abatement of Rent. Tenant agrees to limit use of water and sewer with respect to Common Areas to normal restroom use. Tenant shall be responsible for obtaining and paying for its own janitorial services for the Premises.
Notwithstanding the foregoing, HVAC shall be available to the laboratory portions of the Premises 24 hours a day, 7 days per week, except in the case of emergencies, as the result of Legal Requirements, the performance by Landlord of any
installation, maintenance or repairs, or any other temporary interruptions, and otherwise subject to the terms of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord&#8217;s sole obligation for either providing emergency generators or providing emergency
<FONT STYLE="white-space:nowrap">back-up</FONT> power to Tenant shall be: (i)&nbsp;to provide an emergency generator with not less than the capacity of the emergency generator located in the Building as of the date hereof, and (ii)&nbsp;to contract
with a third party to maintain the emergency generator as per the manufacturer&#8217;s standard maintenance guidelines. Except as otherwise provided in the immediately preceding sentence, Landlord shall have no obligation to provide Tenant with an
operational emergency generator or <FONT STYLE="white-space:nowrap">back-up</FONT> power or to supervise, oversee or confirm that the third party maintaining the emergency generator is maintaining the generator as per the manufacturer&#8217;s
standard guidelines or otherwise. During any period of replacement, repair or maintenance of the emergency generator when the emergency generator is not operational, including any delays thereto due to the inability to obtain parts or replacement
equipment, Landlord shall have no obligation to provide Tenant with an alternative <FONT STYLE="white-space:nowrap">back-up</FONT> generator or generators or alternative sources of <FONT STYLE="white-space:nowrap">back-up</FONT> power. Tenant
expressly acknowledges and agrees that Landlord does not guaranty that such emergency generator will be operational at all times or that emergency power will be available to the Premises when needed. Notwithstanding anything to the contrary
contained herein, Landlord shall, at least once per calendar quarter as part of the maintenance of the Building, run the emergency generator for a period reasonably determined by Landlord for the purpose of determining whether it operates when
started. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 12
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant agrees to provide Landlord with access to Tenant&#8217;s water and/or energy usage
data on a monthly basis, either by providing Tenant&#8217;s applicable utility login credentials to Landlord&#8217;s Measurabl online portal, or by another delivery method reasonably agreed to by Landlord and Tenant. The costs and expenses incurred
by Landlord in connection with receiving and analyzing such water and/or energy usage data (including, without limitation, as may be required pursuant to applicable Legal Requirements) shall be included as part of Operating Expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B>Alterations and Tenant&#8217;s Property</B>. Any alterations, additions, or improvements made to the Premises by or on behalf of Tenant
(other than the initial Tenant Improvements (as defined in the Work Letter) which shall be governed by the Work Letter), including additional locks or bolts of any kind or nature upon any doors or windows in the Premises, but excluding installation,
removal or realignment of furniture systems (other than removal of furniture systems owned or paid for by Landlord) not involving any modifications to the structure or connections (other than by ordinary plugs or jacks) to Building Systems (as
defined in <U>Section</U><U></U><U>&nbsp;13</U>) (&#8220;<B>Alterations</B>&#8221;) shall be subject to Landlord&#8217;s prior written consent, which may be given or withheld in Landlord&#8217;s sole discretion if any such Alteration affects the
structure or Building Systems and shall not be otherwise unreasonably withheld. Tenant may construct nonstructural Alterations in the Premises without Landlord&#8217;s prior approval if the aggregate cost of all such work in any 12 month period does
not exceed $15,000 (a &#8220;<B>Notice-Only Alteration</B>&#8221;), provided Tenant notifies Landlord in writing of such intended Notice-Only Alteration, and such notice shall be accompanied by plans, specifications, work contracts and such other
information concerning the nature and cost of the Notice-Only Alteration as may be reasonably requested by Landlord, which notice and accompanying materials shall be delivered to Landlord not less than 15 business days in advance of any proposed
construction. If Landlord approves any Alterations, Landlord may impose such conditions on Tenant in connection with the commencement, performance and completion of such Alterations as Landlord may deem appropriate in Landlord&#8217;s reasonable
discretion. Any request for approval shall be in writing, delivered not less than 15 business days in advance of any proposed construction, and accompanied by plans, specifications, bid proposals, work contracts and such other information concerning
the nature and cost of the alterations as may be reasonably requested by Landlord, including the identities and mailing addresses of all persons performing work or supplying materials. Landlord&#8217;s right to review plans and specifications and to
monitor construction shall be solely for its own benefit, and Landlord shall have no duty to ensure that such plans and specifications or construction comply with applicable Legal Requirements. Tenant shall cause, at its sole cost and expense, all
Alterations to comply with insurance requirements and with Legal Requirements and shall implement at its sole cost and expense any alteration or modification required by Legal Requirements as a result of any Alterations. Tenant shall pay to
Landlord, as Additional Rent, on demand an amount equal to 3% of all charges incurred by Tenant or its contractors or agents in connection with any Alteration to cover Landlord&#8217;s overhead and expenses for plan review, coordination, scheduling
and supervision. Before Tenant begins any Alteration, Landlord may post on and about the Premises notices of <FONT STYLE="white-space:nowrap">non-responsibility</FONT> pursuant to applicable law. Tenant shall reimburse Landlord for, and indemnify
and hold Landlord harmless from, any expense incurred by Landlord by reason of faulty work done by Tenant or its contractors, delays caused by such work, or inadequate cleanup. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall furnish security or make other arrangements reasonably satisfactory to Landlord to assure payment for the completion of all
Alterations work free and clear of liens, and shall provide (and cause each contractor or subcontractor to provide) certificates of insurance for workers&#8217; compensation and other coverage in amounts and from an insurance company satisfactory to
Landlord protecting Landlord against liability for personal injury or property damage during construction. Upon completion of any Alterations, Tenant shall deliver to Landlord: (i)&nbsp;sworn statements setting forth the names of all contractors and
subcontractors who did the work and final lien waivers from all such contractors and subcontractors; and (ii) &#8220;as built&#8221; plans for any such Alteration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 13
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for Removable Installations (as hereinafter defined), all Installations (as
hereinafter defined) shall be and shall remain the property of Landlord during the Term and following the expiration or earlier termination of the Term, shall not be removed by Tenant at any time during the Term, and shall remain upon and be
surrendered with the Premises as a part thereof. Notwithstanding the foregoing, Landlord may, at the time its approval of any such Installation is requested, or at the time it receives notice of a Notice-Only Alteration, notify Tenant that Landlord
requires that Tenant remove such Installation upon the expiration or earlier termination of the Term, in which event Tenant shall remove such Installation in accordance with the immediately succeeding sentence. Upon the expiration or earlier
termination of the Term, Tenant shall remove (i)&nbsp;all wires, cables or similar equipment which Tenant has installed in the Premises or in the risers or plenums of the Building, (ii)&nbsp;any Installations for which Landlord has given Tenant
notice of removal in accordance with the immediately preceding sentence, and (iii)&nbsp;all of Tenant&#8217;s Property (as hereinafter defined), and Tenant shall restore and repair any damage caused by or occasioned as a result of such removal,
including, without limitation, capping off all such connections behind the walls of the Premises and repairing any holes. During any restoration period beyond the expiration or earlier termination of the Term, Tenant shall pay Rent to Landlord as
provided herein as if said space were otherwise occupied by Tenant. If Landlord is requested by Tenant or any lender, lessor or other person or entity claiming an interest in any of Tenant&#8217;s Property to waive any lien Landlord may have against
any of Tenant&#8217;s Property, and Landlord consents to such waiver, then Landlord shall be entitled to be paid as administrative rent a fee of $1,000 per occurrence for its time and effort in preparing and negotiating such a waiver of lien. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Lease, (x) &#8220;<B>Removable Installations</B>&#8221; means any items listed on <B>Exhibit F </B>attached hereto and
any items agreed by Landlord in writing to be included on <B>Exhibit F </B>in the future, (y) &#8220;<B>Tenant&#8217;s Property</B>&#8221; means Removable Installations and, other than Installations, any personal property or equipment of Tenant that
may be removed without material damage to the Premises, and (z) &#8220;<B>Installations</B>&#8221; means all property of any kind paid for with the TI Fund, all Alterations, all fixtures, and all partitions, hardware,
<FONT STYLE="white-space:nowrap">built-in</FONT> machinery, <FONT STYLE="white-space:nowrap">built-in</FONT> casework and cabinets and other similar additions, equipment, property and improvements built into the Premises so as to become an integral
part of the Premises, including, without limitation, fume hoods which penetrate the roof or plenum area, <FONT STYLE="white-space:nowrap">built-in</FONT> cold rooms, <FONT STYLE="white-space:nowrap">built-in</FONT> warm rooms, <FONT
STYLE="white-space:nowrap">walk-in</FONT> cold rooms, <FONT STYLE="white-space:nowrap">walk-in</FONT> warm rooms, deionized water systems, glass washing equipment, autoclaves, chillers, <FONT STYLE="white-space:nowrap">built-in</FONT> plumbing,
electrical and mechanical equipment and systems, and any power generator and transfer switch. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary
contained herein, Tenant shall not be required at the expiration or earlier termination of the Term, to remove or restore the operable windows reflected on the Space Plan (as defined in the Work Letter) and installed as part of the Landlord&#8217;s
Work. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B>Landlord&#8217;s Repairs</B>. Landlord, as an Operating Expense (except to the extent the cost thereof is excluded from
Operating Expenses pursuant to <U>Section</U><U></U><U>&nbsp;5</U> hereof), shall maintain all of the structural, exterior, parking and other Common Areas of the Project, including HVAC, plumbing, fire sprinklers, elevators and all other building
systems serving the Premises and other portions of the Project (&#8220;<B>Building Systems</B>&#8221;), in good repair, reasonable wear and tear and uninsured losses and damages caused by Tenant, or by any of Tenant&#8217;s assignees, sublessees,
licensees, agents, servants, employees, invitees and contractors (or any of Tenant&#8217;s assignees, sublessees and/or licensees respective agents, servants, employees, invitees and contractors) (collectively, &#8220;<B>Tenant Parties</B>&#8221;)
excluded. Losses and damages caused by Tenant or any Tenant Party shall be repaired by Landlord, to the extent not covered by insurance, at Tenant&#8217;s sole cost and expense. Landlord reserves the right to temporarily stop Building Systems
services when necessary (i)&nbsp;by reason of accident or emergency, or (ii)&nbsp;for planned repairs, alterations or improvements, which are, in the judgment of Landlord, necessary to be made, until said repairs, alterations or improvements shall
have been completed. Landlord shall have no responsibility or liability for failure to supply Building Systems services during any such period of interruption; <U>provided</U>, <U>however</U>, that Landlord shall, except in case of emergency, make a
commercially reasonable effort to give Tenant 48 hours advance notice of any planned stoppage of Building Systems services for routine maintenance, repairs, alterations or improvements. Tenant shall promptly give Landlord written notice of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 14
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any repair required by Landlord pursuant to this Section, after which Landlord shall make a commercially reasonable effort to effect such repair. Landlord shall use reasonable efforts to minimize
interference with Tenant&#8217;s operations in the Premises during such planned stoppages of Building Systems. Landlord shall not be liable for any failure to make any repairs or to perform any maintenance unless such failure shall persist for an
unreasonable time after Tenant&#8217;s written notice of the need for such repairs or maintenance. Tenant waives its rights under any state or local law to terminate this Lease or to make such repairs at Landlord&#8217;s expense and agrees that the
parties&#8217; respective rights with respect to such matters shall be solely as set forth herein. Repairs required as the result of fire, earthquake, flood, vandalism, war, or similar cause of damage or destruction shall be controlled by
<U>Section</U><U></U><U>&nbsp;18</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B>Tenant&#8217;s Repairs</B>. Subject to <U>Section</U><U></U><U>&nbsp;13</U> hereof, Tenant,
at its expense, shall repair, replace and maintain in good condition all portions of the Premises, including, without limitation, entries, doors, ceilings, interior windows, interior walls, and the interior side of demising walls. Should Tenant fail
to make any such repair or replacement or fail to maintain the Premises, Landlord shall give Tenant notice of such failure. If Tenant fails to commence cure of such failure within 10 business days of Landlord&#8217;s notice, and thereafter
diligently prosecute such cure to completion, Landlord may perform such work and shall be reimbursed by Tenant within 10 business days after demand therefor; provided, however, that if such failure by Tenant creates or could create an emergency
(i.e., a circumstance which poses an imminent threat of harm to persons or substantial property damage), Landlord may immediately commence cure of such failure and shall thereafter be entitled to recover the costs of such cure from Tenant. Subject
to <U>Sections 17</U> and <U>18</U>, Tenant shall bear the full uninsured cost of any repair or replacement to any part of the Project that results from damage caused by Tenant or any Tenant Party and any repair that benefits only the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Lease, as of the Commencement Date, the maintenance and repair obligations for the
Premises shall be allocated between Landlord and Tenant as set forth on <B>Exhibit G </B>attached hereto. The maintenance obligations allocated to Tenant pursuant to <B>Exhibit G </B>(the &#8220;<B>Tenant Maintenance Obligations</B>&#8221;) shall be
performed by Tenant at Tenant&#8217;s sole cost and expense. The Tenant Maintenance Obligations shall include the procurement and maintenance of contracts, in form and substance reasonably satisfactory to Landlord, with copies to Landlord upon
Landlord&#8217;s written request, for and with contractors reasonably acceptable to Landlord specializing and experienced in the respective Tenant Maintenance Obligations. Notwithstanding anything to the contrary contained herein, the scope of work
of any such contracts entered into by Tenant pursuant to this paragraph shall, at a minimum, comply with manufacturer&#8217;s recommended maintenance procedures for the optimal performance of the applicable equipment. Landlord shall, notwithstanding
anything to the contrary contained in this Lease, have no obligation to perform any Tenant Maintenance Obligations. The Tenant Maintenance Obligations shall not include the right or obligation on the part of Tenant to make any structural and/or
capital repairs or improvements to the Project, and Landlord shall, during any period that Tenant is responsible for the Tenant Maintenance Obligations, continue, as part of Operating Expenses, to be responsible, as provided in the immediately
preceding paragraph, for capital repairs and replacements required to be made to the Project. If Tenant fails to maintain any portion of the Premises for which Tenant is responsible as part of the Tenant Maintenance Obligations in a manner
reasonably acceptable to Landlord within the requirements of this Lease, Landlord shall have the right, but not the obligation, to provide Tenant with written notice thereof and to assume the Tenant Maintenance Obligations if Tenant does not cure
Tenant&#8217;s failure within 10 days after receipt of such notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B>Mechanic&#8217;s Liens</B>. Tenant shall discharge, by bond or
otherwise, any mechanic&#8217;s lien filed against the Premises or against the Project for work claimed to have been done for, or materials claimed to have been furnished to, Tenant within 15 days after the filing thereof, at Tenant&#8217;s sole
cost and shall otherwise keep the Premises and the Project free from any liens arising out of work performed, materials furnished or obligations incurred by Tenant. Should Tenant fail to discharge any lien described herein, Landlord shall have the
right, but not the obligation, to pay such claim or post a bond or otherwise provide security to eliminate the lien as a claim against title to the Project and the cost thereof shall be immediately due from Tenant as Additional Rent. If Tenant shall
lease or finance the acquisition of office </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 15
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equipment, furnishings, or other personal property of a removable nature utilized by Tenant in the operation of Tenant&#8217;s business, Tenant warrants that any Uniform Commercial Code Financing
Statement filed as a matter of public record by any lessor or creditor of Tenant will upon its face or by exhibit thereto indicate that such Financing Statement is applicable only to removable personal property of Tenant located within the Premises.
In no event shall the address of the Project be furnished on the statement without qualifying language as to applicability of the lien only to removable personal property, located in an identified suite held by Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B>Indemnification</B>. Tenant hereby indemnifies and agrees to defend, save and hold Landlord, its officers, directors, employees,
managers, agents, <FONT STYLE="white-space:nowrap">sub-agents,</FONT> constituent entities and lease signators (collectively, &#8220;<B>Landlord Indemnified Parties</B>&#8221;) harmless from and against any and all Claims for injury or death to
persons or damage to property occurring within or about the Premises or the Project arising directly or indirectly out of use or occupancy of the Premises or the Project (including, without limitation, any act, omission or neglect by Tenant or any
Tenant&#8217;s Parties in or about the Premises or at the Project) or a breach or default by Tenant in the performance of any of its obligations hereunder, except to the extent caused by the willful misconduct or negligence of Landlord Indemnified
Parties. Landlord shall not be liable to Tenant for, and Tenant assumes all risk of damage to, personal property (including, without limitation, loss of records kept within the Premises). Tenant further waives any and all Claims for injury to
Tenant&#8217;s business or loss of income relating to any such damage or destruction of personal property (including, without limitation, any loss of records). Landlord Indemnified Parties shall not be liable for any damages arising from any act,
omission or neglect of any tenant in the Project or of any other third party or Tenant Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <B>Insurance</B>. Landlord shall
maintain all risk property and, if applicable, sprinkler damage insurance covering the full replacement cost of the Project. Landlord shall further procure and maintain commercial general liability insurance with a single loss limit of not less than
$2,000,000 for bodily injury and property damage with respect to the Project. Landlord may, but is not obligated to, maintain such other insurance and additional coverages as it may deem necessary, including, but not limited to, flood, environmental
hazard and earthquake, loss or failure of building equipment, errors and omissions, rental loss during the period of repair or rebuilding, workers&#8217; compensation insurance and fidelity bonds for employees employed to perform services and
insurance for any improvements installed by Tenant or which are in addition to the standard improvements customarily furnished by Landlord without regard to whether or not such are made a part of the Project. All such insurance shall be included as
part of the Operating Expenses. The Project may be included in a blanket policy (in which case the cost of such insurance allocable to the Project will be determined by Landlord based upon the insurer&#8217;s cost calculations). Tenant shall also
reimburse Landlord for any increased premiums or additional insurance which Landlord reasonably deems necessary as a result of Tenant&#8217;s use of the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant, at its sole cost and expense, shall maintain during the Term: all risk property insurance with business interruption and extra expense
coverage, covering the full replacement cost of all property and improvements installed or placed in the Premises by Tenant at Tenant&#8217;s expense; workers&#8217; compensation insurance with no less than the minimum limits required by law;
employer&#8217;s liability insurance with employers liability limits of $1,000,000 bodily injury by accident &#8211; each accident, $1,000,000 bodily injury by disease &#8211; policy limit, and $1,000,000 bodily injury by disease &#8211; each
employee; and commercial general liability insurance, with a minimum limit of not less than $2,000,000 per occurrence for bodily injury and property damage with respect to the Premises. The commercial general liability insurance maintained by Tenant
shall name Alexandria Real Estate Equities, Inc., and Landlord, its officers, directors, employees, managers, agents, <FONT STYLE="white-space:nowrap">sub-agents,</FONT> constituent entities and lease signators (collectively, &#8220;<B>Landlord
Insured Parties</B>&#8221;), as additional insureds; insure on an occurrence and not a claims-made basis; be issued by insurance companies which have a rating of not less than policyholder rating of A and financial category rating of at least
Class&nbsp;X in &#8220;Best&#8217;s Insurance Guide&#8221;; shall not be cancelable for nonpayment of premium unless 10 days prior written notice shall have been given to Landlord from the insurer; not contain a hostile fire exclusion; contain a
contractual liability endorsement; and provide primary coverage to Landlord Insured Parties (any policy issued to Landlord Insured Parties providing duplicate or similar coverage shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 16
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed excess over Tenant&#8217;s policies, regardless of limits). Certificates of insurance showing the limits of coverage required hereunder and showing Landlord as an additional insured, along
with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord by Tenant prior to (i)&nbsp;the earlier to occur of (x)&nbsp;the Commencement Date, or (y)&nbsp;the date that Tenant accesses the Premises
under this Lease, and (ii)&nbsp;each renewal of said insurance. Tenant&#8217;s policy may be a &#8220;blanket policy&#8221; with an aggregate per location endorsement which specifically provides that the amount of insurance shall not be prejudiced
by other losses covered by the policy. Tenant shall, at least 5 days prior to the expiration of such policies, furnish Landlord with renewal certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each instance where insurance is to name Landlord as an additional insured, Tenant shall upon written request of Landlord also designate
and furnish certificates so evidencing Landlord as additional insured to: (i)&nbsp;any lender of Landlord holding a security interest in the Project or any portion thereof, (ii)&nbsp;the landlord under any lease wherein Landlord is tenant of the
real property on which the Project is located, if the interest of Landlord is or shall become that of a tenant under a ground or other underlying lease rather than that of a fee owner, and/or (iii)&nbsp;any management company retained by Landlord to
manage the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The property insurance obtained by Landlord and Tenant shall include a waiver of subrogation by the insurers and all
rights based upon an assignment from its insured, against Landlord or Tenant, and their respective officers, directors, employees, managers, agents, invitees and contractors (&#8220;<B>Related Parties</B>&#8221;), in connection with any loss or
damage thereby insured against. Neither party nor its respective Related Parties shall be liable to the other for loss or damage caused by any risk insured against under property insurance required to be maintained hereunder, and each party waives
any claims against the other party, and its respective Related Parties, for such loss or damage. The failure of a party to insure its property shall not void this waiver. Landlord and its respective Related Parties shall not be liable for, and
Tenant hereby waives all claims against such parties for, business interruption and losses occasioned thereby sustained by Tenant or any person claiming through Tenant resulting from any accident or occurrence in or upon the Premises or the Project
from any cause whatsoever. If the foregoing waivers shall contravene any law with respect to exculpatory agreements, the liability of Landlord or Tenant shall be deemed not released but shall be secondary to the other&#8217;s insurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord may require insurance policy limits to be raised to conform with requirements of Landlord&#8217;s lender and/or to bring coverage
limits to levels then being generally required of new tenants within the Project; provided, however, that the increased amount of coverage is consistent with coverage amounts then being required by institutional owners of similar projects with
tenants occupying similar size premises in the geographical area in which the Project is located. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <B>Restoration</B>. If, at any time
during the Term, the Project or the Premises are damaged or destroyed by a fire or other insured casualty, Landlord shall notify Tenant within 60 days after discovery of such damage as to the amount of time Landlord reasonably estimates it will take
to restore the Project or the Premises, as applicable (the &#8220;<B>Restoration Period</B>&#8221;). If the Restoration Period is estimated to exceed 9 months (the &#8220;<B>Maximum Restoration Period</B>&#8221;), Landlord may, in such notice, elect
to terminate this Lease as of the date that is 75 days after the date of discovery of such damage or destruction; <U>provided, however</U>, that notwithstanding Landlord&#8217;s election to restore, Tenant may elect to terminate this Lease by
written notice to Landlord delivered within 5 business days of receipt of a notice from Landlord estimating a Restoration Period for the Premises longer than the Maximum Restoration Period. Unless either Landlord or Tenant so elects to terminate
this Lease, Landlord shall, subject to receipt of sufficient insurance proceeds (with any deductible to be treated as a current Operating Expense), promptly restore the Premises (excluding the improvements installed by Tenant or by Landlord and paid
for by Tenant), subject to delays arising from the collection of insurance proceeds, from Force Majeure events or as needed to obtain any license, clearance or other authorization of any kind required to enter into and restore the Premises issued by
any Governmental Authority having jurisdiction over the use, storage, handling, treatment, generation, release, disposal, removal or remediation of Hazardous Materials (as defined in <U>Section</U><U></U><U>&nbsp;30</U>) in, on or about the Premises
(collectively referred to herein as &#8220;<B>Hazardous Materials Clearances</B>&#8221;); <U>provided</U>, <U>however</U>, that if repair or restoration of the Premises is not substantially complete as of the end of the Maximum
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 17
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Restoration Period or, if longer, the Restoration Period, Landlord may, in its sole and absolute discretion, elect not to proceed with such repair and restoration, or Tenant may by written notice
to Landlord delivered within 5 business days of the expiration of the Maximum Restoration Period or, if longer, the Restoration Period, elect to terminate this Lease, in which event Landlord shall be relieved of its obligation to make such repairs
or restoration and this Lease shall terminate as of the date that is 75 days after the later of: (i)&nbsp;discovery of such damage or destruction, or (ii)&nbsp;the date all required Hazardous Materials Clearances are obtained, but Landlord shall
retain any Rent paid and the right to any Rent payable by Tenant prior to such election by Landlord or Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant, at its expense,
shall promptly perform, subject to delays arising from the collection of insurance proceeds, from Force Majeure events or to obtain Hazardous Material Clearances, all repairs or restoration not required to be done by Landlord and shall promptly <FONT
STYLE="white-space:nowrap">re-enter</FONT> the Premises and commence doing business in accordance with this Lease. Notwithstanding the foregoing, either Landlord or Tenant may terminate this Lease upon written notice to the other if the Premises are
damaged during the last year of the Term and Landlord reasonably estimates that it will take more than 2 months to repair such damage; provided, however, that such notice is delivered within 10 business days after the date that Landlord provides
Tenant with written notice of the estimated Restoration Period. Notwithstanding anything to the contrary contained herein, Landlord shall also have the right to terminate this Lease if insurance proceeds are not available for such restoration. Rent
shall be abated from the date all required Hazardous Material Clearances are obtained until the Premises are repaired and restored, in the proportion which the area of the Premises, if any, which is not usable by Tenant bears to the total area of
the Premises, unless Landlord provides Tenant with other space during the period of repair that is suitable for the temporary conduct of Tenant&#8217;s business. In the event that no Hazardous Material Clearances are required to be obtained by
Tenant with respect to the Premises, rent abatement shall commence on the date of discovery of the damage or destruction. Such abatement shall be the sole remedy of Tenant, and except as provided in this <U>Section</U><U></U><U>&nbsp;18</U>, Tenant
waives any right to terminate this Lease by reason of damage or casualty loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Lease, including this
<U>Section</U><U></U><U>&nbsp;18</U>, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, or any other portion of the Project, and any statute or
regulation which is now or may hereafter be in effect shall have no application to this Lease or any damage or destruction to all or any part of the Premises or any other portion of the Project, the parties hereto expressly agreeing that this
<U>Section</U><U></U><U>&nbsp;18</U> sets forth their entire understanding and agreement with respect to such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.
<B>Condemnation</B>. If the whole or any material part of the Premises or the Project is taken for any public or quasi-public use under governmental law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof
(a &#8220;<B>Taking</B>&#8221; or &#8220;<B>Taken</B>&#8221;), and the Taking would in Landlord&#8217;s reasonable judgment, either prevent or materially interfere with Tenant&#8217;s use of the Premises or materially interfere with or impair
Landlord&#8217;s ownership or operation of the Project, then upon written notice by Landlord this Lease shall terminate and Rent shall be apportioned as of said date. If part of the Premises shall be Taken, and this Lease is not terminated as
provided above, Landlord shall promptly restore the Premises and the Project as nearly as is commercially reasonable under the circumstances to their condition prior to such partial Taking and the rentable square footage of the Building, the
rentable square footage of the Premises, Tenant&#8217;s Share of Operating Expenses and the Rent payable hereunder during the unexpired Term shall be reduced to such extent as may be fair and reasonable under the circumstances. Upon any such Taking,
Landlord shall be entitled to receive the entire price or award from any such Taking without any payment to Tenant, and Tenant hereby assigns to Landlord Tenant&#8217;s interest, if any, in such award. Tenant shall have the right, to the extent that
same shall not diminish Landlord&#8217;s award, to make a separate claim against the condemning authority (but not Landlord) for such compensation as may be separately awarded or recoverable by Tenant for moving expenses and damage to Tenant&#8217;s
trade fixtures, if a separate award for such items is made to Tenant. Tenant hereby waives any and all rights it might otherwise have pursuant to any provision of state law to terminate this Lease upon a partial Taking of the Premises or the
Project. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 18
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <B>Events of Default</B>. Each of the following events shall be a default
(&#8220;<B>Default</B>&#8221;) by Tenant under this Lease: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Payment Defaults</B>. Tenant shall fail to pay any installment of Rent
or any other payment hereunder when due; provided, however, that Landlord will give Tenant notice and an opportunity to cure any failure to pay Rent within 5 days of any such notice not more than twice in any 12 month period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Insurance</B>. Any insurance required to be maintained by Tenant pursuant to this Lease shall be canceled or terminated or shall expire
or shall be reduced or materially changed, or Landlord shall receive a notice of nonrenewal of any such insurance and Tenant shall fail to obtain replacement insurance at least 5 days before the expiration of the current coverage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Abandonment</B>. Tenant shall abandon the Premises. Tenant shall not be deemed to have abandoned the Premises if (i)&nbsp;Tenant
provides Landlord with reasonable advance notice prior to vacating and, at the time of vacating the Premises, Tenant completes Tenant&#8217;s obligations with respect to the Decommissioning and HazMat Closure Plan in compliance with
<U>Section</U><U></U><U>&nbsp;28</U>, (ii) Tenant has made reasonable arrangements with Landlord for the security of the Premises for the balance of the Term, and (iii)&nbsp;Tenant continues during the balance of the Term to satisfy all of its
obligations under the Lease as they come due. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Improper Transfer</B>. Tenant shall assign, sublease or otherwise transfer or attempt
to transfer all or any portion of Tenant&#8217;s interest in this Lease or the Premises except as expressly permitted herein, or Tenant&#8217;s interest in this Lease shall be attached, executed upon, or otherwise judicially seized and such action
is not released within 90 days of the action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Liens</B>. Tenant shall fail to discharge or otherwise obtain the release of any lien
placed upon the Premises in violation of this Lease within 10 days after any such lien is filed against the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Insolvency
Events</B>. Tenant or any guarantor or surety of Tenant&#8217;s obligations hereunder shall: (A)&nbsp;make a general assignment for the benefit of creditors; (B)&nbsp;commence any case, proceeding or other action seeking to have an order for relief
entered on its behalf as a debtor or to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, liquidation, dissolution or composition of it or its debts or seeking appointment of a receiver, trustee, custodian or
other similar official for it or for all or of any substantial part of its property (collectively a &#8220;<B>Proceeding for Relief</B>&#8221;); (C) become the subject of any Proceeding for Relief which is not dismissed within 90 days of its filing
or entry; or (D)&nbsp;die or suffer a legal disability (if Tenant, guarantor, or surety is an individual) or be dissolved or otherwise fail to maintain its legal existence (if Tenant, guarantor or surety is a corporation, partnership or other
entity). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Estoppel Certificate or Subordination Agreement</B>. Tenant fails to execute any document required from Tenant under
<U>Sections 23</U> or <U>27</U> within 5 days after a second notice requesting such document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Other Defaults</B>. Tenant shall fail
to comply with any provision of this Lease other than those specifically referred to in this <U>Section</U><U>&nbsp;20</U>, and, except as otherwise expressly provided herein, such failure shall continue for a period of 30 days after written notice
thereof from Landlord to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice given under <U>Section</U><U></U><U>&nbsp;20(h)</U> hereof shall: (i)&nbsp;specify the
alleged default, (ii)&nbsp;demand that Tenant cure such default, (iii)&nbsp;be in lieu of, and not in addition to, or shall be deemed to be, any notice required under any provision of applicable law, and (iv)&nbsp;not be deemed a forfeiture or a
termination of this Lease unless Landlord elects otherwise in such notice; <U>provided</U> that if the nature of Tenant&#8217;s default pursuant to <U>Section</U><U></U><U>&nbsp;20(h)</U> is such that it cannot be cured by the payment of money and
reasonably requires more than 30 days to cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said 30 day period and thereafter diligently prosecutes the same to completion; <U>provided</U>, <U>however</U>,
that such cure shall be completed no later than 60 days from the date of Landlord&#8217;s notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 19
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <B>Landlord&#8217;s Remedies</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Payment By Landlord; Interest</B>. Upon a Default by Tenant hereunder, Landlord may, without waiving or releasing any obligation of
Tenant hereunder, make such payment or perform such act. All sums so paid or incurred by Landlord, together with interest thereon, from the date such sums were paid or incurred, at the annual rate equal to 12% per annum or the highest rate permitted
by law (the &#8220;<B>Default Rate</B>&#8221;), whichever is less, shall be payable to Landlord on demand as Additional Rent. Nothing herein shall be construed to create or impose a duty on Landlord to mitigate any damages resulting from
Tenant&#8217;s Default hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Late Payment Rent</B>. Late payment by Tenant to Landlord of Rent and other sums due will cause
Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult and impracticable to ascertain. Such costs include, but are not limited to, processing and accounting charges and late charges which may be
imposed on Landlord under any Mortgage covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within 5 days after the date such payment is due, Tenant shall pay to Landlord an additional sum equal to
6% of the overdue Rent as a late charge. Notwithstanding the foregoing, before assessing a late charge the first time in any calendar year, Landlord shall provide Tenant written notice of the delinquency and will waive the right if Tenant pays such
delinquency within 5 days thereafter. The parties agree that this late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant. In addition to the late charge, Rent not paid when due
shall bear interest at the Default Rate from the 5th day after the date due until paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Remedies</B>. Upon the occurrence of a
Default, Landlord, at its option, shall have in addition to all other rights and remedies provided in this Lease, at law or in equity, the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and
nonexclusive, without any notice or demand whatsoever. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Terminate this Lease, or at Landlord&#8217;s option,
Tenant&#8217;s right to possession only, in which event Tenant shall immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in
rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim for damages therefor; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Upon any termination of this Lease, whether pursuant to the foregoing <U>Section</U><U></U><U>&nbsp;21(c)(i)</U> or
otherwise, Landlord may recover from Tenant the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) The worth at the time of award of any unpaid rent which has
been earned at the time of such termination; plus </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The worth at the time of award of the amount by which the unpaid
rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) The worth at the time of award of the amount by which the unpaid rent for the balance of the Term after the time of award
exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) Any other amount
necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, specifically including,
but not limited to, brokerage commissions and advertising expenses incurred, expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new
tenant; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 20
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) At Landlord&#8217;s election, such other amounts in addition to or in
lieu of the foregoing as may be permitted from time to time by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;<B>rent</B>&#8221; as used in this
<U>Section</U><U></U><U>&nbsp;21</U> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. As used in <U>Sections 21(c)(ii)(A)</U> and
<U>(B)</U>, above, the &#8220;<B>worth at the time of award</B>&#8221; shall be computed by allowing interest at the Default Rate. As used in <U>Section</U><U></U><U>&nbsp;21(c)(ii)(C)</U> above, the &#8220;<B>worth at the time of award</B>&#8221;
shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus 1%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Landlord may continue this Lease in effect after Tenant&#8217;s Default and recover rent as it becomes due (Landlord and
Tenant hereby agreeing that Tenant has the right to sublet or assign hereunder, subject only to reasonable limitations). Accordingly, if Landlord does not elect to terminate this Lease following a Default by Tenant, Landlord may, from time to time,
without terminating this Lease, enforce all of its rights and remedies hereunder, including the right to recover all Rent as it becomes due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Whether or not Landlord elects to terminate this Lease following a Default by Tenant, Landlord shall have the right to
terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord&#8217;s sole discretion, succeed to Tenant&#8217;s interest in such
subleases, licenses, concessions or arrangements. Upon Landlord&#8217;s election to succeed to Tenant&#8217;s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election,
have no further right to or interest in the rent or other consideration receivable thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Independent of the
exercise of any other remedy of Landlord hereunder or under applicable law, Landlord may conduct an environmental test of the Premises as generally described in <U>Section</U><U></U><U>&nbsp;30(d)</U> hereof, at Tenant&#8217;s expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Effect of Exercise</B>. Exercise by Landlord of any remedies hereunder or otherwise available shall not be deemed to be an acceptance of
surrender of the Premises and/or a termination of this Lease by Landlord, it being understood that such surrender and/or termination can be effected only by the express written agreement of Landlord and Tenant. Any law, usage, or custom to the
contrary notwithstanding, Landlord shall have the right at all times to enforce the provisions of this Lease in strict accordance with the terms hereof; and the failure of Landlord at any time to enforce its rights under this Lease strictly in
accordance with same shall not be construed as having created a custom in any way or manner contrary to the specific terms, provisions, and covenants of this Lease or as having modified the same and shall not be deemed a waiver of Landlord&#8217;s
right to enforce one or more of its rights in connection with any subsequent default. A receipt by Landlord of Rent or other payment with knowledge of the breach of any covenant hereof shall not be deemed a waiver of such breach, and no waiver by
Landlord of any provision of this Lease shall be deemed to have been made unless expressed in writing and signed by Landlord. To the greatest extent permitted by law, Tenant waives the service of notice of Landlord&#8217;s intention to <FONT
STYLE="white-space:nowrap">re-enter,</FONT> <FONT STYLE="white-space:nowrap">re-take</FONT> or otherwise obtain possession of the Premises as provided in any statute, or to institute legal proceedings to that end, and also waives all right of
redemption in case Tenant shall be dispossessed by a judgment or by warrant of any court or judge. Any reletting of the Premises or any portion thereof shall be on such terms and conditions as Landlord in its sole discretion may determine. Landlord
shall not be liable for, nor shall Tenant&#8217;s obligations hereunder be diminished because of, Landlord&#8217;s failure to relet the Premises or collect rent due in respect of such reletting or otherwise to mitigate any damages arising by reason
of Tenant&#8217;s Default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 21
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <B>Assignment and Subletting</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>General Prohibition</B>. Subject to the terms and conditions of this <U>Section</U><U></U><U>&nbsp;22</U> (including, without
limitation, the terms and conditions of <U>Section</U><U></U><U>&nbsp;22(b)</U> below), without Landlord&#8217;s prior written consent, Tenant shall not, directly or indirectly, voluntarily or by operation of law, assign this Lease or sublease the
Premises or any part thereof or mortgage, pledge, or hypothecate its leasehold interest or grant any concession or license within the Premises, and any attempt to do any of the foregoing shall be void and of no effect. If Tenant is a corporation,
partnership or limited liability company, the shares or other ownership interests thereof which are not actively traded upon a stock exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market, a transfer or series of transfers whereby 49.9% or more of the issued and outstanding shares or other ownership interests of such corporation are, or voting control is, transferred (but excepting transfers upon deaths of individual owners)
from a person or persons or entity or entities which were owners thereof at time of execution of this Lease to persons or entities who were not owners of shares or other ownership interests of the corporation, partnership or limited liability
company at time of execution of this Lease, shall be deemed an assignment of this Lease requiring the consent of Landlord as provided in this <U>Section</U><U></U><U>&nbsp;22</U>. Notwithstanding the foregoing, Tenant shall have the right to obtain
financing from institutional and/or individual investors (including venture capital funding and corporate partners) or undergo a public offering which results in a change in control of Tenant without such change of control constituting an assignment
under this <U>Section</U><U></U><U>&nbsp;22</U> requiring Landlord consent, provided that (i)&nbsp;Tenant notifies Landlord in writing of the financing at least 5 business days prior to the closing of the financing, and (ii)&nbsp;provided that in no
event shall such financing result in a change in use of the Premises from the use contemplated by Tenant at the commencement of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Permitted Transfers</B>. . If Tenant desires to assign, sublease, hypothecate or otherwise transfer this Lease or sublet the Premises other
than pursuant to a Permitted Assignment (as defined below), then at least 15 business days, but not more than 45 business days, before the date Tenant desires the assignment or sublease to be effective (the &#8220;<B>Assignment Date</B>&#8221;),
Tenant shall give Landlord a notice (the &#8220;<B>Assignment Notice</B>&#8221;) containing such information about the proposed assignee or sublessee, including the proposed use of the Premises and any Hazardous Materials proposed to be used, stored
handled, treated, generated in or released or disposed of from the Premises, the Assignment Date, any relationship between Tenant and the proposed assignee or sublessee, and all material terms and conditions of the proposed assignment or sublease,
including a copy of any proposed assignment or sublease in its final form, and such other information as Landlord may deem reasonably necessary or appropriate to its consideration whether to grant its consent. Landlord may, by giving written notice
to Tenant within 15 business days after receipt of the Assignment Notice: (i)&nbsp;grant such consent, (ii)&nbsp;refuse such consent, in its reasonable discretion, or (iii)&nbsp;terminate this Lease with respect to the space described in the
Assignment Notice as of the Assignment Date (an &#8220;<B>Assignment Termination</B>&#8221;). Among other reasons, it shall be reasonable for Landlord to withhold its consent in any of these instances: (1)&nbsp;the proposed assignee or subtenant is
a governmental agency; (2)&nbsp;in Landlord&#8217;s reasonable judgment, the use of the Premises by the proposed assignee or subtenant would entail any alterations that would lessen the value of the leasehold improvements in the Premises, or would
require increased services by Landlord; (3)&nbsp;in Landlord&#8217;s reasonable judgment, the proposed assignee or subtenant is engaged in areas of scientific research or other business concerns that are controversial such that they may
(i)&nbsp;attract or cause negative publicity for or about the Building or the Project, (ii) negatively affect the reputation of the Building, the Project or Landlord, (iii)&nbsp;attract protestors to the Building or the Project, or (iv)&nbsp;lessen
the attractiveness of the Building or the Project to any tenants or prospective tenants, purchasers or lenders; (4)&nbsp;in Landlord&#8217;s reasonable judgment, the proposed assignee or subtenant lacks the creditworthiness to support the financial
obligations it will incur under the proposed assignment or sublease; (5)&nbsp;in Landlord&#8217;s reasonable judgment, the character, reputation, or business of the proposed assignee or subtenant is inconsistent with the desired <FONT
STYLE="white-space:nowrap">tenant-mix</FONT> or the quality of other tenancies in the Project or is inconsistent with the type and quality of the nature of the Building; (6) Landlord has received from any prior landlord to the proposed assignee or
subtenant a negative report concerning such prior landlord&#8217;s experience with the proposed assignee or subtenant; (7)&nbsp;Landlord has experienced previous defaults by or is in litigation with the proposed assignee or subtenant; (8)&nbsp;the
use of the Premises by the proposed assignee or subtenant will violate any applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 22
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Legal Requirement; (9)&nbsp;the proposed assignee or subtenant is an entity with whom Landlord is negotiating to lease space in the Project; or (10)&nbsp;the assignment or sublease is prohibited
by Landlord&#8217;s lender. If Landlord delivers notice of its election to exercise an Assignment Termination, Tenant shall have the right to withdraw such Assignment Notice by written notice to Landlord of such election within 5 business days after
Landlord&#8217;s notice electing to exercise the Assignment Termination. If Tenant withdraws such Assignment Notice, this Lease shall continue in full force and effect. If Tenant does not withdraw such Assignment Notice, this Lease, and the term and
estate herein granted, shall terminate as of the Assignment Date with respect to the space described in such Assignment Notice. No failure of Landlord to exercise any such option to terminate this Lease, or to deliver a timely notice in response to
the Assignment Notice, shall be deemed to be Landlord&#8217;s consent to the proposed assignment, sublease or other transfer. Tenant shall pay to Landlord a fee equal to Two Thousand Five Hundred Dollars ($2,500) in connection with its consideration
of any Assignment Notice and/or its preparation or review of any consent documents. Notwithstanding the foregoing, Landlord&#8217;s consent to an assignment of this Lease or a subletting of any portion of the Premises to any entity controlling,
controlled by or under common control with Tenant (a &#8220;<B>Control Permitted Assignment</B>&#8221;) shall not be required, provided that Landlord shall have the right to approve the form of any such sublease or assignment (which approval shall
not be unreasonably withheld or delayed). In addition, Tenant shall have the right to assign this Lease, upon 30 days prior written notice to Landlord ((x) unless Tenant is prohibited from providing such notice by applicable Legal Requirements in
which case Tenant shall notify Landlord promptly thereafter, and (y)&nbsp;if the transaction is subject to confidentiality requirements, Tenant&#8217;s advance notification shall be subject to Landlord&#8217;s execution of a <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreement reasonably acceptable to Landlord and Tenant) but without obtaining Landlord&#8217;s prior written consent, to a corporation or other entity which is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> to Tenant, by way of merger, consolidation or corporate reorganization, or by the purchase of all or substantially all of the assets or the ownership interests of Tenant provided that
(i)&nbsp;such merger or consolidation, or such acquisition or assumption, as the case may be, is for a legitimate business purpose and not principally for the purpose of transferring this Lease, and (ii)&nbsp;the net worth (as determined in
accordance with generally accepted accounting principles (&#8220;<B>GAAP</B>&#8221;)) of the assignee is not less than the greater of the net worth (as determined in accordance with GAAP) of Tenant as of (A)&nbsp;the Commencement Date, or
(B)&nbsp;as of the date of Tenant&#8217;s most current quarterly or annual financial statements, and (iii)&nbsp;such assignee shall agree in writing to assume all of the terms, covenants and conditions of this Lease (a &#8220;<B>Corporate Permitted
Assignment</B>&#8221;). Control Permitted Assignments and Corporate Permitted Assignments are hereinafter referred to as &#8220;<B>Permitted Assignments</B>.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Additional Conditions</B>. As a condition to any such assignment or subletting, whether or not Landlord&#8217;s consent is required,
Landlord may require: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) that any assignee or subtenant agree, in writing at the time of such assignment or subletting,
that if Landlord gives such party notice that Tenant is in default under this Lease, such party shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments will be received by Landlord without any liability except to
credit such payment against those due under the Lease, and any such third party shall agree to attorn to Landlord or its successors and assigns should this Lease be terminated for any reason; <U>provided</U>, <U>however</U>, in no event shall
Landlord or its successors or assigns be obligated to accept such attornment; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) A list of Hazardous Materials,
certified by the proposed assignee or sublessee to be true and correct, which the proposed assignee or sublessee intends to use, store, handle, treat, generate in or release or dispose of from the Premises, together with copies of all documents
relating to such use, storage, handling, treatment, generation, release or disposal of Hazardous Materials by the proposed assignee or subtenant in the Premises or on the Project, prior to the proposed assignment or subletting, including, without
limitation: permits; approvals; reports and correspondence; storage and management plans; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted
after Landlord has given its written consent to do so, which consent may be withheld in Landlord&#8217;s sole and absolute discretion); and all closure plans or any other documents required by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 23
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks. Neither Tenant nor any such proposed
assignee or subtenant is required, however, to provide Landlord with any portion(s) of the such documents containing information of a proprietary nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous
activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>No Release of Tenant, Sharing of Excess Rents</B>. Notwithstanding any assignment or subletting, Tenant and any
guarantor or surety of Tenant&#8217;s obligations under this Lease shall at all times remain fully and primarily responsible and liable for the payment of Rent and for compliance with all of Tenant&#8217;s other obligations under this Lease. Except
in connection with a Permitted Assignment, if the Rent due and payable by a sublessee or assignee (or a combination of the rental payable under such sublease or assignment plus any bonus or other consideration therefor or incident thereto in any
form) exceeds the sum of the rental payable under this Lease, (excluding however, any Rent payable under this Section) and actual and reasonable brokerage fees, legal costs and any design or construction fees directly related to and required
pursuant to the terms of any such sublease (&#8220;<B>Excess Rent</B>&#8221;), then Tenant shall be bound and obligated to pay Landlord as Additional Rent hereunder 50% of such Excess Rent within 10 days following receipt thereof by Tenant. If
Tenant shall sublet the Premises or any part thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as security for Tenant&#8217;s obligations under this Lease, all rent from any such subletting, and Landlord as assignee and as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for Tenant, or a receiver for Tenant appointed on Landlord&#8217;s application, may collect such rent and apply it toward Tenant&#8217;s obligations under
this Lease; except that, until the occurrence of a Default, Tenant shall have the right to collect such rent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>No Waiver</B>. The
consent by Landlord to an assignment or subletting shall not relieve Tenant or any assignees of this Lease or any sublessees of the Premises from obtaining the consent of Landlord to any further assignment or subletting nor shall it release Tenant
or any assignee or sublessee of Tenant from full and primary liability under this Lease. The acceptance of Rent hereunder, or the acceptance of performance of any other term, covenant, or condition thereof, from any other person or entity shall not
be deemed to be a waiver of any of the provisions of this Lease or a consent to any subletting, assignment or other transfer of the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Prior Conduct of Proposed Transferee</B>. Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;22</U>, if
(i)&nbsp;the proposed assignee or sublessee of Tenant has been required by any prior landlord, lender or Governmental Authority to take remedial action in connection with Hazardous Materials contaminating a property, where the contamination resulted
from such party&#8217;s action or use of the property in question, (ii)&nbsp;the proposed assignee or sublessee is subject to an enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment,
generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any Governmental Authority), or (iii)&nbsp;because of the existence of a <FONT
STYLE="white-space:nowrap">pre-existing</FONT> environmental condition in the vicinity of or underlying the Project, the risk that Landlord would be targeted as a responsible party in connection with the remediation of such <FONT
STYLE="white-space:nowrap">pre-existing</FONT> environmental condition would be materially increased or exacerbated by the proposed use of Hazardous Materials by such proposed assignee or sublessee, Landlord shall have the absolute right to refuse
to consent to any assignment or subletting to any such party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <B>Estoppel Certificate</B>. Tenant shall, within 10 business days of
written notice from Landlord, execute, acknowledge and deliver a statement in writing in any form reasonably requested by a proposed lender or purchaser, (i)&nbsp;certifying that this Lease is unmodified and in full force and effect (or, if
modified, stating the nature of such modification and certifying that this Lease as so modified is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii)&nbsp;acknowledging that there are not
any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and (iii)&nbsp;setting forth such further factual information with respect to the status of this Lease or the Premises as may be requested
thereon. Any such statement may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the real property of which the Premises are a part. Tenant&#8217;s failure to deliver such statement within such time shall be
conclusive upon Tenant that this Lease is in full force and effect and without modification except as may be represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 24
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <B>Quiet Enjoyment</B>. So long as Tenant is not in Default under this Lease, Tenant
shall, subject to the terms of this Lease, at all times during the Term, have peaceful and quiet enjoyment of the Premises against any person claiming by, through or under Landlord. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <B>Prorations</B>. All prorations required or permitted to be made hereunder shall be made on the basis of a 360 day year and 30 day
months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <B>Rules and Regulations</B>. Provided that such rules and regulations are not in violation of applicable Legal Requirements,
Tenant shall, at all times during the Term and any extension thereof, comply with all reasonable rules and regulations at any time or from time to time established by Landlord covering use of the Premises and the Project, including, without
limitation, the use of the Project Amenities, which rules and regulation shall be enforced in a <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> manner. The current rules and regulations are attached hereto as <B>Exhibit E</B>. If there is
any conflict between said rules and regulations and other provisions of this Lease, the terms and provisions of this Lease shall control. Landlord shall not have any liability or obligation for the breach of any rules or regulations by other tenants
in the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. <B>Subordination</B>. This Lease and Tenant&#8217;s interest and rights hereunder are hereby made and shall be subject
and subordinate at all times to the lien of any Mortgage now existing or hereafter created on or against the Project or the Premises, and all amendments, restatements, renewals, modifications, consolidations, refinancing, assignments and extensions
thereof, without the necessity of any further instrument or act on the part of Tenant; <U>provided</U>, <U>however</U> that so long as there is no Default hereunder, Tenant&#8217;s right to possession of the Premises shall not be disturbed by the
Holder of any such Mortgage. Tenant agrees, at the election of the Holder of any such Mortgage, to attorn to any such Holder. Tenant agrees upon demand to execute, acknowledge and deliver such instruments, confirming such subordination, and such
instruments of attornment as shall be requested by any such Holder, provided any such instruments contain appropriate <FONT STYLE="white-space:nowrap">non-disturbance</FONT> provisions assuring Tenant&#8217;s quiet enjoyment of the Premises as set
forth in <U>Section</U><U></U><U>&nbsp;24</U> hereof. Notwithstanding the foregoing, any such Holder may at any time subordinate its Mortgage to this Lease, without Tenant&#8217;s consent, by notice in writing to Tenant, and thereupon this Lease
shall be deemed prior to such Mortgage without regard to their respective dates of execution, delivery or recording and in that event such Holder shall have the same rights with respect to this Lease as though this Lease had been executed prior to
the execution, delivery and recording of such Mortgage and had been assigned to such Holder. The term &#8220;<B>Mortgage</B>&#8221; whenever used in this Lease shall be deemed to include deeds of trust, security assignments and any other
encumbrances, and any reference to the &#8220;<B>Holder</B>&#8221; of a Mortgage shall be deemed to include the beneficiary under a deed of trust. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. <B>Surrender</B>. Upon the expiration of the Term or earlier termination of Tenant&#8217;s right of possession, Tenant shall surrender the
Premises to Landlord in the same condition as received, subject to any Alterations or Installations permitted by Landlord to remain in the Premises, free of Hazardous Materials brought upon, kept, used, stored, handled, treated, generated in, or
released or disposed of from, the Premises by any person other than a Landlord Party (collectively, &#8220;<B>Tenant HazMat Operations</B>&#8221;) and released of all Hazardous Materials Clearances, broom clean, ordinary wear and tear and casualty
loss and condemnation covered by <U>Sections 18</U> and <U>19</U> excepted. At least 3 months prior to the surrender of the Premises or such earlier date as Tenant may elect to cease operations at the Premises, Tenant shall deliver to Landlord a
narrative description of the actions proposed (or required by any Governmental Authority) to be taken by Tenant in order to surrender the Premises (including any Installations permitted by Landlord to remain in the Premises) at the expiration or
earlier termination of the Term, free from any residual impact from the Tenant HazMat Operations and otherwise released for unrestricted use and occupancy (the &#8220;<B>Decommissioning and HazMat Closure Plan</B>&#8221;). Such Decommissioning and
HazMat Closure Plan shall be accompanied by a current listing of (i)&nbsp;all Hazardous Materials licenses and permits held by or on behalf of any Tenant Party with respect to the Premises, and (ii)&nbsp;all Hazardous Materials used,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 25
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stored, handled, treated, generated, released or disposed of from the Premises, and shall be subject to the review and approval of Landlord&#8217;s environmental consultant. In connection with
the review and approval of the Decommissioning and HazMat Closure Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such additional <FONT STYLE="white-space:nowrap">non-proprietary</FONT> information concerning
Tenant HazMat Operations as Landlord shall request. On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Decommissioning and HazMat Closure Plan shall have been satisfactorily completed and Landlord shall have the
right, subject to reimbursement at Tenant&#8217;s expense as set forth below, to cause Landlord&#8217;s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the
Premises are, as of the effective date of such surrender or early termination of this Lease, free from any residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as Additional Rent, for the actual <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expense incurred by Landlord for Landlord&#8217;s environmental consultant to review and approve the Decommissioning and HazMat Closure Plan and to visit the
Premises and verify satisfactory completion of the same, which cost shall not exceed $5,000. Landlord shall have the unrestricted right to deliver such Decommissioning and HazMat Closure Plan and any report by Landlord&#8217;s environmental
consultant with respect to the surrender of the Premises to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tenant shall fail to prepare or submit a Decommissioning
and HazMat Closure Plan approved by Landlord, or if Tenant shall fail to complete the approved Decommissioning and HazMat Closure Plan, or if such Decommissioning and HazMat Closure Plan, whether or not approved by Landlord, shall fail to adequately
address any residual effect of Tenant HazMat Operations in, on or about the Premises, Landlord shall have the right to take such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Project are surrendered free
from any residual impact from Tenant HazMat Operations, the cost of which actions shall be reimbursed by Tenant as Additional Rent, without regard to the limitation set forth in the first paragraph of this <U>Section</U><U></U><U>&nbsp;28</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall immediately return to Landlord all keys and/or access cards to parking, the Project, restrooms or all or any portion of the
Premises furnished to or otherwise procured by Tenant. If any such access card or key is lost, Tenant shall pay to Landlord, at Landlord&#8217;s election, either the cost of replacing such lost access card or key or the cost of reprogramming the
access security system in which such access card was used or changing the lock or locks opened by such lost key. Any Tenant&#8217;s Property, Alterations and property not so removed by Tenant as permitted or required herein shall be deemed abandoned
and may be stored, removed, and disposed of by Landlord at Tenant&#8217;s expense, and Tenant waives all claims against Landlord for any damages resulting from Landlord&#8217;s retention and/or disposition of such property. All obligations of Tenant
hereunder not fully performed as of the termination of the Term, including the obligations of Tenant under <U>Section</U><U></U><U>&nbsp;30</U> hereof, shall survive the expiration or earlier termination of the Term, including, without limitation,
indemnity obligations, payment obligations with respect to Rent and obligations concerning the condition and repair of the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.
<B>Waiver of Jury Trial</B>. TO THE EXTENT PERMITTED BY LAW, TENANT AND LANDLORD WAIVE ANY RIGHT TO TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, BETWEEN LANDLORD AND TENANT
ARISING OUT OF THIS LEASE OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. <B>Environmental Requirements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Prohibition/Compliance/Indemnity</B>. Tenant shall not cause or permit any Hazardous Materials (as hereinafter defined) to be brought
upon, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises or the Project in violation of applicable Environmental Requirements (as hereinafter defined) by Tenant or any Tenant Party. If Tenant
breaches the obligation stated in the preceding sentence, or if the presence of Hazardous Materials in the Premises during the Term or any holding over results in contamination of the Premises, the Project or any adjacent property or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 26
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if contamination of the Premises, the Project or any adjacent property by Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of
from, the Premises by anyone other than Landlord and Landlord&#8217;s employees, agents and contractors otherwise occurs during the Term or any holding over, Tenant hereby indemnifies and shall defend and hold Landlord, its officers, directors,
employees, agents and contractors harmless from any and all actions (including, without limitation, remedial or enforcement actions of any kind, administrative or judicial proceedings, and orders or judgments arising out of or resulting therefrom),
costs, claims, damages (including, without limitation, punitive damages and damages based upon diminution in value of the Premises or the Project, or the loss of, or restriction on, use of the Premises or any portion of the Project), expenses
(including, without limitation, attorneys&#8217;, consultants&#8217; and experts&#8217; fees, court costs and amounts paid in settlement of any claims or actions), fines, forfeitures or other civil, administrative or criminal penalties, injunctive
or other relief (whether or not based upon personal injury, property damage, or contamination of, or adverse effects upon, the environment, water tables or natural resources), liabilities or losses (collectively, &#8220;<B>Environmental
Claims</B>&#8221;) which arise during or after the Term as a result of such contamination. This indemnification of Landlord by Tenant includes, without limitation, costs incurred in connection with any investigation of site conditions or any
cleanup, treatment, remedial, removal, or restoration work required by any federal, state or local Governmental Authority because of Hazardous Materials present in the air, soil or ground water above, on, or under the Premises. Without limiting the
foregoing, if the presence of any Hazardous Materials on the Premises, the Building, the Project or any adjacent property caused or permitted by Tenant or any Tenant Party results in any contamination of the Premises, the Building, the Project or
any adjacent property, Tenant shall promptly take all actions at its sole expense and in accordance with applicable Environmental Requirements as are necessary to return the Premises, the Building, the Project or any adjacent property to the
condition existing prior to the time of such contamination, provided that Landlord&#8217;s approval of such action shall first be obtained, which approval shall not unreasonably be withheld so long as such actions would not potentially have any
material adverse long-term or short-term effect on the Premises, the Building, or the Project. Notwithstanding anything to the contrary contained in <U>Section</U><U></U><U>&nbsp;28</U> or this <U>Section</U><U></U><U>&nbsp;30</U>, Tenant shall not
be responsible for, and the indemnification and hold harmless obligation set forth in this paragraph shall not apply to (i)&nbsp;contamination in the Premises which Tenant can prove to Landlord&#8217;s reasonable satisfaction existed in the Premises
immediately prior to the Commencement Date, or (ii)&nbsp;the presence of any Hazardous Materials in the Premises which Tenant can prove to Landlord&#8217;s reasonable satisfaction migrated from outside of the Premises into the Premises, unless in
either case, the presence of such Hazardous Materials (x)&nbsp;is the result of a breach by Tenant of any of its obligations under this Lease, or (y)&nbsp;was caused, contributed to or exacerbated by Tenant or any Tenant Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Business</B>. Landlord acknowledges that it is not the intent of this <U>Section</U><U></U><U>&nbsp;30</U> to prohibit Tenant from using
the Premises for the Permitted Use. Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and properly monitored according to all then applicable Environmental
Requirements. As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to
be brought upon, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in connection with the presence, use, storage, handling,
treatment, generation, release or disposal of such Hazardous Materials on or from the Premises (&#8220;<B>Hazardous Materials List</B>&#8221;). Upon Landlord&#8217;s request, or any time that Tenant is required to deliver a Hazardous Materials List
to any Governmental Authority (e.g., the fire department) in connection with Tenant&#8217;s use or occupancy of the Premises, Tenant shall deliver to Landlord a copy of such Hazardous Materials List. Tenant shall deliver to Landlord true and correct
copies of the following documents (the &#8220;<B>Haz Mat Documents</B>&#8221;) relating to the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time,
concurrent with the receipt from or submission to a Governmental Authority: permits; approvals; reports and correspondence; storage and management plans, notice of violations of any Legal Requirements; plans relating to the installation of any
storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord&#8217;s sole and absolute
discretion); all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 27
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
installed in, on or under the Project for the closure of any such tanks; and a Decommissioning and HazMat Closure Plan (to the extent surrender in accordance with
<U>Section</U><U></U><U>&nbsp;28</U> cannot be accomplished in 3 months). Tenant is not required, however, to provide Landlord with any portion(s) of the Haz Mat Documents containing information of a proprietary nature which, in and of themselves,
do not contain a reference to any Hazardous Materials or hazardous activities. It is not the intent of this Section to provide Landlord with information which could be detrimental to Tenant&#8217;s business should such information become possessed
by Tenant&#8217;s competitors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Tenant Representation and Warranty</B>. Tenant hereby represents and warrants to Landlord that
(i)&nbsp;neither Tenant nor any of its legal predecessors has been required by any prior landlord, lender or Governmental Authority at any time to take remedial action in connection with Hazardous Materials contaminating a property which
contamination was permitted by Tenant of such predecessor or resulted from Tenant&#8217;s or such predecessor&#8217;s action or use of the property in question, and (ii)&nbsp;Tenant is not subject to any enforcement order issued by any Governmental
Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any Governmental Authority).
If Landlord determines that this representation and warranty was not true as of the date of this lease, Landlord shall have the right to terminate this Lease in Landlord&#8217;s sole and absolute discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Testing</B>. Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the
Premises or the Project has occurred as a result of Tenant&#8217;s use. Tenant shall be required to pay the cost of such annual test of the Premises if there is violation of this <U>Section</U><U></U><U>&nbsp;30</U> or if contamination for which
Tenant is responsible under this <U>Section</U><U></U><U>&nbsp;30</U> is identified; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are
certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right
to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant&#8217;s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to
Landlord or its consultant such <FONT STYLE="white-space:nowrap">non-proprietary</FONT> information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is
liable under this <U>Section</U><U>&nbsp;30</U>, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall
provide Tenant with a copy of all third party, <FONT STYLE="white-space:nowrap">non-confidential</FONT> reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a
confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord&#8217;s receipt of or
satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant. Tenant shall have the right to have a Tenant representative present while Landlord conducts tests in the Premises pursuant to this
Section&nbsp;30(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Control Areas</B>. Tenant shall have the use of 100% of the control area designated as Control Area <FONT
STYLE="white-space:nowrap">B2-1</FONT> on <B>Exhibit H </B>attached hereto. For the avoidance of doubt, Tenant shall not have rights with respect to any other control areas at the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Storage Tanks</B>. If storage tanks storing Hazardous Materials located on the Premises or the Project are used by Tenant or are
hereafter placed on the Premises or the Project by Tenant, Tenant shall install, use, monitor, operate, maintain, upgrade and manage such storage tanks, maintain appropriate records, obtain and maintain appropriate insurance, implement reporting
procedures, properly close any storage tanks, and take or cause to be taken all other actions necessary or required under applicable state and federal Legal Requirements, as such now exists or may hereafter be adopted or amended in connection with
the installation, use, maintenance, management, operation, upgrading and closure of such storage tanks. Notwithstanding anything to the contrary contained herein, Tenant shall have no right to use or install any underground storage tanks at the
Project. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 28
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Tenant&#8217;s Obligations</B>. Tenant&#8217;s obligations under this
<U>Section</U><U></U><U>&nbsp;30</U> shall survive the expiration or earlier termination of this Lease. During any period of time after the expiration or earlier termination of this Lease required by Tenant or Landlord to complete the removal from
the Premises of any Hazardous Materials (including, without limitation, the release and termination of any licenses or permits restricting the use of the Premises and the completion of the approved Decommissioning and HazMat Closure Plan), Tenant
shall continue to pay the full Rent in accordance with this Lease for any portion of the Premises not relet by Landlord in Landlord&#8217;s sole discretion, which Rent shall be prorated daily. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Definitions</B>. As used herein, the term &#8220;<B>Environmental Requirements</B>&#8221; means all applicable present and future
statutes, regulations, ordinances, rules, codes, judgments, orders or other similar enactments of any Governmental Authority regulating or relating to health, safety, or environmental conditions on, under, or about the Premises or the Project, or
the environment, including without limitation, the following: the Comprehensive Environmental Response, Compensation and Liability Act; the Resource Conservation and Recovery Act; and all state and local counterparts thereto, and any regulations or
policies promulgated or issued thereunder. As used herein, the term &#8220;<B>Hazardous Materials</B>&#8221; means and includes any substance, material, waste, pollutant, or contaminant listed or defined as hazardous or toxic, or regulated by reason
of its impact or potential impact on humans, animals and/or the environment under any Environmental Requirements, asbestos and petroleum, including crude oil or any fraction thereof, natural gas liquids, liquefied natural gas, or synthetic gas
usable for fuel (or mixtures of natural gas and such synthetic gas). As defined in Environmental Requirements, Tenant is and shall be deemed to be the &#8220;<B>operator</B>&#8221; of Tenant&#8217;s &#8220;<B>facility</B>&#8221; and the
&#8220;<B>owner</B>&#8221; of all Hazardous Materials brought on the Premises by Tenant or any Tenant Party, and the wastes, <FONT STYLE="white-space:nowrap">by-products,</FONT> or residues generated, resulting, or produced therefrom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31. <B>Tenant&#8217;s Remedies/Limitation of Liability</B>. Landlord shall not be in default hereunder unless Landlord fails to perform any of
its obligations hereunder within 30 days after written notice from Tenant specifying such failure (unless such performance will, due to the nature of the obligation, require a period of time in excess of 30 days, then after such period of time as is
reasonably necessary). Upon any default by Landlord, Tenant shall give notice by registered or certified mail to any Holder of a Mortgage covering the Premises and to any landlord of any lease of property in or on which the Premises are located and
Tenant shall offer such Holder and/or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Project by power of sale or a judicial action if such should prove necessary to effect a cure; <U>provided</U>
Landlord shall have furnished to Tenant in writing the names and addresses of all such persons who are to receive such notices. All obligations of Landlord hereunder shall be construed as covenants, not conditions; and, except as may be otherwise
expressly provided in this Lease, Tenant may not terminate this Lease for breach of Landlord&#8217;s obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
obligations of Landlord under this Lease will be binding upon Landlord only during the period of its ownership of the Premises and not thereafter. The term &#8220;<B>Landlord</B>&#8221; in this Lease shall mean only the owner for the time being of
the Premises. Upon the transfer by such owner of its interest in the Premises, such owner shall thereupon be released and discharged from all obligations of Landlord thereafter accruing, but such obligations shall be binding during the Term upon
each new owner for the duration of such owner&#8217;s ownership. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32. <B>Inspection and Access</B>. Landlord and its agents,
representatives, and contractors may enter the Premises at any reasonable time to inspect the Premises and to make such repairs as may be required or permitted pursuant to this Lease and for any other business purpose. Landlord and Landlord&#8217;s
representatives may enter the Premises during business hours on not less than 48 hours advance written notice (except in the case of emergencies in which case no such notice shall be required and such entry may be at any time) for the purpose of
effecting any such repairs, inspecting the Premises, showing the Premises to prospective purchasers and, during the last 18 months of the Term, to prospective tenants or for any other business purpose. Landlord may erect a suitable sign on the
Premises stating the Premises are available to let or that the Project is available for sale. Landlord may grant easements, make public dedications, designate Common Areas and create restrictions on or about the Premises, <U>provided</U> that no
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 29
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such easement, dedication, designation or restriction materially, adversely affects Tenant&#8217;s use or occupancy of the Premises for the Permitted Use. At Landlord&#8217;s request, Tenant
shall execute such instruments as may be necessary for such easements, dedications or restrictions. Tenant shall at all times, except in the case of emergencies, have the right to escort Landlord or its agents, representatives, contractors or guests
while the same are in the Premises, provided such escort does not materially and adversely affect Landlord&#8217;s access rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of this <U>Section</U><U></U><U>&nbsp;32</U>, Landlord may from time to time during the Term, during regular business
hours and/or otherwise at times mutually acceptable to Landlord and Tenant, conduct third party tours of the Premises (&#8220;<B>Tours</B>&#8221;), which Tours may be held with not less than 1 business day&#8217;s advance notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33. <B>Security</B>. Tenant acknowledges and agrees that security devices and services, if any, while intended to deter crime may not in given
instances prevent theft or other criminal acts and that Landlord is not providing any security services with respect to the Premises. Tenant agrees that Landlord shall not be liable to Tenant for, and Tenant waives any claim against Landlord with
respect to, any loss by theft or any other damage suffered or incurred by Tenant in connection with any unauthorized entry into the Premises or any other breach of security with respect to the Premises. Tenant shall be solely responsible for the
personal safety of Tenant&#8217;s officers, employees, agents, contractors, guests and invitees while any such person is in, on or about the Premises and/or the Project. Tenant shall at Tenant&#8217;s cost obtain insurance coverage to the extent
Tenant desires protection against such criminal acts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">34. <B>Force Majeure</B>. Except for the payment of Rent, neither Landlord nor
Tenant shall be responsible or liable for delays in the performance of its obligations hereunder when caused by, related to, or arising out of acts of God, sinkholes or subsidence, strikes, lockouts, or other labor disputes, embargoes, quarantines,
weather, national, regional, or local disasters, calamities, or catastrophes, inability to obtain labor or materials (or reasonable substitutes therefor) at reasonable costs or failure of, or inability to obtain, utilities necessary for performance,
governmental restrictions, orders, limitations, regulations, or controls, national emergencies, local, regional or national epidemic or pandemic (including <FONT STYLE="white-space:nowrap">COVID-19),</FONT> delay in issuance or revocation of
permits, enemy or hostile governmental action, terrorism, insurrection, riots, civil disturbance or commotion, fire or other casualty, and other causes or events beyond the reasonable control of Landlord (&#8220;<B>Force Majeure</B>&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35. <B>Brokers</B>. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person
(collectively, &#8220;<B>Broker</B>&#8221;) in connection with this transaction and that no Broker brought about this transaction, other than CBRE and Cushman&nbsp;&amp; Wakefield. Landlord and Tenant each hereby agree to indemnify and hold the
other harmless from and against any claims by any Broker, other than CBRE and Cushman&nbsp;&amp; Wakefield, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this
leasing transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36. <B>Limitation on Landlord&#8217;s Liability</B>. NOTWITHSTANDING ANYTHING SET FORTH HEREIN OR IN ANY OTHER
AGREEMENT BETWEEN LANDLORD AND TENANT TO THE CONTRARY: (A)&nbsp;LANDLORD SHALL NOT BE LIABLE TO TENANT OR ANY OTHER PERSON FOR (AND TENANT AND EACH SUCH OTHER PERSON ASSUME ALL RISK OF) LOSS, DAMAGE OR INJURY, WHETHER ACTUAL OR CONSEQUENTIAL TO:
TENANT&#8217;S PERSONAL PROPERTY OF EVERY KIND AND DESCRIPTION, INCLUDING, WITHOUT LIMITATION TRADE FIXTURES, EQUIPMENT, INVENTORY, SCIENTIFIC RESEARCH, SCIENTIFIC EXPERIMENTS, LABORATORY ANIMALS, PRODUCT, SPECIMENS, SAMPLES, AND/OR SCIENTIFIC,
BUSINESS, ACCOUNTING AND OTHER RECORDS OF EVERY KIND AND DESCRIPTION KEPT AT THE PREMISES AND ANY AND ALL INCOME DERIVED OR DERIVABLE THEREFROM; (B)&nbsp;THERE SHALL BE NO PERSONAL RECOURSE TO LANDLORD FOR ANY ACT OR OCCURRENCE IN, ON OR ABOUT THE
PREMISES OR ARISING IN ANY WAY UNDER THIS LEASE OR ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT WITH RESPECT TO THE SUBJECT MATTER HEREOF AND ANY LIABILITY OF LANDLORD HEREUNDER SHALL BE STRICTLY LIMITED SOLELY TO LANDLORD&#8217;S INTEREST IN THE
PROJECT OR ANY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 30
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PROCEEDS FROM SALE OR CONDEMNATION THEREOF AND ANY INSURANCE PROCEEDS PAYABLE IN RESPECT OF LANDLORD&#8217;S INTEREST IN THE PROJECT OR IN CONNECTION WITH ANY SUCH LOSS; AND (C)&nbsp;IN NO EVENT
SHALL ANY PERSONAL LIABILITY BE ASSERTED AGAINST LANDLORD IN CONNECTION WITH THIS LEASE NOR SHALL ANY RECOURSE BE HAD TO ANY OTHER PROPERTY OR ASSETS OF LANDLORD OR ANY OF LANDLORD&#8217;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS. UNDER
NO CIRCUMSTANCES SHALL LANDLORD OR ANY OF LANDLORD&#8217;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS BE LIABLE FOR INJURY TO TENANT&#8217;S BUSINESS OR FOR ANY LOSS OF INCOME OR PROFIT THEREFROM. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">37. <B>Severability</B>. If any clause or provision of this Lease is illegal, invalid or unenforceable under present or future laws, then and
in that event, it is the intention of the parties hereto that the remainder of this Lease shall not be affected thereby. It is also the intention of the parties to this Lease that in lieu of each clause or provision of this Lease that is illegal,
invalid or unenforceable, there be added, as a part of this Lease, a clause or provision as similar in effect to such illegal, invalid or unenforceable clause or provision as shall be legal, valid and enforceable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">38. <B>Signs; Exterior Appearance</B>. Tenant shall not, without the prior written consent of Landlord, which may be granted or withheld in
Landlord&#8217;s sole discretion: (i)&nbsp;attach any awnings, exterior lights, decorations, balloons, flags, pennants, banners, painting or other projection to any outside wall of the Project, (ii)&nbsp;use any curtains, blinds, shades or screens
other than Landlord&#8217;s standard window coverings, (iii)&nbsp;coat or otherwise sunscreen the interior or exterior of any windows, (iv)&nbsp;place any bottles, parcels, or other articles on the window sills, (v)&nbsp;place any equipment,
furniture or other items of personal property on any exterior balcony, or (vi)&nbsp;paint, affix or exhibit on any part of the Premises or the Project any signs, notices, window or door lettering, placards, decorations, or advertising media of any
type which can be viewed from the exterior of the Premises. Suite entry signage and signage on the lobby directory shall be inscribed, painted or affixed for Tenant by Landlord at the sole cost and expense of Tenant, and shall be of a size, color
and type acceptable to Landlord. Nothing may be placed on the exterior of corridor walls or corridor doors other than Landlord&#8217;s standard lettering. The directory tablet shall be provided exclusively for the display of the name and location of
tenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right, at Tenant&#8217;s sole cost and expense, to
display 1 sign bearing Tenant&#8217;s name and/or logo on the Building (the &#8220;<B>Building Sign</B>&#8221;) and 1 sign bearing Tenant&#8217;s name and/or logo on the monument sign serving the Building (the &#8220;<B>Building Sign</B>&#8221;),
which signs shall be in the locations and pursuant to the specifications designated on <B>Exhibit J</B>. Notwithstanding the foregoing, Tenant acknowledges and agrees that the Building Sign and the Monument Sign including, without limitation, the
size, color and type, shall be subject to Landlord&#8217;s prior written approval, which shall not be unreasonably withheld, conditioned or delayed, and shall be subject to and in compliance with applicable Legal Requirements and Landlord&#8217;s
Project standards. Tenant shall be responsible, at Tenant&#8217;s sole cost and expense, for the maintenance of the Building Sign, for the removal of the Building Sign at the expiration or earlier termination of this Lease and for the repair of all
damage resulting from such removal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">39. <B>Right to Expand</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Expansion in the Building</B>. Subject to the rights of existing tenants of the Project and to the terms of this
<U>Section</U><U></U><U>&nbsp;39(a)</U>, Tenant shall have the <FONT STYLE="white-space:nowrap">one-time</FONT> right during the Base Term with respect to each portion of the Expansion Space described below, but not the obligation, to expand the
Premises (the &#8220;<B>Expansion Right</B>&#8221;) to include the Expansion Space upon the terms and conditions in this <U>Section</U><U></U><U>&nbsp;39</U>. For purposes of this <U>Section</U><U></U><U>&nbsp;39(a)</U>, &#8220;<B>Expansion
Space</B>&#8221; shall mean that certain space in the Building commonly known as: (1)&nbsp;Suite 200, containing approximately 9,969 rentable square feet; (2)&nbsp;Suite 205, containing approximately 6,860 rentable square feet; (3)&nbsp;Suite 210,
containing approximately 6,906 rentable square feet; and (4)&nbsp;Suite 215, containing approximately 8,265 rentable square feet, all as more specifically described on <B>Exhibit K </B>attached hereto, to the extent each such space is not occupied
by a tenant or which is occupied by a then-existing tenant whose lease is expiring within 9 months or less and such tenant does </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 31
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not wish to renew (whether or not such tenant has a right to renew) its occupancy of such space. If all or a portion of the Expansion Space becomes available, Landlord shall, at such time as
Landlord shall elect so long as Tenant&#8217;s rights hereunder are preserved, deliver to Tenant written notice (the &#8220;<B>Expansion Notice</B>&#8221;) of the availability of such Expansion Space, together with the terms and conditions on which
Landlord is prepared to lease Tenant such Expansion Space. For the avoidance of doubt, Tenant shall be required to exercise its right under this <U>Section</U><U>&nbsp;39(a)</U> with respect to all of the space described in the Expansion Notice
(&#8220;<B>Identified Expansion Space</B>&#8221;). For the avoidance of any doubt, Tenant shall continue to be entitled to an Expansion Notice pursuant to this <U>Section</U><U></U><U>&nbsp;39(a)</U> with respect to any portion of the Expansion
Space which has not previously been identified in an Expansion Notice as Identified Expansion Space (for example, if Landlord delivers an Expansion Notice identifying Suite 200 and 205 as the Identified Expansion Space, Tenant shall continue to be
entitled to an Expansion Notice with respect to Suite 210 and Suite 215). The term of this Lease with respect to the Identified Expansion Space may not be <FONT STYLE="white-space:nowrap">co-terminous</FONT> with the Term of this Lease with respect
to the then-existing Premises. Tenant shall have 5 business days following receipt of the Expansion Notice to deliver to Landlord written notification of Tenant&#8217;s exercise of the Expansion Right (&#8220;<B>Exercise Notice</B>&#8221;) with
respect to the Identified Expansion Space. If Tenant does not deliver an Exercise Notice to Landlord within such 5 business day period, then Tenant shall be deemed to have waived its rights under this <U>Section</U><U></U><U>&nbsp;39(a)</U> to lease
the Identified Expansion Space, and Landlord shall have the right to lease the Identified Expansion Space to any third party on any terms and conditions acceptable to Landlord. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Amended Lease</B>. If: (i)&nbsp;Tenant fails to timely deliver an Expansion Notice, or (ii)&nbsp;after the expiration of a period of 10
business days after Landlord&#8217;s delivery to Tenant of a lease amendment for Tenant&#8217;s lease of the Identified Expansion Space, no lease amendment for the Identified Expansion Space acceptable to both parties each in their sole and absolute
discretion, has been executed, Tenant shall be deemed to have forever waived its right to lease the Identified Expansion Space. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<B>Exceptions</B>. Notwithstanding the above, the Expansion Right shall, at Landlord&#8217;s option, not be in effect and may not be exercised by Tenant: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) during any period of time that Tenant is in Default under any provision of this Lease; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) at any time that Tenant&#8217;s then-current financial condition and outlook is not reasonably satisfactory to Landlord;
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if Tenant has been in Default under any provision of this Lease 3 or more times, whether or not the Defaults are
cured, during the 12 month period prior to the date on which Tenant seeks to exercise the Expansion Right. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Termination</B>. The
Expansion Right shall, at Landlord&#8217;s option, terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Expansion Right, if, after such exercise, but prior to the commencement date of this Lease of
such Expansion Space, (i)&nbsp;Tenant fails to timely cure any default by Tenant under this Lease; or (ii)&nbsp;Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Expansion Right to the date of the
commencement of the lease of the Expansion Space, whether or not such Defaults are cured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Subordinate</B>. Tenant&#8217;s Expansion
Rights granted pursuant to <U>Section</U><U></U><U>&nbsp;39(a)</U> above are and shall remain subject and subordinate to any expansion rights of tenants of the Project existing as of the date of this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Rights Personal</B>. Expansion Rights are personal to Tenant and are not assignable without Landlord&#8217;s consent, which may be
granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in this Lease, except that they may be assigned in connection with any Permitted Assignment of this
Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 32
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>No Extensions</B>. The period of time within which any Expansion Rights may be
exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Expansion Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40. <B>Right to Extend
Term</B>. Tenant shall have the right to extend the Term of this Lease upon the following terms and conditions: (a)<B>Extension Right</B>. Tenant shall have the <FONT STYLE="white-space:nowrap">one-time</FONT> right (the &#8220;<B>Extension
Right</B>&#8221;) to extend the term of this Lease for 5 years (the &#8220;<B>Extension Term</B>&#8221;) on the same terms and conditions as this Lease (other than with respect to Base Rent and the Work Letter) by giving Landlord written notice of
its election to exercise such Extension Right (an &#8220;<B>Exercise Notice</B>&#8221;) at least 12 months and not more than 15 months prior to the expiration of the Base Term of this Lease. Within 30 days after Tenant&#8217;s delivery to Landlord
of a written request therefor, which request shall be delivered prior to Tenant&#8217;s delivery of an Exercise Notice but not more than 17 months prior to the expiration of the Base Term of the Lease, Landlord shall provide Tenant with
Landlord&#8217;s determination of the Market Rate and escalations that would be applicable during the Extension Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
commencement of the Extension Term, Base Rent shall be payable at the Market Rate (as defined below). Base Rent shall thereafter be adjusted on each annual anniversary of the commencement of such Extension Term by a percentage as determined by
Landlord and agreed to by Tenant at the time the Market Rate is determined. As used herein, &#8220;<B>Market Rate</B>&#8221; shall mean at Landlord&#8217;s option either (i)&nbsp;the rate that Landlord and affiliates of Landlord have accepted at
comparable laboratory/office projects in the Torrey Pines submarket during the 18 month period prior to Tenant&#8217;s exercise of its Extension Right from <FONT STYLE="white-space:nowrap">non-equity</FONT> (i.e., not being offered equity in the
buildings) and nonaffiliated tenants of similar financial strength for space of comparable size and quality (including the Tenant Improvements, Alterations and other improvements) and floor height for a comparable term, with the determination of the
Market Rate to take into account all relevant factors, including tenant inducements, views, available amenities (including, without limitation, the Project Amenities and the Amenities (as defined in <U>Section</U><U></U><U>&nbsp;41</U>)), age of the
Building, age of mechanical systems serving the Premises, parking costs, leasing commissions, allowances or concessions, if any, or (ii)&nbsp;the rate that comparable landlords of comparable buildings have accepted in current transactions from <FONT
STYLE="white-space:nowrap">non-equity</FONT> (i.e., not being offered equity in the buildings) and nonaffiliated tenants of similar financial strength for space of comparable size and quality (including the Tenant Improvements, Alterations and other
improvements) and floor height in Class&nbsp;A laboratory/office buildings in the Torrey Pines submarket (including those owned by Landlord or affiliates of Landlord) for a comparable term, with the determination of the Market Rate to take into
account all relevant factors, including tenant inducements, views, available amenities (including, without limitation, the Project Amenities and the Amenities), age of the Building, age of mechanical systems serving the Premises, parking costs,
leasing commissions, allowances or concessions, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on or before the date which is 300 days prior to the expiration of the Base
Term of this Lease, Tenant has not agreed with Landlord&#8217;s determination of the Market Rate and the rent escalations during the Extension Term after negotiating in good faith, Tenant shall be deemed to have elected arbitration as described in
<U>Section</U><U></U><U>&nbsp;40(b)</U>. Tenant acknowledges and agrees that, if Tenant has elected to exercise the Extension Right by delivering notice to Landlord as required in this <U>Section</U><U></U><U>&nbsp;40(a)</U>, Tenant shall have no
right thereafter to rescind or elect not to extend the term of this Lease for the Extension Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Arbitration</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Within 10 business days of Tenant&#8217;s notice to Landlord of its election (or deemed election) to arbitrate Market Rate
and escalations, each party shall deliver to the other a proposal containing the Market Rate and escalations that the submitting party believes to be correct (&#8220;<B>Extension Proposal</B>&#8221;). If either party fails to timely submit an
Extension Proposal, the other party&#8217;s submitted proposal shall determine the Base Rent and escalations for the Extension Term. If both parties submit Extension Proposals, then Landlord and Tenant shall meet within 7 days after delivery of the
last Extension Proposal and make a good faith attempt to mutually appoint a single </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 33
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Arbitrator (and defined below) to determine the Market Rate and escalations. If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by written notice delivered to
the other within 10 business days after the meeting, select an Arbitrator. If either party fails to timely give notice of its selection for an Arbitrator, the other party&#8217;s submitted proposal shall determine the Base Rent for the Extension
Term. The 2 Arbitrators so appointed shall, within 5 business days after their appointment, appoint a third Arbitrator. If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above specified, then
either party, on behalf of both parties, may request such appointment of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 business days prior written
notice to the other party of such intent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The decision of the Arbitrator(s) shall be made within 30 days after the
appointment of a single Arbitrator or the third Arbitrator, as applicable. The decision of the single Arbitrator shall be final and binding upon the parties. The average of the two closest Arbitrators in a three Arbitrator panel shall be final and
binding upon the parties. Each party shall pay the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties. If the Market Rate and
escalations are not determined by the first day of the Extension Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the Extension Term and increased by the Rent Adjustment Percentage
until such determination is made. After the determination of the Market Rate and escalations, the parties shall make any necessary adjustments to such payments made by Tenant. Landlord and Tenant shall then execute an amendment recognizing the
Market Rate and escalations for the Extension Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) An &#8220;<B>Arbitrator</B>&#8221; shall be any person appointed
by or on behalf of either party or appointed pursuant to the provisions hereof and: (i)&nbsp;shall be (A)&nbsp;a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office
and high tech industrial real estate in the greater San Diego metropolitan area, or (B)&nbsp;a licensed commercial real estate broker with not less than 15 years&#8217; experience representing landlords and/or tenants in the leasing of high tech or
life sciences space in the greater San Diego metropolitan area, (ii)&nbsp;devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of appointment and (iii)&nbsp;be in all respects impartial and
disinterested. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Rights Personal</B>. The Extension Right is personal to Tenant and is not assignable without Landlord&#8217;s
consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in this Lease, except that they may be assigned in connection with any
Permitted Assignment of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Exceptions</B>. Notwithstanding anything set forth above to the contrary, the Extension Right
shall, at Landlord&#8217;s option, not be in effect and Tenant may not exercise its Extension Right: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) during any period
of time that Tenant is in Default under any provision of this Lease; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if Tenant has been in Default under any
provision of this Lease 3 or more times, whether or not the Defaults are cured, during the 12 month period immediately prior to the date that Tenant intends to exercise the Extension Right, whether or not the Defaults are cured. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>No Extensions</B>. The period of time within which the Extension Right may be exercised shall not be extended or enlarged by reason of
Tenant&#8217;s inability to exercise the Extension Right. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Termination</B>. The Extension Right shall, at Landlord&#8217;s option,
terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Extension Right, if, after such exercise, but prior to the commencement date of the Extension Term, (i)&nbsp;Tenant fails to timely cure any
default by Tenant under this Lease; or (ii)&nbsp;Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Extension Right to the date of the commencement of the Extension Term, whether or not such Defaults are
cured. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 34
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41. <B>The Alexandria Amenities</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)<B> Generally</B>. <FONT STYLE="white-space:nowrap">ARE-SD</FONT> Region No.&nbsp;44, LLC, a Delaware limited liability company
(&#8220;<B>The Alexandria Landlord</B>&#8221;) has constructed certain amenities at the property owned by The Alexandria Landlord located at 10996 Torreyana Road, San Diego, California (&#8220;<B>The Alexandria</B>&#8221;), which, as of the date of
this Lease, include, without limitation, shared conference facilities (&#8220;<B>Shared Conference Facilities</B>&#8221;), a fitness center and restaurant (collectively, the &#8220;<B>Amenities</B>&#8221;) for
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> use by (a)&nbsp;Tenant, (b) other tenants of the Project, (c)&nbsp;Landlord, (d) the tenants of The Alexandria Landlord, (e)&nbsp;The Alexandria Landlord, (f)&nbsp;other affiliates of Landlord,
The Alexandria Landlord and Alexandria Real Estate Equities, Inc. (&#8220;<B>ARE</B>&#8221;), (g) the tenants of such other affiliates of Landlord, The Alexandria Landlord and ARE, and (h)&nbsp;any other parties permitted by The Alexandria Landlord
(collectively, &#8220;<B>Users</B>&#8221;). Landlord, The Alexandria Landlord, ARE, and all affiliates of Landlord, Alexandria Landlord and ARE may be referred to collectively herein as the &#8220;<B>ARE Parties</B>.&#8221; Notwithstanding anything
to the contrary contained herein, Tenant acknowledges and agrees that The Alexandria Landlord shall have the right, at the sole discretion of The Alexandria Landlord, to not make the Amenities available for use by some or all currently contemplated
Users (including Tenant). The Alexandria Landlord shall have the sole right to determine all matters related to the Amenities including, without limitation, relating to the reconfiguration, relocation, modification or removal of any of the Amenities
at The Alexandria and/or to revise, expand or discontinue any of the services (if any) provided in connection with the Amenities. Tenant acknowledges and agrees that Landlord has not made any representations or warranties regarding the availability
of the Amenities and that Tenant is not entering into this Lease relying on the continued availability of the Amenities to Tenant. Up to 85 employees of Tenant shall have access to and use of the Amenities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>License</B>. Commencing on the Commencement Date, and so long as The Alexandria and the Project continue to be owned by affiliates of
ARE, Tenant shall have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to the use of the available Amenities in common with other Users pursuant to the terms of this <U>Section</U><U></U><U>&nbsp;41</U>. Passes to the fitness center
at The Alexandria shall be made available to Tenant for up to 119 employees of Tenant employed at the Premises. If any employee of Tenant to whom a fitness center pass has been issued ceases to be an employee of Tenant at the Premises or any
employee to whom an access card (which does not include a fitness center pass) has been issued ceases to be an employee of Tenant at the Premises, Tenant shall, promptly following such employee&#8217;s change in status, collect such employee&#8217;s
pass or access card, as applicable, deliver it to Landlord and so notify Landlord of such employee&#8217;s change in status. Commencing on the Commencement Date, Tenant shall commence paying Landlord a fixed fee during the Base Term equal to $2.16
per rentable square foot of the Premises per year (&#8220;<B>Amenities Fee</B>&#8221;), which Amenities Fee shall by payable on the first day of each month during the Term whether or not Tenant elects to use any or all of the Alexandria Regional
Amenities. The Amenities Fee shall be increased annually on each anniversary of the Commencement Date by 3%. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Shared Conference
Facilities</B>. Use by Tenant of the Shared Conference Facilities and restaurant at The Alexandria shall be in common with other Users with scheduling procedures reasonably determined by The Alexandria Landlord or The Alexandria Landlord&#8217;s
then designated event operator (&#8220;<B>Event Operator</B>&#8221;). Tenant&#8217;s use of the Shared Conference Facilities shall be subject to the payment by Tenant to The Alexandria Landlord of a fee equal to The Alexandria Landlord&#8217;s
quoted rates for the usage of the Shared Conference Facilities in effect at the time of Tenant&#8217;s scheduling. Tenant&#8217;s use of the conference rooms in the Shared Conference Area shall be subject to availability and The Alexandria Landlord
(or, if applicable, Event Operator) reserves the right to exercise its reasonable discretion in the event of conflicting scheduling requests among Users. Tenant hereby acknowledges that (i)&nbsp;Biocom/San Diego, a California <FONT
STYLE="white-space:nowrap">non-profit</FONT> corporation (&#8220;<B>Biocom</B>&#8221;) has the right to reserve the Shared Conference Facilities and any reservable dining area(s) included within the Amenities for up to 50% of the time that such
Shared Conference Facilities and reservable dining area(s) are available for use by Users each calendar month, and (ii)&nbsp;Illumina, Inc., a Delaware corporation, has the exclusive use of the main conference room within the Shared Conference
Facilities for up to 4 days per calendar month. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 35
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be required to use the food service operator designated by The Alexandria
Landlord at The Alexandria (the &#8220;<B>Designated Food and Beverage Operator</B>&#8221;) for any food and/or beverage service or catered events held by Tenant in the Shared Conference Facilities. The Alexandria Landlord has the right, in its sole
and absolute discretion, to change the Designated Food and Beverage Operator at any time. Tenant may not use any vendors other than the Designated Food and Beverage Operator nor may Tenant supply its own food and/or beverages in connection with any
food and/or beverage service or catered events held by Tenant in the Shared Conference Facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall, at Tenant&#8217;s sole
cost and expense, (i)&nbsp;be responsible for the <FONT STYLE="white-space:nowrap">set-up</FONT> of the Shared Conference Facilities in connection with Tenant&#8217;s use (including, without limitation ensuring that Tenant has a sufficient number of
chairs and tables and the appropriate equipment), and (ii)&nbsp;surrender the Shared Conference Facilities after each time that Tenant uses the Shared Conference Facilities free of Tenant&#8217;s personal property, in substantially the same set up
and same condition as received, and free of any debris and trash. If Tenant fails to restore and surrender the Shared Conference Facilities as required by <FONT STYLE="white-space:nowrap">sub-section</FONT> (ii)&nbsp;of the immediately preceding
sentence, such failure shall constitute a &#8220;<B>Shared Facilities Default</B>.&#8221; Each time that Landlord reasonably determines that Tenant has committed a Shared Facilities Default, Tenant shall be required to pay Landlord a penalty within
5 business days after notice from Landlord of such Shared Facilities Default. The penalty payable by Tenant in connection with the first Shared Facilities Default shall be $200. The penalty payable shall increase by $50 for each subsequent Shared
Facilities Default (for the avoidance of doubt, the penalty shall be $250 for the second Shared Facilities Default, shall be $300 for the third Shared Facilities Default, etc.). In addition to the foregoing, Tenant shall be responsible for
reimbursing The Alexandria Landlord or Landlord, as applicable, for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs expended by The Alexandria Landlord or Landlord, as applicable, in
repairing any damage to the Shared Conference Facilities, the Amenities, or The Alexandria caused by Tenant or any Tenant Related Party. The provisions of this <U>Section</U><U></U><U>&nbsp;41(c)</U> shall survive the expiration or earlier
termination of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Restaurant</B>. Tenant&#8217;s employees that have been issued an access card to The Alexandria shall
have the right, along with other Users, to access and use the restaurant located at The Alexandria. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Rules and Regulations</B>.
Tenant shall be solely responsible for paying for any and all ancillary services (e.g., audio visual equipment) provided to Tenant, all food services operators and any other third party vendors providing services to Tenant at The Alexandria. Tenant
shall use the Amenities (including, without limitation, the Shared Conference Facilities) in compliance with all applicable Legal Requirements and any rules and regulations imposed by The Alexandria Landlord or Landlord from time to time and in a
manner that will not interfere with the rights of other Users, which rules and regulations shall be enforced in a <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> manner. The use of Amenities other than the Shared Conference Facilities by
employees of Tenant shall be in accordance with the terms and conditions of the standard licenses, indemnification and waiver agreement required by The Alexandria Landlord or the operator of the Amenities to be executed by all persons wishing to use
such Amenities. Neither The Alexandria Landlord nor Landlord (nor, if applicable, any other affiliate of Landlord) shall have any liability or obligation for the breach of any rules or regulations by other Users with respect to the Amenities. Tenant
shall not make any alterations, additions, or improvements of any kind to the Shared Conference Facilities, the Amenities or The Alexandria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant acknowledges and agrees that The Alexandria Landlord shall have the right at any time and from time to time to reconfigure, relocate,
modify or remove any of the Amenities at The Alexandria and/or to revise, expand or discontinue any of the services (if any) provided in connection with the Amenities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 36
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Waiver of Liability and Indemnification</B>. Tenant warrants that it will use
reasonable care to prevent damage to property and injury to persons while on The Alexandria. Tenant waives any claims it or any Tenant Parties may have against any ARE Parties relating to, arising out of or in connection with the Amenities and any
entry by Tenant and/or any Tenant Parties onto The Alexandria, and Tenant releases and exculpates all ARE Parties from any liability relating to, arising out of or in connection with the Amenities and any entry by Tenant and/or any Tenant Parties
onto The Alexandria. Tenant hereby agrees to indemnify, defend, and hold harmless the ARE Parties from any claim of damage to property or injury to person relating to, arising out of or in connection with (i)&nbsp;the use of the Amenities by Tenant
or any Tenant Parties, and (ii)&nbsp;any entry by Tenant and/or any Tenant Parties onto The Alexandria, except to the extent caused by the negligence or willful misconduct of ARE Parties. The provisions of this
<U>Section</U><U></U><U>&nbsp;41(f)</U> shall survive the expiration or earlier termination of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Insurance. As of the
Commencement Date, Tenant shall cause The Alexandria Landlord to be named as an additional insured under the commercial general liability policy of insurance that Tenant is required to maintain pursuant to <U>Section</U><U></U><U>&nbsp;17</U> of
this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42. <B>Miscellaneous</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Notices</B>. All notices or other communications between the parties shall be in writing and shall be deemed duly given upon delivery or
refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at their addresses set forth above. Landlord and Tenant may
from time to time by written notice to the other designate another address for receipt of future notices. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Joint and Several
Liability</B>. If and when included within the term &#8220;<B>Tenant</B>,&#8221; as used in this instrument, there is more than one person or entity, each shall be jointly and severally liable for the obligations of Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Financial Information</B><I>. </I>Tenant shall furnish Landlord with true and complete copies of (i)&nbsp;Tenant&#8217;s most recent
audited annual financial statements within 45 days of the end of each of Tenant&#8217;s fiscal years during the Term, (ii)&nbsp;Tenant&#8217;s most recent unaudited quarterly financial statements within 45 days of the end of each of Tenant&#8217;s
fiscal quarters during the Term, (iii)&nbsp;at Landlord&#8217;s request from time to time, updated business plans, including cash flow projections and/or pro forma balance sheets and income statements, all of which shall be treated by Landlord as
confidential information belonging to Tenant, (iv)&nbsp;corporate brochures and/or profiles prepared by Tenant for prospective investors, and (v)&nbsp;any other financial information or summaries that Tenant typically provides to its lenders or
shareholders. Notwithstanding the foregoing, so long as Tenant is a &#8220;public company&#8221; and its financial information is publicly available, then the foregoing delivery requirements of this <U>Section</U><U>&nbsp;42(c)</U> shall not apply.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Recordation</B>. Neither this Lease nor a memorandum of lease shall be filed by or on behalf of Tenant in any public record.
Landlord may prepare and file, and upon request by Landlord Tenant will execute, a memorandum of lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Interpretation</B>. The
normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Lease or any exhibits or amendments hereto. Words of any gender used in this Lease shall
be held and construed to include any other gender, and words in the singular number shall be held to include the plural, unless the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way define, limit
or otherwise describe the scope or intent of this Lease, or any provision hereof, or in any way affect the interpretation of this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Not Binding Until Executed</B>. The submission by Landlord to Tenant of this Lease shall have no binding force or effect, shall not
constitute an option for the leasing of the Premises, nor confer any right or impose any obligations upon either party until execution of this Lease by both parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 37
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Limitations on Interest</B>. It is expressly the intent of Landlord and Tenant at all
times to comply with applicable law governing the maximum rate or amount of any interest payable on or in connection with this Lease. If applicable law is ever judicially interpreted so as to render usurious any interest called for under this Lease,
or contracted for, charged, taken, reserved, or received with respect to this Lease, then it is Landlord&#8217;s and Tenant&#8217;s express intent that all excess amounts theretofore collected by Landlord be credited on the applicable obligation
(or, if the obligation has been or would thereby be paid in full, refunded to Tenant), and the provisions of this Lease immediately shall be deemed reformed and the amounts thereafter collectible hereunder reduced, without the necessity of the
execution of any new document, so as to comply with the applicable law, but so as to permit the recovery of the fullest amount otherwise called for hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Choice of Law</B>. Construction and interpretation of this Lease shall be governed by the internal laws of the state in which the
Premises are located, excluding any principles of conflicts of laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <B>Time</B>. Time is of the essence as to the performance of
Tenant&#8217;s obligations under this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <B>OFAC</B>. Tenant and all beneficial owners of Tenant are currently (a)&nbsp;in
compliance with and shall at all times during the Term of this Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;<B>OFAC</B>&#8221;) of the U.S. Department of Treasury and any statute, executive order,
or regulation relating thereto (collectively, the &#8220;<B>OFAC Rules</B>&#8221;), (b) not listed on, and shall not during the term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders
List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and
(c)&nbsp;not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <B>Incorporation
by Reference</B>. All exhibits and addenda attached hereto are hereby incorporated into this Lease and made a part hereof. If there is any conflict between such exhibits or addenda and the terms of this Lease, such exhibits or addenda shall control.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <B>Entire Agreement</B>. This Lease, including the exhibits attached hereto, constitutes the entire agreement between Landlord and
Tenant pertaining to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, letters of intent, negotiations and discussions, whether oral or written, of the parties, and there are no warranties,
representations or other agreements, express or implied, made to either party by the other party in connection with the subject matter hereof except as specifically set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <B>No Accord and Satisfaction</B>. No payment by Tenant or receipt by Landlord of a lesser amount than the monthly installment of Base Rent
or any Additional Rent will be other than on account of the earliest stipulated Base Rent and Additional Rent, nor will any endorsement or statement on any check or letter accompanying a check for payment of any Base Rent or Additional Rent be an
accord and satisfaction. Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such Rent or to pursue any other remedy provided in this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <B>Hazardous Activities</B>. Notwithstanding any other provision of this Lease, Landlord, for itself and its employees, agents and
contractors, reserves the right to refuse to perform any repairs or services in any portion of the Premises which, pursuant to Tenant&#8217;s routine safety guidelines, practices or custom or prudent industry practices, require any form of
protective clothing or equipment other than safety glasses. In any such case, Tenant shall contract with parties who are acceptable to Landlord, in Landlord&#8217;s reasonable discretion, for all such repairs and services, and Landlord shall, to the
extent required, equitably adjust Tenant&#8217;s Share of Operating Expenses in respect of such repairs or services to reflect that Landlord is not providing such repairs or services to Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 38
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <B>Redevelopment of Project</B>. Tenant acknowledges that Landlord, in its sole
discretion, may from time to time, subject to the fourth sentence of the first paragraph of <U>Section</U><U></U><U>&nbsp;1</U> of this Lease, expand, renovate and/or reconfigure the Project as the same may exist from time to time and, in connection
therewith or in addition thereto, as the case may be, from time to time without limitation: (a)&nbsp;change the shape, size, location, number and/or extent of any improvements, buildings, structures, lobbies, hallways, entrances, exits, parking
and/or parking areas relative to any portion of the Project; (b)&nbsp;modify, eliminate and/or add any buildings, improvements, and parking structure(s) either above or below grade, to the Project, the Common Areas and/or any other portion of the
Project and/or make any other changes thereto affecting the same; and (c)&nbsp;make any other changes, additions and/or deletions in any way affecting the Project and/or any portion thereof as Landlord may elect from time to time, including without
limitation, additions to and/or deletions from the land comprising the Project, the Common Areas and/or any other portion of the Project. Tenant acknowledges and agrees that construction noise, vibrations and dust associated with normal construction
activities in connection with any redevelopment of the Project are to be expected during the course of such construction. Landlord shall endeavor to minimize interruption with Tenant&#8217;s business operations in the Premises in connection with any
redevelopment undertaken pursuant to this <U>Section</U><U></U><U>&nbsp;41(o)</U>. Notwithstanding anything to the contrary contained in this Lease, Tenant shall have no right to seek damages (including abatement of Rent) or to cancel or terminate
this Lease because of any proposed changes, expansion, renovation or reconfiguration of the Project nor shall Tenant have the right to restrict, inhibit or prohibit any such changes, expansion, renovation or reconfiguration; provided, however,
Landlord shall not change the size, dimensions, location or Tenant&#8217;s Permitted Use of the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <B>Discontinued Use</B>. If,
at any time following the Commencement Date, Tenant does not continuously operate its business in the Premises for a period of 90 consecutive days, Landlord may, but is not obligated to, elect to terminate this Lease upon 30 days&#8217; written
notice to Tenant, whereupon this Lease shall terminate 30 days&#8217; after Landlord&#8217;s delivery of such written notice (&#8220;<B>Termination Date</B>&#8221;), and Tenant shall vacate the Premises and deliver possession thereof to Landlord in
the condition required by the terms of this Lease on or before the Termination Date and Tenant shall have no further obligations under this Lease except for those accruing prior to the Termination Date and those which, pursuant to the terms of this
Lease, survive the expiration or early termination of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <B>EV Charging Stations</B>. Landlord shall not unreasonably
withhold its consent to Tenant&#8217;s written request to install 1 or more electric vehicle car charging stations (&#8220;<B>EV Stations</B>&#8221;) in the parking area serving the Project; provided, however, that Tenant complies with all
reasonable requirements, standards, rules and regulations which may be imposed by Landlord, at the time Landlord&#8217;s consent is granted, in connection with Tenant&#8217;s installation, maintenance, repair and operation of such EV Stations, which
may include, without limitation, the charge to Tenant of a reasonable monthly rental amount for the parking spaces used by Tenant for such EV Stations, Landlord&#8217;s designation of the location of Tenant&#8217;s EV Stations, and Tenant&#8217;s
payment of all costs whether incurred by Landlord or Tenant in connection with the installation, maintenance, repair and operation of each Tenant&#8217;s EV Station(s). Nothing contained in this paragraph is intended to increase the number of
parking spaces which Tenant is otherwise entitled to use at the Project under <U>Section</U><U></U><U>&nbsp;10</U> of this Lease nor impose any additional obligations on Landlord with respect to Tenant&#8217;s parking rights at the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <B>California Accessibility Disclosure</B>. For purposes of Section&nbsp;1938(a) of the California Civil Code, Landlord hereby discloses to
Tenant, and Tenant hereby acknowledges, that the Project has not undergone inspection by a Certified Access Specialist (CASp). In addition, the following notice is hereby provided pursuant to Section&nbsp;1938(e) of the California Civil Code:
&#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not
require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or
tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 39
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221; In furtherance of and in connection with
such notice: (i)&nbsp;Tenant, having read such notice and understanding Tenant&#8217;s right to request and obtain a CASp inspection, hereby elects not to obtain such CASp inspection and forever waives its rights to obtain a CASp inspection with
respect to the Premises, Building and/or Project to the extent permitted by Legal Requirements; and (ii)&nbsp;if the waiver set forth in clause (i)&nbsp;hereinabove is not enforceable pursuant to Legal Requirements, then Landlord and Tenant hereby
agree as follows (which constitutes the mutual agreement of the parties as to the matters described in the last sentence of the foregoing notice): (A) Tenant shall have the <FONT STYLE="white-space:nowrap">one-time</FONT> right to request for and
obtain a CASp inspection, which request must be made, if at all, in a written notice delivered by Tenant to Landlord; (B)&nbsp;any CASp inspection timely requested by Tenant shall be conducted (1)&nbsp;at a time mutually agreed to by Landlord and
Tenant, (2)&nbsp;in a professional manner by a CASp designated by Landlord and without any testing that would damage the Premises, Building or Project in any way, and (3)&nbsp;at Tenant&#8217;s sole cost and expense, including, without limitation,
Tenant&#8217;s payment of the fee for such CASp inspection, the fee for any reports prepared by the CASp in connection with such CASp inspection (collectively, the &#8220;<B>CASp Reports</B>&#8221;) and all other costs and expenses in connection
therewith; (C)&nbsp;the CASp Reports shall be delivered by the CASp simultaneously to Landlord and Tenant; (D)&nbsp;Tenant, at its sole cost and expense, shall be responsible for making any improvements, alterations, modifications and/or repairs to
or within the Premises to correct violations of construction-related accessibility standards including, without limitation, any violations disclosed by such CASp inspection; and (E)&nbsp;if such CASp inspection identifies any improvements,
alterations, modifications and/or repairs necessary to correct violations of construction-related accessibility standards relating to those items of the Building and Project located outside the Premises that are Landlord&#8217;s obligation to repair
as set forth in this Lease, then Landlord shall perform such improvements, alterations, modifications and/or repairs as and to the extent required by Legal Requirements to correct such violations, and Tenant shall reimburse Landlord for the cost of
such improvements, alterations, modifications and/or repairs within 10 business days after Tenant&#8217;s receipt of an invoice therefor from Landlord. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <B>Counterparts</B>. This Lease may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Lease and all matters related
thereto, with such electronic signatures having the same legal effect as original signatures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <B>Alternative Premises</B>. If at any
time during the Term of this Lease, Tenant is considering leasing additional or alternative space in the San Diego area, Tenant shall deliver written notice (&#8220;<B>Premises Notice</B>&#8221;) to Landlord, which Premises Notice shall include a
description of the additional or alternative space desired by Tenant. For a period of 30 days following Tenant&#8217;s delivery of the Premises Notice to Landlord (&#8220;<B>Exclusive Period</B>&#8221;), Tenant agrees that Landlord shall have the
exclusive right, if it so elects and without any obligation to do so, to offer Tenant additional or alternative premises which satisfy in part or in its entirety the premises being sought by Tenant (&#8220;<B>Alternative Premises</B>&#8221;) on
market terms at the Project or, if Landlord so elects, at another property in the San Diego area owned or controlled by an entity controlled by, under common control with, or controlling Landlord including, without limitation, any of the constituent
members of Landlord or Alexandria Real Estate Equities, Inc. (any such entity, an &#8220;<B>Affiliate</B>&#8221;). Landlord and/or any Affiliate, as the case may be, shall have the right, if it so elects and without any obligation to do so, to
acquire a new project or redevelop any existing project it then owns to provide the Alternative Premises. Tenant shall consider in good faith any Alternative Premises offered to Tenant by Landlord (or its Affiliate) during the Exclusive Period. If
Landlord (or its Affiliate) and Tenant identify an Alternative Premises acceptable to Tenant, Landlord (or its Affiliate) and Tenant shall use good faith efforts to negotiate and enter into a new lease for such Alternative Premises. If Landlord (or
its Affiliate) and Tenant are negotiating a lease as of the expiration of the Exclusive Period, the Exclusive Period shall be extended through the earlier to occur of (i)&nbsp;the date that Landlord (or its Affiliate) and Tenant enter into a new
lease, or (ii)&nbsp;the date that negotiations between Landlord (or its Affiliate) and Tenant terminate. Such new lease shall, if entered into, otherwise be upon terms and conditions acceptable to Landlord or Affiliate, as the case may be, and
Tenant in their respective good faith sole discretion. The provisions of this <U>Section</U><U></U><U>&nbsp;42(t)</U>&nbsp;(x) shall only apply so long as <FONT STYLE="white-space:nowrap">ARE-SD</FONT> Region No.&nbsp;44, LLC, or an Affiliate is the
owner of the Project, and (y)&nbsp;shall not be applicable during any Extension Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B> 10578 Science Ctr./Avidity Biosciences - Page
 40
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have executed this Lease as of the day and year first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AVIDITY BIOSCIENCES, INC.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael MacLean</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael MacLean</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>LANDLORD:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B><FONT STYLE="white-space:nowrap">ARE-SD</FONT> REGION NO. 44, LLC,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">a Delaware limited partnership, managing member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">ARE-QRS</FONT> CORP.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">a Maryland corporation, general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gary Dean Gary Dean</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President &#8211; Real Estate L</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DESCRIPTION OF PREMISES</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp42.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 2</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp43.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DESCRIPTION OF PROJECT</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp44.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WORK LETTER</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
WORK LETTER dated December <U>18</U>, 2020 (this &#8220;<B>Work Letter</B>&#8221;) is made and entered into by and between <B><FONT STYLE="white-space:nowrap">ARE-SD</FONT> REGION NO. 44, LLC</B>, a Delaware limited liability company
(&#8220;<B>Landlord</B>&#8221;), and <B>AVIDITY BIOSCIENCES, INC.</B>, a Delaware corporation (&#8220;<B>Tenant</B>&#8221;), and is attached to and made a part of the Amended and Restated Lease Agreement dated December <U>18</U>, 2020 (the
&#8220;<B>Lease</B>&#8221;), by and between Landlord and Tenant. Any initially capitalized terms used but not defined herein shall have the meanings given them in the Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>General Requirements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Tenant&#8217;s Authorized Representative</B>. Tenant designates John Wallen and Pam Lopez (either such individual acting alone,
&#8220;<B>Tenant&#8217;s Representative</B>&#8221;) as the only persons authorized to act for Tenant pursuant to this Work Letter. Landlord shall not be obligated to respond to or act upon any request, approval, inquiry or other communication
(&#8220;<B>Communication</B>&#8221;) from or on behalf of Tenant in connection with this Work Letter unless such Communication is in writing from Tenant&#8217;s Representative. Tenant may change either Tenant&#8217;s Representative at any time upon
not less than 5 business days advance written notice to Landlord. Neither Tenant nor Tenant&#8217;s Representative shall be authorized to direct Landlord&#8217;s contractors in the performance of Landlord&#8217;s Work (as hereinafter defined). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Landlord&#8217;s Authorized Representative</B>. Landlord designates Chris Clement and Michael D&#8217; Ambrosia (either such individual
acting alone, &#8220;<B>Landlord&#8217;s Representative</B>&#8221;) as the only persons authorized to act for Landlord pursuant to this Work Letter. Tenant shall not be obligated to respond to or act upon any request, approval, inquiry or other
Communication from or on behalf of Landlord in connection with this Work Letter unless such Communication is in writing from Landlord&#8217;s Representative. Landlord may change either Landlord&#8217;s Representative at any time upon not less than 5
business days advance written notice to Tenant. Landlord&#8217;s Representative shall be the sole persons authorized to direct Landlord&#8217;s contractors in the performance of Landlord&#8217;s Work. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Architects, Consultants and Contractors</B>. Landlord and Tenant hereby acknowledge and agree that: (i)&nbsp;DPR shall be the general
contractor for the Tenant Improvements, and (ii)&nbsp;DGA shall be the architect (the &#8220;<B>TI Architect</B>&#8221;) for the Tenant Improvements, and (iii)&nbsp;any subcontractors for the Tenant Improvements shall be selected by Landlord and
approved by Tenant, which approval may not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Tenant Improvements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Tenant Improvements Defined</B>. As used herein, &#8220;<B>Tenant Improvements</B>&#8221; shall mean improvements to the Project of a
fixed and permanent nature as shown on the TI Construction Drawings, as defined in <U>Section</U><U></U><U>&nbsp;2(c)</U> below. Other than Landlord&#8217;s Work (as defined in <U>Section</U><U></U><U>&nbsp;3(a)</U> below), Landlord shall not have
any obligation whatsoever with respect to the finishing of the Premises for Tenant&#8217;s use and occupancy. The contemplated schedule of critical dates for the Tenant Improvements is attached hereto as <B>Schedule 3 </B>(the
&#8220;<B>Schedule</B>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Tenant&#8217;s Space Plans</B>. Landlord and Tenant acknowledge and agree that the plan prepared by
the TI Architect attached hereto as <B>Schedule 1 </B>(collectively, the &#8220;<B>Space Plans</B>&#8221;) and the tenant improvement specifications (the &#8220;<B>TI Specifications</B>&#8221;) provided for on <B>Schedule 2 </B>have been approved by
both Landlord and Tenant. Landlord and Tenant further acknowledge and agree that any changes to the Space Plans or the TI Specifications constitute a Change Request the cost of which changes shall be paid for by Tenant. Tenant shall be solely
responsible for all costs incurred by Landlord to alter the Building as a result of Tenant&#8217;s requested changes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 2</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Working Drawings</B>. Landlord shall cause the TI Architect to prepare and deliver to
Tenant for review and comment construction plans, specifications and drawings for the Tenant Improvements (&#8220;<B>TI Construction Drawings</B>&#8221;), which TI Construction Drawings shall be prepared substantially in accordance with the Space
Plans and the TI Specifications. Tenant shall be solely responsible for ensuring that the TI Construction Drawings reflect Tenant&#8217;s requirements for the Tenant Improvements. Tenant shall deliver its written comments on the TI Construction
Drawings to Landlord not later than 10 days after Tenant&#8217;s receipt of the same; provided, however, that Tenant may not disapprove any matter that is consistent with the Space Plans and the TI Specifications without submitting a Change Request.
Landlord and the TI Architect shall consider all such comments in good faith and shall, within 10 days after receipt, notify Tenant how Landlord proposes to respond to such comments, but Tenant&#8217;s review rights pursuant to the foregoing
sentence shall not delay the design or construction schedule for the Tenant Improvements. Any disputes in connection with such comments shall be resolved in accordance with <U>Section</U><U></U><U>&nbsp;2(d)</U> hereof. Provided that the design
reflected in the TI Construction Drawings is consistent with the Space Plans and the TI Specifications, Tenant shall approve the TI Construction Drawings submitted by Landlord, unless Tenant submits a Change Request. Once approved by Tenant, subject
to the provisions of <U>Section</U><U></U><U>&nbsp;4</U> below, Landlord shall not materially modify the TI Construction Drawings except as may be reasonably required in connection with the issuance of the TI Permit (as defined in
<U>Section</U><U></U><U>&nbsp;3(b)</U> below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Approval and Completion</B>. It is hereby acknowledged by Landlord and Tenant that
the permit set of drawings based on the TI Construction Drawings must be finalized by the date set forth on the Schedule in order for the Tenant Improvements to be Substantially Complete by the Target Commencement Date (as defined in the Lease).
Upon any dispute regarding the design of the Tenant Improvements, which is not settled within 10 business days after notice of such dispute is delivered by one party to the other, Tenant may make the final decision regarding the design of the Tenant
Improvements, provided (i)&nbsp;Tenant acts reasonably and such final decision is either consistent with or a compromise between Landlord&#8217;s and Tenant&#8217;s positions with respect to such dispute, (ii)&nbsp;that all costs and expenses
resulting from any such decision by Tenant shall be payable out of the TI Fund (as defined in <U>Section</U><U></U><U>&nbsp;5(d)</U> below), and (iii)&nbsp;Tenant&#8217;s decision will not affect the base Building, structural components of the
Building or any Building Systems (in which case Landlord shall make the final decision). Any changes to the TI Construction Drawings following Landlord&#8217;s and Tenant&#8217;s approval of same requested by Tenant shall be processed as provided in
<U>Section</U><U></U><U>&nbsp;4</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Performance of Landlord&#8217;s Work</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Definition of Landlord&#8217;s Work</B>. As used herein, &#8220;<B>Landlord&#8217;s Work</B>&#8221; shall mean (i)&nbsp;the work of
constructing the Tenant Improvements; (ii)&nbsp;the construction of certain &#8220;warm shell&#8221; improvements, which shall include (1)&nbsp;the addition of an egress stair and service elevator at the northwest side of the Building, (2)&nbsp;the
addition of glazing to the western and northern fa&ccedil;ade of the Building, (3)&nbsp;the addition of glazing to the eastern courtyard-facing fa&ccedil;ade of the Building, and (4)&nbsp;the addition of an exterior operable sliding/folding door
system on the first floor of the Building and the balcony on the second floor of the Building; (iii)&nbsp;the construction of new lobby improvements, which shall include a new common restroom and the infill of the existing <FONT
STYLE="white-space:nowrap">2-story</FONT> lobby space; and (v)&nbsp;those additional &#8220;warm shell&#8221; improvements and lobby improvements identified on the Matrix attached hereto as <B>Schedule 4 </B>(the &#8220;<B>Responsibility
Matrix</B>&#8221;) as being &#8220;Provided by Landlord as part of Core&nbsp;&amp; Shell Scope.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reference in the
Responsibility Matrix to (x) &#8220;Provided by Landlord at Landlord&#8217;s Cost&#8221; refers to work that will be paid for by Landlord, (y) &#8220;Provided by Landlord at Tenant&#8217;s Cost&#8221; refers to the Tenant Improvements that will be
paid out of the TI Fund, and (z) &#8220;Provided by Landlord as part of the Tenant Improvements&#8221; refers to work that will be paid for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be solely responsible for ensuring that the design and specifications for Landlord&#8217;s Work are consistent with
Tenant&#8217;s requirements. Landlord shall be responsible for obtaining all permits, approvals and entitlements necessary for Landlord&#8217;s Work, but shall have no obligation to, and shall not, secure any permits, approvals or entitlements
related to Tenant&#8217;s specific use of the Premises or Tenant&#8217;s business operations therein. This includes securing county approval of San Diego Regional Hazardous Material Questionnaire which Tenant shall be required to obtain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 3</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Commencement and Permitting</B>. Landlord shall commence construction of the Tenant
Improvements upon obtaining a building permit (the &#8220;<B>TI Permit</B>&#8221;) authorizing the construction of the Tenant Improvements consistent with the TI Construction Drawings approved by Tenant. The cost of obtaining the TI Permit shall be
payable from the TI Fund. Tenant shall assist Landlord in obtaining the TI Permit. If any Governmental Authority having jurisdiction over the construction of Landlord&#8217;s Work or any portion thereof shall impose terms or conditions upon the
construction thereof that: (i)&nbsp;are inconsistent with Landlord&#8217;s obligations hereunder, (ii)&nbsp;increase the cost of constructing Landlord&#8217;s Work, or (iii) will materially delay the construction of Landlord&#8217;s Work, Landlord
and Tenant shall reasonably and in good faith seek means by which to mitigate or eliminate any such adverse terms and conditions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<B>Completion of Landlord&#8217;s Work</B>. Landlord shall substantially complete or cause to be substantially completed Landlord&#8217;s Work in a good and workmanlike manner, in accordance with the TI Permit subject, in each case, to Minor
Variations and normal &#8220;punch list&#8221; items of a <FONT STYLE="white-space:nowrap">non-material</FONT> nature that do not interfere with the use of the Premises (&#8220;<B>Substantial Completion</B>&#8221; or &#8220;<B>Substantially
Complete</B>&#8221;). Upon Substantial Completion of Landlord&#8217;s Work, Landlord shall require the TI Architect and the general contractor to execute and deliver, for the benefit of Tenant and Landlord, a Certificate of Substantial Completion in
the form of the American Institute of Architects (&#8220;<B>AIA</B>&#8221;) document G704. For purposes of this Work Letter, &#8220;<B>Minor Variations</B>&#8221; shall mean any modifications reasonably required: (i)&nbsp;to comply with all
applicable Legal Requirements and/or to obtain or to comply with any required permit (including the TI Permit); (ii) to comply with any request by Tenant for modifications to Landlord&#8217;s Work; (iii)&nbsp;to comport with good design,
engineering, and construction practices that are not material; or (iv)&nbsp;to make reasonable adjustments for field deviations or conditions encountered during the construction of Landlord&#8217;s Work. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Selection of Materials</B>. Where more than one type of material or structure is indicated on the TI Construction Drawings approved by
Landlord and Tenant, the option will be selected at Landlord&#8217;s sole and absolute subjective discretion. As to all building materials and equipment that Landlord is obligated to supply under this Work Letter, Landlord shall select the
manufacturer thereof in its sole and absolute subjective discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Delivery of the Premises</B>. When Landlord&#8217;s Work is
Substantially Complete, subject to the remaining terms and provisions of this <U>Section</U><U></U><U>&nbsp;3(e)</U>, Tenant shall accept the Premises. Tenant&#8217;s taking possession and acceptance of the Premises, respectively, shall not
constitute a waiver of: (i)&nbsp;any warranty with respect to workmanship (including installation of equipment) or material (exclusive of equipment provided directly by manufacturers), with respect to the Premises, (ii)&nbsp;any <FONT
STYLE="white-space:nowrap">non-compliance</FONT> of Landlord&#8217;s Work in the Premises with applicable Legal Requirements, with respect to the Premises, or (iii)&nbsp;any claim that Landlord&#8217;s Work was not completed substantially in
accordance with the TI Construction Drawings (subject to Minor Variations and such other changes as are permitted hereunder) (collectively, a &#8220;<B>Construction Defect</B>&#8221;). Tenant shall have one year after Substantial Completion within
which to notify Landlord of any such Construction Defect discovered by Tenant in the Premises, and Landlord shall use reasonable efforts to remedy or cause the responsible contractor to remedy any such Construction Defect within 30 days thereafter.
Notwithstanding the foregoing, Landlord shall not be in default under the Lease if the applicable contractor, despite Landlord&#8217;s reasonable efforts, fails to remedy such Construction Defect within such
<FONT STYLE="white-space:nowrap">30-day</FONT> period. If contractor fails to remedy such Construction Defect within a reasonable period, Landlord shall use its reasonable efforts to remedy the Construction Defect within a reasonable period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be entitled to receive the benefit of all construction warranties and manufacturer&#8217;s equipment warranties relating to
equipment installed in the Premises. If requested by Tenant, Landlord shall attempt to obtain extended warranties from manufacturers and suppliers of such equipment, but the cost of any such extended warranties shall be borne solely out of the TI
Fund. Landlord shall promptly undertake and complete, or cause to be completed, all punch list items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 4</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Commencement Date Delay</B>. Except as otherwise provided in the Lease, Delivery of
the Premises shall occur when Landlord&#8217;s Work has been Substantially Completed, except to the extent that completion of Landlord&#8217;s Work shall have been actually delayed by any one or more of the following causes (&#8220;<B>Tenant
Delay</B>&#8221;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Tenant&#8217;s Representative was not available to give or receive any Communication or to take any
other action required to be taken by Tenant hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Tenant&#8217;s request for Change Requests (as defined in
<U>Section</U><U></U><U>&nbsp;4(a)</U> below) whether or not any such Change Requests are actually performed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)
Construction of any Change Requests; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Tenant&#8217;s delay in the approval of the Initial Budget or any amendment
thereto, including any changes to the Initial Budget or amendments requested by Tenant or Landlord, that results in the process for review and approval of such Initial Budget or any particular amendment, as applicable, extending for a period in
excess of 5 business days after delivery of such Initial Budget or amendment to Tenant for approval, provided, however, that, notwithstanding the foregoing, collective delays with respect to review and approval of the Initial Budget and/or
amendments exceeding 10 calendar days in the aggregate shall constitute a Tenant Delay; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Tenant&#8217;s request for
materials, finishes or installations requiring unusually long lead times; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Tenant&#8217;s delay in reviewing, revising
or approving plans and specifications beyond the periods set forth herein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Tenant&#8217;s delay in providing
information critical to the normal progression of the Project. Tenant shall provide such information as soon as reasonably possible, but in no event longer than one week after receipt of any request for such information from Landlord; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Tenant&#8217;s delay in making payments to Landlord for Excess TI Costs (as defined in
<U>Section</U><U></U><U>&nbsp;5(d)</U> below); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) Any other act or omission by Tenant or any Tenant Party (as defined
in the Lease), or persons employed by any of such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Delivery is delayed for any of the foregoing reasons, then Landlord shall cause the TI
Architect to certify the date on which the Tenant Improvements would have been Substantially Completed but for such Tenant Delay and such certified date shall be the date of Delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Changes</B>. Any changes requested by Tenant to the Tenant Improvements shall be requested and instituted in accordance with the
provisions of this <U>Section</U><U></U><U>&nbsp;4</U> and shall be subject to the written approval of Landlord and the TI Architect, such approval not to be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Tenant&#8217;s Request For Changes</B>. If Tenant shall request changes to the Tenant Improvements (&#8220;<B>Changes</B>&#8221;),
Tenant shall request such Changes by notifying Landlord in writing in substantially the same form as the AIA standard change order form (a &#8220;<B>Change Request</B>&#8221;), which Change Request shall detail the nature and extent of any such
Change. Such Change Request must be signed by Tenant&#8217;s Representative. Landlord shall, before proceeding with any Change, use commercially reasonable efforts to respond to Tenant as soon as is reasonably possible with an estimate of:
(i)&nbsp;the time it will take, and (ii)&nbsp;the architectural and engineering fees and costs that will be incurred, to analyze such Change Request (which costs shall be paid from the TI Fund to the extent actually incurred, whether or not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 5</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such change is implemented). Landlord shall thereafter submit to Tenant in writing, within 5 business days of receipt of the Change Request (or such longer period of time as is reasonably
required depending on the extent of the Change Request), an analysis of the additional cost or savings involved, including, without limitation, architectural and engineering costs and the period of time, if any, that the Change will extend the date
on which Landlord&#8217;s Work will be Substantially Complete. Any such delay in the completion of Landlord&#8217;s Work caused by a Change, including any suspension of Landlord&#8217;s Work while any such Change is being evaluated and/or designed,
shall be Tenant Delay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Implementation of Changes</B>. If Tenant: (i)&nbsp;approves in writing the cost or savings and the estimated
extension in the time for completion of Landlord&#8217;s Work, if any, and (ii)&nbsp;deposits with Landlord any Excess TI Costs required in connection with such Change, Landlord shall cause the approved Change to be instituted. Notwithstanding any
approval or disapproval by Tenant of any estimate of the delay caused by such proposed Change, the TI Architect&#8217;s determination of the amount of Tenant Delay in connection with such Change shall be final and binding on Landlord and Tenant.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Costs</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<B>Budget For Tenant Improvements</B>. Before the commencement of construction of the Tenant Improvements, Landlord shall obtain and submit to Tenant for approval (which approval shall not be unreasonably withheld, conditioned or delayed), a
detailed breakdown by trade of the costs incurred or that will be incurred in connection with the design and construction of the Tenant Improvements (the &#8220;<B>Initial Budget</B>&#8221;). Notwithstanding anything to the contrary contained
herein, if Tenant does not approve or disapprove the Initial Budget or an amendment to the Initial Budget within 5 business days after Landlord&#8217;s delivery to Tenant of such Initial Budget or amendment to the Initial Budget, Tenant shall be
deemed to have approved such Initial Budget or amendment, as applicable. The Budget shall be based upon the TI Construction Drawings approved by Tenant and shall include a payment to Landlord of administrative rent (&#8220;<B>Administrative
Rent</B>&#8221;) equal to 3% of the total &#8220;hard&#8221; TI Costs for monitoring and inspecting the construction of the Tenant Improvements and Changes, which sum shall be payable from the TI Fund (as defined in
<U>Section</U><U></U><U>&nbsp;5(d)</U>). If the Budget is greater than the TI Allowance, Tenant shall deposit with Landlord the difference, in cash, prior to the commencement of construction of the Tenant Improvements or Changes, for disbursement by
Landlord as described in <U>Section</U><U> 5(d)</U>. Landlord shall make its records with respect to the Tenant Improvements available to Tenant on an &#8220;open book&#8221; basis throughout the design and construction of the Tenant Improvements.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>TI Allowance</B>. Landlord shall provide to Tenant a tenant improvement allowance (the &#8220;<B>TI Allowance</B>&#8221;) in the
maximum amount of $235.00 per rentable square foot in the Premises, which is included in the Base Rent set forth in the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TI
Allowance shall be disbursed in accordance with this Work Letter. Tenant shall have no right to the use or benefit (including any reduction to or payment of Base Rent) of any portion of the TI Allowance not required for the construction of
(i)&nbsp;the Tenant Improvements described in the TI Construction Drawings approved pursuant to <U>Section</U><U></U><U>&nbsp;2(d)</U> or (ii)&nbsp;any Changes pursuant to <U>Section</U><U></U><U>&nbsp;4</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Costs Includable in TI Fund</B>. The TI Fund shall be used solely for the payment of design, permits and construction costs in
connection with the construction of the Tenant Improvements, including, without limitation, the cost of electrical power and other utilities used in connection with the construction of the Tenant Improvements, the cost of preparing the Space Plan
and the TI Construction Drawings, all costs set forth in the Budget, including Landlord&#8217;s Administrative Rent, Landlord&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, the cost of
finishes for the Tenant Improvements consistent with Building and Project standard finishes, an administrative fee of up to 2% of the total &#8220;hard&#8221; TI Costs for project management services provided on behalf of Tenant by a third party
project manager selected by Tenant and reasonably approved by Landlord, costs resulting from Tenant Delays and the cost of Changes (collectively, &#8220;<B>TI Costs</B>&#8221;). Notwithstanding anything to the contrary contained herein, the TI Fund
shall not be used to purchase any furniture, personal property or other <FONT STYLE="white-space:nowrap">non-Building</FONT> system materials or equipment, including, but not limited to, Tenant&#8217;s voice or data cabling, <FONT
STYLE="white-space:nowrap">non-ducted</FONT> biological safety cabinets and other scientific equipment not incorporated into the Tenant Improvements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 6</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Excess TI Costs</B>. Landlord shall have no obligation to bear any portion of the cost
of any of the Tenant Improvements except to the extent of the TI Allowance. If at any time the remaining TI Costs under the Budget exceed the remaining unexpended TI Allowance (including, without limitation, costs for finishes for the Tenant
Improvements that are better than Building and Project standard finishes), Tenant shall deposit with Landlord, as a condition precedent to Landlord&#8217;s obligation to complete the Tenant Improvements, 100% of the then current TI Cost in excess of
the remaining TI Allowance (&#8220;<B>Excess TI Costs</B>&#8221;). If Tenant fails to deposit any Excess TI Costs with Landlord, Landlord shall have all of the rights and remedies set forth in the Lease for nonpayment of Rent (including, but not
limited to, the right to interest at the Default Rate and the right to assess a late charge). For purposes of any litigation instituted with regard to such amounts, those amounts will be deemed Rent under the Lease. The TI Allowance and Excess TI
Costs are herein referred to as the &#8220;<B>TI Fund</B>.&#8221; Funds deposited by Tenant shall be the first disbursed to pay TI Costs. Notwithstanding anything to the contrary set forth in this <U>Section</U><U></U><U>&nbsp;5(d)</U>, Tenant shall
be fully and solely liable for TI Costs and the cost of Minor Variations in excess of the TI Allowance. If upon completion of the Tenant Improvements and the payment of all sums due in connection therewith there remains any undisbursed portion of
the TI Fund, Tenant shall be entitled to such undisbursed TI Fund solely to the extent of any Excess TI Costs deposit Tenant has actually made with Landlord. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Tenant Access</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<B>Tenant&#8217;s Access Rights</B>. Landlord hereby agrees to permit Tenant access, at Tenant&#8217;s sole risk and expense, to the Building (i) 45 days prior to the Commencement Date to perform any work (&#8220;<B>Tenant&#8217;s Work</B>&#8221;)
required by Tenant other than Landlord&#8217;s Work, provided that such Tenant&#8217;s Work is coordinated with the TI Architect and the general contractor, and complies with the Lease and all other reasonable restrictions and conditions Landlord
may impose, and (ii)&nbsp;prior to the completion of Landlord&#8217;s Work, to inspect and observe work in process; all such access shall be during normal business hours or at such other times as are reasonably designated by Landlord.
Notwithstanding the foregoing, Tenant shall have no right to enter onto the Premises or the Project unless and until Tenant shall deliver to Landlord evidence reasonably satisfactory to Landlord demonstrating that any insurance reasonably required
by Landlord in connection with such <FONT STYLE="white-space:nowrap">pre-commencement</FONT> access (including, but not limited to, any insurance that Landlord may require pursuant to the Lease) is in full force and effect. Any entry by Tenant shall
comply with all established safety practices of Landlord&#8217;s contractor and Landlord until completion of Landlord&#8217;s Work and acceptance thereof by Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>No Interference</B>. Neither Tenant nor any Tenant Party (as defined in the Lease) shall interfere with the performance of
Landlord&#8217;s Work, nor with any inspections or issuance of final approvals by applicable Governmental Authorities, and upon any such interference, Landlord shall have the right to exclude Tenant and any Tenant Party from the Premises and the
Project until Substantial Completion of Landlord&#8217;s Work. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>No Acceptance of Premises</B>. The fact that Tenant may, with
Landlord&#8217;s consent, enter into the Project prior to the date Landlord&#8217;s Work is Substantially Complete for the purpose of performing Tenant&#8217;s Work shall not be deemed an acceptance by Tenant of possession of the Premises, but in
such event Tenant shall defend with counsel reasonably acceptable by Landlord, indemnify and hold Landlord harmless from and against any loss of or damage to Tenant&#8217;s property, completed work, fixtures, equipment, materials or merchandise, and
from liability for death of, or injury to, any person, caused by the act or omission of Tenant or any Tenant Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Work Letter &#8211; Landlord Build</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 7</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Miscellaneous</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Consents</B>. Whenever consent or approval of either party is required under this Work Letter, that party shall not unreasonably
withhold, condition or delay such consent or approval, unless expressly set forth herein to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Modification</B>. No
modification, waiver or amendment of this Work Letter or of any of its conditions or provisions shall be binding upon Landlord or Tenant unless in writing signed by Landlord and Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>No Default Funding</B>. In no event shall Landlord have any obligation to fund any portion of the TI Allowance or to perform any
Landlord&#8217;s Work during any period that Tenant is in Default under the Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 8</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SPACE PLANS</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp52.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 9</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp53.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 10</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TI SPECIFICATIONS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>GENERAL
BASE BUILDING INFORMATION </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Applicable Codes:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">California Building Code (CBC)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">California
Electrical Code (CEC)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">California Mechanical Code (CMC)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">California Plumbing Code (CPC)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">California Fire Code (CFC)
California Energy Code (CEC)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">California Green Building Standards Code (GBC)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Accessibility Regulations as Prescribed by the 2013 California Building Code</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Americans with Disabilities Act Guidelines (ADA)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">All Codes and Ordinances Adopted by the City of San Diego</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Landlord shall be responsible for securing all applicable design, engineering, permits and approvals required for the interior
tenant improvement scope of work. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>LANDLORD WORK PLANS for AVIDITY TENANT IMPROVEMENT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BUILDING INTERIOR / GENERAL WORK AREAS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to lease
exhibit plan dated December 11, 2020 for detailed layout: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant Improvements including (12)&nbsp;private offices, (4)&nbsp;medium conference rooms, (1)&nbsp;large
conference room, secured lobby, (2)&nbsp;break rooms with built in booths, open office with approx. (58)&nbsp;workstations and soft collaboration seating throughout. The lab portion consist of open laboratory with (25)&nbsp;island benches and (10)
8&#8217; fume hoods, Tissue culture room to accommodate (5)&nbsp;BSC and (8)&nbsp;Incubator units, Chem storage, Oligos Lab with (2) 8&#8217; FH and (1) 8&#8217; WFH, Mass Spec room with (3)&nbsp;snorkels and (1) 8&#8217; FH, Microscope room with <FONT
STYLE="white-space:nowrap">built-in</FONT> casework, shipping / receiving room and a dedicated storage room for tenant provided freezers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing and New supply air and exhaust air distribution systems. Assume existing fan to be reused, new plenum
and major ducting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory air compressor and vacuum pump systems are provided as part of the existing house systems.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing Laboratory N2 and RO/DI available as part of the house systems. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Electrical infrastructure to support multi-tenant lab/office/campus use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Men&#8217;s&nbsp;&amp; Women&#8217;s restroom core. Fixtures to meet CPC requirements.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STRUCTURAL SYSTEMS </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All structural supports required for base building Mech, Elec. And Plumbing equipment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exterior improvements to new exterior reskin, new egress stair and service elevator at northwest corner is
under landlord responsibility. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MOISTURE AND THERMAL PROTECTION </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing Batt insulation at all <FONT STYLE="white-space:nowrap">non-glass</FONT> exterior walls and rigid
insulation at spandrel glass conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sound Batt insulation at all interior partitions </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 11</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GENERAL / OTHER </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Security &#8211; (6) suite access doors and openings prepared for security hardware for tenant&#8217;s security
vendor to <FONT STYLE="white-space:nowrap">trim-out,</FONT> cable and program into tenant&#8217;s security system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Code compliant interior signage included in tenant improvement, all other provided by tenant.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FINISHES </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ceilings </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acoustical (ACT) lab grade ceilings in laboratory and lab support rooms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Drywall <FONT STYLE="white-space:nowrap">hard-lid</FONT> paintable ceilings at break rooms/ collaboration.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Drywall <FONT STYLE="white-space:nowrap">hard-lid</FONT> soffit/ceiling allowance for lobby area.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acoustical office grade (ACT) ceilings at office and conference rooms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exposed ceilings to structure at open office and common areas. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Walls Finish </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General latex wall paint in conference rooms and laboratory support areas. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Flooring </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory and Laboratory Support areas have VCT tile with rubber base. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conference rooms to have carpet tile flooring. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lunchroom to have premium LVT. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office and conference rooms to have carpet tile flooring. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lobby flooring to be upgraded, flooring to be finalized with finishes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Main circulation corridor to have polished exposed concrete. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glazing </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interior Storefront glazing at conference rooms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New exterior storefront glazing system at entry and outdoor patio at levels 1 and 2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New glazing system between lab and office area to match upper floor or equal. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millwork </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Custom lobby desk. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Custom breakroom booths. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plastic laminate cabinets and drawers at lobby and lunch room. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab Casework </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory casework base cabinets in <FONT STYLE="white-space:nowrap">p-lam</FONT> finish with reagent shelving
and trespa or equal tops. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fume hoods </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(14) <FONT STYLE="white-space:nowrap">8-Foot</FONT> Chemistry hoods </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mobile benches and storage racks to be provided by tenant. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPECIALTY EQUIPMENT </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">N/A </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HVAC SYSTEMS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laboratory </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exiting laboratory air handling unit, 100% outside air for laboratory only. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New duct risers. New mains provided as part of tenant improvement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option for <FONT STYLE="white-space:nowrap">re-use</FONT> of existing laboratory exhaust fan system and new
supplemental exhaust fan systems. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Building Automation System connected to existing system. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(28) Lab SAV w/ RH zones. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 12</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing recirculating AHU serving office spaces. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Building Automation System connected to existing system. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(27) Lab SAV w/ RH zones. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Electrical and mechanical room ventilation as needed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">In-suite</FONT> lobby and general open collaboration areas to be conditioned
with existing; house system equipment is existing, zone level equipment, distribution and controls are new. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLUMBING </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Water and sewer services of adequate size to support the building type. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sanitary sewer, waste and vent lines associated with toilet rooms and house mechanical systems included.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Water systems (ICW, IHW, DCW, DHW,) distributed to associated equipment as needed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory vacuum distributed at lab benches. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory air compressor distributed at fume hoods only. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DI water system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">House N2 plumbed <FONT STYLE="white-space:nowrap">through-out</FONT> lab areas at fume hoods only.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Local O2 and other future gases to be provided and maintained by tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CO2 piping to tissue culture rooms provided as part of the tenant improvement. CO2 source provided by the
tenant. No bulk CO2 to be provided through TI allowance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Condensate drains for HVAC equipment and plumbing equipment runs to nearest indirect waste receptor.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Re-use</FONT> of existing LA, N2, LV, ICW, IHW/IHWR, DCW, DHW/DHWR risers.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FIRE PROTECTION / FIRE PROOFING </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full building fire sprinkler system sized to meet building type and density. System includes vertical and
horizontal distribution per TI test fit and to allow for final modifications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fully functional fire alarm system with horn and strobes to support TI, elevator monitoring and fire protection
flow switches. Existing fire control panel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fireproofing and horizontal fire separations to include structural fire proofing if needed and firesafing as
required to comply with Building Type. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ELECTRICAL SYSTEMS </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Primary service 4,000A for overall building normal power. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing 2MW Emergency Generator with 1600 amps shared with the building. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distribution </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Power devices for laboratory general and specified equipment, office, lobby and conference rooms.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Standby power to -20 &amp; -80 Freezers, and Incubators. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New IDF riser room located on both levels. Tenant to extend existing or new service from the building MPOE to
IDF room. IDF/Server room <FONT STYLE="white-space:nowrap">build-out,</FONT> structured cabling, security&nbsp;&amp; CCTV cabling by tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tele/data ring and string for laboratory and office areas. Conduit pathway from MPOE to Levels 1 and 2 and IDF
access. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Single gang box for tenant card access control system. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lighting </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New LED lighting at office areas, laboratory and conferencing areas. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Enhanced lighting at suite lobby, reception, and break rooms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Title 24 compliant lighting control system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8212; END -- </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 13</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule of Critical Dates &#8211; Tenant Improvements </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Based on 6/1/20 NTP Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">*Tenant Improvement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>City Permit Submittal Complete (Submit for plan check)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">12/14/2020 (Followed by 5 business day review and approval)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>City Permit Approval</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">02/26/2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issue for Construction Set</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">03/01/2021</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review and approval dates are to be business days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the City Permit Submittal is not finalized and approved by Tenant and Landlord within the applicable 5 business day review period noted above after initial
delivery to Tenant for review, then each day thereafter until applicable stage is finalized shall constitute Tenant Delay (unless failure to complete such stage resulted from Landlord&#8217;s failure to provide a response within the required time
period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 14</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RESPONSIBILITY MATRIX</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Core&nbsp;&amp; Shell as used herein refers to the structure, envelope, elevators, and egress stairs. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ALLOCATION</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Provided&nbsp;by</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Landlord at<BR>Landlord&#8217;s</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Provided&nbsp;by</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tenant at Tenant&#8217;s</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Provided by</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Landlord as<BR>part&nbsp;of&nbsp;Tenant</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Improvements</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B>GENERAL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Building Core&nbsp;&amp; Shell certified by the USGBC at no less than LEED Gold (N/A for existing building)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surface/structured parking TBD (see lease exhibit)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marking 4 parking stalls as reserved</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B>Permits&nbsp;&amp; Fees</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Building Site, Core&nbsp;&amp; Shell Permit&nbsp;&amp; Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All Tenant Improvement Related Permits&nbsp;&amp; Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B>SITEWORK</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Sidewalks, curbs, landscaping and asphalt parking.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Tele/Data conduits to main point of entry (MPOE) for local exchange carrier (if service requested is not existing already)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Domestic sanitary sewer to the building with connection to street lateral</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Lab waste sewer points of connection to sanitary sewer.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exterior hazardous material storage shed(s), relevant signage (i.e. NFPA), and Hazardous Material Business Plan (HMBP) submission to AHJ</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Main site storm drain utilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing SDG&amp;E primary electrical service to U/G pull section&nbsp;&amp; meter main</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing SDG&amp;E gas service to meter&nbsp;&amp; pressure regulator.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Domestic water service with connection at the street lateral.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Fire Water service to hydrants and building riser with connection at the street lateral</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Trash Enclosure and Concrete Pad with gate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing exterior loading area to remain</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Service Yard existing to remain with fencing.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Irrigation water&nbsp;&amp; distribution lines (existing to remain)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Domestic water bibs on roof&nbsp;&amp; site as deemed necessary by LL for maintenance and convenience.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 15</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B>LANDSCAPING</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Site softscape including landscaping and irrigation service to include location, species and sizes of trees, shrubs and groundcovers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Site hardscape including walkways, driveways, curbing, patios, and exterior lighting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>STRUCTURE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Structural steel and reinforced concrete decks for new elevator, building reskin, new exterior stair, lobby <FONT STYLE="white-space:nowrap">in-fill</FONT> and balcony.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Concrete pads for base building equipment such as the main electrical meter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Concrete pads in and on the structure for new/relocated tenant building equipment such as air handlers, exhaust fans, chillers, and pumps, etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shaft openings for base building utility risers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shaft openings for tenant utility risers in addition to base building</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Miscellaneous metal items and/or concrete pads for base building equipment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Miscellaneous metal items and/or concrete pads for Tenant equipment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New exterior stair.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ROOFING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New class &#8216;A&#8217; roofing system (at new elevator only)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Roof penetrations for base building equipment&nbsp;&amp; systems.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Roofing penetrations for Tenant equipment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>EXTERIOR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Base building entrances.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Building-mounted Tenant signage, and monument sign, in accordance with City of San Diego rules and regulations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Building <FONT STYLE="white-space:nowrap">re-skin</FONT> of the building on levels 1 &amp; 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Entry canopy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Operable exterior windows</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>COMMON AREAS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing First floor finished lobby.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second floor finished lobby</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing common restrooms for tenant use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Code required bicycle storage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Walls in exit stairways and Base Building utility rooms shall have a final paint finish.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Metal railings in all exit stairways.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Code required signage for all base building rooms.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Janitor&#8217;s closets in core areas.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Main Electrical Switchgear and MPOE rooms.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Electrical closets in core areas.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IDF connected to MPOE.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 16</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common doors, frames&nbsp;&amp; hardware at main entry, shell exit stairs, Loading Dock, Trash Enclosure (gates) Main Electric Room, MPOE Room, &amp; Elevator Machine Room(s).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tenant Premises interior doors, frames, and hardware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ELEVATORS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">One (1)&nbsp;new service elevator</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">One (1)&nbsp;existing passenger elevator</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WINDOW TREATMENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Furnish and install Base Building window treatment, including blocking for window treatment. Window treatments are to be MechoShades or equal for all windows.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Windowsills, as applicable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TENANT AREAS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shipping and Receiving Areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drywall patching at inside face of exterior walls</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Finishes at inside face of exterior walls</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Finishes at inside face at Tenant side of core partitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Electrical closets within Tenant Premises</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tenant Tel/data rooms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tenant break or kitchen areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Partitions, ceilings, flooring, painting, finishes, doors, frames, hardware, millwork, casework, and buildout.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Wire shelving&nbsp;&amp; chemical racking systems</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fixed casework.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laboratory Equipment including, but not limited to biosafety cabinets, autoclaves, glasswashers, bioreactors, recirculating chillers in fume
hoods, high vac dry down stations, air showers, rackwashers &amp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">associated steam generators.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chemical Fume Hoods, bench fume hood, lab casework.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fixtures, Furniture, Equipment (FF&amp;E)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appliances including refrigerator, dishwashers, garbage disposals and microwaves.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shaft enclosures for base building systems&#8217; risers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shaft enclosures for Tenant risers within allocated space in the main vertical Base Building shafts.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All interior code required signage for Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All wayfinding signage and tenant specific signage for branding purposes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>FIRE PROTECTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Control area fire ratings at underside of elevated decks. No fireproofing required at roof.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Fire service entrance including fire department connection, alarm valve, and flow protection.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exit stair distribution piping and sprinkler heads.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 17</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Primary distribution adequate to support ordinary hazard</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All lateral piping, drop heads, and related equipment within Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Modification of sprinkler branch and main piping and head locations to suit Tenant layout&nbsp;&amp; hazard index.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Specialized extinguishing systems (if required).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-action</FONT> <FONT STYLE="white-space:nowrap">dry-pipe</FONT> systems (if required).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fire extinguishers required per SS&amp;C permit drawings.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fire extinguisher cabinets at Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PLUMBING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Domestic Water service with site backflow prevention to building entry.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Domestic water risers serving Tenant Premises</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Domestic water distribution within Tenant Premises</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing domestic hot water generation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing lower level Core restroom plumbing fixtures compliant with accessibility requirements.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing common restroom plumbing fixtures compliant with accessibility requirements.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Industrial Water riser for lab use and reduced pressure backflow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">preventer.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Industrial hot water generation for Tenant use.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Industrial water distribution within Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Roof storm drainage system.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sanitary Waste and vent service for core areas.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sanitary Waste and vent risers serving Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sanitary Waste and vent distribution serving Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab waste and vent pipe risers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab waste and vent pipe distribution serving Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Central lab air compressor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supplemental lab air compressor capacity (if required)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Compressed air vertical pipe riser.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Compressed air pipe distribution in Tenant Premises for specific points of use.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Central lab vacuum system</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supplemental lab vacuum capacity (if required)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vacuum vertical pipe riser.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab vacuum pipe distribution in Tenant Premises for specific points of use.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RO/DI water generator</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supplemental RO/DI capacity (if required)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RO/DI water vertical pipe riser.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DI water pipe distribution in Tenant Premises for specific points of use.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 18</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bulk, Dewar, Cylinder or Bottled lab nitrogen and argon gas sources for Tenant use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab nitrogen pipe distribution in Tenant Premises for specific points of use.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab argon pipe distribution in Tenant Premises for specific points of use.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manifolds, piping, and outlets for CO2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C02 Cylinders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manifolds, piping, and other requirements including cylinders, not specifically mentioned above (i.e. O2, LN2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>NATURAL GAS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Natural gas service, pressure regulator and meter sized for Tenant equipment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Natural gas service to Base Building boilers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Natural gas pipe distribution to tenant program areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>HEATING, VENTILATION, AIR CONDITIONING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing central water-cooled chilled water plant. Chillers and Cooling Towers provided (existing).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Chilled water pipe risers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Chilled water pipe distribution serving Central Air Handling Units</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Chilled water pipe distribution serving Tenant Premises solely.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Condenser water pipe distribution from Cooling Towers to Chillers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing central gas fired condensing boiler plant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">House steam system (if required)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heating Hot water pipe risers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heating Hot water pipe distribution serving Central Air Handling Units</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heating Hot water pipe distribution within Tenant Premises solely</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing expandable Building Management System (BMS) for Base Building Infrastructure.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS (compatible with Landlord&#8217;s system) within Tenant Premises</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">monitoring Tenant Infrastructure.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing air handling units.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vertical supply air duct distribution.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supply air duct distribution, air valves, VAV terminals, Reheat coils, Humidifiers, equipment connections, insulation, air terminals, dampers, hangers, etc. within Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing laboratory exhaust and fans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New laboratory exhaust and fans required for additional equipment that exceeds the building systems capacity.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vertical exhaust air duct risers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhaust air duct distribution, air valves, VAV terminals, equipment connections, insulation, air terminals, dampers, hangers, etc. within Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 19</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Electric room ventilation system for electrical closets within Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sound attenuation for Tenant equipment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DX cooling systems for Tenant Server and IDF room</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Additional/dedicated cooling for Tenant requirements.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ELECTRICAL</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Uninterruptable Power System (UPS)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Electrical utility service to main meter section and house panel at main switchgear</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing 480/277v, main switchboard(s) after shell section</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing standby power generator<STRIKE>s</STRIKE> (if in excess of pro rata share for existing generator on site)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing automatic transfer switch for life safety loads on generator for base building loads.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Automatic transfer switch for Tenant emergency power.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution within Tenant Premises for Tenant loads, as well as for base building critical systems</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lighting and power distribution for site lighting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lighting and power distribution for common Lobby&nbsp;&amp; Restroom areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lighting and power distribution for Tenant Premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shell area life safety emergency lighting/signage.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tenant Premises life safety emergency lighting/signage.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tenant panels, transformers, and distribution equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>FIRE ALARM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Base expandable fire alarm system at elevators</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Building fire alarm system with devices in core areas.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fire alarm sub panels and devices for Tenant Premises with integration into Base Building system.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TELEPHONE/DATA</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Underground local service provider conduit to MPOE room for copper and fiber optic service (if service requested is not existing already)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tenant tele/data rooms.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pathways from MPOE room directly into Tenant tele/data rooms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel/Data cabling from MPOE room to Tenant tele/data room</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fiber optic service for Tenant use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel/data infrastructure including, but not limited to, servers, computers, phone systems, switches, routers, MUX panels, equipment racks, ladder racks, etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 20</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Provisioning of circuits and service from service providers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Audio visual systems</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Station cabling from Tenant tel/data room to all Tenant locations, within the suite and exterior to the suite, if needed.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SECURITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Card access at Building exterior entries.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Card access into or within tenant Premises on separate Tenant installed and managed system.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Video camera coverage of Tenant Premises on separate Tenant installed and managed system.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ACKNOWLEDGMENT OF COMMENCEMENT DATE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>ACKNOWLEDGMENT OF COMMENCEMENT DATE </B>is made this <U>&#8195;&#8195;&#8195;</U> day of <U></U><U>&#8195;&#8195;&#8195;&#8195;</U>,
2020, between <B><FONT STYLE="white-space:nowrap">ARE-SD</FONT> REGION NO. 44, LLC, </B>a Delaware limited liability company (&#8220;<B>Landlord</B>&#8221;), and <B>AVIDITY BIOSCIENCES, INC.</B>, a Delaware corporation (&#8220;<B>Tenant</B>&#8221;),
and is attached to and made a part of the Amended and Restated Lease dated December <U></U><U>&#8195;&#8195;&#8195;</U>, 2020 (the &#8220;<B>Lease</B>&#8221;), by and between Landlord and Tenant. Any initially capitalized terms used but not defined
herein shall have the meanings given them in the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant hereby acknowledge and agree, for all purposes of the Lease,
that the Commencement Date of the Base Term of the Lease is <U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, <U>&#8195;&#8195;&#8195;</U>, the termination date of the Base Term of the Lease shall be midnight
on<U>&#8195;&#8195;&#8195;&#8195;&#8195; </U><U></U>, <U></U><U>&#8195;&#8195;&#8195;</U>. In case of a conflict between the terms of the Lease and the terms of this Acknowledgment of Commencement Date, this Acknowledgment of Commencement Date shall
control for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have executed this ACKNOWLEDGMENT OF COMMENCEMENT DATE to be effective
on the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ROWSPAN="6"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TENANT:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AVIDITY BIOSCIENCES, INC.,</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">By:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Its:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LANDLORD:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ARE-SD</FONT> REGION NO. 44, LLC,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">managing member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">ARE-QRS</FONT> CORP.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">a Maryland corporation,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">By:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Its:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Rules and Regulations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Rules and Regulations </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The sidewalk, entries, and driveways of the Project shall not be obstructed by Tenant, or any Tenant Party, or used by them for any purpose
other than ingress and egress to and from the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Tenant shall not place any objects, including antennas, outdoor furniture,
etc., in the parking areas, landscaped areas or other areas outside of its Premises, or on the roof of the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Except for animals
assisting the disabled, no animals shall be allowed in the offices, halls, or corridors in the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Tenant shall not disturb the
occupants of the Project or adjoining buildings by the use of any radio or musical instrument or by the making of loud or improper noises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. If Tenant desires telegraphic, telephonic or other electric connections in the Premises, Landlord or its agent will direct the electrician
as to where and how the wires may be introduced; and, without such direction, no boring or cutting of wires will be permitted. Any such installation or connection shall be made at Tenant&#8217;s expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Tenant shall not install or operate any steam or gas engine or boiler, or other mechanical apparatus in the Premises, except as specifically
approved in the Lease. The use of oil, gas or inflammable liquids for heating, lighting or any other purpose is expressly prohibited. Explosives or other articles deemed extra hazardous shall not be brought into the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Parking any type of recreational vehicles is specifically prohibited on or about the Project. Except for the overnight parking of operative
vehicles, no vehicle of any type shall be stored in the parking areas at any time. In the event that a vehicle is disabled, it shall be removed within 48 hours. There shall be no &#8220;For Sale&#8221; or other advertising signs on or about any
parked vehicle. All vehicles shall be parked in the designated parking areas in conformity with all signs and other markings. All parking will be open parking, and no reserved parking, numbering or lettering of individual spaces will be permitted
except as specified by Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Tenant shall maintain the Premises free from rodents, insects and other pests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the
influence of liquor or drugs or who shall in any manner do any act in violation of the Rules and Regulations of the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. Tenant
shall not cause any unnecessary labor by reason of Tenant&#8217;s carelessness or indifference in the preservation of good order and cleanliness. Landlord shall not be responsible to Tenant for any loss of property on the Premises, however
occurring, or for any damage done to the effects of Tenant by the janitors or any other employee or person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. Tenant shall give Landlord
prompt notice of any defects of which Tenant becomes aware in the water, lawn sprinkler, sewage, gas pipes, electrical lights and fixtures, heating apparatus, or any other service equipment affecting the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Tenant shall not permit storage outside the Premises, including without limitation, outside storage of trucks and other vehicles, or
dumping of waste or refuse or permit any harmful materials to be placed in any drainage system or sanitary system in or about the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Rules and Regulations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 2</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. All moveable trash receptacles provided by the trash disposal firm for the Premises must
be kept in the trash enclosure areas, if any, provided for that purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. No auction, public or private, will be permitted on the
Premises or the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. No awnings shall be placed over the windows in the Premises except with the prior written consent of
Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. The Premises shall not be used for lodging, sleeping or cooking (except that Tenant may use microwave ovens, toasters and
coffee makers in the Premises for the benefit of Tenant&#8217;s employees and contractors in an area designated for such items, but only if the use thereof is at all times supervised by the individual using the same) or for any immoral or illegal
purposes or for any purpose other than that specified in the Lease. No gaming devices shall be operated in the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. Tenant shall
ascertain from Landlord the maximum amount of electrical current which can safely be used in the Premises, taking into account the capacity of the electrical wiring in the Project and the Premises and the needs of other tenants, and shall not use
more than such safe capacity. Landlord&#8217;s consent to the installation of electric equipment shall not relieve Tenant from the obligation not to use more electricity than such safe capacity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. Tenant assumes full responsibility for protecting the Premises from theft, robbery and pilferage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. Tenant shall not install or operate on the Premises any machinery or mechanical devices of a nature not directly related to Tenant&#8217;s
Permitted Use of the Premises and shall keep all such machinery free of vibration, noise and air waves which may be transmitted beyond the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. Tenant shall cause any vendors and other service providers hired by Tenant to perform services at the Premises or the Project to maintain
in effect workers&#8217; compensation insurance as required by Legal Requirements and commercial general liability insurance with coverage amounts reasonably acceptable to Landlord. Tenant shall cause such vendors and service providers to name
Landlord and Alexandria Real Estate Equities, Inc. as additional insureds under such policies and shall provide Landlord with certificates of insurance evidencing the required coverages (and showing Landlord and Alexandria Real Estate Equities, Inc.
as additional insureds under such policies) prior to the applicable vendor or service provider providing any services to Tenant at the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. Neither Tenant nor any of the Tenant Parties shall have the right to photograph, videotape, film, digitally record or by any other means
record, transmit and/or distribute any images, pictures or videos of all or any portion of the Premises or the Project that could identify the Project or the name of the Project, or that identify Landlord or any other tenants or any affiliates of
Landlord or any other tenants. The foregoing is not meant to prohibit individual employees from taking and disseminating photos of themselves or other people within the Premises or at the Project so long as neither the Building nor any proprietary
information, equipment or improvements of Landlord are included within such photos or preclude Tenant from recording the Premises or portions of the Project in which the Premises is located for security purposes with security cameras included as
part of a security system installed by Tenant as part of the Tenant Improvement or as an Alteration pursuant to <U>Section</U><U></U><U>&nbsp;12</U> of the Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. Tenant shall regularly review the guidelines published by the Centers for Disease Control (CDC) and any state and/or local Governmental
Agencies, and will implement the practices and procedures suggested thereby, as well as industry standard best practices, to prevent the spread of Infectious Conditions, including, without limitation,
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Rules and Regulations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 3</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. Landlord shall have the right to (a)&nbsp;require tenants to implement and enforce
reasonable screening and tracking protocols intended to identify and track the activity at the Project of employees, agents, contractors and visitors seeking access to or accessing the Premises and or the Project exhibiting <FONT
STYLE="white-space:nowrap">flu-like</FONT> symptoms or symptoms consistent with those associated with any currently known or unknown Infectious Conditions including, without limitation, <FONT STYLE="white-space:nowrap">COVID-19</FONT> (collectively,
&#8220;<B>Symptoms</B>&#8221;), (b) require tenant employees, agents, contractors and visitors to comply with reasonable screening and tracking protocols implemented by Landlord, Landlord&#8217;s property manager and/or any operator of Project
Amenities, intended to identify and track the activity at the Project of individuals seeking access to or accessing the Premises or the Project (including the Project Amenities) exhibiting Symptoms, (c)&nbsp;require tenants to implement and enforce
protocols to prohibit individuals exhibiting Symptoms, from accessing the Premises and/or the Project, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) require tenants to immediately
report to Landlord incidences of (i)&nbsp;tenant employees, agents, contractors and visitors accessing the Premises or any portion of the Project while exhibiting Symptoms, and/or (ii)&nbsp;tenant employees, agents, contractors and visitors known to
have accessed the Premises or the Project being diagnosed with an Infectious Condition including, without limitation, <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. Landlord may exclude or expel from the Project any person that has Symptoms associated with any currently known or unknown Infectious
Condition including, without limitation, <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. Notwithstanding anything to the contrary
contained herein, if, at any time during the Term, Landlord becomes aware that any Tenant Party exhibiting Symptoms and/or diagnosed with an Infectious Condition had access to the Premises or any portion of the Project (including, without
limitation, the Project Amenities), Tenant shall be responsible for any costs incurred by Landlord to perform additional or deep cleaning of the Premises and/or the Common Areas of the Project or to take other measures deemed reasonably necessary or
prudent by Landlord which are intended to limit the spread of such Infectious Condition due to such Tenant Party&#8217;s presence at the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. Landlord reserves the right to implement additional rules and regulations relating to access to the Premises, the Building and/or the
Project (including, without limitation, the Project Amenities) which are intended to promote and protect health and physical well-being and/or intended to limit the spread of Infectious Conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT&#8217;S PERSONAL PROPERTY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT G TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MAINTENANCE OBLIGATIONS</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp70.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT H TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONTROL ZONES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp71.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 2</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp72.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT I TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RESERVED PARKING </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp73.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT J TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SIGNAGE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp74.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 2</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT K TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXPANSION SPACE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp75.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>10578 Science Ctr./Avidity Biosciences - Page 1</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXPANSION SPACE</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675dsp76.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g42675dsp001a.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</DIV>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>15
<FILENAME>d42675dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#ff4338"><B>Information contained herein is subject to completion or amendment. A Registration Statement
on Form 10 relating<BR> to these securities has been filed with the U.S. Securities and Exchange Commission. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1<BR><BR><BR> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B>PRELIMINARY INFORMATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED FEBRUARY 17, 2026
</B></FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION STATEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g01a01.jpg" ALT="LOGO" STYLE="width:2.25942in;height:0.515739in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Atrium Therapeutics, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Distribution of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$0.001 par value </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This information statement is being furnished to existing stockholders of Avidity Biosciences, Inc. (&#8220;Avidity&#8221;) in connection with the pro rata
distribution (the &#8220;Distribution&#8221;) by Avidity of all the issued and outstanding shares of common stock, par value $0.001 (&#8220;our common stock&#8221; or &#8220;Company Common Stock&#8221;), of Atrium Therapeutics, Inc.
(&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) to holders of Avidity common stock, par value $0.0001 per share (&#8220;Avidity Common Stock&#8221;), as of the Record Date (as defined below). Prior to such
Distribution, Avidity will effect a <FONT STYLE="white-space:nowrap">pre-closing</FONT> reorganization (the &#8220;Separation&#8221;), with such reorganization generally resulting in the Company owning, assuming or retaining all assets and
liabilities of Avidity and its subsidiaries exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, which (as described in more detail below) target rare genetic cardiomyopathies, including
phospholamban and Protein <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Kinase&nbsp;AMP-activated&nbsp;non-catalytic&nbsp;subunit</FONT></FONT> Gamma 2 Syndrome, respectively, and certain collaboration agreements, including those
with Bristol-Myers Squibb Company and Eli Lilly and Company (the &#8220;Company Assets&#8221;), and Avidity owning, assuming or retaining all other assets and liabilities (the &#8220;RemainCo Business&#8221;). As described in this information
statement, the consummation of the Distribution (the <FONT STYLE="white-space:nowrap">&#8220;Spin-Off&#8221;)</FONT> is subject to the satisfaction or waiver by Avidity and the Company of certain conditions set forth in the Separation and
Distribution Agreement, dated as of October&nbsp;25, 2025 (the &#8220;Separation Agreement&#8221;), among Avidity, the Company and Novartis AG, a company limited by shares (<I>Aktiengesellschaft</I>) incorporated under the laws of Switzerland
(&#8220;Novartis&#8221;) (with respect to certain sections therein), including (i)&nbsp;the satisfaction or waiver of certain conditions precedent included in the Agreement and Plan of Merger, dated as of October&nbsp;25, 2025 (the &#8220;Merger
Agreement&#8221;), among Novartis, Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (&#8220;Merger Sub&#8221;), and Avidity, pursuant to which, on the terms and conditions set forth in the Merger
Agreement, Merger Sub will merge with and into Avidity (the &#8220;Merger&#8221;), with Avidity surviving the Merger as an indirect wholly owned subsidiary of Novartis, (ii)&nbsp;the absence of any judgment, ruling, order, writ, injunction, award,
decision, assessment or decree of any governmental authority preventing the consummation of the Separation, the Distribution or the Merger and any law enacted or deemed applicable to any such transaction by any governmental authority of competent
jurisdiction that makes consummation of the Separation, the Distribution or the Merger illegal, and (iii)&nbsp;the execution of documentation effecting transfer of the Third Party Agreements (as defined below) from Avidity to the Company, in form
reasonably satisfactory to Novartis, among others. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement and the Separation Agreement, Avidity may also consummate
a sale of all of the Company to a third party (a &#8220;Permitted Third&nbsp;Party Sale&#8221;), after which, the Distribution would not be effected and cash proceeds received by Avidity, any of its affiliates or the Company from such sale, net of
expenses incurred in connection with or related to the authorization, preparation, negotiation, execution and performance of such transaction and any definitive agreements related thereto would be distributed to Avidity&#8217;s stockholders and
holders of options to purchase shares of Avidity Common Stock (the &#8220;Avidity Stock Options&#8221;) and holders of restricted stock units denominated in shares of Avidity Common Stock, whether subject to time-based or performance-based vesting,
that are granted under any equity plans, agreements or arrangements of Avidity (&#8220;Avidity RSUs&#8221; and together with the Avidity Stock Options, the &#8220;Avidity Equity Awards&#8221;). In addition, the transfer of assets to the Company
includes certain Avidity assets (the &#8220;ROFN Assets&#8221;) that triggered a right of first negotiation (&#8220;ROFN&#8221;) with an existing collaboration partner of Avidity (the &#8220;ROFN Holder&#8221;). Avidity was permitted to negotiate
the sale of Avidity assets subject to the ROFN (&#8220;ROFN Sale&#8221;) with the ROFN Holder, and, if an agreement was reached, consummate the sale of all or a portion of such assets. On February 5, 2026, the negotiation period under the ROFN
expired and, as a result, no ROFN Sale will occur. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Avidity Common Stock as of the close of business, Eastern Time, on February 12, 2026 (the
&#8220;Record Date&#8221;), who do not sell or otherwise dispose of such Avidity Common Stock prior to the close of business on the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of occurrence of the Distribution (the &#8220;Distribution Date&#8221;), will be entitled to receive shares of Company Common Stock pursuant to the Distribution. Each such holder will
receive one share of Company Common Stock for every ten shares of Avidity Common Stock held on the Record Date (the &#8220;Distribution Ratio&#8221;). If you sell shares of Avidity Common Stock up to and including the close of business on the
Distribution Date, you will be selling your right to receive Company Common Stock with respect to those shares in the Distribution to the purchaser of such shares. There will not be any trading of Company Common Stock on a &#8220;when-issued&#8221;
basis or any &#8220;ex-distribution&#8221; trading of Avidity Common Stock before 9:30 a.m., Eastern Time, on the trading day following the Distribution Date (the &#8220;Ex-Dividend Date&#8221;). This means that Company Common Stock will not trade
separately from Avidity Common Stock prior to the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date. For Avidity stockholders who own shares of Avidity Common Stock in registered form on the Record Date through the Distribution Date, the
transfer agent will credit their shares of Company Common Stock to book entry accounts established in their names to hold their shares of Avidity Common Stock. Our distribution agent will send these stockholders a statement reflecting their
ownership of shares of Company Common Stock shortly after the Distribution Date. For stockholders who own shares of Avidity Common Stock through a broker or other nominee, the shares of Company Common Stock received in the Distribution will be
credited to their accounts by the broker or other nominee on or after the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date. Avidity stockholders will receive cash in lieu of fractional shares of the Company. The Distribution will be taxable
to holders of Avidity Common Stock. See &#8220;<I>The Separation and Distribution&#8212;Material U.S. Federal Income Tax Consequences</I> and &#8220;<I>&#8212;No When-Issued Trading or Ex-Distribution Trading</I>&#8221; for further information. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although stockholder approval of the Distribution is not required, such approval is being sought in connection with transactions described in Avidity&#8217;s
Definitive Proxy Statement on Schedule 14A, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on January&nbsp;30, 2026 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39321)</FONT> (as amended or supplemented, the
&#8220;Proxy Statement&#8221;). We are not asking you for any other proxy, and you are requested not to send us any proxy. Avidity stockholders will not be required to pay for Company Common Stock to be received by them in the Distribution, or to
surrender or to exchange Avidity Common Stock in order to receive Company Common Stock, or to take any other action in connection with the Distribution. There is currently no trading market for Company Common Stock. We have applied to list Company
Common Stock on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;RNA,&#8221; which is currently the symbol for the shares of Avidity Common Stock listed on Nasdaq. To facilitate the Distribution and transition of the stock
symbol in connection with the closing of the Merger, Avidity Common Stock will temporarily trade on the Nasdaq Global Market under &#8220;&#8195;&#8195;&#8195;.&#8221; See &#8220;<I>The Separation and Distribution&#8212;No When-Issued Trading or
Ex-Distribution Trading</I>&#8221; for further information. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN REVIEWING THIS INFORMATION STATEMENT, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DESCRIBED
UNDER THE CAPTION &#8220;<A HREF="#toc42675_4">RISK FACTORS</A>&#8221; BEGINNING ON PAGE&nbsp;18. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WE ARE AN EMERGING GROWTH COMPANY AS DEFINED IN THE
JUMPSTART OUR BUSINESS STARTUPS ACT OF 2012 AND A SMALLER REPORTING COMPANY AND WE CANNOT BE CERTAIN IF THE REDUCED REPORTING REQUIREMENTS APPLICABLE TO EMERGING GROWTH COMPANIES AND SMALLER REPORTING COMPANIES WILL MAKE OUR COMMON STOCK LESS
ATTRACTIVE TO INVESTORS. REFER TO &#8220;RISK FACTORS&#8212;RISKS RELATED TO OUR COMMON STOCK.&#8221; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR
ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES OR DETERMINED IF THIS INFORMATION STATEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS INFORMATION STATEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity stockholders with inquiries related to the Distribution should contact our distribution agent, Computershare Trust Company N.A., at (800) 564 6253.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this information statement is February 17, 2026. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_1">PRESENTATION OF INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_2">QUESTIONS AND ANSWERS ABOUT THE SEPARATION AND DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_3">INFORMATION STATEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_5">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_6">THE SEPARATION AND DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_7">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_10">UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_10a">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_11">CORPORATE GOVERNANCE AND MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_13">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_14">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_15">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_16">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_17">INDEMNIFICATION OF DIRECTORS AND OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_18">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_19">CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc42675_20">INDEX TO COMBINED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_1"></A>PRESENTATION OF INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business (as defined below) has not historically operated as a standalone business, and the financial information of the Company Business
contained in this information statement is derived from the consolidated financial statements and accounting records of Avidity. All historical financial information included within this information statement is that of the Company Business and not
of the Company as the Company has had no operations or activity as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Separation and the Distribution, Avidity
expects to assign to the Company, the agreements, leases, licenses and other contracts and assets necessary for the Company to conduct the business described in this information statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was incorporated on September&nbsp;30, 2025 as a wholly owned subsidiary of Avidity and has had no significant operations or activity other than
its initial issuance of shares of Company Common Stock for a nominal consideration and entry into the Separation Agreement and the RemainCo License Agreement (as defined below). Prior to the Distribution, and pursuant to the Separation, Avidity will
undergo an internal reorganization that will generally (as described in more detail below) result in (a)&nbsp;the Company owning, assuming or retaining all assets and liabilities of Avidity and its subsidiaries exclusively related to Avidity&#8217;s
early stage precision cardiology programs, and certain collaboration agreements, including those with <FONT STYLE="white-space:nowrap">Bristol-Myers</FONT> Squibb Company and Eli Lilly and Company (the &#8220;Third Party Agreements&#8221;), and
(b)&nbsp;RemainCo (as defined below) owning, assuming or retaining all other assets and liabilities of Avidity and its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_2"></A>QUESTIONS AND ANSWERS ABOUT THE SEPARATION AND DISTRIBUTION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief summary of the terms of the Separation and Distribution. Please see &#8220;<I>The Separation and Distribution</I>&#8221; for
a more detailed description of the matters described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the Separation and Distribution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The Separation is the method by which Avidity will separate the Company Business from Avidity&#8217;s other business, creating two separate companies. The
Separation will generally result in (i)&nbsp;the Company owning, assuming or retaining all assets and liabilities of Avidity and its subsidiaries exclusively related to Avidity&#8217;s early stage precision cardiology programs, including ATR 1086
and ATR 1072, which target rare genetic cardiomyopathies, including phospholamban and Protein Kinase <FONT STYLE="white-space:nowrap">AMP-activated</FONT> <FONT STYLE="white-space:nowrap">non-catalytic</FONT> subunit Gamma 2 Syndrome, respectively,
and the Third Party Agreements, and (ii)&nbsp;Avidity owning, assuming or retaining all other assets and liabilities of Avidity and its subsidiaries (Avidity following the Separation and Distribution, &#8220;RemainCo&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Distribution, Avidity will distribute to its stockholders as of the Record Date who hold their shares of Avidity Common Stock through the Distribution
Date, on a pro rata basis, all of our common stock. Following the Separation and Distribution, we will be a separate company from RemainCo, and RemainCo will not retain any ownership interest in us. The number of shares of Avidity Common Stock you
own will not change as a result of the Distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What is being distributed in the Distribution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: 15,514,966&nbsp;shares of our common stock will be distributed in the Distribution, based upon 155,149,646&nbsp;shares of Avidity Common Stock outstanding
on February 12, 2026. Company Common Stock to be distributed by Avidity in the Distribution and the shares of Company Common Stock issuable upon vesting of the Make Whole Awards (as defined below) to holders of Avidity Equity Awards pursuant to the
Merger Agreement and Separation Agreement will constitute all of our issued and outstanding common stock immediately after the Separation and Distribution. Fractional shares will be aggregated into whole shares of Company Common Stock and sold in
the public market by the distribution agent and stockholders will receive a cash payment in lieu of a fractional share. For more information on the shares being distributed in the Distribution, see &#8220;<I>Description of Securities</I>.&#8221;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What will I receive in the Distribution? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A:
Holders of Avidity Common Stock will receive a distribution of Company Common Stock equal to one share of Company Common Stock for every ten shares of Avidity Common Stock held by them on the Record Date and through the Distribution Date. As a
result of the Distribution, you will own, as of the effective time of the Distribution, the same percentage of equity securities and voting power in the Company as you own in Avidity. For a more detailed description, see &#8220;<I>The Separation and
Distribution</I>.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What is the record date for the Distribution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Ownership of Avidity Common Stock was determined as of the close of business, Eastern Time, on February&nbsp;12, 2026, which we refer to as the
&#8220;Record Date&#8221;. Holders of Avidity Common Stock as of the close of business on the Record Date who do not sell or otherwise dispose of such Avidity Common Stock prior to the close of business on the Distribution Date will be entitled to
receive shares of Company Common Stock pursuant to the Distribution. Each such holder will receive one share of Company Common Stock for every ten shares of Avidity Common Stock held on the Record Date. If you sell Avidity Common Stock up to and
including the close of business on the Distribution Date, you will be selling your right to receive Company Common Stock in the Distribution. See &#8220;<I>The Separation and Distribution&#8212;No When-Issued Trading or Ex-Distribution
Trading</I>&#8221; for further information. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: When will the Distribution occur? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Subject to the satisfaction or waiver of the conditions to the Spin-Off described below, it is expected that the Distribution will occur
on&#8195;&#8195;&#8195;&#8195; , 2026. We expect trading of shares of Company Common Stock to begin on the trading day following the Distribution Date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What will the relationship between RemainCo and us be following the Distribution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Following the Distribution, we will be a public company and RemainCo will have no continuing ownership interest in us. We and Avidity entered into the
Separation Agreement for the purpose of accomplishing, among other things, the Separation of the Company Business and the Distribution of shares of Company Common Stock to stockholders of Avidity. On October&nbsp;25, 2025, we entered into the
License Agreement with Avidity (the &#8220;RemainCo License Agreement&#8221;), pursuant to which we granted to Avidity certain exclusive and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses under our platform technology and other
intellectual property, and Avidity granted to us certain exclusive and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses under certain RemainCo intellectual property, in each case taking effect upon the effective date of the earlier to
occur of any Permitted Third Party Sale and the Distribution. Concurrently with the Distribution, we will enter into a transition services agreement with RemainCo (the &#8220;Transition Services Agreement&#8221;), pursuant to which we will provide
certain transition services to RemainCo, and RemainCo will provide certain transition services to us. Under the Separation Agreement, Avidity and the Company agreed to indemnify, defend and hold harmless the other party, and its affiliates and
certain representatives, from and after the Distribution Date, from losses in connection with, among other things, (i)&nbsp;the liabilities assigned to, or retained by, the other party, as applicable, and the failure to pay, perform or otherwise
discharge such liabilities, (ii)&nbsp;the breach by such party of the Separation Agreement, and (iii)&nbsp;any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, with respect to all information contained in the&nbsp;registration statement of which this information statement forms a part (the &#8220;Registration Statement&#8221;), this
information statement or the proxy statement filed by Avidity in connection with the Merger (including any amendments or supplements) or any other filings with the SEC made in connection with the transactions contemplated by the Separation Agreement
(in the case of Novartis, only with respect to any such liability arising from information supplied by Novartis or Merger Sub in writing expressly for inclusion in such filings, and in the case of the Company, excluding any such liability to the
extent relating to information supplied by Novartis or Merger Sub in writing expressly for inclusion in such filings). Avidity and the Company, each on behalf of itself and its subsidiaries, and, to the extent permitted by law, all persons who at
any time prior to the Distribution were stockholders, directors, officers, agents or employees of Avidity or the Company or their respective subsidiaries, in each case, together with their respective heirs, executors, administrators, successors and
assigns, agreed to release the other party from, among other things, any and all liabilities existing or arising from any acts or events occurring or failing to occur on or prior to the Distribution, including in connection with the Separation, the
Distribution or any other transactions contemplated under the Separation Agreement, the RemainCo License Agreement and the Transition Services Agreement, and each of Avidity and the Company agreed not to bring any proceeding or claim against the
other party in respect of such liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<I>Certain Relationships and Related Party Transactions&#8212;Related Person Transaction
Policy</I>&#8221; for a discussion of the policy that will be in place for dealing with potential conflicts of interest that may arise from our ongoing relationship with RemainCo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What conditions must be satisfied to complete the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The Spin-Off is subject to the satisfaction or waiver by Avidity and the Company on or prior to the Distribution Date, as applicable, of each of the
following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfaction or, to the extent permitted therein, waiver of the conditions precedent in the Merger Agreement
(with certain exceptions) to the Merger; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any judgment or law prohibiting or making illegal the consummation of the Separation, the
Distribution or the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execution of documentation effecting transfer of the Third Party Agreements from Avidity to the Company, in a
form reasonably satisfactory to Novartis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued effectiveness of the RemainCo License Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execution and delivery of the Transition Services Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Separation having been effected in all material respects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides that Avidity may waive any of the conditions to the Distribution and proceed with the Distribution even if all such
conditions have not been met. Notwithstanding Avidity&#8217;s contractual ability to waive the conditions in the Separation Agreement, Avidity cannot proceed with the Distribution if there is a stop order, injunction or law preventing the
consummation of the Separation or the Distribution, if the Registration Statement is not declared effective by the SEC or if the Registration Statement does not remain effective. However, Avidity could still proceed with the Distribution even if
there is a stop order, injunction or law preventing the consummation of the Merger. See &#8220;<I>The Separation and Distribution&#8212;The Separation Agreement&#8212;Conditions to the Spin-Off&#8221; for more information.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the reasons for the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Avidity&#8217;s board of directors has determined that the separation of our businesses from Avidity&#8217;s other business is in the best interests of
Avidity and its stockholders. The Avidity board of directors considered the following in making the determination to consummate the Distribution: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that stockholders of Avidity would have the opportunity to receive securities of the Company under the
terms and conditions of the Merger Agreement, in addition to the consideration being paid in the Merger, allowing stockholders of Avidity to continue to recognize value from Avidity&#8217;s assets and liabilities related to its early stage precision
cardiology programs and the Third Party Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avidity&#8217;s board of directors&#8217; recognition of the potential value in the assets to be transferred to
the Company in the Separation and that the Distribution provides an attractive option for these assets, including with respect to the potential development and commercialization and future profitability of the early stage precision cardiology
programs and the potential achievement of specified milestones and royalties under the Third Party Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall value of the Merger and the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> in the context of
Avidity&#8217;s current and historical financial condition and results of operations, competitive position, assets, business and prospects and the risks and uncertainties inherent to the research, development, manufacture and commercialization of
Avidity&#8217;s three late-stage clinical programs, delpacibart etedesiran (&#8220;del-desiran&#8221;), delpacibart braxlosiran (&#8220;del-brax&#8221;) and delpacibart zotadirsen (&#8220;del-zota&#8221;) as well as the further research,
development, manufacture and commercialization of its other product candidates and platform, and that the certainty of value and immediate liquidity to Avidity&#8217;s stockholders was compelling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Merger Agreement that was negotiated between Avidity and Novartis contemplated completion of
the Separation and the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> or the consummation of a Permitted Third Party Sale as a condition to the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Separation, in combination with the Merger, provides Avidity&#8217;s stockholders with more <FONT
STYLE="white-space:nowrap">after-tax</FONT> value as compared to a direct sale of the del-desiran, del-brax and del-zota assets by Avidity because the Separation, in combination with the Merger, avoids subjecting the proceeds paid by Novartis for <FONT
STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT STYLE="white-space:nowrap">del-zota</FONT> to the corporate-level income tax that would otherwise apply if Avidity, as opposed to its
stockholders, had received such proceeds on a direct sale of the <FONT STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT STYLE="white-space:nowrap">del-zota</FONT> assets;
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the allocation of certain assets and liabilities related to Avidity&#8217;s early stage precision cardiology
programs and the transfer of the Third Party Agreements to the Company (subject to exceptions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the tax treatment of the Separation, including that the Separation will be a taxable distribution to Avidity
stockholders and that the Company generally will provide a tax indemnity to RemainCo for the Company Indemnified Taxes (as defined below) and RemainCo generally will provide a tax indemnity to the Company for any RemainCo Indemnified Taxes (as
defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the parties have agreed to make an election under Section&nbsp;336(e) of the Internal Revenue Code of 1986,
as amended (the &#8220;Code&#8221;), with respect to the Company, which is expected to result in the Company receiving a fair market value tax basis in its assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, immediately prior to the effective time of the Distribution, Avidity will pay and contribute to
the Company an amount in cash equal to $270&nbsp;million, minus the sum of the amount of marketable securities and cash and cash equivalents contained in any bank and brokerage accounts owned by the Company as of the close of business on the day
prior to the effective time of the Distribution (such net amount, the &#8220;Company Funding&#8221;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the guaranty by Novartis of the performance by RemainCo of its obligations under the Separation Agreement, the
RemainCo License Agreement, the Transition Services Agreement and the occupancy license agreement which RemainCo and the Company may enter into for purposes of shared lab services on or following the effective time of the Distribution (the
&#8220;Occupancy License Agreement&#8221;) following the effective time of the Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<I>The Separation and
Distribution&#8212;Reasons for the Distribution</I>&#8221; for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will the Company be financed? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: In the event of the Distribution, and not in the event of a Permitted Third Party Sale, immediately prior to the effective time of the Distribution, Avidity
will pay and contribute to the Company an amount in cash equal to the Company Funding. However, if the aggregate amount of marketable securities and cash and cash equivalents contained in any bank and brokerage accounts owned by Avidity and its
subsidiaries as of the close of business on the day prior to the effective time of the Distribution is less than the Company Funding (such difference, the &#8220;Company Funding Shortfall&#8221;), then Novartis will cause RemainCo to pay, or pay on
behalf of RemainCo, the Company Funding Shortfall to the Company concurrently with the closing of the Merger. In the event Avidity consummates a Permitted Third Party Sale, Avidity will not be obligated to pay the Company Funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RemainCo&#8217;s liabilities under the Separation Agreement include payment of certain transaction expenses in connection with the Distribution and the
Merger. Except as otherwise set forth in the Separation Agreement, the Transition Services Agreement or the Occupancy License Agreement, RemainCo and the Company will each bear its own costs and expenses incurred after the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: In what event would the Distribution not occur? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A:
Following the Separation, Avidity may consummate a Permitted Third Party Sale, subject to the terms and conditions specified in the Merger Agreement and the Separation Agreement, in place of effecting the Distribution. In the event that Avidity
consummates a Permitted Third Party Sale, Avidity will still effect the Separation, and, generally, the provisions of the Separation Agreement would remain unchanged, except that, among other things, the Distribution would be replaced by
consummation of the Permitted Third Party Sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Avidity consummates a Permitted Third Party Sale, cash proceeds received by Avidity, any of its
affiliates or the Company from such sale, net of expenses incurred in connection with or related to the authorization, preparation, negotiation, execution and performance of such transaction and any definitive agreements related thereto (any such
proceeds and/or any such proceeds received in connection with a Permitted Third Party Sale, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the &#8220;Permitted Sale Proceeds&#8221;), will be distributed to holders of Avidity Common Stock as of the record date used by Avidity for such distribution, on a pro rata basis and subject to
applicable tax withholding. In addition, in the event of a Permitted Third Party Sale, the holders of Avidity Stock Options and Avidity RSUs as of the record date used by Avidity for such distribution will receive a cash payment from the Permitted
Sale Proceeds, subject to applicable tax withholding, equal to the product of the per share amount payable to holders of Avidity Common Stock in such distribution and the number of Avidity Common Stock underlying each such Avidity Equity Award. See
<I>&#8220;Executive Compensation&#8212;Executive Compensation Following the Distribution&#8212;Make Whole Awards&#8221;</I> for additional information relating to the treatment of outstanding Avidity Equity Awards in the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What do I have to do to participate in the Distribution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: No action is required on your part. Stockholders of Avidity on the Record Date who hold shares through the Distribution Date are not required to pay any
cash or deliver any other consideration, including any Avidity Common Stock, for our common stock distributable to them in the Distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What
is the Merger and what effects will it have on RemainCo? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The Merger is the acquisition of RemainCo by Novartis following the Separation and
Distribution, whereupon Merger Sub will be merged with and into RemainCo, the separate existence of Merger Sub will cease, and RemainCo will continue as the surviving corporation and a wholly owned subsidiary of Novartis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the proposal to adopt the Merger Agreement and the Separation Agreement are approved by Avidity&#8217;s stockholders and the other closing conditions under
the Merger Agreement and the Separation Agreement have been satisfied or waived, (i)&nbsp;you will own one share of Company Common Stock for every ten shares of Avidity Common Stock you hold as of the Record Date and through the Distribution Date,
and (ii)&nbsp;each share of Avidity Common Stock issued and outstanding immediately prior to the closing of the Merger (excluding each share of Avidity Common Stock (a)&nbsp;held in the treasury of Avidity, (b)&nbsp;owned by Novartis or Merger Sub,
or owned by any direct or indirect wholly owned subsidiary of Avidity or Novartis immediately prior to the effective time of the Merger, or (c)&nbsp;held by any stockholder who is entitled to demand and has properly and validly demanded their
statutory appraisal right of such shares (&#8220;Avidity Appraisal Shares&#8221;) pursuant to, and who complies in all respects with, Section&nbsp;262 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;) and who, as of
the effective time of the Merger, has neither effectively withdrawn nor lost such appraisal and payment rights with respect to such Avidity Appraisal Shares), will be cancelled and converted automatically into the right to receive an amount in cash
equal to $72.00, without interest and subject to any applicable tax withholdings (the &#8220;Merger Consideration&#8221;). RemainCo will no longer be a publicly held company and the current holders of Avidity Common Stock will no longer have any
interest in the future earnings or growth of RemainCo. In addition, following the completion of the Merger, Avidity Common Stock will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), and RemainCo will no longer file periodic reports with the SEC. The Company will be a separate, publicly held company following the Distribution subject to reporting obligations under the Exchange Act. We have applied to list the
Company Common Stock on Nasdaq under the symbol &#8220;RNA,&#8221; which is currently the symbol for the shares of Avidity Common Stock listed on Nasdaq. To facilitate the Distribution and transition of the stock symbol in connection with the
closing of the Merger, Avidity Common Stock will temporarily trade on the Nasdaq Global Market under &#8220;&#8195;&#8195;&#8195;.&#8221; For more information on the treatment of Avidity Common Stock in the Merger, see the Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will fractional shares be treated in the Distribution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: If you would be entitled to receive a fractional share of our common stock in the Distribution, you will instead receive a cash payment. See &#8220;<I>The
Separation and Distribution&#8212;Manner of Effecting the Distribution</I>&#8221; for an explanation of how the cash payments will be determined. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Can holders of Company Common Stock demand appraisal rights of their shares in connection with the
Distribution? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Holders of Company Common Stock will not be entitled to exercise appraisal rights under the DGCL in connection with the Distribution.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What will govern my rights as a holder of Company Common Stock? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Your rights as a stockholder will be governed by Delaware law, as well as the Amended and Restated Certificate of Incorporation (the &#8220;Certificate of
Incorporation&#8221;) and the Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) of the Company. A description of these rights is included in this information statement under the heading &#8220;<I>Description of Securities</I>&#8221;. The
Certificate of Incorporation is attached as Exhibit 3.1&nbsp;to the Registration Statement and is incorporated by reference into this information statement. The Bylaws are attached as Exhibit 3.2<B>&nbsp;</B>to the Registration Statement and is
incorporated by reference into this information statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will Avidity distribute Company Common Stock to me? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Holders of Avidity Common Stock as of the Record Date who hold their shares of Avidity Common Stock through the Distribution Date will receive Company
Common Stock in book-entry form. Stockholders who own Avidity Common Stock through a broker or other nominee will receive a credit to their accounts by the broker or other nominee for their shares on or after the Ex-Dividend Date. See &#8220;<I>The
Separation and Distribution&#8212;Manner of Effecting the Distribution</I>&#8221; for a more detailed explanation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the material U.S.
federal income tax consequences to me of the Distribution? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Under U.S. federal income tax laws, a U.S. holder (as defined in &#8220;<I>The
Separation and Distribution&#8212;Material U.S. Federal Income Tax Consequences</I>&#8221;) must include in its income as a taxable dividend the fair market value of the Company Common Stock distributable by Avidity to the extent of its current or
accumulated earnings and profits (as determined for U.S. federal income tax purposes). Avidity has not calculated earnings and profits in accordance with U.S. federal income tax principles. Accordingly, U.S. holders should expect to treat the
Distribution as a dividend. Avidity or other applicable withholding agents may be required or permitted to withhold at the applicable rate on all or a portion of the Distribution payable to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders
(as defined in &#8220;<I>The Separation and Distribution&#8212;Material U.S. Federal Income Tax Consequences</I>&#8221;) of the shares of Company Common Stock, and any such withholding would be satisfied by Avidity or such agent by withholding and
selling a portion of the shares of Company Common Stock that otherwise would be distributable to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders or by withholding from other property held in the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s account with the withholding agent. See &#8220;<I>The Separation and Distribution&#8212;Material U.S. Federal Income Tax Consequences</I>&#8221; for further information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Does the Company intend to pay cash dividends? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: We
do not expect to pay any cash dividends on our common stock in the foreseeable future. All decisions regarding the payment of dividends will be made by our board of directors (the &#8220;Board of Directors&#8221;) from time to time in accordance
with applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will Company Common Stock trade? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: There is not currently a public market for shares of Company Common Stock. We have applied to list our common stock on Nasdaq under the symbol
&#8220;RNA,&#8221; which is currently the symbol for the shares of Avidity Common Stock listed on Nasdaq. We expect trading of shares of Company Common Stock to begin on the trading day following the Distribution Date. To facilitate the Distribution
and transition of the stock symbol in connection with the closing of the Merger, Avidity Common Stock will temporarily trade on the Nasdaq Global </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Market under &#8220;&#8195;&#8195;&#8195;.&#8221; See &#8220;<I>The Separation and Distribution&#8212;Listing and Trading of Our Common Stock</I>&#8221;<I> and </I>&#8220;<I>&#8212;No When-Issued
Trading or Ex-Distribution Trading&#8221; </I>for more information on the listing and trading of shares of Company Common Stock following the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Will there be any &#8220;when-issued&#8221; trading of Company Common Stock or any &#8220;ex-distribution&#8221; trading of Avidity Common Stock?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: There will not be any trading of Company Common Stock on a &#8220;when-issued&#8221; basis or any &#8220;ex-distribution&#8221; trading of Avidity
Common Stock before 9:30&nbsp;a.m., Eastern Time, on the trading day following the Distribution Date. This means that Company Common Stock will not trade separately from Avidity Common Stock prior to the Ex-Dividend Date. See &#8220;<I>The
Separation and Distribution&#8212;No When-Issued Trading or <FONT STYLE="white-space:nowrap">Ex-Distribution</FONT> Trading</I>&#8221; for further information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors are encouraged to consult with their financial advisors regarding the specific implications of buying or selling Avidity Common Stock on or before
the Distribution Date. The trading price of Company Common Stock after the Distribution may be lower than the trading price of Avidity Common Stock prior to the Distribution. See &#8220;<I>Risk Factors</I>&#8221; beginning on page&nbsp;18. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Who is the distribution agent for Company Common Stock? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Computershare Trust Company, N.A., will be the distribution agent for Company Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Where can I get more information? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: If you have
questions relating to the mechanics of the Distribution of Company Common Stock, you should contact the distribution agent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any other
questions relating to the Distribution or the Company, you should contact: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atrium Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10578 Science Center Drive, Suite 125 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (619) 876-0700 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_3"></A>INFORMATION STATEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of certain of the information contained in this information statement. This summary is included for convenience only and should not
be considered complete. This summary is qualified in its entirety by more detailed information contained elsewhere in this information statement, which should be read in its entirety. Please refer to the section entitled &#8220;<I>Risk
Factors</I>&#8221; for a discussion of risks related to the Company and the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references to
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221; refer to Atrium Therapeutics, Inc. Where we describe our business activities in this information statement, we do so as if the Separation and Distribution have
already occurred. All historical financial information included within this information statement is that of the Company Business, and not of the Company as the Company has had no operations or activity. Furthermore, we describe our business
activities in this information statement assuming a Permitted Third Party Sale has not and will not occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company pioneering the delivery of ribonucleic acid (&#8220;RNA&#8221;) therapeutics to the heart to transform the standard of care
for people living with cardiomyopathies. Our proprietary technology leverages the targeted RNA delivery platform initially developed at Avidity (the &#8220;RNA delivery platform&#8221;), which combines the tissue selectivity of monoclonal antibodies
(&#8220;mAbs&#8221;) and other targeted delivery ligands with the precision of oligonucleotides. The Company&#8217;s unique combination is designed to allow selective targeting of the underlying genetic drivers of disease that were previously
undruggable. Through targeted, <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery of small interfering RNA (&#8220;siRNA&#8221;) to cardiac tissues, our approach has the potential to overcome key limitations of nonspecific viral and
nanoparticle-based delivery systems, including challenges related to tissue specificity, immunogenicity, and redosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe we are well positioned
to become a leader in precision cardiology given our expertise, strategic partnerships and the RNA delivery platform. The RNA delivery platform, initially developed at Avidity&#8212;in addition to the scientific, clinical and regulatory expertise
that powered Avidity&#8217;s development&#8212;serve as the backbone for our long-term vision: to pioneer precision RNA medicines for the heart and profoundly improve the lives of people impacted by cardiac diseases. We plan to achieve our vision
through a commitment to scientific rigor, patient-centric development, and operational excellence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net losses of the Company Business for the fiscal
years ended December&nbsp;31, 2025 and 2024 were $49.5&nbsp;million and $25.1&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are building a cutting-edge biopharmaceutical company with a focus on precision cardiology and a three-pronged strategic approach: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pioneer precision <FONT STYLE="white-space:nowrap">RNA-based</FONT> therapies that transform the
identification, treatment and care of people with cardiomyopathies by leveraging the RNA delivery platform, our</B> <B>development expertise and our deep understanding of the underlying disease pathophysiology. </B>The RNA delivery platform was
initially developed at Avidity and was used for the first-ever successful targeted delivery of siRNA to the muscle, supporting the advancement of three rare neuromuscular programs into registrational development. We are expanding the reach of the
RNA delivery platform to precision cardiology and are advancing next-generation technology innovations, which we have observed to </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
improve siRNA delivery in cardiac muscle. Our management team, which includes multiple alumni from Avidity, brings deep expertise in identifying targets that are well understood and are believed
to directly address the underlying biology of a disease. Our rigorous target selection process is designed to maximize the probability of technical success in clinical development and prioritizes targets based on high penetrance, clear
genotype-phenotype correlations, and the ability to develop animal models that recapitulate the key features of human disease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Advance a precision cardiology pipeline that achieves proof of concept of RNA delivery to the heart and
addresses the underlying causes of cardiomyopathies, redefining standard of care paradigms.</B> We are prioritizing advancement of our initial product candidates, ATR 1072 and ATR 1086, for the treatment of Protein Kinase <FONT
STYLE="white-space:nowrap">AMP-activated</FONT> <FONT STYLE="white-space:nowrap">non-catalytic</FONT> subunit Gamma 2 (&#8220;PRKAG2&#8221;) syndrome and phospholamban (&#8220;PLN&#8221;) cardiomyopathy, respectively, into the clinic. PRKAG2
syndrome and PLN cardiomyopathy are both severe, life-threatening rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. If supported by positive Phase 1 trial results, we expect to advance ATR
1072 and ATR 1086 into potentially registrational clinical trials while continuing to develop these and other pipeline programs, expanding into broader cardiology indications with high unmet need. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Build a fully integrated company based on our understanding of the unique needs of people with rare diseases
and pave a new path for cardiomyopathies from drug discovery and development through to patient care and clinical practice.</B> Our leadership and management team is comprised of pioneers in RNA medicines with deep scientific and rare disease
expertise. Our employees are dedicated to and guided by transparency, integrity, teamwork, excellence and innovation to help us achieve our mission rapidly, responsibly, and efficiently. We plan to maintain a disciplined approach to capital
allocation and to align program prioritization with the highest probability of technical and clinical success to positively impact patients worldwide. We are focused on employing a patient-first strategy through highly collaborative patient
community engagements and partnerships ensuring their perspectives and insights inform our strategic approach and guide our decision-making. Ultimately, our goal is to rapidly advance our pipeline assets from research and development to
commercialization, providing access to patients and clinicians around the world. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Development Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initially selected genetically validated cardiology targets for our development pipeline. Our precision cardiology pipeline currently consists of two
primary, wholly owned precision cardiology development candidates for the treatment of PRKAG2 syndrome and PLN cardiomyopathy. Each program is designed to address a specific genetic disease or disease mechanism associated with severe
life-threatening forms of heart disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have strategically prioritized rare cardiomyopathies. For our initial programs, we plan to use the same
proprietary mAb targeting TfR1 across our cardiac muscle programs, which we believe gives us significant leverage of development costs and timelines associated with each incremental cardiac muscle program. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pipeline is supported by strong human genetics evidence, robust preclinical data, and a clear path to
clinical development. The chart below represents a summary of our wholly owned development programs. We also have two additional pipeline candidates in research and development targeting undisclosed rare cardiology targets which we may develop in
the future. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g17a01.jpg" ALT="LOGO" STYLE="width:6.30556in;height:1.13209in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Experienced Leadership Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our senior management team has extensive experience in successfully developing and commercializing RNA therapies for rare genetic diseases through their
involvement with major pharmaceutical and biotechnology companies. Our team members have led research, development and <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities in rare diseases, including discovering and developing the
innovative Antibody Oligonucleotide Conjugates (&#8220;AOC&#8221;)<SUP STYLE="font-size:75%; vertical-align:top">TM </SUP>technology. They have collective experience in advancing RNA therapies including gaining alignment with regulatory agencies on
both accelerated regulatory pathways as well as paving global approval paths for rare diseases that require novel endpoints. The team has worked extensively with rare disease patient communities and understands the challenges and opportunities of
rare disease drug development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathleen Gallagher, our Chief Executive Officer, has exceptional executive management expertise and
tenured experience in the biopharmaceutical industry. She has over 20 years of experience and has led investor relations, portfolio strategy, program management and corporate affairs for preclinical to commercial stage companies, including Avidity,
Akcea Therapeutics, Inc. (&#8220;Akcea&#8221;) and Merrimack Pharmaceuticals, Inc. (&#8220;Merrimack&#8221;). She has directed companies through multiple financings and an initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Hughes, M.D.,&nbsp;our Chief Medical Officer, has over 25 years of experience in the biopharmaceutical industry. He has contributed to more than 50
clinical trials and multiple product filings and launches across cardiovascular, neurology and rare disease therapeutic areas at Avidity, Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;), Biogen Inc. (&#8220;Biogen&#8221;), CSL Behring (&#8220;CSL
Behring&#8221;) and Sanofi S.A. (&#8220;Sanofi&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephanie Kenney,&nbsp;our Chief Corporate Affairs Officer, has more than 25 years of experience
in the biopharmaceutical industry leading corporate affairs, investor relations, and marketing at preclinical to commercial stage companies in autoimmune, cardiovascular, and renal therapeutic areas. She has held roles of increasing responsibility
at Avidity, AstraZeneca PLC (&#8220;AstraZeneca&#8221;) and Hansa Biopharma AB (&#8220;Hansa Biopharma&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rocio Martin Hoyos,&nbsp;our Chief
Strategy Officer, is a seasoned strategist with over 20 years of experience in management and commercial roles in the biopharmaceutical industry. She has held leadership positions at Avidity, Audentes Therapeutics Inc. (&#8220;Audentes&#8221;) (now
Astellas Gene Therapies), Celgene Corporation (&#8220;Celgene&#8221;) (acquired by BMS), Kronos Bio, Inc. (&#8220;Kronos Bio&#8221;) (acquired by Concentra Biosciences, LLC) and Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brendan Winslow,&nbsp;our Chief Financial Officer, has extensive experience in financial leadership roles in the biotechnology and healthcare industries. He
has held senior positions involving global operations, commercialization, and strategic transformations at Avidity, Acadia Pharmaceuticals Inc. (&#8220;Acadia&#8221;) and Baxter International Inc. (&#8220;Baxter&#8221;). </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Husam Younis, Ph.D., Pharm.D.,&nbsp;our Chief Scientific Officer, has over 20 years of experience in drug
discovery and development, including in rare disease. He has held senior leadership roles in development science at Avidity, NGM Biopharmaceuticals Inc. (&#8220;NGM&#8221;), Ionis and Pfizer Inc. (&#8220;Pfizer&#8221;). </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Past achievements of our management team may not be indicative of future success. Please see &#8220;Risk Factors&#8221; and &#8220;Corporate Governance and
Management&#8212;Executive Officers&#8221; for further information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal risks and uncertainties affecting our business include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have not operated as a standalone public company, which may make it
difficult for you to evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred losses since inception. We expect to incur significant losses for the foreseeable future. We may
never generate product revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary
capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All of our development programs are in the discovery or preclinical stage. If we are unable to successfully
develop, obtain regulatory approval for and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our approach to the discovery and development of product candidates based on the RNA delivery platform is
unproven as applied to cardiac targets, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render the RNA
delivery platform obsolete. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any difficulties or delays in the commencement or completion, or the termination or suspension, of our ongoing or
planned preclinical studies and planned clinical trials could result in increased costs to us, or delay or limit our ability to generate revenue and adversely affect our commercial prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may find it difficult to enroll participants in some of our clinical trials. If we encounter difficulties
enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of our product candidates could be associated with side effects, adverse events or other properties or safety
risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of approved labeling or result in other significant negative consequences that could
severely harm our business, prospects, operating results and financial condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an organization, we have never submitted an Investigational New Drug Application (&#8220;IND&#8221;),
completed any pivotal clinical trials or submitted a Biologic License Application (&#8220;BLA&#8221;) for regulatory approval and may be unable to do so for any of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming,
and such regulation may cause unanticipated delays or prevent the receipt of the approvals required to commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the
results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our preclinical studies and will rely on third parties to conduct our planned
clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval
for or commercialize our product candidates may be delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties for the manufacture of our product candidates for preclinical development and expect to
rely on third parties for the manufacture of our product candidates for planned clinical development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such
quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on the RemainCo License Agreement to enable our use of certain important intellectual property and data.
If, after the consummation of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> RemainCo ceases to effectively maintain such intellectual property or data, then our business could be materially and adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under certain circumstances, Eli Lilly and Company (&#8220;Lilly&#8221;) or Bristol-Myers Squibb Company
(&#8220;BMS&#8221;) may each unilaterally terminate its respective agreement with us for convenience, which could materially and adversely affect our cash flows. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The commercial success of our product candidates will depend upon the degree of market acceptance of such product
candidates by physicians, patients, healthcare payors and others in the medical community. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition, and if our competitors develop technologies or product candidates more rapidly
than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may face direct competition from Novartis (through its control of RemainCo) in the cardiac space, including
with respect to products that are the subject of the RemainCo License Agreement, including the RNA delivery platform technology, or other products that RemainCo or Novartis may develop independently. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter difficulties in managing our growth and expanding our operations successfully.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and
cost for us to commercialize our product candidates and may affect the prices we may set. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain provisions of the RemainCo License Agreement provide RemainCo rights with respect to development
candidates discovered thereunder, which could limit our ability to engage in certain strategic transactions that stockholders may consider favorable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent protection for our therapeutic programs and other proprietary
technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize
our therapeutic programs and other proprietary technologies we may develop may be adversely affected. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the
section entitled &#8220;<I>Risk Factors</I>.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was incorporated on September&nbsp;30, 2025 under the laws of the State of Delaware as a direct, wholly owned subsidiary of Avidity Biosciences,
Inc. We changed our name from Bryce Therapeutics, Inc. to </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Atrium Therapeutics, Inc. on December 8, 2025. Our corporate headquarters are located at 10578 Science Center Drive, Suite 125, San Diego, CA 92121, and our telephone number is
(619)&nbsp;876-0700. Our investor relations website is located at www.atriumtherapeutics.com. We will make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> proxy statements, our directors&#8217; and officers&#8217;
Section&nbsp;16 reports and any amendments to those reports as soon as reasonably practicable after filing such materials with, or furnishing them to, the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this information statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 12, 2026, we effected a
15,514.966-for-1 forward stock split of Company Common Stock (the &#8220;Forward Stock Split&#8221;) in connection with the Separation and Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references to outstanding shares of Company Common Stock upon consummation of the Distribution (or Spin-Off) or shares distributed
in connection with the Distribution (or Spin-Off) gives effect to the Forward Stock Split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;) enacted in 2012. As an emerging
growth company, we expect to take advantage of reduced reporting requirements otherwise applicable to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may rely on the relief provided by these provisions until the
last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). However,
if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, our annual gross revenues
exceed $1.235&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the Registration Statement of which this information statement is a
part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than that which you might receive from other public reporting companies
in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of an extended
transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We have elected to avail ourselves of this exemption. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company,&#8221; meaning that the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this transaction is less than $700&nbsp;million and our annual revenue is less than $100&nbsp;million during the most
recently completed fiscal year. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations
regarding executive compensation, and the ability to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> We may continue to be a smaller reporting
company as long as either (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most
recently completed fiscal year and the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Separation and Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see
&#8220;<I>The Separation and Distribution</I>&#8221; for a more detailed description of the matters described below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution Ratio</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each holder of Avidity Common Stock will receive a pro rata distribution of one share of our common stock for every ten shares of Avidity Common Stock held on the Record Date and through the Distribution Date. If you sell shares
Avidity Common Stock up to and including the close of business on the Distribution Date, you will be selling your right to receive Company Common Stock with respect to those shares in the Distribution to the purchaser of such shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securities&nbsp;to&nbsp;be&nbsp;Distributed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on 155,149,646 shares of Avidity Common Stock outstanding on February 12, 2026, 15,514,966&nbsp;shares of Company Common Stock would be
distributed. Company Common Stock to be distributed by Avidity in the Distribution and the shares of Company Common Stock issuable upon vesting of the Make Whole Awards to holders of Avidity Equity Awards pursuant to the Merger Agreement and the
Separation Agreement will constitute all of our outstanding common stock immediately after the Distribution. Avidity stockholders will not be required to pay for our common stock to be received by them in the Distribution, or to surrender or
exchange Avidity Common Stock in order to receive our common stock, or to take any other actions in connection with the Distribution. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, in the event of the Distribution, holders of Avidity Equity Awards (subject to certain exceptions for New Hire RSUs and any unvested portion of
the 2026 LTI Awards (each as defined below)) as of the Record Date (including outstanding Avidity Stock Options and Avidity RSUs held by RemainCo&#8217;s directors and executive officers) will receive a non-transferable Make Whole Award that will be
settled in shares of Company Common Stock at a ratio of one share of Company Common Stock for every ten shares of Avidity Common Stock underlying each such Avidity Equity Award, as required by the terms of the Separation Agreement and as permitted
by the SEC&#8217;s Staff Legal Bulletin No.&nbsp;4.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fractional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No fractional shares will be distributed. Fractional shares will be aggregated into whole shares of Company Common Stock and sold in the public market</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="70%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by the distribution agent. The aggregate net cash proceeds of this sale will be distributed ratably to Avidity&#8217;s stockholders who would
otherwise have received fractional interests. These cash proceeds generally will be taxable to</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">those stockholders to the extent the cash received exceeds
the fair market value of the fractional interests of Company Common Stock on the Distribution Date.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution Agent, Transfer Agent and Registrar for the Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Computershare Trust Company, N.A. will be the distribution agent, transfer agent and registrar for our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Record Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The close of business Eastern Time, on February 12, 2026.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to the satisfaction or waiver of the conditions to the Spin-Off described below, it is expected that the Distribution will occur on &#8195;&#8195;&#8195;&#8195;&#8195;, 2026. </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No &#8220;When-Issued&#8221; or <FONT STYLE="white-space:nowrap">&#8220;Ex-Distribution&#8221;</FONT> Trading </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We expect that Company Common Stock will commence trading on a standalone basis on Nasdaq at 9:30 a.m., Eastern Time, on the trading day
following the Distribution Date. There will not be any trading of Company Common Stock on a &#8220;when-issued&#8221; basis or any <FONT STYLE="white-space:nowrap">&#8220;ex-distribution&#8221;</FONT> trading of Avidity Common Stock before the
Ex-Dividend Date. This means that Company Common Stock will not trade separately from Avidity Common Stock prior to the Ex-Dividend Date. See &#8220;<I>The Separation and Distribution&#8212;No When-Issued Trading or Ex-Distribution
Trading</I>&#8221; for further information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material U.S. Federal Income Tax Consequences of the Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under U.S. federal income tax laws, a U.S. holder (as defined in &#8220;<I>The Separation and Distribution&#8212;Material U.S. Federal Income Tax Consequences</I>&#8221;) must include in its income as a taxable dividend the fair
market value of the Company Common Stock distributable by Avidity to the extent of its current or accumulated earnings and profits (as determined for U.S. federal income tax purposes). Avidity has not calculated earnings and profits in accordance
with U.S. federal income tax principles. Accordingly, U.S. holders should expect to treat the Distribution as a dividend. Avidity or other applicable withholding agents may be required or permitted to withhold at the applicable rate on all or a
portion of the Distribution payable to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders (as defined in &#8220;<I>The Separation and Distribution&#8212;Material U.S. Federal Income Tax Consequences</I>&#8221;) of the shares of Company Common
Stock, and any such withholding would be satisfied by Avidity or such agent by withholding and selling a portion of the shares of Company Common Stock that otherwise would be distributable to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holders or by withholding from other property held in the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s account with the withholding agent. See &#8220;<I>The Separation and Distribution&#8212;Material U.S. Federal Income Tax
Consequences</I>&#8221; for further information.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock Exchange Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is not currently a public market for our common stock. We have applied for the shares of our common stock to be listed on Nasdaq under
the symbol &#8220;RNA,&#8221; which is currently the symbol for the shares of Avidity Common Stock listed on Nasdaq. To facilitate the Distribution and transition of the stock symbol in connection with the closing of the Merger, Avidity</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Common Stock will temporarily trade on the Nasdaq Global Market under &#8220;&#8195;&#8195;&#8195;&#8195;.&#8221; We expect trading of shares of Company Common
Stock to</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="70%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">begin at 9:30&nbsp;a.m., Eastern Time on the trading day following the Distribution. See &#8220;<I>The Separation and Distribution&#8212;No When-Issued Trading or Ex-Distribution Trading</I>&#8221; for further information.</TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Relationship between RemainCo and Us after the Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Following the Distribution, we will be a public company and RemainCo will have no continuing ownership interest in us. Prior to the Distribution, we and Avidity entered into the Separation Agreement for the purpose of accomplishing,
among other things, the Separation of the Company Business and the Distribution of Company Common Stock to stockholders of Avidity and the RemainCo License Agreement to enable continued access to certain intellectual property and data.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permitted Third Party Sale </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the Separation and in place of effecting the Distribution, Avidity may consummate a Permitted Third Party Sale, subject to the
terms and conditions specified in the Merger Agreement and the Separation Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If Avidity consummates a Permitted Third Party Sale, the Permitted Sale Proceeds from such sale will be distributed to holders of Avidity Common Stock and Avidity Equity Awards, on a pro rata basis and subject to applicable tax
withholding.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conditions to the Separation and Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Distribution is subject to the satisfaction or waiver by Avidity and the Company on or prior to the Distribution Date, as applicable, of certain conditions, including, among other things, satisfaction or, to the extent permitted
therein, waiver of the conditions precedent in the Merger Agreement (with certain exceptions) to the Merger; the absence of any judgment of law prohibiting or making illegal the consummation of the Separation, the Distribution or the Merger;
execution of documentation effecting transfer of the Third Party Agreements from Avidity to the Company, in a form reasonably satisfactory to Novartis; continued effectiveness of the RemainCo License Agreement; execution and delivery of the
Transition Services Agreement; and the Separation having been effected in all material respects. See &#8220;<I>The Separation and Distribution&#8212;The</I> <I>Separation Agreement</I>&#8221; for more information on the conditions to the Separation
and Distribution.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Separation Agreement provides that Avidity may waive any of the conditions to the Distribution and proceed with the Distribution even if all such conditions have not been met. Notwithstanding Avidity&#8217;s contractual ability
to waive the conditions in the Separation Agreement, Avidity cannot proceed with the Distribution if there is a stop order, injunction or law preventing the consummation of the Separation or the Distribution, if the Registration Statement is not
declared effective by the SEC or if such registration statement does not remain effective. However, Avidity could still proceed with the Distribution if there is an injunction or law preventing the consummation of the Merger. See &#8220;<I>The
Separation and Distribution&#8212;The Separation Agreement&#8212;Conditions to the Spin-Off</I>&#8221; for more information.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Post-Distribution Dividend Policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We do not expect to pay any cash dividends on our common stock in the foreseeable future. All decisions regarding the payment of dividends will be made by the Board of Directors from time to time in accordance with applicable
law.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk Factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stockholders should carefully consider the matters discussed under &#8220;<I>Risk Factors</I>.&#8221;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the following risk factors, together with the other information contained in this information statement, including our
combined financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; We cannot assure you that any of the events discussed in the risk factors below will
not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline substantially. Additional
risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations or financial condition. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and have not operated as a standalone public company, which may make it difficult for you to evaluate the success of
our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a preclinical-stage biopharmaceutical company with a limited operating history
upon which you can evaluate our business and prospects. We were formed in September 2025 as a subsidiary of Avidity in anticipation of the Separation. All of our development programs are in preclinical development or in the drug discovery stage. Our
operations to date have been limited to activities required to effect the Separation and Distribution. We are focused primarily on organizing our company, business planning, identifying product candidates, conducting research and preclinical studies
and ensuring appropriate transition arrangements are in place prior to the Separation. Our approach to the discovery and development of product candidates based on the RNA delivery platform is unproven as applied to cardiac targets, and we do not
know whether we will be able to develop any product candidates that succeed in clinical development or products of commercial value. As a company, we have not yet initiated or completed any clinical trials, obtained regulatory approvals,
manufactured a clinical- or commercial-scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. In addition, we have not yet demonstrated an
ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Consequently, any predictions made about our future success
or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred losses since inception. We expect to incur significant losses for the foreseeable future. We may never generate product revenue or
become profitable, or, if we achieve profitability, we may not be able to sustain it. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any products approved for sale and have not
generated any product revenue since our inception. If our product candidates are not successfully developed and approved, we may never generate any significant revenue. The Company Business&#8217; net losses were $49.5&nbsp;million and
$25.1&nbsp;million for the years ended December&nbsp;31, 2025 and 2024, respectively. As of December&nbsp;31, 2025, the Company Business had a total deficit of $62.7&nbsp;million. Substantially all of the Company Business&#8217; losses have resulted
from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. All of our product candidates will require additional development time and resources, which
would be substantial, before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will
increase as we continue our development of, seek regulatory approval for and potentially commercialize any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To become and
remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and
clinical trials of our product candidates, discovering additional product candidates beyond our current lead product candidates, obtaining regulatory approval for these product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We may never succeed in these activities and, even if we do, may never generate
revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or
when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse
effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms,
or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our preclinical studies for our development programs, prepare for and
conduct our planned clinical trials and seek regulatory approval for our current product candidates and any future product candidates we may develop. If we obtain regulatory approval for any of our product candidates, we also expect to incur
significant commercialization expenses related to product manufacturing, marketing, compliance, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual
amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, following the Distribution, we expect to incur additional costs associated with operating as a standalone public company.
Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We do not have any committed external source of funds or other support for our development efforts. If we are unable to raise capital
when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the Distribution, Avidity will pay and contribute to the Company an amount in cash equal to $270&nbsp;million,
minus the sum of the amount of marketable securities and cash and cash equivalents contained in any bank or brokerage accounts owned by the Company as of the close of business on the day prior to the Distribution Date. Following the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> the Company anticipates the Company Funding, as well as cash generated from our collaboration agreements, will be sufficient to meet our working capital requirements, capital expenditures and other general
corporate purposes for at least twelve months following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and through Phase 1 clinical proof-of-concept for our product candidate, ATR 1072, for the treatment of PRKAG2 syndrome. Whether these
resources are adequate to meet our liquidity needs beyond that period will depend on our growth and operating results. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we
currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, including through public or private equity or
debt financings or other capital resources, such as potentially additional collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we
believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities, which may adversely affect our ability to develop our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors,
including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of researching and developing our current product candidates, as well as
other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining marketing approvals for our current product candidates for
our current and future indications, as well as other product candidates we may develop and pursue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of future indications and product candidates that we pursue and their development requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if approved, the cost of commercialization activities for our current product candidates or any other product
candidate that receive regulatory approval to the extent such costs are not the responsibility of our collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to the receipt of regulatory approval, revenue, if any, received from commercial sales of our current
product candidates or revenues received from any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our organization to achieve our objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, and maintaining and protecting our
intellectual property rights, including enforcing and defending intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other variables with respect to the development of any product candidate could significantly change the costs and
timing associated with the development of that product candidate. Additionally, our operating plans may change or we may experience increased costs and be required to raise additional capital much sooner than anticipated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to raise additional funds will depend on financial, economic and market conditions, the progress and timing of our research and development
programs, the cost and outcome of clinical trials, the level of investment required to establish and operate as an independent public company and other factors, over which we may have no or limited control. Market volatility resulting from
geopolitical and economic instability could also adversely impact our ability to access capital as and when needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may
cause dilution to our stockholders, restrict our operations or require us to relinquish rights to the RNA delivery platform or our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or
other capital sources, including potential additional collaborations, licenses and other similar arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Any future debt financing and preferred
equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring
dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future
revenue streams (including future revenue streams from the BMS Collaboration Agreement and the Lilly Agreement (each as defined below)), research programs, product candidates, or grant licenses on terms that may not be favorable to us and/or that
may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our
product development or future commercialization efforts or grant rights to other parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All of our development programs are in the discovery or preclinical stage. If we are unable to successfully develop, obtain regulatory approval for and
ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our
development programs are in the preclinical or drug discovery stage. We will need to progress our preclinical-stage candidates through IND-enabling studies and receive allowance from the Food and Drug Administration (&#8220;FDA&#8221;), or the
equivalent regulatory authority in other countries, to proceed under an IND, or its equivalent, prior to initiating their clinical development. Our ability to generate product revenues, which we do not expect will occur in the near term, if ever,
will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies with favorable results, including those compliant with Good
Laboratory Practices (&#8220;GLPs&#8221;), toxicology, pharmacokinetic and pharmacodynamic studies in animals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allowance to proceed with clinical trials under INDs by the FDA, or under similar regulatory submissions by
comparable foreign regulatory authorities, for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment of study subjects in clinical trials and completion of clinical trials, in accordance with
applicable regulatory and scientific standards including Good Clinical Practices (&#8220;GCPs&#8221;) with favorable results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating safety, purity, potency and efficacy of our product candidates to the satisfaction of applicable
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections by relevant regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities, including BLAs from the FDA, and
maintaining such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with our third-party manufacturers for, or establishing, clinical and commercial
manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if
and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product
candidates, and defending these items, as required; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining an acceptable safety profile of our products following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting post-approval requirements from regulatory authorities in any jurisdictions in which we commercialize a
product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of people who can develop and commercialize our products and technology.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to develop, obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may
not be able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline and preliminary data from our preclinical studies and future
clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may disclose interim data from our preclinical studies and future clinical trials. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may materially change as participant enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments for their disease.
Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may
publicly disclose preliminary or topline data from our clinical trials and preclinical studies, which is based on a preliminary analysis of then-available data as of certain data cutoff dates, and the results and related findings and conclusions are
subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the
opportunity to fully and carefully evaluate all data. As a result, the preliminary or topline results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once
additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the data we previously published. As a
result, topline and preliminary data should be viewed with caution until the final data are available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies,
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or
commercialization of a particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically a subset
of more extensive and detailed information from the study or trial, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to
disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual
results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects
and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the discovery and development of product candidates based on the RNA delivery platform is unproven as
applied to cardiac targets, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render the RNA delivery
platform obsolete. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on the
proprietary RNA delivery platform, which leverages a novel and unproven approach as applied to cardiac targets. While the RNA delivery platform has produced favorable preclinical and early clinical study results in certain neuromuscular indications
studied by Avidity, we have not yet succeeded and may not succeed in producing final data demonstrating safety, purity or potency for any product candidates in clinical trials or in obtaining marketing approval thereafter. Our research methodology
and approach to oligonucleotide-based therapy may be unsuccessful in identifying additional product candidates, and any product candidates based on the technology platform may not be effective, may be shown to have harmful side effects or may have
other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. We may also be unsuccessful in developing and demonstrating the potential of our product
candidates in our cardiac disease programs, as well as under the BMS Collaboration Agreement and the Lilly Agreement. Further, because all of our product candidates and development programs are based on the RNA delivery platform, adverse
developments with respect to one of our programs, or with respect to RemainCo&#8217;s product candidates developed using the RNA delivery platform, may have a significant adverse impact on the actual or perceived likelihood of success and value of
our other programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future
success will depend in part on our ability to maintain a competitive position with the AOC approach. If we fail to stay at the forefront of technological change in utilizing the RNA delivery platform
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to create and develop product candidates, we may be unable to compete effectively. Our competitors may render the AOC approach obsolete, limit the commercial value of our product candidates by
advances in existing technological approaches or the development of new or different approaches (including, for example, using different mAbs or transporter protein combinations with oligonucleotides than us), potentially eliminating the advantages
in our drug discovery process that we believe we derive from our research approach and proprietary technologies. By contrast, adverse developments with respect to other companies that attempt to use a similar approach to our approach may adversely
impact the actual or perceived value of the RNA delivery platform and potential of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced
to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and
early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical and clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any
preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, we may not be able to meet expected
timeframes for IND submissions. The historical failure rate for product candidates in our industry is high. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from preclinical studies or
clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and early clinical trials. In particular, while we have conducted preclinical trials
in potential product candidates, we do not know whether these product candidates will perform in ongoing or future studies as they have performed in these prior studies. It is not uncommon to observe results in clinical trials that are unexpected
based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. If unexpected observations or toxicities are observed in any of our studies, this will delay clinical
trials for such development programs. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks
in clinical development even after achieving promising results in earlier studies. For the foregoing reasons, we cannot be certain that our ongoing and planned preclinical studies and planned clinical trials will be successful. Any safety concerns
observed in any of our preclinical studies or clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our
business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any difficulties or delays in the commencement or completion, or the termination or
suspension, of our ongoing or planned preclinical studies and our planned clinical trials could result in increased costs to us, or delay or limit our ability to generate revenue and adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to obtain FDA approval to market a new drug we must demonstrate the safety, purity and potency (or efficacy) of our product candidates in humans to
the satisfaction of the FDA. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Clinical testing is expensive, time-consuming and subject to uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can initiate clinical trials for a product candidate, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory
authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IND or similar regulatory filing required for authorization to proceed with clinical development. The FDA or comparable foreign regulatory authorities may require us to conduct additional
preclinical studies for any product candidate before it allows us to initiate clinical trials under any IND or similar regulatory filing, which may lead to delays and increase the costs of our preclinical development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations
may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union (the &#8220;EU&#8221;) has recently evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repealed
the EU Clinical Trials Directive, became applicable on January&nbsp;31, 2022. While the EU Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;) to be submitted in each member state in which the clinical trial
takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to
make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by
all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the
centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January&nbsp;31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.
Compliance with the CTR requirements by us and our third-party service providers, such as contract research organizations (&#8220;CROs&#8221;) may impact our developments plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, even if clinical trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any delays in
the commencement or completion of our ongoing and planned clinical trials for our current and any future product candidates could significantly affect our product development timelines and product development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not know whether our planned clinical trials will begin on time or if our ongoing or future clinical trials will be completed on schedule, if at all.
The commencement, associated data readouts and completion of clinical trials can be delayed for a number of reasons, including delays related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on
trial design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our
clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards (&#8220;IRBs&#8221;) or ethics committees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs or ethics committees refusing to approve, suspending or terminating the trial at an investigational site,
precluding enrollment of additional participants, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our clinical trials are put on clinical hold by a regulatory authority; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participants failing to enroll or remain in our trials at the rate we expect, or failing to return for
post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients choosing an alternative treatment for the indications for which we are developing our product
candidates, or participating in competing clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable
foreign regulatory authorities to temporarily or permanently shut down due to violations of current Good Manufacturing Practices (&#8220;cGMP&#8221;), regulations or other applicable requirements, or infections or cross-contaminations of product
candidates in the manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not
performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCPs or other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or
regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such
trials are being conducted, by a data safety monitoring board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to
conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a
clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In
addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which
may impact the costs, timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials in foreign countries, as we plan to do in
the future, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to the clinical protocol as a result of differences in healthcare
services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks, including war, relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in the completion of, or the termination of, any clinical trial of our product candidates, the commercial prospects of our product
candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product
candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many of the factors
that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. For example, we may make formulation or
manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical or clinical studies to bridge our modified product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates to earlier versions. Any delays that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors
may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll participants in our clinical trials. If we encounter difficulties enrolling participants in our clinical trials, our
clinical development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials for
our product candidates if we are unable to identify and enroll a sufficient number of eligible participants for these trials as may be required by the FDA or similar regulatory authorities outside the United States. Participant enrollment, a
significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of participants to clinical sites, the eligibility and exclusion criteria for the trial, the
design of the clinical trial, the risk that enrolled participants will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and
clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are
investigating as well as any product candidates under development. We will be required to identify and enroll a sufficient number of participants for each of our clinical trials. In addition, the FDA and other regulatory authorities may require that
we have a certain proportion of participants in our trials from the United States or other jurisdictions in order to establish that the clinical trial results are applicable to the relevant patient populations. Potential participants for any planned
clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We are initially developing product candidates targeting rare cardiac conditions with small
patient populations from which to draw for clinical trials. Genetically defined diseases generally, including those for which our current product candidates are targeted, have low incidence and prevalence. We also may encounter difficulties in
identifying and enrolling participants with a stage of disease appropriate for our planned clinical trials and monitoring such participants adequately during and after treatment. In addition, the process of identifying participants may prove costly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timing of our clinical trials depends, in part, on the speed at which we can recruit participants to participate in our trials, as well as completion
of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. The eligibility criteria of our clinical trials, once established, will further limit the group of available trial participants. If patients are unwilling to participate in our
trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of participants, the timeline for
recruiting participants, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of participants for any of our ongoing or future clinical trials would result in
significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our current and future clinical trials and, while we have
entered and will enter into agreements governing their services, we have limited influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that our
assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude
approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of approved labeling or result in other significant negative consequences that could severely harm our business, prospects,
operating results and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with biopharmaceuticals generally, it is likely that there may be side effects and
adverse events associated with the use of our product candidates. Results of our clinical trials could reveal a high and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unacceptable severity and prevalence of side effects or unexpected characteristics. Although other oligonucleotide therapeutics have received regulatory approval, our AOCs, which combine
oligonucleotides with a mAb, are a novel approach to oligonucleotide therapies, which may present enhanced risk and uncertainty for our product candidates compared to more well-established classes of therapies, or oligonucleotide or <FONT
STYLE="white-space:nowrap">mAb-based</FONT> therapies on their own. Moreover, there have been only a limited number of clinical trials involving the use of oligonucleotide therapeutics or the proprietary technology used in the RNA delivery platform.
It is impossible to predict when or if any product candidates we may develop will prove safe in humans. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
and could result in more restrictive labeling or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect participant recruitment or the ability of enrolled
participants to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect
to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which
may limit the commercial prospects for the product candidate if approved. We may also be required to modify our study plans based on findings after we commence our clinical trials. Many compounds that initially showed promise in early-stage testing
have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we test our product candidates in larger, longer and more extensive clinical trials, or as the use of these product candidates becomes more widespread if
they receive regulatory approval, it is possible that illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by
participants. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participants treated with our product candidates may experience previously unreported adverse reactions, and it is possible that the FDA or other regulatory
authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain or maintain approval of our product candidates. If safety problems occur or are identified after our products, if any, reach the market,
we may make the decision or be required by regulatory authorities to amend the labeling of our products, recall our products or even withdraw approval for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such
product, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against
its manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings in labeling, such as a &#8220;black box&#8221; warning or
a contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), including with
limitations on where and how product is distributed, or create a medication guide outlining the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to conduct additional clinical trials or surveillance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly, or the product could become less competitive; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly
harm our business, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As an organization, we have never submitted an IND, completed any pivotal clinical trials
or submitted a BLA for regulatory approval and may be unable to do so for any of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are continuing to develop our product
candidates, and we will need to successfully complete IND-enabling studies for our preclinical product candidates. Following such studies, we will need to successfully complete our planned early-stage clinical trials, and later-stage and pivotal
clinical trials in order to obtain FDA or comparable foreign regulatory approval to market any of our product candidates. Carrying out clinical trials and the submission of a successful BLA is a complicated process. As an organization, we have not
submitted any INDs or comparable foreign filings, have not completed any clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted a BLA or other comparable
foreign regulatory submission for any product candidate. As interactions with the FDA or other regulatory authorities may not be comprehensive, we cannot be certain how many clinical trials of any of our product candidates will be required or how
such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require
more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from, or
delay us in, submitting BLAs or comparable foreign submissions for and commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are subject
to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the approvals required to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preclinical and clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing,
distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in
foreign markets. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the
commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the
FDA and other foreign regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical
development of product candidates, regulatory approval is never guaranteed. Neither we nor any current or future collaborator is permitted to market any of our product candidates in the United States until we receive approval from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial
evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe, pure, potent and effective for their intended uses. Results from
preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable
foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval,
or may object to elements of our clinical development program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product
candidate for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with the design or implementation of our or our collaborators&#8217; clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical
significance required by or otherwise acceptable to the FDA or comparable foreign regulatory agencies for approval, and such authorities may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by
individuals using drugs similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in
countries where the standard of care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any of our current or future collaborators may be unable to demonstrate that a product candidate is safe
and effective, and that product candidate&#8217;s clinical and other benefits outweigh its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not agree that the data collected from clinical trials of our product candidates are
acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or
with other significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may find deficiencies in the manufacturing processes, quality policies or facilities of our
third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulations of such authorities may significantly change in a manner rendering our or any of our potential future
collaborators&#8217; clinical data insufficient for approval; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the
submission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may
involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA
and comparable foreign regulatory authorities in reviewing new drugs and biologics based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or
inability to obtain, applicable regulatory approvals could prevent us or any of our potential future collaborators from commercializing our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may attempt to secure approval from the FDA through the use of the accelerated approval pathway for certain of our product candidates. If we are
unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary regulatory
approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we
have obtained. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future pursue accelerated approval for one or more of our product candidates. Under the accelerated approval program,
the FDA may grant accelerated approval to a product candidate designed to treat a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint
or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible
morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself
a measure of clinical benefit. A surrogate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or
mortality or other clinical benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway may be used in cases in which the advantage of a new biologic over available
therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is contingent on the sponsor&#8217;s agreement to conduct, in a diligent
manner, additional confirmatory studies to verify and describe the biologic&#8217;s predicted clinical benefit. The FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval
being granted. If such confirmatory studies fail to confirm the biologic&#8217;s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to
seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or
approval. Furthermore, if we decide to submit an application for accelerated approval for our product candidates, there can be no assurance that such application will be accepted or that any expedited development, review or approval will be granted
on a timely basis, or at all. The FDA could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review
or approval for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the
marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial
resources, we have focused our attention on a limited number of product candidates. As a result, we may forgo or delay pursuit of opportunities with product candidates that could have had greater potential. Our resource allocation decisions may
cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially
viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licenses and other similar
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits
associated with orphan drug designation, including the potential for market exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including
the United States and Europe, may designate drugs or biologics for relatively small patient populations as orphan drugs. In the United States, the FDA may designate a drug or biologic as an orphan product if it is intended to treat a rare disease or
condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In
the EU, orphan designation is granted by the European Commission based on a scientific opinion of the EMA Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i)&nbsp;the product
is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii)&nbsp;either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b)&nbsp;the
product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for
marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. There can be no assurance that the FDA or European Commission will grant orphan designation for any indication
for which we apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward
clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it
has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same product for the same disease or condition for seven years, except in
limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in the EU, but
such exclusivity period can be reduced to six years if, at the end of the fifth year, a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can
be approved for the same disease or condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve another drug for the same disease or condition if such regulatory authority concludes
that the later drug is clinically superior because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity in the United States may also be lost if the FDA later determines that the initial
request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs containing different active ingredients for the same or similar indication. In addition, if a subsequent
drug is approved for marketing for the same or a similar disease or condition as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan
drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Receipt of Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates may not lead to a faster
development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to
address unmet medical needs for this condition, the sponsor may apply for Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product
development and, once a BLA is submitted, the application may be eligible for priority review if the relevant criteria are met. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of
the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable,
and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Breakthrough Therapy designation may be granted to a drug or biologic that is intended, alone or in
combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biologics that have been designated as Breakthrough Therapies, interaction and communication between the FDA
and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The designation also includes the same benefits as Fast Track
designation, including eligibility for rolling review of a BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether to grant Breakthrough Therapy or Fast Track designation is within the discretion
of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations
for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA review procedures and does not assure ultimate approval by the FDA. In addition,
the FDA may later decide that the product candidate no longer meets the conditions for qualification and rescind granted designations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may
conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could
materially harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may conduct clinical trials for our product candidates outside the United States. Although the FDA may accept
data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the
United States, the FDA will not approve the application on the basis of foreign data alone unless those data are determined to be applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of
recognized competence; and the data are considered valid without the need for an <FONT STYLE="white-space:nowrap">on-</FONT> site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data
through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. For clinical trials that are conducted only at sites outside of the United States and not otherwise subject to an IND, the FDA requires the clinical
trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if it deems such inspection necessary. For such
clinical trials not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the clinical trial design or
protocol for a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which could require us to conduct additional clinical trials. There can be no assurance the FDA will accept data from clinical trials conducted outside of
the United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our
development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting clinical trials outside the United States also exposes us to additional risks, including risks
associated with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA, the USPTO and other government agencies caused by funding shortages, staffing
cuts or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all,
which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA and foreign regulatory authorities to review and approve new products can be
affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s and foreign regulatory authorities&#8217; abilities to hire and retain key personnel and accept the payment
of user fees, and other events that may otherwise affect the FDA&#8217;s and foreign regulatory authorities&#8217; abilities to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent
years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies
may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Furthermore, if the USPTO
experiences significant decreases in funding or personnel, it could significantly impact the ability of the USPTO to timely review and process our regulatory submissions, which could have a material adverse effect on our business. For example, in
recent years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current Trump administration has issued certain
policies and executive orders directed toward reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA and the USPTO, and it remains unclear the degree to which these efforts may limit or otherwise
adversely affect the ability of these agencies to conduct routine activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, if a prolonged government shutdown occurs, or if global health
concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and
process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our preclinical studies and will rely on third parties to conduct our planned clinical trials. If these
third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval for or commercialize our
product candidates may be delayed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dependent on third parties to conduct our preclinical studies and will rely on third parties to conduct
our clinical trials. Specifically, we intend to use and rely on medical institutions, clinical investigators, CROs and consultants to conduct our preclinical studies and clinical trials in accordance with our clinical protocols and regulatory
requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have and will have agreements governing the activities of our
third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our preclinical and clinical trials is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GLP and GCP requirements, which are regulations and
guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in preclinical and clinical development. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors,
principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLPs and GCPs, the clinical data generated in our preclinical and clinical trials may be deemed unreliable, and the FDA or comparable
foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our applications to conduct clinical trials or our marketing applications. In addition, our clinical trials must be conducted with
products produced under cGMP and similar foreign regulations. If we fail to comply with these regulations, we may be required to repeat clinical trials, which would delay the regulatory approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time
and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise perform in a substandard manner, our
clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other biotechnology or biopharmaceutical entities, including our competitors, for whom they may
also be conducting clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our clinical trials are expected to serve as scientific advisors or consultants to us from time to
time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have
affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by
the FDA of any BLA we submit. Any such delay or rejection could prevent us from commercializing our product candidates. Similar risks may exist in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially
reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can
be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties
increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities. We expect to
rely on third parties for the manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. The facilities
used by third-party manufacturers to manufacture our product candidates must be approved by the FDA and any comparable foreign regulatory authority for the manufacture of our product candidates pursuant to inspections that will be conducted after we
submit a BLA to the FDA or any comparable application to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP and similar foreign
requirements for manufacture of products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory
authority, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Our AOCs consist of a proprietary mAb conjugated with an oligonucleotide. All of our mAbs are manufactured by starting with cells
which are stored in a cell bank. We have multiple working cell banks and one master cell bank for our mAbs manufactured in accordance with cGMP, and we believe we would have adequate backup should any cell bank be lost in a catastrophic event.
However, it is possible that we could lose multiple cell banks and have our manufacturing impacted by the need to replace the cell banks. As an independent company, we may need to develop a new cell line to support future clinical and any commercial
manufacturing. We may not be successful in timely developing a cell line which is comparable to those currently used to produce our mAb supply, which could delay our clinical development or commercial efforts. In addition, we have no control over
the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture of our product
candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply
with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, denials of approvals, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates
or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our or a
third party&#8217;s failure to execute our manufacturing requirements on commercially reasonable terms and in compliance with cGMP and similar foreign requirements could adversely affect our business in a number of ways, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate clinical trials of our product candidates under development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize our product candidates, an inability to meet commercial
demands for our product candidates or any other future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to establish any agreements
with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates and any products that we may develop may compete with other product candidates and products for access to
manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial
measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our existing or future
third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit
margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on the RemainCo License Agreement to enable our use of certain important intellectual property
and data. If, after the consummation of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> RemainCo ceases to effectively maintain such intellectual property or data, then our business could be materially and adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> RemainCo will retain all intellectual property and data that was not exclusively related to
cardiology, other than certain platform-related intellectual property that will initially be owned by us (subject to a right of RemainCo to obtain assignment of such intellectual property, subject to a grant-back license to us, as further described
below). The RNA delivery platform was leveraged to develop RNA therapies across multiple disease types. Accordingly, much of the intellectual property and data that is material to our cardiology programs is owned by Avidity, and will be owned by
RemainCo after the consummation of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and subject to certain existing third-party obligations. Therefore, in connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we entered into the
RemainCo License Agreement to enable our continued access to such intellectual property and data. Even though the Separation Agreement granted us term-limited ownership of certain intellectual property covering the RNA delivery platform, the
RemainCo License Agreement provides that we must assign to RemainCo ownership of such intellectual property and intellectual property related to modification or enhancements to the RNA delivery platform that we may develop after the Spin-Off,
without additional compensation, at RemainCo&#8217;s request, following the completion of target selection under (or any earlier termination of) the BMS Collaboration Agreement, or prior to a change of control of the Company. In the event of such
assignment, we would receive (i)&nbsp;an exclusive (including as to RemainCo and its affiliates), worldwide, royalty-free license to exploit products subject to the Lilly Agreement or BMS Agreements (as defined below), and (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-free right to exploit cardiovascular products in the cardiovascular field. In connection with the RemainCo License Agreement, Avidity is, and RemainCo will be, primarily responsible
for the prosecution, maintenance and enforcement of the patents and patent applications (with regards to the RNA delivery platform, following transfer to RemainCo) directed to all such intellectual property. Avidity&#8217;s or RemainCo&#8217;s
failure to file relevant patents that cover intellectual property that is important to our programs, or to prosecute, maintain or enforce intellectual property that is important to our programs, would impair our competitive position and have a
material adverse effect on our business. Further, our business relies on continued access to <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and data that are owned and controlled by Avidity. This reliance pervades various aspects of
our business, including the conduct of research, the performance of clinical trials, the making of scientific publications, and the submitting of regulatory and patent filings. If Avidity or RemainCo fails to provide or maintain the foregoing, then
such failure could have a significant impact on our ability to conduct our programs and have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we currently rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary
technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure
would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Under certain circumstances, Lilly or BMS may each unilaterally terminate its respective agreement
with us for convenience, which could materially and adversely affect our cash flows. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2019, Avidity entered into a Research Collaboration
and License Agreement (the &#8220;Lilly Agreement&#8221;) with Lilly for the discovery, development and commercialization of AOCs directed against certain targets in immunology or the Lilly AOCs. Upon the closing of the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> the Lilly Agreement will be assigned to and assumed by the Company. Lilly granted Avidity a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under certain Lilly technology solely to conduct
research under the Lilly Agreement. Under the Lilly Agreement, Lilly will be solely responsible for funding the cost of clinical development, regulatory approval and commercialization for the Lilly AOCs. Lilly primarily controls the development and
commercialization activities, pursuant to the terms of the Lilly Agreement, and our lack of control over such activities could result in delays or other difficulties in the development and commercialization of the Lilly AOCs. Any dispute with Lilly
may result in the delay or termination of the development or commercialization of the Lilly AOCs, and may result in costly litigation that diverts our management&#8217;s attention and resources away from our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and which may adversely affect our business, financial condition, results of operation and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, Avidity entered into an agreement with BMS (the &#8220;BMS Collaboration Agreement&#8221;) for the development of compounds directed to up
to five targets using our RNA delivery platform (such compounds, the &#8220;BMS AOCs&#8221;). The BMS Collaboration Agreement will be assigned to and assumed by the Company upon closing of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Under
the BMS Collaboration Agreement, the Company will be responsible for conducting research activities for a designated period of time at its cost, subject to the parties renegotiating the research activities in case the Company&#8217;s research
spending is anticipated to exceed $50.0&nbsp;million. BMS will be solely responsible for funding all future clinical development, regulatory and commercialization activities for the BMS AOCs. Any dispute with BMS may result in the delay or
termination of the research, development or commercialization of the BMS AOCs, either on an individual target basis or collectively, and may result in costly litigation that diverts our management&#8217;s attention and resources away from our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and which may adversely affect our anticipated cash flows, business, financial condition, results of operation and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Lilly or BMS may unilaterally terminate the Lilly Agreement or the BMS Collaboration Agreement, respectively (including for convenience), and in
either such event, we would be prevented from receiving any research and development funding, milestone payments, royalty payments and other benefits under the respective agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any decision by Lilly or BMS to terminate the Lilly Agreement or the BMS Collaboration Agreement, respectively, may negatively impact public
perception of our AOC product candidates, which could adversely affect the market price of our common stock. We cannot provide any assurance with respect to the success of the collaborations with Lilly or BMS. Any of the foregoing events could have
a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have entered, and may seek to enter into
additional collaborations, licenses and other similar arrangements which are important to our business. If we are not successful in doing so, or if we are and we relinquish valuable rights or fail to realize the benefits of such relationships, our
business could be materially and adversely affected.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into the RemainCo
License Agreement, the Lilly Agreement and the BMS Collaboration Agreement. We may seek to enter into additional collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product
candidates, or those of potential strategic partners, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. We may not be successful in our efforts to establish or maintain such collaborations
for certain product candidates because our research and development pipeline may be insufficient, the product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view the product
candidates as having the requisite potential to demonstrate safety and efficacy or significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. We may have to
relinquish valuable rights to our future revenue streams, research programs, product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into
additional agreements with other potential collaborators. We cannot be certain that, following a collaboration, license or strategic transaction, we will achieve an economic benefit that justifies such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the RemainCo License Agreement granted us rights to certain of RemainCo&#8217;s intellectual property that are important to our business, and
which imposes certain obligations and restrictions that could impact our anticipated cash flows. The RemainCo License Agreement contains provisions that restrict our ability to develop or commercialize products that are competitive with those
licensed to RemainCo and that require us to share certain intellectual property rights. Pursuant to the terms of the RemainCo License Agreement, for a period of five years following the RemainCo License Agreement&#8217;s effective date, we may not
engage in any RNA therapeutics business, other than with respect to cardiovascular products in the cardiovascular field (each as defined in the RemainCo License Agreement) or products subject to the Lilly Agreement or BMS Collaboration Agreement
regardless of whether such activities use any of RemainCo&#8217;s intellectual property. Additionally, we may only exploit the RNA delivery platform for the development of cardiovascular products in the cardiovascular field or products subject to
the Lilly Agreement or BMS Collaboration Agreement; therefore, even following expiration of this five-year period, we will not have the right to use the RNA delivery platform for programs in other therapeutic areas, and would need to independently
develop or acquire the technology to be used in such programs. The terms of the BMS Collaboration Agreement similarly restrict us from developing or commercializing products that are competitive with those licensed to BMS and the Lilly Agreement
restricts our ability to research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the Lilly Agreement. For a period of ten years following the RemainCo License Agreement&#8217;s
effective date, the RemainCo License Agreement also grants RemainCo a right of first negotiation over our development candidates and prospective transactions, in each case, other than with respect to cardiovascular products or products subject to
the Lilly Agreement or BMS Collaboration Agreement. If we do not consummate a transaction with RemainCo with respect to any such transaction and the negotiation period expires, we must notify RemainCo of any proposed third-party transaction we
desire to enter into in the twelve months following the expiration of the applicable negotiating period (the &#8220;MFN&#8221;) with respect to such transaction, that is on terms less favorable to us than RemainCo&#8217;s last offer. Following the
receipt of such notice, RemainCo may accept the Company&#8217;s offer to enter into the transaction on the terms of the last written offer proposed by RemainCo, make a new offer, which we must consider in good faith, or inform us that RemainCo is no
longer interested in pursuing a transaction. As a result of the foregoing and other restrictions we may be subject to, we may be unable to pursue the development of promising product candidates and may be required to redirect our business focus. Any
restriction on our ability to develop or commercialize products pursuant to the RemainCo License Agreement, including as a result of RemainCo&#8217;s exercise of its right of first negotiation or the MFN, could negatively impact our ability to enter
into new strategic partnerships for our product candidates, and could have a material adverse impact on our financial condition, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, following the closing of the Merger, RemainCo will be owned by Novartis, a large, well-capitalized pharmaceutical company with significant
resources and experience in the development and commercialization of cardiology products. The RemainCo License Agreement provides RemainCo a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, irrevocable, royalty-free license under
the RNA delivery platform technology to exploit any cardiovascular products other than products subject to the Lilly Agreement or BMS Collaboration Agreement. As a result, we may face direct competition from RemainCo in the cardiac space, including
with respect to products that are the subject of the RemainCo License Agreement or other products that RemainCo or Novartis may develop independently. RemainCo and Novartis may have greater financial, technical, and marketing resources than we do,
and may be able to devote substantially more resources to the development, commercialization, and marketing of competing products. This competition could limit our ability to successfully commercialize our product candidates, reduce our market
share, and adversely impact our revenues and profitability. Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us, and we may not be able to maintain our current or any future collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate
is questioned or the sales of an approved product candidate are unsatisfactory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, future collaborations may be terminable by our strategic
partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product
candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the
development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to
comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following potential approval of any our product candidates, the FDA and foreign regulatory authorities may impose significant restrictions on a product&#8217;s
indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a
REMS as a condition of approval of our product candidates, or to maintain any approval after received, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as
restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging,
distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other
post-marketing information and reports, registration, as well as continued compliance with cGMPs, GCP and similar foreign requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our
products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of approval of the product or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved
applications filed by us or suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require
us to expend significant time and resources in response and could generate negative publicity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates for which we intend to seek approval as biologic products may face competition
sooner than anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Affordable Care Act (the &#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation
Act of 2009 (the &#8220;BPCIA&#8221;) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under
the BPCIA, an application for a &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not
be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of
the reference product if the FDA approves a full BLA for the competing product containing such company&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the
<FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be
reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way
that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients,
healthcare payors and others in the medical community. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates may not be commercially successful. Even if any of our product
candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend significantly
on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of clinical efficacy and safety compared to other more-established products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indications for which our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in
relation to alternative treatments and therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government
healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our products as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our or any of our current or potential future collaborators&#8217; sales and marketing
strategies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians,
hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products
may require significant resources and may never be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. If we are found or alleged to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if any of our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory
requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the
product&#8217;s approved labeling, and promotion must include appropriate disclosure of information on the safety risks of our products. If we receive marketing approval for a product candidate, physicians may nevertheless, in their independent
medical judgment, prescribe it to their patients in a manner that is inconsistent with the approved label. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#8217;s
communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, or if we are found not to have complied with
other requirements for advertising and promotion of our products, we may become subject to onerous government investigations and significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health
insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability
to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and
Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of
reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Moreover, we are initially developing product candidates targeting rare and genetically defined cardiac diseases
with small patient populations and expect to expand into broader patient populations thereafter. In order for products that are designed to treat smaller patient populations to be commercially viable, the pricing and reimbursement for such products
must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate with a smaller patient population that accounts for the smaller
potential market size. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find
unacceptably high. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate
reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors,
including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third- party payors
will decide with respect to the coverage and reimbursement for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that coverage and reimbursement in the United States, the
EU or elsewhere will be available for any product that we may develop, and that any coverage will be adequate. Further, any reimbursement that may become available may be decreased or eliminated in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and
Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among
third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require
us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and
regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third- party payors may refuse to provide
coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the
less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors
may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If
reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying
price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing
regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to
generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad
to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to
experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on
healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are
more effective, our business and our ability to develop and successfully commercialize products may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and
biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop
products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.
We believe that a significant number of products are currently under development, and may become commercially available in the future, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition amongst RNA targeted therapies. Our competitors include larger and
better funded pharmaceutical, biopharmaceutical, biotechnological, therapeutics companies and specialized cardiovascular treatment companies. Moreover, we may also compete with universities and other research institutions who may be active in the
indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our
ability to execute our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, we will face competition from Novartis, a large, multinational pharmaceutical company with
substantial resources and a well-established presence in the development and commercialization of cardiology products, which following the Closing, will own RemainCo. The RemainCo License Agreement provides RemainCo a non-exclusive, worldwide,
irrevocable, royalty-free license under the RNA delivery platform technology to exploit any cardiovascular products other than products subject to the Lilly Agreement or BMS Collaboration Agreement. As a result, we may face direct competition from
RemainCo in the cardiac space, including with respect to products that are the subject of the RemainCo License Agreement or other products that RemainCo or Novartis may develop independently. The greater financial, technical, and marketing resources
available to RemainCo and Novartis may enable them to advance competing cardiac products more rapidly or effectively than we can, potentially limiting our ability to gain or maintain market share in this therapeutic area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will also face competition in establishing clinical trial sites, enrolling participants for clinical trials and in identifying and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our clinical
trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition could reduce the number and types of participants available to us, because some participants
who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same
clinical trial sites that some of our competitors use, which could reduce the number of participants who are available for our clinical trials in such clinical trial site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to face competition from existing products and products in development for each of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to
develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Inc., Aro Biotherapeutics Company, Dyne Therapeutics, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, PepGen, PeptiDream Inc. and AstraZeneca
plc, as well as gene therapy and CRISPR approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with strategic partners, have substantially greater
financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and
achieving widespread market acceptance, which could render our product candidates, if approved, obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Merger and acquisition activity in the biotechnology and biopharmaceutical
industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial
sites and participant registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our
comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products, if
approved. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of other drugs. The key competitive factors affecting the
success of our programs are likely to be their efficacy, safety profile, convenience, level of promotional activity, intellectual property protection and availability of reimbursement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The precise incidence and prevalence for all the conditions we aim to address with our product candidates targeting cardiomyopathies are unknown.
Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These
estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or
prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates approved for sale
for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing
and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become
increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential
target populations are very small, we may never achieve profitability despite obtaining such significant market share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no
marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter
into agreements with third parties to market and sell our products, we may not be able to generate product revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no internal sales,
marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting
distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our
own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks
involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a
geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter
into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower
if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary
resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future
product revenue and we would incur significant additional losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be
subject to additional regulatory burdens and other risks and uncertainties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and
commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never
receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among
other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to
additional risks and uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to
fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate significantly, which makes it
difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development, regulatory approval and
commercialization activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the
terms of our agreements with third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of the milestone or other payments we may receive under our current or future research and
collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any approved products, which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result,
comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our future
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or
investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of
analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue, earnings or other guidance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or
recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in part on our continued ability
to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, as well as our senior scientists and other members of our management team. The loss of services of
any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our preclinical studies and clinical trials or the commercialization of our product candidates. Although we expect to
execute employment agreements or offer letters with each member of our senior management team, these agreements will be terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical
development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified
personnel among biopharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain
and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement
and execute our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties in managing our growth and expanding our operations successfully. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Distribution, we expect to have 47 total employees, all of whom will be full-time employees upon the closing of the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> As we continue development and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to expand our financial, development, regulatory,
manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers
and other third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively
will depend, in part, on our ability to manage any future growth effectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to various federal, state and foreign healthcare laws and regulations, which could
increase compliance costs, and our failure to comply with these laws and regulations could harm our results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose
us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how
we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and
willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order
of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary
penalties laws prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or
statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a
claim including items or services resulting from a violation of the federal Anti-Kickback Statute, or from improper advertising or promotion of an item or service, constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil monetary penalties laws, impose civil fines for, among other things, the offering or transfer
of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by
Medicare or a state healthcare program, unless an exception applies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), created additional
federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up
a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services (&#8220;CMS&#8221;)
information related to payments or other transfers of value made during the previous year to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers including, among others,
physician assistants and nurse practitioners, and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held during the previous year by physicians
as defined under statute and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some state laws that require biotechnology companies to report information on the pricing of certain drug
products; and some state and local laws require the registration or pharmaceutical sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our
current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices
may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs,
such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions
can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of
the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions
from government funded healthcare program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted legislation, future legislation and healthcare reform measures may increase the
difficulty and cost for us to commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign
jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and
reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state
levels that seek to reduce healthcare costs and improve the quality of healthcare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, in March 2010, the ACA was enacted in the United States,
which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. ACA provisions of importance to our product candidates established an annual, nondeductible
fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; expanded the entities eligible for enrollment in the 340B program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new Patient-Centered Outcomes Research Institute
to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery
models to lower Medicare and Medicaid spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects
of the ACA, and on June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in force in
its current form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate
reductions to Medicare payments to providers, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032. On </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. On March&nbsp;11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate
cap, as of January&nbsp;1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other
things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most significantly, in August 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;). This statute marks the most
significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be
negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D
coverage gap discount program with a new manufacturer discount program (beginning in 2025). CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15
drugs that will be subject to negotiation. The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS
has and will continue to issue and update guidance as these programs are implemented, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot
yet be fully determined, it is likely to be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in implementing
regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. Some states have also enacted legislation creating <FONT STYLE="white-space:nowrap">so-called</FONT> prescription drug affordability boards, which ultimately may attempt to
impose price limits on certain drugs in these states. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare
programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare
reimbursement and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to participate in the Medicaid Drug Rebate Program and other governmental pricing
programs. If we fail to comply with our reporting and payment obligations under any programs we participate in, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect
on our business, financial condition, results of operations and growth prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medicaid is a joint federal and state program administered by
the states for low income and disabled beneficiaries. Manufacturers that participate in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;), have certain price reporting obligations as a condition of having their covered outpatient drugs payable
under Medicaid and, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable, under Medicare Part B. The MDRP requires the manufacturer to pay a rebate to state Medicaid programs every quarter for each unit of its covered outpatient drugs dispensed to Medicaid
beneficiaries and paid for by a state Medicaid program. The rebate is based on pricing data that the manufacturer must report on a monthly and quarterly basis to CMS, the federal agency that administers the MDRP and other governmental healthcare
programs. These data include the average manufacturer price (the &#8220;AMP&#8221;) for each drug and, in the case of innovator products, the best price, which in general represents the lowest price available from the manufacturer to certain
entities in the U.S. in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. The Medicaid rebate consists of two components, the basic rebate and the additional rebate, which is
triggered if the AMP for a drug increases faster than inflation. If the manufacturer becomes aware that its MDRP government price reporting submission for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data,
it must resubmit the corrected data for up to three years after those data originally were due. If the manufacturer fails to provide information timely or is found to have knowingly submitted false information to the government, it may be subject to
civil monetary penalties and other sanctions, including termination from the MDRP. In the event that CMS terminates the manufacturer&#8217;s rebate agreement pursuant to which the manufacturer participates in the MDRP, no federal payments would be
available under Medicaid or Medicare Part B for its covered outpatient drugs. If we participate in the MDRP, our failure to comply with MDRP price reporting and rebate payment obligations could negatively impact our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Medicare Part B, a pharmaceutical manufacturer must provide CMS with average sales price (ASP) information for its drugs or biologicals
payable under Part B on a quarterly basis. ASP is calculated based on a statutorily defined formula, as well as regulations and interpretations of the statute by CMS. CMS uses this information to compute Medicare Part B payment rates, which consist
of ASP plus a specified percentage. The Part B payment rate is the amount that CMS reimburses the provider for drugs and biologicals administered to Medicare beneficiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IRA imposes rebates under Medicare Part B and Medicare Part D that are triggered by price increases that outpace inflation (first due in 2023), as
described under the risk factor &#8220;&#8212;<I>Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to commercialize our product candidates and may affect the prices we may
set</I>,&#8221; above. The Medicare Part D rebate, if applicable, will be calculated on the basis of the AMP figures we will be required to report pursuant to the MDRP if we enroll in the MDRP. The Medicare Part B rebate, if applicable, will be
calculated on the basis of the Part B payment rate, which in turn is based on the reported ASP figures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Federal law requires that any company that
participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and, if applicable, Medicare Part B. We intend to
participate in the 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), and will require us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for
our covered outpatient drugs that receive approval. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a
disproportionate share of low income patients. The ACA expanded the list of covered entities to include certain free standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, but exempts &#8220;orphan
drugs&#8221; from the ceiling price requirements for these covered entities. The 340B ceiling price is calculated using a statutory formula based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP, and in
general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. If we enroll in the 340B program, we must report 340B ceiling prices to HRSA on a quarterly
basis, and HRSA publishes those prices to 340B covered entities. In addition, HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and
intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized a revised regulation implementing an administrative dispute resolution process through which 340B covered entities may pursue claims against participating
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. If we
enroll in the 340B program, our failure to comply 340B program requirements could negatively impact our financial results. Any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under legislation
or regulation could affect our 340B ceiling price calculations and also negatively impact our financial results if we enroll in the 340B program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order for any product candidates, if approved, to be paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also intend to participate in the U.S. Department of Veterans
Affairs (the &#8220;VA&#8221;) Federal Supply Schedule (the &#8220;FSS&#8221;) pricing program. As part of this program, we will be required to make our products, if approved, available for procurement on an FSS contract under which we must comply
with standard government terms and conditions and charge a price that is no higher than the statutory Federal Ceiling Price (&#8220;FCP&#8221;) to four federal agencies (VA, U.S. Department of Defense (&#8220;DOD&#8221;), Public Health Service, and
U.S. Coast Guard). The FCP is based on the <FONT STYLE="white-space:nowrap">Non-Federal</FONT> Average Manufacturer Price <FONT STYLE="white-space:nowrap">(&#8220;Non-FAMP&#8221;)</FONT> which we will be required to calculate and report to the VA on
a quarterly and annual basis. Pursuant to applicable law, knowing provision of false information in connection with a <FONT STYLE="white-space:nowrap">Non-FAMP</FONT> filing can subject a manufacturer to significant civil monetary penalties for each
item of false information. The FSS pricing and contracting obligations also contain extensive disclosure and certification requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also intend
to participate in the Tricare Retail Pharmacy program, under which we will be required to pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to Tricare beneficiaries. The rebates
are calculated as the difference between the annual <FONT STYLE="white-space:nowrap">Non-FAMP</FONT> and FCP. We will be required to list our innovator products on a Tricare Agreement in order for them to be eligible for DOD formulary inclusion. If
we participate in the program and overcharge the government in connection with our FSS contract or Tricare Agreement, whether due to a misstated FCP or otherwise, we will be required to refund the difference to the government. Failure to make
necessary disclosures and/or to identify contract overcharges could result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or
enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects if we enroll in the program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and
combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements of pharmaceutical manufacturers under such laws include advance notice of planned price
increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation
could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements,
including the untimely, inaccurate, or incomplete reporting of drug pricing information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary among products and
programs. The calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. CMS, the Department of Health&nbsp;&amp; Human Services Office of Inspector General, and other governmental
agencies have pursued manufacturers that were alleged to have failed to report these data to the government in a timely or accurate manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of
participation, some of which may have implications for amounts previously estimated or paid. If we enroll in the government pricing programs, we cannot assure you that any submissions we are required to make under the MDRP, the 340B program, the
VA/FSS program, the Tricare Retail Pharmacy Program, and other governmental drug pricing programs will not be found to be incomplete or incorrect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be
required to limit commercialization of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and professional indemnity risks as a result of
the clinical trials of our product candidates and will face an even broader risk if we commercialize our product candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a
drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial
liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects or identify patients who should not use our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, clinical study,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of
warranties. Claims may be brought against us by clinical trial participants, patients, healthcare providers, pharmaceutical companies or others using, administering or selling products that may be approved in the future. Claims could also be
asserted under state consumer protection acts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have agreed to indemnify the licensors of the intellectual property related to our product
candidates against certain intellectual property infringement claims. Any claims against us, or with respect to which we are obligated to provide indemnification, regardless of their merit, could be difficult and costly to defend or settle, and
could compromise the market acceptance of our product candidates or any prospects for commercialization of our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we
cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and
management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#8217;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant negative financial impact; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in our stock price. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies may be expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to have product liability insurance coverage once we enter into clinical development. In addition, we may need to increase our insurance
coverage as we expand our clinical trials or if we commence commercialization of our product candidates. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an amount
adequate to satisfy any liability that may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the
commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance
or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. If a successful product liability claim or
series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include property, general
liability, employment benefits liability, business automobile, workers&#8217; compensation, malicious invasion of our electronic systems, directors&#8217; and officers&#8217;, employment practices, fiduciary liability, and product liability
insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business, including preclinical studies and planned clinical trials, and financial condition, are subject to risks
arising from pandemic and epidemic diseases. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> worldwide pandemic presented substantial public
health and economic challenges and affected patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. Any future pandemic or epidemic diseases may cause
disruptions that could severely impact our business, preclinical studies, clinical trials and financial condition, including impairing our ability to raise capital when needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The extent to which any other outbreak of a pandemic or epidemic disease impacts our results will depend on future developments that are highly uncertain and
cannot be predicted, including new information that may emerge concerning the severity of the incident and the actions to contain its impact. Further, to the extent any pandemic or epidemic disease adversely affects our business and financial
results, it may also have the effect of heightening many of the other risks described in this section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be affected by
litigation, government investigations and enforcement actions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to operate in a number of jurisdictions in a highly regulated industry
and we could be subject to litigation, government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability,
environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings which may arise from conducting our business. Any determination that our operations or
activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and
remediation of any such findings could have an adverse effect on our business operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal proceedings, government investigations and enforcement
actions can be expensive and time consuming. An adverse outcome resulting from any such proceeding, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs,
healthcare debarment, injunctive relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants and
vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed
to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or
negligent conduct or disclosure of unauthorized activities to us that violate: (i)&nbsp;the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate
information to such authorities, (ii)&nbsp;manufacturing standards, including cGMP requirements, (iii)&nbsp;federal and state data privacy, security (including cybersecurity), fraud and abuse and other healthcare laws and regulations in the United
States and abroad or (iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of
clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always
possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to maintain compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct,
even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without
limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment,
contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as asset purchases or sales and licensing of intellectual property, products or
technologies. For example, we have collaborations with Lilly and BMS pursuant to which we have granted them licenses to our intellectual property in connection with certain targets. Additional potential transactions that we may consider in the
future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near- and long-term
expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired <FONT STYLE="white-space:nowrap">in-process</FONT>
research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These transactions may never be successful and may require significant time and attention of our management. In addition, the integration of any
business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we
will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions of the RemainCo License Agreement provide RemainCo rights with respect to
development candidates discovered thereunder which could limit our ability to engage in certain strategic transactions that stockholders may consider favorable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RemainCo License Agreement provides RemainCo a right of first negotiation over our development candidates and prospective transactions that would give a
third party the right to acquire, develop, commercialize or promote any pharmaceutical, biological or other drug product, in each case, other than with respect to cardiovascular products or products subject to the Lilly Agreement or BMS Agreements.
If we do not consummate a transaction with RemainCo with respect to any such transaction and the negotiation period expires, we must notify RemainCo of any proposed third-party transaction we desire to enter into in the twelve months following the
expiration of the applicable negotiating period with respect to such transaction, that is on terms less favorable to us than RemainCo&#8217;s last offer. Following the receipt of such notice, RemainCo may accept the Company&#8217;s offer to enter
into the transaction on the terms of the last written offer proposed by RemainCo, make a new offer, which we must consider in good faith, or inform us that RemainCo is no longer interested in pursuing a transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the foregoing or under any other strategic partnerships that we enter into in the future, third parties may be unwilling or unable to
consummate any strategic transactions with us on terms acceptable to us or at all. The inability to consummate any such transaction and the perception that we may not be able to do so may materially and adversely impact the price of shares of
Company Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inflation could adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From 2021 to 2024, the U.S. economy experienced a material level of inflation. The impact of geopolitical developments, such as the conflicts in Ukraine and
the Middle East may continue to increase uncertainty in the outlook of near-term and long-term economic activity, including any impacts on inflation. Increases in inflation raise our costs for commodities, labor, materials and services and other
costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along with the uncertainties surrounding geopolitical developments
and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional
financing. Historically, the stock prices of companies in our industry have been highly sensitive to actual or anticipated changes in the interest rate environment. A failure to adequately respond to these risks could have a material adverse impact
on our financial condition, results of operations or cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We, our collaborators and our service providers may be subject to a variety of
data privacy and security laws and contractual obligations, which could increase compliance costs and our actual or alleged failure to comply with them could subject us to potentially significant fines or penalties, regulatory investigations,
negative publicity, liability or otherwise harm our business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently maintain, and will
continue to maintain in the future, a substantial amount of sensitive information, including confidential business data related to our preclinical studies and, in the future, patient health information. As a result, we are subject to laws and
regulations governing the privacy and security of such information. The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the
collection, use, disclosure, retention and security of personal information, including as our operations continue to expand or if we operate in foreign jurisdictions. Implementation standards and enforcement practices are likely to remain uncertain
for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate
in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with
these laws, regulations and standards is high and is likely to increase in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of
personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of
operation, and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, there are numerous federal and state data privacy and security laws and regulations governing
the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, security breach notification laws and consumer protection laws. Each of these laws is subject to varying
interpretations and constantly evolving. By way of example, the regulations promulgated under HIPAA and the Health Information Technology for Economic and Clinical Health Act impose, among other things, certain standards relating to the privacy,
security, transmission and breach reporting of individually identifiable health information. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA,
any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">aiding-and-abetting</FONT></FONT> or conspiracy principles. Consequently, depending on
the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s
requirements for disclosure of individually identifiable health information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Federal Trade Commission (the &#8220;FTC&#8221;) also has authority
to initiate enforcement actions against entities that mislead customers about HIPAA compliance, make deceptive statements about privacy and data sharing in privacy policies, fail to limit third- party use of personal health information, fail to
implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section&nbsp;5 of the Federal Trade Commission Act (the &#8220;FTC Act&#8221;). Even when HIPAA does not apply,
according to the FTC failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the FTC Act. The FTC expects a
company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce
vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain state
laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same
effect, thus complicating compliance efforts. For example, California Consumer Privacy Act, as amended by the California Privacy Rights Act (the &#8220;CCPA&#8221;) requires covered businesses that process the personal information of California
residents to, among other things: (i)&nbsp;provide certain disclosures to California residents regarding the business&#8217; collection, use, and disclosure of their personal information; (ii)&nbsp;receive and respond to requests from California
residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii)&nbsp;enter into specific contractual provisions with service providers that process California
resident personal information on the business&#8217; behalf. Additional compliance investment and potential business process changes may be required. Similar laws have been passed in other states, and are continuing to be proposed at the state and
federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to
or affected by HIPAA, the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, in Europe, the General Data
Protection Regulation (the &#8220;GDPR&#8221;) took effect in May 2018. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of individuals within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
European Economic Area (the &#8220;EEA&#8221;) or in the context of our activities within the EEA. In addition, some of the personal data we process in respect of clinical trial participants is
special category or sensitive personal data under the GDPR, and subject to additional compliance obligations and to local law derogations. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of
data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well
as detailed notices for clinical trial participants and investigators. In addition, the GDPR regulates the transfer of personal data subject to the GDPR to the United States and other jurisdictions that the European Commission does not recognize as
having &#8220;adequate&#8221; data protection laws, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. On July&nbsp;10, 2023, the European Commission adopted its Adequacy Decision
in relation to the new <FONT STYLE="white-space:nowrap">EU-US</FONT> Data Privacy Framework (the &#8220;DPF&#8221;) rendering the DPF effective as a GDPR transfer mechanism to United States entities self-certified under the DPF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GDPR imposes substantial fines for breaches and violations (up to the greater of &#128;20&nbsp;million or 4% of our consolidated annual worldwide gross
revenue). In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease or change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/or
civil claims, including class actions. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting
from violations of the GDPR. Further, from January&nbsp;1, 2021, companies must also comply with the United Kingdom GDPR and the amended UK Data Protection Act 2018 (together, the &#8220;UK GDPR&#8221;). The UK GDPR retains the GDPR in UK national
law. The UK GDPR mirrors the fines under the GDPR, for instance, fines up to the greater of &#128;20&nbsp;million (&pound;17.5 million) or 4% of global turnover. On October&nbsp;12, 2023, the UK Extension to the DPF came into effect (as approved by
the UK Government), as a UK GDPR data transfer mechanism to United States entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and
regulations that may affect how we conduct business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect the existing legal complexity and uncertainty regarding international personal data
transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As
supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory
investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation
of our relevant systems and operations, and could adversely affect our financial results. Compliance with these and any other applicable data privacy and security laws and regulations is a rigorous and time- intensive process, and we may be required
to put in place additional mechanisms ensuring compliance with the new data protection rules within required time frames. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect
our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Artificial intelligence (&#8220;AI&#8221;) and emerging technologies may create risks
to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We leverage data science, machine learning, AI, and other emerging technologies across various aspects of our business and
operations, including specifically with respect to the RNA delivery platform. While these technologies present significant opportunities to enhance productivity, efficiency, and decision-making, their introduction and incorporation may also result
in unintended consequences, new or expanded risks, and potential liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we continue to integrate AI and related technologies into our
operations, we face ongoing challenges in ensuring these systems function as intended and do not introduce unforeseen risks. There can be no assurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that our efforts to manage and mitigate these risks will be successful, and any failure to do so could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to effectively use and manage AI technologies could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective utilization of AI and related technologies is becoming increasingly important for establishing a competitive position and achieving strong
financial performance. If we are unable to successfully implement or manage AI technologies, or if our competitors are more effective in developing or deploying AI capabilities, we may be placed at a competitive disadvantage. This could result in
less efficient operations, reduced market share, or a diminished ability to capitalize on emerging business opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the pace of AI innovation
accelerates, competitors may adopt or develop more advanced or effective AI solutions, increasing the risk that we may fall behind in operational efficiency or market relevance. Any of these factors could have a material adverse effect on our
business, financial condition, or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AI systems in research may produce flawed or biased results, leading to increased costs,
or failure to achieve our desired outcomes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our use of AI systems involves the possibility that
<FONT STYLE="white-space:nowrap">AI-generated</FONT> analyses or outputs may be deficient, flawed, or biased, potentially resulting in operational disruptions, data loss, erroneous decision-making, or other adverse outcomes. The effective
development, management, and use of AI technologies in the biopharmaceutical industry is novel and complex, presenting unique technical challenges. Achieving desired levels of accuracy, efficiency, and reliability in
<FONT STYLE="white-space:nowrap">AI-driven</FONT> research and development processes can be particularly challenging. The algorithms and models used in AI systems may have inherent limitations, including biases, errors, or an inability to process
certain types of biomedical data or address complex biological scenarios. These challenges could impact the effectiveness of our research and development efforts, potentially leading to delays, increased costs, or failure to achieve intended
scientific or commercial outcomes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AI technologies are subject to evolving regulations that may increase compliance costs or expose us to penalties
for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rapid development and deployment of AI and related technologies may amplify
existing risks, including those associated with regulation, litigation, compliance, ethical considerations, confidentiality, and data privacy or security. Multiple governmental authorities have already proposed or enacted laws and issued guidance
specifically addressing the use of AI, such as the EU Artificial Intelligence Act and various state laws in the United States. In the United States, there are ongoing debates regarding passing federal legislation addressing AI, including currently a
debate that may result in Congress acting to preempt state AI laws. These evolving regulatory frameworks may impose new or more stringent obligations on our business, potentially making it more difficult to implement or expand our use of AI
technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the regulatory landscape continues to develop, we may incur significant costs to comply with new laws and regulations, and there is a
risk that such requirements could ultimately restrict or limit our ability to utilize AI in our operations. Failure to comply with applicable <FONT STYLE="white-space:nowrap">AI-related</FONT> regulations could result in regulatory fines, penalties,
or other liabilities, any of which could adversely affect our business, financial condition, or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The use of AI systems
increases the risk of cybersecurity threats, such as data breaches and unauthorized access to sensitive information, which could lead to financial losses, legal liabilities, and reputational harm for the Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deployment of AI systems could expose the Company to heightened cybersecurity threats. These threats may include data breaches and unauthorized access to
sensitive information, which could result in financial losses, legal liabilities, and reputational damage. As AI technologies become more integrated into our operations, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complexity and potential attack surface of our systems may increase, making it more challenging to safeguard against evolving cyber threats. Any failure to adequately protect our systems and data
could adversely affect our business, financial condition, or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the use of AI systems may expose us to heightened
cybersecurity risks, including data breaches and unauthorized access to sensitive information. Such incidents could result in financial losses, legal liabilities, and reputational damage. In addition, inadequate management or oversight of AI
technologies by our employees could compromise our confidential information, intellectual property, or overall reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our
Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent protection for our therapeutic programs and other proprietary technologies
we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our
therapeutic programs and other proprietary technologies we may develop may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability
to obtain and maintain patent protection in the United States and other countries with respect to our therapeutic programs and other proprietary technologies we may develop. We seek to protect our proprietary position, in part, by filing patent
applications in the United States and abroad relating to our therapeutic programs and other proprietary technologies we may develop. If we are unable to obtain or maintain patent protection with respect to our therapeutic programs and other
proprietary technologies we may develop, our business, financial condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in
either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of
our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will
provide sufficient protection against competitors or other third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and
we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and
development output in time to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research
and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such
output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the
prior art allow our inventions to be patentable over the prior art. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, publications of discoveries in the scientific literature often lag
behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were
the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. The patent position of biotechnology and
pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect our therapeutic programs and other proprietary technologies we may develop, or which effectively prevent others from commercializing
competitive technologies and products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the claim coverage in a patent application can be significantly reduced before the patent is
granted. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any
competitive advantage. Any patents issuing from our patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our therapeutic programs and other proprietary technology will be
protectable or remain protected by valid and enforceable patents. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing and
regulatory review of our therapeutic programs and eventual product candidates, patents protecting the product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not
conclusive as to its inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party
<FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the United States Patent and Trademark Office (the &#8220;USPTO&#8221;), or become involved in opposition, derivation, revocation, reexamination, post-grant and inter
partes review, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third
parties to commercialize our therapeutic programs and other proprietary technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing
third-party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our therapeutic programs and other proprietary technologies we may develop in all countries throughout the world
would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all
countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our
products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our
intellectual property and proprietary rights generally. In addition, some jurisdictions, such as Europe, Japan and China, may have a higher standard for patentability than in the United States, including, for example, the requirement of claims
having literal support in the original patent filing and the limitation on using supporting data that is not in the original patent filing. Under those heightened patentability requirements, we may not be able to obtain sufficient patent protection
in certain jurisdictions even though the same or similar patent protection can be secured in U.S. and other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our
intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted
narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have
limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business,
financial condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, beginning June&nbsp;1, 2023, European applications and
patents may be subject to the jurisdiction of the Unified Patent Court (the &#8220;UPC&#8221;) unless they explicitly opt out. Also, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent, which will be
subject to the jurisdiction of the UPC. This will present a significant change in European patent practice. As the UPC is a new entity, there is no applicable precedent on which we may rely, increasing the uncertainty of any outcome from the UPC. As
a single entity can now invalidate a European patent, we may opt out of the UPC in certain cases, in which case each of our European patents would need to be challenged on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees, and various
other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances,
we rely on our licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with
several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed
intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
<FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential
competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the
prosecution of patent applications and the enforcement or defense of issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Leahy-Smith America Invents Act (the &#8220;America
Invents Act&#8221;), the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the
USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a
patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&nbsp;file any patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application related to our therapeutic programs and other proprietary technologies we may develop or (ii)&nbsp;invent any of the inventions claimed in our patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent
litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post- grant review,
inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially
provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt
to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of patents issuing from those patent applications, all of which could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of
biologics and pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. It is unpredictable how decisions by the U.S. federal courts, Congress or the USPTO may impact the value of our patent rights. For example, the U.S. Supreme Court held in Amgen v. Sanofi (2023)&nbsp;that a functionally
claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act. In addition, the U.S. Court of Appeals for the Federal Circuit recently issued a decision involving the interaction of a patent term adjustment,
terminal disclaimers, and obvious-type double patenting. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by Congress, the U.S. federal courts
and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our therapeutic programs and other proprietary technologies we may develop could be found invalid or unenforceable if
challenged in court or before administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we initiate legal proceedings against a third party to
enforce a patent covering our therapeutic programs and other proprietary technologies we may develop, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or
<FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT
STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of,
cancellation of or amendment to our patents in such a way that they no longer cover our therapeutic programs and other proprietary technologies we may develop. The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to
prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our therapeutic programs and other proprietary technologies we may develop. Such a loss of patent protection
would have a material adverse impact on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension for our product candidate, our business may be materially
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidate we may develop, one or more of
patents issuing from our U.S. patent applications may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments
permit a patent term extension (&#8220;PTE&#8221;) of up to five years as compensation for patent term lost during the FDA review process. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product
approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay
caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate (&#8220;SPC&#8221;). The USPTO has recently rejected several PTE applications based on patent coverage that
it has deemed not sufficiently specific to the approved drug, similar to SPC requirements in Europe and other jurisdictions. If we are unable to obtain adequately specific patent claims to obtain patent term extensions or equivalents, our products
may not receive such additional protection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents and other intellectual
property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patent rights, trade
secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing
our therapeutic programs and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, trade secrets or other intellectual property. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our therapeutic programs and other
proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our
trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for our therapeutic programs and
other proprietary technologies we may develop, we also rely on trade secrets and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information and to maintain our
competitive position. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. In particular, the trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relevant to our programs and other
proprietary technology might be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel with scientific positions in academic and industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We seek to protect these trade secrets and other proprietary technology, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and
confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into
confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary
technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a
claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to
protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or
independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to
claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from conflicting obligations of our employees, consultants or others who are involved in developing our product candidate. Litigation
may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive
ownership of, or right to use, trade secrets that are important to our therapeutic programs and other proprietary technologies we may develop. Such an outcome could have a material adverse effect on our business. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be
subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our current employees, consultants and advisors or those we will hire in future may be employed or were previously employed at universities or other
biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to
execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual
property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our
intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the
development and commercialization of our therapeutic programs and other proprietary technologies we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in
part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual
property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable
proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have also been implemented. As stated above, this reform
adds uncertainty to the possibility of challenge to our patents in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications
owned by third parties exist in the fields in which we plan to commercialize or develop our therapeutic programs and in which we are developing other proprietary technologies. As the biotechnology and pharmaceutical industries expand and more
patents are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued, the risk increases that our therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot assure you that our
therapeutic programs and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a
competitor in the fields in which we are developing our therapeutic programs, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe
we have valid defenses to any claims of patent infringement, could be found to be infringed by us. It is not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party
patent does not pose a material risk, but in another country, the corresponding third-party patent may pose a material risk to our planned products. As such, we monitor third-party patents in the relevant pharmaceutical markets. In addition, because
patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that we may infringe. Generative AI resources that are publicly available also present a risk that a company
may inadvertently obtain, incorporate or use a third party&#8217;s intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that any third party claims that we infringe their
patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are
valid, enforceable and infringed by us. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties and/or redesign our infringing products or technologies, which
may be impossible or require substantial time and monetary expenditure. In this case, the holders of such patents may be able to block our ability to commercialize the infringing products or technologies unless we obtain a license under the
applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license
would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary
license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of
management and other employee resources from our business, and may impact our reputation. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial
resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on
our business, financial condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents and other
intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties, such as a competitor, may infringe our
patent rights. Accordingly, we may in the future pursue invalidity or infringement proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable, and in an infringement proceeding, a court may
decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the patent does not cover the technology in question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our patent rights may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive
and time consuming. An adverse result in any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property
claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect to our business. Such proceedings could substantially increase our operating losses and reduce the
resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to
sustain the costs of such proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. If we do not prevail in the patent proceedings the third parties may
assert a claim of patent infringement directed at our product candidates. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the
marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names may be challenged, infringed,
circumvented or declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an
opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark
applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our product candidate in
the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an
evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional
resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining
a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or
trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered
trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to
compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in
substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain our competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, intellectual property discovered through government funded programs may be subject to federal
regulations such as <FONT STYLE="white-space:nowrap">&#8220;march-in&#8221;</FONT> rights, certain reporting requirements and a preference for United States-based companies. Compliance with such regulations may limit our exclusive rights and limit
our ability to contract with <FONT STYLE="white-space:nowrap">non-United</FONT> States manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not currently own issued patents or
pending patent applications that have been generated through the use of United States government funding, our future owned or licensed intellectual property may be generated through the use of United States government funding or grants. Pursuant to
the Bayh-Dole Act of 1980, the United States government has certain rights in inventions developed with government funding. On December&nbsp;8, 2023, the National Institute of Standards and Technology (NIST) released the Draft Interagency Guidance
Framework for Considering the Exercise of <FONT STYLE="white-space:nowrap">March-In</FONT> Rights (the &#8220;Guidance&#8221;) to the public for comment. The Guidance represents the first federal framework specifying that price can be a factor in
considering whether the government may exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> authority pursuant to 35 U.S.C. 200 et seq. (&#8220;Bayh-Dole&#8221;). These United States government
<FONT STYLE="white-space:nowrap">march-in</FONT> rights include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any governmental
purpose. In addition, the United States government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these
inventions to a third party if it determines that: (1)&nbsp;adequate steps have not been taken to commercialize the invention; (2)&nbsp;government action is necessary to meet public health or safety needs; or (3)&nbsp;government action is necessary
to meet requirements for public use under federal regulations, also referred to as <FONT STYLE="white-space:nowrap">march-in</FONT> rights. If the United States government exercised its <FONT STYLE="white-space:nowrap">march-in</FONT> rights in our
future intellectual property rights that are generated through the use of United States government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us,
and there can be no assurance that we would receive compensation from the United States government for the exercise of such rights. The United States government also has the right to take title to these inventions if the grant recipient fails to
disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting
requirements, compliance with which may require us to expend substantial resources. In addition, the United States government requires that any products embodying any of these inventions or produced through the use of any of these inventions be
manufactured substantially in the United States. This preference for United States industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful
efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This
preference for United States industry may limit our ability to contract with <FONT STYLE="white-space:nowrap">non-United</FONT> States product manufacturers for products covered by such intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may partially depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply
with our obligations under our intellectual property licenses, if the licenses are terminated or if disputes regarding these licenses arise, we could lose significant rights that are important to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be dependent, in part, on patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology licensed from others. Our licenses to
such patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology may not provide exclusive rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products in the
future. The agreements under which we license patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology from others are complex, and certain provisions in such agreements may be susceptible to multiple interpretations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with obligations under any license agreements, our licensors may have the right to terminate our license, in which case we would not
be able to develop or market technology or product candidates covered by the intellectual property licensed under these agreements. In addition, we may need to obtain additional licenses from our existing licensors and others to advance our research
or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for
manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors fail to adequately protect our licensed intellectual property, our ability to develop or commercialize product
candidates could suffer. We may not have complete control over the maintenance, prosecution and litigation of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications and may have limited control over future
intellectual property that may be <FONT STYLE="white-space:nowrap">in-licensed.</FONT> For example, we cannot be certain that activities such as the maintenance and prosecution by our licensors have been or will be conducted in compliance with
applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we
conducted them ourselves or may not be conducted in accordance with our best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the resolution of any contract interpretation
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology, or increase what we believe to be our financial or other
obligations under the relevant agreement. Disputes that may arise between us and our licensors regarding intellectual property subject to a license agreement could include disputes regarding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the RemainCo License Agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary
rights to product components and processes for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use third-party proprietary
rights. For example, our product candidates may require specific formulations to work effectively and efficiently, we may develop product candidates containing our compounds and <FONT STYLE="white-space:nowrap">pre-existing</FONT> pharmaceutical
compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates, any of which could require us to obtain rights to use intellectual property held by
third parties. In addition, with respect to any patents we may <FONT STYLE="white-space:nowrap">co-own</FONT> with third parties, we may require licenses to such <FONT STYLE="white-space:nowrap">co-owners&#8217;</FONT> interest to such patents. We
may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our
business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party
intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such
alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also receive access to the same technologies licensed to us. In
that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or
development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we
hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to
others, potentially blocking our ability to pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a
competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to
commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us
to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the
additional product candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to
abandon development of certain programs and our business financial condition, results of operations and prospects could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our use of open
source software could impose limitations on our ability to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our use of open source software could impose
limitations on our ability to commercialize our product candidates. As a result, as we seek to use the RNA delivery platform in connection with commercially available products, we may be required to license that software under different license
terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software components on terms that permit its use for commercial purposes, we may be required to replace those software components, which could
result in delays, additional cost and additional regulatory approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use and distribution of open source software may entail greater risks than use of
third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that we
make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain of the open
source licenses, be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product
sales for us. Although we monitor our use of open source software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose
unanticipated conditions or restrictions on our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to
<FONT STYLE="white-space:nowrap">re-engineer</FONT> our product candidates or to discontinue the sale of our product candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on
our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on
appreciation, if any, in the price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our common stock. We currently
anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will
therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at the time of the Distribution or such later time at which stockholders have
purchased their shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider
favorable and may lead to entrenchment of management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws contain provisions that could significantly
reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our Board of Directors. The provisions in our charter documents include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified Board of Directors with three-year staggered terms, which may delay the ability of stockholders to
change the membership of a majority of our Board of Directors ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our Board of Directors, unless the Board of Directors grants such right to the
stockholders, to elect a director to fill a vacancy created by the expansion of the Board of Directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the shares entitled to
vote to remove a director for cause and to amend the prohibition on removal of directors without cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our Board of Directors to authorize the issuance of shares of preferred stock and to determine the
price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our Board of Directors to alter our Bylaws without obtaining stockholder approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least two-thirds of the shares entitled to vote to adopt, amend or repeal the Bylaws
or repeal the provisions of the Certificate of Incorporation regarding the election and removal of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual
or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive
forum for certain actions and proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the Board of Directors, the chair of
our Board of Directors, our chief executive officer or our president (in the absence of a chief executive officer), which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of
directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice and other procedural requirements that stockholders must comply with in order to nominate
candidates to our Board of Directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of
directors or otherwise attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to the anti-takeover provisions contained in
Section&nbsp;203 of the DGCL. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other
exceptions, the board of directors has approved the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be
the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of
Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of
breach of fiduciary duty by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or Certificate of
Incorporation or Bylaws; or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other
claims for which the federal courts have exclusive jurisdiction, in which case such claim must be brought in a federal court sitting in Delaware. Our Certificate of Incorporation will also provide that unless we consent in writing to the selection
of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. In any case, stockholders will not be deemed to
have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal
proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our Certificate of Incorporation also provides that any person or entity purchasing or otherwise acquiring or holding any interest
in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. If a court were to find the choice of forum provisions in our Certificate of Incorporation to be inapplicable or unenforceable
in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop or be sustained, or be liquid enough for investors to resell our common stock quickly or
at the market price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no public market for our common stock, and we cannot assure you that an active trading market will develop
or be sustained or that any trading market will be liquid. If an active market for our common stock does not develop or is not sustained, it may be difficult for our stockholders to sell shares of our common stock without depressing the market price
for the common stock or to sell their shares at all. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares of our common stock and may impair our ability to acquire other companies or
technologies by using our common stock as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our common stock may be volatile and may fluctuate due to factors
beyond our control, and purchasers of our common stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price may be volatile. The stock market in
general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders and
investors may not be able to sell their common stock at or above the price they paid for the common stock. The market price for our common stock may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initial lack of when-issued trading of Company Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive or negative results, including preliminary or topline results, of preclinical studies and clinical
trials reported by us, strategic partners or competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any progress or delay in the commencement, enrollment and the ultimate completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological innovations or commercial product introductions by us or competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to successfully develop and commercialize any of our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments, announcements or changes in government regulations relating to drug products, including related to
drug pricing, reimbursement and healthcare coverage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring additional complementary product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments concerning proprietary rights, including patents and litigation matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">public concern relating to the commercial value or safety of any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financing or other corporate transactions, or inability to obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements relating to our arrangements with RemainCo, BMS and Lilly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed expectations of the investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in our operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by us or by any securities analysts who might cover our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by therapeutic drug product providers related to pricing of therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant licenses, acquisitions, strategic partnerships or joint ventures by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports or comments by securities or industry analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to attract or retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock, including sales by our directors and officers or specific stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market or regulatory conditions in the pharmaceutical industry or in the economy as a whole;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events and factors, many of which are beyond our control; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this information statement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our securities to fluctuate substantially,
regardless of our actual operating performance, which may limit or prevent investors from selling their common stock at or above the price paid for the common stock and may otherwise negatively affect the liquidity of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some companies that have experienced volatility in the trading price of their stock have been the subject of securities class action litigation. Any lawsuit
to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our
reputation or adverse changes to our offerings or business practices. Defending against litigation is costly and time-consuming, and could divert our management&#8217;s attention and resources. Furthermore, during the course of litigation, there
could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Volatility in our stock price may also affect our ability to attract and retain our key employees. Employees may be more likely to leave the company if the
shares they own or the shares underlying their vested equity have not significantly appreciated in value relative to the original purchase price of the shares or the exercise price of the options, or conversely, if the exercise price of the options
that they hold are significantly above the market price of our Common Stock. If we are unable to retain our employees, or if we need to increase our compensation expenses to retain our employees, our business, operating results, and financial
condition could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantially all of our total outstanding shares of common stock may be sold freely into the market.
This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of substantially all of our
common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. None of our
directors and officers appointed or to be appointed in connection with the Distribution will be subject to a lock-up agreement. Immediately following the Distribution, substantially all of our common stock will be freely tradable, without
restrictions or further registration under the Securities Act, subject to certain restrictions applicable to shares of common stock held by our affiliates as defined in Rule&nbsp;144 under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth
companies&#8221; will make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS
Act. For as long as we continue to be an &#8220;emerging growth company,&#8221; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth
companies,&#8221; including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an &#8220;emerging growth company,&#8221; we are
required to report only two years of financial results in certain Securities Act registration statements. We may take advantage of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an &#8220;emerging
growth company&#8221; until the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act, although we will lose that status
sooner if our revenues exceed $1.235&nbsp;billion, if we issue more than $1&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in a three-year period, or if the market value of the shares of our common stock that are held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter. We cannot predict if investors will find our common stock less attractive because
we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the price of our common stock may be more volatile than that of an otherwise
comparable company that does not avail itself of the same or similar exemptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a&nbsp;smaller reporting company, and the reduced reporting
requirements applicable to smaller reporting companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting
company&#8221; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Exchange Act. For as long as we continue to be a&nbsp;smaller reporting company, we may take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not smaller reporting companies, including reduced financial statement and other financial information disclosure, and reduced disclosure obligations regarding executive compensation in our
annual and periodic reports and proxy statements. We will remain a smaller reporting company as long as either (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700&nbsp;million. Our public float is measured as of the last business day of our most recently completed second fiscal quarter, and annual revenues are as of the most recently completed fiscal year for which audited financial statements are
available. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our
common stock and our stock price may be more volatile than that of an otherwise comparable company that does not avail itself of the same or similar exemptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because there has not been any public market for our common stock, the market price and trading volume of our common stock may be volatile and you may
not be able to resell your shares of our common stock at or above the initial market price of our common stock following the Distribution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior
to the Distribution, there will have been no trading market for our common stock. We cannot predict the extent to which investors&#8217; interest will lead to a liquid trading market or whether the market price of our common stock will be volatile.
The market price of our common stock could fluctuate significantly for many reasons, including in response to the risk factors listed in this information statement or for reasons unrelated to our specific performance, such as reports by industry
analysts, investor perceptions, or negative developments for our customers, competitors or suppliers, as well as general economic and industry conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Distribution will be taxable, and the resulting tax liability to holders of Avidity Common Stock will have to be funded from other sources.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity has not calculated earnings and profits in accordance with U.S. federal income tax principles. Accordingly, the Distribution will be
treated as a taxable distribution with respect to Avidity Common Stock for U.S. federal income tax purposes in an amount equal to the fair market value of any of the Company&#8217;s common stock (including fractional shares for which cash is
received in lieu thereof) received pursuant to the Distribution. No cash will be received in the Distribution. Accordingly, the resulting tax liability to U.S. holders will have to be funded from other sources. Avidity or other applicable
withholding agents may be required or permitted to withhold at the applicable rate on all or a portion of the amount payable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, and any such withholding will be satisfied by Avidity or such
agent by withholding and selling a portion of the shares of Company Common Stock that otherwise would be distributable to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders or by withholding from other property held in the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s account with the withholding agent. For more information, see the discussion below under &#8220;<I>The Separation and Distribution</I><I>&#8201;</I><I>&#8212;</I><I>&#8201;</I><I>Material
U.S. Federal Income Tax Consequences</I>.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our historical financial results as a part of Avidity and our unaudited pro forma combined
financial statements may not be representative of our results as a separate, standalone company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical financial information we have
included in this information statement has been derived from the consolidated financial statements and accounting records of Avidity and does not necessarily reflect what our financial position, results of operations or cash flows would have been
had we been a separate, standalone company during the periods presented. The historical costs and expenses reflected in our combined financial statements include an allocation for certain corporate functions historically provided by Avidity,
including general corporate expenses and employee benefits and incentives. These allocations were based on what we and Avidity considered to be reasonable reflections of the historical utilization levels of these services required in support of our
business. The historical information does not necessarily indicate what our results of operations, financial position, cash flows or costs and expenses will be in the future. Our pro forma financial information set forth under &#8220;<I>Unaudited
Pro Forma Combined Financial Information</I>&#8221; reflects changes to our operations as a result of the Separation. However, there can be no assurances that this unaudited pro forma combined financial information will appropriately reflect our
costs as a publicly traded company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur material costs and expenses as a result of our separation from Avidity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incur costs and expenses greater than those we currently incur as a result of our separation from Avidity. These increased costs and expenses will
arise from various factors, including financial reporting and costs associated with complying with federal securities laws (including compliance with the Sarbanes-Oxley Act). In addition, we will have increased corporate and administrative costs and
expenses to those we incurred while part of Avidity, even though the Company will be a smaller, standalone company following the Distribution. These costs may be material to our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We incur significant costs as a result of operating as a standalone public company, and our management
is required to devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a new public company, we incur significant legal, accounting and other
expenses that we would not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business
and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring the
establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory
reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules and regulations applicable to public companies have increased and may continue to increase our legal and financial compliance costs and have made
some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of
operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business. For example, in recent periods obtaining director and officer liability insurance has become
more expensive, and we may be required to incur substantial costs to obtain coverage. We cannot predict or estimate the amount or timing of costs we may incur to respond to these requirements. The impact of these requirements could also make it more
difficult for us to attract and retain qualified persons to serve on our Board of Directors, our board committees or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a newly
public company, most members of our senior management team have not previously held senior management positions of the same level at a public company, which may impact our ability to efficiently manage the transition to public company status and
meet new regulatory and investor expectations, potentially harming our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, following the
Distribution, we are unable to satisfy the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, or our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned and our stock
price may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;404 of the Sarbanes-Oxley Act requires any company subject to the reporting requirements of the U.S. securities
laws to do a comprehensive evaluation of its and its consolidated subsidiaries&#8217; internal control over financial reporting. To comply with this statute, we may eventually be required to document and test our internal control procedures and our
management will be required to assess and issue a report concerning our internal control over financial reporting. Furthermore, if we lose our status as an emerging growth company, our independent auditors will be required to issue an opinion on the
Company&#8217;s internal controls over financial reporting pursuant to Section&nbsp;404(b). The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant
documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline
imposed by the Sarbanes-Oxley Act. If our management cannot favorably assess the effectiveness of our internal control over financial reporting or our auditors identify material weaknesses in our internal controls, investor confidence in our
financial results may weaken, and our stock price may suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports or publish
unfavorable research or reports about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock
depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. If these analysts cease coverage of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, the trading price for our stock would be negatively impacted. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of
these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk
is especially relevant for us, because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of our
management&#8217;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or current or potential future
collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United
States federal and various state and foreign governments have adopted or proposed laws, regulations and requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to
individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and dissemination of such data. In the ordinary course of business, we collect, store, transmit and otherwise
process large amounts of data including, without limitation, proprietary business information, preclinical and clinical trial data and the personal information of our employees and contractors. It is critical that we do so in a secure manner to
maintain the confidentiality and integrity of such confidential information. Despite the implementation of security measures, our internal technology systems (including infrastructure) and those of our current and any future CROs and other
contractors, consultants and collaborators are vulnerable to attack, damage and interruption from computer viruses and malware (e.g. ransomware), misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, malicious code, cybersecurity threats
(such as denial or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">degradation-of-service</FONT></FONT> attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks),
unauthorized access or use, natural disasters, terrorism, war and telecommunication and electrical failures, employee theft or misuse, human error, fraud, and sophisticated nation-state and nation-state-supported actors. Attacks upon information
technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the
post-pandemic continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who continue to work remotely, which may create additional opportunities
for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to
anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate
incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. There can also be no assurance that our and our third-party
service providers&#8217;, strategic partners&#8217;, contractors&#8217;, consultants&#8217;, CROs&#8217; and collaborators&#8217; cybersecurity risk management program and processes, including policies, controls or procedures, will be fully
implemented, complied with or effective in protecting our systems, networks and confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and certain of our service providers are
from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our
operations or result in the unauthorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure of or access to proprietary or sensitive personally identifiable information, it could result in a material disruption of our development programs and our business operations, whether
due to a loss, corruption or unauthorized disclosure of our trade secrets or other similar disruptions. Some of the federal, state and foreign laws, regulations and requirements include obligations of companies to notify individuals of security
breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any security breach or other incident, whether real or perceived, could impact our reputation, cause us to incur significant costs, including legal expenses,
harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse
effect on our business. To the extent that any real or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or
accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could
incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. Any adverse
impact to the availability, integrity or confidentiality of our or third-party systems or confidential information can result in legal claims or proceedings (such as class actions), regulatory investigations and enforcement actions, fines and
penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. Further, our insurance coverage may not be sufficient
to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems. For further discussion on the potential liability related to the violation of these laws, see &#8220;<I>Risk
Factors&#8212;Risks Related to Our Intellectual Property &#8212;We, our collaborators and our service providers may be subject to a variety of data privacy and security laws and contractual obligations, which could increase compliance costs and our
actual or alleged failure to comply with them could subject us to potentially significant fines or penalties, regulatory investigation, negative publicity, liability or otherwise harm our business, results of operations and financial
condition.</I>&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations, including research activities, manufacturing and clinical trials, could be subject to earthquakes, power shortages,
telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted
if the operations of these suppliers were affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. In addition, our corporate headquarters is located in San Diego, California near major
earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could
seriously harm our operations and financial condition and increase our costs and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes,
anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for
violations, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export
Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and
regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money
laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising,
offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell
our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government
agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not
explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges,
debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, U.S. export control laws
and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. export controls or sanctions. Sanctions and export control restrictions change from time to time with little
warning and may require the Company to unwind or terminate business relationships, potentially on commercially unfavorable terms and/or at a significant cost. U.S. sanctions that have been or may be imposed as a result of military conflicts in other
countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. Additionally, the U.S. government has indicated its intent to alter its approach to international trade policy and in
some cases to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. The U.S. government has announced, and threatened, the imposition of tariffs on global imports to
address trade imbalances and various other goods considered critical to national security. Global trade disruption, significant introductions of trade barriers and bilateral trade frictions, together with any future downturns in the global economy
resulting therefrom, could adversely affect the Company&#8217;s supply chains and the financial performance of the Company. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including
fines and/or denial of certain export privileges. These export and import controls, and economic sanctions could also adversely affect our supply chain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious
adverse consequences on our business, financial condition and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global credit and financial markets have from time to time
experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and
uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of inflation, tariffs, military conflict, terrorism or other geopolitical events. Sanctions
imposed by the United States and other countries in response to such conflicts, including on Russia and its allies, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or
others could exacerbate market and economic instability. Future adverse developments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working
capital needs, and create additional market and economic uncertainty. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be
adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more
difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to
delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our
operating goals on schedule and on budget. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws may impact our future financial position and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied
adversely to us, any of which could adversely affect our business operations and financial performance. For example, the United States government may enact significant changes to the taxation of business entities including, among others, a permanent
increase in the corporate income tax rate, an increase in the tax rate applicable to certain foreign related income and elimination of certain exemptions, and the imposition of surtaxes on certain types of income. The likelihood of these changes
being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, our customers or our
suppliers, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of operations and cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_5"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This information statement contains forward-looking statements about us that involve substantial risks and uncertainties. All statements other than
statements of historical facts contained in this information statement, including statements regarding our plans, objectives, goals, strategies, future events, financing needs, plans or intentions relating to product candidates and markets and
business trends, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;design,&#8221; &#8220;seek,&#8221;
&#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, potential registrational quality, and results of our research and development
programs, preclinical studies, any clinical trials, IND, and other regulatory submissions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product
candidates and the potential advantages of our product candidates compared to alternative therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success and capabilities of the RNA delivery platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market
opportunity for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that we will enroll in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and costs involved in obtaining and maintaining regulatory approval of our current product
candidates and any future product candidates that we may identify or develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to meet future regulatory standards with respect to our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development and manufacturing of our product candidates, including for
additional indications that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and therapeutic benefits of our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop or partner and progress our current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, product candidates, research programs and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the success of competing therapies that are or may become available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current license agreements and collaborations and identify and enter into future
license agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected potential benefits of strategic collaborations with third parties and our ability to attract
collaborators with development, regulatory, manufacturing or commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct preclinical studies and clinical trials of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to efficiently and cost-effectively conduct our current and future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties for the manufacture of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to sales strategy, manufacturing and commercializing our product candidates, if approved;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated regulatory developments in the United States and foreign countries in which we may seek regulatory
approval for our product candidates in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of the achievement of milestones pursuant to our existing collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of consummating a Permitted Third Party Sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the planned completion and timing of the transactions contemplated by the Merger Agreement and the Separation
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future
operating expenses and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of our current and future product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of our existing resources, estimates of our expenses, capital requirements and needs for
additional financing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those
described in the section titled &#8220;Risk Factors&#8221; elsewhere in this information statement and reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this
information statement. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on
our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the
forward-looking events and circumstances discussed in this information statement may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that
&#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this information statement, and while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this information statement to conform these
statements to new information, actual results or to changes in our expectations, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this information statement
and the documents that we file with the SEC with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_6"></A>THE SEPARATION AND DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At or prior to the time of the Distribution,
Avidity will separate the businesses described in this information statement and transfer them to the Company through the Separation, which will generally result in (a)&nbsp;the Company owning, assuming or retaining all assets and liabilities of
Avidity and its subsidiaries exclusively related to Avidity&#8217;s early stage precision cardiology programs, including ATR 1086 and ATR 1072, which target rare genetic cardiomyopathies, including phospholamban and Protein Kinase <FONT
STYLE="white-space:nowrap">AMP-activated</FONT> <FONT STYLE="white-space:nowrap">non-catalytic</FONT> subunit Gamma 2 Syndrome, respectively, and certain collaboration agreements, including the BMS Collaboration Agreement and the Lilly Agreement,
and (b)&nbsp;RemainCo owning, assuming or retaining all other assets and liabilities of Avidity and its subsidiaries. Following the Separation and except in the event a Permitted Third Party Sale is consummated, Avidity will distribute all of our
issued and outstanding common stock pro rata to the holders of Avidity Common Stock in the Distribution. In the Distribution, each holder of Avidity Common Stock will receive a distribution of one share of our common stock for every ten shares of
Avidity Common Stock held by them as of the Record Date and through the Distribution Date. In the case of a Permitted Third Party Sale, Avidity will thereafter distribute the Permitted Sale Proceeds of such sale to Avidity&#8217;s stockholders and
holders of Avidity Equity Awards, as of the chosen record date for distributing such proceeds, on a pro rata basis and subject to applicable tax withholding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manner of Effecting the Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general terms
and conditions relating to the Distribution are set forth in the Separation Agreement. Under the Separation Agreement, the Distribution will be effective following the satisfaction or waiver of the conditions described in &#8220;<I>The Separation
and Distribution&#8212;The Separation Agreement&#8212;Conditions to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT></I>.&#8221; For all Avidity stockholders who own shares of Avidity Common Stock in registered form on the Record Date who hold
their shares of Avidity Common Stock through the Distribution Date, our transfer agent will credit their share of Company Common Stock to book entry accounts established in their names to hold their shares of Company Common Stock. Our distribution
agent will send these stockholders a statement reflecting their ownership of our common stock shortly after the Distribution Date. Book entry refers to a method of recording share ownership in our records in which no physical certificates are used.
For stockholders who own shares of Avidity Common Stock through a broker or other nominee, the shares of Company Common Stock received in the Distribution will be credited to their accounts by the broker or other nominee on or after the Ex-Dividend
Date. As further discussed below, fractional shares will not be distributed and Avidity&#8217;s stockholders will receive cash in lieu thereof. Following the Distribution, stockholders whose shares are held in book entry form and are not affiliates
of the Company may request that their Company Common Stock be transferred to a brokerage or other account at any time, as well as delivery of any physical share certificates for their shares, in each case without charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AVIDITY STOCKHOLDERS WILL NOT BE REQUIRED TO PAY FOR OUR COMMON STOCK RECEIVED IN THE DISTRIBUTION, OR TO SURRENDER OR EXCHANGE AVIDITY COMMON STOCK IN ORDER
TO RECEIVE OUR COMMON STOCK, OR TO TAKE ANY OTHER ACTION IN CONNECTION WITH THE DISTRIBUTION. AVIDITY STOCKHOLDERS HAVE NO APPRAISAL RIGHTS IN CONNECTION WITH THE DISTRIBUTION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional share of Company Common Stock will be delivered to Avidity stockholders as part of the Distribution or credited to book entry accounts. In lieu
of receiving fractional shares, each holder of Avidity Common Stock who would otherwise be entitled to receive a fractional share of Company Common Stock will receive cash for the fractional interest, which generally will be taxable to such holder
to the extent the cash received exceeds the fair market value of the fractional interest of Company Common Stock on the Distribution Date. An explanation of the material U.S. federal income tax consequences of the Distribution can be found below in
the subsection captioned &#8220;&#8212;<I>Material U.S. Federal Income Tax Consequences</I>.&#8221; The distribution agent will, as soon as practicable after the Distribution Date, aggregate all fractional Company Common Stock into
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whole Company Common Stock and sell them in the open market at then-prevailing market prices and distribute the aggregate proceeds, net of brokerage fees and after deducting any taxes required to
be withheld therefrom, ratably to Avidity stockholders otherwise entitled to fractional interests in our common stock. The amount of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such payments will
depend on the prices at which the aggregated fractional shares are sold by the distribution agent in the open market shortly after the Distribution Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<I>Executive Compensation&#8212;Treatment of Outstanding Awards</I>,&#8221; for a discussion of how outstanding RemainCo equity awards will be
affected by the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have applied to list Company Common Stock on Nasdaq under the symbol &#8220;RNA,&#8221; which is currently the symbol
for the shares of Avidity Common Stock listed on Nasdaq. Company Common Stock will not trade separately from Avidity Common Stock prior to the Ex-Dividend Date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity&#8217;s board of
directors has determined that the separation of our businesses from Avidity&#8217;s other business is in the best interests of Avidity and its stockholders. The potential benefits considered by Avidity&#8217;s board of directors in making the
determination to consummate the Distribution included the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that stockholders of Avidity would have the opportunity to receive securities of the Company under the
terms and conditions of the Merger Agreement, in addition to the consideration being paid in the Merger, allowing stockholders of Avidity to continue to recognize value from Avidity&#8217;s assets and liabilities related to its early stage precision
cardiology programs and the Third Party Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avidity&#8217;s board of directors&#8217; recognition of the potential value in the assets to be transferred to
the Company in the Separation and that the Distribution provides an attractive option for these assets, including with respect to the potential development and commercialization and future profitability of the early stage precision cardiology
programs and the potential achievement of specified milestones and royalties under the Third Party Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall value of the Merger and the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> in the context of
Avidity&#8217;s current and historical financial condition and results of operations, competitive position, assets, business and prospects and the risks and uncertainties inherent to the research, development, manufacture and commercialization of
Avidity&#8217;s three late-stage clinical programs, <FONT STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT STYLE="white-space:nowrap">del-zota,</FONT> as well as the further research,
development, manufacture and commercialization of its other product candidates and RNA delivery platform, and that the potential for value and near-term liquidity to Avidity&#8217;s stockholders was compelling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Merger Agreement that was negotiated between Avidity and Novartis contemplated completion of
the Separation and the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> or the consummation of a Permitted Third Party Sale as a condition to the Merger; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Separation, in combination with the Merger, provides Avidity&#8217;s stockholders with more <FONT
STYLE="white-space:nowrap">after-tax</FONT> value as compared to a direct sale of the <FONT STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT STYLE="white-space:nowrap">del-zota</FONT> assets
by Avidity because the Separation, in combination with the Merger, avoids subjecting the proceeds paid by Novartis for <FONT STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT
STYLE="white-space:nowrap">del-zota</FONT> to the corporate-level income tax that would otherwise apply if Avidity, as opposed to its stockholders, had received such proceeds on a direct sale of the
<FONT STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT STYLE="white-space:nowrap">del-zota</FONT> assets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity&#8217;s board of directors also considered other terms of the Separation Agreement, which are more fully described below under &#8220;&#8212;<I>The
Separation Agreement</I>&#8221;: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the allocation of certain assets and liabilities related to Avidity&#8217;s early stage precision cardiology
programs and Third Party Agreements to the Company (subject to exceptions); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the tax treatment of the Separation, including that the Separation will be a taxable distribution to Avidity
stockholders and that the Company generally will provide a tax indemnity to RemainCo for the Company&#8217;s share of transfer taxes and any income taxes, calculated on a pro forma basis, attributable to the assets and liabilities associated with
the Company Business or imposed on the Company (in each case, other than taxes related to the Separation, Distribution or any sale of the Company to a third party) for any taxable period prior to the Distribution (&#8220;Company Indemnified
Taxes&#8221;) and RemainCo generally will provide a tax indemnity to the Company for any taxes arising in respect of the Separation, the Distribution, any sale of the Company to a third party, RemainCo&#8217;s share of transfer taxes, and taxes of
RemainCo or the consolidated group of which RemainCo was the common parent that are not the Company Indemnified Taxes (&#8220;RemainCo Indemnified Taxes&#8221;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the parties have agreed to make an election under Section&nbsp;336(e) of the Code with respect to the
Company, which is expected to result in the Company receiving a fair market value tax basis in its assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, immediately prior to the effective time of the Distribution, Avidity will pay and contribute to
the Company an amount in cash equal to the Company Funding; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the guaranty by Novartis of the performance by RemainCo of its obligations under the Separation Agreement, the
RemainCo License Agreement, the Transition Services Agreement and the Occupancy License Agreement following the effective time of the Merger. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity&#8217;s board of directors also considered certain aspects of the Distribution that may be adverse to the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the price of a share of Company Common Stock may fall as certain Avidity stockholders sell their
shares of Company Common Stock because they are not interested in holding an investment in the Company Business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that certain factors such as the size and expected market value of the Company may impede
investors&#8217; ability to appropriately value the Company Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, because the Company will no longer be part of Avidity, the Distribution also will limit the
ability of the Company to pursue cross-company business initiatives with the RemainCo Business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, after the Distribution, the Company will not own any rights to the RemainCo Business, including
the three late-stage clinical programs <FONT STYLE="white-space:nowrap">del-desiran,</FONT> <FONT STYLE="white-space:nowrap">del-brax</FONT> and <FONT STYLE="white-space:nowrap">del-zota;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Separation includes certain assets of Avidity that triggered the ROFN, which may result in the
Company owning less than all of the ROFN Assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, under the RemainCo License Agreement, the Company will not be permitted to engage in the business
of developing or selling RNA therapeutics outside of the cardiovascular field for five years following the Distribution, is prohibited from using the RNA delivery platform outside the cardiovascular field (with limited exceptions), and will be
subject to certain rights of first negotiation in favor of RemainCo with respect to products and product candidates outside of the cardiovascular field for 10 years following the Distribution, as more fully described below under
&#8220;<I>Business&#8212;Intellectual Property&#8212;RemainCo License Agreement</I>&#8221;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, as a result of the Distribution, the Company will bear significant incremental costs associated
with being a publicly held company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of the Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the Distribution, we will be a public company and own the Company Business. Immediately after the Distribution, we expect to have approximately 13
holders of record of our common stock and 15,514,966&nbsp;shares of our common stock outstanding, based on the number of stockholders of record and outstanding Avidity Common Stock on and after giving effect to the delivery to stockholders of cash
in lieu of fractional shares of our common stock. The actual number of shares to be distributed was determined on the Record Date. You can find information regarding equity awards that will be outstanding after the Distribution in the section
captioned, &#8220;<I>Executive Compensation&#8212;Treatment of Outstanding Awards&#8212;Make Whole Awards</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Distribution and the issuance of Make Whole Awards will not affect the number of shares of Avidity
Common Stock outstanding or underlying the Avidity Equity Awards, as applicable (assuming the Avidity Stock Options are exercised for cash). For more information on the treatment of Avidity Common Stock and Avidity Equity Awards in the Merger, see
the Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No When-Issued Trading or Ex-Distribution Trading</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Avidity Common Stock as of the close of business on the Record Date who do not sell or otherwise dispose of such Avidity Common Stock prior to the
close of business on the Distribution Date will be entitled to receive shares of Company Common Stock pursuant to the Distribution. Each such holder will receive one share of Company Common Stock for every ten shares of Avidity Common Stock held on
the Record Date. If you sell Avidity Common Stock up to and including the close of business on the Distribution Date, you will be selling your right to receive Company Common Stock in the Distribution. There will not be any trading of Company Common
Stock on a &#8220;when-issued&#8221; basis or any &#8220;ex-distribution&#8221; trading of Avidity Common Stock before the Ex-Dividend Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Separation Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a summary of the material terms of the Separation Agreement. The description of the Separation Agreement in this section
and elsewhere in this information statement is qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which is incorporated by reference as Exhibit 2.1 to the Registration Statement of which this
information statement forms a part. This summary does not purport to be complete and may not contain all of the information about the Separation Agreement that is important to you. We encourage you to read the Separation Agreement carefully and in
its entirety. Capitalized terms used in this section but not defined in this information statement have the meanings ascribed to them in the Separation Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement and this summary of its terms are included to provide you with information regarding its terms. Factual disclosures about Avidity
contained in this information statement or in Avidity&#8217;s public reports filed with the SEC may supplement, update or modify the factual disclosures about Avidity contained in the Separation Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer of Assets and Assumption of Liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Separation Agreement identifies the assets to be transferred to (including the contracts to be assigned) or retained by, and the liabilities to be assumed or retained by, each of RemainCo and the Company, and it provides for when and how these
transfers, assumptions and assignments will occur. For the purpose of the Separation Agreement, and subject to terms of and any exceptions set forth in the Separation Agreement, the assets consist of all right, title and ownership interests in and
to all assets, properties, claims, information generated for the business, intellectual property, contracts and rights (including goodwill), wherever located (including in the possession of vendors or other third parties or elsewhere on behalf of
the applicable person or entity), of every kind, character and description, whether real, personal or mixed, tangible or intangible, whether accrued or contingent, in each case, whether or not received, recorded or reflected or required to be
recorded or reflected on the books and records or financial statements of such person or entity, including rights and benefits pursuant to any contract, license, permit, indenture, note, bond, mortgage, agreement, concession, franchise, instrument,
undertaking, commitment, understanding or other arrangement. Liabilities consist of any and all debts, guarantees, assurances, commitments, losses, remediation, deficiencies, penalties, settlements, sanctions, costs, expenses, interest and
obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, known or unknown, reserved or unreserved, or determined or determinable, including those arising under any law, proceeding, whether asserted or unasserted, or
order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any governmental authority and those arising under any contract, agreement, obligation, indenture, instrument, lease, promise, arrangement, release,
warranty, covenant, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commitment or undertaking or any fines, damages or equitable relief which may be imposed and including all costs and expenses related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, following the Distribution, the Company will own, assume or retain all assets and liabilities of Avidity and its subsidiaries exclusively related
to the Company Business, and RemainCo will own, assume or retain all other assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the Separation Agreement provides that
subject to the terms and conditions contained therein, the following assets will generally be retained by or transferred to the Company, subject to certain exceptions (collectively, the &#8220;Company Assets&#8221;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain specified intellectual property related to the RNA delivery platform and intellectual property
exclusively used in or exclusively related to the Company Programs or the Company Business (the &#8220;Company Intellectual Property&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all information technology assets (i)&nbsp;located at Avidity&#8217;s offices at Science Center Drive in San
Diego, California (the &#8220;Company Real Property&#8221;) that are exclusively related to, as between the Avidity Business and the Company Business, the Company Business, (ii)&nbsp;used exclusively by certain employees to be transferred to the
Company (the &#8220;Transferred Employees&#8221;) or (iii)&nbsp;otherwise specified in the Separation Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all licenses, permits, registrations, approvals and authorizations which have been issued by any governmental
authority that are held by a member of the Company Group (as defined below) that are exclusively related to, as between the RemainCo Business and the Company Business, the Company Business, or to the extent transferable, exclusively related to, as
between the RemainCo Business and the Company Business, the Company Business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all deposits, letters of credit, prepaid expenses, trade accounts and other accounts that are exclusively related
to, as between the RemainCo Business and the Company Business, the Company Business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all inventories of clinical products, goods, materials, parts, raw materials and clinical supplies that are
exclusively related to, as between the RemainCo Business and the Company Business, the Company Business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all real property leases for the Company Real Property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Third Party Agreements and any other contracts that are exclusively related to, as between the RemainCo
Business and the Company Business, the Company Business and all rights and obligations arising under any such contracts, and the portions of any contract (other than any Third Party Agreement) that relate to both the Company Business and the
RemainCo Business (which we refer to as a &#8220;Commingled Contract&#8221;) that are exclusively related to, as between the RemainCo Business and the Company Business, the Company Business, and all rights and obligations arising under any such
portions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specified lab equipment and other tangible assets to the extent such assets are not necessary for the conduct of
the RemainCo Business as conducted in the twelve months prior to the date of the Separation Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all rights under insurance policies and all rights in the nature of insurance, indemnification or contribution
that are exclusively related to, or to claims arising out of, the Company Business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any goodwill that is as of the effective time of the Distribution exclusively related to the Company Business;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other assets (other than intellectual property) owned or controlled by Avidity or its subsidiaries and
exclusively related to, as between the RemainCo Business and the Company Business, the Company Business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the assets other than the assets allocated to the Company will generally be retained by, or
transferred to, RemainCo. The Separation Agreement also identifies specific assets that will be allocated to RemainCo, including, subject to certain exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specified trademarks and domain names; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other intellectual property (i)&nbsp;owned or controlled by Avidity or its subsidiaries, but excluding the
Company Intellectual Property, or (ii)&nbsp;otherwise specified in the Separation Agreement (the &#8220;RemainCo Intellectual Property&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specified <FONT STYLE="white-space:nowrap">in-license</FONT> agreements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all assets (other than intellectual property) owned or controlled by Avidity or any of its subsidiaries, other
than the assets to be retained by or transferred to the Company as described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides that liabilities
arising out of or resulting from the ownership or operation of the Company Business or the assets allocated to the Company will generally be retained by or transferred to the Company, including the following, subject to certain exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from any benefit plans maintained by the Company (or a
professional employer organization or employer of record engaged by the Company) and offered to the Company employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the employee benefit plans to be retained by or
transferred to the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the employment or engagement of the Transferred
Employees, either (i)&nbsp;exclusively arising following the effective time of the Distribution or (ii)&nbsp;otherwise allocated to the Company pursuant to the Separation Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities allocated to the Company or any of its subsidiaries following the Distribution under the
Separation Agreement with respect to employee matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the payment of the amounts under any retention bonus
program or individual retention bonus awards established by the Company or individual award agreement entered into by the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the payment of certain amounts under or with respect
to Avidity RSUs or cash awards granted to a newly-hired Avidity employee following the execution of the Merger Agreement, to the extent such newly-hired Avidity employee is a Transferred Employee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the payment of certain amounts under Avidity&#8217;s
Special Bonus Program granted to a Transferred Employee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities pursuant to any agreements or obligations of the Company, or following the closing of the Merger, any
member of the Company or any of its subsidiaries as of or after the effective time of the Distribution (the &#8220;Company Group&#8221;), under the Separation Agreement, the Merger Agreement, the RemainCo License Agreement, the Transition Services
Agreement or the Occupancy License Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the liabilities of Avidity, other than the liabilities allocated to the Company,
will generally be retained by or transferred to RemainCo, including the following, subject to certain exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from any assets allocated to RemainCo;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the ownership or operation of the RemainCo Business,
as conducted at any time prior to, on or after the effective time of the Distribution; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from transaction expenses incurred by Avidity or any of its
subsidiaries in connection with the Merger Agreement and the Separation Agreement, whether paid on, prior to or after the effective time of the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from the employment or engagement of all current and former
employees and service providers of RemainCo, whether arising on, prior to or following the effective time of the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities to the extent arising out of or resulting from any Avidity employee benefit plan which is not being
transferred from RemainCo to the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities allocated to RemainCo, any of its subsidiaries immediately following the effective time of the
Distribution or any entity that becomes a subsidiary of Avidity prior to the effective time of the Distribution upon which Avidity and Novartis mutually agree (the &#8220;RemainCo Group&#8221;) with respect to employee matters; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities pursuant to any agreements or obligations of Novartis, or following the closing of the Merger, any
member of the RemainCo Group, under the Separation Agreement, the Merger Agreement, the RemainCo License Agreement, the Transition Services Agreement or the Occupancy License Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Materials Separation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Separation
Agreement, Avidity, the Company and Novartis agreed upon a data and materials separation plan (the &#8220;Data and Materials Separation Plan&#8221;), pursuant to which Avidity, the Company and Novartis will (i)&nbsp;jointly review and determine
which data and materials in possession of Avidity, the Company or a third party are (a)&nbsp;exclusively related to the RemainCo Business, (b)&nbsp;exclusively related to the Company Business or (c)&nbsp;related to both the RemainCo Business and the
Company Business (such assets, the &#8220;Commingled Assets&#8221;) and (ii)&nbsp;with respect to the Commingled Assets, determine each of Avidity&#8217;s and the Company&#8217;s respective possession of, and rights of access to, such Commingled
Assets. Except as otherwise specified in the Data and Materials Separation Plan, Avidity will retain possession of each Commingled Asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity, the
Company and Novartis will use their respective reasonable best efforts to (i)&nbsp;implement the Data and Materials Separation Plan prior to the effective time of the Distribution (or, in the case of transfers of tangible embodiments of Company
Assets pursuant the Separation Agreement, as promptly as practicable following the date of delivery of such assets) and (ii)&nbsp;from and after the effective time of the Distribution, comply with the requirements under the Data and Materials
Separation Plan with respect to the maintenance of Commingled Assets that by their nature cannot be fully disentangled. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consents and Delayed Transfers
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides that Avidity and the Company will use reasonable best efforts to transfer any transferable licenses, permits,
registrations, approvals and authorizations to the Company and obtain any consents with respect to, among other things, contracts required in connection with the Distribution or, at the written request of the other party, the assignment or novation
of certain obligations under contracts, licenses and other liabilities of the parties. The Separation Agreement also requires RemainCo and the Company to cooperate with each other from and after the effective time of the Distribution to, among other
things, execute and deliver, or use reasonable best efforts to cause to be executed and delivered, all instruments, and to make all filings, provide any notice and obtain all consents and/or approvals under any licenses, permits, waivers, orders or
authorizations in order to effectuate the transfer of the applicable assets and assignment and assumption of the applicable liabilities pursuant to the Separation Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and after the Distribution, with respect to any asset whose transfer or assignment is delayed (excluding any Third Party Agreement), the party retaining
such delayed asset will hold for the use and benefit of the party or its subsidiary entitled thereto (at the expense of the entity entitled thereto) and use reasonable best efforts to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cooperate with the intended recipient to agree to any reasonable and lawful arrangements designed to provide the applicable party or its relevant subsidiary with the economic claims, rights,
benefits and control over such delayed asset and assume the economic burdens and obligations with respect thereto in accordance with the Separation Agreement, including by subcontracting, sublicensing or subleasing arrangements to the extent legally
permissible. From and after the Distribution, with respect to any liability whose assumption is delayed, the party or its relevant subsidiary intended to assume such delayed liability will, or will cause its relevant subsidiary to, pay or reimburse
the party (or its relevant subsidiary) retaining such delayed liability for all amounts paid or incurred by such party in connection with the retention of such delayed liability. The party retaining any delayed asset or delayed liability will, or
will cause its relevant subsidiary to, treat such delayed asset or delayed liability in the ordinary course of business in accordance with past practice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transition Services </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the date of the Separation
Agreement through the effective time of the Distribution, RemainCo and the Company will, and from the effective time of the Distribution through the applicable Service Period (as defined in the Transition Services Agreement), the Company will use
reasonable best efforts to, subject to certain exceptions and limitations: (i)&nbsp;establish replacement contracts with respect to the Company Business with any vendor or service provider with respect to specified transition services to be provided
under the Transition Services Agreement; or (ii)&nbsp;establish other reasonable and lawful arrangements designed to provide the Company Group with the rights and obligations contemplated under the Transition Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement requires the parties to take certain actions in connection with, and as a condition to RemainCo&#8217;s obligations to provide
certain services under, the Transition Services Agreement, including (i)&nbsp;using reasonable best efforts to establish separate information technology systems in order to receive information technology services; (ii)&nbsp;agreeing upon and using
reasonable best efforts to implement a lab recommissioning plan for the Company Real Property; (iii)&nbsp;establishing arrangements to prevent cross-contamination and entering into the Occupancy License Agreement for purposes of shared lab services
in the event that the lab at the Company Real Property is not recommissioned by the closing of the Merger; and (iv)&nbsp;establishing a quality management system for the Company in order to receive manufacturing services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a Change of Control Transaction (as defined below), RemainCo will not be obligated to provide any of the Transition Services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commingled Contracts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides
that any contract to which the Company or any of its subsidiaries following the Distribution is a party that relates to both the Company Business and the RemainCo Business will be treated as a Commingled Contract. From the date of the Separation
Agreement until the date that is twelve months after the Distribution, to the extent (i)&nbsp;the rights and obligations under any Commingled Contract have not or are not contemplated to be transferred to either the Company or RemainCo or provided
pursuant to the Transition Services Agreement, (ii)&nbsp;replacement contracts, contract rights, bids, purchase orders, or other agreements with respect to the Company Business or the RemainCo Business have not been obtained or are not contemplated
to be obtained pursuant to the Separation Agreement, and (iii)&nbsp;requested by either the Company or RemainCo in writing, each party will use reasonable best efforts to assist the other party (a)&nbsp;to establish replacement contracts, contract
rights, bids, purchase orders or other agreements with respect to either the Company Business or the RemainCo Business, or (b)&nbsp;to establish reasonable and lawful arrangements designed to provide either the Company and its subsidiaries or
RemainCo and its subsidiaries following the Distribution with the rights and obligations under such Commingled Contract to the extent related to either the RemainCo Business or the Company Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the Distribution, if RemainCo holds any asset of the Company or the Company holds any asset of RemainCo, RemainCo or the Company, as applicable, must
inform the other party and use reasonable best efforts to transfer such asset to the other party without extra cost. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing of the Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of the Distribution, and not in the event of a Permitted Third Party Sale, immediately prior to the effective time of the Distribution, Avidity
will pay and contribute to the Company an amount in cash equal to the Company Funding. However, if the aggregate amount of marketable securities and cash and cash equivalents contained in any bank and brokerage accounts owned by Avidity and its
subsidiary as of the close of business on the day prior to the effective time of the Distribution is less than the Company Funding, then Novartis will cause RemainCo to pay, or pay on behalf of RemainCo, the Company Funding Shortfall to the Company
concurrently with the closing of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Company holds in its bank or brokerage accounts marketable securities, cash or cash
equivalents having an aggregate value exceeding the Company Funding, the Company will, not later than immediately prior to the effective time of the Distribution, distribute to Avidity marketable securities, cash or cash equivalents that are
sufficient to reduce the value of the Company&#8217;s remaining marketable securities, cash and cash equivalents to $270&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the Distribution (and assuming a Permitted Third Party Sale has
not occurred), Avidity will distribute, on a pro rata basis, to holders of Avidity&#8217;s Common Stock as of the Record Date who hold their shares of Avidity Common Stock through the Distribution Date, all of the shares of Company Common Stock, as
of the time of the Distribution. Avidity&#8217;s board of directors (or a committee thereof), in accordance with applicable law, has established the Record Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Avidity stockholder on the Record Date will be entitled to receive one share of Company Common Stock for every ten shares of Avidity Common Stock held by
such stockholder as of the Record Date and through the Distribution Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the event of the Distribution, holders of any Avidity Equity
Awards as of the Record Date are entitled to receive Make Whole Awards that will be settled in shares of Company Common Stock at a ratio of one share of Company Common Stock per ten shares of Avidity Common Stock underlying such Avidity Equity
Award, subject to certain exceptions for Avidity RSUs granted to address promised equity awards in offer letters with recently-hired Avidity employees, which had not yet been granted as of the date of the Merger Agreement (the &#8220;New Hire
RSUs&#8221;) and any portion of the Avidity RSUs granted in connection with its annual performance award cycle in the ordinary course consistent with past practice if the Merger has not closed by March&nbsp;1, 2026 (the &#8220;2026 LTI
Awards&#8221;) that is unvested as of the Distribution Date. See &#8220;&#8212;<I>Employee Matters</I>&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Distribution Date,
immediately prior to the effective time of the Distribution, Avidity will instruct its stock transfer agent to effect the Distribution by distributing the shares of Company Common Stock to Avidity&#8217;s stockholders as of the Record Date who hold
their shares of Avidity Common Stock through the Distribution Date, and to credit the appropriate number of shares of Company Common Stock to book entry accounts for each such holder of shares of Avidity Common Stock. Avidity will instruct the stock
transfer agent to deliver the shares of Company Common Stock to a depositary and to mail each such Avidity stockholder on the Record Date who hold their shares of Avidity Common Stock through the Distribution Date, a statement of the shares of
Company Common Stock credited to such holder&#8217;s account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is subject to the satisfaction or waiver by Avidity and the Company on or prior to the Distribution Date,
as applicable, of each of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfaction or, to the extent permitted therein, waiver of the conditions precedent in the Merger Agreement to
the Merger, other than (i)&nbsp;the completion of the Distribution, (ii)&nbsp;solely in the case of a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Permitted Third Party Sale, effectiveness of the Registration Statement, and (iii)&nbsp;any conditions that by their nature are to be satisfied at the closing of the Merger (provided that such
conditions are then capable of being satisfied); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any judgment, ruling, order, writ, injunction, award, decision, assessment or decree of any
governmental authority preventing the consummation of the Separation, the Distribution or the Merger and any law enacted or deemed applicable to any such transaction by any governmental authority of competent jurisdiction that makes consummation of
the Separation, the Distribution or the Merger illegal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execution of documentation effecting transfer of the Third Party Agreements from Avidity to the Company, in a
form reasonably satisfactory to Novartis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued effectiveness of the RemainCo License Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execution and delivery of the Transition Services Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Separation having been effected in all material respects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides that Avidity may waive any of the conditions to the Distribution and proceed with the Distribution even if all such
conditions have not been met. Notwithstanding Avidity&#8217;s contractual ability to waive the conditions in the Separation Agreement, Avidity cannot proceed with the Distribution if there is a stop order, injunction or law preventing the
consummation of the Separation or the Distribution, if the Registration Statement is not declared effective by the SEC or if the Registration Statement does not remain effective. However, Avidity, as a standalone company, could still proceed with
the Distribution even if there is a stop order, injunction or law preventing the consummation of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Access to Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides for the following access to information, subject to certain exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the Distribution Date, each of RemainCo and the Company, or any of their affiliates, agrees to provide to
the other party, as soon as reasonably practicable after written request therefor, specific and identified agreements, documents, books, records or files (whether written or electronic) in the possession or under the control of such respective party
or any of its subsidiaries which relate to the requesting party or its business or which are reasonably necessary or advisable for the requesting party to prepare its financial statements and any reports or filings to be made with any governmental
authority or for legal compliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">from and after the Distribution Date, RemainCo and the Company will each use reasonable best efforts to make
available, upon reasonable written request, its and its subsidiaries&#8217; representatives as witnesses and any agreements, documents, books, records or files (whether written or electronic) within their control or which they may make available
without undue burden, as reasonably required by the requesting party in connection with the prosecution or defense of any proceeding, with the requesting party to bear all reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses in connection therewith; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for a period of five years after the Distribution Date, upon reasonable prior notice, each of RemainCo and the
Company will make available to the other applicable party&#8217;s officers and other authorized representatives reasonable access, during normal business hours, to its employees and properties that relate to the other party&#8217;s business, and
will furnish promptly all information concerning such other party&#8217;s business, and such other party&#8217;s properties and personnel related thereto, as may reasonably be requested, provided that neither party will be required to
(i)&nbsp;permit any inspection or disclosure of any information that, in the reasonable judgment of such party, would be detrimental to such party&#8217;s or its subsidiaries&#8217; business or operations, result in the disclosure of trade secrets
or <FONT STYLE="white-space:nowrap">know-how</FONT> of third parties or violate confidentiality obligations, be reasonably likely to result in a violation of any law, fiduciary duty or binding agreement entered into prior to the date of the
Separation Agreement or involve </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
information that is reasonably pertinent to a litigation or proceeding between the Company and its affiliates, on the one hand, and RemainCo and its affiliates, on the other hand, after the
Distribution, (ii)&nbsp;disclose any privileged information or (iii)&nbsp;submit to any invasive environmental testing or sampling. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Releases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides that, subject
to certain exceptions specified in the Separation Agreement, each party, on behalf of itself and each member of its group, and to the extent permitted by law, all persons who any time prior to the Distribution were stockholders, directors, officers,
agents or employees of any member of its respective group (in their respective capacities as such), effective at the time and conditioned upon the occurrence of the Distribution, will remise, release and forever discharge the other party and the
other members of the other party&#8217;s group and their respective successors, stockholders, directors, officers, agents or employees from any and all liabilities to the extent existing or arising from any acts or events occurring or failing to
occur or alleged to have occurred or have failed to occur, and any conditions existing or alleged to have existed, on or before the Distribution, including in connection with the Separation, the Distribution or any of the other transactions
contemplated under the Separation Agreement, the RemainCo License Agreement, the Transition Services Agreement and the Occupancy License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Separation Agreement, subject to
certain exceptions, RemainCo agrees to indemnify, defend and hold harmless the Company, each of its affiliates after giving effect to the Distribution and each of their respective directors, officers, employees and agents, from and against all
losses to the extent arising out of, by reason of or otherwise in connection with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities described under the section entitled &#8220;&#8212;<I>Transfer of Assets and Assumption of
Liabilities</I>&#8221; as allocated to RemainCo following the Distribution pursuant to the Separation Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of RemainCo, any of its subsidiaries following the Distribution, or any other person or entity to
pay, perform or otherwise promptly discharge such liabilities, whether prior to, at or after the effective time of the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach by RemainCo or any of its subsidiaries of the Separation Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except to the extent related to liabilities described under the section entitled &#8220;&#8212;<I>Transfer of
Assets and Assumption of Liabilities</I>&#8221; as allocated to the Company Group following the Distribution pursuant to the Separation Agreement, any guarantee, indemnification obligation, surety bond or other credit support agreement, arrangement,
commitment or understanding to the extent discharged or performed by Avidity or any of its affiliates following the Distribution for the benefit of the Company or any of its affiliates following the Distribution that survives the effective time of
the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information supplied by Novartis or Merger Sub in writing expressly for inclusion in the Registration Statement in connection
with the Distribution and the related information statement (including any amendments or supplements), the proxy statement or any other filings with the SEC made in connection with the transactions contemplated by the Separation Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain tax liabilities that RemainCo is liable for pursuant to the Separation Agreement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities relating to, arising out of or resulting from claims by any of RemainCo&#8217;s stockholders, in
their capacity as such, in connection with the Distribution, except to the extent relating to, arising out of, or resulting from existing agreements between such stockholders and any the Company indemnitees. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain exceptions, the Company agrees to indemnify, defend and hold harmless RemainCo, each of
its affiliates after giving effect to the Distribution, and each of their respective directors, officers, employees and agents, from and against all losses to the extent arising out of, by reason of or otherwise in connection with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities described under the section entitled &#8220;&#8212;<I>Transfer of Assets and Assumption of
Liabilities</I>&#8221; as allocated to the Company following the Distribution pursuant to the Separation Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the Company, any of its subsidiaries following the Distribution or any other person or entity to
pay, perform or otherwise promptly discharge such liabilities, whether prior to, at or after the effective time of the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach by the Company or any of its subsidiaries of the Separation Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except to the extent related to liabilities described under the section entitled &#8220;&#8212;<I>Transfer of
Assets and Assumption of Liabilities</I>&#8221; as allocated to RemainCo following the Distribution pursuant to the Separation Agreement, any guarantee, indemnification obligation, surety bond or other credit support agreement, arrangement,
commitment or understanding to the extent discharged or performed by the Company or any of its affiliates following the Distribution for the benefit of RemainCo or any of its affiliates following the Distribution that survives the effective time of
the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information contained in the Registration Statement in connection with the Distribution and the related information statement
(including any amendments or supplements), the proxy statement or any other filings with the SEC made in connection with the transactions contemplated by the Separation Agreement, excluding any such liabilities to the extent relating to information
supplied by Novartis or Merger Sub in writing expressly for inclusion in such filings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities relating to, arising out of or resulting from claims by any holders of shares of Company Common
Stock, in their capacity as such, in connection with the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain tax liabilities that the Company is liable for pursuant to the Separation Agreement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any liabilities incurred in connection with RemainCo&#8217;s performance of certain services to be provided under
the Transition Services Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Separation Agreement, the amount of any indemnifiable loss will be reduced by (i)&nbsp;any
insurance proceeds actually received, and any other amounts actually recovered from third parties in respect of the indemnifiable claim, less (ii)&nbsp;any related costs and expenses of such receipt or recovery, including the aggregate cost of
pursuing any related insurance claims and any taxes. The Separation Agreement provides that an insurer who would otherwise be obligated to pay any claim will not be relieved of the responsibility with respect thereto or have any subrogation rights
with respect thereto solely by virtue of the indemnification provisions of the Separation Agreement. Pursuant to the Separation Agreement, the indemnified party will use reasonable best efforts to seek to collect or recover any third-party insurance
proceeds or other indemnification, contribution or similar payments to which the indemnified party is entitled in connection with any liability for which the indemnified party seeks indemnification pursuant to the Separation Agreement. The amount of
any claim by an indemnified party under the Separation Agreement will also be reduced to reflect any actual tax savings received by any indemnified party that result from the losses that gave rise to such indemnity and will be increased by an amount
equal to any tax cost incurred by any indemnified party that results from the receipt of payments under the Separation Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation
Agreement also establishes procedures with respect to third-party claims subject to indemnification and related matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Matters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement will govern the respective rights, responsibilities and obligations of RemainCo and the Company after the Distribution with respect to
tax liabilities, tax returns, tax contests, and tax sharing regarding U.S. federal, state, local and foreign taxes. The Separation Agreement will also provide special rules for allocating certain tax liabilities resulting from the Distribution and
related transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Separation Agreement, the Company generally will provide a tax indemnity to RemainCo for the Company Indemnified Taxes
for any taxable period prior to the Distribution and RemainCo generally will provide a tax indemnity to the Company for any RemainCo Indemnified Taxes. The parties have also agreed to enter into a written, binding agreement to make a
Section&nbsp;336(e) Election with respect to the Company, which is expected to result in the Company receiving a fair market value tax basis in its assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Solicit</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Separation Agreement provides that, for a period of twelve months following the effective time of the Distribution, none of RemainCo, the Company or any of their respective subsidiaries will, without the prior written consent of the other party,
subject to certain exceptions, directly or indirectly recruit or solicit employees of the other party or its subsidiaries, or subject to certain exceptions, induce or attempt to induce any such employee to terminate his or her employment with, or
otherwise cease his or her relationship with, the other party or its subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Covenants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement addresses additional obligations of the parties relating to, among other matters, further assurances, guarantees, provision and
retention of corporate records, confidentiality, privilege and ownership and exchanges of information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Novartis Guaranty </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement includes a guaranty by Novartis of the performance by RemainCo of its obligations under the Separation Agreement, the RemainCo License
Agreement, the Transition Services Agreement and the Occupancy License Agreement following the effective time of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Matters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Distribution, Avidity or an affiliate of Avidity will transfer and assign the employment of specified current employees of Avidity and its
affiliates (the &#8220;Company Employees&#8221;) to a member of the Company Group (or a professional employer organization or employer of record engaged by a member of the Company Group (an &#8220;employer of record&#8221; or &#8220;EOR&#8221;)) in
accordance with applicable law. Any Company Employee not actively at work for RemainCo Group as of the effective time of the Distribution by reason of approved leave with RemainCo Group (an &#8220;Approved Leave Employee&#8221;) will remain employed
by RemainCo Group, and a member of the Company Group (or an EOR) will offer employment to the Approved Leave Employee following such leave (if the Approved Leave Employee returns within twelve months following the effective time of the
Distribution), subject to certain limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain employees set forth on a schedule to the Separation Agreement will not be Company
Employees for a period of time following the effective time of the Distribution (each such employee, a &#8220;Transition Employee&#8221;), and a member of the Company Group will offer employment to each Transition Employee as of the end of the
applicable transition period set forth on a schedule to the Separation Agreement. Each Transition Employee who commences employment with a member of the Company Group shall be deemed to be a Transferred Employee, except such employee will not be
eligible for severance benefits in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the termination of their employment with RemainCo or its affiliates. For a period of twelve months immediately following the effective time of the Distribution (or, if shorter, the date of
employment termination of the relevant Transferred Employee), the Company will, and will cause its affiliates or EOR to, provide each Transferred Employee with, subject to certain limitations, (i)&nbsp;a base salary or hourly wage rate and cash
incentive compensation opportunities (excluding equity-based incentive opportunities) that are each no less favorable than such offered to such Transferred Employee immediately prior to the effective time of the Distribution, (ii)&nbsp;employee
benefits that are substantially comparable in the aggregate to the employee benefits (excluding equity and equity-based compensation or benefits, defined benefit pension benefits, nonqualified deferred compensation and post-employment welfare
benefits (collectively, &#8220;Excluded Benefits&#8221;)) provided to the Transferred Employees immediately prior to the effective time of the Distribution, and (iii)&nbsp;a primary work location at the same work location or another location within
50 miles of the work location as of immediately prior to the effective time of the Distribution. Nothing in the Separation Agreement creates any obligation on the part of any member of the RemainCo Group or any member of the Company Group or an EOR
to (A)&nbsp;continue the employment of any individual or permit the return from a leave of absence for any period or (B)&nbsp;change the employment status of any individual from <FONT STYLE="white-space:nowrap">at-will.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will assume and honor, or will cause a member of the Company Group or an EOR to assume and honor, specified employment and individual agreements,
including any severance obligations in respect of Transferred Employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Distribution Date, RemainCo will, or will cause one of its affiliates
(other than a member of the Company Group) to pay all Transferred Employees for their accrued, unused vacation and paid time off through the effective time of the Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that a current employee at the executive level of any member of the RemainCo Group as of immediately following the effective time of the
Distribution resigns from employment with RemainCo or any of its affiliates under circumstances entitling such employee to severance payments or benefits or any accelerated payment of any deferred cash, retention, transaction or similar bonus or
award (collectively, the &#8220;Separation Benefits&#8221;) and such employee commences employment with the Company within 24 months following the effective time of the Distribution, the Company will reimburse RemainCo for the aggregate amount of
the Separation Benefits within 30 days of the employee&#8217;s commencement of employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will, or will cause its
affiliates or an EOR to, credit each Transferred Employee the service credited to such Transferred Employee by RemainCo as of the effective time of the Distribution for purposes of eligibility, vesting, level of paid time off benefits and future
paid time off accruals and for purposes of determining severance amounts, other than as would result in duplication of benefits for the same service period or with respect to any Excluded Benefits. The Company will, for the first plan year of such
participating Transferred Employee, use reasonable best efforts to (i)&nbsp;waive or cause to be waived certain benefit plan requirements to the extent such benefit plan requirements would not have been applicable to or were otherwise satisfied by
such Transferred Employee prior to the effective time of the Distribution under an analogous Avidity employee benefit plan; and (ii)&nbsp;credit each Transferred Employee with all amounts paid prior to the effective time of the Distribution with
respect to any Avidity employee benefit plan that is a group health benefit plan for purposes of satisfying all applicable deductible, coinsurance, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the effective time of the Distribution, Transferred Employees will cease active participation in the Avidity Biosciences 401(k) Plan
(the &#8220;401(k) Plan&#8221;). Prior to the effective time of the Distribution, Avidity will fully vest all employees of Avidity and its affiliates (including the Company) who participate in the 401(k) Plan in their account balances (to the extent
not already fully vested). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of or prior to the effective time of the Distribution, the Company may establish a severance plan to be effective with
respect to qualifying terminations from the Company Group following the effective time of the Distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the effective time of the Distribution, the Company Annual Incentive Plan (as defined in the
Separation Agreement) will be established, which will have terms and opportunities that are comparable, with certain limitations, to those in effect as of immediately prior to the effective time of the Distribution under the corresponding RemainCo
employee benefit plan except that performance metrics under the Company Annual Incentive Plan shall relate to the Company Business and the Company may modify the terms of the Company Annual Incentive Plan as it deems necessary and appropriate to
comply with applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Distribution, the Company will have full responsibility with respect to any liabilities arising or relating to
the employment or engagement of all Transferred Employees to the extent exclusively arising following the effective time of the Distribution and under the employment and individual agreements and benefit plans transferred to the Company (inclusive
of the payment or performance of any obligation arising out of or relating to any annual cash bonus or other short-term cash incentive plan or program in which the Company employees participate (including responsibility for the payment of the
bonuses thereunder with respect to the entire calendar year in which the closing of the Merger occurs)), with certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the
Distribution Date, Avidity and the Company will cooperate to establish, according to the terms of the Separation Agreement, (i)&nbsp;the 2026 Incentive Award Plan (the &#8220;2026 Plan&#8221;) and forms of standard award and Make Whole Award
agreements thereunder, which plan and standard award agreements are intended to be substantially similar to Avidity&#8217;s 2020 Incentive Award Plan and the forms of award thereunder, and (ii)&nbsp;the 2026 Employee Stock Purchase Plan (the
&#8220;ESPP&#8221;), intended to comply with Section&nbsp;423 of the Code, which plan is intended to be substantially similar to Avidity&#8217;s 2020 Employee Stock Purchase Plan. The Company will adopt such plans, and Avidity will approve such
plans as the Company&#8217;s sole stockholder prior to the effective time of the Distribution; provided, that, except for the Make Whole Awards, no awards will be granted under the 2026 Plan and no offering periods will commence under the ESPP prior
to the effective time of the Distribution. After such adoption and approval, and prior to the effective time of the Distribution, the Company and Avidity will take all steps necessary to register the equity compensation plan under the Securities Act
on Form&nbsp;S-8 or other appropriate form. After such registration, the Company will grant the Make Whole Awards to all holders of outstanding Avidity RSUs (aside from New Hire RSUs and 2026 LTI Awards) and Avidity Stock Options who are current
service providers to Avidity and its affiliates (including the Company) as of such grant. &#8220;Make Whole Award&#8221; means an award evidencing the right of holders of Avidity Stock Options and Avidity RSUs as of the Record Date to receive one
share of Company Common Stock per ten shares of Avidity Common Stock underlying such Avidity Stock Options and Avidity RSUs, as required by the terms of the Separation Agreement and as permitted by the SEC&#8217;s Staff Legal Bulletin No. 4. subject
to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the effective time of the Distribution, RemainCo will not, and will cause its affiliates to not, seek to enforce the
terms of any Avidity Employee Invention Assignment and Confidentiality Agreement between any member of the RemainCo Group and a Transferred Employee with respect to any such Transferred Employee&#8217;s right to be employed by or provide services to
the Company Group, but not with respect to (i)&nbsp;any obligations of confidentiality or <FONT STYLE="white-space:nowrap">non-use</FONT> of RemainCo&#8217;s confidential information that is unrelated to the Company in connection with the Company
Business, (ii)&nbsp;relating to employee <FONT STYLE="white-space:nowrap">non-solicit</FONT> obligations that apply to the Company under the Separation Agreement or (iii)&nbsp;invention assignment provisions with respect to the RemainCo Business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensed Names and Marks </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Separation
Agreement, the Company and the Company Group has granted to Novartis, RemainCo and the RemainCo Group a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use the trademarks in the Company Intellectual Property, including
&#8220;Avidity,&#8221; &#8220;Avidity Bio&#8221; and &#8220;Avidity Biosciences&#8221; (the &#8220;Company Marks&#8221;) to conduct the RemainCo Business outside the Cardiovascular Field (as defined in the RemainCo License Agreement). This license
generally expires six months after the effective time of the Distribution but expires four years after the effective time of the Distribution with regards to the &#8220;Avidity&#8221; trademark. RemainCo has agreed to cease using
&#8220;Avidity&#8221; (or variations thereof) in corporate names for RemainCo Group entities as soon as reasonably practicable after the effective time of the Distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Likewise, RemainCo and the RemainCo Group grant to the Company and the Company Group, a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license to the trademarks in the RemainCo Intellectual Property (the &#8220;RemainCo Marks&#8221;) to conduct the Company Business. This license expires three months after the effective time of the
Distribution. The Company is prohibited from using &#8220;Avidity&#8221; in conjunction with the words &#8220;Bio&#8221; or &#8220;Biosciences&#8221; after the effective time of the Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both parties and their respective group members may use the Company Marks and RemainCo Marks, as applicable, solely in the manner in which such trademarks
were used by RemainCo during the <FONT STYLE="white-space:nowrap">12-month</FONT> period prior to the effective time of the Distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Technology
Transfer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the requirements set forth in the RemainCo License Agreement, pursuant to the Separation Agreement, RemainCo, together with the
RemainCo Group, will, as soon as reasonably practicable, but in no event later than nine months following the effective time of the Distribution, complete or cause to be completed, the transfer to the Company and the Company Group all tangible
embodiments of all assets transferred to the Company, including all trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and any other confidential or proprietary information included therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise set forth in the Separation
Agreement, Transition Services Agreement or the Occupancy License Agreement, all costs and expenses incurred on or prior to the date of the Distribution in connection with the preparation, execution, delivery, printing and implementation of the
Separation Agreement, the Transition Services Agreement, the Occupancy License Agreement, the Registration Statement and the related information statement, and the transactions contemplated thereby, including the Distribution, will be paid by
RemainCo and deemed to be liabilities of RemainCo. Each party will bear its own costs and expenses incurred after the date of the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement will terminate
automatically and concurrently with any termination of the Merger Agreement and may be terminated, and the Distribution may be amended, modified or abandoned, at any time prior to the Distribution by an agreement in writing signed by Avidity and
Novartis, without the approval of the Company. After the Distribution, the Separation Agreement may only be terminated by an agreement in writing signed by RemainCo and the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Governing Law </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to the Separation Agreement
have agreed that the Separation Agreement is governed by, and will be construed in accordance with, the laws of the State of Delaware. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jurisdiction
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to the Separation Agreement have agreed that any suit, action or proceeding seeking to enforce any provision of, or based on any matter
arising out of or in connection with, the Separation Agreement or the transactions contemplated thereby (whether brought by any party or any of its affiliates or against any party or any of its affiliates) will be brought in the Delaware Chancery
Court or, if such court shall not have jurisdiction, any federal court located in the State of Delaware or other Delaware state court, and each of the parties irrevocably consented to the exclusive jurisdiction of such courts (and of the appropriate
appellate courts therefrom) in any such suit, action or proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Third-Party Beneficiaries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the indemnification provisions relating to indemnified parties, the Separation Agreement is solely for the benefit of the
parties to the Separation Agreement and it does not confer upon any person (other than the parties to the Separation Agreement and their respective successors and permitted assigns) any right, benefit or remedy of any nature. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Waiver </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to the Separation Agreement agreed
that, at any time prior to the effective time of the Distribution, either party may extend the time for the performance of any of the obligations or other acts of the other party, or may waive compliance with any of the agreements of the other party
or any conditions to its own obligations, in each case, only to the extent such obligations, agreements and conditions are intended for its benefit, provided that such extension or waiver is set forth in a writing executed by such party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Specific Performance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to the Separation
Agreement have agreed that irreparable harm would occur that monetary damages could not make whole in the event of any breach of the Separation Agreement, and that the parties to the Separation Agreement are entitled to specific performance, or
other <FONT STYLE="white-space:nowrap">non-monetary</FONT> equitable relief, to prevent or restrain breaches or threatened breaches of the Separation Agreement without posting any bond or undertaking, in addition to any other remedy to which the
parties may be entitled at law or in equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Permitted Third Party Sale </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a Permitted Third Party Sale, among other things: (i)&nbsp;the Distribution will be replaced by consummation of the Permitted Third Party Sale;
and (ii)&nbsp;certain tax rights or obligations will no longer apply to Avidity, the Company or any of their respective affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change of Control
Transaction </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement provides that, in the event of a Change of Control Transaction, among other things, (i)&nbsp;the scope of
intellectual property to be transferred to the Company will be adjusted according to the terms of the Separation Agreement; and (ii)&nbsp;RemainCo will not be obligated to provide any of the Transition Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement defines a &#8220;Change of Control Transaction&#8221; as a transaction with a third party or third parties involving (i)&nbsp;the
acquisition, merger, or consolidation, directly or indirectly, of the Company or its affiliate or, if there is a person that controls the Company or its affiliate, such &#8220;Controlling Person&#8221;, and, immediately following the consummation of
such transaction, the stockholders of the Company or its affiliate or Controlling Person, immediately prior thereto holding, directly or indirectly, as applicable, shares of capital stock of the surviving or continuing company representing less than
50% of the outstanding shares of such surviving or continuing company, (ii)&nbsp;the sale of all or substantially all of the assets or business of such party or, if there is a Controlling Person, such Controlling Person, or (iii)&nbsp;a person, or
group of persons acting in concert, acquiring, directly or indirectly, more than 50% of the voting equity securities or management control of such party or, if there is a Controlling Person, such Controlling Person. For the avoidance of doubt, a
Change of Control Transaction includes a Permitted Third Party Sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Consequences of the Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section describes the material U.S. federal income tax consequences of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> to stockholders of Avidity.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section applies solely to persons that hold shares of Avidity Common Stock and Company Common Stock as
capital assets within the meaning of section 1221 of the Code (generally property held for investment). This section does not address all aspects of U.S. federal income taxation and does not discuss all of the tax consequences that may be relevant
to a holder in light of such holder&#8217;s individual circumstances, including state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences, estate and gift tax consequences, and tax consequences arising under the Medicare tax
on net investment income or the alternative minimum tax. Moreover, this section does not address the Foreign Account Tax Compliance Act of 2010 (including the Treasury Regulations promulgated thereunder and intergovernmental agreements entered into
pursuant thereto or in connection therewith and any laws, regulations or practices adopted in connection with any such agreement). This section does not apply to holders subject to special rules, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a dealer or broker in stocks, securities, commodities or foreign currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a regulated investment company or real estate investment trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trader in securities that elects to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for securities holdings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a bank, financial institution, mutual fund or insurance company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person that directly, indirectly or constructively owns 5% or more of the combined voting power of Avidity or
the Company, or of the total value of the shares of Avidity Common Stock or Company Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person that holds shares of Avidity Common Stock or Company Common Stock as part of a straddle or a hedging,
conversion, or other risk reduction transaction for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person that acquires or sells shares of Avidity Common Stock as a part of wash sale for U.S. federal income tax
purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person that is, or holds Avidity Common Stock through, partnerships or other pass-through entities for U.S.
federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person that is an expatriate and former long-term resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person required to recognize income or gain no later than such income or gain is required to be reported on an
applicable financial statement (as defined in Section&nbsp;451(b) of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person that acquired shares of Avidity Common Stock or Company Common Stock pursuant to the exercise of
employee share options, through a tax qualified retirement plan or otherwise as compensation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a U.S. holder (as defined below) whose functional currency is not the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section is based on the Code, its legislative history, existing and proposed regulations, published rulings and court decisions, all as of the date of
this information statement. These laws are subject to change, possibly on a retroactive basis. Any such change could alter the tax consequences to the holders as described herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is intended to provide only a general summary of the material U.S. federal income tax consequences of the Distribution in the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> to holders of shares of Avidity Common Stock. We do not intend it to be a complete analysis or description of all potential U.S. federal income tax consequences of the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> The U.S. federal income tax laws are complex and subject to varying interpretations. Accordingly, the Internal Revenue Service (the &#8220;<I>IRS</I>&#8221;) may not agree with the tax consequences
described in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds shares of Avidity
Common Stock, the tax treatment of a partner in such partnership generally will depend on the status of the partner and activities of the partnership. Holders that are partners of a partnership holding shares of Avidity Common Stock should consult
their own tax advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not sought, and do not intend to seek, any ruling from the IRS with respect to the statements made
and the conclusions reached in the following summary, and no assurance can be given that the IRS will agree with the views expressed herein, or that a court will not sustain any challenge by the IRS in the event of litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STOCKHOLDERS ARE URGED TO CONSULT WITH THEIR TAX ADVISORS AS TO THE TAX CONSEQUENCES OF THE <FONT STYLE="white-space:nowrap">SPIN-OFF</FONT> AND OWNERSHIP
OF THE COMPANY COMMON STOCK IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES, INCLUDING THE APPLICABILITY AND EFFECT OF U.S. FEDERAL (INCLUDING THE ALTERNATIVE MINIMUM TAX), STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> AND OTHER TAX
LAWS AND OF CHANGES IN THOSE LAWS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, the term &#8220;U.S. holder&#8221; means a beneficial owner of shares of Avidity
Common Stock that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized in or under the laws of the United States, any state thereof or the District
of Columbia or other entity treated as a domestic corporation for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if (i)&nbsp;its administration is subject to the primary supervision of a court within the United States
and one or more U.S. persons have the authority to control all substantial decisions of the trust; or (ii)&nbsp;it has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income tax regardless of its source.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">&#8220;Non-U.S.</FONT> holder&#8221; is a beneficial owner (other than a partnership or other
pass-through entity for U.S. federal income tax purposes) of shares of Avidity Common Stock that is not a U.S. holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of Company Common Stock in the Distribution (including fractional shares for which U.S. holders receive cash in lieu thereof) in the event of
the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will be treated as a taxable distribution to U.S. holders for U.S. federal income tax purposes. As a general matter, a distribution by a corporation to a stockholder with respect to such
stockholder&#8217;s shares of the corporation&#8217;s stock is treated as a taxable dividend to the extent of such stockholder&#8217;s ratable share of any current or accumulated earnings and profits of the corporation, with the excess treated first
as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital to the extent of such holder&#8217;s adjusted tax basis in the shares of the corporation&#8217;s stock and, thereafter, as capital gain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, RemainCo has not calculated earnings and profits in accordance with U.S. federal income tax principles. Accordingly, U.S. holders should expect to
treat the Distribution (including fractional shares for which U.S. holders receive cash in lieu thereof) in the event of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> as a taxable dividend for U.S. federal income tax purposes and the
remainder of this discussion assumes such treatment. Dividends are generally taxed as ordinary income. Dividends paid to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder (including an individual) that constitute qualified dividend
income are taxable to the U.S. holder at the preferential rates applicable to long-term capital gains, provided that the U.S. holder holds the shares for more than 60 days during the <FONT STYLE="white-space:nowrap">121-day</FONT> period beginning
60 days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date and meets other holding period requirements. RemainCo expects that any amount treated as a dividend paid by RemainCo to a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder pursuant to the Distribution will constitute qualified dividend income to any U.S. holder that meets the applicable holding period requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. holder&#8217;s tax basis in the shares of Company Common Stock received in the Distribution generally will equal the fair market value of those shares
on the Distribution Date, and a U.S. holder&#8217;s holding period for those shares will begin the day after the Distribution Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. holder that receives cash in lieu of a fractional share of Company Common Stock generally will be
treated as having received a fractional share and having received such cash as consideration for the sale of such share, and will recognize capital gain or loss (if any) based on the difference between the amount of cash received and the fair market
value on the Distribution Date of the fractional share of Company Common Stock deemed received. Such gain or loss generally will be short-term capital gain or loss. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although RemainCo will ascribe a value to the shares of Company Common Stock it distributes in the Distribution for tax purposes, this valuation is not
binding on the IRS or any other tax authority. These taxing authorities could ascribe a higher valuation to those shares, particularly if the shares of Company Common Stock trade at prices significantly above the value ascribed to those shares by
RemainCo in the period following the Distribution. Such a higher valuation may cause a larger reduction in the tax basis of a U.S. holder&#8217;s shares of Avidity Common Stock or may cause a U.S. holder to recognize additional dividend or capital
gain income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions on Company Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not anticipate the Company declaring or paying cash dividends in the foreseeable future. However, if the Company does make distributions of cash or
property on its shares, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from the Company&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. Dividends received by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders (including individuals) may be taxed at preferential rates applicable to qualified dividend income, provided certain holding period
requirements are met. Corporate U.S. holders that meet certain holding period and other requirements may be eligible for a dividends-received deduction for a portion of the dividend received. Amounts not treated as dividends for U.S. federal income
tax purposes will constitute a return of capital and first be applied against and reduce a U.S. holder&#8217;s adjusted tax basis in its Company Common Stock, but not below zero. Any excess will be treated as capital gain. Such gain generally will
be taxable as long-term capital gain if the U.S. holder&#8217;s holding period in the Company Common Stock exceeds one year, which is subject to preferential tax rates for <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale or Other Taxable Disposition of Company Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a subsequent sale or other taxable disposition of a share of Company Common Stock, a U.S. holder will recognize taxable gain or loss equal to the
difference between the amount realized on the disposition of the share and the U.S. holder&#8217;s adjusted tax basis in the share. The gain or loss will be capital gain or loss. A <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder
(including an individual) with a holding period in excess of one year generally will be eligible for reduced tax rates for such long-term capital gains. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the reasons discussed above, <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should expect to treat the Distribution (including fractional shares
for which U.S. holders receive cash in lieu thereof) in the event of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> as a taxable dividend for U.S. federal income tax purposes. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should
consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively
connected income, to the extent that the Distribution of Company Common Stock to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is treated as a dividend, it will be subject to U.S. federal withholding tax at a rate of 30% of the fair
market value of the Company Common Stock (including fractional shares for which U.S holders receive cash in lieu thereof) distributable to such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder (or such lower rate specified by an applicable
income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable (or other applicable documentation), certifying qualification for the lower treaty rate). A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess
amounts withheld by timely filing an appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RemainCo or other applicable withholding agents may be required or
permitted to withhold at the applicable rate on all or a portion of the Company Common Stock (including shares for which U.S. holders receive cash in lieu thereof) distributable to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder. Any such
withholding with respect to Company Common Stock would be satisfied by RemainCo or any of its withholding agents by withholding and selling a portion of the shares of Company Common Stock that otherwise would be received by such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder, or by withholding from other property held in such holder&#8217;s account (including cash in lieu of fractional shares) with the withholding agent. Any such withheld and sold shares will be treated
as distributed to the holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Distribution to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder maintains a permanent
establishment or fixed base in the United States to which such Distribution is attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption,
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder must furnish to the applicable withholding agent a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> certifying that the Distribution is effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder maintains a
permanent establishment or fixed base in the United States to which the Distribution is attributable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder for which the Distribution is effectively connected or attributable to a permanent establishment or fixed base in this manner will be subject to U.S. federal income tax with respect to the Distribution on a net income basis at the regular
rates that apply to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) thereon,
as adjusted for certain items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions on Company Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not anticipate the Company declaring or paying cash dividends in the foreseeable future. However, if the Company does make distributions of cash or
property on its shares, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from the Company&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s adjusted tax basis in its
Company Common Stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below in the section entitled &#8220;<I>Material U.S. Federal Income Tax
<FONT STYLE="white-space:nowrap">Consequences&#8212;Non-U.S.</FONT> Holders&#8212; Sale or Other Taxable Disposition of Company Common Stock.</I>&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder of Company Common
Stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder
furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable (or other applicable documentation), certifying
qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts
withheld by timely filing an appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder
are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder maintains a permanent establishment or fixed base in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder will be exempt from
the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT>
certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, that the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder maintains a permanent establishment or fixed base in the United States to which such dividends are attributable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at
the regular rates that apply to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax
treaty) on such effectively connected dividends, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult
their tax advisors regarding their entitlement to the benefits, and the application, of any income tax treaties to them with respect to distributions on Company Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale or Other Taxable Disposition of Company Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable
disposition of Company Common Stock (including with respect to any cash received in lieu of a fractional share of Company Common Stock) unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s
conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder maintains a permanent establishment or fixed base in the United States to which
such gain is attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company
Common Stock constitutes a U.S. real property interest, or &#8220;USRPI,&#8221; by reason of the Company&#8217;s status as a U.S. real property holding corporation, or &#8220;USRPHC,&#8221; for U.S. federal income tax purposes at any time during the
shorter of the five-year period ending on the date of such disposition or such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s holding period of such Company Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates that
apply to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively
connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of
30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder (even though the individual is not considered a resident of the
United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder timely files U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, the Company does not anticipate becoming a USRPHC. Because the determination of whether the Company is a USRPHC
depends on the fair market value of the Company&#8217;s USRPIs relative to the fair market value of its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and its other business assets, there can be no assurance the Company
will not become a USRPHC in the future. Even if the Company were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder of Company Common Stock will not be subject to
U.S. federal income tax if such stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder owned, actually and
constructively, 5% or less of such stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#8217;s holding period, or if another
exception from these rules under the Code applies. No assurance can be provided that Company Common Stock will be treated as &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on an established securities market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding potentially applicable income tax treaties that may
provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting generally will apply to payments to a holder pursuant to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> unless such stockholder is
an entity that is exempt from information reporting and, when required, properly demonstrates its eligibility for exemption. Any payment to a U.S. holder that is subject to information reporting generally will also be subject to backup withholding,
unless such U.S. holder provides the appropriate documentation (generally, IRS Form <FONT STYLE="white-space:nowrap">W-9)</FONT> to the applicable withholding agent certifying that, among other things, its taxpayer identification number is correct,
or otherwise establishes an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information reporting and backup withholding rules that apply to payments to a holder pursuant to the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> generally will not apply to payments to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder if such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder certifies under penalties of perjury that it
is not a U.S. Person (generally by providing an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other applicable IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8)</FONT> or otherwise establishes an exemption. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors to determine which IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> is appropriate. However, information returns are required to be filed with the IRS in connection with any distribution of the Company Common Stock in the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder, regardless of whether such distributions constitute dividends or any tax was actually withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain stockholders (including corporations) generally are not subject to backup withholding. Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules generally will be allowed as a refund or a credit against a holder&#8217;s U.S. federal income tax liability if the required information is properly and timely furnished by such holder to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE FOREGOING SUMMARY DOES NOT DISCUSS ALL ASPECTS OF U.S. FEDERAL INCOME TAXATION THAT MAY BE RELEVANT TO PARTICULAR STOCKHOLDERS. YOU ARE URGED TO
CONSULT YOUR TAX ADVISOR REGARDING THE PARTICULAR TAX CONSEQUENCES TO YOU OF THE <FONT STYLE="white-space:nowrap">SPIN-OFF</FONT> AND OWNERSHIP OF THE COMPANY COMMON STOCK IN LIGHT OF YOUR PARTICULAR CIRCUMSTANCES, INCLUDING THE APPLICATION AND
EFFECT OF ANY FEDERAL, STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.,</FONT> OR OTHER LAWS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing and Trading of Our Common Stock
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is not currently a public market for shares of Company Common Stock. We have applied to list shares of Company Common Stock on Nasdaq under the
symbol &#8220;RNA,&#8221; which is currently the symbol for the shares of Avidity Common Stock listed on Nasdaq. We expect that Company Common Stock will commence trading on a standalone basis at 9:30 a.m., Eastern Time, on the trading day following
the Distribution. For stockholders who own shares of Avidity Common Stock through a broker or other nominee, the Company Common Stock that such stockholders are entitled to receive in the Distribution will be credited to their accounts by the broker
or other nominee on or after the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date. There will not be any trading of Company Common Stock on a &#8220;when-issued&#8221; basis or any &#8220;ex-distribution&#8221; trading of Avidity Common
Stock before the Ex-Dividend Date. Investors are encouraged to consult with their financial advisors regarding the specific implications of buying or selling Avidity Common Stock on or before the Distribution Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There will not be any trading of Company Common Stock on a &#8220;when-issued&#8221; basis before the Ex-Dividend Date. We cannot predict the price at which
Company Common Stock will trade after the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date. Particularly until shares of Company Common Stock are fully distributed and an orderly market develops in Company Common Stock, the price at which
such shares trades may fluctuate significantly. In addition, the trading price of Company Common Stock held by stockholders after the Distribution may be less than, equal to, or greater than the trading price of the Avidity Common Stock prior to the
Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Common Stock distributed to Avidity stockholders will be freely transferable, except for shares received by people who may be
considered affiliates with us or shares subject to contractual restrictions. People who may be considered our affiliates after the Distribution generally include individuals or entities that control,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are controlled by, or are under common control with us. This may include certain of our officers, directors and significant stockholders. Persons who are our affiliates will be permitted to sell
their shares only pursuant to an effective registration statement under the Securities Act, or an exemption from the registration requirements of the Securities Act, or in compliance with Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for Furnishing This Information Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
information statement is being furnished by us solely to provide information to holders of Avidity Common Stock who will receive our common stock in the Distribution. It is not, and is not to be construed as, an inducement or encouragement to buy or
sell any of our securities. We and Avidity will not update the information in this information statement except in the normal course of our and Avidity&#8217;s respective public disclosure obligations and practices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_7"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company pioneering delivery of RNA therapeutics to the heart to transform the standard of care for people living with
cardiomyopathies. Our proprietary technology leverages the targeted our RNA delivery platform initially developed at Avidity, which combines the tissue selectivity of mAbs and other targeted delivery ligands with the precision of oligonucleotides.
This unique combination is designed to allow selective targeting of the underlying genetic drivers of disease that were previously undruggable. Through targeted, <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery of siRNA to cardiac tissues,
our approach has the potential to overcome key limitations of nonspecific viral and nanoparticle-based delivery systems, including challenges related to tissue specificity, immunogenicity, and redosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The field of precision cardiology represents a significant scientific, clinical and commercial opportunity in cardiomyopathies, which impact approximately
4.42&nbsp;million people worldwide. Current treatments focus on symptom management rather than addressing underlying genetic drivers of disease. We are committed to redefining standard of care paradigms by delivering disease modifying precision
cardiology therapies to address genetically driven cardiomyopathies. Genetically driven conditions account for nearly 1 in 3 cardiomyopathy patients worldwide. We will do this by leveraging our proprietary technology, including next generation
innovations, expertise and deep knowledge of underlying disease pathophysiology, and strong business acumen, geared initially towards rare disease patient populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of programs that target genetically validated drivers of cardiomyopathy&#8212;PRKAG2 and PLN. These genetic drivers are
associated with PRKAG2 syndrome and PLN cardiomyopathy&#8212;genetic heart conditions associated with severe, often life-threatening forms of heart disease. There are currently no therapies specifically approved for PRKAG2 syndrome or PLN
cardiomyopathy, and current approaches rely on standard of care for heart failure symptoms (e.g., ACE inhibitors, beta-blockers). Given the heterogeneity of these diseases and underlying genetic drivers, new precision cardiology approaches are
needed to more precisely address the underlying causes of the disease. Our programs are supported by robust preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform
technology at Avidity. We have observed potent and durable messenger RNA (&#8220;mRNA&#8221;) knockdown, reversal of disease phenotypes in animal models, and favorable tolerability profiles in <FONT STYLE="white-space:nowrap">non-human</FONT>
primates (&#8220;NHP&#8221;) in our preclinical studies in cardiac disease. While we are initially focused on targeting rare cardiac conditions with high unmet need, we believe our technology, coupled with the robust preclinical data across two
different therapeutic areas, supports our strategy to expand the pipeline to treat a broader range of genetic and cardiac diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are well
positioned to become a leader in precision cardiology given our expertise, strategic partnerships and our proprietary RNA delivery platform, for which we have retained certain rights (see &#8220;<I> &#8212;Intellectual Property&#8212;RemainCo
License Agreement</I>&#8221; for more information on the RemainCo License Agreement). The RNA delivery platform, initially developed at Avidity&#8212;in addition to the scientific, clinical and regulatory expertise that powered Avidity&#8217;s
development&#8212;serve as the backbone for our long-term vision: to pioneer precision RNA medicines for the heart and profoundly improve the lives of people impacted by cardiac diseases. We plan to achieve our vision through a commitment to
scientific rigor, patient-centric development, and operational excellence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are building a cutting-edge biopharmaceutical company with a focus on precision cardiology and have a three-pronged strategic approach: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pioneer precision <FONT STYLE="white-space:nowrap">RNA-based</FONT> therapies that transform the
identification, treatment and care of people with cardiomyopathies by leveraging the RNA delivery platform, our development expertise and our deep understanding of the underlying disease pathophysiology.</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<B></B>The RNA delivery platform was initially developed at Avidity and was used for the first-ever successful targeted delivery of siRNA to the muscle, supporting the advancement of three rare
neuromuscular programs into registrational development. We are expanding the reach of the RNA delivery platform to precision cardiology and are advancing next-generation technology innovations, which we have observed to improve siRNA delivery in
cardiac muscle. Our management team, which includes multiple alumni from Avidity, brings deep expertise in identifying targets that are well understood and are believed to directly address the underlying biology of a disease. Our rigorous target
selection process is designed to maximize the probability of technical success in clinical development and prioritizes targets based on high penetrance, clear genotype-phenotype correlations, and the ability to develop animal models that
recapitulate the key features of human disease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Advance a precision cardiology pipeline that achieves proof of concept of RNA delivery to the heart and
addresses the underlying causes of cardiomyopathies, redefining standard of care paradigms. </B>We are prioritizing advancement of our initial product candidates ATR 1072 and ATR 1086 for the treatment of PRKAG2 syndrome and PLN cardiomyopathy,
respectively. PRKAG2 syndrome and PLN cardiomyopathy are both severe, life-threatening rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. If supported by positive Phase 1 trial results, we
expect to advance ATR 1072 and ATR 1086 into potentially registrational clinical trials while continuing to develop these and other pipeline programs, expanding into broader cardiology indications with high unmet need. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Achieve clinical proof of concept for ATR 1072.</B> ATR 1072 is specifically designed to silence PRKAG2 mRNA,
the gene product that when mutated causes increased <FONT STYLE="white-space:nowrap">AMP-activated</FONT> protein kinase (&#8220;AMPK&#8221;) activity and drives cardiac glycogen accumulation. At the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> stage, we expect to show PRKAG2 RNA knockdown, glycogen depletion, changes in <FONT STYLE="white-space:nowrap">N-terminal</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">pro-B-type</FONT></FONT> natriuretic peptide <FONT STYLE="white-space:nowrap">(&#8220;NT-proBNP&#8221;)</FONT> and at later times changes in electrocardiogram (&#8220;ECG&#8221;), chamber volumes. Changes in AMPK activity
will be difficult to measure due to the complexity of the AMPK system (multiple isoforms and subcellular locations), inherent technical limitations of detection methods, and the subtle, transient nature of the changes themselves. Subject to
successful completion of regulatory submission and clearance for ATR 1072, we plan to initiate the Phase 1 clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in the second half of 2026.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Progress ATR 1086 into clinical development.</B> ATR 1086 is specifically designed to silence PLN mRNA, a
negative regulator of sarcoplasmic reticulum Ca<SUP STYLE="font-size:75%; vertical-align:top">2+</SUP>-ATPase 2a (&#8220;SERCA2a&#8221;), a critical protein in cardiac muscle cells that regulates calcium handling and contraction. When overexpressed
or mutated, PLN disrupts calcium homeostasis and impairs cardiac function. In <FONT STYLE="white-space:nowrap">PLN-R14del</FONT> cardiomyopathy, which is the most prevalent disease-relevant PLN mutation, ATR 1086 reduces PLN protein aggregates that
disrupt sarcoplasmic reticulum (&#8220;SR&#8221;) function, prevents disease onset and early mortality in preclinical models, and shows favorable tolerability in <FONT STYLE="white-space:nowrap">non-GLP</FONT> studies in cynomolgus monkeys, a NHP
species, with ~80% PLN mRNA knockdown over three months. Beyond rare genetic cases, ATR 1086 has broader therapeutic potential in heart failure and other cardiomyopathies characterized by impaired calcium handling and reduced SERCA2a activity,
offering a precise approach to restore normal calcium handling, improve heart muscle contraction, and slow disease progression. Subject to successful completion of IND filing and regulatory clearance for ATR 1086, we plan to initiate the Phase 1
clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in 2028.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Build a fully integrated company based on our understanding of the unique needs of people with rare diseases
and pave a new path for cardiomyopathies from drug discovery and development to patient care and clinical practice. </B>Our leadership and management team are comprised of pioneers in RNA medicines with deep scientific and rare disease expertise.
Our employees are dedicated to and guided by transparency, integrity, teamwork, excellence and innovation to help us achieve our mission rapidly, responsibly, and efficiently. We plan to maintain a disciplined approach to capital allocation and
align program prioritization with the highest probability of technical and clinical success to positively impact patients worldwide. We are focused on employing a patient-first strategy through highly collaborative patient community engagements and
partnerships ensuring their perspectives and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
insights inform our strategic approach and guide our decision-making. Ultimately, our goal is to rapidly advance our pipeline assets from research and development to commercialization ensuring
access to patients and clinicians around the world. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RNA delivery platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are committed to pioneering the delivery of
RNA therapies to the heart muscle and overcoming the current limitations of oligonucleotide therapies to treat a wide range of serious cardiac conditions. The RNA delivery platform is built on the foundation of the AOC technology, originally
developed at Avidity, which we utilize to design, engineer and develop therapeutics that combine the specificity of mAbs with the precision of oligonucleotide therapies targeting the underlying cause of cardiac conditions previously untreatable with
such therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have accumulated deep experience regarding oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and
conjugation, and drug delivery techniques. We collectively refer to the <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology borne out of this experience, and its systematic application in the design and development of our
product candidates, as the &#8220;RNA delivery platform.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond AOCs, we are also developing a next-generation RNA delivery platform with the
potential for subcutaneous and less frequent dosing which we believe will help achieve greater durability, increased potency and ultimately increased patient adherence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our deep experience with oligonucleotide
therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques provide a solid foundation for our efforts to address the current limitations of oligonucleotide therapies for cardiac conditions. The
disruptive and broad RNA delivery platform also affords us the option to deploy various types of oligonucleotides to treat cardiac conditions including siRNAs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our RNA therapeutics are designed to do the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combine validated tissue selectivity of targeted delivery ligands, including mAbs, with the precision of
oligonucleotides; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver to cardiac tissues and cell types previously untreatable with RNA therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">address the underlying cause of rare and genetically defined cardiac conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">leverage and scale the RNA delivery platform, our existing <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
and clinical experience and experienced manufacturers who can utilize well-established and scalable methods for manufacturing mAbs and oligonucleotides. We also have the ability to use a single mAb across multiple programs, providing significant
leverage around development costs and timelines associated with each incremental program. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of the RNA delivery platform
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our product candidates derived from the RNA delivery platform will have the potential to offer the following distinct advantages
over existing RNA therapeutics: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential to directly address genetic cause of cardiomyopathy in patients</I>: the RNA delivery platform is
designed to enable <FONT STYLE="white-space:nowrap">non-viral,</FONT> specific delivery of RNA therapeutics directly into cardiomyocytes&#8212;with the potential to achieve potent, homogeneous gene silencing in genetically defined cardiomyopathies
where existing small-molecule or viral approaches face limitations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expand scope of cardiac conditions addressable with oligonucleotides</I>: (i)&nbsp;utilizes identified cell
surface protein-antibody pairs to design oligonucleotides to precisely target the underlying cause of diseases previously untreatable with RNA therapeutics; (ii)&nbsp;flexibility to deploy an appropriate oligonucleotide type for cardiac conditions;
and (iii)&nbsp;optimize all structural components of the RNA delivery platform for effective delivery&#8212;the oligonucleotide, the mAb and the antibody conjugate design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential for a favorable safety profile:</I> (i)&nbsp;utilize the same antibody and oligonucleotide
therapeutic modalities as Avidity has used in its clinical trials which have well-studied properties; and (ii)&nbsp;utilize targeted delivery and selective and specific target pharmacology limiting potential for off target effects;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Infrequent dosing</I>: ability to deliver oligonucleotides to tissues and cells at concentrations that produce
pronounced and prolonged pharmacodynamic effects as observed in our preclinical models; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Readily reproducible and scalable</I>: (i)&nbsp;AOCs synthesized using well-established and scalable methods
for manufacturing mAbs and oligonucleotides; and (ii)&nbsp;ability to use a single mAb across multiple programs provides significant leverage around development costs and timelines associated with each incremental program. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Experienced Leadership Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our senior management team
has extensive experience in successfully developing and commercializing RNA therapies for rare genetic diseases through their involvement with major pharmaceutical and biotechnology companies. Our team members have led research, development and <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> activities in rare diseases, including discovering and developing the innovative AOC technology. They have collective experience in advancing RNA therapies including gaining alignment with regulatory
agencies on both accelerated regulatory pathways as well as paving global approval paths for rare diseases that require novel endpoints. The team has worked extensively with rare disease patient communities and understands the challenges and
opportunities of rare disease drug development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathleen Gallagher, our Chief Executive Officer, has exceptional executive
management expertise and tenured experience in the biopharmaceutical industry. She has over 20 years of experience and has led investor relations, portfolio strategy, program management and corporate affairs for preclinical to commercial stage
companies, including Avidity, Akcea and Merrimack. She has directed companies through multiple financings and an initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Hughes,
M.D., our Chief Medical Officer, has over 25 years of experience in the biopharmaceutical industry. He has contributed to more than 50 clinical trials and multiple product filings and launches across cardiovascular, neurology and rare disease
therapeutic areas at Avidity, Ionis, Biogen, CSL Behring and Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephanie Kenney, our Chief Corporate Affairs Officer, has more than 25 years of
experience in the biopharmaceutical industry leading corporate affairs, investor relations, and marketing at preclinical to commercial stage companies in autoimmune, cardiovascular, and renal therapeutic areas. She has held roles of increasing
responsibility at Avidity, AstraZeneca and Hansa Biopharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rocio Martin Hoyos, our Chief Strategy Officer, is a seasoned strategist with over 20 years
of experience in management and commercial roles in the biopharmaceutical industry. She has held leadership positions at Avidity, Audentes, Celgene, Kronos Bio and Ultragenyx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brendan Winslow, our Chief Financial Officer, has extensive experience in financial leadership roles in the biotechnology and healthcare industries. He has
held senior positions involving global operations, commercialization, and strategic transformations at Avidity, Acadia and Baxter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Husam Younis, Ph.D., Pharm.D., our Chief Scientific Officer, has over 20 years of experience in drug
discovery and development, including in rare disease. He has held senior leadership roles in development science at Avidity, NGM, Ionis and Pfizer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Past
achievements of our management team may not be indicative of future success. Please see &#8220;Risk Factors&#8221; and &#8220;Corporate Governance and Management &#8212; Executive Officers&#8221; for further information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Development Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing the innovative
RNA delivery platform to develop potential treatment options for people with cardiac conditions. Despite the availability of drugs that treat cardiomyopathy symptoms, many patients remain at significant risk due to a lack of disease-modifying
effects and limitations with the currently available therapies such as poor tolerance and efficacy. This treatment gap represents a significant commercial opportunity both in rare and in broader cardiac conditions, where new therapies are needed to
address the root cause of disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initially selected genetically validated cardiology targets for our development pipeline. Our precision
cardiology pipeline currently consists of two primary, wholly owned precision cardiology development candidates for the treatment of PRKAG2 syndrome and PLN cardiomyopathy. Each program is designed to address a specific genetic disease or disease
mechanism associated with severe life-threatening forms of heart disease. The pipeline is supported by strong human genetics evidence, robust preclinical data, and what we believe is a clear path to clinical development. The chart below represents a
summary of our wholly owned development programs. We also have two additional pipeline candidates in research and development targeting undisclosed rare cardiology targets which we may develop in the future. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g00k12.jpg" ALT="LOGO" STYLE="width:6.33333in;height:1.13297in;">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our programs is supported by a comprehensive
translational research strategy, including biomarker development, patient identification and engagement with clinical centers of excellence. Our pipeline is designed for expansion into additional indications based on shared mechanisms of action,
with the potential to address larger segments of the cardiomyopathy market. Our capital-efficient approach ensures resources are allocated to development programs with the highest probabilities of success, while maintaining flexibility to pursue new
opportunities as the technology and science are further validated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Cardiac Disease Pipeline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that cardiac tissue is the next frontier for RNA delivery with potential broader applications in both rare and more common conditions. We have
strategically prioritized rare cardiomyopathies. Based primarily on observations from human genetic studies, we believe PRKAG2 and PLN are cardiology targets with high probabilities of clinical success. Specific mutations in PRKAG2 or PLN drive
cardiomyopathies by disrupting how heart muscle cells are built, powered or electrically coordinated. Over time, these disruptions change the heart structure and performance. We have generated preclinical data (see &#8220;Preclinical Data and Next
Steps&#8221; below) that demonstrated reduction of these targets in the heart with the potential to alter the course of the disease. However, even if these targets have the highest probability of success as compared to other indications, we may
still fail to develop an approved program for any of these indications. For our initial programs, we plan to use the same proprietary mAb targeting TfR1 across our cardiac muscle programs, which we believe gives us significant leverage of
development costs and timelines associated with each incremental cardiac muscle </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program. In addition to our internal discovery efforts, our collaboration with BMS across several targets in cardiology is a testament to the broad potential of our approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About PRKAG2 Syndrome </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRKAG2 syndrome is a rare,
autosomal dominant, early-onset genetic disorder caused by mutations in the PRKAG2 gene, which encodes the <U></U><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2&nbsp;regulatory subunit of AMPK. AMPK is a critical enzyme responsible for maintaining
cellular energy homeostasis. Pathogenic variants in PRKAG2 disrupt the structure and function of the <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2&nbsp;regulatory subunit, altering AMPK&#8217;s activity leading to abnormal glycogen accumulation in
heart muscle cells which can lead to thickened heart muscles, electrical conduction problems, and arrhythmias. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both overactive AMPK signaling and
excessive glycogen storage converge to impair cardiac energy homeostasis and remodeling potentially contributing to conditions such as hypertrophy, ischemic injury, diabetic cardiomyopathy, and heart failure.&nbsp;Cardiac manifestations include
ventricular preexcitation, supraventricular arrhythmias (atrial fibrillation and flutter), high-grade atrioventricular block often requiring pacemaker implantation, myocardial hypertrophy and progressive heart failure, and risk of sudden cardiac
death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRKAG2 syndrome represents approximately one percent of HCM (as defined below) patients, which has an overall prevalence between 1 in 200 and 1 in
500. In a third party study conducted with 25 carriers, researchers observed 100% clinical penetrance in some families, with a high incidence of the condition in genotype-positive carriers, supporting our belief that a mutation in the PRKAG2 gene
may have a higher likelihood of leading to the disease.&nbsp;Currently the management of <FONT STYLE="white-space:nowrap">PRKAG-2</FONT> syndrome focuses on symptomatic treatment that includes managing arrhythmias, and monitoring and supporting
structural heart changes caused by the disease. There are no therapies currently available to address the underlying genetic drivers of the disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Mechanism of Disease </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRKAG2 Syndrome
is a Progressive Disorder Driven by Aberrant AMPK Activity Driving Multiple Cardiac Pathologies </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03a18.jpg" ALT="LOGO" STYLE="width:6.33334in;height:1.18006in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Therapeutic Rationale for ATR 1072 in PRKAG2 Syndrome </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A precision cardiology approach is needed to normalize AMPK activity and reduce glycogen accumulation in the heart caused by PRKAG2 syndrome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome. As shown in the graphic below, the siRNA works through
a sequence-specific gene silencing mechanism to reduce PRKAG2 mRNA, normalize AMPK activity and reduce the pathogenic glycogen accumulation, all potentially leading to improved heart function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we will pursue ATR 1072 initially in PRKAG2 syndrome, there is potential to expand to broader HCM and heart failure populations given that elevated
AMPK activity has been observed in human heart failure and preclinical models of cardiac disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03b18.jpg" ALT="LOGO" STYLE="width:6.33332in;height:1.18327in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATR 1072 Designed to Silence PRKAG2 mRNA to Normalize AMPK Activity and Reduce Glycogen Accumulation in
PRKAG2 Syndrome </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Preclinical Data and Next Steps </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on comprehensive preclinical studies conducted by Avidity, ATR 1072 was selected out of our potential preclinical candidates as one of the most potent
and selective molecules for PRKAG2 silencing in human cells. Since the siRNA component of ATR 1072 is cross-reactive to the mouse PRKAG2 gene, we were able to demonstrate robust in vivo activity utilizing a mouse surrogate AOC (&#8220;mATR
1072&#8221;) that contains the siRNA component of ATR 1072 conjugated to a mouse targeting anti-TFR1 antibody. Marked reductions of PRKAG2 mRNA were observed in the heart of wildtype (&#8220;WT&#8221;) mice (see Figure 1A below, n=4-5/group). We
also observed substantial reductions in PRKAG2 protein in the heart. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also observed functional activity of mATR 1072 in a mouse model of PRKAG2
syndrome. In this model, mice exhibit impaired ventricular filling as observed by reduced diastolic function and increased p-wave amplitude relative to WT mice (Figure 1A, n=10/group; Figure 1B, n=9/group; 1C, n=16-20/group, respectively). Mice
treated with ATR 1072 were observed to have improved diastolic function and restored p-wave amplitude (Figure 1B, 1C, respectively). We believe that this preclinical data establishes a link between PRKAG2 molecular target engagement and functional
cardiac benefit, and the potential for ATR 1072 to be a disease modifying therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, preliminary tolerability data in cynomolgus monkeys, a
NHP species, has been evaluated. ATR 1072 was pharmacologically active in cynomolgus monkeys, with robust and durable PRKAG2 mRNA knockdown and reduced protein expression observed in the heart. In these subacute studies in cynomolgus monkeys (n=3),
ATR 1072 was well tolerated, with no adverse findings in ECG parameters or heart morphology and with a preclinical tolerability profile comparable to that of the neuromuscular programs developed at Avidity using the RNA delivery platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical toxicology studies and CMC manufacturing are ongoing for ATR 1072. An IND filing is expected
in the second half of 2026. If the IND is accepted by the FDA, a Phase 1 clinical trial is planned.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 1: Preclinical pharmacologic activity of
mATR 1072. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03a19.jpg" ALT="LOGO" STYLE="width:6.33334in;height:2.01844in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Figure 1A:</I></B> <I>Reduction of PRKAG2 mRNA in the heart at Day 28 (n=10 mice/group) following a
single dose of mATR 1072 (3&nbsp;mg/kg).</I> <B><I> </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Figures 1B and 1C:</I></B><I> Improvements in diastolic function (E/A ratio, n=9
mice/group) and <FONT STYLE="white-space:nowrap">P-wave</FONT> amplitude (marker of atrial size, n=16-20 mice/group) at 24 weeks following repeated treatment of mATR 1072 (3 mg/kg, q12w) in a mouse model of PRKAG2 syndrome (PRKAG2</I><I><SUP
STYLE="font-size:75%; vertical-align:top">R528G/R528G</SUP></I><I> transgenic mice). Dotted lines indicate WT levels. Data are presented as mean </I><I>&plusmn;</I><I>&nbsp;SEM. Student&#8217;s <FONT STYLE="white-space:nowrap">t-test.</FONT> * p
&lt; 0.05.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>About PLN Cardiomyopathy </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLN
cardiomyopathy is an autosomal dominant, progressive cardiac disease caused by mutations in PLN, a small protein that normally inhibits SERCA2a calcium pump in cardiac muscle cells. SERCA2a helps pump calcium back into the sarcoplasmic reticulum
after each heartbeat, allowing muscle relaxation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">PLN-R14del</FONT> cardiomyopathy is the most common disease-relevant
PLN mutation PLN cardiomyopathy is characterized by early phenotypic expression <FONT STYLE="white-space:nowrap">(II-III</FONT> decade) usually dilated, arrhythmogenic, or hypertrophic cardiomyopathies with biventricular involvement, family history
of premature sudden cardiac death, high incidence of ventricular arrhythmias, or cardiac transplantation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is estimated that over 10,000 patients in
the U.S. and EU are affected by pathogenic PLN variants. Patients, including younger individuals, face increased risk of heart failure and sudden cardiac arrest. There are currently no treatment options for PLN cardiomyopathy to treat the underlying
genetic driver of the disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Mechanism of Disease </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLN Cardiomyopathy is a Progressive Disorder Driven by <FONT STYLE="white-space:nowrap">PLN-R14del</FONT> Protein Aggregation Abnormal Cell
Function and Death </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03b19.jpg" ALT="LOGO" STYLE="width:6.33335in;height:1.18695in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Therapeutic Rationale for ATR 1086 in PLN Cardiomyopathy </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ATR 1086 is our second lead product candidate and represents a disease-modifying therapy for PLN cardiomyopathy. The program targets PLN. Excessive PLN
activity, as manifested in PLN cardiomyopathy, disrupts calcium homeostasis, leading to delayed relaxation, impaired contractility, and progressive cardiac dysfunction.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While initially pursuing ATR 1086 development for <FONT STYLE="white-space:nowrap">PLN-R14del</FONT> cardiomyopathy, we believe that ATR 1086 has the
potential to address a broader population of heart failure and cardiomyopathy patients, particularly those characterized by calcium handling defects and reduced SERCA2a activity. By selectively reducing PLN expression, ATR 1086 is expected to
relieve SERCA2a inhibition and restore calcium cycling dynamics, which may improve cardiac performance.&nbsp;This therapeutic rationale is further supported by human genetic studies, which have identified a common SNP at the PLN locus that
upregulates PLN mRNA and is associated with increased heart failure risk. These findings suggest the therapeutic potential for PLN reduction for calcium-driven cardiomyopathies.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATR 1086 is Designed to Silence PLN mRNA to Prevent Protein Aggregates in PLN
Cardiomyopathy </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03a20.jpg" ALT="LOGO" STYLE="width:6.31956in;height:1.19228in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Preclinical Data and Next Steps </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on comprehensive preclinical studies conducted by Avidity, ATR 1086 was selected out of our potential preclinical candidates as one of the most potent
and selective molecules for PLN silencing in human cells. We established a mouse model that expresses wildtype human PLN (&#8220;hPLN WT&#8221;) to evaluate its pharmacologic activity in vivo. We tested a mouse surrogate AOC (&#8220;mATR
1086&#8221;) that contains the siRNA component of ATR 1086 conjugated to a mouse targeted anti-TFR1 antibody. We observed robust PLN mRNA reduction in the heart of mATR 1086 (Figure 2A, n=10/group) suggesting ATR 1086 is pharmacologically active
towards the human PLN mRNA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also observed functional activity of mATR 1086 in a humanized mouse model of PLN cardiomyopathy (&#8220;hPLN<SUP
STYLE="font-size:75%; vertical-align:top">R14/R14</SUP>&#8221;). This model is homozygous for the human PLN 14del mutation resulting in rapidly progressive heart disease where animals die within 8 weeks of life (Figure 2B, n=10/group). Remarkably,
100% of the mice treated with mATR 1086 in this model survived through the duration of the study for at least 20 weeks. Importantly, mATR 1086 treated mice had substantial improvement in cardiac function marked by increased ejection fraction
(Figure&nbsp;2C, n=23-24/group). The observations from these preclinical studies support our hypothesis that reduction of the gain of function mutant PLN can lead to improved heart function and be disease modifying in this severe preclinical model
of PLN cardiomyopathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, preliminary tolerability data in cynomolgus monkeys, a NHP species, has been evaluated. ATR 1086 was observed to be
pharmacologically active in NHPs, achieving robust and durable PLN mRNA knockdown in the heart. Sustained PLN mRNA reduction (~80%) was observed to be well tolerated for over 3 months in <FONT STYLE="white-space:nowrap">non-GLP</FONT> studies in
cynomolgus monkeys (n=3), a NHP species, with no adverse findings in ECG parameters or heart morphology and with a preclinical tolerability profile comparable to that of the neuromuscular programs developed at Avidity using the RNA delivery
platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CMC manufacturing is planned for ATR 1086 to support initiation of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies in
2026. We are targeting an IND submission in 2027. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 2: Preclinical Pharmacologic Activity of mATR 1086. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03b21.jpg" ALT="LOGO" STYLE="width:6.33335in;height:2.05537in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 2A:</B> Reduction of human PLN expression in the heart following repeated treatment with mATR 1086
(6&nbsp;mg/kg). PLN mRNA levels were measured in cardiac tissue in transgenic mice expressing hPLN WT. <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figures 2B and 2C:</B> Improved survival
(Kaplan-Meier survival curve) and ejection fraction following repeated mATR 1086 treatment (6 mg/kg) in a humanized mouse model of hPLN<SUP STYLE="font-size:75%; vertical-align:top">R14/R14</SUP>. Ejection fraction measured at <FONT
STYLE="white-space:nowrap">6-weeks</FONT> of treatment. Dotted lines indicate WT levels. Data are presented as mean &plusmn; SEM. Student&#8217;s <FONT STYLE="white-space:nowrap">t-test,</FONT> *&nbsp;p&nbsp;&lt;&nbsp;0.05. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment Landscape and Limitations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Precision
Cardiology Market Opportunity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardiomyopathy, a group of diseases that affect the heart muscle, represents a significant market opportunity where
therapies primarily treat the symptoms and fail to address the underlying etiology of the disease. In the U.S. alone there are over 2&nbsp;million people with cardiomyopathy. According to the Genetic Cardiomyopathy Awareness Consortium, close to
half of all cardiomyopathy cases have some underlying genetic driver of disease. There are several types of myopathies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dilated cardiomyopathy (&#8220;DCM&#8221;): the heart muscle becomes weakened and enlarged, especially the left
ventricle leading to reduced pumping ability and heart failure symptoms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hypertrophic cardiomyopathy (&#8220;HCM&#8221;): the heart muscle becomes abnormally thick, which can cause
obstruction of blood flow and increases the risk of arrythmias. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arrhythmogenic cardiomyopathy (&#8220;ACM&#8221;): the heart muscle is replaced by fatty or fibrofatty tissue in
the right ventricle, which can lead to dangerous arrhythmias. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the graphic below, there are three major types of cardiomyopathies among U.S. patients. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g03b22.jpg" ALT="LOGO" STYLE="width:4.13647in;height:3.58194in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Source: Independent third-party consultant analysis commissioned by Avidity. Based on KOL interviews and
literature search. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent advances in human genetics and the increasing adoption of genetic testing have enabled the identification of
mutation-specific subpopulations that are ideally suited for RNA therapies. As such, we believe the current cardiomyopathy treatment paradigm is primed for disruption&#8212;moving away from managing symptoms towards addressing the genetic drivers of
disease through RNA therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy is to initially target rare, genetically defined populations and expand to broader cardiomyopathy indications
based on shared mechanisms of action. This approach is designed to maximize the probability of technical and commercial success while maintaining capital efficiency. We believe precision RNA therapies will experience rapid clinical adoption and
utilization due to (i)&nbsp;increasing adoption and reimbursement of cardiac genetic testing, (ii)&nbsp;improved understanding of human genetics in cardiology and (iii)&nbsp;the advancement of RNA delivery platforms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, only a few disease-modifying therapies&#8212;such as tafamidis and mavacamten&#8212;are approved for small subsets of cardiomyopathy patients, and
these therapies do not address the underlying genetic causes of disease in most patients. We believe our focus on genetically validated targets and <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery provides a competitive edge, enabling the
Company to address mutation-specific subpopulations with high unmet need. We believe the success of Avidity&#8217;s neuromuscular pipeline, Lilly&#8217;s clinical progress with the AOC technology and the preclinical progress in the BMS collaboration
differentiates the platform and can enhance its credibility with investors, clinicians, and patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The competitive landscape is expected to intensify
as more entrants pursue precision cardiology, driven by advances in human genetics, delivery technologies, and regulatory pathways. To establish and maintain a leadership position we plan to continue to drive scientific innovation with the targeted
RNA delivery platform, expand our intellectual property portfolio and rapidly execute our strategic priorities. We actively monitor the competitive environment, adapt our strategy as needed, and invest in platform improvements to stay ahead of
emerging threats. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely on third-party manufacturers and suppliers for the manufacture of our product candidates and related raw materials, including for antibodies,
oligonucleotides and linkers used to make our AOCs, for preclinical and anticipated clinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval.&nbsp;We expect to continue to do so to meet
our preclinical, and future clinical and commercial, activities. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. We do not own
or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities.&nbsp;Our third-party manufacturers are required to manufacture our product candidates under cGMP requirements and other
applicable laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe there are multiple sources for all of the materials required for the manufacture of our product candidates to
supply our anticipated clinical trials and commercial requirements. Our AOCs consist of a proprietary mAb conjugated with the oligonucleotide therapy. All of our mAbs are manufactured by starting with cells which are stored in a cell bank. We
currently have multiple working cell banks and one master cell bank for our mAbs manufactured in accordance with cGMP, and we believe we would have adequate backup should any cell bank be lost in a catastrophic event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and biopharmaceutical
industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product
candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a
significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition
amongst RNA targeted therapies. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological, therapeutics companies and specialized cardiovascular treatment companies. Moreover, we may also compete with
universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development
personnel, which could negatively affect our level of expertise and our ability to execute our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The competitive landscape in precision
cardiology is rapidly evolving but we believe we are positioned as a first mover with clear differentiation&#8212;the RNA delivery platform is uniquely differentiated by its ability to achieve targeted delivery of siRNA to the heart. Furthermore, we
are not aware of others with preclinical or clinical programs targeting PRKAG2 syndrome while a few (Ionis Pharmaceuticals, PLaN Therapeutics, Solid Biosciences, Souffle Therapeutics and Tenaya Therapeutics) have disclosed programs targeting PLN
cardiomyopathy.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Several companies are developing therapies for cardiomyopathies, however, the majority do not employ tissue-specific delivery to heart,
such as small molecules, viral vectors in the case of gene therapy, or other delivery systems.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to note that well-resourced companies like
Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. are investing in targeted tissue delivery technologies, including to the heart, aiming to expand the reach of RNA therapeutics beyond the liver. Direct competitors include companies
pursuing antibody-based and/or peptide-base approaches for cardiac delivery. Although several companies may be pursuing <FONT STYLE="white-space:nowrap">non-tissue</FONT> selective delivery technologies, we believe these possess significant
challenges, including potential for toxicity, immunogenicity, and limitations on redosing.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will also face competition from Novartis, a large, multinational pharmaceutical company with substantial
resources and a well-established presence in the development and commercialization of cardiology products, which following the closing of the Merger, will own RemainCo. The RemainCo License Agreement provides RemainCo a non-exclusive, worldwide,
irrevocable, royalty-free license under the RNA delivery platform technology to exploit any cardiovascular products other than products subject to the Lilly Agreement or BMS Collaboration Agreement. As a result, we may face direct competition from
RemainCo in the cardiac space, including with respect to products that are the subject of the RemainCo License Agreement or other products that RemainCo or Novartis may develop independently. The greater financial, technical, and marketing resources
available to RemainCo and Novartis may enable them to advance competing cardiac products more rapidly or effectively than we can, potentially limiting our ability to gain or maintain market share in this therapeutic area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to
develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Inc., Aro Biotherapeutics Company, Dyne Therapeutics, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, PepGen, PeptiDream Inc. and AstraZeneca
plc, as well as gene therapy and CRISPR approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with strategic partners, have substantially greater
financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and
achieving widespread market acceptance, which could render our product candidates, if approved, obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Merger and acquisition activity in the biotechnology and biopharmaceutical
industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial
sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies like us may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our
comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products, if
approved. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of other drugs. The key competitive factors affecting the success of our programs are likely to be their
efficacy, safety profile, convenience, level of promotional activity, intellectual property protection and availability of reimbursement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual
Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strive to protect our product candidates and our RNA delivery platform through a variety of methods, including seeking and maintaining
patents in partnership with Avidity intended to cover our RNA delivery platform, our products and compositions, their methods of use and processes for their manufacture, and any other inventions that are commercially important to the development of
our business. We rely on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop and maintain our proprietary position. We also rely on
trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> that may be important to the development of our business. We seek to obtain domestic and international patent protection and endeavor to promptly file patent applications for new
commercially valuable inventions to expand our intellectual property portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that we have a significant global intellectual property
position and substantial <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our product candidates and our technology. In addition to filing and prosecuting patent applications in the United States, we often file counterpart patent
applications in additional countries and jurisdictions where we believe such foreign filing is likely to be beneficial, including Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Singapore, New Zealand, Taiwan, and South
Korea. We also file patent applications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to the Patent Cooperation Treaty, or PCT. Our PCT patent applications are in the first phase of the PCT process, which is the international phase, in which patent protection is pending
under a single patent application filed with the United States Patent and Trademark Office, or USPTO, as a contracting state of the PCT. These PCT patent applications have not yet entered the second phase of the PCT process, which is the national
and regional phase, in which rights are continued by filing necessary documents with the patent offices of separate contracting states of the PCT. The national phase of the PCT patent application process occurs 30 months after the earliest priority
date of the PCT patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continually assess and refine our intellectual property strategy as we develop new product candidates and
technologies. To that end, we are prepared to file additional patent applications in any appropriate fields if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities.
Further, we are prepared to file patent applications, as we consider appropriate under the circumstances, relating to the new technologies that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may own or
license in the future, nor can we be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our technology. Please see &#8220;<I>Risk Factors&#8212;Risks Related to Our Intellectual
Property</I>&#8221; for additional information on the risks associated with our intellectual property strategy and portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property
Relating to ATR 1072 and Other PRKAG2 AOC Product Candidates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to ATR 1072 and other PRKAG2 AOC product candidates, as of
February&nbsp;9, 2026, we owned one granted U.S. Patent, two pending U.S. patent applications, one pending patent applications filed pursuant to the PCT, eleven pending patent applications filed in Taiwan, Europe, Brazil, Canada, Mexico, Japan,
South Korea, Israel, Australia, New Zealand and Singapore. These patent rights relate to the ATR 1072 and other PRKAG2 AOC composition of matter, formulations containing ATR 1072 and other the PRKAG2 AOC, methods of manufacturing, and methods of
treating diseases, using our PRKAG2 AOC. Any patents issued from these applications are expected to expire in <FONT STYLE="white-space:nowrap">2044-2045;</FONT> however, a patent term extension may be available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Relating to ATR 1086 and Other PLN AOC Product Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to ATR 1086 and other PLN AOC product candidates, as of<B> </B>February&nbsp;9, 2026, we owned one granted U.S. patent, one pending U.S. patent
application, and ten pending foreign patent applications filed in Europe, Australia, Brazil, Canada, Mexico, Japan, Israel, South Korea, New Zealand and Singapore. These patent rights relate to the ATR 1086 and other PLN AOC composition of matter,
formulations containing ATR 1086 and other PLN AOC, methods of manufacturing, and methods of treating diseases, using our PLN AOC. Any patents issued from these applications are expected to expire in 2044; however, a patent term extension may be
available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Relating to the RNA Delivery Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;9, 2026, we have patent rights to 20 families of U.S. and foreign patents and patent applications generally covering the RNA delivery
platform. These families include 15 issued U.S. patents, 22 granted foreign patents, 21 pending U.S. patent applications, 3 pending PCT patent applications and 59 pending foreign patent applications in Europe, Australia, Canada, China, Israel, Hong
Kong, Japan, South Korea, Mexico, Singapore, New Zealand, Brazil and Taiwan, relating to key aspects and components of the RNA delivery platform systems. Our patent applications contain claims covering (i)&nbsp;proprietary antibodies or other
binding moiety structures; (ii)&nbsp;proprietary oligonucleotide chemical structures; (iii)&nbsp;proprietary formulation compositions; (iv)&nbsp;proprietary AOC structures; and (v)&nbsp;methods for manufacturing and using our AOC technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20
years from the earliest date of filing of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application. However, the term of United States patents may be extended for delays incurred due to compliance with FDA requirements or by delays encountered during prosecution that are caused by
the USPTO. For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, it is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent. In the future, if
and when our biopharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. We intend to seek patent term extensions to any of our issued patents in any
jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such
extensions. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2037 to 2046, unless we receive patent term extensions or patent term adjustments, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the actual protection afforded by a patent varies on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends upon many factors,
including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. As discussed in more detail in
&#8220;<I> &#8212;Intellectual Property&#8212;RemainCo License Agreement</I>,&#8221; the intellectual property relating to the RNA delivery platform is subject to the terms of the RemainCo License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Collaboration and License Agreement and Securities Purchase Agreement with BMS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, Avidity entered into (i)&nbsp;the BMS Collaboration Agreement to expand on its research with MyoKardia Inc. (&#8220;MyoKardia&#8221;) and
(ii)&nbsp;a Securities Purchase Agreement with BMS for the sale of 5,075,304 shares of<STRIKE> </STRIKE>Avidity&#8217;s common stock in a private placement transaction (the &#8220;BMS Purchase Agreement&#8221; and, together with the BMS
Collaboration Agreement, the &#8220;BMS Agreements&#8221;). Under the terms of the BMS Collaboration Agreement, as assigned by Avidity to the Company in connection with the Separation, BMS will have the right to select up to five targets (each a
&#8220;Target&#8221;) for collaborative research programs under which the Company will utilize its RNA delivery platform to conduct research and development activities in order to identify, generate, and optimize AOC compounds directed to such
Targets with the goal of generating an applicable development candidate. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Target</FONT></FONT> basis, after the Company completes specified research activities in
accordance with a research plan, BMS will have the right to develop, manufacture and commercialize such compounds generated during the research term, and products containing such compounds, worldwide. The research and activities conducted under the
BMS Collaboration Agreement is governed by a joint steering committee comprised of representatives from Avidity (and following the Separation, the Company) and BMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BMS Collaboration Agreement, Avidity granted BMS and its affiliates an exclusive (including with regard to Avidity and its affiliates), worldwide,
royalty-bearing license, with the right to grant and authorize sublicenses under the Avidity patents, know-how and Avidity&#8217;s interest in any such intellectual property generated pursuant to the BMS Collaboration Agreement to develop,
manufacture, commercialize and otherwise exploit the licensed compounds and licensed products worldwide for all uses. Avidity received approximately $100.0&nbsp;million upfront, including a $60.0&nbsp;million nonrefundable cash payment and
approximately $40.0&nbsp;million from the sale of Avidity&#8217;s common stock at $7.8813 per share. The Company will also be eligible to receive up to approximately $1.35&nbsp;billion in research and development milestone payments, up to
approximately $825.0&nbsp;million in commercial milestone payments, and tiered royalty payments representing a percentage of net sales from high single digits to low teens. The Company will be responsible for its own research costs incurred under
the BMS Collaboration Agreement, subject to the parties renegotiating the research activities in case the Company&#8217;s research spending is anticipated to exceed $40.0&nbsp;million. BMS will fund all future clinical development, regulatory and
commercialization activities coming from this collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS can terminate the BMS Collaboration Agreement (or a target, country or program) at will
and with or without cause, with appropriate notice to the Company. In such event, material licenses granted to BMS expire, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (other than termination for safety concerns) BMS will negotiate and conduct a product reversion to the Company. BMS can also terminate in response to the Company&#8217;s bankruptcy or uncured
material breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Collaboration and License Agreement with Lilly </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2019, Avidity entered into the Lilly Agreement with Lilly for the discovery, development and commercialization of AOC products directed against
certain targets in immunology on a worldwide basis. Under the Lilly Agreement, Avidity granted Lilly an exclusive, worldwide, royalty-bearing license, with the right to sublicense (subject to certain conditions), under Avidity&#8217;s technology to
research, develop, manufacture and sell products containing AOCs that are directed to up to six mRNA targets. The Company agreed that it will not, itself or with a third party (including by enabling a third party), research, develop, manufacture or
commercialize or otherwise exploit any compound or product directed against targets subject to the Lilly Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the rights
granted to Lilly under the Lilly Agreement, Avidity received a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront fee of $20.0&nbsp;million, and the right to receive up to $60.0&nbsp;million in development milestone payments, inclusive of the
$10&nbsp;million milestone payment received in August 2025 as the result of the achievement of a clinical development milestone for a collaboration target, up to $140.0&nbsp;million in regulatory milestone payments and up to $205.0&nbsp;million in
commercialization milestone payments per target. Lilly will be obligated to pay the Company tiered royalties ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> to low teens, expressed as a percentage of worldwide annual net sales of
licensed products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed products, and for payments owed to third parties for additional rights necessary to commercialize licensed
products in the territory. Lilly&#8217;s royalty obligations and the Lilly Agreement will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the later of ten years from the date of the first commercial sale of such licensed product or when there is no longer a valid patent claim covering
such licensed product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lilly can terminate the Lilly Agreement (or a target) at will and with or without cause, with appropriate notice
to the Company. In such event, material licenses granted to Lilly expire, and the Company and Lilly negotiate in good faith a product reversion to Avidity. Lilly can also terminate the Lilly Agreement in response to the Company&#8217;s uncured
material breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RemainCo License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;25, 2025, we entered into the RemainCo License Agreement in connection with the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Under the
RemainCo License Agreement, we granted to Avidity (i)&nbsp;an exclusive (including as to us and our affiliates), worldwide, irrevocable, royalty-free license to intellectual property we own or control for all purposes and uses other than for
exploitation of cardiovascular products and products subject to the Lilly Agreement or BMS Collaboration Agreement and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, irrevocable, royalty-free license under the RNA
delivery platform to exploit any cardiovascular products (other than products subject to the Lilly Agreement or BMS Collaboration Agreement). Except for products subject to the Lilly Agreement or BMS Collaboration Agreement, we agree not to assert
patent rights we own or control against Avidity and related third parties (e.g., sublicensees, suppliers, distributors and customers) for exploitation of Avidity products incorporating the RNA delivery platform technology. Further, we agree to keep
Avidity reasonably informed regarding the prosecution and maintenance of our patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity grants us a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-free license to intellectual property owned by RemainCo as of the effective date of the Distribution to exploit cardiovascular products. The RemainCo License Agreement
provides that ownership of the RNA delivery platform can transfer to RemainCo at RemainCo&#8217;s request, following the completion of target selection under the BMS Collaboration Agreement, or prior to a change of control of the Company. In the
event of such transfer, we would retain our (i)&nbsp;exclusive (including as to RemainCo and its affiliates), worldwide, royalty-free license to exploit products subject to the Lilly Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or BMS Agreements, and <FONT STYLE="white-space:nowrap">(ii)&nbsp;non-exclusive,</FONT> worldwide, royalty-free right to exploit cardiovascular products in the cardiovascular field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a period of 10&nbsp;years following the effective date of the RemainCo License Agreement, the RemainCo License Agreement grants RemainCo a right of first
negotiation over our development candidates or prospective transactions, in each case, other than with respect to cardiovascular products or products subject to the Lilly Agreement or BMS Agreements. Furthermore, the RemainCo License Agreement
provides that, if we do not consummate a transaction with RemainCo with respect to any such transaction and the negotiation period expires, we must notify RemainCo of any proposed third-party transaction we desire to enter into in the 12&nbsp;months
following the expiration of the applicable negotiating period with respect to such transaction, that is on terms less favorable to us than RemainCo&#8217;s last offer. Following the receipt of such notice, RemainCo may accept the Company&#8217;s
offer to enter into the transaction on the terms of the last written offer proposed by RemainCo, make a new offer, which we must consider in good faith, or inform us that RemainCo is no longer interested in pursuing a transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a period of 5&nbsp;years following the RemainCo License Agreement&#8217;s effective date, we will not engage in a competitive RNA therapeutics business,
other than with respect to cardiovascular products in the cardiovascular field or products subject to the Lilly Agreement or BMS Collaboration Agreement regardless of whether such activities use any of RemainCo&#8217;s Intellectual Property.
Additionally, we may only exploit the RNA delivery platform for the development of cardiovascular products in the cardiovascular field. or products subject to the Lilly Agreement or BMS Collaboration Agreement; therefore, even following expiration
of this five-year period, we will not have the right to use the RNA delivery platform for programs in other therapeutic areas, and would need to independently develop or acquire the technology to be used in such programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the
United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion,
advertising, distribution, marketing and export and import of products such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of
the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biologics Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States,
biological products are subject to regulation under the federal Food, Drug and Cosmetic Act, the Public Health Service Act, and other federal, state, and local statutes and regulations. The process required by the FDA before a biological product may
be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP
regulations and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical
site before each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with GCP requirements to
establish the safety, purity and potency of the proposed biologic for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of a BLA after completion of all pivotal trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biological
product is produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity, and potential inspection of selected clinical
investigation sites and/or the trial sponsor to assess compliance with GCP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for
use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage.
Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies, in an effort to support subsequent clinical testing. The conduct of preclinical studies is subject to federal regulations and
requirements, including GLP regulations for certain studies. Prior to beginning the first clinical trial with a product candidate in the United States, the trial sponsor must submit an IND to the FDA. An IND is a request for allowance from the FDA
to introduce an investigational drug into interstate commerce and administer the product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results
of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product candidate, chemistry, manufacturing, and controls information, and any available human data or literature to support the use of the
product candidate. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period,
places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical
trials due to safety concerns about ongoing or proposed clinical trials or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the
hold has been lifted or modified to allow such continuation. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human participants under the supervision of one or more qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP regulations, which, among other things, include the requirement that all research participants provide their informed consent in writing for
their participation in any clinical trial. Clinical trials must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness
criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies
performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events,
findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <I>in vitro </I>testing suggesting a significant risk to humans, and any clinically important increased incidence of a
serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, an independent IRB at each institution
participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial
subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding
that the participants are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study
sponsor, known as a data safety monitoring board or data monitoring committee, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that
there is an unacceptable safety risk for participants or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically
conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>: The product candidate is initially introduced into healthy human volunteers or patients with the
target disease or condition. These studies are designed to test for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>: The product candidate is administered to a limited patient population with a specified disease or
condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. Multiple Phase 2 trials may be conducted
to obtain information prior to beginning larger and more expensive Phase 3 trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>: The product candidate is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy, and to further test for safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish
the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product approval and labeling. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional
experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and
biological characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be
conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are also requirements
governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products are required to register and disclose
specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is
then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being
studied has been approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Review and Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, including
from preclinical and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other
relevant information are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The submission of a BLA is subject to the payment of substantial user fees, unless a waiver or exemption applies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA
accepts it for filing. The FDA may refuse to file any BLA that it deems </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has
been accepted for filing, the FDA&#8217;s current goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In
both standard and priority reviews, the review process may also be extended for a three-month period by the FDA in response to new data or other information designated as a major amendment to the application. The FDA reviews a BLA to determine,
among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may also convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an
advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will inspect the facility or
facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving a BLA, the FDA may inspect one or more clinical trial sites as well as the trial sponsor to assure compliance with GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial
marketing of the biologic with prescribing information for specific indications and other conditions of use. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL
usually describes the specific deficiencies in the BLA identified by the FDA and may require additional clinical data, including additional clinical trials, or other significant and time-consuming requirements related to clinical trials, nonclinical
studies or manufacturing. If a CRL is issued, the sponsor must resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the
BLA does not satisfy the criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases
and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 clinical
testing to further assess a biological product&#8217;s safety and effectiveness after BLA approval, and may require additional testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may
also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed
REMS. The FDA will not approve the BLA without an approved REMS, if required, which could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other
risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Pediatric Research Equity Act, (&#8220;PREA&#8221;), requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active
ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required
assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in
adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pediatric clinical trials begin. The FDA must send a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral
current or fails to submit a request for approval of a pediatric formulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor may seek approval of its product candidate under programs designed to expedite FDA&#8217;s review and approval of biological products that meet
certain criteria. The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing product candidates that meet certain criteria. For example, product candidates are eligible for Fast Track
designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product
and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted,
the application may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted,
if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first
section of the BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough
Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs
or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast
Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of FDA senior
managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product candidate with a Fast Track designation or Breakthrough Therapy designation,
may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. A product is eligible for priority review if it is designed to treat a serious condition and, if approved, would provide a
significant improvement in safety or effectiveness. The FDA will attempt to direct additional resources to the evaluation of an application for the product candidate designated for priority review in an effort to facilitate the review. For original
BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date (as compared to ten months under standard review). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, depending on the design of the applicable clinical trials, product candidates studied for their safety and effectiveness in treating serious or
life-threatening diseases or conditions may receive accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can
be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition
and the availability or lack of alternative treatments. As a condition of approval, the FDA will require the sponsor of a drug receiving accelerated approval to perform adequate and well-controlled confirmatory clinical trials to verify and describe
the anticipated effect on irreversible morbidity or mortality or other clinical benefit, and may require that such studies be underway before granting any accelerated approval. In addition, the FDA currently requires as a condition for accelerated
submission of promotional materials prior to their use, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval on an expedited basis if,
for example, the sponsor fails to conduct the required confirmatory trial in a timely manner or if such confirmatory trial fails to verify the predicted clinical benefit of the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast Track designation, priority review and Breakthrough Therapy designation do not change the standards for
approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period
for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to FDA review and approval, including prior approval for more significant changes. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and
their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain
procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of
production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of approval of the product and complete
withdrawal of the product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to
safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses and requiring the inclusion of safety </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information about the product in all advertising and promotion. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective
advertising, onerous and costly government investigations and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those
tested by the manufacturer and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the
best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <FONT
STYLE="white-space:nowrap">off-label</FONT> use of their products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or
condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in
the United States for this type of disease or condition will be recovered from sales of the product. orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its
potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the
product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biologic for the same disease or condition for seven years, except in limited circumstances, such as a
showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.
Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation
are tax credits for certain research and a waiver of the BLA application user fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A designated orphan drug may not receive orphan drug exclusivity if it
is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for
designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and reference product
exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA, signed into law in 2010, includes BPCIA which created an abbreviated approval pathway for biological products that are
biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires
that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies.
Interchangeability requires that a product is biosimilar to the reference product and a determination that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products that are
administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use
of the reference biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date
that the reference product was first licensed by the FDA. In addition, the approval of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT>
period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and
well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing
exclusivity periods. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of existing exclusivity protection, may be granted based on the voluntary completion of a pediatric study or studies in accordance with
an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#8220;Written Request&#8221; for such a study and the satisfaction of other requirements for the conduct and submission of the study or studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to FDA regulation of pharmaceutical products, U.S. federal and state healthcare laws and regulations restrict business practices in the
pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the business or financial arrangements and relationships with healthcare
providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, and physician and other healthcare provider payment transparency laws. In addition to the federal laws summarized below, we may also
be subject to similar state and local laws and regulations that may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT
STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback
Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for
purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs.The federal civil and criminal false claims laws, including
the civil False Claims Act, and civil monetary penalties laws prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using
or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal
government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute or from improper advertising or promotion of an item or service constitutes a false or
fraudulent claim for purposes of the civil False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal civil monetary penalties laws impose civil fines for, among other things, the
offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services
reimbursable by Medicare or a state healthcare program, unless an exception applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit,
among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Physician Payments Sunshine Act requires certain
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made during the previous year to physicians (defined to include doctors,
dentists, optometrists, podiatrists and chiropractors), certain other health care providers including, among others, physician assistants and nurse practitioners, and teaching hospitals, and applicable manufacturers and applicable group purchasing
organizations to report annually to CMS ownership and investment interests held during the previous year by physicians as defined under statute and their immediate family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims
laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by
<FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require
drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that
require the registration of pharmaceutical sales representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Violation of any of such laws or any other applicable governmental regulations may
result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to
resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare
programs and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the
United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Health Administration,
as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by third-party payors. For products administered
under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the
reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover a product, the extent of coverage and amount of
reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own
coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a
time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or
obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of
medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit
sales of any product that receives approval. Third-party payors may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebates required to secure favorable coverage may not yield an adequate
margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party reimbursement for any product or a decision by a third-party
payor not to cover a product could reduce physician usage and patient demand for the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that
could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of
containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example,
in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. ACA provisions of importance to our product candidates
established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; expanded the entities eligible for enrollment in the 340B program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new
Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to
test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its
enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without
specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in force in its current form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes
have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will
remain in effect through 2032. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. In addition, on March&nbsp;11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate
cap, as of January&nbsp;1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other
things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most significantly, in August 2022, the U.S. government enacted the IRA. This statute marks the most significant action by Congress with respect to the
pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under
Medicare Part B and Medicare Part D to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new
manufacturer discount program (beginning in 2025). CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation.
The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented, although the
Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. Some states have also enacted legislation creating <FONT STYLE="white-space:nowrap">so-called</FONT> prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states. In
addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs Furthermore, there has been increased interest by third
party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, MA, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to
obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to
the United States apply similarly in the context of the EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval
in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining
regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-clinical</FONT> Studies and Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly to the United States, the various phases of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research in EU are subject to
significant regulatory controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are performed to demonstrate the health or environmental
safety of new chemical or biological substances. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> (pharmaco-toxicological) studies must be conducted in compliance with the principles of GLP as set forth in EU Directive 2004/10/EC (unless
otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, both in vitro and in vivo, must be
planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. These GLP standards reflect the Organisation for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on GCP as well as the applicable regulatory requirements and the ethical principles that have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor
must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The CTR, which was adopted in April 2014 and repealed the EU
Clinical Trials Directive, became applicable on January&nbsp;31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes
the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which the clinical trial takes place, to both the
competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR
allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an
investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all
member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized
EU portal. Once the CTA is approved, clinical study development may proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CTR transition period ended on January&nbsp;31, 2025, and all clinical
trials (and related applications) are now fully subject to the provisions of the CTR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medicines used in clinical trials must be manufactured in
accordance with GMP. Other national and <FONT STYLE="white-space:nowrap">EU-wide</FONT> regulatory requirements may also apply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing
Authorization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To market a medicinal product in the EU, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product
candidates can only be commercialized after obtaining a MA. To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA application (&#8220;MAA&#8221;). The process for doing this depends, among other
things, on the nature of the medicinal product. There are two types of MAs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure based on
the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;), of the EMA and are valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types of products, such as
(i)&nbsp;biotechnology medicinal products, (ii)&nbsp;designated orphan medicinal products, (iii)&nbsp;advanced therapy medicinal products, and (iv)&nbsp;medicinal products containing a new active substance indicated for the treatment certain
diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute
a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their
respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of
application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure, an identical dossier is submitted to the competent authorities of each of the member states in which the
MA is sought, one of which is selected by the applicant as the reference member state. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the maximum
timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the above-described procedures, before granting the MA, the
EMA or the competent authorities of the EU member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, new products
authorized for marketing, or reference products, generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic or biosimilar applicants from
relying on the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on
which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of
the reference product in the EU. The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the MA holder obtains an authorization for
one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will
be considered by the EU&#8217;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the
definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA
detail the type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene or cell therapy medicinal products, and so it is unlikely that
biosimilars of those products will currently be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan Medicinal Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for designating
an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1)&nbsp;the product is intended for the diagnosis,
prevention or treatment of a life threatening or chronically debilitating condition (2)&nbsp;either (a) such condition affects not more than five in 10,000 persons in the EU when the application is made, or (b)&nbsp;the product, without the benefits
derived from the orphan status, would not generate sufficient return in the EU to justify the necessary investment; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been
authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan
designation must be requested before submitting an MAA. An EU orphan designation entitles a party to incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan
medicinal products are entitled to ten years of market exclusivity for the approved indication, which means that the competent authorities cannot accept another MAA, or grant a MA, or accept an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application to extend a MA for a similar medicinal product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal
products that have also complied with an agreed pediatric investigation plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation
does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The orphan exclusivity period may be reduced to
six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance
of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, MA may be granted to a similar product for the same indication at any time if (i)&nbsp;the second applicant can establish that its
product, although similar, is safer, more effective or otherwise clinically superior; (ii)&nbsp;the applicant consents to a second orphan medicinal product application; or (iii)&nbsp;the applicant cannot supply enough orphan medicinal product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, MAAs for new medicinal
products have to include sponsor plans for the results of studies conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed
to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the
efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in
children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained
in all EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in
the case of orphan medicinal products, a two year extension of the orphan market exclusivity is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally
applicable in the EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with EU and member state laws
that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and
anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product
withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines
and criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to laws and regulations governing data privacy and security, including the protection of health-related and other personal information. In the
United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g.,
Section&nbsp;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> laws, such as the CCPA and the GDPR govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and
many of which differ from each other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil
and/or criminal penalties and private litigation. Data privacy and security laws, regulations, and related obligations are constantly evolving, may conflict with each other, and can result in investigations, proceedings, or actions that lead to
significant civil and/or criminal penalties and restrictions on data processing, any of which could cause a significant disruption to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Distribution, we expect to
have 47 employees, all of whom will be full-time employees. 13 of our employees have a Ph.D. or M.D. degree. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our
employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company was incorporated on September&nbsp;30, 2025 under the laws of the State of Delaware as a direct, wholly owned subsidiary of Avidity Biosciences, Inc. We changed our name from Bryce Therapeutics, Inc. to Atrium Therapeutics, Inc. on
December&nbsp;8, 2025. Our corporate headquarters are located at 10578 Science Center Drive, Suite 125, San Diego, CA 92121, and our telephone number is <FONT STYLE="white-space:nowrap">(619)&nbsp;876-0700.</FONT> Our investor relations website is
located at www.atriumtherapeutics.com. We will make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> proxy statements, our directors&#8217; and officers&#8217; Section&nbsp;16 reports and any amendments to those reports as soon as reasonably
practicable after filing such materials with, or furnishing them to, the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use our company website as a means of disclosing material <FONT STYLE="white-space:nowrap">non-public</FONT> information and for complying with our
disclosure obligations under Regulation FD. Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts. Information relating to our corporate governance is also included
on our website. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this information statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will have operating lease obligations related to our office and laboratory facility in San Diego, California. In December 2020, and as amended in March 2022 and June 2023, Avidity entered a <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> operating lease for approximately 54,597 square feet of office and laboratory space. The term of the lease expires on November&nbsp;30, 2026 with an option to extend for an additional five years. In
connection with the Separation, the lease and all related rights and obligations will be transferred and assigned to us, and, following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will operate as the tenant under the lease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, in the ordinary
course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of February&nbsp;13, 2026, there were no such matters which we believe would have a
material adverse impact on our business, operating results or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an emerging growth company as defined in the JOBS Act. As an emerging growth company, we expect to take advantage of reduced reporting
requirements otherwise applicable to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may rely on the relief provided by these provisions until the
last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act. However, if certain events occur prior to the end of such
five-year period, including if we become a &#8220;large accelerated filer&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, our annual gross revenues exceed $1.235&nbsp;billion or we issue more than
$1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the Registration Statement of which this information statement is a part
and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than that which you might receive from other public reporting companies in
which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition
period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We have elected to avail ourselves of this exemption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Smaller Reporting Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we are a
&#8220;smaller reporting company,&#8221; meaning that the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this transaction is
less than $700&nbsp;million and our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that
are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation. We may continue to be a smaller reporting company as long as either (i)&nbsp;the market value of our common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our common stock held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to pay any cash dividends on our common stock in the foreseeable future. All decisions regarding the payment of dividends will be made by the
Board of Directors from time to time in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the Company Business&#8217; cash and capitalization as of December&nbsp;31, 2025 on a historical and pro forma basis to give
effect to the pro forma adjustments included in our unaudited pro forma combined financial information. The information below is not necessarily indicative of what our capitalization would have been had the Separation and Distribution been completed
as of December&nbsp;31, 2025. In addition, it is not indicative of our future capitalization. This table should be read in conjunction with &#8220;<I>Unaudited Pro Forma Combined Financial Information</I>&#8221; and
&#8220;<I>Management</I>&#8217;<I>s Discussion and Analysis of Financial Condition and Results of Operations</I>&#8221; and the audited combined financial statements and corresponding notes included elsewhere in this information statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity (Deficit):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Parent Investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,713)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,713)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated based upon the number of outstanding shares of Avidity Common Stock and shares of Avidity Common
Stock underlying Avidity Equity Awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the transfer from Avidity to the Company of cash equal to $270&nbsp;million, minus the sum of the
amount of marketable securities and cash and cash equivalents contained in any bank and brokerage accounts owned by the Company as of the close of business on the day prior to the Distribution Date, subject to certain adjustments agreed to by
Avidity and Novartis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_10"></A>UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information of the Company Business gives effect to the Separation and related transactions, as described below, in
accordance with Article 11 of the SEC&#8217;s Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial
information presented below has been derived from the historical combined financial statements of the Company Business included in this information statement. While the historical combined financial statements reflect the historical financial
results of the Company Business, these pro forma statements give effect to the Separation of the Company Business into an independent, publicly traded company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information consists of the unaudited pro forma combined balance sheet as of December&nbsp;31, 2025, and the
unaudited pro forma combined statements of operations for the year ended December 31, 2025. The unaudited pro forma combined balance sheet gives effect to the Separation and related transactions described below as if they had occurred on December
31, 2025. The unaudited pro forma combined statements of operations give effect to the Separation and related transactions described below as of January&nbsp;1, 2025, the beginning of the most recently completed fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined balance sheet as of December 31, 2025, together with the unaudited pro forma combined statement of operations for the year
ended December&nbsp;31, 2025 have been prepared to reflect adjustments to the Company Business&#8217; historical combined financial information for the following transaction accounting and autonomous entity adjustments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the distribution of 17,114,391 shares of the Company Common Stock in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> after giving effect to the Forward Stock Split (which number includes (i)&nbsp;15,514,966 shares of Company Common Stock distributed in the Distribution and (ii)&nbsp;1,599,425 shares of Company Common
Stock underlying the Avidity Equity Awards issued in accordance with the terms of the Merger Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of our anticipated post-Separation capital structure, which includes a cash transfer to the Company
from Avidity equal to $270&nbsp;million of cash minus the sum of the amount of marketable securities and cash and cash equivalents held by the Company as of the closing of business on the day prior to the Distribution, subject to certain adjustments
agreed to by Avidity and Novartis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the Separation Agreement, and Transition Services Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">non-recurring</FONT> transaction costs associated with the
Separation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the aforementioned adjustments on the income tax expense of the Company Business.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma adjustments are based on available information and assumptions that management believes are reasonable given the
information that is currently available. However, such adjustments are subject to change based on the finalization of the arrangements under the Transition Services Agreement between the Company and Avidity. The unaudited pro forma combined
financial statements are for informational purposes only and do not purport to represent what the financial position and results of operations of the Company Business would have been had the Separation actually occurred as of the dates indicated,
nor do they project the Company&#8217;s financial performance for any future period. The historical audited combined annual financial statements of the Company Business have been derived from Avidity&#8217;s historical accounting records and reflect
certain allocations of expenses. All of the allocations and estimates in such historical financial statements are based on assumptions that Avidity&#8217;s management believes are reasonable. The historical combined financial statements do not
necessarily represent the financial position or results of operations of the Company Business had it been operated as a standalone company during the periods or at the dates presented. As a result, autonomous entity adjustments have been reflected
in the unaudited pro forma combined financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information should be read in conjunction with
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the audited combined annual and unaudited condensed combined interim financial statements and corresponding notes thereto included
elsewhere in this information statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December 31, 2025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Pro<BR>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">272,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right-of-use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>270,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>278,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease Liability, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>71,066</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>71,066</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(b)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>17</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(b)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>207,270</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Parent Investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(a)(b)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(62,713</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>270,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>207,287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities and Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>270,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>278,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the year ended December&nbsp;31, 2025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Autonomous<BR>Entity<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Operating expenses:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(c)(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(f)(g)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(c)(d)(e)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(f)(g)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(49,631</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(14,184</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(76,814</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(49,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(14,184</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(76,826</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(49,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(14,184</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(76,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(h)(i)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4.48</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average common stock outstanding, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(h)(i)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>17,114</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTES TO THE UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the cash transfer from Avidity to the Company for the Company Funding, subject to certain adjustments
agreed to by Avidity and Novartis. Immediately prior to the effective time of the Distribution, Avidity will advance to the Company an amount in cash equal to $270&nbsp;million, minus the sum of the amount of marketable securities and cash and cash
equivalents contained in any bank and brokerage accounts owned by the Company as of the close of business on the day prior to the Distribution Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the reclassification of Avidity&#8217;s net investment in the Company into Company Common Stock,
$0.001 par value, and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, to reflect the number of shares of the Company Common Stock expected to be outstanding following the consummation of the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> The assumed number of outstanding shares of the Company Common Stock is based on (i)&nbsp;the number of shares of Avidity Common Stock and the number of shares of Avidity Common Stock underlying
Avidity Warrants, each outstanding as of December 31, 2025, plus (ii)&nbsp;Make Whole Awards issued to all the holders of Avidity Equity Awards, excluding certain awards, assuming a Distribution Ratio of one share of Company Common Stock per ten
shares of Avidity Common Stock underlying each such Avidity Equity Award, upon the effective time of the Distribution as stated in the Separation Agreement and assumed to be issued and outstanding by the Company following the consummation of the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> Subsequent to December 31, 2025, all Avidity Warrants were exercised and converted into shares of Avidity Common Stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects incremental depreciation related to the Company&#8217;s Business&#8217; property and equipment that
will be transferred as part of the Separation Agreement. The following adjustment has been recorded (in thousands): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the incremental lease expense related to assignment of lease between Avidity and the Company that will
be entered as part of Separation Agreement. The following adjustment has been recorded (in thousands): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects estimated <FONT STYLE="white-space:nowrap">non-recurring</FONT> transaction costs of
$10.5&nbsp;million expected to be incurred subsequent to December&nbsp;31, 2025. The transaction costs were incurred to effect the Separation and Distribution, including third party legal, audit and advisory fees. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the incremental costs the Company expects to incur on a standalone basis in relation to the Separation
and related transactions. These charges primarily relate to employee costs, insurance, and other expenses. The Company expects that the relevant contracts will be executed, and the associated employees will be transferred immediately prior to the
effectiveness of the Distribution. Accordingly, the pro forma combined financial statements have been adjusted to depict the Company Business as an autonomous entity. The additional costs have been based on estimates the Company believes are
reasonable. However, actual incremental costs that will be incurred could differ materially from these estimates. The following adjustments have been recorded (in thousands): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the costs associated with a Transition Services Agreement that the Company and Avidity will enter into
in connection with the Separation. Pricing under this agreement will reflect Avidity&#8217;s costs plus a profit. The following adjustments have been recorded (in thousands): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,483</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of Company Common Stock used to compute basic loss per share for the year ended December
31, 2025 is based on the assumed number of the shares of Company Common Stock outstanding at that date, applying the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> distribution ratio. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of Company Common Stock used to compute diluted loss per share is the same as the basic
Company Common Stock as described in Note (h)&nbsp;above, due to a net loss reported in the unaudited pro forma combined statements of operations for the year ended December 31, 2025. The Company has not considered the effect of outstanding options
and restricted stock units expected to be issued by the Company as awards subsequent to the Separation, if any, since their inclusion would be anti-dilutive. The weighted-average shares used to compute basic and diluted loss per share reflect the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> distribution ratio and any shares issued for awards vesting at the Distribution Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_10a"></A>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of the financial condition and results of operations of Atrium
Therapeutics, a business of Avidity Biosciences, Inc. (the &#8220;Company Business&#8221;) should be read together with our audited combined financial statements as of and for the years ended December&nbsp;31, 2025 and December&nbsp;31, 2024,
together with the related notes thereto, included elsewhere in this information statement. The discussion and analysis should also be read together with the section(s) entitled &#8220;Business,&#8221; and &#8220;Risk Factors&#8221; and our unaudited
pro forma combined balance sheet as of December&nbsp;31, 2025, and the unaudited pro forma combined statements of operations for the year ended December&nbsp;31, 2025 and the year ended December&nbsp;31, 2024. See &#8220;Unaudited Pro Forma Combined
Financial Information.&#8221; The following discussion contains forward-looking statements that reflect future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that
may be outside of the Company&#8217;s control. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the
forward-looking statements include, but are not limited to, those discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; included elsewhere in this information
statement. Furthermore, we describe our business activities in this information statement as if no Permitted Third Party Sale has occurred or will occur. References in this section and throughout this information statement to &#8220;Avidity&#8221;
refer to Avidity prior to the effective time of the Distribution and references to &#8220;RemainCo&#8221; refer to Avidity at and after the effective time of the Distribution. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Separation from Avidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;25, 2025,
Avidity, Novartis and the Company entered into the Separation Agreement. Pursuant to the Separation Agreement, on the terms and subject to the conditions set forth therein, prior to the effective time of the Merger, Avidity will effect a <FONT
STYLE="white-space:nowrap">pre-closing</FONT> reorganization, which will generally result in the Company owning, assuming or retaining all assets and liabilities of Avidity and its subsidiaries exclusively related to their early stage precision
cardiology programs and Third Party Agreements, and Avidity owning, assuming or retaining all other assets and liabilities. Thereafter, Avidity will either (a)&nbsp;distribute to its stockholders on the Record Date who hold their shares of Avidity
Common Stock through the Distribution Date, on a pro rata basis, all the issued and outstanding shares of Company Common Stock at a ratio of one share of Company Common Stock for every ten shares of Avidity Common Stock, with the Company continuing
its existence as a separate and independent company, or (b)&nbsp;consummate a Permitted Third Party Sale subject to the terms and conditions of the Merger Agreement and the Separation Agreement. Following the completion of the Separation, Avidity
will have no continuing ownership interest in the Company. The Separation includes certain assets of Avidity that triggered a ROFN with an existing collaboration partner of Avidity that was notified concurrently with Avidity&#8217;s announcements of
its entry into the Merger Agreement. On February 5, 2026, the negotiation period under the ROFN expired and, as a result, no ROFN Sale will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
historical combined financial statements of the Company Business have been prepared on a stand-alone basis and are derived from Avidity&#8217;s consolidated financial statements and accounting records and are presented in conformity with United
States generally accepted accounting principles (&#8220;GAAP&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial position, results of operations and cash flows of the Company
Business historically operated as part of the Avidity&#8217;s financial position, results of operations and cash flows prior to and until the distribution of Company Common Stock to Avidity stockholders. These historical combined financial
statements of the Company Business may not be indicative of the future performance of the Company and do not necessarily reflect what its combined results of operations, financial condition and cash flows would have been had it operated as a
separate, publicly traded company during the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transition from Avidity and Costs to Operate as an Independent Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined financial statements reflect the operating results and financial position of the Company Business as it was operated by Avidity prior to the
Separation, rather than as an independent company. The Company Business has incurred and the Company will continue to incur ongoing operating expenses to operate as an independent company. These costs include the cost of various corporate
headquarters functions, information technology-related costs, and costs to operate stand-alone accounting, legal, and other administrative functions. As an independent public company, our information technology operating costs may be higher than the
costs allocated in the historical combined financial statements. It is not practicable to estimate the costs that would have been incurred in each of the periods presented in the historical combined financial statements for the functions described
above. Actual costs that would have been incurred if the Company Business operated as a stand-alone public company during these periods would have depended on various factors, including organizational design, outsourcing and other strategic
decisions related to corporate functions, information technology and back office infrastructure. On the Distribution Date, the Company will enter into the Transition Services Agreement with RemainCo, pursuant to which the Company will provide
certain nominal transition services to RemainCo, and RemainCo will provide certain transition services to us. During the transition from Avidity pursuant to the Separation and Distribution, the Company may incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> expenses to expand our infrastructure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company pioneering the delivery of RNA therapeutics to the heart to transform the standard of care for people living with
cardiomyopathies. Our proprietary technology leverages a targeted RNA delivery platform that combines the tissue selectivity of mAbs and other targeted delivery ligands with the precision of oligonucleotides. This unique combination allows selective
targeting of the underlying genetic drivers of disease that were previously undruggable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initially selected genetically validated cardiology
targets for our development pipeline. Our precision cardiology pipeline currently consists of two primary, wholly owned precision cardiology development candidates for the treatment of PRKAG2 syndrome and PLN cardiomyopathy. The chart below
represents a summary of our wholly owned development programs. We also have two additional pipeline candidates in research and development targeting undisclosed rare cardiology targets which we may develop in the future. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42675g48g48.jpg" ALT="LOGO" STYLE="width:6.33333in;height:1.13297in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ATR 1072 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead
product candidate, ATR 1072, is a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome. Preclinical studies to date have demonstrated ATR 1072&#8217;s potency and selectivity for PRKAG2 silencing. A mouse surrogate AOC (mATR
1072) containing the siRNA component of ATR 1072 conjugated to a mouse targeting anti-TFR1 antibody demonstrated robust in vivo activity. Marked reductions of PRKAG2 mRNA in the heart of wildtype mice were observed in mice treated with mATR 1072. We
also observed substantial reductions in PRKAG2 protein in the heart. We have also observed functional activity of mATR 1072 in a mouse model of PRKAG2 syndrome. In this model, mice exhibit reduced diastolic function and conduction abnormalities
relative to wildtype mice. Treatment with ATR 1072 improved diastolic function and restored electrical conduction parameters, which we believe establishes a link between PRKAG2 molecular target engagement and functional cardiac benefit. In addition,
preliminary tolerability data in cynomolgus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
monkeys, a NHP species, has been evaluated. ATR 1072 was pharmacologically active in NHP achieving robust and durable PRKAG2 mRNA knockdown and reduced protein expression in the heart. In these
subacute studies in NHP, ATR 1072 was well tolerated, with no adverse findings in electrocardiogram (ECG) parameters or heart morphology with a preclinical tolerability profile comparable to others in the RNA delivery platform. <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> preclinical toxicology studies and CMC manufacturing are ongoing for ATR 1072. We expect to file an IND in the second half of 2026 and the Company plans to initiate a Phase 1 clinical trial upon IND
acceptance by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ATR 1086 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second lead
product candidate, ATR 1086, is a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. Preclinical studies to date have demonstrated ATR 1086&#8217;s potency and selectivity for PLN silencing. In a mouse surrogate AOC (mATR
1086) containing the siRNA component of ATR 1086 conjugated to a mouse targeted anti-TFR1 antibody, mATR 1086 demonstrated robust PLN mRNA reduction in the heart. Preclinical studies have also demonstrated the functional activity of mATR 1086 in a
humanized mouse model of PLN cardiomyopathy (hPLNR14/R14). This model is homozygous for the human PLN 14del mutation resulting in rapidly progressive heart disease where animals die within 8 weeks of life. mATR 1086 treatment in this model resulted
in 100% survival through the duration of the study for at least 20 weeks. In addition, mATR 1086 treated mice had substantial improvement in cardiac function marked by increased ejection fraction. These data demonstrate that reduction of the gain of
function mutant PLN led to improved heart function. Preliminary tolerability data in cynomolgus monkeys, a NHP species, has been evaluated. ATR 1086 was pharmacologically active in NHP achieving robust and durable PLN mRNA knockdown in the heart.
Sustained PLN mRNA reduction (~80%) was well tolerated for over three months in <FONT STYLE="white-space:nowrap">non-GLP</FONT> studies in cynomolgus monkeys (n=3), a NHP species, with no adverse findings in ECG parameters or heart morphology with a
preclinical tolerability profile comparable to others in the RNA delivery platform. CMC manufacturing is planned for ATR 1086 to support initiation of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies in 2026. We expect to
file an IND for ATR 1086 in 2027. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we initially focused on targeting rare cardiac conditions with high unmet need, we believe our technology coupled with the robust preclinical data across
two different therapeutic areas supports our strategy to expand the pipeline to treat a broader range of genetic and cardiac diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of
Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Separation from
Avidity, we will continue to generate revenue from research and development and clinical trial activities. This revenue comes from license and research collaboration agreements, including reimbursements for services, upfront payments, and milestone
payments under current and future agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to generate revenue from product sales until our candidates successfully advance through
clinical development and receive regulatory approval, if ever. Consequently, our revenue may fluctuate quarterly, influenced by the timing and amounts of payments related to our services and milestones. Any setbacks in preclinical or clinical
development, or failure to secure regulatory approval, could adversely affect our ability to generate future revenues and our overall financial position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Separation from Avidity, our operating expenses will reflect the costs required to establish and operate as an independent, publicly traded
company on an ongoing basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses represent costs incurred in connection with our discovery research and ongoing efforts to progress preclinical programs into
clinical development as well as to execute clinical trials. These expenses include both external and internal costs, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">External costs, including fees paid to CROs, contract development and manufacturing organizations
(&#8220;CDMOs&#8221;), consultants, scientific advisors, and other third parties involved in preclinical and clinical development, and regulatory activities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Internal costs, including employee-related expenses (including salaries, benefits, and stock-based compensation)
for personnel engaged in research and development; costs of laboratory supplies and preclinical materials; and allocated facility, information technology, and depreciation expenses of leasehold improvements and equipment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses are recognized as incurred. Nonrefundable advance payments for goods and services to be used in future research and
development activities are capitalized until the goods or services are received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We manage our research and development spend in the aggregate and
evaluate programs based on factors such as development progress, probability of technical and regulatory success, commercial potential, and availability of capital or partnership resources. Because our personnel and infrastructure support multiple
programs, the Company Business does not allocate internal costs on a program-specific basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects our research and development expenses to
increase as the Company continues to conduct ongoing research and development activities, advance preclinical research programs toward clinical development, including <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and conduct clinical
trials following the Distribution. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming and can vary significantly for each product candidate and development program.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development costs may vary significantly depending on factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of ongoing preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient enrollment and trial site costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory requirements and safety monitoring; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> and process validation activities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stage of development and success of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative
expenses primarily consist of employee-related expenses (including salaries, benefits, and stock-based compensation) for our executive, finance, legal, human resources, transaction costs, and other administrative functions. Other general and
administrative expenses include professional fees for legal, accounting, audit, tax, and consulting services; costs associated with insurance, investor relations, and public company compliance; and allocated facility and <FONT
STYLE="white-space:nowrap">IT-related</FONT> costs, including depreciation, not otherwise included in research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
expects general and administrative expenses to increase over time as the Company operates as a stand-alone public company and continues to build the infrastructure necessary to support our increased research
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and development activities, commercial readiness initiatives, compliance costs, and other corporate activities following the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years
Ended December&nbsp;31, 2025 and 2024 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue
increased by $7.7&nbsp;million for the year ended December 31, 2025, as compared to the same period in 2024, primarily due to the recognition of a $10.0&nbsp;million milestone under the Lilly Agreement, offset by a decrease in revenues under the BMS
Agreements in 2025 due to variability in research and development services performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates the components of our research and development expenses for the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External Costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ATR 1072</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ATR 1086</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total external costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, lab supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Unallocated costs primarily relate to shared development and manufacturing costs for monoclonal antibodies used
across all programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $25.1&nbsp;million for the year ended December&nbsp;31, 2025, as
compared to the same period in 2024. External costs increased $18.0&nbsp;million primarily due to a $6.6&nbsp;million increase in contract manufacturing and service costs, $5.6&nbsp;million increase in process and analytical development
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs, and $4.3&nbsp;million increase in licenses and toxicology costs. Internal costs increased $7.0&nbsp;million primarily due to personnel costs including salaries, wages, annual bonuses and
stock-based compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $19.1&nbsp;million for the year ended December&nbsp;31, 2025, as compared to the same period in 2024,
primarily due to $11.5&nbsp;million in professional fees related to the Separation, and $6.3&nbsp;million in higher personnel costs including salaries, wages, annual bonuses and stock-based compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Provision for Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax amounts in the
Company Business&#8217; Combined Financial Statements have been calculated on a separate return method and are presented as if the Company Business&#8217; operations were a separate taxpayer. Therefore, tax expense, cash tax payments, and items of
current and deferred taxes may not be reflective of actual tax balances prior to or subsequent to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2025, the Company Business continued to maintain a full valuation allowance against net deferred tax assets, which are comprised primarily
of deferred revenue, transaction costs and stock-based compensation. The valuation allowance reflects management&#8217;s assessment that it is more likely than not that these deferred tax assets will not be realized. As a result of a book to tax
difference related to deferred revenue recognized for tax purposes, while maintaining a valuation allowance against its deferred tax assets, the Company Business generated taxable income and corresponding tax expense in 2024. The Company Business
recorded an income tax benefit of $0.1&nbsp;million and income tax expense of $11.9&nbsp;million for the periods ended December&nbsp;31, 2025 and 2024, respectively, which primarily represents U.S. Federal tax and state taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business has incurred net losses and negative cash flow from operations since inception and we anticipate the Company will
continue to incur net losses for the foreseeable future. To date, the Company Business has depended on Avidity to fund its operations as Avidity uses a centralized approach to cash management. The Company Business does not have any bank accounts
and, as such, had no cash and cash equivalents as of December&nbsp;31, 2025 and 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company anticipates that Avidity&#8217;s funding support of the
Company Business through its centralized cash management system, as well as the cash generated from the Third Party Agreements, will be sufficient to meet working capital requirements for the next twelve months if the Separation and Distribution do
not occur. Following the Separation and Distribution, the Company will no longer participate in Avidity&#8217;s centralized treasury system and will independently manage its liquidity. Immediately prior to the effective time of the Distribution,
Avidity will pay and contribute to the Company an amount in cash equal to $270&nbsp;million, minus the sum of the amount of marketable securities and cash and cash equivalents contained in any bank and brokerage accounts held by the Company as of
the close of business on the day prior to the Distribution Date. Following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the Company anticipates the Company Funding, as well as cash generated from its collaboration agreements, will be
sufficient to meet its working capital requirements, capital expenditures and other general corporate purposes for at least twelve months following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and through Phase 1 clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for our product candidate, ATR 1072, for the treatment of PRKAG2 syndrome. Whether these resources are adequate to meet the Company&#8217;s liquidity needs
beyond that period will depend on the Company&#8217;s growth and operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> until
required for use in our business, we expect to invest our cash, in accordance with our investment policy, in money market funds and fixed income securities including U.S. treasury bills and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government securities. We will attempt to minimize credit risk related to our cash and cash equivalents by maintaining a well-diversified portfolio that limits the amount of exposure as to
maturity and investment type. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, the Company Business had no cash, cash equivalents, or marketable securities on hand because we did not have any bank accounts.
The primary uses of cash by the Company Business are to fund its operations, which consist primarily of research and development expenditures related to its programs and, to a lesser extent, general and administrative expenditures. We anticipate
that the Company will continue to incur significant and increasing expenses for the foreseeable future following the Separation and Distribution as we continue to advance our product candidates and further our research and development initiatives,
expand our corporate infrastructure, including the costs of being a public company, and incur costs associated with potential commercialization. We are subject to all of the risks typically related to the development of new drug candidates, and we
may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any products approved for sale and have not generated any revenue from product sales since our inception. We do not expect to generate
revenue from any product candidates that we develop until we obtain regulatory approval for one or more of such product candidates and commercialize our products pursuant to our existing collaboration agreements or enter into new collaboration
agreements with third parties. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we may never achieve or sustain profitability and, unless and until we are able to develop and commercialize our
product candidates, we will need to raise additional capital. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations with the Company Funding, revenue generated from the Third Party
Agreements, if any, and through public or private equity or debt financings, or potentially other capital sources, such as collaboration or licensing arrangements with third parties or other strategic transactions. There are no assurances that we
will be successful in obtaining an adequate level of financing to support our business plans when needed on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the
ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through
collaboration or licensing arrangements with third parties or other strategic transactions, we may have to relinquish rights to our intellectual property, future revenue streams, research programs, or product candidates or grant licenses on terms
that may not be favorable to us. If we are unable to raise capital as and when needed, or on attractive terms, we may have to significantly delay, reduce, or discontinue the development and commercialization of our product candidates or scale back
or terminate our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with research, development and commercialization of
pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could significantly increase as a result of many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scope, progress, results and costs of researching and developing our current product candidates, as well as
other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing of, and the costs involved in, obtaining marketing approvals for our current product candidates for
current and future indications, as well as other product candidates we may develop and pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The number of future indications and product candidates that we pursue and their development requirements;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If approved, the cost of commercialization activities for our current product candidates or any other product
candidate that receives regulatory approval to the extent such costs are not the responsibility of our collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to the receipt of regulatory approval, revenue, if any, received from commercial sales of our current
product candidates or revenues received from any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our headcount growth and associated costs as we expand our organization to achieve our objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The costs of preparing, filing and prosecuting patent applications, and maintaining and protecting our
intellectual property rights, including enforcing and defending intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other variables with respect to the development of any product candidate could significantly change the costs and
timing associated with the development of that product candidate. Additionally, we may experience increased costs and be required to raise additional capital much sooner than anticipated. Further, our operating plans may change in the future, and we
may need additional funds to meet operational needs and capital requirements associated with such operating plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, the cash flows from operating and financing activities of the Company Business reflect the impact of funding provided by Avidity under a
centralized cash management structure. As a result, the financial statements of the Company Business include intercompany transfers within operating and financing activities. Following the Separation, the Company will no longer participate in
Avidity&#8217;s centralized treasury system and will independently manage its liquidity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows and cash and cash
equivalents, for the periods indicated (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year-Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $41.1&nbsp;million for the year ended December 31, 2025, compared to $22.6&nbsp;million used in operating activities
for the year ended December 31, 2024. The change primarily reflects higher research and development spending as well as general and administrative expenses as described under &#8220;Results of Operations&#8221;. Operating cash flows of the Company
Business historically represent funding requirements for Company Business activities, which were financed by Avidity through intercompany transfers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in
investing activities was $1.4&nbsp;million for the year ended December 31, 2025, compared to $0.3&nbsp;million for the year ended December 31, 2024. The change primarily reflects the acquisition of lab equipment to further the research and
development of product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $42.6&nbsp;million for the year ended December 31, 2025, compared to $22.8&nbsp;million provided by financing
activities for the year ended December 31, 2024. These amounts reflect net transfers from and to Avidity to fund general operating, investing and financing activities and settle intercompany balances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following
the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the Company will have operating lease obligations related to our office and laboratory facility. In June 2020, and as amended in December 2020, Avidity entered a
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease for approximately 47,737 square feet of office and laboratory space. Avidity entered into an expansion lease in June 2023 with both leases terminating concurrently on
November&nbsp;30, 2026. In connection with the Separation, the lease and all related rights and obligations will be transferred and assigned to us, and, following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will operate as the tenant
under the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, prior to the Separation, certain facility and service arrangements were comingled within contracts held by Avidity. Under
the terms of the Separation, Avidity will retain those comingled contracts and continue to be the obligor. We will not assume any of Avidity&#8217;s obligations under those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into contracts during the ordinary course of our business for purposes such as contract research services, contract manufacturing services,
professional services, and a variety of other operational needs. Our agreements often include clauses requiring payment in the event of early termination, with the amount depending on both the timing and specific terms of each contract. As a result,
the Company classifies these contracts as cancellable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Critical Accounting Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined financial statements of the Company Business have been prepared in accordance with U.S. GAAP. Preparation of the financial statements requires
certain judgments, estimates and assumptions that impact the reported amount of revenues and expenses, assets and liabilities and the disclosure of contingent assets and liabilities. An accounting judgment, estimate or assumption is considered to be
critical when the estimate or assumption is complex in nature or requires a high degree of judgment and the use of different judgments, estimates and assumptions could have a material impact on the combined financial statements. Management
periodically reviews these estimates and makes adjustments when facts and circumstances dictate. To the extent that there are material differences between these estimates and actual results, its financial condition or results of operations will be
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are
highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the combined
financial statements. Management believes that the critical accounting policies reflect the more significant estimates and assumptions used in the preparation of the combined financial statements. The critical accounting policies, judgments and
estimates should be read in conjunction with the Company Business combined financial statements and the notes thereto and other disclosures included elsewhere in this information statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant accounting policies of the Company Business are described in Note 2 to the combined financial statements included elsewhere in this information
statement. The following accounting policies with financial estimates are the most critical to understanding and evaluating our historical and future performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration and Research Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is
recognized under collaboration and research agreements based on the transaction price allocated to performance obligations within each arrangement. The transaction price typically includes fixed consideration, such as
<FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront license fees and research funding, and excludes variable consideration&#8212;such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, regulatory, and commercial milestone payments&#8212;until it is probable that a significant reversal will not occur. Royalties on net sales of licensed products are recognized when
the underlying sales occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In applying ASC 606 (Revenue from Contracts with Customers) and ASC 808 (Collaborative Arrangements), significant judgment is
exercised in determining the amount and timing of revenue recognition. This process involves identifying promised goods or services in the contract and determining whether they are distinct performance obligations, measuring the transaction price
including applying constraints on variable consideration, allocating the transaction price to performance obligations based on observable standalone selling prices when available, and recognizing revenue when or as performance obligations are
satisfied. Key judgments include evaluating whether contractual obligations represent distinct performance obligations, assessing whether options provide material rights, determining whether licenses are functional or symbolic, assessing the timing
of satisfaction of obligations, and estimating the probability and timing of milestone achievement and related variable consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These estimates
require consideration of contractual terms, collaborator billing schedules, progress toward milestones, and whether arrangements involve joint operating activities or customer relationships. Because these judgments involve inherent uncertainty,
actual revenue recognized may differ from initial estimates. Estimates are regularly updated as new information becomes available, and any adjustments are recorded in the period identified, which may materially affect reported revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accrued Research and Development Costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses are recorded as incurred. These costs include salaries, benefits and stock-based compensation associated with research and development personnel, third-party research and development expenses, license fees, laboratory supplies,
facilities, overhead costs, and consultants. At each reporting date, services performed are estimated but not yet invoiced based on discussions with vendors and review of the project progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These accruals of research and development expenses requires estimates of expenses incurred, including estimates of the time period over which services will
be performed and the completion of contract components. If the actual timing of the performance of services varies from estimates, the accrual or prepaid expense are adjusted accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although material differences between estimates and actual amounts incurred are not expected, variations in the status or timing of services could result in
reporting amounts that are either overstated or understated in a given period. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Allocation of General Corporate Expenses and Avidity Costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Separation, the combined financial statements of the Company Business included certain costs of Avidity that were allocated to the Company
Business for corporate functions such as finance, legal, human resources, information technology, and other shared services. These allocations were made on a specific identification basis when possible or were allocated on the basis of a
proportional cost allocation method primarily based on a percentage of the operating expenses. These cost allocations are a reasonable reflection of the utilization of services provided to, or benefit derived by, the Company Business during the
periods presented, though the allocations may not be indicative of the actual costs that would have been incurred had the Company Business operated as a standalone company during the periods presented. Management believes the allocation
methodologies are reasonable; however, the amounts reflected in the combined financial statements may not be indicative of the actual costs we would have incurred as a standalone entity. After the Separation, the Company will incur these expenses
directly as part of our standalone operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recently issued and adopted accounting pronouncements are described in Note 2 to the combined financial statements of the Company Business included elsewhere
in this information statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_11"></A>CORPORATE GOVERNANCE AND MANAGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets
forth information concerning our executive officers and directors of the Company following the Distribution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathleen Gallagher</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief&nbsp;Executive&nbsp;Officer,&nbsp;President&nbsp;and&nbsp;Member&nbsp;of&nbsp;the&nbsp;Board&nbsp;of&nbsp;Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Husam Younis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Hughes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brendan Winslow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephanie Kenney</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Corporate Affairs Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rocio Martin Hoyos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Strategy Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Management</FONT> Directors:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Boyce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Member of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">W. Michael Flanagan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Member of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carsten Boess</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Member of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simona Skerjanec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Member of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Wilson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Member of the Board of Directors</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kathleen Gallagher</I></B> has served as the Company&#8217;s CEO since December 2025. Ms.&nbsp;Gallagher is also a member of the Company&#8217;s Board of
Directors. Ms.&nbsp;Gallagher will be appointed as the Company&#8217;s President in connection with the Distribution. Ms.&nbsp;Gallagher joined Avidity in April 2021 and has served as Chief Program Officer since September 2024. Ms.&nbsp;Gallagher
previously held the roles of Senior Vice President and Global Program Head, Myotonic Dystrophy Type 1 (DM1) at Avidity from July 2023 to September 2024 and Senior Vice President of Corporate Communications and Investor Relations at Avidity from
April 2021 to July 2023. Ms.&nbsp;Gallagher brings more than 20 years of experience in the biopharmaceutical industry leading investor relations, portfolio strategy, program management and corporate affairs in preclinical to commercial stage
companies. Prior to joining Avidity, Ms.&nbsp;Gallagher was Vice President, Investor Relations and Corporate Communications at Akcea&nbsp;Therapeutics, Inc. (acquired by Ionis Pharmaceuticals) from September 2017 to April 2020, where her
communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Waylivra<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Previously, Ms.&nbsp;Gallagher held roles of increasing responsibility during her tenure at Merrimack Pharmaceuticals from 2003 to 2016, where she provided leadership and direction through
multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Ms.&nbsp;Gallagher earned her B.S. in English from Boston University. We believe
Ms.&nbsp;Gallagher is qualified to serve on the Company&#8217;s Board of Directors because of her leadership and communications strategy expertise gained from her experience in the biopharmaceutical industry and her deep knowledge of our preclinical
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Husam Younis</I></B> will be appointed as the Company&#8217;s Chief Scientific Officer in connection with the Distribution.
Dr.&nbsp;Younis has served as a Senior Vice President of Development Sciences at Avidity since January&nbsp;2023, after serving as a Vice President at Avidity between December&nbsp;2020 and December&nbsp;2022. Before joining Avidity, Dr.&nbsp;Younis
held senior leadership positions at NGM Biopharmaceuticals, Ionis Pharmaceuticals (Nasdaq: IONS), and Pfizer Inc (NYSE: PFE). He began his career as a post-doctoral scientist at Isis&nbsp;Pharmaceuticals and as a staff pharmacist at WalMart Inc
(Nasdaq: WMT). Dr.&nbsp;Younis holds a Doctor of Philosophy in Pharmacology and Toxicology and a Doctor of Pharmacy, both from the University of Arizona. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Steven Hughes</I></B> will be appointed as the Company&#8217;s Chief Medical Officer in connection with the Distribution. He has served as
Avidity&#8217;s Chief Medical Officer since February 2022. Prior to joining Avidity, Dr.&nbsp;Hughes&#8217;s served as Chief Medical Officer at Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Organovo Holdings, Inc. (now VivoSim Labs, Inc.) (Nasdaq: VIVS) from January 2021 and February 2022. Dr.&nbsp;Hughes has over 20&nbsp;years of experience building and leading clinical development
and medical affairs teams at various biopharma companies. He has contributed to over 50&nbsp;clinical trials for more than 25&nbsp;drugs across all stages of drug development and in multiple therapeutic areas including cardiovascular, neurology and
several rare diseases with successful license approvals for several rare disease drugs. Dr.&nbsp;Hughes&#8217;s previous positions include the Chief Medical Officer at Arcturus and Organovo, Chief Clinical Development Officer at Ionis
Pharmaceuticals and clinical leadership positions at Biogen, CSL Behring and Sanofi. Dr.&nbsp;Hughes is board certified in pharmaceutical medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial
College Business School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Brendan Winslow</I></B> will be appointed as the Company&#8217;s Chief Financial Officer in connection with the
Distribution. Mr. Winslow has served as Senior Vice President of Finance at Avidity since 2024. Before joining Avidity, Mr. Winslow served as Vice President, Strategic Finance at Acadia Pharmaceuticals Inc. (Nasdaq:&nbsp;ACAD) between 2020 and 2024.
Mr. Winslow also held leadership roles at Acadia Pharmaceuticals, Synchrony Financial, PepsiCo, and Baxter International, supporting global operations and strategic finance initiatives. Mr.&nbsp;Winslow holds an MBA from the Kellogg School of
Management at Northwestern University and a Bachelor of Science in Finance from Miami University, and is a Certified Management Accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stephanie Kenney </I></B>will be appointed as the Company&#8217;s Chief Corporate Affairs Officer in connection with the Distribution. She has served as
Senior Vice President, Corporate Affairs at Avidity since August 2025. Before joining Avidity, Ms. Kenney served as Vice President, Global Corporate Affairs &amp; Investor Relations at Hansa&nbsp;BioPharma (Nasdaq: HNSA) from December 2022 to August
2025. Her earlier experience includes senior leadership positions at AstraZeneca (LSA: AZN), where she served as Global Head of Corporate Affairs for the Cardiovascular, Renal &amp; Metabolic business between September 2020 and November 2022.
Ms.&nbsp;Kenney holds a Bachelor of Science in Communications from Mansfield University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rocio Martin Hoyos</I></B> will be appointed as the
Company&#8217;s Chief Strategy Officer in connection with the Distribution. Previously, she served as Senior Vice President, Global Program Head, FSHD at Avidity since April 2024. Prior to joining Avidity, Ms.&nbsp;Martin held several senior
leadership roles at Kronos Bio, Inc. (Nasdaq:&nbsp;KRON) from January 2021 and April 2024. Her most recent role was Senior Vice President, Corporate Strategy and Portfolio Management, from January 2024 to April 2024, and she previously served in
various vice president roles dating back to January 2021. Earlier in her career, Ms.&nbsp;Martin served in leadership roles at Audentes Therapeutics, Inc. (Nasdaq: BOLD), including as Vice President, Global Marketing, and at Ultragenyx
Pharmaceutical Inc. (Nasdaq: RARE), Neuroly and Metabolic. Ms.&nbsp;Martin began her career in the biopharmaceutical industry at Celgene Corporation (Nasdaq: CELG). Ms.&nbsp;Martin holds a Master of Science in Biochemistry from Universidad
Aut&oacute;noma de Madrid and an MBA from IESE Business School. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Management</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sarah Boyce</I></B> has been a member of the Company&#8217;s Board of Directors since December 2025. She has served as President and Chief Executive
Officer and a director of Avidity since October 2019. Prior to joining Avidity, she served as President and a member of the board of directors of Akcea Therapeutics, Inc. from April&nbsp;2018 through September&nbsp;2019, where she led the
commercialization of the company&#8217;s rare disease products. Ms.&nbsp;Boyce served as Chief Business Officer of Ionis Pharmaceuticals, Inc. from January 2015 to April 2018, and Vice President, Head of International Business Strategy and
Operations at Forest Laboratories, Inc. from 2012 to 2014. She previously held various positions with Alexion Pharmaceuticals Inc., Novartis AG, Bayer AG and <FONT STYLE="white-space:nowrap">F.&nbsp;Hoffmann-La</FONT> Roche AG. Since November 2022,
Ms.&nbsp;Boyce has served on the board of directors of OmniAb, Inc. (Nasdaq: OABI). Ms.&nbsp;Boyce also served on the board of directors of Berkeley Lights Inc. from July&nbsp;2019 until May&nbsp;2022 and the board of directors of Ligand
Pharmaceuticals Incorporated (Nasdaq: LGND) from October 2019 to November 2022. Ms.&nbsp;Boyce holds a B.S. in Microbiology from the University of Manchester, England. We believe Ms.&nbsp;Boyce is qualified to serve on the Board of Directors based
on her senior leadership experience and business and operational expertise in the biopharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Carsten Boess</I></B> will be appointed a member of the Company&#8217;s Board of Directors in
connection with the Distribution. Mr. Boess has served as a director of Avidity since April 2020. Mr. Boess has also served on the board of director of Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) since 2018. Previously, Mr. Boess served as Executive
Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) from August&nbsp;2015 until February 2020. Before Kiniksa, Mr. Boess was the Chief Financial Officer at Alexion&nbsp;Pharmaceuticals (Nasdaq: LXRX) from 2004 to 2005
and the Senior Vice President and Chief Financial Officer at Synageva BioPharma Corp. from 2011 until the company&#8217;s acquisition by Alexion Pharmaceuticals in 2015. Previously, Mr. Boess served in multiple roles with increasing responsibility
at Insulet Corporation (Nasdaq: PODD), including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance at Serono Inc. from
2005 to 2006. Mr. Boess also held several financial executive roles at Novozymes of North America and Novo Nordisk (NYSE: NVO) in France, Switzerland and China. During his tenure at Novo Nordisk, he served on Novo Nordisk&#8217;s Global Finance
Board. From August 2020 until January 2023, Mr. Boess served on the board of directors of Health Sciences Acquisitions Corporation. Mr. Boess received a Bachelor&#8217;s degree and Master&#8217;s degree in Economics and Finance, specializing in
Accounting and Finance from the University of Odense, Denmark. We believe Dr. Boess is qualified to serve on the Board of Directors based on his extensive business, financial and operational experience in the biopharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simona Skerjanec</I></B> will be appointed a member of the Company&#8217;s Board of Directors in connection with the Distribution. She has nearly three
decades of broad international experience in the pharmaceutical industry and has led multiple research and development efforts that have resulted in regulatory approvals and launches of commercial therapies in therapeutic areas including neurology
and cardiology in the United States and other countries. Ms. Skerjanec was the Senior Vice President and Global Neuroscience Head at F. Hoffmann-La Roche AG (&#8220;Roche&#8221;) (SIX: RO) in Switzerland between October 2020 and January 2024 and led
the business and global strategy for Roche&#8217;s portfolio of neurological and rare diseases, including Ocrevus<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for the treatment of multiple sclerosis and a novel monoclonal antibody for
the treatment of Alzheimer&#8217;s disease. During her <FONT STYLE="white-space:nowrap">nine-year</FONT> tenure at Roche, she also served as a General Manager of Roche in Portugal. Before joining Roche, Ms.&nbsp;Skerjanec held positions of
increasing responsibility in development and commercialization. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular franchise head at The Medicines Company where she held various roles of increasing responsibilities in
development and commercialization. She also held positions at Eli Lilly (NYSA: LLY), Pfizer (NYSA: PFE) and Johnson &amp; Johnson (NYSA: JNJ). Ms.&nbsp;Skerjanec has served on the board of directors of Immunic Therapeutics (Nasdaq: IMUX) since
April&nbsp;2024 and the board of directors of PerceivAI, a private, AI-driven precision medicine company, since October 2024. Ms.&nbsp;Skerjanec holds a Master&#8217;s degree in Pharmacy from University of Ljubljana and an MBA from Fairleigh
Dickinson University. We believe Ms.&nbsp;Skerjanec is qualified to serve on the Board of Directors given her business and operational expertise in the biopharmaceutical industry, both in companies based in the United States and internationally.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Troy Wilson, Ph.D., J.D.</I></B>, will be appointed a member of the Company&#8217;s Board of Directors in connection with the Distribution. He is
the co-founder of Avidity and has served on Avidity&#8217;s board of directors since November&nbsp;2012, where he served as Chair since January 2021. Dr. Wilson served as Avidity&#8217;s President and Chief Executive Officer from November 2012 to
February 2019. He has been President and Chief Executive Officer and chairman of the board of directors of Kura Oncology (Nasdaq: KURA), Inc. since August 2014 and has served as a member of the board of directors of Puma Biotechnology (Nasdaq:
PBYI), Inc. since October 2013. He has served as Executive Chairman of the board of directors of Abintus Bio, Inc. since October 2020. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences, Inc., a
privately-held biopharmaceutical company, since July 2012, and has served as the sole managing member of Wellspring Biosciences&#8217; parent company, Araxes Pharma LLC, since May 2012. Previously, Dr.&nbsp;Wilson served as a director of Zosano
Pharma Corporation from June 2014 to October 2019. He also served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019, and as President and Chief Executive Officer and a member of the
board of directors of Intellikine, Inc. Dr. Wilson holds a J.D. from New York University and a Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
California, Berkeley. We believe Dr. Wilson is qualified to serve on the Board of Directors because of his extensive experience as a senior executive and board member of companies in the
biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>W. Michael Flanagan, Ph.D.</I></B> will be appointed a member of the Company&#8217;s Board of Directors in connection
with the Distribution. Dr. Flanagan currently serves as Chief Scientific Officer and has led Research at Avidity since January 2025 and previously served as Chief Scientific and Technology Officer at Avidity, where he led both Research and
Manufacturing from February 2023 to January 2025. He previously served as the Chief Technology Officer of Avidity from January 2021 to February 2023. Dr.&nbsp;Flanagan has extensive experience developing multiple therapeutic modalities, including
RNA therapeutics, antibody drug conjugates, and bispecific antibodies. Prior to his time at Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc. from January 2012 to January 2021, where
he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, Dr.&nbsp;Flanagan served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc. (Nasdaq:
GILD) and Merck &amp; Co. Inc. (NYSE: MRK), where he was Senior Director of RNA Sciences. Dr.&nbsp;Flanagan received a B.S. in Genetics from the University of California at Davis, a Ph.D. in Biological Sciences from the University of California at
Irvine and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford School of Medicine. We believe Dr.&nbsp;Flanagan is qualified to serve on the Board of Directors because he is a proven biotechnology
executive, recognized for his deep scientific and operational expertise, with more than 25&nbsp;years of experience advancing first-in-class therapeutics, scaling innovative companies across RNA, oncology and immunology, and leading organizations
through major milestones (including platform creation, clinical advancement, capital formation, partnerships and acquisitions). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors is divided into three classes and will have six members. There will be no family relationships between any of our executive
officers and directors. Each class will consist, as nearly as possible, of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors, and each class will have a three-year term. Vacancies on the Board of Directors may be
filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, will serve for the remainder
of the term of that class and until the director&#8217;s successor is duly elected and qualified. If the number of directors changes, any increase or decrease will be apportioned among the classes so as to maintain the number of directors in each
class as nearly as possible. Decreases in the number of directors will not shorten the term of any incumbent director. Our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I will consist of Simona Skerjanec and Carsten Boess, and their term will expire at our first annual
meeting of stockholders to be held after the completion of the Distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II will consist of Troy Wilson and W. Michael Flanagan,&nbsp;and their term will expire at our second
annual meeting of stockholders to be held after the completion of the Distribution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III will consist of Sarah Boyce and Kathleen Gallagher,&nbsp;and their term will expire at our third
annual meeting of stockholders to be held after the completion of the Distribution. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These board provisions could make it more difficult
for third parties to gain control of our company by making it difficult to replace members of the Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors will undertake a review of the independence of each director. As a result of this review, the Board of Directors is expected to
determine that Sarah Boyce, Carsten Boess, W. Michael Flanagan, Simona&nbsp;Skerjanec and Troy Wilson are independent under applicable Nasdaq listing standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will establish two standing committees&#8212;Audit and Human Capital Management&#8212;each of which will operate under a charter that will be approved by
the Board of Directors. Director nominees will be selected by a majority of the Board of Directors&#8217; independent directors (as defined under Nasdaq rules) in a vote in which only independent directors participate. All of the members of each of
the Board of Directors&#8217; two standing committees will be independent as defined under Nasdaq rules. In addition, all members of the Audit Committee will meet the independence requirements for Audit Committee members under <FONT
STYLE="white-space:nowrap">Rule&nbsp;10A-3&nbsp;under</FONT> the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee&#8217;s main function will be to oversee our accounting and financial reporting processes and the audits of our financial statements. This
committee&#8217;s responsibilities include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the qualifications, independence and performance of our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the audit <FONT STYLE="white-space:nowrap">and&nbsp;non-audit&nbsp;services</FONT> to be performed by
our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual audit
and the review of our quarterly unaudited financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and
regulatory requirements as they relate to financial statements or accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and our auditors any earnings announcements and other public announcements regarding
our results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing oversight of the Company&#8217;s policies with respect to risk assessment and risk management,
including with respect to cybersecurity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating periodically the performance of the audit committee and its members.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our Audit Committee will be Carsten Boess, Simona Skerjanec and Troy Wilson. Carsten Boess will serve as the Chair of
the Audit Committee. All members of our Audit Committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. The Board of Directors is expected to determine that Carsten Boess is an
&#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and will have the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. The Audit Committee may delegate its authority under
its charter to one or more subcommittees as it deems appropriate from time to time as further described in its charter. The Audit Committee will operate under a written charter that satisfies the applicable standards of the SEC and Nasdaq, which the
Audit Committee will evaluate and review at least annually. Both our external auditor and internal financial personnel meet privately with the Audit Committee and have unrestricted access to this committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Human Capital Management Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Human
Capital Management Committee&#8217;s main function will be to oversee human capital management and compensation of our officers and directors. The Human Capital Management Committee will review corporate goals and objectives relevant to the
compensation of our chief executive officer, evaluate the performance of the Chief Executive Officer in light of those goals and objectives and approve the compensation of the Chief </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive Officer based on such evaluations. The Human Capital Management Committee will also review the compensation of other executive officers and in connection with such review oversee the
evaluation of such executive officers. In addition, the Human Capital Management Committee will review and approve or make recommendations to the Board of Directors regarding the issuance of stock options and other awards under our equity plan.
Furthermore, the Human Capital Management Committee will periodically review and recommend to the Board of Directors compensation for service on the Board of Directors and any committees of the Board of Directors. The Human Capital Management
Committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to time as further described in its charter. The Human Capital Management Committee will periodically review and evaluate its
charter, as well as periodically review and evaluate the performance of the Human Capital Management Committee and its members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our Human
Capital Management Committee will be Troy Wilson, Sarah Boyce and Simona Skerjanec. Troy Wilson will serve as the Chair of the committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of
Business Conduct and Ethics for Employees, Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will adopt, upon the effective time of the Distribution, a Code of
Business Conduct and Ethics that applies to our officers, directors, and employees, which will be available on our website at www.atriumtherapeutics.com. The Code of Business Conduct and Ethics will contain general guidelines for conducting the
business of our company consistent with the highest standards of business ethics and is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section&nbsp;406 of Sarbanes-Oxley and Item 406 of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> In addition, we intend to promptly disclose (1)&nbsp;the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer,
principal accounting officer or controller or persons performing similar functions, and (2)&nbsp;the nature of any waiver, including an implicit waiver, from a provision of our Code of Business Conduct and Ethics that is granted to one of these
specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital
Management Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our directors who will serve as members of our Human Capital Management Committee
are expected to be, or has been at any time during the past year, one of our officers or employees. Sarah Boyce, who will serve as a member of the Board of Directors, previously served as the President and Chief Executive Officer of Avidity prior to
the Separation and Distribution. None of our executive officers will serve, or in the past year will have served, as a member of the board of directors or compensation or human capital management committee of any other entity that has one or more
executive officers serving on our Board of Directors or Human Capital Management Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our Board of Directors will adopt a director compensation policy for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors to be effective upon the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company was not formed as of
December&nbsp;31, 2024, we did not have any directors or pay any compensation to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors with respect to service on our Board of Directors, during the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical information concerning the compensation paid to or earned by directors of Avidity may not be directly relevant to or indicative of the compensation
that any such directors will receive (as applicable) as directors of the Company following the Distribution, but is available in Avidity&#8217;s previous annual proxy statements filed with the SEC. Disclosure of the compensation that Avidity
directors received during the year ended December&nbsp;31, 2024 is included in the proxy statement that Avidity filed on April&nbsp;29, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a newly formed entity, the Company did not have any executive officers or pay any compensation during the year ended December&nbsp;31, 2025. Historical
information concerning the compensation paid to or earned by named executive officers of Avidity may not be directly relevant or indicative of the compensation that any such officers will receive (as applicable) as named executive officers of the
Company following the Distribution, but is available in Avidity&#8217;s previous annual proxy statements filed with the SEC. Disclosure of the compensation that Avidity named executive officers received during the year ended December&nbsp;31, 2024
is included in the proxy statement that Avidity filed on April&nbsp;29, 2025. Detailed information on the compensation arrangements of the Company&#8217;s named executive officers will be provided in the Company&#8217;s first proxy statement
following the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<I>Corporate Governance and Management&#8212;Executive Officers</I>&#8221; of this information statement for the
list of individuals who are expected to serve in executive officer positions of the Company following the Distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation
Following the Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentive Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that equity-based compensation will be an important component of the executive compensation program of the Company because we believe it is important
to maintain a strong link between executive incentives and the creation of stockholder value. Accordingly, prior to the Distribution Date, Avidity and the Company will cooperate to establish, according to the terms of the Separation Agreement,
(i)&nbsp;the 2026 Plan and forms of standard award and Make Whole Award agreements thereunder, which plan and standard award agreements are intended to be substantially similar to Avidity&#8217;s 2020 Incentive Award Plan and the forms of award
thereunder, and (ii)&nbsp;the ESPP, intended to comply with Section&nbsp;423 of the Code, which plan is intended to be substantially similar to Avidity&#8217;s 2020 Employee Stock Purchase Plan. The Company will adopt such plans, and Avidity will
approve such plans as the Company&#8217;s sole stockholder prior to the effective time of the Distribution; provided, that, except for the Make Whole Awards, no awards will be granted under the 2026 Plan and no offering periods will commence under
the ESPP prior to the effective time of the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The material terms of the plans are set forth below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Incentive Award Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility and
Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under
the 2026 Plan. Prior to the Distribution, employees, consultants and directors of Avidity, and employees and consultants of Avidity&#8217;s subsidiaries will also be eligible for awards, in order to facilitate one-time grants of Make Whole Awards
under the 2026 Plan, as further discussed below. The 2026 Plan will generally be administered by our Board of Directors with respect to awards to non-employee directors and by our Human Capital Management Committee with respect to other
participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under the 2026
Plan, Section 16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the
administration of, the 2026 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2026 Plan, including any vesting and vesting acceleration conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitation on Awards and Shares Available </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of
shares initially available for issuance under awards granted pursuant to the 2026 Plan will be equal to 17% of the number of shares of our common stock outstanding at the consummation of the Distribution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(on a fully diluted basis) (the &#8220;Initial Share Reserve&#8221;). The number of shares initially available for issuance will be increased by an annual increase on January 1 of each calendar
year beginning in 2027 and ending in 2036, equal to the lesser of (a) 5% of the aggregate number of Outstanding Shares and (b) such smaller number of shares as determined by our Board of Directors. For purposes of the foregoing, &#8220;Outstanding
Shares&#8221; means the sum of (x) the number of shares of our common stock outstanding and (y) the number of shares of our common stock that are issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire shares of our
common stock for a nominal exercise price (if any), each as of the final day of the immediately preceding calendar year. The number of shares of common stock may be issued upon the exercise of incentive stock options under the 2026 Plan will not
exceed the Initial Share Reserve. Shares issued under the 2026 Plan may be authorized but unissued shares, shares purchased in the open market or treasury shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an award under the 2026 Plan expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised
or forfeited, any shares subject to such award will, as applicable, become or again be available for new grants under the 2026 Plan. Awards granted under the 2026 Plan upon the assumption of, or in substitution for, awards authorized or outstanding
under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2026 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2026 Plan provides for the grant of stock
options, including incentive stock options (&#8220;ISOs&#8221;), and nonqualified stock options (&#8220;NSOs&#8221;), restricted stock, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights
(&#8220;SARs&#8221;), and other stock or cash-based awards. In addition, prior to the effective time of the Distribution, the Company will make a one-time grant of certain Make Whole Awards under the 2026 Plan, as discussed further below. Certain
awards under the 2026 Plan may constitute or provide for a deferral of compensation, subject to Section 409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2026 Plan will be set
forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post termination exercise limitations. A brief description of each award type follows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock options</I>. Stock options provide for the purchase of shares of our common stock in the future at an exercise price set on the grant date. ISOs, by
contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. The exercise price of a stock option will not be less
than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute options granted in connection with a corporate
transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the plan administrator may apply to stock options and may
include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SARs</I>. SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the
grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute SARs granted in connection with a corporate
transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted stock and RSUs</I>. Restricted stock is an award of nontransferable shares of our common stock that remain forfeitable unless and until
specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be
accompanied by the right to receive the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Delivery of the shares underlying RSUs may be deferred under the terms of the
award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service, the attainment of performance goals and/or such other conditions
as the plan administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other stock or cash-based awards</I>. Other stock or cash-based awards are awards of cash, fully vested
shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in
the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to receive awards. The plan administrator will determine the
terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance awards include any of the
foregoing awards that are granted subject to vesting and/or payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria
upon which performance goals are established by the plan administrator may include (but are not limited to): net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization and non-cash equity-based
compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including, but not limited to, gross profits, net profits, profit growth, net operation
profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash
flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures;
expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation,
completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals;
customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios
(including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and
marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to our performance or the performance of a subsidiary,
division, business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Non-Employee Director Compensation Limits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2026
Plan, the sum of any cash compensation or other compensation and the grant date fair value (as determined in accordance with ASC 718, or any successor thereto) of any equity awards granted as compensation for services as a non-employee director
during any fiscal year may not exceed $750,000, increased to $1,000,000, in the fiscal year of a non-employee director&#8217;s initial service as a non-employee director. The plan administrator may make exceptions to this limit for individual
non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award such
compensation or in other contemporaneous compensation decisions involving non-employee directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with certain transactions and events affecting our common stock, including a change of control, or change in any applicable laws or accounting
principles, the plan administrator has broad discretion to take action under the 2026 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such change in applicable laws or
accounting principles. This includes canceling awards in exchange for either an amount in cash or other property with a value equal to the amount that would have been obtained upon exercise or settlement of the vested portion of such award or
realization of the participant&#8217;s rights under the vested portion of such award, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares
available, replacing awards with other rights or property or terminating awards under the 2026 Plan. In the event of a change of control where the acquirer does not assume awards granted under the 2026 Plan, awards issued under the 2026 Plan may be
subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable. In addition, in the event of certain non-reciprocal transactions with our stockholders, or an &#8220;equity
restructuring,&#8221; the plan administrator will make equitable adjustments to the 2026 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Participants, Claw-back Provisions, Transferability and Participant Payments</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to foreign participants, the plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards,
subject to the share limits described above. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy or in the applicable award agreement. With limited
exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2026 Plan are generally non-transferable prior to vesting and are exercisable only by the
participant. With regard to tax withholding obligations arising in connection with awards under the 2026 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2026 Plan, the plan administrator may, in
its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions, a &#8220;market sell order&#8221; or such other consideration as it deems suitable or any combination of the foregoing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment and Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors
may amend or terminate the 2026 Plan at any time; however, except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2026 Plan.
The plan administrator will have the authority, without the approval of our stockholders, to amend any outstanding stock option or SAR to reduce its price per share. No award may be granted pursuant to the 2026 Plan after the tenth anniversary of
the date on which our Board of Directors adopts the 2026 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2026 Plan is intended to conform to all provisions of the Securities Act, and the Exchange Act and any and all regulations and rules promulgated by the SEC
thereunder. The 2026 Plan will be administered, and awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal Income Tax Consequences </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The material federal
income tax consequences of the 2026 Plan under current federal income tax law are summarized in the following discussion, which deals with the general tax principles applicable to the 2026 Plan. The following discussion is based upon laws,
regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual
circumstances and from locality to locality. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock options and SARs</I>. A 2026 Plan participant generally will not recognize taxable income and we
generally will not be entitled to a tax deduction upon the grant of a stock option or SAR. The tax consequences of exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon whether the option
qualifies as an ISO or an NSO. Upon exercising an NSO when the fair market value of our stock is higher than the exercise price of the option, a 2026 Plan participant generally will recognize taxable income at ordinary income tax rates equal to the
excess of the fair market value of the stock on the date of exercise over the purchase price, and we (or our subsidiaries, if any) generally will be entitled to a corresponding tax deduction for compensation expense, in the amount equal to the
amount by which the fair market value of the shares purchased exceeds the purchase price for the shares. Upon a subsequent sale or other disposition of the option shares, the participant will recognize a short-term or long-term capital gain or loss
in the amount of the difference between the sales price of the shares and the participant&#8217;s tax basis in the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon exercising an ISO, a 2026
Plan participant generally will not recognize taxable income, and we will not be entitled to a tax deduction for compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase
price will be an item of adjustment for alternative minimum tax purposes. The participant will recognize taxable income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two
categories: qualifying and disqualifying. A qualifying disposition generally occurs if the sale or other disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred
upon exercise. If the sale or disposition occurs before these two periods are satisfied, then a disqualifying disposition generally will result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a
qualifying disposition of ISO shares, the participant will recognize long-term capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a
disqualifying disposition of the shares, then the excess of the fair market value of the shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the
participant. If there is a disqualifying disposition in the same year of exercise, it eliminates the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital
gain or loss by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the
participant makes a disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon exercising or settling an SAR, a 2026 Plan participant will recognize taxable income at ordinary income tax rates, and we should be entitled to a
corresponding tax deduction for compensation expense, in the amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the
subsequent disposition of the shares the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#8217;s tax basis in the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted stock and RSUs</I>. A 2026 Plan participant generally will not recognize taxable income at ordinary income tax rates and we generally will not
be entitled to a tax deduction upon the grant of restricted stock or RSUs. Upon the termination of restrictions on restricted stock or the payment of RSUs, the participant will recognize taxable income at ordinary income tax rates, and we should be
entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds the amount, if any, paid for them. Upon the
subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#8217;s tax basis in the shares. However, a
2026 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#8220;risk of forfeiture&#8221; (as defined in Section 83 of the Code) may make an election under
Section 83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the grant, in an amount equal to the fair market value of the shares of common stock on the date of grant, less the amount paid, if any, for such shares. We will be entitled to a corresponding
tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section 83(b) election is made, the participant will not recognize any additional ordinary income on the termination of restrictions on
restricted stock, and we will not be entitled to any additional tax deduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other stock or cash-based awards</I>. A 2026 Plan participant will not
recognize taxable income and we will not be entitled to a tax deduction upon the grant of other stock or cash-based awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of
shares that the participant receives will be taxable to the participant at ordinary income tax rates and we should be entitled to a corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of
the shares at the time of the payment, and upon the subsequent disposition of the shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the
participant&#8217;s tax basis in the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2026 Employee Stock Purchase Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shares available; administration</I>. A total of 1% of the number of shares of our common stock outstanding at the consummation of the Distribution (on a
fully diluted basis) are initially reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2027 and ending in 2036, by
an amount equal to the lesser of: (i)&nbsp;1% of Outstanding Shares and (ii) such smaller number of shares as is determined by our Board of Directors. For purposes of the foregoing, &#8220;Outstanding Shares&#8221; means the sum of (a)&nbsp;the
number of shares of our common stock outstanding and (b)&nbsp;the number of shares of our common stock that are issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire shares of our common stock for a nominal exercise
price, each as of the final day of the immediately preceding calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors or its committee will have authority to interpret the
terms of the ESPP and determine eligibility of participants. We expect that the Human Capital Management Committee will be the initial administrator of the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I>Our employees are eligible to participate in the ESPP if they meet the eligibility requirements under the ESPP established from time to
time by the plan administrator. However, an employee may not be granted rights to purchase stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total
combined voting power or value of all classes of our common or other class of stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant of rights. </I>The ESPP is intended to qualify under
Section 423 of the Code and stock will be offered under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll deductions
will be used to purchase shares on each purchase date during an offering period. The number of purchase periods within, and purchase dates during each offering period will be established by the plan administrator prior to the commencement of each
offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation, which includes a
participant&#8217;s gross base compensation for services to us, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan administrator
will establish a maximum number of shares that may be purchased by a participant during any offering period, which, in the absence of a contrary designation, will be 50,000 shares. In addition, no employee will be permitted to accrue the right to
purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering
period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each participant will automatically be granted an option
to purchase shares of our common stock. The option will be exercised on the applicable purchase date(s) during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. The purchase price of the
shares, in the absence of a contrary determination by the plan administrator, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date, which will be the
final trading day of the applicable purchase period. Participants may voluntarily end their participation in the ESPP at any time at least one week prior to the end of the applicable offering period (or such shorter or longer period specified by the
plan administrator), and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant&#8217;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions. </I>In the event of certain transactions or events affecting our common stock, such as any stock dividend or other distribution,
change of control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or
certain significant transactions, including a change of control, the plan administrator may provide for (i) either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (ii)
the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (iii) the adjustment in the number and type of shares of stock subject to outstanding rights, (iv) the use of
participants&#8217; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (v) the termination of all outstanding rights.
Under the ESPP, a change of control has the same definition as given to such term in the 2026 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan amendment; Termination. </I>The plan
administrator may amend, suspend or terminate the ESPP at any time. However, stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number or changes the type of shares that may be sold
pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase
plan within the meaning of Section 423(b) of the Code. The ESPP will terminate on the tenth anniversary of the date it is initially approved by our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Laws. </I>The ESPP has been designed to comply with various securities laws in the same manner as described above in the description of the 2026
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal Income Taxes. </I>The material federal income tax consequences of the ESPP under current federal income tax law are summarized in the
following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax
laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify under the provisions of Section 423 of the Code. Under the
applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee will not recognize taxable income on the date the employee is
granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or disposition, the participant will generally be subject to tax
in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of more than two years from the first day of the offering period during which the shares were purchased and more than one year from the date of purchase, or if the participant dies while holding
the shares, the participant (or his or her estate) will recognize ordinary income measured as the lesser of: (i) the excess of the fair market value of the shares at the time of such sale or disposition over the purchase price; or (ii) an amount
equal to 15% of the fair market value of the shares as of the first day of the offering period. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price
that is less than the purchase price, there is no ordinary income and the participating employee has a long-term capital loss for the difference between the sale price and the purchase price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shares are sold or otherwise disposed of before the expiration of the holding periods described above, the participant will recognize ordinary income
generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the purchase price and we will be entitled to a tax deduction for compensation expense in the amount of ordinary income recognized by
the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of
them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described above but are sold for a price that is less than the purchase price, the participant will recognize ordinary income equal to the excess of
the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled to a corresponding deduction), but the participant generally will be able to report a capital loss equal to the difference between the sales
price of the shares and the fair market value of the shares on the date of purchase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Make Whole Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Distribution is completed, holders of Avidity Equity Awards (subject to certain exceptions for New Hire RSUs and any portion of the 2026 LTI Awards that
is unvested as of the Record Date) as of the Record Date (including those Avidity Stock Options and Avidity RSUs held by RemainCo&#8217;s directors and executive officers that remain outstanding as of the Record Date) will receive a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> Make Whole Award pursuant to the 2026 Plan that will be settled in shares of Company Common Stock at a ratio of one share of Company Common Stock per ten shares of Avidity Common Stock underlying
each such Avidity Equity Award, and required by the terms of the Separation Agreement. After the adoption and approval of the 2026 Plan, and prior to the effective time of the Distribution, the Company will grant the Make Whole Awards to all holders
of outstanding Avidity RSUs (aside from New Hire RSUs and 2026 LTI Awards) and Avidity Stock Options who are current service providers to Avidity and its affiliates (including the Company) as of such grant. To the extent such Avidity Stock Options
or Avidity RSUs are exercised or settled, as applicable, prior to the Record Date then such holders will receive shares of Company Common Stock in respect of the Avidity Common Stock in connection with the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Company&#8217;s
executive officers is expected to enter into new employment agreements with the Company, in connection with the Distribution, which will provide for contractual severance protections in both change in control and non-change in control scenarios. Our
Board of Directors will approve such employment agreements prior to the effective time of the Distribution, and the employment agreements will be effective from and after the effective time of the Distribution. Below are written descriptions of the
employment agreements. Each of our executive officers&#8217; employment is &#8220;at will&#8221; and may be terminated at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment
Agreements with Ms.&nbsp;Gallagher and Mr.&nbsp;Hughes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will enter into an employment agreement with each of Ms.&nbsp;Gallagher and Mr.&nbsp;Hughes,
which sets forth the terms of their employment. Ms.&nbsp;Gallagher serves as our Chief Executive Officer and is also a member of the Company&#8217;s Board of Directors. Mr.&nbsp;Hughes will serve as our Chief Medical Officer. Each of their
agreements will set forth their annual base salary and, commencing in 2026, eligibility to receive an annual performance bonus with a target amount (55% for Ms.&nbsp;Gallagher, and 45% for Mr.&nbsp;Hughes) of their then-current annual base salary.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which their employment terminates, Ms.&nbsp;Gallagher and Mr.&nbsp;Hughes will
each be entitled to receive amounts previously earned during their employment, including unpaid salary and cash out of unused vacation. In addition, Ms.&nbsp;Gallagher and Mr.&nbsp;Hughes will each be entitled to certain severance benefits under
their employment agreements, subject to their execution of a release of claims and compliance with post-termination obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each employment
agreement will provide for severance benefits for certain terminations that arise during and outside a change of control period. Upon a termination without cause or resignation for good reason outside of a change of control period (as such terms are
defined below), each executive will be entitled to: (i)&nbsp;an amount equal to 12 months of their base salary, paid in a lump sum, and (ii)&nbsp;payment of the COBRA premiums for them and their eligible dependents until the earliest of (a)&nbsp;the
end of the 12-month period following their termination, (b)&nbsp;expiration of their eligibility for continuation coverage under COBRA, or (c)&nbsp;the date they become eligible for health insurance coverage in connection with new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a termination without cause or resignation for good reason within 59 days prior to or 24 months after a change of control (such period, the change of
control period), each executive will be entitled to: (i)&nbsp;an amount equal to 18 months of their base salary, paid in a lump sum, (ii)&nbsp;an amount equal to 150% of their target annual bonus for the year in which the termination occurs, paid in
a lump sum, (iii)&nbsp;an amount equal to their prorated target annual bonus for the calendar year in which their termination occurs, paid in a lump sum, (iv)&nbsp;payment of the COBRA premiums for them and their eligible dependents until the
earliest of (a)&nbsp;the end of such 18-month period, (b)&nbsp;expiration of their eligibility for continuation coverage under COBRA, or (c)&nbsp;the date they become eligible for health insurance coverage in connection with new employment, and
(v)&nbsp;accelerated vesting of any unvested time-based vesting equity awards. In addition, in the event that their termination occurs after the occurrence of a change of control and after the conclusion of a calendar year in respect of which no
annual bonus has yet been paid, Ms.&nbsp;Gallagher and Mr.&nbsp;Hughes will each be entitled to their annual bonus for such completed calendar year based on actual performance, paid when annual bonuses are paid to the Company&#8217;s employees
generally, but in all events prior to March&nbsp;15 of the calendar year in which their termination occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Ms.&nbsp;Gallagher and
Mr.&nbsp;Hughes&#8217; employment agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;cause&#8221; means (i)&nbsp;executive&#8217;s willful failure substantially to perform executive&#8217;s
duties and responsibilities to us or deliberate violation of our policy; (ii)&nbsp;executive&#8217;s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in
material injury to us; (iii)&nbsp;executive&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of ours or any other party to whom executive owes an obligation of nondisclosure as a result of executive&#8217;s
relationship with us; or (iv)&nbsp;executive&#8217;s willful breach of any of executive&#8217;s obligations under any written agreement or covenant with us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;change of control&#8221; has the same meaning given to such term in the 2026 Plan (and provided, for the
avoidance of doubt, that the Distribution will not constitute a &#8220;change of control&#8221; for purposes of the employment agreements); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;good reason&#8221; means executive&#8217;s resignation from employment with us if we take any of the
following actions without executive&#8217;s prior written consent: (i)&nbsp;a material reduction in executive&#8217;s base salary or target bonus if such a reduction is not made in proportion to an across-the-board reduction for all senior
executives; (ii)&nbsp;a material reduction or material adverse change in executive&#8217;s duties, responsibilities and/or authorities (including, following a change of control, the executive ceasing to report to the board of directors (for
Ms.&nbsp;Gallagher) or the chief executive officer (for Mr.&nbsp;Hughes) of the ultimate parent entity of the Company and/or ceasing to serve as the applicable executive position of such ultimate parent company); provided, that changes in the
executive&#8217;s position, title and/or duties as a result of the Distribution shall not constitute &#8220;good reason&#8221;; (iii)&nbsp;relocation of executive&#8217;s principal place of employment to a place that increases executive&#8217;s
one-way commute by more than 50 miles as compared to executive&#8217;s then-current principal place of employment immediately prior to such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
relocation; or (iv)&nbsp;any other action or inaction that constitutes a material breach by us of any agreement under which executive provides services. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreements with Our Other Executive Officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will enter into an employment agreement with each of Ms.&nbsp;Kenney, Ms.&nbsp;Martin Hoyos, Mr.&nbsp;Winslow and Mr.&nbsp;Younis, which will set forth the
terms of their employment. Ms.&nbsp;Kenney will serve as our Chief Corporate Affairs Officer, Ms.&nbsp;Martin Hoyos will serve as our Chief Strategy Officer, Mr.&nbsp;Winslow will serve as our Chief Financial Officer and Mr.&nbsp;Younis will serve
as our Chief Scientific Officer. Each of their employment agreements will set forth their annual base salary and, commencing in 2026, eligibility to receive an annual performance bonus with a target amount of 40% of their then-current annual base
salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which their employment terminates, Ms.&nbsp;Kenney, Ms.&nbsp;Martin Hoyos, Mr.&nbsp;Winslow and Mr.&nbsp;Younis will
each be entitled to receive amounts previously earned during their term of employment, including unpaid salary and cash out of unused vacation. In addition, they will each be entitled to certain severance benefits under their employment agreements,
subject to their execution of a release of claims and compliance with post-termination obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each employment agreement will provide for severance
benefits for certain terminations that arise during and outside a change of control period. Upon a termination without cause or resignation for good reason outside of a change of control period (as such terms are defined below), each executive will
be entitled to: (i)&nbsp;an amount equal to 9 months of their base salary, paid in a lump sum, and (ii)&nbsp;payment of the COBRA premiums for them and their eligible dependents until the earliest of (a)&nbsp;the end of the 9-month period following
their termination, (b)&nbsp;expiration of their eligibility for continuation coverage under COBRA, or (c)&nbsp;the date they become eligible for health insurance coverage in connection with new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a termination without cause or resignation for good reason within 59 days prior to or 24 months after a change of control (such period, the change of
control period), each executive will be entitled to: (i)&nbsp;an amount equal to 12 months of their base salary, paid in a lump sum, (ii)&nbsp;an amount equal to 100% of their target annual bonus for the year in which the termination occurs, paid in
a lump sum, (iii)&nbsp;an amount equal to their prorated target annual bonus for the calendar year in which their termination occurs, paid in a lump sum, (iv)&nbsp;payment of the COBRA premiums for them and their eligible dependents until the
earliest of (a)&nbsp;the end of such 12-month period, (b)&nbsp;expiration of their eligibility for continuation coverage under COBRA, or (c)&nbsp;the date they become eligible for health insurance coverage in connection with new employment, and
(v)&nbsp;accelerated vesting of any unvested time-based vesting equity awards. In addition, in the event that their termination occurs after the occurrence of a change of control and after the conclusion of a calendar year in respect of which no
annual bonus has yet been paid, each executive will be entitled to their annual bonus for such completed calendar year based on actual performance, paid when annual bonuses are paid to the Company&#8217;s employees generally, but in all events prior
to March&nbsp;15 of the calendar year in which their termination occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Ms.&nbsp;Kenney, Ms.&nbsp;Martin Hoyos, Mr.&nbsp;Winslow and
Mr.&nbsp;Younis&#8217;s employment agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;cause&#8221; has the same meaning as given to the term in Ms.&nbsp;Gallagher and Mr.&nbsp;Hughes&#8217;
employment agreements, as described above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;change of control&#8221; has the same meaning as given to the term in Ms.&nbsp;Gallagher and
Mr.&nbsp;Hughes&#8217; employment agreements, as described above; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;good reason&#8221; has the same meaning as given to the term in Ms.&nbsp;Gallagher and
Mr.&nbsp;Hughes&#8217; employment agreements, as described above; provided, that for each executive, prong (ii)&nbsp;in the definition of &#8220;good reason&#8221; means a material reduction or material adverse change in executive&#8217;s duties,
responsibilities and/or authorities (including, following a change of control, the executive ceasing to report to the chief executive officer of the ultimate parent entity of the Company and/or ceasing to serve as the applicable executive position
of such ultimate parent company); provided, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
further, that changes in the executive&#8217;s position, title and/or duties as a result of the Distribution shall not constitute &#8220;good reason&#8221;. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted the Certificate of Incorporation and Bylaws prior to the Distribution, which contain provisions that limit the liability of our directors and
officers for monetary damages to the fullest extent permitted by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment to, or repeal of, these provisions does not eliminate or
reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate
of Incorporation and Bylaws provide that we will indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding by reason of the fact that he is or was one of
our directors or officers or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust, or other enterprise. The Certificate of Incorporation and Bylaws also provide that we may indemnify to
the fullest extent permitted by law any person who is or was a party or is threatened to be made a party to any action, suit, or proceeding by reason of the fact that he is or was one of our employees or agents or is or was serving at our request as
an employee or agent of another corporation, partnership, joint venture, trust, or other enterprise. Our Certificate of Incorporation and Bylaws also provide that we must advance expenses incurred by or on behalf of a director or officer in advance
of the final disposition of any action or proceeding, subject to very limited exceptions. Our Certificate of Incorporation also provide that, to the fullest extent permitted by the DGCL as the same exists or may hereafter be amended, a director or
officer of the Corporation will not be liable to the Corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, prior to the Distribution, we expect to enter into indemnification agreements with each of our directors and executive officers that may be broader
than the specific indemnification provisions contained under Delaware law. These indemnification agreements will require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their
status or service. These indemnification agreements will also require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit, or proceeding. We believe that these agreements
are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification
provisions that are included in our Certificate of Incorporation and Bylaws and in indemnification agreements that we enter into with our directors and executive officers may discourage stockholders from bringing a lawsuit against our directors and
executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and executive officers, even though an action, if successful, might benefit us and other stockholders.
Further, a stockholder&#8217;s investment may be harmed to the extent that we pay the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. At present, we are not aware of any
pending litigation or proceeding involving any person who is or was one of our directors, officers, employees or other agents or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to obtain insurance policies under which, subject to the limitations of the policies, coverage is provided to our directors and executive officers
against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to us with respect to payments that may be made by us
to these directors and executive officers pursuant to our indemnification obligations or otherwise as a matter of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their
relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company
pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will contract
with a broker to buy or sell our common stock. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further
direction from them. The director or officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances. Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material nonpublic information subject to compliance with the terms of our insider trading policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the effective
time of the Distribution, we will adopt a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective
immediately upon the completion of the Distribution. For purposes of our policy only, a related person transaction is a material transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which
we and any related person has or will have a direct or indirect material interest. A transaction involving an amount exceeding the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal
years is presumed to be a &#8220;material transaction.&#8221; A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any
entity owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, our management must
present information regarding the related person transaction to our audit committee for review, consideration and approval or ratification. The presentation must include a description of, among other things, all relevant facts and circumstances
relating thereto. In addition, under our Code of Business Conduct and Ethics, which will become effective as of the Distribution Date, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship
that reasonably could be expected to give rise to a conflict of interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no transactions since January&nbsp;1, 2023 in which we have been a participant in which the amount involved exceeded or will exceed the lesser
of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any of our directors, executive officers or holders of more than 5% of our share capital post-Distribution, or any
members of their immediate family, had or will have a direct or indirect material interest, other than the Separation Agreement and the Transition Services Agreement, as described under &#8220;<I>The Separation and Distribution</I>,&#8221; and the
compensation arrangements described under &#8220;<I>Executive Compensation</I>.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws contain provisions limiting the liability of directors and provide that we will indemnify each of our directors to
the fullest extent permitted under the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we intend to enter into indemnification agreements with each of our directors and executive
officers. For more information regarding these agreements, see &#8220;<I>Indemnification of Directors and Officers</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_14"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the expected beneficial ownership of our common stock as of February&nbsp;12, 2026, on a pro
forma basis, giving effect to the Separation and Distribution by the individuals who are expected to be executive officers and directors of the Company named herein, as well as all of such expected directors and executive officers as a group, and of
beneficial owners of more than 5% of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of our common stock as of February&nbsp;12, 2026 assumes that
the Distribution occurred as of February&nbsp;12, 2026. The information below assumes further that the holders of Avidity Stock Options and Avidity RSUs as of the Record Date received Make Whole Awards entitling the holder to receive as soon as
practicable following the Distribution, shares of Company Common Stock at a ratio of one share of Company Common Stock for every ten shares of Avidity Common Stock subject to the applicable Avidity Stock Option and Avidity RSU, rounded down to the
nearest whole number of shares. Such amounts are indicative, as such persons&#8217; interests in shares of our common stock as of the Distribution Date may differ from the interests set out in the following table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for persons listed in the table is c/o Atrium Therapeutics, Inc., 10578 Science Center Drive, Suite 125, San
Diego, CA 92121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership representing less than one percent of our outstanding common stock is denoted with a &#8220;*.&#8221; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,321,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoro Capital Advisors LLC<SUP STYLE="font-size:75%; vertical-align:top">2</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">T. Rowe Price Associates, Inc.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">978,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Management, L.P.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc.<SUP STYLE="font-size:75%; vertical-align:top">5</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Group PLC<SUP STYLE="font-size:75%; vertical-align:top">6</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">822,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathleen Gallagher<SUP STYLE="font-size:75%; vertical-align:top">7</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Husam Younis<SUP STYLE="font-size:75%; vertical-align:top">8</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Hughes<SUP STYLE="font-size:75%; vertical-align:top">9</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brendan Winslow<SUP STYLE="font-size:75%; vertical-align:top">10</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephanie Kenney<SUP STYLE="font-size:75%; vertical-align:top">11</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rocio Martin Hoyos<SUP STYLE="font-size:75%; vertical-align:top">12</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Boyce<SUP STYLE="font-size:75%; vertical-align:top">13</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7<BR></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;<BR></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">W. Michael Flanagan<SUP STYLE="font-size:75%; vertical-align:top">14</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carsten Boess<SUP STYLE="font-size:75%; vertical-align:top">15</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simona Skerjanec<SUP STYLE="font-size:75%; vertical-align:top">16</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Wilson<SUP STYLE="font-size:75%; vertical-align:top">17</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (11&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">478,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to Amendment No.&nbsp;3 to the Schedule 13G filed with the SEC on October&nbsp;30, 2025, The Vanguard
Group (&#8220;Vanguard&#8221;), an investment adviser, was deemed the beneficial owner of 13,219,759&nbsp;shares of Avidity Common Stock. Vanguard has shared voting power over 878,441 shares of Avidity Common Stock, sole dispositive power over
12,196,279&nbsp;shares of Avidity Common Stock, and shared dispositive power over 1,023,480 shares of Avidity Common Stock. The address of Vanguard is 100 Vanguard Blvd, Malvern, PA 19355. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 6,875,000 shares of Avidity Common Stock held directly by Avoro Capital Advisors LLC
(&#8220;Avoro Capital&#8221;) and Dr.&nbsp;Behzad Aghazadeh and (ii) 3,060,792 shares of Avidity Common Stock that were issued in connection with the exercise of 3,060,792 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants of Avidity Common
Stock held by Avoro Capital, in each case, as reported on the Schedule 13G filed with the SEC by Avoro Capital on </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
November&nbsp;14, 2024. The Schedule 13G filed by Avoro Capital reported that Avoro Capital held 3,060,792 shares of Avidity Common Stock issuable upon exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, which warrants have been exercised. The address of Avoro Capital is 110 Greene Street, Suite 800, New York, New York 10012. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Amendment No.&nbsp;7 to the Schedule 13G filed with the SEC on November&nbsp;14, 2025, T. Rowe Price
Associates, Inc. (&#8220;T. Rowe&#8221;), an investment advisor, was deemed to be the beneficial owner of 9,787,912 shares of Avidity Common Stock. T. Rowe has sole voting power over 9,583,549 shares of Avidity Common Stock and sole dispositive
power over 9,787,417 shares of Avidity Common Stock. The address of T. Rowe is 1307 Point Street, Baltimore, Maryland 21231. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to Amendment No.&nbsp;2 to the Schedule 13G filed with the SEC on November&nbsp;14, 2025, entities
and individuals affiliated with RA Capital Management, L.P., including Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P., have shared voting and dispositive power over an aggregate of 8,641,031 shares of Avidity Common Stock. The
address of RA Capital Management, L.P. is 200 Berkeley Street, 18th Floor, Boston, MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to Amendment No.&nbsp;5 to Schedule 13G filed with the SEC on October&nbsp;17, 2025, BlackRock, Inc.
has the sole power to vote or direct the vote of an aggregate of 8,455,367 shares of Avidity Common Stock, and has the sole power to dispose or direct the disposition of an aggregate of 8,631,771 shares of Avidity Common Stock. The address of
BlackRock, Inc. is 50 Hudson Yards, New York, NY 10001. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to Amendment No.&nbsp;4 to Schedule 13G filed with the SEC on December&nbsp;5, 2025, Janus Henderson
Group PLC has the shared power to vote or direct the vote of an aggregate of 8,224,930 shares of Avidity Common Stock, and has the shared power to dispose or direct the disposition of an aggregate of 8,224,930 shares of Avidity Common Stock. The
address of Janus Henderson Group PLC is 201 Bishopsgate EC2M 3AE, United Kingdom. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 24,056 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 22,044 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 42,186 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 13,250 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 5,460 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 16,352 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 248,463 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 48,075 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 11,005 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 5,902 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes approximately 4,520 shares of Company Common Stock deliverable as soon as practicable following the
Distribution in respect of Make-Whole Awards, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales or the availability for sale of substantial amounts of Company Common Stock in the public market could adversely affect the prevailing market price for
such shares. Upon completion of the Distribution, we will have outstanding an aggregate of 15,514,966&nbsp;shares of Company Common Stock, based upon 155,149,646&nbsp;shares of Avidity Common Stock outstanding as of February&nbsp;12, 2026. All of
the common stock will be freely tradable without restriction or further registration under the Securities Act unless the shares are owned by our &#8220;affiliates&#8221; as that term is defined in the rules under the Securities Act. Shares held by
&#8220;affiliates&#8221; may be sold in the public market only if registered or if they qualify for an exemption from registration or in compliance with Rule 144 under the Securities Act (&#8220;Rule 144&#8221;) which is summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as currently in
effect, a person who is deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale would be entitled to sell within any three-month period a number of our common stock that does not
exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one percent of the number of shares of our common stock then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the
filing of a notice of Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 are also subject to certain holding period requirements,
manner of sale provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Issued Under Our Equity
Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register
the shares of our common stock issuable under the 2026 Plan and ESPP. The registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> is expected to be filed following the effective date of the Registration Statement of which this
information statement forms a part and will be effective upon filing. Accordingly, shares registered under such registration statement will be available for sale in the open market following the effective date of the
<FONT STYLE="white-space:nowrap">S-8,</FONT> unless such shares are subject to vesting restrictions with us, or Rule&nbsp;144 restrictions applicable to our affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_16"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description summarizes some of the terms of the Company Common Stock and reflects your rights as a holder of Company Common Stock upon the
effective time of the Distribution. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of
incorporation (the &#8220;Certificate of Incorporation&#8221;) and amended and restated bylaws (the &#8220;Bylaws&#8221;) that will be in effect prior to the effective time of the Distribution. For further information, please refer to the full
version of our Certificate of Incorporation and Bylaws which is included as an exhibit to the registration statement of which this information statement is part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;12, 2026, our authorized
capital stock consisted of 400,000,000&nbsp;shares of common stock, par value $0.001&nbsp;per share, and 40,000,000&nbsp;shares of preferred stock, par value $0.001&nbsp;per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 12, 2026, we effected a
15,514.966-for-1 forward stock split of Company Common Stock in connection with the Separation and Distribution, whereby each one share of our Company Common Stock issued and outstanding or held in treasury was subdivided into 15,514.966 shares of
Company Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
the Certificate of Incorporation and Bylaws, as applicable, our Board of Directors is authorized, without action by the stockholders, to designate and issue shares of preferred stock in one or more series. Our Board of Directors is able to designate
the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our Board of Directors may authorize the issuance of preferred stock with voting or conversion rights that could
adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could,
under certain circumstances, have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock or delaying, deferring or preventing a change in control
of us, which might harm the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors will make any determination to issue such shares based on its
judgment as to our best interests and the best interests of our stockholders. Upon the completion of the Distribution, we will have no shares of preferred stock outstanding, and we have no current plans to issue any shares of preferred stock
following completion of the Distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except with respect to a vote to approve the amendment of the Certificate of Incorporation that relates solely to the terms of one or more outstanding series
of preferred stock if the holders of such affected series are entitled to vote thereon, holders of shares of our common stock will be entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election
of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so
choose. Subject to the supermajority votes for some matters, other matters will be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such
matter. Our Bylaws also provide that, subject to the rights of holders of any series of preferred stock, our directors may be removed only for cause and only by the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT>
in voting power of the outstanding shares of capital stock entitled to vote thereon will be required to amend or repeal the Bylaws, or to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our Certificate of
Incorporation, including the provision relating to the appointment of directors, classes and removal of directors, the provision prohibiting stockholders from acting by written consent and the provision providing for Delaware as the exclusive
jurisdiction for disputes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock will be entitled to receive ratably those dividends, if any, as may be declared by the Board of Directors out of legally available
funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our
liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights and Preferences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock
will have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fully Paid and Nonassessable </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding shares of
our common stock will be duly authorized, validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have applied to list the shares of our common
stock on Nasdaq under the ticker symbol &#8220;RNA,&#8221; which is currently the symbol for the shares of Avidity Common Stock listed on Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some provisions of the DGCL, our Certificate of Incorporation and our Bylaws contain provisions that could make the following transactions more difficult,
including an acquisition of us by means of a tender offer, an acquisition of us by means of a proxy contest or otherwise or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to
accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to
encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited
proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Meetings of Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate
of Incorporation provides that a special meeting of stockholders may be called only by the Board of Directors, the chair of our Board of Directors, our chief executive officer or our president (in the absence of a chief executive officer). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of
candidates for election as directors, other than nominations made by or at the direction of the Board of Directors or a committee of the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of
Directors is divided into three classes. The directors in each class will serve for a three-year term, with one class being elected each year by our stockholders. This system of electing directors may tend to discourage a third party from attempting
to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws provide that, subject to the rights of holders of any series of preferred stock, no member of our Board of Directors may be removed
from office except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of
the outstanding shares of our common stock entitled to vote in any election of directors will be able to elect all of the directors standing for election, if they choose. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation
provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or
common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty by any of our directors, officers, employees or agents to us or our stockholders, creditors or other
constituents; (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or Certificate of Incorporation or Bylaws; or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The provision would
not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claims for which the federal courts have exclusive jurisdiction, in which case such claim must be brought in a federal court
sitting in Delaware. Our Certificate of Incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the exclusive forum for the resolution of any
complaint asserting a cause of action arising under the Securities Act. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of
similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our
Certificate of Incorporation also provides that any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provision requires approval by holders of at least two thirds of the total voting power of all of our outstanding voting
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, our Certificate of Incorporation and our Bylaws could have the effect of discouraging others from attempting hostile
takeovers and, as a consequence, they may also inhibit temporary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the
composition of our Board of Directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Takeover Statute </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the
provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a <FONT
STYLE="white-space:nowrap">three-year</FONT> period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination
between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our Board of Directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our Board of
Directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the o<I>utstanding voting stock which is not owned by the interested
stockholder.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder
of 10% or more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity
or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_17"></A>INDEMNIFICATION OF DIRECTORS AND OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will enter into, upon the effective time of the Distribution, indemnification agreements with each of our directors and executive officers. These
agreements, among other things, will require us to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement
amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the DGCL.
Further, we intend to purchase a policy of directors&#8217; and officers&#8217; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_18"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement, of which this information statement forms a part, under the Exchange Act and the rules and regulations
promulgated under the Exchange Act with respect to our common stock being distributed to Avidity&#8217;s stockholders in the Distribution. This information statement does not contain all of the information set forth in the registration statement and
its exhibits and schedules, to which reference is made hereby. Statements in this information statement as to the contents of any contract, agreement or other document are qualified in all respects by reference to such contract, agreement or
document filed as an exhibit to the registration statement and you should read the full text of such contract, agreement or document for a more complete understanding of the document or matter involved. For further information with respect to us and
our common stock, we refer you to the registration statement, of which this information statement forms a part, including the exhibits and the schedules filed as a part of it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to furnish the holders of our common stock with annual reports and proxy statements containing financial statements audited by an independent public
accounting firm and to file with the SEC quarterly reports for the first three quarters of each fiscal year containing interim unaudited financial information. We also intend to furnish other reports as we may determine or as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement, of which this information statement forms a part, and its exhibits and schedules, and other documents which we file with the SEC
are available to the public at the SEC&#8217;s website at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information that we file with the SEC after the date of this information
statement may supersede the information in this information statement. You may read these reports, proxy statements and other information and obtain copies of such documents and information as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No person has been authorized to give any information or to make any representations other than those contained in this information statement. We take no
responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. Neither the delivery of this information statement nor any distribution of securities made hereunder shall imply that there
has been no change in the information set forth or in our affairs since the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_19"></A>CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 23, 2025, the Audit Committee of the Avidity Biosciences Board (the &#8220;Avidity Audit Committee&#8221;) engaged BDO USA, P.C.
(&#8220;BDO&#8221;) as the independent registered public accounting firm of the Company Business for the fiscal years ended December 31, 2024 and 2023. On November 5, 2025, the Avidity Audit Committee engaged Deloitte &amp; Touche LLP
(&#8220;Deloitte&#8221;) as the independent registered public accounting firm of the Company Business for the fiscal year ending December 31, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Avidity Audit Committee dismissed BDO as the independent registered public accounting firm of the Company Business effective at the time of the initial submission of the registration statement on Form 10 of which this information statement forms a
part, on December 10, 2025. BDO&#8217;s report on the combined financial statements of the Company Business for the years ended December 31, 2024 and 2023, did not contain any adverse opinion or a disclaimer of opinion, and was not qualified or
modified as to uncertainty, audit scope, or accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December 31, 2024 and 2023, and in the subsequent
interim period through December 10, 2025, (i) there were no disagreements with BDO (within the meaning of Item 304(a)(1)(iv) of Regulation S-K) on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or
procedure that if not resolved to BDO&#8217;s satisfaction, would have caused BDO to make reference thereto in its reports; and (ii) there were no &#8220;reportable events&#8221; (as defined by Item 304(a)(1)(v) of Regulation S-K). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provided BDO with a copy of the foregoing disclosures and requested that BDO provide a letter addressed to the SEC stating whether it agrees with such
disclosures. A copy of BDO&#8217;s letter is filed as Exhibit 16.1 to the registration statement on Form 10 of which this information statement forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through December 10, 2025, neither we nor anyone on our behalf
consulted Deloitte regarding (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company Business financial statements, and neither a
written report nor oral advice was provided to us that Deloitte concluded was an important factor considered by us in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a
disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATRIUM THERAPEUTICS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A BUSINESS OF AVIDITY BIOSCIENCES, INC.) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc42675_20"></A>INDEX TO COMBINED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Audited Annual Combined Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_1a">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_2">Combined Balance Sheets as of December&nbsp;31, 2025 and 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_3">Combined Statements of Operations and Comprehensive Loss for the years ended
 December&nbsp;31, 2025 and 2024 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_4">Combined Statements of Changes in Deficit for the years ended December&nbsp;31,
 2025 and 2024 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_5">Combined Statements of Cash Flows for the years ended December&nbsp;
31, 2025 and 2024 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc42675_6">Notes to combined financial statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_1"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of&nbsp;Avidity Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying combined balance sheet of Atrium Therapeutics, a business of Avidity Biosciences, Inc., (the &#8220;Company Business&#8221;) as of December&nbsp;31, 2025, the related combined statements of operations and comprehensive loss, changes in
deficit, and cash flows, for the year then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company Business as of December&nbsp;31, 2025, and the results of its operations and its cash flows for the year ended December&nbsp;31, 2025, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company Business&#8217; management. Our responsibility is to express an opinion on the Company Business&#8217; financial statements based on our audit. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company Business in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
Business is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company Business&#8217; internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte &amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;17, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company
Business&#8217; auditor since&nbsp;2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_1a"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the
Combined Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying combined balance sheet of Atrium Therapeutics (a Business of Avidity Biosciences, Inc.)
(the &#8220;Company&#8221;) as of December&nbsp;31, 2024, the related combined statements of operations and comprehensive loss, changes in deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the
&#8220;combined financial statements&#8221;). In our opinion, the combined financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2024, and the results of its operations and its cash
flows for the year then ended<B>,</B> in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These combined financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the
Company&#8217;s combined financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to
the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of
America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the combined financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included
performing procedures to assess the risks of material misstatement of the combined financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the combined financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of
the combined financial statements. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ BDO USA, P.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We served as the Company&#8217;s auditor in 2025<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;10, 2025 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_2"></A>Atrium Therapeutics </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Business of Avidity Biosciences, Inc.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combined Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Parent Investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_3"></A>Atrium Therapeutics </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Business of Avidity Biosciences, Inc.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combined Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss and comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;(49,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;(25,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_4"></A>Atrium Therapeutics </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Business of Avidity Biosciences, Inc.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combined Statements of Changes in Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Parent</B><br><B>Investment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2024 </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;(70,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from Parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from Parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_5"></A>Atrium Therapeutics </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Business of Avidity Biosciences, Inc.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combined Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;(49,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;(25,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfers from Parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 42,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 22,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental schedule of noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs incurred, but not paid, in connection with purchases of property and equipment included in
accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets distributed from Avidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc42675_6"></A>Atrium Therapeutics </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Business of Avidity Biosciences, Inc.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Combined Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of Business and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;25, 2025, Avidity
Biosciences, Inc. (&#8220;Avidity&#8221;) entered into an Agreement and Plan of Merger with Novartis AG (&#8220;Novartis&#8221;) and Ajax Acquisition Sub, Inc., a wholly owned subsidiary of Novartis (&#8220;Merger Sub&#8221;), pursuant to which
Merger Sub will merge with and into Avidity (the &#8220;Merger&#8221;), with Avidity surviving as an indirect wholly owned subsidiary of Novartis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the Merger, Avidity entered into a Separation and Distribution Agreement (the &#8220;Separation Agreement&#8221;) with Atrium Therapeutics, Inc. (the &#8220;Company&#8221;), a newly formed Delaware corporation and wholly owned
subsidiary of Avidity, and Novartis (with respect to certain sections specified therein). Pursuant to the Separation Agreement, Avidity will undertake a <FONT STYLE="white-space:nowrap">pre-closing</FONT> reorganization (the
&#8220;Separation&#8221;) to transfer to the Company all assets and liabilities related to its early-stage precision cardiology programs and certain collaboration agreements. Avidity will retain all other assets and liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Separation, Avidity will distribute all the outstanding shares of the Company&#8217;s common stock to Avidity&#8217;s stockholders on a pro rata
basis (the <FONT STYLE="white-space:nowrap">&#8220;Spin-Off&#8221;).</FONT> Upon completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the Company will operate as an independent, publicly traded company. The Company will be capitalized
with $270&nbsp;million in cash, minus the sum of the amount of marketable securities and cash and cash equivalents contained in any bank and brokerage accounts owned by the Company as of the close of business on the day prior to the date of the <FONT
STYLE="white-space:nowrap">Spin-off.</FONT> The Company will be led by a dedicated management team and board of directors. Avidity will have no continuing ownership interest in the Company following the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement and the Separation Agreement also provide for (i)&nbsp;a potential sale of the
Company to a third party (a &#8220;Permitted Third Party Sale&#8221;) as an alternative to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> and (ii)&nbsp;a potential sale of certain Avidity assets that are subject to a right of first
negotiation (&#8220;ROFN&#8221;) to an existing collaboration partner (a &#8220;ROFN Sale&#8221;). The combined financial statements have been prepared under the assumption that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will be
consummated, and that neither a Permitted Third Party Sale or ROFN Sale will occur. See the section titled &#8220;Subsequent Events&#8221; for further information related to the ROFN. The Company is expected to focus on advancing its pipeline of
precision cardiology and executing collaboration agreements, leveraging the RNA delivery platform to develop novel therapeutics targeting diseases with high unmet medical need. The Company&#8217;s operations are subject to risks and uncertainties
common to early-stage biotechnology companies, including, but not limited to, the development of new technological innovations by competitors, reliance on key personnel, protection of proprietary technology, compliance with regulatory requirements,
and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development, including preclinical and clinical testing and regulatory approval, prior
to commercialization. These efforts may require substantial capital, personnel, and infrastructure. Even if development efforts are successful, there is no assurance that the Company will generate significant revenue from product sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Combination
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined financial statements presented herein represent the combined balance sheets as of December 31, 2025 and 2024 and the related combined
statements of operations and comprehensive loss, combined statements of changes in deficit, and combined statements of cash flows for each of the years ended December 31, 2025 and 2024 of Atrium Therapeutics, a business of Avidity (the
&#8220;Company Business&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying combined financial statements present, on a historical basis, the combined assets,
liabilities, expenses and cash flows directly attributable to the Company Business which have been prepared from Avidity&#8217;s consolidated financial statements and accounting records and are presented on a standalone basis as if the operations
have been conducted independently from Avidity. Historically, separate financial statements have not been prepared for the Company Business and it has not operated as a standalone business from Avidity. As a direct ownership relationship did not
exist among all of the various programs comprising of the Company Business, Avidity&#8217;s net investment in the Company Business (Net Parent Investment) is shown in lieu of shareholders&#8217; equity in the combined financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined
statements of operations and comprehensive loss include all costs directly related to the Company Business, including costs for facilities, functions and services utilized by the Company Business. The combined statements of operations and
comprehensive loss also include allocations for various expenses related to Avidity&#8217;s corporate functions, including, but not limited to, research and development, legal and regulatory compliance, information technology, human resources and
facility management. These expenses were allocated on the basis of direct usage or benefit when specifically identifiable, with the remainder allocated on a proportional cost allocation method primarily based on a percentage of the operating
expenses. These cost allocations are a reasonable reflection of the utilization of services provided to, or benefit derived by, the Company Business during the periods presented, though the allocations may not be indicative of the actual costs that
would have been incurred had the Company Business operated as a standalone company during the periods presented. It is not practicable to estimate actual costs that would have been incurred had the Company Business been a standalone company and
operated as an unaffiliated entity during the periods presented. Actual costs that might have been incurred had the Company Business been a standalone company would depend on a number of factors, including the organizational structure, what
corporate functions the Company Business might have performed directly or outsourced, and strategic decisions the Company Business might have made in areas such as executive management, legal and other professional services, and certain corporate
overhead functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax amounts in the combined financial statements have been calculated on a separate return method and are presented as if
the Company Business operated as a separate taxpayer. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company Business&#8217; actual tax balances prior to or subsequent to the
distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All material agreements are either Avidity agreements, or those Avidity expects to assign to the Company upon separation. Accordingly, all
considerations paid by Avidity in association with these agreements are recorded in the combined financial statements of the Company Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the separation from Avidity, Avidity and the Company expect to enter into a transition services agreement whereby Avidity will provide certain transition services to the Company and the Company will provide certain nominal transition
services to Avidity. The Company expects to incur certain costs to establish itself as a standalone public company, as well as ongoing additional costs associated with operating as an independent, publicly traded company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deficit balances in these combined financial statements represent the excess of total liabilities over total assets. Net Parent Investment is primarily
impacted by contributions from Avidity which are the result of net funding provided by or distributed to Avidity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business has devoted substantially all its efforts to therapeutic drug discovery and development. The Company Business has historically been
dependent upon Avidity for all its working capital and financing requirements as Avidity uses a centralized approach to cash management and financing of its operations. The Company Business does not have legal ownership of any bank accounts and as
such, had no cash and cash equivalents as of December 31, 2025 and 2024. Financial transactions relating to the Company Business are accounted for through the Net Parent Investment account. Avidity is expected to continue to fund its cash needs
though the date of Separation and <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Immediately prior to the Distribution, the Company will receive cash balances of $270.0&nbsp;million, minus the sum of the amount of marketable securities and cash
and cash equivalents contained in any accounts held by the Company as of the close of business on the day prior to the date of the Distribution, subject to certain adjustments agreed to by Avidity and Novartis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company anticipates that Avidity&#8217;s funding support of the Company Business through its centralized cash management system, as well as the cash
generated from its collaboration agreements, will be sufficient to meet working capital requirements for the next twelve months if the Separation and Distribution does not occur. Following the Separation and Distribution, the Company will no longer
participate in Avidity&#8217;s centralized treasury system and will independently manage liquidity. Immediately prior to the effective time of the Distribution, Avidity will pay and contribute to the Company an amount in cash equal to
$270&nbsp;million, minus the sum of the amount of marketable securities and cash and cash equivalents contained in any accounts held by the Company as of the close of business on the day prior to the Distribution Date. Following the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> the Company anticipates the Company Funding, as well as cash generated from its collaboration agreements, will be sufficient to meet our working capital requirements, capital expenditures and other general
corporate purposes for at least twelve months following the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Whether these resources are adequate to meet the Company&#8217;s liquidity needs beyond that period will depend on the Company&#8217;s
growth and operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of combined
financial statements in accordance with GAAP requires estimates and assumptions that impact the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities of the Company Business at the date of the combined
financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these combined financial statements include, but are not limited to, determining the allocations
of costs and expenses from Avidity, revenue recognition under collaboration arrangements using an input method based on incurred and estimated total collaboration costs, and the recognition of accrued research and development expenses. Estimates are
periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business has
contractual payment terms with each of its collaborators, and the Company Business monitors their financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. As of and for the years
ended December 31, 2025 and 2024, there were no receivables from collaborators and no write-offs or allowances of accounts receivable related to credit risk for the Company Business&#8217; collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deficit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business&#8217; equity on the combined balance sheets represents the historical investment by Avidity in the Company Business and is presented in
Net Parent Investment in lieu of stockholders&#8217; equity. The combined statements of changes in deficit includes net cash transfers and other assets and liabilities between Avidity and the Company Business as well as the net losses after tax.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
Business has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operations of the Company
Business constitute a single operating and reportable segment, headquartered in the United States. Operating segments are defined as components of an enterprise for which discrete financial information is available and is evaluated regularly by the
chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources and assess performance. The CODM of the Company Business is Avidity&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who reviews combined financial
information for the purposes of allocating resources and assessing performance. Factors considered in determining operating and reportable segments include the organization of our business, the nature of technology and the information reviewed by
the CODM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All revenues and assets were derived and held within the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, all the Company
Business&#8217; revenue has been derived from collaboration and research agreements. The terms of these arrangements include the following types of payments to the Company Business: <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront
license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by the Company or for manufacturing supply services the Company Business provides through its contract manufacturers;
and royalties on net sales of licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of a collaboration arrangement, whether the contractual arrangement is within the scope
of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) is assessed to determine whether the arrangement involves a joint operating activity and involves two (or more) parties that are
both active participants in the activity and exposed to significant risks and rewards dependent on the commercial success of such activity. Then whether the collaboration arrangement in its entirety represents a contract with a customer as defined
by ASC Topic 606 (&#8220;ASC 606&#8221;) is determined. If only a portion of the collaboration arrangement is potentially with a customer, the distinct good or service
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">unit-of-account</FONT></FONT> guidance in ASC 606 is applied to determine whether there is a unit of account that should be accounted for under ASC 606. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following steps are performed in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these
agreements: (i)&nbsp;identification of the promised goods or services in the contract; (ii)&nbsp;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract;
(iii)&nbsp;measurement of the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations; and (v)&nbsp;recognition of revenue when, or as, the Company satisfies
each performance obligation. Significant judgment is applied when making estimates and assumptions under these agreements, including (i)&nbsp;evaluating whether contractual obligations represent distinct performance obligations, (ii)&nbsp;the
assessment of whether options represent material rights, (iii)&nbsp;determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, (iv)&nbsp;assessing whether any licenses
are functional or symbolic, (v)&nbsp;determining when performance obligations have been met, and (vi)&nbsp;assessing the recognition of variable consideration. Each performance obligation is evaluated to determine if it can be satisfied and
recognized as revenue at a point in time or over time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business receives payments from its collaborators based on billing schedules established in each
contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration arrangements. Amounts are recorded as accounts receivable when the
Company Business&#8217; right to consideration is unconditional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">License fees, <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fees, and
funding of research activities are considered fixed, while milestone payments are identified as variable consideration and excluded from the transaction price. Revenue will be recognized for sales-based royalty if and when a subsequent sale occurs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 3 (Collaboration, License and Research Agreements) for additional details. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs and Accruals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with research and development
personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and consultants. Nonrefundable advance payments for goods and services that will be used in future research and development
activities are capitalized and recorded as expense in the period that the Company Business receives the goods or when services are performed. Payments for these activities are based on the terms of the individual agreements, which may differ from
the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying combined balance sheets as prepaid assets or accrued liabilities. Actual results could differ from the Company Business&#8217;
estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax
provision of the Company Business was prepared using the separate return method. The separate return method applies the concepts of ASC Topic 740, <I>Income Taxes</I>, to the standalone financial statements of each member of the combined group as if
the group members were separate taxpayers. The calculation of the Company Business&#8217; income taxes using the separate return method requires judgment and use of both estimates and allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement
carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it
is more likely than not that some or all of the deferred tax assets will not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business also follows the provisions of accounting
for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure
and transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating results of the Company Business have historically been included in the federal and state tax returns of Avidity and the
resulting tax attributes will be retained by Avidity and will not be available to the Company for future use. As a result, any hypothetical net operating loss attributes and related valuation allowances are deemed to have been distributed to Avidity
through the Net Parent Investment. As part of the separation, Avidity will retain all rights associated with the unused federal and state net operating losses, and research tax credit carryforwards to offset future taxable income. As a result, the
Company Business does not have any associated deferred tax assets and liabilities for the years ended December 31, 2025 and 2024. Future income tax provisions may be impacted by future changes in the realizability of the hypothetical net operating
loss deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are
recorded using the straight-line method over the estimated useful lives of the related assets. As of December 31, 2025 and 2024, the Company Business&#8217; property and equipment consisted of lab equipment, computers and software, and office
furniture and equipment with a useful life ranging from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the remaining lease term. Repairs and
maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company Business has not recognized any impairment losses in any of the periods presented in these combined
financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether an
arrangement contains a lease is determined at the inception of a contract. Lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets represent the Company Business&#8217; right to use an underlying
asset for the lease term and lease liabilities represent the Company Business&#8217; obligation to make lease payments arising from the lease. Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities are recognized at the commencement date based on the present value of future lease payments over the lease term. The interest rate
used to determine the present value of the future lease payments is our estimated incremental borrowing rate based on market sources including interest rates for companies with similar credit quality for agreements of similar duration. The operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is
reasonably certain that the Company Business will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments that do not depend on a rate or index, payments associated
with <FONT STYLE="white-space:nowrap">non-lease</FONT> components, and costs related to leases with terms of less than 12 months are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disaggregation of Income Statement Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2024-03,</FONT> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40),</FONT> to
improve the disclosures of expenses by requiring public business entities to provide further disaggregation of relevant expense captions (i.e., employee compensation, depreciation, intangible asset amortization) in a separate note to the financial
statements, a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and the total amount of selling expenses and, in an annual reporting period, an entity&#8217;s
definition of selling expenses. The transition method is prospective with the retrospective method permitted, and the ASU will be effective for the Company for its annual period ending December 31, 2027 and interim periods for the interim period
beginning January&nbsp;1, 2028. The Company is currently evaluating the impact on its disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU)
<FONT STYLE="white-space:nowrap">2023-09,</FONT> Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures, primarily through standardization and disaggregation of the income tax rate reconciliation and
disaggregation of income taxes paid. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> is effective for annual periods beginning after December&nbsp;15, 2024. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2023-09</FONT>
prospectively during the year ended December&nbsp;31, 2025. Refer to Note 8 for further details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Collaboration, License and Research Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Collaboration and License Agreement and Securities Purchase Agreement with Bristol Myers Squibb Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, Avidity entered into (i)&nbsp;a Research Collaboration and License Agreement (the &#8220;BMS Collaboration Agreement&#8221;) with Bristol
Myers Squibb Company (&#8220;BMS&#8221;) to expand on the research with MyoKardia Inc. (&#8220;MyoKardia&#8221;) and (ii)&nbsp;a Securities Purchase Agreement (the &#8220;BMS Purchase Agreement&#8221;) with BMS for the sale of 5,075,304 shares of
Avidity&#8217;s common stock in a private placement transaction. The BMS Collaboration Agreement and the BMS Purchase Agreement are referred to herein as the &#8220;BMS Agreements.&#8221; Under the terms of the BMS Collaboration Agreement, BMS will
have the right to select up to five targets (each a &#8220;Target&#8221;) for collaborative research programs under which the Company will utilize its proprietary RNA delivery platform to conduct research and development activities in order to
identify, generate, and optimize AOC compounds directed to such Targets with the goal of generating an applicable development candidate. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Target</FONT></FONT> basis,
after the Company completes specified research activities in accordance with a research plan, BMS will have the right to develop, manufacture and commercialize such compounds generated during the research term, and products containing such
compounds, worldwide. The research and activities conducted under the BMS Collaboration Agreement is governed by a joint steering committee comprised of representatives from the Company and BMS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business received approximately $100.0&nbsp;million upfront, including a $60.0&nbsp;million nonrefundable cash payment and approximately
$40.0&nbsp;million from the sale of Avidity&#8217;s common stock at $7.8813 per share, which included an $8.7&nbsp;million premium for the per share amount in excess of the fair value at the time of the transaction. The Company Business is also
eligible to receive up to approximately $1.35&nbsp;billion in research and development milestone payments, up to approximately $825.0&nbsp;million in commercial milestone payments, and tiered royalties representing a percentage of net sales from
high single digits to low teens. The Company Business is responsible for its own research costs incurred under the agreement, subject to the parties renegotiating the research activities in case the Company Business&#8217;s research spending is
anticipated to exceed $40.0 million. BMS will fund all future clinical development, regulatory and commercialization activities coming from this collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It was determined that the BMS Agreements should be accounted for separately from the research collaboration with MyoKardia (the &#8220;MyoKardia
Agreement,&#8221; also separately defined below). There are two distinct units of accounting identified under the BMS Agreements. The first distinct unit of accounting includes (i)&nbsp;a license to technology and patents; (ii)&nbsp;collaboration
services, including research services and technical and regulatory support; and (iii)&nbsp;participation on research oversight committees. The Company Business has determined that these elements individually are either not capable of being distinct
or are not distinct within the context of the contract and, therefore, will account for them as a single distinct performance obligation for purposes of revenue recognition. The second distinct unit of accounting is related to the sale of common
stock, which will be accounted for as an issuance of equity at fair value in accordance with the applicable accounting standards. Consideration received related to the premium on sale of the Avidity&#8217;s common stock was allocated to the
transaction price for purposes of revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time the BMS Agreements were entered into, the fixed and determinable amount related to the
first unit of accounting was $68.7&nbsp;million, which includes the upfront cash payment and premium on sale of Avidity&#8217;s common stock. The Company Business will recognize revenue using the input method in an amount proportional to the
collaboration expenses incurred and the total estimated collaboration expenses over the seven-year period in which it expects to deliver its performance obligation as this method provides the most faithful depiction of the Company Business&#8217;
transfer of services under the BMS Agreements. The Company Business periodically reviews and updates the estimated collaboration expenses, when appropriate, which adjusts the percentage of revenue that is recognized for the period. The remaining
$31.3&nbsp;million was allocated to the second unit of accounting related to the sale of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial consideration related to the $60.0&nbsp;million cash payment and approximate $40.0&nbsp;million
sale of common stock was received prior to December 31, 2023. $8.6&nbsp;million and $9.8&nbsp;million in revenues were recognized related to the BMS Agreements in 2025 and 2024, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Collaboration and License Agreement with Eli Lilly and Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2019, Avidity entered into a Research Collaboration and License Agreement (the &#8220;Lilly Agreement&#8221;) with Eli Lilly and Company
(&#8220;Lilly&#8221;) for the discovery, development and commercialization of AOC products directed against certain targets in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, Avidity granted Lilly an
exclusive, worldwide, royalty-bearing license, with the right to sublicense (subject to certain conditions), under Avidity&#8217;s technology to research, develop manufacture and sell products containing AOCs that are directed to up to six mRNA
targets Avidity agreed that it will not, itself or with a third party, research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the Lilly Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the rights granted to Lilly under the Lilly Agreement, the Company Business received a <FONT STYLE="white-space:nowrap">one-time</FONT>
upfront fee of $20.0&nbsp;million and the right to receive up to $60.0&nbsp;million in development milestone payments, up to $140.0&nbsp;million in regulatory milestone payments and up to $205.0&nbsp;million in commercialization milestone payments
per target. In August 2025, the Company Business received a milestone payment of $10.0&nbsp;million as the result of the achievement of a clinical development milestone for a collaboration target. Lilly is obligated to pay the Company Business a
tiered royalty ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> to low teens, expressed as a percentage of worldwide annual net sales of licensed products, subject to specified and capped reductions for the market entry of
biosimilar products, loss of patent coverage of licensed products, and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Lilly&#8217;s royalty obligations and the Lilly Agreement
will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the
later of ten years from the date of the first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are multiple promises to deliver goods and services identified, which include at inception of the agreement: (i)&nbsp;a license to technology and
patents, information and <FONT STYLE="white-space:nowrap">know-how;</FONT> and (ii)&nbsp;collaboration, including research services and technical and regulatory support provided by the Company Business. One performance obligation for the promises
under the Lilly Agreement has been identified since the elements are either not capable of being distinct or are not distinct within the context of the contract. Accordingly, the Company Business recognizes revenue for the fixed or determinable
collaboration in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses over the <FONT STYLE="white-space:nowrap">5-year</FONT> period in which it expects to deliver its performance obligation.
Periodically estimated collaboration expenses are reviewed and updated, when appropriate, which adjusts the percentage of revenue that is recognized for the period. In connection with the Lilly Agreement, the Company Business recognized revenue of
$10.0&nbsp;million and $1.1&nbsp;million for the years ended December 31, 2025 and 2024, respectively. In August 2025, Lilly paid the Company Business $10.0&nbsp;million as the result of the achievement of a clinical development milestone under the
Lilly Agreement for a collaboration target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts received that have not yet been recognized as revenue are deferred on the combined balance sheets
of the Company Business and will be recognized over the remaining research and development period until the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance obligation is satisfied. A reconciliation of the closing balance of deferred revenue related to all collaboration agreements for the years ended December 31, 2025 and 2024 is as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January 1, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 69,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized that was included in the balance at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December 31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized that was included in the balance at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December 31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 50,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Composition of Certain Combined Financial Statement Items </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other current assets (in thousands) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current
assets consisted primarily of deferred contract costs of $1.2&nbsp;million and other receivables of $0.1&nbsp;million as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and equipment, net (in thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December 31, 2025 and 2024, the Company Business recognized depreciation expense of $0.3&nbsp;million
and $0.2&nbsp;million, respectively, after allocations to Avidity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Liabilities (in thousands) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued manufacturing and technical development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other accrued liabilities consisted primarily of accrued transaction costs of $3.4&nbsp;million as of December&nbsp;31, 2025.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020,
Avidity entered into a five-year lease agreement, as amended in December 2020, at a location in San Diego, California. Avidity entered into an expansion lease in June 2023, with both leases being assigned to the Company in connection with the
Separation and terminating concurrently on November&nbsp;30, 2026. The leases contain base rent of approximately $0.3&nbsp;million per month with 3% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in
connection with the ownership and management of the property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental balance sheet information related to operating leases as of December 31, 2025
and 2024 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2025&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the weighted-average remaining lease term and discount rates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December 31, 2025 and 2024, the Company Business recognized operating lease expense of
$0.6&nbsp;million and $0.2&nbsp;million, respectively, after allocations to Avidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future minimum lease payments by lease classification as of
December 31, 2025 are as follows (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liabilities for loss contingencies
arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that liability has been incurred and the amount can be reasonably estimated. There are no such matters currently outstanding for which
any liabilities have been accrued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business enters into contracts in the normal course of business for contract research services, professional services, and other services and
products for operating purposes. These contracts may include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain provisions that could require payments for early termination. The amount of any such termination payments will vary depending on the timing of the termination and the specific terms of
the contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company Business currently has no stock-based compensation plan. Avidity has stock-based compensation plans under which it may issue common shares or restricted common shares or grant incentive stock options or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options for the purchase of common shares, to employees, members of the board of directors and consultants of Avidity. Avidity also has an Employee Stock Purchase Plan (the
&#8220;ESPP&#8221;) which allows eligible employee who are participating in the plan to purchase shares of Avidity at a discount. Stock-based compensation has been allocated to the Company Business by using a proportional cost allocation method
primarily based on a percentage of the operating expense. The amounts presented are not necessarily indicative of future awards and do not necessarily reflect the costs that the Company Business would have incurred as an independent company for the
periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense is incurred related to stock option and restricted stock grants, and to shares sold under the ESPP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense for stock option grants is determined using the Black-Scholes-Merton (&#8220;BSM&#8221;) option pricing model and is
recorded at the estimated fair value of the award as of the grant date and recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award. Stock-based compensation expense for
Restricted Stock Units (&#8220;RSUs&#8221;) is recorded at the market price of a share of Avidity&#8217;s stock on the date of grant and is recognized as expense on a straight-line basis over the service period. Stock-based compensation expense for
Performance Stock Units (&#8220;PSUs&#8221;) is recorded at the market price of a share of Avidity&#8217;s stock on the date of grant and recognized on a straight-line basis over the requisite service periods beginning when the achievement of the
performance condition is determined to be probable. Stock-based compensation expense for employee stock purchases under Avidity&#8217;s ESPP is determined using the BSM option pricing model and is recorded at the estimated fair value of the purchase
as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable <FONT STYLE="white-space:nowrap">six-month</FONT> ESPP offering period. The estimation of fair value for stock-based compensation requires
management to make estimates and judgments about, among other things, the estimated life of options and volatility of Avidity&#8217;s common stock. These judgments directly affect the amount of compensation expense that will be recognized.
Forfeitures are accounted for as incurred. Stock-based compensation expense attributed to the Company by classification included within the combined statements of operations and comprehensive loss was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table presents loss from continuing operations before&nbsp;provision for&nbsp;income taxes for domestic and international operations&nbsp;(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before Provision for Income Tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> Income Taxes (Topic 740): Improvements to
Income Tax Disclosures on a prospective basis. As a result, our rate reconciliation for 2025 is presented in accordance with the new disclosure requirements, while the reconciliation for 2024 continues to be presented under disclosure requirements
in effect for that period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company
Business&#8217; income tax expense is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>US federal statutory tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>State taxes, net of federal benefit</B><SUP STYLE="font-size:75%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax Credits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and develop tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in valuation allowances</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nontaxable or nondeductible items</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in Unrecognized Tax Benefits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% or more of our state tax provision relates to the California state jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company Business&#8217; income tax expense is as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes benefit at statutory rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income tax benefit, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sec. 162(m) Limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business made no material income tax payments during 2025 or 2024 for Federal and state jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business&#8217; net deferred tax assets (liabilities) are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net deferred tax assets </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business has established a valuation allowance against its net deferred tax assets due to the uncertainty that
such assets will be realized. The recoverability of the deferred tax assets are periodically evaluated. At such time as it is determined that it is more likely than not that the deferred tax assets will be realizable, the valuation allowance will be
released. The change in the valuation allowance was a decrease of $0.8&nbsp;million and an increase of $13.7&nbsp;million for the years ended December 31, 2025 and 2024, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2025, the Company Business has federal and state net operating losses (NOLs) carryforwards of $17.5&nbsp;million and $36.0&nbsp;million,
respectively. The federal NOLs can be carried forward indefinitely and can offset 80% of future taxable income. The state NOLs begin to expire in 2043 unless previously utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2025, the Company Business has federal and state research and development tax credits of approximately $1.8&nbsp;million and
$0.6&nbsp;million, respectively. The federal research and development credits begin to expire in 2043 unless previously utilized and the California state credits can be carried forward indefinitely. The Company has not recorded any DTA for net
operating losses or R&amp;D credits as the NOLs and credits generated will stay with Avidity subsequent to the Separation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the
beginning and ending unrecognized tax benefit amount is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross unrecognized tax benefits at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to current year positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to prior year positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross unrecognized tax benefits at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2025 and December&nbsp;31, 2024, included in other <FONT STYLE="white-space:nowrap">long-term</FONT>
liabilities is a balance of $0.6&nbsp;million and $0.6&nbsp;million which represents gross unrecognized tax benefits less federal benefit of state tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefit amounts are reflected in the determination of the Company Business&#8217; deferred tax assets. If recognized, these amounts would
affect the Company Business&#8217; effective tax rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefits presented in the table above relate to tax attributes that will remain with
Avidity subsequent to the Separation. These unrecognized tax benefits will not be presented in the financial statements of the Company Business subsequent to the Separation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business&#8217; policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company Business has no
accrual for interest or penalties as of December&nbsp;31, 2025 or 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Parent Investment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business has not
historically operated as a standalone business and the combined financial statements are derived from the consolidated financial statements and accounting records of Avidity. The following disclosure summarizes activity between the Company Business
and Avidity, including the affiliates of Avidity that are not part of the planned <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net transfers from
Avidity represent the net effect of transactions between Avidity and the Company Business prior to the Separation. The components of net transfers from Avidity are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from Parent as reflected in the combined statement of cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease expense for Avidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation for Avidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets distributed from Avidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from Parent as reflected in the combined statement of changes in deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers between the Company and Avidity were recognized in Net transfers from Parent in the combined statement of equity at
the Company&#8217;s historical cost and consisted of property and equipment, net, of $0.6&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost Allocations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined financial statements reflect allocations of certain expenses from the consolidated financial statements of Avidity, including research and
development expenses and general and administrative expenses. These allocations include, but are not limited to, executive management, employee compensation and benefits, facilities and operations, information technology, business development,
financial services (such as accounting, audit, and tax), legal, insurance, and stock-based compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These allocations to the Company Business are
reflected in the combined statements of operations and comprehensive loss as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost allocations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cost allocations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes these cost allocations are a reasonable reflection of services provided to, of the
benefit derived by, the Company Business during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company Business operated as a standalone public company. Actual
costs that may have been incurred if the Company Business had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by the Company Business
employees, and strategic decisions made in areas such as research and development, information technology and infrastructure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Business participates in Avidity&#8217;s share-based compensation plans, the costs of which have been allocated to the
Company Business and recorded in research and development and general and administrative expenses in the combined statements of operations and comprehensive loss. Refer to Note 7 for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Segment Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations constitute a
single operating and reportable segment and reflects how Avidity&#8217;s CEO, who is the CODM, manages the Company Business, including allocating resources and measuring performance. The Company Business derives its revenues from its research
collaboration and license agreements with BMS and Lilly, which are further described in &#8220;Note 3 &#8211; Collaboration, License and Research Agreements.&#8221; Segment performance is measured based on net loss, which the CODM uses to evaluate
the results of the segment and to make operational decisions when managing the Company Business, such as how to allocate the resources of the business to advance our preclinical and research programs and to monitor budgeted to actual expenditures.
The measure of segment assets is reported on the combined balance sheets as total combined assets. The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included
within combined net loss. Research and development expenses and general and administrative expenses are adjusted to exclude depreciation and stock-based compensation for segment presentation. Other segment items include depreciation, stock-based
compensation, other income, and income tax expense (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted research and development<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted general and
administrative<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other segment items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Depreciation and stock-based compensation expense is removed from both &#8220;Adjusted research and
development&#8221; and &#8220;Adjusted general and administrative&#8221; expense for the years ended December&nbsp;31, 2025 and 2024. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Subsequent events were
evaluated to assess the need for potential recognition and disclosure in this report through February&nbsp;17, 2026, the date on which these combined financial statements were available to be issued. Based upon this evaluation, it was determined
that no additional subsequent events required recognition or disclosure in these combined financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2026, the negotiation
period under the ROFN expired and, as a result, no ROFN Sale will occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g42675dsp001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  D /0# 1$  A$! Q$!_\0
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M>.+(P<D>9(, #L: ,ZW^/FC7$.HL^C0K;6=Q;[IXA$\8@FD6-,_./F.#DC@
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7PMH6#1P1HV<Y5 .@P/TXH L 8H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g42675dsp002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp002.jpg
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M P,# P,#_\  $0@#< (6 P$1  (1 0,1 ?_$ -(  0 " P # 0$
M   &!P0%" $" PD* 0$! 0 # 0$!             0(#! 4&!P@0  $$ @(
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M"CCO_P#I:OR_T?\ O:<_^T<_[M\A?D:/V7COQ?S=&O\ <YZOQ<__ +&C]O\
M]7'7\?5CR[YJ9%GWJB) <C:BHC\U[VKWE%<W+/88@^G*2W#]FEXU0\J?[3$S
MEQ?BTQZ2\>3'GQGS\[=?&>Q7=9&SE]_&E:=$EQT&Y9CF68_G+1IET7JEJ7JZ
M>!Y]O.?*L=O3.GV[Q4]U+5W(/F+(QAB6(:9_M3[FJ/J?IAI?I]7ZBYN?&'Z4
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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MC"C*X_F(D$Q5.QQF6<=6C]*># X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M>G4]C5MR!F^VPK95QS7+U?\ 5OONUX)5(%31*'9+*&F#$>"J$[.(R,B9<-_
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MHZ)J*:H'E*V"2C#=@'XPPLE[6VHTF ]'#'Y<VOUXI!$BF-AW,8OP,21@IL+
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M592P45=_HJ<Q78#C><V"KDRA:7(ES-2[+"9"253FH3ZR47UF<N-9;6NDT_\
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M3H2S0Z^7TX6]VR8[Y&%%.OQG8*TOR/4P)B2Z(GW7GLI5]@7@MH*NZ<1K434
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M,-'/]'WCTE/YUSOJ?KW8>&96R]3ZR"6FP;KB;C;#G9 ;85LH-\W-6@&_=CM
MET!D=-6X9M\+)L"N0T[_ !3,-UZ&*U+P+0M^ZM';&O +85DZU[MLC->TV]O&
M%=11.N^Z2M*U:><L0B >UG7=O1S-^,5;8_ER&@E )!J 5>S-CJ9;]63@$FEX
MFZM-MZJ6_JZ6WW9]6VG%-KUWM]L@AZ/;1DO8I?8][L;]?.Q==7C3NU)0HS+V
M=8+,J$J,/LJ8$W,K,:6AOTW&6A.J>"$EK;T D;*EUI.LYTDC"H.DX]?P :*"
M]7WFB;=JB=9T\Y3J[ M@RFV0K0J!980V?/6-2=!!"T!$=S,=UG"!?5@M?5V]
M-(1M=[]V$G25XU>PC4H+LWL:DVI%,)/[#US8M=F(H"Z"X@#8%MHC\ZR5G6$D
M9.8D2X$M4F G)%&$N-R'!&GTZG'PW<W1.#1*R1KNJ;\%P[N C20)@)VBJ-4R
M.LM,U*J:F#5^Q<'M0,J4JG *-<Y >/71%J=8%SES(?NR.XR[G$-8DW_0ZEF;
MGZY5BQ'K$[IR]9C:H*;IV"/V@HC5Y;I^^ZAU5.J^YHM;C$-G?679UQ*O7'P$
M^?)&9K<\S PEV6N1B-(<I,29J)NV^N@(_>1M>Z\7@\=Z>42 D9"&%]>C3,2D
M:@?A/Q,5VO6;;86R1 H6 =<FB9QV% AV&*R\H?(F^#>'&1A_7Q();MQ]3-H;
MHJNI=G:#O ?:&UR](/S6L7^BC;HR3VC0FJO":(A=:[QSLBQ4>=KBBP&;.H/!
M)UAF#':45\4QI"V PTLKP-9;M]] Z_1B-V8TZ.=%2=K;TT&3G/&=7:K233<:
M78[G?RQ&[W_:-#KTS6FSZ1"]K!IE%/-)CJAXB1(^8S:8P)2SXER4W8G7[<'8
M#(^OT_>](V+L#6=7LLTXYL:PZPCRA1G5,(P!F&--Q]M#2Y.?7JI9T#\6!RHS
M1L ]%S!S/Q.AH0@3#2\L&;LO<76':L2[TFRU/86P++H#:50U=78-=)$:WL"V
M7N_MS:%#^K6\A[O42F1!4Y!/UP[+GE1,',D 63.\T2/AYP,-?U/2N[.ZFCYO
M6T*WK.92"NR=FDI.NQ<!ZN.C=;WG4M+A:-@%"1BAW@S5AP,D#8%TP8H-)(#R
MJB<6*XWE+KV4!A]37C>T?5'8=ODCI-$NJ;5='NM&Q&TE@OL_RNEVPQ!#:[)A
M50[,]'+E-7D'QN3L.-C+\)LC!<]*2F0C/ TLK>@[=ZYQA=+W?J7JSMLM(#W:
M@ZBKX</?=9^SU2QGZG7=3:^*$Z45["?(@#>LT\M&K,]^9';N8:&AR&20Q'\O
MJ"M/P;+GVOCJL-W8:UW>Z]L-&PMVZ\F[6M<8)L/80BJ.2];P@92M>N/ ;'$U
M^N;9(B-,R)@(D,ALS'(U+G+S.:]).) BSC/T*)5M_H;>:?0MDV2D;<)U,?3M
M=R35KNIS91LS68^P[!LHU3-5[^9F[%,7"XD8.TZ 0!L 3[9V!#LA2##B)RV1
M0M0UB2Z%KW^E=:A.-?5")U7V05O)W7.-A3ZMJF9'J&SZ)2J]<JA:9ARYVL)M
M*EDS5L$;!E1EL-#BYD_.GIG>QXD-N2U.B)OZ]"SME[2Z]UG1*]RWBGV6V4[5
M1>_:@$ B++ELNAN3#MIC0%K#Q8%DL;BKEFRX#R?5R3EO290[SOO^#OJ8P(D\
MX*,*VCI-6]F0]7R*_LE8W8HQRC$BD78^Q)>CS(*O=8ZI9Q)*T@\[1S72R26F
MV1@J"5>$22$B?'81EWU?1?4+ZL$\O^X-1[3TKJ7><KK=LG:E<[(5FLZUB@\R
M-?5JWUP1M*QUYVN5VV0;3M"JPQ!)VXIB*Q)%RY4L3-B>LEYGTTN9$PT\9\"N
MG=G=%IGULPDOW$F68@=@-G;/UR,W1<B)&E632>Z0$:UE!]$A;>6+UCLFU;<(
MQ9E;GB&!<V7*=4M$F.MY27!<2Z&\U6YU_LNS]2C-9:)W2/&;#TVU>QM\&[?=
M"T*=2Q!.5,.1-M4N'OE!F[W(+?-KRH97)D"8G22T^4XX^^AMQY(/..K\S$IV
MT>DGRYDTX-J4I6K%>]IE^OEQES0[ Z$UG\OFOV"]TVXW0BBTN^6AUL0#:^3Y
M16'9LU$J(Q+:2TRXF,#4E_'U-)6=J])+B'U\0"Z%M*9V\(.PJ;3!GR<AQ+7>
MK'9]K"B^U-<6.5!N#CRK>P3#0[O/]\R\):KK,@I'D9:BD$LAB7U)CM/>'5 5
MV+,Z?O6L9YB_5VY!.P+IIHQ2GEO;0U]H@E;:[:!]0<V-#V&^L1JS7N8#9' /
MW!B<TS&>>]9>5X$2EC*\"%C=B]4"/5[;_9E[7FTY.KVCC-GL-/JN_<;/F(L%
MBNU;V&JRZ]K^M>PEMHVL[M$N]H:)_P#1,L&;B2,.*:2E+B,.BX><>98P#M%U
M=T4B[BZTQL ?4J/MO7G7^2IN2X=J$H_:@,W<!_9@&49M$N84!"(%X+$KO99*
MLD93XB6ZYB8N.TMT32V5_N+:O56.(NXS9F@=FP:-JZV=C9-?O@L^%K ^WWP1
M'.;#WS4P%CK6W@ER!1KLRZ5FRHMAP(KI=B _ZRO38CIR*E+R+;OFTNNMHZC1
MMLW?7<]6KZ"2%MT6I:ON%),6\>?#%$Z_J<#4EKT5LU\,+L,A9-0R*T*L,1YJ
M*^]%?]-M3S61,23QYD2:?Z=E"$?1U?TA*MNLK9+TC2RUU@3:^C7<D_$A1-XZ
M@ X58=ABM@W4G%'WB+8)TL,+*)P@XATD\M+LK+(OJ77S,09V2ZJ5N-L/LY4
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M4HN7+N777E*BDPK-6M/7.MYDQ+GM*I6>ZG1.NK 3$K9!P"I# YUI.?.][)C
MO7&?H;FS]VM)R:\,VU9-97AJ!1Y%&O&J#-B.ZDK/RA$;F*?4[6;] P7VT.;H
MP(Z-OBW$+N: *G!,WUVFE/)6TR)I?@>;-O71U_L$1ZYZ.MYT+=]8ZGIEZV/
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M%U27%D K;*'%D##KX]7D4SY\C.%E?<YFLWY@79>O2:JR_P!/2D1XQ4]B$B$
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M?#UC&KRDO4P>+=!T,WC$$_*F*#H$3(LYIM,O,;&71-*.I^IO8[/9S6 S8C@
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M=;W44OY%G]BSP<D19WLO5QL?8J#+LT44Y-F-SA;3$:6.0^VEU"4H6VGPQC/
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M-O-# HF.F-#C>U2GYTQ[RXSE;TJ?/E.R)#SBEO2)#JW7%*6M2LAXDHX X X
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MZP18I.IO^!0*IQ*G?5]1A#P:"1; _,%"@J=UAO=2K3IH#N/#-[V=ED/=+/\
M5=I(5.$U>]W$A+J5?E) JJ=KM,-Q<XXR.%J'#">5K;?:0C */B2[3/=?Z[-O
M4ZB *77!=5LU4V]9I)F3M2G&[8-10RFL8M4A$*=6Y!*2!/GH%UFO$PY!U@@(
MQ#;4K#J5.90(XX63M9%IK+J4J;L0)Q*TLJ0I!<>M*DR?8?9U)RF1G"DO^\XW
MDSC_  O:&O#Q]1'B,C%IK&4^?%C!91A*%Y7@N/RGRN)\S:O-B1X>5:<^.,_N
M9Q^YP JTUA*5K58P24-85EQ:BX_"6\)3.4K*U9D>",)2,DYSX_N8CN_R:O
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M< V4>/'B,,Q8K#,:-';0RQ'CM(988:;3A+;3+3:4MMMH3CPPE.,8QC@&O*
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M($,S#9C-0V8K0N"W&:AL0?=;,5IA#&&FXS(S_FZ6\8PE+'\7C'D_1P#V)5\
M8%RP9<&(*A""W%SPY(;"G"YJW9?M[JY8^4R[$DK=G9]965H5E3O[_/[[]/ /
M1RMUUU*D.@ KB%IBI6AP7!6E28"X+D%*DJ8SA28;@R,IK&?^3S':RGPRVCP#
M)XC5FMPQL0+$KX2*'@2D38(F,)@,#84UN8H@W+B0&HZ8L:4W/7E_#B$)7A[.
M5XSYL^/ /:+7*]"%Q <("&B!8#;C4 /%%P8XN$TZU(CNMQ![3"(D9MQB6ZA6
M$(3C*'%XS^A6<9 \YKP#*GEY!A\KD)>1(7D9"\SZ)&',/H>5Z'BZE_#R_/A7
MCA7FSX^/CG@'P35*NAHBPBM@$,%W2SY9E(<<EHH^?PVDZ\1;Q&PB:Z:2RC$M
M3N%9DX3CU/-X8X!E-@@;,9,)D,*:AI%-@DQ&QT1$9(1IM330=+"6<-8%-M*R
ME,?P]'"<YQA/AP#X1:Q6H,C,J%7@<.5F<0)YDQ1,"/(R2+,MQRI#+S4=#F9Q
M*.RA$AWQ]1Y"<)7G.,8QP#PBK5EI*4MUT$VE"64H2@0/0E*8WL/LZ4X3'QA*
M6/=D;R8Q_@^SM>'AZ:/ !BK5C"?)BN L(RE",HP('X3Y6T^5M/EQ'\/*A./#
M&/W,8_<X 55JPI*T*K@)2'<*PXA0@?E+F%)G)5A:<Q_!>%))R<9\?W<2'?Y1
M7B <J]9=PK#M=!.87A["\."!Z\+Q)R25(PK"H^?-B0HS,ROQ_P /,M[Q\?57
MY@/*ZQ6G,YRY7@:\J]3S96)@*RKU5D'7?'*H^?'U'2TI2O[ZI+N<_I<7X@03
M9P"7&HECET2M!WK9'A-."\,A13\U*&YS3Q!P6S(CY8?,,#W9+L)M?BA<S*,*
MQG"L^(J_X'!\FI=^:W,)2JF U_;FLF2B \*^XUXAIAE!ZH$19);H5,*=!$#A
MPF3#@MQ)#.5MY3(4/'NL1V<C7I++TL$[:0[?7!VZJMK-=;A&0L;!NK5VNLSB
M84?KX\Z8-V-T:Z] '%%7\%6E0V8,:$EK+?E;]1EK&61'IQT\3M]NKUEGTLLU
MT$UEGTO1],0/;]+T$06V/2\L?'I^BV,C)1X>'EQ':QC]#:? 9/":M6$83A%<
M HPA*4(PD0/3A*4LICI2GPCX\J4QTX1C&/W$8PG]S]' &:M6,I6C-< Y0YCR
MK1D0/RE:<IE)RE:<Q_!6/+->QX9_N/+_ /UE>(99Y75ZRXEQ+E=!+2]ZF7DK
M$#U)=]7!/#OJ85'SASU<&IF%>/CYL2WO'_E5^8#RJL5I?J877@:\.J<6[A0F
M KU%O>\/66YXQ\^=3OO>7YLY_2KVIWQ_Y1?B!G0Q8P<IY0\=!@*DY2J0J'$C
MQ5/Y2IU:<O98;1EW*5OKSCS>/AE:L_W<\ C%2_ZVV'_WU;_\%TW@K)KP0< <
M < @K7_F7/\ ^XHC_+YO@>1.N <[]HJYM.[:ALNO]4! 90OL* 4I!8H:N,RF
MKI8>QAB0_P"6XY^& .O&Y%=)NQW71Z,PWGXWJ99?PZA#;@JQGJ1#67536U/+
M=FU$-5ZQ0#W?L-)1 ^'7!+T<W1U:UUR+D!;+#6-:9S&>V (-D%0\^JPIZ8J3
M_P K(<\!6\X^QQG2^D5WUM=M%3 ^L*6^+IO7;35$+SJ\K4*8%=VU6E;*=V+;
ME.W?6IG8#3AHC;($Q1*LDA$\DY'5F5XK0UGCSR75G^YT9TNZ\;EZ_P PX!V+
M:(-JHXG2'7776L)3EG.V2UBOD,WL\G>*O:)9J(W[UBUFP75$4(7]9R7/!IBL
MRTX?AJ>?$DT_ [WX,G!'9:A=V+,+TE'TWL"HP[%7[RX;V78:^\4UH&(AXUHK
MDL6-S4S)#96"@9ZF-E8<UJ3,GX=GK8<1%2AW+D$:6GKDIIZK]Q*+UL U*_WM
MF9N0EV1&0*=LDC+1=(82M%&%Y!6+9!.6$0 !P6K8AW#2666HSB7X,6-'8DRF
MA;8OIST\,&HB==N^)')&:K;)VF1\!Y<FIP%;9@6B\P" "J;H=I%8V#L)O6@S
MY=@L[3LX8G(QF.EO M6(3GKMQGDR@S$WEEZZ]GG]#ZLJ6JMG2ANZ-1;(W^\4
ML$W;AHY&PC8 ';::C.L+C\*0[851H%Y#O01)%I"@F)3#S>5>QMY<#*SGR-.Q
MH_OZ"I)@[.WD2*6E=9GU]0@[L2(* BJ;FF#GD3,/0:_GV?9@6S1WD^^U%?/(
M;;\79R4O.R.!F)HH?6GO99Z!3Y5TW@?L%B9FZN78 ]?W$H-7C=7H3^MK:F:)
M,"J2TZW;[%:*M,]I(J4XW.ARE-/X<8?=3D,QST+VU_J?NY%ZUF:=:-M1HF](
M^T)<BL7J58<6%Z9KHUB"!.2K*\NOJ&X,BH1DR7#0XD5N#[;"&84S":4["C"-
MQS]BBCW5'MAL\U2++:]NJ+NK/U)-X)ZWVK.J<$*^*N0>;>,A8XVM)8.*J#%/
M5 &-3$JD1"K[CZ<-9P\G@NJ/T+WM>H.SE[T_J .&VXB<=K%#OS5@-Q[9"F"+
M_;5':?&U64MLF/6U1KJ+A5.(5>G)QB*U((N-K6ES.<*0(FDSDO36H^\&W9A6
M_P!@N.Z-=DJ<3*@:MG8MP(U^?89QZ3U9E[$EMUZ;KX)-9U<==IMR='C'(ZV8
M,IUE,&2MC+*XPTW%'3)K1W;Z'J?JA0M?WPG7B&O=:@:3LZ?(VK*?(-7$3BA#
MW;S9#\VIFRVV@"JJ&L,5(]2QLER>6BRE+2ZRF3"&<QRV::R=;.V=*U)U#UEU
MRV U4,ZLUA/I>T/?=XFNB9]F(U &/S;BY'Y/S;'<9XDVV4DQ'W<OMOS9*7)$
M+*UIFPA<QR\F4[K'O^:CW2_-7B!4+W&B#W]4ZTE[,P>US&E3K/)A6>%L!\?0
M(.3?DHZT2(#K;2TQ"24I1C./,ZH,Q\/(^,[1'>(,FS!:UMO!"E./VRT18[=P
MC5V^'B,C<\]GY)0[*S29,*KXNN@ICLQ17"%O#KN\E['[S&9"0S'Z$5QH+\PI
MIJ@E9&YG3IE&S8*[E6RNQU?(KZI6*+014(04P*HX&<:/C9S5D20F,-I0:)OL
MRGH>6W6%"@S'Z%>E.NG>76P/3]0J]VO5W#CV!=%?D!-K00=W%PI&CJ3+*^]=
MF3]:G9 2B"-RTTK(:PJ.[EV._$A(PA,AMMEYE3BS]D*E%L4&JUF%;R<,W;8=
M?#1;09'Q<08!>Q1QL9HV3@P<)1B'#GDD.NM-83CTT+PGPQX<'&2#@#@'Y4;?
MZG[VVF_>M<2&QT'6\_8VS[_ O K:M@!66P!MNE "9%1A#A89DK2S%,&OE'&B
M#<YYM#L6(J+CSR',1"-J27\R$DNCG9&_S#0W:=VJ): 7V?&G$[/#4,._*&DU
M[9%)+@["5UU=JB=H2K2?J%02^5%O0Y8IDN^]B-_$^DI NI+P.P-J]3JA<S/6
MF9&HFO3:='RRT)TD:KP$9,C5V/J.]5VK1 D(.$CC8+$+8A,22;AQ&HD2"['Q
M(CH0MAI/!E2QDX5U]^65L$-BB4^W6>L$:8Q/U!;;<3B534TF"T1IVB=OT.RU
MB;J@EJJ3K>]'7-A72-/Q<B4%T\3'2&VGUMO"([\D5R7D="=MNI>XMN7LT7U0
M<"UVM6[K.4ZQVB$_9S-<<^1%LF7,[9G@<,-!?BCST8@,KL"#+1Z3C$$@0\JT
M>FA#H1DDNOU*H5TG[,1)RK4%N06*?=+Z] G:_,O%F=JUIUDCN)M'=UU]1AJ#
MEL5>:G4K"%E@)B65>NXB>&?4B)*P^T&I?Q_(L#<76+M;>MM;?V8"NM+36-FA
MF=4_5>Z?O%;D9U)1)%>N%6C$+T)*3A\)R_V<191)%N!7V9XX5L&2XJ;-]W,Q
M\@FDL$QJ/4,61N/7Z^'.O6GM;-:QOVQ;!\CAAUV]/5&N%JS/S3H8@C/!0Q42
M5$V')48P,$MQA E]W#L;+DC#KS@FKQ63OBU1[5+ $(])+@ -G<Q']UEK172%
MK!1%)EL+E9GU\59Z;/(8=@I=;;PV2C>FZM+F<K2G+:QDU$@[=6?;,,41,S+#
MDM$56+.,C8GH8^4_LKV$N,KS$Q.]U#?WJ\JRU[U_?9S[*[YA>@=/71.'_2H6
M'?3=D(8Q\J1;?M#3?O[T'?WT?/I>T^[X/[W/CE'O#]/_ "#GB(>??MS\<_\
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M_P#,N?\ ]Q1'^7S? \B=< < < < < < < < < < < < < < < < < < < <
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MM!^7/A%1&\<_]G_'QRI/JY_3_P KG.?\'][@0X9W!V5+:ON!NL0AU\L\4/\
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MF+0]Y8"TJ!Q2*=MOYBN\$63;$>I:2;<%:BNIH8VHHU8A\&V5] [:XE&; 0)
MX^::2K)S7S!.1ZZHC4B&0C-.JAQWFY[H:5CQ.B=%]R+_ +GO1:J2M1RZ>.^J
MA^]0G9D2[1K97Y[-<H!<9)MH.S4T (C =@2[M+:KR69SLUW%?EY>:PK+R(8C
M21S_ *1_,-WU<#77.DVG044P]LB16 ]RV@$G6"MU*01(@:#(L\.MB[E6JX7^
M6.N9]LFNV$9B,\TTD0^TPYA7K9ABN*Z]2Q^P?Y@%WU";V#5ZSI=5J.Z\/GFC
MC<QZVPF(M/AR-+?)BRHD,U18HE+N\?8Y1 ^$U.0M]X.I+"GW_&-D%'/F5A?O
MS%M\LU_?6*[U\3195)-FZS3+5?7K1,;%RF:YLV?6G+K2JW53MK@G[U-HPY8"
M&]"C-2<V*&R[GSX;]L!173J6YO/LKV>U[M:$!HM5I%FK<+6M%V)(!&A%U'F3
MC&-6]K;=L:(\?"A+! @+2<U3688]N.PMUF?/::>\42T8R"2QU(FG\QN]0(MO
M)V/1$H6-$*L\<=Z"=A2YX2VQ:CM8O3]0WF+]7K28VS[ 6UU ]1 U4T>B)8X>
M6GG%985,#0OJ1"#^8-ORW6\K\BM8T B%UW#+6G8-0B$]A3[%&KV!I6?BAE2"
MM<LL"=S 55]QE+,/$X%.>E_O9>4L_OPTK'4Z/W+VQW#K#8=_"CM.@S.OJY.@
MU41<9)6\(EPSDNE4*[D[[<8 >B%X<74U/&6V9[R?'R)A'_HI[R-8SA6$"**:
M(93.W6[K#J+?>S3=!&Q2-'O&F8VNZ76AEPP8,T:X1]:Q#%G7)LU68F&:U;")
M0P0#2FQD>2T(\K<EMB2RM>!=*Z&S+=H.Q3W6D]LIW7U+H>RJYM#1]?*P7&KU
M;JI\A-H#M+V\R5@)=KE<L"RU<!;5>$ON+BYB,%!;[KF4MX4TT&%G'D06C]X.
MQL>W=?=8;#Z]0I)^_EJP%O5X"&2HJK)38J5I^V*?K4>Q@@TQZRUL=M)^67')
M:>2A(*4AE6,96N*&E8;3-/OWOYMVD;WMFHZ70*^'KU'LM7;(;(NX[8#E;P+4
MBL(L<>UM5ZGG# D45Q=6719.'&<9<R->PA;[2GW8@**QED@Q^8%MUN68?D]9
M32&!L,/[SID9R\R=DT$O:'0%4H(Z_CW-?Q 'H;*V#=!BQSXR7+]AK48D0G(:
MS$<:0&E?4FE/[<[JV'2NX3J]..:WM&A6+! H[KLKY5R3AP7+N(EE@C6FF69W
MKO\ R6C%XJ?!&)8PS%\J/!.'WX-*RBHJAWRWM8KJ II36(VE"A=UTIFY7&RC
M+>60YKB[H>BVR424+K0,?3+.\9G1&!*9;3<5UMIUQ"Y+>'EQ;U*XK!^N\:2Q
M,C1Y<5U+T:4PU)CO(SXH=8?;2ZTZC/Z/%+C:L9Q_P9X.,^_ ' ' ' ' ' ,;
M$.(F8L@F+&Q/=C-0W9N&&L2W(C#KS[$5R3A/K+C,O2'%H1E64I4XK.,8RK/B
M!D\ QH\*'$5*7%BQHRYTG,V:N.PTRN9,4RS'5*E*;2G,B3F/';1E:_%7D;2G
MQ\$XQ@#)X X X X X X X X X X X X X X X X X X!C,PXD=Z7)8BQV)$]
MUMZ<^RPVV]->98:BM.RW4)2N0ZU%80VE2\YREM"4X_1C&, 9"DI6E2%IPI*D
MY2I*L8RE258\,ISC/Z,XSC/ /C%BQH,:/"A1V(<.&PS%B1(K+<>-%C1VTM,1
MX[#24-,,,-(PE"$XPE*<8QC&,8X!]^ 0JI?];;#_ .^K?_@NF\%9->"#@#@#
M@$&9_P#,LAG^YBC!_'/][Q/G/#_[^&> 3G@#@#@#@#@#@#@#@#@#@#@#@&DQ
M6JZFQN7# (1BV.A&:TY9O=T3W\JNQY[Y1D%DMZ7MWNALE)<D8C>IZ/K*ROR^
M;]/ -WP!P!P!P!P!P!P"&T_75 UZ@RW0J34Z6BQEY!\^BJU\4 2:-R\^,DL4
M2+BQ<3R#^<_OGG?,O/\ ?X&<^),N . . . . . . . . . . . . . . . .
M . . . . . . . . . . . . . . . . . . . . . . . 0JIX\"VP_']'_
M &U;S_\ >E4W./\ [XSP5DUX(. . . 1TQ4:O89#,LY7Q!65&95'8DSX$>1(
M:CK7AU3"'G$9<2RIS'F\OCY?-^GP\> :GZM-?_,VN_JN+_-\%RQ]6FO_ )FU
MW]5Q?YO@98^K37_S-KOZKB_S? RQ]6FO_F;7?U7%_F^!ECZM-?\ S-KOZKB_
MS? RQ]6FO_F;7?U7%_F^!ECZM-?_ #-KOZKB_P WP,L?5IK_ .9M=_5<7^;X
M&6/JTU_\S:[^JXO\WP,L?5IK_P"9M=_5<7^;X&6/JTU_\S:[^JXO\WP,L?5I
MK_YFUW]5Q?YO@98^K37_ ,S:[^JXO\WP,L?5IK_YFUW]5Q?YO@98^K37_P S
M:[^JXO\ -\#+'U::_P#F;7?U7%_F^!ECZM-?_,VN_JN+_-\#+'U::_\ F;7?
MU7%_F^!ECZM-?_,VN_JN+_-\#+'U::_^9M=_5<7^;X&6/JTU_P#,VN_JN+_-
M\#+'U::_^9M=_5<7^;X&6/JTU_\ ,VN_JN+_ #? RQ]6FO\ YFUW]5Q?YO@9
M8^K37_S-KOZKB_S? RQ]6FO_ )FUW]5Q?YO@98^K37_S-KOZKB_S? RQ]6FO
M_F;7?U7%_F^!ECZM-?\ S-KOZKB_S? RQ]6FO_F;7?U7%_F^!ECZM-?_ #-K
MOZKB_P WP,L?5IK_ .9M=_5<7^;X&6/JTU_\S:[^JXO\WP,L?5IK_P"9M=_5
M<7^;X&6/JTU_\S:[^JXO\WP,L?5IK_YFUW]5Q?YO@98^K37_ ,S:[^JXO\WP
M,L?5IK_YFUW]5Q?YO@98^K37_P S:[^JXO\ -\#+'U::_P#F;7?U7%_F^!EC
MZM-?_,VN_JN+_-\#+'U::_\ F;7?U7%_F^!ECZM-?_,VN_JN+_-\#+'U::_^
M9M=_5<7^;X&6/JTU_P#,VN_JN+_-\#+'U::_^9M=_5<7^;X&6/JTU_\ ,VN_
MJN+_ #? RQ]6FO\ YFUW]5Q?YO@98^K37_S-KOZKB_S? RQ]6FO_ )FUW]5Q
M?YO@98^K37_S-KOZKB_S? RQ]6FO_F;7?U7%_F^!ECZM-?\ S-KOZKB_S? R
MQ]6FO_F;7?U7%_F^!ECZM-?_ #-KOZKB_P WP,L?5IK_ .9M=_5<7^;X&6/J
MTU_\S:[^JXO\WP,L?5IK_P"9M=_5<7^;X&6/JTU_\S:[^JXO\WP,L?5IK_YF
MUW]5Q?YO@98^K37_ ,S:[^JXO\WP,LD8<$&K\5<(&+@"8CCZY3D<?%9B-.R7
M4H0Y(=0RA&''UH:2G*U>*LI3C'CX8QP0VO ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' .+]N:
M&V79-MO[BJEH?]6M)TJ_5*1&LTZLQK%\C+T9,[ #6,RW ()B ;!6BV,(AMLN
M,32$:,N5E*&$XR-)K&"DG>M?:%YY,L#; ]2DC-G;)V3/;=O1G#NPTWHJ9!"Z
MK)L=7K8HK78%8UG<S"(\TA&L#D0RF"]'C^$1EUH,HVNI^M.^*E)V/\IBHR4]
M8]1G:3KXU'M_M$BGRI,8\P)9+914H,V.8S(GLO2Y@)8\4I>,N-#VEIQC@N5_
MQ*NB].>W@P!'"*V_!LKXX,Q"JA8WLB[O+KKYB,?GVV*=8>KSQ(]D88.R8]<,
M0R$ E!@+C1)3<J&W(9<@U+)*&^F6W2D(CD@7"P81+7)NDM5=ZT$8\L:;72#T
M0%:562GA@4%X<Q=IC4IT6R/8\7\L$O:/:H66)5&I%L[0Z\[6,;8DV2G*&3-9
M8KU8$DZ 7V-8PT>UA:XR+9C4P2\'KR9=&@JEQ')4Q+T@S!GY::PAJ(N5/6L1
M-8Z^)5Y#JCV:(5:-4$;"&#[ 3DSPE_W3C9VT)UALU-M(2V5YU,"F,8#CH1C6
ME7LN!HF5B<Q/FR(S,[,J([A>%"Y18KNG>R]BT(5U[<)X5S9,787RGBV\+L@J
MR#M+,@B4GIDSAQ"FS944)%DNQG'P2\I_>>?V.='D,1GL"96<^1 P'5OL!& Y
M%ER028;E$+_[0?QLZW!HP>R6DW"("MK!55<$-LEBD!@3$L:P--S'Y6$2L-.3
M'(SLK"A<H\&.JW9"SW5S8$ZYA0ZR1:FHE4]B^6Z6X( "X1X588X^X1PP];L$
MGXPY<H4F S%)Y?5AUUIV&TX^&46K3NJ]UI\N4]7[X1J\=_7>UQD,6,M%@G@1
MNT[+83L?7NQT#IS6),DA6*!87H#J52,1\Y;8\&%N1H[[0F5YD4H'6/<X+<E<
MV;*.!:Y3 Y6O(BZLAWFWVUZN!&*K>@UF2'NI@?#D2V#EO,0SDL<_$]G(8?6V
MXZT[$9<<#*Q]S42NI.W#05'MAT8(M(D>2B##C>P[L;?F75_6MRKI+<&'9H]E
M PO=+P5#E7A*F9,6$H0AWSNNK4G,+J6?L1XGU [!&K-?L%=B0"B;1<F38>^G
MYS!IN'6XMJ('6P1>BPP->?>;DMK8PZ-A%(@?*4YPE"7$I<Y1E8-[>NL78:Q6
M$*1$V>%$6WHNB4(<:E[5NSI#7FPZ^X(?M%QB):!,?*U^PC84D:N8XF+(FIDY
M7);2VMQ& RO^)#8_37L#,'(@KN,$76BVO)=/L] )7HV^.S9!6L-OBJ??@4JI
M5X .&&FMBWN$]/RW&;7.A1X\EY2I@R,ET-2_J6,UTYV1[SV^99V62KT\Y=!B
M]1.5VS%6I-(U\FV*?-!VR<T5*F#LDJ$1G"\#V_:8#2GDOM>G*:9DM!J1"HO4
M;LL%LQZ:ULB#:=;E;CL*R3-5'-BW_#$\/((4:'0JL/..1)#XP'+K B0HK!6I
M4?$\7%2A:FR9)Q(:D3"R]<.T#]IU=<0>R1.&ZR T/%V'0L7O8$:N68GIT==R
MT]ZLDB+!PE E6FQ'6A<Z21]K45%R$/SO4?&QFW1,HI$WTK[>$"CTJ5MB*5JS
M^P&MC/U!K9EMS)5)/B:@$M-62]8*P4KLZOAAM*CY&1Y<1R$N;.GR51VE/_IA
M=2)D$Z>]BDPA:3-T$YLE>LI>T$;$NVEIRKV\]8 LX9#'%VP4&UU<G$ 1ID:,
M8(.F) N0\GT&7(ZG&LT:E_0N*T]9=HW+:4 O/L\<33F-DG[;;2+5I,'9NR:[
M,=*3:#7Y]&,B'JP 3JR,ZV)8PVX[B6P\J6E3+[>$Y$RL?<C-XZZ=HC6P;9;!
M^P0)$1:-GCM@5\$_;;<#&4!=8Q+I@49)&L02ORB#'=>0ALR7D3(K4T786G7H
MZY7K2''Q<K!#A'5;LZ)@/HS9*T9CQ14494JY8MF7WTQ%A8*6$@-V+:C%4%55
M%B/UZ637GSCXHA<^/,Q)6A!*)YY :D1*'TU[5CED8!O9,:_06-2FZ)1"TW8)
MG!JM&2VO*P/CDC\FQ54Q*F2@=O;*18I4<]')2!3<-R3YWE2$9%U1_P")^GVJ
M:_.JNO:O7R0](J<+@NQY,!$H7-2PO,V4[CPDA!((4YEU+F%Y]"(PA.5>'ESG
M&<Y&'XEA<$' ' ' .7=_=E6=(733M#8J35F-[BF6>,)>G6ABJBQR:O*I\.2V
M[+6'-NRB,]^YQ_9FL--M92T[EQYOP3YA4LGUI/;W2>Q+76Z34B%R(V.W*G2Z
M_"?UK?Q;4^K1!<4S%V)B:5KL*&SK0_!FM>ZCRW$C2;J\-1W7'<*1@-+1H+-W
MHZU5)H2\:N\Z.T7M0:CI=Q4K6MD7;3A2:$C5\^]@-Z84K$+0\,S([^4OP_79
M<=0EI>%\%TLC\[\P7K57=<578UWM<^G1;2/2ZP$G@C,XJP;CB->&#-8:R,@2
M8A,L%C;.&9<S&<<:=;]=QI2T1WLH#2R;;*[F]?-3CPI>X6\@T&L-""[*#FA=
M5LY@++JMH-B:Y4'U%QXEX;$(W Z;CQAD-]UJ5+6I:DH]-IU:!%%LAAC\P[J>
M#J3U^G[!*(HGMP48*NB:%?/DK:2A@/(L+XNH'W*XV+LY2M H;\HQ%ANNR!:&
M'4/H0ZVIO NE^'F9\_OIUI!A+&;L5[0)8K1T^&DM)$6":N:T)/RZV-+"U-"&
MT3Q=C,M,P(DAOS1EE9"(6'5/?NAI9O-7]R=.;KV#6:+JJ18KA!LM'M%V:OD>
MLGAE&CXJ_P!7#DRLMV P-@P2EK;C;,@N2H,5;KX[*%MR4MN8RE(:6EEG5W!D
M< < < < < < < < < < < < < X,7^8_UC"IF,; L9_6Y>)?K%0VA-JJ-FCK
M+?)V[; I$FVU^>R)<&V*EIFZT*NOD83K[$/#'IO92[E"%C6EF->?S*.K]+8G
MQOE!9#%I9"V8\%IS%,M0XY:H-7-V8"\NN-% \5!+!Z=2#F RF_,@O@2][+ES
MSL>L&EE]43M!IO8]@%U&LGRJK:5=GL)JQBIVFOV >Z'39V3J3(LT(@R0Z:^8
MII(7.7(PAN.6C^R*5ZSC25B--%*?[R/J2]@0P/V*_*+6,O;0-<#R*U91$TH6
MJ,F(-?:7@N*AX&1"ITE$'Q'Y7I-N3)&&U>13;WI"Z)%WZ[[#U"^:+?W_ "H!
MBK4^!#NQ$I&(1_>A6 /HILX&*R?9 >)[DS+N03CS3;.''%(4G'AYO''!&L/!
M1^?S)NHF!"S>-@EUP6Z%]8KRFZ)=7%,@<7J;K1;+N4 \M)),W<;(@NM^;+;*
MF5...)9\KBA=$C:DOS >N *269.6&QQXX=V8N>3$T#85B%"(#5*)W\4_9R B
MIOQ:L0LM<KY-P;!EJ1)F.#W&FL*>4VVH-+)Q8^X>BZAIF;OFSFK* H JR%:@
M;R7H=R&V>OV,$1(C3@H_3YH1BR!I ET1(<=]HC-X4TA*F\K]5G#@FEYQYE<6
M?\Q#KH"J]ZL(J5L"VSJ;#LDN#6P6K=B*+WAFK-[$P6)4GVFLLQSU5@3=4GH\
MHTRI0N&N I3SR4N,9=%TLL*R]N]8TS9$W65I%;!'%8X2@&8AB%1;#8ZZ6^7@
M':UK]C'D:W"+9\]5JVG3$\J\\AJ/'80WA*UN+2C(:65Z'_,=ZGG(.2@^Z6AX
M4P$/FR95&LMC/B0GR<9V5)GA3!:+6) V'97XFH+&[$'^JJ3,;&J4RE>'6/5#
M2R.I_,OZWQ[E#!'IUBJ]4/ ];DJ7L(_7RT,'="&P\&7GQX2&F"[.3"I,2!$R
M8GOX:C1WB3+:?/CQ7P-#P="L]HM/.:_JFSI)<^+I]X#W*PU::9I=M$SBU?HE
M4/7@X;:#3@[)=@:[4JY)GPG'6&_;V/3RQAS+K>%"8?@4\Y^87U^42KL(>QM(
MI%L10N+9)QM2W]AIM4.(0^3LV&/G@HANQ#=AV(5("5U\7%FME3#2H[6?'PSD
M72SK6@7RM[,J0JZU*3,DA"V2#+>"0HF"+02 8I-!'0QH&:B02X4X!.C),*;#
ME,M/QI<=QM:<*3G'!E]#\Z:QUCTAV$[2=Y3>Y*8_>"=4V_J2L5MZ?;KQ!8"5
MY?531!]0@8.#V4<,A0UG#4R6O#;*5.2)3BUY5E7Z!O+45@NG_=Q=+OL3B?UW
MV7],^":I#_=Q=+OL3B?UWV7],^!JD/\ =Q=+OL3B?UWV7],^!JD/]W%TN^Q.
M)_7?9?TSX&J0_P!W%TN^Q.)_7?9?TSX&J0_W<72[[$XG]=]E_3/@:I#_ '<7
M2[[$XG]=]E_3/@:I#_=Q=+OL3B?UWV7],^!JD/\ =Q=+OL3B?UWV7],^!JD/
M]W%TN^Q.)_7?9?TSX&J0_P!W%TN^Q.)_7?9?TSX&J0_W<72[[$XG]=]E_3/@
M:I#_ '<72[[$XG]=]E_3/@:I#_=Q=+OL3B?UWV7],^!JD/\ =Q=+OL3B?UWV
M7],^!JD/]W%TN^Q.)_7?9?TSX&J0_P!W%TN^Q.)_7?9?TSX&J0_W<72[[$XG
M]=]E_3/@:I#_ '<72[[$XG]=]E_3/@:I#_=Q=+OL3B?UWV7],^!JD/\ =Q=+
MOL3B?UWV7],^!JD/]W%TN^Q.)_7?9?TSX&J0_P!W%TN^Q.)_7?9?TSX&J0_W
M<72[[$XG]=]E_3/@:I&C_+^K8FDUGLO1*VW-AU.D=P]T5NIAYA@R;; @8\2G
MS&! ^6>($R#0]F7-><0SEW+;:G5>3"<9\.!+KA_8[ZX,C@#@#@&AEU<#.L@2
MWRQK+UEK@JP PI92GL2!XFTR $NP06DH<2RMDI)JX];GG2K.%14>7./T^(%6
MZ\ZVZ0U2:Q8M?Z_&UTVA)=F.2:G&ITB"/-MAF90(9DJ3G(%UF+' 1&X(J-AH
M<,::RB&PPE;F%"MMD2LW3/K'<)DB>?U("E3)FP+!M*?(BD+$(63O=K?J,NR'
M"ON<S P5P:FT$+(D19&'83DD7&>RSZK2%X#4S6S^CO5<C)E3).I!R)4D<*&-
M285CN@U\3'#1*I AOUIT=9(JZH5=@T<4S*G#,Q)LYJ&E$EUU*EX4+JD63=.O
M>G-A#UC+?1X!6,JM5^HM.(GF1D^"!J9V/9ZS'%%1!* 4#S %@B-RXDR*\S,8
M>1A2'<<$RT0"=TJZPD<SUR=504ND' [ZGXEBN0Z2/EA1Z!34\!)'V.+(K),N
M,1B.7E#E19!UGQ217*QG.,BZI&]+=3NNIQTM)):IKKTTW7BU6($67"L(ID(:
MV6]N.='A%()&,0%24[2>R=CRHKK,J&12AV.XUEM'E$RSU!]4M&56Q,6^I5*;
M5;3'&A@[9T';+?&F^ZQ!"D3WHSC;IV1#=?LJ-<AHIN6IK,XU"@ML37GD8\.!
ME^!D675FY#!\L4!=GKK4@\Z8I\=68&N-.%(02,I"$I@QB)RD$#$QI"DY5YY+
M[KF<J\,J\,8X&5]#1_4WOG]K_8/]E.A_N]Y"Y7T'U-[Y_:_V#_93H?[O>!E?
M0?4WOG]K_8/]E.A_N]X&5]!]3>^?VO\ 8/\ 93H?[O>!E?0?4WOG]K_8/]E.
MA_N]X&5]!]3>^?VO]@_V4Z'^[W@97T'U-[Y_:_V#_93H?[O>!E?0?4WOG]K_
M &#_ &4Z'^[W@97T'U-[Y_:_V#_93H?[O>!E?0?4WOG]K_8/]E.A_N]X&5]!
M]3>^?VO]@_V4Z'^[W@97T'U-[Y_:_P!@_P!E.A_N]X&5]#?5?5VX@MA$E3_9
MNZ7$-!DY>(U<CKK3PF$:8RRZWB))) *4.,PV\.K2YYX[[:_%&,>/AG.,TF5]
M#%.=3.O%BF#")76(EPD'(K*#"<0E819.')?L]UN4YIHB*,0IN1I:Q[$-2)T/
M*\Q)^)ZVI#3K*6VT!EHPS_3SK99E>8UJP5)2JJE:4\PR6LP^)-K)DA82TH<1
MA#3<2(35&(VPF]"D2$.R1RR$CV1QGU5^(:F;"@]9-8:VV2SLNK0),0B+UJ_J
MRMCWG$3&@5=,W:;L6Z2UFYK<FU6,[>[G(:GDIA:?.><DL>HC*''Y2WP;;6".
MC>DW5P.;^4@W4HN(?66*F99AL[;LD"DDO$'PI$(Y*78%NG@$2,)BI@BYN7Q@
MW,=M41AA2$YP&IDYC]=-01J3:-9(JGFUI;ZXNK&=?N%C+E5]VR3%G/$GQP]4
M_P XDN8*6R2[*FQG&Y3F6X_@O'L[/D#+\?,KA717JHM@>PO4\9?N@2>$"I"K
M;?E3QK=H/EK182D$GFU9(Q;26-G9KKQI#J2ZDRG6O:?26I&1=4B!G/RYNMQ>
M\TNS0P4^MU"H!G1+^I*T]%$Z^M*T56R4@9,LK#$3!V>H35+;-AL,^VX993E"
MF4LJ5)S)#4\8+[OO631>SJG.H]WU\/,U<E=3FQ)HU!,^*6[<K/$-#K&;P1"E
MAQ1ET\,L<^+,:0\F/)B37F'&U-.*1D3+1&CO37K+90#58+ZG#/!F(#HIEB*4
ML@N2T*E$KT5("VR@LU"*H&%Y>S3^)T?#_HSF"K[$A+K"L-X#4R;6[KUIB^')
MUCM]"%'BQ.HKHA!V;(*9BS:HNOWJJJ$RAC4]H6^G-;V:>@^LIG,C$8F\C#GE
M\N$@FUX$) =->M%8"3Z^&U:/8&E)ZRI+,H[;2A*>5<A7P<LK+.%3\TV^45%V
M<>Q[2J1E[SDG%^;SX;4@-3\3U@],NLHN'6H0W5 H<BI$HA<')@F+3$)M3HLD
MA-=<(&8YULL=9+SBC\@FS/?DLEY"\.S42'$H4D-3)9<>M>D+]0JAK"V4& 3H
ME#8:AU*OM$CPMD,/:KD^H+%M3!!6 2D")M6*2!\N(^\[&F1'E-OH<3GPX";7
M5&E+]2>NIV$/@$M8"5QQ,*$.&9BDK".DP(@UJU-C&XDT:8B36%C';H1D1G$N
M8<CS'6Y+:DR(T9UD,LN*DTFK:YJP>E4H.P"K(%AU@:-8=DR?3]HDOSILJ5-G
M/RB!(D2(2G9,N7)=>E2Y3SCSSBW5K7D3Q. M8;\T5JKM%W[![0W5J36YN=N_
M3Y.$&ONR*;3R\L8OJ)U\C-DHXRPFATUX>Y)C.MI?2WEI3C2TX5E2%8P-M-Q6
M/XZG2OQE]0/VK.MO]N>L/I1P9P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]J
MSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E'
M P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]J
MSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E'
M P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]J
MSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E'
M P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]J
MSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E'
M P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HQ\9?4#]J
MSK;_ &YZP^E' P_HQ\9?4#]JSK;_ &YZP^E' P_HRE^@=GK5T$]K;33K$!MM
M8-]U=WRPUDK!@>? %XN(%)8S)&&!,B6.GL)?:6C*VG%IPM"DYSYDYQ@673'\
MCOK@R. . . . . . . . . . . . . . . . . . . . . . . . . . . .
M . . . . . . . . . . . . 0LUK?7=DGN%;%0J6?*.H::=)&JL#*3W&V48
M;9;<F3H+\A:&D8\J<95G"<?HQP7+-5]3.G_LIUM_46K_ .:^!E_4?4SI_P"R
MG6W]1:O_ )KX&7]1]3.G_LIUM_46K_YKX&7]1]3.G_LIUM_46K_YKX&7]1]3
M.G_LIUM_46K_ .:^!E_4?4SI_P"RG6W]1:O_ )KX&7]1]3.G_LIUM_46K_YK
MX&7]1]3.G_LIUM_46K_YKX&7]1]3.G_LIUM_46K_ .:^!E_4?4SI_P"RG6W]
M1:O_ )KX&7]1]3.G_LIUM_46K_YKX&7]1]3.G_LIUM_46K_YKX&7]1]3.G_L
MIUM_46K_ .:^!E_4?4SI_P"RG6W]1:O_ )KX&7]1]3.G_LIUM_46K_YKX&7]
M1]3.G_LIUM_46K_YKX&7]1]3.G_LIUM_46K_ .:^!E_4?4SI_P"RG6W]1:O_
M )KX&7]1]3.G_LIUM_46K_YKX&7]1]3.G_LIUM_46K_YKX&7]1]3.G_LIUM_
M46K_ .:^!E_4?4SI_P"RG6W]1:O_ )KX&7]1]3.G_LIUM_46K_YKX&7]1]3.
MG_LIUM_46K_YKX&7]29A0(.MP$"JZ&$@!C2W'6AH4=#%P&W'E>=YQ$."RQ'0
MMU>?%6<)\59_3G@AMN . . . 57L3;@76DD7%*U3:EC668E/LNZ[U1?]CQHB
M8CC#:VRDFF #+ I]W+^,M-R%-K=2E64XSA*O 7!7/Q4T_P"S#LU^&#>?T&X&
M!\5-/^S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5
M-/\ LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33
M_LP[-?A@WG]!N!@?%33_ +,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[
M,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_P"S#LU^&#>?T&X&!\5-/^S#
MLU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/\ LP[-
M?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@
MWG]!N!@?%33_ +,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y
M_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_P"S#LU^&#>?T&X&!\5-/^S#LU^&#>?T
M&X&!\5-/^S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/\ LP[-?A@WG]!N
M!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?
M%33_ +,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4
MT_[,.S7X8-Y_0;@8'Q4T_P"S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/
M^S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/\ LP[-?A@WG]!N!@?%33_L
MP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_ +,.
MS7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[,.S7X
M8-Y_0;@8'Q4T_P"S#LU^&#>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/^S#LU^&#
M>?T&X&!\5-/^S#LU^&#>?T&X&!\5-/\ LP[-?A@WG]!N!@?%33_LP[-?A@WG
M]!N!@?%33_LP[-?A@WG]!N!@?%33_LP[-?A@WG]!N!@?%33_ +,.S7X8-Y_0
M;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8'Q4T_[,.S7X8-Y_0;@8
M/&>U5/QC.?JO[-Y\,9SX8ZO[TSG/ACQ\,8Q1O'.>!@Z.&SFR@Z 398FQFB,*
M+.:C$H,H81CMRV&Y"&)XV<TQ-'S6DN82ZP\A#K3F,I6G"L9QP0S> . . . <
MQ;YTY?-OV2A00NP3M"I@A!R=9)E:*3AIE4]49$45B$W"F1$22'JRL/Q7W_59
M@.Q,N>FM:T)R*FE_,H&1US[8$%.3&-N5JJG<CM4I]\L7"_6U#[^JA IYT.X/
M6!IDQH7LBX5^/*-2/;W?^92Y3"XDO+BUNC68GO3.K78$5!V*,L&V&9*;9K>3
M3*J67>[M8RE,ER; ^2>>D9F5X Z=>EQ9"\NSX\@4M7BEG,52DJEN"91'#G3+
ML=%(.OT/M)9A6$&9)\<0,6"X/RH\H6/L\>K!S N+*]VV:MORIXY,Z.\II;4"
M.[&:4YG++K0NI?0M8SUIVBSK]BKT[83@HZ\>O9=XW(ONS6W 96TI'HK-S&S$
MSYY$Z2H3,%UJ,#EJ9"RL35K<\BFD><3*R8['538;="K=;=VR:7;:8SM-5:O<
M>U72%.CE+3 :D4 L^*;FN!Y>:=8F&G'8DUDA!D--+SAKR278V RB'$>G^YQI
MQ\U4=X'7W'V-I+&Q[)>+GF!5C1$DY/U*?3$7$.RK80#LI:BF\N2AGM,5I#36
M5-I4EP74C6C.F6]XL];YCL2?L\*2AZOS(A&V; AOO5(<ZN-6UND8)-,Q\O[C
M'PFR+>%-MR2#CT[#N'<92^ZC4OH2F3U=WK'I5WKE2W Y4#\JZP+12+4U<+H;
M4D6)I5H#P*K98,R#$)YK[ILG$3+8R2(*?B)6\VXQ(:8Q@3*SU*O,=0>YA5)5
MN3VF8E1"J&B3\&(9V&!3@FZ0M-B? L2<3#OL@"&9O$^*A]+6?:AD0:TN&TW#
M;CX%U1^A9NPNMO:&S31<^D;^AZ[B#*" K,*LPIUQ(0(=BJ=2L:!IV>1C/A8M
MCB62VVV5%,,^ZQ[[@J/#D-O>U18S3 F5]#6S^LG9U6JJY3Z[N4363@,N3,E6
MWK?LZR1+<N5KL%KN6-F7&2Z*L@B#9WYMBL<C&(DUD6;EPU1F'7(_M6!<HU<W
MJ)V"*2GUL[A^241L\5L,..+V-M"RXD#E@&(U*UW)][LC,P VMB3#K,,VPI9*
M:W-5+<89?CML.!J1A2^I795\$$'Q-M(&DH-7>#&9;.VK\XP9+?*#)J.;PTQ0
MH&8\J1*PT[.6[[4J7&8]CSA+JFB<8,HLO;V@>RFQ[6*N%,WB_J[#-*K56+56
M&9M+X0A*B6^.7M!3V8?*9;AE" L='Q GMK5,C>9Z,XIQE]Q?!$XKR-27Z^]F
M9]0L]1"WNNU&*;^4$4)(@;8VZ<EU 38QU"]*"/*&@BCL]^I3J,^Q#?7,9Q(8
M.RG4-P<-)BOAE$8D=4.SV3RC0??BZZ D21K#^KV[SLLU6HU1CY.D)5-'6B7F
M#88\G$Q4 >V<2PW,4*D3?%A+B(>&@ROH3F=UCW(2;JQ@AM-;Q&L4:JUB31!=
MUV-7ZC;O=UGN\\^&/W%B21MS F77; +91.9BJGR)H=EQU*(W_->!E$-7U!W]
M/"D($O?<V+8Y!4@D??%VS9!<R)@'@PH983D07 *T^"LD^N"YD</>=>]U>IYT
MD7\^1+1EU+Z$RM6C.R=VUY0JP:MM2@6^LRMG$BEZK>SMG@R#QVQPIK=(+0FA
MU7B.2P8<@<D/2@<IS+:/=T!#,Q367VLB)I,RW^LVW1E*H%7 [<(%"@$%8F#%
MC-W'8(1P99S?NEQ9RO0J[/4\>B.QH4L>B*6E93!21=FM*6[XQEAE$"9ZK]A6
MCHXK]8 WW5"O;=GE5G&V]G3XA&HX&0HP#6[LH]5RS'N[64F,]F 05%5*-XF*
M5(Q!4VCQ%U(M;8V@=L;+V('LOU@2*557#=4/V,4+MUKE3Y(02"&L3-6IKS3<
M:FK"L6N&\8P93Y9TIZ6N.IIME"5+$RDON5[=.L_9JR7*UG&MWM. +%8[L>%A
MX5NO5075!5G$)K$>G0$18-HARVX@("*?BDD(ALCR<@BZL9.0^I#H)HC;O5#M
MB\V*PUV+8&EH1".6^542R;+D2H# F(/?#4B/67I[0 O5G[0);FE'YF?6(194
MJ%AEEM3#K NI'O3NKO9JIN5L@2V/"L)40@\B609V5<'G9!@V;#28%I4/,TYI
M,Y B%&<;>AOS\N+C(RCVB1AST,"-H_37@R. . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M;9EL(D--SA9./$)#9B$.8P['D--/LKQE#B$JQG&!#,X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MSR G)T@Y791N9'P["0;6&6SB0S'DS66E8PE,AWPSG R\9Z>!T;P0< < < Y
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MKBHN8+%/0<DN2@U3BP71XV?"P%!>S(?9EM8EMS,O)=\%8\J1EXST\#H/@@X
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M")<.7$DO0Y*?-&?E1GXSCT=2V'FW%MO,*0XG/@K'!QFZX X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M'^NK_LN?Z6..H]'W);1_B9^4D3ZROJ*^2'H3/;_D-\O_ )2>T^SJ]@]D]_\
M_1?H>U>7UO/^^]/Q\OZ>4CT^62AH?0ZJP$1YLK;>W[F?C68Q:B1.Y3=<8E;
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MTP7GV<IG!BD:6SGS>#L:0VZGQ0M*LB&YX X X X X X X X X X X X X X
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MY6GH]@?&OI.K6+&RV*==6WVT2&V)3\_'K9SG&51@RCY9U/V-,P%FV]TL"+A
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M30&/0:D>SO0UX3B,Q+0[/E#6KI]R0B_RR-)"+6[;H=ZV^J:@,+""H<LS2YD
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M < < < < < < < < < < < < XAZ4?XQW!_^;V[_ /)E%X-2\OY';W!D< <
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MD#KM?JR[)"N#R33;-8/PYSGJIBOJ<$PLX*%+;Z_,9USKA<IK44[8UJ+V)=D
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M@#@#@#@#@#@#@#@#@#@#@#@'$OYCW_L;[*_^G,O_ "D-X-0_4CMK@R. . .
M. . . . . . . . . . . . . . . . . . . . . . . . <0]*/\8[@_\
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M X X!Q#TH_QCN#_\WMW_ .3*+P:EY?R.WN#(X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X!Q+^8]_[&^RO_
M *<R_P#*0W@U#]2.VN#(X X X X X X X X X X X X X X X X X X X X
MX X X X X X X!Q#TH_QCN#_ /-[=_\ DRB\&I>7\CM[@R. . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . <2
M_F/?^QOLK_Z<R_\ *0W@U#]2.VN#(X X X X X X X X X X X X X X X X
M X X X X X X X X X X X!Q#TH_QCN#_P#-[=_^3*+P:EY?R.WN#(X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MH>3'V-[QG=O=O#C-Z[^.47N8JJ;=*G"5D'-8Z*=<)V0?_-7&5D<PBVM(C?\
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MN)41<:^[?"-TEAU4K7ZTYN$-&MO3*2ZEJ\Z!\2. . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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MXNWA^$X>_9^X(=N3NG"VJ3N3BKDJK-U<JMM.&95TN,[(2:S9CHNF^>&?C@X
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M%I[&9(T66*+<;;P3GMHSG$=C#SK+><+>2VC.%9 LA.?'&,_W\8S_ /?' //
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M2DQ]]6&%->GN?*<HMQV?Q*HVT1BVGU<4I.3ZM_\ /JC''5XC%+KG/9WOR/\
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MB?)SY/>I-]@]S>Y/5]J=]X>Q^Q^P>I[=X^M[;Z'Z?6\?-Y_WW[O!#=\ < <
MAMS8..PX.0,XA#DIGHP_B U >4[%4Q(ROU4SX<O"4)=0C'BCRY_??\/ (.J=
MLE0HUF<A426U\E,CUB8+DW/HO0T+L"4?\UD3,/\ M7BAQ2(TG,?Q\4-KQC/A
M4D"2+EVM8N&ZTQ-C37*22D/I=AQ)LEBR-^Z_84O,M8BL/RL)7(SZ*?30OPSC
MRISC&,/,&B>D7]VI#7!B9K1U\S*&//$(L5;K(Z>J7#AV!V,_!&+]F$N.,R,H
M<CM/*:1G"TJS^G-6G5U\"2\#6UZ1LXK)8S8VBH)B4=8(M,PT!EXCUV5&)H<"
MSE^Q25M/#Y(^*M2_-A[.)JL>;.$I\NI:5^DQ%9\37L2]I.C8+[.2?MS#3TDN
MQ,B-Q_.\F6"0B+%CR:Q%1-_YJY,REIIQ*,^7"O:<^&$YF4:THU[1?>")<!UT
M2XL<-"-,%T-QQB)18NA;T19"$UE/G4EU,],G++:F\(S"\N,9PXK&=8AYOJ9:
M><+P,],O<,-,EAZ.Z_&9@Y7F3&:AS"69SXOS06XJL"A\:5&077Y9F/0PXPWX
M81A>,*7S/I.3R-N*GWA<T6EU=C<SYPJ9#<P2RD6ZRLE/39')\N4#"R8RX8M+
M*HWDPWYG<XPG#N,JXDUCI@REYFRN&=C8(S7*JORQ$014:&RXB(MIX@2>)Q)L
MG#4D>[Y<"\*CR5.+DH;0EKR^DYY\\D=.?5X"2;70BV7]LN1FRK^9H]M95B#-
M$QXK,N8AMF#&;DS8B(M>(/-#UDV7L^KCVK+S;R<X0TG'CS;TKP,89,:5+N*#
M$AFS9F+'D(DB0(R\RA2VG8Q4DVIJ;ED0-4.<4)]E4EIU3OJ>.5>9*O%&.-^/
M0Y(^![[ FW..M'R120=F8"$W!D=B!%EBIE@1+@('Q3\F2RK,(:MA3N5K2\QG
MRX5G"LJQA.84QH<BZ.UZUXC.F,S4CX^*W--"8;!5!AV!E4]/N]$>*Q)@0)V4
M9:\[?E7GSIPI:$X5PB-96"&RB&VYJS:/2.B"3-A]F"QQHT4^$E5R*.0B:2R0
MF0Y>,/RBS;BHJ''$NY9RTGT\^+BN:>,81$L-EI7-RTPP;$>H-NSSCST9E,N1
MF$E#+$5"Y4J5+4\TB'A<Q,7T,8PE.,K?\4^&<8SC)HKO)>^R'HRY+5U@-26#
MSY6*.KP:2@7-P^E=3'"GI,)Q<N/*B9SB6XK+S>'$I]9QC"LXYK"R#Z5G&SR_
MN=,Z<3%81 BOGG2$2/$6B6X]%]NBPXSM89:D2$L>JEO#3GH,+\%X>>3^]S&E
MY GC:K1"H*9*5S2EK8%,D'8\QF$F7.G,)9E2A.&X\>+$;7-0VN.C.$X\F7,9
M\?'&,\+&>H\2("4[-D@[;[ZGS8Q>&2@,5Q8\>,CN28K,&$[+DMI?BRF)+,M^
M<MO.%I\4*CYPG./W<V6,]"))'J0E[&9*#(\A,]-7R3M+)$F#@-D+-[%'>0FL
MONQ%#GHV&Y2O#"EL-.94WG.581CQ4E%1P\^)3WK$C815ZII-^^Q7LL.(S;D9
M&"XC,LPF*;D2E86Y&EI7#R[&AH\\1?I?QN4I5YLY\L>,]/ &=L.=L> Y)<I$
M/)!K P<RB*F/#=>:)RS>4/$(ZI2FTO8A#&_*\RO/ERA["T_I;5XECS!ACEWM
M1,C);FV:0#2^'2'9,#!4.4^PX4"L%W)D5 J',0IF.N8IOS>GG+:<*\N?!.<P
M&/826RH]C1%CQB"JK+/$LN%!0Z/))"P\8!&Q&C);]EG.R$33[B5(?0P^ZEE4
MC&4?Q;>>7ICIX@M2KODY($6^:CO12KL)C,]E_#>'42$XRASU,--,M86K*?-G
MRH1C]]_@X_<Y 8MJI=8N\2' M0ILQ!@SFB4>(^_*;C^V,(6AEUYJ,^RF4EKU
M,Y2AWSHPO&%>'FQC. (0R'7K6P"<B94N34;5-AU^<.*DR920".>S2_<Q,7+(
MR92TCB"6&X+\7*DI0OT%MYQX.)43SX M2>/@E(CX\E#BD(,IOTI4*;'9EQ)+
M6<^.6I$:0AUAYO.<?I2I.<< Y^OU3H=;^3H*-6@%5K5G-Q6[F=8BX#C7@@5#
MLIFOF" ]II6<'I4WT$8DNMQU,^LE:\^.&UZCEO[F9>'4KU-!+3MG&S.MC@IN
M17T0S]8C2'BLFAL#[D/GBY3J71\UU*S$>;"DR/8V4^[I#7I)SZ:TY4G3>%A^
M9E+++;E[9*4PB) [#K#K,XQE48.0ISKEF;/RHS\>-(=; ,LM&@K"T26W,>KA
MY"5>9KSJ5A'J9QYKJC?1%QBRL S BDALIN9"F-8>8D-87A"TX5E"\92XE#C;
MC;B<I6A>$K0O&4JQC.,XYDOB0/:L_94"OPUZM&AR)]XHXB7[[@K(PXHN."-D
M,+1#;/UM3DB<8A0X25>T^#6)>7,H5A.?#O;"&RG<_P ^4HTJ/32\-O5%>.F7
M@FY>'7&#['V3M?:&ZY2R/O2[<4\7&E./9FJY2LE=3##FZ-PE&%4[;FNWZNTH
MJ2<NO.*-A=R'""/-I.B-1W+'*AJ0Z7?4IH='F(]W0W9S9):%1)8E:IF2J6\L
ML2T^SYCY5GGL_A^W%'_]JW.A/P\\=7C'BI>G3XM=<GZU+VK\ PVKQ[BY)VK:
M1GE51ZSE!]R:@ZT]4;4JOQG+5.I]U6I(R)5N[/0M82C#>MVKI?IVS)"X%=-!
M086&.J<(+&)#%>[V;Q/]V,ILX_,9B8N;.?2I>)*FVTJ3Z46WX.>^5??[6T5"
MS)2E)N;EA]="SZ'EK3%?\N7Y\5/!?#>X]Y0V$^7EQWMBOAXJ=]-MULY[F=TJ
M[/6]G#N/\>?<G4J:8-)TJ4VGKAI>T=SYJ3"(]/<B8FV8>_"8AAJVE#$&)7ZU
M[_K#,^3>I"H5>:,>\/1,N-29!=6,X;C049;4KLU4>VHZ7*Q/$'G+EXN4M,L*
M'66-.892AYN3R?0;'AO]OFW=$K=^INO9SC.4K=P]4Y7[CL[APCLXZ[W5V->U
MC*N&U33E;N9*26U&6_N6-&SXC] #V$QAZ>H?.+BA,:$2DQ1B4Y>DMB[U 8 0
M0TZ,RN"VAN2LXIQQ/G@Y3AWG'/;^VIS4E=*%73*3;:3?EF#U.2;U>&CITEX'
M2WG!?[?MWO*KZ^4OVFPTPUPJLME.N,K'TB[-G-WSMA*:NDY5K9J,7IW.=!)&
MK5VHG;$!UF=KX= I42PH38+L+C"H*2@P9=!D1)"-#F6L\\T/MU1<EO2(OI^U
MPULX3AS]\C+O ]OP,=G*^%TGNG#TP>7AN#>,J,>L)X2?@\^'CCR)\)\*;;VI
MN>8VW*W6^XI[5NC:62MGV[+-I9+MRE';4ISVNZ54*[-7:M4VW'I)0T91_MK&
M%O@J?4Z^$$"KC*BUJ'#CCF)JJ?6+14IP:%)+R;4N!#"W !.(C<I9@LR!L.#A
M2,^=2?'FKC[?E8K=Q9.5DJDY-YQKE&:DTE'+E"2C+K)J3EUZ'H[*OX,MWD>2
MY[?;K<[^_81EN)RE9*'Y6XV^ZA;.-4=LISMVMT*+TYW3A?;<U):4S<KL_;0Q
M#(931:6S#]H2/'M'*NM$XX$='V9^82)"X^U'$U]^?+B#H>8/M,C+2'EO9<5Y
M\-L<2H]OUR7^6W5C+TRZ1EF.$FZO5A.3U86<8QTR^A'AO@W8;BI/DN0EN-&N
M;IW*<*;E/;J%==DN-7?C",K[>]VZ]3C&M06ESMAY*W]R%*P!#:N%5P0"BQ8S
M4P&,!--ETP1SXV.-%,2+K.0(#EI4MF0EQO&'Q343TU8<QE65]BO;^W/]6V^4
M[)MO$G+IEYR_0LM)-=>DV\]#WMGP/P!%?N?(<U=N]_N9RDXW67-U:YJR5EKC
MM(.VVJ,9UN,GHW,K=:<7A1LJJVWM#/M(QNPZ[JHJJM$1:#;N!Z&BCRRDX?#L
M; R2U?"#2(-11(DO,$E1G,G&6<93&B^/[_I;C;\%#;R=-UDMPT]/7IT3<<KM
MKK/"3CGT-_JD?(<WP7PSM>%NGQ7+;V_FY56.E=QNM*N$YT2LB]E!N>Z<:XSV
MZLBMG*;3NNQZ8B:O/;=S8Y5 ;5L-NGB#!B)7T280;,.X)=+^[AWR@)?+14VN
MQ60(M$UHPPS)]/,U3+D!Q6,--=BK:^WELXNV]_D2BG+#EF'IR]*T8D]3TN#:
M_3E37B_=X[VW\%P]I4RY#FK'S]^WJE>XSMU[7%7<L[%?XBA?)W6.F6UG.O5V
M59#<Q3<Y^2=^[=R0<F! UI$&%9F1+@NQ0P89:A\&(*/3K@U.KI'89".S-C'&
M( P2CUWTD8[BY?\ %^?"65>T]NJU3G>Y5K.8N4NK;BH8DJT\..J4^BTOT]?.
M;/VO\$4\E#<[KF)W;*ONJRB5UJ4YRLIAM7"^&QA)PE3*[<;EZ(.B<8T>O3FR
M?7VX=AQ=HLL6F:[%E0$.=#4 GK$Q)ZI<-=7CR&9[DIS8 !^40+7-QT1*CXAL
M8$C6_>"GG\92ROJ;3;</91"6YNE&YKU++6'K::QVY=%#$T\O5)Z,+Q7S'MC@
M/BG>\+L[O<'+74<I97+OP5LH*,UN91<%%;&Y1A5M%'=5S[L_R;Y?BJNMIV1B
M0BP]K##&Q/?E0A523"UKM*%1XP <">BS[[$4'=HDJ,2(6.7+3E&)<B.A$AMB
M!,6RIWS)0E.5=FRG@*W3VK'8G?4YN3EE5O.M-**7DF\9DLX/=W_%?"6PLXG]
MMW]F]ILYCCI[R5]ERE#92[JWL95PV\8]=,)MPE.ZI24-+DVEI"VR>XD5Z.R$
MTX#GQD!"<A1J>*C0'I#N#R_=TO(:)L*?('$2P:-A3X[U'LQI2TN9<6W^\QR5
M[+VY)-V[F2EJ7I3;_P"7JLNM)I2\)=,KIC/4]'8^T/@.ZN=G(^X-S5<]Q7'L
MPLE-1797<CW9;&$;*ZK9-0OTP5E:<%&,O46=K"V[WE7&:-V5K1(FIS(<V<-*
M0O=DP@,+.VJ0V.@F9;%FGQI,5L&[YD9B-.^SMQTX6K]\VI[H[[;\5';J>ROU
M;A-)IY2:T]7%:4T]7UQG/\\?&^\^#^-*> KWGM#F'?SE=D(65S[D(65+;1=D
MZHO;PE&3N6&K)1[DIMQ72<:^BR 4254/62'0YRA1*.9'>U,(>Q$*Q&G6(I!E
M*\93B7%;>5Z2_#*FU>"D^"L8SCQX6V5Y4)-:HX>/-/Q7\GYGY/M>1WVQC;'9
MVV5*^F55FEM:JY-.4'C_ )9-+4O"2RGE-IY^&FL>&<-MXSC+BL9PA/Z,NJRI
MW./T?HRXK/BK^_G]WF,LZNN;\6_+S^G1?V\OH>5-MKSC*VT*SC]S*DI5G'AA
M2?T9SC/_ .2M6/\ BSG^_P F6%.<>D6TOY_Q]%_89;;5_A(1GP5A>/%.,^"T
MXQA*_P!./\+&,>&,_N^'+EA2DO!OPQ_3Z'E*4IQG"4I3C*E*SA.,8QE2E94I
M6<8_=4I6?'.?[N>0CDWU;;>,'C#3:<XREM&,X]3PSA"<9QZJ\..^&<8_1ZCF
M,*5_?SCQSRY97.;Z-O'3S^BPO[+HOHCY2HL>;&DQ)327H\MAZ+):5XXPZP^V
MIIYM2DY2K&%MJSC]&<9XC)QDI1_4GE&Z;K=O;"^F3C;7)2B_I*+RG].C/C"&
M#1L&(,'P(<(=!A1AL*#%CM,1(H^$UAB)"CL-H2VU%C,IPEMO&,)0G'AC'-2L
MG.;G-MS;;;;ZMOQ?\V<FYWF[WFYGO-U;99N[;)63G*3<I3F\RG*3>7*3ZRD^
MK?B9W,'6' ' ' .&.[07OI9P=+K?28OHNJ-$R!5.V[;M*T6:M7L?74-PDBQN
MGYH[6&UJN*/EG%R$RBI85.P/;0C,>*X\O#K(U''F?EWK'JC^8SH_N+6=V:QZ
ML=*(SDKKYLW7U_V39NV^^+[8[Z6MVT-/6M1;9VSK5H1_:5LOZ&::\H4PN#("
M,0E26TR('EC1G!I^&&S^B/S/^R^;R->T^CX^GYE>CZ_D_P #S>'F]+U/T>/A
MX^'!CIG'D9'!!P!P"!7J%:Y;0S%5EN1'5/R(Q%Q#S3.&(:V,S&IB?5QG#CR9
MD!N-C&/TX;EK5_<X6/,$!R*VG,]J5.?D1XTL,S';CCCN(LT>;;5'+.36W&&6
MV_9,R)TH?CP?5YV(\?.6_P!&59O3^H-A,$79\N>C1)1EF&^2"H$S7B,K$)D,
MTL![P2IQBR,2L27&V)6%>2*U(5E2L^MGS_IF01J4%W:MEJ%#*+PJ0^"<?(R"
M4)E41,4=##F6VO(S)>5&D+EO3T9]-Q?KQ$XSX^?].HN*_41Y:Z&TR(VV[GVQ
M)+$*7B.P-S'S*<FP\R8PR"PX6S'7,8B/09)*.Z_Y$ML2EX=\JEI3XXY6X^1$
MFBV*S@DD-':-,R,$XWJ,S)#TAF4F<_A:E.38CC*O%,.0I>5,MK0VII&<(RG'
MEY@T5&>&;04[(5[47E1' -N;$LUN?$#S(5CDF,KJLDM(F%<-D(T45^A2DH2R
MW^XXTY^CRWIC[@D,9%QF6$=-Q$L(Z*E0;VMJ=/&X$X@,0R+9UE\;%)3$NSIL
MM;*F5H1YL9\,Y6E*5)Y ?,Z&M;1 G(@R+/+@2ITM3$0<?2T^TI8&%[L?C^V3
M([,4='.JDY=;2K&58RWG*5M)\O -K-5;DK:B(:F2G9 .LH>(PGA[8Z,9B$WW
M+$\XF1*CR6TS(2D)1EMI:5)QX8\,XX!I2$#8CUI6^.E2(T-) PI<J4[[6 <"
MN _3"0V1#1<<[B>R5QXN*RUY\.9\_J*:SY.58\P2.L S<:I/PS<XPZ7E^W9<
M><-RI,UO+BG$Q$Q)J'EJBX2WA&<>GG&,9\<YQX^/#\>@\#0!15TA% Z94@Y(
M1'='*FRI9IN6)4(^3F&RH^3&<EJE23J[.M3B'LM*\&LI\KN&T^GR T9H5L_,
MZ3EB07>@Q630T5@<02VN:M;C<X*9GX;-A5-O>68J&KU,OI3B)YU-9\^.7IC[
M@V T#L9 ^P#"!AY3SMDKR@T_VZ6M+()# YPXAMWWBDSAOUL/I7A<G#J\YSEO
M.$>5.'0$U!@C\55ACD3T^5&6VB$ ?<<PIV+'>B>TR)BG5N//OS&"4MQII;RL
MKQ'8:3GS*PI:H"N( G<#A,;(,2U)$*:RHO BFFXTG"SB<0)D:&N+'QGPJ[<!
MN6PYZS2E+ENX3Y\XPG&EIQU\0;-0F\1EP&6I!V2INCL1</Y*KD-MVU<0M[5(
MG/.G8R7%)F/1_!:XTMO&$XPCRX3^B9Z_8&@(!MSQ8\^.)*.3%/0)T2*XX3;:
M;:>RXV5@S8KQ%^;/0XXJ*J K+SCF4XE^I_@MIQCDS4_)X!L4!ML^G 3**Y5*
M$Y7AZ3$(N90;3*,CYOG0GQ'L8<AC7I,;.)49:$H:\48\V4KY&Z_+(+"I2+''
MA.0[9ZDPNE:'5DVUL^[9*%L1\-LPHOK+?A*B^7+;J5^;U'D+=PM6',<XP3K"
M<8_3C'Z?#P\?^#Q\?_P\ \>5.<^/A^G_ /3P!A"<?W/[OC^[G/\ ^'/ /&6T
M9\?''[O[OZ<__CX![8QC'Z,8QC_BX!YX!66X,N)U^8S%PCWE[;7L!%+=4RAJ
MP+L@A !]QQM#CJ66"ZF5N80E2U-85A.,YSX<0]+R_J"RF_4\B/5\F'/*GU,-
MY5E&%^7'GPC*L84I.%>/AG.,9\/[G (_9["#K0MR>>?;:B/.-PFF%->T/$Y<
MG"\1QD.&G"ES)<KR*PEO&,_O<9RKP3A6<5$EX'.U<NNE0!:1L11"51_>P]P.
MZ*R^B53Y+KRDF<R8"ZX@H =//MCW/XJ/)]3*VG_!K*\K6K34GXF%)(KZN4R_
MWC:<Z>1(F4BVRT0K8[3DID40&P5#Y!.JU"K!XLA$VL^H'-^67C#LK#K$GU7/
M2E>&$5M*."XU//D=L!0@JNC8XD-":'CXOJY9BLY6I*5OO.2)#BG'5+=>>D2'
M5..+7E2UK5E2LYSG.><9LH/M-L;:NK]9MV73M7C6^WY/LPL!Y@0Z>BN0,@S\
M];C\6N*238;5.'QVO53A6,9<\OAYE)SCVN!V6PWV^['(V.O;Z,Y4HQ>=45XR
MZ>#;Q]C]<^%?:?LGWG[Q?#^_M[/8<#^*Y]V%U-,E/O4P2C*__&WHG.6EXSIS
MG"94MR[.;4UO-HM$E:J1L6^F=%P-L')M>DEQ4%GW"TD)LN4_6XH*QV(;$!6^
MP5Y46(VU*FS8!";Z#;D@<IE[T-MP>PWL;=U'<=G:1W3JBI)-^KU5+4Y1BW*$
M;,O*C&48Y:4\K[KV_P##GLGW=M^2]RT<V^)]L;?W+/C*87QJLF^\^]Q\8[B5
MU%%DKMK1OE99*5=-5]&W[DXU;I65[?6/:/8%XN4"H&]"6ZMKDU>R6?)1<2U)
M&38 8'7)8.6+(G*>!&I:NYDE.8'QIK\,FTS#PN3%9<RXTUQ[[@MGM=L]Q5NZ
MYI3C'&8Y3E*2DFHSD_0E%R<4XMOTR:PWT/>/PQ[6]M^W[>>X[W/L-Y&&]V^W
M[:EMNY"=MU\;HV5T[JZQO9U5TSOLIA;MY3M<:;K(*$YUIJ;M]O.X6<$*M/7T
MI &6V_#!$.5"$[+&X U\A6M8NE87M%BUZ/8*&M?&;.7E'99'W$/<B"WF!JYS
M[6?-W>0]N\5MZ)6;?>1<ZZFVFZWJDI6X?IL>(V*,%!1URS).>E,^O]\_ WQM
MP/#;G>\+[IIMWFQXRRV<9V\?9WKX;CD57/31OIRKJWU6WVM>SJH_,OC;N*[-
MY';5SZ;RV=N-U5@U<(".L9\P-#VHT+K)8;+NDILX(!V?;5;BIG,P=;SEC[#>
M9.M8*0J&/:QOC98+DN6PSX+=XJ/;W&7U5S_.A&<H1<DU!:7*-,GC-BS&"MEK
MSB7^.2C%OP\W@_@KX\YGC]ANI>\=KM]Y?LJ;-Q59':1=-MVWXS<2T.>_@IT;
M./(7/=N?;O\ _C]S"BBRS,:_C/[+]A0P+2)R9IB08DV[;NUZ-M4+7JW<//0Z
MG6+<8 56U2ER8LB>RU@?%BO/+:8EL$5OX<CK1$RM]JPX3B++=U5'<J,:]O5.
MJ4I0]<I04I1\4O'*75..,-.71\FU^'_BK?\ )>X^-V_N&%%6QX+C=YQMU^XV
MN-[N=QM:K]SMHJ,HP;URLA!2G5.A0<+8ROTUSKHAW^W0%J,6VV'J/9*U Q0K
M[=B\D[:9T,>(75F"#L0'+?137Y;1B%*A-Q2D53&)*%R4.1&Y*?WF>W7[3XVW
M</;T\A"<^[""TQ3;U-+4O7C#3;B\XZ-2<?$^LVO^U[X]Y#GI\%Q7OK:;S<_N
M>RVE4:=M"=EJW,JU*Z,7NE%U3C.5FWL4^VU7*%\J7ZE==A['[G9K&F;!6M)S
M"!789BV #(22BWQ@HKW?L2N42M7"87<I.+*$J!\25=L<?VT1'FY%IQAQI"TN
M93YU/"\8[MS5?NDH4QA*,EHU/-<K)02UZ93BTJWB;6KP?@?G?%?$GQ[9S/N#
MB^7]Q5U;+BJ-M=5=%[65UFO8W[W<;6-2WGX]VZHMJCL)]G=65+<O,)RBXJ6:
M9[0;*&A=8%HV@+++F7?2I39Y2MYQ<'##5O@5Y15.HP2Q=!+16[6F6GP<<.9"
MMJCJQEE+K_F81BO@]E.V^N6[@HU;I5*7HQH<L=V6;$]&/#1KZ^.%U.OQ_P ,
M^T-WR/,[&[W1LX;?CO<5?'5[C_I54]K._MOD[E9O:I/;./Z8[/\ +DII]QPK
MTV2J$YW&['NA3$BK]:ELJACE('64HULTB'*36GK[-59AM<9UV$L4JCRZY0LN
MLY?5$*8DEH:,Q5)RE3WHT^W.&[D%N-[XOK%=M-+%:TN3L<5-2LP\9CB$O5]/
MO.,^ ?B2'(;>KF?=ZDK+<V;>M\?7;7!K90_'LO>^NHCO(W[W3+0K=LZ]M?)7
M)IJO+^-#=AQBXPJWUS+C" R7LV#3S=J$;9;"VR;5JK7S%0%PP\+6*#K1VP$S
MDAMQJ;D= ],/*2B=AW/@SA^VN,JE5*[>1E"2J<XQ=6J"E*2FVW9ITQ45U6J7
MKCZ<>/7_ /\ GOXZXZSC]QR_NRB[:W0X^>ZIVUO&.W;0W.YOJW5D[9\@Z731
M73"495=^[5NJ7+;N"S.=W_M'NBEE=)@@/7"Q;*SM:E4DT5MU;S8AU7I=@LLF
M, )0S\>=6)),0/%V2PAGE8EY9E-"'ITEUM'N]Q*^MM."XS<U[JVW>PH_'MG%
M0EI<IQBG).+4DFW&,UTRG-1BGZUCYKVO\+_'ON'9>XN3Y/W;M.'_ &3D=W35
MM=QV+-QNZ-O&5]<Z)0W$:[9V;>C=13JUURW4-M3"4ORH.-<:M[4=HS]MIL2X
MZ2C-5<L1 BK$W'KNPP%B P;>]H6""L3[Y.ORPLN2+>V29EDHJ%1X[<(2_P#Q
MS3L9Q"NYO^!X*G;V2VVZ??BI./JKE&3AWW*/22:3[<%%]6W-=&I(^M]Z?"GP
MQQ?!<A?P'N.;YJBJZRAROV-U%T]JN:G=0HUWQNC&Q;#:5;>QJ<Y6[FO_ !SA
M="2RS':WLW5;[LF))Z^.7VH5$U<PH<73A%[%VLG@;.V9*I$R'-*@)]?.*L *
MI#,S%,.MQF/>K+C*W5N8C8S7P'![C:42CO.UN+(PDW-P<%E5*::4E*.F4Y8R
MLO2TTDM1P;#X1^'.:]L<1?3[J7&<]OMOM+;;-U;LK-M7W(<?'>0G"J^%]/8N
MW.X52G&5D_QK(61A&/><RNG:/<]?U=K39 O0Y$F6L]-O]@LM)C234YH3+KEB
MJ0<#A1R!5Y,F-@X),2B<:,_$8=<0UZ"UHRAQU/5VW!\;=O+]I9NHQA"RN,9M
M)9U1G*7I<EG2THMIO&<XZI'S_M[X8^/N4]Y\Q[2WON:JG8[+D-E1M]W*-,'9
M&^C=6W?X9[B,9=FVJO;V60LG&+EW(QDI1@XO,[O[2@2;2B5U<V S&$RA; 5Y
M(J_R%$5'=;VFVA(<]IC72I TO+LP&,)D,*:\L!1!I;R_#+>7NQ#VQL9J&G?4
MYEG/6OIILA"37^3JE&3DGGU:7CSQ[6W_ -N/LO<U;*5/O3BY77PL=J[FRCH[
M._VVVNG!RW^FRJ.WNLW,)J6;E1.-<<J?;M#2W8_<&U+XQ6C_ %])ZUK[<_:^
M"1VQERKDR/!H4RDC ,%$%%78'MV*R3;>ZYEIZ8W&S$'/.QG9./'".CR7#<=L
M-H[ZMVKKL58C%+#=BFY/.O.F*@NJCG,DI*/G\9\A_$GL+V5[9ES'&>Z:>7Y5
MU<;VZ:*JE"4][#=V73<WN93=&WAM8K5"J5BMOKA="GHY>=*]D-M;5NXJN&M"
M%* !<$7$V=L9R3;&$CG04/7RH%*AQS-% ,S+I#,7A^"3RIYL9Z@:4N!)FHPK
MTG)<-Q^PVLKZMW&ZW5",8Q4.N79F;Q.6(-04H]-7KBIJ/F^0_B3V-[)]MW\O
MQ_N>GE.35^UIIV],=M+6KI[Y3W<Y5;RYPVDZMG"[;XC+<:=U3'<T[>6-=2ZZ
M[B[ZLEIB0;#UO/PPUCV!6P ]$<3L.#)K0HF%U2D^%G$#%"B0C%LIA2[F)I22
M]@4"3"K4YF)-E.I2OG?WGMSBJ:'*G>P=L*I2?6MJ33MTM*,VU":KA&*6J>;8
MN48KH?<>Z_@+XQXGA9[GBO=VULY#:<7N+['*W8SCN+*[>2=%T(5;V4ZMMNZ]
MGM:=O7![G>.WD-M9?MZ8-Q);=>V>Y*F?OPUCK<9*A:_8# NKV./(O,J,6@5Z
M87ANS#4,+K0S-A.V^; BP@F("23*Y)%ER2XQ'PMW'!MO;_&[BFF;WL(V3A%R
MCZ,IRTO";LBGH3<IZM+Q%I)OH>'[=^#?C_G.+XO=V>[MO1R&ZVM5FXHE'9QE
M5.^-4E"F=O(50FMK"=EN[[[V\U719"F%EKC!_$OV/[%CM<UZ[Q=-1B5B;W#N
MX%;M>(%W:$3BZWU]7=H6"I(;()"EO1N%A9K(=IB4RQ*#DI<]#;#C>'T^E:^&
MX>>\GMI;G33^/1*%F8-.RR549],KT1U3;3:G%1;:>.N]A\2_$^[]V[KVY=[@
MG3Q+X#B+MKOG9LYURW^^OXZC<MP[M6=K0]QNI3KE.O=;>JF4K(2=;UZJ)W.W
M.0E&D">IM^.1(UXN53!.QD6H/*)1ZG5QU\:G$H5DHXMX/@W7(IH=$<SZL=^R
MP8T!*_&8A2.1^VN-C&+LY"F,G5"<OTM+7)UX3C-ZM,G"37BJY2GCT]>]?_M\
M^/=K3MI;[WSQ>VNGQNTW-RD]M;&N6YW%FR<*YT;RQ6]F^6TOMBM,X<?=;NG'
M&WDI2LKVQV6(TOI_9;_7ZQRK/L:[-UXS11>;27>KX!LU+'R+ HB+I<Q0]Y\4
MPF<RP48@(\N'&LN94CS9ZU? ;*WDMQLENX*FFK4IO2M4M*>G#FLX?I;BY>3Q
MUP>)L?@[V?O_ )"Y[VA7[IVD.&XGCG?5O+/QJE?>Z8SC1V[-W#6E8W3*>WG<
M\Z9J"4L+5Z_[>[5L5RU;1+CH%=..;5+(C"?/932VAHN!KZ@[4M)(FP9I8&<V
MFO56Y2!ZE8;S'<L8U<'+J%.)RGEWGMW84[:_=;;=]RK;QR_2NK=EE44M,Y+U
M2@I>.57)2P\'=]T? _LGBO;_ #7N7@/="Y#C>$H<K<;>E.RR>^WO&[:NMU;N
MZ#[^YVM=Z3EKCL-Q'<Z)*+3_ $ Y\B?RX. . . ?GUV[H^\-I;XZGZWHVQ][
M:GTH;B;],;TN6C" BM$&YE<K5*=U:%L5S)UBROUX>8+3B6&D1?99$I;:L)=Q
MZ?AP:1^03>UM[-=10_5Z8(_-(S^9MK:\W$Y2;)'KNX2]..[=FVFP1J@8M?8"
M4.=Z_7SJ&D00C9D131-V.FOH4E49)-",8!I_T/Z:/,8^3OCYAGR@]S^'F_CO
M<WOKV+P\?Y?W9[?_ /U^E_P\&3=< < < < >'A^YP!P!X< < 8QC'[F/#_BX
M X X X!X\,?N^&/'@'GPQ_>_^O\ ZQP!X< >' ' /'AC^]C@'G@'CPQX>'AC
MP_O>'Z/_ +< \\ < < >'_U__#_\' ' ' ' ' ' ' *ZV8O$4*(,/(6X.KUM
MK)PPE#;CN6Q4,DVB5-4VSA3BFQ&7TS%^&,^"(^<^'Z. 3@<2'%X3!$5/ADQ\
MI'GC3H$EF7%D(QG*<J:D,+6TYC"DYQGPS^C.,XX\/$'Q+!A1V&J 8'PR4-2L
M+S'FQFI+:7$I6A+S:74JPV^VE>?*M/@I.<^.,XY4\ Y\%=?*)4X$V46.D'1,
M=;$TTPK,,:#FAP#$/W4P:@):>94X.9'K4_+8S'>EYD2,.9RAY2.:U#"+-U-#
MEM4H>2*Q5Q3EED3[,;]9*D/.SB\IUYE:FE_OH[30W$=EEG/AEB.VAO/Z4YYF
M7B"R>0%!]E&]\OZK*,=;EC6-HOS8C8N:5F@8<4?&].2MR6MNR CPD@TF6AA#
M\=:&7%QENJ:>2ZE"5^MPKXI;^+YG4]BD\I*3;\.GIE%KIG#Z]<96#]/^(9_&
M5?O6FWY<5TO9D:Y.R%<+I2G+,4HI[>ZFV#TN;A-.<58H*<'"4G'DZQ:W[M'C
MT.PYL.!9QDG;@Q1\ =U^&K\VL3[",*4;(Q,.H,71P-50#$EMR,2)R)?OV6\Z
MWE<):L*^@HWOMBJJ5.C54U!K5&R4E)1:GG,]&9RQUC%+0DGZD?N'$^[O]NG%
M\99Q7XG>XV5.UMK5].^MOAN(465[SN:MT]HK=S?*N4;-OMZZ_P .JN$M.XBF
ML0[1._3L\)93FTDCF*Z_8EF&]<M!Y;4D6"@7NLU<NNCOU@ABWOV##0>U$Q3+
M*9>9$QT9#7G$6.G.JMW[24)T549<U'3W-2PY.$I+7J6C3ZZHR;QA*<OU-G/Q
MGN7_ &P0VNXX?C>%=MN[C0JGOW;%QLNGL]QN:EO([B'XL:,[KC=ON9R=7;JA
MO-Q%=ZUJQ9 WN?=-<:"L,(S#H6P#CDRP;B%I4#:51!%TLU9)M5 8**B)X.P%
M]=T>20&M/SHLA3LZ+A]?F<<\>=.,_;6VWF[IG%V[2&(TOU>MPC):VTU**LFH
MRQ%K$7CP1\I5O/\ ;W[>]V>Z.*W&WLY/VOME"CBK/\S6\MVFWW%;W5EE=L+J
M*M]O(T;B4*;*U&FQUQQ&.#UMTGNPU#T75:H3!XO1S4]I>V_89]:@2J-7]AU$
M"/G5\ADQ&#8@X1?[=*P+DPF,I6U!6[+B,)]G7G#;Q]L.6ZOW$9_BQW$>S%2:
MG*N<FI+#>?\ '!:E)^,L1D^J+P5/^W:=_N7F^;IW+]M;;G-LN+HAN)QWE^QW
M5TX7U]J5NO.RVL?R*[IY4KE"B^U]V*<+E1OS%"(V,Q6[#44P#4-,X5:9<[61
M$X#$Y?VLW$CG4P:ABL6"USAY:HRLRQL9(?S#GTI;\''/:.S&7LZ$F[X6=R/1
MQ2L2E+%6=.9ZHQ35RQ)Z_4NO18^AHN_VH;7=SMY?:;][K;V:+-M&'(5TW6Z>
M-<I4Z]U^11MH65<G7VMQ8]UB^IN>81[5C[T"]QR.P(@S4LBO2]0IHD&#8LV"
M10)1NP&\$U/&WQ8X[3'HPRX.!XOHP7)F9==5(DH6_$;0VOG2XNSVY#9N?(*:
MY'NMQT]Q**QZ<M3ZPR\RQBS"Z2>4?)?&O(? .T]K3WGOF.[A[\?)SG1V([V-
M-%/;Q2K+*=VI6;56RU71J56^5=<HU7RE*)$;,CO/$9*-#K,%&D"E@#0ZC@L:
MU*U'E07=>F'!HJ(VY1&Y$NR1;^PQ+MWF\[4X-'E8 -Q'/)A'8I_[6DXN4)RA
M&#<\*WQ[BRWZ^D77E5><9N/=<CW>'E_MMOLIGNMGN+MK3M;9[KM4\FY1FM]4
MK+)-;QQCMY;*4ZN,QB5.[G2^3G?'5J]9@G\Q B1GMM62F (8<I/5!E0$T:;'
MMS,4_>Y@SS1R56ES@H F"G (CK:E()-YA/*P\E:U.N6-GLZ$$W"V<I164]:<
M,QK3\)).2DK&O^7U+IA85V^^_P!J6UVE4Y[/D-UN+Z8:XS_,A+:N5&SA9ZJ]
MS&%M]=T-[;&23V\E;6G7*,5"/TF:N[@1ZAH"2,V+9W[EKFF;#@;,:E7.LK7>
M["3MM$@"R3GKUA58/G/JZ9L:P#I2)D>-)O0G)S#BDN*Q%OO;KW&\4Z8+;765
MNK$)>B*A-M?JU17<[?<47JE%246NABCWG\"V\][HJW?$[./M_EN0V,^/<=IN
M$MG17M=Y.RM8W'Y%%/Y[V"WL=M:K]QMX;B.VMBG!$JAT[N,3U!=V+E?&D[3D
MW334VI,T:74 ,.%2ZPYJXMLF!$+/53R^_+?)CV6+*]NP[$<QEI,9,6,YX<X)
M;GVW#D:GMJO^@55RGK4Y-SEW56VM?Z8+MM:<-==6J2/%W'/_  %L_?G'6>W^
M,D_94./Y6&Z>\CNKISW>X7(U;"<JEN?]':QEQ]E?9TVQQ.5SONCDK[6]<[X4
M@_I,'?=I5(AKZ,4#C[Q-L*JH;NEA=?HU!>G5SWL^T ED8S=HBV=J#*CKDFW%
M>S/2?:F<+PGM[V[VKNJMS;M*+%NVI."CJC"*UV8ECU)>EU.2>(?J2TL^I]W<
MM_MF]Q\7[BY+VQPN^J]TSIMGLX4?DT[2A1WF]4+^TG=&N3V\N/E=7-5[2*[U
M=/9L<<ZLK2>^2[%=9&N-I1,@W;9M%P23+'J-:/+&3;=QEZ56XHPA69@X.,$I
M(U@5-;<9P3CXA2F?:/30WG')7NO:BIJCO:'W>W5E*,X_\E*G)M23;>+91>=+
MS%XRV=W9>XO]LL>)XZKW;PL_W*.QXY6UU4[S;^I[;BJMWN)65[B%EMEO;Y'<
MTRC-[>SNTV=K7*:=@45[N>"/;#F;.NU+.5(-KFQB*5""":G(.$]E-OH53G#3
M@[ J0W<B,+RNO0&(.1<IN='2RVRZE:5]/=+VW;53'8U6POE=%S<G)15?77IS
MGT)]%)O4M+RVCY;W)7_M\Y+C.*H]G<=R.VYS<<M1;NYW6[F--?'M/\I4JSN1
M>TKGF,+YW?D5RIM<Y60<91JH,/\ S.S=;KD]-LJE?44H!62N)80.OI-U&VZ>
M!9]E;N&8H836Q\F&??R^+2/@2&F(K7LY1EY[.7>=^R?LBJ^<'79-1M2S&5B@
MXJ7_ "9;DTX]):I)MO,&ET/MN0W7^S?CN7W>U>QWVZC3RE<5*B[?1VEFUA<]
M3VNJVW<3C.A:-R[[ZY3LEW=E976E EQ 5WK&2[.JJWVG3*LLU?/DN7,&*;,5
M*$S;OL)@+!EO3JU(4QM&<S,KC(;R+15Q^6Y<:9 6O#2<]>%GM6Q5]^FU7Z(:
MU%36&H5Y:Q+K4L6.?_Y9>F49XR>%M=[_ +:MY1LX\WQ?(5\TMOLOR:JJMW#3
M;#9[%VSBH;B.>.@X[^6[RGR-^JB[;[F,=<C:.@^[U1UEH]  VDU9 3FT9VZX
MM@)5JSF3,"<6(E*.ELVL+(?(F XIW#3<,3$9CR9/IQ_-&CI2XCC[OMC<;[<N
MV.FB?:5+BI146HI3].5A.75N3;2R^KZ/I0Y+_;ESOO'W'+D]L]OQ&Y7'0XB5
M%>XV]54X55U[S-*MBH56VK5*W<VSG77JMQ;:Y1E!ZO"_,U)BPQ279J<+BS]=
MDYK(BRA:.Y<6+=* NK1"N,H4(#@Q)5!UU#@14 ?)A18Z,,%V'G/4<SVKY>R(
M62KC"V35R3<93T:%)=8)MR:TY4]4DV^M;71'T?,[C_9WL][N-E1L^0NNJY6N
M#MV]N\6U>UC<EKVL;;;;K:W2G'=JZ^NVR;=FPLKAI@L,K2.YM@N-<V'7=KIB
M!'U0/D2$L.SJ^]5K#+("](JQ(MXN@"@]>MDS#=;MCV6!2$0<I6IR,QYI#CBM
MU[KVU3MI[.[;YM2>MQJEKBD[OT.QN4%ZJEF3SY2?1)=G9>X_]OO%\!N_:G+<
M([.1BI_F74<=>MS1&%G+K3M;-[9;?MH9W'&0U[EN[*4;;,51C&P]5U7O6]L;
M29+<]NA3Z<!]ZDK[&KTFG5R'+=E53;H? RT!0,*5+M))@X7K#\!R%,CB4QXK
MKS\1$U"59Z>^W'M5;+<PXVMK<SPH.2G)K$J7F#DTH+2K5)-.>6DI.+/D_>O-
M_P"VJOVG[BVGQ]L;*N?W7:KV4KX[J^45'<\7;W-M;=.,=M6Z:N1A=&VJS<N=
MD*Z[Y;>31#=9M]XZU8=?TBP6W%@$SMGR:W=9DK-=O9*ETP;'1L<Y8BEP'UQI
ML5@N'ACZX#%F773"L6=Z9E3K<**IKL[U^UKZ;MU57HL5&J"6J"G-_P".,5!R
MZX;E9.4$H?XE'HY2S]#[PE_MOY?BN4]Q\7L/Q=]7PT=QM(Q[^SKW>[LD]A31
M7M9WMV=JV=^_WFXVL8[5?M]>W2A+<7*<PO%=[Y/[)N)>M'X,J@A;F3*ZU"PC
M]'JSY((1U7LL+##6%N53;'D@'#7N< F^K.=5)<>0O.(_D9PMSK;6[VHME77?
M%K=RK2L;C.235M3;CB<<-P5BQ%)8QZNN#P/;G*_[9JO:&PV/+[6R'N?<<?77
MR%LZ-YN8UW5\EQ]L[:''=4:+;=G#>U::8J"@XIVZK'&,7H=0_,:@6:JD;3>P
M;PPM=JA-V*S,^1)V-$J(P?"%D1==#1(%?8#^\F!TN07<AOJ>7/GQ7H2?(U*8
MSS[K<>S9T3A15/N1JFJ\:XMS;;3DVY9PVE!-8TQDI>,6>S[FY[_:9N>'WNTX
M7C-S'>4<=NH;%Q_+IE+=63G979?;*=[M[;LJAM8VP4%33=7N'JG3895RJ?>A
MO9=KL&HRM(G5IRP[4)5LK9SM7L'_ $<NL_\ 9G7W_2=;G62HAY6PZL/C2T#Y
MV8[#$F8ZY'Q(894N;;<>UGLJZN0C:KM%2DHQE'KJ]5G22C.2KE)K5'+:BD\-
MXX?;_.?[;)^T-CQ?OJCD:N76TXVO<5[>G<4?Y/R/^HWW^/<0HW5L=CN;[*I7
MTJ<YUT0A:ZK)J/2O6U?9 >!GU[LNX(L%TCNNSX]SJD</ J<L4U,?KHL<Q!@Q
MX,QLZ3B@/?\ -0IE3,11E,5MS*6$XQXG-?LL[E=PFJ&V:QHGES3QJ;R\K2G+
MMQZY>C4UU/R'Y=C\2;KDZN5^'U?M?;THJ$MIN96SW,;7%7V6.<Y3BZ:Y7?A4
MM24[5M'?."=C;Z8YXA^/#@#@'YM]XM[[?IFV.JO7G5VTZ'UQ1V7.[$"RNP^Q
MJ"O8T,59JA"JJZ9IR@UJ>;KU.?VQMN58I+HM9J2N/F&$F(CQ)<E;:$#2/Q\I
M_>GLW2NO5I[&V'\U#2E^W/3[9<PJ_P O/:FC=+5S:5BL]3V 3J(OKU+@:T*U
M?<P?=%UCP&F8<B"(D0&B4]E:8TF GVEPQ)KR/ZCO;97R?]Y>Z9?MONGV_P!Q
M>HS[=[7[)[3[I];S^S^V>O\ Q/F\WD\_Z?W.#)N> . . . . . . . . . .
M . . . . . . . . . . . . . . . . . . . >,XQG]W_Z_P#Q\ K4MJ:G
M%9$Z6VT<!RB+OM4UVK6FQU=$F=A&48(/1 A.% =GY3G.%.J:RIS_ /+\WACP
MWKEAQ\F"-^GN<.^,J;,P&;ARU*PC94D4I4@1%APG'?8SU2;+Q/;R)"0TAMN<
MQ+2SG*U9<90K"?-GHEE@P[+J^YE:Z?95L I83)B+.C2!91N()J4P?+C*8P,C
M#1\>2X%E1W,X>CSDK?=2^G'JX=;RI')JC+P!<=?270#$)L&8V3V!L'!E4):G
M(:BB8K*9RHJU-M*4PJ3A64YRE.<X_N8X!N. <A]TX&2^JJZ$C7%[7Q8_M.A@
M1EV9FE(>:[&,3)0^WR%8%Q):I*B&NY!F$TA_+$=M^4AY3S.6DKQ]%[9GV]_.
MV5?>KA19)PPGJ:2</%K&+-$GC+PFL/.#]W_V\;G\'WMN^1NV$>5V.UX7>W6;
M1PKGWY50C/:Q_P DHZ=&^CM;9.&N<H5RK5=BFXOBPEKK0TV62,5_OB"KL.QD
M; 6B0GBK,E#E1FDC\,L@HB9?(4@A;*VC9(P)&,^6*V-&"Q\1Z$XZPIWGTE>\
MY:,5"WBI3E%16<8]246L8@\0EVI3<.NJ4IR4DG@_H;:>[/DW;T5;#E/C+<[O
M<;2JBN4U4XM;J%=$JG6X[*<8;:]\?N-W9M,V._<;C=7U[B,+% G]VU-KPAJ7
MJ^V![&5D!K6)?;4^_M0@1*QREWLUZ29AB)]5<:-,1&[O'L\A2H4Z?+<CC9+"
M'<,/Y2EC/4VO(;N._P!\[=G.>\=4,5))J$88;4O3G0X^,8K,D\97B?+^W??'
MNO:^^?><^3]I[S=>[Y\9ME'C85URKV>WV?:G;#<IU.3V<MO%*ZFFJ,[ZYR@[
M*TW:J0N>M]*SJI4(6L.W88Z=M+]0U/6H+,@V2<MUR.72/'*J*/@+)+GL4NT+
MV\.(FXBH^4S9C J1@C'82EM7J;;><G'<62WW'2A36IVR>(K1!0RL:HI:X]F4
M8//I3L6AOJ?HWM_W=\A[;G-_N/>7L3<;;C=E'=<GN)N--:VNUIVDI5]M7[>,
M'N]LN+OHV=JLS35/>U/:6V-R4A!:JZXA[?89EP[@&3D76QD)%OE(M_RH% 1\
M'3UH$"K#7/<\^RX'(U?&LK340?AV/.Q!RZ^TF=+0X]C/#;ON9LV\%M^.C"5\
M&ZYPTN3=L9.,M2CGNN+;EAQSA-QCA'E<E[V^6M_P.UHX#V%M]M?R^WNELMYM
M?Q[+ISY3;VVT;CNPV_<?(RV[E;?IG2[E&N<MM1*-;6\U'2-*Z\QL[5V.U-#9
M S]3UCK)K(?6;2IN>!NUJI[]/NMZCU)N:F*,LEJ>UV)RU$@SI;+$P%/EI?C>
M\'6&>/D=UR>\[&__  +7;'<2W-KE'I*$9ZX0<\9<8]R>7**;5D(XEH3?G>^O
M<?R'[J_9O>;]D\G+DZN<W'N'D+-QMLPNVFVW2W6TV<MRX:K-OMEOMSJMNIJG
M.K>;6AU7?BPLLK8!K?K7; 27Z7W)>IX67=J[:G*N?&$X1^2D%N+8(JK9#B3-
MOAVH/@Q.O8\# >8;2N4,8@Y4PM$MC".Y=O>:V]NG<\;W+55*.J+3CZJ:W++C
M!P>%7*<D^BDY=4XL^NY/W=\O<'R;K]P_'\=_R$..OVRW%%E<Z(][BMC9N>[;
M5M9[:WM0V5^]NA.35>XGN<61E1:Y3;%6T;;>NX77US[9:XQ;(MYD;Q6;?-R-
MDQ4U+,,UJ#6((0U()T@Z<8K%')@X$4A%Q'=(%H:)^&5XF?QG6>XY3;\Q+>;;
MC[OQW4J-.GMO7F-ULGA3C'5-3DXO*C!Z,K3T^=?-?)'!?*VX]T^W_8_+?L<^
M-CPZI5,=A)[G53RG(W6N->\II>XWE>\NLHL<XT;:V6V=D?Q_3] VO])U>?5[
M,8[?6R0F\1079\*O;<.VSHY*@VEWW36C$Q;UJ$ H^QQ,JR--!IK#<>1$983[
M0,EML8<;EF[Y.^-E-?'5KMN6VEVG!8L@LR2]+DZVHMS3RFWTG%O#QR'NCY%Y
MG:[WA]A[#V,'QL[O;MW[9/:PE7O=LN[N*H);:VZ6PMCMY2W=,Y3A;.;[6\HE
M:XRB^P-(]>:(8KE(VAVR/,DI%<#%!4A0BSM5"("N(,I&@7!9B):Y86.[=F-1
M%)QJ8N<MN<6E29?IQ69:6L<^SY/F-U5/=;'CX:%.2:S'6Y0DFX:7%-Z.]&,%
MIS&*C',G')[7M?Y%^5?<VPW?N/V9['VLMI'=W5VQ[NW>ZE=M;JY3VJJEMHVR
M6T?*;>G:5*E2IVU=-&NZRAS+VJ^G]3#=*]K*NOMS+NT6P'8K6QM@$K*:,$=<
M$H1=^6F.7C"KVVGVM^2^H?E<3(U,R+$:AOID>RKQGR=QR._LY+8W_MZJ<8/M
MUJ*2L3BET;AX)+5UU8;<EIU'YGS/OSWQN_D/V3S,?8D..NVNVD]AL:]O55#?
MUSJC'55*W9OTQBE>E:MPZK+9WUNKO1:HNS:AT29'/,'^^5+/#*L[3W66[&('
MF(+1V36*>A10@R(OH>(28*0Z+F?#3 3#P+3+=4MUU*O,OUJ>1Y6N>:>*MA.Q
M3_2VGI4I]%FMM-.>EZLZL+HC]+X?WY\E\?NXV<7\9<AM=YO8[I-[>V=4W3'<
M;I]N#MV5LJW7+>*FUWNU[AU0480:Q'Z M-:K2^5G7'N]"CFVH>U*]D2Y?"EF
MKONZK[6N6P#*[/+P?ID&SPR]=<S"N4!R.EJ;)A26X4QE47*TR[D=^U&.WXMN
MK_%+/;499G5"N.E:9N+C+U4R3S%2BY1>K#QR?R![U==&VX#XXLGQTK.-O[JV
M5>WOU[CC=ILJEMX]C=SV\JKTK>*NC8Y4UVTRW&WL5VEV8JE]9I]5GT@?V"I+
MI"[[GH._(1>H@&$2:L8H=-17I4I;+UH(21B',:4-N#9$A_VT7+96E29GLB\K
MZ2W/-PW"W4]G;HJVUE#4Y=)J<]2_Y4G_ *U:DDM,EC].I8^/7N'YAVW-5^X]
MU[5Y&.UX[V]O>%G5NKY..YJWN[=\8IK;0C8U^[[..XA"'9W%4XM/;]^*CK1X
M+K_;]0#M#!.Y V(:C;GHMD!VZ*P2&"W;$=K$3-;J=($%K<H88073E$^:R]/+
MQ$V2<\M^,W(?8C-:LMY:CD'RUO'-U/;3BX-IO3&;<IS:AE8_3%J,'VXK$FDV
M^WNN2^4>!]^6_)O(^P+K./G[>WFWNVLI5V6*BG<R_(W.\MJVO<J=76FJ<:=K
M:]A37&NZ=5=ELX38^N&A UZ$5";VJ!Q?DM;Y%3CT 70_;(0>V9OQSM/%B7IP
M+9U#_:H$.GRW5.S&HR67FUN-JCN.H8QVJ>:Y6W:RW$=A)]RM3[CGAN/;CMFX
M:HYZN:Z)O*>'E+)]%Q/RU\G;_P!M7\]M_9.YG^;L([F6]LWNF=NV_"I]N2EL
MU;M]>F<]U5%1JE8Y1E&$E;&$K7-*H'T-)TW Z^U/NSZML8V4*,#-D6!\T1=L
M9W9-..5:  CM&[A%B&R)2%.?D26QI%AB/95I==BLONYC.=:ZSE8\B^8OXS_I
MW2TZXI+3&N:FY=(-Q2PDG*+;KZ*32ROG^;W_ ,FT^_[?E+G/CK'!RXBVJS84
M*F"HIV&ZIW,[Y.G:RE3"N<(0KEN*)SGQZ<(76505T+S#=#U5\N,,P=QGB*XU
MF@6@P(LP@L:KEF*0;#M4K'*&!3-X&NK.B16Q8<,7)0^EJ"L!$=6P^GRLM>7;
M[K[U<JI;:$4X.*<6E**<:EA/0_2W6W)8R^Y)97B_S;D/]S*Y38W;#<\!M:HS
MV<]O5;M[:JK]O7.CC:Y5U6/9V)4VV;"VW<5N#E<M[?"-E3S9. N?EMD5L+@(
M[&6R$)12:]284$55?=&6(E=I$FFP9SZQMOC,2IS&)\F0P[AEM]G#ZFO55C&%
MX[:]Z5J7<>RK=G=E-MSSUE/6UU@\+HDUG#QG!]1#_=UM(V+=2]I;&S?/D;]W
M.=FY[NJ5^\CNYPBK-K*482T5PG'5*$]"GH3S$E,;\O6../ 2(?>VQP@4)>?E
MKBLB)A\?!<D(/6(G"S&DQKBW)AE0P8G"$0I"LO16AP_T78CS;WD:Z\O=[G5*
M%FTIE;*K1J:BW^F*>5HPTVI3DNC<I94DUE^)=_NIMW?&;K:;_P!M<1N>0W/&
M_B?D6PIG-1=%%<]49;5QG7;;7=NKH+39*^_N0OKG7JGARNB-F$Z8QJ2L[,$S
M7CV\:YLNV60M7#0R,X$$ZJ#ZUG-O AUOE3K/82+U:BEI#CY6(S)*ONO^#:4(
M9SN/NJBSDOW"^B24-K*N$5*+]3M=J]3@E&*U."Q%M1277+9V*?\ <OP^^^0?
M^^N8X>^NO:^V[^/VU%5]-DE=;R5O(0:NLVL8;>BM;BS;0C#;6SKVT(5YFY2L
M7O:N@QI=>(8J.[K:JV9$[4>;+GWBS94U9KJ]9)86=)L\$XXZ#<<C%H@8[*3
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=W <)]/.M=A(QZG@0\%(]52?#&?\ \KPS_<X!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g42675dsp008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp008.jpg
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M P,# P,#_\  $0@"%@-P P$1  (1 0,1 ?_$ 0H   $#!0$! 0
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M+;;F[%]9C9>I:2RVETULVZQ[I+TY+NR+6MS6"RM;J"6W(0Q7@1QU$.(=H?U
MM=/1V-KI>>9ZG'L\%R"YY[>165E)17O0]MG:/6:SG%NQZ*376H^8O/S&B5CW
M_F@X)S?)L@J)-L9>T8!*J03.Q6682+056-&9%D'(C4NE\O*64\&RO^Y?TN;%
M'N4-EM&ZW5Q+#N>Z17T)CC$T-C:3S6UM?Q$>62)KB'H7@('R\DULV:3513Q_
MZ@\O1>K:7FF4QM$*E'MP,E%:6&ZYOHIWPV?7J'D0QTU)@^E:.[1T=E%=%2>H
M:*)L$87JD8A#'2(N.T/D[!+VXD8ZHB] DB\(FE(U21*O#0!F375X90M^_I83
MM/LFS[PWO<+ES<[<]R8TL[^  Q[7-NC()KW;X(<XS:1K21F+M<45NDP2C<_*
M/Y*Y.IN2]+#Q>:87Y'1_'@(C*<T[5KYHBPLA8[&TU<F0RNAO];>0$C"L&@
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M],D5Z]B^37(J_7\%\21L'<&K2]A>JW@87_=B,=\V8"OS=M_XB_OQ<_\ HQ7
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M_B]9_OPW^M\'0F_@;ZC@U+XC!^>4O_%ZS_?AO];X.A-_ WU'!J7Q&#\\I?\
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MC0@2)4="K D--0&AI3MS28]\;2ZPV#0"QW -)(5^;0EK'2ML"P8PR48W1",
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MC=)G@/8/37XC((G*5)7Q/;"V/<7.[PWR[9W+':0[1>2#I/%1)(CI<A/Y;%Y
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M76ND4>BA3[SYB3QX##*V'Z3'RNV>6UF>S>;X/*%UC@/&N1=<SM5VO"P27C^
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M0Y?_ #2*,]_X?1WX>$Q.UR[,DB%U45#0GZ!ED/><*DZ,"=26,E6R'3GJ2?\
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M)>[KS-)S32U5I99$>UFNZ7F_QTP><*L94H0K*D/;9@7IEKZYM3<H/&AKX_1
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ML$,2 *3&QLL<C-%LD";IV#M>SF6\CN]LN[B&>-G%!K9YHW<CXY9-8T,*5(<
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MP!.5#]X/R(Y#PR.".."Z_P Y#($N%XTX!N09>)KS/#"G0Z,DBQ?F=,(-3:V
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M[8#(GN7W5C:UZ*KD3S\L->6RMI+K7WX%MYV74J$J<9S#2C&C"FA%#FA'"C'
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M7VIE6]K_ *HMDB_1806PW Z('Z4O  Y5/@=1X'AEF.(QL6GW';QKG7YB/FP
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M T5B;##<EY'0WFO(,O7SC9LLFSL]1345."E)=.B'FA!L;4-K9/20K=^S3GU
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MA90,KS] Z%)6S1.(F>;Z',FC0Y7I&NEO;]WG6*[K!?TJ)4;2)%//F *&C ^
MS&-]9[6K6C2V ^:V\_%%(QU1L."$ @U.="/IP^,; 9:"VUGQS::JL-HCD#UO
M(]5I[&^@SUG.U)V053=@ZP^PK3(T>HHY40L;V-=$R:M>Q[(H=T8UI%ND,;.]
M2LZ+I9P.-66F8) '+Q!%,2[6)F7_ -*ED32:/ [,P0G@%#$T4YZO&F+;/T&1
MUVDN!*BO'Y+VBI'6WN:FM%.H*_1!2E-AFT4=8 4!;A^X:YC"IPYY&1RR1J^2
MR'DC>\EDN(($DN&,VV," S4=DR/E)-<ES-#G3/+!#%;7-S)!:@0;ZASHQ5&]
MH!KG]?NQ(E3N3 [@#EW8:L9A&GD?692PNA 3*;8FLBDF=03DQB0Y^VM91V/D
M%?% ',5Z',F"%F2/[B%)8ITVN]K(6( %PN6@?Q4XZ?[M2<_B(KC80[A(9$L-
MS4F9C2-V (8\-#5%-=>?#V8=!D!W-HDM*IYMK@!E]5QGYYIS[/&A-]2RW>5*
MG=.>515S?XBZN5TSX!D60)S$C4:1B-(;UEA90MT<T?@&/(,.1]N66)C(^WGY
M@$FU4TD09LH/$J? >VN%.YS,SB7Z["D 5^H(9 3/_>N;F-P(UK7PAZ2,?SCE
M>0.GD);1M<8&KFKYS0>N!^5N40"WN0Q' DYE:'(K7W\^.&KBQ+$W-J:. 20.
M# \*CQ&*K&4'2\V*3,.<%*,80D'E)^7ZK%ZBKE<*=$,9&CW5EU5%L=%)Z?7
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M'TI^\X4Z@7BMS*G]N/'P>_\ L$/ZS'_[S?BM_P#/5F/"X/\ R4WO'ZQC$O\
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M/<_%KD#M;KJ&GIA#(3>P6'.:&UO=CWC:BR>PE?B,CG*TN:C@,]N, 'W#)O\
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M2D9NNUUN5/&-64P+&MC@C4T^=L05?![  _J^C6,1\GA1DFO)E@3*,'(#@ *
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M!16"L&(937%YLN-8#>$51>CK[=Y-/7,J1B:C6:S-E3UD)X%L*%8FYR[JC+.
M*XJQS(/?DD6(J))&JCE<JIMMRN[0,L)6C&IJB,*T() 92!4$@TX@TQ'V#U [
MH[9BG@VF6 0W$IE99;:VN%$A1XF>-)X9$C+Q221/H50T;%""*4^77%>:7PN4
M%-S;8/Y#HG9S#EU5E;TUGCJQ743F)F;2J/#L*8V)N;#C:3!(PA((W1>OVI9F
M2$6YWL+2,KUZK:G! (<^;X@001YB:$4KG2H!&=O]0^\-LFOIK>[+?F=SU[Q9
M(XI8[J3\:OS$<B-'*A^8E8QNI36ROIUI&RW!/'^<FY7.8DO-13YG)BQ!T-8X
M^U:P."(7[-&R$1'1EFOD@\T>Z>21TCE5SE5RJOA*[C>).]RKTGD-6-!GG7A2
M@^BF&H>_>[;?>[ON*"\9=XOG+S2:(B68MKR4H50!N 15"@ "@ &,<ODU1U'.
M.9\JK>="WV9L<EK@:#FE+@J6TM"XXR\U?59&=&0 N)]!1S4+YHIS6^L@09%:
M(WWG1M7=;'+)>WT[WA1TDC+2-(P R93J-1YFU4(7@3\65<=9]'MRON[>\-[O
M.['MKRTOK!YMPEO9HXU)6XAD6=M:D3S"8(R0FB2R&LYZ88AK;@W<\[^+&5U4
M5NW-:D'<V&RVK*IFGS?YE:;/0[ VV96TNZDP.AM)0-7IH;>"I*;7"6KP&P.A
M2OE=$K]JMK>;]) 5UVYB")72U BH!4Q]115%*%QJ*ZJUUBN-UVY;]M]U^M5[
MLCP?.;+)MJ6MH9#;W'3CM(+5(C)-9B]@C#VUN]J]S&9Y;83&02&Z02#)?@#B
MI><"D$7FXO8BKS2$5LW0Z71TNH JG71;:^K,363EWEM"(.Q/;L'SSC'-=[HC
MD$= QFDW?2+T@+$A"K7ILK*3I%2-%%%?X: KP;S5..0>J(A3NUXHK;;;:1+:
MW606,L$MN\@B77(ORRK#$68^: (DD)&B<&<2,TO6,$A5><+%Z%E)#*@C25R-
MC]R:!\;/<<L)"-9ZG)YK[;_)/\UWX+KD(5PQX C%#M)5@NHIGKH216-.- 03
M3-<_#S#WCCC$#X7<@)Y!B]?6S=+YEU%EGJ8D==<OQF8Q=546>?I@,W=YBT#R
MY1XQ]O1V=9)&^::6.5C?*!!1&1-A2Q]S;BNXW,;B">#3'\,KLY(9BRL"P% P
M(R (YZF)KCO/]0G?L/?G<%A>1[/O&RM#9'\+<;NXNY)8YY7N(;B-[A49(IHY
M P1592:R=:=G,F,R_%:QY^PE7EW4YJEM]'?'05E'059]U<61*N0>OJZL64VP
M-G5K7.2$46![W>2*ODWZ(OAR**2>588@6E=@H YDF@'TG$W;=NOMXW&#:=LC
M:;<KJ9(HHU^)Y)&"(@K059B *\SC%/+_ #D^/G0NM<VY!S'9UW0[_H@^V,4C
M/RRL@S86*H8KR<RVAL!A)Y8+%)FP1+#ZE;*J>I/+ZIOKCM;>+/;YMQOHFAAA
M*#S?>+MIH*$\.)]F.V[S_3?ZI]J]C;OWYWCM\NU;7M+VB:9P";A[N8PJL11F
M :.A=M5*KPSQC_\ JX_+CJOPS^*$?2N-)00;C3=(SW.!+G05GYS%G!+Z@UMP
M3>UE9+-'7EW(KLXQ@Z&,($:LJNDAE1$;XVWI_P!OV/<F_?);CJ-LD+2$*::B
M&1=)/&AU9T(.61&.H_T*^A797]0/K>>T/4#YINW+/:)[]HH).D9VAGMHEADD
M +K$W7)?I%)#I 61*DXX_P#B/Q:^;'ZFO4[?5U4.IZ'86%@R/;]OZ9:V$.,H
M%\_4T0[3EPDME>%#(GL4]3"01#"K4B&9"GFWT/N>_=L=D6*V[&.(!?)#&!K;
MW**<:9LU%)XM4X^\WJ-ZT_T[?T>=EP;'>M9;5:Q1$V>T;?&ANYN6I+=2M Y!
MUW5RZ([UUS-(:'HE^-7Q!_31_36ZSS7#]ZZ?2=$^9&P3*6.+,W&1TA=366.H
MOR,YG)N<9RNI;S-T)$^D!?!!961<]G%+%[K)1(W>A..[WW%WIWI8376V0M#V
M]'J#A'0,0JZF#L65B-)S50%(-#K(KCY1^KWKS_5]_5YV/N_<?IELUQM7H#8&
MYCNUL[JW662.WA6><7\\DT-Q,JV[AW@MXDMV5M#).RZL=#GCD6/E5@\&#!X,
M&(\NBRH^FX(..]HQ!"LQT*8G/%B,DT%U,(5AFC6-*8H<L@M?1H3(TYC9X4E<
M8.JMD]"*RPV443=LW\S03O*MU: 2JQ$489;G4DBZ@&>6@,1*MI$<E"NHZJ?N
M<\Z=[[3;I=6L=N]CN!:W= ;B8JUCIDA?02L<&IA.!(@<S0U5](T2'XKV+ACE
M*_5:'OW?J&=3(( 2?#1_II[]]@9/GZPNO9;02;>1E<9:FUI9#IC0_4V$9KV0
MN>]J2?1_FGK;TF-I_P L;=7<?,GNB'+SY+^ -5 P!XD5ICR_ZE"=O4>90/\
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M(!XD,!6N=2<\8?V>1Z-R/5UG(M#:7%]E+B]*T'QSZ-73?E-IF=?"DA3\<(=
MZ(?-7EJ*V6*>B<Y,YH(7R,$8%++$&RW1SVNZV4F[VP47L2A;N!Q0=,T"2LOP
MNI.9< 2J<W)XXI<]G>;)<IM5P6:SD<M:7"<0X-3'JX@@9:6)CK\*C+$R$["4
MP'&=E?;3Y,Y"HLGI-Z#7_:UMB&EG_+]GD.RY&;[,0'3<_P!1&CXU)2".4=A*
M!3A3$,@30+;(AEV[^<FO5&A-2&I4-"Q^X17@:<,LL;J6Y:D6Z5$,A%)9145%
M:4G44!DK0'('#^T,9U3T;,7J/CYAT>[.;C](X*!+#$=.@+_@S%P1%+]FFC(H
M[IK!%AF<-?U@EC)Z)%A8V1\6+1/82V]!<V>;JU")(M/Q)4\*BIK71EXXV+AX
M+^"Z4?+;CDK+4&.75FKT7CPI0>85RYXJZY[9=7D] 1[_ #/J8MB#E[2R 4<V
MNV61O)DJQ9(B9QA@M]GZ'2DAD?EYC8K*LCE(]*#+*D[BU-;4V\96>P=*K6NI
M66G <58_Q? :<#EA%XH%PMS+6UW7J48BE'4T ()J&5?X::P",ZG%STZ=IE6)
M-KPW9?HF+)32XK79TF48>Z@K_P"_TE9DM#,R0H(F\SL1#":&P]WWG>AWH-BC
M27PC;R\+GH5DBD!#HWF*MPS'PFG(CES&%[G")$TW%8KJ)@4DH%# \".?F_A:
MI&'-K(66><M<-U5 C<SHA4KZKHH," U,9TWUHC[X>&57XC2A&NBG&/AD_+WS
MQHZ*8:16P)&LVZ5\+S;@>JF;1MSSSR^%T_N$:O'$V]4RVOR&ZD"&1?+(G!<N
M)/W6IS%/?CYC+S6U&3H+RR2PVF=+KX5M/;B6PVF7L!72!7+5A8BOV^>&L1Y6
MHK6NMH8D_B^]^JM=ND@>[8*RK)6H-:"3CRXJ?8*##=I)<"T6:0-+;UHRT\T7
MT\'6F9K4X7^8'5SJNYI*8\2TI,[>RP9LX(AA0S\K<B"7]")#.DCO4RF982U[
M&_5T;!$8_P!+F*U&+Y6)65EH\D(U5J*,*BH'@<3MNT#J*CAA'<$(0:U7B0WM
M'(?7A0B:VEZ(1#%_ #NZ BUDA:GI8FFR#J^N)+1/-6MEM,]:BLD7\7?ES555
M<OAMRTVW#41JB(!\2K<*^S(TQB.-+?=2 *),I*CD&7,G[1CQN6MK9<OL8D1D
M^;O@P#Y?JGNYG7%!YVZ'E1/+UPC&D!'M:OT20%JIY>,VK,W6M%^%E8K["*$4
M]N,WB)%T;ZGF21-9\58D$'ZU\.&''IZ%FGH+;/2R+"ZR$=$,2U?2\"RA>TJJ
MLH5;_$V>LM((2&*GDJ/B1?#5O+TKF.<FBA17]>?+#UY;?-V<EOQ9F.GV>X\<
M4\C>OT.;H+Z5B#$GU89)T7\+$&LF1^S:0_BC61C6,,S$_8B,\_P\+NX>@\B#
M)E<$'V'/#ME*MS;Q29%&0J?:1EC1Y\D>NSZ;IMWS?/LN(L=R>YN:S'10TNLK
M/S$3;(Y;^6O,LJGEM=-GG$RETT;9-+M,?=TXT*ST!">?J@[A,LTRSCRJRTK0
MYD<\PHS.618$<L)VNW^6A>U/%7).=: GAQ)]N8!'(X=OQT^,LFZOZ"TZ& C^
M9:FM.QQU(3'"E9=RY^K,GJJ&,6*NK@B*^7)B&5DS(Q1:T<.& 4$(." >&-RU
MM_FK9@PK)'YJ?Q5RI[A[O=3&+J06UXG2:J2>4_W.=?>?^VN.+K]1_P")71?T
MGOGK/3<_O;;,T5/IZONWQ-Z5',Z(O^4H+];/-0--<YK"M!S>^#=36D2JOO(,
MR21/:+:CJE<PO9W%!52#5?9_V<,65&6:.GQ#@?;[?IQ^A'^FO\W,9^H)\7>3
M_(O+OK0M#:.@R_6LA7DQ3_R)US..$'V.?6-KW2PUAD\L=E5.>B++5'#N^KO5
MY62VG6YMQ(.-,QX']/LQIIH!$Y0CW>['!=^EN4,_]=;AT;"('2+\P^XM1C9H
MW/5R0]>\T1J.555/+Q7[7_ZX+_C/[<;6<?Y8^&D?LQ^E/YKXM.--I7'YP/\
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M<,(6"PL-Q?CG./ F$J]M'4E)<7+*RUNWU-6?9,IJ(>(N[MG BRE-K*<6<@2
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MXXV%K/\ T\V-N;:S]/Y8[@>0RKOM\)6'Q F3I5RK0$4IPKR&./0OBER3E&Q
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M4)F' 5^%?T^O"DDD_,W!9M)@6F9I\;</HQ(FI!"K0\/!7!B5XU9O\HP ($:
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MH.CUHEM'+6.QM07'/7V-*4\IJGY[H-X/$(+YHZ:.&,V"=&S#O\XX2SMK5[U
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M45L[9B18NSPZB8R6+EB+IFJ;M:+<=15 'N'FE' 3 4PS5+(-:YNYC;)KM%+
MXO*T;L]613#OL'0SUQ(+O</&>BP6!?D00U\R>OQ@WDI4J0E"K+\"\';4<Z<0
M?A/%1Y1083)W5N<L#V[1V.A[>YA)%I;AM%U/\Q*581U617&F"4$/;Q?@PLD?
MEQ8Q\CSD84%>T_:K /35%%'(_=:QY;@J31_S0%/,8ZT4F:TELE]LDMSE(*!_
MV65SH/X/"C?3ERY6*I9F_EI2K+H.5.%,P. ;S#//$IN]MY>Z:[,.V]5[F:<@
M6-H$US6_RKJ$$6E8A'YHX@!'%/\ CQJLOFQ6*Y7GS/OO>.V#?S!-ND_V^UU
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M<?9O)HOR\?\ *2'6-K.39GNF ]MRS$223R^?JD<YRJJ\YN.M\P_S I/K.H4
MHU<\A0#/D!0<L>"-^.Z'?+P[VH3>?FI>NH1(PLVMNJO3C"QI1]0T1JJ+P4
M##B\,XU.#P8,'@P8/!@QBU\IQ\I=Y.ISFC?DFDLM6:.ECZ%=]*RN+GMJD0V*
MM4Z\P#Q&FEBV!,<C02)G^;?[YD2R1QO;OMA:XBN&FAZFG3I;IK&ST)%:+)6@
M('Q >PFA..T^BLN][;OD^[;2+XPF P3&QAV^YNQ%*R&31#>AM"LBLIFC44/X
M;.$9U,F<,=8OY5D76Q-T99*,<IA5[+8$%3S+;'JL@1-L=96Q- Y%3\KE*GE)
MDK?8=*OK5R)!W71\_)TPH2HH%I3@.(  #?Q  #56F6*?ZDBT7O:^%BEO'::T
MT+"$50.DF3K$D<2S_P#U0L:+&L_4"#2!B6?&OQ1L)5]/(+1W),2CME'JK&>-
MQ9SJP5LD0<TC%)LF2POKQT<W^.='L6)OFY')Y>?AR(!I54UH6' 5/'PY^[GB
M=MD:S;E;POJ*//&#I02-0L =,9!#MX(00Q\M#6F-:WZ=.WO]['T*UN8KFY^V
MDJF2[&;I]KK0Y;8RHHW7.:LL]H>V]6O)/RJP#D_(;MT<,-C4(]Z.CDDECDNG
M>-M%:F&./0M:^01!30%J,&6")<P?Q$J2KTX@ CUY_5CVYMG;#[59;>UO;ZQ(
M1:C;H[9Q$DLW2N(YX-HVV$=5'7YVS#,\%T54AT5&39]XH^/&N&ULX8R,?JAY
MLG'O(I\Y=PRX>9M.^'91RUI,;\M,W0RP4#HM UWVCD.>P3TRK[SDC]2^'[8D
M7,9$G2(=?/GY,QY_+YO+Q\N>66>-QV](\6_64L=\=L=;N$B\'5!M")%(N08
MT]8/YHZ(,M5_#!>F->OPC^*W?>(GC7VVWE?@,-(#JVI\:<7I--TG(0$Z+36=
M_GSR])N)6U>'-Q-/81U4=1B:NHI96BM?)(2GI\K=W/OVT[FIBM8FFN@5_P P
MZK&YTJ%8!4&IPY!;7,[N-1%!CU1_47ZU^F'J-:OMG;NV2[IW*)+8_P"H+NWM
M["Z98+>.&=%M[,=2\2[EC:Y:ZW>XNKM3(55(37&R_P 4K'C_ !R._(+_ .V+
M^>__ *_\)_\ I,9OQW_:O_Q/R?\ NI__ *++C[I>EO\ _P GMT__ )7O/_WU
MN,*'ZN7_ -F)^$O_ +Q_&3__ "(UO@]/_P#\7.Y>^Y_^YTQ'_H5__(&]1?\
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M<48KT81]Y'X=OK&6SA^5AF5K=@'+J*5;_AUKD4X-XFN9RPG:YCNC_/70"3_
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M66DUNMG(GT]?<,'?[D0\\+["WIY'L1B/8ZO7R] K9'&O[;>)GO9UHT(UNM"
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M%*]LL))&><)2/_N6^I/4X>7R285?)?KY*C?WHOX>&I8#0RP>68<"!E4T"U'
MYG#>IB1JSC!JP\54$G]6-:^ G-;6Z3IU@&0/38KN _:3JI@0R75D3U .HR>.
MH0HUB2>XL!\-H7FM]M5G0JP"8J,1OI2^73H9TVO,23VG0!U&B]*K.3R4:Z@
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MGS+<DW&RT1EJ:'-:R//1TQKHO=+EEG\V1*B*C:KN4GSC+<3.J2]-CF#F0:!
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M8VQHJN;[$WJ3Z>V_^RKD()E4+\18?K]X_6/>,3MK223<[>.$$S-/&% -"27
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M:ZA-MP0(D?H7QMC841Y0C>Z]S?4K&5?:>W9^TNQ;^ROY8VE:.XD)4G2-46D
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MU=%/9EPCFB7!!.Z]H(R];&-<L@*@@5S1QBXI'(CFL:KI/2_U[Z)K;GT\2-W
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M1'HQIPZ?YW]RU/04QOXN?%^"?56IXR+E@0ERI4\CR/[OIPSG7(XLQ"IQ)/7
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M86%MM=GI=WE,DH%1J*J3J>E*1"E0#YFH&H%(..82SW.XW=UN]UJ2V'X<9/\
M 2!^&!F936FH"G$>.,A[2FS%#8\=J=14QY_G&?'U#,CR40622XT4E/25U=5R
M:($%QQ-Q9$EV[)$HAFS+ZWK/8S/D]4<->%Y>SI<O:'7=/(NJ9B:#4:G0& H
M!Q/AD!6N+%);6L$EI#>J(MNBA<K$N9)73I9@M>.H_7GAQVTQ%OOR=%T]P.6R
M$&%K"1,,A35"=-6:T]U//MI W3,U-X\NU>\6K@4@6&96M3[R=&/B;BAAAV]H
M;8"2^ZKMU&S^)5U4'W149U J*<,29&DEW-;O<&2*T,"+TN)(4MIK2M<C]%<7
MD-'?[3I-BMZRRP>$T>"KK&>E.=/7:S9QYB]L1/=O8Q7-L<M3SBZ1GK!C>P\B
M)J(1(,Q7P.'NXK.Q58M-Q>"0K5::4+@5T5\K,:<:T&=*G D<]YNA6:L.WM&&
M !^(1UIJ(S4"N0&?CBG/>#D]!I*_E4,,5)=Y&VR16X*KXHLC7RXX\>TK0\12
MC.9!IK&N M;*)DJ/95#+Y(YY#HW#^ 17!LGFOC22.525%2S*Q*DL3DN=,R=7
M]W&9) VY"/;0-$D3+U#DJL@J HXF@SJ,O;BYT]G2<KO,#-G:^6SUEK=$T=C6
M M@/VNQ$V \(3+K06]@J-B$@U5?5HIQDD (K'+# C4]$"Y@MI+]).N_X 4R5
M9B$33]T4XM2M--2:>RN'+R6':I8 AZMU*X5M/QN6K1F/A[Z84MQDM<^BDZ;M
M[%D^EY\3!O,]6_F3PLACXL^YQ%Q'71V4@TEG<V>;F-#GM2XFO1DRH/$-&JL>
MQ;W%DD_R5FHZ<JLCG-F.K+,@&BU -*^_"KZVN6M?S*^<"2%U=02*#2:@+G]>
M>+NV$F[+2V--4W,N>YSH:V4,K:) 5'H-* ?"GM2804@![ZVM1KVR-NB8TE<K
M?,&)?X2VHB9-MG280ZKI7+:3IH*5XYC[OW?9GX8=GD;>+=HTU1VCQBCK74S<
MA3B,S2I%,4<CI*'/8G+T@,"F;%HQ]4F*S@$GWI%]0V1-/HK8XLB1!ZJI)N@Y
M2";0Z1&N67S5\T[FQO5<0W<UZ\C B!F#ZB0/*5#*H'AF: 99D88LIX+:R2)2
M'NUC*Z0#76&*LQ/"N69KA.Y9BX:;0Z4+67,!NCSIB6V0'%KS'9_(Y#<M+L5J
MLF(0]TC5$O8K(&:PF:A9 \$;$2$?T#M7N,\DD49MXM,+"CG4I+,.;'+(@ TX
M5\3GC&TV0BO)/FY.I*@!C&?E0TX<M6JN?V8P;_5>P7R Z-P:Q^.WQC%-.T?S
MCT>*^-G0-BR&U@SG'\ 25-:=$ZKLI1YQ#8Z&3E5;94I31'*60V2%D2*YJ*W4
MSJ;FP,,<)ZT3  BGP-F:Y\N7OQMH56UW;4[ 1RJ:5YN/#VG]F--_R'_3S^:.
M)X?^I-\=-#RCG/8,'V7E>$^8W#;CXTXF_P [QG#=\YF?F.9]0Y'GLKO=5>:'
M/[W=<JRX.C%C0N6 XZN5\/E*OM>(,:NB36LD6<BC32M P.5*:@?<33,YUH#L
M+EHEDBO":=-J$G^%LB3[!SQE]1_ IO2>]?,[NHOP^WN:S%5^G%P++? JDU&;
MM,4_#=,?\<.Q8/69O'8070K74?3***W J"4,C?*&A:,9*GN/=XC (6=M3+I'
ME!^G+AEE0?3B3KHJ@$$$U/TT/]N,4.B_'+YB83B7<^8C?%'Y';O8?)S]#/X<
M_&G&+@Z^NOJW&_(+C6;V(W4<9U*Z,T-</@]/6NNQY(HW.FFLWHL KIYU:SQC
M3.ZUC!9= %>%**01]OTX4&2O'@Y^K#M[E^G1V'IQWRSV[_CAO+WHUC\NOTKR
M.)Z01]@!JQ..9;E?%,;\I+;FEG#>B6.>J0Q@[>NU9(,@TY,8;F2+(R&#RQ(A
M$IZZYU'_ ,[7A[*_H,"N  *\C^W&X_\ 3;^.>D^--Y^H-A;/E,G'^)V/STWN
ML^-^7< M5EUY+=<VYJQMERNEJB7AU.1/U0E@J1,C'@^[254C15\U>LY)%!$)
M(>OLIP'C[:X:E-:'B:8O.4\QZ'2_J\?,#N!F1T51R#=_"SXJ\]Q72+T-I6:T
M&TQ>\Z99:K, %0R3.DLZ"NN!)2&N@<D;9D5%^OEX<$-Q\P6D76*9Z2!6NK]Y
MK[\8+#I <ZG]F-*_QU_3:^5'+>8?I^;'C_!]5Q3Y/V6 _52QO>^JE.2FN<T1
MTG$=2'^- O5[=UD6@F977DU!&>B2*4>M)D83&R)ZO>L;1$%0"JS>:OOST_LY
M_MP\SJ2U35<O[<0EA?@S\FO_ $2SYG9?$<!^2&"Z9IO@'R7B6EY2+P"FX;0]
M9^2^=Z[D-%:;*JO)OD%TO3=][5F:L"X=8=!&KJFMOJVPC<LWO,0=,K#==,T!
M"T%> K[>.?OS_=DNNM:D4K[_ /LQ-?ZG?Z?>_0*N^/WQ$^#EK9\ZS?PMUI7%
M^B<OY4;V+5Q_);4[T_9[K)G:[H_6:O,_&34%'C0WTVWAKK#77TY+@PC45L0R
M)G40CILM&H<^)K4\.7AG2OM\<1N#YB<Z_I[\1#UWDNS[;W']33"Y[XS]MZQ\
MRR=E^FZ'\=>\T@3I1OBMUT'X_P#&+W;Z7>;,G4UA'%S@:^J(,M[-!9DO8QW@
M222O8R%V2K2RGY=2#Y:9C+(9_M)]M#C*D*HJ0%SJ/',XRLQGQ"^4DWZG]GMM
MEB^O1="3]0\SN63^3V1X12WF9L_B7'BHJ^FP.E^4]YW;/ Y[CA&>2?.G\T'Q
MY-F/:K&>/%.J^XU;1R+*7N@VFM32F8_AK7]I_;A.I=&5.'#V^[]N$#XP?&OY
M069'Z:_QY[)\3^YT&6^+5]^I[A?D7J>HT5=)QF[!^0.1ZB+SEF=MHM,>3O,=
ML@[X>%+.$9H,!!,<'NI+Z_;S J3%(HT)=0U:4%:UIF<99@-3 C.E/HQ$WQQ^
M%_RRJN$?%+$<6^/O7OCAUO!?IO\ ZFO#M]IM-22\ZKJOY@](AYJ'S[4S7*6C
MF3S]%_*GQTFCC5\#_LUE8Z-L'J7 AND1104HU!D".&?+G0@Y^PXRSI4DD$:A
M]6)L+^)T&S^$W>^?<2_34^9OQ8F,Y!\.J;L!U!#CJ#1=FZ;RK:!W&W&J_C-O
M-LN-^0@N4D$G.U5U*2,3TBM*_+XIRGM;X;4VY0JP;7E[<Z^'#W_54X3JHP)8
M$9_I7]*8R[_3)V&\^+_)<MR?NWQEON>UO?/F_M>;\-O.?<F(X(RQSUMRV?H#
MNQ]+^-.NZCJQ?CYG+RUQME6P4>::P9)(6F?EPL4LD\DF(748'3&E6;W#A7AF
M1P_LPB32Q)!X+[_MYX</ZF'QW[/UKY,\CV?&.7;3HN8SWZ=GZHO,[?0Y\=DT
M51TKKG(\U3<KR1C?=#E&O=K="2P5L;4D9+*Q?-[$3S\)G:=I!U?*=+4X>P\2
M>?CEC*4"$?WAC7C<_ 3Y0<@YKHQ_C;QO8<3W/7OT*L=Q[HVHKK%<R=M_FX1T
MW!0S9+8:(^]>1/WR]S!=K5C6LS_=%A(]#28H8T1I%;]5^G Q,AA)^D9D5 \*
MBOVX:FN$AC,L_P#+$H]N1-.'@*UI[,;$?@U%E/C?C>A7G _TV/EEP/,69GQ7
MYOH,[9-'RVEZ?LY0_P"3M]U /@EMLFTN<H>-QF*7L-K%+$5JX?5- P]1F*KX
MZ32&2* A210>\TIG3E3E])XX8Z<R1JDTVI@I)/MX\?#P'AR'#&V3"CB6D5WM
MB+=TQ&TMY#:Z5HALKOY2JEEJ<>V%9O8](Y57$ZQ]/T_O;"1?)57S\;:[8QN+
M=(0IBH:U'Q',\/?3Z,:O;UZT+7$S5:0D _W0:+]%,1FN;FI^DV%OBF36V1PX
MJ0GX)@[!F#ZS:0ML[ZZP3RBHPJ^S#S*B^[63/8&3^8S>RX:9[EEF_,2-9B.Y
M4+<3'RL#D0,AKH*TKSS]H.(/1GCW$R6C=2UMU!*#C4GD304IR%<7VVKL=UU<
M+1U%X[WI+X^Z+O!JXL#19(3'P"&6-28*:,3+7SV&C+JQ3JT^!82(%>V:)Z(U
M?"+:>]VUI+F:(D4TE:J4+-D&7D/80:\\.WD5INIBM[=PSEM1;@=*\5((!&?L
MH<7.KU]_G*.PS>C)K ]1H5$R>.U(321<EJ[K4F#T *M^\];\W>P.LG$SUALB
MLE9"]19R6(]&-Q01/=*_381Q$O(M 2@ U:B5K7A0%>!XC/"KN]N$@>"6@ZH"
M1N<A+7(KGPRRHU*\1A96BT_$*+UY"&QN.99BH?(9B)#(B3,]5TP7KD*Q%@;,
MX%1&CC.=)3%R10M<JJ)-"O\ L\F5FL-WNJ3!4OI)/YG#42># >;4>9I3ZL8C
ML[C9[/7;DO8Q19Q ^92N9*GA05-!6OAAMX.M U60H-?G+$(#>%,(/N]$'72Q
MS37=^;-H[C);RB<ZM).#KS[)T+12F0'@M8CAI(555>Y='Y:5H)2[6PHB@FJB
MF093G0?3XU&%64*7$/S5B1\X07<\*U :CUXY4S_=BSPT^5W@EQ6;D(C,:S5;
M6_T%(R8DEP%@F>(;F*6WYSL!HQ35.K:O/QR(Q(XK 9)'>[$Z!_K>]>_.;=,I
MBI-"D*JX7B21J.L<N/U<\1[&2WOH) WX<TLY=&.9"TI5&%0,QP-"/#%G3/.H
M)ND1]-%ATN.N-D1G4Z"HPLU,\+/TE)2P [@()GVM!(TF&5Z6<3(P))W/?)]G
M(C&JIWBNH(C:^6=(>H82<_,?N5R((Y5)H>>&X3I>>'=/-;&<1]6M>' -Q-?!
MJ4&*N8)GI1NAA;"KFZ1RZSW5D)-:$_=76MSU?74N:!@?;S#I*=JLZ,,!$^"Q
MB;+9"-C;)*V?R4IB;F*$M$]D1;W\<"F@/D8ECD!P#$?=) 8_5ARS66(SI<?C
M[9+<,#S= !D2>! / "IQ%)XQ%9Q6BT ]Q-?4/.]$9I\-TZJ''NM-@&Y+;V(5
M@/?O8I+-'0G944D-]M!ZV$1/6*Q9'_"6[8BY!W=_FD$<UPNB2.I"2:D%"N8T
ML& \AY_"6'E.F>'1L<;0.7MX)-4<F>N-@V:MSTN,CE2@H>((3N6:?3\)['K,
M;>0 UG+M^H^VJI0/8CQV</N4@'GT6-D>BBV/+[VX5([""15*S91]?[ZN#(0I
MLC<[:SWK:X9EU?F<(:-Z@ZV"')6YZU&8(\KKJIFM,1MJN;G9MWE@DTC:IR'4
M@@1J6 #.@KDI84*TJIX\:G/S[84]SF0,^P/\U10W.7[,B3S\E:/*_P#B%F]7
MT2.15:OX-7Q2H[B1$'WX_'F/\7@?&H%.>.A,%)_#IH/"G ^T>PX2G1DC3>2M
MF'G@D_:UT4L<C%_I_B8YKOW+_P OB6-,RZ<B&P!64ZCE3"NQ\%FOM$>T+8.5
M$C,]#8QS'.7S]!GDGMP3N5/I,WR1RK_&G^=X@4>!=2@M: D9<<N('.GT>[&9
MJ-'I+:0QX\AXG&MK7Z?,]\Z]ERP[>V=S[G5K<"5UE3PMF9?60EC#2V4>02-[
M2;+5;_0QPUE26,GF#1U9Y<;V(?#-'T&&VO-DVB2,@?-7$8H&R\I&I.IX(E=3
M*WQ,5!'E..;S7D'<6\1O%46=G(:.!6M,G*C[Q<>4$ Z>.)(K3%9S_:W/Y4&5
MT73YWH=GD*!DJ,RO).?62'4E-'=$BL; UMC5TXB-(C:AMJZ.(0=/M('S,T\L
M9AOHQ 2UE$\9=AD9G%&<J,LES7212@U<2,;*$=/;YIE3_-S+(53BMNAU*F?'
M41YCSJ2. PZ-H&93<^VN+RD\MUKA:6#_ !$Z-<Q0R1TUH!$%)"A20(VO-U$$
M<<:5M,/Y!UD7H?/Z(U1A*+699+M;R8:;9YF=$&=5\U:#B/II[,3;E&7:3!&=
M5T+=4DE.6EF*T]^7#36E*8>>E9&5C]OS+!#M+MW4^F34[ZZ?+9#4]H74%N+7
M1'(Z.37;@Q/;2 -CFL 1(UG4<9D([XD)Z-Y#N-S3H]1/P1E5:@^6OPBGQ5S/
M*I-</SE3MT^WV(+2].0M*<PITGXC]XU^"A-#QI3%>A/;0UM?F,57)>[>UK:F
M^U-C<3D%"UEA<U@14FFZ'<QQL(+/+B<GV=="C"2(&-CAC&%;[D6&59I?FY3T
M[59'T+PJ U*"O@*YG"[9TM[?Y2Q$DM\\:!W.8KT\J^.?A7#;YRM;SS) U,,)
MVPZ)8G:"D6%CHTOM!'E-);T@3RI9'RBY7%4(@K(V.>L8(355L;929/3*_>E[
MBX>34([55!'-14 _2Y\17(TPFP-O8[<L2@R[@[:2*^8D&K \E04! )%2,1'\
M9!+"K^8OSZ=>/JB[JPB^)UQ8NJ:]!J\<M_+M+!#$&LR.+*_+PQHXD-G5")_3
MZE;&BMC;7MWE21HND&6((0*GCG4T\![,>@N[5N(_1+LH2L.K)+OM:$BH-X@T
MGQX4IP-,9_K+ G\" P^E&I%Z$%@]*,:_[A(4;[?DC&R_WB-_!'?Q>7G]?&H#
MMQJ?K_3W8Y.+J0@-U7KD:ZSQII)K7C3RUXTRX989NJQ.8VA%83? 'RNK(KB&
M*((Z>O',BT(T8QB640OH0YR/@CG@>Y4?$3$V1%7R5%DV][/;!EB(\Q'$ D:3
M44KPY@^(-,6/8N\M\[;AF@VJ6-1.T))=%D9#;L63IEJZ,F9' R:-F4@5!#2D
MXC@)H70R#:EZOKPZZ2==)8?<R?9$13V![Y41/_.KH8X60VDR(GW0[?1Y1_5W
MB2-XO :@Q\2?A%,Q0#W+Q4<CGGC?IZL=UQR"1'L0!*\@7Y>/2-:E8T _X4!8
MO:I_NY#JJ_#"M7\KQ59;@W8@%U]Y77EOH!XY[<L@)Q-["(/]D0'(BQ$4U:T&
M)0!G?PCO8BHKO-45M]SNGC,3%=)0*<@#1:Y@\F-3J//$"[]1^Y;W;Y=MGEM_
MEYK6*W8K$BOI@+-K5QFLTFMA/(,Y :$+04DK[B-JHOV;&N:YDB+[$2.:\=OL
MQR(OM^:/'9_ UWXL;_"GDGT\0=1\3]>*9UW84ZC$$$?$>#9D<>#',C@QS-3C
MY[L*(C$ B1J-;$C/M8$:C(G^^R)&^UY)'%)_>-;^#7?Q(GG]?!K/B?KQGYF6
MNKJO6M:ZSQ(TDUKQ(\I/$C+AE@6:%WGZ@HW>OW?5YC0N]?WGE[_J\XU]?W?I
M_O//S]WR_B\_!J/B?K\/W?9C N)%X2,*4^\<M'P\\M'W?X>5,??N8T5)/M&(
MY'-E1_L1>I'QL^W9*C_1YH^.)?;1WGYM;_"B^7T\&H\*X.L]-.MJ4I34>!.H
MBE>!/F(X$Y\<\?$E@1/0@,2-1K(T8@T"-1@[O>BC1J1>2,'D7UL;^#'+ZD\E
M^O@U'C4_7^G'&?F92=74>M2:ZCQ8:2>/%AY2>8R-1C5G^LO&RR^">CJVVLF6
M^^[1P'ST WYA!+1++TRIDFO8UI"J^W=."KON50:6(B5S?)LB.7S\6?LV?H]S
M63K%\Q,)TTQFE&.H *22!0UIGECJWI$CWFZ;]";@V]>R.X09LR8D&VRC4M*G
MR#@!P H!RQR-ZV6I_F0>/+P%5F>%FSM.,Y$GD)T*UDD,Q%W>DROELIC[6929
MX_>E)0%DZ#QO<R-B+[\M%N#MS2[F_59Q(Y)/PE@=*)6E%3),OX<LL\?+VZFM
MUOH3M'X%O'+;QA <I &2KS*%8^<'6K'*K4J#ECJL_2Z$#'_4C_5F(ALP323=
M?RZ6<(2"W@(K4C360L=9)8!BAREV:-2;UB.EB5GDGJ14]*>5/519!Z7]F"2/
M2WR=QGY?-^(,\B6YT\P&?#+CWGTX*?\ ,ON\*Y8"[BR.=,C[!PX?I0= GCSX
MN0 ]F.ZX/&<&#P8,6=C 637GC5YRUAY 94 5D@T1BUY<L#XQCD$G5("E$F<V
M3VW_ ,#_ $^E?HOA2%5<,XU("*BM*CF*\J^.)%I)!#=1374?6MDD4O'J*:U!
M!9-2YKJ%5U#,5J,QC21\GLYKZ7JAM?L[P[IUZS/4DDNLCSS<LT@:6,K[<'\G
MSE185<:A(U4]QLBO?ZOXD3R3QU#8YK:6P#VR""+6WDU:L\JFK,#G[L?1?T;W
M?8MQ[*CNNWK:/9ML-W,!;&?YG2P*ZGZL\J2'7EY2M!3(FN-P7)4\N6<V1(G0
M>6#R+?8<LBNB\J"O3VW++'#*KF>7DOJ8UW[T3\/'.=P_\_/S_%?_ .*./!/?
M))[UW<EM7_J=UGEG^,^>1(S]A(]IQ(/B'BK8/!@P>#!@\&#!X,&#P8,'@P83
MK=T+:FT<0:VM';7&NGL7RO@97PH-*LIKIXYAGPM%9YR*]LD:M1OFCF_BBXZ]
M1:#4:C+QSX<^.)=@)#?0B*,S2F5*1@!BYU"B4(8'4<J%6!K2AX8UL?"/-\/I
M^BZ"RYUT+):V_N><CGP05G">@\BL;K+DW%.A.^J[C<:&T&W &@-&"2TM@8YI
M[4E!)SBYWM'5;IW//N<MFB7D,D<2S$9SQS , :(0B@H5!.E&("C4%49X]>?U
M&;OZCW_:=K:=V;5?6.UV^[,A,F\V.Z1Q7"Q2Z;*2*S@C:S>!&E^7MIF5+:/K
MQVT$:F48V<>*1CQQA@]6T&LR?+^C:G!9E=IN,WA=9?8['M]WSU.HJ*(\^ASR
M(.YI#EN+0>(?RC5)'>YY-7U*GB78107%]#!=/T[5Y45W_A4L S9Y9"ISQ9^R
M=KV/?.\MIV7N:\_+NW+O<K:&ZNLO\M;RS(DT_FJOX4;,]6&D::G*N,&/BMVX
M;HFVS AWSNJ^SZ:VR]C:7'%!>28OG4@=B@4)%BD824\70L^N1)>Z-P=@;,2S
MR5A*N>BJEIW[;&L[5V7:FMH%< 3&5Y*BN6=>FVOQ4 ?PY8])^M?IS-VIV[>3
MVWII-V]L\%Y''%NS;G=WP9-96.K]4V,_S2@,)8(DC-0T(530O_\ 4/\ C]\>
M?D)\<;6J^46\T7-N0<YOZ_JM[KLU;U5,7739ZLNJ8=A!%MGM.PH8J/221L&@
M%<422Z*.'S>Y&/A=H[ON^S[PLFR1)-N$R&(*P)!J5;DR4II!))T@5)RSQ5_Z
M5/5+U5]*_5J"]]&=LM-W[\W:U?;8;6XBDE603R0RL56*>W*LIMU8R/((XXP[
M244%EY3I\7^@Q#/-#'U_YSE1Q32QL*@I,BV ED;W-:1"TKG8Q+89FIZFI)''
M(C53U-:OFB=X%WZJD FVVT'PK+E]4A'U''VSB[A_^::21K(^P^FR,R@E6ENJ
MJ2*E3IOF6HX'2S+7@2,\2KP/*?HEP]UXK-S[I_S6,WT76^<2X@2_J,>RA*U\
M>QIGYH:[?!B!YV5$]RD+259(QZ0J[TN:ODJ0-VNO4L[5<B\@VX6A@DUE>KJ"
MZ#JI5Z5I6E<J\<4KU.WS_P":*2>FO<4?=.S>G<?;#;%?B\:"6Z,RVIM91<-"
M#>,IE$6LQU4C6!4$98[0O'F_'Y[\'@P8/!@Q'ET 1-TW!6+,P$>,#F.A#3ZR
M6P]D_.2GE89P]2'6_=1_?#Z9 GOFD]F7[=:^-/4SW/)]ALIXT[9O[<W3QR/=
M6A$ 2J3!5N:R,^DZ3#J 4:EU]5LFTY4[<[2:3OC:;Q;&.6"*QW!6NC)1[<NU
MB5B2/6-:W.AB[:'Z?RZC4FOS2'XKV+CCDQ_60)J6_J W@I%99.N5_3:Z>0+:
MP7<88?Y7'8[MQ8+Z1M;)+:2-)C9*^52X6CQM]7H>GGX]=>BPO%]-A*'06J]T
M0*24\P9A!0AZMY1P(Z;'PH*U\N>J9M_^9)0HYF;MZ;,&HRZ[4(HM*@&GG //
MAC1_A+">SW_,3&T@03XNP<,-/:)GP 8:_P!?6,.'(H+ATB:# Z<B-LLK6N=/
M+(J?YWBY>K%O'9=A7EOU08:QE22:MHD  I2OQ#C2E...N?T9W8OOZ@+*[B _
M^M._(4$:C2S;)N)DS&2H*#1FQ:I (X8[V#+14+)_C7_V(F\_K^WW'+_E\>'C
M&2^K*F+W"X,2)[/U 8M_S7_RE_K_ .OPKIGV8>RP?FO_ )2_U_\ 7X.F?9@R
MP?FO_E+_ %_]?@Z9]F#+!^:_^4O]?_7X.F?9@RP?FO\ Y2_U_P#7X.F?9@RP
M?FO_ )2_U_\ 7X.F?9@RP?FO_E+_ %_]?@Z9]F#+!^:_^4O]?_7X.F?9@RP)
M;(GU5R^2>2K]43]J?M7S\O $ (+?#7&"0HJ>&-<?PE;JZSH?SILL[/#:MN/F
M7UJ^GQEE,.'!="USJ3.6A>=N7Q(M/?AO'&\V$K*"2A$;9$'54G2X5A.S6L4^
M6A64L.56)&H<P0:$C,',5X8Z?ZX"ZBWKMJ6.F?8VRL!XA3<@CW^:HY9&IQF-
M;1!:;H.'UV&L$RVU>3?872Q6]:D$ZFV5+'>4U!T?/>N$MX<K\JZ,4Z&5L[6N
M8\0F6)48]4<C6UE<0W.EK32CK3XJ Z&"GAP:M#ER(QP>Y2.>^M9[.L>Y%WC8
M'(!3YP32N=5ID,>.K6E9H*NJ2U%-P'0>=W=!HZ^Q%>*4>345FA DT]SEK::!
ME?M,L^K?/.2!/#[L44:*0,/-Z9/#6VQ36LA:,K);W".E#R++Y5\4(R\X/$\3
MA6Y/#>04FU075O*KL0!5E4Z21XU)X9GV8J]&!EU67ML=O AZ;6P GF<_W=)-
M,+2':(*%3:R7/6I'W,V<OCR0XV34AZRCG>KV8W'0^IJ%LT-M-'-:U:+45DC/
MQC+205&3#PD!J!GD:XQ?(UQMS6MVJ]?2.E*#Y#1M0XT:M,B"./T8MMZ5%O\
M"0T^Q2"N_-:7\SY7UBE1*H%+^T"B.H9[B7U.7(:.PL$':4(4Z6DL41(FO7S^
MU;G;_P#)WO6M]+:9*31-5B%)H0/XE KI(.H<3PKA.X%KZT*[@&"O&IBE6@4E
M14*_-6K0$D:2>=,-C3E6VGS.:W1Z#YKI%(+4:K ="KA"6976F I).5SO45B%
M12 7%K&0;6)2&$-B=82J^M*]SUQL?5K:TDELU_&M')C>(FCH#\#QGG4T8/\
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M>=>!F7B+<[=\L!T;'4@JV3,%:I(''AP]N*VMM3S.>:,#G(/\G8<3/68%=H8
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M^WXK/==NN;.1T:\UHES"\+.FJ<KJ57)6H(J!4$8W]^.3X^7^#P8,'@P8C2]
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ME&EM^N;5:(IH3 S-R931L;A<A'019/,1909P>7CS],S.".$/ <-1-KATJ1W
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M,8[_ /J.P?\ \XW4/%Y]'_\ ^Z)/_M-__HD6/9?_ ,RF_P#RDMP__P 2O?\
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M<L*>W>6V9[Q(Y81F&C?2Q'LK2A\ "/IQBP!\Q*NOYMH^G<UQ/<S>;2 9Z<'
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M+%FE!+ MI1DG=]GWUS7 9L7Y*_'UMMM"%KQ65E?)!'1Y(R'V;*Y(6:9Y T,
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M\],(D9]-.8)H;RAJ9QJ.'[,HR)[(YG^[ YX_DQB-1S/#B64/2K\K.Z,U5$;
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M%&MBG]&V%GK*;15WR&Y\1.5$;C/:S^>NIX*FPL[ROL*RNN:J$:VOTBN+/.D
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M2ULY-C 9Z2ZN-LK$&@G#D?Y^E\3?&TOTL[EK=Y+1X]49+*SZ=94 9.309FI
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M/9N1(C96O9*JF-EC\5B0P]O7-S:[J-,DBM-%.*/'<Q/FA6A:C/4ZEX1E54
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M40T]FV5!I5C=70F->),>U_DL+946-TGDCD5OGX7'3J+6E*CCPX\Z9T\:8EV
M0WT(D$1C,J5$A81TU"O4*48)3XBIU!:D9TQK"^!&[Z7K-I?U6RN>JFU>9YY
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MK_BY<2*<JYXN-)\>6_XCWNQH?DR[(Y#H^^RW7^I<M?P$0.30ZW-@Y:DF6AZ
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MLA<7T<,%?!;]$ZIV>BO6-B1$_P!I3H=;9%12.1'/F;"]K5:Y5<BIX1-N%Y)
MZJ[1VH.6F&V:I/"AC"L#QY>XC@9,=MM^M7=(Y;K/-YKF,CWB0NK>\4'CB9@+
MYE?#^699O \K5P-:YS0-XTZ)_P#>>F6P*$KZ#-*3.2Y?4LLI"*Y51/4WR1?&
MJ5>,\[7<CMQ'3-<N %:Y#E3+&V::2U%8DLH*+QZHH?::4^FN,6[C=:&U-O7;
M;Y#_ !PT>/JR;J=,K865E4 E(.:B5=/:Y*FG_-=* J+[+GDDGB2(B/\ ;>J*
MJ;E+>(1JUK9WJW4@%6R+ _>8:B=!YZ12GLQWZ#M'L#HV5QN6V]VG<Y%MZBR2
M-K764U/(LJ]9C(6&M(V*%>!49$KN<W6QTH5E4D1\,QE?IZ^MOLQI79@>CSH(
M3)US=DJYC20B/UT+88)JT=WLA1O^J-*]"(GA$MM;VQ#![N703K!):I^(5*^9
M3F&/AS .'M_K/N$.X=G;/W;?WEE,]M<?.S21L*J)XNC\LQNHSFEP4("B@+J&
M.+ZUR60P-6#;Y3K/QTT6_M[BR)+M][G,.Z:RDC"J64-!FZ[*@E)&-5&3S)!6
M5[4ED:>J,]Z9%>YA;N:\F,-Q#>):!1FC/R)J6+4XC@3S7&SVF[;:OG-X[]VW
MO&WV)88NH+:[OW$; RF625KEP.FR*@ (,:M#YOB8% NS=#T34&$91W$\]SD<
M)#+#"ZO)6M3?ZE<H%-=6UMKAJ:F@47+CG!O+BIR9?<5M;#,3'ZW>PLN!+:PA
M"S"Z:ZKDX<,%U&@"ZC\5#0GGJIP&&-NLSN&UP7'><'=YW+YI3;307<3*QGD6
M*V5(Y9B48*RKK":G>X8'II'5VQ:]O&S.H9A*?0_#.T[";#5Z:GS-?2W;H*:E
M6_KJF?6Z>Z=5L$ %2\(D@2.*3\Q5)1U'17RK*BAMS7-N9Y%W%=K#,"Q8 L=)
M- M:TTYFOER(/(8Z=<]A[C!VTO=#;1ZEW';1F>Q,SS0Z1.UO+.(@@FU$+;()
M69E,1*21GS!4+=M>X\JQE!;W9G9/B];763OPL7VJ]M<U:6HQ/6MP3>Z"]$@$
MH,G:ZRPEM*QP3AT%)D"%C!G&F1KV-]N1;V-W/(L<=M>A'4O$NI:B- H6I9@H
MH:FA%3J4C(XD=L>C7?US);;#'L??JV-_;S[CM@%U##(^WVW0C%Q*T]U%9PA)
MNL'#Q)(5DMWA+1@ZW%PCL6<Z/-M]GROHGQX==<U92U&?S^2IKS/%5>7*>2FB
MTFIHKG-#[>.OOF+7UU*=&/*LH4<TD:1R&*QT;<MMN(1';7\-X(Y2Q9G96#,*
M:0K*Q3+S%E)\*U RKGJ-Z8;QVGOVVS>I&R=YKM5_\TL$MY/!<)+<L(P'M9H+
ME[(2(4G>6(RHX#*)/PUJ/7?.Z:Q,S74V\Z7\7&":2,T>P+>EW>KDPB2*^O<R
MMH8&W>F/T.I%.DJP! JZ2TELB6MCC5D4TD:]HVVU$A>U@ONJM0/A&JF=2QTJ
M%4BI8MI !).&>T_3O;-X[B_T_P!F;3Z@#=9$#_A-#;5MT5VFN);HF&V@AMF5
M'ZLLXA*5;5RQ-.9ZGP7H.?\ YBJ^R\M&_DB(.HUV;O\ G]#2DXK0Y^BKWW58
M74=5J:7>YR&$-ON0P$BQSQBO:C7JU$\:JYM=XMI3%);3_BDE2DC$.K$Z36(M
M&W($@D$XA;KV#ZA^GM]'V\G;6]R_/J7LIX+Z>9+NVFF=8'2;:Y9K">K>1C%(
MRM(K%J$G$=C=;Y0F)UW9-#U7XL/XGHH!(.>:D'*#O;6WFNTME7\^)TU:'G?O
MG@"A7(8$Z$#,1A STFDA5\_B3\I?":*PB@O?S%#^("_%54%PA+4J2"PH<P10
M'+%ON/3CU%W#N:P[#L-E[ZC]1[)V.X6SW;#J06MO&]^EHS7'3#M)#+.A20UC
MD70L@6+%MH^Q5N1+RF(OM?\ #T_1WP^NBQ .FSVQ'@/KLZ)'J+Z4,$>@AK!1
M1*X><HEB)#$^3T)$^:5%]Q<>W&Y5[I8]P6!2FLJ4K5CI7/54FM ..7&@X2=H
M].VW:WO^Y=CVSU#_ "RT>T-[+!<VK=.2X<VT 9FGZCL\C)%$3K8+J+JD9&G[
MRWY7<WU>H'J']<^)P.=VU(<97#$<WW>-/V%+55A=B _+IM,OFZ/3B,)4 Z>*
M&<]T42RR1M5B1*AN&P7,%N9%@OVFC85(DC<(20#JT.S*::E!HM30$UKC8]W^
MB??>P['+NDVQ=[MN>W7")*?GK*]2UEDD2-Q<K97-Q-;/IZT,;,D 9NFKD-U!
MA6?U#,Q<[@Z$S4_#5>;U>:@Z36[.PJ63%#YXBM*DM=&ZBJ:8+TRS5IDC&)#6
MQ3?@U\*R(YOACY"<7?RICW+YQGZ90'(FN2ZBQRJ,_,1[:8UT/;>Y7'>;]F?E
MGJ,O>4UZVWR6R/1#.LBB. 2RS/I D522;DK]Y9 A4X5\9\GLUT"^@S'&>U<:
MN,U#5 R-;H<)U+-#9M*RKJA[Y:VY3$9K,1CRZ"R;.V,PUOM0$,_@1/KXQ<[-
M<V<)FW.VN5E+$>5XFU5)TU76S?"*9+F0<1>Z/07<.V=L?>/4;M_N&/=C.XK#
M>[=<2S&221H.HGS=Q<DB",I5(3J>-O,3B\.[IGL3OZRH[1V'XI9(S>U%B%GB
M*)2;'<C$2ROJ*C1$7<HME6PT-Q.@T35MB6B%3(P-O][_ '?A,>V2W-HTNVVU
M_((6&H-01D#,J%R)89GR"H%6X9X@Q>E6^]R=J2W'IOV_WQN%AMEQ&9TN"(;0
MJH$LL"QZHYGFB7J,1:QL\:ZIRHC\V%;JEQS/G'.-5MW=>X&5%4K47NAN-[B<
M4T:AS0S7CV$Q6>SU(?H+ XV(X-(O4+)-"D34:QK7.3PBP6ZO;U+>2"Z0-50(
MW<5;B/,S!0!0USH?JQJ^Q]H[T[F[NL^V;'8.Z6:?K0Q0V=[>%I;AB&C"2W,T
M=NB(4EUD2A6U$DU53A%U^VS.8H^#[:OWWQ:#MMX3G\M2%D41A5)M.B%5XM[7
M#8NTSU$9;T4-?0 ,>.-,\540MJR2P+!"QZX(I)I+NT>*],<>ICY@&6,$@E@S
M ,23F17AD#4D;'8>T-WW[=NZ=AO-L[XFAVI)[J:(7*I+9V"NT,ANUGF2*8R3
M.1(R]0'I$(LHDD98D3Y1<ZT.G7+VG3/AP)JKB^L<Q3%F<_Z75UI>R(TEC1%!
MNU^AQ0V0*(=J!&C*KC)T)LHY8TE5_DWQ/_)KN"'YB*'<#;JH8_B1$A-((.E7
M+CRFO $+0TQT4^A7=]CL0WL;/Z@R;';VT=U*D=_M[NEHMO',K?*VUVUS3Y9C
M)E$C1V[(U M3A[]![]S3"WU5R;=]-^,-5UO-6GY'89,C"Z&3EF;*T3\X?C\U
MI-&1C[:BRUS9PV1<RP&6U5/[]D))Y.8Y6RQK3:KZ[A;<+6"^;;W74&UKU6TZ
M@[*NL,P% *A'%%8>ZO\ :GI'W?ONT7'?W;6T=ZW/8MW!UHYH[N ;C<) +B.Z
MN(+5;N*>ZCC,<2=1+:Z31;SIDP!24ZK0*/:VYY>C^)^4T9 Q#**YI!:P@L3>
M##U0X,QL]HDSZM!ZJF(\O3Z$8][8W>I6L>NODMCTE"IN$D-1J#$T*&I-*<<V
M'Z_9B@W,<5Q:6]G:6/?5QMB.IFCN>IH:R9I2ZHL6D-JEFCY&H#.-(9E$4V?S
M,MC]9+RJ?LWQ>M[NXTI&#1KZGHA>"(O)*HB9:!>F'TXW-;/71D>B.:GA,<0]
MCE8D*R^<2;%.VX4M_P P-O?)&J!\C&) M?BZ0/5"<PY%/;3/%SC_ *?DLMA_
MUO\ Z;[TCV>"S6^)$FWK>K")5'7&W1S-N4-J5J4NVB$:L QDZ=',B ;OD%Q9
M4G)+/LW$\?U<C,E::]Y_D,OG=)FKD.PN#LZ/I H[\"=C62PM<*3$DJ2HUKW/
MC]GZ^(K6NXVZM?I;7$NWZP%D=B'% &H=)K[1]'/%)N>SN]8+&Y]0=M[<[FO.
MRDO5MH+V\NKB">*2.)+@V[&"0,:&DL;4(J5"DOEAI9+K')BMULK"LZ9\6M3R
MOEUM<Y'= R4]#6Z>AO:O*U UG"VPDI1A6")=,+G>0*I0#@SY(6J[V6HR7<;=
M?/:QUAO8KZ90R48E2"Q(R#5K2@H:-4 GCGN]Z[*]1ML[7V_;;_9.^;3O7?((
MKJR;K3RVL\,EU,T;*G6=]9A,2+'((IA- DCJ.HQ: M5W_GQ&6KZROZI\7'KN
M\_G.IXB>JY1U=TEE3#W!9F4U1M7D>?GQAU,&IIG0L4QCO=9"1YMB=(B-V=KM
MUX92S0WQ2-S&Y,L1TF@U %Y!6H(KIRH0,^=XN?0/N3N*6:4[-WQ;;ELNX2V4
MHDW3;%^7ODCC,MO')=7RZG:WD!D$+:=,B+YE!+2SP;LZ=5N,>F$TGQ(N"YL[
M'NK6AR]$?+>4=13ZR*GTU]GRHA$B;)2:'[P4=TA2QN5P\[HFI)(_Q W?;DLX
MY&NH]P3SZ%+,*$E255L^8H<APJ >&*%WEVQ/VOL%_>]W[7ZB6,27C[=6_FB5
M?F7M3)#:W"%V-)H.C,VF,AXS(J.PZ8Q!&E^1_'.8[O88%W2?C'+67$%GH*^2
MXP6YTMC1B;N=VA!R!A^'PLXZUQU+9,L0!GR$2I Z6%TB(-&B;:VVG<[NWCN6
MAO>HA /XB*&TC23223B&%*T'++/%Z[2]"O4/>-AL]SM-D[[&W]91&T6XV-O%
MUK9NC/H2_P!P$BNETK1AD58LP$05(:?;+<6>,J<]U+G72/BY33U'/5M=1#;6
M .5S=_E;.Q/M7Q%2B"5MDL4-+",X%IDD4@5C ]9F^F>9'ZEK*&XD-C=17K:I
M]*T!9E8 #F2,VK4J,QP.6.5S]E-W!O\ +MN^;'WU>[DFYR6UJD2FYF9A'$CV
MYZCR0@M<AG+QAD92NAM"Y7^&ZU6?(VIATTVZ^,VVY(IUA0::IM([2LVU4/,!
M3RVXLN<U2#W.6O@W&I"]DWH3^*.5JN8L4GA%Q:2[,P@$5[%N.D,&%&5LVIYE
MR*T%:#G]6)7>?I9_R[L[C94V3OK:^[[JSCEC4&-H*LTO3+36C-'/$V@LLD3,
M05=-2NKC"H?H68ROGJ]KU#G6S$L\W(1SOH.SP^*DI8/N30J$2RW5F/7S&5Q<
M4U1]DRP8KP;)(6K+[,D;6NQT/F)1+:PS1%6\ZJ[ZF-"=(7*N1KXBO'/%$V2Z
MWS:KV.PDV'>X=ABO4BN18WM]+,%5&F-OTB_E>DPEUT&C422"YK;&82>TK:,G
MFVX^*AG4+FSLR2P8:RDL\+N\_P"\V'+B.I:X.6=-/6AG#J^V":A2K V!8IH7
M)[:DW!(I&6]BODL54"OF#HU/,:DY*:&@)(%:Y<[+/HM^X+ON&ZA[]C[0BLH%
MH9YUEBEIKGEDD:0*8B4E1(V;2HE9W8,@1F;/T._T3#,CT?,?'(.J JCO=)/P
M^TU&;KP<Z-^:>Y6:"DJ"XJ$*N+B*G?(0T&0=OE(R-LK7.=(^4@C(N;"2]:34
M,@Z@M7+.ISJ*"AX\#RPY\OVS80M\U;]_0->W$2!A<6@5YKEQ"C$QREW>4-%&
M-2@ELF8+ITOCBEM95%%IK*N['\=[\0%D0(H5.\.=5EHASDG"N-+$?07[I8I/
M;:,PF$]8VN<K55KF><?=DB.E9X+M&TG)LM5:4_B4CCJ//Z\<S]3(;>ROK.TV
M=^X(JH\ZQ[U)U2$E*Z&MEJ7T&CZW=V9B%#'4K8QLY_O/FW\@^1\RZY8ZC],B
MM;ON<Y7H%<#?T/=8]?FJO89X&_\ Y8+N*[JT)ZE54=@K'I&^)CW,<K6L148E
M>MA=QA9XC((Y"*_ADJ#3(T+4/AR\<<MNQ8RF1+B.W=E!J3*H;+(\%)7_ .=Q
M1K^9?*^>"6*AZO\ %'/%$D-/>+Q3GWS5TP9,S(W-A=.&'W2/'G#2H_\ C9./
M[<COQ=ZVHJ;UMQW-6 N?EGCTT'5A@04I3CJ#5RRSXY 'AC216.UFK6:W,3GB
M8)IGK[" I6GM( _O+QQ0T//?U JN""SN-W\))AO3"(>FWY?T?E6AM85C;"V2
M!*CO6\W%P<9$Y[7QR6-6V1S48GDB^2(MKEI)3!;2"%V ($:22@-4FAJZ*@RX
MT?RGAC-TBK'U9D9D3XM<D4;$?0DC,?8&4X9<6*^8M-(5:YG6<0X]6%CMC)LX
M>#=]Y'S=L,$D;'3Z/8-^0.J-T$/IA14?+$R.:%7?1$<JI-$NX76N&22SNF!.
M1!DDJ17)*KI(K0 U%<Z<:PA%M4,BSZ+VVB(J&H((OI8 F3WL 3PQ)A>;^;NE
MS\-#@.J_"#L=')[7YODN>\"ZUE,0=8/<GWT^EZ#6=V*!F);ZE1\<)<,LGFGJ
MA57>7C5V\UW;$W-X?EI ,G<&1](% 40/0C+EE7*N6-HT=G=Q&VLZW<'!DB9%
M4_XY-&H>^M<-YV<^:V*<+G8]_P#'KA1\S;*:UQ?Q_P")]YWWYQ'/!*S[B4.B
M[[HC@WK%'ZONGT5;*Z9&HI**O\4D_-WJF4M:WS4R>X7I >\EU'+RC4X')3PQ
M'"[?9R_+PK=6:G[EJW4J? A59L^%2BC^\..%JIJ/F)#FK^LO.V?IW9:!7).-
M:])X+T87=$^GU2$6.F"N._%"QV3H&HD,Q$ATZ.\_6U'(J*W7<=:20B61J?[H
M.8U\*4=:"M00JJ,J&N%P-M;QR02F*,5S$_361J'G6/B.(J2? UQ98?F_Z@D9
MC3<")\9BG$)&*[IX%+\APVFA)(03,N;KMI\A*,@N%$16M'$J@JMWN(V%_H;]
M&[NYF=D^<N(51!_*,% *T%7*<?\ $S%AX9X:M+>#4TEC9SLY/\WYD&OL4."!
M3C2@KERPK%\I^>MK916/0NO<&UZB2.D$K.A?#+I>MS%8Y))'1OAJL=W$BKF+
MB8Y&>_.XHM?3Y^MKO/P\MU,E?E%L0*$:UE>)CXY,X-/ #EEB2]C!JIN#7;/Q
MT21K(O\ LE(R"/?G7#\'SGR:D!9'<[KX'I/7R,E@^Y^&7R1RCFQS2-8WT02=
MPA\HHIO3Z6^G\%54^GEYZ[5ND@5M3M V8 ?4 PKF*R#CGB8HV95T.L(8<FC"
MT_\ T8/[<>9*OY!.G6>;H_P"FG\FL>Z;XP?(^=ST:BHUKD([C+&ODJ_3Z>7C
M,2[S$^N$R(WB*#[1)@DDV%_YGR[#P-/U%,*L[/F9!%#-C^S_  BHT]MXK_Y0
M^%WR&.)AF']"*_S![?-"][V.:Y5?#Z55/JB_CX:"WR._776!GYY&%*GV2&@]
MF'A\B4_RTA52/ABBC8'Z6082VT/Z@I[XWD=1Y%KGH]LJQ)\?NX<ZII5145JR
M/@^1F!E? _R7^W+-Y(JHO[O#[ZXUI*;*)>1TF0UIPS)_5QXX R.0*7TI!^$D
M1K]&FE3[/#/#PI\9\_\ +(=(E]\ ^;4Q<2$J8_D7:)K(I\L?N(1:2#=\8%*^
M-$\WNELR'+Z5_B_SEAB6695$DO6*FE-+$+0G*@(X\>'/$A&2WK+%!\LY-=19
M*O[26!S'#QPQ"JCYCWD\J67</BEV4ADRO9047QY[W:Y,9\3T<QDU;GOD&#BG
MI%)Y?QW!LZM\O/U)XG+^9* D8AMX]/F:GF85J *DL2?[H5J95Q#:XVEI6ZTT
MMS/]U.*5 Y@ * .!+ C"]!OOFOD.H<$PW8KOXSTF![/K=SBT+Y?A-Q2;[*Q8
MSCNYZ@-:(7L.G[KGM=%._&H&Z%8#DABG61KT<Q&^(8DCCF"@B<5-0 W',T\Q
M)J*9@@>_CB:'N)H6$:BV( .96E*BO!1R-13G3+&6%#:9JLD/CYQ46>]OCY?1
M<ZC[^><0PB)SF_\ LP=*N8Y R(!G_5HM>IOL?5(A6I]/$B7KD?YW3';4\JG)
MO8: _;B*C675T[<IFO0?,Y!&.>W]>>,Q^K^,SKZ(=;!,[U)28:>8@D9"EDY8
MK5K_ 'T@LT%AE=$SWG,;)[WI]+465(E]"?T^&@WE(*Z"\''GE(?L&8]M.>.'
M^LZL\NV/<K\,<U6 !Z8)7/V9Y&F=*\L:=,,.L6OY2D+U'Y]52Z>2HN39"Q:_
M1ZJ;(U!FY U!<#)3:*N" )CBA:-%.Z-D?N0P3123&,ZSO;.VU;F]0=ZU6VI<
MC2'J?@LBL50L:'42RL!J9=3@ U+MZ!'WW:F4G\B1+KIN2ZAYFBI.LS(KNB "
M@ 4AL@P5"S"3<!7SKUKY4Q54FM@NTXUV>^S-53YVF_+K$^HR'OYT_?C5;[2A
MS>C&=/)8CDUTWO06:^U_L_K5DNDW:9?],=NM*+9K?\RLDG9Y)#H#3'JQVTC@
M2O$74"C  JJZA0 XM';<,B]X]TF#YI;A=EOY(!'%$-<J0TAENTC9XHK@1LQ!
M4Z@S&E"2,2S\ Y<!%E,-)3.U)VOEXQ?SY^T"RV(7>5&ECT=\([^4S-%81TMF
M5 9%[=- Z9Q*,A9)Z8%3S95O6^3?;B^NXKTQ_D1W8!D,LXMVB9;<DRE8\F8D
MF55JM2V9S.+;_3\FQPV=G\HLW^H#L^J.7I0&X6;5="D74D34@TJ(RQJ0%I49
MK/ =S\BK'C/5Y_FV#<D$#9'G4_-@C*#"F8]M<1GK5\=P9#+9D:(SK\C)2?YD
M#"8Z-$9_%ZF,]#*4+/L%>\MKB]*VA*_,W@NG6282K(-6I(ZHH-HATBV)8%N(
M!Q>A/W\_9.]77K;'*\BV5F;1'2 P,I*Z7E!<GYMP7^90+I4 $TQ@IDQ*&"?]
M0.2FN.AQ92CRW'Y76.<S=2TP?7DF/J2:D" 1QCJ#%7%"8>+.9"@Y<84CHWL5
MCECE[%<SWUS#V1--%MS;S)-<G1+(0&C$2ZG:M29]0!564ZI.(J-0X?L]IMG_
M .$!;.6^AVR*"T8-"BC3,977I@@@+;],LK,K+2*@^$@%">!(GQZYL)5MCATL
M6WSQ5*+4@ )%>S_SM?C9")@@LAA5K36<KKI;4DV)UHPD$0;[!1G.DCV3W")W
MYN!F9OE?EW61M3,ZJ(XC<Y-41B*L1@$)8,7F(<D&FD:T<>FNUB(1INHOD,:!
M%"NQEE%L:J/Q#(>L+CK!6 6$&, @F(=$.!+J8)96N#MR9:XK2UD4\\X%%L93
M&0Z$0<T]\H21MLY&*CFNECBDE^W;(^)7NDL-O<"+9WC0-\HL$HAJJJ3 5_#.
M7'(DU(J<SXTK-Q;J-\C=@J7G4B-PJN65;@NAE"U)"CADIT"N5!CK*_2;94Q_
M/#]6=H3[S\Q_Q7YM^<16XU8,,V=&;S[5]/\ 8/\ ?(#>*K5=(1'%+ZU5JHOI
M]3O+/J^UVWI]V7U@! +*<)3,D50Y^!]U:CV4QVOTQ6!?4/NY8S5_FXZ\<LY<
MC7GSY9$&E2<;_P#QY[QW?!X,&#P8,-'H$#B<%MQF1>^XC(Z6!L/VWWOO.EIC
M8TB^S6ET:%^XKO+VORX_W//T_;3^?M.D69TW<1X4D7G3[PYZEI[]2_XAQQON
MUI!#W/MTK-I"W]N:ZM%*2H:ZNK!IIQU=>&G'JQTUC2!QG X>JVM01V+F1%OS
MV,"R;:UC?CWH+ELI<E?(VL?^593X!<PNI5B.5KO..V&:SR\WQRM18UZCN5W=
M26S+MLX6\)%#\PJY5SS:_E'#Q0^\<<?1OU![G[DO>W9XNPMX6#NHRQ]*0[Y!
M%10XZ@ZESWKN$0JE1YK:0G@K(?.-YV591QY?.,S *UF;915#<_6K5F4:U](T
M =*H):6Q%"L*A104C9]K/##-!Z?0]C7-5J<LN#*9W,YU3ZSJ-0U6KF=0)!J>
M8)!X@X^;6]MN3;S=MO,G6W<W,IGDZB3:YM;=1^K&SI+J>IZB.R/74K,""5_P
MSC5X/!@P>#!@\&#!X,&#P8,'@P8L[ >,L X66&4B(D,D>0>$AXDT\<T+XWPQ
M%1RP2#2RM=Z6R-D8K%7S1R*GGX4A*N&!H01[?LYX?M96@NHYD8(Z2*P8J& (
M(()4A@P'$J5((RH>&-9OP(X)ON4ZC8W/0>"E\LFGSQ6<R=[_ (GX[3129(77
MERU&4N<QDH5F*T(M2&$2^_L3[8HQ5D;ZQ5=)'/=^[-VM+^"*.SNQ. ^IUZ3K
MYR@JX9_NDDCIJJ 9?%D1[#_J=]3NU^]MFV_;^UNYX]ZC6Z6>YA_+KNW(NFM5
M$MS%<71HL#2O+&+*"&VCBHATS!4:/9]XHV/&N(]ZX5O0>5=,-Y6"-9].$P&Q
M)YW7&.@8*=N8,]8RY00AQ2M%]DB]; QR2JV)47R>YK?-R2]O6U:_@6^)6R,J
M"0CDFH:CEG\->&>+5V+#VS<][;/;]ZR/#V=)NEJM](FHLEF9T%RRZ?-58=9&
MD%A3R@F@.%G!-M\OMGU;(ZG5UFTJN%: #6Y<G(]*Y[E,3JZ8/ 8GGT%9U;0H
M$T/55>VZKU4^^9!3N9^519\5DT<$$B-DELN[6W;]M8200&)MT1D8/'([J>H\
ME8EK52D402K_ !F0D$D9#T+ZG=N^@_;_ &1?[+L<VWS^I5K+;7"W5A?7-W;2
MM>W=\TFVP:]5M):;;MJ61>Z!^9:]D:-I9$U*D8_K)47R;T/Q4S8/Q0@["1TI
MG:<D18,XD;J -<F2CRVZ99N*FR1(MFM$EG*%[S7.]E9?:5R>:-\IWIS-LL&^
MN^_?+_)?+,!U@A35KCI37EJIJISI6F+E_0#N7H[M7K9>7/K>VP+V@>WKI4.[
MI;/:_,FYLS'I%TK1];IB700->G70TKCEQN</^LSG*BSO]"_Y]45%2@%VMQ=7
M.S['65556 02%&GV-@;?P"!ABCQ.?))(]K6M3S5?'=(KSTWFD6&%=J:5B  $
M@)).0  %23[,?9W;^X__ )GYNU]#M>U#TPN=RN)5CBBBM-JDEDD=@J)&B0EG
M9F("JH)).0PP?B9\H_E[M/E)\<LL_P"1'R.U8MWW'E@=EG%ZQTN\@MZ9VUI9
M+L4ZI_/BHSZQ:B.=Q;)(W1?;->LB>A'>)?<.Q]NVNPWEP+.RC9;:4ANE$"#H
M:A!TY&M*$9UX8L_KCZ+^@_;WHOW9O2]J=I6,UOVWN+QS_EFWPF*7Y240LDO1
M4I)U2@C*L&ZA73YJ8_0O\>0L?E:P>#!@\&#$>71Q,73<%7LT=:"*;F.A$$9>
M<!)K702@E89HUI76*B2.!$SB&2,)C2>+WU/B7TR>WYLL-E!&_;-_<-;2/*EU
M: 3AJ)$&6YJCIJ&IIM(*'2VGI/FNKS4_<[J:/O?:;-;V&*"6QW!FM6CK+<%&
ML=,L<F@Z%M];"1>HG4,Z'2^CR2'XKV+ACDQ_5G(5OZC'48YJ0-@<?Z9/0)':
M=U08^RAD<=KF2@"7<"O$'B^U<KG13-1RN5/2OI>YKO7'I&M?3.W$1D,Y[JB\
MJD#@L-*5RY\/V8\P>HS4]3W#]-(AV_*2[<A205( )XT -*<<:/@LT21@;EF6
M&_,M%N[FHY[G1@"P)3F *>(9L+MM=9N%EEJ*8A:\"R/&(ADKT-]:RM5CH_'7
MWW)?SZ#YQ:6EG#)<2L1Y"^@]"&BAO/(E2-0IXTK3%5&URCMZZ;;RIW"]F2UC
M3[X&I?F)SJ850,(5+!PP9@ >.,C\D)F]'I/\2WH#L*SD067Y[SIX4EXE4%H*
MO+-K+KK.\J[^0JT",L]Q&I-'!$4+&KPHR8CEC9'%)SZ\N+^RMH]@ EANMS+7
M%S45:2)G$D5K;LIT-IA $@%:(V9!;'3MNM=LW.]G[H CO-OV=8K.U-/*DPB:
M.2ZNU*EPS3U9&!6K+34=(PX[+E.F[%4YRXH;2A.Z1C!1LW;4&A+!KP^N<[I'
M'D!"6.E^TKQL]TC,_FQ$E1:O>V*5Q,L)TGH;ZO&JC[HV[M$W.WW,5R.W;IC*
MDL8K\G-Y%?IIF&MY5"K(A (*$Z<QC>7/:.[=\10[E9/;2=W6/X4D<KB,7MNH
M9E$L^82[A<L8)%\C"18RU0<(M-VOYRYC'3\JA^+W>23AB\]1UKA-!;D9>2D,
M$':>))H0JTL:"2ZE2%X\<),L!$5A,ONI_=^K;7?9WH]NN^KW0F^[88G_ !"S
MQZ9'8D$-TQ1LZ$ :<@N9QJ[/OCUXV?8V[./;F[K,NF-5#5C6,J2%ZP!0%T8$
M^;S5U<#A5P?&]MRJ)G4.ANJ*#<1YX-^ YE =6ZIV<O2JLFGT?2M[IHV7-?;:
M]&7)HE4&R606M")<^;_:6JC8&Z]X6/<S+VYL)?\ *>LPGO-)59N)^6A1Z%(V
M 7,@&IR!&)FS]D;WV>A[I[E6"#<XXXVMK,LLC0EU*&XN)5J)+E2SJD:LRI&I
MS#,*)U_%4T!F,[I.&R:YP!F,RN[MK&QM4INI8M\\P-L$0RDC30&=4JL\HJPI
M!,5(?!7MCC'#]IJN=LK@W&WWG9[-,FWW\<TEK&B1]2U=0LBA6K18 Q=7)XU8
MU(-,1MPB_+[NR[[01M>[<8(;J5WFZ5T@+(^I6&MKDJ$>$*3\(58U913'A^1+
M!RNPI;LAA+\1K9=7G=":T8&+5<ZV@M>MGH:H#W;>]L*>G,EK)S2229?L#++V
M',A2)ZI?EW))MTM]Q"T@N;1(I4H6,%U#6,@M01@R],J*55J'/'-_R26+8KS;
M)W!^0O'F@=J(UQ9706171&U2TBJDC:RKH)%)4D&O39^AVV*/XIZJ,9K_ +=O
M5-^Q7N<]?.2$;FT343S>YKT;&GI1?)%1&^2^:^IR^;_6_P"8_P!5I\RI69;6
MV!!X@%)&7W9$&@RI3QQV#TK:(;&(H&#0B:XH1]XB2,,:_>-006Y_1C<,>"!;
M!R5UJ %:5TWDZ4"R$'."E5$^BR"EQS0/<B?@JM\_P_<GCDP$J!98&*L!3(T-
M/"OA[,=,FB@G'1N!Y/'#.9@00/)<S>Z?)(BHK1*JU6QI&JB^:(F<TD5W3#Q-
M7_,&A@1$^B>7B8+HLNF>)),N8I]HS)]^-9\A GFMC)$_]TU'_=.0\<>#*W?2
M0($65@MI6^EWF)HJ,ZBFE<JN]2RR"S::H5[T7R5S0&)^WR^J^&T:UCKH%Q%Q
M/D//EG495XX)(;RH),4X\'KG^[[<-PS+, 8$G^#Q-5,D+B93.<;X6K:Y2'N1
MTS1H+3"3N<Z&-K6I[+G^CZ?3QF*0RE7-SK8,0%D!H 1Q- 5;/QK3#;0:!J>T
MZ9IQB?/Z.>>+=D<L#XVPI\A:B2561-C:T350M;(Y&*U/>;KX$1/5YKZWJ]4_
M>J>)DKJBF9S:-4<!5:4]@'/]>&PHKY1?)[:AOUG"B;H"(S)O3NNQ01C2Q1M'
M/YBXV22*.-C(H5^PYNJN:UL:JY6*BHJ_VD_#Q'2S+0@FUMB3G76:^^FK"C>K
M&=)O+D>PQ$T]E0/[<5PM+.2;'*S<]48P&&8R2$;DEC$LGM,56KZCN=2?QI(Y
MOX*BHGU^OA,EKTXP'M;:K&@)>GZF&,B[5CJ%Y<Z>?X>7U%"3A)>:86[^]NOD
M%8>OS5709.NJFR.<J^KVB6Y*JF'1R_7S66-/)?/S\OIX>4(#H5+5#6F9:BT]
MN?[<-F25C\5\RUXZ5%?;Q''Z,74=4LP);Y,9VF]]UT(2.T/11Z@:1'/]Z5)!
MQ^AA0R,]MK47S@5_U\_Q^GAJ5M<R1M);47(E4)]E>%6I7"S$",XKP^PE0OT^
M;%J)CB&/=(!R+G-;*_Z.-TM^NA.7S^J/?[.7LIYE3S_B1QC7+_I>7XR)KI 5
M+W,WE% 4333*@(J10\J^&,+:R,"D5K 5(H>HP-1X&@:OV>_%1>4:FNA#=G-P
M#R[WW36,]7S;,,6@)=-ZHH$,S^NM[O+N5$C]:RC509#T7R];555\-+>6T\KR
MSQM<OD TK>;QX@:N?\1'LR&$IMM[!&$M98K1/X(T\OVFGU >W#-M>56=B7 9
MT*KNNM$0,? -H\QK#,/J1XYV+$YL><J#<H-_$R3R],%O*GJ^K8?/R\I<6XK;
MDBV*6XXZ677'X\2&Y\?+]>&I=HEF;7N!:X'\4;:'/LT@ B@RKJQ>A5N7I9Y,
M[E+K,BLD] BX?LF+'J+8Q(D5'Q,O7 4=W:2N>CO[V>.[<OT7U.\_-6NI<3(9
M[M6!D)?5"_&I.>BM!R\HH* "E,$<-I#2*T9 %%-,J>8> +MQ(X%JFO&IPO@5
M1F=)1[<]T; PP)(5*1SZVAZ'C71-:Z1\BY4X8XL469_EYLAI!U\O\[Z>?B-,
M\;Q4:2&5B0*2@QN:F@SR4E1G\0 I]&%JCVQUO#/%$.)A;K1T]NKS&O@ 3]6&
MJD=+>V4\XY?(];=RR/DE?!-=\9Z&LWU61)IJZ8PZ<EKD7S\X!F(OE]&IY+XF
MT:*(%EF1  M/+.E0?XJ9 \0 .?$C##+%/.$5K<@@FHI ]?:#IJ??SP]86:FC
M#+EDB[;2-D8@4#8"L?U:H\I/_8AD*V#;G22QM'8K$]3&KY.]3D1WB$XBEFH/
ME'!HWF#0MER6G$UX@T&51A]8Y8E.=[&@XZ0LR'WU-!]%?;A!2\&$\FSZW-"2
M2-1$CUO"M#3N5//S1\JQE44<JH]/XW(C(_-%\OV>'WAE*%I(I=9J$*SJ>'#(
M!CERJ0<-=:WT%NI!I''7:4^LFGZL8P$6?O%WDH)'P!LP!VGW1MH580AV5542
MWIZ$1VX:WSW)()#!(R3W%]C[UCVN6-'.<FWC6,Z3<#=210*HU49@HS4^VH('
M'3XX]8VNZV>W[5MNWMOG>VV[C=B&-5BMM,-Q<_+Q:/EUUJ3U&>-HXUK+T)$-
M9&"U1;6ZT&FK:.NM]9\13*\"*8*.LH+6A22M@>=/)% ,1+'L[R#[>9ZS2H,V
M'W?N)?-S7QM6=<200-)<E-QKQJP;P&9H%!/+S5&0-/"-;[EVOMM_=]'N+OZ&
MZGD1F>"S6.24Z%!+JJU(9:*M351&A (<])S"BT]!L[[1<LY9R?=1TEO86(.]
MT+SX-!1. $4@6S%TFH('B%]6<&$,(C&EC\EAE7TMC]M_A'XHMA#N$\\32*IZ
M8K1J\O+6OF) KXCG48BVN\[=N6P6VV;I>]^]66W2%XXK=W@N!))ID1C/T@^J
MY::*.A9:.@6K!TQ+%ENODEH,O 2(=\?LU3$5ENS6AR[8:SLI89R2G1US+LW[
MFFIXOR6!\<S/MC?<1DTSE8]J0)KC:[0DVD_-O+J&C2I]E:@4).HY>&5,JG&G
MV[M+LIMXGLV3NBQ,4T!MYH[/J7341-=(]*HC&X8:'1GR*JI(/5QJJZG7E<O^
M5-]T.DY=RO2,X=B^/W>DR6'4_7W_ $L"RONOX?J.?$"GBN9++="9[;-><$;+
M Z"($![/2U(8EO=@5O=B6QDGG1[F68*7HHBH(7C9C4>34F39U+./$CW'Z:[S
MV=O?HC8>E]SW-OUON_=N[;O#!<WSG_(3I!M%]MU[=3(5:"Q>XLB(;J@B9IKJ
M*OQ$1^7\9>@TH%X .1B<E?L^3?Q*NK>SK<-F-%0C6VCYE/:[7:W>ILPKK.D9
M2FW>@G%-@42>H85/'%,Y[TC:DI=[M9'21Q(\?R-VH4NRDA9:(@0:6#%%!!!#
M<2,L7RU]7^W^[GM-P[C@W2X[=E[([PMX]MDOYEDGMX-U2+;K<PP]&Y%Y+M]M
M'- D4Z3Z!(ZEU#-B>>;W&HXKO>XNUY'/.I=0O:O.UD?49!:O_"*\X0-:&Q4O
M/&5_)<< 'F>FX[;7S3]()]N9:'5_VA,$<0GK4/4WD<.Z6EJ8!<6]DK,3$">J
MLQ U2$RN28W1=,>8 ;4#5N/*^_IMC]2NWNU=I[)M=XV[M:VN[@R;6CO^96.^
MO K2[E<2[M>N\^UWEE;FWVUTDCBBNOF+:0O/0SRM\D\(5C\D"/H.5<WBM8.B
M8S=:;JW%M 6O9N?6<45A'F^J4F7K:"_L+'%YXAA8DU3 !9A+73332PD^LN9-
M?L=P+BX:1;F9E,3QI%,H$+C+5&Q+*H9A32VI2&  (R!I_H'?6K[S=)M'<>^W
MDEQM=Y:"TWR!/RK=5JG7VF2X>X@BMY61HVMI>O;21SHBK+'(8P^/A!'9^R\Q
MV..F&X_T;5]=Z]SWF%)\C=CR^?EUCK>?V.0U.G[%+M+43.YFPCIZ4?/B9X'0
M155<AQ%]*&'[L\;I$W(_+]LO4N ;B&W@MY)6MTEZH20.BQ: 685;49&0NVD(
M&:@QW2WL/3CTW[TV[NK7W%LNP=N]OW^Y3=N6FYC<TM;^.[MK;:!9Q-<7*=69
MIY;^:P>ZGZ,=E'<W'3B8+A,O^3=8JTN?C!H>7</K,KLOD'Q/J-0=RP6ZMLH%
MS?J.FOJ?88>OO3/:D_*,%T.EFL2QR"'J"&>LD:QC-:^-R*_V]RN]03W+3QV<
MT1$I 8R1JK*Y495>-@H('F*TS-:S]M]0^R-XDMO6W9-Z[HEWO;NT=ZVR2#<F
MABN7W';;:":TO7@2H,M]83);PR(@$TT&APTQ976'2_(C9:WCFUZGS[*W6IYC
MIM'\74KM#*:3)-!S?X_]VI+?I5A'*2@+*+K6UL5/K3$>UIY50*@RR>EB2-C\
MHMX+BULY72WFC6YJM/\ >7$#",95U1(-+"GE#MJIG2+$GI!V?L/<7;79&ZWU
MOM6]64'<NN (JH=QWW9)8MN0JNLW&U6B"&>*A,$5U.9@FIBL^<.^.O2NC_'K
MXT7GR#[QSYPO(.;9FVQW)B.9XR-E.;!R8C*9"GVEP5H0]?:7&?&TLR+6>@)%
MM$BD(C>YC6)J-SWBSL]XO8MIM)==Q.P>42OG^*&<H-)0!BH\V?EJ 16N.4^I
M?JYVCVMZN]Z[?Z3]K[NJ[]O%Q#>;N-RO#U(SNJW5W+90+;O:1Q7#6R4G!F/R
MQ=(F579SC?\ S[CM#\.+7X]8WGF1@W@'PRKL_?Y:VX?TO-]DGW];RV@CGIJ6
MPO\ %5F?O=83T:59 819R"K",I)!XYG1^I^]^2N(^XEWF[FD^5.Y%E83QM#T
MS*U"0KEE7IY,2 %IF17':&[>[BVO^H>V]5-ZW2_/:<WJ,\\-U#O6W7.U?)2;
MG.1--';WDMQ!:"P&F9Y(XX[<Q:)9(E>BY"?&GIU^:?;YF#I>1[M25&6FNG97
MHW%['CO/LA[PH,5GHC[YO!.;5_YLX:2&O:*:?)&?#[DD;?4R/RTV]V,2HDK0
MR6DADIKCF$SOF:*%Z\AIQ:H6JF@)S..2^L7:.S;+:V^_-LFX=M;U<WH@^9V_
M>$W>^N:,YCMU@.^[A(8PP>=I(8 T#:$=J,]8*^3R]#9WP/10<HYDFAQ>5YT)
MSS@_/\_MR.;?+"B-+;K;RIUFVR(TU03-S+?B>^,/<%TXE8M<DQ$18MK(V"?L
MRVGY2T33SF"220R3.T?4MF TJ420@CJH:$H&+:J JT>?7/1&?M&[]*FVZ]WO
M>%V[<KV_:^WB_GLTW#MF9%-I!-:6=TPFC&Y6+Z'>TCNI+CY@QPO!-8J9<G>[
MC:_H7PUUUN/R;X_W,VSR7.-'?UF=H[?+= &O/YSQ)][7$X%]=:Z88"KC4E\X
M]@B6,0JO0EWN(]7Z/:#;VO<D:-<7:K%)(JEF#)IT.%/4J%).5"OE)^'*E./^
MF=WL7:W]0=AM]YOO=-O!M^X7\%N\TT=Q:&+Y2\CAD%Z)([=VE(C"2P'Y=Y='
M0&DJ%@0?)]=K+SEV23$8BNP?Q*^2O(>>X2Y2:47.6K-AW:KZ"O2P+"M@F_FB
MAHN/561I;.P<^):U[;")[Y')*K-OU["2.>XZDK7>X64TCCBPT0&/ID$^5FF,
MKJN>KR&@RKU";N#L&_VO?-ZN-QW&??\ OKL[=+Z]BTAIH?E-EDL#MTR2,#;W
M$^ZR;I=V]N W74VKA4!0,TX>=]_,Y)'I.JVT.C^.U/\ (OLLO4.%T5)SX;I7
M\D0?)G9Z1YW.C5QI/5K*AJM/*R_+IVV8]G=U*S0!R0>N%\DEKG:5W#H62Z-Z
M>SA$4S-(8]?RR+1QK$08KY VDJC4+ T(&RN>^_2NS[Z_)>Q;=K7U4NNT=I&V
M;W--?-MIO3V[:0"*_47:[9!/+; V,5T;=[>SNNE+<))ID57;VFR"R6U[WM\7
MJBG=@M^B1EP?'W6_'Z'JW ^_RW<^:%J]Y6[66DOQ\/5=!S[(UL8DT]='2V@S
MW&QHL2OF:VZ*2>VM;6ZC VU(3_F%N.E/!342A0,NLHU=),3%U(T\:"J^G5I<
M;_V[VIL.\V(_Y>0;2ROOMKOS;9OVP"$7+RV,MF)H#?/8SDBW9MNN6O+:15MV
M(<"//46RRNDHJ$6GROQ3AUF<LRJ3HOYQ!-39*VV\_P#*%@]N*O"J_P"TT-=6
MAZ8!A98TI,*V-I!"CX9(7L\5:2"X@D9Y)+\V[J&CTG4P0:QYU!JI)5J @'2I
M.8./+$T6\6NYW,NZWO?2[5>0K-MS0LLMRED/FXQ\] DFNVDD>VG,44JQL(+:
M20JZ2*V-<"6G2L7TZPY_D<-FJ?4IUWT6WPP[!STKJ7*1BKKH,UB?T;"=+ML+
M60<[YRM!8RZX.SBTLX0\KOM6"-<K1TN'3L;JP6[GE<P_+Y7D4@BE-$H(WC#D
MR2:@(F4QZB/,6/''L<6W:>[=FQ=S]S;C>7.P#MZL?=VUWZ[;N;)#8"./;[W;
MHKV1K_<.O&NU36[;<DTBCKM<$5E*G;XONKJZ3YC!<Y^/:4 _=+'>2<7A%TB]
M5*XY74#^.0X$?*S?:B34MUF6VNR2K97_ )D0>C2')[Z^W&TD^V!_].O->=8V
MHCZU5Z75+=7J:LS4-IAU:M(7+AF8%AO?I=)/_P!/QWCNT[@_;"6 W8O;?EL>
M[R3C>#?M<C4_6AN/EMH^:ZYMXX-4(/2&MVCE^0:R+?Z[%)S'G4=5\G^D]<YC
M:&!@S)7X6NS'R#-Z,/MC_P TAAAJ,1J>47-_44EC_>K9R+7,A=&YS$FD7&X6
MQM(KH3S&2Q@BD )S<M;B/0*<764([KEI\]:CAO=W]1NWINT]OW^?>]W:][)V
M;:=RB#N.K=R7.Q)M[6D?28F:]MMTBL;J^MCI%LOS;2!PK&-S_'BE^7=!H.8P
M<WT//^)'U'QBK,"\N\S4=]5^VG9^O::ISME_,\]$'F]361D-+<!"PB=*4B K
MV'1N1J(WB?8)H9_G4EN8VO2]%:A_DQ*6&G464G+4:#6"M:XK_K%=^@-_M>]7
M'>-IN_<MM/WS)?@6]RT$H;\GVFVEG3Y59GGMI"IB$SF-#>1R0B4,"2^PZ6H^
M)?8\>8_0TM7;E_%309[=:BOY9JNT576M[?\ ?=)K-,#I+?E6?7^7='8A6JF1
M^[!$&/%,P5(E'CC2."\LN_[;(JJS1B_5HT,J0-%&L"JE!*V8!&G(DD^8YDXY
MKW!-W+Z_>G&Y7W;5C)/<0=^V]U;V-QNEKLC6^WV^PV]E:])=SE8R1P&,0I*K
ML[2(TLK%Y';$(7FGR%M\K/DP'=;NTX_DNB4_,[?*X+/_ !878Z70VS.7UHE6
M^QJ['CO2Y\S816)LT-JT9T$\4KF(V-[W*]NYB@G_ ""S_"%U<PF17=[GIA1U
M"201+'J% "IS!X@@4QT'MVQW'=_Z=>RC:[$F]]R[5/ND-])N'<XL%LXANLAF
M"/#O.W"ZBTHCV4X::"11U$G"!0V1W<V="A^,.CO:7G7QNZQCKF@QF>NNH4P%
MC8=/RF"WT>?JSM@=SD>DKK2QTT%/>160D+!X;@;WH'R!F3P.:[0;4ML=[2-Y
M[V&XC9R(G(Z<CQZB%ZI+#35=)-=)S&H UQR7TDL]FV[URV_8M[WSO3;;Z"YO
M;FTLKB:*.VFOMO\ F)8]O>_:5H'MC- UJ]SU#!-I=&FBCEZX8'PF$=J>A:KF
MUO0<TMJ'/D$7=5\I]55[*OZ/VD6WOK$:[U.A3H@453>G5:?E53^4V0 L<T(\
MA]=$T54\I7<A$=C'?HUPLYHK6RLFB$A11!TJZ0?,^H$T-%8ZL6+^J&#:!M-E
MWEV]OF^[=WO*JVD_;NUW-C)9;&\<$4D%F(;)G802DW5YUT:<HTJVUS(+D%CG
M5;KU)E/&+K.7_%?H N1&@KH;D#1UM<:"T:U6"W#FQ1ILM.)*-<$/'8HMBULT
MLS/6C7OD8VL1&TZAEM;B^B$AJ49:\1D0^1IISKQH,ASQYBM[W:K&_;Y2_P"]
MK>^O9'9EMH'43:D)A<R2%&?7 JNVH, L;Z5*!#AKEU=+1Z(+24.0Y-SR]:10
M7 .G_P#._D"*_0%T5('=R5 =2#=XR\F/T,D+A_1(KI6NC\T<YWNR2=;-&R22
MW$\%"K*"'#+J;2*M1Z@5U J:9YTR&GDW?9]QV67:-[W/OJRZ*7*-;1PR,DEN
M)YY(_F*ITU5( [.75J$2'4JCIJ^\WV?>7Y9(&Z[Q\9:++VM;>52&6]E07-I-
M80DV-7!%84X.DRH1=58L'5'^:,E<WUI*V-S58L.;;;.UHUK:7[2A@U!50*T.
M3!6((]W'@:8JV[[!V-LL<%UVU<=Q7._03P2E9K,0!H66.3RSHG4AECKY7$3+
MJ*L-:D-AY5-CEZW/7Z5?5OC)=N($.4D?&<]&CB'*@KIAGE2"4G3;QQI=F%#
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M:N\>NSNY%)CAD#!8H)PQJY=59UDZ8S(&K+'/.XM@BV3:;_M#:ST>LD5_:0N
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MVKGC92FN?#9!VAU96%U\K45LT1!(\$D:JV26-BJY)%F";N( D'J+P)!^(<"
M2#X$ GP!QONU5=^Z-M2-I4<W]N T3.DBDRI0QO&DDBN.*,D;NK4*HS *=,?Q
MDZES'&]7SNFT=%\:.?T8E7>PD:S(<PX'D+@&0JHF@@'%O\#WC>Z,6$R5Z12,
M@K9XY&*K9'QL57ITK?+"_N;!X(7O9I2R^1Y9W!H>:R01J:<15A[*G+'T&]8N
MR^\>X.R+O9]HN>\-TW*2>$K;76X[U=1.%E#,S07NS64#% -2E[A&4C4BNU%Q
MN\JK2NO*NMNJ@N&PJK< 2TK#QG>L<VO/'C*#+@?Y)ZH2!Y6O:O[6JGCF$D;Q
M2-%(")%)!'@1D1CYRWUE=[;>S;=?QM%?02M'(C9,CHQ5U8<BK @^T8O_  C$
M7!X,&#P8,'@P8/!@P>#!@\&#!X,&#P8,'@P8/!@P>#!B(>U=[X]\=,D-N^W;
MZCYSD#+P/-BWU^XIH4U[8"'G!UK%$&*E^X($JR)&^;?3Z8G>:^)^W;7?[M.;
M7;HFEG"EJ"E: @5S(YD#Z<7OT\],>_?5C?'[:].MKN=VWV.V>X:&#3K$*,B/
M(=;*-*M(BG.M6&6.5#]47G'Z9_R(2][Q\6_DWQC']T5I5KK\$TNSI\CUR2..
M4@DX%74L8.;Z(4K?^V\XP;67_P!B/:(>\I_=^QK_ +RV@KM6^6<\NU&@5_*S
M1\@#YJL@^EE'"H 4?;+^C'NW^L#TI-MZ9^L_9W<%_P"FU5BM;W3'+=;8"0JH
M])2]Q8K_  ^::V7^5KB585=_Z3'ZQ^MS]]@/BG\H3;?:9O0V])A^3]5D:1:Z
MO,6=P6-3YW([1R>Z=HLT0<1$.)8+[AM<KVLF645&N$9[_P#3B"2*7?MC"QRH
MI>6+@K "K,O)6 S(X-[&KJT?]<?] 6Q[IMFZ>MGHS'!M^[VD$UYN6VC3%;7$
M<2M+/=6G!(+A45GD@\L,]"T82>HGZWO'G_'PNP>#!@\&#$>70),W3<%8,SE:
M<*%F.A#D:F<](;7/RG%89PU575RF1N-%T:!R/)D2"7V% B3U1^YY/L-E/&G;
M-_;M<RI*]S:$0!:I*%6YJ[OI.EH=0"#4NKJODVGRT_<[6>3O?:;M+*&6WBL=
MP5KII*2VY=K'3%''K&M;C0QD;IOTS @U)K\\A^*]BX8Y,OU7Q@3?U'NK@"P7
M\NCL/TQ-V$R(*2JBJC:HFQU\4PTT11 1Y9BSN1J.CE]$,;U54\U1S?6WI5)<
M+Z50-J@6S7NJ&I8N'#4B-1I4^6E0>>/+WJ+%#-ZIR1!)6NI.W90-(4C_ 'PX
M,RCGP)%33E6FDK.3+E'W=#J,E]RVSK(Z_64)$%=(,<-;Q"K4.8])G?;70YY4
M!01,*O<,3Z9?-/)WEU+>3/N%J+[;;@1QQS&2"2G!T'4H?*'TR(#K4T%/+JSQ
M!V0C9)[BSW2QJ\J1I=1@*H>-Y1%4TD=1)%*0\<JU8'[A PYZ>\-H:[4KF,-4
M7/,;&KTC+QNW%S9%WD(+<R,-PM7H0JFYM'UM):Y>H4AB"L GAB8J5\_N3L\:
MZ_L[3<;M#?WCP]QAUT-:M,$<(HDH8W*)U&,LE"7J-1I(N6-EM=]=;;:W$FU6
M:7/:DD+M,MRL DB#,4U"94=WC3IP:EZ0'E4B)JL%^1Y_FE\\"PV%G>]#/D*6
MO&I!;4D#F@=I"';Q25V6;+4AZ.7+6U#?>@N.6.LD]U?6ST-C@BC)MQ[CMU,6
MVQPV-M$5UOH5KEE #-U:$IJ#L&0!G\\GF- 2$P;9VI?M'>=P2S[C<S2*%C1W
MBLXWSC*PU'4,;JI5P4B\J$J*E5P@3C\:1Q=H10"!GU[C@'948!ZX^X-D)%=7
MZ"Y!(&(MCR:86H+25/N?49*.CT5$DG0J86[G:00I,DJ3(SFX:G6B!4$HE**5
M<,IJRU4LU02!2!3LI%.X26XC>VE"_+B,-;L58JLCJP=P4TNI"N2^D$-&"07"
M1F.8 R26E4[6\WTE>)7$64^3LY2J<A"OSA*<:T#M$GM8<Y<6UZXJU="81-*L
MB>S'$YD2L@C=.XYM5O+\M>V4E0@F11-$E \DL3*-)D6($('T\.; %MD-D[4L
MZ75L+K;-P@%7:!BT#'SK%')&6U=)I9!U6!D=QIH$6H7Y:W=Q9Y2OJYL_CPN;
MB2ZN&ZWF%K*<FZO+A]LZ\N#<[8WM'D[^JHO=H::#VH6!/DGC:A$9;73S.5:P
M6%ON;7D<]RV^F"-H8)W=4CB"")6?0TZ,=4CD@DG.BE<B$W$U_>[;%LEQ:V2=
MNZITEN+2*%I)G:0S2&(21V[1@"- **E"OFZAJ2EWYM3:AU>5R>)=3TR6I(E-
M3JRLF=/JK*:(I2[JR%CJQ[FT*"L!!VRMAABC$;'&UK&L5OB786UY9WD^X[E=
M*]RT2L3I8#H1 YY%M.IZ9*"W"N5::VYN;*XL;3;=FLS#"L[M%$65F^8EDTJI
M91&LOE4LSR  !BB\CCIJ_1'K+>G^*E\!>"MKC8^E](E:#)[2&>@@S SD$2K
M89#) A\LK8U]7FC?)/)$3Z^<?6>[LK[NTSV+*Z=&"K+KI4I(:><*:_13'7O3
MBSW';NW(+3<D,<I:=T!T:M#2* 6T%EK4'G4#V8W'>.9+\(QT#!XS@Q4B1%D8
MB_@KV(J?T*Y$_P#5^$O\!]Q_4<9'Q#%W:*JV)JK^TJ;^I'JU$_Y$3Q'LQ1/H
MQ)?X,>ZOZ$2N\_)6 GO;]?+ZH+,G_J%\%V?(O^*G[<-1<3A-_8G^1/#T2Z5K
MXXS-\0]V%"-WE5%?3ZN.$;^[S:V$AR?U.=XB3?SOHQA7HM,6"?BG^5/$T9)7
MV817S5PH'^?LU;5\_H CT_H5Y)/G_P WB% WXQ;Q.)#_ ,LXLX&^N:%OGY(Z
M:%%_Y7HW_P"^\2IOY9PS%\6+BQ<KCS7*OGYED?U)(YJ?Y?P\(M?Y(&%3<1[L
M5JYWDITGE_%%6%N:OG_G/:V-5_\ ,9%\-7*^9?:<.14TC":JJJ^?E]5^OEXF
M 46GLQ'/Q_3A15?34M7R\EEL)%7S_:D0K&HB(OXHGNN_Y?$%12=C_"/VXD-\
M&$YC'S/;%&QSY'JB-8U/-SE<ODGE_P!/[/"Y)JKG0881:FF'"<Z$"9B,_OC8
M1!(55S46 160M7S1BJK2)_[SS1?)6M_'ZK^#4*-,#G2,G,4K7#C'I'+,_IP.
M+.G5\MN(YSW+(Z=9'/5?XG.:U\GJ<O[416_T^,W"0Q@Z$ -..%J\C*0&<KX$
MU^VG/[,8,7. D*O-&3-\81MK<F2:%)KP7IK:X :8ZSE;..M*=?'CQV1#H72J
M:UL2>I?-D;'(_P 6:*]988U%]TXQI\O2J<AX@#+E3/W\,>G;#O.&QVJTM8^^
M'L+5!!^$^W=5J)&*,)4MT+HM0O38O04!=@5.''F\%:<XKHC,9\:*JYLMA35L
M6NKYM2!-9Q6=7;%_;1GG:HLFN)CBJXABYYX!_6Z>9$5&-;YHFYO5NY MQ>LH
MB8Z#I-*%16@7,9U %0*#GC0[KO6U=[RS0]Q]W-%;[?=M\I+\FP3I2PAG9%MD
M61"TIDB57D"B-3FQ.?NP GZ-:UV1U/QFIYL[4W)=??Z #<4T F>=<5U-]]9
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ML.\?3C:]N]3.Z+G9^[]NWFVN[GY'9(K8[C9ZW2>U)M; 6_SFW6TLDMC>.O3
MEO8GB<I#*R+RSB'2LKOL6?@_@UIN$4*T&LJ.SX=OR7R^EY?U:IL<O&RJK.?Y
M,G8:&+/SC;86NL1+02"J]NOA0:9DOO(UC]]N=E<6DJ7>ZI=2AT,+_+,LL1#9
MF1]"ZJH64J2U6.H4IGL>^/4CLWN+M7<MJ[L]3K'N?>TN[:?9[X]N75MN6V2Q
MW!,LFX7*VEO\PKV37$$MO(]UJG<SQLG2U-D;U#B.JGYY85>-^*&4-T>CS5):
MSYGH>[)L:.NO;^K@CV&1U^C@U) F@H$K9S:N=PG^S)/[9J/EC\VNTUCN< O
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MC!TR%W4.7/$?RUEZ^F$^)>VL:N"2V7.UFJL:/7&UK"#*R.[B&L-)]^M9(4#
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M_P#I^7[?&#\+?X3^K&1\0Q?VOU/G<GX2.CE1?WI+#&]/^3R7Q%LOY?T8DR?
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M;?Z_KX>UNHXD8SA0M'(IY+6JJI'(D7U_9[;&Q(G_ .#\8AJ*$8-1\<>JM/\
M;6/5%\HHYY5_H1H\JHO]*>KR\2+D_@-3G3]>"/XL)WGY^E?WHBK^SZJGFO\
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M "_3Q(QC4OB,>?;3^G_T_P#D\&,X]>R[_1?_ %+_ -'@J,8U+XC![#O]%_\
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M@(;]%]UL:*OFB>3D^O\ 1XP6J0A^*N%<JC%B/+&UBCD(LHSU=YM]2>Z.]?\
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M-_\ )$8XWW2/8&?2V,*C^9G^SA_DFMLO0ULS5A8U7^XD@]?"C7/1OW,DR_.
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M)-+%#>'JM&ZI$4DH(W=%"I1;@27?Q(^1W6.RWW+LO<]>[/?7>Q^$..ZM:MH
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MQ9VC-!G$!&R8MGG<Z?"-9'@6#?24K9HW1SN>V5<[K9))*7A8Q3$JIZ1 3RR
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M))! 4$TKC2!57B<RRM+6'5Y>PY3K'E^^/-9WE"7$=99H:LU.6A+J;*BSH^C
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M'&\96IYK]$_%?V>.*KCJ./GDG[D_J3PK!@\D_<G]2>#!@\D_<G]7@P8OG(A
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M_O(;>>WN],UVCW-BSSUG2W^7N%MPZ*C%M%#2_._O&2Q_R#BQWR8^,770>?\
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MS3Z3^F<OJ%WY:]@;_LDEE)>WH,TD&ZD-9V499[JZG62]FD9[6%)7U=(1F2-
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M]6N9&+/J5,P:UC:5:]R-D60YQ49E8E=]R#6I%,>DL#)8;,N*T<17!L!]:PI
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MI6LC DF0 T5AG0 EB0*6J#UZL(+[9>X-X[<[YO.\-NV^?:-R(8_+;ULMW:O
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M%O\ ;@@!ENP0 "-1I6G#W</HU>(QZ'L.]NPX=NAAEW3NE;A($4JL[=,,J$$
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M273"6#*I6%"CLR%M04!T(B9 ?.K827\QZ?#(3(3Q+XPRR1@TH1-LT(X<@J6
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M5Q$SXIG*J&*C556HOD0JJZ&7R3R\O;<OE]/\SZ>')8^D@8'!CX1(^*=D<?\
M"@GIC9]/_-L;U663R7S55>]?ZO)/V>,*M02>!P8N)6LA@>3%_"XQOML9Y?\
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MDK$7E"NG7TM]+WQ>2L]STO:UJN:GXO\ +TKZ!2""'=9 2#JMZYT%#U!GQ/U
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MN4\V^1NBT_&>1IC<I*^'5YEN]?,5$5*3 +]I]F4KJ. #E3WU_3^S& B9C/\
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M*KFO1F!I3Y:*NGR6X)I+4$^-:8<2#OBVO[?Y_?$MYV9C&0JW,4BU :ZG=5"
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MA+*VN KGV405T".C^Z9(R1KI7(YS4O\ J5+&2/<K-FN)&#(L +5!IKC:2/\
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M6<@$@YR#@L']^I(8!)--,B/E&D@29O\ &][D5//=JL.Y;>+Z9;B.!8)BA5Y
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M\P]GN_1&#<@.RGSRZ)V?J^ R%^2^LO+ '#_$K:082LTI,<=A>"#2!-0>&1/
M8VYUR _7^[&>HO+Q/ZOWXC/J_P"GW\E(^C@?&7*<AH=MFK3COZFQ_#66O:^E
M8;DGQUI>M?+7G][\5M[6:JBH;VO9T3AN;O?S.IS#_;L AQR6UI#7P>:X*-\(
MK05_6*<OU84'6FH^SZ<L\2)V7],W]07;];^0.YI[#F3+?>\1^3_&Z_JV8[+:
MX_0=8BZ'P7#8OBNEWE29FR=C2Z&CWV/F+LU??SU%088PFDK16_<RS*9'J?<?
MU82'CH!RJ#]N*OR+^(7R!^,Y>F?\88KK,;SKWRTS.8^*V.Q!_4MUG N;]_\
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MJ;C7?%?=ZWC[>MT%)B.EZCC>_P"N:#J5O)+5<\#L)A]=2;D&*J.V)NFT-[!
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M6KDFDT:#34DA,AC2VA7>MSA@[8[:ZW<4B%+6&6/K0/#0$/*.GH,(IJ@#9A5
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MP.(1\9#ON7/:ZD[E'^1;E<KNDCZ9$EN1<E@_SD9>@8%2%$C,P5D((A U* H
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M^1N]F26>$ML;1)1AI&1JV!C8/I]/4[S>[S]ZP0Z?3KLO\0LC64YTY>7^6*9
M$\ <R<ZXO/IKJ_YD=WJR:6%Y'GQU>::I\#4U-: _KQT$^//..[8/!@P>#!B!
M_E%8:.J^.7;[#(1FS:87F&RDI(:ZCK],;,?^2%MAA&SMK2::OO))5=Z?M):V
MQ2?S]""D*J1/VNQ)#)O-JEQ00&=-56*BFH<6#*5]X9:<=0XCIGHQ:[3>^K7;
MEKOQC79WWFT$Q>9[= G64DM/'-;O"!QZBW$!3XNM$ 77";],O-%UE9U2RKP.
MRXG&K99NOK.>;W#8_"XEFD7/ 3:[1XX.JX/PO0VDZV\+AU-EKH1R05'<]GW*
M21BV;O>8/+ CFWEN=+$R([.^G40BN3/.!EG342&K0Z:%O17]8>\07EYLMG=2
M]O[CW!T;AY+ZRO+J\NS!UW%K!=/)O.\P1CI$/T5G:2.82A6Z.EYF]T#=TD7:
M--Q>ZZEP;/D4_5A=I2[O8PU=O99G7=.UL=GD\YF 9!VT.#V&8&RI 9@I;)(=
M838MFG+%.F?%,_:6LIVU-RB@NW#6^AHTJ R1I1F8UU2(VH$$9Q!:!64 C:]K
M=L[B_I[9^H6W;+W-=17&R-:365J9(H[BUV^U,=S<7#ANM>VMPURDL4D95]MC
M@,<<$UM&KQSW\QMLSFFAY]?S:'G,4>YJ=-R2/-;P> \1CKU!=-8;*URH\@MI
MTO+TU'E2A2*12AHD),@EB64AT<3M3VY;?.PS0A)JQ,LNJ/(^6JA ^8B9F8$/
M0F@(-%J<<Q] >W6[OVK=-KCM=V+[;/;[F;BR9D8]'5;I:QW+!H]ON)9KF.1+
MOIR,8XI$?1$&<*%<VGF^%L]GG>I<R)S T)&RH]GFSZT'G=5G*CHO\V#8VFTD
M5:QU7)45X2T$%TH;+8$]C3/80Z)&>$.9!W-HG@G$Y\C(P)D+&/07*USJ3U"E
M=#+Y:Z37$6[-_'_4*MGNVR[PF\.RVDUI<)(]])/+8?+-=RVYD/4$KO\ .O:=
M4VTT)-OU#;/JP@_#OH%+U?9[?HM;KN/P7.GR>?N]3S3 5H8VN"_F.SL-%E-#
MNS'^X=;'5=!9+4_FPLTH-Y)&Z=\8D\2C,>[CM);"UBLWCN3$DC!)9"=!T@*R
MQC@ 6&O00&3A5@=6-GZ^]K;AV1V]MO:EW8[\UA9WT\-MN%[([6K]"-(+F"S0
M42)))H_F?EI$6:S5EC5IXG$S0E2;BC-[A3\?L^H<%!N>9]I8%G=E90UEGJ='
MI=+HQ>EV65P4J0IG\6<7C[=F9GS+8V+)8/D.$,E+#<.[9RVLJ[6VXQP79CFM
MJL@J%554QAY/O. XZHE_AHK*%:N.B[CVWN-OZ<3]^V>S=SR[?O';Q>>TC,D=
MM!;V\#;?'<WHKU[M%NHCN";@2=, 2VGMT@G$HE[Y=="KN;=(H(+J_P"52U'5
ML0-D['-=(C2QK:FEPMU>[W1Z30Y "+\VV=-?U;/RH,A9'OS9?N%B"EK.5"[7
M=O6CWMFQB2XZL$I<-'D2SJJ*JN<D93YR/]X**S+13BA^A/:MUW=VE=2;=:[V
MM_LFXM<QW%@>G)+->0PV4%O!=.>E:2P2'YF5-(%_%H@GF@$4,@<^RM <=\-L
M=NXNH8#2T7,ZK)])CUE=94E!D]WF\:1^?BY7'ZRN#*AI2+FI&96U]D$.I9;V
M(U6,4F7TL6Z-<=R2VI@ECEG9X]!#,\;.-)=T)&K23J96-!XG2,:;M^RN=_\
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M6KC*C)AE1)FQIY^OPIBBJ5DHQ/ ^&'-+H#I!!Q1;C/A7%L>FY>7*_%)N[TU
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MGU=[F"L1#0YY^>VG1NSX>T9^3R1K7'2WVWY1J''#K$OW#9&SRH[[OZJ18GJ
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MST#XJ:;IF-TW(["IS.DY7T2RY9/3\Q^,'7/CJ"VT$)TLNG@T5DG14O&%1O\
M(-(I T9(U4)>D1LYZ8X"O@.%?;3GA747VTQ >1_2[Z;<YF\KJO0&99O)MKI>
M?8Y>F3;O$4G9.>VOQ'^.W -ATF(#AW0J[69VACU/*3&YZM)-=#99R60&>.!D
MT),>)5\VA> -/L QDR#CXC]I.)PM_P!-SH9G.^I\7SNR^/!G/-4%HM)F=;O>
M-W^E[#6;FWQ>"S(E!<[2SUEF\'FM6=@X$:1!.7?%4B#54CE^T4LATQ:8R232
MF7O]U?K]GNQ@2"H-,\9%?-GXAWWRE.YM+77W.\F?C<5U#'Z1VDR%AK@2I=W+
MR[35ZT@D1E8\O-A['DXE?:U1;X([7,6IT"20SJSU B+(K5SH13P\/KPT9-.0
M!IEPPN9[XP]'!X!\KLQH-AR[.=>^5NAV>IDGP7.WF<:YI>Z+D>0Y34J!@-G,
M=+KAI:S$065S)8QQ.M; R=ZCL:D:*F-&UE0V9&>%*X)!H:#_ +<83Y;]+SKL
MQ/0BM#V+#%W'1+#4V,L8T?4M:RGDTU5\1J=L)6FZ!?V>BOF5PWQDF<L[U#B<
MVU@A@$&A%]#LM'0-7+C^SVGPPDRU84!H#^_]^,N?F#\1];WW<ZBZQ>MYG45G
M3>$W/QJZ6G3,%:[*[RN*LMV;LW[CB9%;<5H]+T*$BSFC=%8-0*<P&I-=(UU:
MV$C"0.Y6O T'V86KA>7.N+X_X9S'?"?O/QB O,37V/3=OVS;4VFL<G,7F!K/
MIG;-/U[*C:>E$08ZZGI1S@:RPGB>R9_V[I8/2UL3$)5(<HM=6?ZSC&OS!CPR
MQC7U;]-&QZECC*/^?L3BKZWW_P O>C7%WF<S=C_?'_([K.&ZUE\Z:?66&?T)
M^;SAF#$J;E4*&),K6L^U="^&)&+2W:A:I)PH2CD/#$@ZOXB]!POZ?WR\XX)#
M1]$ZQWBCZ[K@\Y26G0-I4W>OZ%G:2E IB++LVTN]+J(B1Z*!UC,875P63Y)4
M0<?U.>_":S$8E7,DU/UY5X?]IQC6G4!)H!A/JOT\[[8=&ZGT+INRY=5WO9^2
M_)CF5Q6<;Y_:46<YZ1VCF/Q]Y1GM1R\;2V1IHM[5Y;A#R[<F=\,IQUE'!%Z1
MQ?5(AH'0>:H-?W>WPQGJ#@. IAHZ?].#INSHM%<7_3^.<X['?Q\GY\,5P[EU
MWF,'3\*RO/-QQ?J]/^3V=Z1;+T+KO)^GVD$,Z.06@+J,\UOW,=7[LV!$[95-
M*_7[OT\/#!U5'#"A??IR;=_3J+H?-N@\YPK*SNNDVS;.NSFW;K:+G5SU/$]*
MI^;#9Z/23<FZ13#!9*0**NT=$^*GL)66E<;%+'[#CIE6T\/;PQCJ*5\PQ88;
M]-W?<]CS.59TGDA^4=LN"].VF@_P^OYNO4.R^/'MMS.6Y5KY+AE=5874MK16
MGJ5&I=:P^[C@81^:>H;*PLQU9Z!^S 95^FGZ\).N_2WOG9+EF<PFAY)7WW/?
MCS\4^5 %QT_2L!,S9<%SO<Z#1]'S6JY3HL[H\Y9: /L\K8$+AMQR 6&@6 LL
M)ONPBI1*\QE^OV^W"7DHQR-*G[:>/NQEKM_C/T>PPWQ)KLMNN9;3KWQ>^W;+
M;=;YX_\ PEZE8VG';;C^ELK'%84FK7'6$<%T\^I?7->.(ONA)$D!+Y6$L;E-
M9J* ?9SQE&4$Y9'"3\4?AN%\8Z_>TDVAHM>-L.7\-YJ^S'R8])9.BY3SVZQM
M](>(Z8X?\@N#KCUU=8D\T=?7#Q"O?)Z$>NQB@T'4WPZ0/U9_IX\<1VEU$>\G
M&/\ RO\ 39O<KB*FHT>SYBFCS-M\%'0:+#8ZTJ2Q\W\/*XC*G.I"[%TEC2Z#
M=TY<I4*L<X<&Q/*]2RQ2.=)!2)EF4?;[OT_[</R3*5-.=?MP[OAM\(.A_$BE
MW[@.B8[1;63B&-XERO22E=DN@XQN;1ZTO%ZS?TNYWNEJ:IJWFAB(GI,X+ *+
MY%I"7(PID(\H1Z4(-*@4&=:T^GGA(E5SGEG7EAAP?I9NR(?)0\1VG2::B94\
M9I>\4G;#+;H%;T"7@?R0P?R2S-UB:M6,"R9Y&PAV;9AYT(&>W7.<J_[,B/8M
MXSJ9:Y:A7ZP:\?U8))A7VYTI[13%UI?T[-C8[32:JCV7(:H>OZQU;KW-Z(S
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M+G0Y1* ,I"OIU5Q>+1]=*K;0BS[G82U%C=!W&M26WTL3S=*(CG6%Z2P?0B4
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MA6RNYY)]O(Q(6K[OK>Y\LCY9WS3*Y[G^:JUGF7UUUGO!"_Q"TMM1_O:)*_\
M;CKWI*L<?;96)B8C=714'BB:XZ#/D?B!Y Z>(IC=Q^SQR5?A&.IX/&<&-:/R
M[^6/4N)=;3)9'0<WSD%-S3GF\PO.=KBKW2[#YA[78=3N\-H^*\FNZW1TR9S0
MXVDK )I%""N+",K0"EE0,K!Y?>AW$DBMI7X:?O\ ;G[J'C6F6<B*-6%36M?J
M]_Z>S$;MMNSYG]/#YD]&TG7]9JNKV78/E"94;>L(UV?L\Q68SY*7W+<M2XT
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MXRZSI6G'H0.D6>%JNL:\8N05+**BBB2$H@F,=\[ID(O5KO.US;0-NW&.\!,
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MS<UU-?S2?E>EI$_F6Q_)]#B8F1U\,/L'P01S/ >USXETK]/>C#N=_<W=OO\
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M%F6MG@B:283S*I+MQW(]T"!#2HCT>QT:3ED0+3GP^L5Q&*L34#+C^S&'V_\
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M.]W?#ZM_5=+G;&6A@R-BVUY'IIM8'#6SR9+8B=*S=1H,191T5O ="ZTK873
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M\4EYT?(:ZAQUJ)1GY@6RK3_RV:,,A\D:)X=AECCCT-\!_3]/'!I>M>>%#/\
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MM]NN$C7YAI8XVN-[V<,DDBP"8J+K\'7$1 95DQF=\5:/)9OA6%I,71:'.U
M,T)5=I,CO,$4Z_0B3^9+"MQO1HH-)FL]:WGODUXGMQB0B2L:,U(49XK6_2W,
MVZRRW3H\I/%7C<::>4%XZJS!:!C4DD'4:UQY\];-RWW=_4O<MQ[AN;2[OY9
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M+6)Q'E)$V1/)R!&>)Z'B^7M'M_;AR1PKA@.6,0,#^E=C,A><:)J^V:L5>5=
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M^VN&+@_T]?Y#Z'R_J%?W_12[/E/+<]S:EO >4\ZS%MHFY#DY/(LK_B%<9?\
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M7Z-3S5?-K45/Z?&N8:[@*? _V8E%-*U4#5[>&&T;=5%6WSLKFIK$:U7JMC9
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MK*Z.NS=P7.2(PPFG9(4^6*8Q8'.C35;*;B2S>*)9LG:CK )E0R*%;,$.I8
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MUD5U0= K@(J";:6%CS^<-W;+756N-J;R#LPU=7#8^&LK-&'5ST5D;8Z)BC/
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MJ8R645&HF@S%M,9QWEW-*D?C9;MK5=%J*DS1=,9=%:76ZHW-/2HJZ73:!H=
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M$;$":QQW=:_INJZRF/DK3[&LN<]TZOO)7Q02'B!C_=RKLX]P,D5[:*;<9 R
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M"@^4'0=!52/YMW6]IL_U2IT/2SL%N+K.W^9M:?C>RJ)+#HMST#L'9;42HO\
MK9%';%.M28 [(FJ4F $."0F-ZG[:DVJ.%=WN!':%B>G-(%K^$U>D]M+*7&K2
M%3JU+&K1!2<'^IH=SEFEV>V2>\B4?B1(7TDS* '6:*, A-3%A&0H%%D)IC,+
MX@\Z^;.9R$EGW3)75'4Z;8U O^/)6\+[OJC;$&JT:Z+2=5QVD[SL>?"!2%#!
MB?<!C4[;.R*8K:0-&-D35[6^V[>\MM2>=&,9Z4BI"Y\OFHR-*<B -2G\3428
MUQN=WBW#<^E?!XH2->J>,O,E PTJ581\B3I-0E  [5QM#@YQHY P;S8WINMR
MPT$S*SKG(K67$6>;B9Z8+2.PSAD4/\C'#SL2.2"<[\M1_DPB5B_W2NW&Z6=L
M"EFJBZ?_ '4R$F@/ETNCCJ5-/.5!RX%<S#%A<L5DO"\]J!_-A?A[T9/P_'0&
M89\<\265265Q2.**@S_=>:QR1ANB,%U67W^<02."5!M-7YJX(;/8"IZ)6' 5
M;I4:])&#-A<DZP1<2)($1GMKUR6)&@QMS&FHK3,"A)K3.IR&U%N9H3-+''>[
M>I J6<2*/%J4S'N_?AXXI^G+BL-!RGH^IO*RK^U-M>6]$N@=@75J1*]@,>8O
M+0R>6\I"WP/9 Q]M'$JPOC:?#)&\=FKO'5PEK?PQB1SE)&- H#F6I]_Q-#XT
MH<2K0REWGVN=WAC&<4K:F&7!1I/E]YK3"[F[?#;J^)K+BB9A^F,0F5Y6=E+R
MER;)$Q)RY!R88JRV0X1KO=DKK.&;^Z_O8E,%\YU5)%<6,&NV(>T!%01JRKX\
M0/:.>6)EM/:7;%+M!'N)^$J=(K[!P^@T\<2)+8V.2!F$Z,@&LQ-O*VC#U9U6
M#YUQ1SXX8X.@4K8?R>0!R2MABMQXH14GD:TF"#U),_6F*.YF"VM([CXB QHR
M^*TYUXJ<2YGFMA_FSUK/AJ(%4;P:O*G CGBSFHK?"-<7CT,N<[ G_G0YZ42\
MHD45OJ]PC 6!TB3A%0HU%;3D3.!G\E8.HKE_CD1RQ3GI3@)*30/09L. =>'^
MT,QX8Q+'-8%9;75)$:%D)-%7F4/[\L7!%-5:N$+>8BXAI[\\.&8#3"#R2!7P
MC7*QE5LJ?S&== 1R,?"]DWMV ,J.]F6&1JM5(GDB)AN5)BY@YD>U*^/@:>&%
MO;P3+UK-],WLR'MUTXT]F*P<]-T.HM*#4TC(+:G+'%T.?D)>LU-:(S[BMNJ&
MW'08M!2XD^YJK,989_2B^?MS1RL9@]2RG%Q!3HD5!&:GV,#S'WN7(5QD"/<H
MOE+A=-P#GXC^\O\ =/+AEQQ2H;:WH;J#%ZHY]E(:PB?%ZJ9&13Z4,*%)C:6[
M2%L4$>TI1&^Z]\:-BL@VJ0QC)(R&,4ZB: 7D !-2SI_#QS7EI/+G7Z,9AD>W
MN!MUS_+H-$G\9K\+?WJ>&.?_ /6QI/S#JGQBQN8KJF&4FBZND@WG%5UM-700
M\V.+MC5:@RUU."WUNGF&9(R*:2))'QI(JM[?Z-7D=OM^\[G<5K$;<@5(=B3(
M BD9@EB*D'@"#5:J>.^I5M+<;UMVUV2>20S%BPK&@H SR,?A4*2*T;CD 3J&
MGO9!3A S=-J:"UL:?2U!7'>;$&1-NJ*KR8-B3A]9JJ^Q#(&T&6TVXII)U</!
M(C:.:UE):^=["%9U^Q>.Y8=M74L<=Q#,;J>JIU&=@DT46F0B,QJVEFI2NFBH
M#D:CO :U0]UV4$DEK- +.UH6>)+=&DM[B1#&>HLLBB4AAJZ74#:R,Q/POVFC
MYKD])FPSF8[/5@V59EH(VP/YE<T7LUTN:@CA)C)""T(-;$=$<K!5LEG<LRN(
MC(]-+N%EL>X+FRO77\RGE:4,PT"\2:KEB6JA((*NA4Z2!HH#B]EH=Q[;M+[:
M8RVU6T21F(#4UD\5$"J%)<:EHZR!EU!B9*FN'5V7F7Q_WW-V=*Z!L]-R'I5I
M.-1B7'-+):[>[\7*4L[:::ZRLL<XVM"I)%*%_.GDA2#) 3 \F98HQ_&I[4[B
M[UVC>GV+;K*'==FB'69+E=4%N6.;0RG4\1S44_$IJ'D&=-_W=V_Z?[WVZ.Y]
M\O+O9MZFD%NKVL@%S=K$ND]:!%$<HR),I:/X6JY-,0ERSC7QUU72<W6=+^6?
M<=@ ZHH: <?<3 \NQ+W?8KG;;%Z:\#N-87"^BJK/VB"40+[Z*0A$,B]/NRV_
MN;N;O?:=@N;C8^VMJLW665F$(6>;ID@I*@T(&#'-=/G6E67+%"[5[5["W/N>
MV@W[NK>[NWT1*G7+VD)85C:"4N\S+H!(%" ZGROGB?M75K::ZLQ.2Q'Y=!E!
M%S6<R], ^KJJ&NJ"VQU< (:RR"U[@E6$EA$L;'+YK-+(LDSGI3]NG:+:Y=VW
M2[9Q<R=225BS,\C#.I.9+4T$4T^(6@K>MXM6O=UM]JVBQ&FRCZ<429)% A\G
ME(\@5B'4GSL:MJ<,VG&+I5G1[/J&AQ5953:H;8T@/.]+T""E;;VNIUN$D6?(
M;NB4PN>G63)Z"T<+^8D*05=5-20Q\S8G-;)?-HM9]L[:MM\OG6VDMYC<PP.V
MB)(9J]6&0TZC:DC!HA(4L#Q&.;]T;C!O'=-ULNV1O>"ZA2VGF11)-+/;!3'<
M(H)B4H[E"\OFFZ; FA-6GT^LMZZN:<6)+^:\[-K>7]*=:6L=G=@24$,HV:VE
M])+.L046DS=7/$9$KUD#M0?LX%(^X&:FPV*YMKE6B:15AOH/G( JE8P9%K+!
M'4')&-5+HU0?NM7&I[AM[VUC@F>)FNK"065V>H&E'2D_!N"P*BKQ@*PB9#J2
ME'!&.EO]+HBNE_4>_5DA"JU%+&V'*6W-I^=S63+4N<?3S"JE>2 &^E>&(Y(W
MQ1NEA5R?1RJBJO /5(70],NS7N&!1K2X*@ Y#6IXDFN1'/\ 7E?_ $YZ8]2>
M[8T&:W,.= *CS"M.)S!S(KR/#'0%X\_8[K@\&#!X,&#P8,'@P8@6U^.7/K@R
MX^Z-W$><T=V=H]%@1=SHAL'=W-K:.N[@D[.QFI&@]U</>28+$^(,J6219(G>
MY(CMK'O-W&BA5BZR*%60QKU  *"C4X@9 FK 4H<ACIUEZL]TV%O;B&/;3NUI
M;)!!>M9P->PQ1Q]&)4G*5U11 1Q2,K2QJJA'&A:.S;\GSNXN*S236>LS.GJ:
MTRD%TF*TUEFK:2CL"A3BZ8YP<BB6-?(:%%,UD\,CH9&JZ)S%<_U,6M_-:QM"
M%C>%B"5=0PJ*@$5S!H2,CGSKC1]N=\;KVY83;3'#8WFS3S),T%W;QW$0F161
M94UC5&X1V4E&4.IHX:BTI,XU@F\](YFH%G)FR[.2_*GDT-Z[1D:>73IMGZR7
M5?F":!=,FP:VR:8A"2L*:U6^36HU [C=?."]JO6 T@:5TZ=.C3HIITZ/+2G#
M"V]0.YF[I7O 2PC=TA$*J((?EUMQ;_*"V%MHZ'R_RM;<Q:-)C)!J23C[B^1Y
MS%WI>I9:[#4Z@NI3/IH-MJ;/2V(5#]ZVQ?3UB%R-"K@ISXV33>U"V2=\<:RO
M?[;/3FYW":YB$&F.. -JTHH4%J4J:9DTR%309TXG!W#WWNW<.VILK06%ELJ3
M]?H6=M';QO-H,8EDTC7(ZH2J:F*H&;0JZFJUQ?CGS\0T58C=NN:!T8^M"Y[+
MM]#)SX30!Z!FL#,BS3C%A44+3QM/A"<]P$1#&JV!&M:U'FWF[9""L76*:#)H
M7J%2NDC53B5\I;XB.>-Q-ZL]TSV[AX]M_.)+1K9[X6< OF@> VSH;C174]N3
M"TH F9"09"227+L.09[7Z!NL2ZVV3TCZ<+/GV^'U]OF9[BCK#;*QK*RW'#F<
M"=%6FW)D@\CH?N(%*E1DB->J>&;;<9K:+H:(I(=18!T5J,0 2"<Q4 5%:&@R
MQJ-@[\W78=K.QFWVZ^V@3O.D5Y:Q7 BFD2-))(F8:T,B11*ZAM#]-"R$J#CR
M3Q7G\^!I.;PUUC6YW,FA6V=GJ[ZZ"T%+>UYTUF-H0M+&=^=K>+8DRS3$232/
M)?-(DWN-D>UPNY78NVO"5:9P0P*J5*D4*E::=-*   4H*4H,9A]0^Z8^Z+GN
MZ26*;=KR-XYQ)#"\$L+H(V@>W*='H]-51(U11&$3IZ2BD7^&Y=G\&=<W(EAJ
M-%H] )4UUMIMEH[+2W9-512VA%-40SG2J.!5UQ-X9*R$:*%CI29'O]3W>?A-
MU?2W:K&RQI"A)"HH5:M2IRS).D"I)R  Q&[D[SW3N:VM]OGBLK3:;5Y9(K>T
MMX[>%9)A&LLI5!J>2188E+R,Q"QJJT44Q)'B%BHXL;2SKZ6M/N+8P>NJZH,F
MPL3RY&PBA APO(**)F>J-B@'@C<Y[E^B-15\+C1Y7$<8)D8@ #B2> Q)L[.Z
MW&[BL+&-Y;V>14C115G=R%55 S)8D #F3B*L=\@./] V9.!Q>XJ-+HQLTS6+
M#422& 34ZV,E40H]M"QU;*?7E)&I J2_<11$0R*SVY$=XGW.T;C9VPN[F)DA
M+Z,\C6E14<:$5H:4)!%:C%VW_P!+N_>UNWD[G[AVV>SVE[PVU90$<2],2+JB
M)$@1UU:)-/39DD0-J4C$Q^-;B@8/!@P>#!@\&#!X,&#P8,'@P8/!@Q&5\(+)
MUCG!DE-HBC!<ETR$:]"<J9BHA+,Y\XH&_8@[T=9W+AHW5RK+'Y-%)_A?Y_PV
M:PEE7M/<85FMUA:[LBT3?SI"JW>EHLQY(ZD2^4YO%F.='W:WMW]0-EN7MKQ[
ME-OW)5G3_P M$&?;]23C2?Q9M*FW\ZY13Y-]V3?%9Q>,<L'ZKVEVPWSLZI1,
M$\^=1?IQ;F[-/3&4YTB:@:7=0UU=#M5K5T%.\X8F2% HC(QREF_O(I&^I%]4
M^D]CM[>G]O>LTPW+_4D*BDCA-!Z(.J,'2>'Q$$^&/,OJ3<W/_,2>S41F#_3D
MKYJI:HZWWJ%N(',#ZZC2+C1]!:'W&VSSB(NBU%9Y"P#MB-&U^29G;[,:RKJA
MFW^3)@LP\/?'%0BL+FC)E3T#C,FC:CNM[LNW6]E!MEQH.S2E=55(:&X#ZPU6
M724DEHHDX*,N6*[M,>ZWT\V]6]1OL:M0ZE9;B Q&&5,I Y9(B6,5:EP& KAQ
MFY8WK^=M=G2 5F6ZIE*VWEW-+7Z&EH0M._,"9JMEU#:*VO:C:@6P(-W;(28Q
MEF%*E*V=UD Z*5K]7'NMOVS.FU;A)+=;!*56)V1Y#%K=R8M:ZHZ,$15U$, 2
MRHQRQLYMHG[RL_S6PBBL^YK>%A.@=81+TTAT3A*B8.I:4G2&0]- T@H2?$O4
M-#H6)AM_I.B=EM19Z^$[FW-ZFNJ66MJ .9?<\?TSH9]09LM9.$=3-A$B'3VX
MYGC3N.0B2.195QL4%A*=YV6&RV]*'I7,DA)4MJ$D<4"'IIY""Q9F+$TJ,P$1
M]TWFXVXV/?9]RW;4_P"-;6JJBR$#5#)<SM^(Z51D14":2NJAR)\/U$04@N<G
M^/ <6UD@5<Q43)C))BL]7PGCP6S[0H!,[4@T8]C- 4)9A%$'NE+E))AFKF->
MG\NBE'S]GO++M09FE==903, &3RE6;6NG426"G):DX2^[HDZ[==[!7?"@C@1
MQ'G$*LCU)(3H^8F.G"K&@!Q6BZ-9<T9)7Y1_1OC[;W)%?+'E]G0U&[YO<[<\
M<VLS]]FY3L]_-..TT>5S<,D) RG0.9,+!)[$/V\34R;)#O1_SK66ZP6B!4DA
MD>*ZAA&I@C*0$FA.HA@Q5R1D.>)=KW'-L<@79QN.PWMVXU)<1QS64LSK0NA)
M,D,A6*JGS1A2 #3+%.GQQF*JI.R]7]O7VDI]]9Y;/76NI;2'0W5/JJ@,?5WM
M=:7EMN-2-637=L6D E<2DA-2B3G5S8'Q*[/NB;C>Q]H]MZK.T4('D6-TZ::)
M9#$A9-*F14C&MJ, YXU&(%CM'Y/8GO7NLQ7-R#))&LDZN)9#(@6=HE?6^GK3
M%8T!4&)=1C(-$C7.UYU=F.A[8<J/6!D PXO/1-6K2JIZ4O3V!5Z<R34:JRB%
ML-UJ;B"&-&5TY T<<[O.'VT?*VYMMAN).W+&5C8M$_S+:RYD9VC"J#159 BT
MU$:@VHC,XB;J=VNK2#N+=8=&X12*L$(4(D:1]4R2LP+,':60:55J44%LM..A
MW])%NCT?PXNPJ]Q,#MCU[?T]I:!JT8BCI2#,.S360\39615SIZX0AH;861HR
M<^&3THY%<OGOU86VA[S"1H1##;0Z%)- !')0?8#7V$\SCKGITUW<]M!G?4\M
MQ<:V %6.M"Q/O))]E33&XBU/K,;F+"R8)&/49>BFG'K0V)%'&%4 *@58%&G\
M,:.; R"%OX>:M3Z^.5K$]VZDFLDCAB?U_5CI<A2TMCIH%2$@#D*G+%AA\^50
M4$,=FK2-);SR:#6&L^JG:2V;'(?Y*OU42N1&!"-7Z1!C1,3Z-\+N75[@D9QH
M"JCP']IS/MKAK;XS!;CE.Y#.>9YT]U,)64C;?7VCW)#4E3[NRQ>555];1L[0
M6#Q+HR#U>?HGT>J#(?,Y/J\805J_1B)X5.O36.T3*JZF]^17Z*>/.M*8:LS\
MQ/->/Q74L9\!0AOMRQ8:8NN/UD45\6$%D>=5H.ROI3YXQZ^;36)1L&2BL9)5
M]M\%". 2>V)W]HR4-Z(KXV)X=BUQ6[-;ZFN)6*CV#[Q'ZO=7"+@QO<A;O2+6
M! QSS:N0J/?AOZ6VUG1UH\#4OL<+C.AV)0UC?31E@;NRR]36S':$^D@<L1&$
M MQGPUT9Q"?FJH>DL4(SHV2NS;Q06*&\D59;J!*BF:%F-*4S+,*ZJ TR-2<,
M7=S=7VFU@8Q6;G22<F"TJ:CDI\<)=G=OR>.)S7!\W25XU<8%EZS2%BRSXX;1
M6=B)GZ^&J@CGA,Z#;#'DL<5.TA XVQ.24J21BP*N"%I[PW>\.T@<:C&"%)%=
M53_#X9YD#VC#<\T=K9+:[)'HA5B.HW ,10FHS-.(Q6K%RG)J#45.(K9MQM*0
M"SNMEO-(?),]+#VY[2X;M=2R%\BV=T7_ '@U#6L;*DKF,]D:-S9O"+LR7EXD
M]_6.Q9PHC3F@  *CV<"6R-*FO##4*PV-N8K =;<0E7<GRAB*BI]O@,^7'#?H
MP L&^WTEY'_B'W,BL_FCH%V1(X6AP2K6+-,$V>53A<'EJ(*-PX%>.TJY-AC<
MJ^\LLDR2+EFNRJ0@P[*K%8@*:SGDQ'WG(J23116HRRPFPZ5JKWDO^8WIDUR<
MU4D5T \ JDY5\Q'MQ:5Q'Y0%;=$TM>G1N^?DP=U=+.I(^,YC6O&]6:PM,&^6
MP;16H,9D4$(8RE7UL?/++))##*CXTS:=<=G'6'95D(72 9'8\7)YZAEQ"J!E
MPS;@810R[M*!<[VR5>IHD:5R4>%#0^)X<\1P?<V&80;2 VE7>=LWY$5-<=FM
M*U]Y19N4 ?U7%'Q#$/**BLJ7'"SN@A0=ZA%6,K7%3F2SD)%LQ'%=*;6=&38X
M06%L  TA/P]60<VR)'$+P  SUCO+;$7D9ZF]2&IN#4*@_P#D*'+(9:N%?;B+
MN>\]$^71=\(#E  ?CO6Z$BRM]7;2,T&\[)MQY7MNM2NQE]9>CTDDODV0N!W\
MOT@J)$%$<1[2UFPN[RZ[-:%C+*-\"555-(H4:A5%CX %:$U&MB?,1G6#:;=#
MW?K@:!?].EAK9JF:5Q\;-(<\SP RIPPYNA<EZ!\?:B)W-,Z!TWX\@>X9H^2S
M9X&ULLVR,A#)=/74([0R+&X!?YS)<T$]=;M>U)"A3ID^]CQMVX6&^.3NDGRV
M\2Y)-J(5VK\#',%3P*."M34&@IA[<MHO]@A";4JW.QQY-"P!:-1P(K_\*P\W
MCAUX?1P],RP>%-,7?X;?U#[+GU?TBT,M(-8( ULI=)ENMD!NM0NHXLF))X!;
MT9+=R1*]T(LPT[WPKRUDVF=]PTBWNX6T2&(!>FQR!>"I4Q/0T* J*T!H1B7M
M]P-VMDL0QEMI1JA64UU#F@E.8ECRJK>&)'PTUS<U-]SN:T+DTM)"13Z_E?4)
MGQ%W><)@D2KUN0OX9K2VJJVX#3U,(ADNZD>Q@FCA2%(FN;K+OIHR;AHU6C+5
M)HN*L?NL!0$"N>0-#PI7&PL%FFADVJM+A7\\,U"'09ZP>.HTRIEAQ\Y;7W,$
MM%5V!7,.NT)=C3:K%FBBDYS8EU<<4J7P68^X;E]$V_I3!#BI*(@0R-Y3O7(S
MR]OQ&NVGLZ-(/F=OH"C@4*UX5(\P(S U^7+$NP6WN@- ^7W,'0RLQTL*T^$\
MN'F&8PGY4NK  =CNH4S: _GFD.S&:Z!6G6$=,"#*P.WS(]=LX) ]%B2H*"[$
M%;%8J/#-[7H28CS7S=N("^BXLW#VLT(<Q-GG4@Z@/+4$9:<QQ-,L(MI$3JV-
M^FBYAG=0ZY#3R.KXC7V\*98=.<379/7=!JX6R[JBF,S>M1C75U;M(/YFIYZZ
MQ>+&R.OSVICE)RSYY6I^7DRNG5R*1(]45N[:T:UMY$5UN@'1F/G0:#50HXJ0
M&H3F,@?;ARP:XMKFXMXB); %&T\'K(#J-3DR^4%1Q-2#A%%IJJ3I-1H>4WG\
MH6AN4U8=[7"5SORB2SIKS+V H.NPAJ@%4!O_ )URW/>.E:<JR>ISY$5/4^\E
M=L,5XJ31":/.I)74"M%89,>!SKPY9XBQK"V[+<V#-!</&X(I0'2:U*GA6IJ.
M6%7HV@I;V'%9KK&8$HS2>F8=@EHWSM,+>D36,H2RU=NL(;ZBXD%*>C("F@'^
M:JD'O*U)/#-A'>6_6?;'9XNA+J!IJ4#],\2=RFBN$ABWA #\S %8?#F>&KC[
M<.749[:8[.:*:G)EZ!CXJ&\0VCM;&%VKJ0/RLKW_ ,FTIWH_-8H85<OVERUD
MZHWZ'^:(Q8\-Q9W4\8E_#NBU :9',5#_ $Y BO.HQ+NH[NUM9&M29;'0<FR8
M ?P <1[\.'FNTK]-C\^C9&V)U5GLZ#=@60QE=H:2P2H$;*';!$QCV]=,^1BN
MC]]KF2L\G1^MBHY6;ZR,$DC@\)&(TD%"*5R/#WT\>6).WW<5W;QZ<JQJ"#DP
M))RH<^ R\<5<,VKG7<3-E*%;+TC4^AKHV&1^8D=97S?QL?#(O^U!/3^RJ_3P
MN[:X3I5"L3"IK[ZXSM@3HR&,DJ9FX_0/V8K1I[751G@7 \,E9SDV2215('5R
M7NKK&01R(^%8U\_Y;E_A=ZD\E_=X0Q4[=26*H:8UY_"OUCCG7"G_ /KMU!]R
M%3[]1/[L*?0"W&@Y820^OA-.Z'@V0K&X<@.5U?H!K^=917P.G@\@J63S6/S9
MY_BU$\1+1.F[N5D,0ADK0$$$K3W'CC-^O4AC0D!S-']2N#^S#OL3"Z.M*N2;
M"J%&$!+/4F >"5%A#&E(G5LPU>J)Y11JOI547R^BIXC0QPS2K$ Y+&E.&)DQ
M58GD8T"J3]APUN=$1B<ZP]?8'%PFQ9//)+)5"H.K))ZT4B=LL;W#QRI')(K4
M5K&N\D1/KXD;F"]_-<*M%>0G,UYG@?IPQMX,=C!"WQK'G]>7UC#S6OE1S"A0
M";-GFKHCR3IT8QJ(B^J6%K1'#.:GU_C?Y?7Z*OB"&3@YH?8/WXETQ4_,?)DB
M6)8L2R>:^JE:B'(YR*C&23P-4>=G_P <D]7G]?5Y^%K&K'3!4M[>&#%K&'[B
M)/3B+:*Q4]R8E[W$PR+Y*GJ$188T;ZOV^N9J^7GXPP*>28D'V<,&*LY:21.A
MO"XRO)R^4 /F\L>9?HYONP+$$B-^GFU_K_;Y)Y^!$);\')O;SP8^#Q)(WU9Z
M%LTL;$=(\ABOLX7,^GKC]Y5"A\U7Z.B_C1/Q\O#C5!I<YKR\,'MQX(DC8]6:
M"1"R6-\O;B\GV$*K]6->=_=CM:GG_9?[R?7Z)XRH9O\ ROE3VX.&/D*NF54S
MWHAF8SSEB>CV6ODGDBN0V1WL^ARI_P":G1>?^CXPQ"'_ #A8IR X8/=CX0Z.
M)SF7GE,:GEY-'9Z;%'?BUQ!GH:&^/R_%7-F<OC"L&JUGY0/'!BK!+-(OM9V9
M@SE1'/%1OV]I(K4]7G(3(DK"4]2?@CFQ^7^9^Y.I3YK@:O;@Q2(A@B_]O8[8
M2Y$];6US488_U>7FI'FGY:B+]?4J>;O"UU2^6$DKX'A^_!BO";,]S8*(D=L2
M-6)H<S58?*WZO="^0MSV31>IRKZ(WM;YKYHQ%\(,2H:S@U\10C!BG,(..U)K
M0>2FG5%="T"9SYY/XD<J_9SI+&.W]Z^ZU?W(OA08O2.(ZAX-D/KP8KK9R2(Q
MH!0+VM8Z-&V+U;82M?Y>;'ES-:B([R^B1RL1%\_"C;A?C#?1P_?@QY0!\+7S
MEB&5$;?3ZYQ"Y)7/>Y/4GLC>B:23U>2>2K(UG_E>&24/E0U/"AP886TMXABN
M<%B'F1N#Z"$/.4>-]R3$V]S^DHHW->QTT8\3SK&"/R8U%17^;E5$\;"SMWT7
M":=1:"@H>8=6]_ '&OOB%DMI3\"7 )/^PX^K,86-<#96^,UT0]C6R?>9?1",
M(G&]CUSD5!D,/\9 *23/;-(GT:JN\O#=C(L-[%*%82+.#09TH0?UBF';X.UG
M)&H^*(_;A4S-O(9GL^7568Q$EE04Q\1,GJ9(C"ZL8E$@ '&5C%1)/-72J]R*
MGX)X1+ 6G<3*RL'.5.5?']V'[<JT$9!XQK7Z@,,#&#-^ZWHAMBUY0?1]7)-Y
M#&$SJVQCK=!"Y$=''Y1H';,1?JB>:+^Q/&QN3TX8"D9(,"#D/O:?&M?HQ#LQ
M03K_ /)F;Z_W8].@%@Z:-,L%@9&7S8Q!O6U!1U4#6UKBWI[?OR*UR6D"?1R+
M]4\OV^$G7)8Z*J@6>N6;'CAH(8]P#I5I6AH/H/[<-/K&Q<"3CLS5U)=WH)M_
MC3'9&B'1)T%0V;[$O0V!/K%I*^2T]CT3'2L=(YOE R63R8LC;+0GJW,[HL(A
M?-R 3P^$5%33D/;B'N]^4:&" &27KI71P&1R:OM(X8IZ[$VQN4U5UU>\KX @
M<W>V/\I!DD5N3K?9JRIHY+I\SA[;6SQ2,1RR6/VU:KE\VAL5/-<6=XBW$-OM
MRL?Q%&JGF/FS*\@!6E>=!A5[;RO:S7.YNJMTG.@&JB@RJ>.=/UX,CJ+:TR64
MJ^75(]+1"9?/!P=#U%;+&,H\5.%&S^1\@UP)1\*,3S83.\(%/+SC<2U?3X3=
MVPBG>7=&9Y3*U$0\#6GG;F,J$?=\!@LKB:YMTCVI5C@2%:R-Y<M(J%'.E<JX
M9F!'S.<.OK%\%QO>G76TVQ#9%^UN=C,$%?%T0A3E7["CP]+]C40L=,JU@*HS
MR5[WHB>)^Y/<_AJ=,%HD$8\HHH.9I3BY-37CF>0Q&V]+-!(Z@SWDEQ+F15C0
M*14\%(\,7C!33MANM1T+1#Y:GS=#F,VM;07;@:\02RC-U-BRVVT\8%H603/8
M",D8 @$,JPM8BD)Z7*R//91QVZZYFD9VU#C1@H&GAI K[>-<(19I+^6ZW!^E
M$D:QKH^+S*6)9CF#E2@RIA.%_.M7MLYF><YR''Y+(TQ>O9;7-!,.VQMM#(;G
M*6SH,4QP1I9 H,%G(PNW41JOF;/[<Z-:JNJD=E8NU\[/*\F@ 'RA5S*$FM <
M@0/=EC.N2\OA'MJ"*UB@#LQ%&9B:!Z'XM/$$\*X2[H6EO-K0Y/' KUG2UJNT
M^ZVVDL&&9VH&KC/ML_FV7L8<M5&P_31/G*K\X$K?;K'#S^CW7/\ &;<L+![J
M;3;6;-H2-<F<_>('%0JD4+<2V7/#5Q2>^2TLR]Q>$:Y9&II"\O95B#4#@!A#
MV8TO3];_ "":65UU:1X]MTH,,QN:Y)1F>Y]Q3XF]DC(/B?*5[3CK&,M]S:J!
M%'%[,,9;G,DP$[5;B[ $"G*.H#2-7BX6AKQ !R (-#44,>[C3<YC:!VGG05D
M(;IPH ?A9N=!0T'FSQ#W5.L3RPUUI816?1Z8NVGQW,.<T%-9 <_Z9I(/>#((
MJL36R?GO3L=12(Z*&6Q(9FWHU2I)451!9-IMFTR3R_+QE(7H)9IG8:XHZU-9
M"=,9I0D#SG)5&9.-+N6[1@B5T::!08X84!$<C?W8QFU6J"[>7C7#@J?B5?\
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MPZ(6@*:LJXO=G%O+;?;P6!A79 I%84D5FM>H]2J2N]Q49!1<UE-)"IJ0<,&
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M>Z36I>ZZ4FW:8Q+ITF<S*L2'4;0+Y>E0.5*HN;2"H.*!*;(7T/R1GAW>0RF
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M#UN:]5Q*(H8+.RUBL#G4/O'4222."FO#+VUY:ZV2.2XGO=S8]1)U0#@ NFM
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MS"/=]*14$1!=)/"@K60/354U(S:H./G0TZ,P*F@W#:Z>Y>3*F?@(@V!6R_Q
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M9CJ6;,%*\= '%UIQ!.>D<\5KJO2[Z#D-?S$RJ,+BS]UM[H1AKDR^XB.CARE
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M<)<MZ;5C05ZVO%FD5E7 2-/-,X.V>.9-(WW1V3M82Z"_]X"5]CAEN3)U_F
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MJ7\4TM->G[W,\Q;B]A>LZE5OAR./Z%E^Y[GH.LZ,8^$)0H[G)TX\L0DHOO\
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M=J![4RY^WE$_-RK&(-AA%G]H1)%]P]ZR^V]S?5Y*J*ZUW=-&(FED,072 6-
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M\L &=&(J8WJ132.!%1IYURQYKZ1G%!);5ISS<79E&W72RIV>W^4:FWG>;?\
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MJ9&L2(>D&"R?-:"VHJ3'\M12NLUD-?P\5[%QQR4_JWE5[/U%>K1-KCY;J/\
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MVU%U242\[7WYTVM^271:M4DL+??6H44$.>RI-C$:.#SSD=8R'/Y>M?#()'5
M(^>*64PQTTF.T8 F5V+-QIER^T##9?,:?A'#]/;SQ,>3QE7EFM,<YM[JI@Y
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MA[:'G[<8O]GYAM=[\>NNF4-CI0.J;C,%VN?KL+N+/':<5PH)<&,PB&@'5#S
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M@I07$/D$.,FF3;B#<$"S!0]LA )-.KF-,8-/BS(4\P"IPY?M^6,>GY8KEE)
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M)(N#:K_SM#$*$E@.=!':M?D1.OGHVK+/B>?/(^'#]^%&1"*94J?V8=.IYO\
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M\#7C3#M_(NX,LENE;2$J92.+QY'I)S/3.;'EII2F%3J!A-^?$9AY2I4S%?\
M_!-NZ&?TS&\WMVP65GBZ6:"-RE[ RO>EH&Z)S7UPR.<U62&PHY-@B0(R7O\
MO'I&IY2"M)2>2$BGB21A6Z:YD67;R&""LK\ 8#QC'BZCB,*O1"GUP.1(Y/7U
MUGOZZIEEPU*!Y)3F8)XXS+B"Z;&^&.+). C'>!YN8Z:VA%CA^KI51%D1/+-!
MNK-^6LU).1$E:+I\? ^(J?##NXOT+>&7:D'SRQZHEKD8N+:B,]0'F IQ%,52
MZ_*B\Q T57?2Q$030;6DW)@RDW-IM;5C8$*L*T=C";,[53R+5$5$2(YX\B!0
ML;[42,1$]U+N!MYA\58R@^'0O.IR '\1X^_#DT=HNV_.I_.!#B3BSN?A2GB>
M '+GECSD:QO3Z:RTV[K)@+ZXC*S<V10KUF\M2L-BE)HA#H_-6ZZ.Y$@L)[.)
M$61\8OL*L$,3WN7,T>W3"VLF_!4@ZN ER\#Q4 E0/ L3F<-6<#[E;/=7X/78
M%2E<X:5J">35S8C_  BHPF4-X=T\RUP%[**9488M@.[M(?;8'U+VY98ZB*L'
M:UT'\JF*)(E_Z%6!]F//5M5\3)T\+FC3;D6^BKKE%8Z_%$?O(?[PKY*YD4.6
M%6\DF\L^W7  CC.F2G"4#)76O(_?I4*V6%"?1F<UL@N:5P3;8K41F/XX(3,]
M1QH0HTEOL[?E-]<PE'A8)$,'F\EDEJU02+U3PM]:&M%O8'W"3RK$09SQ/F^!
M@.9?($<C4\,)%U)MLPVN+S2N=, Y *<P3RTT-/'+&@_]=,4JLO\ XU!DDD:(
MZ',=0_-;P@?U&'$)#RMY<_VHWLL@9+&JI&R)%^WA<C6/1R.5>\^@#)*=V*%8
MQ)+;TS% "910DYTH>6>7"E<<*]:9)K6XLFF'4"1S%Z"K'3I)T@9:@.%2 ??C
M4CS6TKZG:\F;H2IX*GF7/^H]GV%M63-L;G(YP_(V=W7TT$HQ\UYG7(,%62"C
MOK2H$*N?=C1OJEB=U[?(9+[:=R>U54:^NH+2")Q1)'232[/6BNAJ'\K C3JY
M8HW;KPVF^;7!N#-\M8VEQ>7,BM^+%$Z"2.C %E>@" %2/.5YG$TX:MSN/O3=
MUV"#/$;_ +*.E))SRFC4T[FG&.AYH>IMQUB;1U=11[8W,W8P\H:#J575\/N+
M.D\[H&5/>GN;VU79^W3,=OVI1^,Q*&XNH90PT$ZM255]+ T:O 8M>SFQL]R;
M?>YP@WC<R8S;K1_E+2:,CSD!!'(590ZA32@YXL^'=" ^*=RS!=*)I*K#9.EL
M,YH*7<#5+\AV_$:LZU)K=CE[3\D)N;6JNCY9H;$ >(DR@)?Y,<CVN? ]W9LZ
M^HEM^8[0CW&^3NLD;6]3+9RJ$U12)J$:L"E%U$:O9C/9V_/Z;7R;1O+Q6^U0
MPLDD=P MO>PEGTRQR!6EE5E<UZ(9A7EG3++Y&?*;XY"YY^5X@=PKG&BTG,<%
M^;Z+%M"L;(SG>6I;8FJSZQVU-$"2V"HE1X8K)TM#9_MX2XGHBI'SGL_L+O5[
MX;KW2NYWD-O<3_AW46BEQ)\<C.'9XT%2<UTHM<=%[[]1.R&VH['V>VRV5]<0
M6RF6TD+GY>(56'2Z(DCQT C6O4+$"AQB1D<]A::DW!?6\]:9'_T:#0YZQT=5
MI 8"=)AL1D*Q69+3SU]:!6/IMM>ZBP=>"U<#Q?;8.,(1+[,TZ^.F;I=;M<3V
M:;!+;W'Y%$R(\7E2>21E,D:4KK3I@1"7@X!*YBAYIMECM=E;W<?<D,L![CD2
M5XI%!D@ABKTG8@J$E>5C,T69110U!%&-M0;S&\6NL)=OI]/>\FO^4=3RUM1(
M[0XK<\HM=+JZROU+RR \4*9+1:^TD /^^*4B*(A!IVI&&KI-KL]S8[CW<N_6
M6NVV^]BNK9UD/3DM[D+&7C!JS,) !H(4&B,!0D Z;=H[_;NU/R6_,5W=;;<6
MMVDD9UI<69FFT2D:56L+,W4U,=744$T3$):PA)=Z;8!N_-P;\VHTU><\I+5A
M6?U#!K*M%9<MG973/JQ2) G(Q_L*L<L3/[KU-6S66L;$(9U"7$,3I)Y2IZD=
M58E3GYLFKX$<\4_<37?-<+%[6:X2:-JZOPI=+IF,AIU%=(!"Z>.>.LK])Z2N
MD^>7ZM3 Q;&(R+K7.F6Y)MD'8#SE?^SZH\==$&*.E8,,#[;5'D?/(UZ*Y9/X
MO0WR?ZPI*/3?LI6<-&UE.0*9K4Q^7QRI7E6O#F?1'ID5_P"8_=PTD-\U#G2E
M<Y,_K]I\*Y8W^^/.^.\X/!@P>#!@\&#!X,&#P8,'@P8/!@P>#!@\&#!X,&#P
M8,'@P8TG?&CI/R(Z;U'"8RI[ITS?Z[F'0%3Y1'3]'^'&HX'-CP1M.,8/B:CF
MM0[M_OZ6W97LK8RQ0'UZI*PV9'Q*V3IN]V6T6-A+<R6D$-O/#_EAT[Q9]9TD
M%S(>AY1JU4+:LBHH<OHGZP=H>E/9W9>Y]P7W;6S[7L6\[7_]CJ"P[JM]Z%T[
M6[*UW+N$OY12WB,YG:*283^1K>/2X*[;NMU$U_R[H5(/?U&5FM<;H@8M+?C
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M'((!GLYFZN5#(]'C:0HZ&UNY3@%CA"C=$Z.0IT4"TCN'9'[ME-ALIGMMQ?\
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M (=P3Y1<TU,>NZKV&\[3%4D;!U?E?\5-0-4VEUK;CFM3'LBJPK-4E4/7UN:
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MW9$6^UA)RYQE=S;7EB8WH&QK)G0?F&I@D>!G'8\R/S5D)BL=1V]W&BL:YX<
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MQAV^[CZ+-&$)B:149-()I& "T8KY0U*98ZK_ -*G\Z_]'I_5;2PI8*RK9U7
M_D1\>8@H)+\>4GH3S;#[^,0:?20P'>N%I<SI9/-JM]2(B-3ROZLBW_Y>]F]-
MF:46<P8%M04_A\!]VH(-.8-<=_\ 3;K#U#[M#Z>G\W%2@ /^\XT Y4QOM\<
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M%UB:637"YS,4FD+0$!BT;4 G%#H45 .'R<W,19D?CO7=S94E[A*O2&\KVF2
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M=0&Y89%LUQ/);V_Q44M5K:'E0]1O,%;*R">W!!QLL(+3&QR2"0WD(L3W4MW
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M1-XME:LB#J,1DP!(U@<G!!1^99=7WL-]J7)V^:38[HUT2$QCG4@&A\5/QKR
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ME1U5'2G6,O3NDPY\B442")9\FYBM]4:KXCVX!9G!+  *">)IF3R\:?1AR0Y
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ML2W+W<<23-,( LTMQ!<*]K;_ #SUZD4B/:0),=:O"K Q_P#$6Z!T6PTIU/\
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M?"S!CIQ4)G+[6;-B.?#AX/BG,J4VV0:YIKA]>V)DU523:W9 &^BYV._U^EJ
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M''# K(=<M%<RRJZ%54L3I()?BHQL2:[X/:5.OKB1]_QGHL^@JKVMLLL6$)J
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M'6]7<=-MNH,-S&P4O[!]Z,Y%J^VF$0*S?AFQ<?Z_6/N\H+&CL)T&,:5K+.B
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M,0F3:?G@U38XXGE&:K,C0D->1]^/!<WMD3-&UKP)(GK[3FU;/N.V0M)/6)=
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M:3-')67T\HC:QZ3P-65JMV]WLJVNWMN"7-O-$)41>F:DZE<DE6TR)IT@4:,
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MN3G21YC)7\%58FH4-7RC[Q3/+'%.[Y=OWGOC:_RI&:[._P  !1JKTE4=8L
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M*O8CJUT*V% =%G;&:%R.8_[W.:.5U;ZY&(J.2&T6-WGY>VU/X?"1\C+YD+P
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M^"$234+#U[=E5-Q1DN$L*ZP EY[&A0_N>]"YL!+7QRADQS#3P^<<C',<J>.
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MCQ2[>T;)(D@ZG28J!+'- 03HF9U*^=JZZY:,9 TO=+-V=*T7-\Q7?&FST(I
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MM(JT423!@"4L8!8TE2VC!&$01!1FCJUL"HK_ +A))W\1]5VDC[\1+ZD[K;Q
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M1/)?!K@_C3+VC&?^E'^HBFK_ $KNE![1S]G'[,?%_5;_ $Z$_P#KM>;?O_\
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M<\CEC6Y_X-?ZGG_<^Z-_Y],+_P"A;X<_,K+_ (B_6/WX]/?]7']./_M59?\
MA77_ ,#X/_!K_4\_[GW1O_/IA?\ T+?!^967_$7ZQ^_!_P!7']./_M59?^%=
M?_ ^#_P:_P!3S_N?=&_\^F%_]"WP?F5E_P 1?K'[\'_5Q_3C_P"U5E_X5U_\
M#X/_  :_U//^Y]T;_P ^F%_]"WP?F5E_Q%^L?OP?]7']./\ [567_A77_P #
MX/\ P:_U//\ N?=&_P#/IA?_ $+?!^967_$7ZQ^_!_U<?TX_^U5E_P"%=?\
MP/@_\&O]3S_N?=&_\^F%_P#0M\'YE9?\1?K'[\'_ %<?TX_^U5E_X5U_\#X/
M_!K_ %//^Y]T;_SZ87_T+?!^967_ !%^L?OP?]7']./_ +567_A77_P/@_\
M!K_4\_[GW1O_ #Z87_T+?!^967_$7ZQ^_!_U<?TX_P#M59?^%=?_  /@_P#!
MK_4\_P"Y]T;_ ,^F%_\ 0M\'YE9?\1?K'[\'_5Q_3C_[567_ (5U_P# ^#_P
M:_U//^Y]T;_SZ87_ -"WP?F5E_Q%^L?OP?\ 5Q_3C_[567_A77_P/@_\&O\
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M4@1DI<*2-+"O_@[\_-0ED#9_I^]Q$S6FP)>&+R0&PX@_-\T2?(Y7/-L^0!3
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MLNXI))"J;B$>S^=N;R2W($8TN#+&L<BTH$9*Z2,7%]\:OU,)[NTN<]^GUU4
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M&>;]%\_/S]$;?/S\_KY_CX>3N*./RBZ++XDBOZL);9K5_-T8E;V _OQ:NX$
M]45W.1$\O/R;%Z8(V^:^:^F.$Z.-OFOU7R3Z^'/]2Q?_ %2?K'[L-/L<!%%C
MC^H_OP?X!5_DB.YM6S(BJJ(6*&<B*KO7YI]\01Y*COJGE^'A![E7@MR2/>/W
M8PFQP**=.*ON.%@'D)%6[U5>!JJU_EY)(#4T@DOI\_/R]V!C)/+S^OX^&SOU
MN[:WG&NGC^X8=7:U1="QII'M_?A==B=>[R]5*6OE]/K*,OX?1/QG_=X:;=;
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M[:TMS951%OS5^MQ^AH0:BP)M8B#A;NVJGC122NGB=(_R1D1N\O2VUGEOMBN
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M<'M-_<G]7_7X*-XCZL&E?[WUG![3?W)_5_U^"C>(^K!I7^]]9P>TW]R?U?\
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M^Y[?N>KTKZO9]7\7GZ/Q]/[/!@PFF_R_^8U/YC^4?F_K+_(OO/L_S/W?M_\
M;_R?W_\ :_7]K_VOL?7V_P"U]/!@Q\N_Y>_+)/YD_)_R;U#>]^>?9?EGK]^/
M[/WOO_\ 9/7]UZ/:]7U]SR]/U\O!C(KRPH2?9^R_WOM_8\T]SWO;]KS]3?3Z
M_<_A_M>7EY_M\O+P8QBY3R\D]/X?L\&##6+O+-D93$QNDE:QD[4E85D$9*UK
87(DD:2:N.5&/1/-/4UKO)?JB+X,&/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g42675dsp42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp42.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +1 <H# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M$*<"@#TC6_$L^F^*_#FE1QQO#J;7 DD?.Y/+CW#'UH Z4#(ZT +0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /&_VO- ?Q/^S]XGT^.&"ZD=K25;2YE$279CNX9/(W' #2;?+7/\
M3@4#1\)RZYI-Q$7ETL6LUK<23^(-5NK:>&5K-I$,R78DB54S")H_+W-N>6-5
M#!$*@V?2_P >?VR_#'[)W[.WA&>4QZIXMO\ 0[5=(T0O\TA\A1YLN.5C4]3_
M !'@<Y("3Y__ ."2'Q0\2?&3XK?&WQ;XLU*35=:OXM.>6:0\(-]QM1!T5%'
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M'CDVL&&0>N" ?PH YS6_@EX'\3:7;Z;J_AC3]4T^WQY-I>1^;%'CIA6R!^5
M&=XC_9K^%?C"_2]UWX?^'M8NTA2W2>]L(Y76-%"H@+ X4   4 :W@'X,^!?A
M9+>2>#_"6D>&7O JW#:7:) 9@N=H;:!G&X]?6@#KS;1%]QC0MUR1S0!Q'B[C
MXF>!/]Z^_P#1(H [L=!0 M !0!A^.?\ D2?$'_8/N/\ T6U %KPW_P B[I?_
M %ZQ?^@"@#2H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H X/Q=_P E,\"?[U]_Z)% '=CH* %H * ,/QS_ ,B3X@_[!]Q_
MZ+:@"UX;_P"1=TO_ *]8O_0!0!I4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 <'XN_P"2F>!/]Z^_]$B@#NQT% "T % &
M'XY_Y$GQ!_V#[C_T6U %KPW_ ,B[I?\ UZQ?^@"@#2H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X/Q=_R4SP)_O7W_HD
M4 =V.@H 6@ H P_'/_(D^(/^P?<?^BVH M>&_P#D7=+_ .O6+_T 4 :5 !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MM97L2^'[F6*26 @/N9FB=U9G/S$EB3GGF@#UCPW_ ,B[I?\ UZQ?^@"@#2H
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M&1))79I2'\[>93OW[]V[=SG- 'L7AO\ Y%W2_P#KUB_] % &E0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M=H2))TW@9V+\S'\!S0!:@F6XB610P4]-RE3^1H <6 H 3S5W!<\GH* 'T %
M!0 4 % !0 4 % !0 4 % "9% #?-3?LW?-Z4 <-XN_Y*9X$_WK[_ -$B@#NQ
MT%  : /G[QA^U%K^A_%3Q!X&T3X0^)_%M[H\%O<RW6GW-I%')#,I*2()95)7
M<KJ3C@H10!WMCXKU7QI\(=8U36?"VH>#;Z2RNU;2=3EBDGC 5@&)B9EP0,C!
MZ'F@#L_#?_(NZ7_UZQ?^@"@#2H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * $R/6@ R* #(]: #-  2 .M $33D@%%W<X.>,4 07$\
M</$\RC=R%'!/X#DT (MWN(\JVD;_ &F&P?KS^E $DOF[PP=5C'4%<G\\T 5Y
M;$W$<C[V=FYC5R=J\<<9% &'%X<O[E0MR\"#!!4DR*>V0@VJ.N>AH TX?"UN
ML7ESRRW$>0?+)")Q_LJ /SS0!I6]A;V<>V&*.->N$4"@!S2EPR1 ;@<<]!0
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MN]A[84?SH K(+MI +6SAL%;Y?-N/FD/'4*O]30!:T_3)(7>XEE:>[8;3+*
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M_)>E %NWM_+"B.-88^I0+C^7% %B.)8^%^M $E !0 4 % !0!%)*1@(-Y/&
M>E "QQ!<G)8DYY[4 24 % "%@!G(H @N+Z"U4--/'$"< NP&: *)\01RD+;6
M\]V2<;HXR%_[Z.!^7]10!!MU:[&2(;1<YPQWGZ8&/YF@!QT(.&:[OIY@3EDW
M>6GY#GIQU[4 .MDTZS8BUA1VR23%'N.23G+?7WH LF>Z<J$A2)3_ !2MD_D/
M\: *LLR-,8Y;S<5/SQQC&1CIQSW'>@!8HU68^19;B!_K)3AL_CS0!,+:[D \
MR=8P#G$2\G\3_A0 ?8[?;F423\X ERPS_N]/TH OQ1)&@"*%'H!B@!5C"L6[
MF@!0@5B0 ">N.] "T +0 4 <'XN_Y*9X$_WK[_T2* .['04 #' H ^5=>\&V
M?QH\>>(;CQ'\5O&%OX6C\0MX;M_">DL-,MC<QPJSQO-#F696^<[F9!SC' R
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M*X>:_1&9@ERVY 68L3M&!WQTZ4 :=EX>T[3EQ;VD40P%X7L.@S[4 :*J%Z4
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MY\!0,$C!QQ7VV3U%3I<C1K3DEH>RK<(Q*!\L!NP/2OIC<=&X=D8%^?7(_,4
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MIQ0 )9NH7-S*V#GD+S['B@!!9. R_:ICGN0O'Z4 .^R-YF[[1(1_<PN/Y9H
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M>E "%1Z4 5[AF2SD93@@'!% %%U)N['@8$TF=O3HW6@#7% '">+O^2F>!/\
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MVVPB\T$KNO;G=)C)[#<3PS8'X4 6[>[OF&RWMTB4C)\BT;J0<_,Q /(';\Z
M,#XE>/;/X7>%+KQ+XJO9].T2V>*.6Y^>0[I) B*$@0L2S%%'7[^* /&KC]IV
M/6#&?"_PW\:^)F!!2XGTI-.@;@8/F7CAL88C[I[]: ,G7/'/QY\<:-JNG:;H
M7AGP##?P&*.^U'47U.\M"5P'1(XUB# \C)89_4 K^%?V;O"6ES6^I^(8)O&_
MB50&EU?Q),U])YA^\T:R$K&"<G"J.M 'JD<,<**D:+&BC"JH  'H,4 /H *
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MR] '?>$_#5GX-\,Z5H.G^:+#3;:.TM_/D,CB-%"J"QY.  ,F@#6H * "@ H
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ME5S\U 'JGAS4M4U3X)ZH=:U'3=6U6UM=0L;F\TB!X+>22!Y821&^2A&S!&2
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M?4%=QTA0 4 % !0 4 % !0 4 % !0 4 (W0T 1?L'9_X9=\)9_Y[:C_Z7W%
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M2\EQY@/F"1$88((&5' % 'H/AO\ Y%W2_P#KUB_] % &E0 U\A#MY;'% %*
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M\\5>+O%$OCKXWW'A;5+>_FL;31M-\9G1UT^*(E%8PI(N^1B#(6E##Y@ ,#!
M/2OAEXJF\8_L[WM_-K,?B(Q0:I8IK$;(POH[>:>!)R4^4F18E8E>"6.* /5/
M#?\ R+NE_P#7K%_Z * -*@!#TH I"%=FX$ABYS@^_I0!8V2[0 X//5A_^J@
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M_P! % &E0 AZ4 5D&8@/]L_S- %D=*  T 8&FR-'JVNA59CYZ%1@X_U*?UH
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M8LYE<\G*7,X(R..LIS^%?99=;V&FQV4MCZ+KT3<* "@ H * "@ H * "@ H
M* "@!K_<;Z4 <+^PK<*/@#H 'GKMGU,96(D?\A%^G% 'TAX<.?A[8'G_ )!Z
M]>O^KH T]!7_ (I[3>/^6$?\A0!:MEVSSG;M+/DG.<_*/RH M4 <'XN_Y*9X
M$_WK[_T2* .['04 (_W: /AKXU0VWCCXI:_I%[\'M0T'0;>Z*7?BC2_ 3:OJ
M>L\ LT$_D&.%#T\PF1S@X"]: /HCX>Z!X;\+?LZG2?".B:CX=\/VNEW:6VG:
MM;2V]U'_ *PL9$E^<,S%F^;KNST- 'IOAO\ Y%W2_P#KUB_] % &E0 UQE:
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MHF5RMP)8Q)(<;N8KA<Y'RT >P^!X- M?V?IX?#.D:IH6CQZ=>I%8:TDJW<3
MR"3S1*S.6+[SEB<YSG!% 'I'AO\ Y%W2_P#KUB_] % &E0 V3[IH YBTS')=
M@NS![],;L@CY4_S^% '4#I0 M &78*%U;4@%4 LC$C.2=@'/X 4 :6P>E '/
MW["+6;.;:S,EPT&0>%#1@]!UY"]>G/(H XK7XY-/^(NH1AI1%?V<5RH3!VLC
M&-L \=/+)]<#@]" ?/-MX>L?!'[7OB:1].A2?Q?H,&J6U](BF826SB"XB#_>
M"E6MGQG!(SSUH ]BZ4 % !0 4 % !0 4 % !0 4 % !0 4 <%\%';PI^V/XT
MT[)6W\5^&;35T7! ,UK*;>3O@G9)"3P3TYQ0!]<4 ,EYC8>U#T ^5]9O)Y-1
MUR16"3I?R,C@ G"R#';J=H&:^$KXB=/&W3./F_>7/IO0[X:CI%I=*<K-$KC\
M1FOMH2<HIG6G?4\D_:-A2W@T/4&A6X"RR0M&<?,"N['/KLKR\Q@W137<PKR=
MK(X_X4ZM_9OC/2XV5HW=FA<*=R%64.K;CC/W2. <=.@KGP?N5D84)<SM<^FE
M.1FOH3O&RH)(G4C(((Q30'R%XNTMM&\7:NID;RXIA&R*#E0P5P,!>C$ 9[9S
MSS7Q^.C&C6DK:M'FU5)35CR?X0>&+O5/VCO$%['<VT%AX.@?35MPK^?.MXD4
MP+-G;A&B8<+D\\G%>_@(KV":.ZGL?3M>@:!0 4 % !0 4 % !0 4 % !0 4
M(W*GZ4 <1^Q#</#^SUX1/DY3[1JQ+[\?\O[=J /I7P;D^#=(SU^R1_\ H(H
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M4P-U]"<<  'I(Z"@!: "@ H * "@ H * "@ H * "@ H \7^+27/AO\ :$^
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MXK2:.U(7+%HM_P"7(Y_.@!\EC=B-E2[+Y&,2*N/T H CDB>SM;"$MN99$1F
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M!E,6]#(!NV9YQZTKH!6NX4*!G4,_W1G[WTI]+@-_M"V"EC/&%#;"2XX;T^M
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MTMH[[^S-82\$,85G8"SP[8"YS],=<5Y^7PY.:)%.RN>_5ZQH% !0 4 % !0
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M=UWEA0 4 % !0 4 % !0 4 % !0 4 !Z4 <;^QS(R^!_%  FP?&^NCY ,?\
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MCKFOK,J5-3?LRE-.+43[K'PC\#9_Y$WP_P#^"J#_ .)KZF[.'FG_ #,!\(O
MP_YDSP__ ."N#_XBGH+GG_,Q?^%1^!O^A,\/_P#@K@_^(I60_:3[@/A'X&_Z
M$WP__P""N#_XBBR#VL^XA^$7@8_\R9X?_P#!7!_\119![6?<7_A47@7_ *$S
MP_\ ^"N#_P"(HY4'M9]Q/^%1>!Q_S)OA_P#\%<'_ ,119"]I/N'_  J/P/\
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M:4 --ML?\\U_E0 F/^)MG_IC_6@"Y0!P?B[_ )*9X$_WK[_T2* .['04 +0
M4 8?CG_D2?$'_8/N/_1;4 6O#?\ R+NE_P#7K%_Z * -*@#/\0+OT._ .,V\
M@S_P$USUE>$EY";T9^>/BN]DTBU$MLIN9&6>?[/;CYIMK!2GH1@YY/.WVKXG
M!4;SDWT#!04Y-LB^%7AK3_$>O-=ZE>7,^EQ1F^NKF)&0JVPE!&Q&2Q)P%&>
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M8T7 \#_;P/\ QB1\2<<?\2]/_1T=3+5'3A_B-'2_^0=;?]<E_D*YSV2U0 4
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M H * /(_'G_)QOPK_P"P;K7\K6@#UF@ H * "@ H * "@ H * "@ H *  T
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M "@ H * /(_'G_)QOPK_ .P;K7\K6@#UF@ H * "@ H * "@ H * "@ H *
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M "@ H * /(_'G_)QOPK_ .P;K7\K6@#UF@ H * "@ H * "@ H * "@ H *
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M H * "@ H * "@ H * "@ - &7^PJ2_PS\8$CD^-M<_]*C0!]#:E_P >,_\
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MX2MT4JZI%H=N/G7."3MY7U7H: -&T_9'^#,-LB2_"SP9-(!\S_V#;#<?ILH
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MM^.O% & /V@=()('A/Q]Q_U)>I__ !B@!?\ A?\ I/\ T*?C_P#\(O4__C%
M!_PO[2?^A3\?_P#A%ZG_ /&* .R\%>,M,^('ABRU_1WEDTZ\#F,SPM#("KLC
M!D8!E(92,$9XH W* "@ H * "@#/\0:_8>%=#U#6=5N5L]-L('N;FX8$B.-
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MQZT &\"@",S*LC;CCIUH >CANASWH X;Q=_R4SP)_O7W_HD4 =V.@H 6@ H
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M+/[3(S\#_$PQGY8.O_7Q'04?7BZ/8E?^/.W_ ._2_P"% #/#RA=(MU484;@
M.WS&@"\QY'UH AO_ /4?\#3_ -"% %@=Z %H * .<UQ?]-!_V!_,T 9] !0
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MV/;G'(.?H0: )5Z9H 6@ H YG69 ]^P!Y0!3]?\ )H I4 % !0 4 % #9/\
M5M]#0!T?AK_D7-*_Z]8O_0!0!I4 8VOZJUC$T*VLUR98V ,90!>,<[F'K0!!
MIOB-#:QQ2VEQ;M&BKE]A!..V&/I0!=\.3K<Z'92+P#$O7Z4 := &="1_;MSZ
M^1'W_P!J3W_I0!:D,BSH556C.0V3@CTH XGQ=S\2_ G^]>_^B10!W@Z"@!:
M"@##\<_\B3X@_P"P?<?^BVH M>&_^1=TO_KUB_\ 0!0!I4 17*JT#A_ND$'(
MS0!G6F#;:<V><8.2>3M.?U'I0!F:7I5Q>Q1W*W_[O<Q51&"5&X@KNSR..AH
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M8?"VW"F12KVVI$Y1F4CAC_=S^-','U>)8LC^UG=QJ_E_"B(,$8%EU C!//\
M%V'/XT^?R']7B69[7]J^&6-0_P )Y4<X9UCU'Y/<@MT^E'/Y"^KQ$:T_:Q%M
MO!^$QE_YY;-0]?7=BES"^K1'6UG^U=/$KO)\)X"5!VM'J)(/IPU','U:)###
M^UE)(ZLGPHC QABNH$')Y_C[#FCF#ZM$=>V?[5ZLL2GX4312?(SI'J V9[X+
M=*.8/JT3D?AA\"OCO\,_A]H?AF$> +N+3HO(6:6\O59^2V2!$0.O8U!UI65C
M/\2?#OXR?%G1M7\):@/ NDP.ML;J9;N\\R/]X'**K1 %AY?(/'S#UH&?:0U"
MV5>;B+Z[Q0!!X>8-I$!!R#NY'^\: +[\,OU% "N^P9P3]* (_M."1Y<A]PM
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M@@&%A@]>QZ=N* /.-5^(6NWGQ-O?".C1Z;#);6"W\LNHI+@(S[%&4]2K_@M
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MD_U;?0T ='X:_P"1<TK_ *]8O_0!0!I4 <YKW_(1_P"V2_S- &>* -+X?_\
M(H:=_N-_Z$: .AH 8O\ K&H A0DWTHR<!%(';O0!QGB[_DIG@3_>OO\ T2*
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MQP[$>9 -S%68#[IY)_*@#UJ*_@FX25&/INYH G# ]* %H * "@ H * "@ H
M8\JH0&8 GIDT .#!NE &)IT2/KVL%E#'?%U'_3,4 :,\*(\155!W=0,=C0!#
MI5Y&\"6XD\R6)0'SD'TSS]#0!HT 13N4 V[=Q.!N. : (P)VE3<L84')VL<_
MRH BNF\V]M8\9PQD;\!Q^I'Y4 7J "@!&.%)H X^<[[V[DP 6E8' QG'RC/X
M 4 -H * "@ H * &O]QOI0!TGAQ63P_IBNI5EMHP5(P0=HXH T: .<U[_D(_
M]LE_F: ,NXE$$$DC'"HI8GV'- '0>$[<6OAS3HPGE?N5;9DG:2,D9/UH UZ
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MW_$Y/Y4 7Z "@""\G6VMI96^ZBEC^ H X^!2L2[OO'EOJ>3^M $E !0 4 %
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M?3'_ (Y[T =M;1+! D:+M1 %"CL!0 \H"<]Z #;[_I0 ;!G/>@!U !0 4 %
M!0!DZS?R!DLK7'VJ;(![(.Y- $^EV:6*>2G15&2>I/.2: +] '!^+O\ DIG@
M3_>OO_1(H [L=!0 M !0!A^.?^1)\0?]@^X_]%M0!:\-_P#(NZ7_ ->L7_H
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M)8F-L "@"SX=5D\/Z8KJ4=;:,%6&"#M'% &C0 4 )F@ S0 V258UW,P4>I-
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MIJEK?*3!/'(!U"MR/J.U %E@'7GD4 8<][-ILK6-K"US*Z[H03A4'/WCV H
MP;5I'EN!<_\ 'ZDA2?W8 8(]B""!Z$4 6: "@"*YN4M86DD.%49.* )+&SN$
M'E8\O5+Y?WA[VT [?7K]6)["@#K;.UCL[>.&)=L:*%4#T% $] !0 4 % !0
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M'_/Q$2\7XG&1^(Q[T 9WB**&&:'5(Y$\F11%*X/RD?P-GZ\?\"'I0!7!STH
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MQAN[*<#@GD_A0!/'=Q2@;9%;/3:<T 2;Q0 !P>] "T +0 4 % !0 UE#C!H
MR+KP\B;WL6%I(^2R!<Q.3UW)TY]1@^] '*WL%SX<&Y[4K:# *1G<BC./D/51
MT^5N!C@]J 'VD\6IA)BIFCR##:*/GF/JP_A4'U].: .LTC3'MRUS=.);V0?,
MR_=4=E4=@/Y\T :E !0 4 % !0 4 % !0 4 0WAQ:RG_ &#_ "H Y$=* %H
MT/"L+)=ZC*2-KNBC'7A>_P"= '1T <'XN_Y*9X$_WK[_ -$B@#NQT% "U('G
M_P 6K;6;A/#1T(1F^CUB)\SJQB5=DF3)MYV__6I +Y7Q,"C]_P"%?^_5S_\
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MA@?0CJ* +N0>] !F@!: "@!I0,,&@!J01Q@A4"@\G QF@"2@ H * "@ H *
M"@ H * "@"MJ1Q87!!P=AH Y6@ H UO#!R+T>DH_] 6@#=H X/Q=_P E,\"?
M[U]_Z)% '=CH* %J0.6^(<-P_A^6:#Q%_P (NMN?.FU#RXW"1@'(._@#W]J0
M'CFB>+X?$>IV^FZ?\:[F6[N6V6ZOH\48E/HK-& WX&J0'I?B2VO=LJ#5)(WM
M+$2SR^5]_"N-PPRC)))QTRH]J8'::2P>PMV5VD!C4[F&">.I%2!=I %4@"F
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MW2 *I %, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M*3 *D H 9,0$.>E,#SE/BW;RZE<Q0>'M8FT2UG:VEUU8D^RJZ-M;"E_-*JP(
M+A"O!YP,U1.Y;\5$?\+(\!XZ;KW_ -$B@H[O% #ZD")PK]31;S!7?0XKQ)\)
M-!UR\;4K59-"UOJ-4TI_(FS_ +6.'''1@11=+J&O8DU[P7J&L)9K%K\UO)#%
MY;N%;]XVTC<0KJ,YP>AY Q3N.S.OM(6@@C1G+E5 W'J?>D(GI %4@"F 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 -9@HR2!]:!,Y+6OBAH.B7\ME
M)<SWEY#CSK?3;2:\DAR,C>L2L4R.F[&:%&XKFAX9\;Z-XN64Z9?)<-"0)86!
M26(D9 =&PRG'J!2<6MQIFW*-R'O4^HSRE?AOXV707TJ+QG8Q6;(T0C_L8%@A
MSQO\T9.#]['OBKNMD*QM^*5V_$;P&#U!O1Q_UQ% SOATH 1FP*@-]CRGXT?%
M4^"=/2RTYU_MBY'RG (B3^\1^@%>WE67O%2YIK0^3SS./[/I<D'[[/E/QY\4
M/C"D,FI>'?%E\;:!=]Y MO"XAC[R ["<<\U]-B,MPE*UEOW/E\OSK$UVTWL1
M?"K]KGQCH'BNR;Q3K$FM:+*XCNA-#&'B4G'F*54<CKCN,]ZX,3EM-TFX;GLX
M?-:GMK3>A]]Z3JMMJ^GV]Y:3I/;3H)(I4.5=2,@@^E?'-.F^6>Y]Q":J+FCL
M7:18M4@"F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <A\4M;N=%\
M)R_89EM]1O)X+"UE9=P26:18U;'?;N+8_P!FFB9.R.$'C/P1\-]'>WNM;TWP
M[90(JWT]U>Q^9GNS'.XN[%LN1DX)ZFK5.<W:*$I0/&[[]H#2/%/QNCN_ ?B#
M3=<T?0M%:^E&F0%795FC26"20GYU*$LH"D X/6MI4I1A[Z,U43V/L=F+6X.<
M9'6N/9FZU/"+C5O$FJ>+6TCP_P#$"\FM-/GSK.IW%M9?9;0 Y-M'^Y#/+C@_
M,=@(+$GBKZ"ZGH'BLY^)'@,YS\U[SZ_N12&=Z.@H AF;*L 0#64IJ+7,R6FT
MU$^7_B?\(_%$_BZ6Z@$NM1WTA\N<<&+GA6'8 8YZ5]WEF:X:E1Y7HT?EF<Y-
MC*N+52.J9Z]\-_A19^#_  W+:74<=Y<WT>V\=AE7!!^3_=YQ[\U\]CL;+%U>
M=.R6Q]CE.44\%0Y9+WGN?$_[1_P#O/A+XDEOK*%I?#%[(6MI4!(@8\^4WICL
M>XKW\OQ4:\.5O5'@9E@)T)\\%H=?^S%^TPO@98?#'B>=VT)F M+S[WV0G^%N
M^PY_#Z=.7,,O]JO:0.O+,SC0:IU?D?=%CJ-OJ-O%/;2I-!(H9)(V#*P/0@BO
MDFG!\LD?;1DIJ\661S5E"T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '(?%'1+C6?"^ZSMS=WMC=6^HP6X8 RM#*LFP$\98*R\]S37F)GD4_P/\
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M:9/)3Y^5_P!GVXKFQDL-67-%V9Z^7PQ6']V:NCZTA8M&":\0^G3NB2@84 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H *3 *D H 9+G8<?I3 \@;QWX^-
MJZCP=JKL+:11<1?8P#/N^1@&N,[,=BNX^E7H1?4Z3Q22?B/X"W<$F]S_ -^!
M2+.]'04 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !28!4@% #)F"QDGI3M<#R_5?VA/!=E8W)MM9C>_B#*ENUM-\T@XV<
M+Z\9JN6PK&KXJ8O\2/ 1/4M>GC_KB*!G> C H =0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !28!4@% #7 *G/2@#@?$'Q:
M\-Z'J+:-!.^KZUG8-+TJ(W4ZG'\:ID1CD<OM'O56>Y#;3%\5<_$?P&<8YO>/
M^V(IE([W% QU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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0@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g42675dsp43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp43.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,4 ?8# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M1P"3Z4 =#0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!XU\;?V?'^-&MZ;+?:O:C0K6+:^DW=D\G[X,2MQ#/'-')!( 2N5
M;!'!!&, '$:3^Q@V@^-]!UC3/%IL=.T[48=2N[0VLUQ=:I)$#Y8N+N:X=V5<
MG:HPH))VYH \:^./_!*_5?VA?B#?^+_&'QHO[O4+D[8H4T51#:P@_+#$OG?*
MBY/N223DDD@'T)^QK^RC;_LA?#O5_"EKXBE\2QZAJC:F;F:U%N4+0Q1[-H9L
MC]T#G/>@!C?L4>!6\2-JYU;Q:$;6#KITH>(+@:?]J-S]IW?9]VS'F_-C'6@#
MT'XB\>+OA]_V%9/_ $GDH [^@ H * $- ''_  A_Y)SHG_7)O_0VH [&@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * .!^(W_(W_#[_ +"LG_I/)0!WU !0 4 (: ./^$/_ "3G1/\ KDW_
M *&U '8T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!P/Q&_P"1O^'W_85D_P#2>2@#OJ "@ H 0T <?\(?
M^2<Z)_UR;_T-J .QH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#@?B-_R-_P /O^PK)_Z3R4 =]0 4 % "
M&@#C_A#_ ,DYT3_KDW_H;4 =C0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ' _$;_D;_A]_P!A63_TGDH
M[Z@ H * $- ''_"'_DG.B?\ 7)O_ $-J .QH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * (+J[BM(R\KA% /)H P$\4S//(L%C-<H%#JZC *GCO\
M2@#1T_Q!!>S>2RO!/_SSE&TGZ>O?\J -6@ H * "@ H * "@ H * "@#@?B-
M_P C?\/O^PK)_P"D\E '?4 % 'S=\0_VU[;X=>*M9T:X^#WQ5U>+2YGB?5M*
M\.>=8S!>3)'*9 &3'?B@#N_V<?VB_#W[3O@*X\6>&M/U33=/@OI=/:'5XDCF
M\R,(6X1W&/G'?L>* .E^$/\ R3G1/^N3?^AM0!V- !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % "$A1DT <M=-%J6MW27CQI8V:*<2'"DD9).?;- '*0
M_M _#2;XB:5X1L?&VB7OB6Z$T,6E65XDTORJ7;<$SM("'@XH Z_Q 1>6?VFW
MM96N+<^9'*1L ([<D$C\* -G2+J6]T^">5$1I$#@1L6 !'J0* +M !0 4 %
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MBJ>9YC2$OYGW<AN1Q0!W'PA_Y)SHG_7)O_0VH [&@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#@?B-_R-_P^_P"PK)_Z
M3R4 =]0 AZ4 ?!?CGXP#PY\3/$'BB_\ VA;'0M1TGQ?%IW_"O+N>S2U_LU;F
M."7S(V_>[VC+S>9D8], $ 'V?X#\?>%_B/HK:MX2U_3/$FF"5H6O=)NDN(?,
M&"R[D)&0",CW% %3X0_\DYT3_KDW_H;4 =C0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ' _$;_D;_ (??
M]A63_P!)Y* .^H * /,/B9X.^%GA30=?\;>+_"/AZ6TL8)+_ %'4;C1HKB;8
MHRSM\A9S@>YH [3PIX:T+PQI2V_A[2;'1M/F/GBWT^V2WC+,!\VU0!D@#G':
M@#)^$/\ R3G1/^N3?^AM0!V- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <#\1O^1O^'W_ &%9/_2>2@#O
MJ "@#Q[Q1\?OA'K'Q N?@_KVO:7>>(KY/LL^A7L#20S[T!\AF9?*+LI!\LMN
M((XY% '?^$O&FB^+SJ\&BW0N?[%OI-*O%6-D$-Q&JEHQN S@.O*Y'/6@"A\(
M?^2<Z)_UR;_T-J .QH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#@?B-_R-_P^_P"PK)_Z3R4 =]0 4 >(
M:G^RMX<\1+\0;#6;NYU#0?%>H1:S%9;5CETG4 NU[FVG4;U9BL3#).TJ<<,1
M0!L_L]?!6Z^"'AO7M.O?%%WXPO-6UB?5Y=4OX$BG<R)&F'V<,P$8RP R2>!0
M!TOPA_Y)SHG_ %R;_P!#:@#L: "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H 3- "T % !0 F: %H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@!,T +0 E "T % !0 4 )0 M !0!P/Q&_Y&_X??\ 85D_
M])Y* .^H * /!_&/[8OA/P1XIU/0;WPOX[N[JPF:"2?3?"EY<V[D=2DJ(5=?
M<'% %C]EKQ==>/=-^('B"6TUNQL-0\4W$NG6^O6DMK<);?9K91B*4!E7>'P,
M8ZT =/\ #CQ=I6A^"O#=C?7:VUQ<6[21!P<,/M"1=>F2\T2@?[0H [W3-5M]
M7@>:V?S(UEDA)P1AXW:-QSZ,I% %R@ H * "@ H * "@ H * "@ H * "@!,
MT +0 4 % !0 4 % !0 A.!0!5FU.")RF\/(/X(QN;\A0!")KZXD!6-+6(=Y#
MN8_@.!^= %TRK&N68#W/% #9+@(!A6?/38,T )(\A4; H]=QZ?A0!5;4XX6\
MLO\ :)^3LA4D_P!<?C0!/:22F%3/M$IY*J>GM[T 3>:2"54GZ\4 *-V[)(QZ
M4 /H * "@ H 8\FW( W-C.T'K0 Y22H)&#Z4 +0 4 % !0 4 % #!("2 02.
MU #3.H4$<@T 0S:C% "794'^TP&: (!JC28,,,D_NJ[1^9P* '*;Z8Y(A@7T
M.7/]!0!=7Y5&3DXH B:^B!(#;V'!5!N/Z4 -^TS-G;!@>LAQ_C0 JRF$,TTB
M ?3 'ZT -?4%W;8D:5B,C:/E_/I0 A-RYZ1Q#U/S'^E $RNS @'+#C)'!H E
M (ZG- '!?$;_ )&_X??]A63_ -)Y* .^H 0]* /A/4?VZ-#^#_CCQ?X8\3ZQ
MK+ZG:>.[@21MI=Q=QQ:247"Q.J%0 PX5?4\<T >V?L=_%-OC)X:\>^)H=0U#
M4-&N/%UZNDMJ4<D;QV8B@*(J. 54$O@8XR: ,/QG?^&=*^%_@Z[\0Z'X5UPQ
MPSF&/Q#<RI, ) S>1'%;3O)RJLV%XVJ>>M 'LGP6MI;7X<Z4LVEKHC.9I1IR
M1/&+97F=UC"NB-PK ?,BD]2!0!W- !0 4 % !0 4 % !0 4 % !0 4 % $91
M@Q(/7L3Q0 "3& PPQ_*@!_6@ S0 4 &1ZT 13W<-JNZ:5(UZ98XH I2ZN[9%
MO;229Z.RE5_EG]* (?)N+K_CX9VS_P LE/EI^><G\?RH O):"%56!8X5] @H
M 2\D@C3,UQY:CCE]M %=+JV# Q0/,V3\R1G_ -"/'ZT /+WLH^2*. >LC;C^
M0_QH 0V'V@#[1-)<C/*@[4_(=?QS0!;CM42/8%4+_=5<"@"4(%H =0 4 % !
M0 E #&8L65>#ZXXH <J '..3U- #J "@ H * &LX4$D@"@""6_AAP7=0.Y)Q
MB@"H;\S8$<,D_.<@8'7U/% #A]OF4\0P>S9<C\L4 ']F-)CSKJ5QZ*=H_3G]
M: '10V-DWRK&'^F6/]: 'F>24'RXB/1F^7^?/Z4 -=7SNEE6/"_PCGWY/^%
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M$/J !0 XO]Y4&2.Y'%  $!(9SEL=,\4 2 @< @>U "T % !0 4 % "$@ DD
M"@"/!D9@00O8@]: ) ,  =!0 M ";AZB@"*:[B@&7E1/J: *W]J>8,P02S^X
M7:/S.* $!OY^HBME/U=OZ#^=  --1_\ 7W$DQ[C=M7\A_7_&@!RK9P/B-4W_
M .PN3^E $@FE8?)$%'K(<?H,T -;?_RTG"+Z(H'\\T 1%H3]U7N3ZG+#]>*
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M <N,@?E0!84R]$A6(?[1_H./UH >+9FSOF<Y[(=H']: 'I9PIR$!/JPR?S-
M$FP4 .H * "@ H 3(H C-Q&"0&!([#DT -%P[_=B;ZMP/\?TH :$F<C<X0=P
M@_J?\* $DMVC)DC9V?NI8D$>GM0!-#,LR;A^1[4 24 <#\1O^1O^'W_85D_]
M)Y* .^H * /$/%?@7]GC4/$NI7/B71_AS<:_),6O9=4AL6N6D[^87&[=]>:
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M/&02O3!Q_(BF Y+E5"^;O1AU+#C\^E $Z7"NV Z$=.#SGO0!+D>M  6 [B@
MW#U% $<EQ'%]YP#Z9YH 8;EF'[N-F^ORB@ 832KC<L?^[R>_K0 "U5OOEG]B
M>/RZ4 2I$J<*H4>@&* '4 +0 4 0F!5F$@)4GAL=#0!-0!P/Q&_Y&_X??]A6
M3_TGDH [Z@ H \B\3?LC?!GQIX@O]<UWX;>'M6UB_E,UU>W5FKR3.>K,>YH
M[3X??##PI\)M"?1?!V@6/AS2FF:X-GI\0CC,C  M@=R%'Y"@#C?"?PN\,>/_
M  /X2O==TP7EYIL,PL[A9I(I(!(V'"LC*>0J@_2@#TW1=%M/#VFP6%DCI:PC
M:BR2M(P'NS$D_B: +U !0 4 % !0 4 % !0 4 % "4 ,+%]RJ",?Q$<4 *J
M<]_6@!] !0 4 % !0 4 -90W6@!KMSA1DYYH 5$"=\G/>@!V: $+@=\T (91
M0!')=+&,LRJ/4\4 56U2)FQ%NG/_ $R4L.GJ.* &^=>2CY+=8B>AE;^@S_.@
M!393RG,UV5&?NPJ%[],G)_EW_  #96-N0\@#N/XYFW'K[T /:<21E$A=U(Z;
M< C\: *NE3"-KFV=LM%)D*.2 PR.@^OY4 7S<!.FT?[QH A-P\H)4NV.T:X_
MQH Y'6K>X@UBZC(9+:YC688_OC*GD_\  :Y:MTM *GV 'GS&:0')$F&R/H:\
M]SE?<":-@4+L#F/DDDX3.<>WM6L+_$P) =H4D9([UA*5W<3-'1[V6U,@6$S9
M.X!><"NBE-IB1TL,@N$CE"$AESGN*]-;%$4UNK@/'(T<@XWYYQZ=.:8#B]P!
MM(5P1PRG!_*@!OF+!*%,!Z?ZS*_XY_2@"-O+61GBT]F<GE@BJ3^)(S0 R>-G
M5"]N$!_AV%S^G2@"1[:-MKR>?A.@7</T7K0 [9;+;]'B1CC/S*W^- "H(([;
MY9V2-<DNSG@>Y:@ 1DD3S([S<AX#95AQ0 Y99&;"3Q. >0%[?G^M #A//@$)
M'(,'E6/7\J '17@9@DBF)ST5N_T/>@">@!: &OVH =0!P/Q&_P"1O^'W_85D
M_P#2>2@#OJ $R/6@!: $:@#C_A#_ ,DYT3_KDW_H;4 =AD'O0 M !0 4 % !
M0 4 % !0 4 ,:0(,DX% #6!ER""%]0>M $@&!B@!: "@ H * $S0 ;AZB@!K
M2 >] ##/N^Z1@'DF@!CW,5LN6D1 3W/4T 5SJ\#,%20RY_YY*6'YB@!OVNYE
M53'9R9.,^80N!Q[T .*7SC[T,/&.[G/Z4 ,%FX/[VYFD/<*0O\@": $,&GVQ
M+,B;D_CEPQ_,\]A^5 $ZW0V+Y4;L,<$+C^>* (IKUHN99(H._)+''?CBD] ,
MN[UZU@8AY996/  .P'UZ<U'.NH%2;Q(4!-K9MSP'*X_^O6$JZ3L!GW.JZCJ
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M;^-=N?#GQMO]5\;?&;X9R;9Q=Z%X;\<0S2+I$6!L9;>.ZBC9^I$SH6Y." *
M/K3X5:CK.K^#;2^US6=!U^ZN,R1ZAX:B>.REB)^0H'ED)XZG<0?:@#Y[\?SV
ML7A;X?VUW;V*KJ5E=V4=U=Z5<:JYD,L<BQ0VUM+'+YGR;Q*I)39V)S0![O\
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M[H=;V44>'1Y6R.-TK,/R)H F:+(QN8?C0 UH"1_K'_,?X4 'V8_\]I?S'^%
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M\\_A7#6?O"9*[[8XP"3D@<]ZXV21J"LI3=EB=YP.!QQ^-=M/X3CK7NK%@0R
MLPB!4<-)W^GO_P#7HE44 5)R5R>Q#P74<A*?,^T+C!P"1GK2C5;:L=$:26Y\
MHZK^T7^T%XI\;^,H_ WAOPK+X:T37[S1;=]1G=9G-NYC9FP1G)!88 QD#G&3
MW[ZFX+\9/VL$557PIX$"@8P;J3_XJD!S'B3]M?XT_!GQCX-3XI:%X4T[PQK%
MX\-Q<:;<+YBQQIN?#2S(BM@C&X\T >HC_@IE\'O^?F?_ ,&>D_\ R;0 Y/\
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M6N\9<I@(: .%U"=()[QG>-$$SEGE( 5>Y.>P%<,US3$S%7Q?I+,7.L:45^Z
MM]%^>-U8RHRELA(</%VAK$)?[8T]68$G%[%TQQP&_P Y-=-*DU&S,W"[-5?%
M.AI;*8M>TD8 (3[;'ASQUYX'ZU/L6WJ;+16+^E^*O#<#/)+KVD>83\I%]&<#
MZY]:WC32 ^8O@+<17;?$V:"1)H)/'NNLDD;!E8&Z."".HK8#U2@"M>Z99ZDJ
MK>6L%TJG*B:,.!^8H J?\(MHW_0)L?\ P&3_  H 3_A%=%_Z!%C_ . R?X4
M3V>AZ;I\WFVNGVMM+C&^*%5./J!0!>H * /GS]M6-I? /@L(I9AXVT8X SP)
M\G]* /O<S1J!N=1]30 HF1AD."/4&@!] %;47\NRF;KM4F@"4G<JGUH CML[
M(MW7;S0!8H X'XC?\C?\/O\ L*R?^D\E '?4 (: /C[XJVFI? KXD:IXWTZ+
MX8Z5J^N3O%81OH]_=ZW?[L92.&&7YY&P"[1H,X!8\9H ]I_9GL_$EK\,8Y?%
MGA73?!VM7=[<W<NFZ8"%(DE+B60&20B5\EF&\X)QVH \!^.>JQ:-X*^'$_\
MPFFD>&;B2"X5;&^OM0MKB\VS1NK1&TGCR$8 _O!@%E.]>X!])?L^F)_A%X<D
MA8NDD+RF1IA,SLTKLS%Q/.&)8DD^:^2>O8 'HA.* ,W4TS>:<!G)G)^F(WH
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M"/0UR15YD]3FH?V%OA&88_\ B5:N!M' UZ] Z?\ 76NM*R&._P"&%?A%_P!
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M19CQDE97*\X_NT >C>'/ _ASP="(=!T'3-%B P$T^SC@&/\ @('J: -N@ H
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M:]\1^)? R:GJ'A?5?"UM!?:I/I<]K;F]MYV$81I47=F*4CT_=GKQ0![Q0 4
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M)("Z$$-MRPY'1C@C-0MR%N?0"@  #H/2K+%H * "@ H * "@ H * "@ H *
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M0!\3_M4-+I_[0WP1NUA4JWB"^MGF89(62T) SVR8R?PJ%N0MSV&K+"@ H *
M"@ H * "@ H * "@ H * "@#QOX].8_'_P  F'4?$*S/0G_EUNO2@#[;'04
M17?_ ![2_P"Z?Y4 0W()6WP,_O%H 6V^;RF  ^0].G:@"W0!P/Q&_P"1O^'W
M_85D_P#2>2@#OJ $/2@#YL@^&7PZ^,6MZQK_ (MU34?%=QJ&M7N@:7!J<CPQ
M:5-;/*'2Q2/ BD7[-(WVC_6'9PP&%H ]0^"EI+I'AO4=&E\3ZIXM;2=2GL1?
MZRBBZ"J05C=U \TH&"^81EL9/.30!S/A[P]XMU7PIX*NO"]]H&F&WMKI;B[U
M?2Y+Z5=[C:(@D\.T':=V2>B\<4 >K^'K;4K32X(]7NK:^U(+B>XL[8V\4C9/
M*QM)(5'L7;ZT :1Z>E %.[+B[LQD;=Y_]!- %M.IH =0 4 96B2;--)/.)9?
M_1C4 32Q"222#&4:,=?Q'X]J /F+]N/3X4\ ?#?Q9<0130^&_%^FRW2R*"OD
M3,UK+D$@'_7+U!Z4 ==%%'%&$C140=%48% #Z "@ H * "@ H * "@ H * "
M@ H * /(OVA;G_A&Y?AOXRWB)/#GC'39YY3T6WGD-I-D]AMN,_A2:OH,^L-1
M2X:[MIHX_,"D@CIQ@\YK&5T.X;KAF.Z'(QG.ZI 07$D,0=H%C!/S!GZ#UJHJ
M^P/3<H?:%EL+NZLV,\15R&$@P#C/3'MTJFK";,72"RZ*6=2A8$@#OSP?T_6L
M-WH9O5:&UHY!MW/8%=W7/W!BNN*=AHBU#5(/.2+S3O#?-_M-_#C]?RIM.Q1:
MT5HFU147:P6,?*/QS_2N:#=]0&7K-'JKLO#,1M '09'/X>E9S=YI@=7I7_(.
MM_\ <%=@"SWH@F6/8[9QE@.!DX%,"SUQ28'Q?^VA!<VGC'X1ZA# 72'QU;AI
M".%#VURGZG^59Q^(A;GK.<UJ6% !0 4 % !0 4 % !0 4 % !0 4 % 'BW[0
MK^7XV^ [95<?$&S.7E,2C_1;KJPY7ZT ?;Z9VC/I0!!J+F.SE(Y.,?GQ_6@"
M0?=7Z"@"&V)S%R#\AY QZ4 6Z .!^(W_ "-_P^_["LG_ *3R4 =]0 AH \#E
M_9/\%:UJ]YJ%EXK\961;5KK5#;Z3XGN(;>VO9FD,[QQHV(V)FE! P1N(H ]/
M^&WPXT_X7Z!-I6G7FI:A'-<R7<MUJ]Z]W<RRN1N9I'.6Z#KZ4 ,^$/\ R3G1
M/^N3?^AM0!V- !0!7N%#30$KDJ21[<8_K0 Y91\YYPO!XH >94&,L 3T![T
M.)X- &9H"+]@SQGS9><?]-6H GFG2"0RNY6/:V<].,?_ %Z /%/VL-#C\8?L
MR_$O1HW,=PVDW%U:MM(VR1#SXB3V^=%P30!S7PZ\3IXU^'_AKQ!&<KJFFV][
M]#)&KD?^/4 =%0 4 % !0 4 % !0 4 % !0 4 % !0!YU^T5X7D\8? SQQI<
M"EKN32YIK8*<'SXU\R+'OO1: /;O OCM/'/P=\&>+8FRFLZ;:7A5&VDF2)6(
M'7H3T]JE:RU$W97+<+7=BDESYC^<1DY!92,G (]L]176X)1V.7VLE+08D1UB
M&8R2-<2*^,.QQD] N.,#!_*LZ<8QW"LY?$7[5!965\@!=VC+%<A< +TQ_AZU
ME46NAI3DVM3*TF0OHO.$.SH?]X\5QQ3N:+8(]5DMK=!"YW#;U1L=  .._P!:
MZN9) 4K;3FNY6DNU!E?.=X!*C'&.?>N2I5: MVNFM'<M)!(ZR1Q%RR<2L><X
MQU[\?2HIR;5R;L--O3J%X99U:.Y3:&![\C)_^M4ZN1:N>C:5_P @^W]/+%>D
M4-N3^]<?]<__ $(T 7&.U<T ?&G[=^;SPOX/O;4E_L'CG299'4YP#,\>/;F0
M5C'XB%N>JUL6% !0 4 % !0 4 % !0 4 % !0 4 % 'C7Q^D\KQY\!'Z8^(5
MGSN"_P#+K==SP* /MQ?NB@"KJO\ QXR?A_,4 3#[B_04 5H/OP8Y_=M@D>ZT
M 7J .!^(W_(W_#[_ +"LG_I/)0!WU "'I0!\FZQ\+?%GC_XMZYKWPQCC^$JQ
M7LEOJ/BZ.Z6\.M31MMD_XEJL86Y&WS9BL@VGY: /H?X:^'O$WACPO'8^+?%?
M_"9ZPLCLVK?V=%8;U)^5?*C)48'&>] $7PA_Y)SHG_7)O_0VH [&@ H C?\
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M7[*WG:'X&UWP/=C;>>"?$%_H!!SDPI*9(#SS@Q2QX^E 'L] !0 4 % !0 4
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MRN1F@#Y*U:R7X?\ [:'C/31B*R\;:!::_"#P#=6S&VGQ[E#"Q^F: /3: "@
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M?VWEL[2R^%.H2 K<6OCS3%5E;;GS$G0Y]<!JTP[-$>IUW#"@ H * "@ H *
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MQL?B/\(?"/B1VW3ZAIL,D_M,%"RK^#AA^% '<4 % !0 4 % !0 4 % !0 4
M% !0 4 -D021LC ,K#:01D'- &5^P3JAC^!\WA.5PUQX.UW4M *ELL(XKEVA
MW# Q^ZDCQVQB@#Z2H * *&JL5A0@[<..32;L!<C;?&A]0#1N!F>)8A)IC,21
ML8-D#WK.:NB9*Z.9AEC62$B2(['  4]!TQU]ZYX_%8E1:9W,+;HU/M78C0?3
M Y_Q/$ UO-@\-M./>N6JG:XF9"*F"0,;1D>O-<4I71DHV=SY7^.UU-;?M6_!
M"X*@0S6^MV;-@_\ /*!AD]#]WI[5WT/A-$>S_I704% !0 4 % !0 4 % !0
M4 % !0 4 % 'C7Q]@%SX_P#V?T)VC_A8U@V1[6UT?Z4 ?;M %/5AG3;GM^[;
M^5 $MQR\'_73_P!E- "6@ W@9^\W7_>- %B@#@?B-_R-_P /O^PK)_Z3R4 =
M]0 4 <U\1_%-SX'\#:WK]GH]SK]UIUK)<QZ79@^=<LHR(TP"<GIT- '0Q@%
MP7:6&30!R7PA_P"2<Z)_UR;_ -#:@#L: *C[Y .-AW#*]S\P_I0 V^ %Q8G'
M_+8_^@/0!+:C][<?[X_]!% %B@!& (H JZ65;3[<J,*8U(_*@"Q+&)8V4CA@
M10!D%BV@1L 6=$7&WKE3_P#6H U5VS1 D95AWH ^)/V>--;P#JWQ,^&S\+X5
M\37!LEQC%E=@74'_ *-D'_ : /9: "@ H * "@ H * "@ H * "@ H * "@#
MC/V7;H^&/VC/C3X58F.WU+^S?%%K&> QEA-O.P'^_;+D\]1F@#ZNH * ,GQ$
MY2QRIPVX <D<YXZ5,M@+>F7 N;*%P<@KUIK8"R\:R*58!E/4&F!6_LRUSQ;Q
MC_@(J'%;H"RB"-<#@52 =3 R_$,!FTUR,@J0PQ[<U$U="9R0L6_M,7 ^XV"#
MN&,<=?\ />O.<="3YR_:MDFM?B[^S_?1/Y<"^(KJSD7D$F2SEQT[?)730O8I
M'JU=8PH * "@ H * "@ H * "@ H * "@ H \6_:#W_\)Y^S]Y>[=_PL?3Q\
MO7'V>YS^E 'W#0!4U;_D&77_ %S;^5 $MQ_K+?\ ZZ?^RF@"""1Q/L(P#O//
M7[W'\Z +M ' _$;_ )&_X??]A63_ -)Y* .^H 0T >)_$;XZ>+_AX^K7=S\+
M[B7PWI[-_P 3VY\1Z;9V[QCHY$TRE ?1L&@#JO@;\5I?C/X MO%$GA[4/#*7
M$LJ16>HX+NBMA958<,CCE6'!&#0!I?"'_DG.B?\ 7)O_ $-J .QH J7,ZVY4
MLI(+J@(]20!_2@"._P#FN]/';SB?_(;4 6+="LDY/\3 _H!_2@">@!#T- %7
M2SC3K8\X,:]O:@"<N67Y!G_>XH R]+3$-Y ZLJB5OE/)PW/]: +FE.TEC'NX
M8#:1[CC^E 'R/\3-//@#]MJTN\>5I_Q \+F,\'#W^GR C\?(F/\ WS0!Z30
M4 % !0 4 % !0 4 % !0 4 % !0 4 >;6MT?"/[9OPXU,$K!XGT+4O#\Y 7#
M/#LNX<DCT6;N* /L-3D4 +0!E>(<?8UR ?WB=1GO6=3X= (_#,K/9%&X*,0!
M[9./TH@[H5S9K084 %*X!3 @O(_-MI$_O*11T XA8VB= REBN%R%Y*CICGBO
M/DUJC)NS/F[]LNR,,GPBUA;A8DMO'MB"&!SF2&X0 'TR?UK2@RE<]7KL+"@
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M)9L0H'7!,?O6>'E?02/7*[2@H * "@ H * "@ H * "@ H * "@ H \8^/\
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M0!]/0[^=_7/% "RP).,2*&7T- $']F6V,>0F/I4\NHK%B*)85VHH4>@JACZ
M"@ H * *VHQ">SE0C(92,?A4R5U83/D#]N"^A3X7>$[Z91OTSQCHET J[CG[
M2J?R<US4DU-W$CT_KUZUUE"T % !0 4 % !0 4 % !0 4 % !0!YQ^S8ER_[
M6WQ\%M+%"PT_P]N,L1<']Q/TPRT ?7-NK^4HE*O(/O,JX!/L"3C\Z )J "@
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MO=4C-_.3USOG+L#R>AH ]HT_1;#2K=+:RM8;6!/NQ0H%1?H!P*5P+JQJHQM
M_"BX"X'I3 6E<"GJ5^-/A$A&1G&*&[:@9@\3'<J_9VRRENH_QJ%43)N7M/U7
M[9($9?+;&=I/-.,U+8HT:L H * "@!&&X8I,3/F#]OS0[31_V7/%.I6\9%S;
M7NE2QDL2 PU*VYI)) D=-&Q>-&/4@&J&.H * "@ H * "@ H * "@ H * "@
M#S;]FRUAN/VO/CWYT7FA=-\/8&,@?N9Z /K>PW+$5:)854E5"G(V]NW'TH M
M4 % !0!5MU8.=W!)8@$]BW% %J@#@?B-_P C?\/O^PK)_P"D\E '?4 (1D4
M?,YMOBQXM\1:UX,GMM:\/V=SK=S=7GC+=:"&'2@Q^SVVG!<R>:Z",,TJY1C,
MP))04 >F_ >P\1:5X6U*QU\ZH\-KJ=Q#I<NN21R7\MDI 1YFCX8E@Y4GYBFP
MM\V: -OX0_\ ).=$_P"N3?\ H;4 =@W0_2@#SJ]!^UW/R^8?,8@ ]?SKRZB7
M-8YI:E"U"QQ,P4Q2M_ [9QTI+4I*X_3I1;W<I*/,L,C(I0$#.>2>QZGFNU4T
MC5*Q->21;$N4+1ECM"%=H& !_0UDX7-'#FV,V[!O82F"A!W!EQQVZ5*C8:HI
M$NFZ?J=VSP1MYRJ!G:I7&>,D@^U;1@I;"DN7<UHO"5Y"GG3W"94%@)&/IT'.
M/;I5J*0:&=Y<40=BJJS8Y QG'O\ E479M\A\UJU_!"PD+]%)W9ZY!'TX-.5E
MJB+(JZ;EXBH;&28\*N-H]B*YY.TKF#5CE/VJ-!D\8?LR?$"RMV!N_P"Q[MK=
M(UVLLB)YJ9'KN1?7J*[8E&3\._$T?C/P!X:U^(@IJFFVUZ"/^FD2L?U/>K F
M\5>./#W@;3VOO$.M6.BV@_Y;7LZQK^IH \DO?VS_ (=2W$EMX<;6O'%VA*F'
MPSI,]YSS_$%"]CW[4 ,_X7!\8/%9*^&/@X^D0-PMYXNU:*V"^YAB#O\ R[>M
M $B> ?CIXL4'7?B5HWA*%A\]KX4T?S9![">Y9L?4(* )%_9#\(:JS2^+=7\2
M^.YCR?\ A(-8FEB)_P"N*LL8[=%["@#K]$^$?@GX?O87'AOPGI&C"&=5,ME9
M1QNP;*?> R0-^<DT =MJUF-0TF\MAQYT+(#Z9!H 9H=Z=1TBSN&SNDB5SGU(
M&: +S$*I/8<T 97PBLH7\&_&%Y+**:4:W=?O&520?[-M.YYXH ]:TW7;[[#;
MX&_Y!A57H/K7*YOFT)<DAU[XJN;/R@2"[Y.5&X ?G3]J]K G<E3Q!?O(/F C
M/(.S[W'0<T_:VW%S(Z'3[MKS35FR0S#//8UKS75T4G<Y^76]3,K"-HPNX@!E
M.17-.NXZ"O8AN]1N[M?+G9'4$,2J],'TSS3YI3B)R*5]<O;QB1(_-61L$C@@
M>F>PK%-K1DMFKI%X7O[<@$(V590.A'K^1K6CO8M/H=8#D9KL*%H * "@ H ^
M;_\ @HA_R:-XR_Z^=+_].5K0!JP_ZF/_ '10 ^@ H * "@ H * "@ H * "@
M H * /-/V<)+N/\ :X^/;6D44W_$N\/;EDD*'_47&"#M/>@#ZZLII)HR9(6@
M8'&UB#^/% %F@ H 3I0!&/\ 6G_=H EH X'XC?\ (W_#[_L*R?\ I/)0!WU
M"'B@#@OASXWU;QX_B:\ETRWL-&M-3N--TR3SR\US]GD>&:210,(/.C=5 ))5
M<G&<  A^"GQ!U3Q]X;U >(-.M=*\3:+J,VDZK:V,QFMQ/'M;=$Y )1D>-QD9
M&[!Y% &G\(?^2<Z)_P!<F_\ 0VH [!NA^E 'FLEU%+>W:Y/,K)D=L'->74TF
M<XVRGBBN40A5!?@'GK_^JJA%LN*+.DQF*SNCL'FS([RE5ZD/C/Y"N\VL&K$?
M9$*@\2$XQCL>E96-$['.R7H#8!))4LN$W'\P/\YJY1Y=PYA+2YN5B<&=XUD
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M%+;T_1P* -:0Y0CUXH YOX&(-3\#?&>:X>[DF7Q/J<0\J:15VK:6ZJ,*0.
M.G..: /:].T:\^R6V8=R&)<X;@\=\US>SDG<B46QT^AWTQ): [^H;<,_3&#^
M=0XSDP2:%.DZC'LV6RD!0,^9^%'L9=R7%W-WP_:36VG^3.NQ@QX]JZ8KE5F:
M+0R[[3;U+F5X(@Z,<@;O_K5A4I.3N2TVRLVD7N\%K;<O+=1P?:DH-"Y6.GT>
M\F0 Q<[RQ??@CWX%2Z;8^5B66D7T$\3O"%"-NX.[^E:0@XRNQI6.Q3[HKI*'
M4 % !0 4 ?-__!1#_DT;QE_U\Z7_ .G*UH U8?\ 4Q_[HH ?0 4 % !0 4 %
M !0 4 % !0 4 % 'A'@;XH:;\$?VHOB_JOB;0O$=QI^MV.BQV%UI6@75]'(8
M89?-&^*-@,%U!Y[T >Y:5^VK\,[S4-(T^7_A)-(N=4O8=.M%U/POJ%K&\\K[
M(T\QX0@+,1C+4 >^#D4 +0 V1/,0J20",9!P: ,ZQ!34;M,L57;@,Q.. >_U
M- &G0!P/Q&_Y&_X??]A63_TGDH [Z@!#TH ^/?$^NV#W^M3>"]8\7Z%XAUCQ
M+=Z38>%M$UNT5-4N8G*W5VR30S_9(@T<S.X"DA0^TM( 0#V?]FI[.'P+?Z;%
MIDVE:KINJ7%MK$<^I?VD\E\2LLLINB!YVX2*V2%(SM*J5V@ ZOX0_P#).=$_
MZY-_Z&U '8-TH \UOU6*]NRJAAN<\=<UY=769SDVELC;0Z;5<<(PYSD 9]ZT
MI-&M/WBSIUBD32P*\@(/)#\;2<A?\?K79<V*NMVY2T4!AM5BQWGZ\#':A*XK
MG-1PQ><P\WSE;.W9GCJ",9]!651W=AEK$,$D>]U!8A5WL#SWX_E]*YV[(BHW
MT+L:),5>*3>S$$2!L_CFLDVR(WZBYBTO6A=Y*LZ.S YQ&N/J.^*ZZ;L66K/4
MK&ZDEDCV;MYR\@ )/IGO6LBS6B<2JJ,!LR!UXQ57)L:(LX4B"-(_D]%&\@8_
M'&>]7HQ#E-O;-C'SGN:0'S5^W9'_ ,6HT!T&$/C#0N/4_;XN:=P.VC DCP0"
M.F*8 0T?*Y8?W2>: &B3SS\IPG<]S[4 2A0 ..E "D9&#T[T 9F@-LT\6YZV
MTCVX!]%8A?\ QT"@".!!#XBOX3]RZACG'^\I*-^@CH T5)=D!ZC)/'?_ ":
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M1"N=EX40II0!;<-[8^F:[H7MJ:6L;-:#"@#YP_X*'?\ )H_C+_KZTK_TYVM
M&I#_ *F/_=% #Z "@ H * "@ H * "@ H * "@ H * /(/VC4W_\*J!Z'XB:
M /\ R:% 'VO0 A&: %H JI_Q_2?]<U_FU %J@#@?B-_R-_P^_P"PK)_Z3R4
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M>.E5H]RK<QS\&H%(HT((GBSO1U^\@P"?Y?I6,H&+C<N07,DK>;'"P9N 688
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M!/V>=*T?P_IL&E:7;>(]+\FVMUPJ;KY7;'U9F/U- 'T]0 4 % !0 4 % !0
M4 % !0 4 % !0 4 >0?M&D@_"G')_P"%B:!@?]O0H ^UATH 6@ H JI_Q_R?
M]<U_FU %J@#@?B-_R-_P^_["LG_I/)0!WU !0 4 (: ./^$/_).=$_ZY-_Z&
MU '8-P#]* /,]:1KC49WX7#LK8R,CL??]*X:K1A*96N;Q(1(KYSL;:2.-P'3
M/K7-%%)7*129KIV,>Q0A!5^%4CC(/?-=MCL2TNC6:^6UT>*!<$9+N67'/;;]
M.G-4FFK$QTE=E2-9))9V<C:%QA>GX<9SZUC6?8QJR-6ZU+[-9JN!N,:D8Z<?
M_JK:,.8JYDI=7,TK7+P@QR$B(+][@XZ?4T<J'&9H1B$W5N\<R2LS[#MX;!(5
ME((![]:4T!$H$<IC0D[6('&!BN9Z'/(SO%P_XI'5QC)^QS8YY_U;4J6LR%O<
MR?V0/^36OA/_ -BU8_\ HE:]V)YE;^(SU^K.8* "@ H *3V+N?F'^SY\<O /
MPG^*?[0UEXN\4Z?H%U=?$+4YH8KMRK.GG."PP.F017*SWX6Y$>Y?\-D_!/\
MZ*1HG_?T_P"%26'_  V1\%/^BCZ)_P!_C_A3L A_;)^"G_11]$_[^G_"BPF<
M_P#LF^/?#_Q)_;@^*6M^&-5M]:TF3PMI\:W=JV4++( P_"M(G)B]8H^ZZUN>
M1N%4G<35@IB"@ H * "@ H!*X4%I:GD_QY_:A^'_ .S9!HTWCS4KG3DU=Y8[
M/[-9RW)<QA2^1&IQC>O6H<K&\*3J)V/GR[_:Y^&O[2'QI^&NE^!M4O-0O--E
MU&ZN5N=/FM@L9M&4$%U )R>@K"3N=U"FZ;U/>:@[0H * /GS]N3_ )(I9_\
M8QZ1_P"E<= 'T'0 4 % !0 4 % !0 4 % !0 4 % !0 4 >/?M(.8T^%CCJO
MQ#T _P#DT* /M@=* %H * (5BQ,S]RH7\L_XT 34 <#\1O\ D;_A]_V%9/\
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MY^TKGR/A=C@_\+"T'G_MY% 'VTHP * %H * &K]YOPH =0!P/Q&_Y&_X??\
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MJYV_=+L<UXLN V@ZZ_RI$EE<C=P,XA?/]:NEI(<=[%#]D#G]EKX4?]BU8_\
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MKF/CW]LW_DY/]F+VU;5O_21*YYGIX1;^9ZEKG.BW_P#U[R?^@FL]CT;'*_\
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M_L/:3_Z5I6,]4=>&2]H>B0<P1_[H_E6!ZW5DE,84 % !0 4 % !0 4 % !0
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MTK.6QV89/VEV>B0<01_[H_E6!ZMMV24P"@ H * "@ H * "@ H * "@ H *
M/'/VE/\ 4_"[_LH6@_\ I2* /MK&0* &32^2@;&[Y@/S(']: )* *\1S=2?[
MJ_S:@"9.E '!_$;_ )&_X??]A63_ -)Y* .^H * "@!#0!Q_PA_Y)SHG_7)O
M_0VH [!NE 'G^K7JVKO$Z9)E.'0C R3QCKGFN&<>I,W>)79FDAB$4C6T;,J3
M8S\V >F.F1C\C5I)^\"=C5M99;,YDC\Z$ !!&F"N/49Y[=*Y7J$9\QI-(DT
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M 5X'#74I']U1^K4 /LV+VZLQR3G^= '$?$;_ )&_X??]A63_ -)Y* .^H *
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MY4 /H * "@ H * "@ H * "@ H BDNH(FVR31QMUPS &@!OV^U_Y^8?^^Q0
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MPR#0!]AJ0S*1N^[^% $HH 6@"&/F9_8#^M #; YM4_'^9H XGXC?\C?\/O\
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M-0;Y@(O* 5<=\G/]*!&%XW01^!/$21D "QNMW!ZF)B?YT >:?L@?\FM?"?\
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M?$>YQYV#.,]\5B>J.H 0C(Q0!$T!YQ-(,]ACC]* $M)/-A#<GDC)Z\'% $]
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M*_5?_DBB[#DCV#_A@CX2_P#/'Q5_X5^J_P#R11=AR1[!_P ,$?"7_GCXJ_\
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M@<#)H KFYEX_T:3_ +Z7_&@"*WNG,0*V[D9/0KZ_6@"7[3+_ ,^TGYK_ (T
M2QR%URR%#Z&@!)OGB<#J5(Z4 8<"&."-#U50#^5 #Z "@ H * "@ H N:5_K
M9O\ =7^;4 :5 #9/NT 8,7^J3Z"@"MJO_(/F^E '4#H* %H 8G5J %'WV^@H
M X/XC?\ (W_#[_L*R?\ I/)0!WU !0 4 (: ./\ A#_R3G1/^N3?^AM0!V-
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MC0!4N;?#B:,E90,9ZC&>XH DCFE.0\0!QU5L@T 0NTCH3*5MX1RQ+<D?7H*
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M %R;_P!#:@#L: *TFH6\:Y::,#./O#KZ4 5/[0$Q/V2!YF8??QL7ZY/7\,T
M*FFM=,KWLOF[3D0CB,'Z=_QH T$C6,< #- #Z &2*2!@X([T "2!BPZ$=C0
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M[BW4G'/ZT ,L6\ZZO)>WF"-3[ <_J30!>H * *UV=QB3IEQS],G^E %@<@4
M5 ?L<^,8AD.!_LM_]?\ G0!;H 6@#.U*\/\ J(F D/WF_NC_ !H HH@C4*HP
MH& * %H * (KB1HT C7?*YV(OJQ_IZ^P- %O3K7_ $D+NWI:KY88]6D/+,?\
M]S0!L4 % !0 4 % !0 4 % !0!%/.EO$TCD!5&30!FV;+?W?G2N RC,<)(RH
M_O8H U5ZF@!U ' _$;_D;_A]_P!A63_TGDH [Z@ H * $- ''_"'_DG.B?\
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M@"&TE92893F1!PW]X>M $=_?B#]W'AICV[*/4_YYH SE7;G)+,3DL>I- "T
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M7EV,0.=VT$Y]<4 ):PQR0M(T:[G8MG'49X/Y 4 )!"KO,REEPP48/H!V_$T
M(!<"<JDH*A0?G7/)SZ8]J )#<3),D;(K%@3E6[?Y(H <]XL;JKJZD_[.?Y4
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M=S#"RI@;I93TC7_''3\^W(!;LK$3^6JIY=A%_JX^\A_O-_GWH V ,4 +0 4
M% !0 4 % !0 4 % %;4!FW_$4 95 !0!H:3_ *F3_?\ Z"@"]0!P/Q&_Y&_X
M??\ 85D_])Y* .^H *@#COB9JNIZ;HMK%H^H6&EZA?7<=G'=:@"RH7R/E4?>
M?CA3QZ]* .<T#]GGPI;)-=>(+-/%FMW)W76IZPBS/(W;:IX11V5?UJP/1=$T
M33_#VG0Z?IEI#8V4"[8[>! B(,YP .G))J +] !0 4 %6 4 % !0 4 % !0
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M &2ZG;03")Y0'QG&"<#ISZ4 317,4Z[HY%D7U4Y% $@8'O0 M !0 4 % !0
MUD# @C(/8T 9EWHJ21,D)"*3DQ.-T9_#M^% &4\6H6DGE&!Y4/25/G*^OIG\
M<?C0!?M=+:95C>-H;4'<R.<O*WJQ_+B@#: P* %H * "@ H * "@ H * "@
MH K:@<6_XB@#*H * -#2CF*3_>[?04 7J .!^(W_ "-_P^_["LG_ *3R4 =]
M0 5 'FOQQ\+ZIXLT;P_::2TT5Q%K=K</=0!2]M&K'=* W!VY!Q@_2@!O_"K_
M !+_ -%-U\?]L+7_ .-58&\;^\\$Z-I]M,U_XGN"QB:Z$:^:[89@6" *,G"Y
MX'.3BE8#8\.:O<:Q9&6YM#9S*[(T>XL.&(RI(!(..#@46 UJD H *L H * "
M@ H * "@ H * "@ H * "@!,4 ->%)00ZAP>S#(H J_V1:ARZ1"-CWC)7^5
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M1_8X7\A-SD$A68@%NV3SBBX'@WB+4/'%_K20^-+JY\)^&A;S2S'PY;F9&(9
MB/=X9U!5F)_=0D8X8UMHD1+H>A?$/_D;OA]_V%9/_2>2L[W+/0* "H YWQM+
M;Q:2INM!F\21>8H^Q00QRMGGYMLC*O'U[T <-]MTK_HD6H_^"VQ_^.U8&SJC
MW,GA:Q?2]-M]#5MX%AJ2K'Y1*N%^5%D4$-AL#C'>@#I?"DLTEB3.L"%G8K';
M-N1%SP,[5S]<4 ;E0 M !5@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MSQ5 =%4 % !5@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MUGQ&)!"+<2#7KK(0=L;\8]L5K[26UB%!)W-#XB#'B[X??]A63_TGDK,L[^F
M5 &%XS\+1^,="N-,DO+VP69<?:+"<PRK]&';U'>@#R+PGX)\4? JWEBL=%L/
M%^B[B[7-G$MMJN#U+Y^68_B#Q6F@'9>*?&5C>^$+#59$U"U@N22L#V\:3 JK
M$HZ3 @'Y3QU) Q2 Z/P#?C4?#\$@;?M+(3F,C(8]"BJI'T H Z6H * "K *
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M7MU.VR.))@"[>@SC)K.6&KPC>432.,H2ERJ:/0TV@;ACGTKFNSKNMQ]2,6@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * &LH<<U+$<U>_##PEJ6K_VK=^&])N=3W!_MDME
M$TVX=#O*YR/7-.["QTB1+&,*.*0$-_=16-I+<3-LBB4N[>@'4TAG >-;'P)=
MZ(_B;5+FTLHI(@HUFUN!#,RD@JJS(0S<XPH)STP<XJTY(AI%CXA_\C=\/O\
ML*R?^D\E!2/0*!B,"1Q6;5U8#E?&_AC^W;)7@5?MD7*D\;AW%?(9_D_]I4.:
MFO>6QK"7<^>_BE8^/H+%M.\,>&=2GNY.);V( +&O=5.>21QZ $U\#E^08ZG+
MVS5K&.+KSY>6G$Y#PG\&_&OB"XMX+S0+G2"[ 2RW. B#N1SS].M>VLEQ4ZB<
MXZ,\NE3E-W9]A>$/"]GX1T&TTNS3;# @7=C!=N['W)R:_1\+0CAZ?+ ]1+E5
MD;>VNVXPQ1UN M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4F 5(!0!1UF*>?3;E+8H+AHV$9D&5#8XR.XSBF@/(+'X"W.ESV_B
M ZM%JWBR-S.6O[138"1@=WDVZX$!.?\ 6*=Y_B9^16CGT8'6_$/_ )&[X??]
MA63_ -)Y*B]P/0*8!2L TJ#3 /+%(5@V"AJXQ0,4DD@%IV *+ %, H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ I, J0"@"AKLUQ;Z
M/>RVB[KI(7:( 9RX4[1CZTTP/)KSQO\ $*;0[O[-X(U^&\-A']GE<Z<0+GYM
MS.OVHG8?DX )QNXSBM=#.[OH=1\0@1XM^'V>O]JR?^D\E1>Y:\ST"@84 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !28!4@% %>^N(;2UEGN'$<$:EW=NBJ!DDT <#XD^.'@S0_#]YJ5IXET
M+4)8(C*EK'J<.Z; R%7!)R>PP<G%:J+9#T9-\0SGQ=\/C_U%9/\ TGDJ+6+/
M0*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 %)@%2 4 17,$=S \4JJ\;J596&0P/4$4 <KXHU7PEX2TWS
M-:?3=/M3\BK<JB^8?[JJ?O'V')JFI$-IF=\0_P#D;OA]Z?VK)_Z3R4RST"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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G !0 4 % !0 4 % !0 4 % !0 4 %( HL 4 %, H 0J">E "T ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g42675dsp44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp44.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ). CL# 1$  A$! Q$!_\0
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M<A&WQGHY!X&+I>:GEEU"S)6^.WP^5V0^+])#+PP^TKD4^5A9D1^/WPZW;?\
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M@LC1GH<KU&#S7?I-6:."=:5.K;H7Y-/NO&GB271I](1M9DE%L-4MDWQ)+O+
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M5ND\L>8>>6C./]D<$]ZYY4F:PG"3U/=_#WBCP]XNTN*?2K^TL;R0>88(YEG
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M5OKK>;)'+8MS')%(7,;'@!6SPV,>E<\H-Z,N+)_B#%I]SX2>QN3]B4S*C/<
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M9&/V#6K6)+2,D?*82RL&((7^->V/<J-[&6C=SJ]5\;^/OV>+0IXGL=.\9>&
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M@<&6>W0!F7'*@]JS:MN)LP[6SM? >LV>M?;;JXMYIO(U"2[D,I>-D90I)X5
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M*4*R3,=Z1 \ L!QSZ<8KQ885PE:3#GN]#SWQ!_:VN_9IVTX&Y,NU+ERJ1,O
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M?%=U_:JK9WEQ(&'FQLD;A3D]<>I.>G#5?-=:''*,HLZK6!;3:2NJH\28E_=
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MU NEM))' N7$F578/]WD'IWQ7ERQ#A&S6IT*"Z&E(;&WBN+&\:ZD@"LS+L9
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MBFK&=?Z+;:A*LDJXE7&)%X; .2/H:!%ZWACAB1%^6->@+$_SH 4J"V!W/&*
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M5%B6)M)O0(70CC;'T#J.Q3(^E-V>PSLHW)D( )/IUJ7HBK%M4"(78$;1N)[
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MEL9R,EB0, 8(/<5S5Y_NO=>IWTW>5FCG=0O;N*WTJRT>>.2V4L7,6[9Y8&%
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MAE&=JL!C]X,UZ%-W2//KZ7:-#P1\3]6\$)IR>>]MJ=Q+)"H!.Q#EMC ALJ"
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M7GNY3\\KBVF/R^H'3/?K7M4:')'FEN*3T/OBMS(\._; O9+'X4Q21W4EIF_
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M-UKJ$/ES6YQN1L'@$8)['Y?7BO>C4C)MIGY97YZ4^11T?4RG^']A=WOQ&O\
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M5OIY.W=&3IO[,MWX9L="DT/Q*EMK6EQ7=J;J\T];B&X@GG:<H\1<8*NWRLK
M\'L<5G]4Y;.#U.R?$#JRFJU.\96>CM9I6_$ZWP9\&Y?#'C&Q\0W.M3:I=6^A
MG1Y//B ,I:X\]I<@X'S$@*!@#'/%7'#.+YEN>9B,UEB<-+"QARISY][]+6,"
MS_9^U#PO!H-UX=\2KI^MZ7:7&GM=W%D)XKBVEF,I5HMZX96(*L&^H(.*%A;-
M<KL=4\ZCB'4^L4^:,[2Y4[>]%6O]R&2? '5])OX=1T+Q9+'J\UC'8:C=ZU9K
MJ'VS8S%)N64HXWN!@E<;1M(45/U22ESQEJ7#/(3A]7JTOW:?/'E?+RWM>/G>
MR]+>9ZUX'\-_\(EX<L=)-Y<:B]K$J-=W;;I96YRS$8&2?08%=D8<D4CYZO7>
M)JRJR5F];=ET1Y5^US\2K/X8_#ZRU"YB>XFGO1;P0)CYW,;GDD@ #')KBQE2
M%.G>;L=F7X>OB*MJ$7)^1^=_C[]K+Q0ECIFS1]/F90RE@C,Q4G)!PQ QVKPZ
MV%PF,]YU$FNY["RW-4K>P?W,\VFU;2/&\UB]\]WI=VLQ8Q1*1'(A.\*&/W,=
M/SKTJ#HT$H1J)_,Q_L/,IZO#R^YGH>GMI;J;Q[ZUMV$>S%VZM* HQC[W.>W\
MJFK7H1U<U\M3JH<.YK5?)'#2];:'+ZPT/B9#+>"6*Q2/RX[:UCV1(H/!=G^4
ML:C^U8J/+2C=GH_ZH5(>]CJT:2\W^AP^J^ -'O+F!IGA7:K, C*6"CKG: &/
M/0<UO"KF%6.BLA.EPU@7:3E7?E[J^\[7PK\/M-G6"X@@+3)%^["Q>6PCR0,=
M#@URU,/.7\2;+_UII8;W<LPD*?F]7][*]X4TZWU(W5E':QHQ5-V3P!RQ[GGM
M7?AL'2IM.)\[C<_S+&Q<:]9V[)V1+X&\$GQ?X$U#5+<VDL-C<?:V#1,77^'@
M#MA@<>]?1IJ#44?/RO+6YZ'\%?B3H>E_$ZQTK5I!;0W\<NG7&R%8X721"HW$
MG/!P1GO5U$DKHS4N@Z:R:PDGM)>7MYI+=B"#]UBO]*J#NAN\3 OH[2WN4:YB
MCE*2*X609R0?2IKT8U(69MAY6JEL:]%-<7$36HFDB.TJ2221T  ZYKY2> <9
M<R/HFZ:6Y1GTF]N+.74+32+Z2:U+7LDEM&=L"D<GYL8'R]_PJH4YPE<XJW)+
MJ<AI,&BB6*_O-0N+,2S?O;T .T1)^8JN,]3[XR>M>C"O:>IS5\)"=+F1ZCX?
MCGT::QL[B:'6;-HV<ZG;@%/E7Y1(G5<EL<X_'(KW*>)A)63/GITYTY62&SV2
MZG8PW&E3A85N2LD8(,38&'0@_=QU /' YKHAKJSFDW'H=3X,\=>)/"6H"6UF
M^R-8,$0S,?FB8!OD<$D9R>.5QU%93A&9T0D^Q]:?#?\ :4LM=AM;?7Q%!>2%
M8_E&) V.I7HX/JG/^S7%.A9Z'4I7W/;;34;.^@AFM[F":&8[4=9!ACZ#WKD<
M919;+;0[4. >M5N,=&BE,D=/6@!)HX)2N^-7(.0&4<'VH X;Q7KOBSPK=W=]
M%IB^(]%(.V"P&V]@&.H5CMD&<],'V-7%*3L)R:6A^>/[5_[1E[K[S>$; 7]L
MDRCSI;A9(I=I;.Q0V&.<$-D#TKUJ%.*5[G)5J,O_ +-GPOTGQU\,M<L[G6;C
MP_;6,I6XN+<KR6"L#R.^T#WVUS8JNFVC>A3<]3I?C9\:KAE@T#P\)FM[6%8?
M.QB6<@ ;CCA0<9XKAH1<M6=3A[+4Y?X.?$+6;7QI8:-J\"ZQ;\RW$N<_9NZ@
M#UR._K73*E'J3[:6UC$TS3/^%G?M':X\[RFRO;Z2.>0E08X(0=V&YQS\N:Y*
ME/VC44#5]6SS36/#&F:SK][?VTNK+I<4C?9FCD02[ S;<%<$]L?A4SBH*UB'
MH&N?#[3DBANK&[NF==L<D;2[ESU*L,'O@G%8PJ)NR5A:L[WX$?!GQ5\389Y+
MFV^P:>L;/!JE]= +(PP!&H/S-W/.".<UVNJZ;3W-XQBUJ3ZUH<7AK4I;274M
M-NS;OLE>RO8YE3!P<A3E<'CD=:ZZ5:G5;:%.*,$Z]IEV%N&L;F2T\S:EYY7R
M9'0@]<<=<8JI5*5^6Y@WY'L_@3XW>*O"LE@K7LFMZ9;@XBN'(E*GI^\_BQV#
M9[=*ITH\ONL+)GO7@CXL>#?B8C:?%=_9]2E)CELM2(BF)[@<X?C/W2?PKSY1
MDM6BU%-JQ\V_%32O!UM\1H?#UMJWGV9NQ)J4D2CR[6%,?NMP&2V[J>V>N:\'
M&U95*T,+T;N?I?#F'A@<%B\WGO%<L?\ $^J]$?44OPF\-7W@NR\-3Z<FIZ3;
M+^Y2\_>,F>058\C /!%>M)M:7V/SR4FY.1T7A+P[I7A/1HM+TFSBL+*U&U(8
MDP >Y/J3Z]ZRGKN*ZW%\2^%]+\7Z>]MK=I#<6HY5Y!AHV ^\K?PGW'2A1TNV
M.,Y7NCP*'PUX?UFXU%-"^(J+I>ER,;X:J27AB&0QCD("NHZ!CN''6LFH5'<W
M^M26Z.0T_P" GA;4[B\U?3_B-IUQX8M4=]0GE($T"K_&2."..N![5PUL'&O*
M\78R59S6I23]B=/B+>?VYH'BK2-<T"YR]MJ*2-)L*_*$7'W2,X)YZFNRG2=)
M<L3!2]XXWQ5^QCXZ:Z>V/A9-233(UFCOK*13)M#DG8>"QZG979[2_0[9*FM4
M=]X0TBW_ &=?"R^*]7M0WQ%UIGM]'TV\CVO!;]!)(O56(.<$]P/6N+$5/9Z1
MW,:GD5?!'PNAO_&S>(O'FBWWB>>,17*6>Z*2)&8F1S+&SJS/@ _Q*H<9'3&F
M!I.G#G>YRSBV=EX^\8W?B[7OM,ZI L&8].@C^[%"!A9".AR 0,?_ *_7NU"P
MHPUN<;L>XG6WCR1NYXR36=SK/7?V<<VGQL\.VT4ZM&!.)%4]6%M*<>^#_6HG
M)M:DO8^X:YC,\Y^.Q4>"XMW>Z 'U\N2N>N[1-Z*O(^(_VBO"3>)? =S+',RF
MU*L54$87/+9'3'7\*\N$K,]*I%M'COP5U>?X->.M&\1_:(I83,))MTWWE;*O
M@'N%R?7D>M>M":<3SIP9^K^DZG;:UIUM?VDJSV=S$LT4BGAE89!'YUT)HY)6
M+XQCCI6\4F2%79 (PX_PK%K4+GQM^VY\+%TV[M/'FG*UJMP/LFI/ IW*Q 6.
M3([\_I6<DK7-XMFM^Q!XSD\3ZUJ$-]/))JEGI[1$R$YEC$L>).1]!U/2N>G4
M3=ASB^8]>\6^(/%/B_XL2^"?#VM-X:L=.TR/4[_4X;>.:X=I7=(HHQ(K(HQ&
M[%B">@&.M93G.=7V<-#W\-0P^'R_ZYB8<\YR<8QO9+E2;>@Z/Q=K_P (=&OS
MXUU)O%"RW\=KHLME;HM]?&11MB:)=L>\,&^8;1M&3MP:N$I4HWJN^MD9?5Z6
M95O]AAR-*\KO16Z^EAE[^TII6CZ1JUSJNAZUINHZ7>6MG=:2\4<ERK7+;877
M8Y1T8YY5B?E/&>*S>+C"G*H^G0TAD%>O."HS34U*2?1<JO*_H8_BG]H76+5M
M*@T_PCJ]MJ3:[;Z=>Z?>?9A-Y<D;2)L/G[-S@<'=@88''%2\3)RY;6=_TN;4
M<D4XRE.M'EY6TUM=-77XF[JO[1>E:7?7\ATC5[K0--O/L%_KT$2&TM9\A6!R
M_F,JL0K.J%0>IX-7]:I[]#GADE>:3YTFU=1>[7<U?!WQGC\;^,=5T33="U9K
M72[J:RN]6DBC6TCFC(^0'>6;(((P.,C."<"H8B-1M16W4Y\9E53!4(UZU2*Y
MTFH];/N<KXIN_&'BOX\ZMX7T?QI>^&=-LM M;]([2SMIB\LDTR,6,L;'&$7@
M'M63=2I6<%*R2/4IT\)A<IAC:M#G;GR[VTL9FC_'[4O!.G:CI?B^VNM?\0Z?
MKZ^'HY-&ME#7SR6_GP/Y98!2R_*0"0&YZ$D13Q:IQM4U:=OO-<1DD<1*%;"6
MC3E#G]Y[6=FC3\-_':--9U3^UTUJ!9-:L=)^Q7=M;JNES7%LCHC-&Y+*68 L
M22'< <<BZ.)BW)O=.QQXG):RI0G3<6^5RTOJHO7?\C?U/X]Z?:W@T^QTC5-9
MU6;4;C3K2QM$CWW+0*IFE5F=56-"Q4LQ7Y@0 >*MXJ$9)=[G/3R>K.#K3DHP
M24FWLN;9>KM<ZOX;>/;'XCZ3/?6UM<V<MM<R6=U9WT82>VG0_/&X!(R,CH2"
M""#S6U*KSQ.#&8&I@:D:=5IMI2379[,[+:/2M3A:3  "@9\R_MVZ?%?> /#2
M26_VA?[:3(,8<*##+DG/0>]>3F5/VE';8[L'BZ^#J>TP\W%^1^8?QZLDT'3[
M?[(SVY61P&MB%WDD=2OH,\?2N7+*-&4;SBCUJO$&;*5UB)?>96O>%;_1_AYH
M>L74\D;2QQSRKYI7<I!^\<9R<#C->E&.']KR\B%_K%FW7$2^\O>'+VQ\:W(F
MBM]08J@,<<4:B)>,'<<YXQD<UVU<)1@KQBC&IGN95?BQ$OO9NW6E6NFM)>ZM
MXC41,^3'(!&S ?P@'+<'TKBCH[16AX]2K4K.]23;\SG/%5C:Q7JWLYEU718P
M!;W"2XECZ#<#CYL<#!["NZ$KQM8YY*ZL= T^O^&YTUBUU,7\,5FP:.:';]HC
M52PRPR PSZ5C*/-I;4$FC"E\43_$&WM;JWMXHBP+R1ABV"I!Y&,=L_2K5Z5K
MC;ON=5\'K*TUFQN8K?5EM+J[N"C6*(-DS<,<8Y">PZG%%>4]&C>DE+1E.'PO
M>>*_'FD0Q:>[7(G\R( B- R L,GY<?=[GVKT:4K4K;F%2/*SW#XPVG]D>/+B
M1(C;V>IV\6HQ1D#Y2Z[70'^+#JW(SUK;#Z[BGT/,=7"ZA]X':.@-=329*TU1
MD2+>WV(A>WQ13M8?:"L8XP,D_P"(K&4(VV*<Y-;GJ/[*^H:/X>^)3Z9JM[90
MV.J6-Q8RP/(&)&#)N+DG.-K ?[WX5P5(6TB:*+6K.'TK1I=;\7Z]I,4HCL;.
M]DB^UO,@\^428.W/)Z#+=*\:=*K4TCN>E"M!4K-'M-[X<T/X9:6C&5K?5)=S
MV[64?S,R@MM"]6//4Y/.:[J6$]A'VDI:G$YNH^5*YS/VB7Q+I^GV[1-H^HAQ
M=2SV\7E2X9^5E4X+!@/7M^>]+%J,K2=T85<'/L9.K>*[CP[J[VU]87,%B6/D
M74:EXW0<DE<97'%=4<13>QR1I3@[,V+36;+Q/9"XLW#(PPV'!#D8R-W8_7D&
MNA5(R6Y,[VYCT[X?>//%.BZHUCX6U'4=3LVD"I%<19E3.",<$YY(P<CC/2IG
M&+5V*A.4K\R/JZ#QIXA\,:;:2>*-*)MW13)>V"F1HB>TD8Y';)7(Z]*Y>2+^
M%G0KQW.QTW6+;6+-+BQN(KBV?[LD3[P?R[UG*+3*YDQ]S!]IBV^9)'D@[D<J
M?S%3OHA7UN<CXL^(46B/)9Z>J7E\H_?2N^V*V&!DNW3.#G;U^E=-*E=W9G4J
M)*Y\8_'W7K;XZZMI7@[PY$-;\1/?[UU"1@-HV2[BIQQ&NTDD<<=ZZX/V=VV<
M<:JJOE6YK?#_ .&6G^ -$UK2!J,U])8QK,TJQ[8UFVX9MQ.&Y 'T KRJ[<I:
M'LTFZ6IY7X^U*]MM66XL=/MY[=P=KE@QW =6/+$>U;4JGL]&='LI5=1_A";P
MSX/75]1U\![TZ3_:%Q?6.5N'D,JI! JG)W,P( [X[C%3.JY2T*J048V,RWT]
M_@Y\!]2UUOML^O\ BV:2WM%F?,MI9CYGY'4L?ESQ]X&KY[NRT/-DCA?ASX?7
M4-&MKN5GNH7<,!*RH=H9CMP>N.E<->J]4BHK34ZC5;.TN)[A+>&2/"!RVTA0
M<<# _4XZ5Q1D[K0#SK3?!T.HZ[$T2+/MN=@<LQ$9(!*GGGUZ<G/I755JM1Y4
M$(-LZ;XFZ?J_B+2M#T/1[>5[&&<&_N0RH%Y7&#P ,;LFN&A4E2YKG1-)61O:
MEX6DL($T[1D)2WC(,TBYC '\)8]1Q7ETZ\YU.:0*&C.-\5ZIJW@I_M<^IO8V
MT>PPV"[2)=QY&2,D=?RKZ3#8R4I**.9Q9WDFOV=^?*BN(IG=0X 8,0/IVKZ)
M1C):LFUG<H:7XQU32?&4&H_N]0FB@P(]1B$Z;0X(&&SC\*^?K8>+S*R_DO\
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M!^M>O3G='ES@?KCX:\1V'BWPYI^N:;-Y]C?0K/$XZ889K=2.-Q?0YOQK\</
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M,!S@EAQ@X(Z]Z+I1O<]&SML>I:U:_P#"M#K*.L-N'NX)4L1$6^VAH@SN6Z!
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M5G4 ]2P0DGCH*<;7(YH]R&T^&_Q %REM_P *W\5-#=$127,FF7*H%)[J4X
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M;5IVNSJ/V>?%VK>(7U2UO[Z2[BMU5D,C9(SGIWKVI1Y=#F@[GK,T:S7#-@,
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M598@C]_D0!?QQ5JC%;!=G>>%-?U_QIK4=C+#I^J )YMQ/JEJKI!"OWY'9<$
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MQ@U]'1C[=)3>IR2M'8[:Q_:]OOB--:3QZ=-IUM?R-#',D2RK$5X"LV2$/3C
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MD<\'&/RKYG$9E6D^6"/2P^%NO>.FE^#]D;[4FNA>W4FI/YUPL<V%<],$#^'
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MRN?*[GJ0PUUJ;/A[3M/\):5'96,$%B%.2L:\LWJ2.M3.3J>\=<:2CHC?M_\
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MLN]EW8_BV@@\\?6O,P>$E1^&1TQJ>\?.'C3P4^I:WIEQIM]$E]<2)&T).'*
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M.>-6$C"0##;>"#G!Z^]=4JBE&Z''<Z"Y\'3:/Y4U]J!+1,3\QQ*%4_PX)S^
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M<52!]W)/<UWRM*+]IH;5*BDB#X6^(M1\>^.TTC4].^R0PPE[D7.]3(0#@=B
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MP[X=+JO]J:I=I;O(<=1'@NP]R?6KJ0YM0IKE=^6Q.NJ*@*_:3YER2%NF(V,
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M7+*QP,9ZU<(^\A\UC\XO@CHNGZG\=]6UZP:*WLU^UZA%& 0D9+F).!G'^L+
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MG_CCQI-/I>I6=I=1V,8A/GWDDWE[,G''<]#T]*FJII6B;12;3/+HOBGX<O\
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MV:W-&K.Q+)^\CZX)/TH$1,IC0(&)- #1Q]Y1[DF@ W[0!QMSTJD,D$@+$Y/
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M$#.G'FQ.J/L+#&X#.<UN(V+2RN4NH +O*O;P (Z*,D*1G/7^'\*CFB3$\?\
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MMK3S,G VB.+=U&.IJ9/E*]LEIW(M=T#P-X$DM3XCUK79I[G<\'V[5;P[AD#
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MZMFBMHY&"/+D9(R".> 3Q_A7S%6K+G\CLY$E9GZ-Z;H":+86B6%NEK T2;A
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MU!#-B4 L"I;.,MU_^M5?6'!6$J$;:FE\/KBTC\(V-ZWA30-(UE S7$.GV,0
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MWB;YK\Y8_P ,W3\,URII7*=.^IX;\5/"T6I>+-8TJ'5DCN?&]D;:)I(B3$4
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M3VK&6(J.5A.DF<OJ?["/PRO3&(+WQ#9$,2%6:)U'3/5<UM3Q3O[Q+HHPK_\
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MM#:V]RKAX($5Y$P.,MQP#W]JY.>49V2->AY?X;UO2]*M;Z-[B\O[FU"/!&[
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M1721.05/2LE3LQ^TDU8N)*TJE49<X_A(K3E($C0XW<MGWJDK"'$!@7_A/I3
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M37K+!Q]FEJSS>%I) [O))+,Y+RS2<L[DY+$]R?6OI+**Y8GSVN\F7'C8K']
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M55C7/^>E?)8NI)U+=#TJ<4E='SA\2X_#.F>%=:71-6NM0WJGFQR[B+>5G^9
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MXJ:FQJ]C[UKE,SYK_;]L5OO@?;!FQY>J++C^]BVN./UHO8I;GY6WNCKJ-O\
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MP9&.!@!>A(P*QEA*#6QTQS*HTXL=K6M_%K^R;:WBUKP-<:?;/OEQ!<0/='&
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M'/3)_6I=%O:0KWZ"M^R!K,4$K2S:E!'&NY%-DDIR3R%*MUZ5#HU?YA63,8_
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M9[:CB(>XK(J*DG<^AOVJ_"?@?Q7>Z3;> 9K;5[&.T1GNK"ZFFCFD+%2PP2N
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MKJ22:V9@&N/,<;AR2P!7."-O&>Q]:^AA2DU=H^?G&\N8SKBYVPO'8^3&RP/
M[Y/,9)/1AP2..*3IKJ+1&C9:%++?^;))#.8XE)\B54)8<*N[@@X[UMR<RM8E
ML] T70+W2--22TEB;6KES*SW&HI)$L?'RX .#GKSS6;H)V3+C54=5N<IJ$VL
MW-P'E2UOF+DL5N5+'GW(X[?2O3IQO&RZ'/.ISN\CJ)?$-VFDR(FESQSK%MC
M>/;DCYNA[_R%4X-[&?,D>;7FBZG=W0/]F3RRRG> !N)]>!5.+L-3B69/#VL:
M3!-)?:1<K%<*'622-E8#!.!GISBO(JP;EH;<O4Q4@AN6198S&[,1M_B*]>I]
M/6B,6*UC[*_8$TFS\/:;KFJ3W,<4UW<B)=[#*QIWQGIDD>]*::0:]#ZQ\9>
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M\93Y8F&T*67N,#CJ,<US8*KS.[W.I6<3F]%G:VO["XF*K;>9Y4H&,[#E7_\
M'6-?27.(>T:VE]/;+()1!(T+.IZE21D?7%04KLZOP)J/]F^+M)O<MY<$H9PO
M5E!!('N5W#\:YJOO1LBXW4KG8^$_ 5QH_P"W?X1UZ"(R:;J-O<OYX7&'6QG7
MD$9'RF/]:XU\1U2=Z3/NVMC@/G3]NSQ#>^&O@Q:W6GQ137+ZHL:K,K,.;:X(
MX7GJ!4RBI*S-(;GYZZ+I>IWFE74E\Q>621Y7$&X*I)W;<L23R3U->75BN;0[
M9)LP/#UPUIXA:Y,R+;K"UN@"AP\AR2-N>2,@GVKNI05AP@VSM_.LI[O1KYPE
MW]@W&U"@E1N&TA4Z GMZ>O%$UT.U**:+,5Y_PGMF6L+:XOC$H=8;&01RD@9\
MMM_.21@X]1BL^5&T[S5HG5>,/A_I7CGP5X=TG6K?4-&NHX5O6MX75VCF=00C
M \';WR">3SWK2A-PEH>7B+2]UGGLO[,5E?1W$;:\DLLK&59;G3\.&R.2R'\,
M'VKU/K+//]BDCZ)\'_#^'X*_"G2O"]F1]KU"1[^\D.-[EN1G ''. #T %<?,
MY2NS1>[L,N9#%&53]*W3L5<99^7+& C>9SRRGI]:KF-6]-#@OB)\6=*T6TU3
M2]*N4OO$4$9 M8U+!6Y!#$$ ;3C//&1[UG&:4O>,I-M'PGXBU:[.JWTVH>;%
M,\K>8DI(8,#RIST]*]M\G*FCSW?F/N#X7_!CX9'2- \5Z?\ %G5/#$UU^Z6V
MN9X!$I=02&1H5(4G;RWH.>*^?Q="EBGRU$=,7*VAVNC?!B+XDO/_ &3X[L_$
M,=G*R(]Y:12I*NY@)!Y+A6&591GT]Z\.63X:+M%;FKG*QX=J_P *_C'\//B_
M?ZA#X,\2^+]$8O ;FTM'V;,GY8L$_(#TSGC\:[ZN64705*.YCSR6HW5/$/Q<
MU&XL]+'PF\0Z;<WDJ6C7-U8W!BB#.%W#"@#J.K5Y^&R.G2?-)W*<W-6/>=2_
MX)?SK>-?:?\ $J:/4I"S275Q#\Y+##8(Z=J^CO3Y53:T1AR-.Z.8\2?\$N_$
M%_<O<CQ[97][(2[S7[R%F]\[:Z(5:5-<L(V&TT[GS9\7O@)KW[+/CC3K6XU3
M3/$M]/"TLFFV\[^7L8E07!4#!Q^8IU*%/$PMU#FLC@?&/CKQMXGL_LDT!L;"
M//[NT1@".IWM_%@CC-8T<JA0U74CGYEJ=;X*^-8U!XK;QI! D%K%^[OXX6ZJ
MI :15R2W/WN*\7'95--U*:O<Z(58QT9T'B[QIHVF6,,]CXMU*STB0-Q9W,;O
M('==RHJN64@9.& ^\?2O.H86JU:I MN]V>=^-_B;IWC;1]&T33;B]CL;6,L;
MK5COG\P=LJ<8.2>!7U66X/V,[O2YPU)HPH?!5Y):B>.XBEC?#=&&Y?45]2XN
MYRJ>I2D\-W>6*Q.Z]L(P'ZBLY19MSIF?=Z5=VY EB9,YQGBL))HOG1Z3\%--
M\ZVN9$D3S5D;CS5# 87D#/)&>E<,G9^\7OL6/&L>O0W<T<,-XZF%4^XQ#*IP
M#_6M8\O07O=#@[^^U&U1()+B5%WX).<KZ_S-:<L6M31-]3U_X(:AK-MH6IW,
MEI/-I\0)AFRV"S2 #&3@ <YZ5Q320.;1:^(&H%O#NHZI'9K)>ZA)A&D!+)&B
MG>R9XY9E'X&G&*N',RW\ ]>T2^NH[.Z@,=[;':=@^\[ GTYX4552-D:QLSZ(
MV66IP.J184'YBR;37"IM'0HHDM?#%C;QETCC4DYS@9)I.39?*:%M:1*5<J9,
M_P 0.:+DO1'#?'K6Y-/\-LXN)5\J- @W\+EP/ESTXK>FKNQR3U1\?GQ(\NKQ
MS3?ZF.7>2O)8#M^=>E&"CN<FJT*-MX@FM=0EF^247#$.L@P3GN/>JDUT-(ZH
M[[P1KTC6.M-;,\(B"M"&<^6)<]QCT+>G0>]<->3C&Z-8[G1Z";7POX02>^@-
MR;YBUPK* /,YYW] ,>M>#4FZKT-W%/5#-0O]"O[5-.MH)5"A N?G$3=NA_E5
MTJDJ;2;)<=#C[/P\+[Q9:V=U,H28D2*@Z'L!SC)_+UKWU7]R\3G<>Y[%\.?#
MT.@>.K4^? -!%NLAGD55EYP" 1][G@_2N2%;VT;,TA%(^G$A4' F8H0.N>/I
M6"D]CJYG:R(KL2+MQ,BJQ RS8R3T'/\ *B5VK,3]U$ME'>HY\Q05'?CC\JR2
MBUL$6][GD/QI\7&2]GTNUUJ:UU*.,N72\EB$;8.%)7@>HS6M+#QE>5C1UIK2
M^AN?"7Q[?:]X0L[>\UJXDU:$O'-%+=>9*I5B.0>:YZE&,MT;0Q$XQT9P/[0O
MQ(U3P5)#YM\$:1=\,$>T32G&#VSCIZ<44\'%F/UVLM+D7PM^-=M\0+!(IK.S
M@UQ"LAM7@B!=1CYQ\HR,]NM7/!P3T*CC)M^\CT>YBTZYTI+O4/#6GRA(@Y::
MT!W< Y^5OZ5R2PL7*QT?7+=#YD\7>-;_ ,2^)[5([P:?HQOA"MJLN%*JW?@@
M GMQUK?ZC34;'%4K.<^9(^I=+\):/>:/9+?6S7($*\_:!A3MZ_=[9/>N"> A
MW/0ABX6M*-SG]*D^&WB#5WT>PUZY?5XYO*^SN5:=6"_=!*C(&?7M7//*T]Q/
M$TIZ2B;%U\.+".1[H:UJL6$(<2*K(%QUP,?7'K7-]02?*-/#6NXGE$%ZVL^(
MY]/L]9L[72;9?*>?4;=E/F @A <XRP/IG/XUU/*THG#/V4Y^Z]#2O+RR@\5#
M3X[R*33X4#_;%?:%<L%*Y*\C'0?7M7.\J:V.R'L5I<;XMO;72K1I6U73+BW:
M0^66F\N0$$ =L'&#UXJEE\UL*4()W@<EI.MV.KZI;P1Q1O*\B_*98BLFT99>
M"..G(]:RJ82<8MV,U#G?O,W=1^&OC$7$2VWA"46$9$ZLJY4<Y'(/3UQWKD5*
MHB/J\UK \$^*\VM:4T=E<6<UG#,&6%22I0 X/.?7(^@KZ/"X=-<R1QU*4D[R
M.&/@/6&MM\D:QJ0GE!7#;]W\7!] :]ZC1]W0RD<E<+-'OC^5VC<KWQFM.7DW
M(2;)K:U?SIHR\858R'=L =O6ES)[%J$GK8Z7P^IN;RSLY+YTMXX9"# P4+QC
M)SVZ9QZ4.20XPE+8^Z/V,=3.M?"'7O!]UJ8O[BQ>00L."D<HW*,GT?<?QKRL
M5%2CRHVA"45=G;?!W2O$&H7>H6M]HEU'X?FAEM9+V2$A&<]#SP0&SR/6O#P5
M&2JW>QU1TC8Y>>QDL9;RRG3%Q"Q5UX.."#7U2U7,861JZS81^;;W,4+0"ZMX
MI'RI'SK^[D//JT9;_@5 DK&BOAZ:&6)8W8*Y*[E[''4'\ZPE-WL6E<][_9R\
M:V/BCQ+I%AK,R?\ "3:498;9Y!\]Q"87P<]V"JP;Z#UK"44F*6Q]44C$^;_V
M\[:XN?@S8"V8K(FKQN<'L+>X_P#K4F[&]&/-(_.FYN-9MM+4QM)<R+.5,$8^
M\G S^&>M<[BF[GJ\ERNMS#H&GZD]ZDMVMM*TL<*0K^\8@;0I!SC.03QQ71!6
M(NHLY#5O'U]#YL"13:+92MYD: !I, \C(],?6NCDC*-T82JI'L?P$U+0]<\7
MG4IV$<T,)07",Q65"-S$C'#9!]^E>=6C;0UC4;6A[M/>IJ4DLOV!)%9]QD+%
M2_X9. *W@K1..HVV;GA30X-6UFVAC@6$(!+,Y;*A01G@CGM5Z=02T(?%OB Z
MOJEQ=!=L:DQPJ/[HX%5;L3)61R&H7<S&.& %KJX.U21D(.['V%:(@M:E=6GA
M#PK<2L2L%M'U52S,QX'N220/QK"K/EB[%.2L?*VH0Z+/<VMW<1W<MW(OVIB%
M8R@9! W!L''?/7\*\!5:LKH.AYI:?#I?B#\2;C2=-G=VEW7):XR=B; [$XST
MY&,_XU]32<_JZYSF5N;4[WPM!INN6\MO?JRB,>7&KD;Q&,  =@.O KYC$5YQ
ME[K.J*5M#K_!'ARXU+76LO"FJWEJ\<L-K##;LP.995&T,.3G'/)'KBM\/6F[
M7,ZC1^K'A^Z^RZ39VUO<_:4@C$8</OX4;1ENY^7GKSFO7O=[F5B+QAKL]EHL
MC &:0$.J#J2IR.AS][;56:V%8Q/ 'B;4_$UG<2WB10I"_EED!&6QSWJ1G7;"
M7#!S@C&#THNUL!5NM)L-0_X_=)L+\XQNN;9'/YD&E%RB[W%9&)J/PQ\$WH,M
MWX.T)Q&C?\N,:G&.>@K95JBZF;IIGCWQ>_8\\&^-?"1L_#7AS1?#GB"Y"&:X
M<2F-4/WPNT@9[9QQS71#$5(/5W3(=.^Q\B3_ /!*;QM)N-EXG\/WC*3D^9)'
M\WI@I76L339')-;'.W'_  2U^+]E*)8Y='N=AW?Z/=H>![,16JQ,/L[A[-_:
M/G?Q>/%7@'6+O1KNZC?[/*UNTMJJ21L5)!"N!C(QT_\ UUU>VDTK&;II,R1\
M0/$-F26F.?\ II O^%4YSW8W!2"3XFZG*RF?RYI%&0VP+S^%9^WMN0Z>IZ_^
MSW^T;KOP_>]NX?#.D:VDWRM'>$J 3CO@^GI7!6J>T9LH6&Z_^TC9:_XFB>]^
M'^E6TNYE9H905#,?O']V,@<G&151G&,;M7-8PZ7(/%.EZ-%HMWJ<MO;O;1RA
M96L'.0#D[MH/'TJZ>)A-V:L*I2:ZG?? '0+KQCH6H+X9UG1Y].M4 GL=21$E
MR6.,/@,AXSE@1P*,1*%M"81-:TLM(UW6'TUA=0&VQ9_9IHP$7# D*RG:P9L\
MJ2,D>N*X^9Q5SIY3U7X:?L\>'-,U>XU:*WE612I4^:2#(%.?R)-92K<PTK'J
M?_""G:71RH.25*YQ6-T7S:E>;P3-QM:-@?4U1HY%4>![M)5"1J%ZEE?^E0G[
MQ#>A\:?M-^+I+CQ;<>'X&:5+*3;,>OSY *_ABO=H4KJYPU96/#;F-E(!78V>
MV?ZUU6.>YI:?:Q.#'*(XW*,WFNV2I4AL#Z@$?C64XVU-H:K0]+TMWT/PE8W<
M.V:_OYC+.J)N ([ #N5!KS:TERV9M%,V9S>^+)8+O4HA-;VJ'_10OEXR3@D=
MR,?YXKQ+Q3=C:^ECH--O1'8FUN;/)C9=KB+( .<'@9/I7+--ZCC<QOB/I-M$
MEK?R1&.> '$T,> HXZ@<@^V/6N[#UVDX$3CKH:OPDT*__P"$OTN6QN6NH'"_
M:+=HLQM$V=Q.YA@=^.<@5O3DEH$4?35S/'$[NWR01#>S@G( ZFK=D[G1;0^-
M_B1\9K;Q7\1UO)&E3PK;28B+EA),L;9\P 'Y<E<#CO79""<;G.V[V9]?Z-X[
MMM0TFTU"?3GMDGS)&UL&8&/<=A(SW&/H:Y'&QLCXQ^*.JV^H_$379M'O]2N'
MEOY(A:?9G"D8Y&2N6ZL,8XV\5VTW&$5S.QG)-WL2_L^^+[[5?C5;6\%PMN2%
M:<[]H=8]H;(()R1VSUI5(QY;HQ3DM&4OCWX1\1ZC\5+BXDM)$N+YV8;)1*B(
MK?*Q(  7&!SWS2I-)#:U(OV9+G2!XXO+KQ1K2Z9IEC:RR"=;%IRK?+SM3#*
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M)DTBWAAN9$DDB>Y3_5X21@69CCC'0^XKOE56DBXP;,M/"5_IOC/4?#=U"(C
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M<H]H^!-BS?%SPQ-O_P!2+D,#U(,$F/YUS;1L:5%I<^Q*S.4^0_\ @J#XBO\
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M2%X)ZXP!45<'.:21E2JQ6Y)>>#?A]KPO8K3QCX;O8YHMK1P:XA9449=LDY'
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M559[>Z7?@CGB(XS[],'->G&KO<\V5--)(ZWP[\-]4NI?^04\C1#9Y)?R<D$
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M;%':CH >6OI2LQ6$\M<8VC'TI^H,4(.X%%DQIL-@]*8, @% M1=HI6 38HZ
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g42675dsp52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp52.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +2 =X# 1$  A$! Q$!_\0
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M;:E/HW@_6[^U8)<VMC//$Q&0&6,D''?D"@#9C),:D]<4 .H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M.M:)H]G?6^MPLES*#)/]EEC;R0BVP!<MO9\C  H _5.@ H YKXE_\D\\3_\
M8,N?_134 =''_JU^@H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % 'SQ^VEI<>I>!O#A%PD-[#K:&UBFRD=PS031O$90&$+
M&.1]DC#:'"9P#F@#YMU74=;\,ZQX87Q)I36X'EZ?9VD-I")[@R%H@2D$TX$8
M\T2/*Q0'R(@J\< %[_@H/^W+XC\%6]]\./A1IFJW'B%P8=3\16UE*T=DI'S1
M0,%^:4]W'"]OFY4 E_X(W:9JNF?!?QX=8L[RSN[CQ%YI^VQ.COFWCRWS#)YS
MS0 [QC'\<=.FNM?\)Z9\3AX[O;R2+4OM$>GR:.;4.YC%M$TA*[1Y8#$ D%B>
M30!^@$\GDPO)V4%CB@#GOAQX\T_XF>"-%\4Z6LT>G:M;+=6ZW*A9 C=-P!(!
M_&@!OQ)<-\//$^.VF7/_ **:@#I8_P#5K]!0 Z@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * &M&K=0#]: &.D48W,J@>OI0
MY8TZA!S[4 *(U7.% SZ4 +M'I0!#>J6M)E'5D('Y4 ?G?\,OV6?V=+;P)HT?
MC3XG0Z?XK6 #4[6S^(2Q117&3O542;:H!XP.E 'V/;:)H7AO]GJXTSPQ?_VI
MX>M- FAL+W[7]K\Z$0MM;SLGS,_WLG- 'IT?^K7Z"@!U !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M!ZT =+;0+;P)&HPJC ^E $M !0 4 % !0!Q_Q?\ ^29^(O\ KT>@#KDZ?A0
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M /EJVM?#*?M.-)#%8CQJVK,7)BTWRC9^0>00/M'G8P.3OSG_ )9T ?4J?=%
M$&I7!M;"XF4,6CC9@$0NQ(&>%')/MWH \K^"OQ,UWQR=8N]<C:PL8!&;>*[T
M>YTZ= =VXR^:2F>!\J,VWN>0  >L1W44TC(CJSJ 2H(R <XR/P/Y&@"6@ H
M* "@ H * "@!,4 5Y]/M[E]TT$<K#H74''YT .M;2*SB$<2!$&<*.@YS_6@"
M>@ H * "@ H * ./^+__ "3/Q%_UZ/0!UR=/PH =0 4 5[Y=UI,.,E& S]*
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M#ZKOK'Q!IWP,U"W\5ZA::IXCBT.=+^\L83#!--Y3;F1#]T'TH ]#C_U:_04
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M"  >E4 % 'FGQ9T&^U_4=(@M+>Z> 1S?:)[298W5=T7R#+)NW8/!;&%/!.W
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M_AW$A\#?$:SL=<A\36<^E&9[K3O-M6@N)!,)8&:XDD4.,*<G!&<,O2@#TCX
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ML<R6L8D?,SB2)\Y"\;,N/+8A><@ ^B(N8>N<CKGK0!\ZSVFJK\4X;B6TMO\
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MP")WWI#%"^]4 ,Q*,I&1N."IH ^B]+.[3;4^=]HS$I\[&-_ ^;'OUH M4 %
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MY=^T'X6TS7/%EI<ZM9:A+)!89TLV&CI?)<7/F,3'.QBD\M/N=3&I\QR6R 5
M/H"'B'!&".H% 'RL_C[5-3_:%3PH_B:P?3H=:62.QN! +E CF0H"UWYF23@!
M83E /N]: /JFXR87 !R1QCK0!\\?LV>*Y=2\2ZKI4_B;Q%JDUK$N;'5KK3)X
M4"I#&60VR+)PZNG4J<$GYFH ]B^*4,D_P[\2QQ9$ITZ?:1(L94[#@[F(48ZY
M) XZT >6?LJZC%K&E:Q<RZQJ>M:G%-]GFN-0N+=U,8EE>)D2)V*;A(6(8G[W
MRD@4 =)^TG?#3OA\9VU6\TB-9]IFLX7?.Z*10'*S0A%!8-O>14#*H/7% %S]
MG-)#\*-+N&EB>&[>6ZMT@E$B112.71%(DDP #TWMCIGB@#AOVK?$%OX?33'N
M[RY$$\$B&Q\F3[--AXS\\HNK=%/1=K,Q8,<*>: /:_!5I-8>$-%M;B8W%Q!9
M0QR2F3S-[!%!;=D[LG)SDY]30!MT % !0!Q7QF@URY^&>NQ>'7O(]5:)0C::
M5%T(]Z^;Y!;@2^7OV9_BVT >':GXWE\=>-=!N]&A\666AV[:9::A#XDT^>QA
MDF35K(P/%'.BL\N'F#R+E2-@)SMH ^I/X: /F'X@^'5C_:-TJY_LC4[87VHV
MCRZW<11&V C1"J12K;.Z@M$J;7ECYD? PQ) /1U\%M>>/A.FO645A;ZJ=3%D
M=/9+U[CR-A47!DPZ;6 XCSM 7=B@#'\$S-_PL_6K1?#][HMN5O)/M\UU<_9-
M28S'+I#_ *M2,\LX#'^#>OST <Y\%WM;;3?%5FLE]!*^FM-&=3U#4;FUFB$8
M3S8UNHU4ID8W1EOE*@]02 87PMEOI_AA\0]/US2OL^H1Z8\JW.H_;?.N[>02
ML#(GV6$X#!QNA3<<\C(RP!WO[-5Y;:O/XBU.U\MXIO)B\S[;?W<AVO.5#/>
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MW6/*L#[X)! +G@GPPO@[PW;:4)Q=-&TDCS")8U9Y)&D8A!PJ[G.%'08'.,T
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MS0 Z&PM[>YDGC@BCFE55>14 9PN=H)[XR<?4T 6* "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#C_B__P DS\1?]>CT =<G3\* '4 % !0
M4 <U\2_^2>>)_P#L&7/_ **:@#9?4K:U:&*:>**20817< M] >M %L'(S0 M
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH X_XO\ _),_$7_7H] '7)T_"@!U !0!7OI8H+6668A8D4L[-T"@<Y_"@#XH
MB^!<GBRQ/BCP[^S?\))/#]T1<V.GZL?)U.\MV&X.Q6W,<3N#N"DMC/S'.< '
MT+H6JZ%K?[-7V[PUI*Z#H4_AV5[32UA$(LT\EOW.P<*5.5P..* /-OCMX&UK
M6?&FLZI#H6H7^ABP@M[T6%M:W-U<95]A@6:TD8*I^5A%*&7.\)GJ ?2^CAAI
M5GNC:)O)3,;DEE.T<$GN* +E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#C_B__P DS\1?]>CT =<G3\* '4 % $5P66)B@!8 X!]: /@G
MXD^./B>]U:P_%W5O&/@323J,,=VOA'3ECT?[$7Q*SZA \TP(3N?*^E 'U7;0
M>';;]GJXC\)7@U#PR- F_L^Z%TUR)8?)8JWFL2SY]22: .8^);ZLNJ>*8+&&
MPO+74K-+6:[NM6GM9=-\N$RDQQI$X?:I,H*%6)X/08 /;-)?S-+M&$QN T2G
MS2,%^!\V/?K0!;H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#C_B_P#\DS\1?]>CT =<G3\* '4 % $-TS)"[+RP4D#'4XH
M^)? WQ#\5^#_ !%X<UR\\+?&K6KNZCEC\46%_ILES8,S1,P>UC+[4VS!54(%
M&QCD'K0!]/ZOJD&M?!75KZWTNZT6"XT6>1-/O;?[/-;@Q-\CQ_P,.X[4 >,_
M'GX?:;XI\::MJ5]8:U_:5G:1'34TSPK_ &A;WCB,G_2)3;2[@6/E[0Z;5'OD
M 'TWI.\Z9:;X1;MY*9A QL.!\N/;I0!<H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#C_B__ ,DS\1?]>CT =<G3\* '4 %
M$-UM\A]_*8.X>U 'PDL?Q0DT*^'@2#QI'\"S.N^&:1!XF-N=WF?V:9?W@MON
MX$A\['^JP * /IO2$\.I^S@Z^$DGC\-CP]+]@2Z$HF$7DM@2>;\^[KG=SG.:
M .6^,/BW5M.\>6=AI?Q'?P_ D=K)>Z1!I(GFBB,A)F63R)=V\(RA#M&5//!%
M 'OEJV^WC.XN"H^8C!/'7% $M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % ''_%_P#Y)GXB_P"O1Z .N3I^% #J
M "@"O?'%I,1V1C^E 'QU\"OVE_A'\._ 6FKI_@WQ-I6IWUO%<ZI-IO@[4IA=
M7)0&1S/Y3&8;LX8NV1T- 'T?K7B>S\9_!?5M;T^*ZALK[1IYXDO;=[>95,38
M#QN R-[$ B@#O(_]6OT% #J "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQ+(O1AD4 ->X"7$<1'+@D'Z8_P : )J "@ H * "@ H * "@ H * "@ H *
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MGT% $%O;-)+Y\X_>#A$[(/\ 'WH M@8H 6@ H 0C- %6:T(?S(3Y<GZ-]10
MZ*[R_ERCRY.F#T/T- %C.: %H * "@"K=G=)#&.[@_@.?\* &W7^CRQS=E.U
MB?[I_P#KXH 2<@ZE:_[K_P!* +AZ&@"KIZCR7_ZZR?\ H1H M;: *B#&JR_]
M<D_FU %R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $[T
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M+#<%D1D+9RK[>_'U!JU%M"<XIV-A_&@4$C2;YB!T!AY_\B4G!B]I$KCQY/\
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M+3]*TRQN([Q;G4;I;>..6-MR-N9@#@C.* ,_Q!XHTSQI\&]8US1KR/4-)O\
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M#%I40Y]#*E;T%[P2V.Q;0M.FB57L;=U ^ZT2D#]*]I;& ?\ "/Z9L"?V=:[
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M_P >X^I_F: +% !0!Q_Q?_Y)GXB_Z]'H ZY.GX4 .H * (Y\F,A<!L<9Z9H
M_/KXP>"]1TKXD%Y?"GP<\<?$N[8S0Z-IOA:ZN;^3GB6X)G$<2]"99BH]SP*
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MS&1:WX(GUGQ+'JBZO-91QVOV=;>""(D$N69MSJ>ORC&/X<Y]7&2BK(:=A/\
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M6ZY% &;=3)'K5I)%.B_\3,9D0J%'^C2>V* -'7M2,FB7:F_CP8S]UEST[<4
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M1.F,;@W=>@Q0!L^)-'NH]!O&>\CVB(D[8GSP.WSF@#IM._X]A]3_ #- %J@
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MJ2I// .#P/SHI/WD4CMK.Q@TRUBL[6,0VUNHBBC7HB+P /H!7U,%[J);)6.
M3Z53)N4V2*=F+1J25)SP:AZB'/L@=6VJ/E)]*GJ(M*VY01WK4LY[QSX3_P"$
MQTF*R,WDB.XCN5?T:-@Z]C_$JY]LTF*[3+>@Z6^D60M9)!,P=VWC R68L> !
MCECP.V*SV!N[+UN)0YWYV\\$@_RH)'')5JJP!$K;3NW9SQN(-(!8^G/<G^=
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MFW=K;[Q%'>S@!W+'_6$]3R: .CH * "@!#0!3TR8R1.I1T*,0=PQGD]* +M
M!0!Q_P 7_P#DF?B+_KT>@#KDZ?A0 Z@ H 9,BR1LK<JPP10!\])^R_\  ZVT
MZXU..2^M]/TS?;2W,7B_44AM "-\9(NML8!"Y7@# XH ](U;POI'@OX):IH>
M@P_9]'L=&N(;6,RO+M3RFQ\[DLWU))- '?1_ZM?H* '4 1S_ .J;Z&@.IXYX
M8(.E)C^\:\>O\1R5/B+<VGK+J4%YN(:*&2$*.A#E"3^&P?G7-S6,D5-.\,V5
MC;-$T2S,TLDK.Z\DN[.?RW8_"GS/H!+_ &%9^>DIM8=R9VD+SSC/\J.9]1CY
M-#LGC=1;1+O4J3M]>*:F^@%'P[X4M_#=A86=ML2&SB,2)%$(U(P.<#H>.?4F
MARON(W:S3 R9_#UM-J<E]Y%OY\L:QR.\>695+8&0?]H_G5J20#-0\-VL]C-#
M#:VXWHPV,G!)_P#KU:J(:=C!T3PC?6^EV,%\D?GVT*1>;;3E9<*!QYNW=CCM
MM_&AU$5<H>*O NI:EH-UI^F);0F[VK/)))MD8;ADLX7]YP. WXFJ530=T=M#
MHULH(D@A;L-J8X_.LI3:9! GARUBN9Y$MX L[!Y!Y?+$*!U^@%"GH*_8DDT"
MR:)%2T@!CP4W)D*1P,?@34<S078Z+0K(,9)+6!IV38SJF"5[#Z5:D]PNRE9>
M#]/T^6=[2UMK(S7*W4AMK=4,C@YRYZDGUJG.3W WJR: S=::06%V$5&3R7W%
MG((^4]!C^M73^)#1U#??;_>/\Z^MA\*)8T]#GI38BG-YJ.1$D6S:>I(_D*R$
M.P[2J)%0ICUSZ>U %H  <=*M:%(4U0,JLDAD8K*%!).-F?ZUF]Q""*XW ^>N
M/^N?/\ZD0QHYPC8G&?\ KG_]>KNK 2&.<?\ +<?]^_\ Z]0 Q(YRN1., D?Z
MOW^M,!WE3Y!\\>G^K_\ KT 6(01& QR?7&*J.XT46_Y'3PS_ -=9_P#T2U95
M-SHH;L]+'W1]*Q.HY?\ X0:%]0UFZDN';^T;B*X9  -A2-4 SSD';GGO]* -
M?4M%AU2**.7($;B0;<<D=,YH 6^T:&_:!I!CR7WJ!C&?4T ,T'11H<-Q$KAU
MEN9KC(0+CS'+X..N-V,_2@#(\2> X_$6KKJ/]HW=C,+5[-A;[-KQLP8@AE/<
M"@#-C^%LT*%(_%6O1KG.%N%'_LM &!K?AN3PYK,0?5+W4_-CB.;R169<7"=,
M ?YQ0!U'P]_Y"_C/_L,M_P"B8J .TH P/"5P9UU52C)Y>H3KEAC=\V<_K0!O
MT % !0 4 06O_+7_ 'S_ #H GH * ./^+_\ R3/Q%_UZ/0!UR=/PH =0 4 5
MM1@DN;&>**4P2/&RK* "4)& >?2@#Y9\.^/-/^&/PTC^&^K?!;Q3=7$=LUE=
MV>G:.ESINIR/\LDQN2PC*RL2Q:4@_-\PS0!Z?X6\+:EX)_9>@T+6"/[2T_PT
M]O.BRF41L(#^[#GE@HPN>^W- 'KT?^K7Z"@!U $<_P#JF^AH#J>.>%U"Z2@
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M_P#>/\Z^KI_"B6-(R"/453#H4_+$+,K;1E.U9LD=,GFD*-N=I^]TI+<"THP
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M%PP"1^8$9W.6(7 !]+>!'CD_90LC#JHUN ^&'\O4%$H69?);!7S<.5QP"_)
M!/)H ]HC_P!6OT% #J (Y_\ 5-]#0MPZGCGA<$:2F3DY]/85XN)7[PXZNY;N
M5C,GSF8'_ID7Q_X[6!DB"2. H1OO.W0RT#'>7!_>N_SE_P * &)'#N<EKS!(
MQS+Z"A@3PI#YJ[6N-WI(9,?KQ1H MCJ]CJC72V5[;W;VLI@G6&57,4@ )1@#
M\K $'!YYJK,=CA_BSX7U'Q=HFM:;8S&U>]TUK6.X6(N8W9N3Q['/X'OBKA)1
M>HC5\.>&X;#PQHUC,;GS;2W@1V E7<R* >.V<4W4UT0$I\,VDFOQ:D)KY66
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MM(3'--&B*S')S]S@ YS@<9/K3&]SM8(5P#@YR1U/K0(:F;CB7!P,@KD8Y_\
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M&YC,,F2&4MG\>O?K0!@P?$K6?#.B^+K^"?RX=+NF_=P$(7144DLQR,X)YX'
MZ=:FP'0:=XOU+7XS<'6;DR211F:))C\FY=P4@'T;T[T6 PAXE\87_BO5M/LO
M$<MK#:10/^\5G9MZN,'Y^Q0=AQQ[T6 TY-;\;6ULD#>+8(XP=L1DM?F#$# W
M;LGYNW?@>]%@+$&M>/+0;8?%,80# 5[3=P,8ZM_O=/4>G)8!?"_Q0\72^+=8
MTB_UD2QVZ0F.46RKDNZ9 .#CY7_,=J0'T+H\.^RMYY6:6=HQF1SD]/TH T:
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M6,9"4M7Z&IX,!;P9H?;_ $"#_P!%K7Z9#1(^3J:S.>^'OA.\TFQL)+BW.GO
MUP'M0Y8-O?(;.['Z=^W<BFC6I535D=+J<4DGB_P&41G":ZK-M&=H^RW')]N:
MFO\ "=&7JU5L]X%<*9]%86@HS/$'AVQ\3V(L]1@2YM@X<Q2QJZL1TR&!Z'GZ
M@4FE86PNDZ5#HMM':6@6&UCR$A1%54'H  ,=ZA:,3=]RTL[2N% :,\GD Y%-
MRN] !C(FX^9T/H*5V%QV^21#P8R#C'!HNPN)$)&()?(R>U%V%Q!(\S;03$1]
M#D4787)H\[.3D^M:)Z!8X?XH^(;#PTWA^ZU*&22T^USJ[QP--Y9-G<*I*J"<
M%F49[9K.2;V-(3C3?O,\JTCXJ:#9:59V\HU!9(H41@-.G(!  ZA*CV<NQK+%
M44_B-C2M>L?&;R20-,+" !62>&2$NY]0P&5 Q[$GGI3]E(GZU1_F/'-)U*&'
MX<>*O#U_!>0ZA>7DXC2:QG=&4.  2JGCY2/IBI<)+H/ZU1_F/1?!.KV6K3M9
M6TTJ9A22X'V*>W'R(L87S'X;/'3:<+TYI^SEV!XFBE?F-#PA- _CKQ7%;Q^6
MD,5I&1MV\_O3T_'K423CN;0J1J1YXO0B^)2&74O!ZA%8#6(V+LX4Q_(XR >I
MYQCWSVI&AK>!=9U#6[*_DU*![:>&Z\H0R !D7RHV&< ?WL_C0!6\*Q _%#Q3
M)L&Y;>UVOM'!WP]\Y[^G'\H ^J]&_P"07:_]<Q_*@"[0 4 % !0 4 (: *]I
M9_97E;>S^8V[# <?D* +- 'R?^TI\.-8^(GQ0O\ 3O#7C?1O"PO_  JEIXI_
MM*R9KJ#1_/F)EM9^%C9\S(P8XPJM_"* )=8\$:/X8\9^+ET[4M.ALK+P%:6.
MCZ)I]NRLE@)2//EE^[)ETVH 3@ G^*@#ZI3[H],"@!U !0 4 % '-?$O_DGG
MB?\ [!ES_P"BFH Z./\ U:_04 .H CF_U;?0T!U/&O"[K)I<;*<C)Y_*O)Q#
MM(Y*FYLUP,R"@ H * "JB 58!4M7&%):;CM<*'KL)JP4UH 4[@<W\1=:N/#_
M (,U2_M$BDN(D4(LV=F68+DXY[U$TI1):.&AT[6YKVTDO;VQ>&&0N?L]LZ.?
ME(QDR$8Y]*\EN.R.9F%\0-+N-2\6>$!%;1S0B:X69W3)53"1U*MC)QZ?B,BM
M:4E%2N-/0ZO0-+&B:9%:#;MBX4(  !V&  /R KGD[M$[Z&;HQ87FNI&$\Q[X
M@$<_\LH^3_GTK>ILC1L@\8 6/A+5(&)P869#C)([CW/-:876O%H47JSF_"?B
MS5(/"NC1IX3U.9$LX561);<*X"#D9D!P?<5^GQJ625CYNI13DVV:O_"8ZK_T
M)VJ_]_K;_P".UK[2W0A4(I;FCX5\<RIXT\/V^H^'=1TT7ET;>">:2%D$IBD(
M!".3]U6[5A6E>-SMP5)*K=,][KA1]"G<*8P-)B*S28=OF'!X!!J'N(9$T4+9
M!4 \_*#4]1#GG0H_.3GN#BJ8#(W"*0I4#/.%-2 1W "\NIY/\)]:8"P.D;8R
MH!_NJ: +,1W*".E6BD<WX]_Y!L'_ %U_H:Z:6K/(S#2-['A'Q \?W_A#4OLU
MGIPOMU@]VF2!O99$7R^HP2&/)XXKL;Y>AY-&BIJ[-GP]KM]JFJ7MO=6S6\<(
M!1F7 D]U]AT_ TXOFZ"J0C$Z0#O6MDM&CDN&,=*FR);;*$.D0+J%_>6EPUMJ
M4XC$K!]ZX0-L#(> /F.<8)]:\K%)7T/K\I_@._<9K&@'Q=;:2]PT=L;2[2YE
MB:)9-Y7(* G[N?4<X/O7#<]YFW9:=:Z9$8[2WBMHV;<4A4*"?7 [T7$<WX30
M#XH>*VQ@FVM02 N[[\/XGMUXJ0/JG1N-+M/^N8H O4 % !0 4 % !0 4 % '
MRE\??AIXN^(GQFU[3O WC3P_H>H:KX(32M5T[6=+N+F3[%)<7($T3HRJI+.Z
MX))^7.,8H 9HWP6^(G@K3_%GB3Q]XFT#777PI#X?LHM#T^6U"10R,X>3?(^X
MG=VQ]* /JY.@^E #J "@ H * .:^)?\ R3SQ/_V#+G_T4U '1Q_ZM?H* '4
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M$-TO_G@W_?U_\: .*\<>'['2+N-[6W6.2:-=[ DNV)HL<GM0!Z)HW_(+M?\
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MJ4P0&3;$43;\[%CSMW#D] >WX4^5()UI3W.C@T!];\5>%G20QBPU'[:V%SN
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M'MZG<?(NQZ7\*H([>"Y2*-8UVJ=J  ?>:OOLGDYX6\F?.XU6J62/0*]\X!:
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M2NA-7,#38;8 3PJS.Z*/.D#;V7MDMSW/'O7AS34F<SW+5S.+:+S""1D+@>Y
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MG,9_$.^'2O:.$6@#@/B9Q/;'D#8O7I_KHJ .RT;_ )!=K_US'\J +M !0 4
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M]# P<)GLHZ5P'T@PPC=GG/3K0 \#C% $1#!CR "<]*S;U$-BD$K8.<^ZD4A
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MK\?-4\=ZGXW?2O _Q=T_X;C1M".M:M!J'AU-01K<R2*)_-<@(%\J0%1D\9H
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MP)>D27BQ*LLZX42-W.T$X_,UXM22E)G,WJ3:W9P7$,,TL,3S0RH8I'0,8R6
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M"T >?_$OBXMN ?W8X[_Z^+]* .ST;_D%VO\ US% %V@ H * "@ H * "@ H
M^'?VUX+:P^+-L9_C3'\)(O$_ADZ!=&]\-_;[2[M_.E+*]RQ"PD^<1SM..<T
M;7PY^$/B'PWX3\6^,]<^+NG_ !7M[CPS#HFGW&G:9!:QV]O%(SJ-T+L).6/)
MY]Z /L9/N@^HH =0 4 % !0!S7Q+_P"2>>)_^P9<_P#HIJ .CC_U:_04 .H
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M?\_UM_W]7_&@#G?&.JV5RFD1PW4,DG]HPG:C@GOV% &?]J.U/O8#-_ ?4^]
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MAALPR<C_ +_4 8WB;0=:\()IEQ+XBFOK>XO8K62$"2([6R,AO,.,8':@#L_
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MXMRNS(X,J>M '0CI0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M%*G!8@XSWH Z#7[=8M(BB0!46>W"A><8E2@#>7H* %H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#Y#_:6M/A9X?^/%GXC^*/A2?QI9W?AR/3[&QC\+3:P+=X[F5WD+)&ZH
M6$JC'!^7TH 7X?\ B/X,:UX,\?)\+OA_-X,O4TL->S2>%9-'$\>[Y5WO&H?!
MR<#.* /KE/N@>@H =0 4 % !0!S7Q+_Y)YXG_P"P9<_^BFH Z./_ %:_04 .
MH * "@ H * "@ H * "@ H 9)&LJE6 93U!H QT\&:(C[QIEL&QC(0=/\DT
M/'A+2%V8T^W&TY7Y.G.?YXH >/#&F*R,+&'*%67Y>A!R#^8!H U.E "T % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!\[?&W3==^*WQ6M?A]8^/=5^'FA6.BC6-2NM"D2&\O
MFFFDAAB29@?+5?)D9L#)ROI0!S.DZ)XC^&-IXY\":CXZU#X@>'SX?75=,O\
M6G26_M6$IBEADE4#S%.8V4D9'S#F@#ZM3I^% #J "@ H * .:^)?_)//$_\
MV#+G_P!%-0!T<?\ JU^@H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'R)^V)\+M*\:>-]#O)_V?;GXQWJZ>86OK;Q(-,-
MI&LC,L90NN_)9FS@^E '-?!;X:6G@7PM\1;BW_9_O/@TT^D+&;VY\1#5!>@/
MGRPH=MFWKGOF@#[>3[H/J* '4 % !0 4 <U\2_\ DGGB?_L&7/\ Z*:@#HX_
M]6OT% #J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^3/VR!\)5\5>&6\63^,8?B&+>3^P1X$:[_ +3,>_YMGD_)C<?^6GO0
M!B_"(_&1_ ?Q!7QZ=:;P2-. T)O%T=JFM%MWS>>+<XV[<8WX;)YH ^RTZ?A0
M Z@ H * "@#FOB7_ ,D\\3_]@RY_]%-0!T<?^K7Z"@!U !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?*7[5W[3NM_!GQ]H/A
M?1;#PYH=SK%EYR^-/&$LT6FVQ\QE,&8XSND&T-AG4?,* .:^ DGC'QO\%/''
MQ"\8?$N;QO=:DM[IL-E91Q1:7:I;7<L0EMU3KY@0-N))*L.M 'V@G3\* '4
M% !0 4 <U\2O^2>>)_\ L&7/_HIJ .CC_P!6GT% #J "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H H:SH>G^(=.FL-3L;;4;&
M92DMM=1++&ZGL58$$?6@#RSPE^R9\-/A]J'B6Z\*:"/#?_"16XMM0M].F9+=
MP&W!DA)*(W;*@<4 >P*NT4 .H * "D W=1<"KK&EPZYI5YI]R";:[A>"4*<$
MHRE3@_0F@"TB[%"^@Q1<!U%P"BX!3 * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 R0[4)/:@#QB_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MX!;,(U!A4@B,X'RC'I28%VI *I %, H * "@ H * "@ H * "@ H * "@ H
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M,"]4@%4@"F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 A&:
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MD,IR"/6ODVFG9[GVL9*2O'8GIHH*8!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M?8)WU1/3&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % #9&V+GTH \XU/X_\ @.VTBYNH/%^A-)'"TB))?(N2 3@C.1TQTR*?LY=C
M/VD3O]-N?MEC!/@#S(U?CW&:1H2SQ+(A5E#*W!!&<UC4BI1Y9*Z"]CQ_QOX:
M_L"_$D"D6DW*#LK?W:_"^(\H^HU74@O=9V4Y<[L<)XL^.B_#/1FTA)U-_?@K
M; GFWSP7(]/3W/IFNS)<UQ%&A*FOAZ')BZT*?NGC^CZ9>^*];M[&VS<WUY*
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MZJL 4 %, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H :_P!V@#RQO@RF@Z]-X@T62#4M89GD#>(@]VX+?P)<$EXE'8#<!Z5K[1VL
MC+V:O=GI]KO\E/,55DVC<%Y /?%9&I-28!20!5 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
J 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g42675dsp53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp53.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,6 @<# 1$  A$! Q$!_\0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&NDD$K%V99&)+ DGO[4 =#\,/^1)L/\ ?F_]'/0!U5 !0 4 % !0 4 % !0
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MA]\4/$_B36=(L=7TC3[*&Y@F<WMK>1RQW3P[4E\D*Y.!(PZYXH ]:H * "@
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M.!D@9(!&<9&0#M* "@ H * .:^([O'X&UUDD>%Q9R[9(Y?+93M."K=CGI[T
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M H * "@ H * "@ H * "@ H * "@ H YCXH_\DS\7?\ 8(O/_1+T =*GW10
MZ@ H 0\"@#S6^\;_  M^,&L:GX FUW0/$VJZ?-'/>:"MY'+/#)%(KJS1@Y!2
M14/^RP&<&@#M/#?BC2/%ME/=:-J$&I6T%S+9RRV[AU2:)RDL9(_B5E*D=B*
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MXIM[2?Q3XBO+JRM/ET?4KJPN((B%",-\,2R,4SMRQ.[J<GF@#Z4H * "@ H
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MCE5&623Y1L"N/+PJL<%'8X+G(!Z?XRL8M0\-WL,UK+>KM#B" @2,RD,NTEE
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M.F^'O'MI<:7IKV.I7%C<?VWII\.K80:3+N0^7#,($W@ON7!=]X <' )(!:^
M^FW4/Q0/B#4-+::WUN"X_LK7Y],MK?SH2XD$<:Q73F)"G(!A5G"@NVX"@#Z@
MH * "@ H 0]* /G+P[\)_"?Q'^,'Q4M?&FG2>)[BPU:UFM+75;R:XM([.:PA
MV*MLS>2!YJW(^[DXR: /?M#\/Z7X9TJVTO2-.M=+TVV4K#9V<*Q0Q#))"HH
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MH ],(W(P]>.: /.O /AJ7PIXBEM]2AM&U&X@=H+G3HEM[=X$:,,HA &S#.N
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MH'0^5+G.0Z@%EY]J .N^+41G^'.OQBWAN]]LR_9[B4Q1RYP-A<<KGIN'3.:
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M(/'>@"A\6Y;:#P?)+<:S>Z"$N(&CN].M6NIMXD7:JPJK&3)X*[3QR>!0!A_
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MV4_Q0LX+?P[864MM;7.[Q;;0RK/XAWE6#2EH$^\/WQ^=QD#!ZT ?55 !0 4
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M/96D<)"GJ/E XH K>'_A5X*\)ZO)JVB>$-"T?5) RO?6&FPP3N&.6!=%#')
M)YYQ0!U- !0 4 % !0!XW\<O#/B34/&?@;7= T&7Q!'I0OX[JW@NH8)%$R1J
MA'FNH(RASSF@#"^T^/A_S3#5O_!IIW_R10 ?:O'_ /T2_5O_  ::=_\ )% "
M_:?'W_1+]6_\&FG?_)% %O\ 9J^'FL^"=/N;#Q!=2O<1Z7I<+Z1*ZRQ6,J0,
MKB-@2#D]2.#CO0!UUU\ _"T^N:QJT,NOZ9=ZO<"[O1I7B34+**641I'O,4,Z
MH#LC09 YVT :_@SX4^'_  )=ZI=Z='?7%YJ;1M=76JZE<ZA-)Y:E4&^XD=@
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M1+'Q1?R6MKIVL0A&D4W%YILL$)*.48!V !Y!QCK@D4 =50 4 % !0 4 )B@
MH ,4 +0!6M]/@MKNXN40+/<!1(^3\P4$+^630!9H * "@ H * "@ H YCXH_
M\DS\7?\ 8(O/_1+T =*GW10 Z@ H * "@!,8% '+?#$ ^";#(S\\W_HYZ .I
MH 6@ H * ,C7/"&A>)I(I-7T;3]4>(%8VO;6.8H#U + XH ATOP/H6A:A#>:
M9I%EIT\43P*UI L0".R,XPH Y,:$_P"Z* -F:".XC:.5%D1NJN,@T 5DT6P1
MU9;*W5E.01$N0?RH N%0PP0"* &B%!_ OY4 .*AA@@$>AI-)[@-\I/[B_E4>
MS@OLH=V-GMHKJ,I-&LB'G:X!%34IQJ+EDKKS"+<7>+LR"/2+*%U=+2%'4Y#+
M& 1^E9QPM&+NH)/T1;JSDK.3^\L2V\<R;9$5U]&&16\H1FN62NB$VMB)-.MH
MV#+;Q*PZ$(,BLU0I1=XQ2^13G*2LV.N;*"]B\JXA2:/.=LBAA^M:2A&:M)7%
M&4H.\79E>#0M/M95DALK>*1>CI& 1^.*B-&E!WC%)^A<JM22M*3?S)[FPM[U
M EQ#'.@.0LB!@#Z\UT*3B[IG/*$9JTE<B@T>PM91)#9P12#HR1@$?CBFYREN
MR%2A%W45]Q:>*.5<.BN/1AFHV-;+J,6TA0@K$BD=PHIW;%RI=!TMO',H61%<
M YPPS4.*ENAV3&1V4$+[DAC1O55 -)0BM4@22V07-E;WBA9X(Y@#D"10<?G3
ME",U:2N#2>Z&6^EV=K)OAM88GQC<D8!_E4QIPB[QBDR5"*V1:K0L* "@ H R
M]<\+Z/XE^R?VMI5EJ?V29;BW^V6Z2^3*.CIN!VL/4<T 16OA#1K'4O[0MM+M
M+:],DLS3PQ!':20*)&8@<LP1 2>?E'I0!L%01@C/UH 0(HS\HY]J  1H.BK^
M5 ">4F<[0#]*  1(.B*/PH =M4=A^5 "!%!X4#\* %V@=A^5 "T % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % ',?%'_DF?B[_L$7G_HEZ .E3[HH =0
M4 8FK>,--T2Z%O=F[$I4./)LIIEQS_$B$=NF<T 4O^%D:'_>U#_P577_ ,;H
M #\2-#Q][4/_  577_QN@#F?AM\0]%A\&V*,U_N#S9VZ9<L/]:_<1T =OH_B
MK3]>EDCLS<EHQEO/LYH1^!=1G\* ->@ H * "@ H * "@ H * "@ H * $Q0
M M "8H 6@ H * $Q0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ',?%'_DF?B[_ +!%
MY_Z)>@#I4^Z* '4 % "8 [4 &*  @8H Y;X8\^";#_?F_P#1ST =3@'L* %H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * .8^*/\ R3/Q=_V"+S_T2] '2I]T4 .H * "@ H 0]* .6^&'_(D
MV'^_-_Z.>@#JJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H YCXH_\ ),_%W_8(O/\ T2] '2I]T4 .H *
M&OD*2.2!TH ^<?'/[2/Q&^&VG-?^(OA?H6EVA8I$;GQQ$LD[=DCC%L6D<]E4
M$GL#0!ZO\%O'VJ?%#X;Z3XFUGPO>>#;^_$C-HU^Y::%1(RHS;D0C>JAP"H(#
M#(H \J\?_$+4_ 7P[\+266JSZ1:7,]TMQ/IZV3W@(E.PHMVZQ>7DG>W)&4X
M)( /6/A#K&MZUX027Q S-J4<TD9\U8EF" _)YRPN\8DVD;@C%?IT !VU !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M-VX-D!SCH<$$  ]+H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MD'#926.-]N<[2R@D8Y/6@#N* "@ H * "@ H * "@ H * "@ H * "@ H *
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M]: .NQB@!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#F/BC_P DS\7?]@B\_P#1+T =*GW10 Z@ H 1ONG'
M7% 'A&D_M7:/X;NO[*^*^ES?";6 2JW&NS)_9-V0"?\ 1[\?NGXYV,4?G[M
M'K_A/QAHGCS0H-:\.:O8Z[H]QN\B_P!-N4N()=K%6VNA(.&!!P>H- &=\,/^
M1)L/]^;_ -'/0!U5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M!%/>"$V^,%97VY]/E)_I0!8'2@!: "@ H * "@ H * "@ H * "@ H * "@
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MMDN9;F=8%624Q@$@D'(5NX Z=Z (8K[5IK^S2[TV"WA+MF2*Z,A!V-C@HO\
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MN'R_GFKCI\9(A#<U=XDVD<9>^);NU^*EEI+W\<.EMI3W$ENT:DM+YJJK[NH
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MZ#U _*@!->DE@A@EAC:21)0?E7=CY2,XR/7N: -"')C4GJ0,T 24 <Q\4?\
MDF?B[_L$7G_HEZ .E3[HH =0 4 -=0RD'H: /"=+_9=L8?AGHWA>ZUV==2\-
M3M)X:\2Z;;QVM_I:#_5+D960A24?(VRKG<O)H [SX+?#_4/AIX&&CZMK:^(M
M3DO[[4+G4TM1;":2YNI;AB(@S!<&7& <<4 :7PP_Y$FP_P!^;_T<] '54 %
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M^>N#CZ9H [>@ H * *NJ_P#(/G^@_F*4MI>A76/J<9I6E+ VFW*,JJ[K*RA
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M-JS-CX.?+\-_#N#YH-I'N8G_ %?[B'@5^MT/X,/0^.J?$UYGLB??;\*U():
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MO^0?=_\ 7%__ $$T1U:L'8V_A-_R3+PM_P!@Z#_T 5[<M;'6SK*D04 % !0
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M/]^;_P!'/0!U5 !0 AZ4 >5_%=#+<7D88H6@@&Y1R.9N1D8KRLR_A+U.:O\
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MM8H$)*KY8."22>3SU)- &+86-M8_$W44MX4A4Z7:$K&H&?WEW0!VB?=% #J
M.8^*/_),_%W_ &"+S_T2] '2I]T4 .H * &3?ZMN,\=* /B2[L?@7YDP?]D/
MQ1*Y)RZ?#N'YCZAMW>@#WS]E'POJ7A#X.6VGZAI5WX?MCJ-_/IFB7[AI].L)
M+J5[:WD(9N4C91C<VT8&>* .X^&'_(DV'^_-_P"CGH ZJ@ H 0]* /+?B>L\
M^K/;VUO)<S2QP!4C*@]9CW(]*X<91E6IJ,3*K!SCH>7^%?$"^*O#>FZPEK-9
M1WUNEPD$Y4NJL,KG:2.00>O>OD:D.23B>6XN.C,\> M%MM8T_4(8$MI;.6>=
M455P\DP(D9LC.3G/!%:>UG:U@5^AT2N@P R]?6IBI2>P[-NYY5\.?"LFM67A
M;Q1]M$-UIUI<V4, 5C$R-+@LXW#+?NQ@C&,GK715FXIT[%-'?ZDFIC3KH_:;
M0CRFZ6[^A_VZY81O):$\KN=1\(6+_"WPFS+M8Z9;DKG.#Y8KV9'2SK_IUIQV
M$8L?C'16A$CZOI\>3@!KN/UXYSCGC\Z?*V[#2N8FI_$95NM.MM,@BN[BZ#2[
M&GC/[H 9;Y&8CETZCIFMW1Y5=[&G)979H7?C.#3',5^XM9QU7RBZCW+*2%'N
MY6I<4B>5,HZMX\GTC6],M)[:WAM;LKFXGN GW@^T#J,Y4=^_&:.5-"Y34'C+
M3F<(+_3BYZ*+^,D_K[C\ZP:["L-3QKILA(2^TYB,9Q?Q]\8[]\BK4=!#9?'>
MDPPF9]2TQ8@,[SJ$07OWSCJ#3Y!V-#1M<BUJ"*2-=@DA2=06!.UAD=*&F@-.
MLGN(R=:U_P#LBZTZV2SFO;B_F:"**$J#D1O(22Q QM0_I6E.FZCM$:3>PS0_
M$#^(-+@O[:T989<X61P&!#%3D<]P:4H.+<6#5MRY#>W$ZEEM> S)S(.H.#_*
MHL!(MQ.)$$EOL5CC<'!HLQ%CWH>XSS#QW 8]*TA_LKQHVO:7L<LIP/[1@XXY
M.>O-==+^(@/5/#Y_XE,'_ O_ $(U])'0@T:LHBNI_LMM+,06$:%R ">@SV!/
MY"E+8DQ+;Q:;B]>'^RKR. 3M EX^SRI6#["%VL6_O')4#"GI4*8[,VI"?/7
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MM$[@5IRPN$VDD;#P&QW%920$<AE)&%S\P_Y:>_TI"(X=Y\L8V_ZSD.!_%]*
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M>-O"7Q&\:6?A_4-.OX!86KVD[L;62QMI0Q:.-@<RR3=\X XH Z+3OVA?A_\
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M2*-?WJZ[I>6VD8QJ, /..?\ ZU;TOXB&>G^'Q_Q)X,>K?^A&OIH_"03HHAD
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MAS@BK30"&VC/][_OL_XT^8!JV<2#"A@,D\.>IZ]Z>^H#EMT5@<$D=,L3BE=
M2GG-0E>5T!Y?XZN5ETG1H]ETH77=,V&6,JO_ "$H,\XP<\8QVKMI?Q$,]4\/
M<Z1;C_>_]"-?1K8DLLC+*OEQH <\YQZ>U0R1D D,**43&3D$GU/M0!:4 *
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MQ1AR.S*1^%(#N_A_YBZ/HR2(%@#7?DE?H^1U_I4@>PCO0 M !0 4 % !0 4
M9VLRI%' SL%42=2<?PM0!>1@Z!@>",YH ^*/C5I'CGQ9\6/&GPSTGPQXGC3Q
MYJ&FI?\ C2(LNEV7A^&%/.ACDW82<O\ :T*8!/G9).5P ;GP:^&L7POT']H#
M1_#7AW5O"OPXMH&M-'L=4F>1)KF*VF6\N;<.S,(7/D@'/S,K-WP #Z\3[HH
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M96OP2\>_$/PW,WB3^VY?$^CW]L]CI$UY --^SZ:+I%?:R@E([H;1SEN,$YH
MZ#X5?%ZT^-D7[0_B32!K*>'9-.MHK&+6+66U*LMA*)=D<G0%AR1UH ^MT^Z*
M '4 % !0 4 (>E '+?##_D2;#_?F_P#1ST =50 4 (>E 'G'C-V_X2V=-AV_
M8$(?(QG=)QZUQ8GX3"KL5G4,3D9KRDT<[&! ,X0<TQ%*)%_MFY_=KQ!%QC_:
MDHN!/?1K]CG)1>(SV]J5P)O+4=$ [<"F +Q(!C Q0!'J$K06-S(C*CI&S!G&
M0I ZGVIIJ]F!XO9_$[Q0_AC2]1&F2B2Y6V)8-IX7]XR X!NLC[W?IWK5I=!V
M1I0>)]=UN]-M>>'+JXBC<,B+-;+GY#\[>7*S$>PS5))JQ45KH7/"M]=^)=$>
M_OTN+&X2>7SK?3)4MX8L.P&])'W$D#)) SDX]:%%=&-G%7'CC5S%X9U*U\/^
M7))J[V@FM%2&)XAY@7"3.HR0J_,&Z^HP*T220^AUJ^/_ !.M_%#_ &7.RLC/
M@2Z=G@J/^?KCK^OM7/9&92TSXF>*[S5]5M7TBXV6CQHK+)8 G**QSFYQW[$_
MI5<J'H<Y\0_C/XP\/_"S4M>M],9KJ*!60R&Q:,DR!<%5N6;^(#H<$9P:<(IN
MPU9/4]:^&^IRZMH=A<.\C*VGVQ^=2 3M)R">O4?I45%9M(3W.PKG)///C+I?
M]K6'AY)#.EG%JF^ZFMY7B:*/[+<+G>I!4;F5<@_Q8[TW4=.-T)R:V,NRT*P-
MJHM;FY: G(,5[(0>W7=_G\*Y?KU=):F7M9$6K>#K76+9H9+O48"7602PWL@=
M&4Y&TY..1Z5$L;7DG%R#VLFK,Y_QM&/^%C> G\\1E'O5*,%)D4V_(&><\ _+
MZ'-10^!L</A-7X?Z??:?::HM^',KWFX.X(WKY48SS[@C\*PJ.+LXF;>ATUPZ
MQP2.[!5522S'   ZUU8+_>(>IA5_ALYG_A._#0X_X2'2O_ V/_XJOU235V?.
MNG-ZV*]OKOA">YE:'4-$DN)VS(4GA+R''?G)XJ5)(3C4:-3_ (2#2^VI6F/^
MNZ_XU7,C%1E?8]"^%-C:Z=X$TZWLYH+B -,WFVQ!1G:9V?IWW$Y]\UYLMS["
MA=TU?<Z6681W"*P8@J3@*6[CTK"1L'VB';@(_K_JF_PJ;@1VDL?E E6SEL9C
M/]X^WM3LP'O/&H4(&4E@/N$=P* );A_*A9LD8]!D]:MZ#9$;F$'(1\^OE-_A
M68B+S8FN@ K;0F,>6WK]*8%D3QDY"OD_],V_P]Z3TW 6V;? C?-@_P![KUK4
MI'%?&T!OAOJ((R#<68Q_V]15HMT<]9I4VF<K'#'&"$15!ZA1C->I9+<^.YO>
M)#USW]:4DDM!IMM79SGP@'_%N]*'O-_Z.>O#J?$?H-!6I1*?Q3\4+IW@36I5
MM7DMI8S9^>7\O+N=@(XSM!/)_+-9>1T&AX)\1S77AS3IIK,16F/LRS1S&3!1
MC&"P*@@,5X(SU&>YHW$G<W?#^B+H&EQV(NKB^V,[>?=L&D8LY8Y( '&<#CH!
M0,]"\ Y'AW12<Q?OKS _YZ<-S^'X]*C8-SUH=Z %H * "@ H * "@ H * /E
M/Q1^U?J7PI^+7Q"\/2?"_P")/Q MH-3MGMKWPKI O;.U1M.M&,&XR+M;>7<J
M!_RU![T =CX?^-\OQL^$WQ"NY? 'C+P#]ATVXB\CQAIHLI+C=!(=T0#MN48P
M3QR: />4^Z* '4 % !0 4 (>E '+?##_ )$FP_WYO_1ST =50 4 (>E 'G?C
M/_D:)O\ KR3_ -"DKBQ/PF%78IR L& 8J3W':O'ZG.RNMM*JX-W*QQUVI_A6
MG-81$NG.+AIQ=S"1E"'Y4Q@9([?[1HY_("26S>:-D-U* R[3PG_Q-'/Y "6T
MRYS=2M^"?_$T<UP)887C)+RM*?\ : X_("E= 2T70%9;613S=2D8P!M3C]*%
M(#F_%GA;6-6N-.N-.U=(9+69G9+J!60J8V3C !R"0>?R-:1FEN7%I7N5SX2U
M:>6.>[;3K^[C.4NKA9#(I_V<$!/^ XH4A)H:OA/Q#<^(--N[[4[22SM)&D"1
MPGS5)1E&';KU'7GKS0YZ%75CKEMI0,?:I,]<[4Z_]\UG=LS&_8YMV1>2@=QM
M3_XFGS6 2YL7N8VC:YD*,NT@JA!]>JT<SW0QUG8K9 !999!M"_O&ST[_ .?0
M4[MZL1:K-[@8'C'4[;3--A-S,D(FF$4>\XW-@MC\E8_A656+<=")*YYM/XGT
MC3M;#+>I&)05N$'W=V 5?/KCY>/49Z"N%4I2CL8V9;_X3WP^&"G5(=QZ#G)^
MG%1[&IU0690U#7_#6I:AIM[+J48FL)'DAPG=E*GDJ2.">A&>]*"G%-6&KI6-
M$>.=! _Y"47Y-_A2]G+L39DD'BS1]1E%M!>QS2RY58P#\W'3I7=@H2^L0]3*
MHFJ;N1S^']+N#NFTVTE;^\\"L?U'N:_4I+5GSOM9WLI%6RN/#ZRW5K;-IZ26
M63/%&$'D=&)8#[O\)Y]CZ5G>)4Y5E97)AX7T8\_V38G/_3LG^%4DF1-SBOB/
M0OA';Q6O@>WBAC2&);N]"I&H50/M<W0"O.GNSZK#_P --G57!>-A*NW"KCYL
M^U82-AHFE)(Q'D$ @,>,_A1S>0B.VDDCA&_85&]B<GL:F[&2+)),P5=@(VL<
M'/&?_K4Q$\RLT9"$!NQ/2K>NP[%=;ARP!$8W$J#GN*@1$'F-R'Q'GR^Y/K]*
M0%AKAEDV_)PP7.>YZ<?B*<M1DL*LD:JV,CKBM!HP?'_A63QKX3O=&AO?[.EG
M,;)="(2^6R2+(#M)&>5'>FY65R7!3T9YMI/PT\4V6IPRW_C2/4+-"?,MAI*1
M&08('S!R1@X/X5\Y+B&I3FX\M['1_J_2J03O9LZK_A%!@YN3_P!\?_7I?ZR-
M_8,_]6[:\YP.B?!WQ7X>L8K&R\>1QV43,4B;1HV(#,6(R7SU)KAEG3<KJ![]
M+ JG%1N;_CKX31>,?!DN@0:E)II_=>5<B/S/+*,"/E)&1QCJ.N:S6<3YKV*^
MI+N2^&_ABVA^!$T";5I+R[\B6-[\PJFYY"Q+^7G Y;IGMUK.6<5>:Z1JL'%(
MQHOACXU14W_$3>1C<?[%@&[Y<'OQSS^E6\XGV,OJ:6MSU'X?Z?<Z3X>T2SO;
MH:C/%+=H;I8A'N(4Y)49 R<G'O7T5"JZ]-39P37+)H]<6MR!: "@ H * "@
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MR./O/7C9E\$6<F(^$XW[/$>L:?\ ?(KYF6[//#[-%G_5)_WR*5WL&H?9XO\
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MI-GH?@'']AZ;LPH%Q>;]PY)VG&/T]*\6O\;1]O@7?#Q/6AS6!WBT % !0 4
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MP^/_ (P\7> =2^'KZUIT"6NG:G<1S2.L-A+&S;DXQG'8=: /K!/NB@!U !0
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MQIAJ6+:U^SP)&6\QE&-[=2?6@-2;8.X!I:@+TI@+0 4 % !0 4 % !0 AZ4
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M % "8H 6@ H 3% "T % "4 +0 F* %H * $Q0 M !0 4 % !0 E "T % !0
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MKMQXE\+VNH72QK/(\JL(@0ORR,@P"3V4=Z .@H * "@ H * "@ H * "@ H
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ML/\ ?F_]'/0!U5 !0 4 % ",H;J ?K0 @C4?PC\J  1J/X1^5 !Y:'^%?RH
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ML$^Z* '4 % !0 4 (>E '+?##_D2;#_?F_\ 1ST =50 4 % !0 4 % !0 4
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M0 4 % !0 AZ4 <M\,/\ D2;#_?F_]'/0!U5 !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "'H: /A[X\>,+:?]H;
M6_#4O[46M_!Z\V6Y@T*YTJ%+$@P1DO#=2X1MQ.2"P(8L,<4 >P>$?A[XE\!?
M!OQZWB#XIZA\5%U#2YYK2^O[:&$6Z"WD!"&(D,&R#D^E 'T GW10 Z@ H *
M"@!#TH Y;X8?\B38?[\W_HYZ .JH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H 0]* /F/X]>&?C%\6_%NH>$]$\
M'^ +;P+"L>/$?C* :H\[&,%_)LP, JS,N9, [2?2@"C\&?@1X?\ @%\(?BKH
M>E>,X_%>KSV<]QJD%M%;VMO82&WDVI':P_+ &&3M/7&>U 'U2GW10 Z@ H *
M "@!#TH Y;X8?\B38?[\W_HYZ .JH * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MSG  X'6D!>H * "J0!3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)_[$2:ZMI[:YG=I9%NIA+(Q/0L0  2 /E &.F!BI8'2T@"J0!3 * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H :_W
M3VXH \TN/%'COQ!KVHKX9TS1K?0M/F-M]KUF:427LJ\2"-8U^1%;*;V+$LK8
M7&"=/W:5Y;F3YY/1':^%M<?7M(2YGMC9W2N\,]N7W^7(C%& ;C<,J<' R"#@
M5E(M:&Q291Y_\6[WP/9V5@?&]G!>6C2M]G6>R>Y ?') 56QQ30'FG]N_L_\
M_0$T_P#\$,__ ,:I@=](MCJ'P_TT^#-#M=2T=BQM[-[98XU&U]I"2E<8DVY[
MX)Q0!UG@^!X+!D;2DT=1)E;94C3 VKDD(2.3G]*E@=#2 *I %, H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M.<;N#U!53VIW069O^&/#4?AFR:VBF>9"Y?<ZHO8#H@ [>E)@;5( JD 4P"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.N)(B?FBD'WD/T/Z8KY"O0E1FXR/N,-7C7IJ<3K@<US'4+5( I@% !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M#-05!J+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % "'H: (R5P3@<4D[[$M);E31]8@UFWEE@1T6*>2!A(NT[D<JW
MX9'![BGJMQJSV%U72H-6M)+>X0/$X_$'U%>;C,%2QM)TZBO<I-H\7U[1)M U
M&2UE^91S&^/O+ZU_/V:95/+:SA+;HSKA+F.A\*^/[;P]I\R:Q<B&S@0NL\A^
MZ/[O^'N<=Q7VO#F>RIKZMB'=+8FK%1C=GSA\2/'UW\0O$,E_,6CM$^2VMB>(
MD_Q/4FL<UQDL75?,_=Z'@U9N;MT/5?@1X$N/&'A#4;3Q%!'?^$[D[8+*Z3=E
MQU=#U7ZCOTK[3AN>)H+FYO=Z&OL(UX<M1:'4_P##(?PN_P"A=/\ X&S_ /Q=
M?H2S+$;7.9Y5A^B.R^'WPD\/?#&.>+P[:S6-O,VYX&NI9(RW]X*S$ ^XKAJ5
M9UI<T]SNH8>%!6B=H*S.H6@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * $894B@3U//[_X,Z5J-]=W<NL^)XI+B5I6
M2U\0WD$2ECG"QI(%4>P%6JK6AE[)/<Z'P1X.L? F@KI.GS7EQ;+-+-YE_=R7
M4Q:1V=MTDA+-RQZDX&!VJ6W+5FB2CL;S DUE*ZV*,'Q7X8C\16:IN$4\9RDA
M&<>Q]J^:SO*(YO1Y7HS2$^1W/ OBE^SOXX\?".SM=7TJQTJ-@^QFD+RL.A8A
M>,=@*^6P?";P[YG+4Y,7SUM(E/PM^REXBBF@CUW6;![=" \ED',CK]"H /O7
MJ1X>ES+G::,*=%\MI'TWI&E6^C:=;V-K&L5M;H(XT4<  8K[6C2C1@H1Z':E
M96+U;#"J0!3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H 1NAH \@^(/B+Q]!JL]K:10^&] \Q(TUFVLY-5N9%)&
MYO*4 08&X[G60<5O%02N]SGJ.=[([+X8)8+X3@_LSQ#/XIMVEF9M5N)TF>:0
MR,7RR*J\-D84 #&,<5C-FL-M3KJ18A&:5D @2@ VT]0'5-@"BP!30!3 * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
DH * &[>","@6K([>UBM598HUC#.7(08RQ.2?J3S2>H)6/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g42675dsp70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp70.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *X ?P# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M9\5_V@[/X4>!]!\07NAZC?7&L3P6UOIMJJF82R#(4\XR/K7#6KPH5U0EUO\
M<MPIKVM)U5M_F5O G[5WP^\;>']'U%]771;C5)WMH-/U+$<YE20QLNT$]'!'
M6NV<>3;M?Y,E<ZC*4EI%V?J;<'[1_P -+EM66/QEIC'2@#>_O<"$;@N3ZC)
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MMV73YCH2=&,V]Y-/[E_F=EX[_91;QW\)_AYX'OM<DGMO#EU:37ES(\BRW:1
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M'7_&MWKNHMXATY;Z_P!9M]62V5)X;<>7"\;1DQN'&=^058=*QFD_9:7Y>?\
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M<+!O%%PL&\>M%PLPWBF(-XI70!O%%T.P;Q2YD%@WBG<+!O'K1<+,-XIB#>*
M#>* #>* #>* #>* #>* #>* #>* #>* #>* #>* #>* #>* #>* #>* #>*
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MK8? T)\DUK:YO1JXNO'F@]+V.(>'Q+'%%*VH>(EBE.V-S?705SZ*=_/X5T+
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M<^P?:H?^>J?]]"CVM/\ F0>SGV#[5#_SU3_OH4>UI_S(/9S[!]JA_P">L?\
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M_P""J'_XFCGEW#ECV#_AD_X-_P#1,/"G_@IA_P#B:.>7<.6/8/\ AD_X-_\
M1,/"G_@IA_\ B:.>7<.6/8/^&3_@W_T3#PK_ ."J'_XFCGEW#ECV#_AD_P"#
M?_1,/"G_ (*8?_B:.>7<.6/87_AD_P"#?_1,/"G_ (*H?_B:.>?1BY(]CR;X
MF_LT_"G3OC7\(+&V^'?AN"SOKG4UNH(]-B"3!;,LH88YP>1FDY2;NV59+1(]
M9_X9/^#6/^28>%/_  4P_P#Q-/VDNXE"*Z!_PR?\&_\ HF'A3_P4P_\ Q-'/
M+HP<(OH'_#)WP:_Z)?X4_P#!5#_\32YY_P PN2/8/^&3O@U_T2_PI_X*H?\
MXFCGG_,/ECV#_AD_X-?]$O\ "G_@JA_^)HYY_P PN2/8/^&3_@U_T2_PI_X*
MH?\ XFCGG_,')'L'_#)WP:_Z)?X4'_<*A_\ B:?M*G\P<D>QY-X@_9I^%4/[
M3G@[2D^'GAI=-G\-:G/+:C38A&\BSVH5BNW!(#, ?<TG*3=^8JRVL>L_\,G_
M  :_Z)AX5_\ !5#_ /$T_:5+?$3R1["']D_X-#_FE_A3_P %4/\ \32]I4_F
M#DCV.*^('PI_9\^'UMMN_AOX4NM3DD2"WTJUTN![F>5_N*J8SS@\GC J(U:D
MI*,6_P#(KV<5'F:.FT/]ECX47FF03:A\)_"-G=R+N>"/3(F"9_ASMYQ6LI3C
M)I2(2BU>QH?\,G_!O_HF'A3_ ,%,/_Q-+GGU97+'L>3_ +4/[-/PJ\/_  @O
M+S3?AYX;L;L:EIB":WTR)'"M?0*PR!T*L0?8FIE*4E:Y245T/5Q^R=\&_P#H
MF'A7_P %4/\ \35>TG?XB>6.]A1^R=\&A_S3#PI_X*H?_B:'4F_M!RQ[!_PR
M?\&O^B7^%/\ P50__$TN>?\ ,'+'L)_PR=\&O^B7^%/_  4P_P#Q-'//^8.6
M/8/^&3O@U_T2_P *?^"J'_XFCGG_ #!RQ[!_PR=\&O\ HF'A7_P50_\ Q-/V
ME3^8.6/8\ZNO@;\/_!'[5?PS?P_X,T31G_L?5[C=96,<1\Q&M0C\#J [8/;<
M:3G)Z2=PY5T/IS!J2AU 'R+'X @^*'B7XJ:'=>(H="L8O'D=Y>)YH66XC2QM
MOD&3P"3^E3&*]M&K/HG]^R^5B^=J+@OM:/T+6D_L^7_@G6--O?#?CS0[J+2]
M2N[NRMM<'G*L=RG[Y6*N"6WEV!'KBM*<Y1CR2UNN5OK9.ZL9<L???\UG\T6K
M_P"!=_?Z!XS\-2>,/#/]A>()Y[U951ENXIY"6*[Q)CRP3C YV\9KG<.:"B]X
MNZ_X)O[67/[3JU9^7FC-3]G"6U\/V<-AXC\,Z;KL=ZET^JQ75T\@VC;E2\Y.
M2N00V5Y''%=&OM(5%TO?YZZ'*J:Y9)]3T7X0^ YOA[XA\27>H>+-(FTO4V,D
M6G6<S!$D)R\GSNVTM_=7"\]*A?P718W']\JJ.5L_A#KNF^$-8\"V_C?PT/!=
MR9C:[T;[=$K'<J,XDV,H;K\N2,BLIT_:T(4Y[PY;?]NRNKG2Y_[14JQVGS7_
M .WHV90T[]GR34=?TS7/$?BWPW/>VEUIS-;Z?'Y=N\%HLH4;6<_.QE//3@<5
MV>T]VW^)_.6_R.2-/ECR+;EY?D:.G_ Y]$NO#%Q8>+]"W:5?ZM<3+-RKPWKL
MVU,.,,H;J>/:LV^:,H/9PC#Y(WE9II?S70P? ^;0?#/@2V\.>*O#*ZKX=T]]
M/F.H1^9;3J\95I%17!#9/7/-9UDZM6K+[,X\O^%7OIYCOHN\9<R]?,W_ (-_
M"2R^$']LF#Q7IFH?;-,M+&$3.N%>%9,LWS<J3)T'85TXFK]84M-7?\3.G%1Y
M+]#R/QY\ -6LO!'B.XTWQ#HMMXCO]3M)]-M_#8,-KIY+".:18W=MNY&<MC P
M37+%+W(RV5[^:?3Y'1&TI-RTCV[OS/1++X(PZ5XSTC4=(\3:)HND0:<MC>V]
MO*WG7JB)UPX,GE\,VX,%#=1GFG72JPK4I[35EY(YJ,G&--]8NYR-[^S#<:E_
MPC[WWBWPY>G389[)[<SW$,4EN\OF+Q',IW]0<\' XXJT_?\ :/>T5_X#L'(O
M9J"Z.3_\".KMOV>-#M]16Y&O:'L364U1$.UBJK!'$$R6)S^[ZFLTFE&/1*:]
M7+J_07*^5Q\XM?\ ;I!IGP+GT+5/!=SIGC+0K)]"(CN+R)V$UQ!YH=H=OF;"
MI&1\RDCJ*VPTO934I[<MGYONQ3BY1G%;2ES?B?1J^)=( P=6LC_V\)_C4&HO
M_"3:/_T%;+_P(3_&@ _X2;1_^@K9?^!"?XT '_"3:/\ ]!6R_P# A/\ &@ _
MX2;1_P#H*V7_ ($)_C0 ?\)-H_\ T%;+_P "$_QH /\ A)M'_P"@K9?^!"?X
MT '_  DVC_\ 05LO_ A/\: #_A)M'_Z"ME_X$)_C0 ?\)-H__05LO_ A/\:
M#_A)M'_Z"ME_X$)_C0 ?\)-H_P#T%;+_ ,"$_P : #_A)M'_ .@K9?\ @0G^
M- !_PDVC_P#05LO_  (3_&@ _P"$FT?_ *"ME_X$)_C0 ?\ "3:/_P!!6R_\
M"$_QH /^$FT?_H*V7_@0G^- !_PDVC_]!6R_\"$_QH /^$FT?_H*V7_@0G^-
M !_PDVC_ /05LO\ P(3_ !H /^$FT?\ Z"ME_P"!"?XT '_"3:/_ -!6R_\
M A/\: #_ (2;1_\ H*V7_@0G^- !_P )-H__ $%;+_P(3_&@ _X2;1_^@K9?
M^!"?XT >.?%?Q!I<GQW^"SKJ-HR)=:J683IA<V1 SS0![&/$VCX_Y"ME_P"!
M"?XT '_"3:/_ -!6R_\  A/\: #_ (2;1_\ H*V7_@0G^- !_P )-H__ $%;
M+_P(3_&@ _X2;1_^@K9?^!"?XT '_"3:/_T%;+_P(3_&@ _X2;1_^@K9?^!"
M?XT >.^(_$.EM^U?X)E&I6AC'A;55+B=< FXM,#.?:@#V+_A)M'_ .@K9?\
M@0G^-  ?$NCG_F*V7_@0G^- '!:A\./A]JGQ4LOB%<S6$GB2SLS9Q3_:5V[=
MQ.XKG!89X)Y':BDW24E'[0YMU(J,NAW@\2Z./^8K9#_MX3_&@6V@O_"3:/\
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MOX:_\%T?^% !_P ,K_"#_HF_AK_P71_X4 '_  RO\(/^B;^&O_!='_A0 ?\
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MO2[2T?XE>&KIX(EC,TNLVY:0@8W'Y^IZU<Y.<F^YA3A[.*CV+O\ PT!\,?\
MHH?A?_P<6_\ \74FH?\ #0'PQ_Z*'X7_ /!Q;_\ Q= !_P - ?#'_HH?A?\
M\'%O_P#%T '_  T!\,?^BA^%_P#P<6__ ,70 ?\ #0'PQ_Z*'X7_ /!Q;_\
MQ= !_P - ?#'_HH?A?\ \'%O_P#%T '_  T!\,?^BA^%_P#P<6__ ,70 ?\
M#0'PQ_Z*'X7_ /!Q;_\ Q= !_P - ?#'_HH?A?\ \'%O_P#%T '_  T!\,?^
MBA^%_P#P<6__ ,70 ?\ #0'PQ_Z*'X7_ /!Q;_\ Q= !_P - ?#'_HH?A?\
M\'%O_P#%T '_  T!\,?^BA^%_P#P<6__ ,70 ?\ #0'PQ_Z*'X7_ /!Q;_\
MQ= !_P - ?#'_HH?A?\ \'%O_P#%T '_  T!\,?^BA^%_P#P<6__ ,70 ?\
M#0'PQ_Z*'X7_ /!Q;_\ Q= !_P - ?#'_HH?A?\ \'%O_P#%T '_  T!\,?^
MBA^%_P#P<6__ ,70 ?\ #0'PQ_Z*'X7_ /!Q;_\ Q= !_P - ?#'_HH?A?\
M\'%O_P#%T '_  T!\,?^BA^%_P#P<6__ ,70 ?\ #0'PQ_Z*'X7_ /!Q;_\
MQ= !_P - ?#'_HH?A?\ \'%O_P#%T '_  T!\,?^BA^%_P#P<6__ ,70 ?\
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M\,1_S4/PO_X.+?\ ^+H 3_AH#X8_]%#\+_\ @XM__BZ #_AH#X8_]%#\+_\
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M &X4 &X4 &X4 &X4 &X4 &X4 >,_%DY^/7P3Z_\ 'UJW_I$: /90PQ0 NX4
M&X4 &X4 &X4 &X4 &X4 >,^)&_XRT\$'_J5-6_\ 2BTH ]FW"@!"0:+7 \I\
M1_ #3/%'QDTSQY?:C>RQV-N$71FE8VCSJQ*3E#QN4$@8HI2='F<4FWM?IW'4
MDZD(PZ=3U2,!!Z?2C;8E))60_<*!GC/[7+#_ (4G>\_\Q32O_3C;T >S;A0
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M/_H,V'_@4G^- 'D/BK7M-O?VJ?AF+?4+6X)T+65Q%,K<E[3 X/7@T >Z4 %
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M2^!O!\*(YBD\RP@4I(!DHV1PP'44-I6?0J-Y.R6NGXG-MX8_9E&NZ+I*>'/
M\UYK._["L5G PFV\-@@8Z\4DVYSA;6*N_OL2Y6C&723LONN:]O\ "[]G:\M;
M^Z@\*^!YK:P8)=2K:VY6!B< .<<'/'-+FT32T>WW7+^URO=#=&^&/[.WB*_@
ML=*\+>!=1O)T:2*"VM;=W=0<$@ <@&M$FWIY_@[&4JBC&_\ 6JN<YXT\,_ G
MP/<^)4OOA7H4D&@:?'?7<T&E0L!O8@1@!<[L#/T(J8-5+6ZSY/G:]SHY;.TG
M;1OY7:O]Z.>N]7_9MTOP\FK:C\--'L(QJ2:7/%/H:!X)6Y!8;?NXYW=,4)WJ
M4::_Y>.27_;NYE*7)3JU']BU_P#MYV1J>.H?V;OA_P"(Y-%U/X?^'FO(M+DU
M:3[/HT<BI"J[N2%^\PY [U,)\TJD.L+/Y-\M_OT"4E!4Y2VF[+U2YG]R-'3O
M!?P6N[GPQ#<?!_2-..OSRV]N;K2(4VLB%QGY>A X/O6Z@^9Q>G;S)YFZ?M$M
M+G5ZG\&O@%HVL6FDW_@WP79ZI=_\>]G/90+)+_NJ1DUE?6RW-;/EYNA!IOPH
M_9[UF]N[2Q\)>"+NYM$,D\4-I;LT2C()8 < 8/Y4DWR\S7]?\$G>2BNIB^$O
M!/[/WC?Q-K.DZ/X#\)WZZ7;QW$UW;V,#Q88L, @=1M.:(2YJ$J[T2;7W$RER
MU/9/?3\2IX.\)_ OQMJ,ZV'PDTM=)0R"/6IM"1+.7R\AB)"N-O!PQX/:JNE#
MVDG9:?B6[\_(M7>QMQ?#K]G"?2IM4C\->!'TV)S&]VMM;&-6'52<<'@\>U%T
MHJ3Z[!%.;:BMM_+H4F\)_LSKXI'AT^&O!(U0V']IB,V4&#;_ -\-C'3GZ<T)
M2O--?"TG\U<ER249='?\-R[)\._V;HH+*9O#G@017LAAMG-M;@3.#@JIQR>1
M23;:5MTG\GHANZC*71?\.4+7P-^S\-4UJSU#P'X2TD:;>)8F:\L8(TFD9<@)
MD<TJ3]K&ZWYI1M_A'4M2GRR_E4O_  *_^1<\9_"SX)>#K[1;23X8>';NXU-I
M#&D.FPY6*-=TDG3D*".GK0G>3CV_K\=AI-QC)=7%?^!?Y'%>'9_V>-=MH9I_
MA7I>E+=63ZA9->:$D:WD**68QL4PQ"C.WKBHG4C3HRK2^RN9KJ:0IRJ5(TXZ
MWDX_/833KO\ 9SFTV[N]2^%^E:)Y%@=22*^T%4-Q;[@NZ+Y/G.6 P.>:VDG'
M1:OMZNR.:%2-2*FOA?7IIK_7H:MMX8^"QLM.N[[X+V&D07>H0Z?OU#1(X=KR
MX$1Y49#%@..AIJ-YQAU=_E;H7)I0E):V/4D_9@^$+@?\6U\,<_\ 4,B_^)J0
M3OJ._P"&7?A#_P!$V\,?^"N+_P")H&'_  R[\(?^B;>&/_!7%_\ $T '_#+O
MPA_Z)MX8_P#!7%_\30 ?\,N_"'_HFWAC_P %<7_Q- 'DWQ/_ &=?AA8?&SX/
MV5OX!\/0VE[<ZFMS FGQA)@MF64,,<X/(]Z /6?^&7?A$?\ FFWAC_P61?\
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MAD#H5)!]C0!ZU_PR[\(O^B;>&/\ P61?_$T )_PR[\(?^B;>&/\ P5Q?_$T
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MZ7!!?Z?:W<.F:K:74\.X>?)<SI)&2<<J F#]>**[<Z4H1ZV_ 2Y>9LZ?X*_
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M(/@__P *:?\ ^1*L _X2KXZ?]"#X/_\ "GG_ /D2DMP>P'Q5\=#_ ,R!X/\
M_"FG_P#D2F G_"4_'3_H0/!W_A33_P#R)1ML'J*/%7QT_P"A!\'_ /A3S_\
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M ,B4DNXM=;#AXJ^.@'_(@^#_ /PII_\ Y$I^@_4/^$K^.G_0@^#_ /PIY_\
MY$H /^$K^.G_ $(/@_\ \*>?_P"1* #_ (2OXZ?]"#X/_P#"GG_^1* #_A*_
MCI_T(/@__P *>?\ ^1* /*?B9XD^,<GQH^$;W7@GPM%?)<ZG]DAC\0S.DI-H
M=^]OLPVX7D8!R>.* /5AXJ^.N/\ D0/!_P#X4\__ ,B4 '_"5_'3_H0?!_\
MX4\__P B4 '_  E?QT_Z$'P?_P"%//\ _(E "?\ "6?'09_XH'P<![^)Y_\
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M3ZE'05)J+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?Q\1<MJ/PZ4>IM+X?^U*3=AVN*(?CZP!&H?#LC_KTOO_ (Y5=-1*SO87[/\
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MO\:Q\:?A&+N^\"F_-SJ7V,Q6MX(@?LAW^8#)D_+TP1S0!ZM]E^/W_00^'?\
MX!WW_P <H /LWQ^_Z"'P[_\  .^_^.4 'V7X_?\ 00^'?_@'??\ QRCT#3J)
M]C^/N<_;_AWG_KSOO_CE*RV#S%^R_'X?\Q#X=_\ @'??_'*?H ?9OC]_T$/A
MW_X!WW_QR@ ^S?'[_H(?#O\ \ [[_P".4 >4Z_;_ !K'[3/@\27W@7^UCX;U
M(PLEK>>0(O/M=^X>9N+9VXP<=: /5OLWQ^_Z"'P[_P# .^_^.4 'V;X_?]!#
MX=_^ =]_\<H :\/Q]0$G4/AV .I-I??_ !RBZ6[L'4CM'^.]_#YMOJOPYFCR
M1O2UO2,@X//F>M&O7<;)OLWQ^_Z"'P[_ / .^_\ CE CRG]IVW^-B_"*[.K7
MW@5[+^TM,W"SM;P2;OMT&SEG(QNVY]LT >K?9OC]_P!!#X=_^ =]_P#'* #[
M-\?O^@A\._\ P#OO_CE !]F^/W_00^'?_@'??_'* #[-\?O^@A\._P#P#OO_
M (Y0 ?9OC]_T$/AW_P" =]_\<H /LWQ^_P"@A\.__ .^_P#CE 'GLT7Q33]J
MSX9'Q/=^$Y8O[(U;(TFWN4;R=UMYGWW/S9V8[=<T ?5% !0!\2>.M3@TR_\
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MFLK1AS7V2?W_ .1V7Q[UGQ'J?PD^'4CQ75QJFKZS9BYLM/G^S/,DD<K>5NR
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MW(SP9",5&(BJ5"5M9;G8W>M"*VMJ>;_#7QEI-O8>)?$>K^(+F^^)]E>:@?\
MA'Y-2*R;$E<0QBWS]SRPC=,'.>]<5>;HX7VE-7;6I:A[?$*-1V2>AE>$_P!H
MCXG>)O"]K*EUIB2ZGJ%C:PWN^VF:U\]T5T,<3-]W<<;\$XYKN]ES8B-.^FJ?
MR5_QV.!U_==2W1.WJ[?AN7;SQCXMTWQIXUTG4?&G]J7$&L6$-I8/ D;VT<CX
M\U0.<?I7#0?M:%-VU<ZR^2B[?B=K]RO*/]VD_P#R=7_ Y#P/XWUWX0_#[0-1
MA>+4]2OM$GU.>]E@$>V1I3F20#[P7.23Z57.URT_**^\>(CRSJ55K[[LO*QV
M'Q+_ &E=7\#Z%X>_LGQK8>)M1G!NI9K6&V6&YC$D:,FXL "-^,)EN^*WD_WW
M*MDU'[^I"_@SJ/=)F>/BKXGL]?\ $TFH>(/[8,?B*V%KH;QJKP0O;[P5Q\Q4
MMD>F164KT;):VDU]W4TE[RYK_P#+M/YMEW3_ -IOQ;)'=7-OJNFZU+<:??74
MFFP1+NT62%]L:2D<G=_M=P<5;5Z,Y+HHV?FR</:K5BI:;_@OU/5?@=\0_%NN
M:QXDTKQ--;ZK<645K=026D0BXEA60QXX!P6(!/IS6DFE"2ZQ=O4YXR<G1?2:
M;]+,/CKK^O:O\!=?N1H]WX>U1Y(X8[66Z3S&!F1<[XF( 8$]\USS7[VAV<HW
M^\NJW##XF2W4)V]>5V///&WC'Q)\'[.U@L;*WMM4MO#MS=I').]PBR!SMR3R
M1TJYOVM=TH:)^R7WMIFM2T*$*K6\I_A33_,JR_'7XE:;\6+3PD9[&[-JM@TK
M7+VUJ+]9^964.P;*#H(P<G -=.'Y*U63DK+WE_X#I?YF$DXT(=VE+[WL?7<>
M2HS6-K-V->P_% PQ0 8H ,4 &* #% !B@ Q0 8H \:^+7_)>O@G_ -?6K?\
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MU= .^S_'_P#Y_/AU_P" ]]_\70 ?9_C_ /\ /Y\.O_ >^_\ BZ #[/\ '_\
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MG7X?C9_PTSX0$EUX$.K?\(WJ7DLL%YY'E>?:[]PW9W9VXQQC.: /5OL_Q_\
M^?SX=?\ @/??_%T 'V?X_P#_ #^?#K_P'OO_ (N@3$:#X^IR;WX= >]O??\
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M-I%KH.FV]A91+!:V\8CCC08"@4VW*3D915EKN7J"CQG]KG_DB5[_ -A32O\
MTXV] 'LU !0 4 % !0 4 >->,_\ DZCX9_\ 8!UK_P!#LZ /9: "@#Y*\-ZA
MXXM_B)\98]$\,>$]<T+_ (2H/)-XAU9[8K+]BM> @@D7&,<YI:67=E>\E[OS
M.RCU;XJ:A;)IT?P]^'-Q;JOG):KXAD9 ,\,%^R8ZYYQ3:=[RZ$Z):;,NK/\
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M?AV,^FF7W_QZCU+N(-(^/FTC^V?AV 3G']F7O_QZDU?1[$KJ[ZO_ "L#:/\
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MZ#?P[_\ !;??_'J #^SOC]_T&_AW_P""V^_^/4 ']G?'[_H-_#O_ ,%M]_\
M'J #^SOC]_T&_AW_ ."V^_\ CU !_9WQ^_Z#?P[_ /!;??\ QZ@ _L[X_?\
M0;^'?_@MOO\ X]0 ?V=\?O\ H-_#O_P6WW_QZ@ _L[X_?]!OX=_^"V^_^/4
M']G?'[_H-_#O_P %M]_\>H /[.^/W_0;^'?_ (+;[_X]0 ?V=\?O^@W\._\
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MU;P++9?VCIH9;/3[Q9-WVZ#9@M*1C=M)XZ9H ]5_L[X_?]!KX=_^"V^_^/4
M+_9WQ^_Z#?P[_P#!;??_ !Z@ _L[X_?]!OX=_P#@MOO_ (]0 ?V=\?O^@W\.
M_P#P6WW_ ,>H /[.^/W_ $&_AW_X+;[_ ./4 ']G?'[_ *#7P[_\%M]_\>H
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M\8^"-'UB*:2Y2[MUD\V:,1LQ[DJ.!R.W%:UHJ,N4Y<//VD.8ZBLCI"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H \9^+7_)>O@G_ -?6K?\ I$: /91TH 6@ H * "@ H * /&?$G_)V
MG@C_ +%35O\ THM* /9J $)Q0!X;\3X/B1XO^)EEX/L+:+3O %W;K<WVO6TA
M6X4*Q#VP]"_'S#H/K2HI5&YSTY>G>_\ E8JKRJFE'=_@>S:/I-KH6FV]A90K
M!:VZ"..-!@*HZ"KE)R=S*$>56+M26>,_M<_\D2O?^PII7_IQMZ /9J "@ H
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MN[L-:E2W\-?%B[DB2'XT:+*\JEXU3PQ"2ZCJ1B?D575KK_P;$\R6K_K2Y?\
M^%??&;_HKNF_^$G%_P#'J"A/^$ ^,O\ T5S3?_"3B_\ CU3<-!/^$ ^,W_17
M--_\).+_ ./57<6H@\ _&8G'_"V]-_\ "3B_^/4].X7U:'_\*^^,W_17=-_\
M).+_ ./4AA_PK[XS?]%=TW_PDXO_ (]0 ?\ "OOC-_T5W3?_  DXO_CU !_P
MK[XS?]%=TW_PDXO_ (]0 ?\ "OOC-_T5W3?_  DXO_CU !_PK[XS?]%=TW_P
MDXO_ (]0 ?\ "OOC-_T5W3?_  DXO_CU !_PK[XS?]%=TW_PDXO_ (]0 ?\
M"OOC-_T5W3?_  DXO_CU !_PK[XS?]%=TW_PDXO_ (]0 ?\ "OOC-_T5W3?_
M  DXO_CU !_PK[XS?]%=TW_PDXO_ (]0 ?\ "OOC-_T5W3?_  DXO_CU !_P
MK[XS?]%=TW_PDXO_ (]0 ?\ "OOC-_T5W3?_  DXO_CU !_PK[XS?]%=TW_P
MDXO_ (]0 ?\ "OOC-_T5W3?_  DXO_CU !_PK[XS?]%=TW_PDXO_ (]0 ?\
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MU5G6E'H%3^#S+=,^L0>,U #Z!A0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P"/TV).XO\ P@'QH_Z*SI'_ (2B?_'Z!A_P@'QH_P"BLZ1_X2B?_'Z #_A
M/C1_T5G2/_"43_X_0 ?\(!\:/^BLZ1_X2B?_ !^@ _X0#XT?]%9TC_PE$_\
MC] !_P (!\:/^BLZ1_X2B?\ Q^@ _P"$ ^-'_16=(_\ "43_ ./T '_" ?&C
M_HK.D?\ A*)_\?H /^$ ^-'_ $5G2/\ PE$_^/T '_" ?&C_ **SI'_A*)_\
M?H /^$ ^-'_16=(_\)1/_C] !_P@'QH_Z*SI'_A*)_\ 'Z #_A /C1_T5G2/
M_"43_P"/T '_  @'QH_Z*SI'_A*)_P#'Z #_ (0#XT?]%9TC_P )1/\ X_0
M?\(!\:/^BLZ1_P"$HG_Q^@ _X0#XT?\ 16=(_P#"43_X_0!Y1\3/!7Q9B^,_
MPCBN?B9I<]Y+<ZF+6X7PTB" BT)<E?.._*\=1CK0!ZO_ ,(!\:/^BLZ1_P"$
MFG_Q^@ _X0#XT?\ 16=(_P#"43_X_0 ?\(!\:/\ HK.D?^$HG_Q^@!/^%?\
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M/^BLZ1_X2B?_ !^@ _X0#XT?]%9TC_PE$_\ C] !_P (!\:/^BLZ1_X2B?\
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M'LOK7,_YK?<K&9J/P?\ &'@Y_!PM]7N-'NKO5+O45BTW=.EBOV24K&K/GJ<
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M$C0850.@ I7YGS&4596+&:91XU^UQ_R1.]_["FE?^G&WH ]ES0 9H ,T &:
M#- !F@#QOQG_ ,G4?#/_ + .M?\ H=G0![+0 4 ?+'@/X=>(O%OQ/^,MWI7Q
M$UOPG;IXI"&RTVVM)(V86-K\Y,L3MDYQUQP*-!)W5COO^%&^,R0?^%V>*_\
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MXZ=_\CT[:_)+[NHE:R:[W_X H^!?C-0!_P +L\5\=!]AT[_Y'IBMMZW,+7O
M^N>&=5TG3]0^//BFWO=5F-O:0FRT[,CA2V!_H_H#6:E&4_9K<I^Y!SEL;O\
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M$(1<$#:.3N(XZ9/% 'JX^.7C/_HB'C#_ ,"]._\ DF@ _P"%Y>,_^B(>,/\
MP+T[_P"2: #_ (7EXS_Z(AXP_P# O3O_ ))H /\ A>7C/_HB'C#_ ,"]._\
MDF@ _P"%Y>,_^B(>,/\ P+T[_P"2: #_ (7EXS_Z(AXP_P# O3O_ ))H /\
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M97;+']N?'W_H4_ /_@]N_P#Y&IC#^W/C[_T*?@'_ ,'MW_\ (U "?V[\??\
MH5/ /_@]N_\ Y&H 7^W/C[_T*?@'_P 'MW_\C4 )_;OQ]_Z%3P#_ .#V[_\
MD:@ _MWX^_\ 0I^ ?_![=_\ R-0 O]N?'W_H4_ /_@]N_P#Y&H /[<^/O_0I
M^ ?_  >W?_R-0 ?VY\??^A3\ _\ @]N__D:@!/[=^/O_ $*G@'_P>W?_ ,C4
M 4-<\=_&[PWILU_J/AGP%!:Q#+N-:O&P/7 M2:76Q45S7L6-/\6?'75;*"[M
M/#'P_GMIT$D<J:[=E64C((_T;TJY1<969E"7,KLL?VY\??\ H4_ /_@]N_\
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M_P"#V[_^1J #^W/C[_T*?@'_ ,'MW_\ (U !_;GQ]_Z%/P#_ .#V[_\ D:@
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MUZ;J]+O[EN9>B?M7:=J$6MF[\-:Q:7%GK<FAV=JD:22ZA,J[SY0W8R%!)!P
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MU_R7KX)_]?6K?^D1H ]E'2@!: "@ H * "@ H \9\2?\G:>"/^Q4U;_THM*
M/9J $)Q0!XC\4OC/K%M\0;/X:^&='NU\3:C"MS'JL\.;."VR1)+N!Y92,;3C
MK2IQ=65_LK?YE3_=0YGN]CUOPUHYT+1[>S:XFNWC7Y[B=LO(W4L?<GFKDTWI
ML8PO:[-2I-#QG]KG_DB5[_V%-*_].-O0![-0 4 % !0 4 % 'C7C/_DZCX9_
M]@'6O_0[.@#V6@ H ^)]2U#3M4\:?%S0KWPUXVO;JV\9QZE9:SX6TO[3]DG6
MQM@I#$[=P&<J01@BH<;R4D[-?U8N,^5.-MS)E\$^';T3W5_X6^+.HZ[+J/\
M:)U2Z\*0.V_REB*^65\L@H@'W<U5E>-NA#;<7"^]OP.LO)O#NH6EQ!+X ^**
M_:-'&BN8?#2Q#RMP;<%7"ALCL,>U2XIW\Y*7S6R]._YDRBI.[[-??^IB6/AS
MPMINIZ[<6_@/XGQVVKK/YUN?"<+,CRQ>6[)*09 <?[6*W4VDT_ZUN%O>B_Y2
M;QQI/A[QUK6AW]UX-^+4":5%:Q);)X<1D?R'1T.7R5)*#.TC/-8P7)4E43UD
M[_UY%R]Z*AT2DO\ P+?YKI^HZ]L=+FO[R]LO#GQ@TVY?66UVUD@\.1G['<-&
M8WV!@0593T;--<\5%)_#'E_[=[>@FDXN-M[?@;_@35_#_@+4M%O[/X?_ !3N
M+K3+>Y@WS^'_ /7F=P\CO@CG<.V!S51?)SJ.TE%?^ [6]>I,TZD_:5'>5V[O
MS.C\1_%#2_$OB_P[XBN/AU\3ENM#6X6"-/#I".)D"-N^;/0<8I1]WGM]M6?_
M  "WJDNSN>=:%I/A[PY_;2Z=X)^)L$&I>;MC;P=;.8!(26 =D+,.2,,3Q6<8
MJ-%45LK>MD[I>B!OFJ^U>^OXJPNDZ5H6C+I?V?PK\7@;/3;O2Y-WAY<7$-QM
M+@CHN"H("X Q5R]Z$H/[22?G84?<ES+I+F7D^WH6[U/#[:7?V]OX#^*GFW%U
M:WJE_#_ EMP!&.HX.!G\:RJ72BX:-<W_ ),K/_@&5.G'WE+9I+[M58\\_9QN
MO&?PTDO[6_\  _Q*TBPEC7,L.@Q3S22+-O&Q@H*QE=RE6W'YN"*[X3O2M4U=
MT_N5C.<&ZM[^1[-\1O%?A[XH:A9W6L?#?XGG[-8W-BL2>'B%99MFYC\WW@8U
M(]ZX*E)5$UM?L=\*LH1Y.APUEX/\&:?H TRV\!_%J(KIL>GK=?V#NE#+*\HG
MR3S(7D8DGCVKHJ2]I-3>EFG\UL<\%R4G1OHVV_._^70V]$DT73=0BU.]\'?%
MG5]9^WC4)]0N?#JJ\[K'Y:JP3"A0O' '2ETBNR:^_<+>[*"?Q<O_ )+M_P $
MH2:3X>"VJ6W@_P"+EI%%I=[I$J)X>4B>"Y(+ALYP00"",=**;=."IK6*MH_+
M8U<KU'5^TW?^O(V+B\\.3^+Y?$9^'WQ3-V]S;W1A/A_]V6A@\E1US@KU]ZBS
MLNMN:U_[RLR''GI^P;LGRZ]?==U^)5_9W\3Q_![0-;MY_AE\1?M6I7\L^$T!
MG\J D^7$&W]%R<?6E&/+A:="]W%:WZMO7\"9OVF*G6VOLELK=CC;'X:^&M.\
M6Z-KUMX<^,4,VCW3W=G GAN)44L[,5<XS(,NV-Y.-QQBMJ$O8;:JUK/^MS6K
M+VO-?[6YZ-XYU+PC\2/%,FM^(OA?\3=1D_L_^SXK9] 810J2Q+J P^8[L'_=
M%<SI)J:O\=K_ "U0N9V@OY6W]^FIA:7IWAK2]"DTL>"/BU/$Z64?F3:!EPMM
MM\L9SWV#-;5?WLI2?VI*;]5I;T_'S)[]N64+=E+>WFMU^HNKZ;X5UG1#I<_@
M+XK_ &<SWMQE?#_.ZYC:-^_0!B1]!2NXV:W4%#_MU--?D1R+G4^TG+YM6MZ?
MJ84_@_2+Z.^>_P!%^,E]?7MU'=375QX;A;?LA\I4,>W8P"^JGGFG4][E\FW]
MYT*HXWMU-71]!\)Z+I>G6,7@7XL2)90V<*,_AX?,+:3>A.#CDCFKE-O$?6;:
M]NFUOZU.:<.:$8?RW7WNY?\ @?XFC^&7BOQUK<OPR^(L;ZYJ7F6L*: S+#:J
MN40?/Q\[2''^U4TFZ>$A1[-^NOZ+H%2%\2ZG2WR/8_\ AI>+_HF?Q'_\)UO_
M (ND:!_PTO%_T3/XC_\ A.M_\70 ?\-+Q?\ 1,_B/_X3K?\ Q= !_P -+Q?]
M$S^(_P#X3K?_ != !_PTO%_T3/XC_P#A.M_\70 ?\-+Q?]$S^(__ (3K?_%T
M '_#2\7_ $3/XC_^$ZW_ ,70 ?\ #2\7_1,_B/\ ^$ZW_P 70 ?\-+Q?]$S^
M(_\ X3K?_%T '_#2\7_1,_B/_P"$ZW_Q= !_PTO%_P!$S^(__A.M_P#%T '_
M  TO%_T3/XC_ /A.M_\ %T '_#2\7_1,_B/_ .$ZW_Q= !_PTO%_T3/XC_\
MA.M_\70 ?\-+Q?\ 1,_B/_X3K?\ Q= 'E/Q,_: COOC1\(KP?#[QY#]DN=3;
MR)M"999MUH5Q&N[YB.I]!0!ZM_PTO$/^::?$?_PG6_\ BZ #_AI>+_HF?Q'_
M /"=;_XN@ _X:7B_Z)G\1_\ PG6_^+H /^&EXO\ HF?Q'_\ "=;_ .+H /\
MAI>+_HF?Q'_\)UO_ (N@ _X:7B_Z)G\1_P#PG6_^+H /^&EXO^B9_$?_ ,)U
MO_BZ /*=?_: CF_:9\(:E_PK[QX@A\-ZE#]E;0F$[[I[4[E3?RHVX)[$CUH
M]6_X:7B_Z)G\1_\ PG6_^+H #^TO$?\ FFGQ'_\ "=;_ .+H KM^T39&X%P?
MA?\ $3SPNT2_\(VVX#TSNI+W=NHGK:_0G'[2\7_1-/B/_P"$ZW_Q=.PQ?^&E
MXO\ HF?Q'_\ "=;_ .+H \I_:=_: 37/A%=VB_#[QY9$ZEIK^=>Z$T48VWT#
M8W;NIQ@#N2!0!ZM_PTO%_P!$S^(__A.M_P#%T '_  TO%_T3/XC_ /A.M_\
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MNH__ !F@ _X:O\$?\^?BO_PE=1_^,T '_#5_@C_GT\5_^$KJ/_QF@ _X:O\
M!'_/IXK_ /"5U'_XS0 ?\-7^"/\ GT\5_P#A*ZC_ /&: #_AK#P1_P ^GBK_
M ,)74?\ XS0 #]K#P.>EIXJ/_<JZC_\ &:/,/(/^&K_!'_/IXK_\)74?_C-
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MPGE;B/E.2!@<9ZB@#U?_ (:O\$?\^GBK_P )74?_ (S0 A_:N\$'_ET\5_\
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MXJB2J7CLSUK8OI0 ;%]* #8OI0 ;%]* #8OI0 ;%]* #8OI0 ;%]* #8OI0
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M =:_]#LZ /9J "@#XSN=0\+77CKXD6>J^--$\-ZII/Q AUJ*UU.\BB><1Z?
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M_P#P;P?_ !5 !_PT'\,/^BA^%_\ P;P?_%4 '_#0?PP_Z*'X7_\ !O!_\50
M?\-!_##_ **'X7_\&\'_ ,50 ?\ #0?PP_Z*'X7_ /!O!_\ %4 '_#0?PP_Z
M*'X7_P#!O!_\50 ?\-!_##_HH?A?_P &\'_Q5 !_PT'\,/\ HH?A?_P;P?\
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MGPZ]C%X8U2&2Y&J0F-':>U*J6W8!(4X'L: /7?\ AH/X8?\ 10_#'_@W@_\
MBJ #_AH/X8?]%#\+_P#@W@_^*H /^&A/A?\ ]%#\+_\ @W@_^+H 3_AH3X7_
M /10_"__ (-X/_BJ %_X:#^&'_10_"__ (-X/_BJ /(_VJ/CA\/-7^#MY;6/
MCGP[>7!U/3'$4&IPNY5;^W9C@-G  )/H : /7/\ AH/X8?\ 10_#'_@W@_\
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M_0JZ+_X+X?\ XF@ _P"%9>$/^A5T7_P7P_\ Q- !_P *R\(?]"KHO_@OA_\
MB: #_A67A#_H5=%_\%\/_P 30 ?\*R\(?]"KHO\ X+X?_B: #_A67A#_ *%7
M1?\ P7P__$T '_"LO"'_ $*NB_\ @OA_^)H /^%9>$/^A5T7_P %\/\ \30
M?\*R\(?]"KHO_@OA_P#B: #_ (5EX0_Z%71?_!?#_P#$T '_  K+PA_T*NB_
M^"^'_P")H /^%9>$/^A5T7_P7P__ !- !_PK+PA_T*NB_P#@OA_^)H /^%9>
M$/\ H5=%_P#!?#_\30 ?\*R\(?\ 0JZ+_P""^'_XF@ _X5EX0_Z%71?_  7P
M_P#Q- !_PK+PA_T*NB_^"^'_ .)H /\ A67A#_H5=%_\%\/_ ,30!X_\5?A]
MX7@^.?P8AC\.:3'#-=:J)(UL8@K@61(W#;S@\\T >OCX9^$/^A5T7_P7P_\
MQ- "_P#"LO"'_0JZ+_X+X?\ XF@ _P"%9>$/^A5T7_P7P_\ Q- !_P *R\(?
M]"KHO_@OA_\ B: #_A67A#_H5=%_\%\/_P 30 ?\*R\(?]"KHO\ X+X?_B:
M#_A67A#_ *%71?\ P7P__$T >/\ B+X?^%T_:J\%VR^'-)%N_A?5':(6,6QF
M%Q:8)&W&1D\^Y]: /8/^%9^$/^A5T7_P7P__ !- "'X9^$/^A5T7_P %\/\
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MX:\^$/\ T/.G_P#?$O\ \30 ?\->?"'_ *'G3_\ OB7_ .)H /\ AKSX0_\
M0\Z?_P!\2_\ Q- 'E'Q,_:@^%VH_&GX17]OXQLI;.PN=3:YE"28C#VA5<_+W
M/% 'JX_:\^$'_0\Z?_WQ+_\ $4 '_#7GPA_Z'G3_ /OB7_XF@ _X:\^$/_0\
MZ?\ ]\2__$T '_#7GPA_Z'G3_P#OB7_XF@ _X:\^$/\ T/.G_P#?$O\ \30
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M#3EY8\\MCO/#EG>1Z1;C5O(EU KNF,* (&/)"^PZ"M9<M[)F$&VKLT_LT/\
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M /12?"O_ (.+?_XN@ _X:4^$_P#T4GPK_P"#BW_^+H /^&E/A/\ ]%)\*_\
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M2O\ P"B_^)H /^$#\-?]"]I7_@%%_P#$T '_  @?AK_H7M*_\ HO_B: #_A
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M (; ^$7_ $.$7_@'<_\ QN@ _P"&P/A%_P!#A%_X!W/_ ,;H /\ AL#X1?\
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M"$E*K'JG%??N9\W,_=[-_<96M?MBZ5I&DQ.OABYFU<27$5SIDD\<30F"3RY
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MJYZ?]GB_YYK^52,/L\7_ #S3\J #[/%_SS3\J #[/%_SS3\J #[/%_SS3\J
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M@]* #8/2@ V#TH -@]* #8/2@#QKXM*/^%]?!+C_ )>M6_\ 2(T >RA!CI0
M;!Z4 &P>E !L'I0 ;!Z4 &P>E !L'I0!XWXD _X:T\#_ /8J:K_Z46= 'LFP
M>E  5 [4 >/_ !-^/EEX7\5P>!M#B?4?'M\J-:Z>\;+&L;$@SLV,;%QSC/)
MI4X5:\^6FM%JWV_X<T<53C[2>QZ;X;L;RPTBWAU"[-]>A09KC;M#.>N!V'H/
M2J;3>AA#F<;R-/8/2D6>-_M< #X)7N/^@II/_IQMZ /9-@]* #8/2@ V#TH
M-@]* #8/2@ V#TH \;\9J/\ AJ?X9C_J ZU_Z'9T >S4 % 'Q@WB[X8)\1OB
M?H?CW5WLY['QS#K$-L+2699"EC;A=^V-E*DDY'!XI**4N9;C3:IRAW+7Q8\1
M_ 3XN7D,VI>.-1T^..S^PFVL+&98FBW;L;6MVVG)QE<''%.G>G66)3U07<J7
MLT2ZYXC_ &>?$OAK4-!U+Q1=7>FW^HKJ<\+V5R=T@8-M_P!3]W(_^O6?)>2F
MMTVUZO<3;E-R?5)/Y;%>\U[X!ZE9Z?;WGCS5KK[#;1VD<LMK<%]B3QSKD^1S
M\T2CZ9K>E-TYRGU=K_+8SC34;<O2Z7H]SRWXNCX?ZIXQMM8\&^-VC#->7+M<
M0W$9BN9YA*7(-JXDC!'W.#_M4J,G&I&4MXVM\MCIK252@Z3V_P"!;\CVCQA\
M5?A-XZ_X1>\NOB7JNC:WH:82]T:QGC,C%0'!#V[#!QTK-JU=XB.S35O)M-_D
MC%+FI+#3V34OFDTG]S9CZ9K_ ,"=/\11:C)\0]:O;.&\.HQZ5<6DYMENBNTS
M8%N&W8R>N,L>*()4Z:A'HG'Y2W7S^_L$ES3=1[MJ7SCL_E]W<V+/XB?!"W^&
MFN^!IO'FI7NBZL9]PGLK@R0I*Q9D0B ?*"3C(-2XWITH/["2^XJ@_JU9U8[M
MM_-[AX[\?_ CQSX=T?1CXPNM&M=+D,D']FZ;,@8E"IW(UN5;()ZCKS15A[>H
MI/I?\=Q46Z%'V:V,/0M0_9YT'3].M(/&FI.EC%:11M):7&2+>3S$SB =3U_I
M71.I*I7EBWN_SY7'\FU^.Y,HN=.,)/1:+YR4OS2?X;%VT\5_ ?3M9M-2LO'F
MJVLT)NPZQV=QMG2X<NZ/FWZ!CD8QTKDE3C.G[*HKQMR_+MW^>Y;DU\/\W-_V
M]W_X&Q5@U?\ 9\M-%U#38_&6H^3>1V,3DVEQD"UE,L6/W'=CS[5V2JRDU)O5
M?Y6)HI4[+U_'<XG]GWQEX5^%7Q"OM1O?'$1T>;[494%M<3>>9)=T91?LRM$%
M!.07;.:5.RI<@8CWZD:BW1L>.=*_9Z\>Z_?:E=?$37;-+N\%^UI:6DRQK.%5
M=P)MBV"%&5)(]JPH7P[@X_9V_KK\Q5K58N#V9Z7XK^+WP-\;C0!K'BRXNUT=
M95C5K"YQ,)(3$WF#R>?E)Z8YI5:<:[;?4TIRE2I.FNIPFEI^SIHN@Q:79>--
M5A2.QN;'[0+:Y,KB9T=W8F#ELHN.V.QJJRE4C%-[67R0H/V<91[Z_,2R7]GB
MU\-G1W\<:K/$S7SM,]E,KLUTCK*<+;@#ASC XJZ;]E)SCNTH_)2YDOOU[_(B
MSYHS;UC9KY+E7X:?\$V=>\4_ ;7)-0F'CK5+&[NUL1]IMK2X#Q?9,^45S 1S
MDYSG\*J,W&I3JQWIMM>3DK2];KOMT"2BZ?LNEDON=U^)!#XA^ UMXFUC6(O'
M6H*=69Y+NV.F2,CR/$(V<,;8N"5 Z,!FLZ?+3IJC%>['9?._KOW+=FXR>Z_(
M@UK4?V?]9L[2#_A.M6M'M=-L]+BE@M;C=Y5LS-&2#;D$DN<Y&#Z455[:]]FV
MWZM6?X#4E[T;:-6%\.ZA^SWX;T>33X/&VIS+):W=H\LME.&9;EV>0_+;@ Y8
MXP,"JK-U^;GZQ4?^W5LOEWW[ETZLJ52%6.\'S+U[]G\Q]UKGP'GOM2:/X@ZQ
M;:?JM@FG:EID=I/]GO8UC:-2X-N3D!CT(J97=/V;[M_-JU_N^1A2A&BXNGHH
MZ?*]^OF==\+?C/\ !KX6Z=/9VGCF[U%9&4B2ZTJ564 8 _=VZ9_'-:.;Y5%D
M\BBU;IL=S_PU[\)O^AJ/_@NNO_C50:!_PU]\)O\ H:C_ ."ZZ_\ C5 !_P -
M??";_H:C_P""ZZ_^-4 '_#7WPF_Z&H_^"ZZ_^-4 '_#7WPF_Z&H_^"ZZ_P#C
M5 !_PU]\)O\ H:C_ ."ZZ_\ C5 !_P -??";_H:C_P""ZZ_^-4 '_#7WPF_Z
M&H_^"ZZ_^-4 '_#7WPF_Z&H_^"ZZ_P#C5 !_PU]\)O\ H:C_ ."ZZ_\ C5 !
M_P -??";_H:C_P""ZZ_^-4 '_#7WPF_Z&H_^"ZZ_^-4 '_#7WPF_Z&H_^"ZZ
M_P#C5 !_PU]\)O\ H:C_ ."ZZ_\ C5 !_P -??";_H:C_P""ZZ_^-4 '_#7W
MPF_Z&H_^"ZZ_^-4 '_#7WPF_Z&H_^"ZZ_P#C5 'E'Q,_:A^&>H_&CX17]OXD
MWVEA<ZFUS)]AN1L#VA5>#'DY/'&: /5_^&O?A-_T-1_\%UU_\:H /^&OOA-_
MT-1_\%UU_P#&J #_ (:^^$W_ $-1_P#!==?_ !J@ _X:^^$W_0U'_P %UU_\
M:H /^&OOA-_T-1_\%UU_\:H /^&OOA-_T-1_\%UU_P#&J #_ (:^^$W_ $-1
M_P#!==?_ !J@#RCQ!^U#\-)_VF?"&K)XDW6%OX;U*WEE^PW/RN\]J5&/+R<A
M3R!VH ]7_P"&OOA-_P!#4?\ P777_P :H 0_M>_"8_\ ,U'_ ,%UU_\ &J ,
MN7]I7X(3Z]%KDFM0OJ\4)MX[UM+NO-2,G)4-Y60":%[J<5L]_D$O?2C+9&H/
MVN_A*G3Q4?\ P77?_P :H\PW=Q?^&OOA-_T-1_\ !==?_&J /*?VG?VH?AGX
MC^$5W9:?XD,]TVI:8X3[!<K\JWT#,<F,#A5)_"@#U;_AK[X3?]#4?_!==?\
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M5Q\*/BU::Q#&L/F:>HMDD16!"NB7(##(Z&LX0C3<W'[5K^=DTOP;+DW+EO\
M9O;Y[G/_ /".>#$T^^LX/@E\3[5+YX9KF2W@5))9HG5XYF87&3(&4?/UZ^M7
M!NG%0B]$2U=N3W9JK<:)'KM]JL7PC^*\,M^K"[@CC58)V9"C.\?VC!8@G+$9
M/%1R+E<.C-'-N49O>.B)M8OO#>O6&FV5[\$/B/-;:=92Z?;H;&+Y89"A8?\
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M ;5%O)%"/.-:T[>RCH"?,SBE%*":CI<4DIM.70MCXP_$@=/@AK/_ (/-/_\
MCE,8O_"XOB3_ -$0UG_P>:?_ /'* #_A<7Q)_P"B(:S_ .#S3_\ XY0!Y1K_
M ,4_'S_M,^$+Q_A!JT=['X;U*-+ ZQ8EY4,]J6<,)-H"D 8)R=P]* /5_P#A
M</Q)_P"B(:S_ .#S3_\ X[0 ?\+B^)/_ $1#6?\ P>:?_P#'* $_X7%\2?\
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M&@J=2--N[:;7HEU\S8UG]JC5/#WC#3_#DGAI]2OH[:VGU0V"SRB,R]HB(R"
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MX!VO_P D4 '_  T'K7_1'?B!_P" =K_\D4 '_#0>M?\ 1'?B!_X!VO\ \D4
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M]_X4=C_\50 ?\+9^*?\ T1*^_P#"CL?_ (J@ _X6S\4_^B)7W_A1V/\ \50
M?\+9^*?_ $1*^_\ "CL?_BJ #_A;/Q3_ .B)7W_A1V/_ ,50 ?\ "V?BG_T1
M*^_\*.Q_^*H /^%L_%/_ *(E??\ A1V/_P 50 ?\+9^*?_1$K[_PH['_ .*H
M /\ A;/Q3_Z(E??^%'8__%4 '_"V?BG_ -$2OO\ PH['_P"*H /^%L_%/_HB
M5]_X4=C_ /%4 '_"V?BG_P!$2OO_  H['_XJ@ _X6S\4_P#HB5]_X4=C_P#%
M4 '_  MGXI_]$2OO_"CL?_BJ #_A;/Q3_P"B)7W_ (4=C_\ %4 '_"V?BG_T
M1*^_\*.Q_P#BJ #_ (6S\4_^B)7W_A1V/_Q5 !_PMGXI_P#1$K[_ ,*.Q_\
MBJ #_A;/Q3_Z(E??^%'8_P#Q5 !_PMGXI_\ 1$K[_P *.Q_^*H \I^)GQ,^(
MMQ\:/A%//\([RVNH+G4S!:G7;-C<$VA# ,#A=HYYZT >K?\ "V?BG_T1*^_\
M*.Q_^*H /^%L_%/_ *(E??\ A1V/_P 50 ?\+9^*?_1$K[_PH['_ .*H /\
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M?O=D<$9J-&$V[\Z5O-\UI+Y+4^IQT%<9T(=B@88H ,4 &* #% !B@ Q0 8H
M,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* /&OBT/\ B_7P2_Z^
MM6_](C0![* ,4 &* #% !B@ Q0 8H ,4 >->)!_QEIX(_P"Q4U;_ -*+.@#V
M7 H #Q0)GAWQ.\:^.]1^)MC\/O#FBSZ;8WT"W<WBU"'CMX Q61 ","4X&W.>
M":5)>TDY2T42ZEH03CJV>Q:%H\&A:9!90%VCB7&^5R[L>[,3R23R352=W=&<
M4TM2_BD4>-?M< #X)7N!C_B:Z3_Z<;>@#V7 '84 &* #% !B@ Q0 8H \;\9
M@?\ #5'PS_[ &M?^AV= 'LM !0!\F>%=>\0VGQ/^+EKI_P +I?'%G!XO6\CO
M!J-K L,XL;8#"RD'< <[A_>I65[CN[-=S<UF#5_$,*1:E^S-'?1K,]RJSZKI
MK 2-]Y^6ZGN>]$4HZQT"[NWU>_F27']MW>MVFL3?LU+)JEHJK!>-JNFF6(+]
MT*V[(QVJ^9W;OON):)16R-F#QKXXM]-NM/B^ %REC=%S/;KK>GA)=XP^X;\'
M/>HLK*/1;"A[LN:.C*7]M>*6C=/^&='*.\<C+_;&G89H_P#5D_-U7 QZ4))6
MMTO;ROO]_7OU%RK73>WX;?=T['!>,O"$FK6^F+>_L[+IVGVNIKJ$MNNL:8D5
MW+L>-5D!;YO]:2/>BFE&5H[]BOLU'WW\SJY[;5;F#3(9?V9HWBTT;;)3JFFX
MMQG.$^;CGFG_ ,O?:=>XDDJ?*MB:9M<N=:O-7E_9K635+V,PW-VVK::9)D(P
M58[N00 *GECRN%M'TZ&BG)24T]5L^J]")[?5Y='DTI_V9T;3I%17M3JNF[&"
M8V C=VP,?2J?O/F>_P#P+?EIZ:&:2226R_4MV5[XBTVSCM+;]F_R+:.VDLTB
M35]-"K ^-\8&[[K8&1WQ3;;W\OPV^[IV'MMWO\^_KYDFGZMXGTK7Y-<L_P!G
M-[?6)$\M[Z/6-.65E]"P;.*4?=34=+[^?KW$TI--K8T[WQYX^U&]M+NZ^ EY
M<7-HQ>WEDUS3RT1(P2IW\<<4DDI<R6NWR[#W7+T,Z/6/%$5_<7R_LZ.MY<>9
MYLZZQIP=_,55DR=W.X(H/KM'I36B45L@6FWK\^XT:OXH%LUN/V<V$#01VK1_
MVQINTQ)]Q,;ONKV%'EYW^??U\Q-)N[WV^78S6L=3?6KC5V_9CA;5+@.);PZI
MIADD#J5?+;NX)!]<T=&NY?,V[WU)-(@U;0(WCTW]F6.R1Y%E98-5TU0S@$!C
MANH#$9]Z&E-*,M4*[U\RO9IXPL/B!9>*[?X%:A!=V.F?V5:6\>NZ<L<$6\,=
MH#<=,?2B$I1=2;=W/=]7ZOJ9SA%QA%+2.WE?>W:_4[D?%OXG?]$1U+_P?V'_
M ,706'_"W/B?_P!$1U/_ ,*"P_\ BZ #_A;GQ/\ ^B(ZG_X4%A_\70 ?\+<^
M)_\ T1'4_P#PH+#_ .+H /\ A;GQ/_Z(CJ?_ (4%A_\ %T '_"W/B?\ ]$1U
M/_PH+#_XN@ _X6Y\3_\ HB.I_P#A06'_ ,70 ?\ "W/B?_T1'4__  H+#_XN
M@ _X6Y\3_P#HB.I_^%!8?_%T '_"W/B?_P!$1U/_ ,*"P_\ BZ #_A;GQ/\
M^B(ZG_X4%A_\70 ?\+<^)_\ T1'4_P#PH+#_ .+H /\ A;GQ/_Z(CJ?_ (4%
MA_\ %T '_"W/B?\ ]$1U/_PH+#_XN@ _X6Y\3_\ HB.I_P#A06'_ ,70 ?\
M"W/B?_T1'4__  H+#_XN@ _X6Y\3_P#HB.I_^%!8?_%T '_"W/B?_P!$1U/_
M ,*"P_\ BZ #_A;GQ/\ ^B(ZG_X4%A_\70 ?\+<^)_\ T1'4_P#PH+#_ .+H
M /\ A;GQ/_Z(CJ?_ (4%A_\ %T '_"W/B?\ ]$1U/_PH+#_XN@ _X6Y\3_\
MHB.I_P#A06'_ ,70!Y3\2_B=\0[CXT_".>?X0ZA;7,%SJ9@M6UNR8W)-H0P#
M!\+M'//7M0!ZM_PMSXG_ /1$=3_\*"P_^+H /^%N?$__ *(CJ?\ X4%A_P#%
MT '_  MSXG_]$1U/_P *"P_^+H /^%N?$_\ Z(CJ?_A06'_Q= !_PMSXG_\
M1$=3_P#"@L/_ (N@ _X6Y\3_ /HB.I_^%!8?_%T '_"W/B?_ -$1U/\ \*"P
M_P#BZ /*-?\ B=\0Y/VF/"%VWPAU!+Z/PWJ<<=C_ &W9%I4,]J6DW[]H"D*,
M$Y.[CI0!ZO\ \+<^)_\ T1+4O_"@L/\ XN@ _P"%M_$[_HB.I?\ @_L/_BZ
M$_X6S\3<Y_X4AJ.?7^W[#_XN@!?^%M_$[_HB.I?^#^P_^+H /^%N?$__ *(C
MJ?\ X4%A_P#%T >4_M/?$[XB:C\(KN&^^$6H:7;G4M,8W+ZW92 $7T!5=JN3
M\Q 7/;.3Q0!ZM_PMSXG?]$2U+_PH+#_XN@ _X6Y\3_\ HB.I_P#A06'_ ,70
M ?\ "W/B?_T1'4O_  H+#_XN@ /Q=^)HZ_!/4O\ PH+#_P"+H /^%N?$[_HB
M6I?^%!8?_%T '_"W/B?_ -$1U+_PH+#_ .+H \\F\>>,]<_:L^&2ZQ\.+SPZ
MITC5HM\NJVL^(V:UW28C8\*0HQU.X8Z&@#ZIH * /DF;XB:Y\-;GXOZGHFGB
M[,GCN.WN[@Q/*MG UA;;IRB LP7 X [UE?\ >)2TB:PAS*5MSM;K]KGPCH%S
MHVFZAJ$&I7=S;0SW-YILZ&"(2'"MAB&;GLH)'>K:YISIQV3M?Y7.?6%-3J[]
MD=#9?M%:3>:9?ZM_96I1Z#;W"6T6J,J^5=,91'\@SNP&;J0..E&T(SEN]OF[
M%*U24HPVCO\ =<-7_:.T33]8BTJUT[4=4U.75#I,=M;(,F4(78Y) "A03SZ4
M0;G4=-+9-_<*<E"WFD__  +8XRU_:OEM?$@L+SPW>W6DQ:/<:Q<:M;L@$212
M!6_=[LD#H<<Y]J=-\U)U9Z1]W7_%L5*-IN,-9<THV\T3_$32#^TU##;>%?$+
M6$.@WMK<R^9;AX+B4.DA&[.054$8QU85I1C["O#$RV]Y?+O_ )$N:E%TEN?0
MT,92-0[;F Y.,9J11TCJ2XI%AB@ Q0 8H ,4 &* #% !B@ P* # ]* #% !B
M@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q
M0 8H ,4 >-?%H#_A?7P3X_Y>M6_](C0![* ,4 &* #% !B@ Q0 8H ,4 >->
M) /^&M?!' _Y%35?_2BTH ]EP* #% !B@ Q0 8H \:_:Y'_%D[W_ +"FE?\
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M ()+[_XS0 ?\-??"[_H-7_\ X)+[_P",T '_  U]\+O^@U?_ /@DOO\ XS0
M?\-??"[_ *#5_P#^"2^_^,T '_#7WPN_Z#5__P""2^_^,T '_#7WPN_Z#5__
M ."2^_\ C- 'E/B#]J#X=3_M,^#]635[TV,'AO4K>23^R+P,'>>U*C;Y6X\*
MW(&!B@#U;_AK[X7?]!J__P#!)??_ !F@ _X:^^%W_0:O_P#P27W_ ,9H /\
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M>*9XSM=8W#%#Z$#H::TUZ=Q/?ED<+8_'3PEJ.K:QIUI<37$^DRFWNVC@.Q)
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M Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% 'C7Q: _X7U\$^/^7K5O\ TB-
M'LH'% !B@ Q0 8H ,4 &* #% 'C7B0#_ (:T\$<?\RIJW_I19T >RX% !B@
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M:JENX67D_=U79^9U=W\,=37]EG6_!UC+Y^N7<<[06>H7]OE6:0L$WIA%7G
M& .*VJU''$4*T=?9SC)^:ZW"";]K?2^WD<[XK\#>./%LNN^)!H6DZ??W5G:Z
M2FBSZE;SF6%94>64N<QE@%(4$>E9Z04HK7GJ<_\ AM"RMVN]7YZFT+.<'+I&
MS]>_KYG.Z7^SSXHU/PKI]CKC6TLECH6IVUI%)J<7[BZD>-K8C80HQM;! PM:
MVBX0N]5R7?IO]_7N<M/G3GVE*Z\EV7EY"?$+P!J/@BYM+"STRWUC0KWQ';36
MNC0ZBD<<J?9SYP8DX4%^2#P:Q4N9TX6UO-/T^R_ET['5RI4:TEVC;UOK]_4I
M#X ^.+F;PS]ON3_9<4+J--LM2M2=*8RHRA7E!S@ _,F#V[T4O<DX57?2.OFG
MK]_7N92DVG./5O3M?;[CLM:^!M\/!?BP^3'J7B2^UA;FUF_M& N\*Q*JB0R9
M5DW!LH1WS0TO9TK;IN_S?^0Z*=YQGLU9>I]'?#N]EL_!.B0:W+IUIJT5I$ES
M!:S)Y4<@4!E7!Q@'TK>K9SNB*:<59G2?VSI__/\ 6W_?Y?\ &LC4/[9T_P#Y
M_K;_ +_+_C0 ?VSI_P#S_6W_ '^7_&@ _MG3_P#G^MO^_P O^- !_;.G_P#/
M];?]_E_QH /[9T__ )_K;_O\O^- !_;.G_\ /];?]_E_QH /[9T__G^MO^_R
M_P"- !_;.G_\_P!;?]_E_P : #^V=/\ ^?ZV_P"_R_XT ']LZ?\ \_UM_P!_
ME_QH /[9T_\ Y_K;_O\ +_C0 ?VSI_\ S_6W_?Y?\: #^V=/_P"?ZV_[_+_C
M0 ?VSI__ #_6W_?Y?\: #^V=/_Y_K;_O\O\ C0 ?VSI__/\ 6W_?Y?\ &@ _
MMG3_ /G^MO\ O\O^- !_;.G_ //];?\ ?Y?\: #^V=/_ .?ZV_[_ "_XT ']
MLZ?_ ,_UM_W^7_&@ _MG3_\ G^MO^_R_XT ']LZ?_P _UM_W^7_&@ _MG3_^
M?ZV_[_+_ (T ']LZ?_S_ %M_W^7_ !H /[9T_P#Y_K;_ +_+_C0!XY\6-5LG
M^/'P587EN56ZU;<PE7 _T(]>: /8QK-A_P _UM_W^7_&@ _MG3_^?ZV_[_+_
M (T ']LZ?_S_ %M_W^7_ !H /[9T_P#Y_K;_ +_+_C0 ?VSI_P#S_6W_ '^7
M_&@ _MG3_P#G^MO^_P O^- !_;.G_P#/];?]_E_QH \;\2:Q8G]K'P2_VRWV
M#PKJH+>:N ?M%I[^U 'LG]M:?_S_ %M_W^7_ !H /[9T_P#Y_K;_ +_+_C0
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M0 ?\+I^'_P#T._AW_P &D'_Q5 !_PNGX?_\ 0[^'?_!I!_\ %4 '_"Z?A_\
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M._AW_P &D'_Q5 'D/[57Q9\$ZI\&KR"S\8:%=3G4]+810ZE"[$"_MR3@-G
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M/(0+LSG@]NQK5*4OA(4OB_NG=1_!GX?R*&'@CPY@C(/]DP?_ !-04._X4MX
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M8/\ XF@ _P"%+^ /^A(\.?\ @I@_^)H /^%+^ /^A(\.?^"F#_XF@ _X4OX
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M^U-X,LE\(:$MI)X8U21X!IL(1F%Q: ,5VX)&3@^YH ]?_P"%+^ /^A(\.?\
M@J@_^)H 0_!?P!_T)'AS_P %4'_Q- '$_$'3OA)\/K(F[\'^&[K4G=(;;3(-
M,MVN)Y7SL15VYYP>?0&HBYRDHT]_TZCDG%<\NAT?AWX/>$;S2+>;5/ /ABUO
M9%#201:7 RQD_P .=G..F:UDE&7+'9$1ESKF-3_A2_@#_H2/#G_@I@_^)J2C
MR']JKX2^"=,^#=Y/:>$-"MIQJ>EJ)(=-A1@#?VX(R%SR"1^- 'KH^"W@ ?\
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M_9E:^L=7_MCQ9H-WJ&H:1J5@SQQ_)'-=3"3>H+$[5Z8Z^]:\]-*E",?AY?\
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MO?[1U#^S3%#H#>;;RX!Q*A7<O!!Y'(JH1<ZD:*VE&4O_  $SJ2Y*<I_R\O\
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MX94^#_\ T3CPY_X )_A0 ?\ #*GP?_Z)QX<_\ $_PH /^&5/@_\ ]$X\.?\
M@ G^% !_PRI\'_\ HG'AS_P 3_"@ _X94^#_ /T3CPY_X )_A0 ?\,J?!_\
MZ)QX<_\  !/\* #_ (94^#__ $3CPY_X )_A0 ?\,J?!_P#Z)QX<_P# !/\
M"@ _X94^#_\ T3CPY_X )_A0 ?\ #*GP?_Z)QX<_\ $_PH /^&5/@_\ ]$X\
M.?\ @ G^% !_PRI\'_\ HG'AS_P 3_"@ _X94^#_ /T3CPY_X )_A0 ?\,J?
M!_\ Z)QX<_\  !/\* #_ (94^#__ $3CPY_X )_A0 ?\,J?!_P#Z)QX<_P#
M!/\ "@ _X94^#_\ T3CPY_X )_A0 ?\ #*GP?_Z)QX<_\ $_PH /^&5/@_\
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M7:!\(+N\TWP%H5E=#4M,030V2*P5KZ!6&<=U8C\: /6?^&5/@_\ ]$X\.?\
M@ G^% !_PRI\'_\ HG'AS_P 3_"@ _X94^#_ /T3CPY_X )_A0 ?\,J?!_\
MZ)QX<_\  !/\* #_ (94^#__ $3CPY_X )_A0 ?\,J?!_P#Z)QX<_P# !/\
M"@#S>]^!W@#P7^U9\,I-!\(:1I,@T?5[D-:6JH?-1K4(_'<!V /^T: /IZ@
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M\&]O_P#%T '_  OWX:?]% \,?^#>W_\ BZ #_A?OPT_Z*!X8_P#!O;__ !=
M!_POWX:?]% \,?\ @WM__BZ #_A?OPT_Z*!X8_\ !O;_ /Q= !_POWX:?]%
M\,?^#>W_ /BZ #_A?OPT_P"B@>&/_!O;_P#Q= !_POWX:?\ 10/#'_@WM_\
MXN@ _P"%^_#3_HH'AC_P;V__ ,70 ?\ "_?AI_T4#PQ_X-[?_P"+H /^%^_#
M3_HH'AC_ ,&]O_\ %T '_"_?AI_T4#PQ_P"#>W_^+H /^%^_#3_HH'AC_P &
M]O\ _%T '_"_?AI_T4#PQ_X-[?\ ^+H /^%^_#3_ **!X8_\&]O_ /%T '_"
M_?AI_P!% \,?^#>W_P#BZ #_ (7[\-/^B@>&/_!O;_\ Q= !_P +]^&G_10/
M#'_@WM__ (N@ _X7[\-/^B@>&/\ P;V__P 70!Y'\4/C/X!O?C;\'KRW\:^'
MIK2TN=4-Q/'JD+)"&LRJER&PN3P,]30!ZY_POWX:#_FH'AC_ ,&]O_\ %T '
M_"_?AI_T4#PQ_P"#>W_^+H /^%^_#3_HH'AC_P &]O\ _%T '_"_?AI_T4#P
MQ_X-[?\ ^+H /^%^_#3_ **!X8_\&]O_ /%T '_"_?AI_P!% \,?^#>W_P#B
MZ #_ (7[\-/^B@>&/_!O;_\ Q= 'DGB#XS^ 9?VH?!NHIXU\//I\/AG4X9+I
M=4@,2.T]J54MNP"0I('L?2@#UO\ X7[\-/\ HH'AC_P;V_\ \70 A^/GPT/_
M #4#PQ_X-[?_ .+H Y.\\6?!"_\ B!:>-9_%GA*3Q+:6C64-\VK6^Y(B=Q ^
M?U/6G!R@I*/44^::47T.L'Q\^&@_YJ!X8_\ !O;_ /Q=)#%_X7[\-/\ HH'A
MC_P;V_\ \70!Y)^U+\9_ &M?!V\M;#QMX>O;DZEICB&WU.&1RJW]NS$ ,3@*
M"3Z &@#UO_A?OPT_Z*!X8_\ !O;_ /Q= !_POWX:?]% \,?^#>W_ /BZ #_A
M?OPT_P"B@>&/_!O;_P#Q= !_POWX:?\ 10/#'_@WM_\ XN@ _P"%^_#3_HH'
MAC_P;V__ ,70 ?\ "_?AI_T4#PQ_X-[?_P"+H \PU?XH>$/$_P"U1\-/[(\4
MZ-JA_L;5X,6=_%+^\9K4JGRL?F(5L#J=IQTH ^C* "@"G+I%E/(TDMI!)(W5
MFB!)_&@!O]AZ=_SXVW_?I?\ "@ _L/3O^?&V_P"_2_X4 ']AZ=_SXVW_ 'Z7
M_"@ _L/3O^?&V_[]+_A0 ?V'IW_/C;?]^E_PH /[#T[_ )\;;_OTO^% !_8>
MG?\ /C;?]^E_PH /[#T[_GQMO^_2_P"% !_8>G?\^-M_WZ7_  H /[#T[_GQ
MMO\ OTO^% !_8>G?\^-M_P!^E_PH /[#T[_GQMO^_2_X4 ']AZ=_SXVW_?I?
M\* #^P]._P"?&V_[]+_A0 ?V'IW_ #XVW_?I?\* #^P]._Y\;;_OTO\ A0 ?
MV'IW_/C;?]^E_P * #^P]._Y\;;_ +]+_A0 ?V'IW_/C;?\ ?I?\* #^P]._
MY\;;_OTO^% !_8>G?\^-M_WZ7_"@ _L/3O\ GQMO^_2_X4 ']AZ=_P ^-M_W
MZ7_"@ _L/3O^?&V_[]+_ (4 ']AZ=_SXVW_?I?\ "@ _L/3O^?&V_P"_2_X4
M ']AZ=_SXVW_ 'Z7_"@ _L/3O^?&V_[]+_A0 ?V'IW_/C;?]^E_PH /[#T[_
M )\;;_OTO^% !_8>G?\ /C;?]^E_PH /[#T[_GQMO^_2_P"% !_8>G?\^-M_
MWZ7_  H /[#T[_GQMO\ OTO^% !_8>G?\^-M_P!^E_PH /[#T[_GQMO^_2_X
M4 ']AZ=_SXVW_?I?\* #^P]._P"?&V_[]+_A0 ?V'IW_ #XVW_?I?\* #^P]
M._Y\;;_OTO\ A0 ?V'IW_/C;?]^E_P * #^P]._Y\;;_ +]+_A0 ?V'IW_/C
M;?\ ?I?\* #^P]._Y\;;_OTO^% !_8>G?\^-M_WZ7_"@ _L/3O\ GQMO^_2_
MX4 ']AZ=_P ^-M_WZ7_"@ _L/3O^?&V_[]+_ (4 ']AZ=_SXVW_?I?\ "@ _
ML/3O^?&V_P"_2_X4 ']AZ=_SXVW_ 'Z7_"@ _L/3O^?&V_[]+_A0 ?V'IW_/
MC;?]^E_PH #H6G'_ )<;;_ORO^% !_8>G?\ /C;?]^E_PH /[#T[_GQMO^_2
M_P"% !_8>G?\^-M_WZ7_  H /[#T[_GQMO\ OTO^% !_8>G?\^-M_P!^E_PH
M /[#T[_GQMO^_2_X4 .CT>QAD62.T@C=>0RQ*"/QQ0!<H * "@ H * "@ H
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M9-N-Z[@ >A..N*V<;!&7,;E06% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'D7Q]T/7_$$/AA=%\*'Q
M1_9^IIJ3H-4BL@C1@A V]&W*V]LXQTJ/9QG\1<*DH<R1\ZV?P*\<:"VL3Z%\
M-KO1+V_UH:Y%<0^*K1S:2[0K)&KPD;"%Z$'VJ8P:Y.66R:7H]Q5.6NWS]4OP
M-32/A1\1=(NK"YB^&]R\R0W4.H._BBS_ .)B+AB\ID_<_*2QS\N*JI&-3W'\
M/+R?B"J2Y=)?:YOP,[2?@C\1]%\(ZCX?M?AO&MK=H(1*=5THR)&"3MS]E^;D
M]6R> :J3E**@]EH3!1@W*/4]Q^#D_P 2M%U.UTC7O!LUCX?%O' MU<:[;W1M
MA''C(5(U9RY SDG&>..*UG/G?,S*$/9J,8GN=9FH4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y/\4OB!
MXC\&^/?A_8V$%@^A:YJAT^[>4M]H4F&20%,?+C]WSGFE07M*LX2Z*XYJU/FB
M6/C?\1M4\":7H-KH<%M+K6O:I#I5H]YGR8GD#'>V.< *>*RA>K7C1CV;^X:L
MJ?-(XOQE^T;%\#WLM'\;R6VK:[)"UY(VFN(0ML&(#[7QN;((VKD\5M"HJE3V
M<3-TYJ'M'L]/N-.^_:@TJV\53Z1!H6HW%M#-#:R:D JPK-,FZ),$Y.[(&>@)
MYJ*?-6LH;OF^^._X$.48*\]E;[I/3\3)\!?M27WB?2_"YO?!-]!JVOS3);6U
MM/&Z>7&^UI2V?E&#GGTIP<9J+C]I7^XUJQE2J5(R^S+E_"Y1\1_M5)J$&J6&
MB6ZV&M:;JVGVLJR2Q7"O!-=1Q,<H2%.&(P>036E"/MI1G]D4I1I5?93_ ).8
MZWQSX[\5WOQ.L? _A%M.L[@:<VI7=[J*LPP&4)&JCKDDY/;%84)*I.K_ "T^
M7_R8B3C"-+^:?_MIRUK^T7JOAWXDZWX>\1:7+/9P7UO8)JEF@$$$LD.X Y^9
M@2&Y[<9J*;YZ<Y_WI<ORB;5Z4J52-OAY(RE_X'RG,:I^TUXA&N[+*XA.GB*%
MLR0 $$W\T#_^.QBM^10A2E+[<H?^30YA_P#+BK./V.?_ ,E.PTS]LOPC?W>O
MQQPSRP:5:W-T)HI$<W @R9 $!W)]TXW 9K*/OTO:Q\I?]NR,Y7A4C2_[=_[>
M-'XG?'35="^"$'C*STY?#]Q=7=I#&NK,&$44TR)YC!?9R<>U74BJ=>G1E*_-
M?_TDJDXSC*7\IR7@G]H[Q-<ZK:R:_I<,%N-"N;]X(\0"X:.Y6))5:7&U'4Y&
M['6MJJA3I.I%WEI[O;04(>T5O-FW!^V-H>HZ!:7^G:#J&IW,[74;V=H\;^4;
M<*TV9 =A #9!!P:B4>6<;]8\WXV*C!RAS/\ FY/P-_P9\=KSQI\48O#MEX<D
M_L.71K?5EU5IE!7S&8!63.?X3T%.,7+FOLC&HW"%.2WDVON-#XW?&!_A1J/A
M(M9S7=GJE_\ 9KA;6W>XF5<#E$0$G\JYH24L3&C/JI,JI%J@ZL>DHK[SS33_
M -M;2+#P_)?ZMI\@N9]6OK2TLGQ:2^1 [#>XEQAL+]WJ3P*J#;Y?1M^B=D:U
M8JG4<8;*R7K:[.NU3]JW1+/7]&TFWTV6Z?6K8RV$@N8@TLGDO*J&,G>H(0C<
M1BG-\JG;H1!<\%+N8>A_M3R/X-\.^)]?T:;28[[0I-8ETV$K,S*O0JP)ZCH#
MSS6F)?U>O*CU32^;DH_J9U)_N(XF.UY_^2HNZK^V#H^BZ%/<WWA[4+758[D0
M#2II(T=@87F5]Y.T I&QQGMBAZ1G-?9;O_V[)1_4Z(4U*O+#]N7_ ,F-GQ]\
M>)O#?P@T+QQ;:5-$FH7$"M9.GG2I%(3T"9W-CTHJ15'%T<,]IR47Z<K9RPDZ
MN#K5X;PBVO\ P)(YS0/VKH=2U?Q-!%H=_>RPZM%IFEZ<;=K6ZN"T$<C;EE V
M@%^IP,8K.+=1)/=\S_[=CN;5%&E*_P!E1A?_ !2E)&IX-_:4G\=_$W2?#NF>
M%Y_[.N;*::[NY9T5[.:*8Q/&RY^;# C(_E6W([SYMN2,U\W8FHE1ITYOK.4/
MN5S"^,_[2NL_"C6O%.EKIEO>7MJ+*XTF#)#74#'-T?<HH)XK&C.$I1A4TM-J
M7I;F7X#G2FH<T=W%->M^7]2]+^U$-*T/Q%XHN;"&^\.6U\;.RDBN8H&<1I^^
M),A .&!  Y-7/W(Q4U9MO3RZ,(MSOR[)+[V,?]KFUM-8\0SWNA20^$],TRTU
M&/6//3]X9^$0H3D98@9Z#O0TX.:ENFDBTO:>S]G]I2;_ .W31T7]K31M?TC3
M[C3=#OKW4+S5O['2PMY8Y,3;-^?-!V%=O.0?;K1"/-5C3CU3?W&#ER0;]/Q.
MZ^-?CV^^'GP?\2^*+*!&O].L3<QPS#<N[C@XZXSVJ*LG!VB=>&A&O-*6QX'9
M?M'^.]>^%OQ!UFQETZVU/PD!,/M5I)"]S$8!)\T3@,O)QG&".170XQM2G'[3
MLSFI24ZG(^J;7R._TWXK^*M(\0C1=::QO+C_ (1>?7#<0(4!D5T"ICTPQS65
M;EA0Q%6.].45]X4).<J<7]K7[BC\4OCYXG\)_LZ^%_'6C:5:ZAK^J_80;%\[
M&,S(&5??YN*Z:T51S!89_ N=R](*Y-!^TP[J^2_77Y&/K'[7H7XD^$+32XK6
M;PA=6;W&L:B22\+?9I)U5,<' B?-9PI)O$QGM""E'UNE+_TI&T4Y1HTW_$D[
M/R\OGN2:A^VK8WO@K6]8\,>'9=5OM.DM#]F-W$5DAGEV*^Y6P#Q]T\C(S3IT
MW4JTXK:;M_Y*V)-)N_5-_<^4ZC_AK?PW%\0!X2N+.:&_CF2SN#YT;F&Y:,2"
M(H#N(PP^<#;[UE2O53:Z*3_\!=A.-E"/\S2^]V%TC]JJPU:?0%7PS?VL.N73
M6]E/>310+*J]7&XCOG"]3VHI*56HH=X\P5_W+G'^67*=?\?_ !YJ'PX^$FN>
M(]*C\V_LXU>- H8L2P& /H:RDW&=*FOM22^\J-YTY371-G/^&?VE-)UK6K70
M;[2;[2-?>ZELYK*<JQA=(//!+*<$,F",>M;RIKDE5ALD_P '8SL[<KZ)?B<=
MXT_::DN-)T;4?#KF"+4H+&[2.XB!(BEO887R?7;(:TH4W[2=.7V;+[U<TM[_
M "^396UG]JJ]O_%VG1Z3I=S9>&IK*_G74[A%9;LP;!E ,E0"3UZUQ1DG*\MF
MK_>[#JQC"EIOS6_"YTVA_M3Z3>:S9:=-H^HF![FVTZ;5]JB%;F6W29%V]>5;
MMTKLE23G.*V5W]QA%MQBUNTF;'PS_:.T_P")WCC4O#VGZ-=0QV<#W(OWEC9)
M$65HON@[E.Y3P1GI6*BWAWB7M_3*G)<ZIQZF3<?M<:#8/JLUYHNI6VG69ND@
MO'"[;I[=PLRH.HQD')ZCI6E"$J_)R_:2?WW*E[DFNVAL^*OVD='\.S:M;1Z7
M?:E>V&HVFF_9K<#=+-<(CQ@$\ 8<9)Z5SVE/DC%7<^=?^ ;_ (%-)1YGY?BT
ME^+1S>E?MAZ)>6MU=7OAO5]+@AL9[Q6G129&@.)8E YW ]^A[4*<'%5$_B47
M;RD[1_$B;]F[3ZN2^<5=EJ7]K/2K'2+R>_\ #]_IVI6TUM&VGW$L:_).K-#(
MTI.Q58(WWB.1CJ:Z9P<%%OK)Q^:W*A'VO-;I%2^\N?M'?&:^^&OPIT_Q!IC1
MVUS?7$,9X6>2.-U)8QJ,B1A@<<CJ:XL1-TJT:72^OH:X=0K4Y5)=%IZFS\"?
MBC-XY^'"ZEJES:76K6B;KL69! 5D\R(G' 9HV4D#@$UZ.(IJC;E^?^+[7_DU
MSAP]1UD^;?\ 0XN']K&QUVSTZ6'2+_14O_(N+*6[56%W;NY0LH'*X([US5)<
MBC*7PWU.MQM"4NB3^\M?\-5:9>QW\:Z3?Z7&T-[_ &??W*JR74EKN\X*HY&-
MI/(Y[5E-2=*<G]E*7R;"C&4YJ/>_X(GLOVI=+&N6VEW&C:C);H]O;W6K*H$$
M4TZ;HUV]3GIQTS6R:GJMG>W_ &Z<_.G%2[I/[S6^#W[1FG?&#Q-?Z;IFC75M
M;6UN+A+Z6:-ED0N5'R@[E.5;@CM6D82:DY;JWXHTFU3<5':1[(#FH6I76PM
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M &W5!=PW(LUL5>SG,12,3+,,8Z$.BG]*S<+Q<>YT0JRIJT3)\.?LQ^#_  M
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M91W'F%=/FDPLVX#[RH&9E[8ZU2]R$*E1V4G:7D^A+2G4E&&NEXOO;='9Z?\
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M[J3S%(#M!QM]Q79[*49N'];)_DT*Z]FZB/;XWWKGI4M6=A0ES14A](L* "@
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M)N<9P?VG<SA^[E"?6*L:_@/X2Z)\-? ,/A'0C=6VFQ1NBRM+NG^;/)?')&0
M?85%5>T@H2V%"*A-SCNSG?!?P*C^'>O6USHFNZFNG&::ZO[:ZF\UKZ9T15+G
M P%"#  [FMXS?PRVZ"FNL=SK-'^'6BZ-XH\0>(8+=CJ>MM&UU+(=V-D8C4)_
M=&U16-K4W%;,TE/FDGUCHCCM2_9I\'ZAI%O82K?+#:VLMK"\=P1(BR,&+ X^
M\& (/;%*FN7DY=XJR^6PI-U%*$MI2;^]6*S_ ++7A*YT_P N:\UF;5/MHO\
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M>KC81HXJ=.)Y^#G*I0C*6YVE<IVA0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ME< R*8!D>M !D>M !F@ S0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO[N^U1P]S/?W)F8XZ 9Z"G%\L%3^8VN:?M#N*904 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
%!0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g42675dsp71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp71.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *= ;@# 1$  A$! Q$!_\0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M'GD* <8)]!0![Y\6?^1Y^$?_ &,LO_ILO: /3: "@ H * "@ H * "@ H *
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MTI7M/#']EFUL5S(/.=)/F\XI^[&[?_&?E% 'NWQ9_P"1Y^$?_8RR_P#ILO:
M/3: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2(Y>5N3O/  Q0![I\6?^1Y^$?_8RR_\ ILO: /3: "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * $P/2@!#&I(.!D=#B@!U !0 4 >9?M&?\ )*KK_L)Z
M5_Z<K:@#TV@ H * . ^/NE1:Y\%?&^GS78L(;G2+F)[HJS")3&06P@+' ] 3
M0!X1^R?KGPHNO&\VF>"_B#XF\4>(K32@+K3M7NKIX8H]T8+A)5 4YQCV)H ]
MI^+/_(\_"/\ [&67_P!-E[0!Z;0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % 'F7[1G_ "2JZ_[">E?^G*VH ]-H * "@#%\9Q7\WA35
MTTJ_M]*U-K206U]=)OBMWVG:[+D9 /.,]J /EC]B;09=)\1>)GC^)WA/XBS3
M;I-5N],M6&HRW!<;7DE,C?NP RA0-H[=#0![I\6?^1Y^$?\ V,LO_ILO: /3
M: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \R_:,_Y)
M5=?]A/2O_3E;4 >FT % !0!QGQDT6#Q'\*_%NEW.IQZ+;W>EW$,FHRMM2V#1
MD%V/8#J: /GW]G;P9K=K\6M#U/Q#:^%/#L]AX2&GV%AX<N?,?5;<R1G[8PVK
MA!L4*.2-YR: /:/BS_R//PC_ .QEE_\ 39>T >FT % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'F7[1G_)*KK_ +">E?\ IRMJ /3: "@ H JZGJ=IH]A<7M]<1VEG;QF6
M:>9@J1J!DLQ/  ]: .!\!^)_AQKWC36[[PKXBTG5]?U2..6^2QOTG=DB41JV
MQ2<  @9]_>@#'_: O5T[5OAM=/)%"L.NW#F2:,R(N-+ON64<L/:@"C\!EUK3
M_$FOV7B26*XU6>VM[^">R5([5K5RX0+&JJ4;<KY!SQCYC0![=0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?M&?\DJNO^PGI7_IRMJ
M/3: "@ H CF2.2-DE17C8896&01[T <M_P )%X=T;QSI_AF&UC@UF_L9[Z(P
M0 *88GC5\L.AS*F!WY]* .0^/%O<W6N_#.&S$+74FO7"1BX&Z,L=+O@ P[CU
MH =\%O >J>#[[5+B\@TJVM[R*+$&GY9H'4L/+WDDE0I7 X ).!0!ZU0 4 %
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M=['0;Y;@-(I<FXD"_=9\@<\_+R: /;: "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?M&?\DJNO\ L)Z5_P"G*VH
M]-H * "@#DOBQX:U#QC\-_$NAZ3<QV>IZAI\UM;7$K%5CD92%8D<@ GM0!\W
M? ?P9\2/ GQ]TRQ^(.NZ1?&XTC5+RTMM+DG?.Z>TW%BXP F  .OS&@#UO]H>
MSEU"_P#AU;0.\<TVMW,:-&NY@3I5\!@>M &#^S9=K=^(O$<47AYO"XL+6ULK
MBQ2(B.2==Y:8MT+D$ C[P &: /H&@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H \R_:,_Y)5=?]A/2O_3E;4 >FT % !0!F^(M"M_$VAWV
ME7;2K:WL+02F"5HY K#!VLI!4\]10!YM\-OV8?!?PK\6GQ+HW]K3:O\ 9'LE
MFU+5)[L)$[*S!1(Q R47D>E $_QHM!?^*_A7;-))$LWB&>,O$Q5USI=\,@CH
M?>@#IOA]\-K#X<6+V>FWE_<6K8Q'>3^9M.22P. <DG))ZT ==0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?M&?\DJNO^PGI7_IRMJ
M/3: "@ H * "@#S+XL_\CS\(_P#L99?_ $V7M 'IM !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?M&?\ )*KK_L)Z5_Z<K:@#TV@
MH * .6\8^$-3\3O$;#Q?K'A@(!D:7':MOQNZ^=#)UR.G]T=.<@'-?\*C\2_]
M%<\7_P#?C3/_ )#H \\^)_PN\06_C+X7QR?%'Q5<-/X@EC222'3@T!_LZ\.]
M,6@&< K\P(PQXS@@ ]#_ .%1^)?^BN>+_P#OQIG_ ,AT =]H.F3Z/I%M9W.I
M7.KSPKM:]O!&)9CZL(U5<_10* -"@ H * "@ H * "@ H * "@ H * "@ H
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MA9B6@9F:0;P_F2 R$ %@K #CY10![Y0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >9?M&?\DJNO\ L)Z5_P"G*VH ]-H * "@"KJ9N!I]
MR;4 W(B;R@>F_''ZT ?-_P *KNY;QAX3^Q7/B2?Q([S?\);%J:S"VC41/G[X
M" ^=Y839U0GJ.: .W_:'A>XO_AU$D$UT[ZW<A8+>3RY'/]E7PPK=C[T 9_P
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!YE^T9_R2JZ_P"PGI7_ *<K:@#TV@ H * *FJSQVVFW<TH8
MQQQ.[!.N "3CWH ^3/V6W\+O\2=4U3PYK$&G3WR)!<:)?WD=]/<0E'N(I(YQ
MA]P,I#*V[;M*YX!H ]7_ &C[.XU"Y^'MM:*'N9M:N8XU*A@S'2K[ P>M &)^
MS%9?9-3\0A9=*MTBCB@;2K%)(Y;5@SG$B. 5&" ,<'% 'T%0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?M&?\ )*KK_L)Z5_Z<K:@#
MTV@ H * *]^56RN"S%%$;98#)''7'>@#YV^%GB'Q+>^/](M]=TU-(T1O._LK
M4X=,6*76#M?'GXY@(0%PN!NQGCI0!UW[1$DT-_\ #I[>#[5.NMW)2#<1O/\
M95]@9'/Y4 5OV>]9CN)]0T[3[VVU32XK6"X>X@L!:^5=.7$L+8'S%0%.6RW)
M!- 'ME !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YE^T9
M_P DJNO^PGI7_IRMJ /3: "@ H JZE:I>Z?<V\DABCEB9&D!P5!!!.: /(O
MWP#F\.Z]I&L/X]UC7;*RDCN(;.X2W$+E+1K9#N1 2!&V>O)&3F@"W\>5#ZY\
M,P7MXP=>N/GNUW0C_B5WW+CNOJ/2@#,_9S\.Z5H9UI[2\T/4-1N"CW=UI5JU
MN\G+;<H0 $'(7:,=>2>: /;Z "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * $H BN[R"PMI+BXFC@@C4N\DK!551U))X
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M\4/!?F7<\4I:;9!$!MD^4_?RW3Z T 1>._\ DM7PO_W-5_\ 1"4 >FCI0 M
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M\.O'9_L;XC:(&_L[49QM>8J,,CC@YX&X#J/F&""  ?+_ .U;XS\9:3H'P_\
MA?XSMG-SHOC.PGM;J5LOY0#H%!_C3Y@5/X>] '[ B@!: "@ H * /,OVC/\
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M * /,OVC/^2577_83TK_ -.5M0!Z;0 4 % %>^94M)V9%D4(24<@*W'0D]J
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M@="<8Q0!%X82U3XC_#L68@6(W6LDK;,Q0'[-#_>4$?@,4 ?1(Z4 +0!\:_\
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M6@F=>"J?V;#N(Q[9H ^8OA9K6D^*M;\"^";?7]8U?0="U2VOM)TJ/PO]GNS
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M +'BSX=:-\5)+?X\?!X&T\8VL6S4;")L3*0=SJ$S@/DY(QAQSW.0#6FA\/\
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M,2$X)&..>U ' ^*]1\*_L+>&]-O='\.7VN:'IUWH&H2OA(ISO34'Q(6&029
MHX_A&: /#-?_ &Z/&'C[P5-;>%_#.EV<$$NORK%*\UQ=M;WQD>8E$3: B2X#
M$@?+Z4 ><^.+OQ?^TK\:_#NH>+-;BFU=Y]*TR$:;:'RTLVEV^;C.5"LY/S+S
MN'.,9 /:OBQ^Q#XS^+7[4FJ^?/IME;ZCK,EC<76GSN0&BL[:>:01OR,I(3U.
M6.. * ,W_@EQK>L^!OVS+GPW/;2F'5=#DMG6%2D:QHB30S.HXR50#)[R'UH
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M;#Q5:6MV4!7SX-DA+KZC<%X/*ECC@Y(![W>_\C/X&_[&G2__ $I2@#[HH *
M"@ H \R_:,_Y)5=?]A/2O_3E;4 >FT % !0!6U&*":QN$NB!;-&PER<#;@YY
M^F: /'?!GP=^&?A+7/#FN:1/>&XNYO,TLSZE/+%-(MLZ JC,5)$&\#C[H.*
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MOQ!=>+/!VC:S>E6O+_QWHUQ,4&%+-HUJ3B@!\G_)O.G_ /9+?_:D5 '97?\
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M"JS'/S>A.0XX.>"0"OX3U2X^".M7WPG^*T']H>!]3!%E>R F*')XD0GE5SU
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M=>2WBA84 F7<.#]WY#QQT'/O0!T#O#X0TSQ=J6D1V_B&]N=7+7%K"-_D-\P
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M ."D^!'A7P5X9D^*%SJEY_PD_AK5?"=U;ZUJ;272PK-!9E@T*%?,"^:<#K@
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MR,7_ &.=M_ZC4U 'G'BG_DDN@_\ 8F>*O_2^TH ](\;?\C1XY_['CPI_.QH
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M\*W\5YX1\11ZO+:Q1ON$3"R)('JN&&#U&,=@: /NI(8EY5%'T% #]B^E #J
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MZ-KUW'&(4GU*QCG=4!)"@L"<9)./<T 8:_LV?"=  OPV\*@ Y &D0<'U'RT
M.;]G#X4L,'X<>%B,YYTB#KZ_=H #^SA\*CG/PX\+')R<Z1!_\30 A_9N^%+
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M;!HSP1MXP: /T+H * "@ H \R_:,_P"2577_ &$]*_\ 3E;4 >FT % !0 4
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M01XHM[*VUSPC-I4DD:M>GQ#;;@& W?+OY()(_"@"WXV^/\O@/XA>(M*U"_\
M#EMID6EVUYI@U#58+6:>5C()%VL^2ORIAL =<9H JZ3^U?X?O=&>[N_$'@^Q
MNEE"BT;Q';.QCP<MD/U!QQWH AM/VMM"N;*1I-4\*Q723*GE'Q':;6C)P6!\
MSJ.N/2@#Y=^(?[1VC65G\:O"5GJUF=9UK4-*UOP]%I+B[BDF-S KJ'C+#S"T
M0;:>N: .J\+V>F?M:_"+1O[,$>B?%3PO8P@KG9]MC50!@]>H&/[K'T(H VO"
M/BS3/VB-"D^%_P 4(SI'CS3BT6G:K.@65I ,;6S_ !<<CHPZ<T 5OA_X_O\
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M]*BA>38$+RVVI6L\: @<9&_I0!RP\,1>(OA[X9^,/P?F>V\0Z9:Q#6]+MO\
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M-H * "@ H * /,OBS_R//PC_ .QEE_\ 39>T >FT % !0 4 % #)?]4_^Z:
M.0^%UA;/\.?#;-;Q,QT^$DE 23L%)B9\;_$MGC_:#^)L"3V\=I);V:7%FP_?
M74>8,Q0]PY[8KMOHCQ/M,C^),TD>I^%6AGM[=;&>*6R6=O\ D%PAGS'=C'+D
M[>3D_*0 >^$Y^S=S6,7-:%F[^)&C>59 7NEV4EC.)-.M[T2&6QD)7=-<$QY=
M2-Q"CL?<8<I-2C;J"BFFWT.5\5?%'0+FTFAU(+>P3733N=*/S2W2A@LJ%T&R
M/##Y,8//H<J,Y>T<%&Z-.6/LU-RU.\\'^,)?%.F7.H7<EHMQ+:QQZA<X")>Q
M%5/V:&/!"3@8Z>O?C$<T[2]HO=$U!M*F]3CQX^TG0M;O-8L]$6"XL-RZ<[V\
M02!"65Q=$#,DN 0">F?SN'(]8:F34XOEEH7U^,7AF""*"&"#[%'/YUE')<*9
MK>\Z&:1O+YAR"=OH1QV&JBEL#;9&WQA\.M;W$4]O;OIUPYEU.W@N%$UU>?\
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M \R_:,_Y)5=?]A/2O_3E;4 >FT % !0 4 % 'F7Q9_Y'GX1_]C++_P"FR]H
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M2X4B #8-A&2">>N<4 </XMUV#PU\9?A7KMUX:N+O2;'4=3GNM)5 )(8Q<6Q
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M1>.5.,8!' & #Y3\4?'O7_VOO%FH7&A^!M.\,ZMH<>G:A=ZK9ZF&:5Y+JW6
M!&7&[?(/FSQCG% 'TS\/M2TG]J+X>Z3X%U\)X;^)7ARR2.RO95^6Z4( 58<'
MD8)'_ AT(H W=(\:P:U:R_!SXV6;PW<3"*PUV0Y:-ND;%SUST5^A^ZW/4 AT
MOQ!K7[+NH2>!/B%:_P#"4?#?5@4M;X+O1$;J,'T&,IVZ@F@"EJOA;7OV7-:C
M^('P_N_^$D^&^IE6N;-7+!8FZ*_7IGY9.W0CU %UWP-!XNC3XR_!"[:RU*U;
MSM1\/IQ+')U<*HX((Y*]&'(]* )KNS\/?MB:6-2T=H_"?Q8TJ,-+ S%4O-O<
M'KP>AZKP#D8- %"/6=._:9;3O 'CR+_A&_B-HRS6\&K2H!Y\B@ (P.#DD'*]
M#U4]J +7A;XB77@9IO@U\;=/-WH\K>39:O,V1#&>$8-CYD!QANJ]#P#@ LVT
MGB3]C[57M=2C/B[X5:TQ'[L[Q$&[\\;BO4=&^M %;6?!FH_!;4(OC!\&[U=8
M\&7H$E_I"L2%B_B5AZ*> >J=\@9 !-KO@[3OCO:)\6/@[=-H/CC3F\V_T8$+
M+YH&3P.,L/\ @+CT- $D=_8_M?:4(E1/"'Q@\.*&.X%%NU4X.#]X ,/3*'CD
M$T > _ME?$;4?'_PJ\.^&?&MJ=+\;^$?$EE*9I8<O>QE_**9'W3\ZOGHP7/<
M9 /H77BG]K_#' CW?\)%IN[8.?\ C]_B]^GX8H ^V* "@ H ^:?VE/CG\5/A
MQJ+6OA'P1]KTD;/^)]Y;7XW$99#;Q$.G89;@YXH ZOXH:H^M_L[Z;J$M\NI2
M74VB3->)"81.6O[4EQ&22N<YV]J /:Z "@ H * "@#S+XL_\CS\(_P#L99?_
M $V7M 'IM !0 4 % !0 R;_5/_NF@#E_A9_R3;PS_P!@^#_T 4F+N?&?Q!NX
MX/VG_B!"M]=V][<6]O';6MLI*WC[(CY4A'1",Y_SGJ?0\-?%+U,R:3Q1;22&
M34=2L(H&\BY,,3'["S%P((^Y1NIQG_!%!);^,()9D_XF%N+%?.FMHD)33U)4
MB6+_ &L#G'K^; ZKP.FM"YGANH9;V]O$6>"POABWOX\/NN)22,2*.1SG^E)@
M<SX=\1&^UK1I(]:GOKZ^NY;>9)+DL]R55L02Q[^(]RQC/H3TZEML%H/\17GB
MV3Q+K%T)+S3+;3+@6[268WBRW=$@Q_!GCC.<_@L7; H6>G^.H]2%G*ER;**/
M[6]NH;_1P<?Z0@'!;'/!SD^^:74"7XSR^+-1TG3-+M/(M],O]-,][<3S)$EX
MH8;;B8NV%E.>AP>3]!H!U?PR\!Z?KWAWPO$!M%W $M[V0N3?SJ@+6TX5LB%<
ML < 'CVR/8#UFS_9VGLY8KB"YM]/NY4)-[;22&331C_4VNXX$9X!SZ?E%P$U
M'X7ZKIOD2NMDRS'R386\H6"TQ@?:HM[ ^=W_ ,DDN!@^+-&NO"&F76L:I):?
M8K29+:)[V:,0:NS,</=G?@,,#!__ %!H#@?%'B>U\.#3-7-\+K2MS0-/>2>5
M)=/B,M:$<Y@4 $=!SU/>Y(#7MXM,WOJ8U&[M())%,EQ;-\VGN<D10)N^>([E
M!8 \'K_=R J7?BC3?^$ABTN!XDU0RR?;=,MQOBL(UB+&ZB(;_6D#.,]3CKR;
M0&-X@\.V_BKQC;6<5V5U6[L$.D&15!U9/-E+S7&>%=0,C/I]WM0!\^?%"**P
M\0S:?%=1WD5JVQ9C;>5-TY#G S@Y QD>A/6@#=^'MY;^$[_2+G3-3:6YNH?-
MN)5T]EGL6&X?N9#G/N1QSC!QB@"U<ZZVKZ[K@U%!IDT[P7!FBA)5 (@OF!1T
MWCD\X()_&;@>0_&V_P!"?X;-%J00SS:%?I82,A^6=;JQ&?;Y=_\ ]:IJ]#KP
MBU9\O_&.TNK"ZM],>[-[HMKKNJ1VES&I$,O[V(2,AQT.%/4]NE8'H'Z@Z]X)
MU;]F>T74=#4^)_A7XDL!:W5F9-T<D,D>TQNPX#88[9.XZ]S0!\?Z7\,O&7A_
M7I/B+X'TF5_"L6GZ.M_*;:>%;2X@>S1H7\P(LA,RDX0L",'B@#[0T;2]+_:B
M^$?A[QC\/YX],^)WABSA2Y@A<*UV$4+PPZG*G:W8Y4T =/X;\1:)^UQX6;PI
MXK5= ^*&D*R6]U*FQY67[P([Y_B3_@0H C\$^-A''=_!;XT6F(.(;+4ISS"3
MQ&1(>JGC9)_P$^X!5T;6-<_9)\62>$O%L;>(/AGJ[,L%RZ;T"-U.#P" ?F7O
MU% '.>-5C_9H^)]GXG^&NO6FIZ-J=K_:4VA+<;W6T+[2S(#DQ;N _P#"W!.>
MH!T/C;P19_%#3(?C'\')WL?$-HWG:EI%L0)4E RQ"C^+N1T8<CJ00"35=(T3
M]KWP@/$6@-'H7Q5T:-6NK96\O[25_B!X[_=;L>#0 GA'QAH_[1N@-\,_B<O]
MD>.M-+1Z?JTJA)'=>-K9_BXY4\-U'- &!\(OCEI'A?6->^#7CW5=/\3^&;6X
M?3?[0AF$R6,F2 CD?= (/'5"* ,&?XUZ%^Q7\6[SPZ_C+2->\)WK*;W2?M:&
M6W#*#DH2=K;6!'9E- %#XD_$[X??!WQ3IOQ4^$/Q$T(Z=J#A;C1_MBJK9Y:,
MKGE>>G5#[= #1^)_QE^&'Q/T"Q^+WP\\;Z5X8\=Z6!/J6G&[6.4X')([],9/
M#CW H \<_:Y_:&\#?M-?"GP%J]G<Z3#\1=&\26<6I6\%T@>>V.Y=\0SF1=^W
M@9*Y/:@#ZK\0DG5?A?EF('B+3A\R8 _TWL>] 'VK0 4 )0!\&_'CQYXG\&_M
M&:F-"OFG@X:.U?2;F[22=H$W1#RI1DJB^9]W YYSQ0![?KVCWOA_]DOPKINI
M+,FH6D6@0W N%VR"1;VT#!ADX.<]S]30!]"4 % !0 4 % 'F7Q9_Y'GX1_\
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MZ@DD\]: /<Z "@ H * "@#S+XL_\CS\(_P#L99?_ $V7M 'IM !0 4 % !0
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M0NUY<_\ +$=&R<9(KJ?0\1;R]3C;[Q)X!2VNVO\ 2I&=0TNH?96C#S7&6"F
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MQS#\PW$8R >.#6JV @TWX=7.E:\MY<SZ038![B[EMHU3=;E"!Y,F[#2A9,X
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M@"M<?L$_ "[F>:?X7:)-,YRTD@D9F/J27R: (_\ A@#]GK_HE.@?]\2?_%4
M?(-S^SE\,-._;*\8>"T\)Z/;^%H;K2_)TF[E>.R\Q]'U&7YQNZ&1$.>OIUH
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MO*;E,GG:>10![50 4 % !0 4 >9?%G_D>?A'_P!C++_Z;+V@#TV@ H * "@
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MC2(C"L"<9!YVD^M%@)? WCB^CU=4U&YU*TLK.\9[:[:Z>9--)9E!FC"#S#@
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M%]:9D#=PW7/>@#WF@ H * "@ H \R^+/_(\_"/\ [&67_P!-E[0!Z;0 4 %
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M7<2D6@$C%DU!L9+'' ]<Y[YF3U V;>73KZWAA2WN8[!7,B@@&87)49ED./\
MCW/88QC'; J0///V@4B_L"R(CMUFEU6$W[VRJ([J0>8 ]KQ_J\9!Z\E?QM >
MH--()+B4S6YO&M0EY/$$\BXML+B&VXXN0.#COCVP >3>#],TS4;WQ8L\KZ9I
ML4-_(K7T4TDL2B]A W"/YMX!^F>M9U>AUX3=GW9\+;:.S^'/AB"%UDBCTVW1
M'0$!E$:X(!)/ZFL#T#JJ "@ H * "@ H * $QF@ VCT% "T % !0 4 % !0
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M$(+"T\3Z;=L]Y<&+=&;Y]C.EQ)\Y"L.#CCH..F #O/$UOI-_8K=:S,FKV_G
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M[Q^%T$MK\.?#$,_F^<FFVZOYQR^X1KG<<#G\!]!6!Z!U- !0 4 % !0 4 %
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M)R^X%,ZCP1SR?DZ_,WYT>U\@^JON30?LAZ/#(P_X2OQ1)$RX*/J/WNG!PO3
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M_P#QN@0?\,R_$7_HO&N?^"/3_P#XW0 ?\,R_$7_HO&N?^"/3_P#XW0!2UO\
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M&@ZI%Y%W:^8T?F)D'&Y2".0.A[4 ?.__  Z\_9N_Z$%O_!K=_P#QV@"_9_\
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M;V_AZ*6TE!#PL+RT!0Y).0>.230!]%4 % "!@W0YH 6@ H \R^+/_(\_"/\
M[&67_P!-E[0!Z;0 4 % !0 4 % !0 4 % !0 4 )M'H* # ]* #I0 M !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 )@>E &7XE\,Z?XMTIM-U.#[19M+%,T>XKEXI%E0Y!!X=%/X4
M:M ''>+?BEH?A.Y>RFEGO-36/S?[/L(C-/M]2!T'N2*UA2E/5&;J*+Y27X<M
M>/HT\MWI,^C>;<-)%;W4ZRR%" 0S$9"Y.?ESQ14BHRLF%.4I1O)'65D:!0!Y
ME\6?^1Y^$?\ V,LO_ILO: /3: "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#%UWPCH_B*,K?V$,[$8\S&UQ]&'(_.J564=$R7%-
MW:)/#NB'0K66W%[<WD9D+1FZD,C1K@#:&/) QWR>>M$FI;"BFMS6J2PH \R^
M+/\ R//PC_[&67_TV7M 'IM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!Q.O?"^#Q!JDU\^OZ]9-+C,-CJ#11+@ <*!QTK6-5P
MZ&,J:EU-?PAX7B\*:?-:17]]J(>4RF74+@S2 D 8R>W XJ)U'/WFBXQ4=C?J
M2PH \R^+/_(\_"/_ +&67_TV7M 'IM !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % "&@#QSQO\2]3T#Q%JD4%Y<1BV"106,>B7%U'(
M6 )D>6-3TW?=!_A]Z[*=.,X^\<\IRC(Z[X3WEO?^'KF>*^O]2G>Y8W-SJ%J]
MLS2[5R%C=5*H!M  &..YS6%96E8JG\)VU9&P4 <)\1?#NH:UXK^'-Y9VYFM]
M*UR2[NWW >7$;&ZB#<GGYY$&!SSZ9H [N@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H Y+Q1\2?#WA'4(+'4;I_M\R>8MK;6\EQ
M+MZ;BL:L0N>Y&*UC3G./,9RFHZ,W](U2SUFR2[L9EGMY!D.O\CZ'VK.47'<<
M9*6Q>J&68'C'6M1\/Z>E[8V":A%&^;F,S"-UBP<LF>"1QP2,TT!F^$OBMX=\
M:/;Q:=<RO/,I98I+=T(QUR2,?K28'8T@"@ JD 4P"@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M9[XI@=3X,62)KA)&MB-B%?LZ$  CODGFI8'5T@"J0!3 * "@ H * "@ H *
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MF 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M;@3B[*)Y:J0I!"[MV.?N@<>G>I8'74@"J0!3 * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M93PC$_ZMCV!/2O.S/!73JP/:RK,%%JC4W/M1'#C(.1ZBOD]5N?9CJI#"F 4
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M+5SM'0+(<=.F&_.ML=A*:;J4W?N>GEN,K65*K3^9]61L&7([U\_>Y]4/I@%
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M*,M^IT[U-S2G'EB>GA0*^D1J.I@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g42675dsp72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp72.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +/ =,# 1$  A$! Q$!_\0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M8"@#)_8'TVTA\->*-0L-?U7Q3I]S-9V]KJ^HZ7]A2>*& 1IY*YRZ@#&[C)H
M]:\2_P#)R7@3_L7=9_\ 1^GT >I4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % %75;!=5TR[LFEE@6YB>$RP-MD0,""5/8C/!H
M\ZF_9V\'S6C@6LL>J.FTZRA07F[_ )Z;MNWS/]O;GWH Y#XC?L7>"?BE\-="
M\!:WJWB4>&M)W,EM:ZGY9N6+%M\[;"9""21GCF@#*_9]_8!^%O[-/CQ_%W@X
M:R-6:TDLC]OOA-'Y;E2WR[1SE!SF@#T[QY\ / _Q+UI]5\0:1)>7SVZVKR1W
MUQ 'B!8A66.101EFZCO0!W.CZ3:Z#I-GIMC"+>RLX4MX(5)(2-0%51GT  H
M\;_:R\/_  UUOP#92_$_6Y]"TBRO!+;3VMV]O,\Y1DV)L^9R59AM&<T <Y^Q
M"?"1\$ZX/ UCXGM?"\%\MK:R^)KAW:78F#Y*.2T:#I@XY[4 >@^)?^3DO G_
M &+NL_\ H_3Z /4J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* $)P.: $$BL 0P(/I0 Z@ H * &M]TT <)\%/%6I>,O YU+595FN_[4U*VW
M(@0>7#?3PQC ]$C4?A0!WM !0 4 <7\5/A%X7^,OAY-&\5Z;_:%I%,+B K(T
M4D$H! D1U(*L,GD&@#D/V>/AEI'P<C\3>%=&\7WWB2VM[Y;EK+4I%EGTYI5W
M%&DP&;?][+9- &CXE_Y.2\"?]B[K/_H_3Z /4J "@ H * "@ H * "@ H *
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MN+3Q1XXU+QQJ%U+YS7=Z!'Y? !10O:@#M$M()-;B,,2CR%.Y@.<GM0!M4 %
M"'I0!Y9^S7_R3$_]AS6O_3G=4 >J4 % !0!X=^UI9>&&\!Z9JGB+QF/ -UI6
MIPW>DZYL\SR;L9"@I@[P06!'IF@#+_9&7PY<VGC#4])\:R_$/6[W44?6=?$'
ME02RB/")#@;2BKQ\N>O6@#L_$O\ R<EX$_[%W6?_ $?I] 'J5 !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 E &#9^!/#UAK5QK$&BV$>JW#[Y;T0
M+YS'U+XS^M &C>:=Y[B6&1K>8?Q+W^M %6XM=3< "XBQNY(7!"]Z +]G9)9Q
M[4R<G+,QR30!9H * $/2@#RS]FO_ ))B?^PYK7_ISNJ /5* "@ H ^7?V\D\
M-S>%_ ]OXGUZ\\,:?/KOE?VM9[";<FWE!)5T8,",C&.] &S^Q;8>$M$\ WVD
M>#?B#=^/M'L)HX$DNHDC^Q@)Q&NU%SD<Y.: .W\2_P#)R7@3_L7=9_\ 1^GT
M >I4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 AZ4 >6?LU_\DQ/_8<UK_TYW5 'JE !0 4 >)_M3-<:3X4TCQ-;>'-.\1OX
M=OO[0,>JZFMC;PJ(G4R,S AOO8V^] $?[*/Q2U[XP^!+GQ%K/@*'P);37&VQ
MBBE#B\B _P!=]U2 3TSU'- &]XE_Y.2\"?\ 8NZS_P"C]/H ]2H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!#TH \L_9K_Y
M)B?^PYK7_ISNJ /5* "@ H ^??VU-$\"^(/A=:67CR+7+ZREU&);+2_#LCB[
MO[DYV1*JD;NYP>.,T '['S^%U\*ZY;^'9?%,%S:WBP:AI/BZ=WO+"4)\J88G
M:I7!&#@]: .P\2_\G)>!/^Q=UG_T?I] 'J5 !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 (>E 'EG[-?_ "3$_P#8<UK_ -.=
MU0!ZI0 4 % 'B'[4>A6FOZ=X,@B\02>&_%2Z]"WAV\6U-RGVW:V%D3NA3?D\
M8ZT 5OV9?#RZ#K7Q#75O$?\ PDOCF35(FUZX2S-K#&_DCRDB0Y^0)WR<T =+
MXF./VD? A_ZES6?_ $?I] 'J6X9Q0 M !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 AZ4 >6?LU_P#),3_V'-:_].=U0!ZI0 4
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M C*[#D  '- 'KU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 AZ4 >6?LU_\DQ/_8<UK_TYW5 'JE !0 4 9.N^%]+\1S:;-J-I
M'<RZ=<B[M';K%* 1N'X$C\: .?\ !2>#K?Q;XNMO#MK:VNMQW$#ZT+>#RR\K
M1YC9C@!CL[C- 'G_ ,:K"[U3XO\ ABTL]/M]5FF\,:RALKDX293/I^Y?3.,X
MSWH Z3X)^#=8\'G6%U6PL[1+QHIXG@=I)>CYCDD9B7V#8 >!RV.* /4J "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!#TH \L_9
MK_Y)B?\ L.:U_P"G.ZH ]4H * "@#YT_;4\9V_A#P;X=^U^(]4\*VUYJ31/J
M.E7BVSJ5@D<*696!!*@8]2* .9_8.UC1->C\=W^D:YJ/B22ZETZXNM2U.]6Y
ME:1[4-Y6550-F2N* .P^/IO?^%I^&UT^X-M=OX9UB-&67RF;-QIX**_\+-D@
M'L2* .R^#>E7VG76N2?8-2TG0YC!]BLM5N6GF20*WG-EF8A22F 3V)% 'I]
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M8L,7#X(R5  0#H%':@#U"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H 0]* /+/V:_^28G_ +#FM?\ ISNJ /5* "@ H 2@ Q0!
MY=XE_P"3DO G_8NZS_Z/T^@#U&@!: "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@!#TH \L_9K_Y)B?^PYK7_ISNJ /5* "@ H X
M#Q)\3-;T+6;BQM/AOXFUVWBQMO["2Q$,N0#\OF7*-QG'*CI0!F?\+B\2?]$A
M\9?]_=-_^2Z /-_$'Q6\02?M >"[H_"SQ8DL>@ZLBVK2Z?YD@::Q)9?]*VX7
M: <D'YA@'G !Z0?C'XD _P"20^,O^_NF_P#R70!Z%H.IS:QH]I>W&G7.D3S(
M'>QO"AEA/]UMC,N?HQ'O0!H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 (>E 'EG[-?_ "3$_P#8<UK_ -.=U0!ZI0 4 % !0 4
M>6^)?^3DO G_ &+NL_\ H_3Z /4J "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H 0]* /+/V:_^28G_L.:U_Z<[J@#U2@ H *
M,KQ)XDL_"FDS:C?"<VT6-WV:WDG?DX&$12Q_ 4 <YX#^,_A;XDZQJ>E:%=74
MU_IBHUW#<6,]N8@WW<^8B\GTZT <A\3/$MCX0^.O@_5]1D,=G:^&M9=RJY)_
M?Z?@ >IH [WP5\1=/\<2W\%M;7=C>V)3[1:7J*LB!P2A^5F!!"GH>U '54 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "'I0!Y9
M^S7_ ,DQ/_8<UK_TYW5 'JE !0 4 <1\9KR_L/AOK<^F^(K3PI=)#D:O>0^:
MEN.Y"Y&6QD#W(H X#]F&[0:?J%A#JNEWP@VO.D.GSVE\\K<F:?SG+/OZ@X'M
M0!F_M&7)M/B+H<@N#:@>%=:#2+")3M,^G@@ @C)'&2,#.: -/]FNTBTW4/%=
MI;R2QVL1M/+LIH(4>'*R'<SPDQR%O48(VC(H ]UH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MEV>4MC!Z8V'G^]@<"@#WB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0]* /+/V:_^28G_L.:
MU_Z<[J@#U2@ H * .2^)?@P^.O#\5@FK3:)<0WEO>07MNJ,R212!TX<$$$@#
M!% '*_"/X(7'PSU9[ZZ\5W_B-OL;6<*7D,,8B1IVG8_(HR2[GKVH Q/C):SW
MGQ@\-16NFVVL7#>%=;$=C>2>7#*WG6& [=AZT :_[//@M_!^AZD;G38K&_O9
MUFN'M[E)(I'P>(U3A%7H!U[DD\D ];H * "@ H * "@ H * "@ H * "@ H
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MR21GI0![50 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0\::+XH\0SZ+/'I%A+-:W^I:=J=E;ZK;S+=W%RIM0\RD QW2JSKG.UP 020
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M,>:N-GG%?XO4J3^*$^E %#P9X^COY)?A-\:;4W$?F"&PU:\XDAD_A5I.H/\
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MM9;CA6593\KL !D*3CB@"EXE_P"3DO G_8NZS_Z/T^@#U*@ H * "@ H 3-
M",ZJI8L HY))XH Y;Q=\5O!O@*U6Y\1^*='T.W8X$E_>QQ*3]6(H \"\;?\
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M1K]K+5H_M A@:0H >N1P!P>2<<'K0!8^,1_XK7X0_P#8T/\ ^FV]H ]2H *
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MI?AC%O:1A$DNDU8,I8]6;RUDY.3Q0!4^+>@V^B?MD?#;QU=W26]I'\2;[2I
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M8@*3QQF>(1W5W'$F5&3A% X[)[T ='%=36O_  K42ZY<B4W,D<GV@RJ;IC(
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M#X)EU&)V4'?#]OU&.=,G@9C=^?;Z4 8WBWX4^+]+^.W@WQCXO\023V_AN_\
M"UW>27U\)0L$UU<QIC:B* K<XQQD\\F@#LOVS[RVT#X)>-/$DD2R7&B_%JSO
M(9",E,1VI;'U"T ?+'_!0_QCHWQ)7P ="OK+6[Y)/$$\\%C+YTD!DU-I%#*A
M.-R'(W=N: +?[8NN2_M'W/PNO?AW9IXE5_!EAI>H""(2M83O=B.-78\0N7
M)(R&]Z (_P!E/X<Z3X)TEM:E\!WFM?%;PC\0]+TZZ:&] 6TB>0 *!DJ27CD3
M(_O#TH ?\5/^$3\$_$?2%TKX#/X]\5:BVIW]X]X)KFVU%GNIE4K#&,YCV\X/
M<4 >C:9JWQ,\:_LFZK=>'K&P\*7UAX+L(;^VOH"@.EQ7.J1DQ^8"0Q4(P88X
MSB@#@O"7C+Q=\/OC;IWB7XC?&+2_'2PWFE2WFCZ%>C47OH5DE=4C(PH,.&8@
MXX?'>@#]%_\ @GU\0K;XB_LRZ#=VURUTME<W=EEQ@HB3N8EQVQ&T8Q0!](T
M% !0!\X?%B.?_A=VO3VML]Y<V_AC3)(X8T9BQ^V7J_P@D<,>?UH Y[]F#6(H
M]$TW2[_3HO[6:YUR5-0(.^%O[0O-XR0./H.YZ4 =]9BTT^W\!0W$Z7ETU[(T
M4[1-<=9AP&;!!^8#...U &):W/AW3-;O90;RP2;7_*D5$#B:;I_#C:,GJ<T
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MVSJK%C##]G8@D'ECZGKVH [/Q+_R<EX$_P"Q=UG_ -'Z?0!ZE0 4 % !0 4
M<1\;I_$%K\(?&,_A68P>(XM*N9-/<1B0B81L4PIX)SZT ?G[^P1?7NJ_LMVM
M]>W7VB2;XI::"OEJFUA):;N!QZ#'M0!])^"/^2ZVW_8R>*?_ $39T >=S?\
M)/O"?_9/M%_].]K0!Z+XX_Y"OQ+_ .R@^%O_ '&4 'PY_P"0G\)/^QM\5?\
MH>H4 <#X>_Y)GXS_ .R67_\ Z7:A0!B_MGP7EQX+^(":?$\][_8G@UH8XQEF
M8:C<D ?E0 WQ[9P?&W]GK7A):B9/$'CN&Z6V(R-[Z;%(BX_WMHH ^2?@%\4?
M"_PU\*2^$O!6AKKOQ.U+PSK&G:G,]O&(HKHW&X%G=D)5;>,XP3@L?I0!RM[\
M8/B5H0A^%&E:?I^E3K!I>A3WJ123R1*EV;BUD#!0.&D49(.0 .M #OV5_'FN
M_L_?':7X?^*=)U47VL:]H\UQ8B#]\+B*ZCG5RN<D%"^,==P- 'Z4?#_5--T-
MO@S?ZE=6UA;J_BG=<7+K&H'GN?O''IF@#PVPU?PE\6_V=?B=96>L6FJP:1\-
M-.6\-K)YGV:Y@GOI0C@'[P(4XH ^1?">N_";P;\??"FHWR:_XFNVU#33I]S#
MH]II5E=VKO)'.6MDYY#+M/!.&SVH ^\O^"9.H)X6\0_'3X:0,BV'ASQ5.]G&
M <A6EDB;KV'DI^= 'W?0 4 % 'S%\<+\V'QA\0LB/)<2>&-,BA1(P^6-W? Y
M4\$;=WK0!@?LM6BQ^'-)807,DK2ZW;[R JQ#[=>'*H02&RN/O#J,T >B:?HL
MNF:;\-4LXC>VT-T6FGOX )D+N..2VTY/8]A0!GRW^D2ZL(+%##GQ$8[MM0V1
M[I>N8@S?,?;\<4 0^);;3A\8O!]Q;2*;V7QD1<HLZR;"--OPO  VY'.#F@#Z
M.H * ,WQ)K4?AOP_J6K3(TD-C:RW3HGWF"(6('OQ0!^<W[)'Q7\#?M&6'Q(\
M.>+M&?1[+QEXFN]9TBXN2H96EP JM_"Z[3@]&Y% ':>%/%?B;]CKQW)X-\91
MOK7@#4W807)4LC(W5U!_BY^=#UZC)Z@'2^/_  !??"G5K/XH?"V\6ZT*X42N
MD)+Q>6QSL<#K&>QZJ?3N :'B?POI'[2WAS_A._ Q72?'^GJHO],+[&F8#(5B
M/XNZ2#K_ " '>$?%^A?M(^%)/A[\0HS8^)[4F.TO95V3)*HQ@YZ..XZ,* .8
M\!^+=7^ GBBY^%/Q.A74/!FI[H;>ZF!:(1MP&4_W#W'530!F>*_"WB?]CKQY
M%XL\)ROJW@347&]"VY"AY\N0CH?[K_\ UQ0!K_$OX::?\5M(A^,'P?G>UUJW
M;S[[3+;Y94E'+,H'1QW'1AR/< N:)K7AS]L[P4-!\0>3HOQ,TN(_9[O;M^T8
MZ\=U/\2]CR* ,7X8?$Z;P7<7GP9^,UEYNBO_ */;W5T=WV<'[GS]XSP5<<K_
M " *E[9^*_V*/B"FH:>TFM_#_57'?*2IV5NRR =&Z&@#IOB7X M-6M;+XX?!
MVZ"75NWVJ[LH%P<C[^4['DAD[C- &Q(GAG]L?P,^H:>D.D_$#38@+FU+;=Y'
M3GJ5S]UNJGB@#!T7XC6WBGP?K7PJ^+MNPO;>WECT[4[D[)#(B':C-_#(.,-T
M8?J >H?\$[P%_8P^%X'06$V/_ F:@#Z,H * "@ H 0]* /+/V:_^28G_ +#F
MM?\ ISNJ /5* "@ H X'XXZ--X@^&NLV$37JB9 LC:??+9R^7D;L3,"%&,Y]
MJ .&_9C,YLKJ.VGN)]"MXDM[7.L6M_;HRDY5/)4;6Z9R: .E\2_\G)>!/^Q=
MUG_T?I] 'J5 !0 4 % !0!'/&)H71N588(]J /SC^!FHVGP\\3^/O@TUHMC=
MZ'\3M*U>T0,/GM)[F 1X _NJL>3WWT >]>"/^2ZVW_8R>*?_ $39T >=S?\
M)/O"?_9/M%_].]K0!Z+XX_Y"WQ+_ .R@^%O_ '&4 'PY_P"0G\)/^QM\5?\
MH>H4 >$^&O$_BQF\;Z,_AM4\*CX5:B4UKS>6(N+M@-N>[O(O3^"@#U[XIZ%J
M?B'Q'XA@TG2;O6[B'2?!]T]E8[?.>*._NGD*[B!D*">O:@#G?V5_@;XU\!_
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M 4 ?(O[0_P"VKXA^%GQTT[X4Z!X'AU+5]4@2>TU;4+UHK7!4D[E5"< @C.:
M/A[]HWX@^.O@W^T!8_%'7].\._\ "0ZTMG*MKHTDHM9GM+F)_P![O(9F*A1G
M_9'I0!]O?!O7#XF^)7AS6&C\@ZAJ_B.[,><[/,M;%L9]LT <C.<?#WPF?^J?
M:+_Z=[6@"M\7OBSKN@_'_P 5^#HO!UQ=>';_ ,:>&+J[\4&?9;V9 L3L(VD$
M_NU_B'WP: (=+_:<^'G@G6_AS:7>M->ZAIGB?Q)/<V6F6TEU*JRRWRQX$:G)
M8NOX'/3F@#A?!_QJOM;\ >,H--^'WBF9!\.KRT^TW-O%;0^6;N]<W ,D@)C
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M$8^;NL@]OP #PCXNT']H[PQ+\/OB);FR\56N8;2_G39<)*O&"3TD&.1T8?H
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M[*>F?]AG5?\ TLDH ^K: "@ H 0]* /+/V:_^28G_L.:U_Z<[J@#U2@ H *
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M) PM[J6 /N _B\O=CMG'/6@#H-8US3M ACEU"[BM(Y&V*TK8!;TH O@ C.*
M*^HWL&EV,]W<$K! AD=@,D #)XH \F^/VNV?B3]G3Q3J-@YDM9;8;'9"I.)E
M!X//4&@#V&/[B_04 ,NHEGMY8W&59"I'J"* /QL_9=M+^XMI(_!?VN/QII=Q
MJ6JM%!<1/OM8KH)D(',BM^\QM9,, 2,\JP!]JV5]X:_;,\#_ -GZ@8=%^(^F
M1'RYL8+D>W4H>,KU4D$$CD@&3\,_B:VFR7GP:^,EINMS_HUM=7?\//R O_=Z
M%7'3CV- &!>6GBK]BSX@B[M#)K7@'5).5/*2IZ''"RJ. >A ],A #1^)_P ,
MHKBVMOC-\&;MEB5OM-W96G#P/_&P3TSG<G3KVS@ FCUCPK^VUX'NYM*EM=.^
M*WA]-DL44@4RLHSM)ZX.>,\H3@X!.0"U\+/BK8_$O2I_A'\7+=H-6B)M[2^N
MQMD+C("L3T<<X/1AP>X(!FZ#KWB3]CWQG+X;\2Q2:U\/M3=MKE2RJK<%T!S@
M\_,AZ^YP6 -GX@?#^]^&&J6?Q2^%MZMSHDRB5T@)>,1L>4<#[T9SC/53^&0!
M^KZ?X;_:P\.W'C7X?75O8_$/1F\G5-,CE"L\J=8WQT;(^5_\@ M^#?&6A_M$
M^%I?AW\18FLO$UJ3%:WLZ[)TF7C!STD&.>S"@#F? WBO6/V>O%4_PL^)D"ZC
MX)U3=#;W<P+1"-N RD_PGC(ZJ: ,_P 6>$/$O['WCB+Q?X/F;5O FH.-\9;?
M'L/(BD([_P!U_I]* &_'SP1X=^(WPXU/XU?#C4$TBYLK:2YUBT601-"0F7?_
M &7'4]F'(]P#A/V1#G]G'P0?^G5__1TE 'T/_P $RO\ DU/3/^PSJO\ Z624
M ?5U !0 4 (>E 'EG[-?_),3_P!AS6O_ $YW5 'JE !0 4 >=_'75]<TCP&Y
M\.S+!JMS>6UI&V]4<B20*PC+ J'()VYXS0!RW[/>G^/X[G4;OXAP7PU9HQ''
M-)=Q/;^6'.U4CC'#;<%F/4YQ0!M^)?\ DY+P)_V+NL_^C]/H ]2H * "@ H
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ML5OA;>'M-:6%H?,#QF1%;C(R<-QD]<4 ?K-9S+/:PR(I170,%(P0"* )3TH
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M_9K_ .28G_L.:U_Z<[J@#U2@ H * "@ H \M\2_\G)>!/^Q=UG_T?I] 'J5
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M Z2>_1Q[]0#<^ OQE\(?M(W>FVGB%;>'X@^%;P%)D 21Y(C\Z_7^\GOD= 0
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M "'I0!Y9^S7_ ,DQ/_8<UK_TYW5 'JE !0 4 % !0!Y;XE_Y.2\"?]B[K/\
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M4EE^W7^G:>FQHI<#>RQCITPT8'K@=J .D_XIO]M/P3S]GT3XGZ7#WX6Y4?\
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MG.ZH ]4H * "@ H * /+?$O_ "<EX$_[%W6?_1^GT >I4 % !0 4 % !0 4
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MV.N0000,4 >DT % !0 4 % "'I0!Y9^S7_R3$_\ 8<UK_P!.=U0!ZI0 4 %
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M,'!Z &Q\!OC38?$R_P!.\'_$"W6/QKH=R)+&ZF&UYI8\\9XQ)A2".-P!X!!
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M>:?.LT3E3A@&4D'!XH V* "@ H 0]* /+/V:_P#DF)_[#FM?^G.ZH ]4H *
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M>''!SDY ,CPOXH\1?LD>-;CPAXP@;5O NHLV&*EXVC/!DC![\_,G\S@N /\
MB!\/=2^!6MV?Q3^%5W]N\)7.))(H&+I$C?P.!UB/0'JIP/2@"S!\*?!?Q?\
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M((P&&._- %/3KOPM^V/X)7X??$*,Z-X\TEA)I^HPCR9Q)'T>,\$'Y<,G< X
MP0 #YL\._LE^ /A;\3=4\*?%&#Q!::9JLGS7VGZO+;PO\Q*R.JX#H3SR/E_
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M2<#^/&3GHX)[]0 TO4/#'[9/@MM)UA8=$^(VFQD17.S:TF.^.I0]U[$Y'7%
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MS)U'/?E@!_B+PMJ7[-GBFS\<^#)CJW@"^96=(Y-RQ1N<[&(SF,Y^5^Q(S_M
M$_Q0^%UMX]LH/BU\(YFM=;@83WNGVWRR&0<L0HZ..Z\[AR,\A@".77/#'[8'
MPOO]-UKR]$^(>D6DKQ3J,,Y5<D@9!*DXRN<@X(/0T ?-?[!%I<V'P1N;:\CD
MBNX=;NXY4E&'5P5# @]\@T ?6_\ P3*_Y-3TS_L,ZK_Z624 ?5U !0 4 (>E
M 'EG[-?_ "3$_P#8<UK_ -.=U0!ZI0 4 % !0 4 >6^)?^3DO G_ &+NL_\
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M?XEZJ>1C!H ;K>C:_P#LH^+8?$'A^=]6\!ZBRX8ON14/2*0CV^Y)0!G?M&?
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M !0 A.* (9[N&W"^;*D>Y@J[F R2< #\: /,OV:_^28'_L-ZU_Z<[J@#U2@
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M_"L3GK_;>M?^G.ZH ]4H * "@ H * /+?$O_ "<EX$_[%W6?_1^GT >I4 %
M!0 4 % !0!Q_Q*_X\=%_[#5C_P"CUH Z>]_X]9O]PU4=S"M_#D?GEX.\2WGA
M_P"%TSR7<#6(U:[:WMX$#7"3J05,F.?*]?\ "NIWN>5'82\^*>MRW.HW@EMI
M#J,(34I5ML1NA90!;C'RO@GH,YQFE<8^'XF:\M[I/EM!&+$$::9H1\IW _Z1
M_>')^]SD>M2!UO@/Q!+K%EKK:FDLNELZ2ZA;6R 7C2DL%:W YV9&<+V!]Z:8
M"?\ "5:[$-&U2XUB"2_OH+6W*K:1+9I;3%1M8GI,%;&/3GIQ5 4?%OC#^QY[
M;3[%;B+1(#YVGQ7,:FY6<XR9R1DQGT/M4 8.J_$_4G%_$R27":C(!J[P1(/G
M'W3;=U7.<[?7USEW Z6X\?ZCHOAB77S!]N\06%M$NG>3"IM?L[#!251D&4!B
M?7&3QS3 \T^%7AO4=8N?$4UYJ&I>'RT\<JV5I"/->1@[(Q5QGRP,Y/3#<YH
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M^P<+M?@O>B_1X[T:Y>"=)$V,KY7<"N!@YSQCB@#ZT_X)E?\ )J>F?]AG5?\
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MOXG_  PM/B)86_QF^#-PT&LQ-]HOM.M?ED,@Y9@HZ2#N.C#D9[@'(?!GX?\
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MV#W!P 8_@+XA:W^SEXHN/AO\2[8ZGX0NCY<4DRF6-(R<!X\YW1G(RO4'W^^
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M_P#1RT =/>?\>LW^X:N.YA6_AR/A'PYH!U_X3:?$'CALFNKF/S(F*W'VEI&
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MXH?\(C<W/P=^,=MNTN;_ $:VN;PY$.?N OW0XRKCICT!V@&/>67BK]B7Q_\
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M<UK_ -.=U0!ZI0 4 % !0 4 >6^)?^3DO G_ &+NL_\ H_3Z /4J "@ H *
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MSN4&[VZFE6DJ<5*VK/.=$\.6VM_$CQ7>_P#"2.]DL4$$>JR6@D\Z5X<" CC
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M7+D.<N<YY]\]L '/ZQJEVWC?Q%/#X]U465C911175M"I<W$J8%J<\A00R_\
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MQBTHCRYCH)G#7=D"OVR6[PQ\V/C_ %&<GTQ[9I@87P^N'7]H[QK+K[Z9??\
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M%"REMQ8DC@9YQZ54=68U?X<EW/G;X3ZI96GA*59+R#09OM=QNU5I#ONAO/\
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MVM7 "FY^]AI2%]??&<TGJ&IF7FE>%GU?59!X^TJ;[!&3:S_8A_Q,29%;8_/
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M -"AI?\ W[/^-'M6'U2F!^!/P].?^*0TOG_IF?\ &CVC6P?58"_\**^'N/\
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M:I<W6LPR6\/AC5!?VD0CNS<1+=PA=T"+*Q8Y;')H ^N/V:_^28'_ +#FM?\
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M+F?:IN,6F 4 >6^)?^3DO G_ &+NL_\ H_3Z /4J "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H 0C(H CM[:*UCV0Q)$F2VU%
M &2<D_B23^- &9XJ\1Q>%=$N=1FM;N]2$9\BRA,LK^P4?_JJHKF=B92Y5<\Y
MT3Q=XA^)'B"!K2UTG1M)L9XY9&N91=7DB]2@5#MB;'!Y:NJ4%17>YSJ3FSUU
M?NBN%JYU"U0!0!Y;XE_Y.2\"?]B[K/\ Z/T^@#U*@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H :Q ZT 86H>#M(U+4+
M>_FL8EO89%D2YC&R3*G(!88)'L>*KG;5C+D5[F\O0<YJ346@ H \M\2_\G)>
M!/\ L7=9_P#1^GT >I4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % &+XK\,0^*]+^Q37=Y9)O#^;8SF&3CMN'..:J,N1
M\Q,H\RL<K8?!S3]-U"TO!K_B*=[:9)5CN-4=XW*G(#*>H]JTE6<ERF2I<KO<
M]#'05B;BT % 'EOB7_DY+P)_V+NL_P#H_3Z /4J "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "D!QWQ0\23^&/#PGM[Q=.
M>6=(3>-;M<>0#DEO+4$L>,8]ZVI+FDDU<B;M%L\UTGXC6OBGQ9IEAJ/BB>2S
MM;J%;>.VTJXMVOY^"K2L4VJ@)^Z" 2.:WG348-V_$YX3YI6N>\I]T5QG6.H
M* /-_$&E7LWQ_P#!FHQVLKZ?;Z#JT$URJ$QQR/-8E%)Z L$<@=]I]* /2* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M.Y.2./NTT!TOA#3/!UA=/_PCD>FI.$VM]B92VWWP>G HL!UM( I %4@"F 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "'I0!R7B:Z_X1739]0N=
M3O9E+A(K>)5+R2,<(B#'))(%53CSNQ$W:.ABZ;I7C#48)[N_\2G15W_+:6MM
M%,8QC@,[J=QY[ 5T-PB[6N8\LGKS$EQXDUGP!!'=:_>0ZKI!($EQY8BN8 3@
M,RK\K+ZX (]Z2@JGPHOF<%[S._M[A+J".:)E>*10RNIR&!Z$5S/1V9MN5]2U
M*TTJ(37MQ%:Q;MHDF<*N3VR:<8M^ZB'IJ4H/%>BW<\<$.JV4LTAVI&DZEF/H
M!GFGRRM=;!=/0V  146*%/2DQGFGCFSTRR\8Q:K=^&-1\0SO9_9QY%JL\,:A
M\]QPV?TIH";P[J=E-%J)LO"-]X<F6V9OM#V*PEO0*1U/M3 Z3PA=O=0W)?[7
MD/S]K4JV?8'H*5@.BI %- %, H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2F!Z#X!GN+W39;N[^:>63.\LN64#@X XX[4K@=32 *: *8!0 4 % !0 4 %
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MEF(Q3 W?#4<D0N$EDD>4, 1(RDC\@*5@-RD 4T 4P"@ H * "@ H * "@ H
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MH:U<"!I1IC'=%:1]@/O/CMR?PI@=MX3)VW>_ E\P%MP;?TXSNZT =#4L IH
MI@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ/H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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1'FC<!"H(&>U+8!0,"F!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g42675dsp73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp73.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )A D(# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * &2RI#&SNX1%&2S'  H ^/?V@?^"@6G>#]7
MN?"WPVTJZ\;^)((WFN;BPM7N;>UB3)D<;2/,P W.X*"#R3Q0![Y^S]\:])^/
MGPQTGQ7I3JK3H$N[8'F"< ;T^G<'N"#WH ])H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#B_BK\7?#'P:\+S:]XIU.+3[)/E16(,DS=E1>I/Z#J<4
M ?&=QKOQB_;[N9['1H+CX:_"!I-CZL[%;G48L\^6HP9,@>HC&3G>10!]5_![
MX%?#[]GO08M!\/6=O:W5\,375]*KWFHN%Y+NW+G'8< =A0!\JZG#<?L#?M*K
MJ,(D7X.^.IB)(E7]WIMUDLRX[ 9+KZJ67^$4 ??%G>0W]K%<02I-!*H>.1#E
M64C(((Z@B@">@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H J:IJMGHNGW%]?W4-E9P(9);B=PB1J.I)
M/ % 'S]HW[>_PAUGQ;K^BCQ$EM'I-M]I-_/A8KD C(B&=Q/(QE1NYQG% 'SS
MXF_:G\;_ +9_Q%O?A5\(YV\%:4UN9KK7K]A#<2VN[:TD0Y8@YP%3!XY8#(H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@!"0* /+/CA^T?X.^!&F(^N7OVG5KGY;/1K/]Y=7+'H HZ#W/'ID\4 ?'
M4\_C_P#; U :GX[NU\-?#:*[G6/PS9,Z33Q16OG,\K'&/OQ Y&X$MA4(H F\
M._L6_"C2/%.FZO\ \(X5E@NK.6YM+BX<PDQV#7-PI0G#)F2 $'(RA]2* *OQ
MP^&VLZ9!X5^)'PZMGM?'O@JWLDM+"W146>)HI;V]MW7NOES( /8@8)H ^UOV
M?_C;H7[0'PMT;QEH4@6*]CVW%JS R6LZ\21..Q4@_48- 'H] 'B?[5/QSU7X
M&^!X]0TG2H[JXNW:!=1O6VV=D<9#3$'//\(X!. 2,T ?F7X@A^)WQ1^(/AO6
M-1U/4O%7C74X!J.ES:7=(LL,1.U!;QH-L*J1EBPS@$D T ?KA\(H_%<7PV\/
M1^./LW_"5I:(NH&T;=&90,$Y[GIG'&<XXH ZYAN4@C/M0!\"?$'3[O\ 81_:
M0M_'&E0S#X2^-)S#JEE#N:.PNF.20HX )W.N!U+KW6@#[RTO4[76=.M;^RGC
MN;.YC6:&:)MRR(P!# ]P0: += !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MK<Y90.?XERP'8[U[#(!]M]: %H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?,07!/\ %O QOH ^Y]%UFS\0:39ZEI]PEW8W<2S03Q'*R(PR&!]P: +U !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M.S!QZ4 ?<- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\8?$'6?B)X.U73],TC2;"]U'1]3,^JQS2;"-+M[#R8;F/GHYDG( R=YQC@T
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M5=&&0: -6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M8:E8N S1@CJ<8=#ZC'\1H [30M<LO$FD6FIZ?<)=65U&)8I4/#*?\XQ0!H4
M% %+6=+M-9TNZLKZ%+BSN(VCFBD&592,$'\* /G+X9_%/X=_M #Q_P#!*\UJ
MU\6R:+&UA<!CN-U:-\H(8_>DB/R,PZ,JG.30!Y;^RMXPU?\ 9?\ C)J7[/WC
M:X>31YY3=>%=5G.%GB<G:F3ZX(('1U/]X4 ?=8.: %H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#@/B]\;_"?P4\/OJGB341$Q4F"P@'F7-RP
M&=L<8Y/UZ#N: /G31M&^(G[:[V^KZ[?7'@'X5)*P70+1@+[4=IP1.W\ R"""
M!C' [T >S^"_!ND?L]:U!H>BV4>G>#-:E @1!Q:WNT##-U*R@<$G[P(_B H
MZ?XB:=)XMTV.VT=@NMV-RL]K=YV_9)5S\QXY4C<I'=2P[T+XM=@Z%KX?:Q!X
MJT^6_ECDM]4AE,%]8RMDVEPH =0/0]0>X(/>@#QKX\?#/6/#'BN'QIX,L;FX
MU"\N+<,+./S&LIUE#-,L8ZK,FZ*3_>4G@$@ ^BM&N+N[TJTFOK<6=Y)$C36X
M8-Y;D#<N1UP<B@"[0 4 % !0 UW5%)9@H R2>U 'B_C[X]R227ND> XH-7U2
M%H(9M2GS]BMFFF6% &'^M?<V-J\#!R1@B@#R+6_"W]I1W^HS:E>:GXA(OIK'
M7)Y#YJ3-=1VED5VX"*&.X(H X;U- 'T3\(/B)_PG.B74%XR#7-*G:ROT085W
M4X$J#^X^"1^([&@#OJ "@!&&010!\T_%?P^?A%XFGUZVA3_A%;][G4Y5Q\UO
MJ8MG2)5]$E+-]')Q]^@# \7^%='U?P[JVBZ]9QZSH=O'-!/;.,F2&PTX1X]?
M]>\A!ZY<=Z .._8H^)FJ_!KQUJ7[.?CO4&O)=/+2>%=7DR$O;<<O;@G^*,DX
M&>@(["@#Z>LQ_P *Q\9_92 GA;7YR8&'"V5\W+)CH$EY8?[>1_$* /2 <]*
M%H 1N0: /!V_9)\%>#O%^O\ Q"\$:)#I/Q!O[C[;]O,C%'?^.+;G"I)DAL#J
M<\X% '*_M.?!R#]JGX.6FMZ CZ;X^\/2-=Z6[$)/!=1_ZVT=NV2N,],A6'8T
M ;O[&/[1Z_'GX="VU7-KXUT BRUJRE 619%ROF%>V2K C P0>V* /H:@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@"*ZNX;&WDGN)4@@C4N\LC!551R
M22> !ZT ?+GQ7_;(DOK>^TKX-::/&VIV[B.]UU5)TO2P6VEY) ,-CKQ\O!.3
MC% %']ECX-^'O&S+\3O&&HS^-/'UPJ-,-3.^+3\C<@BC/R[2"&5\ $'*A>E
M'M&OW"?"OQ;_ &Z&$/AS6I FIQ]K:X ^2Y [*0-K^F%;H#0!O>)_#;?$+1+G
M2[W=:V4Q^9XG!9AG*NA'0C (/8\CI0!!\.]9NA]K\/ZVP/B'3<+).5V_;8>1
M'<C'7=C##LP(XXH U(_""6GC-]?L[AK8W-OY%[:A<I<%2/+?KPRC<,]P?84
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MN]&'3U.* /4OA]XBO2TWAO7G_P"*@TU0#*1@7L&<1W"^N<88#HP(Z8H [:@
MH 0C(P: /./$D3?#GQ7)XH@#_P#"/ZAMCUJ)>1;N!A+L =APK^VUOX3D ^7O
MVF?!VK?LS_%^Q_:$\"6S7'A^]*0^+=.M\;#&2!]HQC[K# 8C&&",3C- 'V1X
M"\=Z+\2?"6F^(_#]['?Z5?Q"6&:,_FI]&!R".Q% '0T % !0 4 % !0 4 %
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M>6QZ<$JC>VQO6@#[Z0[E!!S0 Z@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H :[K&I9
MB% Y)/04 ?,_Q;_:W/\ PD:^ ?A-8Q^,_'-S(;8S)(!96#8Y>1_XBO4@<#N>
MQ ,_P[^R'<^%;@_$'6]7N/'?Q0@F%]YM^Y:V( ^:WCC/RC()"M@8;!&*!7/H
MSP_XKT[Q'X?MM7MI<6T\>_:XPZ$<,K+U#*<J1V(H&>>Z!-=^#/$EOI+AM/\
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M<\ [1W;L0#9\$^$-'T2>XO([LZWKDF%N]5N75YY/]G(X1/1%P!^9H Z\D+0
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MUO<,?,GCC.P2<_>(X!(ZY#=^ #ZGH * "@ H * "@ H * "@ H * "@ H *
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M+9V\4";MD:!%W,6. ,<D\F@":@ H * "@"*6ZB@($DBIN.!N(&3Z"@"2@!:
M"@"-[>*1T9XU9DY4D<K]/2@!^ !Z4 >>ZCXTGU?5KG3/!5E!J%^'\N\U:8$6
M=HP[,P_UKC^XO3N10!/X9\*:;X:UQ9KNXFU[Q/=C$^I7.#(BX) 51Q%'Q@*H
M^N3DD6JN!/\ &+Q3I_@KX<:WJ^K:3<ZSI$$/^FVMI&'<P,0LC[>X526/? -
M'S%XU^)7B1O[&D^&^H7'BSQ!X31[Z$Q3[K+5='=%+)+S\UP@VC: 6R > Q!
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % "$XH ^=OVE_VRO#GP%,.CV<#^)/%]VZPV^EV>7$3L0$\TJ#M))X7J?8<
MT <O\)_V=]0^,MS8_$;XPZ['XPFNU%SIN@0*%TZRC/*@ISN8=",G'0EC0![/
MX-4?#3Q$?!\OR:)=;Y]"<GY8P/FDM/\ @'WD']SC^&@"UXMTR?QO EQI,8MM
M5TM_M.FW\AP!,!AHG'78P^5AZ'U%'2P&I\/=5T[Q+HJZE;VQM[P,\-U;RG,M
MK,#B2(^F&[=#P>]): ,T#PI>>%_%NI2V+QCP_J>;F2T/!M[K/S,G;:XY(_O
MG^(TP.IN+&WO5C%Q!'.$<2()%#;6'1AGH1ZT 3  =.* %H * "@"EJVLV.A6
M$U]J-U%96<(W23S.%11[DT <U\._BQX?^)\%]+HD\[BTE,;K<P-"S+R!(JMR
M48A@&Z':?2@#SW]I7PY_8NBW/CJSLGNI;*QEL]2BA5F9[)^'E"K]YXT,F/\
M9D>@#R?P5\2=(^,/A&Y\3>'&FFTZ_349HH;B,QR(TC0V$ &1U,:2D=OG^M &
MYXD%W8:E=Z_HS.VI:)-?WUHH(#2B#R+*.W8]TD:*<8]7!Z@&@#Z1\$^+K7QK
MX>M]3M@8W8M%<6['Y[>925DB;_:5@0?I0!OT % !0!#>>?\ 9I?LVS[1M/E^
M83MW=LX[4 <?X?\ AUY&IKKGB&[_ +?\0 ?)-(FV"U_V8(^0GINY8]S2>P&C
M%;:QJ.HV]U-.=.M822UHA#>80>#G X(_SWIQVU$^YR?Q8^/>B?#2UO+:+&KZ
M[!;^>=.BE5/*0LJ"29SQ&FYE&3R<\ TG*,5>;LO,WI4:E>HJ-.-Y/HM3Y9N]
M4UKQ'XMM?%^HQO!H4VO&*?Q-'"1I]NC1>3'+;P,<,P/6=P>W&.!Y:Q_ONT/=
M[]#[9<+34'3G6BL4HN7LUORI7?E>W3<^P/ _PUT7X>^&A8>'(_*G:".,ZC<'
MSIYMBA4+N>6P!@#H!T%>I='P;TT9-J-_IO@&V?5=4N9)KRY98E2)3))/(0/W
M<2#DDXS@=.3P,T)W)MJ9EKH/B'Q]<0WOB)Y="T9&$D.AVLN)I<=&N9%/X^6A
MP.Y;H&4>A*-HQ0!#>Z?:ZE&L=W;174:NL@29 X# Y#8/<'D&@"< #IQ0 M $
M%Y9PW]K-;W$2S03(8Y(W&592,$$=Q0!\OIH'_"O_ !S)X1N% LA<6USIH=RQ
MET^W:YNW;<?XDG>)&R>BH>] 'E/Q]^%=A\3_ (:VUO<ZI!H&JZ=%8RZ;K-T_
MEG3;LQSWTS;LC (DMU/TSVH WOV0_P!LCQ]\<-1\'Z!<^';&Z$-ANU[4H)F9
MQC*I/TVIN*_<.223C&#0!]>>.=6TSP_X<N-7U.U6\6QQ+#'Y(ED:7HBQC^^2
M0HQZT ?(_P */V[?"&B?#G6-5\5PWB?%&YU:6VN_!]G 7OI[@86*.&+KL"!1
MD]"&R: .*UKPY\0OVL[NWU/XH7;^'?"%REC/I/@C2YCL8W%UY<37KC'F':-V
MWIR.E 'LFBZ#IL86STRRM]-TJ62X>.UMHPD)@N+Z*TC 4=,V]L/^^S0!XOX[
MU?4?V??BK9?&K0HY)--U/RW\6V8?Y)X;FYF2WDC7UV0@_@IXR20#[_\ "_B;
M3O&'A_3]:TFY2\TZ_@6X@F0\,C#(^A[$=C0!JT % !0 4 % !0 4 % !0 4
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M@,_3->\1>*M9@ELK$Z-X=B?+W&H1$7-X,'A(C@QKT^9^3V49S0!VHZ<T +0
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M)7^_P ?=:G*@]: %H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M;S*R2C[/'("[ESQLB0 LS'L *ZG9GC+LE9&"VEZY\264ZZTOAOP[(W[O1XY
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MF6]LM2@$UL57B52!Q]><8- '%Z-I\?@SQ/#X6OFD&@WIDFT5RWRQG&9;-O8
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M%GPX\->-XG36]$LM0+*4\R6(>8 1@X<?,./0T >7>*?V>]5TZ*XNO!WB*59
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MT;:?%F&YT#6[;_A'?B!I(\O4]#GW*VX ;I(]P&Y<GMG'J1@D ]K'(H 6@ H
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M\/;!9M(LW#W^LSQDM+;YQ(;%/^6LBCY@S#8<8&[- '??#GP_H.G:)%J.C/\
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M(WAFQU_P]J$.IZ7>1AXIX6##W!]".A':@#?H * "@ H * "@ H * "@ H *
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ML?A_\2?AM'X?^$7A;PW;>$=(FF,?C?Q2"TVH7B1X9+:/'F.2&&97&Q<@@<4
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M$XR>2*$)G!:AX>*ZGJ6I:G?3ZSK36FK1/J-U]XI'<6!1%7[J("3A5 ZGKG-
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M2_L90-P'RR0OC)21#RK#/0T =90 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!\@_MN?'[Q]\.9[7PYX;L9?#FF7PC9_&+@N-WS,;:$ '9*VS;N;@!LT >@
M?#+]K+1?B%:Z#/;Z5?6^GW1@LKW4+EXPMG?2H&C@=0=S;B<;P-N2N.O ![VT
M@2/>QVC&23VH ^4_CW^U+X=O_%6E_#OP7X?T_P"(?C/4IVMH#=11R6%H_.XL
M[\.P"DE5/;DYXH \*\"?"KP]X+\0WESX[\-WGQ$^.,M[*-.\,V<R&TLX0XV3
M?N\)#"2 =S@$8P%]0#COVXOAS\4)?#L7Q"^)'BS3-2T?3[Y(#X5M28["S1U
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M)/#5V)K>50)K=^);>3 )1U['GZ$8(H [N@ H * "@ H * "@ H * "@ H *
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M.>#@>F: /!/V;=?T#2?%P^(_CF&Z\?Z]IY-Y.@WW']DPI*Z-/<$(<R+M!"D
M<ALGL ='H_Q"L?$>N>.8_"T5[X_\<:@\MW<>,-<*'[/HZJIS:QR<)/LG*;0.
M.#@ \ 'NOA?X;^!O#'AZRU[P]>WJ>&X-.U673K-YF>,RXLE654(SYKK*RD#[
MQ(XR,T ?3OPQ^'%UJ^M?\)AXHM1#,MW<7FBZ5*OS:>L^TR/)ZRMMSC^ ''7-
M 'L9(1<G@4 *K!E!!R#T(H 6@ H * "DP,+7M-OM7+VD<_V6T<#=-&2']UZT
MK <WJG@N^\9ZU%9ZPS1^$]-V;+)GW-J4H (>8C_EFO\ <_B(R> !5-B6B.J\
M2>)-.\&Z#<ZIJ4RVMC:IN8@9)QT55'4GH .] SY2\4>$M4_:]\0ZCH>OVKQ^
M#I["WECV<QZ<K2%B<]'NG15'3]T&/.>H _QW^SYJ_P"S->V_CSX&6>RSLX%B
MUGPEN+17L*C!D3G[X&2>^>1W! /H'X*_&KP[\<_!MOKWA^X#?\L[JS=AYMK*
M/O1N!W![]#0!Z!0 4 % !0 4 % !0 4 % !0 4 ,E7<A&2,C&1UH _)[]I7P
MVGP-^,=[KOAG5Y/$4MS<I*=:N+=VNK*]AE$C1?:1@, K*"BY)4X;IN !]0?
M_2_'GQS\(7LVN7.MZ5IFKVDL=]J-],8_M=PLP,$UI"<&.%H\JZ$!6!&,]2 1
M_$S]M6Q^ >B7G@J/P]'JOCK3K=UMK3P_"9=/,21ES*=G,>U1DQ'YAZX^:@#Q
MGP#H-I\>9K7Q7X_\76GC?Q!KFFB2STDLJQ:8;BZB@B$<6<Y5#*Y_NE1G/6@#
MUSXK>'+_ %Z&+7_#4RV/B;1[NZUG1YT&,S-=PV=O _\ TR=%D0K_ +.>U 'N
MOPI_:3\(_$/PGI]]<ZI::/K+,UI?Z7=3!9+.[1MDD+YZ$."!G&>,4 5?C/\
MM-Z#\,!)IFFV[^*/%>T,NDV#C$ 8A1)<2=(DR1R?7IS0!X7X=\ >._V@?%T6
MN^(+V*].G:G.B7+(3HUK%Y!0?9(3_P ?$H=V/F-E08Q@GH0#TK0?#7AW]F#Q
M=>VL*2RKXDTV,VUX]N;B[NKV >68L*,ME&C(08 "GH 30!X2?V,?$/[1'Q(M
MO%'C"XU7PU 80-?@O(H@]W=!^EJ%^58R@C^8C(P!R0< 'W)X%\ :)\.=$32]
M"LQ:VP.YV9B\LSX WR.Q)=L <D]A0!T= !0 4 ?-*_"SQGK_ (Q\2:?/L\.>
M'H[\7$6NAU>::,WLE[MAC.0.6C4L_ VMP:'H!ZYX TCPWX0NKW1-!L&CDR;F
M\O2-S7$K?,7DD/+L=V<GWQ0!Y/\ M0_$S0-?\ :]H&E):ZUJMJGFK<-+MBLY
MU8*A5@"9) Y4;$!.3@XYH YO]CSQIXP\$Z;:>"?B1 ;&6]D9]&GN&PY=MTCV
MQ7^$@995]-P["@#ZVH B,"-(LA12ZC ;'(% NEB3% R"ZL+>]B:.>"*:-AAD
MD0,#]0: .0F^"W@J2\DNX?#EC87<@P]QIR&TD<#D;FB*ENO?- 'D/Q<^&5Y\
M']23XG>"6N[W4+%=NHV%[=NZ7%OC'4Y( X!ZXX;^'! ./M+^\^*EE%XDUS4&
MU.^N[&6*RMPI6TM&N+X6T CC/1PJY+-\WS'D=* -/Q58MK<=]<V#>1J:2WM]
MI,X!(BNC<0V-BXQ[0IQW#'U- 'MG@#XH-XQ\.[DM_.UJUN'L-0BAY2&=,C?Z
MF-\;E(['V- '4:KX>B\8>%YM,UR!"MS%MF2-CA6'(96Z@@@$$<@@4 8OPZ\2
M7DAO/#FMOOU_2-J23$ ?;(#_ *NX4>C8(('1E8>E '#?M&_&SP7X3\.ZAX7U
M2!?$FKZE;F :#;2 2.'X!=O^68ST/7CY0<4 >!?##0_%&B+?^(/$?E6LSPW<
MTFG6V"4FLK<V<;D@=3YT@/)RR9XZ  ].G2/1;Z>61@T>DM)B9#]Y+"P\K_T=
M<S_B!0!K_!3Q)+\-M>'@S4Y8X]"N[@6FCNSDLEY';Q/=0G)^ZTC2E?3:P]*
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M#+$XH BTWXZ>-?&MWXF\26.F:=8>#?"5G;VAT3RELI6TUIHY#<10N=ZD&!<
MDAAG !'(![EIOBW2?B!IFH^(=#N4O](O;;5[N"9>-\8O;!B,'OA2,>M 'BWQ
M#\#^-K?P?\1? 7@33X?".B/J.J:KJ=Y911K/K,/G6Y>WA8<IMCN,9;J<@8'-
M '*?#+]DW2/AM;ZG?^);BXCTRRBU26TT21\M;E7L@/-=3B5FCF"E5^4XQ@T
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M68]23US0!P[:K)\;;F2TTFY>+P-#(T=YJ,+%6U-U.&@A(Y$0((=^K'*CC)H
M\D^-/P=U?X&>()OB]\*$BM#:Q#^W_#6[R[6^ME.6=1@[74%C@8SU'/! /:O@
M7\=?#GQZ\&Q:YH,^V9,1WNGRL#-9R]T< _D>A_.@#T>@ H * "@ H * "@ H
M * "@#S?XN_$C6_!45G9^'O"FI^(]2O=P$]M;-+;6BCJ\NWYCUX5>3[#F@#P
MS5-%\*>#HKOQ9X\T;Q/KEI'=_P!I7":U;PVVG)>%=OGQP,P .,*%YYYY8DT
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M\CGJ >X?![XS>&OC=X2AU[PW=^;$?DN+:3B:VD[I(O8_H1R* .[H * "@ H
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M02 >C^ OAMX1^"&B"RT:T$$URVZ:[G8RW=]+C):20_,['GJ>_% 'EOQ>T9O
MUXWC>RM7M]!U!9;F]L3%AXM2,#0V\I_NJP<HW^T5/<T 5;LQ^'[B[EC#7,&D
M&YDCPQW%+"Q6W0#ZS/+^+4 9=S+=?#?5[?Q-IVR>YT57LKTEN;C3K*R0W"'_
M &O.WNI_O$#N: /J;1M5M]=TBRU*S?S+2\A2XA?&-R,H93^1% %V@ H * "@
M H * $(S0!\S_M._LS1^-8;CQ-X>LO/UJ(&4V2-M;SLJ1=0'HLPVC(Z..#R
M: '?LR_&O3F"?#K6;>UTS5+1Y8=,O+>U%K:ZND;;7:-,#;*I^_'USDB@#XP_
M;&\,_#OP1^T];W&HZ'J%A\/+Z1X[^XTRYB%J=9**Z\'_ %4?[Q/-'0\\9SD
M[SX1PR?%/XT7-I\&((;'PK+I;67B?4[:'R](6Z955Y[.'C:S!1C'#8!P!R0#
MZS\8?LY64ND6&H>#-3DTGQYHF^6UUF23>UU*PRZW?]]7[YZ \< "@#PC4OC-
MJ<-K]@L[&Y\+F:_.G^);*TB%PUCJ!#-(NF,N?WLL:.Q !";E;ACR >T_LN?
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M >A?LPP^.)KF_P#^$SN;+P_<Z9;QV:>"M*MT2WM58!EN"XR79\'E3M'S#J*
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MGXBM$:*+Q2BG_4HW 7 R7"_?QA>,Y /I>YU.RT"*WT^WAPR*J1VT"<1I]T'
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MPYK_ ,>=,GTJ]AN/"/@V4JQ,BJ-2O"K!D9001;J&"D9!?CHM &U\.?@3X?\
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MVO?,.&MX&[*.CR#_ '5.<D(#K]-U33=,NK;0--MU6*WB"B.V4".! /E!'8$
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M "@ H * //?B5\#_  ]\4]0L+O5VNE>V*JZ02[5N(ED641/Z+O1#E<'C&<4
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M[+%_ JD#J26YSUH \U^&'Q)U?X1WUW8ZVLEUH5O>26FJH%):PND@2>YO(_\
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M_P#@#X[\0_$OX2^'?$GBKPY+X5UV_M_,N-,E!!C.2 <'D!@ V#R,T >AT %
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M]BD/ELG&X,.>M 'N]N'6",2,&D"C<P& 3WH DH * "@ H * "@ H :Z"12K
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MZ^9NZON/WP?O<YH \UT:Q\;ZY = N])T9?&4EQ]F\1!8Q<:3/"/]7?LG\$[
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M?;@[^9"[8(53@@#M]#2L,\#_ &R_@FOC?PB?%^E+Y7B#0(C*YC?RWN+5?F9
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M,/Q2MP?%M^PFTS0V&8M'CV*B_+S^\V*N?3D]>@!]: 8% "T % !0 4 % !0
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MU\!;CPO\)?@_-KOB#69=0U_1+&"S\1W]U#FYM#"BJ(C&F=L:#!&,@CYB3UH
M] U;QJFMFVL_ CVVHZGK$*W1U5#YMM:6[#B9R#AB1]U!]XC)X!- %S0M/7P9
M:1Z9X?M)-4NY;@OJ-_=/^\>0XW32L<%B>V.@  & *%JQV-_2?%\6M^(+S3K*
MW>XMK)=MQJ"L/)6;/^I7^\P')QP. >:!'0T % !0 4 )CG-(#+\2R:JND3+H
ML<+:BY5(VN&Q''D@%R.^T9.WC.,9&<T6 K>#O"5OX0TLV\4TMW<S.9[J\N#N
MEN)6^\['\  .@  ' %,#>H * "@#S?XN_%N+P#9/I^FQQ:CXJN+6:YM+%GVJ
MD<8^:>4_PQKD<]22 ,DT >46OP^\9:%XF@\2:LUEJ6E7]K9ZCJE](SBY6XMX
MYY2I4C:D0D>$* ?^68XZF@#E?%_CW3_A?X6BU;5F?R[5M+M!98)FEG2&2_:-
M!W)DEMA_P'GI0!-^RM^S?KNM:EIGQ0^*\23^((K.*#0]%EB&W2H%7Y68'_EJ
M<D^Q8D_-T /L*@!: "@ H * "@ H * "@ H * $(R,4 ?(GQSTC4/V8_BS#\
M8/#%NTWAG67%EXGTPNRP([<1W1PK;0&VY8#@YZ[J /?O#'@9=7NK7Q)XBU"+
MQ%J3();3RQ_H5HI&08$R03@_ZQLL>V!Q0!V>I+=-92+92)'<X^1I!D5-@/,O
M$GCW0_A)(T,ES/K7B._D1$L$D!8%B=A=CQ%'R?F8XP.,]*H#QZRT+QI^TQ=Q
M7M],EMX>:*\MI6DC)LHCYP1'MHV'^D/Y:-B5_D'F_*,@B@#Z<\$>#['P%X5T
MW0-.:9K*QB\J(SON;&2>OU/08 '   H W: "@ H * .6\877B(M!8^';*W$]
MSGS=3O&!AM5'?RP=TC'L.!ZGL4M *NA>$]'\"^;J=]>&\U>YP+C5]0<&:0]E
M!Z(HSPB@ ?K3 [(,"H(/'K0!\E?M;?M&^&-.LH_#_AV4:OX[T^[6XL;NSD!3
M3+I/N[R#ERV2AB4$L&(.,T <7\%_V:M6^/VIMX]^*>IW4O\ I!1]*-Q()V>/
M*F.9>! H/(C4 ]#D9- 'U\WA.UT;18-(TI;?0= MHL>79@0B(*<\8X QU_&@
M#$L?%EYXEFM].\%6T?\ 8]LX2?7;L$P%1]Y(%ZRMVW9"CU)XHN!Z/0 4 % !
M0!3U?44TG2[N]=2R6T+S,HZD*I/]* /D_P -VS>+S9Z]J[F[U[Q#8Z8EY)-Q
MY4=U<&9X8P2=B);Q,,#KM)/)H =?ZVE] MI;V\VJZMJMJ+@Z1:#=.Z7^H>9,
M1G@!84<;F(4 #GI0!Q6M_!'Q-\'?C7<?&5B'\3>([A;6WL;2=C;QRRW2XMIV
M/#*T+, P  :-?J0#Z_\ "FOZ1X]TZP\06=X9+>\0HMJ[C"2HWSH5_OJP8$>H
MH6@$_C_PF?$VCI]DG%CJUBXNK"\ _P!3,O3/JC<JP[@F@#RR+]H#4?B6AT3X
M<Z=]LUR,"+4=0NHV-GIDO =&;@.PYX!YX(!% &E:_LX67V";5=3U%]7\>$K<
M0^(;A 'MYT.4,8_A3/!7)RI(X!Q0!W?A'QRVM>&I[F[M&AU?3W-MJ-A%\S13
MKC<!ZJ00RGNK U+; A\5^$5^)>A:KHNMV\3Z!J%L(UC*_OD?J'YZ$?*1[BJ
M^9?@#XQU']GSXIWWPP\4N(](N9O]"N"J1QK*Q^210I&$D'!PH 8<G)- 'V<#
MN% &#I_A*#2O%6H:S:SR1#4(T%S:#'EO*O E'HVWY3ZA5]* -^@ H * "@ H
M 0G H C29+F%9(W5T< JRG((]10!P.@>+-2TG5M0\-ZOOO\ 4X6-S97*J!]K
MM&;A@ ,%XR0C ?[)Z'@ YOXH_##5_%&C)K22QR^(=-FCGBC@4+]IMDE25[4G
M'1S&A&<@,H/K0(\@M1J6N1Q>(?"]W'8Z]<Q);DW,8>&>2\N[AW@NX_XO+B6,
M<\J<^] SI/V1/"%GX9O-0E\)ZXX\)WENMQ>>&M3B N[*];&)8V7@02)EE &W
M&,8Y% 'K&O:]?>.]8NO#7AB=K2S@?R]7UR'CR?[T$)Z&8CJW1 ?7BE8=S8T3
M3/\ A'K*TM;&&+1- TV-O,CDX+8.2VX]01DDGJ3G-*VMQ%OP?XHN?%LE[>QV
M:V^A[E6PN7)\RZ'.Z3;V0\;>Y )Z$50'39'K0 M !0 4 % !0 4 % '!_$WX
MHVO@=M.TNU5+[Q+J\HM]/L2V%R>LLI_@B7!);VP.: /DOP;JOQ2\=W\WC_P+
MIMGK,VF1SC5+C6K?R_\ A()#+EK2UR?W:)&%0,>-RCKDF@#ZL^$7Q<\.?'GP
M4=2TQ63:S6FI:/?)MN+&<</!-&>C#\B.10!\F_MM^&YOA)\1_AW\0+&V/B:T
M76BTN@73+*&N&(VO'%D'A!MW*&(V1Y&!R ?=6DW;7VFVMP]M)9O-$LC6\V-\
M9(SM;'&1TXH N4 % !0 4 % !0 4 % !0 4 % !0!A^-_".G>/?"6J^'M5B\
M[3]2MWMIE[X88R#V(Z@]B!0!\T?LX_$>Y^"?BG6/@O\ $/4TAFTA&NM"U>\<
MI'=6/)"EW.,J <<_PL/X: -SXC_M&WWB^T;1_AM,WVC4K>[73M6CA\Z2[FC7
M:/LT9_A\QD'FOA "3R!F@#)_9S_95U_PYX7DNOB_KT/B?5;FZCU":SC'[GS4
M'R-<.>9V'7!^0$G@\$ 'TMI&K6=U++:6*CRK7]T=J[44C'RCMT(Z4 3:GXAT
M[1KBS@O;V&VFO)1#;Q.P#2OZ*.IH T!R* %H * "@ H X?QWJ?A_PE:3ZYXN
MU.W@TF!P\*W'&Q\?=4#ER>RC)-*/N@?)'C'X_P#Q"_:DUBY\)?"JPO=%T(JB
MW-]+"\$X1FP6ED8 1+M!(1-SGVI@>S_"C]D+1OAGHEQ>&ZBO_&\EO*EOK+6D
M:I8RNI :&+&W()!+-EFQR: .*TOQ]=ZCX3\4MX@CO-/UJW0Z+XST[224GAG*
M[(-2M^1A7&,G.,$9QM- &W\![WQ'\2)K_P %?%*YF&K^&8X@VE+Q'J=NP_=7
M4T@/[W.,%!\NX'.Z@#W'7M,M[6V6ZU2_CTC1],;S$:&7R8P@& &Z  <<5'+[
MW, OACQ?J7BW4VGM-*:T\-",^7?7N8YKINS1Q8R$Z_,V"<C QR; ["@ H *
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M@P:CHTQ"SV,P^^)/7)!._OSWS0!H27<_QDU Q6X*>!+:3$TQ&#K$BG[B?],
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M212 V_V;?C#<^*(I/#.J1^7-:V*WVES3RG[1=6)FEB3S$(RLD?E!6R>3S[T
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M2"<')H \V^$'Q:U/P5\.[+7=4U";[#IAA_X1J_NIYE-OY;_Z19VT3$_:MX8
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MM8S+<V%\!DP2CU'=6!*LO<$^U '0P!Q$OF8\S W;>F>] $E !0 4 % !0 4
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MZ_M)-6NO$#KOA6YDFD=)W&?W/FQ[<HV&SM.WF@#[0H * "@ H * $8[5)]*
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M<8Q3 ]S^.WQNU#XI7MC\*_A#?IJ&O:W$LFIZW9OF+2;%QS(7[.P/ Z@'U(H
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MZD=#F@"/]G'X?#2O&NH^*--NI](NKVU%OXJT/4HV:>YO0=T-Z&8Y7>A)QTY
MP"I% 'K7B'QU':ZO/I/AG3UUWQ,V!,B-M@M1T#7$H!V@?W1ECV'< FKCM#\,
M1Z+JL.L^)M735/$,_P"YAD?$<%ONZQV\?\(]6.6;N<<4=;!TN=T&!) ()';-
M Q: "@!#R* .4U[X5^%?%'B6SU_5='@O=5M(Q%'-)G!4,'4,N=K[6&5W [3D
MC% '5*H0 #@#M0 Z@!#R* *.D:3;Z+:M;V\D\B-*\I-Q.TK9=BQ&6).,G@=
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M123M;!Y[@<=<T ?28X% "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#M"]'.1TY'^]UH ^H8(([:)(HD6.) %5$& H'0 4 24 % !0 4 % !0 4 %
M!0 4 % !0 A&: /FO]JK]B+PK^TM+8ZFS1Z+XCM9$#7ZQ%EN(0>4D567) )V
MG/'0Y'% 'L'PB^$7AOX)^";'PSX8L5L[&V4;WP/,G?&#(Y'5CC\. .!0!UUY
M9P:A;2V]S$D]O*I22*10RNIZ@@\$4 ?(?Q+^&'Q!_9?NM:\7?!9(]1\+W4;S
M7WA&Y626.VF(_P!?$H.=HZE4&>HY&, &3^SGX6\:?M6>)=$^*WQ;L[:VTO1(
MO*T/0[>-A;R7()$EUM8G(R./<8R0O(!]L*-J@ 8 '2@!: "@ H * "@ H *
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M4 >D 8H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0@$<T -BA2%
ML:A%' 51@"@!] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 9'BSPQIWC3PYJ&AZO;+=Z;?PM!/"W\2L,'Z'T- 'R9\$M"U+P9\0
MM1^!'C/Q!='0K -?^'H%/EG5;-F8F)Y0<[8\?ZL8R2W)4 4 ?74>G1Z5I0M-
M+@@M4BCV00J@6-,#@8'04 <KJ=]I?P_AG\2^)M6$!95C =R0&)&(XT'+,S$
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MK>! B(OH .!0!<H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MX&22<!: /L'X3_%71?C!X1M?$6@>>^FSA=LDT>W)*@D#GG:25/N#0!VM !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M >=^+9=.\8^*](N_#.GQ:YXFT1YHXM4\QDL[#S$V2+*Z_P"M['RER<@$[>M
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M@!U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\O\ [5?P
M\U3P=KNF?''P1;,_B;PVN-5LX0?^)EI__+16 ZE5YZ$X'^R, '>>#_B/J7[0
M7ARTU+PD\N@^%[E,2ZM,H^UNW1XH8S]PJ<J7?N/E!X- 'I/ACPAI?@_3_LNF
M6PB#$O+*Q+RS.>KNYY9CW)H S[M]2O=26YGF_LG2;)B\NYL&3&>2?[N#GGTI
M1\P>@GAGQXGC#4IETFQGN-%B4XUA\)#,^<;80>9!ZN,+Z$]F!U= "T % !0
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MO@8SD#@CN#0!],4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MT')))'L.I('- '-?!#XNW7Q9TO6;B[T?^R9M/U"6S CE\Z&0(Q&5DP 6!!#
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MCD6102,J<C(ZB@"2@ H * ,7Q3/I^FZ3+?:E=&SL[;]Y)+GMTQT.<YQ@<\T
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MP^\7P/'\2O#\FRZO[N1I)M1M>/+E5W))11M7 .,;3P2: /J9BNWYB N.<]*
M/GCQY^U?X2T#Q-<>"/"%_I]_XD@E\N[<-N@L69'<95?FE<[<!$[D D4+0'J9
M/@/X%>(/B->)XC\=W%W:I>6MN+BUN,+>W3)+YI#$$BWB+!/W2?-\O)Y(H ^E
M=-TJST:QBL[&VBL[2)=J00H%11[ <4 6Z "@ H * ,WQ!I+:YI4]BMY<V F
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M5/IG>?\ 9J;@=EX+DTZ#1$M],TYM+T^WRD43*%!7^\,=<\\]?6J Z$'- "T
M% #7C60889'H: .$^*?B/0/!VB7&H^)-3DM].6(M]BAR99RGS8C5?F)]<=AR
M0,TK >$ZCXK\:_&;Q _AW0M,.F:/IM]%'/IJOMMS 8@Y^V3KGG<P'D1Y.0=Q
MQ3 ]F^%GP)T/X;V4$T@75]<6 V[ZE-$JD1EBQCC0<1IEC\H[=2: /G/4/$#_
M +%'QXEL+9!>?#KQO)YUMIL4JJ=,O<@,1N.$C/'/ QC^[0!]JQ2B1 P((/(Q
M0!)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?-/[67PN
MU>VFTSXO>!E:+QIX3S+-!$/^0C9#F2%L=2 21UXR.N, 'D_@G]J/Q7^V=>^)
M-!\)^&]2T/1;.)+??(0D<TK'YVN)U^Y&%!Q&F6?(SQQ0!]$_"_\ 9?\ !WP\
M\5WWC&32[._\9W^!+J0MPBVZ!0JQ6Z<^6@4 =V(')- '?WEWK5[J?D6")9VT
M,F)I;A,^8O\ L'_ZU$?,MI(?'XZTRY\4-X?M)'OM0B0O<_9DWQVHQD"5QPK-
MV7J<],<T$'1T % !0 4 % 'CW[0_[2'@GX!Z?I9\27*3:OJ-PL.F::A'F2RD
M[59B>$3) +MQ]:5@/,--\.^.?C_XDM]2O;U+72-,U-I8+]%)L?)^SE1]DB;'
MG.'D)\Z3Y<Q@J".*8'T'\/?AGH'PTT2+3]%M-FV-4DNICYD\VT8!=SR?IT'8
M"@#ROXC?"6_T?XGQ>)-!L3?>'O$X&F^*]+1UC 7'[N^4D\/'SDCG&".: //_
M  )X!N?$7QHM?%VEZW!KGBG1+S[!JLM^FVUU+2R-L4]L0N#)'C:6&<MN!;&*
M /I3QGXATCPR;>ZU&XE>:7,4&G6X,DMVW]U(QRQ_0=32L!@-H>J^*U74_&$X
MT+0H2LD.A03;>AR&N91C<>G[M3M'<MV3=@/1K6XBN;>.6%UDB=0R,IR".QJ@
M)J "@ H XGXD_"70_BC%:+JWVB%[<21^=9RF*1X9!B6$L.=C@#('H* 'G09M
M T^+1O#UO;Z%ID"C]\@ 4(1\V!_>R2<GOR:"M#*E\8ZEXU?^R_!LV;9#Y=UX
MFFB#P)CAA .!+(?4?(O<G&V@DI^,?V=_"GC/X?:SX:U*W>[DU-=\VJ73>;=M
M,O*2[SW5N0!@#D8P30!Y;^Q]\1M6M=:\2?"OQKJ5S/XQ\,&.")9VS%/9H-J2
M1')).,%LL21M/'( !]2]: %H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@K\6M'^-?P\TKQ3HT@\JZ3$T!.6@E'WXS]#W[C![T =U0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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ME=3D,#T(- $E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&@#U>@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H P?'7@S
M3?B#X1U7P[J\ N-/U&W:WE0@' (X89[@X(/J!0!^9-G^S)\9/@5J?B7QAJLE
MUXC\+:+J=O+/87%YDZA9Q*T>4&7<Q"*0_*S(!SP0* /TI^%_BW0/'?@'1==\
M,M#_ &'>VR26Z0 *L:X^Y@< J<@CL10!-KFK:#X#M)M0O9$M5FDR%4%Y)I#T
M6-!DLQ]%'-"T5@.9.E>(?B<F[6Q/X;\-MRNE12;;RZ7_ *;R*?W:G^XIR>[=
M10!Z#IFF6FC6$%E86T5I:0($B@A4*B*.@ % %J@ H * $- 'SW^UZOQEU'P_
MI6B_"01VUSJ4WE75_M&Z)<Y(9RP\I"N?G )SP,=: +'PE_9\L/A[I&B7/C.X
MM==\26L4BPK#&4LX'=_,?8ASO<O@^8^6STQTH ])NO%3^$[6[U3Q)?16]D[!
M+2UCBS*Q[*JC+.Y_NC\J.A"OS>1SFI>#=0^,_P!F;Q18_P!E>&()EN;?26 -
MW.ZG*O,__+(#^XAW>I[4%GIVGZ=;:59P6EG EM;0H$CBB7:JJ!@  4 6: "@
M H * .4\>?$K1/A[IYN-3N&:=T=H+&W7S+BX*J6(1!R< 9)X ')(H \,U?Q-
MKWQ'U2/4/$:QZ=X>L98[J#P\IW"3_0I;G_2F_C93Y7R#Y000=QP0 0:':IIS
MZ;;+&!#9&PBD@88VK:VCWTA'MYD]L#_NT +I$(#:5#+\\<0TR&7>/F0HDFI3
M9]LM:Y^E ',^+/'^A_#WPY9ZGXEO#;6 CTQ'C WS>9++)J,R*@Y9L+:C^?%
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H \_P#CC\(-,^-GPZU+PSJ $<DJ^99W6/FMKA?]
M7(IZC!ZXZC(H \N_9E^.MP= UKP7\2+R'2_&G@T_9[Z2YD"BYMQQ'< GKD8!
M(ZY4_P 5 'I']H>(OB?@:;]H\,>&&ZWTB;+Z\7_IDI_U2'^^PW'L!UH Z;3=
M+T+X=Z,(+6&.PM0Q)YW/,YY+,3R[GJ2<DT :]SJ]G8Z8^H75U%:V*1^<]Q.X
M1$3&=Q)X Q0!P?@?XX:-X^\8ZAH6F6]WLMHV>*^F0)'<[1&7**3NV@31X8@
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M2U 'V9#;QVT2111K'&@VJB# 4>@% $E !0 4 % !0 4 % !0 4 % !0 4 %
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MU:]UJ[8O>ZW?'S+NY<G)RYR0,]@?S/- 'JM "T % !0 4 % !0 4 % !0 4
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M!U$-Q#+ LT<BO$R[E=3D$>N: &6.H6VIVXGM+B*Z@)*B2%PRD@D$9'H01^%
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX@\03Q1&_O9//O[UY7'[QSU6/+;CT4>] 'TJCJP&T@Y&>#0 ^@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\&Z):Z1H6FVVE:9;($AM;6,(B#Z#^= &O0 4 % !0 4 % !0 4 % !0 4 %
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MZ$C(8<$$4 ==0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * &2=5^M "KU- #J "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
: H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g42675dsp74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp74.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *I =0# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M'R[X@CT^/Q5XDCDG$)L"K@ ;C(2<$_2N*M2YI:'I4\1RQY6>@_ /XP:3\/\
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M69^]W[(CSR?LV?#UKDAISI$!<@8!.VF2>O'I0!Y1^SO_ ,@/Q3_V,-Y_Z$*
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MO;0C&[W1Y)^T%XJEU:Y@\$Z<1ON0'NYL9VID?*!7T=-);GC3E:)P?Q'U^T\
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MU:;$M-CD_$.A6\^LW]RCLSF=B4Z=Z]&FER(Y7*5V=_X0\4Z%X=FAAO9Q$D@
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M?=@+=6ME##*%;< ZH <'OR* .1^+W_(P_#[_ +#D?\C0!Z90 4 % !0 4 %
M$-X<6TG^Z::W$S!0_,.U=!"+2L74IG(92* 9\UZI$UIK5[$PP4F88/UH$>&_
MM3::[Z%INH)%O"/L;G\N*I/H(\:^%WAX>)-81-2MP]CNVR1A@A '.<D@8J[<
MOO,I)&_X\T1=&@%S;+9QSO=/$ES9A6C,0'RJP#'#>_M1&::$S%^'FNV\'CO2
M'"L)Q<JN_&.<X_*L:R7(3U*/Q'T7[/X_UAG=53[42 O?)JZ:]TJ3)'L]/?P[
M)^[\J8CA\DXYYK4F+NB'PQIND:BS0W;B:%<$%@1CFDVD,TM?LM+T_P K^S 8
MX(\@G');-9IW"UD%IIRZC"+CRM^[JYIF?4YVUT"'[;YC'?&L^UH]OWAFF:'0
MWOANVBMY'BLA:HK F0 D>W4TUN1:SN=]\,-.75?"?B^QB*N!'OVD=/EZURU?
MXT46G='F0TQX;5P5+*XXXZUUD\UCG[VWDM+>-I$*1R$A<+Z=:92[CHI;N2W7
M[&K&->.4SS1= ;N@^'3J.JQ27,_D/Q)M"YW$=J!G8^$_#=I+XMMHUMX;?S]Z
MF53RN<GIGVK&HU;4E:.YR7B[2$M_$-S"L.\*^3(!UXJH?"A25W<BTC5$U&[6
M&WEG@NX^$ Q\Q]J)I37*T;X6K4PU3VE#1FAXHAO[*S2]U&.ZGAR%.\;3[<XK
MG=%17NG1BL75Q<^:J]2Y\/M1BO4GN;?"6V\!H+AQD\=O6O$S%3<$D.FT]C7U
M:6:_U(K#Y;.HR')^5>>GH:^0E&2>IVF#XQDN_(#W\[//&%$9A0X8>I(XXKKH
MU.5+U.6HFW=&-\3-!MK#0+#493YTUVX)R< * /\ &OO*"3BCC>Y>_9LOXQX@
MUA(84B#6P^9CUP:QQ>EK=PB=(_ARSN;V]:1CO:1W;;_2NU+0A[G)'Q#:VMM+
M;!]^),(#G"CWJ1GH7P:T^34/$,=]%;(PME+>86VC)! Z^E<>)A&HE&3LC*4N
M3X4>G:LEC9Q-?;(Y[Y,EKR?_ %,2]\ ]36<*=*A'F3V.7FG4E9GAWQ4^),TL
M!@TJ]V)*A2><_>F]57^Z*\VICG4T1V1I-;GCNN3KK-I%$MXB2$8&<-\P^E<5
M.?+/4V;2V*WP;AET/Q-)#=2[1<2LH93@!20.?IUKMK33AJ>IAI*<DKGTOX0M
M[G1IY25,MM'NDW/U9"?EKEA)2Y;'J37+'4]2\-POJ_PC\96X^\8V8#\,_P!*
M^FP\;L^:JO5LXKP9=>9\+H23APA#?7-=+TE8\64E*=CS_3I_[1U?5;L#Y5E%
MNK'N% )_4UL7&1J7*![(L6QZBLILJ.DCV/P/?IX@\)VL^T"91Y4R^CKP?Y5Q
M'I1/G3XJ>'5T3QE?QHFV*0^:HQZ__7S2G'J;7//;FW*B0*,G''%9\AM'X3];
M_P!FD$? GP7GK_9L7_H-=!RS^(]-/2@D\H_9W_Y ?BG_ +&&\_\ 0A0!ZQ0
M4 >"_'S3=3UCQE:6>D13W&H2^'-0$<-K+Y<K_P"D6F0K9&"1GN* /--1\ Z]
M+XAL+BP\#^+K?PU%'$+_ $Z35_WL\@(RRG[2>!SGYA0!]"_ O2=2T7X<6-KJ
MMM=V5RMQ=,MM?3>=-'$T[M$K-N;)"%?XC0!3^+W_ ",7P^_[#D?\C0!Z7N&<
M4 +0 4 % !0 4 07O_'M)_NFFB68*<M70"+$0(;.<"A"D>%_$O3WLO&UWA0$
MF E'X_\ ZJ3)/$OVB-/DOOAS(,J-D@Y]ZF/QB/G'P&USX?OXV>^2S260?OI
M651@Y)'I6]1-Q Z7Q?XCM]>A@%OK%I=113?-:P6;P@D<%\D<USQB]P,73Y-"
MT2]6_DM)6EM7\YGC/7;R<5TR?N25KAMJ=]J&D:+\1)(M:TU_]'N0)")U(8'%
M84I>ZN?1F%2:<M#C]3^&\FCQNUU>PK;2R[48!B1GIFME./<A5+%63X<13Z?+
M''J,"N^,,(V'?O0YQ'[6/5CM)^&4MA"ZR:O!(&(.THQI>T@MT/VL>YNQ^#(_
M)V"_BCQTV(XJN>+7NHRE4CT9<MO"D"H$>_B\L')586Y/KFL[V-74BNIH7C:6
MD?\ 9[71_>X8J86P0#]*EU+=!>TCNV=!X&T=-%O;R2P>-(+I-K)L8%N/>LY/
MF:D7&I!O1GF>H:3-=W<EM#/ J*#P'Y!]/PKKN;-)ZF'KGAB[TVP5I EP-W"]
M<4]R-I&7#JMOIL9#PM YX Q@5#+O<ZG3/&^DZ9#;B72Y[B7;EY$'7\:CFL[
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MC&KL;^SB>*_'O]H3_A:VC66G"P%C))<+)/(9-P4XQQ@4J5.4?B->;ECJ<Q\
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MWXK10W4-S=PB4VUV%B^4 _Q;O8\UA7^,#]A?A3@_#S0<9*_94QGZ5B!U9Z4
M>4?L[_\ (#\4_P#8PWG_ *$* /6* "@#S;7'$?QY\-,QPHT#423Z?OK6@#B?
MV??%&BQ7?Q+NX]<FN[&#53-+)=KLC@&WD(>Z^] 'MFA^(].\26S7&FW<=Y"K
M;2\1R ?2@#@/C5*D.K^!'D^XNLJ6SZ;3F@"M\"O$6E3>"];U.W466EQ:E</Y
MDMT)AM&"SENPZ\=J /1-!\6:3XH21]+OHKU8\;C$V<9Z4 :] !0 4 % #)&
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M0!#>$BVDQP<4UN)F-;R,3RQ.:Z!1-"!^W>HD46D.5S6(&'XZT_\ M+PKJ,.
M6\HLH/J.::W$]CYULON@&NA;&1\_^(-+&E>/M06SU"RTDEF!GNX/-3)Y (^O
M>JZ%(YCQRWCUO#=Z\6GV6L:?Y16:YT2".9 O<D 96H0S+L-3NO$/P_17OH9M
M/BM$=25'F"8=8R.O![T^6X$O[/\ ,MM9:G: CY+E_;K\W]:QFK,Y:QZ)X\M$
MO?"MZI /E@29_P!T@T1.$Y?PQIL=U;+(\\2CT9L'%3.4D]#&522?*CJT\/Z;
MQONK?_ONI522,GS,?'H.F%V N+4 '^_FDZDA>\6&T33%VXFMR<]GI7;U9+<D
M<;<:?91^+M1A+Q%6*L/FXZ52.F+;@KFIJ^EI=>$==M[=XW=K<,H4Y/RFMJ>Y
MOAY6DSR#3=:G\/V\T=S#(Z2LH(B./Q-=9Z=[ER[FL[J*&5D5I#G!DQGK0,HV
MT1TW4 &=6P2VU>A!%0Y6 Z/PW<O>K<,Q\J%B%0-SM/<T7N(D\-6]RGC/5XH&
MCDE61&\S/&"@_P *Y);LY:VQO_$C3)KGPKJ@N95%NMLS/@E0 !S4G!'<^;K)
M=,M]-2.QS,IZ2'/ ]*DF<9-Z'3Z%;9=4DCZ_Q9QD5PUWRIL]G"W5E(TO$'B%
M=(ME!F>2!0?D8_*/QKPX2YY'IR:CK$\7N_B-?7.H-< %["&,[&!SY9!(X]#S
M7H*GH<K;;NSZLTFV&H_#K2[\%8$N((C))-_'QTKV,,K1L05/"<Q;Q/-Y,B-Y
M<+, "-N>U=%5<UD0<?XB\4ZO::Y=E9W51*2-N""/:M$K*P'0>$?$\>M^)--L
MYHS^]F53N."QS7+B9<M.3\@7Q(^A?C#"\'A\PVQ4*8M@3('05^?1=W<]!;'R
MW:VC::PNFC#,F5?8<Y%8SE=\@SJT\2H=(2:2!T7/RJ1SGM7F./-.P2CH<+J5
MC?:A?3W3(I@E "QJ,E>>OM7L8;7W(G-+E^(Y[3-/U"#59OM40*6OSJXXRF1Q
M]1FOH:=*4)+E-<-4@TY'3ZWKT6G0?;KN51$20H9N<>WJ*]'E-WB8<WNF_P##
M3QTADL[M5Q9W1\IR#CUY/KR*S7N2-YKVT3Z[^$\UOK\4UJ)E::W4*R==H_A_
M Y->JI:'A55;0[/3O"TVCZLTK;3;^6<XXW$]OPIRD<90U?=9:ANVG:3GZ>U7
M2)&2QB9'<#/I6Q$I''^+&$.DWN>T9 J C\1J^$KR+QKX$,+$><D9A8-_> X-
M1'EY^0]6/PGTK\+[:2S\ :'!*NV2.V16'H0*@LZD]* /*/V=_P#D!^*?^QAO
M/_0A0!ZQ0 4 ><:S_P E\\,?]@'4?_1UK0!Z/0 4 >9_%\9\0_#W_L.1_P C
M0!Z6.* %H * "@ H * (+TXMI#Z+36XF8D#;JZ'L*)HV0!Y/7/%<[*+U(""]
MB\^SGC/1D(_2FA/8^8F4P7DT6,;)&&/H:U,CYT^,\P\._$LW%S#]IL+ORY'M
MPVPOC((![9JD4C5LK/Q9J^B7B^';*R^'_AMH&DO+@CRWDCQ\Q9SF1_PP*7NW
MU&<5X+MBW@F]TZ.ZB95:9#+#$-I4 D%R3GGJ*IVOH!R?P=N#8^.-;TTN#@1S
M@CN&&/\ V6E,PJ['LVO_ +SP_J,9YS"Q_3-91/,ZGF&BW:FW0A@%/(K9CEN:
M$SY(/6D0R/S!GCK0(N03@%/F(/04/87+<Q=2#)XJ^\-KPJV:Q<HI:F\59'4>
M'+IH+F[BR-LUNZ\_A5TVFM"Z?QG"Z]:S6;'(0(<,V>:ZD>FSGKN1)K>/.5V9
M'3'>J74GEN7(I;<I WF@R9"G.3QBL([A>VA8BU8V>FS""4PO&V<YX.>U;!?F
MT'_"'6';QCK+7<P,C1PN">@^\*Y9QU,JJLK'J_CC1XM3\':JDI9O,MW).?:L
M=CSSYXT7P?8Z/HL!<GEMV]CS]*B<K(75&C"\<TXD;B),KR" U?/XRJHJRW/5
MI'(>-K:/589;9)7BBQN !Z>@.>M>=A[K5G<]CRJ*5XKJ>W-MY4.29/(0-E0>
MOL:]^#O%,QEL?4=YXJFU3X,V&EJJ*D$*%9%^5B/>O2PO4P9E_!VU,OB2]WN2
MQ@X&22>:WJ;@5-5LI;?7[KRV8Q^8V!W%:]!GH/PE\"P1>)-,OKG'G23#8I?)
M0YX/UKAQW^[R",?>/9OCI=&WTJ1&5B ,$@9XQC-?G_,>B>(V=E#<1)&%.TCD
M/U/O7EXG5B,3Q'//]F:&*%?+CR%YYJ\-'7WC"<I<QF^&;S[+I-U*T#N[#RR)
M.8V7UY[BOI\+2Y8\QYV*J:G%:[XON-(NIS>[+>%5;:47(8;2 "OY?E7K4??E
MS'-3GS>Z97B&U/Q"\)V$EC<33R11?,?N@Y]L5Z$91N>W##2:YHG8>!-+N-/\
M*:?&!AXD),>>C9Y_#)-<CW/8A'34^C/V?O$\ECX_MS-)@7H%M(0W!;'&?Z5V
MTI>[[QX&.H>SESGV%=0_:(!*!N9>HZ#I6YYQRGB&U\ZSCDQW(R>U7$RD8^GR
M&2WD4=CBM2#COB(QM](+!22S@$#TK2)M0^,C^"5T)([JS<86X9FA/]UUZC\J
MYI_$>K$^Q/"0(\.:?D$'RER#4 :YZ4 >4?L[_P#(#\4_]C#>?^A"@#UB@ H
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MHVC^(+-)KJ)YKM&4Q3 _*?\ /%<3H2YCN=.+ESG0PQI!M%PJ2Q+@'8WR@@<
MUTQT-CUWP ^J>)? ,6DJ55#?"!@AX1#RK9/TKCE+DESFW+&<>0]J^"'Q'83S
M>%-1G,EU:DK;7#@IYBCC'->]3ESQA,^)KTO8SY#T'Q-I\F)+D]%7<S#T]:[#
MC/A#XXWS>(OC!'9VZ,97CCMPZYX623YC_P!\H:NK[E([Z43[JL$6+1+.-!A4
M@11^  KC.D]T\(?\BUI__7%?Y4 ;!Z4 >4?L[_\ (#\4_P#8PWG_ *$* /6*
M "@#S?6CCX]^&3_U =1_]'6M '-?#GQ[?>/=%\?+)JTHDL+U[:)V5;=K5<'
MW'(..NZ@#NOAG>1W>EW 2^GU!HY=KRS7$<P#8'"LF!^8'6@#G_C:S+J?@8H0
M'&L*5)]=IH X_P"'NL7'B'X,>+Y+_4[K5Y8+ZY1YA'M=0I5MBALC '&<?A0!
MH_LV:_I&L#6XM*+R"!HA+*54#=@_+Q$AR.^01Z4 >Y4 % !0 4 07O-K*!U*
MTUN!SB1D')&*W M14"9=MG"J1[U,A1+RN"<5B4<=\6;1;KP=<N1DPLKC\ZJ.
MXF>#N8;NRG@=LI)&5/T(JZFQ"/G?1_&=SX6U6XN-,WP-"QMV=G^5^?[M>9C\
MLPV94E#$QNBE)QV,B\\2WVI1SQ&Z,HEDWR,P[=Q7)A,AP>&J<\%JCC5%7NS!
ML]?MM$\2VS^>8I$G4NI!P<G_ .O7T-1<\>7L=$4EL=9\3KJ;2O$[K;3^2;F-
M9%7&>&[UST816YHVK&78:<?)C6X/VD.=Q9G(.:Z+J.B,N:*W-6PTJUUFUN+#
M3YD4 _O<C)S[4^8.:+V,*[\*VNA:C&)V2:8<%L<'TS7/4<^:ZV-%."7F:UYX
M">$O<W#1S0.G"0@C'I73S<VI+DF[G'>(]8C\-FVBE@=T8$C;CUI"NB+0+>'4
M-7LKO8^\2AD[;:4GT%?4M^)+S5+;Q-);G:;4R <XSS3@K:%,FUGPO?PP8BD"
MR@@E>:W Q/\ A(_^$6LDM=1MYFN'D9U9".G _H:R:L[B-#2QIMW+:ZJ\B%9'
MW>4S?/CTQZT^8#U/0I+/6;5U@B<(L3$*_!R!6,Y:E61\VZIJ@N;^XAB4K<F1
M@,# ZULE?4G8O6>H2Z%93?VG%-%%<#;$X]14O0#4T5FFU&W"2-<1E05([?6O
M*QND;G90.]DU*<7:6[VOF*%P&4\<]S]*^1G[[N=[29YG\0/"*7\%]<6UC&7\
MILRHW"MUR?7H:JE4DI(RE$N6OVC4_AIHFEF6.*)(!MPN2"3R:^QPD>=*1YTY
M6=CH?A/X3GT#7Y;C[<LVR D!H]N.>]==;<Q>K1B>)=$@DUN^N?.)E:5R$VC\
MJM1ND:<QN?LWV.L#XCQBZAD%OY;E"<8]LUX6;?P5ZFD/B1ZW\4YVB66;S%;R
M^J;>17QLH<\O>.R4HGAL^L7TLP2YTGS8@K91G&6ST[5]#A:2I)2B>76G X_Q
M1X9L+VWBD^Q)ITB+EMTA4L_M_P#7KUHG)*4>QQOQ;UR'PGX-LM$MX&BG0^9(
M_#.Q/."1TZUI3W-8'C^K/+I'A7&HH[C5'::)T)R@ _3/%;/67,;4XG6>#;M]
M6^&J:(T8BBBF#)=0MGJ>C+_6L)MQU-H1YY'O/A'2X[/1+.VD=W:*!0I R2P'
M>HBN<]MU.2!1U3Q!Y7B;^P@"Z-$)O-Z88]1^E3-<AG2K1K:'MW[/FM)]GO\
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M#J/_ *.M: /1Z "@#S3XN.Z>(?A_M=E#:W&"%)&1@\&@#TH<4 +0 4 % !0
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MM[6S\]HFPL8<2+G&3UKKB]#66YCV&K'087^RX6*0@-YG-#28)V.U\,:RFIZ
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M)"09P)(\^HK*)F?:7A7_ )%^Q_ZY"M@-4]* /*/V=_\ D!^*?^QAO/\ T(4
M>L4 % 'G&L_\E\\,?]@'4?\ T=:T >CT % 'F?Q>_P"1A^'W_8<C_D: /3*
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M /.-9_Y+YX8_[ .H_P#HZUH ]'H * /,_B]_R,/P^_[#D?\ (T >F4 % !0
M4 % !0!%<_ZE_I0!C,N<UN@(3&%Z4P&!_F(H)8]3CCO3$:%KD'FHD4C!^*&F
M_P!H^#[K RT.)1^%9(35SY_O8?M&BWD>,EH6X_"K9#5CXQGUF?4M5EMI-@*N
MV%08(P:N.PAFJ2ZKX?U&&: !A(NY2Z@X]JWCHKC-[X;Z>;/QQI-S=72,+AR'
M1<]&'3VZUSUYMI%1W,OQ)X-1/%>H6=Y=;[$739",<A<\?C6T'>*,G*S,?Q#I
M&G^$_(ETN25HI7.Y@^2<>M:#3N9%SK'VB[BD5#@N.M!,XMJZ.ANK&:UM&?=Y
MA+[0O(-2R[6T.DT!9QHZR%<,#\R$^E- 8M[:W=Z;RW@MA'"_S><3GW_"BZ(D
M=?HL$MG\%]=MIG4K!()04Y R1FN2?\:(0;1Y;9:L;B.14+.J')&.<^U=)HW=
ME:ZDNX=3BO =N\?+$1W]Z!&MHEW=)97&(5\Z3.,KG&:2W O:;Y]MJB&6,LNP
M O&IPQ-%389>\3^.]1T&]_LZST^2:VV*2=AXR.>:BG%2U%<\CT^[DEUN3?,W
MEG< BGH<BG5^$2EJ=/;63%E16X<Y(8[J\+$Q]T[J3YE8YS6="O[+49)#*5AF
M&T(O0CT->"G9V)E$X;QI'-_9MQ*C%$1=KNQY;'8?SKOHNSMW.5H]\_9_LX-:
M_9ROXK.X<WTCR 1.<?\ +1N<U[E+30HD^'GP_P!:T[69+J]MH;RW2([8V?>"
M_;BMZCTO'<A1U,^37=)MO$MU#/<.@:4AH@#QST%7"I)Q3D,]=T'2K&T\#RVJ
M.\<+W!<J222#@=:^=QRYZWR-J>YRGB+4DFANPD26R6D01%9MS$'(R?RKQY1Y
M$=L3-\HR:2K.H$S0N2H_W31ES_VU&56)YLZW,6JV-];%0]JXD4,<<@Y[5^@,
MX3:\=^,M;^(-M80WR0JMFS%&#,2=WKG-)*2C[Q1=3QI=0_#R/PFFEVD-IYZW
M$TJR,6F8'//IG H7PD1B:<OQWU*+QOI^OR:=;EK"W-O#;;VV#(QO^HJ'[Q"A
M[Q4TOXT77E>*XA8+]L\0$O))'($6/C&0,=?QJ&^5\QTQ][<XJ\\)W]A+9B;&
MZZ02*=W !]36<<0I,T]E+H9DR2VDFR0;22<;N_.,BJ]M$(T9/W8E_P#L"\EC
M1]@7<0%R>M92K1-/J\CHM-^"?B37;=;BUAB*L2N6?H?>N>6(C\)TPPLIGT'\
M&]%7P=X>T^QU5%AGCD=F<'(SG&*\&LYNISP/4P\(TZ7O'MOPLNK;Q WB'1-1
M :RU'>T<73:.A _G7K.'U?DFCS\2?3/@+08/#'A#2]+MF+6]K L:,W4@"O3Y
MN?WCRC?/2F!Y1^SO_P @/Q3_ -C#>?\ H0H ]8H * /.-9_Y+YX9_P"P#J/_
M *.M: .[&IPRQ7#0MYK0@[E''.,XH YGX;>/W\>:=<W$UI#830R[#!'<>:P&
M.K<#!_SF@#$^+YQXA^'Q_P"HY'_(T >DPW$=PI,;J^#@[6S@T 24 % !0 4
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M*]]3TJ'P#;2_#*'4R'M&-GYCJQ' ]*YHJTF%[Z'G%MJNE>'--DDMKDL"?GW
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MI_">'4^(]/TH8TZ#_<%>K#X3ED6STJQ'E'[._P#R _%/_8PWG_H0H ]8H *
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M )+YX8_[ .H_^CK6@#T>@ H \S^+W_(P_#[_ +#D?\C0!Z90 4 % !0 4 %
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MGAC_ + .H_\ HZUH ]&9@H))  [F@!%D5_NL&^E 'FOQ>_Y&'X??]AR/^1H
M]+H 6@ H * "@ H KW__ !YR_P"[36X'*28YKI,2$^YH&14 ."YH 4)SDGD4
M 3*!@>M(:&:]J0T#PMJFH,<&"W=Q]<<5+'<^)O[3$LLDTL)D9R3\QY))JX[&
M4GJ0K!',G$80.<X SBKL9[LL6/A^$Z@DI39''ERQ]:PJN2T1JC \2645V]W=
M0\L055CW-:15D,\\OM&E6,AAO)/TQ5$=;E-M%E$T*8"1$C<Q' IE-V)KW0[+
M2F$]JQ,C9RZ-NI$-7U.0UV62YU$( TG0$DX)JMA-6,3PQI;WOB226XE8VBJV
MX#KCVIW*B=Y<:=:>"_#MU-93)*)L,"6R">F,UBU=Z,MO4XO4-1M?]"N;Y(WC
M:3+(!O!&<&KC=&3>MREJYTJ3Q%<W%A;O%:("RXX &/2M>81G1>)+B#2'F"/J
M*O+M 7@H,4G?<!?['76M0M9YH8$DDVX25OF'Z5+T0/70B\5W\FFZU!80W<?R
M;=R2L-W)[#%%-)*X;%33?%UC>:M=+>VOD08;<\ARI)/ Q6RV$W8?Y=K<EY+>
M2)[:WW2D6PP ..H/4UY>,M%7-Z4N9V.F>[%SHT9.3O4[,J0R_P#UZ^0JS]X[
M'H<#=011ZA/--&QC2,F147#$GHPQSD=:ZJ,^7K<S:33.Z_9IT*(:)XF24A[=
M)P]HTIP5!'\\YKVJ52+:L8)'K&FS"TO82[LP'5P_.!7IRM)#B;OPUVW'C.V%
MNA \QG9E;D@=<UY68Q:PYK#<]+\<7:'2[AD5)&ZG'.?:OC*LG&+L=1X;>W]U
M!>))Y#>4?EPK?=_"O(?O/5BYK&YI,<FK3JBLV\CHN0,5A4BH[F]-\QYK\9-<
MO-)\3164953%;(&X[\U^CY347U1*YQU/B/-I_&6HIT=/P6O93N8M>96;QWJP
M! >/_O@5I'0CF!O'&J;%S(A_X#1)LT(9/&6H2?>:,Y_V10URJXA8=9NKGN/P
M%9\S&:OARYN8M2A#/$4E.S:N-WY>E859\VQW48<ZY3I-?T=GCMOM*'[1;R J
MK'.U<]A7#)W.VG3C3V-8!GVME2T9W!B.O &*YSHV/HG]B?3S-\1-7NU/RPVO
M/7EB1R*QGV.>MK$^WH&+!N.U==SSI:G;:6/] @_W17HT_A.:1;/2M1'E'[._
M_(#\4_\ 8PWG_H0H ]8H * /.-9_Y+YX8_[ .H_^CK6@#IO'^FWVL>$=4LM.
M95NYX2B%WV ?\"[4 <M\#M-U;3/#UVFK36D\C3[HVM)_-&W&.3]10!6^-ERE
MGJG@6=V"K%K"N2>@ 4T 7O@KX_O/B'H-]J%P]M-%'=O#%+;9 *CL00.>GYT
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M$YO'4J('UC1U*\<;SQ1S!9CX/^">7C^'4UE34M#@A (++O+?6G[3R"S+D_\
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M-JSR1M'=A"NT _,,CGD5WX..$A64L3"\>QC6Q>*</W,K2/F+4O\ @FG\39Y
M+;Q5I\4( &/-DR?K7T<\1DTMJ-CCPV)S&E%N<[L[;2?V _&]CI\<;ZSIK7"*
M 7W.<G'-?F^-P$J]67LG9,]R&85N7WF7;O\ 82\;ZCI@M+G5=*(5?EQNY/J:
M\=9-63OS'//$.>Z,^R_X)\>,]"<7VEZYIL>IJ,;G#;3^%>O1P4H1U9Y]1.;'
M:M^P?\1KIXKB#6]'%U(O[]G5B-W?%=<<.UN9RI\VQ&O_  3]\=2Z?)'/K6D&
MX<\N%; ].*U]@3[)GGE]_P $O/B9<:G'?Q>*M*BN8W# D/M(^E6Z/-NRU%QV
M.7O/^"3'Q5O_ !%?ZI-XET R3]!AR#]15^S5N4W.]^$?_!,[X@^ _'WA_6]1
MU_2KRTLI1)-$&<LN#T7-85:-XVB=%.HE&S/OQ/!-VL*IYL60?>LHX9HKVJ()
M? =[(?\ 71=_6LIX)SZE1K6.MT2TGL=*M8+A@TT:!69>AQ7I0CR1C%'--IRN
MC$^)W@=/B-X+U'0))S;I=IM,@[5J0>=_"7]G#_A5OAG2]&BUE[N&QO9KL.5V
MEP[[@I'M0![<!B@!: /-=>*K\=_#;,VU1H&HDGT'G6M 'F?A'15N/!?Q+U*&
M6#3+>[OI&AO+>\,ZOM_Y:D#[KT ==^R];M'X1U*5]0GU-WO6!N+@,"< 8P&Y
M[_GF@#2^.2E[_P $J(UESJR_(_W6^4\'VH R_@;X@;3OAEK-_JFAV7AN"UO;
M@"WTR(B-T& ' [D_K0!6_9DLA]CUS4TCDB6]N-Y61P2#D]1U4\]* /<Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M -(P +'U..* ): "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MFB+#!*L,C(_&@#S^Y^,D:_&^R^'T$"-*]JUU/,2<@;20 /PH ].H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * &3
M?ZI_]TT >4? #_DD5S_V$M7_ /2V>@"S^S3_ ,D?T7ZR_P#HQJ /4: "@ H
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MG% "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ,F_U3_[IH \H^ '_)(KG_L):O\ ^EL] %G]FG_DC^B_67_T8U '
MJ- !0 4 % !0!%<SK:P/*YPB L3[4 </J7C.]U><VNDPM@\>9C)/^% $^D>
MO,D%SJDAFD)SY8/'XFG<#L(;2&WC6..)40= !2 ?Y2?W1^5 #@H48 Q0 M !
M0 4 % #)IDMXFDE<)&HRS,< "@"&PU&VU2W$]I/'<0DD"2-MP.#@\T 6: "@
M H * /.-9_Y+YX9_[ .H_P#HZUH \R\>%X_VS/ H2&;9)H\YDD7&PD-QGWH
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M "@ H * "@ H * "@ H * "@ H * &3?ZI_]TT >4? #_DD5S_V$M7_]+9Z
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MLK;%RHPIZXZ\4 0"?7=5_;DLI(]'B_L.QTR6"6\+L71MAVD#;@ ].IH ^IZ
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M)9 QYY(X_.@#MO@Y;:=9^"H(=(@>WTY99!"DDHE;&XY)8<')STH [F@ H *
M"@#SC6?^2^>&?^P#J/\ Z.M: /,_&L^KWO[87@Z-+"X_LBSTZ7==1Y,>]N0&
MXP/SH L^$=1DNM7^--[]B@MPLACWLA3S2D6"6;)ST Z4 >9:!]@7]BI(8,PQ
M/>.L,M[ND2!O-.&8[> .: .Z^+>J7^C:3\&+"&Z9X[NZMHK@P\)* J'D^F>>
MHH U+@A_VRK-'$0\O1]T3>7A^5((#=Q0!]$T ?FM_P %5O$CMXJ\*^'B8VB>
MQ:[V%/F!$A&0:<$W478YZ[2@^Y\(Z?;H)EW9QWKVJ5HS/'FWRGW-^RMKC^'-
M C;3-6N=-FEQN57^0\_W>E?3JCA\1!<R/)]K5I2NF?5EU\6[FUT&ZF\3VMCJ
M6BQ0E[J62//R <DCH:\W$Y3AXP<XRL=U+,:SDDT?%GBG5?@)\2_&OVKPQ<WW
M@B_=SLO[:-K>$M^>*^7C[..L%;S/8E*<MW\CB9/$WC/X?ZSI[74D/B/1WG\N
MVO'7#.-W0D=Z]?#XW$4)*,GS)]3BJ8>%6+>QZ'^V%H<>IZ?X0UQ8CO>$)(,=
M 0.*]'-&XQIUGW.;!I-SIQ/A#Q+HQTK6YX@,+GY37A8NG:IS=]3U<,[TSWSP
MAXFU;Q-\+%TV34?#VFV0B:US=3&.4X]1T)/%><UV.U:%O]A"$P_M9>#(]RN$
MFN%W+T.(7&1[5)6S/VR7I04+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ,F_U3_P"Z: /*/@!_R2*Y_P"PEJ__ *6ST 6/V:_^2.Z-]9?_ $8U "?L
MU?\ )*+3_L(:E_Z73T >IT <5\6[B*T\'W$LT=]*@8<:?)LE_ T <!J,=H_Q
M8\$W2K>-<_8@%\T @)Y9^^<9S0!Z1X&\:2>+Y-1S;);QVL@C7;)N9N.<C'%
M'5.X12S'"@9)]* *_P#:=I_S\Q?]]BG85P_M.T_Y^8O^^Q18+A_:=I_S\Q?]
M]BBP7#^T[3_GYB_[[%%@N30W$5PNZ*19%Z94YI#*B:@DFIR6>P[DC$FXGCDD
M8_2@ L]0CU"WEE"';&Q4@^HH DTN_74K-;A%**Q( /M0!;H \.75;H>+_'MG
M'HZ6R1V32"Z+L?M+9Q]TG&/<4 =9\ Y3+\--/+6J6;!Y08HQ@#YVH ]%H *
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ML;>%+WP;^U[X'L+\ 3D2R?+G&#"_%91J1GL6XM/4_9?( JRA: %H * "@ H
M* "@ H * "@ H * "@ H * "@ H 9-_JG_W30!Y1\ /^217/_82U?_TMGH L
M?LU_\D=T;ZR_^C&H 3]FK_DE%I_V$-2_]+IZ /4Z .$^,]K!?>![J"?5)-(1
MB/\ 28EW,,'. ,C^= '(SZFEK\2O!=FDMW.)+ $2;U5" AP74J3S[-0!I?!
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M;NABMUD#R!5PHW8V\9[4 ;[Z(]K^V1#>KY(@GT8E@TV)-X&.$QR,=\T ?0U
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M !0 A.* $#ANAS0 Z@ H 9-_JG_W30!Y1\ /^217/_82U?\ ]+9Z +'[-?\
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M,_\ 8!U'_P!'6M 'FOCW08F_:Y\&:H=5OI+U+&2..PCC06\<1^\6.=Q.>>E
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M]TT >/? S4[;3_A28[B98FGU35TCW' 9OMDYQ]: -/\ 9L_Y(]H_UF_]&-0
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M_&:VT^ZL-+2_+96Y\R)!/'&&88.#O(R/I7B)6/2/1+7FWB_W1_*F!+0 4 %
M'&?%]=,;X>ZP-8T]M3T[RU,MJKA#(-P[D@=<4 8W[/U]I.I?#&QFT72%T+3/
M,D$5FC[P@!QG- &1H TB#PUXUET2X>\<LYE2"(Q,'^;@%N"3ZT <@VHQZG\/
MO"$M_P"?!&]UPAG*N7W?=)  (]C0!V'B 2/\:-+=--BFMX[5M]VKG>AVY QT
MH T/@?8:99_\)$^G:@]Z\UZ7G1XO+\E^?E]Z /4J "@ H IZQ-]GTJ[E R4B
M9L9QG /?M0!YO\!]4&L6&L73:;_9L[7(\Q#.)2_'#9'J* /5* "@!DW^J?\
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M:6079\V2+RF#)G& 2,?E0!O>(1IP^-VD-)';_P!H"S8(?-82%<'/RA<8^I%
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MN(Y3&V7RH / Y'7% &O\"M%O=%LM;2]M);-GNQMCFA6-C@?>^4D$'VH ]2H
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M!#=?\>\G('R'D]!Q0!\U?LG;1XW^(HCU"*[C-RA,0NO.9&WR9/4[5/8''(-
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M%)(/I0!X1^SOXXTGQ;XQ\:6VD:'IVD0V$B1O):+B69]\F2_MGI]30![W0 4
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M%_*@#TB@".9/,A=?[P(YH \S^&_PJF\"_P#"2!6MP-48N FYAN);D@]OF'%
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MM_<6PQC9$1C^5 %&31/)<*^MW*,>@+J#_*@#9T^U-I;+&9WN"/XY#DF@"S0
M4 % "'I0!Y1^SO\ \@/Q3_V,-Y_Z$* /6* "@#SC6/\ DOOAG_L ZC_Z.M:
M/0KC/D28.#M/(H \M&L:A8>"X)(=82&=M1,;W-Q.LIV[N4!"8SVQCB@#HO'-
M]':W7A\2:;#J+27(422S!##Q]\ CYC[4 ;.IZ\+#6=/L3 S?:6XD!&!@'.:
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M4]DL./E997C8DGU'E#\Z -Z12Z,H."1C/I0!QUI\/9;;P^NF-JSRD7;7+3M
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MO&Y#X*<)XELB> 6Q7D85VJH\W#M*H>W)]T5],>\SR_XVZ4T\6FWH9_+B<B7
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M^T#_ /H)H XC]G'_ )(5X(_[!D7\J /2* ,F_NKN:_%G:%8R$WO*PS@'I@4
M,MKJ[M-02TNW69903'*JX.1U!% !:32&_6!I#B/)X')^M &P.E "T ,F_P!4
M_P#NF@#RG]GZ\33OA--=2AC'#J>K2,%&3@7TY.!0!D^$?VK]$\=:0-4T3PAX
MOO[!I'B6>+3 %9E8J<;G!ZCTH ]FTZ]_M&QM[KR9;?SHUD\J9=KID9PP[$4
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MZ: /)/@)<QQ?"B2)W"O)J>KA 3R<7DYH N_LU?\ )']%^LO_ *,:@#U&@ H
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M,KKSB2/.&.1W&:Z83FM+'/4C#>YW'P2\53ZS\%=)U:ZNI]3D%NV9V11)(%.
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M?""V_M%;@)'K6JNDL&[Y"+R?[V.QZ4 =E^S3C_A3VBXZ9E_]&-0!ZC0 4 %
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M]OG_ (:6U #J?"\7_I4U 'JO84 % '(?$^,/X<R7V[9%('K0!Y'0 4 % !0
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M050[/")MJYY.P@@GV(H \8_8Y%S>?##3KO2Q<2P-J]Z'D2-(E">:,[DP /P
MH ^LE/% "T (>E &#JOB#4;"\,5OH5S?1@ ^=%(BJ3Z8)S7'4K2C+E4;EV12
M_P"$KUC_ *%:]_[_ ,7^-1[>K_SZ?WH+(BO/$.JWUM)!+X6OO+D7:=MQ&#CZ
MAJF=6I-6=)_>@LD4?#\]WX;MWM[/PKJ"QR/O;S+J-SGUY:LJ4I4ERQIL;U.\
MB<R(K%=I(!*GM[5ZB;:3,Q]4!Y3:\?M,:B>__"+1<?\ ;TU 'J0W8S@?G0 F
MX]P: .&^)D=W?6UI#;PRR1Y+.%7/;B@#S%E*'##!'4'M0 V@ H * "@ H *
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M?\*>%[/PEHMOIUD@2*)<$XY8]R:_2\+A882DJ4.AZT(*"L;-=IH% !0 4 %
M!0!Y_P#'>[NK#X7:Y<6:6LEQ'%N5;Q%>,GT*MP: /GC]F#7]<7P!HA:\CT][
MS7KO[5;V-LK0G]YT!! 4=.F: /L9>E "T % %>]G%G:33D;A&A?'K@9H2OH#
M=CXTG_X*5Z-!/)&?!5Z2K%<_;4YP?]VNI85,Y7B$A'_X*4:7&@=_ FHQH>C/
M=  _0[*:PL7UU%]8>]M#VO\ 9T_:3L_VA+?5I;719M'_ +/=$99IA)O+9Z8
M]*QJ4/9[LVIU?:;'M-9&H4 >4VPW?M*ZCC@_\(M%_P"E34 >GJQ(QD$^XQ0
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MD>"-"T&Z^TZ=I5I93XVEX(50D>G%*IB*M56G*Y=+!T,.[THV-S'%<YV@!@4
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MU '16MA;VUFL*HA5!M!84 <GK7PX35KU[E+L0%_X-O H R)OA1<K_J[R)O\
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MB@ H * "@ H * "@ H * "@ H * /'OCUJEGI7B3X8S7MW!9Q#Q#R\\@0?\
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MPO(K2') ((XSS^- $'QC\7:'J7B/X9P6NL:?<S'Q&N$AND=O^/:?L#0![;0
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M /\ T*NG?]^J *%W^SC\.;S6M'U9O"]G'J&DW N;.>(%3'( 1G@\]>] 'I5
M!0 4 % !0 4 % !0 F* #% "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g42675dsp75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp75.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *- <0# 1$  A$! Q$!_\0
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MP)JT2RQ"H\R,]/F%4MR6>JV_^H3_ '1_*O6CLC@ZLDI@% !0 4 % !0 4 %
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MEBFL5.YH9"02/; Z]J8!J:)#8Q1PIA5#(%P2I)Z C^M," WY>>.*ZB2WVQ%
MMM&6"MU &2!FFA,K:AJJQ&8122PLR!V,G#RD  C'2GJW=; A;S1KB&&RO"AN
MK0^7*J?<:!B.<@YW?A5MJV@F>B?!K63-\3K5'G!1XY1&%&%. ,C'K415V2SZ
M3P%P1\W:M]C(GMES,G;YA2ZBEL>JP?ZF/_=%>O'X4<3W)*H04 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MQX'!(S[540>QZM;?\>\?^Z/Y5ZT=D<A+5 % !0 4 % !0 4 % !0 4 % !0
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M)*H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:U\+_$-E9S>;<2VC;5QZ<_TH*B=9\,9<^"/#8 '&G0*QQC_EF*"3LZ "@ H
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M7>'+NW^'.K:T0K6BVLA;GD?*10,]E^%Q(\ >' 8CM%A!M8D'_EF*"#LJ "@
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M0Z,I&01@B@#SZ_\ A';SWK2V]TT,3<F,KG!]J +NC?"[3K#<UU_IC'H&& *
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M_G'0Z7XW@NVN1XVO#,P()*C'/MTH_P!8'_*'^HZ_G%O=-\;ZCY8G\;795&R
MJA?Y4_\ 6!_RA_J-'^<JR>&O%S'Y?&E\GL&-+_6!_P I/^HL?YR_IUIXXTYH
MU7QI=20HV3&Z [AGD9/-'^L#_E'_ *CK^<]NTOXU2:8MJR^&=-DN8 O[YI9\
MLP ^;_68ZBH_U@E_*7_J/#^<[Q/VU_&"*%72-)  P/ED_P#BZ/\ 6&7\I/\
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MUQ^M 'D]M-JMK-I&F3Z?!#8V]^KQW*7AG+[O-/=!Z'OQ04CUP=*"2.XYA?\
MW32Z,75'Y<>+5V^+=9YS_I4G_H1K\TS?_>C^A.$O^1=#U,NO%/L5L@IC"@ H
M * "@ H * "@ H * ,WQ#_R"+CZ#^==>"_WB!XV<_P"X5?\ "S]/OA7*#\/_
M  WL 9#I\&",_P#/,9//OFOUH_F,N_$G3I-6\#ZM:11&9Y864(L8D)_X"2 ?
MSH%$\W_9@\$WGA'0K\WNE6%A)/)E9;.8,TH']] ,(?;<U!I+8]OH("@ H *
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M\C?[+=H0"_M[D8YKI2U5C.3NM3[BN0,(S9X KI9R"V@!N8RK G(SBDMQG/\
M[8,NJP?!_?I-M'/.D\3EFE6-TP1]PL1\WICFM1H[[X$WMEJ'POT.XL+"33H7
MBR89I4D<OGYF9E)!).2><\\U2)EN>@4R3/UT%M(O@.IA?'_?)K.I\#-J'\:#
M\SR7X"0):W>HQJI$I!:;,J,5;/ PK'M7C8#XV?59YK"#/:1TKW3X\6@ H *
M"@ H * "@ H 9,GF1,F<;AC- 'DMYX0/@O4=&DN=>>XBEU$;+>;"*"0YP.?>
M@I,];4\=:"1D_P#J9/\ =-+H/JC\K_&>H6EGXQUJ.:[A1Q=R?*T@!^\:_.LU
MHU)8EN,=#]YX6Q-&GE\(SDD[F.-9L#_R^V__ ']7_&O&]A5_E9]>L7A[+WU]
MXHUFP/\ R^V__?P4_85?Y6/ZYA_YU]X?VO8_\_D'_?P4>PJ_RL/K>'_G7WA_
M;%A_S^0?]_!2]C4_E#ZYA_YU]X?VQ8?\_MO_ -_!1[&I_*'US#_\_%]X#6+
M]+VW_P"_@H]C4_E8?7,/_P _%]X?VQ8?\_MO_P!_1_C1["K_ "L/KF'_ )U]
MX#6+ G'VR#/IY@H]C4_E8?6\/_.OO+6]2 <C!YI>QJ?RA];P_P#.@WK_ 'A^
M='LJG\H?6\/_ #H/,7^\/SH]E/L'UO#_ ,Z,[Q P.DSX(/ Z?6NS!TYK$P;1
MY&;8FC/ U%&:=XM'Z=?#"1Y? 'A<I&\6;" '!!  0>GK7ZG$_FPE^,7GCX::
M\8+M[&5;9F$Z.J%<#/5B /SIB1X9^P]K;^(-/\1W<=U<2V7G)$B331N-RC!8
M!6/7U[T&DGH?4PH(%H * "@#RG]J9BG[/WC<C&?[-EZ_[M-;H#^?EXV!;B/'
M6NTSZF5,!DL<=:YY#&1YWJ1ZU!2/<?V=UW?$B?\ VK4G]!2J?"6CZ<N<L5!Z
M*,5RK8WZ'KOPJ\7PZ_9P>&-5D #<6%R__+)^RGV)K&I#L5%V.FEDNM+OY[:Z
MM/(NK=BOD_=W>X]J\YQLSIC),P=3MD1X[D%7F,F-FX O[?05);*-]?FUU<"Y
MM0T,RA-_&$8= /7% ;&-K$,5W*]O>71520 0OR[ARN3^&*I(3,FXNYY;H6GF
MB*SA :<1$'C('/K]*M$L3XA?#Q]*\2Z;/IC(;+48VWHS87(&5]@371I:[..E
M-NHXLL26=E:2K:QZD+*XB?<&@4L8\]%&.OUKEE+4[T[71S#ZEJ>H:M)#=7HC
M<MY3W4QPK1J3D'MGO^-:Q=MB&KEFVFD2UU*6$&ZN8Y%*"24%FC/3!].]2EK9
MA:R.K^'^JH==TB#589/M-S(&;/S,3NPO/MBM8IRE=,ENT6FC[+NV)*A",;1@
M$UZ)YX^T^26,,!G<.GUJ>HS&_:MEO+;X9V=SINA:GK^HP74,L$&EQ[Y%8$')
M'<5J.Z1U'[.@NF^%NG37NF7NCWEQ+-/-::@FR97:1F.X=LDDTT0]6>G4Q%'6
M3&NF7AE4O&(6+*.I&#FLIVY7=&U%/VL>7>YYQ\&Y=($E]'INGFR+?O"?,$FX
M9[D'@^U>=@G%2:BCZ#.%5M#VK/5%Z5ZI\R+3 * "@ H * "@ H * "@#A?B'
M\*;/XC7VCW%[?W=O_9=TEY D#;1YBAAD^OWJ -G_ (1F]_Z#EX/Q% %S3M'G
MLC+YNHSW@==H$O\ #[B@#Y<\7_\ !-SX>^-/$E[K5_J6K_:[N0R2;)L#).>!
M42A&6Z-8UIP5HR:,>/\ X);?#)&8G4M:;/\ T\4*G3_E0O:U._XEB/\ X)A_
M#6)<+J&L#W\^G[.G_*C3V\_Z8^'_ ()D_#F$ ?VGK#<8_P!=1[.G_*B?;5._
MXD,G_!,#X<N5_P")KK( .>)NM3[*'\J'[>I_3%C_ ."8/PWC+8U/62">\]+V
M4/Y4'MZG],4?\$POAMO5O[2UC@YQY]'LH?RH/;U/Z9+-_P $R?AM,03?ZOD?
M]-ZOV=/^5$>UJ=_Q&V__  3'^'%O<1S+J>L;T8.,S9Y%3[*'\J*]M4[_ (GM
M^D_ >'2_LB#6KB:WMPJB&2!"&4#&#^5+V5/^5#^L5OYV=TG@G0E4 Z/9''?[
M.O\ A1[*G_*@^L5OYW]XO_"%Z#_T!K+_ +\+_A2]C3_E0?6*W\[^\X'X[^$]
M&M/A'XGEATFS25+1BK+"H(/'?%-4H)W44'MJDOBD[=CJ/ALS_P#" ^%@D8_Y
M!\&\Y^[^[%:F!J>./#1\7^%[[21.;8W*;?-"[MOX4 <3\%/@Q+\)QJ7F:J=1
M^UON"B,(J<]L4 SU,4 +0 4 % 'E'[5 S^S]XW!&?^)=+Q_P&FMT!_/[*B@N
M?(/&>M=K,^IC2_.>.!Z5S2W*0@RI%)%'NO[.9#_$.-U_BLFJ:GPE(^F;@9)'
M?-<T=C?H1V\SVK;T<HZMN5@<$$4[70'T;X/U]/BYX9C02)%XMTV+:K'_ )>H
MQV-<4XE1=CF(-3AGM'D.P:K;2M#);N,,CCVKEE!KH=4971E:_;)K%W:3W(8V
M4)\WS$/W6P!@CTS6:W&SE_$UM>1Z>RS S;Y W+?*JDC:1^.*V$45T&35P(UC
M$TZIEUWY8]L#WQ0!J^';[5M5T2VL)E-M!;LXA\U</[Y;K52EV,HTU&3D<[#I
M<D%[+=K/-&\V2Y+=#VQ[&LKVU:-1NI>&PVDP2R7+PO'(9'MAP#SG@^XQ34K[
M 7+BQLX[^)T4:C'(%+0H=AC']T$=1VIW[C.A\)1PPZW9+K-QY4AOU6VB5N(H
MQRJ.1UY/'O5Q3YB)M<I]G[!\@(XV#!7Z5Z4=CS@A8BY10W1AP:.HS;^+_P (
MK;XR>#H=$NM2O--B5TE\VRD*-E>1R*V07L=1X)\.S^%/#EGI=QJ-QJLENNW[
M5=-ND89XR?8<?A3);N;U C/UT!M(O0<@&%\D''8UG4^!FU!VKP]3RKX'6J1W
M5VZ7#S@(5"/,7,7S=.?6O'P"?.V?49X[Q@CV1>E>X?(+06@84 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 )D4 +0 4 % !0 4 % 'GG[0)(^#WBDCG_0V
MXH*CN:/PPF+^ _# !(!TZ#*X_P!@4$G94 % !0 4 % !0!Y5^U*"?@!XV .#
M_9TO/_ 336Z _ ">*<&0M,".>!7:S/J813GK7,RD-) Z4K,H]K_9RO%B^(&F
M@G"RV\B?CQ2J+W2D?5=]"8K@CL1FN5;'0MC/F3G'7-,1=\-^(KOPUJ]O?V-P
MT4T#!U*G'X&IDDQ'K/BN27QY;P^./"]NKZC;KY>KZ>@R7/7?CN?>N679EQE8
MS)=3L]0\)>:'>XA 9I%S@AO0#J#U'X5QRCRLZDTUH<M:FWU(6#W$OEASY6QW
M.6&1@'O^!JP#4L:65E@LK>S:*0F>96/W@?E('O28$B27EW-//#,^(H_,:5RL
M:@#L<U%G<#!ABNX[J4VUA9LB,9&#8;'?-4U=612-74=:.H:IISB&26&:W ,T
M7R6[8YQ@=P3WHC%I68F27NE6Z(D<\!MKJ6-B%A;:2'Y#%>W-4G9[$M7,/0K/
M4].USPXT=T)A8WJQ72R1X=E+9!)]1FNA--Z&,DTC[QNM4E6*.11N4H,&NU;'
M(7+2:.XFA8X5B1FEU ]>MAB",?[(_E6R)9+3$% &=KQ(TB^*D!O(?!89 ^4]
MN]9U/@9M0M[:'-M<\R^!4EVL-[#J#V\]T"66:(')0GIZ >U>5@-'),^DSN,?
M<E3TB>NKTKV3Y46@ H * "@ H * "@ H * "@ H * "@ H KWU_;Z;:R7%S,
MD$$8RTCG  H ;INIVNKVJ7-G<1W,#_=DC.0: +5 'D'Q*\?:YX>\6165M)-;
M6#>65ECLS+O<MCRRW0 C/OQ2N4CUV,YC4^H%,D=0 FX>M KBT#"@ H \\_:
M_P"2/^)_^O1J"H[FC\+(WB^'GAI=_F2?V? ?FXX*#L*"3LJ "@ H * "@ H
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M0-Q+>E$='H1(^Q+E]Z0N%"[D!('8XKN5SDEN,A<-/'D _,*I;DGK-M_J(_\
M='\JW1+):8@H S]=?R](O6R1B%SD'!Z&HJ:09M05ZT/4\\^"6OPZOIT\0U&Y
MNYHB=T5S@E.>Q'6O-P512NNI[V<X:5&:;6AZDO2O5/FQ: "@ H * "@ H *
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MFU%M<6H@,W[Z.X7G9A,[<]3]*\#$\\:R2[GVV4^Q="3FM;?YGM6F1K%86ZH
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MZG9/&5ZBBI2T1+X=\(:7X6C=-,M!:(YR55V(_4UI3I0I_ K&=;$U<1_$=S:
MQ6ISBT % !0 4 % !0 4 % '&?%6!Y?"LC1LR2Q2I*CI$)6!'< D<_C04CSK
MQIXG(^'UA?W!M]="SE'34AY>)." P!(/&>.1S4C6YB?$.+3/%_PYT&?7'M-%
M1I6,,:2&!5P,KAE!! /.,<XIH&8?[0]S;Z</!N_4HGA-N(VB^T.HF&!R<=1]
M:+@?4FDD'2[0KC'E+C'3I3(,7XD(\O@?6HXY6AD:U<+(BAF4XZ@'J:!K1GBG
M@SP9K>G?!;4=)U6"37+B23S$34+?)=3TRH8$G\:FQHWJC6TGPQXD\._!V>SM
MM.-GJB2&1+'3I1 I0]0A()!Q2)EK*YZ3\)K>[MO FF)?"<7.TEUN3F123T)S
MS5DO<\=^+_VF;XP60M1,9(1"RLC@*K;NI!!R,9XXJ1F]K]M;'XT6$DBYN_,B
M*!I, CN0/:O JI?7(ZGVF&E)Y7-7T(_BQJ5A_P +"L+.Y@N8MSQ&21"-DZ\<
M9*G!'L17T)\8OA.:^*_B:]L/C;I>EP:-<W5O--!*;M BJAP!]XJ21@#CCZU
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#S']HH/_ ,*OU+R]Y8,ORQ@%C[#)%!2W/'=6T'4]7^ ND0:=H@NV2X:2
M6.[N$CVC'4L6QW]:ECV9L_$'P3=Z[\)/#&GVPMK=83NDAN;Q0C-@_(&&<]::
M!E[XH^'=(U ^&+:_N-.TZ_M+5&\VXC:81KP"%0#:P^I%)@?0.GJ$L8%5@RA
M P& 1CKCM31+,;Q]]G7PCJ4ES;-=PQPES C;2^.<9[4Q;GF.K_$&;6OAA<ZJ
M^FJC6<J^4EO=Y4 =-SCJ1W S044=6\>1^,OA*-<UF*>S@M9RD@L+GRI9!T^0
MGO[&I&>B_!A8Q\.]*,*W20,K-&+QR\NTGC<3WJB6><_%N.;3/B+;WL>GBZ,Z
MQ*L@D<%2&'8*1WJ;#-;Q#K.G0_%W3].DW?;YBA1W$1"_[I+A@?;!KCEAHRJ>
MTZGJT\=*G0=&VC.4^/.KK%\0]*LGU"^BW-$%M;9 T4A..)">1^&:[CR_LLTO
MB7XAUFS^*FCV]@]J;(2QK<1O9^9* 0.0W8>]0(](OOBE:VWB%=&ALKQ[E;E+
M=Y6MW\GD9)#@8XJQ6.YH$>+?M2B3_A XS&LLI68-Y4.-S$ D8R1]:"HGGGBS
M0M1UCX/>"/L>BI=0Q*&G%Q<)"T0/?+-UJ!K1FU\2_ EYKOB7P7)'):+:6=I$
M5BNKL*7=<'  !W'WSBK!:D7QLU+6K'Q-I9M+Z2SMUE'G1"^BCRNV/("DY/>L
M]).[1:G-+E3T/HK1YUNM+M94)*O$I!8<GBM#'8\H_:,AUB32=-?1[**[F25@
MQGC5T0''8L#GZ ]*"H[GFWQ@TF9-;^'MO+JLUO,5B!@M[<,TS!E/)/('7M4E
M-'=^*].UBX^+ND/;6"36L=W%)+,T0W)'C&0<\\_C5"/<1T%! M !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 <+\9+K3K/P9-)J=HE[;B5,12.43=V+$ G'X4#6YYCK\WAW6OA;I=I=
MZ?,;9[TPFWTN<H[N03\F_&X<CKCI4E,H_&;1K[1?AWH<?A[3+P000LHCGN(X
MI8N.K[L@\9Z50&?\8]+U'5M.\.2VEC+=-8V$=Q(D:"0%>-P<[UP,9Y&>E2&Y
M]-Z2<Z7:$J%)B7Y1VXIH@P/BE:2WWP]U^"$R"62SD53$NY@=O8=Z8T[,^<_A
MQI\FA_L[>(8[E;B\5;EB\5W^[D(R,X!'R>W6@HV--O-#'[/;W=S]H735N& A
MLI-TP).-I8IR?PJ1/='LOP6EM9?AOH[6<-Y!;>6=D=^P:8#/\1%4)[G%?%OQ
M#J6C^,+2"PN[,6UP8Q=0R[VG"[AS'M0A?J32N-'#>.-9^S_M-Z'9"ZT^Y6>:
M FWD4F6$\?,#@8)^IZTK#.D^+GC*3PW\3-.:6PLKZT5XHVCE1A(=V.0P4CC/
M?%4"^$@^)NFV6H_%W3)(SLU%9H4RU^T0( !QL$9SU]:@1'J6OW4W[0L>GG4/
M(TE)AYMDJ2$O+M^5B<8'<=>U5<9]&CI3(/,_CE<Z;;Z#;?;[.*[D:1A!]HD9
M(D;8WS,5!/3/:@J)Q'B6/PWXP\#>#X;C3+Q[2ZX@M=)GQ("!U ;&Y>.YJ;#,
MOXOV&KZ;XR\.'3-.NGTM=/2&1S=Q1-%@\;@V3QWQ5 M#1^(7AS1;OQ%875_K
M]@MU&ZS?8IM/>Y<X1/E!4C';GZ5-BKGO6CR)-IEK(BE$:,$*5VX_#M5&;/$?
MVGI88KGPN)VO AEFS]DN&B.-HR3A6SC\*!K0RO%5IX9CN/!%SKVHZ@EX(8Q;
MBTG#,3D8W KR#QDYJ2[DGCJ"]O/V@- GA+QV%K/$L[0%E=V/W0PW8*YZ\51)
M]%!QCK00.H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX"$#\Z";'U%0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#SKX\"Z;X>7HM-%.OS%TQ9!6;=SUPO/%
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M[_E0-:GUE00% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M I!/XU07/H2@D* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M6P_Y\K?_ +]+_A0!SVJ6<%EXQT'R(8X=WF@^6H7/RCKB@#KJ .8\4?\ (?\
M#?\ U\2?^@&@#IATH Y^]_Y'33O^O:;^:T%=#H!T%!)R^B?\CIKW^[#_ .@B
M@#J!TH 6@#S'X\7RV7A[2_-266WEOXXY8HHXW+J5;C$@(]_PH&E<L^ ;3PI+
M8P7<.E:=:W\+;?,-M$LRDG )*J,$Y[4#E<?\?V(^#_B?:2I^R-@CB@25R]\,
M6DD\"^&V+;D%A!C'/'EC.?QH$=I0 4 <SXX_U&D_]A&'^9H*CN=*.@H)%H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H Y?7O\ D<O#_P#VV_\ 010!U% ',>*#
M_P 3_P -_P#7Q)_Z :!V.F'04".?O?\ D=-._P"O:;^:T%=#H!T%!)R^B?\
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MT0/(3/MTH$]SN:!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MEJ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $/2@#\\?\
M@IXH;Q9X!SU$_!_&N3%_P)^AZ.7?[Y2]3RN+_5)]*_)GNS^H:?PH?4LT7Q(L
M?LN1(_[;VFLP#$:6Q (Z'UK]%R/_ '9GX%QC_P C'[C]5UZ5]"?#"T % !0
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MV,?S[MS(VX;<>AJ1L^F?#+O)X?TUI"#(UNA8CIG JB#3H * "@ H * "@ H
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MD^E?D[W9_4$/A0^I9:^)'7?L3?\ )Z6K'_J6&_\ 1R5^BY'_ +L_F?@7&/\
MR,?N/TQ7I7T)\,+0 4 % !0 4 % '-?$#_D6I_\ KI%_Z,6@#HT^Z* '4 %
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M G+G"JZ]: .F^&FH:AJ&J>()-05HYA<HOE'@*-I[4"/0J "@ H * "@ H *
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MW<*7%M+%(H>-U*LK#((QR* .1^%&@Z?X?\)BUTRSAL;87=RPB@0*N3,Y)P*
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MDG\R:9!I4 % !0 4 % !0 4 <1\;-4NM%^%'BF^LIVM;N"PE>*9#@HP'!!H
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M^_R7_=S\+XP?_"B_0^FZ^C/A!: "@ H * "@!#TH ^7_ -IN/S/'%E[6@_\
M0C04CQ=XV1CCB@3)89L4#1VOPMN-_P 1O#8_Z>C_ .BWH$S[/H$% !0 4 %
M!0 4 <U\0/\ D6I_^ND7_HQ: .C3[HH )/N-]#0!SO@#_D7_ /MYN/\ T:U
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M[OG/'%(9V'PRU5H?B'\9)8F'F_:[4J3TS]GIA8A.HB_^+GP@G=D8FSU L8U
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MATZW(7T/EBOUT_EN6]SL*" H * "@#GM9_Y&C0?]Z;_T T = .E "T % !0
M4 <7\9CCX5>*C_U#IO\ T$TAGS1\/[26R_9O\ .)X(//AB^:89!&\\#WI##P
M@OV+QG\7"T?G;;JV)4GK^XZ9I#*LTTEI\2OA<2L<;"RU!BD1)4#9TR: )'U]
MIO'_ ,+KAHM@74M1 50!D;(^: .O_:3UDW?P'\<M"IC4V2JRGH?WB\UE5^"7
MH=&&_CT_5'QU9?\ 'E;#_IDG_H(K\DJ?Q)']1T/X$?1'V7^Q$@_X0W7"3S]M
M7C_@)K[_ "7_ '<_#.,=<PEZ'5_M$Z9XKO-4\*R>$+BWL]5%P8X[FX@,JH6&
M.?0>M?2'P\=CUCPA!JUKX9TV+79XKG64@07<T"[4>7 W%1V&<T$MW-F@04 %
M !0 AZ4 >$?&2+S?'48]+,?^A4%(\_N;3&:!F7<6V#TH O> 8=GQ&\-G'_+V
M?_1;T$L^OJ!!0 4 % !0 4 % '-?$#_D6I_^ND7_ *,6@#HT^Z* //?B+-)+
MJ]K8?\(Z^KPW,)#7"*/W>"3M+'H#]*"D;/PQ(;PC;%8?LRF6;$)_Y9CS&^7\
M.E!)A?';^S9?!T=MJME+?6]S=)"J0SB$JQ!P=QZ5)4=S!UOPA!J/PVTG3;-D
M*6<V )[F.4#Y2,%F&#UIHI[G>^%HS#X'CC+QR%(&7=$^]> >AIF9\\?L\-CX
M.>&_^N3?^A&I92$^,^AIJUE87"ZB=,O(G*1R^9M!SVQ@YI"N8?B:*73] ^$%
MM-<QW<L6OP!YX?NN=C\B@9[OJTIN=*OH1((S)$ZAV; 7(ZDT#/+_ (%K'X>\
M1:P[ZE!=J8TC\F"7>5(8G.,=/UIW(-+]GWQ-%:#Q[B*1]_BB[8;1V^6BX[#?
M%7CN\?XP:9;1Z;$]F;B!C?7$>9(1D;A&<=^^:+CL=#\<[^WO_%/PF:&17 \2
MQ ^O2J)/:9;?(/>@#QS]K.'9^SIX]/\ U#C_ .A+4S_AMFM->_$_/'P5_P B
MQIO_ %Q3^5?DV+_CR/Z:RK_=(?(W:Y#UR*Y_X]Y/]T_RKIH?Q('#CO\ =:G^
M%GZ8_#(1MX&\.DR9<6,&X9. ?+7@>E?KI_+4M[':4$!0 F: %H Y[6?^1HT'
M_>F_] - '0#I0 M !0 4 % '$_&PX^$OBSG'_$NF_P#030!XW\$]+LM1_9_^
M'$M_*J06UI"^&A\P,Q8@#&>/K2&5_"^EVZ?$7XR,LHC5+RWVYSD#R..@-)C1
MQVJW"I\3?AE.SF<FSU EBI!;Y/0@']*0S)N_$4^K?$#X:W5R I74-0146,+M
M 2,?C0!U/[0=TS? OQL"3@VB_P#HQ:RJ:PDO(Z,._P!_3]4?+%E_QXVQ_P"F
M2?\ H(K\DGK*3/ZCH?P(^B/LS]B,@>#=<ST-ZHQ_P$U]_DO^[GX9QB_^%%^A
MJ_M4>-/$OA230U\,Z@EM=SB;= VP;U"Y+;G8#Y>O6OI#XF*T/5OA!JUQKWPR
M\,ZA=W)N[JYL(999R,>8Q0$G%!FSL*!!0 4 % "'I0!XE\5X]_CM>/\ ER'_
M *%04CB[FVW#I0,R[BVX^E $_@J'9\0/#A'_ #]_^TWH)9]7T""@ H * "@
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M\+0;/'?ATX_Y?/\ VF]!+/J"@04 % !0 4 % !0!S7Q _P"1:G_ZZ1?^C%H
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M4*/H!BOB&W)ML_8XQ4(<BZ(^Q_V(EQX.UPCK]M7_ -!-?H.2_P !'X/QB_\
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M(U(S ^-=QJ-O;VSZ:CN\+,SJ$RA4#G=Z4B3F/&5]+JFA?"2[G0)+-KL#,%&
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M>E '+0C=\0[L'_GR3_T(T :MY9 YP* 3,6ZLL$\4%(YO4+;9X@\/$\?Z</\
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MLK'KHZ4$"T % !0 4 <M\3_"]QXT^'^O:':2)%<W]H\$;R?=5B.": /S)?\
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M48%,R%I@% !0 4 % !0!0U+0=-UC'V^PMKS;R//B5\?F*!D0\,:0!_R"[/\
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MD$D ?V+W_P!^@=CG]>(_X0GPXNX;O^$A@.,_]-FH'8W_  I_R-DAS_RVNO\
MV2@+&_XC8#Q%X<R0/W[]?^N;4$G2,X"G) % M3BM*_Y$G5O^N]U_Z-:@99U_
M_DG9_P"O:+_V6@#I=+_Y!UK_ -<D_D* +5 %'7)6@T:^E0X=(793CH0#0!'X
M=G>YT*PFD.Z22!&8^I*C- /0TJ "@ H * "@ H * "@ H * "@ H * "@!",
MT <9K'P=\':]XVL/%U]H5I<^(+%"D%Z\>64&@=V=FJA1@4"%H * "@ H * "
M@ H 0C H \G\=^/YO OC^)X- U373=01Q,--MS)Y2[N6;'0"@:1UMQ\1+*S@
M$UQ9:E!'D+N>S<#)Z#I0.PLGQ%L8KB*![/45FESY:?8WRV.N/I0%CC-:^)<F
MJ_$31- 'AS6+>W6X28:G/:LENS%'RF2.M!)ZX!GDT +0 M !0 4 % !0 4 %
M !0 4 % !0!'-_JI/I0);GG?P,_Y%F\_Z_)?_0C04SC/B!X7MO#7CX^+9M8U
M.&<R.5M+&8",)M )=3U- RGX_P!*TWQ+KOA""Z\2:V6O]SV;0-LB=B,X?'6@
M+$OQG^$UKX@T'2?[3UK4--2PMX[7&EW BD=V< 9/]V@9A^,/V8(M2\/>&4G\
M2ZM;26LD-IMCN#AD\QFWGGE^<9H)N=3\,O@G!X+^*5SJR:WJ5[-;6I@:WN)=
MT15\;7Q_>X.:!G2?';P;%XJT"TN)]1N].@TJ1KUFLI-DK;5/ H%8Y#QS)H_B
M+P1.M[XKUJ&TCF2*3[*0K@]1EAV]Z"CO_"FEII'PK$,-P]U;O"\T,TOWW1R6
M4M[X(H(-+7_^2=G_ *]HO_9: .ETO_D'6O\ UR3^0H M4 9WB+_D :C_ ->\
MG_H)H B\+?\ (M:9_P!>T?\ Z"* D:U !0 4 % !0 4 % !0 4 % !0 4 %
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M]Y/_ $$T 1>%O^1:TS_KVC_]!% 2-:@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M %J@#.\1?\@#4?\ KWD_]!- $7A;_D6M,_Z]H_\ T$4!(UJ "@ H * "@ H
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M 2V?B:UU<W3R-;1R0Q1D<*C8XS^% 7.M&*!"X% !@4 -DB252KH'4]0PR#0
MX *  , 4 &: ,_Q$?^)!J/\ U[R?^@F@"+PM_P BUIG_ %[1_P#H(H"1K4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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@!)ZF@19H * "@ H 0C-  !B@!: "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g42675dsp76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675dsp76.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +, ;8# 1$  A$! Q$!_\0
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M<NBKIOE(K_:KR.V;=V5LY(]^* -H=* %H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M% %^@#D_B#]W0/\ L*P_^S4 =6.E "T % !0 4 % !0 4 % !0 4 % !0 4
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MZ!_V%8?_ &:@#JQTH 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#\WOB?;VW@WXS>+Y-3TM=2LK[5KJX1XV;RIWD2((=Z@_/$4D4H>?G.
M<T#1ZK^R1XIT+P@_C/5-<O+?2I-.TZ&74YKIPGV>$2RF$29Z$1D<'D9 ZT S
MXD_:B_;TU#]I#X^^#_"_A6ZFL_AU8:_9"-!E&U"03I^]D']W^ZOXGK0(_13]
MMG6;"/X<>'_#^J7.E:5IVOZDMK/K&L67VN"P5(9)?,$?&7)C"CW:@"S^S5XB
MBU_]F?4(;=---MI1OM,AN=(MOL]K=)'G$R1_P[LY(]<T >Y^$?\ D5])_P"O
M6+_T$4 :] ')_$'[N@?]A6'_ -FH ZL=* %H * "@ H * "@ H * "@ H *
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MW= _["L/_LU '5CI0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!C>,_^11UK_KSF_P#0#0 [PC_R*^D_]>L7_H(H UZ .3^(
M/W= _P"PK#_[-0!U8Z4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 8WC/_D4=:_Z\YO_ $ T .\(_P#(KZ3_ ->L7_H(H UZ
M .3^(/W= _["L/\ [-0!U8Z4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 8WC/\ Y%'6O^O.;_T T .\(_\ (KZ3_P!>L7_H
M(H UZ .3^(/W= _["L/_ +-0!U8Z4 +0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 8WC/_ )%'6O\ KSF_] - #O"/_(KZ3_UZ
MQ?\ H(H UZ .3^(/W= _["L/_LU '5CI0 M !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!C>,_^11UK_KSF_P#0#0 [PC_R*^D_
M]>L7_H(H UZ .3^(/W= _P"PK#_[-0!U8Z4 +0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 8WC/_D4=:_Z\YO_ $ T .\(_P#(
MKZ3_ ->L7_H(H UZ .3^(/W= _["L/\ [-0!U8Z4 +0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8WC/\ Y%'6O^O.;_T T .\
M(_\ (KZ3_P!>L7_H(H UZ .3^(/W= _["L/_ +-0!U8Z4 +0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8WC/_ )%'6O\ KSF_
M] - #O"/_(KZ3_UZQ?\ H(H UZ .3^(/W= _["L/_LU '5CI0 M !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!C>,_^11UK_KSF
M_P#0#0 [PC_R*^D_]>L7_H(H ULT <G\0/NZ!_V%8?\ V:@"_P")O$[>'$MM
MMC-?/<%D1(%+'>!E0< X!/!;H.IH NZ%J%SJ5@LMY9_8;D,R/#OW@$$C(.!D
M'KTH T: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2IR!0 L<BRH&4Y4]"* %) H 16#=.U #J "@ H * $R#0 M !0 4 % !0 4
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M0!*?-(^9DB'H.?YT 027UM&/+>;S6_NJ-Q/X"@!!<3S*/*M_*7LTQQ^G7^5
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MA>(U([GUH T86M803%&-W<JO7\30!.LTDB@A55?]HYH C:1'?:9R6'5(QS0
M",!ODA+'^](?\F@"<)*W5E4>@&: $%HA^^3)_O?X4 2J@084 #V% "XR* %H
M * "@!CRH@Y8#\: &^:3]U"?J,4 !\QO1/U- "H67 <Y/KZT 24 8WC/_D4=
M:_Z\YO\ T T .\(_\BOI/_7K%_Z"* -1X4D.64-CID9Q0!R/Q+1;+PW%>1*!
M-:7MO+'QQN,BIR._#&@#IKNU-Y!&F[:N06'J/2@"RJA0 .!Z4 .H * "@ H
M* "@ H KS6,%PX:2,.P&,F@!4L;>/[L*+]% H EVJ!T %  !DY(Z=* '4 %
M!0 4 (: ,K4=<-A=+!Y!8N!L;/!]?TH RCJVH7EW&B+(D*[F9HUZCL.?K^E
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M 4 % !0 F!0 C(K#! (]Z &- H'R#8?510 UN2%<8/9A0 ^-B#M;\#ZT 24
M1P_=;_>/\Z %E^XWT- &7X2_Y%G2_P#KVC_]!% &MD#O0!R/Q5(/@V?!S_I%
MM_Z/2@#>U;6;?0K%+BY+[698T2-2S.QZ*!ZF@!VD:W:ZW#(]LS$QMLD1U*LC
M8S@@]\$?G0!?H * "@!* #- #?,ZXY(H !\Q.3D'M0 X8 P* #</44 ,>XBC
M^](B_5@* ('U.V3_ );*?]WG^5 "?VI$?N+(_P#NH?ZT 'VV9ON6DA_WB%H
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M,Q(H L;+6+@[2?\ :.: $(M?X8P_^ZN: '%83G%N2?0I_C0 +N4@);[/RQ0
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M*PCD?,$;7&) )-^-GI7!*%M1%2.\D6>03H3$H!#9)!-9[Z"V$N+1;Z9&0.I
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ME(/_ ([0!&/C1X?[WZ'_ +82_P#Q-.P$5W\<_#%C"99]6A@B'5I(95 _$K2
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MR%=X!2>P'/\ BJ-)/LN[KN; _P" USUMA,PO,BMPR!SN)X&,<5Y]1/H2*<.
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M$GND" '^IH6NP"32V=K&&EOKBW0=7G<A?Q)XH>FX&7)XFL)-R:>USK+C^&S
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MT9R[C+QXYK=1DP$H05VYP/KVHA=W'NTT1Z&"9XR3O)(R<8SR*JEI(L[,=*[
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M_3%<M6I['5FD).;M8L?%:#XJZ1J&BZ19P:%IDVHQW$HFB=[PD1&($8<1!?\
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MWXZD_P J % _TA^!V_K0!+"<H#V- "R_<;Z&@#+\)?\ (LZ7_P!>T?\ Z"*
M.6^+\?B"72+-?#]E<WEQYQ,GV:7854(V/^6B=3@=>_2@#AM)TK6-*^'VMKK&
MF7%C--?6<OG7FPS3$R1;@Q1VR%.5!.#@"@#W8#*)]!0 D@RK_2@"O9\VEO\
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M7F@#PC]IR^U32;#1[JRO9K>VN%:":-3\K'&1^F: /F=R7?>QW/\ WCR: "@
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MOAN34_ 1OEA$ALY$GW@_=XVM^F/RH ^5* "@ H * "@ H * "@ H * "@ H
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MN==KIU,3@P_:_)"2><<MC[W&.WW:LE;DOQ,U&9/#?AN*S>2&W:..4W"R!0H
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MVFI6MY)' ZI)$1LW9)P!GH,XKIJ^SA0E#F5_4PQ^*6+J2K;7/!_L?C0_\O\
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M 0Z?&J0[ADLW+%CG)H ^,OCOX?\ ^$?^)>JHJ[8KEA<IQQ\W)_7- 'GU !0
M4 % !0 4 % !0 4 % !0 4 -=-Z,N<9&,CM0!]I_ 3Q!)XB^&&D2SR!YX4\E
ML#& O"Y]\8H [9=%LE;(MU!SGVH FEL()R"\8+#H1P?SH 6&PMX,;(E!'0XR
M?SH GH IW.EPSD, 8G'1H^/_ -=)JZL!6L?#MM93&4EII2VX-)S@^U0H).Y*
M5C5 P,"M"C'\31'[(L@S\K#.*RJZP9,MCG#ER3R3]T'->>ES.QF0W44CQ(T>
M3\P''&::M%V*1XO^SCI>L6S:M<3K =*CFGLH\-^\#I.Y(QCIEC7MT]D<T]SV
M&&>ZN8RVZW5=S#!!/ 8CU]JVW,U9[F3\4=?\NUTW0X8H?M<T2O&90FT]<\,I
MP  26[<>M>+BYJ3Y$M3[S(,++E^L.7NKM_P#J='?ROAKIK6^X!;2,H)^3@ =
M<5U8?X(GSN9MK$U+]S'OY9)K9 CM&7@=_D..0!CG\:]#H>'U%\-M+_PCVG&Y
MV+<FWC,H0Y&_:,X_&LX[,?0R(CN^,^CD8(&B7F<'_IM;UYV/VB=F&.$^-GC%
MI?B98Z-!I9N_L.FW'GR/*$4^=Y;J ,'/%N_XD5\[B%>*5PQ5FDCRG2O%3,WE
M:;X?>*[O5-M#-<W *!N!R ,@<BN-QLMSSTK':^.5OM,^'RI9\ZE$L21!.<R#
M &,^]90:YM2$E?4V;2!]?\+)::@TBS30".YV_*P; W8I-RC*T6#;Z%VTTZ/2
M--:"UW[5!(W'<<T.4YN[%KU//XM4\36^MNEPEX;/$A#A2RDE?E' SUXK1Q@X
MZE/8[/PY9RR_&[P'>3J! L=PB[CR)3"QQCZ UZN6-<[7E_D=.&/JBOHSO*UQ
M_P ?-O\ 4_RH ?D"3K@DG^5 $D./+7'I0 2_<;Z&@#+\)?\ (LZ7_P!>T?\
MZ"* ,#XJ7%E#HL,=S;W5U-++L@BM[F2!=V#DR,A!" 9)ZT <8FB6.A?#;4(K
M;5Y]7N9KRUFN'FN994C)ECPL8D)*IC&/7J: /9TX1?H* (F.Y9#[?TH CMN;
M:W_#^1H MT % &<FYK:94!R9'Y_X$: +DK?NSE<G'3UH AL?E\Y/[KG ^O-
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MJ 'P?ZI?I0 LOW&^AH R_"7_ "+.E_\ 7M'_ .@B@#G/B9>PZ>NF7/\ :?\
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M=SW%N\3,YDC)7YE!.WIGGI0!ZMC,:\9XH KQ$%[C'M_*@!MH<VEMSGG_ !H
MO4 % $%J?W9^I_G0 ]GW XR>W% &>) ^F[FQNC/?_9- %V6-;NV=&Y21"I^A
M% 'P5XX\/OX7\7:KICKM\B=@O^Z>5_0B@##H * "@ H * "@ H * "@ H *
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MP_Q'U'7TAWE6X&;FW^I_E0 \]^?XZ 'P?ZI?I0 LOW&^AH R_"7_ "+.E_\
M7M'_ .@B@#!^)5ZNBV]AJMQ$T^FVLCK=(DBHZH\;)N7<0&.6Z9[T <';VMDW
M@36=2TJS33]'O+RR^RP(4)(22-6=MI(!)'KVR>M 'MO_ "R7MP* *\1 FGR0
M"<'/KQ0 EI@V\/LQZ?4T 7: "@"O ,QL!V8_SH E!.!\O/UH I6B?-=0LV3N
MS] 10 J3R1:8SQ@%XT.!VR* /CKX\ZU;ZS\0;MH8I(YH (9F=0HD8?Q >F*
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MUU('+ #=@8/'!%9Q;LS:25T=Q^SMXTN!?/X0OM&N=/N;>VDNX[B:99$EC\W
MV@<K]X<&OD,?0E"?/(^YP&(C5I<JZ%KXR7JGXH^#;9$(9;:^9V[-E8<#\.?S
MJ<&MSMD<6WC&[,;S"./R$.'DVDJASP"?RKU"#C/C3X@&J^#/#S)&OFR:U8-M
M+<9\P''2N?$?P9>AG4^$]%NM9;0="O;^6V::6*1O]&A898YP ">/SKXCE;:/
M)L00>-/MGA^6]-A=6UTF4>SPKR(W/H<'CFG*"YK7&D4M(\9SW.I/%)9WZ0QR
M>6Y>-<H=H/S<Y[_K3G!*.X-(UO"NI0W_ .T#X.MXUE#6R799RF$8F$\ UZ^5
MJTWZ?Y'7A]SZKKZ,[BM<?\?5M]3_ "H DQDG_>H =!_JE^E "R_<;Z&@#+\)
M?\BSI?\ U[1_^@B@#EOBMJEIHC:'?W]F+^S@N7+0-+&@W&-@#^\90<9H XN/
M5[77?#/BF]L+5;&REU"Q*VRS1/M8/$&.(V8#/6@#W ?ZI?H* ( N^63(S\HX
M].M #+7Y88A_M'^9H O4 % $%K]QO]]OYT 3T 44.W4!@ "2/&?<&@!UJ%+7
M,1Z!S^1% 'RC^TOX4_L'QA;7\>YH;^$$D@#YEX[>V* /(: "@ H * "@ H *
M "@ H * "@ H 0T ?4_[+.LP3>$;K30<7$-PTA'J#C_/XT >WT 4M8Q_9T_^
M[43^%@<_IA_TVU?H <?F*\^B[S(CNSK<UZ99RWB%#%J!?E59021Z\UR5+*29
ME-%OPS)EIUXQ@'C\JTI.XXF]6YH5]0B\^SE3N5.*3 \Q\6HR^'+PQE@_EEAL
M^\I /(^E>?'66AE%6EJ?.'P<TVTM;8W5LKF2_M8[FXED<LTLI9MSL3SDXKZZ
MC#E@CXG&3E.<K]#=EO="CNY[;8JS$/*4,ZKGYB">O'.:U;BCF:E96-VQ\$Q7
MFE0D:;)Y4T88JFYEY'.#W'-3S0+]E52NT4O$/A_2_#&G)=ZAITD5LC!%)5N"
M> .:GFCW!TZBW1K@HVG@Q_+&8\IQT&.*WZ'.MSF=$U73H])2&[D,I< D>2V!
M\H']*B.B=S:2U.J^$=[::C\9)9+=F)CT1D 92O'G*>_X5\]F_P!D^FR72,B?
MXP2@?&CPG$<AOL5XXR.",1#K^%<&#U3L?0R1YT&'DEQ@,A(^R=Y^?O\ X5Z.
MYF<Q\:-)AA\&^&-0^U.4CU'3P;</\O+C)Z\<USXE?N9+R,Y_"=MXAU-8=%^Q
MI#,5N62170%E0%P/O8P?7FOBU<\RVAOC3([+2-5="7G(E)D8XR=O7CI^ K-W
M;$87@19;ZYOKJ<LOF7\F8#A@!Y*8.2,]*TF#V-WPQ9+:_M"^"1%Q&8KMBO).
M?*;G/Y5Z^6?$_3_(ZL,?6%?1'<5+@_Z5;_4_RH E/?G'ST .@_U:_2@!9?N-
M]#0!E^$O^19TO_KVC_\ 010!B?$CPWKGB6QLX=#U=-(GCE+L[[_G^4A?ND'A
MB#CIQ0!RVH^&=2\,_#F]CU:YM[Z^FN[626[A\S=,WG1@LV]CS[# Q0!ZLW^J
M3J>E %2.0K?2KU'E*??J: $M%W)SG*R%/RS0!?4]CQ0 (2P)]Z ([8;?,7T8
MG\^: )"V3@<>] %*<JDD$H/W7P?QXH ?GR[_ -/,3//J#_\ 7H \K_::\-C6
M/ (OT&9M.F$N?]@_*?Z4 ?(] !0 4 % !0 4 % !0 4 % !0 4 % 'M?[+6I
M"#QA=VCR[5E@)5?4Y&?Y"@#ZJSF@"CK8+:;,!C..]1/X6!RUC,5DC+<$,"!C
M'%<D(J$KF$7[QVR'<H/M7:]C<I:AI4=^ZLS,I QQ4R@I;B>HEAI*6$S.LC-N
M&,$"IA'E"UB_6HQ'&Y2#T/% 'G^MZ='Y5["Y.U5?!'<$<_SKSI)PFB.I\L?!
M27&E06Y^9HK3:3VXGE%?7497@CX?%KEJM,WQX4T%=2N[WR3/=RHRL3&7XW$D
M#C^\36CBGJ<JDSVJ[\;WOA72_"UC!%%#9W%E&S32E%>+"G.5+#T ^IKY?&5Y
M4ZMH['ZYDF6T<7A74J;HV_&DPU?X6_:-1CBWS0Q22J@$B!L@G'4'ZUVX:4I-
M-GSF;TH4E.,>C/)5""U 4_N]O!'I7OO8^!^T9$.O6NG6]LET9($EPL&],LXQ
MZ+FI>AIRM[&W\+[R.Y^-"^7O _L.8_.A7_EM%ZBOGLVLU$^FR1-*5S1^,/A/
M_A(/&UIJ<UW>64>EV_EK-8XWJ).H88.<[1]*\.E5=-:'U+5SYVN+Z674O&&E
M:;J&K2-82HMO=S, (E9(R<\<\N>*]:$W[-R,;*Y]!WW[+6EZ[H%C9:OX@U*Y
M^RR17"O&40;T.4/3MQ7ERK2FK,'"Z/-K:674_A;FXG-S=F1HS,0"[8E(%>+5
MAR5&D>3/2=D=3#"MOX9O+>8,N\R)M/+9(/I7-U,'N<[X"TZ&VU2^%K#.D(OW
MVM*V<#RD)'6M:B]VY3VL=-X>1H_VC_!<FPA7M;I-V.O[MS_A7J96M6_(ZL-H
M?5U?1'<<,_B/4'^*R:,SQ?V:MF9@NW]YOXYSZ<T =F<YXY^>@!T'^K7Z4 ++
M]QOH: ,OPE_R+.E_]>T?_H(H P_B1;37]M8V]I<+878E,J:@2=UJJ*2SJO\
M$=N1M/!SS0!@^);AI/!%]')K,FL2>?92AWB";4>6,KC [CF@#TBX?9;#!(/0
M$5G.7*!DK=20ZAG8\F^+YB,8&*F$^;<"_IQS"&/&Z4MS[BMM@+CL$!88]Z *
M*ZW96\"&6YC4D=,Y-*X&;)XKMK>ZNQYHVH5^5@0>E%T!4/BM?ML*'SFCD3S
MV, =J?2XKD46L>=J4,9S'&2?,YY8@Y'.* N='+ FIQ1N7= .08SC\*!G+?%>
MT7_A5_B&&"-Y2+-Y%0<EB/FQ^.* /AV"43Q)(O(90P_&@"2@ H * "@ H *
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MEWJ=KJKWD[3M'JD\,3%=N$!&!T'3D4 =5!_JE^E "R_<;Z&@#+\)?\BSI?\
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M#Q(/]D'Y?TQ6PRC0 4 % !0 4 % !2N 4P  DX )- %^ST#4M1=4MK*>9F.
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M Q0!RUK]I@^&=_97QC74+.[LX;B$6GV>16$D7+_O'#EASN#8.: /4/%*AM'
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ML7^Z* ))?N-]#0!E^$O^19TO_KVC_P#010!KT <A\5?^1,G_ .OBV_\ 1\=
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MK:;:V1]LN"<CG_6-57 [2XF$0  W.W"J.],"JNG/"[3QL%G;[P/W3[?_ %Z
M+,%R)"4=3'(.JG^8]: )CRIH \N\%A=-U#Q!H[X3['J\C11$9VQRKO3'IU8U
MXV(C[S-HO0W/"U]%+X@\4:0_^M1X;LG_ &94*K^L)KOPWP6(DM31,IG\)7[O
MGS&CE+ =<\UU$%#3UV#PX3'<)\HYEDW+_J_3- '8!@1D'(]10 BR*^=ISCK0
M Q+A'8J&&X=J!7$>Y59 G))H&,%\H0.RD G'2FDV(:^H+&SKM)(Z>]+<9(ET
M'DVX(XZT 3;@!UH$+U% SE[31#=Z]JMTMW/!()0F(]N -HZ9!H 6RT>9M;U-
M!J5TI58LL"F3D'_9H T-)TP:7?7BB:2;S CDR8ZG=TP * /A_P 2^$],\1_%
MCXHR:M?2V5K!JDC,Z.J@#ODD5ZF&5XNY\OF%1QJ)):DO@O2_#T?AG6I=(U"_
M_LU23<*=F'XZC"^E=<$DGJ>34E*^J.@\=^-[C0'TJ&SMHY9+C;++YR,P6+/.
M O.[GBG)\I%.#=V>5>!_B6^E_P!KR6%J)%?4?M$WGJ[[8B#D+@<-QW]:SC.V
MYTSI-I:GO=YJ4KZ-'=VMM]I:9%98BX0@,,]3Q73?34X$G%G*2>'YKQ+;SM.D
M640A=@NEYX&>#Z5BS:,E:YV_PB:=?C!!%+9BS5-#G"@.&W?OH?2O"S97C$^B
MR=W4K'J_B/QI+HFKSVC+%%;QP)/]HE)VC+,&S],"OD:]9TFDD?7PIJ:N9+?%
M6U4@'5=.&1D<]O\ OJN?ZW+L:>P1+;?$4W\<QLKRQNWBC+E(P3Q[X:A8M]4'
MU=/J/\.>/]/\<:"C+-Y&H>296A*$*6&[(7</F&5/3TKTG=PN^IS+W9'GWBB6
M.7PS<R74(N%:-2T8_B)QZ>]?"-/VDK.VI].O@1Y?<W>GVNJREM#4W'V==\BD
ME0N3U.[\:[U&3:UN<[W.Q^ HTB\\>^'9;>P2TVP2O;NKGI@ KR3ZG\J]S)E:
MM(X,9K37J?7 K['J>&,FN8K< R.$!Z;J8RO=7D$EO(%E5FQP : +-N,0I]*
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MBU;Q%HMW?&6"T_>R*RM\Q!&T XP#Z5K'8U([3Q)KZ:CJ%R+)0LJQA6-K,0<
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MY<TM#*5SU*O6,0H * "@ H * "@"&XA,S0D'&Q]Q_(_XT")L<Y[T#"@ H *
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MR]3^%>F=!%!J$TVJQV]S;^1*J[P5<,&'(_I0!=M.M[_UU/\ Z"* +:?='TH
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M9^'CB6PUS:J+_P 32Y&4Z'D4 =@GW%^E "2_<;Z&@#+\)?\ (LZ7_P!>T?\
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M^6#<G/;KTH Z94DC:+]ZS*>Q ]/I0!/+]QOH: ,OPE_R+.E_]>T?_H(H UZ
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M5L8&?2@!C_>A^O\ 2@!\OW&^AH R_"7_ "+.E_\ 7M'_ .@B@#7H Y#XJ_\
M(F3_ /7Q;?\ H^.@#7\1/LTC(SP5^[19/<%J>?V$V^]GX^8/D9[CCJ*\^I[L
MM#GDVI&EINHH9> 61B<C!X]:7Q[#U-..0VU\I0@Q3\ =,$ G./>LIQ:5['3
MTE;C(%8-V-"O-=J@.Y@H]Z=P.7OKM$OVFA<A,%2Q[9KI;5K'*W<C@"RRJV P
M'(K)Z.QD799!Y7DHPDEEX7'8>M;1:;LR[H\O^)\*IXL\(O\ *(TU>W+L>!_J
MY!_.NG#?$1+:QZXOW17K(YT+0,* (I[J&U"&:5(M[!%WL!DGH!GO0(EH&%
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M8]CSBKC_ !+!8X/XE1,^I>&?/CP#K%NC!EP. Y']*[<,FI;"EM<]>[5ZI@%
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M\MLV;=.SB@",W=V1$PLSM7D_O!TQ0!=23SK</C 92<4 9_A+_D6=+_Z]H_\
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M+GMJ2#Q)",_N7S]13Y.Q7MB&[UV.YMY(Q&X++@'-"B[B=6ZL8M=)B% !0 4
M% !0 4,3V,K3/^2KZ7_V"[G_ -&15S2-Z&QZ3Y#8_P!=)^8_PK,ZB2'/EC)W
M'UH 8Z%Y" [+@#@4 -C0I<MEBWRCK]30!8H * (YP##)D9&T_P J ,!47:/E
M'3TH 78O]T?E0 H 48  'M0 M "%0PP0"/0T -\I/[B_E0!/8B.&ZC8A4Z\]
M* -C[1%_ST7\Z $^TQ?\]%_,4 .25)/N,&^AS0!7N_\ CZM/]\_^@F@"W0 R
M7_5M]#0 U_E@/LO]* (K;_CQC_W/Z4 4O"7_ "+.E_\ 7M'_ .@B@#7H Y#X
MJ_\ (F3_ /7Q;?\ H^.@#J]X2)202,#I0!"ZJ+B-CSD$8_7^E $:*&9AUV%@
M,]<4 16%[:1VD*M+&#L P3[4 3G5;(''VB//UH L0S1W$8>-@Z'HPH DH :0
M1TYSZF@"I;_\?-[SP&''_ 10!Y-\=.GA$$9)UNV _P"^'JZ>DKD5?A.J7IZU
MU'"A:!A0 4 % %/5=7M=&M&N;N3RXP<# )+'L !R342FHJ[.BA0GB*BIQ1G>
M#_%UMXTTR6_M()[>%+A[<"X7:S%3@MCT-8X>LJ\'..R=CNS3+)Y56]C4:;LG
MIY_):]S=KJT/(U"C0-0HT#4*- U"C0-0I#"@ H * "@ H *&)[&5I?\ R5C2
M_P#L%W/_ *,BKFD;T-CT^LSJ([?_ %(^I_G0 X#]X3["@!@_X^C_ +@_F: )
MJ "@".?_ %+_ .Z?Y4 82_='TH 6@ H * "@ H GL@&N4R,]>M &N$7'W1^5
M  8UQ]T?E0!#:;=J@#!V^E #;H9N;7_?/_H)H M4 -D_U;?2@!DO_'LW^X?Y
M4 16_P#QY1_]<_Z4 4O"7_(LZ7_U[1_^@B@#7H Y#XJ_\B9/_P!?%M_Z/CH
MZQ2!&N>F!0!#<,(P'.!@@Y'IWH B53'<,"<EE+4 9]C/:BQB#&,, -V1CF@"
MS]IMP,^8BK_O#K0!+%<F-2%>,KUR>WY4 *+V3(!,><9.&H 7[>^0-L?3/^LH
M J6TUS)<7C1I"4)'.XG^$4 >4?M%F.V\.^%-6FMY94M=8MWF-NC.0@5P3A<G
M'/I5)V)FN96143XZ>#1$K'4WWD[?+6UE+9],;<UT<R./DEV)!\<?!VXJ^I2Q
M-UQ+:3)GZ96GS(?)+L,/QT\'@;A?7++G 9;"<@_0[*.=!R2[&1KG[1GAW3%1
MK2WOM2#.JD16DRD ]\%.U+F0>SD21?M'^$GB1F35E=@,J--F."?^ T<R$Z<C
M&\3?M">&]5@BTZT.JQI<'%Q/_9LP*1=]ORYR<$#TY/:N2J^=\B/9P$'AD\34
M;\O,N:5\=? V@6ACMTU6"WE<R*ITV8*,@<#Y?05O34:2Y8;''B\16QLU4J[[
M?=L7HOVC?"=S*J0IJ<BY =QI\H5!ZGY:TYD<7)(O1_'SP7*X5-0N'8] MC,3
M_P"@4^=#Y)=B;_A>'A/G_2KSC_J'S_\ Q%',@Y)!_P +O\)@#_2KSG_J'S__
M !%'.@Y)=C.U']H'P[9W$:PP:A=PG[\L=G*-GX%<FCF0N20J_M#>$VQ\FK\_
M]0R;_P")I<R%R2%_X:%\)YQY>L?^"N;_ .)HYD')(#^T+X3!^YJ__@LF_P#B
M:.8.206W[0/AB[OD@6/4XHBI+3S:?*JJ1V^[GFCF0^21?'QO\)D_\?5Y_P"
M$_\ \13YT/DEV$_X7CX2QG[5>?\ @OG_ /B*.="Y9=@/QQ\)*>;J\'_</G_^
M(I<R!PEV+?@#QG8>-/BM:R:6MU+;VVF3+)-+;21*&:1,+E@.>#^58R-J47%:
MGMM9G01V_P#J1]3_ #H >/\ 6'Z4 1@?Z4?]P?SH FH * (Y_P#4O_NG^5 &
M"GW%^E #J "@ H * "@"QI__ !]+^- &Q0 C=* .?CEE !$K@].#[T /CGE;
M4+-3(S LV0W^Z: -Z@!DIQ&Q]J $;_4?\!H C6(1Q<$XV],^U %#PE_R+.E_
M]>T?_H(H UZ .0^*O_(F3_\ 7Q;?^CXZ .KV!XE!Z8% $<L(V. "3CB@"!I-
MY@DSC*D'B@!EC+:K:0AS$&"@'.,CB@"#5HY)HXA8-;*^[YB^.GM0!IQ01A -
MB9QV'% #O(C_ +B_E0 &",_P+^5 '/ZA:W,E[<FVO1:JN,QXX)VB@#7TI<Z=
M ,Y.T<^M $GV.)',@AB\S.=P4 _G3N.XLUM%.1YL228'!90:0AZ0HJ!50*HZ
M+C@4#N+Y2 ?='Y4$ZE+6+M-+TJ[NR@801-)@=\ G%3*7+%LVH4W6JQI]S*\'
M:=*NG+?WCB6]O5$LA'W4!&51?0 '^=123LI/J=>-FO:>Q@K*#L="]M'(@1T5
ME'9AD5J<%PCMXX5(C18P>RJ!0%QJ6D4;[DB16]0H!H"Y+MI6$&VF ;: #;0
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M: (4_P"/B3\* %D!=PO\/4G^E $@&!0 M !0!EZH^Z95!^Z,GZT 4Z "@ H
M* "@ H L:?\ \?2CKP30!L4 (W2@#F7E\J#(!9SPJCJ3VH V]+L_L5JJ-@R'
MYG;U)H N4 ,E_P!6WTH JW,GSQ@DA -S<=J 'V][#?VQE@??'@C(H I>$O\
MD6=+_P"O:/\ ]!% &O0!R'Q5_P"1,G_Z^+;_ -'QT =6%WQ 'N* &+(8%Q(2
MP'\0% ##<JTOR NVWI@B@!DDYB/.&G;A4':@":W5HXOFPS'DD4 34 +0 4 (
M3CMF@ "X% %:6PCD<N"T;GJT9P30 6MBMJ[/YCR,V!ESG ]* +&T;@W<#% "
M>7\Y;/6@#SWXTL$\*GSM@@,J+DN4.\L-O." /7-<>*?N'T61*^+5NQJ_"VU2
MU\&6(1456!;$;[U&3V.!6E#2FM#DS:?M,9*1U8^:X)_NK_.N@\@4G,P'H,T
M5YOGU"$?\\T9_P"E "V>6,[_ -Z0X^@XH DC^:60X[@<T 0BQ@FDE8Q*"#@%
M>#T]J &"R8,XBN)(PO !.X?K0 JWDN/+$?F3K]_LH_&@!K3L7(ELV8CNF&H
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M=: +-G V$#?>=O,(]%'3_/UH MWNF0WL9RBI+_#*!RI]: ,W^P;_ /Y_X_\
MOS_]>@ .AZ@/^7Z+_OR?_BJ -/3+%K& B2022N=S,HP#^% %R@ H * "@ H
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MH 2P&[SI>H>0X/TX_I0!<H * (HSND<]LX% #I4WH0#M/8^E "1.2,'[XZT
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M"2.]BFR%;#?W6X/ZT /@YC#>N30!+0!%(3&0X&1T;Z4 17EZEK&,\NQPJ^M
M&4\CRN7<Y8_I0 E !0 UW$:ECT% %^WMPJK .2?FE/\ 2@#2% "T % !0 4
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MH: ,OPE_R+.E_P#7M'_Z"* ->@#D/BK_ ,B9/_U\6W_H^.@#K8_N+]!0 Z@
MH * "@ H * "@ H * *<R3I.TL2QNI !#$@T ,%S*LVZ6V=1C *_-_*@!POX
M'G&7V$+T<8Z_6@"566:XR""%7L: &FYCDO%B#C>H)Q0!*P)F7T -  W-PH[!
M2: (;S#S6Z'NV[\A0 Z.!"TK 88MR1QV%  B,TCX=@HP .M "@RAR,JP'X4
M*)SN8&-L#N.: '+<(S;<X/HW% #PX)P"#^- #J "@ H * "@ H * "@!KHKC
M# $>XH K&R:+)@D,?^P>5/\ A0!0OD)<.Z^3-TY^X_X]C0!75P5)/RXZY[4
M+#&)@)9%/E9^2/O*?\* -FUMV3,DAW2MU] /04 6* "@ H * "@ H * "@ H
M R=2.;G_ ("/YF@"K0 V3HO^\O\ ,4 =".@H ;+]QOH: ,OPE_R+.E_]>T?_
M *"* ->@#D/BK_R)D_\ U\6W_H^.@#K8_N+]!0 Z@ H * "@ H * "@ H *
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MW.@QS2!DE:+U4 $'\Z +=O9"!M[.9'QC<>,#V':@"S0 4 % !0 4 % !0 4
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M*"&C4CW% $9T^,+B-GA]T;I0!$4O+<Y61;A!V88;_"@!8]0Y D7RW/\ "W%
M%D3CNI7W[4 .$J'HPSZ4 .!R* %H * "@ H * "@ H * "@ H * "@#(U(_Z
M7_P$?S-("M1<!DG1?]Y?YBBX'1 BBX$)G27S%5E9E!# '.#CO3$G<S_"7_(L
MZ7_U[1_^@B@9KT <A\5?^1,G_P"OBV_]'QT =;']Q?H* '4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 1R01R@AT5A[B@" Z9",;-T7
M_7-B* &BSGB&([DX' $B _RQ0!8M8C! J$[B.IQUH EH * "@ H 8\2R## ,
M/0B@" 6K0L#%)M3NC#(_#TH G\L'M0 W[.HZ97Z'% !Y;KTDS_O"@!ZYQSC\
M* '4 % !0 4 % !0 4 % !0 4 4KFR%Q+YF_' &,4F!%_9G_ $T/Y5("-I6X
M#$A&"#T]#0!C^.O&4W@W3X[B'1;[6&<E<6:@K'QU<]0/H#5QCS.U[";L97PS
MO3K*ZIJY73H7OBLKV]C<M.\;;>1*2!AO8#BM)I1T1,=SJO"?_(M:7_U[1_\
MH(K,LUJ .0^*O_(F3_\ 7Q;?^CXZ .MC^XOT% #J "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * &4F 5(!0!FZKK]CHS1K>SB#S,E<J3G&,]!
M[TTF]A,K:+?:1J$]Y+I@B:3 $TD<>W=QQDX&:MWZ@F3^$O\ D6=+_P"O:/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H CS28#4F1W*JZLPZ@'D4FF@'T@.$^(GA<>*=2TF"]TB76
M]'A$DLMFLB+&TORA"X9@& !<X/&<'M6D78B19\#:(=!EU&WM]'DT33"%>&U:
M1&16P=VP(Q"CID>M5)W")O>$_P#D6=+_ .O:/_T$5!9KT <A\5?^1,G_ .OB
MV_\ 1\= '6Q_<7Z"@!U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ML[2SGU*>TLXI1++;Q %+C'19 >JYYQT/?BL(RY2VKE_P_H]UHZSQW&J/?H5
MCC:-4$0 Z +3<N8%&Q9\)?\ (LZ7_P!>T?\ Z"*11KT <A\5?^1,G_Z^+;_T
M?'0!UL?W%^@H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!S.O>#8M5U)-2MKF6PU 1^2\L8#++'G(5U/7!Y![9/K5J5B&K;%5_#FNWTLZ
MW>H62V\J;&$=KO,@]6#'%*]G= D^IK>%?"]EX/T:'3; ,(8RS%G.69B<DG\_
MY#H*B3<G=E)6(O%>C:CKFFO;:=K$NBR,#F>"-6?\"?N_6G&2B]1--[&%\-O"
M%YX0M[Z&^7[3=2X:34FN7F>Z;'WF#?=QZ#BM)-/8$FMSI?"7_(LZ7_U[1_\
MH(K,HUZ .0^*O_(F3_\ 7Q;?^CXZ .MC^XOT% #J "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * &4F 5(!0!P_P 0_$>LZ#=Z:F@V<^JZC/O"
MZ<L7[F4#;\TDIXBQZG.<]*T@DWJ1*_03X<:CK>I+J<GB&<)J88;].C@*1V@Q
MPJN?]9GKN[^@JY)):"C?J=+X2_Y%G2_^O:/_ -!%9FAKT <A\5?^1,G_ .OB
MV_\ 1\= '6Q_<7Z"@!U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % #*3 *D H Y_Q%XQTWPO/&FH2B$R0RS*S,H!"%<CDC).X8%5%-[$R:6X
M_1/%5AXBN+N*R<3&WC1G=65A\ZY R">15.,ENA1:>Q:\)_\ (M:7_P!>T?\
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M2Z\(S1Q1M)(;BW(5%R<"9">* .I3[B_2@!U !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % "$FD "BP U%@.3^('@B;QMIB6L6L7VD[22WV1]H
ME!&-KXY*_3%:0?*3(K?#KPE)X+TR;3GTZQM511BZLLYN3CEGW9.[ZDT2=Q1.
MA\+(T7AW34=2KK;Q@JPP0=M06:M "$9H 7I0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
B 4 % !0 4 % !0 4 % !0 4 % !0 4 % "$9H  ,4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g42675g00k12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g00k12.jpg
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M8X/"_\0 %@$! 0$                   $"_\0 %A$! 0$
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MJ,:KMN?.A*ISSY/L,F+](^+<>5C%U%D6GI=;]76]"?%L;6-_ZCH8
M
M
M
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MTJ\+762HIJJ)C'TBSME;&J*JH[--OPV_':!(P
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M$R1$] ',_DXU%3@[27B/ ]TD17OS6-4_"Z2+TMS]#F*KODU#(81_VLL1_P#
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M\M;7SV9=.9 VD'%\6-O)GK;NQ6I4JM/%51M_4F;/'K)\EV*GP5#*P_[*Z_\
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M_P LPO\ \:?^RP#HH%FB_P#!P?\ #;_47@
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M;<3V2HM-ZITJ**?+6;FJ*BHN:*BIM144"&/(]_U/OO\ /T_NVF+\L'_38/\
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M(Q/][GSV<Y;L>#[19<(.PS0Q2I:G1RQ.8^15<K9,];[W/^LH$6^2#^][=?\
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M,D;)4?&L;G)EK(J9+DBY@B706*"1TU#32R+F]\;7.7XJA?
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MLZ,S[R)<-Z \*X?OU!=J*KO#ZFBF;-&V6>-6*YJYIFB1HN7YDM!
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M#LW-=$]ZR.8B[51>=>;GU,B>*&?C5%3U'!NCX6-LFH[G;FF>2_$"\
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M!200N5%6-C6*J>G),BZ$
M
M
M
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M^*Y;"?<"6'[,8/M-E65)G4<#8WR)S.=SN5/AFJ@9T !
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$?DQML46CU8;#6R54_&%DKN%CX-[)7(B(FKFOW=5J9+FN>2_))<
M
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M0<I+!G5+WN\?B B:@0KRDL&=4O>[Q^(.4E@SJE[W>/Q 1R "K@W^H[L'!O\
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M^H[L'!O]1W8!2"K@W^H[L'!O]1W8!2"K@W^H[L'!O]1W8!2"K@W^H[L'!O\
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M'!O]1W8!2"K@W^H[L'!O]1W8!2"K@W^H[L'!O]1W8!2"K@W^H[L'!O\ 4=V
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M:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P]
M'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/
M0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[
M#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A
M.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JW
MH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!J
MMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P
M:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3
ML&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ
M$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K
M>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'F
MJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!
MYJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T
M >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P
M] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3
ML/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ
M$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K
M>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&
MJWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[
M!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A
M.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJW
MH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJ
MMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >
M:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P]
M'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/
M0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[
M#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A
M.P] 'FJWH3L&JWH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JW
MH3L/0!YJMZ$[!JMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0!YJMZ$[!J
MMZ$[#T >:K>A.P:K>A.P] 'FJWH3L&JWH3L/0
M      9IGEFF?0
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M
M
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M?ADJ[-B*3:1'@2CK,>8X3']UIY*6TTD;J>QTTJ9.<U<T=.Y/1GFN7S^"*LN
M        1WI=Q5)::)EKH)%9653=:1[5VQQ\VSXKM[%(/-AT@5SKAC&ZRN7-
M&3+"WX(S[J?U&O&L0                    WC1TD5KH[OB.KB;+'11I#"Q
MR;'2O7+]B?U@:.#>,<M6PXRBNUK;'P%7&E7 KF(YGWDR=LYN?-?S0V#"N*:^
MXX>Q'654=&LU# U\*I3M1$5=;G3T\R 1.#;(L1UN(+[98;BRF6-E9&J)'"UF
M>;D1<\N=#8\68OKK9C"KM\5'0U%''(UB0/IVJKT5J;,^?/:!& -MTH6NCM.*
MY8;>QL4+XVRK$WFC<N>:)T<V>7Q-<M?$TKX5N?#+1HN<B0Y:ZIT)GL ^4$EW
M2MH[CHLJYJ&W0T,$5>V*-C-KLD1JYN<O.Y<UVF#T<VZEGJKC<KC"V>EM=,ZH
M6)W,]VW51?AL7]@&HGA).%L7U&(+Y%:;]3TD]MK%6)(DA:W@E5%U=54V_ UV
M"[5N#KM=:&B;32(V=8W+/$CU745414Z -8!+>#\55M9;KO=;O!0^;Z&'8C*=
M&J^5?PMS_P#SG0T##^('65]7-#0TD]9+EP<TS-;@>?/5;S9KFG8!A#PDRFNC
M\7X+O\E\@IW5-O8V6"J9&C'9KG]W9\LOS(S                   #U-G,3
MIHEQ4^]6Y]OKY%?74C45'JNV2/F15^*<R_-""C9M&U<Z@QI;'M7)LLG .3I1
M^S^M47\@.C@ 94
M
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M53]BF(),TU6!]/=([S Q5@J41DRHGX9$3)%7YHG[",S6(
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M&_\ )JZR_L0P9*.A.P/EK9KW4,5(8D6*!53\3U_$J?)-GY_ "8P 94
M
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M>C+/9\36GX!Q3AS$=WK]']ZMM/0W:9:BHH;C"YS(Y5YW,5O3FNS9Z$VY(2L
M-)T<8'DPQ/=+I=[BMUQ#=7H^KJU9J-R3\+&-]#4^G-DANP
M
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M:3E0TD%!1Q4M)$V*")J-8QO,B%\$4
M
M
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M<#G'E0T_NI+OZ>&.5#3^ZDN_IX8(Z.!SCRH:?W4EW]/#'*AI_=27?T\,$='
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M]#( #'^8[3[+H=W9]!YCM/LNAW=GT,@ ,?YCM/LNAW=GT'F.T^RZ'=V?0R
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M
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MCTG8<J'HU\]13Y^F6%<O_P"N9MU!74MPITGH:B*HA7F?&Y')^P#Z
M
M
M
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MYJ[.=4UD_P"Y.A3)X?OMSJ-/.*++-62/M=-;H98:=<M5CU2/-4^/WE[0)+
M           4RR,BC?)(Y&,8BN<YRY(B)SJI!./\>U-[GEH[9(^"UM75^[L=
M-\5^'P[?AN^F>\OH,/Q4$+E;)7/5KE3^#;M5/S56I\LR#"X@ "@
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ME/*GH^\N35_)<OVG1!%  0
M
M                           'RVZXT-RBDDMU935<<<BQ/=!*V1&O3G:J
MHJY*F:;/B46R[6ZZME6UW"DK4B75D6GF;)J+T+JJN1%/DV_ZF8I_Y[5?W<1$
M^B"JGP)%8,7J]WF*ZU$MKNB>B)4=G')^7]37=('653<**FJZ:EJ:RGAJ:E52
M"&25K7RJG/JM5<W9? L76]VJT+&EVN=#0K)GJ<9G9%KY<^6LJ9\Z$8:4E1VF
M/1<K51466I5%3^2T^72];Z.ZZ8]'-%<J:*JI)DJDDAE;K->FJB[4^:(!+%LO
MMINKW,M=TH*US4S5*>H9(J?]JJ9$BC'^B.P2V.IK\+43++?J*-U125-"JQ??
M:BJC51-F2Y99\Z?L79-#V*)L7Z/;5=JS):QS715"HF6<C'*U7?GDB_F!L&)+
M];<-6>HNEZJFTM% B:\CD5=JKDB(B;555]"&#L^D?#-RLLUV\X<3H8IFT[I*
MYBP??<F;436RSS3;L(W\INZ7%*:RVYMCFEMR7*GF2KX9NI/)D_\ <-7G15Y\
MUV%_'^/*E+'']N-&53YHXPQ,YZV-[4DVZJY(F>?.!*V(,3VNP5%JAN<[HY+G
M4MI*758KM>1W,BY<R;4VJ?547NV4UXI;345]-'<ZIBO@IG2(DDC4SS5$]/,O
M8O01GIU1&W[1JB)DB7^%$1/Y33.X@N5GATP87MU59(JB[U-+,^GN2OR=3M:U
MZJU$RVYY.].S,#?P1QBK2E%8,:RX999:ROKW4K)J5M,[-U1(YV7!Y9?=1$17
M*Y5R1$785X2TCU5PQ=]F,48=J,/WB2%:BF8^=L[)V)GGDYJ(F>2*OIYE D0&
M@XDQ_5T^*I<-X5P_-?KM3PMGJD2H93Q4[7?A17N_65%1<OC\\OFP#I&N6*<2
MUUGJ<*5%M?;UU*V22L8_@'Y*K45N2*J.R7)4V 2)/-'3P233O;'%&U7O>Y<D
M:U$S557T(?+9KK07JWQUUIJX:RCDSU)H7(YJY+DNWYH>WIT++/7OJH4GIVP2
M+)$[FD;JKFU?FFPCS"N+[7:]"28HLUA;0V^".65ENCEYE25S5^_EZ5S7/+T@
M2>"(9]+]RFLRWRRX)N-?A^&-'U%<Z=L662??5C%36>UNU-;8FQ>8DS#=ZI,1
M6*AN]M<YU)5Q)+&KDR5$7G14Z47-%^0'W5$\5- ^:HE9%"Q,W/D<C6M3I55Y
MC%6C%-@O-4ZFM-[MM;4-VK%3U+)'9=.2+GD4XMPO:\64$%#?(7ST<4[:C@4D
M5C7N:BHB.RYT^]GETHA#NG+"EDPVW"E=A*W4]LQ"Z[0PTJ4;$C61-N>:)S[=
M3;\<O2!/51-%3POFJ)&10L36>][D:UJ=*JO,8JSXIL%YJ74]HO=MKJAJ9K'3
MU+)'9=.2+GD1OIDSQ%CS!."II'I;*Z62LKHVN5O"LC15:U53T?==^Q?08[3O
M@^TX:P?!B?"UOI;3=;+4PRQRTD:1ZS5>C-5V7/M<WG^/2H$SW*XT5KI75-SK
M*>CIF\\M1(D;4_-5R/GLE_M%]8]]ENE%7MCV/6FG;)J_/)=AA;IA.P8U6S7>
M^T*5O P:\$$KE6).$1KE56<RKL3G(VNUAMN&_*"P?%A"ECH9:NFF=<*>F35C
M6)$7)RM38F>2_FU/2!,%QQ)8[94K37*]6RDJ$1%6*HJF1N1%YER544M4N+,.
MU=1'3TE_M,\\CD:R..LC<YZKS(B([-5/EON!<+WZX.KKS8Z&LK'-1KI98\W*
MB<R9D2VO"EANFGR*GP[:J6BM>%XDFJGT[,N%JG?@:J_[NQ?FUP$_
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MC'<_H7)2/-$FB>IP#B^[W%;E'56^H@6GIH\G<(QFNCD1V>S8B9;.?X!$M
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M? C<XXY$FE7H:U<U[=B?F=)$TP !%
M
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MJQAA2U8NM\-#?(I)J2*9LZ1MD<Q'.;GEK9<Z;5V&<:B-:C6HB(B9(B>@#T
M
M                                            6:ZEAKJ.:EJF))!,
MU6/:OI13G?&V$JS#-<Y'-=+0/=^XU")L5.AW0XZ.+533PU4#X*F)DT+TR<Q[
M4<BI\448.4 3I=]%=EK)'244M10N7]5BZ[.Q=O[3#+H=3/9?%R_FG^<U41("
M6_T.?Q[_ $3_ #C]#G\>_P!$_P XHB0$M_H<_CW^B?YQ^AS^/?Z)_G%$2 EO
M]#G\>_T3_./T.?Q[_1/\XHB0$M_H<_CW^B?YQ^AS^/?Z)_G%$2 EO]#G\>_T
M3_./T.?Q[_1/\XHB0$M_H<_CW^B?YQ^AS^/?Z)_G%$2 EO\ 0Y_'O]$_SC]#
MG\>_T3_.*(D!+?Z'/X]_HG^<?H<_CW^B?YQ1$@);_0Y_'O\ 1/\ ./T.?Q[_
M $3_ #BB) 2W^AS^/?Z)_G'Z'/X]_HG^<41("6_T.?Q[_1/\X_0Y_'O]$_SB
MB) 2W^AS^/?Z)_G'Z'/X]_HG^<41("6_T.?Q[_1/\X_0Y_'O]$_SBB) 2W^A
MS^/?Z)_G'Z'/X]_HG^<41(7Z*DGKJJ.FHX7S3R+DUC$S55)=H]$%&QZ+676>
M9O1%$D>?YJKC></X;M5@B5MLI&1O5,G2K]Y[OFY=OY<Q*,1HYPDW#-M<ZHU7
MW&H1%F<FU&)Z&)\OVK^1MP!%
M
M
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MK,/>(!?!8X[2]9A[Q!QVEZS#WB 7P6..TO68>\0<=I>LP]X@'YN@ -
M
M
M
M
M
)         __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g42675g01a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g01a01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X4C5:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C
M(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/F<P,6$P,3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C8M,#(M,3=4,#8Z,C(Z,S0K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(V+3 R+3$W5# V.C(R.C,T
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C8M,#(M,3=4,#8Z,C(Z,S0K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R
M(#(U+C @*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX
M;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED
M=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XV,#PO>&UP
M1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA
M=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-5
M1VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C
M>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G
M445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!
M=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%
M2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M+SA!04519T%0045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"
M05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!
M04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"
M04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C
M>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I8
M5T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP
M-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53
M355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$
M9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X
M<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD
M;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C
M>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!
M=T1!44%#15%-4D%$.$$Y531Q,4I):V%.2DEW4TY!5V0R3B8C>$$[04%.>5-4
M:6M!:S!(9R\U,%1A<')%53$P:E0R-F%.3V)453E*6C9Q<4]X83%V04)11EIL
M,G(R3S)B1%,P1#<K4B]1.78W4'AH:4EI828C>$$[4&E$:6I,+V11.3A8:C9S
M>7-'56M-1%5%8D5%6FYV5VM7*W!V>7 X-T1Z5#5::F5D=V15<V%16#8Q,UEG
M9D),+T%-.4%0=G)M;C%'3"8C>$$[9VPU4&U88EA:,S5B35%0;VQV2#E8=V5(
M+VY4+T%/5$PQ:B]O,B\V:%ES,D=L+W5X*T]R,FYS+R]!26Q$+T\O,U)95&U1
M-VPR2W5X5B8C>$$[,DMO;E10.$%J<%=N+T=A4"]I47E-+W!,5FXK:5AU3#$S
M+VY*2"]E,U%V.$%J2&-F.%-J>D,P4%8U5#)3*VY*-S0O<&5--6YV64]X5B8C
M>$$[,DMU>%9L2&MZ.'A0369L83AJ93%U2&US05(V*VYY<U1%>3DK24YE1&8U
M4R]I37!Y-$EZ2&TV>G1$<VY$<5EN:494-E,V+W1E>2]N2"8C>$$[<4YT<68U
M5G!Q3G%38F$X93%N:$I&1'AK4$E62&IV;4)P:%=3:3AH,D1I;&HQ,T),;DAI
M2'EF3U=B5CE#938O.#5!9CAO<F](+T=8+R8C>$$[04IK-7)D1CE294DY;"\W
M+T%#93<Y3'@W>7 O>6Q':B]!4$UD8F8X04HU8WHX=C!N,U!7-C<K-&XO56PY
M>C=&>E)V:VIS5E,S>DXO>28C>$$[:F5Q+SAW9'@O=T%M;7E595EC:E-F,S!0
M-G<K.3AC6G98,3$W9F\O+T%+>G)E9C9S,R]56&UU;B]!2"]Y94PQ2"]'=5!H
M+W58:4=B1B8C>$$[-U(V>BM46#5O2%-P;R],=7-Y+S=J2E=P6EA,;BLT:UDO
M65EN+V1B2#=J-TAB0S%7;G8Q1&TX<C(O=T)J94E$;7AJ,6IM3R]Z.2\S=B8C
M>$$[;T1.83A);S-T-V%73G!.95AC<7<R='5H:VUL8S!65E562D]%0SEM95!(
M2V-H1TES;#AV9FU:*UE6,S5U,68X061L;W1(=%-263(U,B8C>$$[<C)-<FHK
M6G9W1S-J6&)A9D1W1'IF4W5X*WEO-EA(=G9K;'I0-D%W,TUH,T0W6GI14&I4
M1E!/97(X-#5D27-O8F966G=N4%9T15IY="8C>$$[>DQ9>4MY<UE"559C2&5N
M.5)L=4]053=E9FTW4%%92TEY4TIG4#1:+W=I42]N951!=4UC,79!26UB53=6
M-&YT9$]M:U!'4SAS:4MZ828C>$$[5F0Q*WID445C;U,S56HU-60Y;C903654
M=3=)2G8P4W4U9#!:9$UK9C9%=C1N:B]M1%)Z<%=P=F)++W)7>F=3,F1X4VYQ
M=U!V1SE/>"8C>$$[<'-W-TY59',R3T]F14QE=C!M;SA72$9Y4$EJ=5!8.&1Y
M8B]L>#5Y;#AQ95IO3#1K;7AM<$1Q15EQ87=S4E9G0C%:4'1$-W4K47HT=28C
M>$$[3TYD6$4W5S=01W%W;5 X045.-"LO=T1A*W(T6EEP;VMM:6-34E-+2&ID
M5%5-<D-O25!G4FUM9DQP4DE.2&UU>%$X1R\U>5 O04]/>"8C>$$[;S,O35!,
M+WA-6G-D1'E,,TAS;B]!2&,O94=(9FQ&+S5-8E)F*TUK;B]*;#AV,5 Y,EAB
M.74O-&YK.7<K.%!Q<DY/*UE/>%8T6B]Z:R8C>$$[:B]V8F]8+T=/-"\T;$AM
M=S!05C=8,E,K;DHW-"]P64@K5FXO04I-2%$O.$%M22\T,6)-:E4O,UID-3(Q
M+VEM5#-0<2].3RM83WA69R8C>$$[=C5Z+T%+0R]W3&8O04M3.4PV>'A8.4@X
M<65R-C-)8V94+V$K9$\Q835K86$K354W=G-$>&9Z565#-B]I-W$X,WI";3-F
M4VYT+VUN+R8C>$$[04Y:*S!R+U9T=CA!:5IZ6%DO-S@O1C1R4F8X04=T4"]!
M1&YI1V)&-U8W<B]!335!9CAO<F](+T=8+VU4;70P6#%&-&HR6"]V.&YU+R8C
M>$$[4SAE.'%F.$%+56%0+W=!>#%T+WEE6$TO3#E*.7HQ=74O=4HO,4IF8RMX
M8S!B-4DW1E5T.'IF.$%+3C9R+W=!=V1X+WEA8DI2-6AY3B8C>$$[2B]F42]R
M1#<S>'AM.6986'0K:B]!4')/=#4O<7IF.$%56&UU;B]F+T%#94PQ2"]'=5!H
M+W58:4=B1C=26'9,0SAS;FI3-FAA1G!O;R8C>$$[-31G=RLQ1DUO94YX-&AL
M3T%30C5-365737=413-222M)-79B+W=!;69Z4T8Q1D@U8C%Y8T,U:5=M;EAC
M:"LR:6HK-F1J*S!O*WEE-"8C>$$[,C8Y9&1Q=%!8<4A*-'8R9S='-%0T,DEE
M:R]53S=Z67(K8T@U;DAZ1&1N4G1+:U V171N+T%(:VDY3&U25#ER+T%&1E R
M9DAR-%5V,"8C>$$[,D1H,U!.,FY94%DO9U(X5$E0,V@O=T)I4#$Y+WEE9%(R
M1C5*6GI8<5)-8E,S6D5M;2]:5G!+.%9R-&YI8WEJ25A85C,U>7A%:$5N,28C
M>$$[2' W;$1#,E!T2%5B,S9J67I89F]46%!O<5@K<C)Y97!-.5 R551A<'I1
M9U=8>#=&:C0U0TYG6#%/=RM,>64U=E1R3GE13&AD96%+428C>$$[>5%20414
M3F9S0WAR4T%38T)+<3$K>C,V8C5L06-)-W9T:5AP-%DO0FIY.$MX=CA!>#1P
M*RMR<CAC;$QJ.61L=5-Z3&-3=59854HR:B8C>$$[83%E5#!Y3T@Q*S(K1U,R
M=550.$%D,U59-#$V-UDS6#0K-WDX;58X04A19G=I*TMR-3A%=55O;BM+0C-3
M-WHQ-4QM,4A16'5R9$,Y.28C>$$[63@U=T].2&M6=FIM<7$W8VXK,F%B1C9L
M9'!.<%E-,T1,9FM823=--U)'4$QW;C9:8F4W=2M83#-C+W!E3UIS;G-(=C,U
M0RMD+W(R;28C>$$[=C5A=EI+,U9G=D]W3$AD-V9U;GIJ4#A!=W Y<S%M<GA5
M94ED6&A086)S-V=N-#!2-EIC+V8K,S<S<F598GER=V(O;DDO=T0T-T=J9B8C
M>$$[.'<X=B]%>&UX,%!)=F-E>68Y,U S:&@S-5)F*U1',%@O:DI*+W=!;5AY
M+U4O=T(R6&(Y=2]W0THU4&-0=D0V<7I4=FU$<U9E1V8X028C>$$[3U-0*SEU
M:&8X63=J+VE596)$43E8=&9:3#9C;G9J*VPT>FUE.6<W1EA9<3=&5U(K4R])
M974K8DPU66)#27!:;W=&,69/0TEO:#%/+R8C>$$[-U15-DM0,6(U5FQZ0T$S
M-75U-U$W5'AA5TYY4'$V4C9N.6YM.7 O3TQ48F)44'ER5%1R5457.6TY<D)%
M1'5E35HT:79V=&UV,'AV2B8C>$$[6F5/-T)Y;DIR=4]83UA%9FTK8S@R<C9%
M.3$O-7E!+S526%%0*TUV+T%$2GI7-DPV:3A2-TPO,RM4,V9P94UA1&1X5V5U
M861D>D=K3B8C>$$[=F11>7E(+TI344UF=T=B1$E,:5(U4%EA<4)N:6Q%8WI%
M:C=(,E)$3D100VLP3')*1DEO94]20T=6;%E60D)(54A.12M24VE185!.9B8C
M>$$[:6A)+U!'<%=M;F559%AU8G%14GAI,6U286M!<SAI1E515C=S>$%'5'AX
M2FM!2$XW3W=Y>5HT4FIZ-&<K47,S:C9W.78P9CA!.5HQ=B8C>$$[4#E78B]Q
M3'I85"]V+VLX6'%0.$%J6$AW+W=">3A1>EEV85!O>E5V>3ET4$XO=T-79FPX
M249I,64Q,'4Q3FIC;G8K-%%M2B\X;'9W3R8C>$$[+VIM<4=9=WE(=70X.7AD
M<5,P;71Y9&-C<VMR2"MC9#-Z,6973C-96&LQ;&523D)D5S=M3V%*>%)L6F1I
M1&TP:DE%5TAV.&53331I528C>$$[5&-3;5!L4'ER<6YM9E=9=$PP.5!J9C1P
M<&U"-%)2:C=4=5(R2#1N8DE:8V=G3$QJ-C=7=S R37IN.'4X.7HR3#@Q9DQ'
M;"M7=GEP9R8C>$$[,')4:W!&2&51=$I+86,U6D-R8W!(23=M;CA-=TY037EY
M,EAK97AD6E!5831Z;GI-5#A",U!"8S)B,TPV63@U86]U<%AY,F-5361Z8B8C
M>$$[,G U,CDQ6F%Z2%I846LT+T=05'%O3D]G-4XY,F%F1TLO<V9..4)I.$]0
M15124$U3>$=583DO-F=K16MD+V9R.5AU;'5R>$DV1EDY528C>$$[9S O5D93
M;CAT>&%4=S-#+U!*,D(K>7@Y-VY#54EB>#19+S%$3T@R4VE9<"]P;6MZ56I*
M5U$K:U0V5$]:,TMB.4DS=4936D(W0V1H;"8C>$$[4FLT1V)-3BM7+W4K,%(R
M4"ML1$MD3S Q5E5!9U5!-F)F=T%(9G--9U,V,TQL9D\O-74K4T0U63AY3DIB
M2G@P<E5E53%N46)),68S:R8C>$$[6"MX2G%066I.<'!S=D9':GI$-D(R1C)J
M*UIW,4PV-&)(.4)9<&]7=%@R:6%V839R671W=6)345-*-$5$-U-T-TU.:FPX
M-$-1;W4P,28C>$$[3VYJ;7AN2$QL25!R<GDW<C%J<C)I,FUR5U169W5K1&-A
M,4M.,%I'.3%A;T]A4V-$13!8>6Y686%71$EC8W5C6&DO.$%Z:V8O04UD:B8C
M>$$[4G8X06U(;"\T;4UZ.41Y3#)(<VXO9'HY-%ED*U58+VMX=$8O-'E39CAM
M6'DO52\S6F1V,C<O:654,T0W=RMQ<S W-6<W1EAH;B]/4R8C>$$[4"LY=6AF
M.$%'3S0O-&Q(;7<P4%8W6#)3*VY*-S0O<%E(*U9N+VMW9$0O-6E0*TY7>DDQ
M4#DR6&5D=&8T<&LY>C9V>E1V;'EH9E=.<"8C>$$[9C)C,6QD>$Q.83-#3DA.
M13(T6E=&0TU)3D=W>G@U2E%K2E).15!L1'HY-4]U=DMN;4MF5'!+=F%T*SES
M6GHO=7E&:CA0*WE8-TQE*R8C>$$[8FY$;#0T,BMP9&UA*T]Q=VE9*W)Q3S1P
M:BM69FYU5'EP-6A8-G<U+U)&.%9I=FLW3'8X04)-0C1P6&8R<FM.5&@T-#=C
M=S0S8EA:;R8C>$$[,5=,8BLX:G50,69(-S-S4#4V3VMN-61Y=6I",&5E,UI7
M53%"0F%O24EZ0C!N.31(:W9:<U9R040S4V9.5V):.4=F5% U<&548GIZ4"8C
M>$$[-4QT:W-&-39H63A,:3-H<E0Q0G<T=6=R=%5G,4AU33%';GEI13DK5#5V
M,DPR:$A486MM9C!3,E!L-79M;65#84-:-%HT,FEM:DI74R8C>$$[3G=66E-/
M;TE/-$]B8T<S,&5-:$E71%E45%103B]M;E,T:$1P*W)89'1!0E)9635N15ER
M=G-L94DK-TLU66]Y-6AX8S)G=UI48S122B8C>$$[-S8S4G8O2WE04'8O049F
M<GHO:V$R4B],=S=M;BM33DPO<6-F:VQM<2M9.68Q96XV53%'-79653AK4V56
M,U944VQ656YI4&]Y8V-C628C>$$[.&<U3T1367-8,%)J2#-"4C!N4TY3,64O
M:7-.3G0S=6)U53!32D)5*S5*-D%$=51H;$U21FQN;GIW>%)--6UO:#E#*UDO
M3&<X=69K;"8C>$$[9#90>41Y5S%Q1$TT-D=74UE34U4Y=51';G1M<FA0:7EG
M*V)W1VPQ9C5J=$M/5'9L.6Q52'IF;3)F4D@Q.35'+S51<GDO=T0Y<S)Z+R8C
M>$$[04]40UIP378Q;C-L.&XW4R]W05IY9C$U9C=O<U0O3FHX<E8X,%%,<5=L
M2VME=7=G2U%31E<T:C)(1C)04FQ(,E0Y0C=5=# K;S1.:B8C>$$[>61P,DHR
M>BM74$)0*S90,D@X8S O=T1Y*SAI868U43!:8E=+:W0O3E(W-C=P=3<O04UO
M.$58;V\K;G%C<GI:5$TR-$AA;F%5.5AK-"8C>$$[:G1%8V@S9G19+SA!;CDO
M>6=1+S5J268K279L;6LK='HO6FHO04)R+T%$4RMB<S)Z-DDK>"]W1$10;'HO
M04MT5FXO,&IX9CA!3D]A3"8C>$$[:5!E*U)F;3@S."M8>DLK4'DY;T5:<DAP
M='%H+WE927@K<&-(155(5354>FQ,-6Q%4C).;$@O9#(X4V8V<4M0,41',G,U
M2DAM4W)G028C>$$[0V=&0C=91T-#,6)23D@Q94))3E5S-&(R1TYU85)Z;TA!
M86A&4EAV435+36E/4F)S1V]Y66IC2D=*.&MR+W=#5F0K4E K<D19+W=$228C
M>$$[:% V6DQX<#DU8VXK5F16+W%K+VU5,C!V4CE,,&TR3G)P;')&6C(U6759
M659#3'E)04IO4&QK2E-*,TQI-7,X.' T<&MY4&UH.5<X<R8C>$$[*UAT66MJ
M:S%85')E.6MI0E=.<#0Q8W%#86M#=4=--5(U1G-W879,:4)%2D=..7A53$AY
M5C52,"LW:G9,3%(W4S)U;VE41DY(17%U<"8C>$$[24E.0T(T2$-C<VE+2DQ0
M2C)H<4IX35I4:UEN<&%D6D)W,UEQ;'5R*U<Y03%H;VTQ6%0T3#%O45)%6C0Q
M9FE'<%=L96QA6DM->DAK6"8C>$$[27=A=DQI=G<U1TXY>%$Q;#5).&]73C%(
M9#)E:C)L=F-W;FQ&3DA%<7-P.%%134IY>4EO:W1M5'1(551I67EN26<K860U
M0G<S67%L*R8C>$$[<BM8=$,Q9U)$5F)#0RM%3F93.65.6#0X<6-U3E)T5V=Y
M55IM4$ET*T166F-6*TA)>'9U2UAF.$%+=2]);B]6:'-F.$%K46XY36PT,"8C
M>$$[*SAU4B]+=7$O=T)5;CAY;59X-68P4S4P>5!3<FEX:&PP,DE+23=2,$)I
M54HY:T)4=#A08DEI6D)U.3-(:G%C:UHX66M233EE<5<O."8C>$$[<3<X:68Y
M5T=X+S5%2B]42F5.4'9,:V9Y<G%V.55N.'EY0E965D-Q2TMO;T%/=T=6=4%3
M;'5Q958O3&UR4T-453E-=&)Y56)#5V%&2"8C>$$[8T1W-45C<VQ'8VAY3&LT
M9%IM>$-O5&Q%95)+0B]W0U9D*U)0*W)$62]W1$EH4#9:3'AP.35B=C56,5@K
M<50K6F0O>7)V>4HO,5EB2"8C>$$[+VM1;CE-9D=N,VQF-58Q6"MQ5"M:9"]Y
M<G9Y2B]W0E='>"\U14HO5$AX<#DU6"M69%8O<6LO;54Q,'I29$@P<4EX86):
M45=56BLP<R8C>$$[16%X,2MF14-V,#5#56EE8FI:=%)K>6TU>4UJ-6TQ5RMS
M8D\O=$I,4SEH4S1T6FA35T=10FM903%O469C66=K8FAH:GE3:$E3:6%K128C
M>$$[;"\U5C,U12\V<TYJ+W=!:44O<&LO1VXS;'I0-58Q6"MQ5"M:5#(R=&],
M83-I=')E3EER94)&:FAI455655%C5E913V=!1U%*='=P>B8C>$$[36E35%I+
M<&=9=7A60V%P<$=L-G)B9E9D4W19<GDR-4(O4FU53W9)9$11+U!$1U)'-&)C
M3V5E2UA&06U*.&MP+S56,S5%+S9S3FHO>28C>$$[250K;50X869E6$LO;%A6
M9C9P4#5L:T]6=4$W1EA9<3=&5D\U=5E,83-L=6)I4EER94)':VUL8S!655%C
M;5II96=!1T5#,E5)1U)!028C>$$[<VQ)=BM6:6524#A!<2]74"]).5 V-5!W
M6CEX8S,K4W16+W%C+VM5-FYV-T]#>6$K;6U33WI24%9E-%EG24DV5C5&=D-M
M44%*3D](2"8C>$$[2$M5=45$,6-Q535D6#!U3%1"<6MT,45M;D=.6FAD;&=)
M=E1E:%8K6%-H-4-M4$-B<G%Y1T-:;G=!2&IU<38R:49M:6%%5$LT35)8;28C
M>$$[2$(R2VM6<E@U64=S>$XQ,5-(+VQ9;FM4+W$O5U O23E0-C5:-$TK-'5D
M+TI7<2\Q3V9Y2V54,V1T0F%Y6&,P<7@R<U5:;&MM63!6628C>$$[,4A)<U0T
M06(U04,S0VI!>6M)9V)N6DM,6'HQ-4YU-VE/,G1T8G-P6C54>&IJ5V1/5$UE
M9T%R=6-M8U5H>D)C=69:,F]I3&QJ:T%0228C>$$[<#5L8FA)2CEA,&Q.5U13
M1W5O>'%C:V9R2F%6+V5'359(2VYH<V-00V%V;S-$5'I/4'A+4$)D6#!T1S1'
M;$EJ-3@X;&DT3G4R=#)3>B8C>$$[:"]436)4;T-'0G!1,5!J;&YH4W$V3&TO
M>6)Q879W-58W:6YH9$%N<49H=T$U8W4Q3W1C<F-/=6I(+SA!;%EN:U0O<2]7
M4#A!>5!4*R8C>$$[=5=E1%!U3&YF>59Q=CE4;CAI;F-T-6%25V(S<VMQ<&%2
M>&U:-3))0T--3'E,:RM(2&9)061(1&IJ:UIC24AQ=7$X,5 Y2S9B*VIF,"8C
M>$$[<#E::B]2,W K=#EB-40P+U1P6&YY-E5P,W@T5&1D5UAG>C0K0VIX,U9D
M8EAF<$=W+U(S-E,K<THY43E(-GHY835$,"]2-#@O535D3R8C>$$[4$AE=5!#
M8G)Q:G=P8V9"6'%U<38S,TI.+W=!<D4X:68Y6#9X+W=#4C9F,7EF9WHW:35F
M.&QA<B]!1D]F>4MD5#,Y;D):3F945$I(6B8C>$$[;VYQ=F--445%9$LX:3-H
M5$E!16UN1&IJ;$M80T(V=59,-V$U9W5B94LU=#5&;'0U,%=31U9$5E=2>'E6
M;$DV9V<T:U5I8T1%:T55428C>$$[;&5R96-V2W5K6$ET9%,Q5S)T8FMG2#!:
M2D%(05!1;&5O2'IY56-C:GE$:S1.0FYY:FEH0U5H-VLP=')Q,G5R9$QI,FQ3
M93-L2$M/5R8C>$$[3F<V340S1$-O3U%)<'AP=TU456A20U4S6&Y8>6QA86ED
M3G5D6'198C1%2S!$>7%#<DAO<F(P52MX>5EX>4EU=&Y+:#)F;FQ$:FI#4B8C
M>$$[:C,P;#)R*V-.5C V-S%:5'!T=DY:-E999G!)>G)D=4AK:6-40TY22#E8
M2VAI.751,W@P04Y26'!K-#1W44XK6G!Y34=G>#5)=SE5:"8C>$$[2V,K0W5(
M:V9492]&+U,W=FQZ4DAL;GIN1'(R<%AL;D9B1TI,4T,R;4UP8TYY931$:#0K
M24=X:65-;V0K=&-J4$A1='(Q96=/1T5:128C>$$[,WA'42M6569I1&)).')D
M93=&6%EQ-T9867$W1EA9<71L:6IL:F5+5D9K:6M5<DI'=T)6;$EO45%D:4--
M56=K1WAZ96)W84IO<"]/928C>$$[-'1465=X=%)O46M%2&]X*VU(*W1)3UA'
M;$LP-S5K.%(X3"]/+U$Y1$Q56E U3T5U2U8K3GIS+WI75"]M17%P-4,Q,45!
M5E9S2F=Q9R8C>$$[54%!43!!1U999G)(=F1B,E=B,5=0*W50=F5B-GAF965M
M+TM/3T=F5$Q.3D8O4G1Q;W4Q=4=-,V]H62]48C K3D]2,G%+-6MX15!&-28C
M>$$[;3=E:'=9.4XO2T9I8W9%.%-7,T1T92]6-GA:+SAO,4(O=T%W4V8X04IO
M6FAN;3AT:R]V:B]7+U,X<2],1W@X=WIE571,841Y,W!..28C>$$[<#=.2T1F
M6$Q,.5E:9G)$:'E62TAD9'=.*V=Z33%":GAN8S(Y4#)Z:WA$551V3&MJ3&)9
M8W9P2&TY33@W9T1Y4G(T06]"<&PR04(O>B8C>$$[1'9M3FDK<V4X4$\Y;F8T
M>FHO<G@O=T(P2&I%=#$K:U!+1VAE5R\X041%5FIF86]K15=N-B]C1T].5V1/
M3$=66%9E9DIH=%1L53$W-28C>$$[;595>DLK6%(V-DU01#%'5$XT<&Q'0DIL
M05=F:%A*-S9J0S%S9S%Z3'E%15E-,#=B5C1,.%1N-W$U9U!$;C%3,DA-.&YZ
M,V0K6EDW:B8C>$$[55HO4$-2,V@Q<4Q556YS:T5-<&<O4FM3;4UX;5-N049K
M2DQ(*W5B05$R-$YQ<C=8=DEA47AG3DM42'=Z0VIU3#1Z=F1C.6DK9S=#*R8C
M>$$[='(K>'0W,C%F,4QA-6I75T9X,U)W1T(K-#5R>4M.4$(U35IH27AL>D)P
M-&9O=DLW.'5A-7!6=C52;#%M.74W-CEJ:#%(,#1H16I/,28C>$$[1G)->#5+
M67HX6&(U-6UY,FM$>%9S2',X+V]Z63AH>D1(1TU)96UZ9GDX,W)8;"]3-WI3
M=DID;G!T-TE*3'$P<VA&37=.4GE62U5"4"8C>$$[54PP>D5N24=223<S;'16
M;6IL,45P>"MM57(K,35N*U=L:C5K;#AO85DQ<C5A,&TO<VU-=$PR-EIF6%EF
M5TA$8V=54#)4541F;TUY="8C>$$[45DX6C-,,&9B1U1#3E)0:7DU27DR,DA,
M-E(U=E1V3W-92&MN6&\T,6]"<'0R<4EO+W=#6&1W04%->'-8,6HS=D]D;FXO
M0V-:4#@K4"8C>$$[*S9$15AV3%90>4=%:E-R=T]J:45.554Y47 V65@U.#ES
M='(Y.2]N3S!'3U(W57%V.')F=W4O=5ID-5)T4B]G<E)B5S5J1$0Y1S)S528C
M>$$[.%1G340K-%975FAU0T\R535$-FE2,W5Q,3 O.$IY4VEF-#5%9C9::65N
M84AO<F9M,W$Q<S)N,GAT:S!U0C!G34U:44U:0E9G=$M!-28C>$$[85I(=W@W
M,V%:9%)K+TE14$9++T5053EZ2E!Z0U95.&AA-FE!2W$R17=644M!04EA041+
M.% Q:C-U=C=,3C9R2"]82#-Q,VMS=5!),B8C>$$[9VU-075.3'1/05!1;C9U
M;$UC=C%N,VQJ,F@O:E=3+SE5;"]U:7=Z.&]D2#!(5F9,9#5F-G)A=U@R=#-6
M,4].66$V4EI:02]),%)G-"8C>$$[4$5C9#9:9'%*15-O8W5J='4S8RM81FUJ
M1T)-8V-9:F=R664Y-D1O5FAO,6IP8TYT;W%24C9C;DEW<D%1>59,17129U18
M-'$Y.'@U128C>$$[:S)E8F]T5&QY5&U:6D-44'IE5EAM:#9L-6)T9%IU6CE(
M,'IZ4C59;75P<G4U=653<F529W5E65IM-59-9BM4=41836]316E.>D=4,"8C
M>$$[*U!543%%;U)%.&U(34EI24@X2C=V;3E1<UE.13%F4V\W-D\P4G)85F)+
M1D-R;T%7=%=1=DA%=R]L06QB8C-Z1TYX3F1Z>E=35U1&328C>$$[>$HY54I(
M+U1D5#EI2W1.3# R,&UK;71B84]'5V)A5C!52U=R23AU.5 K3$IN8C5K-45Y
M2F$U-7!Z045I4T(K;T0W9T(X159G86Y9<28C>$$[-T9867$W1EA9<3=&6%EQ
M>#)0.$%W>"]J*UAH>2]W051F;S!E<#EV:#E4.5IF*V5D9E5P-S5:-G5$*VIF
M,G5W4&HO;%(O<5!(-6966"8C>$$[>C5)+WI.*VEF.%!A:BML-B]O=C9V2CED
M-#AQ*VQX*T]N1#1U;FAK65AX0W5B4G!013A74&@O6%ER,W!4<5@K15 K5F1P
M.6(U+W=#1B8C>$$[9G%6=GAP-FY0-G124%,V9G9+,#0K*U1(1G@O,')C;D8K
M62].*VXK+S1Z,V96=F9K;CA(,5 Y1E(K;E@V;#9!-&1A*VQW,CDO<S58,28C
M>$$[8T=81GAM+W%V-UAJ='0O>6\S,%8K<F9P3#!D*TAP+W!$:C$S<'@R-C5M
M2'AB,W(W2'):+WEN9G$T3#@O1&5R-FXK:"\X2S-8,7IL*R8C>$$[:'9Q36XQ
M;C=84#9R-DHU.5!J<C9F,#5I>'9I1F,W95EW*THT-#1F-WIJ1F8Q<BM83FIU
M<R]W1$MV4#A!04=N9G!$;"]H>6QV*VI+928C>$$[<C8O3"]D4' X9C-V4&HY
M3DLU6DAJ-'I8,4]F<"]W03,K86QW9C,S<31U5F5D.4M4-WI"*VEF.$%#9#,K
M;&98+T%%5CE6+S!Z*S@Y8B8C>$$[,&5)-3AU4'@Q-"]A*VY+-%AX0W5B9S98
M>%!(:C1D8V9&='EQ+W4Y>2MX+W<O=T0T5F@K<F-0,$(Y4TAP.65(,5@P=3ED
M+W-D83<T1"8C>$$[9D9V>E)K.%AX>GAF,W9&+W-R+U=O*U-F,$8O:&EY+U%0
M<2]O:6HO52]7.51N>#5T6"LY*T]N2W1+.75M,E-Y,WA'*V)0=$1X9D=L-"8C
M>$$[=&5*,7%U-WDR52]*4"M'=C!B9&8T935F5E!R:R]W0EDU.#8O5V%J,6%C
M.396*VI":S1R,U0R:#0S1U!&*W)H1F4W<'E4,C0Y4#!*4"8C>$$[5B]U*TQC
M+SE7;2M18T].,DME3%<S+TMJ9E)8-G0K:W92,S1E;BMK3U!896Y(8G)M869&
M=F5V<V5V;B]+9"MR9W9Z.$XW2F(O0494.28C>$$[2%)C8695+U)7;G%D4%0T
M+W1C=CAN<EA-3C5+6$9X;BMD9C)V2#0O*U9&9G!&9CA!96HV:#E94$AN.5HO
M4G9R9E0X3DLO4CE'6FXW-R8C>$$[-"]#,W%Z+TMF0C T=4@K:G@Q.2\V9FDY
M;EAJ>$A';D=M,4]L37=N:T-K1G(O:'(O04)X9F5J>2]X1CE4:BMT5C4X4'$S
M26-+5BM#=B8C>$$[3'<S>5HT=4AY8S9F:F9L;S,O9&-2<C,Y9DY'*UIV,%0O
M:#=59C!V6#E&+U8U4')V2&Q8,'50># T9D8P.$U%3#1H6$YQ,&YI94Q(=R8C
M>$$[+W)S5C<Q5'DO=T1O,SE!-F(K:DLO;S,V<D(Y4C5C<2MH-F$K;%AL.%@R
M2V1D.%HS6G9M>#%82#1S=5 V*TDS-S<S*S$U<C5W+W=#5B8C>$$[42\T9W90
M<F8Q;CE),% V5B]2;G(X4&8Q+U,K0W8X,S0W-6M9+T5O5GDV6%0P3V<O4"M&
M2&@T940K2&HT9CEJ93<P1'EH+VAN+T0Y<B8C>$$[+VAR,'8P4E$K:#9.859R
M.%A,;#A82W8R=5<K55I/3&DY6$XP5W4X8GA4-#$K2C%V.&-N;60O.$$X<5 O
M045L8R]W0SE0,5@Q4CEF*R8C>$$[<697=C!F-FQF.3)E;CA.2R]W074R6DDX
M5V@K>3-O.%@X<&-!*VYI<C S=SAD958W=EE,4#9R.55G*W%C9G%V<'(Y6#1F
M63E0:4](1R8C>$$[;F)J,'I$3'EK*TQI4$8Y5C=Q=4Q",DMU>%8R2W8O+UH\
M+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z8C5F-V)E8V$M
M-S$V8RUD.30X+3DQ-C,M,3,Y8S!B.3@R,V9F/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F(U9C=B96-A
M+3<Q-F,M9#DT."TY,38S+3$S.6,P8CDX,C-F9CPO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$
M,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD
M969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HT93DW,#9D,BUA,CEC
M+3,X-&4M8C=D9"TY8C5E83,U-#DX-68\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-&4Y-S V9#(M
M83(Y8RTS.#1E+6(W9&0M.6(U96$S-30Y.#5F/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8C(V9C@S-V8M-#9F
M-2TT9C5B+3ED-V4M93$Q,#8U-S1B9F(U/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 Q+3 U5#$Q.C R
M.C0U+3 V.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B S,"XQ("A-86-I
M;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IB-68W8F5C82TW,39C+60Y-#@M
M.3$V,RTQ,SEC,&(Y.#(S9F8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C8M,#(M,3=4,#8Z,C(Z,S0K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C @*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-
M.DAI<W1O<GD^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL
M93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @
M(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O
M<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(" @(#QI;&QU
M<W1R871O<CI)<T9I;&53879E9%9I84EN<W1A;G13879E/E1R=64\+VEL;'5S
M=')A=&]R.DES1FEL95-A=F5D5FEA26YS=&%N=%-A=F4^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I
M<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*
M(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C$P,#4N.3$P,# P/"]S
M=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XS-3(N-C Y,# P/"]S=$1I
M;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N
M:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \
M>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y(96QV971I8V$\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y(96QV971I8V$\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%C93Y-961I=6T\+W-T1FYT.F9O;G1&86-E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N
M=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3
M=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S
M:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/DA6
M7U]?7U]?+E!&0CL@2%9?7U]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"
M86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G
M.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P
M/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O
M=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@
M4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $, !@0%
M!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@+" C
M)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$(
M )L"I@,!(@ "$0$#$0'_Q  <  $  @,! 0$             !P@"!08$ P'_
MQ !5$  ! P("!04(# L%" ,!   !  (#! 4&$0<2$R$Q-D%1870(%")2<8&1
ML1<W0E-4DI.RL\+1TA46(S)58G)SE*'!)#,T0X)C=8.5HJ/3\"7A\37_Q  ;
M 0 " @,!                !00& @,' ?_$ $ 1  $# @$&"@D# P4! 0
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MW\7SEM@YQN]3\*Z;%\0\56=$1.UU=%:K0_[7%E_=O^D<JJJU6A_VN++^[?\
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M$4A.D1$0A7:1$5?7&5X;W;V7>TU=ODGF@941F-TD+@'M!XY$@\>"A2IP-C'
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M?E4W%VS.1WB(;W'S[AYRN?T+WC#6&\.2R7&[4L-QK)-:1CB<V,;N:T[O*?\
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LDI_5-IL%B<V$$ND%L]K =BW2(B@*G(B(A"(B(0B(B$(B(A"(B(0B(B$+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g42675g03a18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03a18.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1,24&AO=&]S:&]P(#,N,  X0DE-! 0
M    $O4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$B$Q!1114I$306%Q@2(S-,'A!A4R4W*AL=$C0O#Q8B1#_]H # ,!  (1 Q$
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M]U,_[V?YCJ( <N]CW3C[J9_WL_S#L>Z<?=3/^]G^8ZB '+O8]TX^ZF?][/\
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MO*JKM-\1S1I['.%?BJD^Y:2,
M
M
M
M                           .7=%GYU6*?A:[[:'41R[HL_.JQ3\+7?;0
MZB
M          4#U9'K)LGQC_C>7\4#U9'K(LGQC_C>!;>C3V.<*_%5)]RTD9'-
M&GL<X5^*J3[EI(P
M
M
M
M                  Y=T6?G58I^%KOMH=1'+NBS\ZK%/PM=]M#J(
M
M!0/5D>LBR?&/^-Y?Q0/5D>LBR?&/^-X%MZ-/8YPK\54GW+21D<T:>QSA7XJI
M/N6DC                    <Y77'&)(KI61QW:H:QDSVM1$;L1'+X#HTY/
MO7_F*_\ :)/M*5O:-[5BO#.SJ_V6P8\M\OM*Q.T1UC?Q2*V8XQ)+<:6.2[U#
MF.E8UR*C=J*J> Z..3K1_P"6HOAV?:0ZQ'9U[6BW%._0_:G!CPVQ>SK$;[](
MV\  %DY0
M
M
M                                           !R[HL_.JQ3\+7?;0Z
MB.7=%GYU6*?A:[[Q#J(
M                          !0/5D>LBR?&/\ C>7\4#U9'K(LGQC_ (W@
M6WHT]CG"OQ52?<M)&1S1I['.%?BJD^Y:2,                   !R?>O\
MS%?^T2?:4N'2A@^JE9)=K'+4)(FV>!DBHBI[9J?U*3?K:SM?/6SVY[\RF[1R
M6F8K,;;.\_9C38Z4MFI?BXMMXVVF-OJRK/\ ^5HOAV?:0ZQ.1&YZ[=3/6SV9
M;\R[=%V#ZN%([O>YIUD5$=! Z151/^3D_H.SLEHF:Q&^Y^T^FQWI7->_#P[[
M1MO,[_59P +EP8
M                                             !\<]K?5.1#R9B.H
M^@\EJ8$WRL3Y3\2UM-"YK99XV*Y-9$5=Z<YK]OB\T>K**6GI#(!X1UE/)ZB:
M-WB4]T5%W*AG6];\ZSN\FLQU  9/
M
M                       <NZ+/SJL4_"UWVT.HCEW19^=5BGX6N^VAU$
M
M      H'JR/619/C'_&\OXH'JR/619/C'_&\"V]&GL<X5^*J3[EI(R.:-/8Y
MPK\54GW+21@                   *HTH8 X=)KQ9(_ROJIJ=B9Z_.YOA\!
M:SG(W>I^%F:AJS8:YJ\-DS0Z[+H<L9<4_./&%6Z+L <5X.[WN+\MZJ"G>GJ?
M^3DY_ 6L>23-4]&N1VY1APUPUX:O-;KLNMRSERS\O@^@ VH@
M
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M3-=K)I&<(D3ER=ESY&4=12\7CBK/)56K-9VD !D\
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MPM=]M#J(Y=T6?G58I^%KOMH=1'1..
M                                    *!ZLCUD63XQ_QO+^* ZLCUD6
M3XQ_Q/ MS1I['.%?BJD^Y:2,CFC3V.<*_%5)]RTD8                 ^.
M753,^GG-Z@#'E?K.R/1M/M17.S0_--JJ]4<W-=Z*1[%%QGCJ^ A>L;4;M5KM
M^?\ 0"1K3YKFUV33SC?J.\2F@PO<IWU?%YG+(US=FL[U.7]387V[06Y[6.C>
MZ14UMFQ#VL3:=H8VM%8WLW35S3,^E>5>-:N-RMIX(F-_Y9N7^Q@]>=TUL]>+
M+FU/_9)KH\DQNA6[2PUG9:(*^H<<5B.1*FD9*WE5B*U?[DML]\I;HS\FCXI.
M5DB9*:[X+X^L-V+5XLW*LMH #2D@"JB)FJY(8<MUM\+M66NI6.YG2M1?Z@9@
M,2"Y4,ZY05M-(O,V5J_W,M-NX                    !&<08MI[<KH:9O#
MU">'M6KX><SI2UYVK#7DRTQ5XKSM"2O>UB9O<C4YU7(P5NU'PBQQS-E?NU8]
MI6JUMSOU4K'SOU%7:UJY-3Y"?X=LL=MIVJY$654Z/_9NR8(Q1]J>:+AU=M1;
M;'7EXRW+5S:BY99GT C)P
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MDY3I-+JZ:FN\=?!QFNT&31WVMSCW2]0 2D$
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MVMWV&$_LW[_Z*KMK\+/SA4>BS\ZK%/PM=]M#J(Y=T6?G58I^%KOMH=1'3N'
M
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MCV^LAKZ6.HIG(Z-Z9H9!*CFJ)B8G:0 !X
M           !@7NY1VNWRU,F2JU.U;[9>1#&]XI6;6Z0,#%5^CM-(K8U1U4]
M.T;S>%2K*B:2HF?+,Y72/7-57E/2OK)JZJDGJ'JY[US\1CG):S5VU-]_='2$
M>UN( !#8A*L%5[562W3N1&2=M&J\CB*GZC>Z.1KV*J.:N:*AECM%9YQO'O\
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MG#)_V'.7U+MNSQ*6R=7I=1748^./JX+6Z2VDRSCM])\8  2$0
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MPPG]F_?_ $57;7X6?G"H]%GYU6*?A:[[:'41R[HL_.IQ3\+7?>(=1'3N'
M
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M.\2TDV&J!Z=HCV+SHXU=9A69N:TLS7IS.[527@AYNQ='FCG3;Y<DC'KL]/\
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M[8Z!%U'4T2:L;6KRHWG\);:&+::^]YZ^[_:G[0P3K\7_ !UZ<XF??\(\=W1
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M?R*FWI-;IH_[MJ3EU'_V-63!6F&]Z\XG:8GZM^'5WR:G%CO.UHXHM'QVZJT
M!5KX         Y0@ MO1'ZVZG]K=]AA4A;>B/UMU/[6[[#"P[-^_^BI[:_"S
M\X5'HL_.JQ3\+7?;0ZB.7=%GYU6*?A:[[:'41T[AP
M                                               "@>K(]9%D^,?\
M;R_B@>K(]9%D^,?\;P+;T:>QSA7XJI/N6DC(YHT]CG"OQ52?<M)&
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MQ$1"7V=H/;6X\D<H_ND4IOSDIX(Z>%L4+$9&U,D1#T .EB(B-H;@ 'H
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MHPO-)D]ICC?W.![9TW=]5.W2W/\ ]]0 $E5
M    "J-)GKUM7BC^V6LWU*>(JG29Z];5XH_MEK-]2GB ^@         "-Z1_
M65=/U6?;:4$7[I']95T_59]MI01SO:_WT?+\Y=A^SWX>W]7Y0  JE\9
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M,+#LW[_Z*GMK\+/SA4>BS\ZK%/PM=]M#J(Y=T6?G58I^%KOO$.HCIW#@
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M/^-Y?Q0/5D>LBR?&/^-X%MZ-/8YPK\54GW+21D<T:>QSA7XJI/N6DC
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MO5-WB-Z1\^6MK;TA-TF&]*;9)^G@  C)@
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M:F2$JH:*GH8N#I8FQM\'*9 ,+Y;W_BEMQ:?'B_@C8 !K;@
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MYB/FTH,NYVVLM=1P%? Z"7+6U79;N?9XC$0\F)B=I95M%HWK.\  /'H$
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MN46I53MU8&.WL9RJOCV?(6\$1$1$1,D0$"]YO/%*?2D4C:  &#(
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MZR+)\8_XW@6WHT]CG"OQ52?<M)&1S1I['.%?BJD^Y:2,
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M1$1R@  >@
M
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M%GYPJ/19^=5BGX6N^VAU$<NZ+/SJL4_"UWVT.HCIW#@
M                                                 % ]61ZR+)\8
M_P"-Y?Q0/5D>LBR?&/\ C>!;>C3V.<*_%5)]RTD9'-&GL<X5^*J3[EI(P
M
M
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M+/SJL4_"UWVT.HCEW19^=5BGX6N^VAU$=.X<
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M*NGZK/MM*"+]TC^LJZ?JL^VTH(YWM?[Z/E^<NP_9[\/;^K\H  52^ $   (
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M6?G58I^%KOO$.HCIW#@
M                         % ]61ZR+)\8_P"-Y?Q0/5D>LBR?&/\ C>!;
M>C3V.<*_%5)]RTD9'-&GL<X5^*J3[EI(P-;6_P"H=XD/ ]ZW_4.\2'@
M  #Z!\              $ !    0^@? @      @       0      !    "
M   FX #Z?   Y          /H4#X$7)<T" #;02))&CDW\I^S H9-5ZL7<IG
M@:VKBX.553U*[4/ VE3'PD2IRIN-7ED       $     $/H'P
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M8J\62LQ#G719^=5BGX6N^VAU$<NZ+/SJL4_"UWVT.HB0B
M                                                    % ]61ZR+
M)\8_XWE_% ]61ZR+)\8_XW@6WHT]CG"OQ52?<M)&1S1I['.%?BJD^Y:2,#75
MO^H7Q(8YD5O^H=XD,<  @    @"   @     @    $"    "         <@
M !         '($ 0  @ (  !]/@  !    (.0      0   '( @0  @ (JHN
M:;S:T[^$B1>7E-49-#)JR:B[G ; U];'J2:R>I<; \ZB/A(G-Y=Z :H#)454
MY0@#G"       !         !R  @     $ #D" <@! $    #Z?   /H'P
M         @     !R  $       '( !GT$FLU6+O3<91J8G\'(CDY#:M5'-1
M4W*!]             5#I/\ 7Q0_!Q?;4MUGJ&^(J+2?Z^*'X.+[:ENQ^H;X
MD ^@         "-Z1_65=/U6?;:4$7[I']95T_59]MI01SO:_P!]'R_.78?L
M]^'M_5^4  *I?  R   !X@$ !      !                    #E
M       "V]$?K;J?VMWV&%2%MZ(O6W4_M;OL,+#LW[_Z*GMK\+/SA4>BS\ZK
M%/PM=]M#J(Y=T6?G58I^%KOO$.HCIW#@
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M')\I^S H9-5^JNYQG@8%='JOUTW*8IMI6))&YJ\IJE14547>FP#X   "
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MWR 6T"K,4:3:VDTD4>$L/VZGK9Y%1)GRO<W@UW\G,F9:: #[F?
M,Z@ES18UY-Q@GZC<K'HY.0#;@^1N1[$<FY3Z           %0Z3_ %\4/P<7
MVU+=C]0WQ(5%I/\ 7Q0_!Q?;4MUGJ&^(#Z         JY)FNX_$$T=1$V6"1
MLD;MJ.:N:*!'M)'K*NGZK/MM*"+]TC^LJY_JL^VTH)#G>U_OH^7YR[#]GOP]
MOZOR@ !5+X0        $LP+A),2+4OGG?!3PY)KM1%S<O)_3I,7&^'4PY<XZ
M>.5TT,D>NU[D1%7;M3^AOG3Y(Q^UV^RC1K,4YIT\3]I'033 ^#Z;$%LJ:NIK
M)*?@9-3M6HJ99(N>WQFS['E#744TMAO#*R2/9EFU6Y\V:;E,Z:++>L6K'7XM
M.3M+3X[S2T\XZ\IV]5< E6#,+-OETK**LFDIW4[<UU$1=N>61(F:/+3523T]
MOOB35<6:.C[5=5?#EM08]'ER5XJQ_=[E[1P8;S2\\X^$^]68)';L,2/QA'8K
M@]8G*KD5[,EV(U7(J>/(Q,6VAEDOD]#%*Z5D:-5'N3)5S1%-4X;UK-YCEOM]
M6^NIQVO&.L\YC?Z-.@0E]/A."7 S[\M3(DS<_P EJIJ['ZN\]JG!],_"*WFV
M5<L[FMUGQN:B:J)ZKH0S[KD\/=O]&KOV&)VW]_#T]Z% F&$<(PWBT5=QKZI]
M-3PJJ-5J(N>2;=_C-A:,(8>N,<",Q B5,NZ%%9K9\V1[329+Q$Q[_B\R=H8<
M<VB=^77:)E7X++N& [#;GZE;B#@)%3-&R:C57I-/8L(4MSLMVKTK)$2CDD9&
MC414>C6YHN?A,K:++6W#/7YQ[F->TL%J<<3.W+W3[T,"&7::5M;<Z:E>Y6ME
MD:Q7)O3-20XOPM#8KQ0T453)*VH1%5SFHBIF[(T5Q6M2;QTA(OJ,=,D8IGG,
M;^B)@LR]:-8:*T5-52ULTLT3-=&.:B(N6_R9D%P[:W7B\4U$U5:DCD1SDWM;
MRJ;,NFR8K12T<Y:\&NPYZ6R4GE7JUH)]C/ M-8+,M;#633.21K-5S41-N9@U
M.$H(L#LOJ54JRN1J\%JIJ[79;SVVDRTM-9CG$;_1C3M#!DK6]9Y3.T<O>AZ
MV.'K8Z\7BFH6*K>%=DKDY$YR5XRP''8[/QZDJI:C5>C7HYJ)DBY[=GARZ3&F
MGR7I.2L<H;,FLQ8LE<-Y^U/1 P :$D Y     ( FX 6WHC];E3^UN^PPJ0MO
M1'ZVZG]K=]AA8=F_?_14]M?A9^<*CT6?G58I^%KOO$.HCEW19^=3BGX6N^\0
MZB.G<.
M             4#U9'K(LGQC_C>7\4#U9'K(LGQC_C>!;>C3V.<*_%5)]RTD
M9'-&GL<X5^*J3[EI(P-;6_ZA?$AX'O6_ZAWB0\    <X     @ YP   ($
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M15R:B*IZ:!J"LMFBVS4ERI*BDJH^&UX:B-8WMSE>J9M5,TV*B_*!6/4\XJ_
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MNY%*H+\TBM1N";FUJ(C48Q$1/UVE!G.]K_?1\OSEV'[/?A[?U?E  "J7P
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M>VOPL_.%1Z+/SJL4_"UWVT.HCEW19^=3BGX6N^\0ZB.G<.
M                                                     4!U9'K(
MLGQC_C>7^4#U9'K(LGQC_C>!;>C3V.<*_%5)]RTD9'-&GL<X5^*J3[EI(P-=
M6_ZA?D,<]ZW_ %#O$AX !S@ .0<@     .0   @         (   '(    <@
M  ( @  (!]/@     @0                <@   $    (  "        ]::
M/A)43DY0,RBCU(]9=[C(";#XYR-:KEW(!C5TFJW43>N\P#]RO61[G+RGX
M   "    $         ^GP       <@  !    0   "   !R      0  ?4 ^
M !  "             "  9-%'KR:R[FF.B9KDAM8(^#B1O+R@?L
M                 1O21ZRKI^JS[;2@D+]TC^LJZ?JL^VTH)#G>U_OH^7YR
M[#]GOP]OZOR@ !5+X0     '(          0     Y0             <@R
M        !   +;T1^MRI_:W?885(6WHC];=3^UN^PPL.S?O_ **GMK\+/SA4
M>BS\ZK%/PM=]XAU$<NZ+/SJL4_"UWVT.HCIW#@
M                                            % ]61ZR+)\8_XWE_
M% ]61ZR+)\8_XW@6WHT]CG"OQ52?<M)&1S1I['.%?BJD^Y:2,#75O^H=XD,<
M]ZW_ %#O$AX           @    $     .0  !R          #Z!\
M                @ !-@0 $/I\          !    &QHH]2+67>XPZ:/A)$
M3DWJ;1-B9 ##KY<D2-/&IE/<C&*Y=R&J>Y7O<Y>4#\@      4       #G
M<@0     0  #Z?       @  ! @ (    Y ";@ FX ?0?
M         ?6HKG(B;UV 9-!'K/5Z[DW&>?F%B1QHU.0_0
M            1O2/ZRKI^JS[;2@CH3'5)/784N%-21.EGD:U&L;O7MT7^Q3/
M6?B#O54]"%#VKCO?+$UB9Y?G+J^P<V/'@M%[1'/WS\(:% ;[K/Q!WJJ>A!UG
MX@[U5/0A5^PR^6?1>=ZP>>/6&AY ;[K/Q!WJJ>A!UGX@[U5/0@]AE\L^AWK!
MYX]8:$&^ZS\0=ZJGH0=9^(.]53T(/89?+/H=ZP>>/6&A!ONL_$'>JIZ$'6?B
M#O54]"#V&7RSZ'>L'GCUAH4'C-]UGX@[U5/0@3!^(.]53T(/89?+/H=ZP>>/
M6&A!ONL_$'>JIZ$'6?B#O54]"#V&7RSZ'>L'GCUAH0;[K/Q!WJJ>A!UGX@[U
M5/0@]AE\L^AWK!YX]8:'(&^ZS\0=ZJGH0=9^(.]53T(/89?+/H=ZP>>/6&A!
MONL_$'>JIZ$"8/Q!WJJ>A![#+Y9]#O6#SQZPT(-]UGX@[U5/0@ZS\0=ZJGH0
M>PR^6?0[U@\\>L-"#?=9^(.]53T(.L_$'>JIZ$'L,OEGT.]8//'K#0@WR8/Q
M!WJJ>A!UGX@[U5/0@]AE\L^AWK!YX]8:$&^ZS\0=ZJGH0=9^(.]53T(/89?+
M/H=ZP>>/6&A!ONL_$'>JIZ$'6?B#O54]"#V&7RSZ'>L'GCUAH0;[K/Q!WJJ>
MA!UGX@[U5/0@]AE\L^AWK!YX]8:$&^ZS\0=ZJGH0=9^(.]53T(/89?+/H=ZP
M>>/6&A"&^ZS\0=ZJGH0=9^(.]53T(/89?+/H=ZP>>/6&A!ONL_$'>JIZ$'6?
MB#O54]"#V&7RSZ'>L'GCUAH0;[K/Q!WJJ>A!UGX@[U5/0@]AE\L^AWK!YX]8
M:$MO1'ZVZG]K=]AA DP?B#O54]"%E:-+576VQ3PU]-)!*ZI<]&NWJFJU,_(I
M.[.Q7KFWM68Y>"K[7SXKZ:8K:)G>/>I;19^=5BGX6N^VAU$<94^-:7 75"8J
MO-=2S54*5=7#P<*HCLW/W[?$65^-%8>\%T^?'YSI'&.@P<^?C16'O!=/GQ^<
M?C16'O!=/GQ^<#H,'/GXT5A[P73Y\?G'XT5A[P73Y\?G Z#!SY^-%8>\%T^?
M'YQ^-%8>\%T^?'YP.@P<^?C16'O!=/GQ^<?C16'O!=/GQ^<#H,'/GXT5A[P7
M3Y\?G'XT5A[P73Y\?G Z#!SY^-%8>\%T^?'YQ^-%8>\%T^?'YP.@P<^?C16'
MO!=/GQ^<?C16'O!=/GQ^<#H,'/GXT5A[P73Y\?G'XT5A[P73Y\?G Z#!SY^-
M%8>\%T^?'YQ^-%8>\%T^?'YP.@P<^?C16'O!=/GQ^<?C16'O!=/GQ^<#H,'/
MGXT5A[P73Y\?G'XT5A[P73Y\?G Z#!SY^-%8>\%T^?'YQ^-%8>\%T^?'YP.@
MP<^?C16'O!=/GQ^<?C16'O!=/GQ^<#H,'/GXT5A[P73Y\?G'XT5A[P73Y\?G
M Z#!SY^-%8>\%T^?'YQ^-%8>\%T^?'YP.@P<^?C16'O!=/GQ^<?C16'O!=/G
MQ^<#H,'/GXT5A[P73Y\?G'XT5A[P73Y\?G Z#!SY^-%8>\%T^?'YQ^-%8>\%
MT^?'YP.@P<^?C16'O!=/GQ^<?C16'O!=/GQ^<#H,'/GXT5A[P73Y\?G'XT5A
M[P73Y\?G Z#!SY^-%8>\%T^?'YQ^-%8>\%T^?'YP.@P<^?C16'O!=/GQ^<?C
M16'O!=/GQ^<#H,'/GXT5A[P73Y\?G'XT5A[P73Y\?G Z#!SY^-%8>\%T^?'Y
MQ^-%8>\%T^?'YP.@P<^?C16'O!=/GQ^<?C16'O!=/GQ^<#H,H'JR/619/C'_
M !O/+\:*P]X+I\^/SE;:<]+]MTBX?M]OH+;64<E-5<.YT[FJBIJ.;DF2^$#J
MG1I['.%?BJD^Y:2,CFC3V.<*_%5)]RTD8&MK?]0[Q(>"&55Q/=.Y6M54R0\>
M E]H[H \P>G 2]S=T#@)?:.Z /,'IP$OM'= X"7N;N@#S!Z<#+[1W0. D]H[
MH \P>G 2^T=T#@)?:.Z /,'IP$GM'= X"7VCN@#S!Z<!+W-W0. E]H[H \P>
MB02^T=T#@)>YNZ //G!Z)!)[1W0. DR_[;N@#S!Z<!+[1W0. D]H[H \PAZ<
M!+[1W0. D[F[H \P>G 2=S=T#@)?:.Z /,'IP$OM'= X"7VCN@#S0'IP$OM'
M= X"7VCN@#S/I^^!E[F[H"02^T=T >?(#T2"7N;N@<!+W-W0!Y@]. D]H[H'
M 2^T=T >8/3@)?:.Z D,OM'= 'F#TX"7VCN@<!+[1W0!Y@]>!E[F[H/G 2^T
M=T >8/3@)?:.Z!P$G<W= 'F#TX"7N;N@)#+W-W0!Y@]. D[F[H' 2=S=T >8
M/3@)>YNZ#[P$GM'= 'D#TX"7VCN@<!+W-W0!Y@]. E]H[H' 2^T=T >8/3@)
M?:.Z!P$OM'= 'F#TX"7VCN@<!+[1W0!Y@].!E]H[H/O 2^T=T >0/3@)?:.Z
M#]PT[W/1'M5&\N8&511ZD>LN]VTR FP^.54:JHF:HFX##KI,UU$7=O,,]712
MN<JJQV:^ ^<!+[1W0!Y@]. E]H[H' 2]S=T >8/1()/:.Z!P$GM'= 'F#TX"
M7VCN@<!)[1W0!Y@]. E[F[H' 2=S=T >8/3@)?:.Z!P$OM'= 'F$V'HD$OM'
M= 2"3VCN@#S0'IP$OM'= X"7N;N@#S!Z<!+W-W0. E]H[H \PAZ<!+E_VW=
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M'Z
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M( #K+PO[FK)]0B]$=9>%_<U9/J$7H@ .LO"_N:LGU"+T1UEX7]S5D^H1>B
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M#&U&,C8U&M:U$R1$1-R(G(?L
M
M
M
8                            /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g42675g03a19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03a19.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1@J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    & T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<W61L;+1%30U0E=R@:'!(U)VE<+#,T9BH^$D0X*#9*(E8_"T\?_$ !H! 0$
M P$!               " 04&! /_Q  O$0$  00! 0<$ @(" P       0(1
M$E$R P0%%#$S09$3%5)QL? A0B*A8<'Q_]H # ,!  (1 Q$ /P#8;_6XXQ'I
MGQ#AO#.)7VZ&EC;.QDCE1C6HR/-$R:JYYOS^LRG0%I<Y>4WC'^K&#/?1XO\
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M]670#.3"$+Z M+G+RF\8_P!6.@+2YR\IO&/]670#.3"$+Z M+G+RF\8_U8Z
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MR\IO&/\ 5CH"TN<O*;QC_5ET SDPA"^@+2YR\IO&/]6.@+2YR\IO&/\ 5ET
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MF\8_U9= ,Y,(0OH"TN<O*;QC_5CH"TN<O*;QC_5ET SDPA"^@+2YR\IO&/\
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M+G+RF\8_U8Z M+G+RF\8_P!670#.3"$+Z M+G+RF\8_U8Z M+G+RF\8_U9=
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M%JF#P;[Z/%_@']*<NA"\&>^CQ?X!_2G+H8J9H]P $K
M
M
M
M                                                 *N29KP  :16
M:5L%T=5+3U-\C9-$[5>U895R7^#3U6;2/A*\5*4]OO=/),[8C7-<S/:B?K(G
M;0#;0$5%1%1<T7C                     8&@QA8J^^26>DN#9+E&JM="D
M;T5%3//:J9?JKQ\1^6_&%BN%\J;/1W!LERIGK'+"D;T5KD545,U3+B7C SX,
M94WZUTUSAMTU="VNE5&LA1<W*J\&Q.#^)DP    &"P]BZQXAJJBFLU>VIG@3
M.1J,<W539VT3MH!G0                         !@\=^XC$7T=4>:<:'N
M8>Q9!X7-]J&^8[]Q&(OHZH\TXT/<P]BR#PN;[4*CC*)Y,'@WWT>+_ /Z4Y="
M%X,]]'B_P#^E.705%'N  E8                                  /G4
MSQTU/+/.[5BC:KWNRSR1-JJ3VHTW:/:>>6&;$36RQN5CV^Q)UR5%R5/:&Z8E
M]SMS\&D^ZIQ7@G#V#+[?\3]'.()K-O-3_P"EWMS4WW-\FOGFUW!DWM<('7&%
MM)&$\55+J>PW=E5,WA;O,D?$J_K-3M*?3&&D+"^#JJ&FQ)=$HII6)(QJP229
MMS5,^L:O&U3CG&]JPOAO$-H?@*_375'/_M'R*U58N:9)L:G#FI0-T[J5N)\+
M_E:3>&RT$:S/;^KU\N8%FZ>FCGE(WR.H]6;U8[S;[[0LK+54MJ*9^>3T:K>-
M4X%1%XE.5Y-'^AIL;E9C^L5V6Q-\9ZLRNY*EJ(<0WBDHWNDM2YN5VS)7(B:O
M\LP+S;-(6%[GB9</4-U26\)K9T^\2)[5%5W7*W5V9+QF2Q3B6T85MCKC?ZQM
M)1M5$616.?M541-C45>%4XCE3"M[HL.[H2NNESDWNEIVU;G*G"O6/R1/C7@,
MA3QW'3YI$J=\G=#AJW/5[(UR8Y&*KD:O [:NJF>W+M =+X2Q99<74#ZW#M;[
M,IF/6-S]Z?'UR(BJF3T1>!R'FQACK#F#MYZ)+DVBW[_AYQ22:W#_ '&KVE,K
MA^ST=@M%-;+;%O5)3M1D;<\\D.6-)E%7:6M*]QMMH5KOR13JQCG=:CFZZ=K/
MC?\ $!U9:;C27>W05UNF2:DF36CD1%363/+@7;Q'J>YK&JYZHC43-54AVY8Q
M$M1ANKPU.N4UGD6-J9;%1TCW.5-O;7M(?/=/XKN-!1VC#]EE2*:ZRNBE=EMR
MZQ&I\BZZY[ -[O&ES ]FK74EROK(:AJJU6^QYG;47+A:Q4XC9,-XDM.)*3V5
M9*QM5!P:R,<WB1>!R(O&A!,-[F6WS6B*6_76LCKGQH[4I9&ZB*J<"ZT>?"?+
M1YHGQA@;2:V>V34[K,J_VDKG.7?(LUR8O6)UV:(NS9\8%_Q/B>SX7H%K+[6M
MI*9-BO5CG]OB:BKQ*8K"FD;"N+*EU/A^[LJYF\+=YDC^\U#2,>Z(ZS&>DJAO
M5VJ:2:QT[$C6F5[DD5J*JY9(W+A5?UB9Z9,.V/!>DC"#,&TC:2N69CW1,55;
MKI(S5SS7,#K 'DM$DLMIHI*G+?WP,=)E_>5J9_S)1IOTJW7 %QM\%MH:*ICG
M5-??VN5R)\63DV@6('.^(].6*+)54E?5X5]C8:J791S5$2I,]%1RIEE+J\")
M_,^F)M..)(X$N^',--EPTFQU75QKFNQ5V:LF7 B_4!<,27^V8;MC[C>ZI*6C
M8NJLBL<_)<E7@:BKQ*:3T]-'/*1OD=1ZLU#2=BRGQKH!9>Z9CXDJ)%UHWHB*
MUS=]8NQ%79FU<MO 23 ^#M&%SP]!4XDQC4V^Y.5=>!CV(C4XN%B_:!U;A+'N
M&L6J],/71M8K%R<F]21[?_FU#^,7Z0L+X/J8Z?$=T2BFD:CVM6"1^:*JHB]:
MU?[J_4<FT-OLN'M+]A9H_N\MUA1<TF<K55'*CT<FQJ?J_%QFV;L+W3VWP6/[
MTH'5E-/'4PMF@>CXW<#DXS7<,X[PWB>NJ:.QW)*JIIG*R5B0R,U53//:YJ(O
M O 2;<PXSF6DEP;>D6*OH4=) Q6_^VJM547;PYO[1@=S#[N\3^$O^UX'1]ZN
MU%9+=+7W2=*>DBVOD5JNR_@B*IB\(8UP_C"*63#EQ;6LB]NJ1/9ESFIVR3[J
MR]:]HL^&*=VM+=*E$>F7M5:YFKGSNTIHVA^"JT7:866*\*UJ7*EZYS=J(U&O
M<W//+C9V@.LP
M             \UTD=#;*R2-<GLA>YJ]I4:IZ3QWK]#U_P Q)]U0.0+7C'2E
MB.XW&/#U9553*:5S7(E0C-5,UR]L]#WPZ4-(^!;E N+8EFI9'=>R9Z2N5/\
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MFC7:SF[/J ZV!\Z5ROIHG.X58BK]1]
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M<TM#45=+5M;+(YLE,YRLVO55VN1%_D>K3EBR3". JZMI(XY*QVHV%LB*K?\
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M);T^ZQ/FWUCG0;UO::K6ZJ)K.V=;_,WD
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MZ-CW(YS&N<G JIF!_%(BI20HJ9*C&HJ?P/J
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M2HJ9HI_<<L<N>]2,?E_=<B@?V
M
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MU41<G+Q'Y@'!=JP/8VVNRI,Z'65SI)E:LCU557KE:U,\L\DV< &R@
M                                 'SFJ(8-7?I61ZRY)K+EF!]
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MXYR-15543),S$6/$MJOE1706RK;-+12+%.U$5-1R.5N6U.VU0,P FW@
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M7"YSXGBJ:6A?&YD=/4-5KEDSC7739P9(J</$7\
M                       /C6,=)2RMCE6)ZIL>B(NK]8'CO=\MMCABENU9
M%2QRR)$QTCLD5RHJHGU-7ZC(L<CV-<Q<VN3-%3C0XNTIXWOE*Z+#]RNM#?(Z
M2I;51542MUDR8Y-1R,:B?K*OU%IT$7^]8IJ'W.Z7ZAFA1F]MM].K%6/),LW=
M:CDX,^'C M(
M                                                 \EU=5MM\[K>
MV-U4C56-),\E7^&TY1TN:1;C/+;K7BFTOI+K;ZA97+$G]G(S5<U%367////B
M3@.K[K2OK;?/3Q3NIWR,5J2-1%5N?R[#G+2#H3BHH+9);Z*NO-?-4*M94(CE
M56ZB\*-7)$ULN!$X0*EHNQ1B3%4\]?=+4R@L\C%6FUD<DCMK<EXTRRUN/B**
M:#H\T;4V!KG62VNX5+Z&=%RI9$16L55;P*O7<#>WQF_
M
M                            2+3M6W&P,IK[;<1Q4#J9KE6AF?JMJDV=
M:F2*NW++A3VQ -'^-;M7W^OHH+O16-+M4[[-4R/5N2J]S\F[%X5V;>VAUS?L
M%V2^7>ENEQHDFKJ5JI"]97HC57+B1<EX$X4-&PIHFA;48DCQ524M30U]4LU.
MR*9Z*UN^N>F:IDJ+[7CX@*9AZ%]/9***2J6L>R)J+.O_ +FSA,@>6U4%/:[?
M3T5$S4IH&)'&W65<D3@VKM/4
M    !@\=^XC$7T=4>:<:'N8>Q9!X7-]J&^8[]Q&(OHZH\TXT/<P]BR#PN;[4
M*CC*)Y,'@SWT>+_ /Z4Y="%X,]]'B_P#^E.705%'N  E8
M                                   !\JJ!E33R0R:VH],EU5R7ZSZ@
M"*8WT.4[</6ZAPE01RS1UK9II*B5%<YFH]%ZYVU=JMV&]X8T?V7#]W6[6^!]
M/621-9*ULB[VJHU$]KP<1N
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MT]M''*-/(JCU9O6&[[;L2V6FNUDJ?9-OJ-;>I=1S-;5<K5V.1%3:U4VH!D@
M                                             _B2:*-4221C%7@1
MSD3,#^P$VIL"JB(JJJ(B<:@ ?Q%-%+GO4C'Y?W7(HDFCBRWR1C,^#6<B9@?V
M BHJ(J*BHO J                     !RUI8TRXTP]I*O%BLDU,M-!+''!
M&M*CWKK1M7+MJN:J!U*#CKITZ5O@J_Y6OX#ITZ5O@J_Y6OX =B@XZZ=.E;X*
M[_*U_ =.G2M\%7_*U_ #L4''73ITK?!5_P K7\!TZ=*WP5?\K7\ .Q0<==.G
M2M\%7_*U_ =.G2M\%7_*U_ #L4''73ITK?!5_P K7\!TZ=*WP5?\K7\ .Q0<
M==.G2M\%7_*U_ =.G2M\%7_*U_ #L4''73ITK?!5_P K7\!TZ=*WP5?\K7\
M.Q0<==.G2M\%7_*U_ =.G2M\%7_*U_ #L4''73ITK?!5_P K7\!TZ=*WP5?\
MK7\ .Q0<==.G2M\%=_E:_@.G3I6^"K_E:_@!V*#CKITZ5O@J_P"5K^ Z=.E;
MX*O^5K^ '8H.+ZO3YI'HY4CK)*:"14UD;+0HQ<NWDOR':
M             8/'?N(Q%]'5'FG&A[F'L60>%S?:AOF._<1B+Z.J/-.-#W,/
M8L@\+F^U"HXRB>3!X,]]'B_P#^E.70A>#/?1XO\  /Z4Y=!44>X "5@
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M3O8<+XOQ*^XQSPRSR1Q3.?$YN\RJW/6:U<T5F?!VCI@
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M@#D3= :),/8 PK07&QS7%]1/6I3N2IE:]NJK'NV(C4VYM0N&YL["V'/DJ/\
M_8E-1W8W8^M'THWS4IMVYL["V'/DJ/\ _8E I8
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MQM1K6IQ(A]0 (!B'WW^&?H]_F*@OY ,0^^_PS]'O\Q4%_
M  ''6'O?9R_353]DAV*8YEBM#+A[/9:J!M=K*_V0E.Q)-9>%=;+//XP,B
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MH6H[%I,?C*.\5$T[JBHJ/8SH6HW.9'HJ:V>>S7_D5D
M          -)TLZ/J?2+8J6V55?+0LIZE*E'QQH]55&N;EDJ_P#5_(RFCW"\
M6#,'V^P05+ZJ.CWS*9[4:KM:1S^!/WLOX&Q
M                      &+N6'K3<YVS5]!!/*W@<Y-IE !XJRU4-90>PJF
MFC?29(W>LLFY)\GR'DK<,V>NIX(*N@BEA@3*-CL\FI]?QJ9@ :_38+P]35$4
M\%JIV31/1[')GFUR+FB\/;/;=+#:[K(R2XT,,[V<#G)M_P#\V&3 'SIJ>&E@
M9#3QMCB8B(UK4R1$38?0 #1=*7YW@?\ Q'3^:F-Z-%TI?G>!_P#$=/YJ8WH
M                <=8M]]G!]-47V1'8II-9HNPI68Q;BFHH)'7IL\=2DWLB
M1$UV9:JZN>7ZJ;,@-V                             <=;K[LGT/T7%Y
MV4[%-)QIHNPIC.[1W+$-!)45;(4@:]M1)&B,155$R:J)PN4W8
M                ,'COW$8B^CJCS3C0]S#V+(/"YOM0WS'?N(Q%]'5'FG&A
M[F'L60>%S?:A4<91/)@\&^^CQ?X!_2G+H0O!GOH\7^ ?TIRZ"HH]P $K
M              !S_B'WW^&?H]_F*@Z (!B'WW^&?H]_F*@OX
M
M                            #G_<X]DK2I]()YZ<Z (!N<>R5I4^D/\
M>G OX
M                                                   T72E^=X'_
M ,1T_FIC>C1=*7YW@?\ Q'3^:F-Z             %SR7++/BS  T>NM.-I*
MR=]+>;3' Z1RQL=%-FUN>Q%R?EGED?'\BX[[^6CQ,WI@;\#0?R+COOY:/$S>
MF8?%J8[P_AVX75UWM$J4D+YE8D4W7:K57+V_Q 58$ZHK9CNJHZ>H2]VAN^QM
M?EO,VS-,_P"^??\ (N.^_EH\3-Z8&_ T'\BX[[^6CQ,WIGMLMKQ?3W*&2YW:
MV3T:+_:1QQ2HY4^)5>J ;B
M               P>._<1B+Z.J/-.-#W,/8L@\+F^U#?,=^XC$7T=4>:<:'N
M8>Q9!X7-]J%1QE$\F#P;[Z/%_@']*<NA"\&>^CQ?X!_2G+H*BCW  2L
M      '\)+&LJQH]N^)M5N>T_99&1,5TCD:U.-5R _H'XU4<B*U45%XT/YWV
M/?=[UV[YEGJY[0/[  '/^(???X9^CW^8J#H @&(???X9^CW^8J"_@
M     //<:ZEMM%-67"HBIJ6%NM)+*Y&M8G;55 ] -0Z9N".5=E\K9^(Z9N".
M5EE\K9^(&W@U#IFX(Y667RMGXCIFX(Y667RMGX@;>#4.F;@CE99?*V?B.F;@
MCE79?*V?B!MX-0Z9N".5EE\K9^)EK!BFQ8A?*RQ7>AN#HD19$IIFR:J+P9Y+
M\0&9
M                   Y_P!SCV2M*GTA_O3G0! -SCV2M*GTA_O3@7\
M       !A<4Q7V:D8W#<U!%49KKK5Z^66S++5_B:K^3])??##GUS_@40 3O\
MGZ2^^&'/KG_ _/R?I+[X8<^N?\"B@"-TUUTBS8PK+"E7A])::..19%W[577:
MKOZ=HS_Y/TE]\,.?7/\ @?Q:^S7?/!Z;S;RD 3O\GZ2^^&'/KG_ _/R?I+[X
M8<^N?\"B@#%8:CO$5L8S$,E'+6HJYNI=;57:N7MMO!D94
M
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M^(^VYDT@XGQI=K[#B:Y^S8Z:"-\2;Q%'JJKE15ZQJ9\'&!?P
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M<
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MW[#Z@
M          #2L6:4<*84N+:&]7)8JERY:C(GR9+\:M1<@-U!YK;74]RHH:NB
ME;+3RM1['-XT5,T/O+(R)BOE>UC$X7.7)$ _H&OX8QC9<35%9#9:M:A](Y&2
M_P!FYJ(JHB[%5-NQ>(P^,=*N$\'W7\G7ZX205>JCM1E.^38J9IM:B]L#> :W
M@G&]CQK235.':I]1#"[4>KHG1Y+_ /)$-D T72E^=X'_ ,1T_FIC>C1=*7YW
M@?\ Q'3^:F-Z         XZW2W9QI/F:7[RG8IQUNENSC2?,TOWE.Q0
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M;EKL/6WY^?SB@5D
M                        (!N<>R5I4^D$\].7\@&YQ[)6E3Z0_P!Z<"_@
M       G^G[L/XG\';YQI.MQI[E<0^&L^XA1=/W8?Q/X.WSC2=;C3W*XA\-9
M]Q .A0               #DS=D^[&P^ +YQQUF<F;LGW8V+P!?.. ZNH_P T
M@^;;]A]3Y4?YI!\VW[#Z@
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M?N2&2W+78>MOS\_G% K(
M                        !X+]=J6QVBJN5PD2.EIVZSW+\N2?S5 />"*V
MO=!V6JN,<=9:ZRBM\JJD5:_6U7[,^!6HG%VRU)M3, 0#<X]DK2I](?[TY?R
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M*/X;6>.D](W"C@2EIF0M57(W8BJN:DS$>TJIFJ?.+/L #"@
M                                  &BZ4OSO _^(Z?S4QO1HNE+\[P/
M_B.G\U,;T        !QUNENSC2?,TOWE.Q3CK=+=G&D^9I?O*=B@
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MFC98)$>Q<ER7)4V<)Z">Z ^QC;/G)O.N*$>.J+3,-M15E3%0 "5
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M?G\XIC=UUV+8/I*'[DADMRUV'K;\_/YQ0*R
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M_$_@[?.-)UN-/<KB'PUGW$*+I^[#^)_!V^<:3K<:>Y7$/AK/N(!T*
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MCC2S5R*]R-SWQFS-2R$U433YKHZE-?&0 $K
M                 !HNE+\[P/\ XCI_-3&]&BZ4OSO _P#B.G\U,;T
M   !QUNENSC2?,TOWE.Q3CK=+=G&D^9I?O*=B@                8_$7N?
MN?@LOW%.9MQC^G<3>#0_><=,XB]S]S\%E^XIS-N,?T[B;P:'[S@.J0
M #CO_G^[^$U'WU.Q#CO_ )_N_A-1]]3U]CY-;WGZ7RV$ &V<J   $ 0  @
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M+6N:DCT1$<YO7IFU5S5%R+#HU3 J5%3T$24KY=5=]WFI679FW/A<O_2!OH
M$PTNTF%,.V"NOMRL\-36.5%:G7*KW.>B+LUD_O9E/([IWPO<\77;#=!34D\M
MMBDE?4OC:JHF;=F:I\;4 SNB'"D>",",<^'*X5#4GJD1<TWS)$5$X-FQ#FS"
M]%BJT8?J[O4X0I+C0Q2+-4U%2C]=&-;FY>M>B9(C?E.T+A!)/0S0P2[S(]N3
M7HU%U?X+L.<ZINEY]AK\*U]M@JV5D3Z=]:R-&L1CVJU4S;&B?K</Q 5W".*[
M,[1>[$EMII([52TTU2^&-$UO[)'*]&HKN'-JY9J:!U3N$.]5_P#$P^M*7HQP
MJW"&"*&QN5)$B1[GY[457N5RI_-38O8%'\$I_%I^ ',.&L:V_'NZ?PU>+3!5
M04R4LL&K4M:U^LV"=57)KE3+KDXSJ<Y]O<4<.Z\PRV&-D;?R>]<FM1$_X%0=
M!         <=: /?"U/[];_J.Q3CK0![X6J_?K?]1V*                !
M%-UUV+8/I*'[DADMRUV'K;\_/YQ3&[KGL6P?247W)#);EKL/6WY^?SB@5D
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MW_!6?6I]+-^BJ3YMOV'L-Y%,6\G&5]2O*?\ +'_D:W_!6?6H_(UO^"L^M3(
MSC&D_4KW+'_D:W_!6?6H_(UO^"L^M3( 8QH^I7N6/_(UO^"L^M1^1K?\%9]:
MF0 QC3,=2O<L?^1K?\%9]:C\C6_X*SZU,@!C&F/J5[EC_P C6_X*SZU'Y&M_
MP5GUJ9 #&-'U*]RQZ6:W_!6?6H_(UO\ @K/K4R &,:/J5[EIMTIXJ:_T\<#$
M8S-BY)\IVJ<7WWW24_RQ_:=H&K[7R=-W9-^G>?\ P  \;9@
M                             T72E^=X'_Q'3^:F-Z-%TI?G>!_\1T_F
MIC>@        ..MTMV<:3YFE^\IV*<=;I;LXTGS-+]Y3L4
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M ,0^^_PS]'O\Q4%_         XZT ^^%JOWZW_4=BG'6@#WPM5^_6_ZCL4
M              "*;KKL6P?24/W)#);EKL/6WY^?SBF-W778M@^DH?N2&2W+
M78>MOS\_G% K(
M           'ANUKMUTI][NM)35,3=J)/&CD;\:9\![CY54._P!.^)55-9,L
MT YVH\?Z-,.(Z@M&&8JFE2349+)3OE5[NTBN8Y5X]F9ONB['%!B6]5-)8K##
M;J.%F<SV,WI=?)%1%;J-7@4GSM&UW?H_6@I+31Q7JSUR5,-0BQK[+R8_+-47
M@S>B9*O$;7H:LV('XKNE^NMO@M-'.QL:4D.HB/<UC6ZRHU<N%J\7&!9P
M @&YQ[)6E3Z0_P!Z<OY -SCV2M*GTA_O3@7\       $_P!/W8?Q/X.WSC2=
M;C/W*XA\-9]Q"BZ?NP_B?P=OG&DZW&GN5Q#X:S[B ="@               '
M)>[)]V-A\ 7SCCK0Y+W9/NQL/@"^<<!U?1_FD'S;?L/J?*C_ #2#YMOV'U
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M_-3&]         <=;I;LXTGS-+]Y3L4XZW2W9QI/F:7[RG8H
M    &/Q%[G[GX++]Q3F;<8_IW$W@T/WG'3.(O<_<_!9?N*<S;C'].XF\&A^\
MX#JD        X[_Y_N_A-1]]3L0X\_Y^N_A-1]]3U]CY-;WGZ7RV ! ;9RH
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MR4L_1752+3/:J14TF:.8[K-N62<2. L(          @&(???X9^CW^8J"_D
MQ#[[_#/T>_S%07\        #CK0![X6J_?K?]1V*<=: ??"U7[];_J.Q0
M             (INNNQ;!])0_<D,EN6NP];?GY_.*8W===BV#Z2A^Y(9+<M=
MAZV_/S^<4"L@
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M1RA;- G8QMG[\WG7%")[H#[&-L^<F\ZXH1HNIREVW1X1^@ $/H
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ME/>;53U]([6AF:CD_JA[@(!B'WW^&?H]_F*@OY ,0^^_PS]'O\Q4%_
M   XZT ^^%JOWZW_ %'8IQUH!]\+4_OUO^H[%                 BFZZ[%
MD'TE#]R0R6Y:[#UM^?G\XIC=UUV+8/I*'[DADMRUV'K;\_/YQ0*R
M                                                   !SUNB;WCF
M@O,%/8DG_(KX$5RT\&^/1^N_/:B9IL1H%OO6);)9&YW>\6ZB7@1*BI9&JKVD
MUE3::_A+278<5WZ:U65TTTD+%>Z9$:L:\' Y'+GPG+-_I\'281JE=<[M68@B
M:KD;6-EC1%R7:B.<J<.1U9HSH[)3X=I'69M$KU9U[H5:YW"N>:IM W
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MG??=)3?_ %_>.L;K-?&XCML=!! ZTNR]E2.>J/;[;@355%_5XT.3K[[HZ?\
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M^8[]Q&(OHZH\TXT/<P]BR#PN;[4*CC*)Y,'@SWT>+_ /Z4Y="%X,]]'B_P
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MW)#);EKL/6[Y^?SBF-W778M@^DH?N2&2W+78>MOS\_G% K(
M                                             &@XST@NPS>$HZJQ
M5=11K$DBU46L],]9R:NJUBKQ(O\ $WXUIV+Z)N,FX;6-_LQ84GULTRR5SF_:
MU0)Q<+]HHQ2BQW2FIZ6J=M<]UJDC?VO;NB^/MF7T48.PU8;K+582OTU71N8Y
M/8CY]9&JN6W+9QY\7&9.GJ,)XKQ;><-U5EIJBIMZ9S+-&US7>U]-#RX0IL(6
M?23<[)8+3'0W.EB1971-:UBM<QC^!$SX'(!3      @&YQ[)6E3Z0_WIR_D
MW./9*TJ?2">>G OX       )_I^[#^)_!V^<:3K<:>Y7$/AK/N(473]V'\3^
M#M\XTG6XT]RN(?#6?<0#H4                Y+W9/NQL7@"^<<=:')>[)]
MV-A\ 7SC@.KZ/\T@^;;]A]3Y4?YI!\VW[#Z@      T+3MV+;U\L'GF&^FA:
M=NQ;>OE@\\POI\H?/J\*OTAMF_15)\VW[#V'CLWZ*I?FV_8>PWM/DXJOE( #
M*0    @8?A^@      &I7[W24WRQ_>.T#B^^^Z2F^6/[3M U7;.3J.Z_3^
M'C;0/Q[=9CFYJF:99IQ'Z )SHUKZRFQ5BFPW&KGJ7QUCZNG6>57N2%4C:B)F
MJY-S1VSMJIJ=]OUX9I3CNT5=4LP]37&"TN@;([>I-\C2595:BY;,E;P?Q,OC
M2K@PCI5I\0S.2*"MM[*!R\3G;Z]_V(>%V'JY- E2M0JNO;8Y:I7IPK(UST:J
M?_'(#8M)ESJ);]A2S6VLGIY:VKCJ'K ]S%=#'(Q7HN66Q6KMS^I3T8RP'#7M
MKKFF(<3TDK('.;%27-\42*UJY=:GR;35< 5+<6Z1(+@Y7/6PTC:==NS6EB:J
MY_'FPK=__05Q\&D^ZH$7T38,=B;#3KA<\5XOW]M2Z-$CN\C6Y(C539M[:ETB
M9O<;6(YSM5,LW+FJDVW/GN%E\-D^ZPI8
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M>#B/+HPTD5V)KO/9L26*HL5YCA6I;3S,<W7BUD:CDUD1?;:R<'$!3
M   ! ,0^^_PS]'O\Q4%_(!B'WW^&?H]_F*@OX        ''6@'WPM5^_6_ZC
ML4XZT >^%JOWZW_4=B@                13===BV#Z2A^Y(9+<M=AZV_/S
M^<4QNZZ[%L'TE#]R0R6Y:[#UM^?G\XH%9
M                                A=^N]!9]T'#/<ZJ.FA6W,1'OX/\
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MG>JHR:-T:JG"B*BI_4^H P."\,4N$[0ZW4,T\T2RNEUIE36S5$3B1.T9X
M                              #1=*7YW@?_ !'3^:F-Z-%TI?G>!_\
M$=/YJ8WH        #CK=+=G&D^9I?O*=BG'6Z6[.-)\S2_>4[%
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M]_F*@OX        ''6@#WPM5^_6_ZCL4XZT >^%JOWZW_4=B@
M     13===BV#Z2A^Y(9+<M=AZV_/S^<4QNZZ[%L'TE#]R0R6Y:[#UM^?G\X
MH%9              8R_4MQJJ5&6JLCI)<]KWL5WV*AKWY#Q;RAIO$.](J(B
M?=$U3$_XAN@-+_(>+>4--XAWI#\AXMY0TWB'>D,8VQG/XRW0$QB;BU^*)[3^
M7*?^S8U^OO+MN:9_WC-?D/%O*&F\0[TC,T6]V(ZDSY4RW0&E_D/%O*&F\0[T
MA^0\6\H:;Q#O2,8QMG.?QEN@,98*6XTE*K+K61U<O$]C%;QKVU7XC)DKB;P
M ,@                                    #1(-'R1:3I,7_ )3SUX-Y
M]B;QP=<JYZ^M\?:-[  $ W./9*TJ?2'^].7\@&YQ[)6E3Z0_WIP+^
M"?Z?NP_B?P=OG&DZW&GN5Q#X:S[B%%T_=A_$_@[?.-)UN-/<KB'PUGW$ Z%
M               .3-V3[L;#X OG''69R7NR?=C8? %\XX#J^C_-(/FV_8?4
M^5'^:0?-M^P^H      -"T[=BV]?+!YYAOIH6G;L6WKY8//,+Z?*'SZOIU?I
M#;-^BJ7YMOV'K/)9OT72_-M^P]AO:?)Q5?*0 &4    !  ';/P#]"    !J=
M]]T=-\L?VG9YQ???='3_ /U_>.T#5=LY.I[K]/X  >-LP
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M_$7N?N?@LOW%.9MQC^G<3>#0_><=,XB]S]S\%E^XIS-N,?T[B;P:'[S@.J0
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ME7)7U*(KEJ$7-'HJJJ<2<7Q&< @&(???X9^CW^8J"_D Q#[[_#/T>_S%07\
M       #CK0![X6J_?K?]1V*<=: ??"U7[];_J.Q0                (IN
MNNQ;!])0_<D,EN6NP];?GY_.*8W=<]BV#Z2A^Y(9+<M=AZV_/S^<4"L@
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M4VAVJU4<U%3:BIF@/XI_S>/]U/L/[/ W(
M          $ W./9*TJ?2'^].7\@&YQ[)6E3Z0_WIP+^       "?Z?NP_B?
MP=OG&DZW&GN5Q#X:S[B%%T_=A_$_@[?.-)UN-/<KB'PUGW$ Z%
M      .2]V3[L;#X OG''6AR9NR?=C8O %\XX#JZC_-(/FV_8?4^5'^:0?-M
M^P^H      -"T[=BV]?+!YYAOIH6G7L6WKY8//,+Z?*'SZO"K](;9OT52_-M
M^P]AX[-^BJ3YMOV'L-[3Y.*KY2  RD  8   "     0( !J=]]T=/_\ 7]X[
M/.,+[[HZ?Y8_O'9YJNV<G4]U^G\  /&V8
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M4+9H#[&-L^<F\ZXH1/= ?8QMG[\WG7%"-%U.4NVZ/"/T  A]
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M7D Q#[[_  S]'O\ ,5!?P        ..M 'OA:K]^M_U'8IQUH!]\+5?OUO\
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MI  & <0     $"   !J5]]TE/\L?VG:!QA??='3_ "Q_:=GFJ[9R=3W7Z7P
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M8IB?)5'*%LT!]C&V?.3>=<4(GN@/L8VSYR;SKBA&BZG*7;='TZ?T  A]
M         !@\=^XC$7T=4>:<:'N8>Q9!X5-]J&^8[]Q&(OHZH\TXT/<P]BR#
MPN;[4*CC*)Y,'@SWT>+_  #^E.70A>#/?1XO\ _I3ET%11[@ )6
M         " 8A]]_AGZ/?YBH+^0#$/OO\,_1[_,5!?P        ..M 'OA:K
M]^M_U'8IQUH!]\+4_OUO^H[%                 BFZZ[%L'TE#]R0R6Y:[
M#UM^?G\XIC=USV+8/I*'[DADMRUV'K;\_/YQ0*R       #3=,?8TOWS+?OM
M.;<&?FE1^^GV'26F/L:7[YEOWVG-N#/S2H_?3[#8=B:7O?C_ ';80@!L7.V
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M-M^P]9OJ?)Q5?*7Z ?AE ?H       "    @&IWWW24_RQ_:=GG%]]]TE/\
M+']X[0-5VSDZGNOT_@ !XVS
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MP        ..M 'OA:K]^M_U'8IQUH!]\+4_OUO\ J.Q0
M(INNNQ;!])0_<D,EN6NP];?GY_.*8W=<]BV#Z2A^Y(9+<M=AZW?/S^<4"L@
M      TW3'V-+]\RW[[3FW!GYI4?OI]ATEIC[&E^^9;]]IS;@S\TJ/WT^PV'
M8FE[WX_W;80 ;%SIQ        ! @  'X ,#C']'P_.I]BF?,!C']'P_._P!%
M(KXR^W9_4AU_3_F\?[J?8?V?Q3_F\?[J?8?V:%VT
M                  0#<X]DK2I](?[TY?R ;G'LE:5/I#_>G OX       )
M_I^[#^)_!V^<:3K<:>Y7$/AK/N(473]V'\3^#M\XTG6XT]RN(?#6?<0#H4
M              Y+W9/NQL/@"^<<=:')F[)]V-B\ 7SC@.KJ/\T@^;;]A]3Y
M4?YI!\VW[#Z@      T+3MV+;U\L'GF&^FA:=NQ;>OE@\\POI\H?/J\*OTAM
MG_15)\VW[#V'CLWZ*I/FV_8>Q#>T^3BJ^4@ 0R@"   $   ( 0    !J5^]T
ME/\ +']X[0.+[][I*;Y8_O':!JNV<G4]U^G\  /&V8
M                        -%TI?G>!_P#$=/YJ8WHT72E^=X'_ ,1T_FIC
M>@        ..MTMV<:3YFE^\IV*<=;I;LXTGS-+]Y3L4
M#'XB]S]S\%E^XIS-N,?T[B;P:'[SCIG$7Z N?@LOW%.9MQC^G<3>#0_><!U2
M        <=_\_P!W\)J/OJ=B''?_ #_=_":C[ZGK['R:WO/TOEL( 3@-LY4
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MGX#ZW3_*/D\)U_PGXELI^FL]'6'OAR^)D_ ='6'OAR^)D]$?6Z?Y1\GA.O\
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M^XA1=/W8?Q/X.WSC2=;C3W*XA\-9]Q .A0               #DS=D^[&Q>
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MQ8,315V),;37BWMC>UU*^2145RIL7)RY;"L
M ?S(Q)(W,=[5R*BG.UZPSI"P;B?$#L%V^*ZVR]2OD?ON?]@CW.<N63V[=O:4
MZ+ $APCAC$.C31/-2X:I(KG?9)$JE@F3-N^.;&US=CF\"-7C_B?QI.PEB/&&
M$[%=8(HZ7$]!(E0ZG:G6JJ(_K6[<T7-4_6+" ('@_"N,\68^HL2X^H(+7^3V
MHV&"%%ZY6N:Y%VN?_=^(\^),*8YP=BB\U& J"&Y4%[;E.DO#$N3DSV/;M_M'
M*G#P'0@ G&@_!M=A/#]6^]/:ZYW"H=5S-:FQBO1%U>/:BY\91P
M          $.W8'8QH?I6+S4Q<33]*6!*32%AZ&T5]9/2115+:E)(417*K6N
M;EMXNO7Z@-BL'Z"MW@T?W4/<?&BITI*."G:Y7-AC;&BKPJB)D?8
M                  (!NR/<78OI#_;<7\TG2KH\H](EIHZ"X5M12,II]_:Z
M!&JJKJJW)<_E-V                           #!X[]Q&(OHZH\TXT/<P
M]BR#PN;[4-\QW[B,1?1U1YIQH>YA[%D'A<WVH5'&4?[,'@SWT>+_  #^E.70
MA>#/?1XO\ _I3ET%11[@ )6                                T;2-I
M"IL#U- EQIWK2U;][25$V([)5RSS1.+^9L&,,04V&<,U]YJNN@I8]\5&[5=\
M2=M33MT'AJ3$>CFM91P[]7TSF2T[43:JZ[47_P#7,DN)<92X[T<X4PO0U377
MBOEB;5:JZSLM23/9\NJ!T#@3$S<489I[UO*TU/.BN;OB:JHB.5%5<_D,[355
M/5(Y::>*9&\.]O1V7RY'/^Z%N%1AK"^&,.6Y\M+2S/:DKJ?-'Y9.1R(C=JYZ
MRKD:-@6\U6',;626QI>ZFEJG-@JF5,4VHW65J([KD5.-R_$!T5:<>TU?C6NP
M]O2LDI4172.V)MU^//\ Z#;X:F&>%TM-+',Q/UF.1R9_*AS/-A>;%FFZ]6]M
MQGH:96IOKH,T<[_BJW)45%3:W^9E] #ZRUX[Q[AJ2OGJJ*VJ](EE<JKFC]7/
M:JY;&IL M6%[W)>&U"RPLBWIZM3555SV(O\ 4RK:VE=4+3MJ8%G3AC21-;ZN
M$YDP+B:X631OC2OIYI'U3*F5L3WJKM1=YC5%V_(9##VBFX3X6MV(Z3%E5'>5
ME699)7JL:ZKW;%SDR5-B 5S2!C^FP??,-VVH@?(^\SK!&YJ9ZJHYC=NW_K0W
M&IJZ>FU?9-1%#K;$WQZ-S^LYYT];]T6Z(4J9&2S-K-5[V*BHYR24^:[.V:'C
M.^OQ%I1Q5'>)[JD%!4RTE/%1;ZY$U)'M1RHS@X$ ['8YKVHYCD<U>!47-%/T
MB>YIO5RJ+;<+3<DK9(Z:5SX)ZJ-['.9DQ$3KOX\9;             UW2'=:
MJR8,NEQH'-;54\:.C5S=9$761.#^)$J7'FDVOT>/Q1 ZAAIJ6)TLCMZC=OS4
MS579?J\&66T#H\*J(F:[$0YV32%I'O& V8MM5/14=MC:YRM=J2+,UFLDB[41
M6[8W;,EX?B*-)CIJ:)WXCKD9%(^GU5Z[)-=R9(O!VU ^]GTJX:NV,ZC"]++4
M)<X9I(%UV-1CG,UM;576V^T7B/KCS279<$UL-+=Z>Y2R2QI(U:6GWQ,E5R;5
MS3;UJ_R.8Z.&*PVK#F,(J^EFO$UPDJ:IJ3-1[62L8F2IFJ\+W\1V!3,M=^H:
M>O\ 8]+5Q2L1T;WQM?FWXE5 )G0[H/!]=,V.FI[T]7.U<TI$5$7^#C+XNTR8
M:PM=F6VY17-]4Z-LJ)!3H_8YJ.3]9-N2H3[<@V^CJL)7R2JI*>:1MP1&NDC:
MY43>V\"JAA]*=S6R[H*.KCL[KOO<#$2C9&KU=_9LXD:[[ +!@O2[AC%MT6WV
M^2IIZO+-&5C&Q*[AX$UE5> H+E1J*KE1$3C4Y>PI4)C73/3U3[3'AIU+&KO8
MST1CY.M_NJC%_5[7&=,W"E2LHY:=SW,21,M9O"@&EW[2OA>S8AIK++5/J:V?
M@]B:LK6+FNQRH[8O6\'R&U7V^4%CM$ERN<[8:5C=;6<Y$SV*N29JF:Y(NPYH
MTDX&MF"L686AMKII9)YM\EFF>KG.=JO3A557B0VO=45$CL-X=H<GI3S5L:O<
MU51%ZR1-5?X*!O.#],6%<575;?02U,%1^K[+8V)'[<NMZ[;_ .3\Q;IAP]A>
M\R6RXTMWDJ(VHY704NNS;\>LG:)IIXMM'9:S1U5VJECIYTJ&Y[PU&*_KH=BY
M</\ Y+9>'VJCPQ+>KK0T:NBI$F<Z:)JJJZN:-S5.WL UO".F7#.*;Y':K=%<
MXZJ3-4]D4Z,:F2*NU=9>TI\K[IOPA9KK+03R5D[XO;RTT;9(V_*[6_\ \S0U
M30)94Q#=\18PK*5L%/63O@HXFQHS4C7KD<G!Q299Y<1]M(%HP9HWP-<K;;Z-
ME3<J]Z/BIYG;_.]RY<"JBN1N4:_%FB]L"RV.[45\MD-PME1'44LN>H]CD<BY
M*J+M153A13W$XW/]@K\/:.:&ENK'PU+G2/6%W_MHLCLD_BF2_P 2C@
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M .Q.M_F!0 :_CF_16'!MTNVNW^QIGR1YKEK.1JJB?QR.==$6(+[9L?6NHO\
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MF!++<;@W5JIZ:-\BY9:RJU%5?Y@;0
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M_@']*<NA"\&>^CQ?X!_2G+H*BCW  2L
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M\F1M<QR*WM]8JH;<
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MQG5.B&RTMBP534M#35%- ]ZS-CGDUW)K(B\/]#<)((I'M>]C7.;P*O$?0
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MB)]B(![@
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MJY]I=@'H
M
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M?1XO\ _I3ET%11[@ )6
M
M                              1K&FB'$6(,3W"Z4.D*YVRFJ7H]E)$R
M16Q)DB9)E*B<6? G"64 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:
MG=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$
M8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\
M0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]
M>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[
M^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5
M^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'
M2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%
MR^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:
MG=_%R^O'2(Q5^U.[^+E]>7\ 0#I$8J_:G=_%R^O'2(Q5^U.[^+E]>7\ 8W#-
MNFM&'K;;JJL?73TM.R&2JD14=,YK417KFJKFN6?"ID@
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ME L0
M               /#-=Z"&1T<M7$Q[>%%7:A_5/=*&H?JP543W=I'''&*,)2
M8UTYWJT054%(]467?)W*C>M:FS8B]OM'DQUHMN&CV@CO,=]MDKXG;(XI7+(N
M;FMZU%8B+[;;M [9J:F&FCWRHD;&SMN78>/\N6SX;#SCG[2/>ZB_[GFVUM;K
M+4K!&V1[N%[M6-5=_',T'!^@RLQ)AJWWB.]VV!E7'OB1R2.1S=JIDN3%[7;
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MT@
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M7^ ?TIRZ$+P9[Z/%_@']*<N@J*/< !*P
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M+A0W?1_A^+"^$+;:(?:TT>2JJ;5555VWZP-@
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MF(B(NU<N!53@R S0
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MB_P#^E.705%'N  E8
M      0;3QI&Q!A#%%II+&L3HYWY.C>BJK_:;$ZY.'-0+R#F/&ND_21@ZMM=
MSO=';HK?7N5T4",<O6)DJHN4GMD1R?%F?7$ND?26MDZ+*&WT5+AUZZ\#7HNN
ML*[4>]$D^/+9VN #I<$]M&DFFFT4QXQKX][;O;GNB8WA5'*F2)FO$G;)?:<;
M:5<94%1?<.4-OCMD>LL+,G-6;5S14RWSAS:J;<@.D@1_1+I6GQ90W>W7JG92
M8@MK'-D:QJHQ[DWS@ZYVU-3;FO'L//H1QW>L4XVQ;;;M)&^FMZY0(U%14_M'
M-VYJO$@%H!$<:X_OEKTV67#E++$EMJH=>1JHNMGK2IV\OU$XC&Z1-*6)9M(:
M80P5#2I/$](YI)VNS1RY9*BH]-G7)Q9@=  A^#L7:0K5C"*T8SME/-0S*V-E
M33\.LY6Y+MDX$UMNSB/;IBTFW2Q7^DPSA*EAJ+U4-UG[\U5:Q%U51476;Q*[
MM\ %C!SQ!I&QS@;$]LHM(-+2/MM>[52:%JJY%R5,DS?LVZO%P*=#,<CVHYJY
MHO H'Z
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M+]SSC>\8RZ)_RW)&_P!@U$<<.HBIDBZ^>>:K_=0"P
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M_ /Z4Y="%X,]]'B_P#^E.705%'N  E8
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ME*ZJK(%SADEED74V*G KU1=BKPH4D
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MMFJU%1<TX# ;E&WUE"N,_9U)44V^5<2LWZ-S-9/[3@S3:!?0
M
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MX$5.//->!.,\&!<%V?!-!44=AI]X@GEWY[==SLW9(F?7*O$B ;(
M                 ,'COW$8B^CJCS3C0]S#V+(/"YOM0WS'?N(Q%]'5'FG&
MA[F'L60>%S?:A4<91/)@\&>^CQ?X!_2G+H0O!GOH\7^ ?TIRZ"HH]P $K
M
M
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M\YB*I]0!^*U%3)414[1_,4,4.>]1L9K<.JU$S/[
M
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;GM\]1/ V1TB/G5-;-R[>!$0S-HBT$7F;R__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g42675g03a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03a20.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[17>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %<$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD9.AL<'1%1@C0E-5<Y*RTA8S-38W5%;A\&)R)(*BPO$E)S1#)D1T8Z.S_\0
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M:#_U-;_G%HGXLND?\W<_G6?R)^++I'_-W/YUG\B#>_=>T'_J:W_.)[KV@_\
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MZ$_U-;_G%HGXLND?\W<_G6?R)^++I'_-W/YUG\B#>_==T)_J:W_.)[KNA/\
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M-)*9.>FR#ZB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B+QSX<0>B#VB^!X/>A)[D'U%\!.-QA"3C8;H/J+P'.SN,+US>"
M$/J+YS8'I(UP<,A!]1/B1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1#L-
MD!%\R<=-U\)/+L-T'I%YYCCINOG,['3=![1? =LKZ@(B("(B B(@(B("(B B
M\@N[PO7<@(OF2A/@,H/J+QSD=0 K2KNE+2@F69@/AE)G3-:S:=1"])5&:1C
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MD?\ $%'WD_:5I-6<%+K:[A31/$E1EA<WWK@,@KI"NH:6OIW4]?30U4#NL4S
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MIM'=+7-2T=42S0[U]:,!8C3M[IKU3.GI'9#7<KAG<%9AO116K-9Z925M%HW
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M)&5G<G)44Q->TL[V^H@W1 1$0$1$!$1 7PKZB#QOSG?965VFD@H)GP OFQZ
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M*QXVO+;;(*>M[%S&D<O-C'M^Y:Q<;8R[:LK;;(&Q,;"'1EC=\^E]RW4 B]Y
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MGYG8PQ'PX_\ IF+#J"DMMOKX8I,.G]6#G&%LN@33/J.9C@23D[+0C)5!V#1
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M*QX<YFS"=MO!75EKZF37UUIWRDP1P\S68Z'+5A:NEJ+3(^G:"QG-EKU8Z/O
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M7,81CN^-0^QKYYVL8"^61V !U<2N=R>3U1TU\O;?A;T>N:OY[DQV]HG[>_\
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M9:USW-#P"-P-_N6S2.# YTA 8T9)Z +7+W0UD->RZ6L9J,<DD>,\S?\ F5]
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MM8)'M!V>&GWP7*QY;4B=/8^I<#!^(N%^8XDZO,>??]I^Z6=$RBGN31-&9 _
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M<M)O$TSJ^3EC'*/8MTDPUKWN?@ +0:L,EJ)CYR?2/BHLD]HA?]/K$VF5(/D
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MWM*<=1URO4TL4WY*'FCC+B=CT"KV_3M;<Y9_P;!)( =W!5:^P5]!1RR5-#)
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M8 +N[/\ P+H\O%;X5+?9Q_3LN/X^6L3WVS^-_6O3#D+SS=Z],&&X5!V'U$1
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MEEDE8(<9SS#=:U4U===(WMH*5S86G,4KVG#L>"Z-HI77]G/M3'7],,S#8Z<
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M'=[C3TSWCF:V21K3CXRLZ2 "2< =ZXMXN><<2^*UPH;>]SHK;"_>/_I#G'Z
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MOV&X\>JVS@[/<ZVFJ:K/GU0T]D997DD-\-\^)6IZD@J+=J>JIKC.!+U(:20
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M8JH/[U;2=%<O[U;2=%K*S1)'#H?_ ,>?WDN/U*V#CYK=6-8>9KC]BN>'(_\
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MD_3%GU!:+LZ[T,-2^.0<KI&!Q'RA;1Y5-MI;5PTHZ*WQ,@IV53.5C&@ ;/\
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M!6*XGZ8J[YY/>GJRAC?*ZBBYGM:TD\O.[?;VJ\\GKB]8+;H^"R7R<4=31,Y
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M+C&>@)\%F3$P]6M/Q+TT;KZMYM,^4E:Q6-1"EYO%^C9\BJ!@ P  OJ+#.H?
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MS3CF'B=E)V$00$SR9=+M<#YS5;'X8^Y;1K7@Q9-5TMKAK9IP*"!M.PM<-PT
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M6TU&6"J@+7CED.,@[JQU/2.9.Q\=.7\VQV)PMT;-3,<7-8 3UPWJCIZ=_OF
M^UH6DXXF%RG,FE^M&(I9^?T8BUO_ &%:I?Z*J=5$F68-]41^Y3OS4O=&P_\
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MGQDXI#AS^#P^V&L%7S;A_*6XQ]ZV_1.IZ+5^GJ:ZVXXCFV+3^8?^%!G44<Z
MXE_TMU5=K0+::84#N3M.?F[3KOCXE(QV=L,[=$!$W (!W.^2.B^'F'O0"[UG
M9!]1>)W=C%(X@GE',#X[*!*SRA)VWJMM]'I>2I?3O+2638V!QE!/R*,>&/&&
MV:VN$MM=224-QC <8G>EOG&,_(L/J[CI3Z:URZP5EI+H62-8ZI;)T!.YP@F9
M%K^H=316K2-3?X8A4PQP&=C0[ =MG'_/%8SA3K?^GFGY[J*(T09.:?D+N8'
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MC9&4S7 / <,C)_V6NZ/XYV;4M[@M@LU;1S3NY8WROR"?D""6D0C!(/5$!$1
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MVK>,=;0VVEL-7;+3$_\ *22QNCW)QOSX[D'KC1<)[KP2TW55;LS.<]I<=LX
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M6AHJ62\15DC:EX:SS9K78).-^9PP@VI[&2\S'QM> =@YN5];&T-Y86M8#T#
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MDG&<^ 4[4%BMENK9ZZ@H8:>:5G)SQ1M:2T[_ &!<NZ%U=J#@W4UEDOMJEGH
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M(1&7;X[B5S/8=51:*XP7NYUM ZK@)+0WER"2P#IT717"3B/1ZYDJXJ*U^8"
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MWR@Z&U7NLMSK5)(ZF>6%S79S@XRLOHSCK8+_ %[:.KBDH)G$!ID(Q])02XB
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MW^R-._MI?J:IJX9?W$L_['[2@V9$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M$'JW&/M4+:AM,6A*_1MXML\3SS1F;D=N#VF3GXL+=>+=IN.O>,M'9325K+5
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M*GXTEG_4%9\\/Y4'12+G7\:2S_J"L^>'\J?C26?]05GSP_E0=%(N=OQI+/\
MJ"L^>'\J^?C26?\ 4%9\\/Y4'12+G7\:2S_J"L^>'\J?C26?]05GSP_E0=%(
MN=?QI+/^H*SYX?RI^-)9_P!05GSP_E0=%+CW@;_C]5>UW\#UO+?*DLQ(S8*S
M'[8?RJ//)WK6W+C4ZMC8YC)@YP:3N/0>@[,7F3^K=[%Z&_1>9/>.P@QXZ'VH
MO?9OP?1/5.S?\!R#PB]]F_X#D[-_P'(/"+WV;_@.3LW_  '(/"+WV;_@.3LG
M_ <@\(O?9O\ @.3LW_ <@\(O?9/^ Y.S?\!R#PB]]F[X#D[-_P !R#PB]]F_
MX#D[-_P'(/"+WV;_ (#D[-_P'(/"+WV;_@.3LW? <@\(O?9O^ Y.S?\  <@\
M(O?9O^ Y.S?\!R#PB]]F_P" Y.S?\!R#PB]]F_X#D$;_ (#D'A%[[-_P')V;
M\>\<C#PB]]F_X#D[-_P'(R\(O?9O^ Y.S?\  <@\(O?9O^ Y.S?\!R#PO4;2
MY[0.B^B)Y!/*57I(RT$N&"4%P!@85I6/_-&ZNG9Y3CJK'D?S$ECB4'A%[[-_
MP')V;_@.0>$7OLW_  ')V;_@.0>$7OLW_ <G9O\ @.04N1N<\HSXK[CQ53LG
M_ <G9/\ @.04@QH! :,%?0 T8:,!5.S?\!R=F_X#D%(M:3DM!/BCFM=[YH/M
M57LW_ <G9O\ @.04VM:WWK0%]7OLW_ <G9O^ Y!3(!!!&05Y[-GP&_(JW9O^
M Y.S?\!R#PO)8PG):"55[)WP')V;_@.04FL:WWK0/8OI:'##@"/6JG9O^ Y.
MS?\  <@IM:UOO6@>Q"UI.2 3XJIV;_@.3LW_  '(*;@'##@"/6O@C8,>@-E5
M[-_P')V;_@.0>%Y#&C.&C?JJO9O^ Y.S?\!R"CV;/@-^1>QL,#8+WV;_ (#D
M[-_P'(*18UV[F@^U QH.0T JKV;_ (#D[-_P'(*1C8>K&E?6@-&&@#V*IV;_
M (#D[-_P'(/"+WV;_@.3LW? <@\)T&5[[-_P'+ZV)Q."T@(/=''N7%7:\QMY
M6@)(2&' R4%M5R9]$=RH'<Y7OD><DL=E.R>/S'(P\(O?9O\ @.3LW_ <C+PB
M]]F[X#D[-_P'(/"+WV;_ (#D[-_P'(/"+WV;O@.3LW_ <@\+XUK6YY0![%4[
M-_P')V;_ (#D'A?&M#?>@#V*IV;_ (#D[-^/>.04BUI.2T$^*&-AR2P$JKV;
M_@.3LW_ <@I-:UOO6@>Q?7-:[WS0?:JG9OQ[QR=F_P" Y!X'3 7DQL)R6@E5
M>R?\!R=D_P""Y!2:QK<\K0%]:T-SR@#/@JG9O^ Y.S?\!R"F6M=[YH/M7U>^
MS?\  <G9O^ Y!2#6M)+6@'U+ZYK7>^ /M53LG_ <G9O^ Y!2$;!OR-^1"QIW
M+02JO9O^ Y.R?\!R"DUK6^]:![%Z7OLW_ <G9/\ @.0>$7OLW_ <G9O^ Y!X
M1>^S?\!R=F_X#D'A%[[-WP')V;_@.0>%<4;#N3W*D(G$X+7*^8WE: @^DX&2
ML75R<\I Z!7U2YXC(8TN)6/[&7J8W904T53L9?T;D[&7]&Y!315.QE_1N3L9
M?T;D%-%[[&7]&Y?>QE_1N04T53L9?T;E\[&7]&Y!X15.QE_1N3L9?T;D%-%4
M[&7]&Y.QE_1N04T53L9?T;D[&7]&Y!315.QE_1N3L9?T;D%-%4[&7]&Y.QE_
M1N04T53L9?T;D[&7]&Y!315.QE_1N3L9?T;D%-%4[&7]&Y.QE_1N04T53L9?
MT;D[&7]&Y!315.QE_1N3L9?T;D%-%4[&7]&Y.QE_1N04T53L9?T;D[&7]&Y!
M315.QE_1N3L9?T;D%-%4[&7]&Y.QE_1N04T53L9?T;D[&7]&Y!315.QE_1N3
ML9?T;D%-%4[&7]&Y.QE_1N04T53L9?T;D[&7]&Y!315.QE_1N3L9?T;D%-%4
M[&7]&Y.QE_1N04T53L9?T;D[&7]&Y!315.QE_1N3L9?T;D%-%4[&7]&Y.QE_
M1N04T53L9?T;D[&7]&Y!315.QE_1N3L9?T;D%/ORLA0Q<K><]2K6&GD=(.9I
M ]:RC1@ ! 1$0$1$&(ONGK5J".-EWH8:ML>2P2C/+G_X6%'#/1YSFPT?[I^]
M$0??<RT?^H*/]T_>GN9Z/_4%'^Z?O1$#W,]'_J"C_=/WI[F6C_U!1_NG[T1
M]S+1_P"H*/\ =/WI[F6C_P!04?[I^]$0/<RT?^H*/]T_>GN9Z/\ U!1_NG[T
M1 ]S+1_Z@H_W3]Z>YGH_]04?[I^]$0/<RT?^H*/]T_>GN9Z/_4%'^Z?O1$#W
M,]'_ *@H_P!T_>GN9:/_ %!1_NG[T1 ]S/1_Z@H_W3]Z>YGH_P#4%'^Z?O1$
M#W,]'_J"C_=/WI[F6C_U!1_NG[T1 ]S/1_Z@H_W3]Z>YEH_]04?[I^]$0/<R
MT?\ J"C_ '3]Z>YGH_\ 4%'^Z?O1$#W,]'_J"C_=/WI[F>C_ -04?[I^]$0/
M<RT?^H*/]T_>GN9:/_4%'^Z?O1$#W,]'_J"C_=/WI[F>C_U!1_NG[T1 ]S+1
M_P"H*/\ =/WI[F>C_P!04?[I^]$0/<ST?^H*/]T_>GN9:/\ U!1_NG[T1 ]S
M/1_Z@H_W3]Z>YGH_]04?[I^]$0/<RT?^H*/]T_>GN9:/_4%'^Z?O1$#W,]'_
M *@H_P!T_>GN9Z/_ %!1_NG[T1 ]S+1_Z@H_W3]Z>YGH_P#4%'^Z?O1$#W,]
M'_J"C_=/WI[F6C_U!1_NG[T1 ]S/1_Z@H_W3]Z>YGH_]04?[I^]$0/<ST?\
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1$1 1$0$1$!$1 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g42675g03b18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03b18.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[11X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %%L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5G-T=92RP=+3,SAB<I7P)%2SPC0U0Z+A\8+#XD1'8X.T_\0 &P$!  (# 0$
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MCNM?>I'ZPA]#T&;[G6^7+4.S.EK[W62UE8ZHF:993EQ =@!28HB[E7WH:/\
M2I_WE+J B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@XZUA_>S@_75#Z(EV*N.M8?WLX/UU0^B)=BH"(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M@(B("(B B(@(B("(B B(@(B("(B B*C6U#*2DFJ)/<1L+SCQ#*'997R\06F
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M0$1$!$1 1$0<=:P_O9P?KFA]$2[%7'6L/[V<'ZYH?1$NQ4!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M/DRLR2 "2< +DZX5KX+NZ:WR/B.\"W#B,D8_BMQ^R#J 6VE@D,>2W=+^&2
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M$%%2.+Z"F&)".3W\>'S$++ZUN;:2G9;J'C5RC<SSW!PSYLJYT-9([90- &2
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M="^2HJ) XG!\%I=P'R K+W>8WR]LHXL][4KVDD<G.X$'Y.*VNDIF04S(MT$
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M$B(B B(@(B("(B B(@(B("(B B(@(3@9/)%J6LM1"CB-+2$&9W!S@?<CC_\
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ME,):R3I'@8!P!P\@\JM 2#D'!1%K6M-IW:=RQ;1;M95=-3=!401U31@-W^&
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MB^07&EEK+);)8J>+W<0#6M8,'B #XB?E579U007K65-27BE;/"YHQUC.\/\
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M[6'][.#]=4/HB78JXZUA_>S@_75#Z(EV*O3KQ$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M)*R2JIF8+('LP,Y!XG>/9YU+Z+"+3'2&4TK,[F%.GACIX60P,:R-@#6M:,
M+&7G3=JO,C7W&D9,]O(G@?\ ?%9=%BRTQ%5INT55%WK-04YA[ P ]?7\JAJY
M[#>AUC155I>#:3*V2:-YXM +3@9.3GPE/B+*+3'9%J1;NL+5:*&U1[M!31PY
M:&DM;C.%?HBQ9"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(AY((]VT-S8Z5WP9"?0MCT'*)=)VUV>/1?Q*BO:U[)TUV?#//(^BD)?&
M"XX&2>&,^1938PROK*F626JG[RIV;K(^D.[O9!Y9[,]2Z5L/W6)WVZN-CXC[
M[:.7OT2^B(N:[(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B M(VD7C
MO>D%!"_$DG%^.8P6D+=)Y!#!)*[W+&EQ^10AJ*N?7W>JF>XD;Y#>/( X"Y_I
M'-ZO'RQWEJ\7DY*:CQ75NOTD<'>M:P3TQ/'/NA\O/J5Z^VTU;'TEIG:\XR87
M'#OD&<E:LJM/42T\@D@D<QPZVDA<&9B\:O&_\M''Q%J]+=87LT,D+RR9CF.'
M4X87PLM2WJGK8Q!=H6Y/ 3L&"/&>!)ZEY76:2*(5%*\3TSN(<, X\F<JF^"8
MCFIUAN4M6\;JQ2(1CFBH9/0"2 !DGJ"VK36E9JW<J*L.B@SD C!/#_Z5SHS3
M8G+*VM'@#BQA X\_4M_8UL;0Q@#0.  X+L\!Z-]9$9,O;PA;2GC+YIX&4\+(
MXQX+!@9YJHB+T,1$1J%HB(I!$1 7CFAPPX CQKU$&D:UT0R\O-51O+*KK!/
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M$0$1$!$1 1$0:YKO3[=0622%C0:EG&(GJ.1GJ[%]:$LGL'8(*>1N[.X;TO\
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MSUJ^,*;ZP)]W_I^A[I[ VKXOI?JPGL#:OB^E^K">SUJ^,*;ZP)[/6KXPIOK
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M=_Z?H>Z>P-J^+Z7ZL)[ VKXOI?JPGL]:OC"F^L">SUJ^,*;ZP)]W_I^A[I[
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MRVH[.:S6.HJ"K@KS2P0Q-C=A@<<ASSGW0^$%'=[AJ;5>C;J=KG0MP ]XP3D
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MNM5(ZI?51&*1L;-\,)=GCX/#W(^=;GI+0%TK1%6:QK7S2M)(A;X('A=>[CJ
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M:5\A+_ \+AD;S<XR"6A!M&V'9);;9IV:\6$&%U(TOEC. TL /$8;SSCK6[[
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MH87-:=P!A:1G'(-.>/D6 M_='P0Z2I[>;/6/NS*>.#I<-Z,N  )]UGCQ\R#
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MM20;SN]_8^9^.K>S$/GPLQKC;'6[2[9'I/0UFK(KA<7[K^G<UKBUGW3P'!X
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M >RM&U[QPWV -=\^,K8T0:=IO9KIG3\W2T% '/'(SD28\F0MQ    & .H(B
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MA\Q:.&\>7$+.?_V\D_,M_@M8T1]\$/\ OK"PSWMZW#&^\1_DF>L-UNHNYO\
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M0^B)=BKTZ\1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MVR.S;'[-;X7%\<%TC )YG[G.?XK1Z&GJ=G(TYK2T;[K=7ET-=%O8;&&N:T'
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M2L5FMDU7)21!LS6%O@'#>>3XBOK;#H^_WG9YH^@M=LFJ:RCI6,GB:6YC<&Q
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MF-RN=/53PY W:<-+O= ?A$?""#9TZEJ&SC7]JU[;9ZRT,J8>AD,3XJAK0\<
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MA/A CF#UK>M$:NVD7._0T^I-(T]OM[B-^=K'@CB.UYZL]2".-A7O]7?] ?\
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MW&X7TB7Q*_<8>U66<YRJD[]YYQR"IC 1 B=JLKU6^QUHK:S=+N@A?(&M!))
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MX44J5M=_>Q5^5G[X44KS/IC\^/E_,J,G<1$7*8"(B B(@*I3POJ)F11#+WG
M"IK9="T<4UTZ>=[6M@\)N\X#)_V59@Q^MR13S3$;G3;IJV.R-M= PXZ1S01X
MB[CZ5K&T*BZ&X153 =R=OR#&/6LI>-74]/<I(3;(JGH2 V4R#LSP\$X5>^ST
MU\TPZ>-T<<K1D-+@2.1(ZNQ=SB)QY\=\5+;F.T>6ELZF)A<14D]=HJ&GI2!,
M^"/=)./@GG\B^)I#8M+&*ND8^H+-UK-[.3Q]2MZFJ$>@V]#.&3"&/&Z_#A[E
M>6^K@U)89*:L?'%4L&Z)'8Y]O'';VK.;UW%:_CFO3R__ $5-#!TUDJ@S@YX(
M'E.\KBQTDUCCN%3=)V-BD<"W+\@#)[?*%;Z6 H+3702S1MD8"!AXX\\8XJUT
MS>(JF:KM=Q<'M?(XL=(=X'F>OLP%&&U*5Q1;I;4Z\M_J1.M*>BJAM5J.YSQ@
MADAWQGL+BJEYL5HJ+I42U%YBAE>[+HRYN6GY2JFFJ&.T:@JX^GC,+F!S';PY
M;Q\?B6IZH<'7^N<T@@OX$>0+6O>,7#1&6L3/-/\ /DQGI7JW76$;(M(;D4@D
M8US '#KXJWT95LNUGFMU6[>='@#/#P>H#Z*\U)-$[1;&-D8799P#@3S6%V?R
M-CO&7O#&D<<G ]RY6Y,NN+I$=IB(G]]IW[S):PJFVNUT]IIG $L&_CCPXC^"
MP^B99#?H6E[B,<B?&$UQ(V2]N+'APW<9!S^$53T6]K+]"Y[@T=I..L+3ODFW
M%Q'A$Q'[,=^\R6T21[;K&&O<!N\@?$%G=&,;)IAS9'[K2\Y<>K@U:[M"D9)=
M8S&]KAN\VG/8LWI::)NE)&ND8UV_R+@#R:MG%:/;<DS^K*/Q2M[+8K1372FF
MI[S%/*Q^6QAS<N/9P*]U1]]MH_.M_>"U;2K@S4-"YQ :).))6S:FEC=JNTN;
M(PM$K<D'@/""QQY*7X:>6O+[T?PB)Z-LGECDF?1R$;TK/!&>? Y6JZ3H&VN6
MYU<^1'!*8FD^(XSYU5U-<64E_MD\4C7 !S3NN[0 OK7-PBI[6(*0L=WRXEY8
MX<.1SP\BV\V2DVMDGOC[?O'3ZLYF._D^]H#B[3=.3S,[?W7*EJ;[R(_\[/2F
MNYHGZ;IVLD8YPG;P#@3[ER7US*C25/!'+&9'R1M WAUE89IW?+__ )A$^*WV
M?TS:>AJ[A)R]RT]A&<^E7L[_ &R:6E?&-ZHC.Z!_B\'/I5::XTVGK! UL<50
MXM&]&'@9/#/45\Z9U)2U\TE.***B8!O<'C#C\P[%..,=*UX:UN\=8_6?U[$:
MCW4:'@461U!2MH[K/'&6F+>\$@@Y"QR\_>LTM-9\%,QH1$6((B("(B I1V>_
M>XS\X_TJ+E*.SW[W&?G'^E=3T1^?^S/'W<O:P_O9P?KJA]$2[%7'6L/[V<'Z
MZH?1$NQ5Z=>(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("ACNM?>I;^L(?0]3.H8[K7WJ6_
MK"'T/077<K>]#1_I4_[REU1%W*WO14?Z5/\ O*74%M5>['D5 *O5>['D5 <$
M0($"!!ZO$1 'C1$ZT#Y$RO%Z.2 B!$!>]2\"("Y;V]T#+IMKT[02G#*D0Q$^
M(R$+J3J4![4=*WVY;;-,W2@M=3/;J>2$RU#&Y8P"4DY/D0AKVQ34DVCX]86:
MYO+'4L!GIF9)P0V1^.!P,Y;V*.=5T3ZBPV_54PQ47NZU#W \3C>:\?O=I4G;
M=-F][N>N::XV"WU$\-?NQ5$D#<]&T-C;EW#A^%V\ED-L6A+O-H;0=KL5KJ*R
M2W-#:@0MR6D1Q@D^4@HECMO;7.V+:/(&0VH:3]6]3'H'WL:/\Q+^\]8+5&@9
M]6[**"SOQ3W.GB#X6S'=:V3!'A8!(&">0496*[[5['H]^G8-(SRQB&2%E4Z-
M_2,WMX[PXXR"[LZD0MNYTH77'4&MZ5IW1/&Z$N[-[I@K&WPZNV(Z@N-<;;#/
M9JEYB=.\A^^QKC@L <"#Q',*4-D&SJZZ.TS?JNL>PWVXP%S.C<28W@2%O-HX
MY>,\^(6"&M-K5/;S;9-$]^=''T#JIT<A=+PQOGP@,GGR1+8Y=H]IU)LUU/?=
M.0NI+G3TTA<V1F) 0&G)<W_,.M:OW)MGH76^ZW9\4<E>7,:)'-!=&"79 .,C
M.Z#SZE>["=E==:K#<G:GB$7LG ^!U*2=YK"6'P@1P/@GK/4M7M&DMH6RC44T
MNFK>+U0U3>,46\]G#&"_ ;@\2!CJR@Z4N=+!)"^HDAC?/#%((Y'-!<S>;QP>
MK.!E<Y["_?EU5^<=^^5ONB[_ *_U'>BW4NGS9K?#!*"UC7 3N<TX!R3R(\ZB
M^SV[7^C]?7R[6;2516LJIG!IEC=NEN\2",$(A-VW3WL[W^8?^XY05L>OFTN@
MTNR+1FGZ"OMN3B6;&][M^?\ U6]9=U=2D.XW'7&L]G^H:.^Z6=051A>VGBB8
M[>E):1UD]JT[9W<MIVB+&VV4&AI*F)I)WYHG[W%SG=3A\(HETG89:V:QV^6[
MPL@N+Z>-U3$SW+)2T%[1Q/ .R.9\JOEAM'UURN5@I*J^40H+A(P&6G (W#@<
M.*S/E*( B(@)S3QH@]1>(@=13EE$0 B H@(O5X$%2%N^]7@X!4J=FZS)YE54
M2^)7[C"59'QJK4.WG\.I4NI$ 1.M @93@B#AUH':@1$!/(B("(O>I!!W==>]
MY;/UK'_T9EN>R.E@K=E-IIJN)DT$L$C'L>T.:X%[@00?$5@.Z9T_==1:'M])
M8J">NJ8[BR5T<+<D-$4HSY,D?.M!M%\VJV[2,6G:+1LL,;(W0MJNC>'MWB>/
M/'#>[.I$L1L^B]A>Z*K;9;!T-!)55C71-\%H:UDQ: !@8&. PL5:Z[4UOVQ:
MAET;;X*^X=\/!CFY8WO\S?2I@V+;+ZW39K+[J.1DUYKF]+@.),;G!Q.<M&''
M?.>?%1W%:M>:6VF7N]V32E37,FG=N&2-VXYN<@C!"#?KMJ+77V*]43ZRME+:
MJWHWQ4_>_#+#$\EV0]V"" L#W/YM>G= W'5M72]]5V'%\@:TR@!TF0UQX\0.
M/'C@+>=)5^J-=6R\6G76G!9J2>G=$U[&.!=O#'#>)XX)4;66P;1ME5XJX]/V
MME[MM2YVY%'OO8UH)+2[ ;@^%X^(*(;59=NNF=2:BME+[7ZWOP2.[WGF;&>A
M):<D'.1D<."T';A=8[)MFMESJ(WR14PZ1S&8WB YW+*O+;IK7&L-J]%J"^:?
M-J:S >7M<UF UW+.3GBM@V@:2OU?MKLMTH[5536^)P,E0QF6-\)W,_*$2U*\
MW)^V_:#9VV2@DI*:A\*=\I:U_1E[-XD@G)"FC:Y=VZ/V45,3)"9VTS*2,#.7
M#P8R<\.HK2=M&@+M2ZIM^KM%T,M5<&SL?/#$,N);@M.,<O  /'K6#VFT.L-H
MM1IJCETW>*.G@(95R20AH!?T8>X<3P!:XA!J]WT1['[&+'J")D8JVS=^RS #
M?=&\,W6YQG@3RRN@K)J%NI]DSKGO$S2TCC(#GP7<>"CZJ[FFS,HI74]XN;JE
MK,M:=S=)[/<Y5+8A8]46;3.H[+>+-74[)8G2P.D9AKG8:W='CYGEU(*?<G_^
M-U=^?9_WK$=TA::2U:YT_<+="R"KJ:G>D,;0W>(+,'@,YXE66SYFT?0%9=W6
MK1<]6VMEWB9XW<,%V,8([5F],;.=6ZUUQ3ZGUS$RCI63.D=22%PE;@'<#6EI
M& 0WKY(,!W1]14S7G2TY ?5.M\3B#UNWY/&I9T)?MJ5;?HX=5Z<M]%;"/"EA
MQO [P_\ \KNK/4M0[H_2>H+QJ>T56GK/4UT5/3-:3"S(#@^0X/SCYUL.F==[
M2Z[4%NI+MHAE';YIV,GJ!'(.B83Q=Q=C@$&CT7]Y^O\ _P#7^Y$I%[I6RT%5
MLRNMSFIHW5M'T1AEW1O#>FC:>.,\BHXU99-:6C;)<M16'353<(B8^C<8R6.P
MQF>1'6W"JZ@M6TW:C6P45YM#;);V.!D;)OLC<.9ZG<?!^<A!(G<T5=34[.8V
MU3B6PRB.+)SA@8W'I*E=8;1^GZ;3.GJ*U4?&.GC#"\\WD#&3XUF40)XDQS0(
M"!"@0$"(@(@\2( 5>F;EQ/4%1:,N "O8V[C0$'TJ<[]UA[2JBLYG;SCV(E31
M$1 B(@(B<R@!.2(@(G4G:@($X]:("(G:@!,(G-!XO>I,\$ YH"(!S0('4B)R
M0$0(@]7B(@=2(B .2(@0$1$! B(')/2GD1 "($0.W/)$56G9O.X]2"O3LW69
MZRJB(B1$1 1$0$1$!$1 1$08#7?WL5?E9^^%%*F+4M!+<[-/24Y8V1Y;@O.!
MP<#_  6D>T6Z?C:3Z;OY5P/2G#9<N:+4KN-?S*J]9F>C5$6U^T6Z?C:3Z;OY
M4]HMT_&TGTW?RKF^P\1\$L.66J(MK]HMT_&TGTW?RI[1;I^-I/IN_E3V'B/@
MDY9:HBVOVBW3\;2?3=_*GM%NGXVD^F[^5/8>(^"3EEJB+:_:+=/QM)]-W\J>
MT6Z?C:3Z;OY4]AXCX).66J(MK]HMT_&TGTW?RI[1;I^-I/IN_E3V'B/@DY9:
MHBVOVBW3\;2?3=_*GM%NGXVD^F[^5/8>(^"3EEJB+:_:+=/QM)]-W\J>T6Z?
MC:3Z;OY4]AXCX).66J(MK]HMT_&TGTW?RI[1;I^-I/IN_E3V'B/@DY9:HBVO
MVBW3\;2?3=_*GM%NGXVD^F[^5/8>(^"3EEJB+:_:+=/QM)]-W\J>T6Z?C:3Z
M;OY4]AXCX).66J(MK]HMT_&TGTW?RI[1;I^-I/IN_E3V'B/@DY9:HBVOVBW3
M\;2?3=_*GM%NGXVD^F[^5/8>(^"3EEJB+:_:+=/QM)]-W\J>T6Z?C:3Z;OY4
M]AXCX).66J(MK]HMT_&TGTW?RI[1;I^-I/IN_E3V'B/@DY9:HBVOVBW3\;2?
M3=_*GM%NGXVD^F[^5/8>(^"3EEJB+:_:+=/QM)]-W\J>T6Z?C:3Z;OY4]AXC
MX).66J(MK]HMT_&TGTW?RI[1;I^-I/IN_E3V'B/@DY9:HBVOVBW3\;2?3=_*
MGM%NGXVD^F[^5/8>(^"3EEJB+:_:+=/QM)]-W\J>T6Z?C:3Z;OY4]AXCX).6
M6J*4=GOWN,_./]*UGVBW3\;2?3=_*MSTK;9K5:6TM2Z-T@>YV6$D<?*%T?1G
M#9<6;FO74:94K,3U<HZP_O9P?KFA]$2[%7$NUN[BP=T;7W@PF<4%?2U/1;V[
MO[C(W;N<'&<<\*0_MJ(OR0?_ *B/Z2] N=+HN:/MJ(OR0?\ ZB/Z2?;41?D@
M_P#U$?TD'2Z+FC[:F+\D'_ZB/Z2?;41?D@__ %$?TD'2Z+FC[:B+\D'_ .HC
M^DGVU$7Y(/\ ]1'])!TNBYI^VHB_)!_^HC^DO/MJ(OR0?_J(_I(.ET7-'VU,
M7Y(/_P!1'])>_;41?D@__41_20=+(N:/MJ(OR0?_ *B/Z2?;41?D@_\ U$?T
MD'2Z+FG[:B+\D'_ZB/Z2\^VHB_)!_P#J(_I(.ET7-/VU$7Y(/_U$?TEY]M1%
M^2#_ /41_20=+HN:?MJ(OR0?_J(_I+S[:B+\D'_ZB/Z2#I=%S1]M1%^2#_\
M41_23[:B+\D'_P"HC^D@Z71<T?;41?D@_P#U$?TD^VHB_)!_^HC^D@Z71<T_
M;41?D@__ %$?TEY]M1%^2#_]1'])!TNBYI^VHB_)!_\ J(_I)]M1%^2+_P#4
M1_20=+(N:/MJ(OR0?_J(_I+W[:B+\D'_ .HC^D@Z61<T?;41?D@__41_23[:
MB+\D'_ZB/Z2#I=%S1]M1%^2#_P#41_23[:B+\D'_ .HC^D@Z71<T?;41?D@_
M_41_23[:B+\D'_ZB/Z2#I=%S1]M1%^2#_P#41_23[:B+\D'_ .HC^D@Z71<T
M?;41?D@__41_27OVU$7Y(/\ ]1'])!TLBYI^VHB_)!_^HC^DO/MJ(OR0?_J(
M_I(.ET7-/VU$7Y(/_P!1'])>?;41?D@__41_20=+HN:?MJ(OR0?_ *B/Z2?;
M41?D@_\ U$?TD'2R+FG[:B+\D'_ZB/Z2\^VHB_)!_P#J(_I(.ET7-/VU$7Y(
M/_U$?TD^VHB_)!_^HC^D@Z61<T?;41?D@_\ U$?TD^VHB_)!_P#J(_I(.EU#
M'=:^]2/UA#Z'K3_MJ(OR0?\ ZB/Z2TK:[MP9M TF+*VP.H"*AD_3&KZ7W(<,
M8W!V]J";^Y5]Z&C_ $J?]]2ZHB[E7WH:/]*G_?4NH+:J]V/(J&%<U$;GN!:.
MKM5(0R?!\Z(4P450PR?!\Z=#)V>=!33K*J= _P"#YTZ!_P 'SH*:#M57H7_!
M\Z\Z"3'+SH*:>)5.@D^#YTZ&3X/G04T]*JB&3X/G7G0/^#YT%,=J*KT,G9YU
MYT$F/<^=!3'),JIT+_@^=.AD^#YT%-%4Z&3X/G3H9/@^=!33Y54Z"3X/G3H)
M.SSH*:][5]]#)V>=.@D^#YT%,<D"J=!)CEYTZ&3X/G04T53H).SSIT$G9YT%
M-!R53H9/@^=.ADX^#YT%-%4Z&3X/G3H),>Y\Z"F.2'DJG0R?!\Z]Z&3X/G04
MAR15.AD^#YTZ"3L\Z#X7BJ=#)\'SKWH9/@^=!215>A?\'SIT,GP?.@I#@BJ=
M#)\'SH('_!\Z"GR7W"W??QY+WH9/@^=7$$>XWCS05 OB9VZP]J^U;S,>]W <
M/*B5OGB@53H)/@^=.AD^#YT0IIUE5.@D[/.O1#)UCSH*74BJ"!_P5[T#^SSH
M*2*IT$GP?.O1#)V>=!215.@?\'SIT$GP?.@I]1"#SJIT$G9YTZ"3X/G04T"J
M=#)\'SH('C\'SH*:*KT#^SSIT,G'AYT%->*IT$G9YTZ"3L\Z"FG7P53H),<O
M.@@D'X/G04TYJIT,GP?.@ADZV^=!3"!5>A?\'SKSH).SSH*8X)VJKT,GP?.O
M.@?\'SH*815.@?\ !\Z]Z&3L\Z"DGB53H).SSIT,G9YT%-%4$,GP?.@AD^#Y
MT%- JO02?!\Z\Z"3L\Z"FBJ=!)CW/G3H9/@^=!315.ADS[GSIT,G9YT%,(.2
MJ= _X/G7H@?GB.'E0?=*SB7%7"\8W=: %ZB5*H?NMP.95IG)XJO+'(]V=WSK
MXZ&3X/G1"FGD53H7X]SYU[T#^SSH*2\57H9./@^=.@?\'SH*80*IT,GP?.G0
MR?!\Z"FBJ]"_X/G7G02?!\Z"FBJ=!)\'SH().SSH*:'DJG0R=GG3H)/@^=!3
MZD[54Z&3X/G3H9/@^=!315.@D[/.G0R?!\Z"DO54$,GP?.G02?!\Z#X7F>Q5
M.AD^#YTZ&3X/G04T*J="_P"#YU[T,GP?.@I(JG0R<?!\Z=!)V>=!\+SDJG0R
M?!\Z]Z%_P?.@I(JO0R?!\Z\Z&3X/G04T YJIT,GP?.O>A?\ !\Z"DBJ= _X/
MG7O0R?!\Z"DG-5.ADS[GSIT$G9YT%//!,<%4Z&3X/G3H9/@^=!33J53H9.SS
MKWH9.SSH*76KV%FZSQE48H2'9>,!7*)@1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1!K=TT)I6[5\U=<].VJKK)B#)--3,<]Y P,DCCP "M?L9Z)_).R?L;/4B('V
M,]$_DG9/V-GJ3[&>B?R3LG[&SU(B!]C/1/Y)V3]C9ZD^QGHG\D[)^QL]2(@?
M8ST3^2=D_8V>I/L9Z)_).R?L;/4B('V,]$_DG9/V-GJ3[&>B?R3LG[&SU(B!
M]C/1/Y)V3]C9ZD^QGHG\D[)^QL]2(@?8ST1^2=D_8V>I/L9Z)_).R?L;/4B(
M'V,]$?DG9/V-GJ3[&>B?R3LG[&SU(B!]C/1/Y)V3]C9ZD^QGHG\D[)^QL]2(
M@?8ST1^2=D_8V>I/L9Z)_).R?L;/4B('V,]$?DG9/V-GJ3[&>B/R3LG[&SU(
MB!]C/1/Y)V3]C9ZD^QGHG\D[)^QL]2(@?8ST3^2=D_8V>I/L9Z)_).R?L;/4
MB('V,]$_DG9/V-GJ3[&>B?R3LG[&SU(B!]C/1/Y)V3]C9ZD^QGHG\D[)^QL]
M2(@?8ST3^2=D_8V>I/L9Z)_).R?L;/4B('V,]$?DG9/V-GJ3[&>B?R3LG[&S
MU(B!]C/1/Y)V3]C9ZD^QGHG\D[)^QL]2(@?8ST1^2=D_8V>I/L9Z)_).R?L;
M/4B('V,]$_DG9/V-GJ3[&>B/R3LG[&SU(B!]C/1/Y)V3]C9ZD^QGHG\D[)^Q
ML]2(@?8ST3^2=D_8V>I/L9Z(_).R?L;/4B('V,]$_DG9/V-GJ3[&>B?R3LG[
M&SU(B!]C/1/Y)V3]C9ZD^QGHG\D[)^QL]2(@?8ST3^2=D_8V>I/L9Z)_).R?
ML;/4B('V,]$?DG9/V-GJ3[&>B/R3LG[&SU(B!]C/1/Y)V3]C9ZD^QGHG\D[)
M^QL]2(@V"S6BWV2A;16>BIZ*D:2X0P1AC 3S. KY$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
E$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g42675g03b19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03b19.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[10^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %"$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*/_  !$( 60'; ,!(@ "$0$#$0'_Q  =  $  04! 0$
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M64/$%:5K>(NK:1[6M)P>:YR6FM=PEXF*N7)%+>%]8M7T]VO<MOB:6N8"03U
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M8J3_ #8W"Q/IN++28IJL_P!VTV':]7W&H:V6V0LAW]TO$A./DI>IJGQ:9DI
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MDF]CY+.VBZ4UTIO&I79QP<T\VGL4KDK:=05R5M.H7R(B[=B(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MJM1_UFL_XBZI7*VS?^55J/\ K-9_Q%U2@(B("(B B(@(B("(B B(@(B("(B
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MC]DO6"#P++3Q@8]4'Y+*LX!6U",4D+!T:/N5TWDM"GZ7QV2W5>;"(BZ<"(B
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MK7G''#0?_P!2]+CKFRU\[2U]4T8X;S![_>M2*VBCY"V3'_%3;JAE<O9"YSW
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MVRY5.T;4[:5D;X;'2N)>#^W@\,CEE;=KS3DFI*RBI'UICIAO.=%C@>7'W_\
M-9O2^G:+3EO%+1-Y\7R$<7'N5W,=7T_$.]3/:/"&]HYA=J62GI8]R&%@B:P-
MP!@ 8 ^I;PRUU-;I6W3-B+'PQL9X?=H;S^*N=2Z9IKCJZD>-QIE:7R@CZ0:6
MC^*PNUS74VGJFBL%E=X%=4M'YW Q&W_K"KSBBW5U*]<.NKJ^6/KM56K3MLFI
M;A *RKJAX0I>!Y]79Z<OM4<7)EZT?_\ $(;7X=LJL/:2<M:#Q Y+#Z_TM>]*
MWYE;=:GST<SMYM2UQ.3P/'*G'2%_L^O=!.M5>^,U+8@U\<@ZMY$+BN.+1%+^
M'%<<6GHMXA>;*;E:M0V&2:"GC%<UF)0X D$CF/K6'L5P?IJ]W*&**,O,CB]I
MX9RXE:MZ/U2VT7F^"JG:VEIXW->\\O5>!D=UE[A<*34FKZVLTUXM4_ ;)EFX
MW P,@GG]BXRQ,8H]OM,?9Q>TQCK,>8EO_P"/,3XL1T^)<<GNX?4LWIB[ON]&
M^62,,>QVZ0#D<S_DHYH]'WF:3Q71@;IX O "D/2=JFM5 YE26&9YWG;G(<3_
M )KKB7Y%[?S8U";!?+>WU1V9M$1:"X(B("(B B(@(B("(B B(@(B("(B H8V
M_P"G8MRFOT30)1NT\H YC)P?CERF=8'75H=>]+U]%&P/F=&3&.[@.'S46:G7
M2:KG Y'\/GK?X^7)+P0YV20.GO6P;/X&U&L[+&>)\PQQ'P<%(&FMBE1*V.74
M5:(P#DP0.<3CWNX8^I27IW06G[!,R>AH6FH9REE)>X'W$Y(5#%Q+[B;=GTO+
M]:X]:VI3O,LY>:GR-GK*GI!"Z3[ 2N/ZN5\TKYI"2][W.R>O$KJ[7[MW1%_(
M/'R,V/\ T%<E-!\.($GB5USI[Q"'_ARL=%[?+)Z?LT^H;Q1VV!QC?4/W2_V1
MU/U+H36=VIM!:)936\-;4F/PH&M ''@"_P"K.5HFP"U>/>:RX/:"RF;X;"?:
M//[PL+MLO1NFKI*9CG&&CB$0'3>WG9/V87F.?:PS>/,I>57^,Y\8)_36-S^6
M@OD?5/?)49>\\72OXN=[RMFT7H6Z:IG_ .R 040=A]0_( ^ QQ*QFD;)-?[]
M36Z)VZV9P#W9^BS(R1[\%=!:SU)0[/K#2TMOI6F=XW8(& -'# ))^L*/#BBV
M[WGM"SS^9?%->/QXW>?]%QI/9U9-/-8\1"KJAC\[.T..?=GDMLFJXH1Q.3V;
MQ6@:1UY3ZI8^-KGP5<7TX3S^((X%;'URTX^ PM&EJ]/T>'R>>F;W9CD;VO9[
MD\[PB: .A)XE6,DKW_I'%WU\O@53'?YJCE[N2E(AYD<,''?@OCCQX +[*^7+
MQ+6-/,\EY.7J5Y.7*:KP?S*\W]5ZNYKR>N96*+:3JK=ZN).JMWKB5FBWDZJW
M?U5Q)U5N_JN)6:/!_56\BN']5;R+F5BCQ<O)R]2O)RY3U>97ST*J53H5Y*2&
M2TI^L-%CVC]Q4PWFC\]:ZNEZRQEHSW4/:3_6*B_>/W%3<>BN<7]+Y;U[^M7\
M?YES_H_157!JB3\(P%E'1N?ZSVY#B. /S6R5#H99I7^))])VZ&MQ@<5(^H'B
M&V3N ]9V!P^*T&'Q!&[\VPYXC*9O/2X]+B8I:T_=E]F\T,=#4L,KLMD<2'GC
MS*\=17 5E<1%*&QQ\CW6*IXY()9)6$-#^#F XXJK XYWH&GCW7$7F*ZE=_AZ
M^].9YRN+8GO-2,?[16$M5!/?;ZRF<QCX0=YSQQP!Q7K?JF -\!\+@?\ 9[K=
M]F=B\C;G54C<23$D9XD#_H*+'3KOJ?"UGS?PO'G)\SVAN%! VGIHX8VAK&-#
M0 ,<E<'D>&4 P,+Z' +1T^0F9F9F6I2?K/Q'(<?L68R.89D!85I<[4TN #P_
M@LP]SF1R$8!PHJ_,K^6/T_AI=S=&^OD)BW@%9GPASAP?@O:H=.:B1S2WGW7F
M'5&]Q:P_6JLQW;>.-5B/\O,^ >I;[@M9NS(C7DLKI6$CEDK;")L .@8??D+5
M[QNBMQ+1M..O!17F>E=XD_5_X6($C<F&O<_I@N*M*^BJ+C'N23L+6\!Q5V8*
M5S7$TY8[/ @KWN]K;;*6.:H>]D4C=X;JAK6?B%O+.*:].7Y_[^&,ET3/#:YZ
MSS4+60MWR"3QX9[+"6^R55?1NJ8@QL8<0=X]0KRMU)5R4LE)3N+*=XW"7G)(
M^:PT=34"#PF33^$>.[O>J3WQE:U=S74OB.1."F6==X?,D;H)7-);O-ZYY)55
M3998CX88YP$8;[\GC\U\F-P:YSAPZN<,85LV$.K(Y6O)>UP<&#W*YQZ5R;ZM
MZC]E>N.TWBL1Y2[IG:3-;=,STM7")*ZF($8>\@/8>'#KPP5)NAK^=1V".N?&
MV*0N+7,:<@$8_P U UQLUZO=6VIBLY8YS T;NZT%2KL>MEVM-MGIKI3.AC+M
MYF7@C/P'P5>.]=_*/4I$1$0$1$!$1!RMLW_E5:C_ *S6?XUU2N5=F_\ *JU'
M_6:S_B+JI 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MUSM=?2RR5U/+OR >LYAW7N:.AZ%9"W/N57!'*VI@,1Z@>M]ROJ^Y4E%AM3*
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MB("(B B(@(B("(B B(@*SO-7Y&TUM5_X,+Y!\0TG^"O%@=>!QTC=0SGY=_\
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MK$]4KE[&O86O:'-/,$9"UV[:=9('2T0:V3V>2#4HSZT/#W?_ %5U!J"F?CQ
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M8U>=(,]*7B*WE&&AM%7>X5L;[O2^6H8WASP]X)DQQQ@'[U.$,;((61Q@-8P
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ML+I-<:0QCP)'SNE&]D=7<>65NNS:.FBT)8FT.[X/DXCD=3N#/S6QN<&M+G'
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MS:G=\Q(<NP<X]RV);7%K:N*(OY:_&I-,41(B(K"<1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1!;7*AI[E05%'61MEIYV&-[3U!&%R_M!TA5Z1O3VACWVV4Y@E&2!
MDGU3[Q_%=4JRO%JH[Q0R4EPA;+"\$$'I[P>A4&?#&6/W:/IW/MP[[\UGS#CJ
M1I<<XX)PP./%;WK_ &<W'3-5)46]CJNT8W@_>R]G<$?Y96B!X(R.9[C"R+X[
M4G5GV_'Y.+DUZ\<JAI/((6D<PO@EYY!5:TGZ1(7*?:J)ZP. ,A,/]D(]4/(K
MY/T6GH.:^R'$$%J]:6FDK)HZ2%N9ICN-'O2.[F>T3,IGV+TOE]-S.<,":<R
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MNJZL-,;&'U7#.3VPJ&3'&2/W?0<3F6XM^J/'S#GN]4,E0]U0USGS<W;QR2L
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M)Y6238X] M&UW;Y'RP5-+XDW#=(P2<Y4G7BG<RN/ATX+7=<+'NAFX@L#0.7
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MU0%541 1,(@!$1 3HB("(B @1 @*JHG= 3HB("(B B(@!$"("!$0.B(B G1
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M+M0TE=[B**ENL?C$@ /(:"2>A//ZD&U5-QHZ21L=35TT,K^+62R!I/P!*NN
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M1TP,\L(.D@>8X. X9/14!X8&21^T#P4*W.QZAT7LNU,VYWN2ODW&FGE8""P
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M2D ;Y4PY=](D\2?AT4BS6BW2120/HZ?P2 W=$8.0@C?T==1.O>@1!.\&6@Q
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A 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g42675g03b21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03b21.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1@F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    & D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" )I!VP# 2(  A$! Q$!_\0
M'0 ! 0 #  ,! 0            <%!@@" P0!"?_$ %P0  $# @(#" L*# 4"
M!0,% 0 ! @,$!081!Q(A"!,7,4%6D],4%B(V-U%TE++1TA4R87%S=9&2L;,8
M(S,U.%)35%5R@:$T0E>DM&+!)$."PL,EHO!C9(.$X2;_Q  : 0$! 0$! 0$
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MS?:AM[TLB+5,'HS_ $BL>?(N].,NA"]&?Z16//D7>G&70RKEM'  "5@
M
M
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M:!S6UE5%"YW$CURS/HIYXJB))('MD8O$YO$![
M
M                                             8/'?>1B+YNJ/NG&
MA[F'P60>5S?:AOF.^\C$7S=4?=.-#W,/@L@\KF^U"H[91/<P>C/](K'GR+O3
MC+H0O1G^D5CSY%WIQET%7)1P  E8
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MO+/-5WK8F7*!UL"/Z!=*TV.X:NCNT;([C3ZN3F(B)(BHY<^3]7Q<I8
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ME-[<D;G_ $*N1V7!(V:&.5BYL>U'(OC10/,
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MJMSRR5VW9GGR_"!MP/"GFCJ((YH7(^*1J/8Y%S145,T5#S
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MP.ZZRX;I)L001T]QD;KR1,1$1F>U$78FW+X#.@
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M3)=JKF8_!. +-@ZXW:ML\<C)KDY'SJY[G9JBN79FJY;7*!MH
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MY2M@#Y[=21T%OI:.'/>J>)L3,^/)J(B?8?0
M
M                               'S7&AIKC1RTM;"R:GD3)S'IFBD.Q#
MN:[-75LE19[O46M'N5VJD2RY9KXU>A>@!"L*[G"QVJX1U5WN<]V5CM9&K$L2
M*OPY.7,LE;9J6IL4UI:Q(J5\6](UB9(U.3)$,B ))HMT*4. L0376.ZR5TCF
M*R-BP[VC,_AUESY2M@                         #'W6R6V[*Q;C14]2K
M/>K)&CE3C\:?"ID !ZZ>"*GB;%3Q,BB;Q,8U&HGQ(A[
M                                      #!X[[R,1?-U1]TXT/<P^"R
M#RN;[4-\QWWD8B^;JC[IQH>YA\%D'E<WVH5';*)[F#T9_I%8\^1=Z<9="%Z,
MOTBL>?(N].,N@JY*.  $K
M        GND?2!48+N%*E79YIK/,FK+7QR?D5V;58C5<N2:R_P! *$BHO$J*
M#E_1?I<JZ9M;1TL-=?Z^JK$WJ-\K_P 7&KG)GFY%1$VMY4.FZ.1\U+#)-'O4
MCV(YS,\]553:F8'M
M
M
M                                                    /EN5QH[9
M3K/<*F*FA1437E<C4S5<N-?C/J-+TN2VR+!E6MXM\EP@56HV"-BN<KE>F663
M79;<EX@/74:0*:+2#1X<2*%U-4TG925R5":J)^,V999+^3X\^4VVV7*BND"S
M6ZJAJ8D=JJ^)R.3/CRV?&APQ-AS%28KIZ;L"Z-<^#?8*1:]%E;3]WDU'9[$3
M)VS).)=FTZUT*R6V3!D26FV3VV-KD;)!.BZZ/U&YYKJMSV9;<N0#?0
M                              &#QWWD8B^;JC[IQH>YA\%D'E<WVH;Y
MCOO(Q%\W5'W3C0]S#X+(/*YOM0J.V43W,'HS_2*QY\B[TXRZ$+T9_I%8\^1=
MZ<9=!5R4<  )6                                             !.
M])V!KEC.H@A=>YZ*RL8JS4].KFOE7BR547)4R5W&B\91 !RKHCT77&H=6W"R
MW>X66NHZQ&]TKVMGC1SNY<B*W-%U6\N1U+2,DCI863O1\K6(CG)RKEM4]H
M
M   &OZ0;O4V#!%\NU"D:U5%223Q)(F;=9J*J9IFFPV T[3'X*\5_-TWHJ!XZ
M',35V,-'5JOEV; VMJEFUT@:K6=S*]B9(JKR-3E-S)CN9_ KA[XZG_D2%.
M
M
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M>+_RRE'&FZ*L-JP]I6LU)8[?34%*ZD@E=% Q&-5RS2(JY)RY(GT'98
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M BHO$J*3S%]YAK)8_<^I5S43;DBM^T_<&WF&CEG6XU2M8K<FZR*NW/X$.?\
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ML5IDK*&&CACDE;(QJ-<V61RIDYR+Q.1?ZG1X
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M'YRI/N8SKDB%WT07FMTXQXVCK[>VW-JX*C>'*_?=5C&M5/>Y9YM7E MX
M                      '(VEG]*:T^76W[8SKDB&-M$%YOVF2BQ?2U]OCH
M(*FDF=#(K]]5(E;K(F353-=5<MH%O                       !@\=]Y&(
MOFZH^Z<:'N8?!9!Y7-]J&^8[[R,1?-U1]TXT/<P^"R#RN;[4*CME$]S!Z,_T
MBL>?(N].,NA"]&?Z16//D7>G&705<E'  "5@            #Y+O^::[Y!_H
MJ1;<=^#2Z?.\OW,):;O^::[Y!_HJ1;<=^#2Z?.\OW,(%T
M
M                        T_3'X*\5_-TWHJ;@:?IC\%>*_FZ;T5 P&YG\
M"N'OCJ?^1(4\F&YG\"N'OCJ?^1(4\                         ?SKTB^
M$#$_SI5?>N/Z*'\Z](OA Q/\Z57WK@.\-&7@WPI\TTGW+39#6]&7@WPI\TTG
MW+39
M                              ");KOP74WSG%Z$I6\,=[=I\DB]!"2;
MKSP74WSG%]W*5O#'>W:?)(O00#)
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M*T?U6>P!003[W/T@?Q6C^JSV#*8;I,60W!'7RNIIZ35]ZQ&HN?\ 1J ;:
M
M           !IVF/P5XK^;IO14W$T_3'X*\5_-TWHJ!@=S/X%</?'4_\B0IQ
M,=S/X%</?'4_\B0IP                         _G7I%\(&)_G2J^]<?T
M4/YUZ1?"!B?YTJOO7 =X:,O!OA3YII/N6FR&MZ,O!OA/YII/N6FR
M
M              >MD\3Y71,D:LC4S5J+M0\I'MC8KGN1K4XU4#R!^,<U[4<U
M45J\J'Z!$MUYX+J;YSB^[E*WACO;M/DD7H(23==^"ZF^<XONY2MX8[V[3Y)%
MZ" 9(
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MXM,VD*:)DL6BVY/C>U'->V*=4<B\2HN]\0'00(!PQ:1?]*[IT%1U8X8M(O\
MI7=.@J.K OX(!PQ:1?\ 2NZ=#4=6.&+2+_I7=.AJ.K OYJ.E;O'K?E8/OF$N
MX8M(O^E=TZ&HZLQ.)]).D*_6::WR:,+M"V1S':[:>=535>CN+>_@ Z#PUWOV
M[Y!GV&2.=[=I8TB45!3TS=%MU>D3$8CE@J$SR_\ XSZ.&+2+_I7=.@J.K Z
M!S_PQ:1?]*[IT-1U9^\,6D7_ $KNG05'5@7\$ X8=(O^E=TZ&HZL<,6D7_2N
MZ=#4=6!?P<\5VFW'E!235==HRKZ:EA;KR331SL8Q/&JJS)$*!H1TC5&D>SW&
MMJ;=%0NI)TA1L<BO1V;47/:B 4<
M                     /QSD:U7.V(B9J!^@C>)=,M2M?4T&",-W"^U-/*Z
M"5602:K'-<K5VM1?$IC$Q=I<D3?6X88QB]UO;D7/+Q?D\P+N"(6S3+>[94.9
MCK"-QM5,CD:E4V"1S57/+C5J)EGE]):+?5PU]#3U=,[7@G8DC'>-JIF@'O
M      -.TQ^"O%?S=-Z*FXFGZ8_!7BOYNF]%0,!N9_ KA[XZG_D2%/)CN9_
MMA[XZG_D2%.                         '\Z](OA Q/\ .E5]ZX_HH?SK
MTB>$#$_SI5?>N [PT9>#?"GS32?<M-D(-N4,7WG$EIO%!>*IL]+:(J2GHV)$
MUF]LU9&Y9HB*NQC>//B+R
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M^=L+?(3^DPZ2PMWL6CR.'T$.;=V?^=L+?(3^DPZ2PMWL6CR.'T$ R8
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M*Y<XD3)/C0"G;F?P+8>^.I_Y$A3B8[F?P*X>^.I_Y$A3@
M         !Q]NJL'6;#%ZM599Z=\51=GU515N=*Y^N_68N:(J[-KW<1V"<O[
MM'_%X2_DJOMB ^C<5_D\8?'1_P#S'3!S/N+/R>,?CH__ )CI@
M
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M3MJ75+8(DJ')JK*C$UE3Q*O'R)] ?2T[ZAD[X(G3L14;(K$5S47D1>-.)#W
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M?%7D,A,-QIWIX@\N;]VA3]-?@HQ5Y#(3#<:=Z>(/+F_=H!T(
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M#WQU/_(D*>                         .7]VC_B\)?R57VQ'4!R_NT?\
M%X2_DJOMB ^C<6?D\8?'2?\ S'3!_-^Q8CO5@W]+'=Z^W)/J[[V)4/BU\L\M
M;55,\LU^E3LO<SW:X7K1C%5WBNJJZJ6KF:LU3*Z1^2*F29JJKD!50
M
M                 $2W7?@NIOG.+[N4K>&.]NT^21>@A)-UWX+J;YSB^[E*
MWACO;M/DD7H(!D@                                    $,T[]]5%Y
M$W[QY[(_R;?B0]>G?OJHO(F^F\]D?Y-OQ(?GO'>\EPJYEY! #XV  ,
M    &C7<9_X:F_G7["XX![R[+Y*S["'8S_PU-_.OV%QP#WEV7R5GV'K^S/BO
MI\L\ #UG4          &#QWWD8B^;JC[IQH>YA\%D'E4WVH;YCOO(Q%\W5'W
M3C0]S#X+(/*IOM0J.V43W,'HS_2*QY\@[TXRZ$+T9_I%8\^1=Z<9=!5R4<
M)6P>.KA56G!UYK[?&LM734SY(F(F>LY$V(0C#6CK&^,K3%?G:1;E;75BN<M)
M%)*YL63E;ELE1/\ +XC<,?:+\7XBQ3<+C:M(%QM5OJ59O=#'),C(T1C6JB(U
MZ)M5%7BY36:'0;C2W0[Q0Z3J^EBS5V]POF8F:JJJN22<JJJ_U I>BC!-ZP<R
MYMON*:O$"U2QK$M0K_Q.KK9Y:SW<>LG%EQ&_&@Z*,'7_  E'<TQ'BJKQ"M4L
M:PK4/D=O.KK:V6NYW'K)Q9<1OP  *J(BJJY(G* !\KKC1-<J.K*9%38J+*W9
M_<]K*JGDB65D\3HTXWH]%1/Z@>T'S,N%$]R-964[G+Q(DK55?[GT@?)=_P T
MUWR#_14BVX[\&ET^=Y/N82TW?\TUWR#_ $5(MN._!I<_G>3[F$"Z
MY9W9_P"=L+?(3^DPZ3PMWL6CR.'T$.;=V?\ G;"WR$_I,.DL+=[%H\CA]! ,
MF               #2M-?@GQ5Y#(3#<:=Z>(/+F_=H4_37X*,5>0R$PW&G>G
MB#RYOW: ="
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M41"_[E#P2Q>6S_:A"MU5X7:OR6#T2Z[E#P2Q>6S_ &H!8@
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M*T]KN&^3HF>I+!)"J\FS7:F?] -D
M      #XKU<Z:S6NIN%?(D=- W7>Y<]B?T ^T$-LNGQM?>Z.&IPY5TMKJGI&
MRK<]51%\>2-S7B79\!MFE#2A38+J:2@IJ&2YW:J1'1TL3E:J-7--95R5.-$V
M9\H%&!H>BK2-2X]HZE6TDE!7TRY2TLBJKFIR+Q)R*GTF^ 1+==^"ZF^<XO0E
M*WACO;M/DD7H(23==^"ZF^<XO0E*WACO;M/DD7H(!D@
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MTF'2>%N]BT>1P^@AS;NS_P [86^0G])ATEA;O9M'D</H(!DP
M   :5IK\%&*O(9"8;C3O3Q!Y<W[M"GZ:_!1BKR&0F&XT[T\0>7-^[0#H0
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MK^;IO14W T_3'X*\5_-TWHJ!@-S/X%</?'4_\B0IY,=S/X%</?'4_P#(D*<
M                          '%.ZJ\+M7Y+!Z);]RA40IHMA@6:/?EK)U2
M/636Y.3C(GNJHI.%BKDWM^]]BP)K9;/>^,^#<Q>&:R?R5'W#P.X@
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MV'+;AO 78]HJII8)+G&]8GR-<V%=[EV-1$351<U7(V2U8'Q-A5U12X0O%O\
M<J955(;G')(Z'^3>W,1.7D7C/FJM$:=IZVNCN&=?/6-JZJJJ$UM\<UKVIQ(B
M\3TX\^(#5L65=9-I5L43+%+?VT5!O\%&R5C-5R+"J29R=SFBKELV]T>_'3\4
MXBNF':J# M5:*RBN$,BU<M;3KG$CT5S-CD547)-B+R&_8NP$Z[5%IN5KKWT%
MZMK6I'*Q<HY43)=61$365JJUN:(J;$/A?@>_8@O5OJ\;7.@FIK?*V>"FMT;X
MV.D:Y%19$D5^?%R9<:@46F5[J:)94RD5B*Y/$N6T]A^-1&M1K4R1$R1$/T
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M=6X8[V[3Y)%Z"$DW7?@NIOG.+[N4K>&.]NT^21>@@&2
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MHQ5Y#(3#<:=Z>(/+F_=H!T(
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M>BIN)I^F/P5XK^;IO14# ;F?P*X>^.I_Y$A3R8;F?P*X>^.I_P"1(4\
M                      )1NH? Y=OEJ?[UISIN8O#-9/DZC[AYT7NH? Y=
MOEJ?[UISIN8O#-9/DZC[AX'<0
M                                   >%1*V""25_O8VJY?B1,P/,&N8
M4QG9L54*SV6KCG>C<W1(N;F+EQ+\)SIC#%=UK<67]]1C=ME6AJY88:'?'-54
M8NQ<LEX\\N/D ZN!I^B*\5U^P#:J^Z=U4R1)G)^TV)W7]S<         (ENN
M_!=3?.<7W<I6\,=[=I\DB]!"2;KOP74WSG%]W*5O#'>W:?)(O00#)
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M=&V19EXG:S&.\?\ U^(W0Y?O.%KCBG=$XNI[5=76V2.*)ZR-XU3>8MG$IM/
MWBOGI-_;V +N#1=%V#KKA)ER;=[T^Z+4K&L:NR_%ZNMG_E3CUD^@WH
M  #Y+O\ FFN^0?Z*D6W'?@TNGSO)]S"6F[_FFN^0?Z*D6W'?@TNGSO)]S"!=
M        <L[L_P#.V%OD)_28=)X6[V+1Y'#Z"'-F[/\ SMA;Y"?TF'2>%N]B
MT>1P^@@&3               !I6FOP3XJ\AD)AN-.]/$'ES?NT*?IK\$^*O(
M9"8;C3O3Q!Y<W[M .A
M            _'N1C'.7B:F:GZ%1%147B4"6XCQ[@:]4%SAO:15=+:ZAC)V2
M*W)LFNJ-Y?&U3YZ+33@2AIVP4E0V*)NQ&M<W).3]8SND*JP_@RPU%SKK,ZII
MI96[^R!J*YRZVQ=KD3C55XS7\*8NT8XDWME(VG@J7HF5/.U4?Q9\BJG]P-UP
M3CFS8R2H6R3[ZD&6OM1<L_B4V@^"TVJWVYCG6VFCA;(B*JLSVGW@  !%]U?=
M.P-'#*9%7_QM0V%?Z(KO_::;HTO>B2\7*DMB8:;2W!$5&U%4C41[O@R>O)\'
M(;]NB+Y36&RT%5<</T]XI%FU?QSG(D;LG;=BI_\ BDKT\X@L&._<.@P4YE9=
M7R-V1)DJ-1)<VK\.U%_J!GL5T%/C;=$P6>[HLMMH*=/Q"^]>B.78OP=VIY82
MH(,#;HNIM5K1(;;74VK' WWK,W1\7U5^D].(JZGP/N@Z:[7URPT%;2M3?N-(
M\UXU^#N%\9[L*U]/CO=%SW6T.2:VT%-K,GY'Y.CXOK*!T@:?IC\%>*_FZ;T5
M,+I3T2T6D&ZT==67:MH74T.\HRG1JHY-95S7/EVDMQUN?;9A_!UYN\.(+G/)
M14LD[8I&MU7JU%7)?@ INYG\"N'OCJ?^1(4\F&YG\"N'OCJ?^1(4\
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MKIRAME-<J.IF=#3U,<DK>-K5VH?62FR7=+==)*M8U<C\]B?#F;%V\,_=G?\
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M#'>W:?)(O00DFZ[\%U-\YQ?=RE;PQWMVGR2+T$ R0
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M3F,DRC1&O5S&N3)R.1R['(G$3>OP'>\7M8["^"$PTQ7(Y*J2JG_&)\2YHG]
M.O45%1%1<T7:"6:!<"XAP3;KG%B6X0U;JE8EA;%*Z1(]77SVN1%VZR?05,
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MFOP48J\AD)AN-.]/$'ES?NT Z$
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MT;EREA &LZ.L+-PAAJ*V[]O\RN6:>7]>5R)K+_54-F
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M3?SK]A<< ]YEE\E9]A#L:?X6F_G7["XX![R[+Y*S[#V/9GQ7T^6> !ZSJ
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M/+F_=H!T(
M    #2M+='8*["SH<5UK*.W*]N<CGJQ,\TR3-')R_"16'#>B*%JI#B:"-/$R
MJ<G_ ,IT/BBR6B_6U:2_P,GH]9':KWJQ,T79M14-(K]%.CF6CF:ZVTS$U5[I
M*J1-79Q^_ \]#-#A2B9<.U&ZMN".U=]RF635\7&]Q3"%[F5E#13XMME"QKTH
M[A)''4M7-)(D=JL3^V>>:\9=         !I^F/P5XK^;IO14W T_3'X*\5_-
MTWHJ!@=S/X%L/?'4_P#(D*<3#<S^!7#WQU/_ ")"G@
M         .+-U?X6IO(H?L<=ID:TJ:#8L?8K?>WW]]"KH60[RE(DGO<]N>NG
MC\0$0T5:;ZC &%O<6&QPUS=_?/OKJE8U[K+9EJKXCKO!=Z=B/"=HO+X$IW5U
M,RH6)':R,UDSRSY3^?6+[.F'\4W>SMG6H2@JI*9)5;JZ^HY6YY9KEGEQ9G=V
MASP684^;H?10#<
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M63N%9(JID]RIQM0Z,PQWMVGR2+T$))NN_!=3?.<7W<I6\,=[=I\DB]! ,D
M         !ZZB>*FA=-42,BB9M<]ZY(G]0/8#7>WC"W.*T^=L]8[>,+<XK3Y
MVSU@;$#7>WC"W.*T^=L]8[>,+<XK3YVSU@;$#7>WC"W.*T^=L]8[>,+<XK3Y
MVSU@;$#7>WC"W.*T^=L]9EK7=:"[0+-:ZVGK(D7)7P2(]/I0#[
M   $,T[]]5%Y$WTWGLC_ ";?B0]>G?OIHO(F_>//9'^3;\2'Y_QWO)<)YEY
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M8=)X5[V+1Y'#Z"'-F[/_ #MA;Y"?TF'2>%N]BT>1P^@@&3
M !I6FOP3XJ\AD)AN-.]/$'ES?NT*?IK\%&*O(9"8;C3O3Q!Y<W[M .A
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MS^!7#WQU/_(D*>3'<S^!7#WQU/\ R)"G
M  '\]M+?A0Q9\Z5'WCCMG0YX+,*?-T/HH<3:6_"ABSYTJ/O'';.ASP5X4^;H
M?10#<
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MF3E\9T0 )=H+P?<\.TMYNM]C9#<KU*V:6!F64>JZ3+BV;4>G(A40
M /DN_P"::[Y!_HJ1;<=^#2Z?.\GW,):;O^::[Y!_HJ1;<=^#2Z?.\GW,(%T
M      !RSNS_ ,[86^0G])ATGA;O9M'D</H(<V;L_P#.V%OD)_28=)X6[V+1
MY'#Z" 9,               &E::_!/BKR&0F&XT[T\0>7-^[0I^FOP3XJ\AD
M)AN-.]/$'ES?NT Z$
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M,!N9_ KA[XZG_D2%/)CN9_ KA[XZG_D2%.
M    /Y[:6_"ABSYTJ/O''0^Y/QE>+_27&SW*:)]#:*:GCI6MC1JM3NDVJG'L
M:G&:1NK,%VC#MQMUWMD<S:R\5-3-5J^17(KLV+L3DVO4RNXO_.>*OD:?TI .
MI
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M
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M._?51>1-]-Y[(_R;?B0]>G?OIHO(F^F\]D?Y-OQ(?GO'>\EPGF7D #XV
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M7T(=>EXNGJU8Q#8KO-E* !]2P
M  -/TQ^"O%?S=-Z*FX&G:8_!7BOYNF]%0,#N9_ KA[XZG_D2%/)AN9_ KA[X
MZG_D2%/                              .:MVC_A,)?SU7V1'P;B_P#.
M>*OD:?TI#(;M'_!X2^4JOLB,?N+_ ,YXJ^1I_2>!U(
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MF'P60>5S?:A4=LHGN8/1G^D5CSY%WIQET(7HS_2*QY\B[TXRZ"KDHX  2L
M           ?)=_S37?(/]%2+;COP:73YWD^YA+3=_S37?(/]%2+;COP:73Y
MWE^YA N@       .6=V?^=L+?(3^DPZ3PKWL6CR.'T$.;-V?^=L+?(3^DPZ3
MPMWLVCR.'T$ R8               -*TU^"C%7D,A,-QIWIX@\N;]VA3]-?@
MGQ5Y#(3#<:=Z>(/+F_=H!T(       #1],O>-4_*Q^D3+"GYG9_.[[2FZ9>\
M6I^5C](F6%/S.S^9WVGC>TNYQKY9@ 'EI  8  -       !@^6Z?FRK^1?\
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M=I-H+9CQN&KM ^D=*S7@J'JFK)W2ILR7_I4#?P./B
M  ?/6UM-0QI)5S-B8JY(KC3<6:2;9A;%E!9;M!+%'61H]M8JIO;<U<F2\O\
ME\0&] _&JCDS:J*GC0_0
M           B6Z[\%U-\YQ?=RE;PQWMVGR2+T$))NN_!=3?.<7W<I6\,=[=I
M\DB]! ,D       #D; OZ7=5\YW#[J8ZY.1L"_I=U7SG</NICKD
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M28=)86[V;1Y'#Z"'-F[/_.V%OD)_28=)X6[V;1Y'#Z" 9,
M &E::_!1BKR&0F&XT[T\0>7-^[0I^FOP3XJ\AD)AN-.]/$'ES?NT Z$
M  !H^F7O&J?E8_2)EA3\T,_G=]I3M,O>-4_*Q^D3+"GYG9_.[[3Q?:7<XU\L
MN #S$@    P        ?+=/S95_(O^Q3/: /\/>_YX?L>8&Z?FRK^1?]BF>T
M ?X>]_SP_8\]#V=[R/WX*I[E9 ![SL
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M%_$HY$5<]B=UFKD7C0L5OHZ>WT<-)11-AIXFHQD;>)J)R >\
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MMF>WQ@;KH[PW4X5PY%:JFO?6I$J[V]R)FUJKGEL1.55-F/QJ(U,FIDA^@
M                                               !$MUWX+J;YSB^
M[E*WACO;M/DD7H(23=>>"ZF^<XONY2MX8[V[3Y)%Z" 9(       '(V!?TNZ
MKYSN'W4QUR<C8%_2[JOG.X?=3'7(                '-&[3_(80_FJ_P#X
M2ZZ-_!YA;YJI?N6D*W:7Y#"'\U7_ /"771OX/,+?-5+]RT#8@       0S3O
MWU47D3?3>>R/\FWXD/7IW[ZJ+R)OIO/9'^3;\2'Y_P =[R7">9>2  ^)@ $,
M       !H  P:[C/_"T_\Z_87' />99?)6?80[&?^%IOYU^PN. >\RR^2L^P
M]CV9\5]/EG@ >LZ@          P>.^\C$7S=4?=.-#W,/@L@\KF^U#?,=]Y&
M(OFZH^Z<:'N8?!9!Y5-]J%1VRB>Y@]&?Z16//D7>G&70A>C+](K'GR+O3C+H
M*N2C@ !*P        Q&+,0T&%[%57:ZR:E+3M179*F:YJB(B9JB9JJHG'RF7
M(QNEY)O<NP0(QSJ6:L8D^S9DDT.68&2P+IOP_BR_16F.EKZ&HG36@6K:QB/3
M5<[D>J\32JG/FF.EHZ+$&C)] R.*3?9&+J<>JC69?:I2-*N*L1X7IK=)A;#4
MU^DG>]LS(F/=O2(B9*NJB\>:\?B W"[_ )IKOD'^BI%MQWX-+I\[R_<PF/JM
M*FDRHI9H':,*YJ2,5BJD,^S-,OU34-%%]TB:.\/5-IH]'MSK8YJIU4LDM-,U
M456,;EDC?^A/I ZS! .%O29_I?6]#/[(X6M)G^E];T,_L@7\$ X6M)G^E];T
M,_LCA;TF?Z7UO0S^R!?P0#A:TF?Z7UO0S^R?G"WI,_TOK>AG]D#6=V?^=L+?
M(3^DPZ3PMWLVCR.'T$.2=+CM(&DBJMLU9@*ZT*T3'L:D5+*[6UE1=N;?@*#;
M=*&DNAMU+2-T8USVT\3(D<L,^:HU$3/WOP =$ @'"UI,_P!+ZWH9_9'"UI,_
MTOK>AG]D"_@Y_P"%O29_I?6]#/[)^\+6DS_2^MZ&?V0+^" <+>DS_2^MZ&?V
M3X[MINQ]9Z"6NNNCN:CHXLM>>=LS&-S5$3-5;EM543^H'18.>:'3-I$KZ.&K
MHM&U344LS$DBECCF<U[5XE14;M0]_"WI,_TOK>AG]D"_@@'"WI,_TOK>AG]D
M<+6DS_2^MZ&?V0+^" <+>DS_ $OK>AG]D<+>DS_2^MZ&?V0*5IK\$^*O(9"8
M;C3O3Q!Y<W[M#&8PQ]I(Q+ABYV6;1K<((ZZ%T+I&03*K47E1%::YHENND/1S
M:ZZBH]'USK6U4R3*Z6FF:K51N66QOP == @'"UI,_P!+ZWH9_9'"UI,_TOK>
MAG]D"_@@'"WI,_TOK>AG]D<+>DS_ $OK>AG]D"_@Y_X6])G^E];T,_LG[PMZ
M3/\ 2^MZ&?V0*1IE[QJGY6/TB8X4_-#/YW?:8S%N/=)&([+);IM&MP@8]S7:
M[()E5,ES_5-=METTA4%(D#='UT>B*JYK33)Q_P#I/-\;X;J=6J]$.=5,S*F@
MGG;#I$_T\N7FTWLCMATB?Z>7+S:;V3X/3^OK\LPE0P3SMATB?Z>7/S:;V1VP
MZ1/]/+GYM-[(_@=?7Y9A*A@GG;!I$_T\N7FTWLGS7+&&.;70S5MRP+6TM)"F
M<DTT,K&,3/+-55,DVC^!U]?DPE3 3.VXOQS<Z&*MMV!:VJI)DUHYH897L>GC
M143)3Z>V'2)_IY<_-IO9'\#KZ_+<)4,$\[8=(G^GER\VF]D=L&D3_3RY>;3>
MR/3^OK\LPE0P3SMATB?Z=W+S:;V1VPZ1/]/+EYM-[(]/Z^OR82WJZ?FRK^1?
M]BF=T ?X>]_S0_8\DE3?-(<]/+$NCVYHDC%;FE--LS3+]4^W ^*](V$XZQL&
MCFXU"5*L5=>GF35U<_$WX3[/!^%ZG2KO5#::9B;NIP0#A;TF?Z7UO0S^R?G"
MWI,_TOK>AG]D]5U=  @'"UI,_P!+ZWH9_9'"WI,_TOK>AG]D"_@@'"WI,_TO
MK>AG]D<+6DS_ $OK>AG]D"_@@'"UI,_TOK>AG]DM6%*^MNF'+=776B=05U1"
MV2:E<BHL3E3:U47;L^$#*@                         #4L=:0;!@ID?N
MS5(D[T1S:=CF[XK5S[K)539FU4/KP5C*SXQMZU=EJ4D:U5:^-7-5[%^%$5<N
M-/I(E:X(<1[J&^T]WB;40V^!=X:_B;DL?MN^D\\%0,PYNFK[0T2;U15-*J,A
M9Q-S6'Q_$H'1AI^F/P5XK^;IO14RU]Q78+!/'!?+U;[?-(W78RIJ&QJYN>6:
M(J\69H>E7'V$J_1OB6DH<2V>HJIJ"5D<456QSGN5JY(B(NU0/HW,_@5P]\=3
M_P B0P&Z)Q+<YJ/M2PO#+5U]=&K*EE.FN]C%3)6JG)FCO$:_HQQU;K-H*LUL
MH[_9Z.^.?-"K*JJ:QU.CYY5214VJF2*U=J<2F]X'O^ \.6Y=]Q=8JFYSKOE5
M4NK8\Y'JJKX]B)GDF2(!+,#;FZJE=;Z[$=;$R%=262E9K:V6Q=1R*U,O$NTZ
M;M5OIK70PT=%$V*")J-:UOP&N\)."N=EC\]C]8X2<%<[+'Y['ZP-L!J?"3@K
MG98_/8_6.$G!7.RQ^>Q^L#;#T5U3'144]3,Y&QQ,5[E5<DV(:UPDX)YV6/SV
M/UDXN^,;#C3$$E/<<66B@PW1R*UT#JMB.K%1RY+_ "YM8J*CMNW/X0EN(K%B
MC37CNIJJ&GBI:&%%AIZB?72)T2.>YKM9K7<:*GTH5[0WH2I\%SK<+W+!771%
M_%K&JJR+9DJIFB+GM7C3BR-UI-(& Z2!D--B>P11,:C6M;61[$38B<9[N$G!
M7.RQ^>Q^L#; :GPDX*YV6/SV/UCA)P5SLL?GL?K VP&I\)."N=EC\]C]8X2<
M$\[+'Y['ZP-L!J?"3@KG98_/8_6.$G!7.RQ^>Q^L#; :GPDX*YV6/SV/UCA)
MP5SLL?GL?K VP&I\)."N=EC\]C]8X2<%<[+'Y['ZP-L!J?"3@KG98_/8_6.$
MG!7.RQ^>Q^L#; :GPDX*YV6/SV/UCA)P5SLL?GL?K R^+>]6\^13>@X_GAAK
MOBM?E47IH=S8FTB8-GPW=HH<4V6262DE:QC:R-5<JL5$1$SXSA*UU"TMSHZC
M)%WJ9DFU<DV.1=H'?.EC%:83P?654*-EKY&ZE- J[9'*Y$7).7)'*O\ 0YAP
MKH,Q;C.-]YK):6WLGF5SFU:R,E?FB.UFHC%1476\?(I8L'7_  M771<38OQ9
M8);C)W5+3+6LRI(US5&JBY=TFNJ+FB\7&4%NDC!#41&XKL2(G(E;'ZP&C? M
MMP-9&4-O8CI79.FF5-LCLD157ZJ&VFI\)."N=EC\]C]8X2<%<[+'Y['ZP-L!
MJ?"3@KG98_/8_6.$G!7.RQ^>Q^L#; :GPDX*YV6/SV/UCA)P5SLL?GL?K VP
M&I\)."N=EC\]C]8X2<%<[+'Y['ZP-L!J?"3@KG98_/8_6.$G!7.RQ^>Q^L#;
M :GPDX*YV6/SV/UCA)P5SLL?GL?K VP&I\)."N=EC\]C]8X2<%<[+'Y['ZP-
ML!J?"3@KG98_/8_6>NHTFX*AIY9$Q399%8U7(QE9&JNR3B1,^,#*8UQ!!AC#
M=;=:E4U8&9HW-.Z551$3C\:H<B6W1WBS2S>KGB&.&FH&5,ZN<M5OC6JN29HU
M4:N?&A8;+BO#&+[ZW$&*<26BFHZ=RI0VV:K8US$R7NWIFG=+K999JG<E(CTB
MX'C;JQXJL+&^)M9&B?:!A]#NC"CP!:G)(YE5=)ESEJ$S5$39W+<T39LSXN52
MC&I\)."N=EC\]C]8X2<$\[+'Y['ZP-L!J?"3@KG98_/8_6.$G!7.RQ^>Q^L#
M; :GPDX*YV6/SV/UCA)P3SLL?GL?K VP&I\)."N=EC\]C]8X2<%<[+'Y['ZP
M-L!J?"3@KG98_/8_6.$G!7.RQ^>Q^L#; :GPDX*YV6/SV/UCA)P3SLL?GL?K
M VP&I\)."N=EC\]C]8X2<$\[+'Y['ZP-L!J?"3@KG98_/8_6.$G!7.RQ^>Q^
ML#; :[:\<86NM?%16S$5IJZR552.&&J8][\D55R1%S78BJ;$
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M-F]@T7@EP3_!/]U/[8X)<$_P3_=3^V?8MO0-%X)<$_P3_=3^V."7!/\ !/\
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M%%KN=JIFJ\;E55VJO&I]X
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MY+ER^,VW1AB*]P:4KGA?&$=#5WEM*E0VO@ACC=J9(NJNHU%78YO&NS("V
M                                     'P7B\6ZS4JU%UKJ:CAXD=/*
MV-%7Q)FJ;=A]YSCI,I6XTT]VW#=TDE6TTC&.? CE1LJ+J*J;%3)>[7;M4"^6
M2^VN^0+-::^EJV(N3MYF:_5^/)5R,D<V62VQZ/-T,RU6=\D%EKXV,CI=\5S4
M56QHJKFJYKFKE_J=)@            /QSD:U7.5$1.50,=?;[;;#3,GN];3T
MD3W:C732-8CERSR3-4\1]U/-'40LFA>CXWIFUR+FBG&>Z&Q?5XPK^R*/6[7J
M*H6DB>CLVR2Y*[639^J[QJ=;8*[U;;\E_P!U S0            #'7J]VRR0
M)+=J^EHV.][O\S8];BXM94SXT/&R7ZU7R)TEHN-)6(WWV\3->K?CR5<CGW3G
M1,JM-%@9BATG:K)!EDKU:Q'HURKMS3+;J<IZ=&5#'3:>7MP.Z7M59K]F:KE=
M&KM25&HBYJB[=7E Z;            ^>XRRPT-1+ S7E8Q58WQKX@/FO-[MU
MFCB?<ZR"F;([59OLC6:R^),U3,^M:J!*3LITT;:?4WQ9'.1&HW+///BRRY3D
M/3)38ODO%GN>+*I$IZBJ<E+2,RRC:CFIMR1.1&KM3E+WCC#EWQ3HLH;78JSL
M2HEIH=9^>6LW43-O&G'F!L]'C3#E9<$H:6]VV6I5VJUC*J-5<O%DB([:IL!R
MQI=P#8\!8$LL]LUXL6I)'JR1S/5\DF;==436V[53DY3HG $E7-@BPRW#66J?
M0P.D5WOE58VYY_"!G@          ,79\06N\RS1VNNIZI\.QZ0RM?J_'DJ^-
M#3=*S,8W">CM6#I6TD,[<ZFK=DNHF:IDB*G'Q+L5"6;CM7++?E>Y7.S7-5Y?
M> ="WO$%IL<;77>XTE&CO>I/,UBN^+-4SXCWVFZT%WIDJ+764]7#^O!*UZ)_
M5%4Y0O\ B'#UUTJ7ZHT@K65MKIOQ=%10ZW<R=PJ+W*ILRUTXN4KFY[H<.PTE
MQJL*72:>DF<F=)*U6K!_17N\7B3C L           *N29KQ&OUN-,-T5=V'4
MWRVQU*+JK&ZJC16KXE17;%/OQ'2U5;8JZFM\N\U4T3F,D_55=F9S_6:(;/AC
M1K>KCC.;LJ](]9&UBS.1R9N9JI[[:N>>WX0.C.R8.QNR-^B['U=;?==-7+QY
M\61A;=C+#MQK^PJ&]VV>H_RLCJHW*[XLG;3G"&^WN#<W1Q5M1.V2MKDIH9=9
M=9(<HU3)>/C1W*>>/-'-NPCHVL&(+$LD%V@E8ZHJFR/19&KFBY)K*C=JIQ =
M5@Q6%;DMXP_0W!=JSLUO[JAE0
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MS]D)&LL21[[J9Y;<\\L_^YB-'6"DPA@Q+!+6-KV]UG*L.HBYHB>]S7Q>,W$
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MK5RQN8Y&^+:YVSB^@HX
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M;,LMF61/.!# O\)_^]2@6FWT]JMU/0T3-2FIV)'&W/B:B9)]@'U@
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M:ZT89M] ],G01ZJI_53,
M
M      8/'?>1B+YNJ/NG&A[F'P60>5S?:AOF.^\C$7S=4?=.-#W,/@L@\KF^
MU"H[91/<P>C/](K'GR+O3C+H0O1E^D5CSY%WIQET%7)1P  E8
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MZ5MMVO5OMS,.UD;JRHCIT>M0U4:KW(W/++X2^@
M                                                     !ZZB>&F
MB62HECBC3C>]R-1/ZJ?L,T4T220R,DC5,T<QR*B_U \P?-!<*.>58H*NGEE;
MQL9(URI_1%/VHK:6F>UE34P0O=[ULDB-5?BS ^@     !\]-74E4YS::J@F<
MWWR1R(Y4^/(^@
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MEJ8JBFPQ9XIXGI)'(RD8CFN1<T5%RV*BFU
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M<E7^H%*
M
M                              !@\=]Y&(OFZH^Z<:'N8?!9!Y7-]J&^
M8[[R,1?-U1]TXT/<P^"R#RN;[4*CME'^3!Z,_P!(K'GR+O3C+H0O1G^D5CSY
M%WIQET%7)1P  E8                             UBZ8YL5LQ+36&LJ]
M2Y5#FMCBU'+FKLLMN67*ALYROITN4EHTXVFMIZ=U3/%)"L4*?YWY,U4_JN1F
M;YI:TB88N%%7XDP_04EDJI$U<V.UDCS3E25>Z1')R99@6[&6,+/@^CBJK]5=
MCPRN5K7:JNS5,O$B^-#4&Z=L!*J(MY1$\>]2>R:-NG+C!>M'6%KDS-M-6ZM0
MF7&C7I&[[%)_1VK1$N&('U5VK_=/L9JR,8]J+ONKM1,X_&!UA9L46>]65]UM
M=='4T+&+(Z1J*F2(F:[%3/B,?@O'M@QD^=M@K.R5A3-_<.;DFSQHGC.<]SA)
M(DN-X:%TSK.VWRK%ON2KQ+DN:9)GQ9F7W'/^)O'R7_N:!T\:8[27A=F+'X;D
MN3679LJPK$K'>^1,\L\LN+X3<SA/2U#72::L2OMC'/J(JQ9$U>-,D0#MG$E]
MH,.VF>Y7:;>:2%,WOR5<D_H?F&K]08DM$-SM,V_4<V>H_)4SR7+E(1?<<=O.
MYXN=;4.C]T(6K#4M8BHFNBM78BJJ\3DY3?=S=X);-\3_ $U VK&F-;+@VG@G
MO]5V-%,[48[4<[-<E7+8B^)3+276DCM#[F^9$HV,61TG(C4XU_L2_=06-MVT
M<R3JCM:WR+4YI\#')M^DT6XXX5-S#2NJGM6KK]^H'Y9\;EF5/[-0"TX.TBX;
MQA<)Z*PUZ5%1#&LKVZCFY-1415VHG*Y#Z,1XZL.'KU06JZ5B15U:Y&PQHQRJ
MY55$3B3+C5#F#15256CC2A8FU:JJ7F)*7;R-=+'[)N-]C[;MT]!3M5'T]H['
MJF*WE1-Y5<_ZJ!;[1CBR7;$DUBHJI7W**+?GQZCDR;LVYJF7^9!8L<V*^7VJ
ML]NJ]]KZ9%62/4<F62Y<:ID3'1]B22LT\W>TK;K?"R*A<]*B-CTE7;'L55<J
M9;?%R&OZ#_#AB7Y-_I =*&K8CQY8,/7FBM=UK-YK*N1(X6:CEUG+JHB;$_ZD
M^DDN(M,.*KQC2IL&CNT4E:E+(K)9)FN5=F2*NQ[4R1=8F>/,1WB^:4<+P8EM
MK;?=J.OA;,QFQCM9\62IW2\C<^/E ZSQ%BRRX>EIHKO7,IY:F1(HF*URJYRJ
MB(FQ%\:?29PXYT^5&(W:3Z'LVFA:L=6GN?DB]WW3-7/NOY?%QE&Q%I'QQ@^X
MX?3$E);VT]QDWI[&1O1S53515SUU3+-P'0 )UIJQU/@W!:7"T)3RU]0]C:9)
MD56N17-SV(J+Q+XS3-).DW$V$M'V$+ND5$MPNB(^I8]CU:W.-KLFY.\:KQJH
M%X!S=7Z4]*#;'%B.DPW0-LBHUR.DC<JJQV2-<N4O+K)R%)L>E2WW#1=48PE8
MC&4OXN:).27N4U?I>@%(!S8W2OI.K+4_$EOP[;5L3%S368Y55FS:OXWCV^(M
M.C/&--CC"T-WI6;VJN6.6/\ 4>B(N7T.0#:N)#4'Z1L.-==M6NUV6N-9*I[6
M.5&(FK\&WW[>(^K25?G8:P/=[M&W6DIH=9K?&N:)_P!R1[GO",5=HAN:5*+(
M^[O=FJ_JY-3+Z6 6?"6)[7BNUI<+)4)44JN5NMJJFW^I@ETI843$\>'_ '2:
MMS?*R%L>H[:YR(J)GEERH1G<O8J99\)XB@K'IJTJNJT1V>:-1K$7^F:DBH[=
M<*2S,Q[(][W17)D<:N_S['+G_P#9D!V_B[%%JPE:?=*^5*4])OB1H]6J[-RY
MY)DB+XE->O.EG"=FAHY;C<=Y95M<^+.-ZZR(N2\2$HW2=Z6^6W#%BHGM5US5
MDC?YD<K?M4I6(-$6'L54=K==^RVOI8$C:D+VHFU$SXVKRH!\_#O@/^,)T3_9
M/NH=,6#:V!T\%S186S1P.?O;T1'OSU4XN7)3G'"^CNS7#3-689J'U7N=%%KM
M5'-U\\V<NKE_F7D*_C;0[8;#HRQ'#:.RW)J=G/65[55%ACD5.)J;.Z4"WP2L
MG@CFA<CHY&HYKDY47:AYDPW.N(YL1:.:1]5J[_3.6#N?U6[&_P!D*>
M
M          E]PT-62NQXW$\DU4E1OKI71(]NHYRJY5S35S_S>/D*@ ,'C7#=
M)BS#=;9J]TC(*EFJKXU1'-VHN:*J+XO$8;1;H]M^CZUU5%;99YDJ)EF<^9R.
M<G<M3+8U-G<FZ@":X^T.X?Q?=&W.5U717!-JRTKVLUUV[5S:NW:??HWT7V+
M;YY[6E1-6SMU)*BH<US]7-%U45&ILS1%-[ $KQMH2P[B6\NN[):V@KWKG(ZF
MD:QK_A7-BKGL0V31WH\LF Z26*S,F?++^4GG<USW?U1$^SD-P &@:.]&-NP3
M<KE5T514S.KE57MF>CD3-<]F34/9@[1O083Q5<KO::FICBK]LM*KTWK6V=TB
M(U%SX^7E4WL
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M_+6?&URY>-4/<8K"MP@N=@HJFF7.-8FHBY9<2(94
M  P>.^\C$7S=4?=.-#W,/@L@\KF^U#?,=]Y&(OFZH^Z<:'N8?!9!Y7-]J%1V
MRB>Y@]&?Z16//D7>G&70A>C+](K'GR+O3C+H*N2C@ !*P
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MP
M
M
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MII*>5US>]&O3)5;O429_V4"I6K#=OMV%J7#[&.EM]/$V%K9%VJU%S3/+(^3
MF#Z#!=JDMUIEJ'4KI5E1LJHNJJHU-F2)^JAL@ U:BP/:Z3&U7BB)T_NC4Q;T
M]%5-3+-%V)EGR)RFPW&DCKZ*:EF54CE;JNRXSZ !IT&CVTPX8H["R2I[!II^
MR&]TW6<O=;%V<7=J??B?"%OQ%3V^&O=,C**9DT6HJ)W345$SS3X5-B &N8QP
M=:L6V!+1=XWOIFJU6JU<G-5$5$5/I,C9[/#:[%#:HI998(H]Z:Z14UM7^B(A
MD@!KF#<'V[";;@EL=,O9LRSR;XJ+W2JJ[,D3]93W8MPO0XHI(*>XK*D<,S)V
M[VJ(NLQR.3C1>5#.@#P@B;#!'$S/58U&IGXD3(\P
M  #!X[[R,1?-U1]TXT/<P^"R#RN;[4-\QWWD8B^;JC[IQH>YA\%D'E<WVH5'
M;*)[F#T9_I%8\^1=Z<9="%Z,_P!(K'GR+O3C+H*N2C@ !*P
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M /QC48QK&)DUJ9(GP'Z
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M=-&/ZJ_VRGJ,12OAFJHHWM['A3-JO1%3WGB.WCU)30(N:0Q(O\J'M
M                                                    !D  &0
M#)/$@ #)/$@R  #B                                       ,'COO
M(Q%\W5'W3C0]S#X+(/*YOM0WS'?>1B+YNJ/NG&A[F'P60>5S?:A4=LHGN8/1
MG^D5CSY%WIQET(7HS_2*QY\B[TXRZ"KDHX  2L
M                     F&Z.\&-P_\ 5]V\IYJFDW"TF,,*U%IBG; Z7/NU
M3/+-JI_W Y0? MHT78!Q=$W.6@KWPIER_CII/B_R&R8/J'XQI])^,9F*B^X4
MU)DO(JPIXMG_ )96J;1&J:(X\'U-6Q\L3Y)(Y\MB.<LF2_TWP^G!>BOM<T9W
MS#253'U5TIYH7SHFS-S7M1?Z(X"-81FJX-S?=EHM;-TDC),DS_%JV;6*[N;Z
M.V+HKI5A9$_?'R[\J[5]\O'_ ',IHVT:QX9P/78<NDS:R"K:^.16YIFUVLB_
M%L<:2[0/<K8^KI\-8GEI;;5YI)"YFUJ+GL15S\:^(#5=#C6P:3L=16[_  &]
M3ZVHNLW6R?EM^/,S>Y-5$Q#I#15VK4P9)_ZZ@I^B_1E:\!VNK@IY'U576HB5
M51)FBR9:V6S-438]4V<9H=5H)K:/$]=<L-XA?00UKW.D9O>:HCE553;GGQJ!
MKD<D<NZLF=&]KVI$K55JY[49DJ&5QKHYO,6D&IQ-H^O%M[/<]SIJ:9=\>BKG
MK(C=1_C=XLC,X.T(R8:Q]#?V71:F-C%1Z2(NL]RIW3OZKFN1]^-M#TURQ++?
M\.WN>VUTBJY\:HKV*J\:[57QKR :U@;'JMTBLL^-L.=@W]6KJ54:*S7[EW=*
MU=5$1<MBHFW,T.6IQ"NZ"OTEGIZ>HN<=54,IV3HN6]YR)L1&KGW.?(5O!6A9
M;=BQ,18DN[[G7M1=5J-U41514XT5/'XC[M(^B&'$E^9?[-<'VR\-3)TC45R/
M3;Q[<DXUY );58?QG<-)UNOUTBMU)<(6:FHQ7M56ZKTSRWM$_P RG5)(\!Z(
MY[1BIF(L0WJ:Y5\:.2-B(K6-S:J*N2*B+L<O(5P
M
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M4V*J9?0H%P
M
M                    &#QWWD8B^;JC[IQH>YA\%D'E4WVH;YCOO(Q%\W5'
MW3C0]S#X+(/*YOM0J.V43W,'HS_2*QY\B[TXRZ$+T9?I%8\^1=Z<9=!5R4<
M )6
M
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MH:.-<VM<]7JFQ$XUV\B&7
M
M                                 8/'?>1B+YNJ/NG&A[F'P60>5S?:
MAOF.^\C$7S=4?=.-#W,/@L@\KF^U"H[91/<P>C/](K'GR+O3B+H0O1G^D5CS
MY%WIQET%7)1P  E8
M
M                                          !ZIJ:"=S5G@BD5O$KV
M(N7TGM '@^*-\6]OC8Z/BU53-/H/&&G@A8K(88XV+QM:U$13V@#U04T%/GV/
M!%%GQZC$;G]![0 /7/!%.W5GBCD;XGM14_N>CW,H/W*EZ)OJ/K 'HAHJ6%^M
M#301N\;(T13]CI:>*19(X(F2+QN:Q$5?ZGN 'C+&R5BLE8U[%XVN3-#Q@@A@
M:K8(HXFKR,:C4_L>P
M
M                                            !@\=]Y&(OFZH^Z<:
M'N8?!9!Y7-]J&^8[[R,1?-U1]TXT/<P^"R#RN;[4*CME$]R>/Q+7X&TUXONK
M</5]SAJE= U(D<Q.-CM;6U5S]Z;/P]UW,*Z]*[JRZ W*/C!%,QQ*%\/5=S"N
MO2NZL</==S"NO2NZLN@,O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'JNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'JNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>J[F%=>E=U9= +QHM5M"^'JNYA77I7=6.'JNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'JNYA77I7=6.'NNYA77I7=670"\:+5;0OAZKN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>J[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CAZKN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OAZKN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CAZKN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>J[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'JNYA77I7=6.'NNYA77
MI7=670"\:+5;0OAZKN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'JNYA77I7=6.'NNYA77I7=670"\:+5;0OAZKN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>J[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'JNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'JNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'JNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>J[F%=>E=U8X
M>J[F%=>E=U9= +QHM5M"^'JNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>J[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'JNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OAZKN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>J[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OAZKN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85
MUZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"
M^'NNYA77I7=6.'NNYA77I7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET
MO&BU6T+X>Z[F%=>E=U8X>Z[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77
MI7=670"\:+5;0OA[KN85UZ5W5CA[KN85UZ5W5ET O&BU6T+X>Z[F%=>E=U8X
M>J[F%=>E=U9= +QHM5M"^'NNYA77I7=6.'NNYA77I7=670"\:+5;<^7_ $UU
M]UL5RMS<#72):NFDIT>LCEU==JMSRWO;EF;CN:Z:>DT8P154$L$J54RZDC%:
1N6:<BE2 FJ+6B&Q3-[S+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g42675g03b22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g03b22.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[20*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (^T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*/_  !$(!#,$V0,!(@ "$0$#$0'_Q  =  $  04! 0$
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M1$!?$[^C@D?YK25]KXGB9/"^*4$L>,$ D9'L0ER172.ONM7O)WC65H]/E/\
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M*GKTI6:XX\KQTV3)>+9I\?#G_N@;@9]34]$#XM+'R[-X-*V3L2MYHM#T\C@
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M<XWLYY^E,F>EZ12(1AZ;)2]KVG<RY:T1227?65NA(,CY)=\C&<[H+OY+K<
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MS3G+,=BME6ICQ([4(5T1%"1$1 5O5GR0KA6M7Y0]2M3RI?PMT1%LP$1$!$1
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MQ"^6BC<U[6-D+#D M'$<>1*168B2;Q,Q+0W<A#-5?01D&,?>%@6V_2MPTKM
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MDNDM2WF6Z7>BGEK92"YS:A[0<<!P!QU+*8WVS3=LI*1]1%24D3!%#TTF. P
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M_J?@*[4N5OI[E;IJ*K:74\K=US02"1ZUA6FMD.D--WB&YVFAGBK(<[CG5+W
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M<M(]SE+!<V5&JKE!50,<'=%3.=X^#R<7-!QZBNB*2FBI*:.GIF".&,;K6CD
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M>+=S"(B K&YNS.&CJ:%?CR@HNN.:J3T$A7Q_DRS?BH(B+=RB(B B!$!$1 1
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MXDDL/65LJ-C8V-8P8:T8 7TO-Q]5..UK1'E[&3H:Y*UK,^%*)G14S6,&-UO
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M0$1$%Q1\W*H!F<^A4Z/FY5V#\H\K&WEO3P^T1%5<1$0$1$!$1 1$0$1$!$1
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MOR\]I*NVQ,:,!HX+AR=3RG;TL71<(U'9#06YQXRG'H'%2$-*&-PQH8.WK5X
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MKY>IT?01DIZN6=597)K< _DZ+>'IDQ_)?4&MHW.'3TA8.UK][^2^*71(W?\
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MU\;@YCAD$=85C?[Q1V&T5-RN<O1TM.PO>X#)P!G@.L\.2A*01:K_ /7K0O\
M?JO_ /:O6:SZLMD6DXM1YJ'VN6%L[71PN<_</'):.(X)I$6B?$K?4&@M,:AK
MS6WJST]75$ &1Y=G &.H^@*=ME!2VN@AHK?"V"EB&ZR-O)HSE8]HG7^G]9NJ
M&V&K=))!@O9(PL=@]8!XD+*T(UY@1$181$0$1$!$1 1$1#%+SL[TG>KC)7W2
MR4U3628WI7EV3C@.14_:[;1VJD;36ZG93P-Y,9R"O$0U$"(B)$1$%Y;O*<JD
MWRI5.W>4Y59?E'+2OAR9?R?"+Q K,@#)&%>@8&%:PC+PKI00(B(D1$0%:W!N
M8P>Q72^)V[T3AZ%$^%J3J8E$(AX'"+-VB)U(@8XJUN9S.&^:T!7;/*'K5A7'
M-5+Z"1]JB?"V+\EN@1%1TB(B B(@(B("*I!"^=X;&TD_<JU0^@MK=ZMJ&OD^
M;8<D*8A6;=^,=Y48HGR'#&DE73;=)_\ %<R+_,X+'Z[5D[\QT,;:>+T<_P"2
M@:BMJ:DDSSRR9\YQ*I.2L?JZ*=)FOWMJO]99VYE!$<3UK0?\.?@J1J[&/*KW
M_5/_ .*P%%7UOT;Q]/CWO/\ 1L!DUHD^3KB?6#\%6;1Q2MS3U43AV$K7*^F/
M<QV\QQ:>T)ZWS")^GS'XWG^;/Y:*>(9+,M[0<JWP0>*QNBO]QI#XM0^1OFR$
MD+(*+4%#7@,KHQ3S'AT@Y$^G@KQ>LN>_3YL?>8W'Z?V?:*[EHB(^EIY&SQ><
MPY^Y6BMK3*MHMX$1%"1$1 1$0$1$%U;7;M6S/(@C["KTC!([%&TIQ4,]:DY>
M$CQZ2KU\.?+^3Y1$4J"(@&3@()*@;NP>LY5POF-NZP#L7TM8<-IW.Q$1$"(B
M B(@(B("U9J>H[YO=2\>3D >Y;/J91!3R2GDQI<M0/=TM27./E.YGUKGZB>T
M0]GZ/3[K7;+TC 8+'!D8WQO^\!3!X#BHRDKZ"FHHHS6TWY-@'"5O5[5!ZBU3
M#WL^GMYWWO!:7]@]"TY5I5Q>AEZG+.H\RQ2^3]]7:IE!R'._EA9I;2:'1SWO
M&"^,D>T8"P^QVV6YUS6-!W,Y>_&0%F.M'MI;"*>,8:XAH]0(6&/>IO+UNKFL
MVQ]-'S#"+5":NZ4\1_;D )]JV-J.O-MM+G,^4.&,]?\ [+!](.@9>6/J9&1L
M:W(<\@#.1VJ=U[)T]OI98G;T!?P(.1G!3'/&DS"O5U]7JL=+>&,6>@DNMP;$
M"?&.7N[ LPN5CMEMLT\CH0^1K#NO>>.<>A0>AZRFI:Z;OE[6%X :YQP!SRKO
M65\BJHQ1TC@]@=E[@>!]7O2G&*3,^5NH];)U,8Z[BL:8]9(#576GB:/*=\5E
M>N[D^)C**(X+QO/]75]RBM!T_2W=TAY1,WOY?S5/6X>+X[?SY QZLE1&ZXYG
MY7R17+UE:S_EC^KS2UB\*2.DF); SGCF2I#6-OH+=10MIH&MF<[B[CG'%7FC
M;G14]I,<TL<4C"2[>< 7<2L=U1=1=*[>C'Y%@W6^GTJ9XUQ_K*E9S9>KG>XK
M5?Z IS)<Y)L<(F_?D+XUY/TEV;%GY-OW@*9T!!T=NFG=@;[L>P?^ZQ&_3]/=
MZI^<X>6Y]1PHGMBB/E.+_$ZVUO\ \QI+:3L#;B'3U6\(&G  /E%6^L:.FH;F
MV.D8(VE@<6CMR5G&G(.]K+31D8(:2?>5K_5,_3WNI.<ACBP>PE3>L5I'RITN
M>^?JK3O[89!HR4T=EKJEP\5HWA[,K%)7S7&X%SCO2RN69P4;V:)>Q@(<8W//
M:0<G^:P^R5$=)=:>:=N]&QW$'U%1?M%:RUZ:8M;+EKWG?^S.8-*4,="8Y&[\
MQ;QD)Y'T+7]0TTM;*QCN,4A:#ZBMC7;4%%3T+W13LED>TAK6.!.3VX6OJ"FD
MN5Q;&T$ND?EQ'5D\U.6*]HJS^GVRZO?-/;]6<:D=-4:8#XP<D O [%A%GDI(
MZYCKA&7P?M!;'JKG0T+HZ.J>UI+,XQP6+:DMUJ;3NJ:"JA$GS3' YX]@Y*V2
MO?E'LRZ'+QK.*U9B+>)C]4W1V:T5<T-70'=Z-P=NL/ ^O/%1^T*?$=-3@\,[
M^/>%$:*GFCO#&1D[CQAS>K&>:^M<3&2].:23T;0T??\ S43>)Q[B-+X\%J]7
M%;6W$1N-K[9[3AU14SG]D -^W*K[1&R%M(6@F,;V]Z^&%6T-/2P6PM=-&)WR
M8W2X;QY8X*3J;I:JITM%52,R#NN$F  >7,JU8B<>ML,F2]>LG)%9F(_],*TU
M);&S/9=8PX.\EQS@>Y9K:K+0T]2VLH7'!'  \/\ SBL+U+04-'*UUOJF2L=^
MRUP=N^T*<V>32O951.<XQ-P6@G@#UJN*=6XS#?K:S?%.?':8B?,,Q1$74\ 1
M$0$1$!$1 1$016GOD*KZ<_A:I516G?D*GZ<_A:I5 6.M_2U?ZV_>Y9$L='Z6
MKO6W^I1/AIB_*%PB(LW6(B("(B($"(@(B("(B B(@(B(/'.#&ESC@ 9)7(.T
MV[U6T3:S#987O[SAK>\HP.31T@8Y_P!@*ZGUA5]XZ7NE1G&Y3OP?21C^:Y7[
MFRE\([3FU-0=YT<;Y3GK<>.?>%:ORRR=YBKJ*DM-/8](,MM'&V.&G@W<-',\
MR?:22N(-#6:+4&KK;:JB1T<55+N.>T9(&"?Y+O&\?HRI_P BXBV/?K.L'_$_
MTE*^Z,D=XAN2\=S;3&"1]IO4G3X\2.:/#/:<DK2$@OVS[5#HA+)25]*_CND[
MK@1V'F,'K"[T7+O=:4\3=36F9HQ*ZE#3Z1OO2L[,E(B-PWOL\U;#J?15/>I"
M&%L?^T<L,>UH+O=E<O;8]HURU9J*KHJ.>6.U0RF**%A WR/%))'/.">/:LVV
M35LU)L%U.Z,N\J9HQ_B8 5K38G0P7#:3:&56"UDK9 #^T0X</M4Q&D6M,Q$?
M+.=&]SW<[I11U5]KFT#9!O-CC:7/ ]((&/>LCH^Y[FM-]MM?;KPVH;2U<4[F
MS,W,M:\$XQGC@%="    < %ZJ\I:1BJT[W5/ZLX?^81?AD7*;:)[;0+BUV&B
MHZ$>O=WEU9W5/ZLXO^81?AD6E]%:>-_V0:B,3"^HHJL3Q-'6=UC3]CBK5\,L
MD;LZ-V(Z@&H=GMME=)OST[!3RD\RYK1D_:L&[JO4/>>G:&S1/<V6KD,KL>:T
M$$'ZP6+]REJ'O>\7"R3R -J6B2%I\X!Q<?< L;VFU4FO=LO@VF<YT/?#:-@'
M#=(PUQ]X41'=:;;HUA7T4M$8VS@M>]N]NGF.*[?V94T5;LHT]35+ ^&:V11O
M:>L%@!7+.WBF91[0ZVFB:&LC9&T ?Y NK-DWZL]+_P#+X?PA+>$8HU:8<Q5T
MM3LIVP3&![F4C)P]S&<0Z%Q#MWCZ,!=AT53'5TD-1$X.CD:' A<U=UM;VQW:
MR5L;>,L<C9#Z1N@?9E;?V&W!]QV96668DRACFN/;X[OY)/C:U.UIJSQ$15:B
M(B)$1$!$1 1$1 B(B1$1 1$07EN\IZJ3?*.[53MWE/52;Y1RTKX<F7\GPB>A
M.I69*],.959?$ Q'ZU]J$B(B B(@(B((FH9N2N'IRJ:OZ^/+0\=2L%G,:=E+
M<H$1%"[V/RV^L*/K/SN?_.?O4@SRAZU85XQ52>DY43X7Q?DMT1%1T"(B B(@
M*YHZ8SDN<0V)OE./4O**E=4R;HX-'$GL4/J>]MD::&@.*<>4[SCG_L$F8K&Y
M*UMEMZ=/YS\*]YU%'3-?2VH#D6OEX<>KA]JQ.21\KRZ1Q<X\R3E?"MC7T8)!
MJZ<$<#F0?%86M-O+UL."F"-1_JN47C2",M(([0O51T"(B @1$!%\A[=\LWAO
MXSNYXX[5XR6.0O$;VN+3AP:<X/I4H2UHO-5;),Q.WXSP,;N1684TM+=X#-1$
M,F'E1'FM>!7%!5RT54R>%V'-*O3)Q[3X<?4=)&3[J=K?[_NS$@M)!&".!7BN
MZ>>&\T??-/PG8/RK/3_X"K7&#@K=YD3/>)[3#Q$10L(B("(B"I!\LS'G!2L_
MRTG^8J,I!FH9ZU)2\97^LJ]?#GR_E#Y1$4J"K4;-^8=@XJBI&@CW8]X\RIK&
MY9Y+:JN41%HY!$1 1$0$1$!$1!9WB":JMT\%,6B21I;EQP.*PG^QER^<I?KG
MX+82+.V.+]Y=?3]9DZ>)K1KT:,N7SE+]<_!7M%HIV]FLG;CL9QS]RS5%$8:0
MUM]3ZBT:WI;4%#3T$(CI8PQOO)]JH7RVLNE"Z!QW7<VN["I!%IQC6G%&2T7Y
M[[M?_P!BZ_?^5I]WMWCG[EE<UFBJ+.RAF_8'!PZBI5%2N*M?#HR]=FRZY3X8
M =%UW28$T'1]N\<_<KNNT?)WK#'1/B,@STCI"1D^C@5FB*/1HTGZEGF8G?AC
MFE+'4VF29U2Z)V^,#<)/9Z%7U'8F79@DC<&5#> <>1'85-O.&.(Y@+6POM?0
MU]0]ARUSRXL>.!46XTKQGPTZ?UNIR3EI.K0O:?1M2V7>JYH6PCB2QQ)Q[ECM
MP,;JV04XQ'G#0I.XZEK[C$8B&1L=P(C!X^_*N=,:?FK*AL]2PLIV<>/-Q7/,
M1:>-(>K2^3#6<O4VC]F66.C=!IYD+,"1\6>/(.(6,#1]P=4;\DE,079/CGX+
M/D75..)B(EX6/K<F*UK5]WPUF["&# (;A8+)I"XR5+I'R4Q#G9/CGX+/44VI
M%O*N#JLF#?#W4:>$1TD<#@"&L#".HX&%BEUT<99W24$C&-=QW'DX'WK,44VI
M%HU*N'J<F&TVI/E@$.BZ[>_*S0!O:UQ)^Y938['3VIA+/'F(XO*ED5:XJU[P
MTS==FS1QM/9BNHM-U%RK75$,S!D8W7G&/L40S1=PWAORTP'H<?@M@HHG#69V
MOC^HYL=8I6>T(6P6"&U OSTD[A@N[%9:ETTZY5'?%*]C)2,.#R<'TK)T5IQU
MF.+*O5Y:Y/5WW8;8M*U-'<(YZJ2$M9DX82>KAU*C<M(5D]7--#-">D>7>.2.
M9SV+.$5?1KK37_Y'/SY[[L!@T76%WY>: -_P$D_<LPM%L@M=-T, SDY<X\R5
M?(K5QUKX9Y^LRYXU>>PB(KN41$0$1$!$1 1$016G?S>I^G/X6J545IW\WJ?I
MS^%JE4!8ZW]+5_K;][ED2QX?I:N];?ZE$^&F+\H5T0(LW4(B(D1$0$1$!$1$
M"(B)$1$!$1$,>VA4KJS15XA;G)@)X#/(Y_DN9^Y;E8S:(Z-SL.?3OW1VX!76
M=7"VII9H'^3*QS#ZB,+C>A=)LYVU@3#H::*O+">RG=+C/'_"%:/#+)VM$NPK
MQ^C*G_(N'MDT\5-M'L4U1*R&)E1ESY'!K0-T\R5W#/BX6HFG<"V>,.83R(/$
M+E<=SMK)KMYM99@<\"*B3_\ YI4R1,S$PZ.N^O-+VJE?/57VW$,&2R*H8]Y]
M30<E<B;6-82:]U?WU31.$#&B"FCR2=W.?O)690]SOJV6<=^U]JZ/K<V>1SOM
M8MJ[.=B5FTM4,KK@_P )5[>+2]I#(SZ!G!]HZTC4(F+7[:TN=GNA)+9L?J+)
M4M+:VO@DD>UPP62/C P?40N58'U^B=9M>Z-[*RVU.0UX+=[==P]AQE=]K7.T
MS9/9];?[2[_8[DWE41C.\,<B,X/(<4B4WQ[B->S[TAM<TM?K?%)-<J>@J<8D
MBJ90S=/H+L94K/M'TK%604K+S23S32MA8VGD;)ESG!H\DGK*Y_KNYRU.V<BA
MK[7)#U&65[7>X,*FM%]S]=[??*"ON]RHV"EJ(YPVG<Y^]NN#L<6CL34$6OXT
MS+NJ?U9Q?\PB_#(L=[E.!M3IF_0O +9)BT@CM8Q;%VVZ/N.MM'1VJT24T=2V
MJ9.34/+6[H:X'B >/C#J49L)T#=M"6VX4]YEHY'SS;[#3/<X8PT<<M'84]DZ
MGGMS7<14[/-HE>RF#V/I'RQPN.6ES3EH*V!W,MF?>M:W/4%6S?; "27#/Y1[
MMX'/^DK-=M>R"Y:RU!!=+#)0Q2&+HYA42.;G!)!&&GM*S78UHB70^E115KH'
MW"1Y=.^$DM=XQW>) ZCV),]E*TF+?HYK[HC]:-T_T?A"ZDV2_JSTQ_R^'\(6
MI=J^QG4FK-:5MVME1;&4LV[NB:9[7< !Q 8>SM6ZM#6J>Q:-LUKK71NJ*.EC
MAD=&26ES6X."0.'L2?"U(F+3+1?==5+!+I^G!!>6RN.#RP6_%;*[GV%\6RRS
MF08#VO</5ON"T%MJN<NMMJG@RV$2-CD%) /\?!KN7^(+K#3-JBLMAHK=3C$<
M$8:!Z^)^TI/@IWO,I-$15;"(B($1$2(B("!$1 B(B1$1 1$07EN\IZJ3>6Y4
M[=Y3U4F^4*TKX<>7\GP%Z./)>+[B&7A69KIHP $1%"1$1 1$0$1$'S(T/86G
MK42]I8\M/,*85E7Q?MCVJMH:XK:G2R1$"HZ0<%:W,?EFN[6A72I7!N]3QO'[
M.0?LPHGPM2=6A'(B*CJ$1$!>M!<X-:,DG 7BO;8UK72U$GR<#=\_:?Y*8C:M
MK<8VL-37#P90LHZ9Q;42>,]S3@@<?^RPE7=UJWUM?-.\YWG</4. ^Y6@7/>W
M*7K]+A]''J?,^6%Z]N=2;C:+';YI()*^0B6:-Q:YD8+0<8[0X^Y2$&B-/,I1
M%)::.9^/&FDA:Y[CG))=CFH;:!"^WZ@L5_P32TTA94GS&N+/&]@:Y9)64=MU
M);H)WRROI3X['P5#XL\QS:1GK4[U$:5BL6R7Y1N?;?PL]*T-=8J2XQW.K?-1
MQ3.?3OE?OO$6ZWF<]H=P5E'K"OJZ>HK;787U5LAWCWP:C<<]K<Y+6;N7<!D8
MYK$K(UU5+JUEDJIZJW" ,@>Z=\K<@@D N)XX4GHR"X2:/@G@U2::FI8 )HN\
MH7"'=;XS22..,$9/8K36.\RQKFM,16FXCO\ $^_Z^S(+OK6EHM)Q7VG@=4PO
M?N&/>W"TC>SG@>1:1R5*KU?74,<5776*2&U/>&]\F?+F@G +H]W(R2!Q[5@=
M^A@BV53/HZBIJ*>6L<YLD\38]XYDR0 2,9RM@;4P!H2O '#I*?\ Z[$XQN(_
M5,9LEJVMO6JQ/M^O]E]J'4T-J90LIX75E97'%/ PXW^7$G!P/&'$JWH]3U#+
MK!07RV&VRU _(.$PE:\^;D  'GP]"Q"]154>J]+RBO\ !\4U)T4,YB;)AY;&
M-W#N&22%>ZCH)67:S4]XU#55M0Z<2T\,-%$UV0'#>)!!W>)'M"B*QI,YK[F8
M]ICXU_<L=PNLFTZY]);@[_961N!J@>B8'N((X<>.1A35@U!; _4TXH(;>RWU
M$@J)68S.6N?EYP!Q.Z3U\U:V']:-]_X./_J.6)""6>T;0A""2RNFD<!YH?*3
M]BG43_12+VQ]X[][,R.LJ]M +G+I^5EH))Z?I_'# 2-[H]W/5]H67TM1%50,
MGIWM?$\9:YIR"%!4EXML6BZ>X3O9);VT[0[@"#C@1@\.8/N4O:9XJJW4\U/
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MW)'ZBK4T1ED'8.:I,:7'#1DE2M/$(H\=?65-8VIDOQA4 P  B(M'((B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B((K3OYO4_3G\+5*J*T[\A5?3G\+5*H"QUOZ6K_P#3_4LB
M6.C]+5_K;_4HMX:8ORA<(B+-UB(B $1$0(B(D1$0$1$!$1 1$0$1$!$1 "(B
M B(@(B("(B B(@(B(@1.I$!$1$B($0$1$!$1 1$0$1$0(B(D1$07EN\IZJ3?
M*%4[=Y3U5E^4<M*^')E_)3YJ\8,-'J5M&,O"NE9E B(H2(B("(B B(@(B("L
MZR#.7M''K5XBB8VM6TUG<(5%>5=/C+V#AUA6:I,:==;1:-P\FCZ>G+/VV\6_
M#[5%*7:2TY',*UN$ !Z:,88[F.PJLPVQ6U/&5DB!%1N*WUPTNM]J<.36.!]S
M5<+S4L9GTY'(.)B=CV?^!)C=93CGCFI/Z_[PPA8#L2_W)9],?PM6?+5.RO4M
MKLNE6TESFF@J!*7;AIY#PW6CJ:1U%85B9K.GIY;5KFI-IUVG_A*ZW'@S6^EJ
MRB CDJZ@T]01PZ1I?&!GU9/O4C;+Y72Z_O\ ;97F2BI(HWQ1-8,@ED9/'F>+
MCS*CBQ^LM5VRX0Q2-M%KD<^.9PW3+)EI& >. 6#F!S5*FBK1M&U<^B8\3.IX
MQ$XC )Z.'K/#M5M=M3\?\L>4Q;E7Q-O]?MG_ )>U-RO<-J\)WJ_QV%\Y<8:*
M2GC=C SNESAG*K46MIYM"P7+<C?<)911Q[I\5\I\4/Y<MX@\ECNE9-/T%BB,
MM#*_4S(G,+3'(7.>6D'CY'(GK2R6NNJMGN64[VU]#<WU;X.6=U^\0,\#Y/#B
MK36/=E7)?_+/F)]YGX_K^D0FM53ZML6FI+I'>65$@;E\3J:-HB!XY!#?&QP&
M#VJXU%?[S!<-/TUMFC#ZT.$@>T8/BNXYP<8QGTX47KW5M)<-$U5)0LFEJG1@
M3L=&YG1-' N)( /' X$\U>7:*1VI='N;&XM:)-X@<!XDG-1$=N\?*\V[S&.T
MZ^WW_5?5-?>M/:AM%-<+GX3I;@\Q>- R(QG+0#XHX^5]BK55UN=YU566:SU8
MH(:)K72U(C;(7$M:0T!PQR=S]"I:_CD?J3218QSFMJ\N(&<#?CYJV;+_ &3U
MK=*NX,>VTW ,,<[6E^Z\-:,$-R?V7=74HCOW]U[3-;37<\=Q[^VOG]UY;[]<
M;7?JFR7N5M9.8'55+4-:&&1H#O%<T  'Q'<L\U86"XWO4U'6U5MU%#!5Q$GO
M 4\;A$3G<:]Q&1R(SQY%5;;TFH-<NU!24\AM]#3&GB>X;IG?XYX \1PD',!1
M5_J-(7.EN4E?05%+>BR2,QB*0R"0 @ .:"S.>1SA3$?HI-IUN;=N^MS,;C]T
M]KB\WBRZ=M,S9(H:Z6L9!.8P'M(+'DXWA_A!Y*G<;W6UFL)++!=F6C<B#HLQ
M,D=.<NS@.'+ ^Q8[J"FN8V<Z;BN+)7U;;@"00'.#,3;F<</)+5DVJ:W3\US[
MSU5;9&LB;TD$[F.>U^21PZ/)'(\TU$)F]K;G>H^WSV]OGV3VG(KS3LJ8;Y40
M50:_\A4, :Y[<GRF@ # QRSS*FHFE\C6MYDK7>S2G,5VO4EKZ<6!\@[W$O#Q
MLOWMT'Q@/)YK:-B@-1=J:,#(+N/J5)C[M.G'D_P>4^V_U_JSN^G-6W_(/O*C
M5>75^_6O]'!6:Z;>7BXHU2($1%5H*4I8^AI@?VW\_0%;4$'2/,CAXC./K/8K
MQSMYQ)5ZQ[L,MMSQ>(@]"OZ.GQX[^?4K1&V%K16-OJC@W&[SO**N41:1&G):
M9M.Y$1$0(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B((K3OYO4_3G\+5*J*T[^;U/TY_"U2J
M L=;^EJ_UM_J61+'1^EJ_P!;?ZE$^&F+\H7"(BS=8B(B!$1 1$0$1$2(B(@1
M$1(B(@(B(@1$1(B(@(B("(B $1$0(B("(B B(@(B(D1$1 B(B1$1 "(B($1$
M!$1 1$1*\MWE/52;Y1RIV[RGJI-\HY:5\.3+^3ZIQXQ/8KA4J<>(2JJEG B(
M@(B("(B B(@(B("(B K*JI>;X_:%>HHF-K5M-9W"%(POII!!8\98[F%?U-,'
M@N9P<H]S2TX<,%4F-.JMHM"/JH#!)CFP^2>T*@I<ALC#'+RZCV*-J(70/W7<
M1U'M5)ATX[[[3Y4E>4T8JZ&LHW<Y(SN>O!5FJM-*89V2#J(]H40O>)F.WE@L
MT9BE?&X8+20<KX63:RMPCF;7P-_(S8#L=3L?]BL97-:O&=/:P98S4B\"(BJV
M%'WR@EN% ^&FK)J.<>-'+$XC#ARW@.8SS'6I (D=D3&XU+$*K35WNL#*2^WF
M"HH,@OC@I3$Y^!C!=OGAQ[%ES&M8T-: &CD L$UAK>NM%_BM-GM/A*I='ON:
M'D.'+J ](5_I+45YN)K'7ZQ26N*"/?:]Q)WNT<0.I7FMIC<N:F7%6\TKO?\
M/_=EJ!:JJMJ5;)/6R6>Q/K+;2'\K4%Q&Z!GB<9&, GFLCN6MXHM#QZBM].)F
M/X='([=P1O \L];2GIVA->KQ6WJ?#,D49IFYNO%AHK@^,1.J(]\L!R&^U2:I
M/9O68M$3 B(BPLJT+2@3SUT@_)QMW1GMR/@5C-/"^>=D40R][@UH])6?] VV
MVR&BCX/QO2'UY./M6N*.^_AP=?DU3TX\V_V6SW%SBX\ROE$6K@%5I8'3R!K>
M76>Q>00NF?NL''[E)L:V%G1Q<NMW:K1#.]^/:/(0UC1''Y+?M]*\:"3@#*^H
MV.D=AHR5(TU.(QEW%RO$;<EKQ6%.EI=W#G\^Q7:(KQ&G-:TVG<B(BE41$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$$5I[Y"I^G/X6J547I[Y"J^G/X6J40%CK?TM7^MO
M]2R)8Z/TM7^MO]2BWAIB_*%PB(LW4(B("(B B(@(B("(B)$1$!$1 1$0$1$!
M$1 1$0$1$!$1$"!$1(B(B!$1$B(B($1$!$1 1$0$1$2(B("(B B(@O+=Y3U4
ME^5*IV[RGJL\9GPM*^')E_)6C&& +Z1%+,1$0$1$!$1 1$0$1$!$1 1$0%3E
MB;(W#A[541$Q.O",FIGQGED=JI9:YACE&6?:%,*WFI6OXM\4JG'X;5R^UD!4
MTKH3EOC,/)P5LIUT<D0(+<M/,<P59ST;9,N@X'F6G^2I-793-'NITCX9H7TE
M8-Z%_P!BPN]6J:UU)CD\9A&6O'(A92]CF$A[2#Z0KD]#<:1U'7=?D2'FU4M7
ME&G3AS3@MRCO6?/]VO$4I>;+46R4[S2^$YW9&C@1_)1:YIB8[2]FF2N2O*L[
MA@>H]1:K9=*B+3-BAJZ.G_)R2SN )D'$X\<<,%O5VJSM6T:KKJNEMIL54RY.
MD;%.2 (FG(#R#GD#GK6R$5N4:\,9PY.6XO/]/Z-/W#3NJ+KM#N5PM=5%;08F
MADQ>UV0&L!;@9(XC/$=2F-G6I;I)>[EI_44K)ZFD.>GQ@GAR/5C@>I6]YTGJ
M*T:LJ;UH]T$G?; V2&8AH9P;GK&<EN?:K_1&BJJD?<KCJ&5LESN#2R1HXA@(
MQSR<GFM)F)KW<>/'DKE^V)CO.]^-*^TVUW"[Z?D=8:^"&FAAF=4QMP>G&[D-
M! Y\'#JYK#JNX4M9L8$%+"(#2R&.2,<@[+S]O/VJY9I#6-B9<K5I]]/+:*S+
M=^1P:YC3O#Q1O<#@\^O@I>LT%4TNSMUGMY;4W"1_22N<0P.)WNWLW@.:1,1$
M1OW5M7)DM:W&8GC,3_QI@5CNTFJ*FP:=JY74=KB86N(X&1P#G<^// "Z!H:6
M*BHX::G;NPPL$;!G. !@?<M;W70-3/HBU0TD,,-\H-US=T@![M[B"[U9*V!8
M36^"*076-K*YL36S!KMX%P R<^O*KDF)\-^BQWQS,9([S$=_^/Y+]>M!<< 9
M)7L<;Y'AL;7.<>IHR5F-CL++>&U=R(,HXLB(S[52E)M+HS]13#7<^?:'WINU
MLME-W[6-'3O ,3>S_P X*K+(9)'/=Q)*^ZJH?42E[^74.Q4FM<\X8"3V +I[
M1&H>1,VM:<E_,O%7IJ9TQSR8.;E<P409ATY]3 KYD,D@#0W=8.0Y *T58WS1
M'A1:&QQ]'"/%ZSUE5H*5S^+N#5=PTS(^)XGTJNM(K\N.V7X?,<;8VX:%](BL
MP\B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B"*T[^;U/TY_"U2JBM._(57TY_
M"U2J L='Z6KO6W^I9$L='Z6KO]/]2BWAIB_*%PB(LW6(B(@1$0$3M1$B(B($
M1$2(B("(B($1$2(B(@1$1(B(B!$1 1$1(B(B! B("(B)$1$!$1 1$0$1$0(B
M(D1$0$1$!$1!>6[RG*Y:,SN/8K:W>4]7C!X[RM*^')E_)](B*68B(@(B("(B
M B(@(B("(B B(@(B("(B 0#S5"6F8_B/%=VA5T1,3,>%A+2EPQ(P2-]Q4=-;
MR.,3N/FNX%9 O"T$8(59K$MJ9[58\R9T;33UT?20NX%KAR]2B:_2\52'2VN9
MN>?1./+[UFCH6.:01P/4K5]MA+MYF8S_ (2J3CWVET8NKG'.ZSK_ &:MK*.>
MCD+*F-S'>D<U;K;;J:1["R8,F9U[PXJ*J=,6^I+L0R0$];"/YY6,X)]GI8_J
MM)[9(_T:Y19I)HV(NQ%5.Q_B_P#96_\ 8JI/DU4/M!^"IZ-_AU1]0Z>?\S$T
M67LT7(/E:IG^G/P5U3Z2H6',T\TCNP<ON2,-D3]1P1XG;!@,G@INU:<K*X![
MVB&'GO/R.'H69TEM@H_S.A#7>>XY_FJTE%4U!_+2M#/-:M*X/EQY?J>^U.WZ
MS_9%T5)0V=A[W GJ#P+R. 7RYTU5)QWGN4U#:H&'+LO_ ,RO&0L8W= X+6*>
MSS[=3&^7F?F4'!;GGC*<?X1Q*DH:/<;B-H8.WF5?  #@BO%8ASWSVLHQT[&<
MQO'M*K(BLRF9GR(B(@1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$5IW\W
MJ?IS^%JE5%:=^0JOIS^%JE4!0$4;I+M7[@)QN_U*?47:_P!+7/UL_J43&UJS
MQG;SO>7S2G>\OF%2J*.+3UI17>\OFE.@D\TJ51.)ZTHH4\OFE.]Y/-*E43B>
MM**[WE\TIWO+YI4JB<3UI17>\GFE.]Y?-*E43C!ZTHKO>7S2G>\OFE2J)Q/6
ME%=[R^:4[WD\PJ51.)ZTHKO>3S2G>\GFE2J)Q@]:45T$GFE.]Y/-*E43C!ZT
MHKH)?-*=[R>:5*HG&#UI10IY/-*=[R>:5*HG$]:45WO)YA3O>7S2I5$XGK2B
MN]Y/-*=[R^:5*HG$]:45WO)YI3O>3'D%2J)Q/6E%=!+YI3O>3S2I5$XGK2BN
M]Y/-*=[R^:5*HG&#UI17>\GF%.]Y/-*E43B>M**[WE\TH*>3S2I5$XGK2BN]
MY/-*=[R>:5*HG&#UI17>\OFE.]Y/-*E43C!ZTHKO>3S2G>\GFE2J)Q/6E%=[
MR^:4[WD\PJ51.)ZTHKO>3S"G>\OF%2J)Q/6E%=[R>84[WE\TJ51.,'K2BN]Y
M/-*=[R^:5*HG&#UI6E#&]CG;PPKM#R*I[[_,4Q&F=K<IVJ(J>^_S$WW^8I55
M$5/??YB;[_,05$5/??YB![_,05$5/??YB;[_ #$%1%3WW^8F^_S$%1%3WW^8
MF^_S$%1%3WW^8F^_S$%1%3WW^8F^_P Q!414]]_F)OO\Q!414]]_F)OO\Q!4
M14]]_F)OO\Q!414P]_F)OO\ ,05$5/??CR$#W^8@J(J>^_S$WW^8@J814]]_
MF)OO\Q!43&%3WW^8F^_S$%1%3WW^8F^_S$%1%3WW^8F^_P Q!414]]_F)OO\
MQ!414]]_F)OO\Q!414]]_F)OO\Q!414]]_F)OO\ ,05$5/??YB;[_,05$5/?
M?YB;[_,05$5/??YB;[_,05$5/??YB;[_ #$%1%3WW^8F^_S$%1%3WW^8F^_S
M$%1%3WW^8F^_S$%1%3WW^8F^_P Q!414]]_F)OO\Q!414]]_F)OO\Q!414]]
M_F)OO\Q!414]]_F)OO\ ,05$5/??YB;[_,05$5/??YB;[_,05$5/??YB;[_,
M05$5/??YB;[_ #$%1%3WW^8F^_S$%1%3WW^8F^_S$%1%3WW^8F^_S$%1%3WW
M^8F^_P Q!414]]_F)OO\Q!414]]_F)OO\Q!414]]_F)OO\Q!414]]_F)OO\
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MA$1 1$05Z3FY5 <3D=JITG-R]><3$KLP_BSMY7"(BT0(B("(B B(@(B("(B
MB(@(B("(B B(@(OE\C6CB50?4$\&\%2V2M?*8B97)( XE4G3M'+B5:EQ/,KQ
M8SGGV6BJN:@GD,*F97NYN7P$64WM/F4ZT]WCUDKQ,HJI$1$ (B=2 O0XCD2O
M$0?;97M_:51M01Y0!5! KQ>T>Z-0O&3,=Z/6J@.1P4>O6N+>1PM*YY]T<5^B
MMF5!'!RKM>UW(K:MZV\*S&GTB(KH$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1!%:=^0JOIS^%JE5%Z>^0JOIS^%JE$!05/^EKA_I_J4ZH*G_2UP_T_P!2
MSR_A*:^5[U(B+C:"(F$!$3D@)U(B#Q>HB B(@!$1 1>+T("(B B!.U 1$0$1
M$#J1.I$!$1 "(B B(@(B("(B @1 @(B! 1$0$1$! B! 1$0>+U$05Z3FY)?E
M')2<W+R7Y1R[,/XL[>5Q$<L"^E2ISXI'8556B!$1 1$0$1$!$1 1$0$1$!$1
M 1%1EG#>#>)5;6BL;DB-JCWM:.)5N^<NX-X!4G$NXDY7BYKY9GPO%3.41%DL
M(G)$!$1!B^H;UJ.WU3VVK2[+E2-9O&<W%D)SQR-TM)Y >]8MIK:/J+4;:QUJ
MT4)!2S.@EWKM&W#VD@CBSCQ!6RJ[\RJ/HW?<5J[N?_S;5'_-9_\ JO5XUJ9T
MAM&ADGFI(Y*NG[VG<,OBWP_=/9O#FJZU;JRLJ]3;3J;2$57/36VFIC6U@@>8
MWR@%C0W?;AS1^5'(]2M+K'+H'6MDI*"LK)K)>-^":FJ*A\SVO#'G?:]Y+AR9
MP!'(]JCB;9W8=4P7C4]_L]/"YIM AWYB>#W2&0$8QPQT?/)SE9$M*;,-.43-
MJ>NI&.K"^BF@="#5R8)<^?._XWC>2.><<>TJRK*^S&X5;M97RKNU\FJNA@MM
MBKI&OB;@[HW&.9GQ6MR<<S[5,U[]AM_6%\&F]-UUW= :@4K0XQ!V[O9<!SP>
MU5]-707O3MKNS8C"*ZEBJA$7;Q9OL#MW/7C/-:,LM\KKGL4U?1W&6JE-OJ13
MPFJ;B5L8,) ?Q))RYW$DGBMP;,?U;Z4_Y32_]%J374#)0B(%1(B(@("1Q'-$
M05XYR.#N([5<-<'#+3E6"^F.+.(*VIFF.TJS5?(J44P?P/ JJNFMHM&X4$1%
M((B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@BM._(57TY_"U2JB]/?(57TY_"U2B
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M88:EEEJK1134XF[W?>7/&\6;VZ9@ _L\;&[GT=2M%=^Z-KO:/KK4=3K=FB]
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M&XK-+2N;<FTY88-YN=[I"<9SCEZ5I[81LVU;IS:3;[E>K-+2T44<S7RNEC<
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M$V%LDK'O9"7PC=RUQ_Q>];!H=&7VP25D&E;]3TULGDZ5E/64SIS"3Q<&$/:
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ME0KQ=6#\5+>1$1;*B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@BM._(5/TY_"U2JBM._F]3].?PM4
MJ@*"I_TM</\ 3_4IU05/^EKAZV_>Y9Y?PE-?*]1$7&T% :STG:M7VA]OO-.V
M6/.\U^!O,.",@\QS*G@O4B=#E/4/<WWNGD?X"N-/6LZA,WH>OUN471]SOK&2
M8-JW4$,>1ES9M\@>K@NP BU]:RO&&N+5LR@9LFI=&7.JZ81"0]\-CQASI'NR
M&YZ@\CFM)TNP37-MN9\%7&*" ^*ZHAJ3$_'J!_FNLT58R6A.H<LZO[GR_/[S
M=9JF*NJ',+JN>JF+'/>0.HYZ][K6Z]F&E[CIS99;[#<A$+A V8/$;]YOC3/>
M./J<%G:).29C4FG,&S'8KJW3NNK7=KE'0BDIW/+RRHWG<8W-&!CM(73Z(HM:
M;=Y(C31>U_8?_:>[2WG3]1%3UDV.EIW,PQY#<9#L\.0ZNM85IS8!JF>1E-J"
MXQTUM:<F**8RAWHQD <0%U2G6K1EM$:-0Y/CV!ZJI-6LJJ.*A%MAKA)%O5/C
M=$),C(QSW0MT[8](735>S^FM%I;":R.6-[A(_=;AL;VGCZW!;'11.29G9IIC
MN?=G5]T-/='WYM,T5#0&=#+O]8Y\/0I3:WLAH-<O%=33-H;JP$&41[PDY8!X
MCLY\>:VGU(HYSOD:<C'8-KVF=)34=73]YD]566!P[2U;$V5[!X-.W2"[ZAJ8
MZRK@=O14XB&XQV.#B<G//APX$ K>O:BM.6TQHB(8'MITO<=6Z)DM=F;$:HS-
M>!(_<;@-<.?M"P[N?MFU_P!#W&Y37UM*UD\6XSH9=_CEI[/05NU%6+S$<37N
MTQW06SJ^ZYDM3K"VF(IM_I.FEW.>,8X>A9-L0TI<M'Z+CMEY$(JFR/<>B?OC
M!<XCC[5L!>ISGCQ-.;=KFQ[5.J->5EVM3*(TDI:6F2?==P '+'H6^](4$UJT
MO:J"KW144U,R*3=.1O 8."I=:TVZZNNFC].4]?9GALIDW7 L#@1EHZP>TJ=S
M?53QW:W[KFUT3? ]R;)&RN=O1F/ WI&\/&[>& /:K7N3-,=-77#4$[,QQ T\
M1+>3O%.0?42%KR<ZPVOZCAZ1IJ'-.ZUQ:&QP-. 2<#.. ZBNO=G^EZ;2&F*2
MU4H!,8)D>"3ON)SGBM+3PIQ1'>=INOHX*^BGI*N-LL$S#&]CAD$$8*YOUMW.
MM7W_ #U6DZV/HWN+F4THW-ST!V3]RZ8"965;S7PG6W)E+L!UI<JEC;[<(61#
MATAG,Y ] )"Z"V:Z MFA+3WK0!LU3)@SU1C#7R$#VD#GPSPR5F*=JFV2;=I(
MC3CKNH_UES?0Q_@:I"W[%KU<M*6V[Z2N.XZLB)FIWR&(>4X>5GCR'4K#NHFN
M.TJ;#21T4?5_@:NDMC@QLUL6?F7?C<M9M-:1I6(W+3NSKN>JNFNT%=JVIA,<
M+@_O:+QQ(1QXNSRSCJ.5M?:IL\I=:Z8CMT3VTM12@=[/#,AN!@-QD<.7N6>I
MVK*;VF=K1#E*Q;"==4=8Z!MU;06^0_E'TU4[+AZ6 C/O7SJON>M1>%G#3_>L
MM$&@"2>HW7/=DY)'''5UKJ_J16]6V]HXPC-+T4MNTW::&IW1/34D,,FZ<C>:
MP X/K"Y]VF; KG<+_47'2\U.^*H<'&"4]'N'&#@Y.>6>0YKI5 J5O-9W"=;:
M;V&;/-1:/BO1U#4,D?5PLAAC;,9 P-WNOJ'C+ ;;L3U=3[1([S(RA[R;<34D
MBH\;<Z0NY8YX7407BF,D[F32&U9;I[GI>NH*4-,\T08W>.!G(Z_8M ;)]C.J
M],ZYM]UNC*(4D&]OF.HWG<6D<L+IE%%;S6)B#3YD8V1CF2-:YCA@M<,@A< Z
M^M5/;]=7.W6V430-G#8WMY'(!]/62MR;7MK.JK#J^ZV6V5#64[0T1NZ)A+,M
MZLMX\U$[#MEEROE_CO\ J* LM\3B\-D)WIW>SJX]HY+;''".4HGOV=![*-.#
M2^A;9;RP,GZ-LDX QF0M <?L67I@!%SS.^ZQZD7B]05Z3FY>3?*.7M)S*\F^
M4<5V8?Q9V?"#CQ1 M517%,,,)5!748PP!"'TB(H2(B("LZ@?E"KQ6M2,29]"
MQS1]JU?*CVIU(BY5Q$1 3>#&N>?V1E%0KW;E,&];S]W_ +JMK<8FWP1&YTC7
MN+GN<>LKQ$7D^70+Q>H@(O%Z@(O%Z@(B(->ZBV4634MVJ[C?YJRKJ9'$0D2N
M:((^I@&3D EQZO*Y*(LNR.MMUTI9)-976HM--*V2*W$O$;6M=EK/E",  #DM
MLHMHSY(C6^RO&&A]LFT:=UT_L?IJLBHYRYK*BX25 B8P%F=T/ZN8R[/ C"RG
M9]1Z:TII*OH]*7>WW>YLB?/++3RL?)([=QG=:7$-\4<,XYJ4K=DNB:VKFJ:J
MR"2>5Q<]YJI^)/\ K4GIC0.FM,54E38K8VEFD;N/=TTC\CLPYQ"UMEQ>G%*[
M_NB*SO<N<]/6_2FH-/:IN^KKBRGU(>GGCB?.(W&4[[ANL)!>=['B^SK4X+E7
MW#N>YA7![H89RRGE<#F1N9/N/#V+<EXV7:.O%?)6W"R1R5,ARYS9I6 ^QK@/
ML4W<M,6>Y6-MFK*%C[:T "!KG, P".;2#UGK6ENJI.O/G?[?LK%)<R:=M5RT
M/)I;6=<6UU!.2S=?QZ!K@YOE'. -[/4NK:&JAKJ*GJZ5XDIYXVRQO:<AS7#(
M(]A454Z4LM3IIM@GH6OM#6A@@+W< '!P\;.]S ZU?V>V4EGMT%!;8C#20M#(
MV%[G;H P!EQ)Y!8Y\T9>\^?^%ZUXKU$1<RPB(@+Q>H@(B(" XXC@41!-->)8
MVR#]H<45O;7[T#V=;3G^2N O6I;E6+,)C4Z$3**R!$[405:;Y17:MJ0>,2KE
M=>'\6=O(B(M4"(B B(@(B("M;C70V^#I:@N#,XX#*NEB>NYR(H(,]>_]X7'U
M_43TW3VRU\PTQ4YWBLK[^U5M\Z;ZB^F:HMKG8WY!ZVX6,Z<LK+J)C+*^-K,8
MW1S4A6Z1<R-SJ2;?(&=U_ GW!>+BZWZGEQ1FI6)K_P!_5TSBP5MQF>[*Z2LI
MZMF]3RL>.L!P)"KK5M#5SV^J#XG%KFG!"V705+:NDBG;R>T''8O1^F?4XZV)
MK:-6ACFP>GWCPQK4.H:JCKGT]*&M#,9<X9SP4SIZX27&@Z65H#P=TXZU5K;7
M15KP^JA:]PZ]XC[BKJG@CIXFQP,#&#D KX.GZJO4VR9,FZ3XA%KTFD1$=U1$
M3([0O28B)D(@(B9':$!$1 1,ID=J B(@(F1VH@(B90%2JIN@IY)=TNW1G 57
M([5XX @AV""HMN8G288/!JJM=5L#FLZ,N W,<?>LWB=OQL?C&\ <*PCLUN9/
MTS*=HDSG.\3]F5(\N2\_Z?T_4X>7\1?EOPURWI;7"-")D=J97HL1$1 1$0$1
M$!$1 1$016GOD*GZ<_A:I51>GOD*KZ<_A:I1 4%3_I:X?Z?ZE.J"I_TM</6W
M^I9Y?PE-?*]1$7&T$1$!$1 1$0$"!$!$1 7B]"("(@Y("(L1VEZXHM"6!UPK
M&-FF=D04_2!AE<.H'!X<1DX.,J8C?:!ER+ MDNO*W7MLFN$UB\&48);%(:DR
M]*0<''B-X9![>2S*ZUL=MME973X$5-"^9V3C@T$_R28F)T+M%S?4]TZ(ZB6.
M+2HEC:\M:_PAC> / XZ/K6\M#:D@U9IBBO%,P1MJ&DF(/WBP@D8)X=G8IM2:
M]Y1$IY.I%B>N=H%@T9 '7BL8)W#+:=C@9#_ISG'+WJL1OPEEB+G.O[IR"*H+
M:+3)J(NI[JWHS[NC*R;9QMUI=8:@I[3+9G4,\^=UPJ.E' $^8%><=HC>D;AN
M9%K?;#M..SME X6D7'OO>YU'1;N,?X79YK ]/=TC'<[U24=7IQM'#,_<=.:_
M>W.'#AT8SQ]*1CM,;@VZ$1>+"-K&OX=G]ABKWT@K9Y91&RGZ;HR1@Y.<'E@=
M76JQ$SVA+.$7-U/W3CI9XX_[)-&^X-SX1Y9/T2W!KW5]=IC2@O=%9C<V-:'2
MQ"<QE@...0UV>9ZNI3-+1VE&V8IU+7NR7:=1;0:*<LIFT%?"?'I3-TAQDX(.
M!GD.KAE;"43$QVE(B(H!$1 "(B B(@(B("(@0$1>(/41>!!<4G-R\F\MR]I.
M;EY-\H5V8?Q9V\OA.2(%JJ]8,N"O%;TX\?*N%"8$1$!$1 5"J' %5U3G;F,^
MA4R1NLICRLT1%Q-!$"("LKH[\HQO8W/O5\WFHRX.S5/]'!8=1.L:U/*W1$7G
M-A$1 1$0$1$!$1 1?8C.YOO+8X_.>=T>]6DURH8,@R&9PZF#A[U%IBD;O.OW
M3$3/A<(HM^H&#(BHP/2Y^?Y*A_:"I_9C@'KC!7//6]/'^;?[1_?2\8K_  FT
M4(-057[4<!]48"K1Z@;_ /&HVN]+7[O\DKUO3S_FU^\?VV>E>/9*HK:"Z4$_
M O="[L<,CWJ\Z/>87Q.;*SSHSO >Y=%)K>-TG?[*3$QY?"(BE B(@(B("(B
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M#=]055=*8Z<F.$G #>9]:M? UQDA=4& [@&\7.< <>K*O-&T;*FXNDD:'-A
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M]!DO@M,Q;MW]C[KY8B\>%OHJ'I+KTF,]&T_:"I_5ETDM]/&R [LLN<.[ /\
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M4PYHQS,S[J4% 'Z?;2C&7Q>XD+ 'LGMM;QRR6,\%M)H#6AK1@ 8 5&II(*D
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MA$B=#%=GVA+/H2W24ED;.[I7;TDT[FND?C.,D #AD]2RI B3.^\@$1$ (@1
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MI/:O5Q8-1JOAA:V_*C%!GB_W*Y  &!R1%V5I%?"DSL1$5D"(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B((K3OYO4_3G\+5*J+T]\A4_3G\+5*("@J?]+7#_3_ %*=
M4%3_ *6N'^G^I9Y?PE-?*]1$7&T%XO40$1$!$[40 B+Q!Z@1$! B=2 B!$!$
M3D@!$1 1$0.I$&$0$1$!$1 1$0$"($!$1 1$0 B!$ (B("\7J( 1%X@]1$0$
MZD1 "($ZD%>DYN55@_+.*I4G-RN&C!=Z2NS#^+.?+U$1:($1$!$1 1$0$1$!
M$1 1$0$1$!$1 3&41!1?3M/D\"J$L.6D2M#F_<KU%E;%6R8M,(*:@=Q= =X=
MG6K0<-YDC=YAX.:5DKHFNZL>I4IJ82##P'#JSS"X<G0^]&M<ORP&ZVA\ =/3
M>/39)]+/05$+9#K<Z,ET+B/0[CE0MRTZV9Q?$##*>);S:?5CE[5\]UGT>\?=
MBC^7]O[.S'U$>+,1175;05-&\MJ(BW'7S'O"M5X=Z6I/&T:EU1,3&X%CM_T5
MI^_U0J;M;6SS!N[OB1\9QDGCND9YE9$BG'DOBGE29B?T[(FL6[2C([#;8K*Z
MT1TC66]T70.B:XC+,;N,YSRZ\Y7Q;].6JWV8VFDI&LMY!!A+W.'$DGB23S)Z
MU+(I];)K7*?._/O\_N<8^$;8;);[!0FCM,!@IR\OW#(Y_' '-Q)Z@I)%<4='
M45;PR")SB>&>0]Y3[\MO>9G^<G:L+=2EJM,E4!-+XE,#Q<>9] 4O;M.!A#JD
M.ED^;' #UYY^PJ=;;GR$&5W ?LMZE[/1_1\EONRQ_+^_]G-DZB([518#6M9%
M"W=C;P:%=P4+G#>E.ZWLZU+04K(AX@W?3UE5FQM;R'%?18N@][N.<OPM((-U
MN(FAH[5<,@:WB>)55%WUQ5JRFTR#@B(M$"(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@B]/?(57TY_"U2BBM._F]3].?PM4J@*"I_TM</]/]2G5$SVASZJ
M6:.J?&9.8#0>WXJMZ\JZ3$Z5DZE;^!YO[_+]1OP3P/-_?Y?J-^"Y_0GY6Y+A
M%;^!YO[_ "?4;\$\$3?W^7ZK?@GH3\G)<! K?P/-_?Y?JM^">!YL?G\GU&_!
M/0GY.2X16_@>;^_R_4;\$\#S?W^7ZC?@GH3\G)<(K?P/-_?Y?JM^""T3?W^7
MZC?@GH3\G)<(K?P/-_?Y?J-^">!YO[_+]5J>A/R<EP@5OX'FX_[?)]1OP3P/
M-_?Y?JM^">A/R<EPBM_ \W]_E^HWX)X'F_O\OU&_!/0GY.2X16_@>;^_R_4;
M\$\#S?W^7ZC?@GH3\G)<(K?P/-_?Y/JM^">!YO[_ "?4;\$]"?DY+@(K?P/-
M_?Y?J-^">!YO[_)]1OP3T)^3DN$[5;^!YO[_ "_5:G@>;^_R_4:GH3\G)<(K
M?P1-_?Y/JM^">!YO[_+]1OP3T)^3DN BM_ \W]_D^HWX)X'F_O\ )]5OP3T)
M^3DN.I>*AX(F_O\ +]5OP3P1-_?Y?J-^"GT)^3DN BM_ \W]_D^JWX)X(F_O
M\GU6_!1Z$G)<(K?P1-_?Y?J-^">!YO[_ "?4;\$]"3DN$5OX'F_O\GU&IX(F
M_O\ +]1OP3T)^3DN$5OX(F_O\GU&_!/ \W]_D^HU/0GY.2X16_@>;^_R_5:G
M@B;^_P GU&_!/0GY.2X16_@>;^_R_4:G@B;^_P OU6_!3Z$G)<(K?P/-_?Y?
MJ-^">!YO[_+]1JCT)^3DN.I K?P/-_?Y/J-^">")O[_)]1OP3T)^3DN$5OX'
MF_O\OU&_!/!$W]_E^JU/0GY.2X16_@>;^_R?4;\$\#S?W^7ZK?@GH3\G)?TG
M-RN5$MM4[?)N$H_T-^"]\&U/[PE^HWX+>E>,:5F=I5%%>#:G]X2_4;\$\&U/
M[PE^HWX*Z$JBB_!M3^\)?J-^"\\&U/[PE^HWX()5%%>#:G]X2_4;\%[X-J?W
MA+]1OP02B*+\&U/[PE^HWX)X-J?WA+]1OP02B*+\&U/[PE^HWX+SP;5?O&7Z
MC?@@E447X-J?WC+]1OP7G@VI_>$OU&_!!*HHKP;4_O&7ZC?@O?!M3^\9?J-^
M""4117@RI_>$OU&_!/!M3^\)?J-^""5117@VI_>$OU&_!/!E3^\9?J-^""51
M17@VI_>$OU&_!/!M3^\9?J-^""5117@VI_>$OU&_!/!M3^\9?J-^""5117@R
MIQ^D9?J-^"]\&U/[PE^HWX()1%%>#*G]X2_4;\$\&U/[QE^HWX()&6GAFC+)
M8F/8>IS00H:LTQ0SDNC!B<?-Y>Y7/@VI_>$OU&_!>>#*G]XR_4;\%AFZ7#GC
M62L2O6]J^)04VCY&Y,54'>@LQ_-69TK</V>C/K=A93X,J?WC+]1OP3P94_O"
M7ZC?@O-O]"Z2WB)C^?\ =M'59(8LW2MP_:$8]3LJZ@T?*[Y6I#/4S/\ -3_@
MRI_>,OU&_!/!E3^\9?J-^"4^@])6>\3/\_[$]5DE:TFEJ*$ATN97#MY>Y34%
M-# S<ABC8WL:T!1_@RI_>,OU&_!/!E3^\9?J-^"]'#TF'!&L=8AC;):WY2E<
M(HKP94_O&7ZC?@G@VI_>$OU&_!="B511?@VI_>$OU&_!>>#*G]XR_4;\$$JB
MBO!M3^\)?J-^">#*G]X2_4;\$$JBBO!E3^\9?J-^">#*G]X2_4;\$$JBBO!M
M3^\9?J-^">#*G]XR_4;\$$JBBO!M3^\)?J-^">#*G]X2_4;\$$JBB_!E3C](
MR_4;\%YX,J?WA+]1OP02J**\&U/[PE^HWX)X-J?WC+]1OP02J**\&5/[QE^H
MWX)X-J?WA+]1OP02J**\&5/[PE^HWX)X-J?WA+]1OP02J**\&5/[QE^HWX)X
M,J?WA+]1OP02J**\&U/[PE^HWX+WP;4_O"7ZC?@@E$47X-J?WA+]1OP7G@VI
M_>,OU&_!!*HHKP94_O&7ZC?@G@VI_>,OU&_!!*HHKP;4_O"7ZC?@G@VI_>,O
MU&_!!*HHKP;4_O"7ZC?@G@VI_>$OU&_!!*HHKP94_O&7ZC?@G@RI_>,OU&_!
M!*HHKP;4_O&7ZC?@G@VI_>$OU&_!!*HHKP;4_O&7ZC?@O?!M3^\)?J-^""41
M1?@VI_>$OU&_!>>#:G]X2_4;\$$JBB_!M3^\)?J-^"\\&U/[QE^HWX()5%%^
M#:G]X2_4;\$\&U/[PE^HWX()1%%>#:G]XR_4;\$\&U/[QE^HWX()5%%>#:G]
MX2_4;\$\&U/[QE^HWX()5%%^#:G]X2_4;\%YX,J?WA+]1OP02J**\&5/[QE^
MHWX)X,J?WC+]1OP02J**\&5/[PE^HWX)X,J?WC+]1OP02J**\&U/[PE^HWX)
MX-J?WA+]1OP02J**\&5/[QE^HWX)X-J?WA+]1OP02J**\&5/[QE^HWX)X,J?
MWC+]1OP02J**\&U/[PE^HWX)X-J?WC+]1OP02J**\&5/[QE^HWX)X-J?WC+]
M1OP02J*+\&U/[QE^HWX+SP;4_O"7ZC?@@:=^0J?IS^%JE5:6RB%# ^/I'2%S
MR\DC'4!_)7: B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
:B B(@(B("(B B(@(B("(B B(@(B("(B#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g42675g17a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g17a01.jpg
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M 0$! 0            <( @,&!00!"?_$ &$0  $# @(%!0T$!0@' PH%!0$
M @,$!081!Q(3(3$4&$&2DP@B45)35%5688&1T=(5%C)Q%R-"E*$S-W)T=;&R
MLS4V.&)S@L$D0\,E)S1C=H.TPN'P)F2%HJ,H1$:$\?_$ !8! 0$!
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M;C77.JBI:.*XW R32NU6MS;*!F?S(03W+I;LMNQ(RQ8GH[C8*^35+#6L88G
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M^OLNC2X14Q)K;FYMO@:WBXR;G9?\@=[\D1[NC3&(QQAUUXBM\E#3.G?%"))
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MK:J""*/8TT E>QN1EDVL>L\GI).:\;N5:"DN>BZ\T=QIXJFEFN,C)(I6AS7
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M72T;KO!+50_RL=.'3&/^EJ ZOO49=U'CBLP[8**RVF=\%5=-<S2L.3F0MR!
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M(V0-<YQ<YP(:#F22=Y/%$5>O?VCHITYTUVKX:>""JEY5)'2/<Z(PRN(D:TN
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MTKKB3$8N4E1+&VHCN4OZL-R R826GW@KX\ Z4+W9M(T^!,=S1UDHJ.34]P#
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M@. =K.:3P<=V:UX$P <%V*IM-IO]Q?2R$OBV[(GF!Y(S<WO>G+@<QO)15?\
M17_M05O]?N/]TJM9>KG2V:TUERN$HBI*6)TLCST- S^*B^S:$*.SXI^\5!B6
M\,NYDDE=,YD+M9S\]?-I9EOUCT=*]7&&C";%].RFOV+KW/1M<'<GC;#%&XCP
MAK!G[\T'>6:L-QM%#6NA= ZI@9,8G',LUF@ZI/LSR7UK&-C8XVL8 &M   Z
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MFNN55(:FJU3F&N( # >G( >_-%2 B(B"(B B(@A#N@,<XIP!56N>S7"F?2W
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M\GS3G-WWT#;.O)\U >S?XCO@FS?XCO@A$^<YN^^@;9UY/FG.;OOH&V=>3YJ
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MOOH&V=>3YISF[[Z!MG7D^:@/9O\ $=\$V;_$=\$(GSG-WWT#;.O)\TYS=]]
MVSKR?-0'LW^([X)LW^([X(1/G.;OOH&V=>3YISF[[Z!MG7D^:@/9O\1WP39O
M\1WP0B?.<W??0-LZ\GS3G-WWT#;.O)\U >S?XCO@FS?XCO@A$^<YN^^@;9UY
M/FG.;OOH&V=>3YJ ]F_Q'?!-F_Q'?!")\YS=]] VSKR?-.<W??0-LZ\GS4![
M-_B.^";-_B.^"$3YSF[[Z!MG7D^:<YN^^@;9UY/FH#V;_$=\$V;_ !'?!")\
MYS=]] VSKR?-.<W??0-LZ\GS4![-_B.^";-_B.^"$3YSF[[Z!MG7D^:<YN^^
M@;9UY/FH#V;_ !'?!-F_Q'?!")\YS=]] VSKR?-.<W??0-LZ\GS4![-_B.^"
M;-_B.^"$3YSF[[Z!MG7D^:<YN^^@;9UY/FH#V;_$=\$V;_$=\$(GSG-WWT#;
M.O)\TYS=]] VSKR?-0'LW^([X)LW^([X(1/G.;OOH&V=>3YISF[[Z!MG7D^:
M@/9O\1WP39O\1WP0B?.<W??0-LZ\GS3G-WWT#;.O)\U >S?XCO@FS?XCO@A$
M^<YN^^@;9UY/FG.;OOH&V=>3YJ ]F_Q'?!-F_P 1WP0B?.<W??0-LZ\GS3G-
MWWT#;.O)\U >S?XCO@FS?XCO@A$^<YN^^@;9UY/FG.;OOH&V=>3YJ ]F_P 1
MWP39O\1WP0B?.<W??0-LZ\GS3G-WWT#;.O)\U >S?XCO@FS?XCO@A$^<YN^^
M@;9UY/FG.;OOH&V=>3YJ ]F_Q'?!-F_Q'?!")\YS=]] VSKR?-.<W??0-LZ\
MGS4![-_B.^";-_B.^"$3YSF[[Z!MG7D^:<YN^^@;9UY/FH#V;_$=\$V;_$=\
M$(GSG-WWT#;.O)\TYS=]] VSKR?-0'LW^([X)LW^([X(1/G.;OOH&V=>3YIS
MF[[Z!MG7D^:@/9O\1WP39O\ $=\$(GSG-WWT#;.O)\TYS=]] VSKR?-0'LW^
M([X)LW^([X(1/G.;OOH&V=>3YISF[[Z!MG7D^:@/9O\ $=\$V;_$=\$(GSG-
MWWT#;.O)\TYS=]] VSKR?-0'LW^([X)LW^([X(1/G.;OOH&V=>3YISF[[Z!M
MG7D^:@/9O\1WP39O\1WP0B?.<W??0-LZ\GS3G-WWT#;.O)\U >S?XCO@FS?X
MCO@A$^<YN^^@;9UY/FG.;OOH&V=>3YJ ]F_Q'?!-F_Q'?!")\YS=]] VSKR?
M-.<W??0-LZ\GS4![-_B.^";-_B.^"$3YSF[[Z!MG7D^:<YN^^@;9UY/FH#V;
M_$=\$V;_ !'?!")\YS=]] VSKR?-.<W??0-LZ\GS4![-_B.^";-_B.^"$3YS
MF[[Z!MG7D^:<YN^^@;9UY/FH#V;_ !'?!-F_Q'?!")\YS=]] VSKR?-.<W??
M0-LZ\GS4![-_B.^";-_B.^"$3YSF[[Z!MG7D^:<YN^^@;9UY/FH#V;_$=\$V
M;_$=\$(GSG-WWT#;.O)\TYS=]] VSKR?-0'LW^([X)LW^([X(1/G.;OOH&V=
M>3YISF[[Z!MG7D^:@/9O\1WP39O\1WP0B?.<W??0-LZ\GS3G-WWT#;.O)\U
M>S?XCO@FS?XCO@A$^<YN^^@;9UY/FG.;OOH&V=>3YJ ]F_Q'?!-F_P 1WP0B
M?.<W??0-LZ\GS3G-WWT#;.O)\U >S?XCO@FS?XCO@A$^<YN^^@;9UY/FG.;O
MOH&V=>3YJ ]F_P 1WP39O\1WP0B?.<W??0-LZ\GS3G-WWT#;.O)\U >S?XCO
M@FS?XCO@A$^<YN^^@;9UY/FG.;OOH&V=>3YJ ]F_Q'?!-F_Q'?!")\YS=]]
MVSKR?-.<W??0-LZ\GS4![-_B.^";-_B.^"$3YSF[[Z!MG7D^:<YN^^@;9UY/
MFH#V;_$=\$V;_$=\$(GSG-WWT#;.O)\TYS=]] VSKR?-0'LW^([X)LW^([X(
M1/G.;OOH&V=>3YISF[[Z!MG7D^:@/9O\1WP39O\ $=\$(GSG-WWT#;.O)\TY
MS=]] VSKR?-0'LW^([X)LW^([X(1/G.;OOH&V=>3YISF[[Z!MG7D^:@/9O\
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MK<SD-8Y9E?H<TN+01K 9D9[P@_40D @$[SP7YK-UM7,:V6>6>_)!^HB("(B
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MA[732S,<X@-<' - ]HZ5[N%\.T&&K8**V-EU"[7?)-(9))'9 :SG'>3D /8
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M5%!,XN?1/&IGXCLR![B'?P4B+*B(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MSYAPL<TMG-$(\NG]23N]P*Y#2Y;JNU=S_@"CN+7,J63:SF/W%H<U[@T^ @.
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MWDN_@I$4U1$10$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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4("(B B(@(B(/OH/Y%W])$1!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g42675g48g48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42675g48g48.jpg
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M 0$                   $"_\0 %A$! 0$                  !$!_]H
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MGR?89,7Z1\6X\K&+J+(M/2ZWZNMZ$^+8VL;_ #CH8
M
M
M
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M5%-51,8^D6=LK8U155'9IM^&WX[0)&                       !B<7?\
M"EZ_D4W]QQS7Y..C?#.,\/7*NQ%0R54U/5I$S*=\::NHU<E1JIZ54ZHDC9+&
M^.5C7QO16N:Y,T5%YT5#X[19[;9H'P6BWTE!"]VNYE-"V)KG<V:HU$V[ *;#
M9;;A^VQV^RT4-%1Q[6Q1-R3/TJOI5?BNTYIT"8<L^),;8ZI;[;J:NA1SM5)F
M(Y69RO15:O.U?BFTZF,?;;):K745$]LME%1SU"YS200-C=(N>?WE1-NU5Y^D
M#GS0I<*K &EJ\X N,\CK?42.XGPB[$>B:[')T:[.?XHAC\8SSZ+?*#=B:NI9
MI+)<G.>LD;<\VO;D]$]&LUVW+HRZ3I&HL-HJ;I%<ZBUT,MQBRX.J?3L=*S+F
MR>J9ID?3<K?1W.E=2W*DIZNF=^**>-)&K^2[ J$-)VG/"]3@NXT&&JJ:ON5P
M@=3,:D#V)$CT5JN<KD3:B*N2)GMR,IH6T?5%!H<N-IO#'4U7?63/D8],G0M?
M&C&HJ=.2:V7HSR)$M>"L,6FK;56S#]JI:EJYMEBI6-<WY+EFAL 1RKHEQI#H
MNJ;U@S2#12P4DLROU^"X1J*K4:[-OZT;FM3)41?EMV8S&%XPG>M,F"7X%@IH
MZ**JI62\7I.+M=)QA%SRU45=F6W(ZKO5AM-\B;'>;915[&_A2I@;)J_+--A\
MUFPEAZR3<-:+';:*;]\@IF,=VHF86H.\LC_T&%O^K4?V1E'E X)I\,6RSXQP
M;2QVJKH96-J%HV)&F2_@?DFS8[8O3K)F3_=[):[RV)MWMM%7MB571I4P-EU%
M7G5-9%R/IKJ*EKZ.2DKJ:&II9$U7PS,1[')T*U=B@0UI/TC0U>@&.\4;T94W
MR)M&C6K^![LTF3\D:].PU7 NBO2!%@VD9:\6P6RWU\*5#Z)8U7+A&IFCMFU<
MLD4GV3"F'I+?#026*UOH87K)%3NI(UC8Y>=4;EDBKTF8:U&M1K41&HF2(GH
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M[J0"<V.:]J.8Y'-7F5%S12EDT3Y'QLD8Y[/Q-1R*K?FGH.=/)LQ'58>Q'<\
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MNLM+B#@.%8SC+<GR:ZHC49EGM1/0NSG Z_+<,\4VMP,L<FJN3M1R+DOQ(_\
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MQ_\ =F%_^M/_ '6 =% LT7_HX/\ IM_L+P
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MDC9*CXUC<Y,M9%3)<D7,$2Z"Q02.FH::61<WOC:YR_%4+X
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M6-S5$<CD5%YUVY(NTL8!T,88P;=&W.F2JK[BS/@YZQZ.X)5]+6HB)G\5S7H
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M1K9$55V=&9]Y$N&] >%</WZ@NU%5WA]313-FC;+/&K%<U<TS1(T7+\R6@@
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ML_NH?46J.)8*2"%RHJQL:Q53TY)D70@
M
M
M
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MK45N?,Y[6HU-OQ7+83[@2P_9C!]ILJRI,ZC@;&^1.9SN=RI\,U4#.@ (
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     !S]1:=<27>Y7&FP_@:2Y-HI
M%:_@)WO<UNLJ(JHC/3DIT"<>Z&](EHT?XCQ9->HJR7C<B-B;31M<JJU[U7/-
MR9<Z!<3EHVTN46-XKG2+0RVN^4,+Y7TLKM=%1NQ51<D78N2*BHB[3X_)SQO>
M\;6.[U&(:B.>:GJ6QQN9$V/)JMSRR::)H8M-SQ!CS%6.ZFWRV^V5,-2L"2-5
M.$=(N>2>LB(BYKS9Y&HZ#,!77'-DN\$>(JBTVB&9NO#3HJK-,K=BN3-/NHG2
MO9S@=B@YZ\FZ\7RKI<888K+G(^6WIJTE1(Y9. >NNQ53/]5%:U43Y])JF,K!
MAFW6BOJI]*==<L5P1ND9J5*N8^1-NHF6:IGEE^+8".L <XQ8TQ36>3.^Z4E5
M4R72"H6EFK&*JRMA1VU^?/GDJ-5W/EMY]IYH1MF&+G7V6XV?&]X3$4:-EKK?
M539).N7WV(U<M9O/M17;.<$='@Y8QGBREQ?I8N]HQ7B>KL.%;6Z2!D=,YS5F
MD8Y&KGDBYJJZRYJBY(F2<YDM"V)_->ER?"MEO]3?<+U<3G4LE0KE6-S8]?9F
MB999.:N2(B[%R!'2-3/%34\L]0]L<,3%>][N9K43-57\D((NOE$4S\4T-NP[
M:5J[?-4-@6LJ'+'KYN1%5C<N9,_3M^"$\3PQU$$D,[&R0R-5CV.3-'-5,E14
MZ#FKRBJ.FM^/]']+04\--31*UK(H6(QK4X9NQ$38@,=,  (        AG'^F
M&ZX?T@OPK9,,^=JI&,<S5F5'R*K-=41J-7F3^Q2K"&FQ:S%D&',7X=JL/W*H
M<UD2R.5S5<[\*.16HJ9\R+M3,CO2)B&CPKY3[+U<TF=1TK(UD2%J.?MIE:F2
M*J>E4])[75M1IFTQ6*XX?M=93V>V+$DU5.S5R:R19%553-$5<\D;FJ^GIR*D
M7#6.[[7:?KWA:IJ(G6:FB>L421-1S51K%1=;G7G4F(Y.K['=,1>4AB2V6:[2
M6E\VLD]5%GKI#J,UD;EDN:[$YT,O@2.[Z.]/L&$O/-3<;76L7629RY.18U>U
MVJJJB.1S<LTYT^8'30(&TEX<L51BBOJ,<:2JJBBD<CJ6V4\R,6G9DF6;?O?'
M;JIGTF#T XEN[+KC2PVZZ37JCHZ66>V/F<KM9S':K%:B[41V;5R".E0<>Z/O
M,V+9ZQV-,<7RT8M=4*D+WSK'&WFRVJFQ=;--7-OH1#??*!Q=76^]8<P=%?)K
M91SPQRW&Y,54>K%<K,_N[<ON.<J)SYH%CH4'(=7B"TX"Q98:W1YC"X7BBFEU
M+A25+W*BIFWGS:U%UD5<MF:*G.=>!$$8HTUXABK[HW"^"ZJLMMMFDAGKI62.
M9FQ51R_=3)J;%YUYN?(W#0UI0I](M#6(ZC6AN5%J\-"C]=KFNSR<U=G0N:>C
M9SF2TLXQH,$X-K:NI='QJ=CXJ2G],LBHOHZ$SS5?_NJ$>^2G@VLLMBK[_<HW
M1.NB,;31N3)>";FNNO\ &5=GP3/TA4[@ (     !!5TTV7[[;7G#N'L'.NLU
MNFDC7@IW*]S6.U5>K4;L3-4[4)U.2+!C2V8%T_8TNEZ94OIY):NG:E.Q'.UE
MG:Y-BJFS)J@Q,6C33#3XLQ!+AZ[VBHLE]8CLJ>5VLCU:F;F[414<B9KDJ<R+
MM/BT'X[ON*\68OH;U412TUOE1*=K(FL5B<(]N6:<^QJ<YI&CF"OTAZ=Y<<4U
MMJ*&QTZJYLDK<M=4BX)K<^97+SKEGDFS/FSU?1AA&Z8RQKC&WT5]GL]N2H<^
ML6GSUYOV1^HWG39^)5VY<VQ?05V"#G7R?:Z[V+2=B7!-?<IJ^AI(Y'1K(Y51
MKF2-:CFHJKJYH[:G2B'S8OPOAQMPN#L9Z5:MUY61[F10S?<IUS75:K$UE3+9
ML35".DP<S:*L9XHJM"N,^*U=16W.U:O%)G*LDC&._%DJ[5U41SDSYOR,=H>H
ML.XB?;*N3'=[H\9I.DDL,]0J-F5'YZC<_P >LFS\6>U=GH"QU4#FG3#B_P \
M:6&X4NN(*BPX7H6MXW+3JY'2O5FOMU47/G:U$7-$VKD8_ N)*7"VF"TV?"&)
MJR^88N>K%)'4N<[@GNS3THFU%1JYHB;%R!'4=1*V""25Z*K8VJY43GR1,R!;
MMIHQDRWR7J@P#/'A]GWN,52OUG,];8B9)\=J?$GTY]TTXTQVEGQ%:HL'R4]E
M59:=UR1'2ZU/FJ:^2;&YM]*\V83$J:+L<4N/\+LNU) ^FD;(L$\#G:W!R(B+
MDB^E,E147XFW$1^3&VQ1:/5AL-;)53\862NX6/@WLE<B(B:N:_=U6IDN:YY+
M\DEP
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M)J!"O*2P9U2][O'X@Y26#.J7O=X_$!$U A7E)8,ZI>]WC\0<I+!G5+WN\?B
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M.#?ZCNP"D%7!O]1W8.#?ZCNP"D%7!O\ 4=V#@W^H[L I!5P;_4=V#@W^H[L
MI!5P;_4=V#@W^H[L I!5P;_4=V#@W^H[L I!5P;_ %'=@X-_J.[ *05<&_U'
M=@X-_J.[ *05<&_U'=@X-_J.[ *05<&_U'=@X-_J.[ *05<&_P!1W8.#?ZCN
MP"D%7!O]1W8.#?ZCNP"D%7!O]1W8.#?ZCNP"D%7!O]1W8.#?ZCNP"D%7!O\
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M5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H
M\U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ
M /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8
M>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)
MV'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]
M"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5
MO0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#
M5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=
M@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0
MG8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;
MT)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U
M6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /
M-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@
M#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'
MH \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=
MAZ /-5O0G8-5O0G8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0
MG8>@#S5;T)V#5;T)V'H \U6]"=@U6]"=AZ /-5O0G8-5O0G8>@
M                   S3/+-,^@
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MR+T(OH7X+VF^$
M
M              %.NW7U-9NOSZN>TJY@ "*BHBHJ*B^E
M  !YK-U]7636RSRSVY'H                           #4-+USK+/HVO]
M?;)W4]9!3YQRLYV*KD3-/R4V\T33K^U+B;^3)_?:!"^%8-)]\T?/Q=;,;3*D
M399.)R[5<D:KGM5%15V;$5#-T^E2]W_R?\1WA)^*7^V30T[JF!$;K(Z6--=$
MYD56N<BY?-,O1JVC5FD^[:,6V7"M!;H\/U*S1<>?(ULN3G*CTVOS3G5,T9GT
M=)MF+,!-T?\ DVXBM\L[*FNJ):>>IE8BHW6X>)$:W/;DB)Z?BOI"L+9J/29<
M-&B8UH<<S.8R"6I6DE3;JQ.<CMJHJ*N3%7)4-SP?I$NV*-!6);S42<!>;;!4
M1<9A35UG-C1S9$3F1?O)S>E/R(?EH,>4N@ZBN5->M?"$J/CDH8,F21,65S5U
MEU<U:KL\]J_B39D3#98+#%Y,]W?A9DK:.:VU,DO#.1TBS:JH_75,DS14RYDV
M(@&%P/I5JK'H.J;[?ZZ2XW=]9+3439W:SI'ZK51%_P"5N:JOPV>E#== M'BM
M^'Y;UC.ZUE3-<M62GI9UV0Q[51V7H5V?-Z$1/RY@M]JKZ#!]@Q<^-+C9J.Y/
MBEHY4SC8Y%8[:G0]-BKTM1/2B'8WVUM<NCR7%M)(C[>RC=5(F>2YHB_L:]#M
M9-7+I @335CS%53CR^4N$;G64UML-,U:GBS]5%76:CW+TJCI$;_-4GO1AB1,
M58"L]X>]%FE@1M0O-E*W[K_EM15^2G+VBW'>&+39\7-Q>RX5%QQ KHY7P0M>
MB1N1V:YJY-JN>Y?R0VOR8+]+4X=Q9A5CU6=8'U=&F>U5<W4=E^?!K^:@??58
MVQII5QE76?1_6I:+%1+E)6I]USFYJB/5R(JIK9+JM;ELY^9<LW#@72MARIIZ
MRU8U6]M;(U9:6L>[[[<]J)KJY.;XHO08;R0ZF'S3BBW1R-AN?",D363[VKJJ
MU%R]*-=_:G28G2#=-)6CZ[V**YXRX\VX2KDD4341$:YJ*BYM].L!*FDZR:0L
M08@AHL)WB&RV)M,UTM3KZLCY5<[-J*U%=L1&]";>=?1%^CO%V,\*:8H\&XFN
M\MVADF2GEX619<E<S68]CG?>38J9IT*NS,G723CBVX$P])<KD[7F=FRFIFKD
M^=_0G0G2OH3\D6*= ^"KG><35.D?%S%955;G2T4+DR_&F7"9>AJ-^ZU.C;T9
MAT":/=M+."+3='V^NQ!3,JHW:CVL8^1K'>E%<U%1%_/8;K41K+3RQM>L;GM5
MJ/;SMS3G0Y+L\%;HAEN%#CG!%+>K-53?[QX)LFSF35>J*F2\^JNJN:J$=*1X
MXPW)?J6RQW>G=<ZJ-LL$+<UX1CFZ[51V6JN;=J;2_B?%MBPNM(E_N45$M6Y6
M0H]'+KJF6>62+TIVD :<H:2FH<":0\'L1M%3)##&C4RU6,^]$U4]&63VK^2%
M^\5T&E'3_ARGHUX:S6REBK'^E,M5)5S^:NC8OR"INJ\?87HZVYTE7>J6"HMC
M4=5LD56\$BY(FU4R5=J;$S7:>81Q[AG%TTT.'KM#5SQ)K/BU7,>C<\L]5R(J
MIS;4Z2 [?ANV8I\I[$-%>X.,T<2OJ.!551KW-:Q$1V7.FW/(^FGM%%A?RK+=
M16*!M'1RQJY8(]C$UJ=ZJB)T9IGET@3?BK2)A7"M:RCOUY@I:MR(O HUTCFH
MO,KD:BZJ?,ANP7.GNGE7RU=NJV55%-2ZT<D3]9CF\5;S?G_28W0M8K;CC2EC
M6X8JI8KA+#(Y605":S45TCDSR7U4:B)T9_(KP58:##7E43VNSQK%0Q1R.CC5
MVMJ:U.CE1%Z$5RY 3A7:2<(T/G3C=\IHW6R5(*IJH[69(JJB-1,OO+FUWX<^
M93[:C&F':;#5/?ZF[4T-HJ&HZ&HD56\)GZ$:J:RKL79EGL.=L!X2M6+O*!QI
M3WV%:FDI*FKJ4@5RHV1_#ZJ:V7.B:RKD?9I"L]!7:=\(X.E@X'#E'%&R*D1R
MZBH[6>Y.?/[RHC5^0$UX;TH8-Q'<&T-HOM/+5O7)D4C7Q*]>ANNB9K\$,Q=<
M66*T7JEM-SN<%-<*F-98HI,TUF)GF[/+)$^Z[G5.8@3RH<*V3#MIL-WP_04U
MKKFU7!9TC$BUD1JN1V3<MJ*U-O/M/@TU4K<1Z4M'5+=$>UERHJ..H1BZKLI)
MG(Y$Z.=0)TLFD[!U[NZVRV7ZEFK=J-8J.8C\N?5<Y$1WY*4T.E#!E??6V>DQ
M!22U[G\&QJ:VH]W-JM?EJJOR7:0)Y1>"K%8<281@L="RWQ5R.AF;!LS1KV(C
MMOZV3UV^G9F?1Y2N"[#@^T89J,-T#*"=)7Q.DC5=9Z-1%17*O.Y%]//M Z1Q
M+B.T89M_';]<(*&FSU4=*NUR]#43:J_!$,3A/2)A7%E4ZFL-Y@J:IJ*[@5:Z
M-ZHG.J-<B*OY$":9*^KN>G##]'+:G7N&EIHGQ6SA-1L[G-<]VU<TVJB9[-J-
MR/HN=BQ5>=(N&;Y:='LF&G4=1&E0Z&6/4D9KIFKD1&HF3=9%Z44$=/  (
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M.D"N=<,8W65RYHR986_!&?=3^S^DUXUB
M                               ]39S$Z:)<5/O5N?;Z^17UU(U%1ZKM
MDCYD5?BG,OS0@HV;1M7.H,:6Q[5R;+)P#DZ4?L_M5%_(#HX &5
M
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M9S\V1LA$FBJX7>U:1,4X)NEUJKO26Z**II*FJ=K2M:]&KJN=Z?QIV+ESDMA
M                     ->TAV"7%&"[M9:>9D$U9#P;9)$56M7-%VY?(V$
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MEM1455V[=BY*A1AO">DQ;[05.*<:TLMOI96R/IJ.')9T3]5RHQFQ?3SDK@
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M1DRHGX9$3)%7YHG]!&9K$
M                    ,Y@>!U1B^SL8F:I51O\ R:NLO]"&#)1T)V!\M;->
MZABI#$BQ0*J?B>OXE3Y)L_/X 3& #*@
M
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M/JZM6:C<D_"QC?0U/IS9(;L
M
M        !\]QH:>XT4U)6Q-EIY6ZKVKZ?_<@O&.CRXV662>@CDK;?SHYB9O8
MG0Y$_M39\B? !R8J9+DO.>'45?8K3<'J^MMM'.]>=[X6J[MRS/C^QV'O8U%W
M:%J1S2#I;['8>]C47=H/L=A[V-1=V@HYI!TM]CL/>QJ+NT'V.P][&HN[04<T
M@Z6^QV'O8U%W:#['8>]C47=H*.:0=+?8[#WL:B[M!]CL/>QJ+NT%'-(.EOL=
MA[V-1=V@^QV'O8U%W:"CFD'2WV.P][&HN[0?8[#WL:B[M!1S2#I;['8>]C47
M=H/L=A[V-1=V@HYI!TM]CL/>QJ+NT'V.P][&HN[04<T@Z6^QV'O8U%W:#['8
M>]C47=H*.:0=+?8[#WL:B[M!]CL/>QJ+NT%'-(.EOL=A[V-1=V@^QV'O8U%W
M:"CFD'2WV.P][&HN[0?8[#WL:B[M!1S2#I;['8>]C47=H/L=A[V-1=V@HYI!
MTM]CL/>QJ+NT'V.P][&HN[04<T@Z6^QV'O8U%W:#['8>]C47=H*.:0=+?8[#
MWL:B[M!]CL/>QJ+NT%'-(.EOL=A[V-1=V@^QV'O8U%W:"CFD'2WV.P][&HN[
M0?8[#WL:B[M!1S2#I;['8>]C47=H/L=A[V-1=V@HYI!TM]CL/>QJ+NT'V.P]
M[&HN[04<TGJ(JJB(BJJ\R(=*_8[#WL:B[M#[:"QVJWN1U#;J2!Z?K1Q-1W;E
MF*1"^#-'5PO$L=1<V245OSS773*21.AJ+S?-?Z2<J&D@H*.*EI(FQ01-1K&-
MYD0O@B@
M
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M<#G'E0T_NI+OZ>&.5#3^ZDN_IX8(Z.!SCRH:?W4EW]/#'*AI_=27?T\,$='
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M[/H/,=I]ET.[L^AD
M                                            :U=\<X?M<CHY[@R2
M5NQ60(LBI^:;$[3"KI7P^BY)%7K\4B;_ )@-_!H'Z5[!^]7#NF_YA^E>P?O5
MP[IO^80;^#0/TKV#]ZN'=-_S#]*]@_>KAW3?\P@W\&@?I7L'[U<.Z;_F'Z5[
M!^]7#NF_YA!OX- _2O8/WJX=TW_,/TKV#]ZN'=-_S"#?P:!^E>P?O5P[IO\
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MC<CD_H ^@
M
M
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M+*1%<J4]4Y*>5/1]Y<FK^2Y?TG1!%  0
M
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M1L7!5[<K&ZSKAJN7+:J)&S)%^&U>U3%^1[&S/%[]1NNDE.U'9;43]EV?(FS
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MD:Y7*DC79HB;4R1%SZ.8E#$EAMF)+3+;;Y1QU=%+DKHWYIDJ<RHJ;47XIM-
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M^?R:=3$'^2EA6:S82K[O74\D-5<ID:QLC5:Y(H]B+DO2Y7=B$X!
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M<HFY\5>K),O0U^62]J(GYD+&L0
M        %^B<YM9 Z/\ &DC5;ETYG5IS;H_M3[OBRWP(W...1)I5Z&M7->W8
MGYG21-,  10
M
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MUVGP-8Z?!#L)1P2I97,=&L:RNULG.5Z_>Y^=0C&V1K?T)4+=5-5</,V9;/\
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MFSI&V1S$<YN>6MESIM789QJ(UJ-:B(B)DB)Z /0
M
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M?TK^1MP!%
M
M
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M.TO68>\0<=I>LP]X@%\%CCM+UF'O$'':7K,/>(!?!8X[2]9A[Q!QVEZS#WB
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M.TO68>\0<=I>LP]X@%\%CCM+UF'O$'':7K,/>(!?!8X[2]9A[Q!QVEZS#WB
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M.TO68>\0<=I>LP]X@%\%CCM+UF'O$'':7K,/>(!?!8X[2]9A[Q!QVEZS#WB
M7P6..TO68>\0<=I>LP]X@%\%CCM+UF'O$'':7K,/>(!?!8X[2]9A[Q!QVEZS
M#WB 7P6..TO68>\0<=I>LP]X@%\%CCM+UF'O$'':7K,/>(!?!8X[2]9A[Q!Q
MVEZS#WB 7P6..TO68>\0<=I>LP]X@%\%CCM+UF'O$'':7K,/>(!?!8X[2]9A
M[Q!QVEZS#WB 7P6..TO68>\0<=I>LP]X@'YN@ -
M
M
M
M
K                                                      __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
